<SEC-DOCUMENT>0001558370-20-005185.txt : 20200505
<SEC-HEADER>0001558370-20-005185.hdr.sgml : 20200505
<ACCEPTANCE-DATETIME>20200505160915
ACCESSION NUMBER:		0001558370-20-005185
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		93
CONFORMED PERIOD OF REPORT:	20200331
FILED AS OF DATE:		20200505
DATE AS OF CHANGE:		20200505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INCYTE CORP
		CENTRAL INDEX KEY:			0000879169
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				943136539
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12400
		FILM NUMBER:		20848888

	BUSINESS ADDRESS:	
		STREET 1:		1801 AUGUSTINE CUT-OFF
		CITY:			WILMINGTON
		STATE:			DE
		ZIP:			19803
		BUSINESS PHONE:		3024986700

	MAIL ADDRESS:	
		STREET 1:		1801 AUGUSTINE CUT-OFF
		CITY:			WILMINGTON
		STATE:			DE
		ZIP:			19803

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INCYTE CORP
		DATE OF NAME CHANGE:	20030318

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INCYTE GENOMICS INC
		DATE OF NAME CHANGE:	20000710

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INCYTE PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19930902
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>incy-20200505x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7401.38943 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 5/5/2020 8:06:42 PM -->
      <!-- iXBRL Library version: 1.0.7401.38955 -->
      <!-- iXBRL Service Job ID: 73b0e7fa-da08-45dd-a9ed-6489e0df8564 -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:incy="http://www.incyte.com/20200505" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member_MP4cDjTkq06lAGevzdzYBw" name="incy:DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" id="Hidden_1LuKVsI460CF2sHZ2dlGqw">P20D</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member_MP4cDjTkq06lAGevzdzYBw" name="incy:DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" id="Hidden_Rv9y-6kA30urzn5y6CwGRg">P30D</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" xs:nil="true" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" name="us-gaap:PreferredStockValue" id="Hidden_IJ-VJlHxY0CEZeshYZ-_Zg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" xs:nil="true" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" name="us-gaap:PreferredStockValue" id="Hidden_00WskpThfUe7BGq8TEau6Q"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_7OOuLSkz1keOYZ2bBUlh2Q">216952325</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_H-VABGyQBEqLMEDhcDPfAg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_0-39tUcKG0i1Uu34pUXyLg">0</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member_MP4cDjTkq06lAGevzdzYBw" name="incy:DebtInstrumentConversionObligationNumberOfScheduledTradingDaysBeforeMaturity" id="Hidden_LuZKOSV89k6ANKuV9BpZOg">P2D</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2016_To_7_31_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_eVPwouvAqkSAUpm9iX0Giw" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Hidden_6RWKpuCFUEKpc6a3v7bZKw">P10Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2016_To_6_30_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_R2nXzmWcpEusNX2tgETvVg" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Hidden_5i-HSeUv7Eq9b9ehfzeLfA">P7Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2016_To_7_31_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember__akggGl53kSTF7JP7JfRbA" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Hidden_OR5-Cr_KuEOxFj4pvVNKEQ">P36M</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2016_To_6_30_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_D0lxLn0JWU2EcDQaGVWl7Q" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Hidden_mWa7sHwgO02SjXEAYJrP4Q">P24M</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Hidden_DXWVUeF4QEyCGxw9FL_y3g">us-gaap:AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Hidden_YKRv1wQ5MU6qRbBLux7YLQ">us-gaap:AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Hidden_fgS4bxuAUka7K61E668xgw">us-gaap:FinanceLeaseLiabilityCurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Hidden_JdEmJ1TRLEuX3trAlTt_1Q">us-gaap:FinanceLeaseLiabilityCurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="Hidden_DZPOj2yYtU-8JCIk7usOfw">us-gaap:OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="Hidden_vm-xD2amQkygzKbNU_aQ2w">us-gaap:OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="Hidden_T_UTUYhcFUKgazgt2tP-VA">us-gaap:FinanceLeaseLiabilityNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="Hidden_kmiwLnkoB0igxckkueRbJQ">us-gaap:FinanceLeaseLiabilityNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList" id="Hidden_GM3GSp9hq06a9WD9qcF_iA">us-gaap:OtherNonoperatingIncomeExpense</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList" id="Hidden_imtwPvcDJU-u5c1IWdvgmQ">us-gaap:OtherNonoperatingIncomeExpense</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="dei:EntityCentralIndexKey" id="Tc_tuye0J3LB0K9tt9PPfsxnw_2_1">0000879169</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="dei:CurrentFiscalYearEndDate" id="Tc_qdv24iowAUWrFPBQbD9_1g_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="dei:DocumentFiscalYearFocus" id="Tc_qhsuMhkhdEiS96dgmoWyMg_4_1">2020</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="dei:DocumentFiscalPeriodFocus" id="Tc_Ip7b-32qOEacMHZPp2erfQ_5_1">Q1</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="dei:AmendmentFlag" id="Tc_QAtdvl1bdEWk9q8E8J5MQQ_6_1">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_incy_ICLUSIGMember_YO1pSkx-YU6EMn97oz0Vig" name="incy:InventoryFinishedGoodsUsefulLifeMaximum" id="Hidden_Z0f1rDx3zUCCp3VLdTAwTg">P36M</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" id="Hidden_GNLsXbAN4UCKMgqU4Rhibg">258622000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_n5eXxN5QFkGcxSpRYcUebQ">216177830</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2020_To_1_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmericanDepositarySharesMember_y989uIAWJUij4EiffRDHoQ" name="incy:StockPurchaseAgreementLockUpPeriod" id="Hidden_LxjukuDojEmG5LuismUbLw">P18M</ix:nonNumeric><ix:nonNumeric contextRef="Duration_6_1_2018_To_6_30_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_GfsaK8p46UWIkVJ17vp0wg" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="Hidden_w_7MzdT-j0OynAIorIKX9Q">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_incy_CorporateAndGovernmentDebtSecuritiesMember__FioQn-7xkq2Ihn7ogju8g" name="us-gaap:DebtInstrumentTerm" id="Hidden_wxfFNirtIkK2gW_Xg1C_gw">P12M</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="incy-20200505.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e2R-5xzxfUC6nZUl8PL1YA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7twDsd2JDEOndz5YGwcBzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fEwSRBjO_Ui2kpLBrnNHdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2hQ7NTSBMUWmxGpMp6-_0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Hj6IUMCWb02gJP3m4OeDnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_xkbc2Y822UqXDVbR6a7_LQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__tiHxydERESGTR76ARwl7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_h7i3Ro_OZUmCp9mkSGukFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4IpabeHWGEeyws0bt-_LIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_-bO_iV0lbkSyipE07mBbnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_OfMjHRm8vkyNOUMTG5Sgug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vUipIgfa4km0rtW5tdmA4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_S1joOk6fhkO10LOQZpl6lQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_XMlG1LUJy0Scx4eCJMw_Og"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AsudZYg1cEuP3-a7_igGEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mHv5WMXrp0O8iRpfgdj6oA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JPMoYCXuZU2eJZVVkKRx5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_YuWnGWZBFEycAhcGmFa2fQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AzTpzCx2FEeghKSIssu86g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_SVG1T8un0UuAR4xiq6ES-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Cbj624ha3kmOoiQSEnwBlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_W9GbI2-s5ES4CTz48UruiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2019_To_4_30_2019_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_incy_LongTermIncentivePlanOneMember_dDGsqWzkwEmzRXEky-0cyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">incy:LongTermIncentivePlanOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2018_To_6_30_2018_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_incy_LongTermIncentivePlanTwoMember_GfdRdjchm0SNfn7rnmSnFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">incy:LongTermIncentivePlanTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2018_To_6_30_2018_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_incy_LongTermIncentivePlanOneMember_jsEmMys8p0GNOaeQtFsmZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">incy:LongTermIncentivePlanOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2018_To_6_30_2018_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_WKzuvMhbXkaBU9jbXYBPQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2018_To_6_30_2018_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_vC6oKQwc_UO2IGuLtg5qng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_7_31_2019_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_TVxp6xaORUq6y8Ownz8CYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2016_To_7_31_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember__akggGl53kSTF7JP7JfRbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-07-01</xbrli:startDate><xbrli:endDate>2016-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2016_To_7_31_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_zIOfLPcoIE-WPja313LTug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-07-01</xbrli:startDate><xbrli:endDate>2016-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2016_To_7_31_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_2XwuCwQyq028NRrBWn-7FQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-07-01</xbrli:startDate><xbrli:endDate>2016-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2016_To_7_31_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_eVPwouvAqkSAUpm9iX0Giw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-07-01</xbrli:startDate><xbrli:endDate>2016-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2016_To_6_30_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_D0lxLn0JWU2EcDQaGVWl7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2016_To_6_30_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_L9F2_6Qez0Ox5Fm8qYePbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2016_To_6_30_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_R2nXzmWcpEusNX2tgETvVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2018_To_6_30_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_GfsaK8p46UWIkVJ17vp0wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2018_To_6_30_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_SZJ4LKIOuESQEpa0eW7EPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2016_To_6_30_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_yPcPm_5LjUyiK3NWPCSUmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_incy_JakaviMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_GNv-lY-ZsUCHv1M3VoVXPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JakaviMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_DevelopmentAndCommercializationMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_3WbzHyKMakilo4AxBzCjyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndCommercializationMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_DevelopmentAndCommercializationMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_y0tgn3-jJkylj0qNlXf4Ug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndCommercializationMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_uP4dhWDKFEyFnudcYGBOSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_Ndda4EOg1kixjWN0CSTfeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_iqotuIRBdEWR4e6oAi-V5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_incy_OlumiantRoyaltyMember_ub66w40qPUKCwKGhu43JRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:OlumiantRoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_incy_JakaviRoyaltyRevenuesMember_zns3wnT-Jk-Ya594Fpdi2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JakaviRoyaltyRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_incy_JakaviMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_b36l365IDEWlJXt_MSsqIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JakaviMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_incy_AchievementOfMilestoneAxis_incy_DevelopmentAndCommercializationMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_RxSzkAad5ES3uONix4NATw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndCommercializationMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_incy_AchievementOfMilestoneAxis_incy_DevelopmentAndCommercializationMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_d2Q6vESwZE6zC2NO5BBD8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndCommercializationMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_-8oLxMS1UkuCYQQOT0HLxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_801prtYWj0OCkCXY8rQvyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_zIkoXlOLU0qoXHFNAsPMOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_incy_OlumiantRoyaltyMember_hSkSbP1pFEi6wsQTwl0CLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:OlumiantRoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_incy_MilestoneAndContractRevenueMember_VtUC1dCVcEWIzn5Q-dz-vg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:MilestoneAndContractRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_incy_JakaviRoyaltyRevenuesMember_gEBfS3KRGEK69j70qm4oIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JakaviRoyaltyRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_incy_JAKAFIMember_J80BHp4_KUeJ-iOOK_2ieg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JAKAFIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_incy_ICLUSIGMember_zX4IHXitz0maYHqKIsHnOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:ICLUSIGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_Y69YgRfz7EyDDBkJJ9glfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_Bgm0Uqs6EEurpHztiTwV7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_CalitheraBiosciencesIncMember_ZVATcnAIO0GBu8wTwLvFPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_vi_h8M1GhkeTPwj2SVyuYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_fZaD2WqykkG-bcDt3R0hsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_us-gaap_TypeOfArrangementAxis_incy_CalitheraBiosciencesIncMember_gwhsiJOFE0CdmH4_ASRROw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2018_To_11_30_2018_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_epQaBen2_U6nG4Y4rp6zig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2018_To_9_30_2018_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_9FaYOW1DOUSCPsDwOUajaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_StockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_iPk_0s54fkWZRS_3UlzhOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_12_31_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_oWgSfS00vUW2MWLkfvZ1zg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_12_31_2017_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_wgLMqUpIOkW0LR2tv0blfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_3_31_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_4TeB7PMOikiSn1N2iwUlEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_us-gaap_RealEstatePropertiesAxis_incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember_vZQPIl3GOUCQvPfbSWPEeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RealEstatePropertiesAxis">incy:LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_OpaZX17-qki74dlsTGJgWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember_-A59uhU7lE2X3hkgLlOppQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_Uc4T8OoznUaWUBZFbSY_iQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_X2RaDJKM2UKzTQvrCqAeaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_Os6xIsQTJkSi8T8XKdZa9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_incy_OperatingLeaseRightOfUseAssetsMember_OnCRjgugL0CS9Eac1n0YMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">incy:OperatingLeaseRightOfUseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_incy_BuildingAndLeaseholdImprovementsMember_ip5R7-17nEmNlOU8G0fwCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">incy:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_Fz8X3N5MXEKKKq7aHQVBHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember_U4SkB6IAZkiT0rKLLkS3fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_VmJWm_2dZ0KLxA_TYtgIWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_H7HrVzI_zk64zWsiLLAWBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_BhUGXoa_EEGIKABq8Fc4Hg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_incy_OperatingLeaseRightOfUseAssetsMember_acMKMXWO1UmpzV7l3A0xFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">incy:OperatingLeaseRightOfUseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_incy_BuildingAndLeaseholdImprovementsMember_nfb1lKsHeUq_kOC7b4Hp-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">incy:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2018_To_7_31_2018_us-gaap_RealEstatePropertiesAxis_incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember_cI046B97zkCNRFIvPRRTaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RealEstatePropertiesAxis">incy:LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1-7nj5ASlkiVwC_JguIJwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_A8RojBoxM0mFmINTN2EuXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HPSBbAExTU2JCIrpO-YFvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_OmvX4naFCU2401ZLjrF4gQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_StockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_01Y2KuG7C02jQlyf-MJXhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmendedStockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_VTRtnBqUMkSsfHzFNQIj2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AmendedStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_7XMbCpbDnEewpK0mRNy-0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2017_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_3dQm43RaIU-3y4wKYTb_YA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_GxCCmVblq0aKTFevJZTWYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_RealEstatePropertiesAxis_incy_OfficeBuildingMorgesSwitzerlandMember_hyf9S0MCgUaWtQ2fty1E5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RealEstatePropertiesAxis">incy:OfficeBuildingMorgesSwitzerlandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_enm1IIwTxE685YL-VEfceg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_kOKA_UdywE2p7qUAsKbRXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_2_qilDUt-02bEAeGgk-4HA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_30_2017_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_V15b5Oo0-k2QDmXipNZJPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-01-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_incy_JAKAFIMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_28xwnjC9e0Sh55l-kRb2nQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JAKAFIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_incy_JAKAFIMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_BdI492nuSkutSDrwULb1hw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JAKAFIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_UHqTF8VUAUCGTkb1EXExuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_eOfQkKzKrUOycC233zEEKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_bwDrZo3Tr0aCPMmzLzjjyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_RmAbn78EhEiQanXoFkVVRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_4sLodCGvRUuTCXxu1AuBbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherComprehensiveIncomeMember_5oSPCzH0LUKKkaLwMadeGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_sIIh4iWJFk2a9UMIC24hHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_XFbZLyELLEuZAhhXTUaIyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_hK2vELdvC0qjgaQxW0SVXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherComprehensiveIncomeMember_9Lxk-PLyx0aRe3tPfUa9JQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_6HXkrhkugk2ANaoLx9Ffjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_t6V1l4OIi0umobNraJpO-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_suFOYxNDt0-4KUvHJ2smxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_JsVzHcwF3UShcd4mtCEitg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_Jr7vn9wY7EugrlmE7e-Utg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_9FgpIjXW30il90Hlca16_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_AAhSlo2yskG8eSk5D_7vWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_GSawLGXUJUqNCpQXIs29TA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_UX-Ls-ObqUaaxVRBpq4VvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmericanDepositarySharesMember_zDA5FKw7iUSQ77Y1CYtdhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AmericanDepositarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmendedStockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_6YWfGDEPXE2CImLh9b1dmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AmendedStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_1_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_StockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_h6YyQFHKjUOT_t4PglWApQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_1_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_e1m5T-pYtEOP3IlBt9OmFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_1_2017_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_0wbD4uybz0Kqy_sngxd94Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2016_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_zhQ6u7Eorky9JUrK75lg6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmericanDepositarySharesMember_1C9RFh6rfkulw5myLWBnDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AmericanDepositarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_3_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmericanDepositarySharesMember_p8hX0lYkjECSDquP0kv7_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AmericanDepositarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_8_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_StockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_q4yqPlQDMkKC2b9hPFXgEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_14_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_dBlEvdYnr0a8IGYwmA0VRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-02-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_23_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_KRP1zQuWsUCnd5bEiI4whg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-01-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_CUAHxIXboUW-AGQxTycjxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tgSRvrejHUqYFIu85rRsPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_uJymqcnIC0WuSGRiCrl9yQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_y8PVaaJJd06F0gOHPbgysg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_-W06vJqxfUKkm8FD3tX-XQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_incy_CorporateAndGovernmentDebtSecuritiesMember__FioQn-7xkq2Ihn7ogju8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">incy:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_incy_CorporateAndGovernmentDebtSecuritiesMember_ZlCggm6Ff0Wzf5NwRBQL8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">incy:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_mf1pSO_8xk-KJN_VOGoSlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">incy:ConvertibleSeniorNotes1.25PercentDue2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_dUhGX9pGs0KEez2XYOKNtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">incy:ConvertibleSeniorNotes1.25PercentDue2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_ByXHMCnwhUuLsKezaFFRag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">incy:ConvertibleSeniorNotes1.25PercentDue2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_Zx-v_c4r70WwWX03gqsXyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">incy:ConvertibleSeniorNotes1.25PercentDue2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_BIl-1RaM1EOPgs_KNzpbiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">incy:ConvertibleSeniorNotes1.25PercentDue2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_rppXeBwyn0KUPPFX6vCgDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">incy:ConvertibleSeniorNotes1.25PercentDue2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_RealEstatePropertiesAxis_incy_OfficeBuildingMorgesSwitzerlandMember_KrB3YVMc5UW_hq4utsVGBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RealEstatePropertiesAxis">incy:OfficeBuildingMorgesSwitzerlandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_srt_MajorCustomersAxis_incy_CustomerDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_incy_SalesRevenueGoodsServicesNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_jdQZkwbreEeOVODBdtyWjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">incy:SalesRevenueGoodsServicesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_srt_MajorCustomersAxis_incy_CustomerCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_incy_SalesRevenueGoodsServicesNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_-RMVb1Fvokicsqve2ojFBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">incy:SalesRevenueGoodsServicesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_srt_MajorCustomersAxis_incy_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_incy_SalesRevenueGoodsServicesNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_sJWHbHVE3k67_lQw54yY_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">incy:SalesRevenueGoodsServicesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_srt_MajorCustomersAxis_incy_CustomerAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_incy_SalesRevenueGoodsServicesNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Fqdfsibh4kKYy4vq1H2Aew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">incy:SalesRevenueGoodsServicesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_srt_MajorCustomersAxis_incy_CustomerABCAndDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_aIRqd3JLu0iLl9imB6WWgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerABCAndDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_srt_MajorCustomersAxis_incy_CollaborationPartneraBAndCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_qEwDHoxU_kykVFnagpQ7eg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CollaborationPartneraBAndCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_MajorCustomersAxis_incy_CustomerABCAndDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_nrSCSBku-kmb34bhbBHQUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerABCAndDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_MajorCustomersAxis_incy_CollaborationPartneraBAndCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_GNwwFEEnHkOgZF7ymHUW2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CollaborationPartneraBAndCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_srt_MajorCustomersAxis_incy_CustomerDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_incy_SalesRevenueGoodsServicesNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_AYtvU5JiEE2vyJD2GOHIpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">incy:SalesRevenueGoodsServicesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_srt_MajorCustomersAxis_incy_CustomerCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_incy_SalesRevenueGoodsServicesNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_eOhzoKcIP0OkJVjjz8gMLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">incy:SalesRevenueGoodsServicesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_srt_MajorCustomersAxis_incy_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_incy_SalesRevenueGoodsServicesNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_guuZvSOjo0u0KsbTuzRxeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">incy:SalesRevenueGoodsServicesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_srt_MajorCustomersAxis_incy_CustomerAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_incy_SalesRevenueGoodsServicesNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_f3XjwLwtRkSypl-ZsaWVPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">incy:SalesRevenueGoodsServicesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2019_dMCk6SsWm0OpwCR3K8OhEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_9ClNYpZejEWe3kBT1B-jvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_BusinessAcquisitionAxis_incy_AriadPharmaceuticalsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_LiabilityMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputCapRateMember_W3i3GxnCAEexsivT7-_BCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">incy:AriadPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputCapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_1_2016_us-gaap_BusinessAcquisitionAxis_incy_AriadPharmaceuticalsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_LiabilityMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_hQh32X0nE0CI4sShb6FASg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">incy:AriadPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_aaFIoA90rESC-8Dh21XUzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wmT2dRGShkmAkpk-MnUNQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_FinancialInstrumentAxis_incy_CorporateAndGovernmentDebtSecuritiesMember__EpAzA1tU0628uub7apmQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">incy:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FinancialInstrumentAxis_incy_CorporateAndGovernmentDebtSecuritiesMember_BpEuHfSwDE-2bwHlTacRhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">incy:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fokaHHGN_US8Vn_P7eshvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_O7zFu8UChUGSYYKQwC_Jgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vzfnNpXOk0-u4q-eKRYLuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_rGtntt3PoUmQLgQUufOvRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_YPDANAjNxES2dszn1Xx1jA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_SgUaszookkqnrXkDEDnurA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2018_us-gaap_RealEstatePropertiesAxis_incy_OfficeBuildingMorgesSwitzerlandMember_sv07bVwxFk-3b4wTy2XUvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RealEstatePropertiesAxis">incy:OfficeBuildingMorgesSwitzerlandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_ZCt4v5dz-02T3ZuSiZnehQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_HcQZwZd8o0Wvrjt6JjzvDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">incy:ConvertibleSeniorNotes1.25PercentDue2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_3H_O8pHEdkix4PC8ZgQ7Mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_2eLdjmLNS0eVWk19LxgYkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">incy:ConvertibleSeniorNotes1.25PercentDue2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ayQXfrU-kEqLMW5XKp3dOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_hdQWjmjVAUOoLAgOzPKlfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_SYkDX7ewnEi-fA1QMyfsXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember__KRsuuuxFUGHFrG9WcT73A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_HQ2dp39OO0S03M-igkKhPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_iAoPlqdY8EuohmWI9wvG1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_w-vcv_NpWkCA4qcaHLsFbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fWoGq7r2vk2UCLk0trvcdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_-OdiLY_HUEi_z6wHQe3vIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_-hgr7X57a0avQlFj1AvRPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_TDSLcpRho0W0O_zxs61WcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_WXNGj9bwXUmUHfhHKe1dLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_TypeOfArrangementAxis_incy_CalitheraBiosciencesIncMember_o_SL5702vkOgfJpisRbc3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_Gb1dDNbr-0mKUzuB4KREFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_CalitheraBiosciencesIncMember_ekerfwlyQkKKU2NodLZECQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_e8xNeuEtLkG3yuzAWXQPAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_8PlbTBxq-kmWb2R31MsmkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_cPCZt8ELeUSjKmzshHEhQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_1_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmericanDepositarySharesMember_y989uIAWJUij4EiffRDHoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AmericanDepositarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2018_To_7_31_2018_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_YelUbuNY80CUvf6lPtpuag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2014_To_1_31_2014_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_a4J1xme2j0qJI7w67u-8Kw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_VmhuMJCx8kyw979O9O77sA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_31_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_incy_LongTermIncentivePlanTwoMember_g0CLhct2S0K4vHe7Em2Zuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">incy:LongTermIncentivePlanTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-31</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_31_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_R6qfbt0g7UGmt1ZGgohMYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-31</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_7_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_xd5AG2VWVEOzpz4FkpHdOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_31_2019_To_3_31_2019_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_incy_LongTermIncentivePlanOneMember_10zMB4kxHUmiN5hoSzLWUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">incy:LongTermIncentivePlanOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-31</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2018_To_6_30_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_incy_LongTermIncentivePlanTwoMember_0cnSLqNMKkOiYjDFx0hr1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">incy:LongTermIncentivePlanTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2018_To_6_30_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_incy_LongTermIncentivePlanTwoMember_F_BDMjdwvUaazt5WAPM0pg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">incy:LongTermIncentivePlanTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2018_To_6_30_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_incy_LongTermIncentivePlanOneMember_DDOU9aUbe0qDsi2WsRXKrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">incy:LongTermIncentivePlanOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_AkK30_Ng-U2hTUpYkJOybQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_8g5N0q7JO0mkbsolYzXxgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_pOoZGDkfJUy5oibDwCrC8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_srt_ProductOrServiceAxis_incy_JAKAFIMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_mfwS80yn5ESSYPVY2L68BQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JAKAFIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_srt_ProductOrServiceAxis_incy_JAKAFIMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_2-_MOs2yjU-WWrny5byzXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JAKAFIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_1_31_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmendedStockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_XLcYraNHWEaKYbjk95TcKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AmendedStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_1_1_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_StockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_DgYpD_a5vUiEMdKdZb3MPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2017_To_2_1_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_tHZmzMoq7UOq_19LypjtHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-02-01</xbrli:startDate><xbrli:endDate>2017-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_1_31_2017_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_RlWLiTnNKk-MYynvIhAMbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2016_To_12_31_2016_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_AHacTrqe70OBJPlyv84qXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_incy_JakaviMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_3GwL6JL350ydhcQXwwZPzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JakaviMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_incy_JakaviMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_AVkAZtSlqUSKsew2Ua_8jg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JakaviMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_DevelopmentRegulatoryAndCommercializationMilestonesMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_incy_AgenusMember_NSPNOPBlrEe3WHqow3Mpyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentRegulatoryAndCommercializationMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:AgenusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_DevelopmentRegulatoryAndCommercializationMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_AgenusMember_7ArCsJGHDU6NWBPNa2r-7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentRegulatoryAndCommercializationMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:AgenusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_kBoYI7PVIk6voJvkwi61Vw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_AgenusMember_rKJqPM2Kx0uzwD7Q93bGZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:AgenusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2017_To_12_31_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_LuJpKL3-sUqsR3zx1Ui6ug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2017_To_12_31_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_Dn4atemmXECcuSaCHD3Xhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_1_31_2017_srt_RangeAxis_srt_MinimumMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_7nNpE5gl0kGtbk0copl0Ew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_1_31_2017_srt_RangeAxis_srt_MinimumMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_0jHvhxDIlEen-mp125RqxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_1_31_2017_srt_RangeAxis_srt_MaximumMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_-UyvIh_1dUGHPh1Oi-HZjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_1_31_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_jKF_MTXq-Em5r2YGQsjucw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_1_31_2017_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_incy_CalitheraBiosciencesIncMember_HQYolQnSwkG5T9dK1t91Ow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_1_31_2017_srt_RangeAxis_srt_MaximumMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_TmMtQTVRAEqEbpqiWMhMKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_incy_PhasesOfArrangementsAxis_incy_PhaseTwoBMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_hx8Gg9ss0k26kPkVIwC0gQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:PhasesOfArrangementsAxis">incy:PhaseTwoBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2010_To_7_31_2010_incy_PhasesOfArrangementsAxis_incy_PhaseTwoBMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_NfiO75iKBky-zhPH0mFJsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:PhasesOfArrangementsAxis">incy:PhaseTwoBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-07-01</xbrli:startDate><xbrli:endDate>2010-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2015_To_11_30_2015_us-gaap_TypeOfArrangementAxis_incy_AgenusMember_y0Dg-8kaqEy_VnxO63h4KA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:AgenusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-11-01</xbrli:startDate><xbrli:endDate>2015-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2015_To_1_31_2015_us-gaap_TypeOfArrangementAxis_incy_AgenusMember_1GF_BNYkFkelmcMuY5Dozw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:AgenusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_incy_InnoventBiologicsIncMember_dJHS72SJ40CyscATO6EB5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:InnoventBiologicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2009_To_12_31_2009_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_1SaePKedd0OWp_iIJJVHXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-12-01</xbrli:startDate><xbrli:endDate>2009-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2009_To_12_31_2009_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_F7owIWcWcESiFzYW1Mzbig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-12-01</xbrli:startDate><xbrli:endDate>2009-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2019_To_8_31_2019_us-gaap_TypeOfArrangementAxis_incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember_fTLP0rPirE6Sgn7TSP_gGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:CollaborationAndLicenseAgreementWithZaiLabLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_1_31_2019_us-gaap_TypeOfArrangementAxis_incy_InnoventBiologicsIncMember_C_ENlXJVxkyNDvDNsqx1-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:InnoventBiologicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2018_To_12_31_2018_incy_AchievementOfMilestoneAxis_incy_DevelopmentAndRegulatoryMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_InnoventBiologicsIncMember_REXXiwthXUuKAJa4ox8rdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:InnoventBiologicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2018_To_12_31_2018_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_InnoventBiologicsIncMember_cY50RxpP-U6RWVnyPyfrmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:InnoventBiologicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2016_To_4_30_2016_incy_AchievementOfMilestoneAxis_incy_DevelopmentAndRegulatoryMilestonesMember_srt_ProductOrServiceAxis_incy_GvhdMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_ZRB_EBm4DkyNeZO2LH5-Dg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:GvhdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-04-01</xbrli:startDate><xbrli:endDate>2016-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2009_To_12_31_2009_incy_AchievementOfMilestoneAxis_incy_RegulatoryMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_QW2Dt4PfxUSmygcBR82y9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-12-01</xbrli:startDate><xbrli:endDate>2009-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2009_To_12_31_2009_incy_AchievementOfMilestoneAxis_incy_PreSpecifiedEventsMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_4-WVfL6AnEGN9XUCN2Qzkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:PreSpecifiedEventsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-12-01</xbrli:startDate><xbrli:endDate>2009-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2009_To_12_31_2009_incy_AchievementOfMilestoneAxis_incy_DevelopmentMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_hql1KJZ8iU62EhDjjNk-sA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-12-01</xbrli:startDate><xbrli:endDate>2009-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2009_To_12_31_2009_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_2tauCzcC80iBzbGQiJbcgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-12-01</xbrli:startDate><xbrli:endDate>2009-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2009_To_11_30_2009_incy_AchievementOfMilestoneAxis_incy_RegulatoryMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_zksZlxX7L0aZmXvNApJ4Eg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-11-01</xbrli:startDate><xbrli:endDate>2009-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2009_To_11_30_2009_incy_AchievementOfMilestoneAxis_incy_PreSpecifiedEventsMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember__tZTD8Vmu0GW3hPdg82qeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:PreSpecifiedEventsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-11-01</xbrli:startDate><xbrli:endDate>2009-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2009_To_11_30_2009_incy_AchievementOfMilestoneAxis_incy_DevelopmentMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_wtKKfm2jZ0yM-1dlYFTMnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-11-01</xbrli:startDate><xbrli:endDate>2009-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2009_To_11_30_2009_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_MJwI5aFJqEO8pUKY2yAKBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-11-01</xbrli:startDate><xbrli:endDate>2009-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2009_To_11_30_2009_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_A9wnHAKOPUiEb-WirPUvYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-11-01</xbrli:startDate><xbrli:endDate>2009-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_rHTnGuemnUagNxNCaIIsSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2019_To_8_31_2019_incy_AchievementOfMilestoneAxis_incy_DevelopmentRegulatoryAndCommercialMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember_2LertgtXmUSbLU3ewDQkAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentRegulatoryAndCommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:CollaborationAndLicenseAgreementWithZaiLabLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_1_31_2018_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_e3Og2WQPREynUroSL3ThVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2017_To_12_31_2017_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_Pvqu3UdMtESm4jPlRmjNxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2017_To_2_28_2017_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_j9-fB82mM0aKB0lMVFtkDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-02-01</xbrli:startDate><xbrli:endDate>2017-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_12_31_2017_incy_AchievementOfMilestoneAxis_incy_DevelopmentMilestonesMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_uSeThvtWXUGOcm74qPJaSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2016_To_3_31_2016_srt_ProductOrServiceAxis_incy_GvhdMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_Vfkt7ZI1EUi8hMQs6ojgVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:GvhdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_7z6twVQHkkaobzJI5jhU7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_Bx9b-kfxkUS7NmglDo36lw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember_71IYyLEOk0qtHTwC9gMr2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:CollaborationAndLicenseAgreementWithZaiLabLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_VI1jInirZE-TkdoXTr7aBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_ZvhiClZSVke50DoQFEthjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_InnoventBiologicsIncMember_ur26l_EwbEWNuQbgjhG5pw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:InnoventBiologicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember_IqSk84yaxE-JJvKAc06yPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:CollaborationAndLicenseAgreementWithZaiLabLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_QXsD9niNL0WfkNO0BEluBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_TypeOfArrangementAxis_incy_InnoventBiologicsIncMember_CDr03ADEikqqqKMjVIsLzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:InnoventBiologicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2017_us-gaap_TypeOfArrangementAxis_incy_CalitheraBiosciencesIncMember_q6cjALmpG0eNfLyGFfZJcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_dei_LegalEntityAxis_incy_IncyteMember_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_Hko43zDhUECuypoYAgazng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">incy:IncyteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_1_31_2020_srt_CounterpartyNameAxis_incy_MorphosysAgMember_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_6F3K0RN-oUSX6n5Ve-1LHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">incy:MorphosysAgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_1_31_2020_dei_LegalEntityAxis_incy_IncyteMember_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_joVwB0DtIkOe9vuko8XrMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">incy:IncyteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_1_31_2017_us-gaap_TypeOfArrangementAxis_incy_CalitheraBiosciencesIncMember_k20QIDKWZ0Cx-yYlqJ-TBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_1_31_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_a6vIFrPYNUSTq51uQB6cnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2019_To_5_31_2019_incy_AchievementOfMilestoneAxis_incy_RegulatoryMilestonesMember_srt_ProductOrServiceAxis_incy_GvhdMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_wl45rQuyWUeKj9KE8YrNQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:GvhdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-01</xbrli:startDate><xbrli:endDate>2019-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2017_To_3_31_2017_us-gaap_TypeOfArrangementAxis_incy_CalitheraBiosciencesIncMember_Ms1l2DuiH0iX52Fe8ib4bw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_1_31_2017_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_7k2NhRIKp0uBjo2oHVvL-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2010_To_1_31_2010_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_D9O6EwtrQ063PpAtibslDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-01-01</xbrli:startDate><xbrli:endDate>2010-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2019_To_6_30_2019_incy_AchievementOfMilestoneAxis_incy_RegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_InnoventBiologicsIncMember_FsIzv8L_HEi55lLcoBwVbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:InnoventBiologicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_ProductOrServiceAxis_incy_JakaviMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_VTtBfVOpYEyYEfKARlTg8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JakaviMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_incy_AchievementOfMilestoneAxis_incy_RegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_IgQggmnvRkCC-yAC7hkMdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_incy_AchievementOfMilestoneAxis_incy_DevelopmentMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_4R2bbsjbu02S1SWTGCefdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_12_31_2017_incy_AchievementOfMilestoneAxis_incy_DevelopmentMilestonesMember_incy_PhasesOfArrangementsAxis_incy_PhaseThreeMember_srt_ProductOrServiceAxis_incy_GvhdMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_PHAppsJyCU6_gL715nvt8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="incy:PhasesOfArrangementsAxis">incy:PhaseThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:GvhdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_12_31_2017_incy_AchievementOfMilestoneAxis_incy_RegulatoryMilestonesMember_srt_StatementGeographicalAxis_srt_EuropeMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_X2hC_LIgGkysVkbfF6pqAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_12_31_2017_incy_AchievementOfMilestoneAxis_incy_RegulatoryMilestonesMember_srt_StatementGeographicalAxis_country_JP_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_uTR5OD0KnkKmPCLLZ5hQIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_12_31_2017_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_ProductOrServiceAxis_incy_JakaviMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_5B46pCgC4U6TcjzvVo1wJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JakaviMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_12_31_2017_incy_AchievementOfMilestoneAxis_incy_DevelopmentMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_54PH53-4h0mdJxINNUsslA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2014_To_9_30_2014_incy_AchievementOfMilestoneAxis_incy_RegulatoryMilestonesMember_srt_ProductOrServiceAxis_incy_JakaviMember_srt_StatementGeographicalAxis_srt_EuropeMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_-D5iCFjOtEOHLfhUWXsfAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JakaviMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-09-01</xbrli:startDate><xbrli:endDate>2014-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2009_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_RegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_POZKRL4X4UeOibd7iQ44iQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-12-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2009_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_DevelopmentMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_lSHmlJZy7kyXkEGNGXcb4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-12-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2009_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_RegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_Y2Gx6SWIbEqR4hwAGpSZ5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-11-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2009_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_DevelopmentMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_9-Pn4E2E_kSLd-r3M4EQbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-11-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2009_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_C1OZWHg3g0uldVYjrprkFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-11-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2020_incy_AchievementOfMilestoneAxis_incy_DevelopmentAndRegulatoryMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_w44LObNwjk6l_m4tp62jQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2020_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_738l7WGg-UO8nbsLnaCpFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_incy_AchievementOfMilestoneAxis_incy_DevelopmentMilestonesMember_srt_ProductOrServiceAxis_incy_TIM3ProgramMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_3cWnTNEGHkS-bqHYm75tQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:TIM3ProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_incy_AchievementOfMilestoneAxis_incy_DevelopmentMilestonesMember_srt_ProductOrServiceAxis_incy_LG3ProgramMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_LEDpSv7x-UqhAEU0sms69Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:LG3ProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2018_incy_AchievementOfMilestoneAxis_incy_DevelopmentAndRegulatoryMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_bojg3Cpm70KP1ASJ64IbcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2018_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_ggAKdTjZ60mONUG4Cc9HQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2017_incy_AchievementOfMilestoneAxis_incy_DevelopmentAndRegulatoryMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_1gx5QmF1QESvqesUmo91qw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2017_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_h51PWrAxiUSRzPvrkcOO8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2017_incy_AchievementOfMilestoneAxis_incy_DevelopmentRegulatoryAndCommercializationMilestonesMember_srt_RangeAxis_srt_MaximumMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_kP1dVDRyl0aHr25XhcLREg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentRegulatoryAndCommercializationMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2017_incy_AchievementOfMilestoneAxis_incy_DevelopmentAndRegulatoryMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_3qBhaaUHQU-hsgEJZZLSGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2017_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_wXhYzKmk30i4bB1talomPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2016_srt_ProductOrServiceAxis_incy_GvhdMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_Sd04Ae5b5U6RhSen8O3xGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:GvhdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_incy_JAKAFIMember__fw2KcDlhEK50BfPWrKV_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JAKAFIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_incy_ICLUSIGMember_YO1pSkx-YU6EMn97oz0Vig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:ICLUSIGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2019_us-gaap_RealEstatePropertiesAxis_incy_OfficeBuildingMorgesSwitzerlandMember_cTCu8-DdLUWDnNq9pv0w3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RealEstatePropertiesAxis">incy:OfficeBuildingMorgesSwitzerlandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2016_To_6_1_2016_us-gaap_BusinessAcquisitionAxis_incy_AriadPharmaceuticalsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_LiabilityMember_-BGrwF-qIkuMeVQ7qNEL5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">incy:AriadPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-06-01</xbrli:startDate><xbrli:endDate>2016-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_3_2020_To_3_3_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmericanDepositarySharesMember_rB3V8pH9lUCWt7qCtdhL8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AmericanDepositarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-03</xbrli:startDate><xbrli:endDate>2020-03-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_8_2018_To_1_8_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_StockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_omIR3ZvvjkKFbSUFw_JzGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-08</xbrli:startDate><xbrli:endDate>2018-01-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_14_2017_To_2_14_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_imIGDtobsUmd4lo8UPrzlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-02-14</xbrli:startDate><xbrli:endDate>2017-02-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_23_2017_To_1_23_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_0W47ULyywE66YQ7w30K3tQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-23</xbrli:startDate><xbrli:endDate>2017-01-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member_MP4cDjTkq06lAGevzdzYBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">incy:ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2020_To_3_31_2020_PdzkVcZmpESGdHSRd_l9Vw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_30_2017_To_1_30_2017_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_6yzhytojOUW72tF5DhREcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-30</xbrli:startDate><xbrli:endDate>2017-01-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_1_31_2017_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_ziZW_6Itd0mRiuWAvHmhMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_-V355oZpTEGL8BHgB8JTrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_XgR3Kyb9BUuL8DSnhdbM0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_BalanceSheetLocationAxis_incy_AccruedAndOtherCurrentLiabilityMember_us-gaap_BusinessAcquisitionAxis_incy_AriadPharmaceuticalsMember_eNBdRdYCsk2AT0YapnXIQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">incy:AccruedAndOtherCurrentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">incy:AriadPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_BalanceSheetLocationAxis_incy_AccruedAndOtherCurrentLiabilityMember_us-gaap_BusinessAcquisitionAxis_incy_AriadPharmaceuticalsMember_Rx_uiVSjYEmmn41tyR4osA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">incy:AccruedAndOtherCurrentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">incy:AriadPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_DbVOFfn2yECjfpwbXtOkuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_28_2020__qchIpXJpESyCkG1opGDWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_segment_jI2Df57rGUiaWugJ41i_Hg"><xbrli:measure>incy:segment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_instrument_X67SygLtqEeZMZZtTj-6RQ"><xbrli:measure>incy:instrument</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_issuer_ywviBYfRh0KpQHOu97pP7g"><xbrli:measure>incy:issuer</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_4BIkJQxqZkOMHOIGydcttw"><xbrli:measure>incy:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_sqft_EcjTExigKk28_NSPhmR_FQ"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_EUR_4KUDkHZ-F0yLQi_l9X6Oxg"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_a5ohNrB_5EyyFWGwZ6Bp_Q_24_6" toRefs="_c9570017_4a29_4e55_9a03_0f1ff68137e8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc__Q4cAi7CLEqE685HxQZrBA_7_6" toRefs="_c9570017_4a29_4e55_9a03_0f1ff68137e8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_zdRH3cfB0EmnrBFFKDc9dg_27_6" toRefs="_c9570017_4a29_4e55_9a03_0f1ff68137e8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_PlsYpJAIuE6KJU9P-Jf3Yw_42_6" toRefs="_c9570017_4a29_4e55_9a03_0f1ff68137e8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_c8L6yPRPEUC8H_B5VSapDQ_41_6" toRefs="_c9570017_4a29_4e55_9a03_0f1ff68137e8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_BUeeFiw5Ckut-I6C_gVPRQ_20_6" toRefs="_c9570017_4a29_4e55_9a03_0f1ff68137e8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc__MmdO33ZVUeSQzItX2z2Jg_10_6" toRefs="_c9570017_4a29_4e55_9a03_0f1ff68137e8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_Fu1im2pBBUiJ7wkCrYnA3A_6_6" toRefs="_c9570017_4a29_4e55_9a03_0f1ff68137e8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_DLg7M2GV3E-urgYITOjCRg_30_6" toRefs="_c9570017_4a29_4e55_9a03_0f1ff68137e8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_wUmYM7gVikiUMMpr1iCtvQ_33_6" toRefs="_c9570017_4a29_4e55_9a03_0f1ff68137e8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_1R6JqLKHeUKe5p6pBSqHQw_5_6" toRefs="_c9570017_4a29_4e55_9a03_0f1ff68137e8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_XhCxSyAePU2EM_yM-GM1VA_40_6" toRefs="_c9570017_4a29_4e55_9a03_0f1ff68137e8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_XUvA6ZO9nUaVao0bSM54wA_29_6" toRefs="_c9570017_4a29_4e55_9a03_0f1ff68137e8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_iiNzPQ3oRkGjQm8ezmHxFw_25_6" toRefs="_c9570017_4a29_4e55_9a03_0f1ff68137e8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_Ub3Aii55Skqo4R4y6lscqg_28_6" toRefs="_c9570017_4a29_4e55_9a03_0f1ff68137e8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_gAYiIHyfn0e7WfvlHupmLg_34_6" toRefs="_c9570017_4a29_4e55_9a03_0f1ff68137e8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_MA46kpgz80e5rQC71pZaow_16_6" toRefs="_c9570017_4a29_4e55_9a03_0f1ff68137e8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_UKZZluQUzkylaZpeYQ7Ubg_18_6" toRefs="_c9570017_4a29_4e55_9a03_0f1ff68137e8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_d7F91iwAoUOZJlHXIhwhvA_26_6" toRefs="_c9570017_4a29_4e55_9a03_0f1ff68137e8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_XhrcmoFpvUStqrhrIbji6A_8_6" toRefs="_c9570017_4a29_4e55_9a03_0f1ff68137e8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_tegNf856j0G9fqa17Rp90Q_14_6" toRefs="_c9570017_4a29_4e55_9a03_0f1ff68137e8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_YrbwcyBevUmVYnmfBmOVBA_36_6" toRefs="_c9570017_4a29_4e55_9a03_0f1ff68137e8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_pGJuowBCK02IV8uC5OqDug_45_6" toRefs="_c9570017_4a29_4e55_9a03_0f1ff68137e8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_AcvH1yHODkm7W7kMpvCnWA_31_6" toRefs="_c9570017_4a29_4e55_9a03_0f1ff68137e8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_ntl_TJoRok2kvgilDz5AQQ_13_6" toRefs="_c9570017_4a29_4e55_9a03_0f1ff68137e8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_ln4GC3egGUipgSru4CVulQ_19_6" toRefs="_c9570017_4a29_4e55_9a03_0f1ff68137e8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_gv7DZ6WyZEymq5cyVQQwbA_17_6" toRefs="_c9570017_4a29_4e55_9a03_0f1ff68137e8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_9NYaJZa-M0C39_pKeh_zIA_35_6" toRefs="_c9570017_4a29_4e55_9a03_0f1ff68137e8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Hidden_00WskpThfUe7BGq8TEau6Q" toRefs="_c9570017_4a29_4e55_9a03_0f1ff68137e8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_gwKKyn1Wr0WkIPsoFWzsyg_9_6" toRefs="_c9570017_4a29_4e55_9a03_0f1ff68137e8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_02jLG0GJmU2xrTW1J5qO1g_15_6" toRefs="_c9570017_4a29_4e55_9a03_0f1ff68137e8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_vcYuBQQlAE631jPaw96jNg_12_6" toRefs="_c9570017_4a29_4e55_9a03_0f1ff68137e8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_ljSkJ9leEUupHlFP7dQgdA_43_6" toRefs="_c9570017_4a29_4e55_9a03_0f1ff68137e8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_OF2q213bxkis1OQGk_1quw_44_6" toRefs="_c9570017_4a29_4e55_9a03_0f1ff68137e8" order="1"></ix:relationship></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;min-height:5.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="color:#ff0000;font-size:11pt;font-weight:bold;"> </b><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="background-color:#00ff00;font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:2pt;text-align:center;margin:0pt;"><span style="font-size:2pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_f0f5e0ef_2c2f_463f_8dae_9dff9e4154ca"></a><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:17pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="dei:DocumentType" id="Narr_gu_d017hq0mss4rZF2ln_Q"><b style="font-weight:bold;">10-Q</b></ix:nonNumeric></p><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (Mark One)</b></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:11pt;margin-bottom:6pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="dei:DocumentQuarterlyReport" id="Narr_w8YCPza3mkqBr-enLt48Rw"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman';font-size:11pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">For the quarterly period ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="dei:DocumentPeriodEndDate" id="Narr_LMV4xUpzekeQpVV10YavEg"><b style="font-size:9pt;font-weight:bold;">March 31, 2020</b></ix:nonNumeric></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">or</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:11pt;margin-bottom:6pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="dei:DocumentTransitionReport" id="Narr_kT2aYn05bEmv8yRN_1qTOg"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman';font-size:11pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">Commission File Number: </b><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="dei:EntityFileNumber" id="Narr_75Bn7-_7dEGMMfr8cBiYPw"><b style="font-size:9pt;font-weight:bold;">001-12400</b></ix:nonNumeric></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:17pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="dei:EntityRegistrantName" id="Narr_sVvaknkCO0qBw88ef2K0yg"><b style="font-weight:bold;">INCYTE CORP</b></ix:nonNumeric><b style="font-weight:bold;">ORATION</b></p><p style="font-family:'Times New Roman';font-size:9pt;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><a id="_0e75be8a_8de4_414e_82bf_7f3aab63dcee"></a><a id="Tc_oNyfVzm8r06bgvScvGP39Q_2_0"></a><a id="Tc_RL4I_cGxQUidnpYwIO1mew_2_2"></a><a id="Tc_ji-AoSnCrU2bGj3ivDI0pA_4_0"></a><a id="Tc_5AQt3uVdvEybJD_qfM5Cuw_5_0"></a><a id="Tc_wU4MD95bsUi2jYdOo_qbxQ_5_2"></a><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="dei:EntityIncorporationStateCountryCode" id="Tc_EX_o2ULuA02oJRxGYvt79A_1_0"><b style="font-size:9pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="dei:EntityTaxIdentificationNumber" id="Tc_PB1_a3BZg0Cjs3Ar10-cLA_1_2"><b style="font-size:9pt;font-weight:bold;">94-3136539</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:center;margin:0pt;">(State or other jurisdiction of<br />incorporation or organization)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:center;margin:0pt;">(IRS Employer<br />Identification No.)</p></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="dei:EntityAddressAddressLine1" id="Narr_tfF5wn9yqk6hOA4VmDDaoQ"><b style="font-size:9pt;font-weight:bold;">1801 Augustine Cut-Off</b></ix:nonNumeric></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="dei:EntityAddressCityOrTown" id="Narr_Vq-rLobz00G-3shb6DP0hw"><b style="font-size:9pt;font-weight:bold;">Wilmington</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="dei:EntityAddressStateOrProvince" id="Narr_afwbFSGwKUOP81diH2070w"><b style="font-size:9pt;font-weight:bold;">DE</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;white-space:pre-wrap;">  19803</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="dei:EntityAddressPostalZipCode" id="Tc_2wjOYxf95Eq3dPHmT9xkUA_4_2"><b style="font-size:9pt;font-weight:bold;">19803</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:center;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="dei:CityAreaCode" id="Narr_wyNbCPUAvkOz5Ew__XSMVg"><b style="font-size:9pt;font-weight:bold;">302</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="dei:LocalPhoneNumber" id="Narr_bfU6JdWSBkuiRRU_WWHm0A"><b style="font-size:9pt;font-weight:bold;">498-6700</b></ix:nonNumeric></p><p style="font-family:'Times New Roman';font-size:9pt;text-align:center;margin:0pt;">(Registrant&#8217;s telephone number, including area code)</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:9pt;text-align:center;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_61e2aa6b_5052_443b_8822_a480c06feace"></a><a id="Tc_B42-butkGEmusHPdVX8hAQ_2_0"></a><a id="Tc_LfJvw6zjO0GDPIVrJSWYcg_2_2"></a><a id="Tc_Fkie2L2Y30qvkZZIdYg8YQ_2_3"></a><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:32.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:32.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:32.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:32.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:32.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Title of each class</b></p></td><td style="vertical-align:top;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:32.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Trading Symbol(s)</b></p></td><td style="vertical-align:bottom;width:32.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Name of exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:32.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="dei:Security12bTitle" id="Tc_0wDq-TDQykyqzRyTBG-NSQ_3_0"><span style="font-size:8pt;">Common Stock, $.001 par value per share</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="dei:TradingSymbol" id="Tc_jdK3Y9AzbEa0C42TlDejKQ_3_2"><span style="font-size:8pt;">INCY</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:32.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="dei:SecurityExchangeName" id="Tc_DaczpX5gh02BnZrU4wFoIQ_3_3"><span style="font-size:8pt;">The Nasdaq Stock Market&#160;LLC</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span><span style="font-size:9pt;">&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="dei:EntityCurrentReportingStatus" id="Narr_DMfoB8LzXEaS0HVDIQWKBg"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span><span style="font-size:9pt;">&#160;No</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span><span style="font-size:9pt;">&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="dei:EntityInteractiveDataCurrent" id="Narr_0q3guYXfBUWXfkLEkxnfrQ"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span><span style="font-size:9pt;">&#160;No</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:9pt;text-align:justify;text-indent:18pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. &#160;See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="dei:EntityFilerCategory" id="Narr_bbC9_KsHdEK9U_HRAK6owQ"><span style="font-size:9pt;">Large accelerated filer</span></ix:nonNumeric><span style="font-size:9pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:center;margin:0pt;">Accelerated filer&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:center;margin:0pt;">Non-accelerated filer&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">Smaller reporting company&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="dei:EntitySmallBusiness" id="Narr_TXSFOr7XUUm0f1f2SCi7Dg"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;text-decoration:line-through;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12.25pt;"><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">Emerging growth company </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="dei:EntityEmergingGrowthCompany" id="Narr_nnkix5uG6U-B6-yaLefmUQ"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:9pt;text-indent:18pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="dei:EntityShellCompany" id="Narr__IsjIRowV0iMPyY_d5FHuA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;Yes&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span><span style="font-size:9pt;">&#160;No</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:9pt;text-align:justify;text-indent:18pt;margin:0pt;">The number of outstanding shares of the registrant&#8217;s Common Stock, $.001 par value, was <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_4_28_2020__qchIpXJpESyCkG1opGDWA" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_MJlnNGm9uUeeOD7Guif_ag">217,373,454</ix:nonFraction> as of April 28, 2020.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman';font-size:0pt;visibility:hidden;">&#8203;</span></p><a id="_a8e9c7c0_ff93_4e90_8d54_24e8a6817d84"></a></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Toc"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">INCYTE CORPORATION</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">INDEX</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">0</b></p></div></div></td><td style="vertical-align:top;width:79.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:87.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><a href="#PARTIFINANCIALINFORMATION_409298"><b style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">PART I</b></a><b style="font-weight:bold;">: </b><a href="#PARTIFINANCIALINFORMATION_409298"><b style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">FINANCIAL INFORMATION</b></a></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_80970"><b style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item&#160;1.</b></a></p></td><td style="vertical-align:top;width:79.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_80970"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Financial Statements</span></a></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDBALANCESHEETS_705037"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Balance Sheets</span></a></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFOPERATIONS_82706"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Statements of Operations</span></a></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><a href="#COMPREHENSIVEINCOMELOSS_470527"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Statements of Comprehensive Income (Loss)</span></a></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDSTOCKHOLDERSEQUITY"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></a></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><a href="#CASHFLOWS_761754"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Statements of Cash Flows</span></a></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><a href="#NOTESTOCONDENSEDCONSOLIDATEDFINANCIALSTA"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Notes to Condensed Consolidated Financial Statements</span></a></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">8</p></td></tr><tr><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysis_93"><b style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item 2.</b></a></p></td><td style="vertical-align:top;width:79.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysis_93"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">38</p></td></tr><tr><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><b style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item 3.</b></a></p></td><td style="vertical-align:top;width:79.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Quantitative and Qualitative Disclosures about Market Risk</span></a></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">66</p></td></tr><tr><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_75416"><b style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item 4.</b></a></p></td><td style="vertical-align:top;width:79.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_75416"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Controls and Procedures</span></a></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">66</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:87.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:87.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><a href="#PARTIIOTHERINFORMATION_534946"><b style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">PART II</b></a><b style="font-weight:bold;">: </b><a href="#PARTIIOTHERINFORMATION_534946"><b style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">OTHER INFORMATION</b></a></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:87.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_692185"><b style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item 1A.</b></a></p></td><td style="vertical-align:top;width:79.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_692185"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Risk Factors</span></a></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">67</p></td></tr><tr><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_714670"><b style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item 6.</b></a></p></td><td style="vertical-align:top;width:79.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_714670"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Exhibits</span></a></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">92</p></td></tr><tr><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_656357"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Signatures</span></a></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">93</p></td></tr><tr><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_548fb4b3_fa3b_4790_a515_1be525180e60"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:36.9pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PARTIFINANCIALINFORMATION_409298"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"><b style="font-weight:bold;">PART&#160;I:&#160;&#160;&#160;&#160;FINANCIAL INFORMATION</b></p><a id="Item1FinancialStatements_80970"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"><b style="font-weight:bold;">Item 1.&#160;&#160;&#160;&#160;Financial Statements</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:5pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">INCYTE CORPORATION</b></p><a id="CONSOLIDATEDBALANCESHEETS_705037"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONDENSED CONSOLIDATED BALANCE SHEETS</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands, except number of shares and par value)</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_d58638d4_a734_48aa_a8e1_e6764399baaf"></a><a id="Tc_9fx0z1XgmEaTOY9hPEpP-g_1_2"></a><a id="Tc_Z2oT8sGYBEWcGdJWsWMTaw_1_5"></a><a id="Tc_0USV84UQVU2iyjuw5Qz2yg_2_2"></a><a id="Tc_zwgNuNHuj0aZPSKFAjNIPQ_2_5"></a><a id="Tc_PoDlAMGCLECaFXQuu0mUEA_3_0"></a><a id="Tc_UoKuv-lCdECkuMriKOtBeg_4_0"></a><a id="Tc_G7laIU62d0-uJeqLUAJw4Q_5_0"></a><a id="Tc_luKMBHxX1kK-c7NI1XL49A_5_2"></a><a id="Tc_fASUSjScJEeK-Vnuqat2fw_5_5"></a><a id="Tc_nf7ksAxrPEWDyHvevNXsEQ_6_0"></a><a id="Tc_vQqnhSUXAUOpjLr6eQhOYw_7_0"></a><a id="Tc_cwczcP6DrEGFZJ4DbgfJyA_8_0"></a><a id="Tc_U91yoNxbb0-PlL6pozqtwQ_9_0"></a><a id="Tc_xjDBxRaAcE-MjK7aqOobJw_10_0"></a><a id="Tc_aoRMnIuJrU6mlmPICCYRTw_12_0"></a><a id="Tc_XEzl23Wk2k2abcfoVdRPJA_13_0"></a><a id="Tc_cjT605ubJ02i9XFpCKrDzg_14_0"></a><a id="Tc_WbL7g16OmUC8P-ObfI37kA_15_0"></a><a id="Tc_6plSaj4AvEC5ZloRajrKCw_16_0"></a><a id="Tc_unWvto70IUmfyGRHku7wHQ_17_0"></a><a id="Tc_Co_ikBX-FUuYZjmfrbRXyA_18_0"></a><a id="Tc_Y945pUVfMUCJsdphjNEn_g_19_0"></a><a id="Tc_KngUTC3wbkWPaMjOxLWljQ_20_0"></a><a id="Tc_-1sK48MBckCKOcFlw-JmSA_20_2"></a><a id="Tc_22dMT1K29ECMv0mRP9CpqA_20_5"></a><a id="Tc_uwOwqOePPUqVkhWXD1V_hQ_22_0"></a><a id="Tc_z-1cgGzDhk2BBtDeXJyTww_23_0"></a><a id="Tc_vbkOtWyMnUeUHNZIAPb1sw_24_0"></a><a id="Tc_Xo1FgmrkakS3h0YsA3jrqw_24_2"></a><a id="Tc_i_jzxiOHwUi0UU-VPidvig_24_5"></a><a id="Tc_PjiyRff6TUmwrO42gFH7VQ_25_0"></a><a id="Tc_muQZpzADNUCgipafyAwc8g_26_0"></a><a id="Tc_fa1P7882K0eYvhYNszd8XQ_27_0"></a><a id="Tc_JeKpCUgKJk2x_oXWy_WwSg_28_0"></a><a id="Tc_w6M_Ia5trkKt0jSRi5FZww_29_0"></a><a id="Tc_VMQhgMSQjU2NXcxtCZCnkg_30_0"></a><a id="Tc_vE6B6T2F30m7atOUizdDlg_31_0"></a><a id="Tc_HLv1amOx7ESWGYjoJXdBIw_33_0"></a><a id="Tc_M3_DbpbDz0StBXEhj6jnhg_34_0"></a><a id="Tc_Kg19qkkOyE6mwxe2NjkCzA_35_0"></a><a id="Tc__5iZ4LiqtUa4vP4ftE6VUA_36_0"></a><a id="Tc_tmQkopz2jUuZ2UmIDOUfKw_38_0"></a><a id="Tc_cUAyYeOTjU-gkgJMiM_szQ_39_0"></a><a id="_a97f8da5_8a91_4c5a_a195_b88b5305a993"></a><a id="_a97f8da5_8a91_4c5a_a195_b88b5305a993_2"></a><a id="_a97f8da5_8a91_4c5a_a195_b88b5305a993_3"></a><a id="Tc_mhWt2XZNc0uB_huDwJSiBQ_40_0"></a><a id="Tc_ZHwbUFe62UibLrGv7wb2Xg_41_0"></a><a id="Tc_8uGJeYUzo0iPSuZUiYNVmQ_42_0"></a><a id="Tc_LKkaoGFiPE62ImK_Z3Dqtg_43_0"></a><a id="Tc_d91ZQiOhJ06-7aF1OkKQIQ_44_0"></a><a id="Tc_fbLxVBLRHEaxgFZ5N2Q4Wg_45_0"></a><a id="Tc_iJcTZNsQt0yDd3NHLN9HBw_45_2"></a><a id="Tc_uxYVnXBpAkeWg4DNmficrg_45_5"></a><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019*</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_e5RHz7blWE-x-1Hi0oC9Kw_5_3">1,043,241</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_1R6JqLKHeUKe5p6pBSqHQw_5_6">1,832,684</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 24.75pt 0pt 12pt;">Marketable securities&#8212;available-for-sale (amortized cost <span style="-sec-ix-hidden:Hidden_GNLsXbAN4UCKMgqU4Rhibg"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$258,622;</span></span> allowance for credit losses $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="3" id="Narr_bjJj1lBz4024CsZtNZuDng">0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="Tc_BSuXgp4u8UO4APyQ0UjXUA_6_3">259,351</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="Tc_Fu1im2pBBUiJ7wkCrYnA3A_6_6">284,870</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts receivable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNet" scale="3" id="Tc_fq5GIWcmokCNWc2_uylf2w_7_3">351,522</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNet" scale="3" id="Tc__Q4cAi7CLEqE685HxQZrBA_7_6">308,809</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_uLg1lMVr30yiKmGSCtckzQ_8_3">13,977</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_XhrcmoFpvUStqrhrIbji6A_8_6">11,400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Prepaid expenses and other current assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_q4-SKzILMkuz_SpJejoCDQ_9_3">48,078</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_gwKKyn1Wr0WkIPsoFWzsyg_9_6">43,725</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_U4oarbLW1U6KpBASOWjCXw_10_3">1,716,169</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc__MmdO33ZVUeSQzItX2z2Jg_10_6">2,481,488</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Restricted cash and investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndInvestmentsNoncurrent" scale="3" id="Tc_j8e5pg7OkUS0Qhpw0RFAcg_12_3">2,548</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndInvestmentsNoncurrent" scale="3" id="Tc_vcYuBQQlAE631jPaw96jNg_12_6">1,023</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Long term investments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="3" id="Tc_HASaQSqiikq4TTHhFOLxkw_13_3">180,993</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="3" id="Tc_ntl_TJoRok2kvgilDz5AQQ_13_6">133,657</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="3" id="Tc_gW0lge5_mk2jAyfxk23WQA_14_3">8,240</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="3" id="Tc_tegNf856j0G9fqa17Rp90Q_14_6">5,105</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_xZhops2Pj0i9A3cdUGk4Gg_15_3">410,034</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_02jLG0GJmU2xrTW1J5qO1g_15_6">377,567</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Finance lease right-of-use assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="Tc__PrjYcWpnES--hQk1FU0RA_16_3">28,622</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="Tc_MA46kpgz80e5rQC71pZaow_16_6">29,058</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Other intangible assets, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherIntangibleAssetsNet" scale="3" id="Tc_Zr9K-gTEzEyuxY6R95YgTA_17_3">188,444</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherIntangibleAssetsNet" scale="3" id="Tc_gv7DZ6WyZEymq5cyVQQwbA_17_6">193,828</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="Tc_ji4xP8lnyEGBg4mWLo44xg_18_3">155,593</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="Tc_UKZZluQUzkylaZpeYQ7Ubg_18_6">155,593</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Other assets, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_YnXWNdLrbkKP3M6gU__l2Q_19_3">61,779</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_ln4GC3egGUipgSru4CVulQ_19_6">49,431</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_bhJVu9QL1UqEi2hYHTJ5Pg_20_3">2,752,422</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_BUeeFiw5Ckut-I6C_gVPRQ_20_6">3,426,750</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Current liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_77ckIicxGkiDCahn_Yw7tA_24_3">60,937</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_a5ohNrB_5EyyFWGwZ6Bp_Q_24_6">83,647</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accrued compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_4EoZVKwF5UeBKH818FH3ug_25_3">57,779</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_iiNzPQ3oRkGjQm8ezmHxFw_25_6">90,706</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Interest payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPayableCurrent" scale="3" id="Tc_vG5WS98oUE-jHnftPqUDUg_26_3">89</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPayableCurrent" scale="3" id="Tc_d7F91iwAoUOZJlHXIhwhvA_26_6">29</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accrued and other current liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_B5RAh36Dp02784kXdeF75A_27_3">330,034</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_zdRH3cfB0EmnrBFFKDc9dg_27_6">285,950</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Finance lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="Tc_U6BKx7lVikC6_QGw_t8NAg_28_3">910</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="Tc_Ub3Aii55Skqo4R4y6lscqg_28_6">664</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Convertible senior notes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtCurrent" scale="3" id="Tc_ZOi6aNOl7k2wTXGVyWhhTw_29_3">18,524</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtCurrent" scale="3" id="Tc_XUvA6ZO9nUaVao0bSM54wA_29_6">18,300</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Acquisition-related contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="3" id="Tc_VT2_2SldbEucCwIrddUsfg_30_3">35,139</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="3" id="Tc_DLg7M2GV3E-urgYITOjCRg_30_6">34,044</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total current liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_bG0YgFGSdEmMzumZvkZ2wQ_31_3">503,412</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_AcvH1yHODkm7W7kMpvCnWA_31_6">513,340</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Acquisition-related contingent consideration</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="3" id="Tc_j6cxKVlQC0SJdP_7D95Mew_33_3">239,861</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="3" id="Tc_wUmYM7gVikiUMMpr1iCtvQ_33_6">242,956</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Finance lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="Tc_CiWxNZnkSEGOVf-98TZCZg_34_3">31,959</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="Tc_gAYiIHyfn0e7WfvlHupmLg_34_6">31,918</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Other liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_kYuQzJLrm0i1XcDcrRd1gA_35_3">39,469</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_9NYaJZa-M0C39_pKeh_zIA_35_6">40,130</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_vZJVYDwJGUKVp5YBcTSryQ_36_3">814,701</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_YrbwcyBevUmVYnmfBmOVBA_36_6">828,344</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Stockholders&#8217; equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_zg0yTVfS8UyWShECY8whlw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_WzjrGstRtEGB5v5gWjzpmQ">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_7xz9usLbgki_MQB9RhTRvw"><ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_eCu9Xhv2mESdU1i1XtE7xA">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_7uyG4sA_2EO5LAPk423VMg"><ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_Wh3d_onWMUe7g4RQDW8ndQ">none</ix:nonFraction></ix:nonFraction> issued or outstanding&#160;as of March 31, 2020 and December&#160;31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_IJ-VJlHxY0CEZeshYZ-_Zg"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> &#8212;</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_00WskpThfUe7BGq8TEau6Q"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> &#8212;</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_YTRUJ-UyEkiCyqpKVzRh7A"><ix:nonFraction unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_pdHAOpQ_E02Z1LhXTK6yvg">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_Hboohi-kBUu-OcOcw3rtlQ"><ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_lDdjUlsfcUap18LtbFEZ6A">400,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_fgg0vJ0XSEe6yPNA_ezLbg">216,952,325</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_Ao-m-fC8MEiJRMmQQx8ZSA">216,177,830</ix:nonFraction> shares issued and outstanding as of <span style="-sec-ix-hidden:Hidden_7OOuLSkz1keOYZ2bBUlh2Q"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">March 31, 2020</span></span> and <span style="-sec-ix-hidden:Hidden_n5eXxN5QFkGcxSpRYcUebQ"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">December&#160;31, 2019</span></span>, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_GmERVU19fUCG-RP4PB_SNw_40_3">217</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_XhCxSyAePU2EM_yM-GM1VA_40_6">216</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Additional paid-in capital</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_0h8iCd4euUmQkIJOeZK9OQ_41_3">4,102,011</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_c8L6yPRPEUC8H_B5VSapDQ_41_6">4,044,490</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accumulated other comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_nzEScCTEQEikBWL5vipvPg_42_3">13,107</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_PlsYpJAIuE6KJU9P-Jf3Yw_42_6">15,542</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accumulated deficit</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_X6UmmjW1kEmLdNcV5k5eBQ_43_3">2,151,400</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_ljSkJ9leEUupHlFP7dQgdA_43_6">1,430,758</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_3Sx3FSrBRUaIpW85w9WxGg_44_3">1,937,721</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_OF2q213bxkis1OQGk_1quw_44_6">2,598,406</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total liabilities and stockholders&#8217; equity</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_q6b5VUlY3k-llQZuvQlELw_45_3">2,752,422</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_pGJuowBCK02IV8uC5OqDug_45_6">3,426,750</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><a id="_277e06c9_a861_4560_9201_719c1fe2c000"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:3pt 0pt 0pt 0pt;"><span style="font-size:9pt;">*&#160;&#160; </span><ix:footnote xml:lang="en-US" id="_c9570017_4a29_4e55_9a03_0f1ff68137e8"><span style="font-size:9pt;">The condensed consolidated balance sheet at December 31, 2019 has been derived from the audited consolidated financial statements at that date.</span></ix:footnote></p><p style="font-family:'Times New Roman';font-size:9pt;line-height:10pt;text-align:center;margin:0pt;">See accompanying notes<span style="font-size:10pt;">.</span></p><p style="display:none;line-height:0pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman';font-size:0pt;visibility:hidden;">&#8203;</span></p><a id="_02abaa82_e79b_429f_b93d_4b39ffe79dad"></a></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:4.15pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">INCYTE CORPORATION</b></p><a id="CONSOLIDATEDSTATEMENTSOFOPERATIONS_82706"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited, in thousands, except per share amounts)</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_955295cf_c1a3_4a25_8f23_d050818325fd"></a><a id="Tc_2QFvHB-G30-GKOuqEQt6Ug_1_2"></a><a id="Tc_PxK_vZbgXka7D-PgDNbhgg_2_2"></a><a id="Tc_lz42SEhz80S8FVWL5Yvf0g_3_2"></a><a id="Tc_NfXCwj52B0idwA3NXGVAzg_3_5"></a><a id="Tc_tvjT2x642kCFVXnNHjNi5g_4_0"></a><a id="Tc_ADFMPJ7UZEuFXsisifCm3w_5_0"></a><a id="Tc_DRXsdgaiQEyP56hyuwV1UQ_5_2"></a><a id="Tc_zJuQ2Mbqc0-h8HLqX9dejw_5_5"></a><a id="Tc_QpeMrokRrUG-RQJh8vp7kw_6_0"></a><a id="Tc_LpsZ4wRZfk-4iio1cRvRGw_7_0"></a><a id="Tc_mccUOR2YuUiVLVY3I7odRA_7_3"></a><a id="Tc_G2CBL_9_sk-ix2CEbf2BUA_9_0"></a><a id="Tc_hBWnN5BpkUmg8CX6pT76CA_11_0"></a><a id="Tc_0H37ZAdfaEqlNB0Nh1KVOw_12_0"></a><a id="Tc_Xuc0nKjVCEiD4dV_GlmHEg_13_0"></a><a id="Tc_U2-KuKL7I0-GPipNox_jcQ_14_0"></a><a id="Tc_esNSKKUASEeDFtVr9NWO7g_15_0"></a><a id="Tc_KN0I663xa0u7wLPmpkKZjA_16_0"></a><a id="Tc_vTUvCOleOkCcWi0kxDQ-qA_16_6"></a><a id="Tc_Q35vL-1a-0Gn83Y1Rdp9LQ_18_0"></a><a id="Tc_MssoCtR6sUei7TmyduR7fA_20_0"></a><a id="Tc_rAuavPsrfUaxiGw1_mzALQ_21_0"></a><a id="Tc_J4VKtvwX2kSNbN1EC-mpdA_22_0"></a><a id="Tc_R6ki1M1oH0qEPl60TBv0rg_23_0"></a><a id="Tc_qBW9buUocEunmBXvDObnlQ_25_0"></a><a id="Tc_izUaeWt8GEyfx4MAXmEPNw_27_0"></a><a id="Tc_IkRgJciap0meFM_bgpt5Dg_29_0"></a><a id="Tc_0IvAgJmYEkeoNP8n2PV_XA_29_2"></a><a id="Tc_FIxeoP4qH0SLp-O-rih8Xg_29_5"></a><a id="Tc_mrghly2k1UCD5F2cysTNXg_31_0"></a><a id="Tc_ZdzmdI_2Aky1UXmPmnlSXA_32_0"></a><a id="Tc_-zOAX_C14kigyBcjZ8g3Ig_32_2"></a><a id="Tc_XlDsRMRirU-1XklHzYPXLA_32_5"></a><a id="Tc_8qC80V_SwUuwupLElrvfdg_33_0"></a><a id="Tc_FdLZB-Fjc0uenOTAa-KLbg_33_2"></a><a id="Tc_VKzk7sqdM0KMJHaJLUtXlQ_33_5"></a><a id="Tc_hRwfw07TmECKks5Qmb8CYQ_35_0"></a><a id="Tc_GTSph5QhnkGfJKAE4YZntw_36_0"></a><a id="Tc_nm7vzKXEUkalO7kIM_zhZw_37_0"></a><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:70.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:25.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months&#160;Ended</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:70.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:25.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:70.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Revenues:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Product revenues, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_iqotuIRBdEWR4e6oAi-V5w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_ZI4uk79OXU-CTrv6qBfnOA_5_3">486,727</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_zIkoXlOLU0qoXHFNAsPMOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_-gAM2Gl5SkOiXW2jaeRunQ_5_6">396,249</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Product royalty revenues</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_Ndda4EOg1kixjWN0CSTfeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_sBvR26CP_EyLa6Y62Ed2kA_6_3">81,780</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_801prtYWj0OCkCXY8rQvyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_sKyFmXBInkiXpPoK9EtKAA_6_6">61,608</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Milestone and contract revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_incy_MilestoneAndContractRevenueMember_VtUC1dCVcEWIzn5Q-dz-vg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_E2xffwJAE0WihR3ABHK9XQ_7_6">40,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_2wPBMtERtkO9zSgpmjRHtg_9_3">568,507</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_-Geduf195EeeoYKZNh842A_9_6">497,857</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Costs and expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cost of product revenues (including definite-lived intangible amortization)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_VP9SblXhsUez6f0g1Zj8pQ_12_3">27,319</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_B4L0rVOscUmqedxpOAruJA_12_6">22,588</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_WBhwXH1u3UOQxW9S6kiUQA_13_3">1,085,287</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_0M9R93Hes0uc5fY9dMr0lQ_13_6">270,545</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Selling, general and administrative</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_96DqryCa5UCo6g0dx82NIg_14_3">111,148</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_11yiVEejUUyKG4eK8poETg_14_6">123,983</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Change in fair value of acquisition-related contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="Tc_Ux-WgDTSu0CpIQZGIFPq2A_15_3">6,627</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="Tc_vRl7xOnTo0SKqHnBMBvQ6A_15_6">6,671</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Collaboration loss sharing</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="incy:CollaborationLossSharingExpense" scale="3" id="Tc_jpvlZZl1oU6K85qtuvCDhQ_16_3">2,130</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total costs and expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_KifjCghf0UetZUYzUGskkQ_18_3">1,232,511</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_zJ5z-8hhh0WfSizx52S3-A_18_6">423,787</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Income (loss) from operations</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_D43chYnqW06S5mlNqts-uA_20_3">664,004</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="Tc_WkL3coVPF0Or0s4oTNX9cw_20_6">74,070</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Other income (expense), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_vXG5yNGBAE-7ho7QPz5fSg_21_3">8,662</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_jcsgeCBL5ECN6sUQkW0wgw_21_6">9,373</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Interest expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_nj8YJCIH1kGPXPY1Kin3Iw_22_3">602</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_bbfUU9c0TEmZmPUgwiIajA_22_6">335</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Unrealized gain (loss) on long term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" sign="-" scale="3" id="Tc_EzcxWgg7xUCMpj45IVKCMg_23_3">48,132</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="3" id="Tc_1n8Q-sE8aEyr2JUsMV5P9g_23_6">20,989</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Income (loss) before provision for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" sign="-" scale="3" id="Tc_5eN1kK8pj0qk2MMXx-UuNw_25_3">704,076</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="Tc_D8Uc9JS5kUqoHQdjhWWzIg_25_6">104,097</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Provision for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_KXJV_Z5gdUuJ4L08milWYA_27_3">16,566</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_ESNB1Fov3UiZVNdriSVs4g_27_6">1,785</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Net income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_4KuhkhhSD02S0DLV2nt7Rg_29_3">720,642</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_4KtvoXJgPUyC9VX96TSpkA_29_6">102,312</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Net income (loss) per share:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:70.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Basic</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_s7No8CJl10KK6uOb8TKQdA_32_3">3.33</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" scale="0" id="Tc_tfWPTyodnEOBbi4TvZkdtQ_32_6">0.48</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_s0-HiNeBfUaMA8MUmSQ3GA_33_3">3.33</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" scale="0" id="Tc_XhWJayICN0SHBRu_vU5PjA_33_6">0.47</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:70.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Shares used in computing net income (loss) per share:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:70.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Basic</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_9sRGfeTxhkq9elF0mos5kA_36_3">216,721</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_HANQlCYImkSrHPLHHzzOCA_36_6">214,065</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="Tc_E4AYa1RT1EaiS1T1sLnW6g_37_3">216,721</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="Tc_Dv7ZSUqfSkav1afuHM2CyA_37_6">217,061</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">See accompanying notes.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_37da1725_56fb_465d_a6a8_9de8d669c260"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">INCYTE CORPORATION</b></p><a id="COMPREHENSIVEINCOMELOSS_470527"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited, in thousands)</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_6a591b24_f0b9_4b86_9146_c5bc1f00dea3"></a><a id="Tc_pB07tq_s6kG7Je4xqrrN9g_1_2"></a><a id="Tc_XgPsY5lp9keK2RYI44Tw5w_2_2"></a><a id="Tc_sYANUktlC0OJ6dvPJYKJgw_3_2"></a><a id="Tc_jfZZ041BvkSkd8K3wRAhoQ_3_5"></a><a id="Tc_N3iMJsyjZUGMKR6WeUvTCg_4_0"></a><a id="Tc_g82IDt1dAEy17LRYF3H-RA_4_2"></a><a id="Tc_1O0MXf3hv0mHIu_Z2o8TnQ_4_5"></a><a id="Tc_MUKV16djW0GeJG-pbufOdA_6_0"></a><a id="Tc_MVfxruG5MEyFGG8ydRlyvA_7_0"></a><a id="Tc_EX-muJTVrUaq6YyeO_E4Iw_8_0"></a><a id="Tc_uh4EmAsB1kiUPqQqZAPiLg_9_0"></a><a id="Tc_ZvGHi7Ig0UejM9fqgECbGA_10_0"></a><a id="Tc_8nE3RYCFMkWj-XIWLWEO7Q_12_0"></a><a id="Tc_Ir7kIhbQOUiwYWzQ2d4JHg_12_2"></a><a id="Tc_2xBX8hkv3UCExShLbvHVFg_12_5"></a><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:73.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:23.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months&#160;Ended</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:73.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:23.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:73.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Net income (loss)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_ZURr9iImD0q6Y0gqRqDtww_4_3">720,642</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_uAG0Ko_ALEet_iWNAhsUYQ_4_6">102,312</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Other comprehensive income:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Foreign currency translation </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_ozvFCqT3CEOdKuRwaehyDg_7_3">1,560</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_sCN29q2eskmZHymJocx1Vw_7_6">126</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Unrealized gain on marketable securities, net&#160;of tax</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="Tc_JYmVHRZhuUqzkP-7akNT-Q_8_3">654</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="Tc_v0w3gdR4NkaGeszPNfeecQ_8_6">681</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Defined benefit pension obligations, net of tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" sign="-" scale="3" id="Tc_iwgkzrpsSE2eW6tgRjYq3g_9_3">221</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" sign="-" scale="3" id="Tc_immEMLX510SFW3oenaHXuw_9_6">111</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other comprehensive income</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="Tc_pTOEngn02UuyXsdWoE8MWg_10_3">2,435</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="Tc_Uv9Tbr-k60mViT5EqKMSxQ_10_6">918</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Comprehensive income (loss)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_Vrw3uJ9fOkq8oBIGrwEu3w_12_3">718,207</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="Tc_ejdnnfxhyk22uPGLUIFYZg_12_6">103,230</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">See accompanying notes.</p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_00a35b84_854f_49e4_9a28_558beba5a927"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">INCYTE CORPORATION</b></p><a id="CONSOLIDATEDSTOCKHOLDERSEQUITY"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(unaudited, in thousands, except number of shares)</b></p><a id="_8332b666_c242_464f_a88d_f838d8c7266a"></a><a id="Tc_JOfbBVp42kat8Pz-wZTYig_1_1"></a><a id="Tc_VVGBjmKwI0iFqV5svFvoZA_2_13"></a><a id="Tc_QajOgpJOAE6bO6zr_P3ZIw_3_1"></a><a id="Tc_S9gCM2sigkefKbWnMof8wA_3_4"></a><a id="Tc_bBHcfKTJX0Gz9XLRJq3Ydg_3_7"></a><a id="Tc_RMbdkFiMAUGtLXqQu02gnw_3_10"></a><a id="Tc_HpIwwp-E10K20w9Ygcr58w_3_13"></a><a id="Tc_Vuas9smE2keY5sIA5vcOcw_4_1"></a><a id="Tc_b_11WrJBHUeKUJe4d6S7BQ_4_4"></a><a id="Tc_BJPZWvwXn0KTOol6fIqv2g_4_7"></a><a id="Tc_EEgHSzH1tE2GWDpDym50gQ_4_10"></a><a id="Tc_pj3CQ4jeIUCnnux5k5T9RQ_4_13"></a><a id="Tc_s9Bn-magikSwYcKLZyWCbg_5_0"></a><a id="Tc_nAuR2beXJ0iDQohXUJaatw_5_1"></a><a id="Tc_CXH6D6uBfUutQDVU9hyq5A_5_4"></a><a id="Tc_UumM9KGsQkapBrzh0W58Ew_5_7"></a><a id="Tc_tIcj8UFoi0G4Vcul0xkXVw_5_10"></a><a id="Tc_FvePDzX-20yOqAKbFi86pA_5_13"></a><a id="Tc_b0inNo8Ya06GfiuYa7GnEQ_6_0"></a><a id="Tc_gTQs1WCTMk2d8OZT3dRoxw_6_8"></a><a id="Tc_IGB9w62cTEujfLv9hf5NQg_6_11"></a><a id="Tc_jEJviTceYk2hLZcEgi2sMw_7_0"></a><a id="Tc_vt6jk71n6ECIXYjIozpdRg_7_2"></a><a id="Tc_7FxRBzMWqUWy_pMGUmz_Ow_7_8"></a><a id="Tc_7wg4m0_970ufIQgIOIeE_A_7_11"></a><a id="Tc_0O02tvMneECcPH1p2gaFyg_8_0"></a><a id="Tc_-Dg_KilO1EWRbx3YG69B6A_8_2"></a><a id="Tc_o3bbMSMJiEKhif7FRtNOBg_8_8"></a><a id="Tc_l5t-G0HwDkKcyoNe-Bdiow_8_11"></a><a id="Tc_sZED9FdnKkKww_eoShoDfA_9_0"></a><a id="Tc_b4Ikj_VPcEi8AbK_AIDJJA_9_2"></a><a id="Tc_tdqEKHP8EEK0_sZrxlzl7A_9_5"></a><a id="Tc_x7wv7lXLHkWLbs2GwNnmkg_9_8"></a><a id="Tc_0v253ke0I0KFPaOD-53TOg_10_0"></a><a id="Tc_ht9TyGcAlEe1cdJ-GhjR0Q_10_2"></a><a id="Tc_NrvVbqXnvEqjMsGSlujLbQ_10_5"></a><a id="Tc_Dey8hTV3B0-wnwF8IABEKg_10_11"></a><a id="Tc_uEpm_xzsgEiwEGRfIJpH8Q_11_0"></a><a id="Tc_4eXQ-oKZBUy1CyiXuI9xwg_11_2"></a><a id="Tc_5ZE6VFFetkG0Mm4Qdz5PMg_11_5"></a><a id="Tc_Fq8tGsm1RkGlmMqQJOqpaw_11_8"></a><a id="Tc_GM9HpZLQukitWfIygLXWzw_12_0"></a><a id="Tc_ItPzhNGoWUuGW9efNyT4NA_12_1"></a><a id="Tc_G6kvIFr5S0Wxg7jLDFboGQ_12_4"></a><a id="Tc_APJooQGMzEWBJ32IA2jA3Q_12_7"></a><a id="Tc_DdHanAfhA06wGgKxvZJCPQ_12_10"></a><a id="Tc_jBNM6SlQOU60Y-gMtoW6yQ_12_13"></a><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:42.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:42.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:57.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Three Months&#160;Ended March&#160;31, 2019</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:42.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:42.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated Other</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:42.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-in Capital</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Comprehensive Loss</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:42.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">Balances at January 1, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mHv5WMXrp0O8iRpfgdj6oA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_guu-NkFa0E6wtTZ_oKXczA_5_2">213</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JPMoYCXuZU2eJZVVkKRx5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ra8eCIvTCkul1cq59TGB5g_5_5">3,813,678</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_YuWnGWZBFEycAhcGmFa2fQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_Eo1RCftGxEWqeg5KbMqHew_5_8">10,165</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AsudZYg1cEuP3-a7_igGEA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_aABhOQCWbkqiJl5io0VVgw_5_11">1,877,759</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2018_9ClNYpZejEWe3kBT1B-jvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_wJX9NzpWL0ODIbfJeVCQkg_5_14">1,925,967</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">Issuance of <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="Narr_lkdrcxD-SUm8oCvv9XhWLQ">1,044,745</ix:nonFraction> shares of Common Stock upon exercise&#160;of stock options and settlement of employee restricted stock units </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7twDsd2JDEOndz5YGwcBzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_2pNgKkCIIEeD4clhP9cgTg_6_2">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fWoGq7r2vk2UCLk0trvcdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_qml5Djh0wEqVaqwEQgqxsg_6_5">15,480</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_nMpLRtpHSk-8R-AHbIJdTw_6_14">15,481</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">Issuance of <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="Narr_JB_gfo0SMU-bUFe5WMV3iQ">1,200</ix:nonFraction> shares of Common Stock for services rendered</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fWoGq7r2vk2UCLk0trvcdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="Tc_iaq63_elqEOv12vG_nzTcw_7_5">104</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="Tc_ZY5BpqVqA0q9dsb9S3M8lg_7_14">104</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">Stock compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fWoGq7r2vk2UCLk0trvcdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_DLwsXI1nbkOJWfqNvwIIPA_8_5">40,690</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_qSGdEBJlqUKNFyEkSi6X8g_8_14">40,690</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">Adoption of ASU No. 2016-02</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_DbVOFfn2yECjfpwbXtOkuQ" decimals="-3" format="ixt:numdotdecimal" name="incy:AdoptionOfAccountingStandardAdjustmentToRetainedEarnings" scale="3" id="Tc_Qg4Tl9BTSEGs4BMFSF5DwQ_9_11">95</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="incy:AdoptionOfAccountingStandardAdjustmentToRetainedEarnings" scale="3" id="Tc_rMRGnrn9PEq_pcDu2yHJRg_9_14">95</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">Other comprehensive income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_A8RojBoxM0mFmINTN2EuXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="Tc_HxQIhA8VEk2Z09gSbIgXqQ_10_8">918</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="Tc_9BZkRKjfHUiHnrMkc0cLqA_10_14">918</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">Net income</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_DbVOFfn2yECjfpwbXtOkuQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_R0EspgGsDUGnwBVPnb8o7w_11_11">102,312</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_VuPit3WYD0y8YaZFfB5QyA_11_14">102,312</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">Balances at March&#160;31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vUipIgfa4km0rtW5tdmA4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_REu-mZT-1kqUj6jxNSJr9A_12_2">214</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_S1joOk6fhkO10LOQZpl6lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_yJKBQuWQa0KagZGlld8zpw_12_5">3,869,952</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_XMlG1LUJy0Scx4eCJMw_Og" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_F15j2VmILUaPNSPdtErsQw_12_8">9,247</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_OfMjHRm8vkyNOUMTG5Sgug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_2PpbkBG9o0GTHhR3eAK56w_12_11">1,775,352</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2019_dMCk6SsWm0OpwCR3K8OhEw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_xBARIAe1f0GaBZIrV2u7hA_12_14">2,085,567</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_4a51b3ea_06d8_4a67_b669_09a06f2d31ae"></a><a id="Tc_JMgsRG8h-0u9JbPR_KDAww_1_1"></a><a id="Tc_iOq2EOgANk61BMHnRztlKQ_2_13"></a><a id="Tc_yfknqMY4XkGy6Ud0jDex8Q_3_1"></a><a id="Tc_obensm0Wxka0WSYRQEwhYw_3_4"></a><a id="Tc_jE6xhrekVEWM8CpykMdaMg_3_7"></a><a id="Tc_Z5bI0BV4L0a11QA9kxu0IA_3_10"></a><a id="Tc_t3Av5781S0u-UMvtfPlFbw_3_13"></a><a id="Tc_G-vdYZFiA0-Zp30LnTgNLA_4_1"></a><a id="Tc_W-cbtF1p502hkJLy2u5nTg_4_4"></a><a id="Tc_wU8RfGMx9U6oKXkA1LxIzA_4_7"></a><a id="Tc_tLlIyLidQkmVINalBqwclg_4_10"></a><a id="Tc_C72O-75N8UuyH5PLG5iF8Q_4_13"></a><a id="Tc_onBu1Ps6vk2J1FJc_z5mwg_5_0"></a><a id="Tc_b4smtZ_SUEOp9JVkpxo_zg_5_1"></a><a id="Tc_sFyOB6FJKky4dhp5K_i6DA_5_4"></a><a id="Tc_iCS96IPNpEGr4RyT_idTwg_5_7"></a><a id="Tc_FC6EA3Ru6kqxMqMDtIfPcg_5_10"></a><a id="Tc_TameqHUn0UGeYZub7v_jyg_5_13"></a><a id="Tc_ev2bei6lJUOhkOFd0DS8nw_6_0"></a><a id="Tc_vOzUiMhqykCl5z9mMBISwg_6_8"></a><a id="Tc_GAfCG875y0C_n7FeIUYUIA_6_11"></a><a id="Tc_Ji1xEPBbfUeaMxMMd52eug_7_0"></a><a id="Tc_iLBaH7A5TkKcu7J--bZpmw_7_2"></a><a id="Tc_rWlwKV5UEUOfa8ptg9y3qA_7_8"></a><a id="Tc_uBda8U50xE-fhjpT4AaY5A_7_11"></a><a id="Tc_NqmQ82FGF0-jIrPE-QABUQ_8_0"></a><a id="Tc_jhDlzLOBe06l4zjLn3FZ4A_8_2"></a><a id="Tc_jjezWIGhQU2xC6Dr8yXImg_8_8"></a><a id="Tc_BKBZbfFyo0iHpQdqUWgfEw_8_11"></a><a id="Tc_QSAY3CvEwES_90NuG3ip4Q_9_0"></a><a id="Tc_tieGhANqBUaL_a1LZkx5RQ_9_2"></a><a id="Tc_7gh6nIUJDk62rKOXLMfM7Q_9_5"></a><a id="Tc_TN_42QeDgkek2KZJ3OMCXw_9_11"></a><a id="Tc_HjKU8hWRPE6QQXYZKKyd7Q_10_0"></a><a id="Tc_jKasF_RIWk6LBShVo-y-KQ_10_2"></a><a id="Tc_jgDaYyhfi06abynDttJ4xQ_10_5"></a><a id="Tc_nxYHv2HQYE6UOEqofA6jAw_10_8"></a><a id="Tc_9eg-OLkNV0qu2GPjY-GyAQ_11_0"></a><a id="Tc_y3iBgzpKikudjGs2IRc8tw_11_1"></a><a id="Tc_VcYTKQ3E202Df9WROQo9qQ_11_4"></a><a id="Tc_I3lOaHzdbk2SPQYKxAQrww_11_7"></a><a id="Tc_mtcTf7kqo0SgUaPx2YU5Pw_11_10"></a><a id="Tc_2i-MFfyPTUCcnLLBULIQxQ_11_13"></a><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:42.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:42.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:57.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Three Months&#160;Ended March&#160;31, 2020</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:42.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:42.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated Other</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:42.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-in Capital</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Comprehensive Loss</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:42.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">Balances at January 1, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_h7i3Ro_OZUmCp9mkSGukFg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_esZPbSOol0y1J9na_kPaTw_5_2">216</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4IpabeHWGEeyws0bt-_LIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Hyke_xD8DUCSD6vvjkQY6w_5_5">4,044,490</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_-bO_iV0lbkSyipE07mBbnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_oxvONU2UpkOpjUw1GHxX7Q_5_8">15,542</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__tiHxydERESGTR76ARwl7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_7Rv5E81PSEqrokNGiqliWA_5_11">1,430,758</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_VW1M5710KUCopAC2UNPdRg_5_14">2,598,406</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">Issuance of <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="Narr_e3kCZoxSRkqX0FC51yxkvg">772,538</ix:nonFraction> shares of Common Stock upon exercise&#160;of stock options and settlement of employee restricted stock units </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e2R-5xzxfUC6nZUl8PL1YA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_PfTsuv2QOkCtfOm3icmaYQ_6_2">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_w-vcv_NpWkCA4qcaHLsFbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_sRB5JZOlPUuJmZi-Mb-K_g_6_5">14,618</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_AdTCz-COyU6SdKuhQH5Jlg_6_14">14,619</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">Issuance of <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="Narr_AAG71Dk3s0yzhONwd93-Yg">1,957</ix:nonFraction> shares of Common Stock for services rendered</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_w-vcv_NpWkCA4qcaHLsFbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="Tc_vSZAhmwf0EyMhMAE7J71cg_7_5">145</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="Tc_QZF4kGqe4UesTrb2Wmf3Fg_7_14">145</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">Stock compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_w-vcv_NpWkCA4qcaHLsFbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_lA3L52C0E0-l5yE5Zsn9XA_8_5">42,758</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_dftJkawjW0K6s72gHYOaMQ_8_14">42,758</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">Other comprehensive income</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1-7nj5ASlkiVwC_JguIJwg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="Tc_dwVy0Cjsu0CX-Qhy6195xw_9_8">2,435</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="Tc_WefEiQG4f0muYLI2uChKLA_9_14">2,435</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HPSBbAExTU2JCIrpO-YFvQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_6s_sEUx8-UWtDd9EA4H92w_10_11">720,642</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_W8Fl6rvweE6TrwZqEtcYxg_10_14">720,642</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">Balances at March&#160;31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2hQ7NTSBMUWmxGpMp6-_0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_moUcuyCNAEKkQD55aVi10Q_11_2">217</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Hj6IUMCWb02gJP3m4OeDnw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_vAU1LBeSj0ii4rGRy_Gf4Q_11_5">4,102,011</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_xkbc2Y822UqXDVbR6a7_LQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_pRDfTMTNBkiLecLDXq1kuA_11_8">13,107</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fEwSRBjO_Ui2kpLBrnNHdg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_xyc2KREVcUeE2UNVegWwVQ_11_11">2,151,400</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_rg_PuBArQEyRqAXjyNg3mg_11_14">1,937,721</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;text-align:center;margin:12pt 0pt 12pt 0pt;">See accompanying notes.</p><a id="_ccbaf8e5_10b9_4364_827e_9ed0c1b4a734"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">INCYTE CORPORATION</b></p><a id="CASHFLOWS_761754"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited, in thousands)</b></p><a id="_e191ca05_91f7_41c1_ab49_59a1fa38b775"></a><a id="Tc_BrRkJVm7NECptFg0-ufERw_1_2"></a><a id="Tc_MmLrTx9us06kbwUAN9TpaQ_2_2"></a><a id="Tc_OPYBFBubxkWmkkEgLtBuVQ_3_2"></a><a id="Tc_MRKWJH0QLESh8E0x8O77Gw_3_5"></a><a id="Tc_lygq6Rh6a0qtpWPLTwjYqg_4_0"></a><a id="Tc_mn3xB5wHUki5YdAkqA9vBA_5_0"></a><a id="Tc_wcLpLowHjkKEBDg0ANBgUA_5_2"></a><a id="Tc_yebOZ8_-5k6_UnDKpe0yVw_5_5"></a><a id="Tc_EZorNFaRrkK7sKdhDFYrxw_6_0"></a><a id="Tc_-3WQrfyLnUq1BObKzsBUZQ_7_0"></a><a id="Tc_pCy8AaD9mU2TyL8bpQlubA_8_0"></a><a id="Tc_cGb4NI2EykaF0zNm2Dj2LQ_9_0"></a><a id="Tc_AgvfhCi_GUWCMc3ltk8CDw_10_0"></a><a id="Tc_WiSJZrqHgEuf6nnLuuJQoA_11_0"></a><a id="Tc_QrnrXAHbUE2RqicgfDYPag_12_0"></a><a id="Tc_I3x3cmkJDkKJJGT6RL0EXA_13_0"></a><a id="Tc_qDG7kpAWl0uZkZ3BTevpoQ_14_0"></a><a id="Tc_DfAYcW3zEUyejGD5Ec3tpA_15_0"></a><a id="Tc_CXJwNrCFoEK2ocgC43ksKw_16_0"></a><a id="Tc_1b1MRK8At0ijn6LuaNh8BA_17_0"></a><a id="Tc_ttu8LyhGtU26GsfUpA5aqQ_18_0"></a><a id="Tc_fItDUMfFwEKEt-pdaSJfEQ_19_0"></a><a id="Tc_kypABfhpeUuMSjuFOww8iw_20_0"></a><a id="Tc_VLCicxO1XEa6u8bjd3isnw_20_6"></a><a id="Tc_QHeSOEcrqU6PNuE-M7VQEg_21_0"></a><a id="Tc_-zAoxuUpFU-xdroENH5uuA_22_0"></a><a id="Tc_eZTxsyuKPUac3yBnak83lQ_23_0"></a><a id="Tc_FypWGL_To0Wl0a_HXGPuMQ_24_0"></a><a id="Tc_K8z-DJbbw0mX8X1pvnzEWA_25_0"></a><a id="Tc_gqkZ2WbIe0eq-P8Bo55FSw_26_0"></a><a id="Tc_D6KpcOkWNEe563SapHQm2Q_27_0"></a><a id="Tc_RyQjeQ4DQ0aZV7qcawFzuQ_28_0"></a><a id="Tc_Q2MjxN6siEyKYbIKiqcnQA_29_0"></a><a id="Tc_FZuqrFcrokK33JvvvJk72w_30_0"></a><a id="Tc_NBIrLXDf50OUnxoBOaK-hQ_31_0"></a><a id="Tc_gdrvA3oFYkWlHKBfyWWTDA_32_0"></a><a id="Tc_cu70NuqaWkKyAWM7hpeQqg_33_0"></a><a id="Tc_mE69TNavhUKWCFd56YcXuw_33_2"></a><a id="Tc_5__zuDl1d0af3RaKZeccFg_33_5"></a><a id="Tc_jErSkCOQ4UW-Yp8IMRZtbA_34_0"></a><a id="Tc_FpYdBzITfECg0dhTRXE3Bg_35_0"></a><a id="Tc_An8ofZ3v7kGtGD2j7GBCtg_35_2"></a><a id="Tc_FlhtagduZUSedhx9xwllVg_35_5"></a><a id="Tc_w0fgpAyvEE6mBsZ9aQI3_g_36_0"></a><a id="Tc_zBP9b4oQJkKbl2ZOaOGbCQ_36_2"></a><a id="Tc_mJyfbxH4eEWsS4__NEXpZQ_36_5"></a><a id="Tc_phhubRlM5E6dOu0_vtHUyA_37_0"></a><a id="Tc_qNObJTOwyUCUre8NxTPxfg_37_2"></a><a id="Tc_OYOgC5Zi106OAqTeupeeBw_37_5"></a><a id="Tc_yKqhWHPI0Eyj9EpH17UGdQ_38_0"></a><a id="Tc_tXmXzwLWD0yl5rp3a2dpuQ_38_2"></a><a id="Tc_5InyfYL5qUOWrQ6SYOAYoQ_38_3"></a><a id="Tc_vss7Q9_IOUKAfW6mJS0RUw_38_5"></a><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:75.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:22.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months&#160;Ended</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:75.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:22.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:75.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash&#160;flows&#160;from&#160;operating&#160;activities</b>:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Net income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_5RcMJ5QfwESUtMvDlQttbg_5_3">720,642</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="Tc_vNDgyJKXjE2jF_1GMjoIyg_5_6">102,312</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Adjustments to reconcile net income to net cash provided by operating activities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_2OwlOeMmvE2urWFqvHn3PA_7_3">13,098</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_HBNsDmfpkkmwV-o_GOG_EQ_7_6">13,891</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_LNjew6gQREG2KjH6TGd4Og_8_3">42,513</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_F3apIExXukSie6-0xoD0GA_8_6">40,592</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNoncashIncomeExpense" sign="-" scale="3" id="Tc_omyrR9eNBUq7kW8SHB42fQ_9_3">145</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNoncashIncomeExpense" sign="-" scale="3" id="Tc_XtaxqCjMaUOhVWx-uFENYw_9_6">104</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Unrealized loss (gain) on long term investments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" sign="-" scale="3" id="Tc_xOSizPbz0EmhgpB7E-02kA_10_3">48,132</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="3" id="Tc_6Pn9k0slS0mIIBh1mg2Mvw_10_6">20,989</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Change in fair value of acquisition-related contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="Tc_rmsM3budd0eEPrJoQ0iURw_11_3">6,627</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="Tc_PGKRrRH1REeiOxVYz5Q5HA_11_6">6,671</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Changes in operating assets and liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Accounts receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_qrEQBFCW80GVMjxx33lahg_13_3">42,713</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" sign="-" scale="3" id="Tc_twzlzVRqPkWZ88vQA7wrSw_13_6">63,517</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Prepaid expenses and other assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_LN74uHylfk6BQ6E5Gmcq_g_14_3">16,701</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_ppICXiaN0Em7_SCdS_lU9g_14_6">5,559</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_kA0NR-g-e0Ogv7csIlolzw_15_3">5,712</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_Jwh0EYn2PEu6XPUfe4ofyg_15_6">600</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Accounts payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="3" id="Tc_jZxWtoOvhkCyWoMbYn43mw_16_3">22,710</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="3" id="Tc_MivBTRLm90eag5qJTnN9vg_16_6">33,464</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Accrued and other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="Tc_t353DsD1s0-7dUUI26YNRw_17_3">14,546</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="3" id="Tc_ys37dmjHfkuh-YsfH3o2Cg_17_6">21,930</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Net cash (used in) provided by operating activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_H4RjT8G1DUaR4_sn20h-BQ_18_3">683,417</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="Tc_8WGmeOjzlE2kZcXRbOcs2A_18_6">155,663</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash&#160;flows&#160;from&#160;investing&#160;activities</b>:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Purchase of long term investments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireLongtermInvestments" scale="3" id="Tc_ZN502eLsJ0-nqUTb1NHCiA_20_3">95,468</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Capital expenditures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="3" id="Tc_6sbbG7LHZ0uqL90EKDwAAA_21_3">39,265</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="3" id="Tc_bS-8XlKu1EGuY8gMLa47hA_21_6">18,267</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Purchases of marketable securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="Tc_vg7p7RfDyE-IfG7DYFSr5g_22_3">147,403</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="Tc_zD3NG6nBB0Cyqm9OtTWuCQ_22_6">34,574</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Sale and maturities of marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="Tc_LOtx6ugHgEyurYtzlNKEIQ_23_3">173,576</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="Tc_qlfqhYGSHEGXAsi4kAMJyg_23_6">28,278</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Net cash used in investing activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_Sd1p8DdEIUOPlbeaKZwdfg_24_3">108,560</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_IvR6CUgpQ0enO9YbxS4KqQ_24_6">24,563</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash&#160;flows&#160;from&#160;financing&#160;activities</b>:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Proceeds from issuance of common stock under stock plans</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="Tc_zwVaGrzpyEqnmgM-JKwd-w_26_3">14,619</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="Tc_vXBHuW-N_k-j1rMYFvRXiA_26_6">15,481</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Payment of finance lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="Tc_ssxNGG0jV0G0HQqzcogfeA_27_3">187</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="Tc_xwMM1-mW8ku6s7J_O5iz_w_27_6">195</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Payment of contingent consideration</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="incy:PaymentOfContingentConsideration" scale="3" id="Tc_YK4e0RAq20S90GcFXk9U_A_28_3">11,933</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="incy:PaymentOfContingentConsideration" scale="3" id="Tc_hT3vHtXXckWY3nLSgQXnig_28_6">10,799</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_7bt3TDUqD0CH9nX503Zd9A_29_3">2,499</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_fKHjXpM1M0i2ca_dyB1Hnw_29_6">4,487</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Effect of exchange rates on cash, cash equivalents, restricted cash and investments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_Gip1H5v-7EahIuHSFhtXmA_30_3">1,560</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_gAYFDfbNYUKQPKDKe6OrtQ_30_6">126</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Net (decrease) increase in cash, cash equivalents, restricted cash and investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_7jhceT7Ff0WCj62g2yMg8g_31_3">787,918</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_Ms3EzN_1AUOwxaLhitTaxA_31_6">135,713</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Cash, cash equivalents, restricted cash and investments at beginning of period</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_v6Zqmdon-kiq1xt41fBX-w_32_3">1,833,707</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2018_9ClNYpZejEWe3kBT1B-jvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_IbA1u2tsaEyX3jWLYZ4COg_32_6">1,164,986</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Cash, cash equivalents, restricted cash and investments at end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_v3OkoTtiHEO2Y4IFJat2Qg_33_3">1,045,789</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2019_dMCk6SsWm0OpwCR3K8OhEw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_4yNpv5-jFkCqefU-jN9Rkw_33_6">1,300,699</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Supplemental&#160;Schedule&#160;of&#160;Cash&#160;Flow&#160;Information</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Income taxes paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="Tc_zmGdCZKtG0G_KfDk15BFaQ_35_3">855</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="Tc_OLS8KdsYyE6BAetd8qFrZA_35_6">448</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Unpaid purchases of property and equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_0UXUEho_mkOymR5hjdRCgg_36_3">13,582</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_1QssCok2s0WGBBsXbsV6mQ_36_6">8,414</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Leased assets obtained in exchange for new operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_5kwyEjqWGkWzQcDJfwC5wg_37_3">1,984</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_kJSg3Bi-xUiUi7Sz5KQQUA_37_6">932</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Leased assets obtained in exchange for new finance lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="Tc_ZMZ09IHWsk6AIdFTdmCtlw_38_6">645</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">See accompanying notes.</p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">INCYTE CORPORATION</b></p><a id="NOTESTOCONDENSEDCONSOLIDATEDFINANCIALSTA"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, 2020</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="Tb_Eup-VL3trEOb1J8RCWTQeA" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.&#160;&#160;&#160;&#160; </b><b style="font-weight:bold;">Organization and business</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Incyte Corporation (including its subsidiaries, &#8220;Incyte,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a biopharmaceutical company focused on developing and commercializing proprietary therapeutics. Our portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products JAKAFI&#174; (ruxolitinib), and ICLUSIG&#174; (ponatinib). Our operations are treated as <ix:nonFraction unitRef="Unit_Standard_segment_jI2Df57rGUiaWugJ41i_Hg" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_25m1gSJGCku2n4yBcTiGHA">one</ix:nonFraction> operating segment.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_ceHk9ALov02Yy0bhzaPPug" continuedAt="Tb_ceHk9ALov02Yy0bhzaPPug_cont1" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2.&#160;&#160;&#160;&#160; </b><b style="font-weight:bold;">Summary of significant accounting policies</b></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_7CXqmB3Ki0yW8DKuYSn3Mw" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Basis of presentation</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. The condensed consolidated balance sheet as of March 31, 2020, the condensed consolidated statements of operations, comprehensive income (loss), stockholders&#8217; equity, and cash flows for the three months ended March 31, 2020 and 2019, are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which we consider necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. &#160;The condensed consolidated balance sheet at December 31, 2019 has been derived from our audited consolidated financial statements.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although we believe that the disclosures in these financial statements are adequate to make the information presented not misleading, certain information and footnote information normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) have been condensed or omitted pursuant to the rules&#160;and regulations of the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Results for any interim period are not necessarily indicative of results for any future interim period or for the entire year. The accompanying financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form&#160;10-K for the year ended December 31, 2019.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:ConsolidationPolicyTextBlock" id="Tb_mSdAWLLrM0i4axJ-Roizkw" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Principles of Consolidation.</i> &#160;The condensed consolidated financial statements include the accounts of Incyte Corporation and our wholly owned subsidiaries. All inter-company accounts, transactions, and profits have been eliminated in consolidation.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="Tb_M-0fqDR43U6wEawDluwqsA" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Foreign Currency Translation</i>. Operations in non-U.S. entities are recorded in the functional currency of each entity. For financial reporting purposes, the functional currency of an entity is determined by a review of the source of an entity&#39;s most predominant cash flows. The results of operations for any non-U.S. dollar functional currency entities are translated from functional currencies into U.S. dollars using the average currency rate during each month. Assets and liabilities are translated using currency rates at the end of the period. Adjustments resulting from translating the financial statements of our foreign entities that use their local currency as the functional currency into U.S. dollars are reflected as a component of other comprehensive income (loss). Transaction gains and losses are recorded in other income (expense), net, in the condensed consolidated statements of operations.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:UseOfEstimates" id="Tb__N3tnyEeqEq3BSYoDXMVUQ" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Use of Estimates.</i> &#160;The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_UYyDh7Nr0EKuCpOwyI01xg" continuedAt="Tb_UYyDh7Nr0EKuCpOwyI01xg_cont1" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Concentrations of Credit Risk.</i> &#160;Cash, cash equivalents, marketable securities, and trade receivables are financial instruments which potentially subject us to concentrations of credit risk. The estimated fair value of financial instruments approximates the carrying value based on available market information. We primarily invest our excess available funds in debt securities and, by policy, limit the amount of credit exposure to any <ix:nonFraction unitRef="Unit_Standard_issuer_ywviBYfRh0KpQHOu97pP7g" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="INF" format="ixt-sec:numwordsen" name="incy:CreditExposureLimitationNumberOfIssuerOtherThanUnitedStatesGovernmentGuaranteedSecurities" scale="0" id="Narr_uREjfAOSNEiWfHjLutxBVQ">one</ix:nonFraction> issuer and to any <ix:nonFraction unitRef="Unit_Standard_instrument_X67SygLtqEeZMZZtTj-6RQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="INF" format="ixt-sec:numwordsen" name="incy:CreditExposureLimitationNumberOfFinancialInvestmentOtherThanUnitedStatesGovernmentGuaranteedSecurities" scale="0" id="Narr_MtLKlSfGqkWmDYE6zaBfxQ">one</ix:nonFraction> type of investment, </p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ceHk9ALov02Yy0bhzaPPug_cont1" continuedAt="Tb_ceHk9ALov02Yy0bhzaPPug_cont2"><ix:continuation id="Tb_UYyDh7Nr0EKuCpOwyI01xg_cont1"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">other than securities issued or guaranteed by the U.S. government and money market funds that meet certain guidelines. Our receivables mainly relate to our product sales of JAKAFI, ICLUSIG and collaborative agreements with pharmaceutical companies. We have not experienced any significant credit losses on cash, cash equivalents, marketable securities, or trade receivables to date and do not require collateral on receivables.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:CreditLossFinancialInstrumentPolicyTextBlock" id="Tb_6OdjJAzYAEGC3oyOxuhbUg" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Current Expected Credit Losses. &#160;</i>Effective January 1, 2020, financial assets measured at amortized cost are assessed for future expected credit losses under guidance within ASC 326, Financial Instruments &#8211; Credit Losses, to determine if application of an expected credit losses reserve is necessary. On a quarterly basis, receivables that resulted from revenue transactions within the scope of ASC 606 and recognized on an amortized cost basis are reviewed on a customer-level basis to analyze expectations of future collections based upon past history of collections, payment, aging of receivables and viability of the customer to continue payment, as well as estimates of future economic conditions. Receivables generally consist of two types: receivables from collaborative agreements, including milestones, reimbursements for agreed-upon activities and sales royalties; and receivables from customer product sales. Collaborative agreement receivables are closely monitored relationships with select, reputable industry peers. Collection of receivables is assessed within each collaborative partnership on a quarterly basis, including evaluation of each entity&#8217;s credit quality, financial health and past history of payment. Customer product sales receivables are independently evaluated on a monthly basis, on which unusual items or aged receivables are closely monitored for signs of credit deterioration, or indications of payment refusal. Customer product sales are with specialty pharmaceutical distributors, wholesalers, and certain public and private institutions, some of which whose financial obligations are funded by various government agencies. These receivables are assessed for signs of credit deterioration and in the Company&#8217;s sales history and future expectations of economic conditions, there are minimal instances of bad debts or uncollected receivables. &#160;</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_ShUyp13Iu0qyI1bnoRwOog" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Cash and Cash Equivalents.</i> &#160;Cash and cash equivalents are held in banks or in custodial accounts with banks. Cash equivalents are defined as all liquid investments and money market funds with maturity from date of purchase of 90 days or less that are readily convertible into cash.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:MarketableSecuritiesPolicy" id="Tb_MYdnr5HIs0y0tvntCCVjAQ" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Marketable Securities&#8212;Available-for-Sale.</i> &#160;Our marketable securities consist of investments in U.S. government debt securities that are classified as available-for-sale. Available-for-sale securities are carried at fair value, based on quoted market prices and observable inputs, with unrealized gains and losses, net of tax, reported as a separate component of stockholders&#8217; equity. We classify marketable securities that are available for use in current operations as current assets on the condensed consolidated balance sheets. Realized gains and losses and declines in value judged to be other than temporary for available-for-sale securities are included in other income (expense), net on the condensed consolidated statements of operations. &#160;The cost of securities sold is based on the specific identification method.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="Tb_mUb693giEU65kKl_kq1L1w" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Accounts Receivable.</i> &#160;As of March 31, 2020 and December 31, 2019, we had a de minimis allowance for doubtful accounts. We provide an allowance for doubtful accounts based on experience and specifically identified risks. Accounts receivable are carried at fair value and charged off against the allowance for doubtful accounts when we determine that recovery is unlikely and we cease collection efforts.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:InventoryPolicyTextBlock" id="Tb_RUL53fsni0m51seQf2LQ6A" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Inventory.</i> &#160;Inventories are determined at the lower of cost and net realizable value with cost determined under the specific identification method and may consist of raw materials, work in process and finished goods. JAKAFI and <span style="-sec-ix-hidden:Hidden_Z0f1rDx3zUCCp3VLdTAwTg"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ICLUSIG</span></span> raw materials and work-in-process inventory are not subject to expiration and the shelf life of finished goods inventory is <ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_incy_JAKAFIMember__fw2KcDlhEK50BfPWrKV_w" format="ixt-sec:durwordsen" name="incy:InventoryFinishedGoodsUsefulLifeMaximum" id="Narr_025DmrSdN0Gsf_wvU4Iy8w">36 months</ix:nonNumeric> from the start of manufacturing of the finished goods. We evaluate for potential excess inventory by analyzing current and future product demand relative to the remaining product shelf life. We build demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance and patient usage. We classify inventory as current on the condensed consolidated balance sheets when we expect inventory to be consumed for commercial use within the next twelve months.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:ConsolidationVariableInterestEntityPolicy" id="Tb_gQmXOQGAIUG41XGO_OnExw" continuedAt="Tb_gQmXOQGAIUG41XGO_OnExw_cont1" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Variable Interest Entities</i>. We perform an initial and ongoing evaluation of the entities with which we have variable interests, such as equity ownership, in order to<i style="font-style:italic;"> </i>identify entities (i) that do not have sufficient equity investment at risk to permit the entity to finance its activities without additional subordinated financial support or (ii) in which the equity investors lack an essential characteristic of a controlling financial interest as variable interest entities (&#8220;VIE&#8221; or &#8220;VIEs&#8221;). If an entity is identified as a VIE, we perform an assessment to determine whether we have both (i) the power to direct activities that most significantly impact the VIE&#8217;s economic performance and (ii) have the obligation to absorb losses from </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ceHk9ALov02Yy0bhzaPPug_cont2" continuedAt="Tb_ceHk9ALov02Yy0bhzaPPug_cont3"><ix:continuation id="Tb_gQmXOQGAIUG41XGO_OnExw_cont1"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">or the right to receive benefits of the VIE that could potentially be significant to the VIE. If both of these criteria are satisfied, we are identified as the primary beneficiary of the VIE. &#160;As of March 31, 2020, there were <ix:nonFraction unitRef="Unit_Standard_item_4BIkJQxqZkOMHOIGydcttw" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="INF" format="ixt-sec:numwordsen" name="incy:VariableInterestEntitiesNumber" scale="0" id="Narr_CDa7Ur6MG0W8ebe35V0fXQ">no</ix:nonFraction> entities in which we held a variable interest which we determined to be VIEs.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="incy:LongTermInvestmentPolicyTextBlock" id="Tb_wGUeknXW4kKKkolpHSKgvA" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Long Term Investments.</i> Our long term investments consist of equity investments in common stock of publicly-held companies with whom we have entered into collaboration and license agreements. We classify all of our equity investments in common stock of publicly-held companies as long term investments on our condensed consolidated balance sheets. Our equity investments are accounted for at fair value using readily determinable pricing available on a securities exchange on our condensed consolidated balance sheets. All changes in fair value are reported in the condensed consolidated statements of operations as an unrealized gain (loss) on long term investments. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In assessing whether we exercise significant influence over any of the companies in which we hold equity investments, we consider the nature and magnitude of our investment, any voting and protective rights we hold, any participation in the governance of the other company, and other relevant factors such as the presence of a collaboration or other business relationship. Currently, none of our equity investments in publicly-held companies are considered relationships in which we are able to assert control. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_vPZjA_50wkSa7nNUC99elQ" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Property and Equipment, net.</i> &#160;Property and equipment, net is stated at cost, less accumulated depreciation and amortization. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets. Leasehold improvements are amortized over the shorter of the estimated useful life of the assets or lease term.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_uHtKJmzhFEm9lOtt0XRJCA" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Lease Accounting.</i> &#160;Accounting Standard Codification (&#8220;ASC&#8221;) 842, Leases, was adopted for the fiscal year beginning on January 1, 2019. All leases with a lease term greater than 12 months, regardless of lease type classification, are recorded as an obligation on the balance sheet with a corresponding right-of-use asset. Both finance and operating leases are reflected as liabilities on the commencement date of the lease based on the present value of the lease payments to be made over the lease term. Current operating lease liabilities are reflected in accrued and other current liabilities and noncurrent operating lease liabilities are reflected in other liabilities on the condensed consolidated balance sheet. Right-of-use assets are valued at the initial measurement of the lease liability, plus any initial direct costs or rent prepayments, minus lease incentives and any deferred lease payments. Operating lease right-of-use assets are recorded in property and equipment, net on the condensed consolidated balance sheet and lease cost is recognized on a straight-line basis. For finance leases, expense is recognized as separate amortization and interest expense, with higher interest expense in the earlier periods of a lease. Leases with an initial term of 12 months or less are not recorded on the balance sheet and we recognize lease expense for these leases on a straight-line basis over the term of the lease. In determining whether a contract contains a lease, asset and service agreements are assessed at onset and upon modification for criteria of specifically identified assets, control and economic benefit. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="Tb_6LfRNSCdb06zWBpPlVz2QQ" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Other Intangible Assets, net.</i> Other intangible assets, net consist of licensed intellectual property rights acquired in business combinations, which are reported at acquisition date fair value, less accumulated amortization. Intangible assets with finite lives are amortized over their estimated useful lives using the straight-line method.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="Tb_-RVoqKVyF0O3NN_QtqqDfw" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Impairment of Long-Lived Assets.</i> &#160;Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. &#160;If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset. &#160;If the expected cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash flows.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="Tb_1GF5gMUFC06JE5Ffcitqdw" continuedAt="Tb_1GF5gMUFC06JE5Ffcitqdw_cont1" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Goodwill.</i> &#160;Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. &#160;Goodwill is not amortized but is tested for impairment at the reporting unit level at least annually as of October 1 or when a triggering event occurs that could indicate a potential impairment by assessing qualitative factors or performing a quantitative analysis in determining whether it is more likely than not that the fair value of net assets are below their carrying amounts. &#160;A reporting unit is the same as, or one level below, an operating segment. Our operations are currently comprised of a single, entity wide reporting </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ceHk9ALov02Yy0bhzaPPug_cont3" continuedAt="Tb_ceHk9ALov02Yy0bhzaPPug_cont4"><ix:continuation id="Tb_1GF5gMUFC06JE5Ffcitqdw_cont1"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">unit. We completed our most recent annual impairment assessment as of October 1, 2019 and determined that the carrying value of our goodwill was not impaired. </p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_VgSWBnQE0U6WS-jIf1hZ-A" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Income Taxes.</i> &#160;We account for income taxes using the asset and liability approach which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and amounts reportable for income tax purposes. &#160;<span style="background-color:#ffffff;">Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized. </span>The primary factors used to assess the likelihood of realization are our recent history of cumulative earnings or losses, expected reversals of taxable temporary timing differences, forecasts of future taxable income and available tax planning strategies that could be implemented to realize the deferred tax assets. &#160;Upon evaluating and weighting both positive and negative evidence, we concluded that we should continue to maintain the valuation allowance on the majority of our deferred tax assets as of March 31, 2020. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We recognize the tax benefit from an uncertain tax position only if it is more-likely-than-not that the position will be sustained upon examination by the taxing authorities, including resolutions of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit that is recorded for these positions is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. We adjust the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Any interest and penalties on uncertain tax positions are included within the tax provision.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Coronavirus Aid, Relief, and Economic Security (CARES) Act was signed into law in March 2020 to provide an estimated $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_3_1_2020_To_3_31_2020_PdzkVcZmpESGdHSRd_l9Vw" decimals="-11" format="ixt:numdotdecimal" name="incy:CoronavirusAidReliefAndEconomicSecurityActFund" scale="12" id="Narr_Dv53azv0CkWlF_2opX7w8Q">2.2</ix:nonFraction> trillion designed to stimulate the U.S. economy during the COVID-19 pandemic. &#160;The Act includes tax relief, government loans, grants and investments for entities in affected industries, which has related accounting and financial reporting impacts. &#160;Disclosure for certain income tax accounting measures are required in the period of enactment and disclosure for government loans, investments, grants, and revenue recognition are required in future periods as federal agencies establish rules and procedures to implement the CARES Act. &#160;During the three months ended March 31, 2020, we have not sought any financial relief under the CARES Act and have determined the income tax provision implications to be immaterial. We have further described the expected impact and risks of COVID-19 on our business in the overview to Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations and in Item 1A. Risk Factors.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:DebtPolicyTextBlock" id="Tb_vXiiBWyTWk2mAtxYsrgqAg" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Financing Costs Related to Long-term Debt.</i> &#160;Costs associated with obtaining long-term debt are deferred and amortized over the term of the related debt using the effective interest method. Such costs are presented as a direct deduction from the carrying amount of the long-term debt liability, consistent with debt discounts, on the condensed consolidated balance sheets.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_vZa0JQw0skyhflfGQlj3-Q" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Net Income (Loss) Per Share.</i> &#160;Our basic and diluted net income (loss) per share is calculated by dividing the net income (loss) by the weighted average number of shares of common stock outstanding during all periods presented. Options to purchase stock, restricted stock units, performance stock units and shares issuable upon the conversion of convertible debt are included in diluted earnings per share calculations, unless the effects are anti-dilutive.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="Tb_tivhvdlwXkKwMiG80KVcwg" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Accumulated Other Comprehensive Income (Loss).</i> &#160;Accumulated other comprehensive income (loss) consists of unrealized gains or losses on marketable securities that are classified as available-for-sale, foreign currency translation gains or losses and defined benefit pension obligations.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="Tb_5VrHyiZUNUyYUYQvauuyhg" continuedAt="Tb_5VrHyiZUNUyYUYQvauuyhg_cont1" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Revenue Recognition.</i> &#160;Revenue-generating contracts are assessed under ASC 606, <i style="font-style:italic;">Revenue from contracts with customers</i>, to identify distinct performance obligations, determine the transaction price of the contract and allocate the transaction price to each of the distinct performance obligations. Revenue is recognized when we have satisfied a performance obligation through transferring control of the promised good or service to a customer. Control, in this instance, may mean the ability to prevent other entities from directing the use of, and receiving benefit from, a good or service. We determine at contract inception whether we will transfer control of a promised good or service over time or satisfy the performance obligation at a point in time through analysis of the following criteria: (i) the entity has a present right to payment, (ii) the customer has legal title, (iii) the customer has physical possession, (iv) the customer has the significant </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ceHk9ALov02Yy0bhzaPPug_cont4" continuedAt="Tb_ceHk9ALov02Yy0bhzaPPug_cont5"><ix:continuation id="Tb_5VrHyiZUNUyYUYQvauuyhg_cont1" continuedAt="Tb_5VrHyiZUNUyYUYQvauuyhg_cont2"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">risks and rewards of ownership and (v) the customer has accepted the asset. We assess collectability based primarily on the customer&#8217;s payment history and on the creditworthiness of the customer.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration:underline;text-decoration-color:#000000;">Product Revenues</i></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our product revenues consist of U.S. sales of JAKAFI and European sales of ICLUSIG. &#160;Product revenues are recognized once we satisfy the performance obligation at a point in time under the revenue recognition criteria as described above. We sell JAKAFI to our customers in the U.S., which include specialty pharmacies and wholesalers.&#160;We sell ICLUSIG to our customers in the European Union and certain other jurisdictions, which include retail pharmacies, hospital pharmacies and distributors. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We recognize revenues for product received by our customers net of allowances for customer credits, including estimated rebates, chargebacks, discounts, returns, distribution service fees, patient assistance programs, and government rebates, such as Medicare Part D coverage gap reimbursements in the U.S. Product shipping and handling costs are included in cost of product revenues. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Customer Credits:</i> &#160;Our customers are offered various forms of consideration, including allowances, service fees and prompt payment discounts. We expect our customers will earn prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized. Service fees are also deducted from total product sales as they are earned.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Rebates and Discounts:</i> &#160;Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program in the U.S. and mandated discounts in Europe in markets where government-sponsored healthcare systems are the primary payers for healthcare. Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or legal requirements with public sector benefit providers. The accrual for rebates is based on statutory discount rates and expected utilization as well as historical data we have accumulated since product launches. Our estimates for expected utilization of rebates are based on data received from our customers. Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known prior quarters&#8217; unpaid rebates. If actual future rebates vary from estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Chargebacks: &#160;</i>Chargebacks are discounts that occur when certain contracted customers, which currently consist primarily of group purchasing organizations, Public Health Service institutions, non-profit clinics, and Federal government entities purchasing via the Federal Supply Schedule, purchase directly from our wholesalers. Contracted customers generally purchase the product at a discounted price. The wholesalers, in turn, charges back to us the difference between the price initially paid by the wholesalers and the discounted price paid by the contracted customers. In addition to actual chargebacks received we maintain an accrual for chargebacks based on the estimated contractual discounts on the inventory levels on hand in our distribution channel. &#160;If actual future chargebacks vary from these estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Medicare Part&#160;D Coverage Gap:</i> &#160;Medicare Part&#160;D prescription drug benefit mandates manufacturers to fund <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="2" format="ixt:numdotdecimal" name="incy:PercentageOfMedicarePartDInsuranceCoverageGapRequiredToBeFundedByManufacturers" scale="-2" id="Narr_xRG934HPpU-hyC3bSVqvaw">70</ix:nonFraction>% of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for the expected Medicare Part&#160;D coverage gap are based on historical invoices received and in part from data received from our customers. Funding of the coverage gap is generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known prior quarters. If actual future funding varies from estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment. &#160;Additionally, beginning in January 2020, the amount of spending required by eligible patients in the Medicare Part D insurance coverage gap increased <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="2" format="ixt:numdotdecimal" name="incy:MedicarePartDInsuranceCoverageGapIncreaseInEligiblePatientSpendingPercentage" scale="-2" id="Narr_KmkYAY19dUSX4IyAcC0Qaw">30</ix:nonFraction>% due to the expiration of a provision in the Patient Protection and Affordable Care Act, which now results in a change in the True Out of Pocket (TrOOP) calculation methodology. The methodological change has resulted in an increase in required spending by patients and, in turn, an increase in manufacturers&#8217; contributions on behalf of patients in the Medicare Part D insurance coverage gap.</p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ceHk9ALov02Yy0bhzaPPug_cont5" continuedAt="Tb_ceHk9ALov02Yy0bhzaPPug_cont6"><ix:continuation id="Tb_5VrHyiZUNUyYUYQvauuyhg_cont2" continuedAt="Tb_5VrHyiZUNUyYUYQvauuyhg_cont3"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Co-payment Assistance:</i> &#160;Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration:underline;text-decoration-color:#000000;">Product Royalty Revenues</i></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Royalty revenues on commercial sales for ruxolitinib (marketed as JAKAVI<span style="vertical-align:super;">&#174;</span> outside the United States) by Novartis Pharmaceutical International&#160;Ltd. (&#8220;Novartis&#8221;) are based on net sales of licensed products in licensed territories as provided by Novartis. &#160;Royalty revenues on commercial sales for baricitinib (marketed as OLUMIANT) by Eli Lilly and Company (&#8220;Lilly&#8221;) are based on net sales of licensed products in licensed territories as provided by Lilly. We recognize royalty revenues in the period the sales occur.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration:underline;text-decoration-color:#000000;">Milestone and Contract Revenues</i></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our license agreements, which fall within the scope of ASC 606, Revenue from Contracts with Customers, include distinct drug compound out-licensing, collection of upfront payments, milestones or royalty revenues from a counterparty, and provision of commercially available products to suppliers. Our agreements often include contractual milestones, which typically relate to the achievement of pre-specified development, regulatory and commercialization events outside of our control, such as regulatory approval of a compound, first patient dosing or achievement of sales-based thresholds. For such cases, we believe that revenue related to these events should not be recognized until the milestone has been achieved. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Some contracts form collaborative arrangements of various types with third-parties. We assess whether the nature of the arrangement is within the scope of ASC 808, Collaborative Arrangements, in conjunction with the revenue recognition guidance in ASC 606 to determine the nature of the performance obligations and associated transaction prices. A collaborative relationship may exist when we participate in an activity or process with another party, such as performance of research and development services or the exchange of intellectual property for use in clinical trials, when both parties share in the risks and rewards that result from the activity and participate and govern contract activities through a joint steering committee. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The regulatory review and approval process, which includes preclinical testing and clinical trials of each drug candidate, is lengthy, expensive and uncertain. Securing approval by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) requires the submission of extensive preclinical and clinical data and supporting information to the FDA for each indication to establish a drug candidate&#8217;s safety and efficacy. The approval process takes many years, requires the expenditure of substantial resources, involves post-marketing surveillance and may involve ongoing requirements for post-marketing studies. Before commencing clinical investigations of a drug candidate in humans, we must submit an Investigational New Drug application (&#8220;IND&#8221;), which must be reviewed by the FDA.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The steps generally required before a drug may be marketed in the United States include preclinical laboratory tests, animal studies and formulation studies, submission to the FDA of an IND for human clinical testing, performance of adequate and well-controlled clinical trials in three phases, as described below, to establish the safety and efficacy of the drug for each indication, submission of a new drug application (&#8220;NDA&#8221;) or biologics license application (&#8220;BLA&#8221;) to the FDA for review and FDA approval of the NDA or BLA.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Similar requirements exist within foreign regulatory agencies as well. The time required satisfying the FDA requirements or similar requirements of foreign regulatory agencies may vary substantially based on the type, complexity and novelty of the product or the targeted disease.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Preclinical testing includes laboratory evaluation of product pharmacology, drug metabolism, and toxicity, which includes animal studies, to assess potential safety and efficacy as well as product chemistry, stability, formulation, development, and testing. The results of the preclinical tests, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND. The FDA may raise safety concerns or questions about the conduct of the clinical trials included in the IND, and any of these concerns or questions must be resolved before clinical trials can proceed. We cannot be sure that submission of an IND will result in the FDA allowing clinical trials to commence. Clinical </p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ceHk9ALov02Yy0bhzaPPug_cont6" continuedAt="Tb_ceHk9ALov02Yy0bhzaPPug_cont7"><ix:continuation id="Tb_5VrHyiZUNUyYUYQvauuyhg_cont3"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">trials involve the administration of the investigational drug or the marketed drug to human subjects under the supervision of qualified investigators and in accordance with good clinical practices regulations covering the protection of human subjects. Clinical trials typically are conducted in three sequential phases, but the phases may overlap or be combined. Phase&#160;I usually involves the initial introduction of the investigational drug into healthy volunteers to evaluate its safety, dosage tolerance, absorption, metabolism, distribution and excretion. Phase&#160;II usually involves clinical trials in a limited patient population to evaluate dosage tolerance and optimal dosage, identify possible adverse effects and safety risks, and evaluate and gain preliminary evidence of the efficacy of the drug for specific indications. Phase&#160;III clinical trials usually further evaluate clinical efficacy and safety by testing the drug in its final form in an expanded patient population, providing statistical evidence of efficacy and safety, and providing an adequate basis for labeling. We cannot guarantee that Phase&#160;I, Phase&#160;II or Phase&#160;III testing will be completed successfully within any specified period of time, if at all. Furthermore, we, the institutional review board for a trial, or the FDA may suspend clinical trials at any time on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Generally, the milestone events contained in our collaboration agreements coincide with the progression of our drugs from development, to regulatory approval and then to commercialization. The process of successfully discovering a new development candidate, having it approved and successfully commercialized is highly uncertain. As such, the milestone payments we may earn from our partners involve a significant degree of risk to achieve. Therefore, as a drug candidate progresses through the stages of its life-cycle, the value of the drug candidate generally increases.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration:underline;text-decoration-color:#000000;">Cost of Product Revenues</i></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cost of product revenues includes all JAKAFI related product costs as well as ICLUSIG related product costs. In addition, cost of product revenues include low single-digit royalties under our collaboration and license agreement to Novartis on all future sales of JAKAFI in the United States and the amortization of our licensed intellectual property for ICLUSIG using the straight-line method over the estimated useful life of <ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_incy_ICLUSIGMember_YO1pSkx-YU6EMn97oz0Vig" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="Narr_jR2vfVnv7EypiUVZxfrowg">12.5</ix:nonNumeric> years from the date of acquisition on June 1, 2016 of all of the outstanding shares of ARIAD Pharmaceuticals (Luxembourg) S.&#224;.r.l. (since renamed Incyte Biosciences Luxembourg S.&#224;.r.l.) from ARIAD Pharmaceuticals, Inc. (&#8220;ARIAD&#8221;). Cost of product revenues also includes employee personnel costs, including stock compensation, for those employees dedicated to the production of our commercial products.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_fV2BpZF8QEuYbvImQQ0a9w" continuedAt="Tb_fV2BpZF8QEuYbvImQQ0a9w_cont1" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Development Costs.</i> &#160;Our policy is to expense research and development costs as incurred, including amounts funded by research and development collaborations. Research and development expenses are comprised of costs we incur in performing research and development activities, including salary and benefits; stock-based compensation expense; outsourced services and other direct expenses, including clinical trial and pharmaceutical development costs; collaboration payments; expenses associated with drug supplies that are not being capitalized; and infrastructure costs, including facilities costs and depreciation expense. If a collaboration is a cost-sharing arrangement in which both we and our collaborator perform development work and share costs, we also recognize, as research and development expense in the period when our collaborator incurs development expenses, our portion of the co-development expenses that we are obligated to reimburse. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We often contract with clinical research organizations (&#8220;CROs&#8221;) to facilitate, coordinate and perform agreed upon research and development of a new drug. To ensure that research and development costs are expensed as incurred, we record monthly accruals for clinical trials and preclinical testing costs based on the work performed under the contract. These CRO contracts typically call for the payment of fees for services at the initiation of the contract and/or upon the achievement of certain clinical trial milestones. In the event that we prepay CRO fees, we record the prepayment as a prepaid asset and amortize the asset into research and development expense over the period of time the contracted research and development services are performed. Most professional fees, including project and clinical management, data management, monitoring, and medical writing fees are incurred throughout the contract period. These professional fees are expensed based on their percentage of completion at a particular date. Our CRO contracts generally include pass through fees. Pass through fees include, but are not limited to, regulatory expenses, investigator fees, travel costs, and other miscellaneous costs, including shipping and printing fees. We expense the costs of pass through fees under our CRO contracts as they are incurred, based on the best information available to us at the time. The estimates of the pass through fees incurred are based on the amount of work completed for the clinical trial and are monitored through correspondence with the CROs, internal reviews and a review of contractual terms. The factors utilized to derive the estimates include the </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ceHk9ALov02Yy0bhzaPPug_cont7" continuedAt="Tb_ceHk9ALov02Yy0bhzaPPug_cont8"><ix:continuation id="Tb_fV2BpZF8QEuYbvImQQ0a9w_cont1"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">number of patients enrolled, duration of the clinical trial, estimated patient attrition, screening rate and length of the dosing regimen. CRO fees incurred to set up the clinical trial are expensed during the setup period. Under our clinical trial collaboration agreements we may be reimbursed for certain development costs incurred. Such costs are recorded as a reduction of research and development expense in the period in which the related expense is incurred. </p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_bimWwQ--PU2sh3WV6FQGnQ" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Stock Compensation.</i> &#160;Share-based payment transactions with employees, which include stock options, restricted stock units (&#8220;RSUs&#8221;) and performance shares (&#8220;PSUs&#8221;), are recognized as compensation expense over the requisite service period based on their estimated fair values as well as expected forfeiture rates. &#160;The stock compensation process requires significant judgment and the use of estimates, particularly surrounding Black-Scholes assumptions such as stock price volatility over the option term and expected option lives, as well as expected forfeiture rates and the probability of PSUs vesting. &#160;The fair value of stock options, which are subject to graded vesting, are recognized as compensation expense over the requisite service period using the accelerated attribution method. &#160;The fair value of RSUs that are subject to cliff vesting are recognized as compensation expense over the requisite service period using the straight-line attribution method, and the fair value of RSUs that are subject to graded vesting are recognized as compensation expense over the requisite service period using the accelerated attribution method. &#160;The fair value of PSUs are recognized as compensation expense beginning at the time in which the performance conditions are deemed probable of achievement, which we assess as of the end of each reporting period. Once a performance condition is considered probable, we record compensation expense based on the portion of the service period elapsed to date with respect to that award, with a cumulative catch-up, net of estimated forfeitures, and recognize any remaining compensation expense, if any, over the remaining requisite service period using the straight-line attribution method for PSUs that are subject to cliff vesting and using the accelerated attribution method for PSUs that are subject to graded vesting. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Long Term Incentive Plans.</i> We have long term incentive plans which provide eligible employees with the opportunity to receive performance and service-based incentive compensation, which may be comprised of cash, stock options, restricted stock units and/or performance shares. The payment of cash and the grant or vesting of equity may be contingent upon the achievement of pre-determined regulatory, sales and internal performance milestones. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="incy:BusinessCombinationContingentConsiderationPolicyTextBlock" id="Tb_qWqT-3KrzUicEv7HNNp0_g" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Acquisition-Related Contingent Consideration.</i> Acquisition-related contingent consideration consists of our future royalty obligations on future net sales of ICLUSIG to Takeda Pharmaceutical Company Limited, which acquired ARIAD (&#8220;Takeda&#8221;). Acquisition-related contingent consideration was recorded on the acquisition date of June 1, 2016 at the estimated fair value of the obligation, in accordance with the acquisition method of accounting. &#160;The fair value measurement is based on significant inputs that are unobservable in the market and thus represents a Level 3 measurement. The fair value of the acquisition-related contingent consideration is remeasured each reporting period, with changes in fair value recorded in the condensed consolidated statements of operations.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="Tb_DHMNWZ0wHU2uVF0XzCHBpg" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><i style="font-style:italic;">Collaboration loss sharing.</i> &#160;Under collaboration and license agreements with shared commercialization efforts, we record our share of the losses from the co-commercialization efforts in collaboration loss sharing on the condensed consolidated statement of operations. For the three months ended March 31, 2020, collaboration loss sharing represents our <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_-V355oZpTEGL8BHgB8JTrQ" decimals="2" format="ixt:numdotdecimal" name="incy:CollaborationAgreementProfitLossSharingRatio" scale="-2" id="Narr_0aThop117kqcgRmgrsnQ2w">50</ix:nonFraction>% share of the United States loss for commercialization of tafasitamab under our agreement with MorphoSys. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_IMIsj86Ga02hSIlBKsMwIw" continuedAt="Tb_IMIsj86Ga02hSIlBKsMwIw_cont1" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recent Accounting Pronouncements</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2016-13, &#8220;Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.&#8221; This guidance applies to all entities and impacts how entities account for credit losses for financial assets measured at amortized cost and available for sale debt securities. ASU 2016-13 requires financial assets measured at amortized cost to be presented at the net amount expected to be collected. The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amounts. An entity must use judgment in determining the relevant information and estimation methods that are appropriate in its circumstances. &#160;For trade receivables, loans and held-to-maturity debt securities, entities will be required to estimate expected credit losses over the lifetime of the asset. &#160;For available-for-sale debt securities, entities will be required to recognize an allowance for credit losses rather than an other-than-temporary impairment that reduces the cost basis of the investment. Further, an entity will recognize any improvements in estimated credit losses on its available-for-sale debt securities immediately in earnings. </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ceHk9ALov02Yy0bhzaPPug_cont8"><ix:continuation id="Tb_IMIsj86Ga02hSIlBKsMwIw_cont1"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon adoption, we assessed each financial asset measured at amortized cost and each available for sale debt security held for the impact of the guidance as of January 1, 2020 and noted an insignificant impact due to the minimal credit risk associated with our financial assets subject to ASC 326. As such, it was concluded that a reserve for credit losses was de minimis on the adoption date. Financial assets will continue to be assessed on a quarterly basis in future periods.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2018, the FASB issued ASU No. 2018-13, &#8220;Fair Value Measurement (Topic 820): Disclosure Framework &#8211; Changes to the Disclosure Requirements for Fair Value Measurement,&#8221; which eliminates the required disclosure of the amount of and reason for transfers between Level 1 and Level 2 of the fair value hierarchy. The guidance also eliminates the required disclosure of the entity&#8217;s valuation process for Level 3 fair value measurements, however public entities are required to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. This guidance is effective for fiscal years beginning after December 15, 2019. We adopted this guidance for the period beginning January 1, 2020 and enhanced our disclosures in Note 4 to the condensed consolidated financial statements to comply with the standard. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2018, the FASB issued ASU No. 2018-14, &#8220;Compensation &#8211; Retirement Benefits &#8211; Defined Benefit Plans &#8211; General,&#8221; an update to Subtopic ASC 715-20. The guidance amended year-end disclosure requirements related to defined benefit pension plans, and does not affect interim disclosures. The guidance is effective for fiscal years ending after December 15, 2020 and is permitted for early adoption. The standard is to be applied on a retrospective basis. Incyte sponsors defined benefit plans for employees located in Europe. We are currently analyzing the impact of ASU No. 2018-14 on the condensed consolidated financial statements.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2018, the FASB issued ASU No. 2018-15, &#8220;Intangibles &#8211; Goodwill and Other &#8211; Internal-Use Software,&#8221; an update to Subtopic ASC 350-40. The guidance directs accounting for service contracts for cloud computing arrangements to follow guidance within ASC 350-40 to determine capitalization of implementation costs. The guidance is effective for fiscal years beginning after December 15, 2019 and may be applied on either a retrospective or prospective basis. We adopted this guidance for the period beginning January 1, 2020 on a prospective basis. New contracts for development of internal-use software were assessed and no qualifying contracts were identified during the period. We will continue to assess contracts and will disclose material, qualifying contracts if identified in future periods.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2018, the FASB issued ASU No. 2018-18, &#8220;Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606.&#8221; The guidance clarifies the interactions between Topic 808 and Topic 606, including clarifications on revenue recognition, unit of account, and reporting disclosure requirements. The guidance is effective for fiscal years beginning after December 15, 2019. We adopted this guidance for the period beginning January 1, 2020 on a retrospective to the date of our initial application of ASC 606, and noted that in assessment of our collaborative agreements, there was no material financial statement impact. Our collaborative arrangements and their associated accounting conclusions are described in detail within Note 9 to the condensed consolidated financial statements.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2019, the FASB issued ASU No. 2019-12, &#8220;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.&#8221; This guidance applies to all entities and aims to reduce the complexity of tax accounting standards while enhancing reporting disclosures. This guidance is effective for fiscal years beginning after December 15, 2020 and interim periods therein. Early adoption is permitted for any annual periods for which financial statements have not been issued and interim periods therein. We are currently analyzing the impact of ASU No. 2019-12 and do not anticipate the adoption of this ASU to have a material impact on our condensed consolidated financial statements.</p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_73d86e65_6fe4_4f4f_814d_daf0da2c5686"></a><a id="Tc_BDZEKOYs-EWw655DVNiJ1g_1_2"></a><a id="Tc_fGjD-F_RpUy2Bavua2l7mQ_2_2"></a><a id="Tc_QqY8d210dEytFuztCcoG8w_3_2"></a><a id="Tc_eNVimMjJ60Gssvq2pRZq_g_3_5"></a><a id="Tc_dwHUjiLRrEypmpTDLMwXsQ_4_0"></a><a id="Tc_gNQThZcV0kKF2fhPbmZwqg_4_2"></a><a id="Tc_J6qcFBdHg0649BF02RaTRA_4_5"></a><a id="Tc_y_JySNQPvEy5roYgX60xlQ_5_0"></a><a id="Tc_5E61WOjDLkCrPbqPaNEFeg_6_0"></a><a id="Tc_1kclK6UEAEWCEQP96gVTJQ_7_0"></a><a id="Tc_1HmZ63tetkagZIVkIpnbJQ_8_0"></a><a id="Tc_n7oNmyoqMkK44XVMQipS-A_9_0"></a><a id="Tc_PsJ5TBnTiECrl4Oux7QhTQ_10_0"></a><a id="Tc_UIBymUbOHk6IkwSI068N4A_10_3"></a><a id="Tc_-ot9CdJqpUa2K1wSOOqCaw_11_0"></a><a id="Tc_2bSZkmXWTU2NqYHbuc3mYg_11_2"></a><a id="Tc_A-anjbTac0uh8fa04KcGkw_11_5"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="Tb_qzMuaNkmKk2LKRg7eSxwWA" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3.&#160;&#160;&#160;&#160; </b><b style="font-weight:bold;">Revenues</b></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="Tb_YLoH4GilP0unUigK-RBqEw" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As discussed in Note 2, revenues are recognized under guidance within ASC 606 and ASC 808. The following table presents our disaggregated revenue for the periods presented (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:41.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months&#160;Ended</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:41.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:18.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">JAKAFI revenues, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_incy_JAKAFIMember__fw2KcDlhEK50BfPWrKV_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_S7lmze4xy0KhBGes3cM04Q_4_3">459,479</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_incy_JAKAFIMember_J80BHp4_KUeJ-iOOK_2ieg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_f2ALsaAONU-yDZ625XEzcQ_4_6">375,611</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">ICLUSIG revenues, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_incy_ICLUSIGMember_YO1pSkx-YU6EMn97oz0Vig" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_q6SEB--3CUCXo2B72etujA_5_3">27,248</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_incy_ICLUSIGMember_zX4IHXitz0maYHqKIsHnOw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_hs0Jw3_g8kSU9DLhPtYnXQ_5_6">20,638</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Total product revenues, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_iqotuIRBdEWR4e6oAi-V5w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_YS9V3JmnEUaVmCEFXUCs7w_6_3">486,727</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_zIkoXlOLU0qoXHFNAsPMOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_qeD8eVL-Hk65u_XaWHGbMQ_6_6">396,249</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">JAKAVI product royalty revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_incy_JakaviRoyaltyRevenuesMember_zns3wnT-Jk-Ya594Fpdi2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_jyzPIO-iLUKVU1ajB7RVmQ_7_3">56,333</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_incy_JakaviRoyaltyRevenuesMember_gEBfS3KRGEK69j70qm4oIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_ow5EecjhJUKqYD0-8fmKMg_7_6">45,571</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">OLUMIANT product royalty revenues</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_incy_OlumiantRoyaltyMember_ub66w40qPUKCwKGhu43JRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_adeJOFt0SECQrU9eDRhPMA_8_3">25,447</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_incy_OlumiantRoyaltyMember_hSkSbP1pFEi6wsQTwl0CLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_O3Wyubj7JU-NERyABaTmkw_8_6">16,037</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Total product royalty revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_Ndda4EOg1kixjWN0CSTfeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_2pOUytN1Y0ynBsX75_HjEQ_9_3">81,780</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_801prtYWj0OCkCXY8rQvyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_z7MaWhraWkKM-yivOpC3ng_9_6">61,608</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Milestone and contract revenues</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_incy_MilestoneAndContractRevenueMember_VtUC1dCVcEWIzn5Q-dz-vg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_x0FWE9MNsEGf__nlN_OtSw_10_6">40,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_kETovZVSfkODMLLJ86f5Zg_11_3">568,507</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.5%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_W4O0zZ6ORkaYIPkYaisrlg_11_6">497,857</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">For further information on our revenue-generating contracts,<b style="font-weight:bold;"> </b>refer to Note 9 to the condensed consolidated financial statements.<b style="font-weight:bold;"> &#160;</b></p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_ECL-M6bHlEW6mxbvpuHI1w" continuedAt="Tb_ECL-M6bHlEW6mxbvpuHI1w_cont1" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">4.&#160;&#160;&#160;&#160; </b><b style="font-weight:bold;">Fair value of financial instruments</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">FASB accounting guidance defines fair value as the price that would be received to sell an asset or paid to transfer a liability (&#8220;the exit price&#8221;) in an orderly transaction between market participants at the measurement date. The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value we use quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of us. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Level&#160;1&#8212;Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Level&#160;2&#8212;Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Level&#160;3&#8212;Valuations based on inputs that are unobservable and models that are significant to the overall fair value measurement.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recurring Fair Value Measurements</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our marketable securities consist of investments in U.S. government debt securities that are classified as available-for-sale. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At March 31, 2020 and December 31, 2019, our Level 2 U.S. government debt securities were valued using readily available pricing sources which utilize market observable inputs, including the current interest rate and other characteristics for similar types of investments. Our long term investments classified as Level 1 were valued using their respective closing stock prices on The Nasdaq Stock Market. &#160;We did not experience any transfers of financial instruments between the fair value hierarchy levels during the three months ended March 31, 2020.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_db997c17_2544_4e8e_af8a_0f62db044053"></a><a id="Tc_gawadY5F-kegXpZnpQgtFQ_1_2"></a><a id="Tc_wpP9G6Xqy0izsANwMCl7Qg_2_2"></a><a id="Tc_leuxrETDDkycQtofMJRKxw_2_5"></a><a id="Tc_9WMd5lxWOE-hU_zBoi9VzQ_2_8"></a><a id="Tc_NobSp-ID-kiZR0b0KS9tmQ_3_2"></a><a id="Tc_qRV87osAXEuoVdKJHdNBQw_3_5"></a><a id="Tc_0ozRnwjB20WSXfxhiyUz1Q_3_8"></a><a id="Tc_FcT9g9EM4Eaxb8qGCEQGKQ_4_2"></a><a id="Tc_68-E7E7-0ECnZgaoC8sYYA_4_5"></a><a id="Tc_6nCU9Q-6OU693pXiHYTpoQ_4_8"></a><a id="Tc_VCowD_OfLkesWl0Ocn2Cuw_4_11"></a><a id="Tc_ucJJKLJJM0yPylRfLBWM0g_5_2"></a><a id="Tc_suz1vzyujU667q9tyCt5Xw_5_5"></a><a id="Tc_DmC3jfu8tk2BYF3IXsZMYw_5_8"></a><a id="Tc_O3bp9Tk_90-gXQgByocPKw_5_11"></a><a id="Tc_DzQuuZuVoUmklGR-YKPXrg_6_0"></a><a id="Tc_bZihZFNv80uy4UJrl4-8Ow_6_2"></a><a id="Tc_1IbYRVReWUmEfYES-vQc4w_6_5"></a><a id="Tc_nPzTfRs3aUW5T-xhOvzQ_g_6_6"></a><a id="Tc_s_KIS5IqP0aELrskuJGX_A_6_8"></a><a id="Tc_5Rh1yNnu4E-lhIUyYGpYgA_6_9"></a><a id="Tc_3lXh9Hxp0EGwxL-wpchbAg_6_11"></a><a id="Tc_bUbBVKiJv0q_QdYa5aV3NQ_7_0"></a><a id="Tc_cq4Zca55MkSFW1VdsFKqiQ_7_3"></a><a id="Tc_otKfHzzrHkOR54GbkBal3g_7_9"></a><a id="Tc_GWNYtQKLGUCmmWL3jP7tfA_8_0"></a><a id="Tc_a8yHsQbndk-3kLgYgPY1nA_8_6"></a><a id="Tc_Skvj-_Ivb0mOnYK4NHnsjg_8_9"></a><a id="Tc_KjxbP78z5Emnp8yAccFOVA_9_0"></a><a id="Tc__nF7MTa8BU2dJHMCVTc9kA_9_2"></a><a id="Tc_WgrLlhY7EUq7gxdw3pP-eQ_9_5"></a><a id="Tc_fU1z_Vfx9katEGXgnKlsow_9_8"></a><a id="Tc_uyBCoKcf-EyVsUu2MSwxXw_9_9"></a><a id="Tc_ioqT4ST8zkudbAAGQUGVow_9_11"></a><a id="_45340503_0a4c_41dd_b748_85d80276cce1"></a><a id="Tc_D_2FtPerO0-YJufbztWccg_1_2"></a><a id="Tc_xzYlJ5chr0OUdDvqnHb7wA_2_2"></a><a id="Tc_6Ev7cJd8oUS7WX6dXbJEsw_2_5"></a><a id="Tc_Sexl7jvTcEK8mxT1ESLa7g_2_8"></a><a id="Tc_lhwiVY_Ba0CqG8OmM9Xcjw_3_2"></a><a id="Tc_7752FxHix0KH_kaRHbqV3Q_3_5"></a><a id="Tc_sy-jtbTxc0uy3s9IL6mmIA_3_8"></a><a id="Tc_Gww3kIvmD06tf3hCyAm3lw_4_2"></a><a id="Tc_d6nHdFNAN0u7bRjcstd5-Q_4_5"></a><a id="Tc_sUjtUPFZ_Umd8PFC1mTRwA_4_8"></a><a id="Tc_als27zuz2EiA7zX9fZ5TgQ_4_11"></a><a id="Tc_jmjdBUpUrUSak2GhEbH_Mw_5_2"></a><a id="Tc_8EAwfHOKaUGZSzA02iNrUg_5_5"></a><a id="Tc_MAl-ievGS0GT5kQ9s-JApw_5_8"></a><a id="Tc_oG1I6u_8okuhWAg-w0SQiw_5_11"></a><a id="Tc_UtL3dMFSvEGJjyTWvN24FA_6_0"></a><a id="Tc_8JvkgitLJk6RV3suweWHeQ_6_2"></a><a id="Tc_NJb6MS7BLUyszuuwnDV24Q_6_5"></a><a id="Tc_-HhDda8hKkuPEipdC5vqCg_6_6"></a><a id="Tc_xB0MHkS_V0SSSzZsvBdilg_6_8"></a><a id="Tc_GdKf8K8dEEOMScH_ip1l3g_6_9"></a><a id="Tc_6kmP3YC54U6uypjkU2ALOw_6_11"></a><a id="Tc_wgeF6SJnz0GfTmhUFadqIw_7_0"></a><a id="Tc_0OzvWT_fg0CvuVAC-OBLPg_7_3"></a><a id="Tc_ahLAh0RrOUyfuFCSOfx94g_7_9"></a><a id="Tc_k8JoAkTYYEawOnVJ4uEnLg_8_0"></a><a id="Tc_Z6zVthKkQ0awFqYWF2xV4A_8_6"></a><a id="Tc_StrfFJCm-UOjY6nW3NAwxA_8_9"></a><a id="Tc_K226WRLg9Uy8CNhojrSPvA_9_0"></a><a id="Tc__KAowvIPJUCDH6ZLyM-4rg_9_2"></a><a id="Tc_DoqB0mCKt0GtzyNmnqI8EQ_9_5"></a><a id="Tc_5-X6D_tmokeWjw1D6Tc4Aw_9_8"></a><a id="Tc_qnS7QEkiUEmoNo-_em8zMA_9_9"></a><a id="Tc_zh7LZcVgpUCARcHHJD1_rQ_9_11"></a><a id="_660ffc65_477b_4df2_bd0d_735e8f4ef6e4"></a><a id="Tc_hPvnCYI6PE2MkTYLPGgfWQ_1_2"></a><a id="Tc_xqr-JcApgkiJNHEvjuI87A_2_2"></a><a id="Tc_zEPv52Z0SEGtJXqonBxbuw_2_5"></a><a id="Tc_D4bcsib8BkSHFANfpUL5kA_2_8"></a><a id="Tc_HqFrhZs3JU6Imiq-KmNG4g_3_2"></a><a id="Tc_ifnqWYYryEKvDddXmwjAyg_3_5"></a><a id="Tc__MwkMTGCy0GW2Vh9G8AFHA_3_8"></a><a id="Tc_l-GAWkSuQEWqnTRhr9ZeYg_4_2"></a><a id="Tc_DGQzFOl1q02M4PtpfOjdRw_4_5"></a><a id="Tc_M2J4SJVR6UqRCd01afB8rA_4_8"></a><a id="Tc_gEcQ1NN8UkefASVQk1Dg2Q_4_11"></a><a id="Tc_8ePDTaqHH0ezBtwFYK4t_w_5_2"></a><a id="Tc_IWVQUN2rPUi3hW2FLcSnjg_5_5"></a><a id="Tc_8qwUPtWwhEyPYG9gjtOrcQ_5_8"></a><a id="Tc_kpW6a6eYvUKeA80fRzJj_g_5_11"></a><a id="Tc_pPRWfjIt0kqCuuR7jINLBw_6_0"></a><a id="Tc_AnO4jnqVzEOrTR96GRwu5A_6_2"></a><a id="Tc_n4XZk3YKNEi0__Lo0cH8Ig_6_3"></a><a id="Tc_L7D1RiFL8UmzRM6RWlJSNQ_6_5"></a><a id="Tc_Ly7Qec9YHEOlAuv1gtx-5A_6_6"></a><a id="Tc_swOEiL17q0iRt8OiyJ24gg_6_8"></a><a id="Tc_limlpkDw_0C8rkyrAs2pZA_6_11"></a><a id="Tc_vJgRailR5Uy6ds5V-6RI7A_7_0"></a><a id="Tc_UXI2MKkpkECsXoU1G4o1og_7_2"></a><a id="Tc_nY0CwY8Xmki2It3lm1bCwg_7_3"></a><a id="Tc_Cb0FjoTglUC_ZysMiBUPqA_7_5"></a><a id="Tc_6495cYJffkqGWNUDpAPAAg_7_6"></a><a id="Tc_Ld7oWde4VUyefkL--9VWkA_7_8"></a><a id="Tc_dju8LUIlA0O2Hdbrha7D3A_7_11"></a><a id="_cd84e999_f8af_459b_8a76_8d9aaaa6582e"></a><a id="Tc_Ld2a-e03zUCoVHcFxZg35A_1_2"></a><a id="Tc_2RBw39T0ykqmgkC8Yb29lA_2_2"></a><a id="Tc_tiYsalUrKEm5P_1CEFbNrw_2_5"></a><a id="Tc_IcJQbt-9AUyjFj_mCx4MOg_2_8"></a><a id="Tc_UhUEVbG8WEKHGmevau1s3w_3_2"></a><a id="Tc_M0rNrsg9okCBBlur1mNA_g_3_5"></a><a id="Tc_cMeJJexmQk6XM2oSNTwJXw_3_8"></a><a id="Tc_-f4SpQ-vDE6iDDJ_t5fsWQ_4_2"></a><a id="Tc_oY0u-xlKY0qaOJCyarktiA_4_5"></a><a id="Tc_oqhSa-uRT0Cmlh6TnE9VSw_4_8"></a><a id="Tc_MfgJBgfDSUG4zlXN616mfA_4_11"></a><a id="Tc__SzGp2ZE8UeiB0q70mBbMw_5_2"></a><a id="Tc_Aq1EoL7A8kOfV-p5BNpC_w_5_5"></a><a id="Tc_6uyIZsZRHESxW3H_JcCWAQ_5_8"></a><a id="Tc_wTRdrSuiY0KoBUaXUdZaNg_5_11"></a><a id="Tc_5zVjMQHid0yARCHVN4apEQ_6_0"></a><a id="Tc_tebQ0MqTbEaX-TOkVrVyFA_6_2"></a><a id="Tc_TbOeKlRwWku6bkAPbqYB-g_6_3"></a><a id="Tc_quPooItrUkScQnowXcuGhg_6_5"></a><a id="Tc_W2L-u8pVfki_DmeYA8wxtQ_6_6"></a><a id="Tc_D9La6P46-Uqt1WaQdEmHgg_6_8"></a><a id="Tc_jscbr4y3fEuxLHMXDwAwEw_6_11"></a><a id="Tc_XMWtTkBckkiUWITZ37hjmQ_7_0"></a><a id="Tc_WUKvxeAQ0EmtCJ3TUud1cA_7_2"></a><a id="Tc_Dyp2ScUnp0yicJN5u6V9xw_7_3"></a><a id="Tc_31s7MSXEq0ml4InKNXYxLw_7_5"></a><a id="Tc_YVuCXolMNEaY8bwBK84q8w_7_6"></a><a id="Tc_2QFAqXmRXUaLpyRNOP6GKg_7_8"></a><a id="Tc_XNwf0od0q0yNqu5ReUfOFw_7_11"></a><a id="_226c47c5_f0b2_4310_b5ac_6ace6ccfb428"></a><a id="Tc_o9CG4OiLEkiqVhEj0zBiaA_1_2"></a><a id="Tc_c34qyNX0ZE-6LH2POaH9vQ_2_0"></a><a id="Tc_K66gqQPpT0W0ctxZ_teCiA_2_2"></a><a id="Tc_1rnLbIsG6kWL1RU_00Ia5Q_3_0"></a><a id="Tc_-YoXAlvni0iTqtV6WJQK4g_4_0"></a><a id="Tc_gf5rbw4vGUSv7nHNYtltTA_5_0"></a><a id="Tc_KZ_o3TY2P0yjawuJYncJDw_5_2"></a><ix:continuation id="Tb_ECL-M6bHlEW6mxbvpuHI1w_cont1" continuedAt="Tb_ECL-M6bHlEW6mxbvpuHI1w_cont2"><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="Tb_e0BJCr3UUEiNQ7WMNuCxsw" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following fair value hierarchy table presents information about each major category of our financial assets measured at fair value on a recurring basis (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:39.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurement&#160;at&#160;Reporting&#160;Date&#160;Using:</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets&#160;for</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical&#160;Assets</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance&#160;as&#160;of</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, 2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_O7zFu8UChUGSYYKQwC_Jgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_o1f7Atu6UUaUIzc6w58ILQ_6_3">1,043,241</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vzfnNpXOk0-u4q-eKRYLuQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_MvBALrDCJEGCTfXKYTkKkQ_6_12">1,043,241</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Debt securities (government)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fokaHHGN_US8Vn_P7eshvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_QPNDWiHI60KGb3Z3rkbJCw_7_6">259,351</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vzfnNpXOk0-u4q-eKRYLuQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_0KjG0qu1sEqiqQivz2aDCA_7_12">259,351</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Long term investments (Note 9)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_O7zFu8UChUGSYYKQwC_Jgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="3" id="Tc_dDBa9fejMEiwIWS0wI3Fmg_8_3">180,993</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vzfnNpXOk0-u4q-eKRYLuQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="3" id="Tc_vP-eo9W2gEmoOaiU3mpm6w_8_12">180,993</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_O7zFu8UChUGSYYKQwC_Jgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_Ewt30lk5REqo3V-s0NHuAw_9_3">1,224,234</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fokaHHGN_US8Vn_P7eshvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_2EERXIfG1ki6t5ILQiWqxQ_9_6">259,351</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vzfnNpXOk0-u4q-eKRYLuQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_ZNYNJR5GJUO3hEzmn4OKVw_9_12">1,483,585</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:39.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurement&#160;at&#160;Reporting&#160;Date&#160;Using:</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets&#160;for</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical&#160;Assets</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance&#160;as&#160;of</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31, 2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_YPDANAjNxES2dszn1Xx1jA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_bQyoQY-OVkmfBssii2qZYw_6_3">1,832,684</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_SgUaszookkqnrXkDEDnurA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_CTLYd5Bfo06j6RcYJbzmxQ_6_12">1,832,684</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Debt securities (government)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_rGtntt3PoUmQLgQUufOvRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_OFoZ8I36AUO-bA73ZUd_wA_7_6">284,870</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_SgUaszookkqnrXkDEDnurA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_BAObm2k2f0a5sAFO5GBW1w_7_12">284,870</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Long term investments (Note 9)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_YPDANAjNxES2dszn1Xx1jA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="3" id="Tc_XrNySBMzu06i9AUKbjOySw_8_3">133,657</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_SgUaszookkqnrXkDEDnurA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="3" id="Tc_QA5AOZh8D0O0DTt63gj0bQ_8_12">133,657</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_YPDANAjNxES2dszn1Xx1jA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_-85Y8msAFEG2aBYtAdUp_A_9_3">1,966,341</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_rGtntt3PoUmQLgQUufOvRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_eHDFV3rcoUSpRHzenpx8wQ_9_6">284,870</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_SgUaszookkqnrXkDEDnurA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_YwvHxBKFTEm3Ax1nkHwP6A_9_12">2,251,211</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" id="Tb_FxVno3y70kGulolTBBjHSw" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following fair value hierarchy table presents information about each major category of our financial liabilities measured at fair value on a recurring basis as (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:39.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurement&#160;at&#160;Reporting&#160;Date&#160;Using:</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets&#160;for</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical&#160;Liabilities</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance&#160;as&#160;of</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, 2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Acquisition-related contingent consideration</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_aaFIoA90rESC-8Dh21XUzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="Tc_XMtSR7qK8U26vYglz5qvEQ_6_9">275,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vzfnNpXOk0-u4q-eKRYLuQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="Tc_aDdrHTwzB02ginhBrTKngA_6_12">275,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_aaFIoA90rESC-8Dh21XUzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="Tc_A4VptjMi1UeHFgR0qE0YXw_7_9">275,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vzfnNpXOk0-u4q-eKRYLuQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="Tc_sSuZWZEOKkCkyWCzIf4eAw_7_12">275,000</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100.5%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:39.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurement&#160;at&#160;Reporting&#160;Date&#160;Using:</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets&#160;for</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical&#160;Liabilities</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance&#160;as&#160;of</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31, 2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Acquisition-related contingent consideration</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wmT2dRGShkmAkpk-MnUNQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="Tc_wON2cM2ynE-9FNV7WPNrYA_6_9">277,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_SgUaszookkqnrXkDEDnurA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="Tc_3Jh_Y42QjE-CD2KOCzM92Q_6_12">277,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wmT2dRGShkmAkpk-MnUNQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="Tc_8_1jJJBB30GjmFNbc18tOQ_7_9">277,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_SgUaszookkqnrXkDEDnurA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="Tc_Jr17SYVS60uKbt0lhH-l2w_7_12">277,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="Tb_5d1Z2AbRi0enPDo73q9ezg" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following is a rollforward of our Level 3 liabilities (in thousands):</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:82.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Balance at January 1, </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_RmAbn78EhEiQanXoFkVVRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_FgosX-pzKEqy1Mg-NE_wug_2_3">277,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Contingent consideration earned during the period but not yet paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_XgR3Kyb9BUuL8DSnhdbM0A" decimals="-3" format="ixt:numdotdecimal" name="incy:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned" scale="3" id="Tc_Kz2tS0gw_0SgjA40JXR0-w_3_3">8,627</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Change in fair value of contingent consideration</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_XgR3Kyb9BUuL8DSnhdbM0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="Tc_i62_Tr-ekkmorxTiWm7xxg_4_3">6,627</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Balance at March&#160;31, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_bwDrZo3Tr0aCPMmzLzjjyw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_MiJK9F_3u0KYZHtfUPck0g_5_3">275,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The fair value of the contingent consideration was determined on the date of acquisition, June 1, 2016, using an income approach based on estimated ICLUSIG revenues in the European Union and other countries for the approved third line treatment over <ix:nonNumeric contextRef="Duration_6_1_2016_To_6_1_2016_us-gaap_BusinessAcquisitionAxis_incy_AriadPharmaceuticalsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_LiabilityMember_-BGrwF-qIkuMeVQ7qNEL5Q" format="ixt-sec:durwordsen" name="incy:FairValueInputsCashFlowsEstimatedPeriod" id="Narr_sEDdpBWtvU2NZyh80lWpBw">18 years</ix:nonNumeric>, and discounted to present value at a rate of <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="As_Of_6_1_2016_us-gaap_BusinessAcquisitionAxis_incy_AriadPharmaceuticalsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_LiabilityMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_hQh32X0nE0CI4sShb6FASg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="Narr_zIXBUPkSOE6nre9LRbMIGg">10</ix:nonFraction>%. The fair value of the contingent consideration is remeasured each reporting period, with changes in fair value recorded in the consolidated statements of operations. The valuation inputs utilized to estimate the fair value of the contingent consideration as of March 31, 2020 included a weighted average cost of capital of <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="As_Of_3_31_2020_us-gaap_BusinessAcquisitionAxis_incy_AriadPharmaceuticalsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_LiabilityMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputCapRateMember_W3i3GxnCAEexsivT7-_BCA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="Narr_3T8ppZcdTECs182Bfzwysg">10</ix:nonFraction>% and updated projections of future ICLUSIG revenues in the European Union and other </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_abefd7b9_6d2a_45da_a107_a1cf0ae14de7"></a><a id="Tc_G9CAhdGWfE-yqVw6o3ZkKA_1_5"></a><a id="Tc_NmUjyis8-k2rW4dvXx9xmQ_1_8"></a><a id="Tc_nzA9iYx-60qXLh4F5w8wOQ_2_2"></a><a id="Tc_8lO6DTSmV0ejErnkXsat8A_2_5"></a><a id="Tc_r79xUafTt0mmMRrmjn6tPw_2_8"></a><a id="Tc_XFxP9hkiz0Goj2flVjvrLQ_2_11"></a><a id="Tc_m3QvpvXOUES4yjPrREN-Tg_3_2"></a><a id="Tc_jEYMyVK91kS_xZ4wK-pl9w_3_5"></a><a id="Tc_nmvoMwYlGESCiky0sOTTuA_3_8"></a><a id="Tc_TDdVBxserUaw1jCvI2vZAw_3_11"></a><a id="Tc_25-d5s3o6kidRB6V7OLg1A_4_0"></a><a id="Tc_2aOnABg5NUm6m6n1hoxXXA_5_0"></a><a id="Tc_K5JBSZMWU0S7VDM9eBq0LQ_5_2"></a><a id="Tc_KiRpw0Gnu0yX5iHLPNwQ5w_5_5"></a><a id="Tc_x6sHH5invkSECKJS6bJaLg_5_8"></a><a id="Tc_oirBEu1zK0Sflhr4nKDKTQ_5_9"></a><a id="Tc_Dw_aOgFDQkGYKztaF_mtJw_5_11"></a><a id="Tc_ZTXrv4nxsUWy0zjOpcs4Pw_7_0"></a><a id="Tc_BRMwLrqNUU-iGZxE3LBzcw_8_0"></a><a id="Tc_-Ta-EQuix0qPjoTd317b-w_8_2"></a><a id="Tc_XVaBLtTavkqWd8-GFv0T7g_8_5"></a><a id="Tc_5tV4oI7X2EaDjZgS3xcTeg_8_8"></a><a id="Tc_qujb5bO7oUuD3fVxyNIwxg_8_9"></a><a id="Tc_s3WYCUlHhEyVhffgcdyjVA_8_11"></a><ix:continuation id="Tb_ECL-M6bHlEW6mxbvpuHI1w_cont2"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">countries for the approved third line treatment. The change in fair value of the contingent consideration during the three months ended March 31, 2020 was due primarily to the passage of time as there were no other significant changes in the key assumptions during the period. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We make payments to Takeda quarterly based on the royalties or any additional milestone payments earned in the previous quarter. At March 31, 2020 and December 31, 2019, contingent consideration earned but not yet paid was $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_BalanceSheetLocationAxis_incy_AccruedAndOtherCurrentLiabilityMember_us-gaap_BusinessAcquisitionAxis_incy_AriadPharmaceuticalsMember_eNBdRdYCsk2AT0YapnXIQg" decimals="-5" format="ixt:numdotdecimal" name="incy:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned" scale="6" id="Narr_Ml7kqkM_KEiCsL_0Ed2f4g">8.6</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_BalanceSheetLocationAxis_incy_AccruedAndOtherCurrentLiabilityMember_us-gaap_BusinessAcquisitionAxis_incy_AriadPharmaceuticalsMember_Rx_uiVSjYEmmn41tyR4osA" decimals="-5" format="ixt:numdotdecimal" name="incy:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned" scale="6" id="Narr_nhtgfjojt0u0C2lgM12uIA">23.0</ix:nonFraction> million, respectively, and was included in accrued and other current liabilities.</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="Tb_BC7xIo3obkiReNUud7sBAg" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"> The following is a summary of our marketable security portfolio for the periods presented (in thousands):</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:99.15%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">March&#160;31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Debt securities (government)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_FinancialInstrumentAxis_incy_CorporateAndGovernmentDebtSecuritiesMember__EpAzA1tU0628uub7apmQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_PGDjAQzSzU-d3o22_WwIqg_5_3">258,622</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_FinancialInstrumentAxis_incy_CorporateAndGovernmentDebtSecuritiesMember__EpAzA1tU0628uub7apmQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_LOe26LIEpUe-xc6sbD66mg_5_6">729</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_FinancialInstrumentAxis_incy_CorporateAndGovernmentDebtSecuritiesMember__EpAzA1tU0628uub7apmQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_QOPjvCIH706rzpCdvfaJnw_5_12">259,351</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">December&#160;31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Debt securities (government)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_FinancialInstrumentAxis_incy_CorporateAndGovernmentDebtSecuritiesMember_BpEuHfSwDE-2bwHlTacRhg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_1XbgrmHgF0uNycWSUiZdYQ_8_3">284,795</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_FinancialInstrumentAxis_incy_CorporateAndGovernmentDebtSecuritiesMember_BpEuHfSwDE-2bwHlTacRhg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_BnPE6ah4TUu9kEPVYfYiRw_8_6">75</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_FinancialInstrumentAxis_incy_CorporateAndGovernmentDebtSecuritiesMember_BpEuHfSwDE-2bwHlTacRhg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_rxevMPTe_kK-XD58eS1Z-A_8_12">284,870</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our available-for-sale debt securities generally have contractual maturity dates of between <span style="-sec-ix-hidden:Hidden_wxfFNirtIkK2gW_Xg1C_gw"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">12</span></span> to <ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_incy_CorporateAndGovernmentDebtSecuritiesMember_ZlCggm6Ff0Wzf5NwRBQL8Q" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="Narr_H2kQyC91X0mpf0-JNGyq5g">18 months</ix:nonNumeric>. Debt security assets were assessed for risk of expected credit losses per our accounting policy as described in Note 2. As of March 31, 2020 and December 31, 2019, the available-for-sale debt securities were held in US-government backed funds and Treasury assets and were assessed on an individual security basis to have a de minimis risk of credit loss.</p></ix:continuation><a id="_769d98df_8203_4fc5_b52a_81f885c3262b"></a><a id="Tc_PMtlH2kRX0Sqt4T72zMWBg_1_2"></a><a id="Tc_Zv9pNWU1eE2htg_AjPJokg_2_2"></a><a id="Tc_4GvAf-W3bEeL2o3K-aVNKQ_3_2"></a><a id="Tc_nadgZVe__kyK7s1QtOSyRA_4_2"></a><a id="Tc_iQ6IAjF9Lk20oAocXIcSUg_5_2"></a><a id="Tc_Pf8K6KYetE6TxHWaisOyDw_5_4"></a><a id="Tc_nmUfhZJL1ES354rKzp9QNA_6_0"></a><a id="Tc_ap8tk7jG40GnDlcBF39JpQ_6_3"></a><a id="Tc_wvvjla-ZfUazdC6l8Z9JvQ_6_5"></a><a id="Tc_kUoiyIFnIkCGIYtHzOYNLA_7_0"></a><a id="Tc_ZMUuhhQRg0G0qh51E46rWA_7_3"></a><a id="Tc_jwVi3s4le0mX-MVbZ7jvxg_7_5"></a><a id="Tc_yXHtIEaFq02WWrLk7Lefvg_8_0"></a><a id="Tc_GZlB5D1FvE2PMmbZd_acSg_8_3"></a><a id="Tc_Wr6PAaJKOU-9Mla31fuv1Q_8_5"></a><a id="Tc_7gkNF_rBIkSx-ihC-72adA_9_0"></a><a id="Tc_RAqIEwDQoUOYH38UoDPAkw_9_3"></a><a id="Tc_brsqk7sDHEmzuYTgOA4m7A_9_5"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:ConcentrationRiskDisclosureTextBlock" id="Tb_9qTWZAkxLE-SlBh1u1p4Cg" continuedAt="Tb_9qTWZAkxLE-SlBh1u1p4Cg_cont1" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">5.&#160;&#160;&#160;&#160; </b><b style="font-weight:bold;">Concentration of credit risk and current expected credit losses</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">In November 2009, we entered into a collaboration and license agreement with Novartis. In December 2009, we entered into a license, development and commercialization agreement with Lilly. In December 2018, we entered into a research collaboration and licensing agreement with Innovent Biologics, Inc. (&#8220;Innovent&#8221;). In July 2019, we entered into a collaboration and license agreement with Zai Lab (Shanghai) Co., Ltd., a subsidiary of Zai Lab Limited (collectively, &#8220;Zai Lab&#8221;). The above collaboration partners comprised, in aggregate, <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2020_To_3_31_2020_srt_MajorCustomersAxis_incy_CollaborationPartneraBAndCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_qEwDHoxU_kykVFnagpQ7eg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_8UzJKz-GpkurFyioHOs0wg">24</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2019_To_12_31_2019_srt_MajorCustomersAxis_incy_CollaborationPartneraBAndCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_GNwwFEEnHkOgZF7ymHUW2g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_d7Se6nSDxUOt36gJl_seaw">30</ix:nonFraction>% of the accounts receivable balance as of March 31, 2020 and December 31, 2019, respectively. &#160;For further information relating these collaboration and license agreements,<b style="font-weight:bold;"> </b>refer to Note 9 to the condensed consolidated financial statements.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2011, we began commercialization and distribution of JAKAFI to a number of customers. Our product revenues are concentrated in a number of these customers that are specialty pharmacies and wholesalers. The concentration of credit risk related to our JAKAFI product revenues is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="incy:SchedulesOfConcentrationOfRiskByRiskFactorRelatedToSpecialtyPharmaceuticalCustomersTableTextBlock" id="Tb_pbKr_AITL0GxJe2R84JeGA" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:26.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percentage&#160;of&#160;Total&#160;Net</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:26.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Product&#160;Revenues&#160;for&#160;the</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:26.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months&#160;Ended</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:26.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Customer A</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2020_To_3_31_2020_srt_MajorCustomersAxis_incy_CustomerAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_incy_SalesRevenueGoodsServicesNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Fqdfsibh4kKYy4vq1H2Aew" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_Hh3ibm1l9kqouxpK_VQp8g_6_2">19</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2019_To_3_31_2019_srt_MajorCustomersAxis_incy_CustomerAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_incy_SalesRevenueGoodsServicesNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_f3XjwLwtRkSypl-ZsaWVPQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_SUTUt6CKQ0O6sMw9Aqbz5w_6_4">18</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Customer B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2020_To_3_31_2020_srt_MajorCustomersAxis_incy_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_incy_SalesRevenueGoodsServicesNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_sJWHbHVE3k67_lQw54yY_A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_nZ0JSZbeREqUi80mRHNgrA_7_2">13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2019_To_3_31_2019_srt_MajorCustomersAxis_incy_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_incy_SalesRevenueGoodsServicesNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_guuZvSOjo0u0KsbTuzRxeQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_oiBTnfin2kiBF_TVzQmQmg_7_4">15</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Customer C</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2020_To_3_31_2020_srt_MajorCustomersAxis_incy_CustomerCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_incy_SalesRevenueGoodsServicesNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_-RMVb1Fvokicsqve2ojFBA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_h1MVYpXmNkCzwTaELts0ug_8_2">18</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2019_To_3_31_2019_srt_MajorCustomersAxis_incy_CustomerCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_incy_SalesRevenueGoodsServicesNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_eOhzoKcIP0OkJVjjz8gMLA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_3mdDKuDiMkarwBKFGFcprQ_8_4">16</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Customer D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2020_To_3_31_2020_srt_MajorCustomersAxis_incy_CustomerDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_incy_SalesRevenueGoodsServicesNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_jdQZkwbreEeOVODBdtyWjQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_J7UEYxconk-LYZf9bJ3M_Q_9_2">11</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2019_To_3_31_2019_srt_MajorCustomersAxis_incy_CustomerDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_incy_SalesRevenueGoodsServicesNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_AYtvU5JiEE2vyJD2GOHIpA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_NfByhtmHakePY_-UH8Y0PA_9_4">12</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are exposed to risks associated with extending credit to customers related to the sale of products. Customers A, B, C and D comprised, in aggregate, <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2020_To_3_31_2020_srt_MajorCustomersAxis_incy_CustomerABCAndDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_aIRqd3JLu0iLl9imB6WWgQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_hRbAIzykB0mDztZ2dHSiig">40</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2019_To_12_31_2019_srt_MajorCustomersAxis_incy_CustomerABCAndDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_nrSCSBku-kmb34bhbBHQUg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_VTz4OQ3cu0aeJqMFJSfe-Q">39</ix:nonFraction>% of the accounts receivable balance as of March 31, 2020 and December 31, 2019, respectively. The concentration of credit risk relating to ICLUSIG product revenues or accounts receivable is not significant.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We assessed our collaborative and customer receivable assets as of March 31, 2020 according to our accounting policy for applying reserves for expected credit losses, noting minimal history of uncollectible receivables and the </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_9qTWZAkxLE-SlBh1u1p4Cg_cont1"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">continued perceived creditworthiness of our third party sales relationships, upon which the expected credit losses were considered de minimis. </p></ix:continuation><a id="_ee318442_4513_4477_a2e7_219d3d0d3e1c"></a><a id="Tc_jDwrq3SNLkWFwD1qh0WKEA_1_2"></a><a id="Tc_pB55Yo3ZtUilXYRywz3Emw_1_5"></a><a id="Tc_8PjlnXlGMUqXy8jGra7t-g_2_2"></a><a id="Tc_K9g_2ZSKgkW_QbMk9BF9Nw_2_5"></a><a id="Tc_pNL-BrNjDUmq7hfMjy2O7w_3_0"></a><a id="Tc_w8YiCCXf4kqhHPMU9amnMA_3_2"></a><a id="Tc_yr7J9Bj6U0qFOstQmwwbAg_3_5"></a><a id="Tc_0Bi1Wf3qhEi-nmDPBpoHRw_4_0"></a><a id="Tc_f-mP9219xE-jKVdCy5NTEg_5_0"></a><a id="Tc_QxjA4mZdt0-f5iGf0F3Znw_7_0"></a><a id="Tc_-frbRr2LEkmdRbWswb_T_g_8_0"></a><a id="Tc_Vv7BadyxHUefIc1HkxU73Q_8_2"></a><a id="Tc_Leq-uJ3lN0qRu-ka9mS18A_8_5"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:InventoryDisclosureTextBlock" id="Tb_ptGI0irUz0Gj4VZUNSAbhQ" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">6.</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;"> Inventory</b></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="incy:ScheduleOfInventoryTableTextBlock" id="Tb_20JSw3cNREKZp4VG2bvjvg" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our inventory balance consists of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_qLz5WnT7CUys28lIc483GA_3_3">1,275</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_yQev0iTdMUyHtfNf6UePvw_3_6">1,275</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Work-in-process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_9UxcJXvMcEOc_9g_W8zIcg_4_3">11,228</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_JhU6lI5UsUqsVwmVg6QYaA_4_6">8,634</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_Rn7000cMBUCzA12fxM4DPQ_5_3">9,714</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_HD3nmf04LESuyjqc1i8O9A_5_6">6,596</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="incy:InventoryNetCurrentAndNoncurrent" scale="3" id="Tc_wgZQqG6K_kqyyFHhXn3A_Q_6_3">22,217</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="incy:InventoryNetCurrentAndNoncurrent" scale="3" id="Tc_JNMLKT5lUEqXu_P0lkpO5w_6_6">16,505</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Inventories-current</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_7NkncYMprkmWPK0k433qSg_7_3">13,977</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_1w8xptrMSEWR-RS3YvoE6w_7_6">11,400</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Inventories-noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="3" id="Tc_Qulo5VSsYkSeU4FCtBLhTA_8_3">8,240</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="3" id="Tc_W_R-X6Cn90uiD8qKRQrbvw_8_6">5,105</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Inventories, stated at the lower of cost and net realizable value, consist of raw materials, work in process and finished goods. At March 31, 2020, $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="Narr_gDAU37xqrE2t1zzFXNdSmg">14.0</ix:nonFraction> million of inventory was classified as current on the condensed consolidated balance sheet as we expect this inventory to be consumed for commercial use within the next twelve months. At March 31, 2020, $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="Narr_8F9iRmNPKU-qNDugjS7VXw">8.2</ix:nonFraction> million of inventory was classified as noncurrent on the condensed consolidated balance sheets as we did not expect this inventory to be consumed for commercial use within the next twelve months. &#160;We obtain some inventory components from a limited number of suppliers due to technology, availability, price, quality or other considerations. The loss of a supplier, the deterioration of our relationship with a supplier, or any unilateral violation of the contractual terms under which we are supplied components by a supplier could adversely affect our total revenues and gross margins.</p></ix:nonNumeric><a id="_666cde74_e844_4f77_a772_b39048edff65"></a><a id="Tc_-TBVW9KzK0--revqNSAEzA_1_2"></a><a id="Tc_LnQQeV5rmEaEQsYG-avlug_1_5"></a><a id="Tc_vH_DX_UYH0G-ny4y1GFDfg_2_2"></a><a id="Tc_CBE671kfH0-nL-1zLMu56A_2_5"></a><a id="Tc_Ddvgwl8M-UenHGCKBWmV3A_3_0"></a><a id="Tc_TdShrkL2UEWZ_XNsYhYzGg_3_2"></a><a id="Tc_lFXbm0vLEkW-51oNCx9_QQ_3_5"></a><a id="Tc_Y_8fpZg-80mUKBibuX81WA_4_0"></a><a id="Tc_yuORj23iPU6M20HpAAf72Q_5_0"></a><a id="Tc_lmLMmpg4vUOHKeFrtaWk3g_6_0"></a><a id="Tc_ZEGZfGGm30u_XJVUbrzUIg_7_0"></a><a id="Tc_I2Ek65nX5kqFj5iISyDXhQ_8_0"></a><a id="Tc_KQc1xdtSqEGmegsv__ZzLw_9_0"></a><a id="Tc_qVwOhE4CYEKhcvdZ5jX0ww_11_0"></a><a id="Tc_SH6fxC0RIkutechCcdyWBA_12_0"></a><a id="Tc_MU5M8DtiTkaIArYkLac-9A_12_2"></a><a id="Tc_frUG2trT5UeOCcrZDbAzoA_12_5"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_lKn_S-EQKkm-4WMXNVQyPw" continuedAt="Tb_lKn_S-EQKkm-4WMXNVQyPw_cont1" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">7.&#160;&#160;&#160;&#160;Property and equipment, net</b></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_R0EKuOUAWkCLTIoy6MNvyQ" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment, net consists of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri';">&#160;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Office equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_OpaZX17-qki74dlsTGJgWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_h1q5ZQiHB0qfdnNPT_b9BQ_3_3">15,285</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_Fz8X3N5MXEKKKq7aHQVBHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_CVEY325EREmlv3r9ka1P7g_3_6">15,303</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_Uc4T8OoznUaWUBZFbSY_iQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_xZA22gqqH0uMVn4hfm1euQ_4_3">72,352</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_VmJWm_2dZ0KLxA_TYtgIWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_mvdt72EZvk2r7V27937m7g_4_6">70,510</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Computer equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_Os6xIsQTJkSi8T8XKdZa9g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_1Sr6ILdegkSBiRXPugQG8g_5_3">60,077</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_BhUGXoa_EEGIKABq8Fc4Hg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_ZidGNiUDlE6DodOhz9UxHA_5_6">59,069</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Land</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember_-A59uhU7lE2X3hkgLlOppQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_Uwyj_AjsDkSpzDrLcr0aMA_6_3">10,227</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember_U4SkB6IAZkiT0rKLLkS3fw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_nAFwRKFHmUmU3gyIuAdkhw_6_6">10,203</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Building and leasehold improvements</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_incy_BuildingAndLeaseholdImprovementsMember_ip5R7-17nEmNlOU8G0fwCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_q_VozUHe1UqJ4eO7kqqPag_7_3">208,276</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_incy_BuildingAndLeaseholdImprovementsMember_nfb1lKsHeUq_kOC7b4Hp-w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_59GjttQVYE-M2wh7MYUg-A_7_6">208,293</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Operating lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_incy_OperatingLeaseRightOfUseAssetsMember_OnCRjgugL0CS9Eac1n0YMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_w_CShMHKVEiwrwpnMDJ2gg_8_3">18,641</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_incy_OperatingLeaseRightOfUseAssetsMember_acMKMXWO1UmpzV7l3A0xFQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_XCvUrmyYLEykyPi2elXcYQ_8_6">19,672</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Construction in progress</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_X2RaDJKM2UKzTQvrCqAeaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_xxta-WwNuEy9J7GCjFxCig_9_3">153,508</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_H7HrVzI_zk64zWsiLLAWBQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_GpZ8cOoZEkO0Ou9KB4fCJQ_9_6">116,387</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_sK9ziIA5NkKjtRc_W2c-9g_10_3">538,366</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_vmuMUGMS0k-5ay2wGKWFBw_10_6">499,437</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Less accumulated depreciation and amortization</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_DJgrBePoLUioqMh7WtKeZQ_11_3">128,332</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_fXFD5MExa0WAX9kFRWpPGw_11_6">121,870</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_2B5fQkkl60iAaVeHvvhwiA_12_3">410,034</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_wfHGENShUU-nHxB8B-IhkQ_12_6">377,567</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2018, we signed an agreement to rent a building in Morges, Switzerland for an initial term of <ix:nonNumeric contextRef="As_Of_2_28_2018_us-gaap_RealEstatePropertiesAxis_incy_OfficeBuildingMorgesSwitzerlandMember_sv07bVwxFk-3b4wTy2XUvQ" format="ixt-sec:durwordsen" name="us-gaap:LesseeFinanceLeaseTermOfContract1" id="Narr_cEhS6YND00CgBgCv9HNWbQ">15 years</ix:nonNumeric> plus one year of free rent, with multiple <ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_RealEstatePropertiesAxis_incy_OfficeBuildingMorgesSwitzerlandMember_hyf9S0MCgUaWtQ2fty1E5g" format="ixt:booleantrue" name="us-gaap:LesseeFinanceLeaseExistenceOfOptionToExtend" id="Narr_GNI8tGCF4k631LxD3IdcVg">options to extend</ix:nonNumeric> for an additional <ix:nonNumeric contextRef="As_Of_2_28_2018_us-gaap_RealEstatePropertiesAxis_incy_OfficeBuildingMorgesSwitzerlandMember_sv07bVwxFk-3b4wTy2XUvQ" format="ixt-sec:durwordsen" name="us-gaap:LesseeFinanceLeaseRenewalTerm1" id="Narr_x44hpv4YmEewHdCOunwvTA">20 years</ix:nonNumeric>. The building will serve as our new European headquarters and will consist of approximately <ix:nonFraction unitRef="Unit_Standard_sqft_EcjTExigKk28_NSPhmR_FQ" contextRef="As_Of_2_28_2018_us-gaap_RealEstatePropertiesAxis_incy_OfficeBuildingMorgesSwitzerlandMember_sv07bVwxFk-3b4wTy2XUvQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="Narr_5HmyOvkc3EaxqRnVnCOhpw">100,000</ix:nonFraction> square feet of office space. This building will allow for consolidation of our European operations that are currently located in Geneva and Lausanne, Switzerland. Building permits were granted by the local government authorities in September 2018 and construction activity began immediately thereafter. In June 2019, we obtained control of the Morges building to begin our construction activity. At that time, we determined the lease to be a finance lease and recorded a lease liability of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_6_30_2019_us-gaap_RealEstatePropertiesAxis_incy_OfficeBuildingMorgesSwitzerlandMember_cTCu8-DdLUWDnNq9pv0w3g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiability" scale="6" id="Narr_w25g0szbV0y5XX4vKovfHw">31.1</ix:nonFraction> million and a finance lease right-of-use asset of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_6_30_2019_us-gaap_RealEstatePropertiesAxis_incy_OfficeBuildingMorgesSwitzerlandMember_cTCu8-DdLUWDnNq9pv0w3g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="Narr_p4agxveGiUKzi9ghmBmybQ">29.1</ix:nonFraction> million, net of a lease incentive from our landlord of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_6_30_2019_us-gaap_RealEstatePropertiesAxis_incy_OfficeBuildingMorgesSwitzerlandMember_cTCu8-DdLUWDnNq9pv0w3g" decimals="-5" format="ixt:numdotdecimal" name="incy:FinanceLeaseLeaseIncentiveReceivable" scale="6" id="Narr_C1JiSwbwNUCYhOC-9k_quQ">2.0</ix:nonFraction> million. As of March 31, 2020, we have capitalized approximately $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_RealEstatePropertiesAxis_incy_OfficeBuildingMorgesSwitzerlandMember_KrB3YVMc5UW_hq4utsVGBg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConstructionInProgressGross" scale="6" id="Narr_ulB-KUFzB0WC2CSizSTxlA">18.2</ix:nonFraction> million in on site preparation, design and construction costs. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In July 2018, we signed an agreement to purchase land located in Yverdon, Switzerland. The land was purchased, in cash, for approximately $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_7_1_2018_To_7_31_2018_us-gaap_RealEstatePropertiesAxis_incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember_cI046B97zkCNRFIvPRRTaw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireRealEstate" scale="6" id="Narr_POusVYbSlkC8Vhhk5BkwCw">4.8</ix:nonFraction> million. Upon this parcel, we are constructing a large molecule production facility. &#160;</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_6d92695f_5024_4a53_a834_b496430dfe66"></a><a id="Tc_EZymwB1-eUWpZiDGFczfVQ_1_2"></a><a id="Tc_b5HOO0pz90CHcR0mFuZjug_1_5"></a><a id="Tc_8oXxYE5ZsUiEWxJsOR5R3A_2_2"></a><a id="Tc_kpxMYXizMEuPEs71AaREfA_2_5"></a><a id="Tc_f6PzeV_UE0Kn1CtIgBeQqA_3_0"></a><a id="Tc_yl_f8nDyWUGRblGJ5p1now_4_2"></a><a id="Tc_yKNHf1g3cE-YO6rZJPqlGw_4_5"></a><a id="Tc_8xUss2iaAE2np_Ubyb5wcg_6_0"></a><a id="Tc_Xj4jVbj5b0-lJ-iYqLxuEA_9_0"></a><a id="Tc_l04C_GVe3UaMWkDHjUharw_9_2"></a><a id="Tc_IWvDRuzFFku1agk2B31HIw_9_5"></a><ix:continuation id="Tb_lKn_S-EQKkm-4WMXNVQyPw_cont1"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Construction activity commenced in July 2018 and as of March 31, 2020, we have capitalized approximately $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_us-gaap_RealEstatePropertiesAxis_incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember_vZQPIl3GOUCQvPfbSWPEeA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="Narr_SmAy3InoKEaqn6zyT5uVKQ">102.8</ix:nonFraction> million in costs for construction, ground preparation and architectural and engineering studies. We currently anticipate the facility will be completed in the second half of 2020.</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="incy:LesseeLeaseLiabilityTableTextBlock" id="Tb_vgICce07DEGtfBen6aU_fQ" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are the lessee of several contracts, including those to secure fleet vehicles, buildings and equipment. Our lease agreements do not contain any material <ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" format="ixt:booleanfalse" name="us-gaap:LesseeOperatingLeaseExistenceOfResidualValueGuarantee" id="Narr_2t4PnkTtck-AQysH7jyHcQ">residual value guarantees</ix:nonNumeric> or restrictive covenants. Some of our building leases include <ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" format="ixt:booleantrue" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="Narr_CBxw0IsJ60qJZhlG5E_G2Q">options to renew</ix:nonNumeric> and the exercise of these options is at our discretion. Our current operating lease liabilities are reflected in accrued and other current liabilities and our noncurrent operating lease liabilities are reflected in other liabilities on the condensed consolidated balance sheets and are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:71.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri';">&#160;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Current</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="-sec-ix-hidden:Hidden_DXWVUeF4QEyCGxw9FL_y3g"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Operating lease liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_WfVAxHpbrkOwJ-5kv3x9zQ_4_3">9,021</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_-pP9g-Py-k-KKfG2x9a2UQ_4_6">9,343</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="-sec-ix-hidden:Hidden_fgS4bxuAUka7K61E668xgw"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Finance lease liabilities</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="Tc_Q6uEYoDs80aSVXxloqI1Ug_5_3">910</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="Tc_RJfM-9RwI0CYYhZuYOF48Q_5_6">664</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="-sec-ix-hidden:Hidden_DZPOj2yYtU-8JCIk7usOfw"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Operating lease liabilities</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_18mg9Q7MqkOAUFciOuJ1SA_7_3">11,151</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_4zZnMtfzN0WYtlm1xRaoDA_7_6">11,854</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="-sec-ix-hidden:Hidden_T_UTUYhcFUKgazgt2tP-VA"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Finance lease liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="Tc_uodjNssHY0C9n7yP04m3Eg_8_3">31,959</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="Tc_RQB7GPERgU6AWW_jtNJEsg_8_6">31,918</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Total lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="incy:OperatingAndFinanceLeaseLiability" scale="3" id="Tc_H-uzBx0Y30alPGMDMyzS-w_9_3">53,041</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="incy:OperatingAndFinanceLeaseLiability" scale="3" id="Tc_AwAVARM5z0-vjPo6tnmWRw_9_6">53,779</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The cash paid for amounts included in the measurement of our operating lease liabilities as of March 31, 2020 and 2019 was $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="Narr_NUYqyqGBKUC6obAvUX60LQ">3.2</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="Narr_s2fOSQfkNUm5wBiBwOhK8g">2.8</ix:nonFraction> million, respectively, in operating cash flows. The cash paid for amounts included in the measurement of our finance lease liabilities as of March 31, 2020 and 2019 was $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="6" id="Narr_234Ew5_k5Uq26E9CdLSxzQ"><ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="6" id="Narr_ztP93M-FH02sZQ9wXqzdzQ">0.2</ix:nonFraction></ix:nonFraction> million in financing cash flows. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">As of March 31, 2020, our finance and operating leases had a weighted average lease term of approximately <ix:nonNumeric contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="Narr_gFnm7IWH3kWTYbcAaA6jtw">15.4</ix:nonNumeric> and <ix:nonNumeric contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Narr_5rPs-2NHdkeqVulD9Mzy5g">3.1</ix:nonNumeric> years, respectively. The discount rate of our leases is an approximation of an estimated incremental borrowing rate and is dependent upon the term and economics of each agreement. The weighted average discount rate of our finance and operating leases is approximately <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Narr_gwrxRwOaM0iAuEBRHiNf4g">3.6</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Narr_FcEsAkP3w02AwZy6CkUjpw">4.4</ix:nonFraction>%, respectively. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">For the three months ended March 31, 2020, we incurred approximately $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="6" id="Narr_TwxJp7ipLUaNeHxob97rSw">3.2</ix:nonFraction> million of expense related to our operating leases, approximately $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="Narr_X7riq-_Us02KzNP-Ot2JGA">0.6</ix:nonFraction> million of amortization on our finance lease right-of-use assets and approximately $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="Narr_BeFGj5TvqUaRuB6nlv0_jg">0.3</ix:nonFraction> million of interest expense on our finance lease liabilities. For the three months ended March 31, 2019, we incurred approximately $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="6" id="Narr_EzVh5pf1OkC7l22nomXIDg">3.6</ix:nonFraction> million of expense related to our operating leases, approximately $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="Narr_MqKlh1gAGkmk8NST-toAgA">0.2</ix:nonFraction> million of amortization on our finance lease right-of-use assets and a de minimis amount of interest expense on our finance lease liabilities. Rent expense for the three months ended March 31, 2020 and 2019 was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="Narr_3ionoq0rX0uArtXQbLbrLQ">3.5</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="Narr_DhLlVDdLNEKM4bfc6EK_8w">3.3</ix:nonFraction> million, respectively. For the three months ended March 31, 2020 and 2019, the cost of our short term leases with a term less than 12 months was de minimis. </p></ix:continuation><a id="_79748267_989f_4334_989e_b481d909c250"></a><a id="Tc_hVuu2gokfk69mcMINY4zpQ_1_4"></a><a id="Tc_cMLsSUEaMkettT2ryJ27sA_1_13"></a><a id="Tc_bkvxtKm0NU-MwvzuHDODmQ_2_2"></a><a id="Tc_4u4Bf-Ao8E-rxRGdNNhQdw_2_4"></a><a id="Tc_fznSgrrFGky4GTnavXplZg_2_10"></a><a id="Tc_q4el8jEXHUiBcSa96_NFog_2_13"></a><a id="Tc_Hcvg0-Ohu0OyydymrI83tw_2_19"></a><a id="Tc_IJFn4RYkIE6cBMr-4e4tzA_3_2"></a><a id="Tc_hOCD0Xe7g0CPIgCDUBGakw_3_4"></a><a id="Tc_dr5FVG9qq0a2FhZFHGGsOQ_3_7"></a><a id="Tc_dyF9dxCh-EO3euhMvoixOQ_3_10"></a><a id="Tc_RPT3GnTw-0SRj5GJ97DgpA_3_13"></a><a id="Tc_HeJzp4g_jUKuFGjrrLeb0A_3_16"></a><a id="Tc_FGsJdZ3Q3E6LAsBRc667Pg_3_19"></a><a id="Tc_TRLBj70gR0S0124-5I7aDw_4_2"></a><a id="Tc_HM5p8kDUGkm0h3Fjkvz7rQ_4_4"></a><a id="Tc_uDUCBWTiPUq6w7WX3NQ00g_4_7"></a><a id="Tc_qoAa5fcPuEqRQ9kUZ_IS6A_4_10"></a><a id="Tc_CP3DtpvPT0-EyURAoZDf9Q_4_13"></a><a id="Tc_xoSVh1svykun9zUUcJHUpg_4_16"></a><a id="Tc_MlmFkqrU00aQNDi57fLzcg_4_19"></a><a id="Tc_w1ZrwaM4J0Cp1PEqJDiLkQ_5_0"></a><a id="Tc_osd3_RrMmkO4kwQBe-jzBg_6_0"></a><a id="Tc_gcwvZigc7U2ChRIUOtfUbg_6_4"></a><a id="Tc_OStsixyiQUKRbQlaTRq9cw_6_7"></a><a id="Tc_NINmqEMadkagEVUeHunPLg_6_10"></a><a id="Tc_E8LQL4WFIk2Isxs38V5kJQ_6_13"></a><a id="Tc_F11i3MUJ_UmXL57LH3n93A_6_16"></a><a id="Tc_oPNgxddsbkK_m-LxfUBxlw_6_19"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="Tb_zne9P99wWUq0PaiV-8a3Nw" continuedAt="Tb_zne9P99wWUq0PaiV-8a3Nw_cont1" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">8.&#160;&#160;&#160;&#160;Intangible assets and goodwill</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intangible Assets, Net</span></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="Tb_AIjQ4uM3Y0u5W41LTyRLgQ" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The components of intangible assets were as follows (in thousands, except for useful life):</p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100.55%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:23.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:23.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="color:#0000ff;font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:30.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at March&#160;31, 2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:30.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at December&#160;31, 2019</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:23.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="color:#0000ff;font-size:14pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:23.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average Useful</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:23.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Lives (Years)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td colspan="3" style="background-color:auto;vertical-align:bottom;width:35.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Finite-lived intangible assets:</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:23.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Licensed IP</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_-OdiLY_HUEi_z6wHQe3vIQ" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="Tc_YI11P3-tOUe4DrYWlbyccg_6_2">12.5</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_UHqTF8VUAUCGTkb1EXExuw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_Ir-cfB9mC0WZVMsHvKbGmA_6_5">271,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_UHqTF8VUAUCGTkb1EXExuw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_SikwbJosAEGcqwgGdFAHjA_6_8">82,556</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_UHqTF8VUAUCGTkb1EXExuw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_CqajxChtskSeMTfRrcvKew_6_11">188,444</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_eOfQkKzKrUOycC233zEEKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_o63Cb9ueAkCD17lsV8aNmA_6_14">271,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_eOfQkKzKrUOycC233zEEKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_UlG75idZJUK5RjybW6lvqQ_6_17">77,172</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_eOfQkKzKrUOycC233zEEKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_xNFtRJB89E68ULTuBJoYSw_6_20">193,828</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_62db1f5a_0bf5_49a5_83a4_9e46f9b663a5"></a><a id="Tc_1CeAJPWjHEa_pGsG1QlqcQ_1_2"></a><a id="Tc_g8o0ent_LUyR6E2pNWeSsw_2_2"></a><a id="Tc_-Tvnx7Gul0CSkLLfm5_DRQ_2_5"></a><a id="Tc_QgDCWbv5j0-EsWt2Em2WMQ_2_8"></a><a id="Tc_27oIIgExG0uLzFHilY5ZwA_2_11"></a><a id="Tc_jrzFAUn_d0qUDrvsRxj40w_2_14"></a><a id="Tc_D4W6AoFFs06ZVlLcIrUpKQ_2_17"></a><a id="Tc_QiuAjtbPOE6IJwMuHjB7Qw_3_0"></a><a id="Tc_e8wP28xnR0avW8kx52W5xw_3_1"></a><a id="Tc_OwL-HImId0my7uKmf92Z0g_3_4"></a><a id="Tc_0p47NS3SkkyvjeY7aZZZdQ_3_7"></a><a id="Tc_k35_QbxI_02-9UpNIo1Jig_3_10"></a><a id="Tc_egds3KUZskOQ3romQS80fQ_3_13"></a><a id="Tc_14XQErxOz0amgS-2OmS0SQ_3_16"></a><ix:continuation id="Tb_zne9P99wWUq0PaiV-8a3Nw_cont1"><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="Tb_WB4bu1UHZ02FT8cOlyPO1A" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Estimated aggregate amortization expense based on the current carrying value of amortizable intangible assets is as follows (in thousands):</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100.01%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:40.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:40.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remainder of</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:40.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Thereafter</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:40.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Amortization expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="3" id="Tc_RXodCQeDjEGW8RpGSbiTXA_3_2">16,152</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="3" id="Tc_0swbum2ck06ghvNIDxf_dQ_3_5">21,536</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="3" id="Tc_irpwwdUVtEGzTWyWkQen8A_3_8">21,536</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" id="Tc_ibImQnpc5E-Z0M9PN6Le7g_3_11">21,536</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="3" id="Tc_FMVgp_reckiYTKmQLU-XHQ_3_14">21,536</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="3" id="Tc_A7Vvu-CKDUegsO9J97Ikwg_3_17">86,148</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Goodwill</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There were <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:GoodwillPeriodIncreaseDecrease" scale="6" id="Narr_9RANwHvxNkWHGYvfYShMSg">no</ix:nonFraction> changes to the carrying amount of goodwill for the three months ended March 31, 2020.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="incy:LicenseAgreementsTextBlock" id="Tb_xIYI6-e6KkOK_cK6DMNvmQ" continuedAt="Tb_xIYI6-e6KkOK_cK6DMNvmQ_cont1" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">9.&#160;&#160;&#160;&#160;License agreements</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Novartis</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2009, we entered into a Collaboration and License Agreement with Novartis. Under the terms of the agreement, Novartis received exclusive development and commercialization rights outside of the United States to our JAK inhibitor ruxolitinib and certain back-up compounds for hematologic and oncology indications, including all hematological malignancies, solid tumors and myeloproliferative diseases. We retained exclusive development and commercialization rights to JAKAFI (ruxolitinib) in the United States and in certain other indications. &#160;Novartis also received worldwide exclusive development and commercialization rights to our MET inhibitor compound capmatinib and certain back-up compounds in all indications. We retained options to co-develop and to co-promote capmatinib in the United States.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Under this agreement, we received an upfront payment and immediate milestone payment totaling $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_11_1_2009_To_11_30_2009_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_A9wnHAKOPUiEb-WirPUvYA" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" scale="6" id="Narr_KL44N3jMaESjrEzQUULtgg">210.0</ix:nonFraction>&#160;million and were initially eligible to receive up to $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_11_1_2009_To_11_30_2009_incy_AchievementOfMilestoneAxis_incy_PreSpecifiedEventsMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember__tZTD8Vmu0GW3hPdg82qeQ" decimals="-8" format="ixt:numdotdecimal" name="incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" scale="9" id="Narr_sR1R5mHcyUuCBhvkz8yTnw">1.2</ix:nonFraction>&#160;billion in milestone payments across multiple indications upon the achievement of pre-specified events, including up to $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_11_1_2009_To_11_30_2009_incy_AchievementOfMilestoneAxis_incy_DevelopmentMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_wtKKfm2jZ0yM-1dlYFTMnA" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" scale="6" id="Narr_RSue9WjEvkm1FbVe1dgx9g">174.0</ix:nonFraction>&#160;million for the achievement of development milestones, up to $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_11_1_2009_To_11_30_2009_incy_AchievementOfMilestoneAxis_incy_RegulatoryMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_zksZlxX7L0aZmXvNApJ4Eg" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" scale="6" id="Narr_VEmmE2BP40mNtbzVF7QeFQ">495.0</ix:nonFraction>&#160;million for the achievement of regulatory milestones and up to $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_11_1_2009_To_11_30_2009_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_MJwI5aFJqEO8pUKY2yAKBw" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" scale="6" id="Narr_HU1lfSNKz0uzgxLxtRRvbA">500.0</ix:nonFraction>&#160;million for the achievement of commercialization milestones. In April 2016, we amended this agreement to provide that Novartis has exclusive research, development and commercialization rights outside of the United States to ruxolitinib (excluding topical formulations) in the graft-versus-host-disease (&#8220;GVHD&#8221;) field. We became eligible to receive up to $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_4_1_2016_To_4_30_2016_incy_AchievementOfMilestoneAxis_incy_DevelopmentAndRegulatoryMilestonesMember_srt_ProductOrServiceAxis_incy_GvhdMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_ZRB_EBm4DkyNeZO2LH5-Dg" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" scale="6" id="Narr_RJvDT_bHUkKQeyY-9uhPzA">75.0</ix:nonFraction> million of additional potential development and regulatory milestones relating to GVHD.  We recognize development and regulatory milestones upon confirmation of achievement of the event, as development and regulatory approvals are events not controllable by us but rather development activities of Novartis and decisions made by regulatory agencies. We recognize sales milestones in the corresponding period of the product sale upon confirmation of net sales milestone threshold achievement by Novartis. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Exclusive of the upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_12_1_2009_To_12_31_2009_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_1SaePKedd0OWp_iIJJVHXw" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementUpfrontPaymentReceived" scale="6" id="Narr_X4zRlAFxuk2HI1RUTkW4XA">150.0</ix:nonFraction> million received in 2009 and the immediate milestone of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2010_To_1_31_2010_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_D9O6EwtrQ063PpAtibslDA" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementImmediateMilestonePaymentReceived" scale="6" id="Narr_wN418WNr_EmeDr2PQKG0Pg">60.0</ix:nonFraction> million earned in 2010, we have recognized and received in the aggregate $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_11_1_2009_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_DevelopmentMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_9-Pn4E2E_kSLd-r3M4EQbQ" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" scale="6" id="Narr_M1awvsqpmU-oQ_pR9fNHRg">132.0</ix:nonFraction> million for the achievement of development milestones, $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_11_1_2009_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_RegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_Y2Gx6SWIbEqR4hwAGpSZ5Q" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" scale="6" id="Narr_5G66E0pUeUOVX8wl3p5oCA">215.0</ix:nonFraction> million for the achievement of regulatory milestones and $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_11_1_2009_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_C1OZWHg3g0uldVYjrprkFA" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" scale="6" id="Narr_4c8k4HHFYkKJMjDYTb4C1g">120.0</ix:nonFraction> million for the achievement of sales milestones through March 31, 2020. In 2018, we recognized a $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2018_To_12_31_2018_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_ProductOrServiceAxis_incy_JakaviMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_VTtBfVOpYEyYEfKARlTg8A" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" scale="6" id="Narr_rVkUh5UAoEShgJH_O0KxaA">60.0</ix:nonFraction> million sales milestone for Novartis achieving annual net sales of a JAK licensed product of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2018_To_12_31_2018_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_ProductOrServiceAxis_incy_JakaviMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_VTtBfVOpYEyYEfKARlTg8A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_rLQquxlUyUmzQzljSsfHrA">900.0</ix:nonFraction> million. In 2017, we recognized a $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2017_To_12_31_2017_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_ProductOrServiceAxis_incy_JakaviMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_5B46pCgC4U6TcjzvVo1wJA" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" scale="6" id="Narr_nQqhreZyrUuu0Z9X97_FXA">40.0</ix:nonFraction> million sales milestone for Novartis achieving annual net sales of a JAK licensed product of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2017_To_12_31_2017_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_ProductOrServiceAxis_incy_JakaviMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_5B46pCgC4U6TcjzvVo1wJA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_FMFkV60afkqIzOds3RkXJA">600.0</ix:nonFraction> million and a $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2017_To_12_31_2017_incy_AchievementOfMilestoneAxis_incy_DevelopmentMilestonesMember_incy_PhasesOfArrangementsAxis_incy_PhaseThreeMember_srt_ProductOrServiceAxis_incy_GvhdMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_PHAppsJyCU6_gL715nvt8w" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" scale="6" id="Narr_ohzdwc0bHUqh7c9b2PrByw">25.0</ix:nonFraction> million development milestone based on the formal initiation by Novartis of a Phase III clinical trial evaluating ruxolitinib in GVHD. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We also are eligible to receive tiered, double-digit royalties ranging from the upper-teens to the mid-twenties on future JAKAVI net sales outside of the United States, and tiered, worldwide royalties on future capmatinib net sales that range from <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_incy_JakaviMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_3GwL6JL350ydhcQXwwZPzQ" decimals="2" format="ixt:numdotdecimal" name="incy:PercentageOfRoyaltyRatePayments" scale="-2" id="Narr_Bl_cNQsWJk2tLhthkpIA8Q">12</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_incy_JakaviMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_AVkAZtSlqUSKsew2Ua_8jg" decimals="2" format="ixt:numdotdecimal" name="incy:PercentageOfRoyaltyRatePayments" scale="-2" id="Narr_Iqn-9J_VEEO4_71ZKjz0KQ">14</ix:nonFraction>%. Since the achievement of the $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_9_1_2014_To_9_30_2014_incy_AchievementOfMilestoneAxis_incy_RegulatoryMilestonesMember_srt_ProductOrServiceAxis_incy_JakaviMember_srt_StatementGeographicalAxis_srt_EuropeMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_-D5iCFjOtEOHLfhUWXsfAA" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" scale="6" id="Narr_z0Bq5hBm6UWdT-7ra4V41A">60.0</ix:nonFraction> million regulatory milestone related to reimbursement of JAKAVI in Europe in September 2014, we are obligated to pay to Novartis tiered royalties in the low single-digits on future JAKAFI net sales within the United States. During the three months ended March 31, 2020 and 2019, such royalties payable to Novartis on net sales within the United States totaled $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_incy_JAKAFIMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_28xwnjC9e0Sh55l-kRb2nQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInRoyaltiesPayable" scale="6" id="Narr__yZpQNEubEi-KMNbzwS0vg">17.5</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_incy_JAKAFIMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_BdI492nuSkutSDrwULb1hw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInRoyaltiesPayable" scale="6" id="Narr_E0P-9AAlgUiMwXUfcZPWCg">13.4</ix:nonFraction> million, respectively, and are reflected in cost of product revenues on the condensed consolidated statements of operations. At March 31, 2020 and December 31, 2019, $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_srt_ProductOrServiceAxis_incy_JAKAFIMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_mfwS80yn5ESSYPVY2L68BQ" decimals="-5" format="ixt:numdotdecimal" name="incy:RoyaltiesPayable" scale="6" id="Narr_3pZBYG1WEEOmzG26_3_HbA">56.3</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_srt_ProductOrServiceAxis_incy_JAKAFIMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_2-_MOs2yjU-WWrny5byzXQ" decimals="-5" format="ixt:numdotdecimal" name="incy:RoyaltiesPayable" scale="6" id="Narr_dQRVapZD5EiijfbgBaet7g">50.2</ix:nonFraction> million, respectively, of accrued royalties payable to Novartis were included in accrued and other current liabilities on the condensed consolidated balance sheets. Each company is responsible for costs relating to the development and commercialization of ruxolitinib in its respective territories, with costs of </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_xIYI6-e6KkOK_cK6DMNvmQ_cont1" continuedAt="Tb_xIYI6-e6KkOK_cK6DMNvmQ_cont2"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">collaborative studies shared equally. Novartis is also responsible for all costs relating to the development and commercialization of capmatinib.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Novartis agreement will continue on a program-by-program basis until Novartis has no royalty payment obligations with respect to such program or, if earlier, the termination of the agreement or any program in accordance with the terms of the agreement. Royalties are payable by Novartis on a product-by-product and country-by-country basis until the latest to occur of (i)&#160;the expiration of the last valid claim of the licensed patent rights covering the licensed product in the relevant country, (ii)&#160;the expiration of regulatory exclusivity for the licensed product in such country and (iii)&#160;a specified period from first commercial sale in such country of the licensed product by Novartis or its affiliates or sublicensees. The agreement may be terminated in its entirety or on a program-by-program basis by Novartis for convenience. The agreement may also be terminated by either party under certain other circumstances, including material breach.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Reimbursable costs incurred after the effective date of the agreement with Novartis are recorded net against the related research and development expenses. At March 31, 2020 and December 31, 2019, $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_ZvhiClZSVke50DoQFEthjg" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementReimbursableCosts" scale="6" id="Narr_SfuH9qyINkiVEdx8Dn2GAg">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_QXsD9niNL0WfkNO0BEluBQ" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementReimbursableCosts" scale="6" id="Narr_lYxJbQLeREWFRge8VkfFuA">0.4</ix:nonFraction>&#160;million, respectively, of reimbursable costs were included in accounts receivable on the condensed consolidated balance sheets. Research and development expenses for the three months ended March 31, 2020 and 2019 were net of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_Bx9b-kfxkUS7NmglDo36lw" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementResearchAndDevelopmentReimbursedCost" scale="6" id="Narr_bN5GOrm90kG8h9J8AkI8IQ">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_VI1jInirZE-TkdoXTr7aBw" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementResearchAndDevelopmentReimbursedCost" scale="6" id="Narr_OlnQCZamo0mIVYKlb7jEjw">0.6</ix:nonFraction> million, respectively, of costs reimbursed by Novartis.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Milestone and contract revenue under the Novartis agreement for the three months ended March 31, 2020 and 2019 was $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_incy_AchievementOfMilestoneAxis_incy_DevelopmentAndCommercializationMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_RxSzkAad5ES3uONix4NATw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_JoakQhgslUi3mF_Vt1XU4Q"><ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_DevelopmentAndCommercializationMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_3WbzHyKMakilo4AxBzCjyw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_dj2vIdz0e0WTjSd6ZdeCsA">0.0</ix:nonFraction></ix:nonFraction> million for each period.  Product royalty revenue related to Novartis net sales of JAKAVI outside of the United States for the three months ended March 31, 2020 and 2019 was $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_incy_JakaviMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_GNv-lY-ZsUCHv1M3VoVXPg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_z26UerTDaEmz3R3jMIMn7Q">56.3</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_incy_JakaviMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_b36l365IDEWlJXt_MSsqIA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_g9Fhkp0lZ0-VC-PIj9GFwQ">45.6</ix:nonFraction> million, respectively. &#160;At March 31, 2020 and December 31, 2019, $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_ZvhiClZSVke50DoQFEthjg" decimals="-5" format="ixt:numdotdecimal" name="incy:RoyaltyPaymentReceivable" scale="6" id="Narr_PrXFeURJAUqRrXpnkP5Xyg">56.3</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_QXsD9niNL0WfkNO0BEluBQ" decimals="-5" format="ixt:numdotdecimal" name="incy:RoyaltyPaymentReceivable" scale="6" id="Narr_-31DzUhKu0-FZvxpdtJq8A">65.0</ix:nonFraction> million, respectively, of product royalties were included in accounts receivable on the condensed consolidated balance sheets.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Lilly - Baricitinib</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2009, we entered into a License, Development and Commercialization Agreement with Lilly. Under the terms of the agreement, Lilly received exclusive worldwide development and commercialization rights to our JAK inhibitor baricitinib, and certain back-up compounds for inflammatory and autoimmune diseases. We received an upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_12_1_2009_To_12_31_2009_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_F7owIWcWcESiFzYW1Mzbig" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementUpfrontPaymentReceived" scale="6" id="Narr_VQRo3_HBUkG2Tfz89xSiNw">90.0</ix:nonFraction>&#160;million, and were initially eligible to receive up to $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_12_1_2009_To_12_31_2009_incy_AchievementOfMilestoneAxis_incy_PreSpecifiedEventsMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_4-WVfL6AnEGN9XUCN2Qzkg" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" scale="6" id="Narr_NPWXfXpk8UO-itY6RnIq7g">665.0</ix:nonFraction>&#160;million in substantive milestone payments across multiple indications upon the achievement of pre-specified events, including up to $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_12_1_2009_To_12_31_2009_incy_AchievementOfMilestoneAxis_incy_DevelopmentMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_hql1KJZ8iU62EhDjjNk-sA" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" scale="6" id="Narr_R8NbGupiZk2udmcKdeSPJQ">150.0</ix:nonFraction>&#160;million for the achievement of development milestones, up to $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_12_1_2009_To_12_31_2009_incy_AchievementOfMilestoneAxis_incy_RegulatoryMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_QW2Dt4PfxUSmygcBR82y9w" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" scale="6" id="Narr_6t1bLlE7MkC5XgTG26jVJA">365.0</ix:nonFraction>&#160;million for the achievement of regulatory milestones and up to $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_12_1_2009_To_12_31_2009_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_2tauCzcC80iBzbGQiJbcgQ" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" scale="6" id="Narr_VOdnEhDrZEeNGyZ2fW0Gww">150.0</ix:nonFraction>&#160;million for the achievement of commercialization milestones. Exclusive of the upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_12_1_2009_To_12_31_2009_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_F7owIWcWcESiFzYW1Mzbig" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementUpfrontPaymentReceived" scale="6" id="Narr_hwmgSmlxj0KkjRGL2S-W4w">90.0</ix:nonFraction> million received in 2009, we have recognized and received, in aggregate, $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_12_1_2009_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_DevelopmentMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_lSHmlJZy7kyXkEGNGXcb4w" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" scale="6" id="Narr_WKYCSoKS50uQGIkBhiuOWg">149.0</ix:nonFraction> million for the achievement of development milestones and $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_12_1_2009_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_RegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_POZKRL4X4UeOibd7iQ44iQ" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" scale="6" id="Narr_ac8unAAq10a4ibFIRsQdlQ">235.0</ix:nonFraction> million for the achievement of regulatory milestones through March 31, 2020. We recognize development and regulatory milestones upon confirmation of achievement of the event, as development and regulatory approvals are events not controllable by us but rather development activities of Lilly and decisions made by regulatory agencies. We recognize sales milestones in the corresponding period of the product sale upon confirmation of net sales milestone threshold achievement by Lilly.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2016, Lilly submitted an NDA to the FDA and a Marketing Authorization Application (MAA) to the European Medicines Agency for baricitinib as treatment for rheumatoid arthritis. In February 2017, we and Lilly announced that the European Commission approved baricitinib as OLUMIANT for the treatment of moderate-to-severe rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying antirheumatic drugs. In July 2017, Japan&#39;s Ministry of Health, Labor and Welfare granted marketing approval for OLUMIANT<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup>for the treatment of rheumatoid arthritis in patients with inadequate response to standard-of-care therapies. &#160;In June 2018, the FDA approved the 2mg dose of OLUMIANT for the treatment of adults with moderately-to-severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor inhibitor therapies.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In 2018, we recognized a $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2018_To_12_31_2018_incy_AchievementOfMilestoneAxis_incy_DevelopmentMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_4R2bbsjbu02S1SWTGCefdA" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" scale="6" id="Narr_y3rN8QKb1E-uIF2psouH_g">20.0</ix:nonFraction> million development milestone for the first patient treated in the systemic lupus erythematosus Phase III program for baricitinib and a $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2018_To_12_31_2018_incy_AchievementOfMilestoneAxis_incy_RegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_IgQggmnvRkCC-yAC7hkMdA" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" scale="6" id="Narr_2hBQ0OnWME670FjaqRzRsA">100.0</ix:nonFraction> million regulatory milestone for the FDA approval of the 2mg dose of OLUMIANT (baricitinib) for the treatment of adults with moderately-to-severely active rheumatoid arthritis. In 2017, we recognized a $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2017_To_12_31_2017_incy_AchievementOfMilestoneAxis_incy_DevelopmentMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_54PH53-4h0mdJxINNUsslA" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" scale="6" id="Narr_H6tXFqDT3USx4pHQVgBrGQ">30.0</ix:nonFraction> million development milestone for the first patient treated in the atopic dermatitis Phase </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_xIYI6-e6KkOK_cK6DMNvmQ_cont2" continuedAt="Tb_xIYI6-e6KkOK_cK6DMNvmQ_cont3"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">III program for baricitinib, $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2017_To_12_31_2017_incy_AchievementOfMilestoneAxis_incy_RegulatoryMilestonesMember_srt_StatementGeographicalAxis_country_JP_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_uTR5OD0KnkKmPCLLZ5hQIQ" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" scale="6" id="Narr_xrZDPPApxkOdbBNeF2R4pQ">15.0</ix:nonFraction> million regulatory milestone for the approval of baricitinib for the treatment of rheumatoid arthritis by Japan&#8217;s Ministry of Health, Labor and Welfare and a $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2017_To_12_31_2017_incy_AchievementOfMilestoneAxis_incy_RegulatoryMilestonesMember_srt_StatementGeographicalAxis_srt_EuropeMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_X2hC_LIgGkysVkbfF6pqAA" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" scale="6" id="Narr_XqG49d90YEC-pPuuQBmbeQ">65.0</ix:nonFraction> million regulatory milestone for the approval of baricitinib for the treatment of moderate-to-severe rheumatoid arthritis in adult patients by the European Commission.  </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We retained options to co-develop our JAK1/JAK2 inhibitors with Lilly on a compound-by-compound and indication-by-indication basis. Lilly is responsible for all costs relating to the development and commercialization of the compounds unless we elect to co-develop any compounds or indications. If we elect to co-develop any compounds and/or indications, we would be responsible for funding <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2020_To_3_31_2020_incy_PhasesOfArrangementsAxis_incy_PhaseTwoBMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_hx8Gg9ss0k26kPkVIwC0gQ" decimals="2" format="ixt:numdotdecimal" name="incy:PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds" scale="-2" id="Narr_7wBw9OJl40yFj4LzReJ6IA">30</ix:nonFraction>% of the associated future global development costs from the initiation of a Phase IIb trial through regulatory approval, including post-launch studies required by a regulatory authority. We would receive an incremental royalty rate increase across all tiers resulting in effective royalty rates ranging up to the high twenties on potential future global net sales for compounds and/or indications that we elect to co-develop. &#160;For indications that we elect not to co-develop, we would receive tiered, double-digit royalty payments on future global net sales with rates ranging up to <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2020_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_kBoYI7PVIk6voJvkwi61Vw" decimals="2" format="ixt:numdotdecimal" name="incy:PercentageOfRoyaltyRatePayments" scale="-2" id="Narr_-tQYyj-JAUO11doXgmgk8Q">20</ix:nonFraction>% if the product is successfully commercialized. &#160;If we have started co-development funding for any indication, we can at any time opt out and stop future co-development cost sharing. If we elect to do this we would still be eligible for our base royalties plus an incremental pro-rated royalty commensurate with our contribution to the total co-development cost for those indications for which we co-funded. &#160;We previously had retained an option to co-promote products in the United States but, in March 2016, we waived our co-promotion option as part of an amendment to the agreement. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In July&#160;2010, we elected to co-develop baricitinib with Lilly in rheumatoid arthritis and became responsible for funding <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_7_1_2010_To_7_31_2010_incy_PhasesOfArrangementsAxis_incy_PhaseTwoBMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_NfiO75iKBky-zhPH0mFJsw" decimals="2" format="ixt:numdotdecimal" name="incy:PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds" scale="-2" id="Narr_K_84_hGv_E2brbQFleeIlg">30</ix:nonFraction>% of the associated future global development costs for this indication from the initiation of the Phase IIb trial through regulatory approval, including post-launch studies required by a regulatory authority. &#160;We subsequently elected to co-develop baricitinib with Lilly in psoriatic arthritis, atopic dermatitis, alopecia areata, systemic lupus erythematosus and axial spondyloarthritis and were responsible for funding <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_7_1_2010_To_7_31_2010_incy_PhasesOfArrangementsAxis_incy_PhaseTwoBMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_NfiO75iKBky-zhPH0mFJsw" decimals="2" format="ixt:numdotdecimal" name="incy:PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds" scale="-2" id="Narr_aMqfQleCREWz44GyjFhj9Q">30</ix:nonFraction>% of future global development costs for those indications through regulatory approval, including post-launch studies required by a regulatory authority. In April 2019, we elected to end additional co-funding of the development of baricitinib effective as of January 1, 2019. We will continue to receive royalties on global net sales of OLUMIANT, pursuant to the terms in the Lilly agreement, as described above.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Lilly agreement will continue until Lilly no longer has any royalty payment obligations or, if earlier, the termination of the agreement in accordance with its terms. Royalties are payable by Lilly on a product-by-product and country-by-country basis until the latest to occur of (i) the expiration of the last valid claim of the licensed patent rights covering the licensed product in the relevant country, (ii) the expiration of regulatory exclusivity for the licensed product in such country and (iii) a specified period from first commercial sale in such country of the licensed product by Lilly or its affiliates or sublicensees. The agreement may be terminated by Lilly for convenience, and may also be terminated under certain other circumstances, including material breach.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Milestone and contract revenue under the Lilly agreement for the three months ended March 31, 2020 and 2019 was $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_incy_AchievementOfMilestoneAxis_incy_DevelopmentAndCommercializationMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_d2Q6vESwZE6zC2NO5BBD8Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_7BFSTZOGUUeA3PzWefW4Xw"><ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_DevelopmentAndCommercializationMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_y0tgn3-jJkylj0qNlXf4Ug" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_d5otEmegjEmgxcJLtQ7acA">0.0</ix:nonFraction></ix:nonFraction> million for each period.  Product royalty revenue related to Lilly global net sales of OLUMIANT for the three months ended March 31, 2020 and 2019 was $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_uP4dhWDKFEyFnudcYGBOSA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_T54hTr-PY0O-vQujtClDHw">25.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_-8oLxMS1UkuCYQQOT0HLxA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_LdZNTHK-pUe3UHp-aN9a-A">16.0</ix:nonFraction> million, respectively. &#160;At March 31, 2020 and December 31, 2019, $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_8g5N0q7JO0mkbsolYzXxgg" decimals="-5" format="ixt:numdotdecimal" name="incy:RoyaltyPaymentReceivable" scale="6" id="Narr_Fyck6QOEwEOZCoN3zopcPg">25.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_pOoZGDkfJUy5oibDwCrC8w" decimals="-5" format="ixt:numdotdecimal" name="incy:RoyaltyPaymentReceivable" scale="6" id="Narr_svqN8hQnO0u1etsZMX0NfQ">23.6</ix:nonFraction> million, respectively, of product royalties were included in accounts receivable on the condensed consolidated balance sheets. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Lilly - Ruxolitinib</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">In March 2016, we entered into an amendment to the agreement with Lilly that amended the non-compete provision of the agreement to allow us to engage in the development and commercialization of ruxolitinib in the GVHD field. Upon execution of the amendment, we paid Lilly an upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_3_1_2016_To_3_31_2016_srt_ProductOrServiceAxis_incy_GvhdMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_Vfkt7ZI1EUi8hMQs6ojgVA" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementUpfrontPaymentAmountPaid" scale="6" id="Narr_RWJqIfgh50qK9nlQFjHprA">35.0</ix:nonFraction> million and Lilly is eligible to receive up to $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2016_srt_ProductOrServiceAxis_incy_GvhdMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_Sd04Ae5b5U6RhSen8O3xGw" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementAdditionalMilestonePayments" scale="6" id="Narr_pO6nBpz3DUS2fYNIpUjMIQ">40.0</ix:nonFraction> million in regulatory milestone payments relating to ruxolitinib in the GVHD field. &#160;In May 2019, the approval of JAKAFI in steroid-refractory acute GVHD triggered a $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_5_1_2019_To_5_31_2019_incy_AchievementOfMilestoneAxis_incy_RegulatoryMilestonesMember_srt_ProductOrServiceAxis_incy_GvhdMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_wl45rQuyWUeKj9KE8YrNQg" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementMilestonePaymentAmountPaid" scale="6" id="Narr_S4FJqBo6o0GL5V9yQjmcfQ">20.0</ix:nonFraction> million milestone payment to Lilly. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Agenus</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In January 2015, we entered into a License, Development and Commercialization Agreement with Agenus Inc. and its wholly-owned subsidiary, 4-Antibody AG (now known as Agenus Switzerland Inc.), which we collectively refer </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_xIYI6-e6KkOK_cK6DMNvmQ_cont3" continuedAt="Tb_xIYI6-e6KkOK_cK6DMNvmQ_cont4"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">to as Agenus. Under this agreement, the parties have agreed to collaborate on the discovery of novel immuno-therapeutics using Agenus&#8217; antibody discovery platforms. The agreement became effective on February 18, 2015, upon the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Upon closing of the agreement, we paid Agenus total consideration of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_2_1_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_e1m5T-pYtEOP3IlBt9OmFQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="6" id="Narr_pZICHV_8dEym0OCq6yM-QQ">60.0</ix:nonFraction> million. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2017, we and Agenus amended this agreement (the &#8220;Amended Agreement&#8221;). Under the terms of the Amended Agreement, we received exclusive worldwide development and commercialization rights to four checkpoint modulators directed against GITR, OX40, LAG-3 and TIM-3. In addition to the initial <ix:nonFraction unitRef="Unit_Standard_item_4BIkJQxqZkOMHOIGydcttw" contextRef="Duration_1_1_2015_To_1_31_2015_us-gaap_TypeOfArrangementAxis_incy_AgenusMember_1GF_BNYkFkelmcMuY5Dozw" decimals="INF" format="ixt-sec:numwordsen" name="incy:NumberOfProgramTargets" scale="0" id="Narr_Lvr_NwYMEEqI7WNNHvB1UA">four</ix:nonFraction> program targets, we and Agenus have the option to jointly nominate and pursue additional targets within the framework of the collaboration, and in November 2015, <ix:nonFraction unitRef="Unit_Standard_item_4BIkJQxqZkOMHOIGydcttw" contextRef="Duration_11_1_2015_To_11_30_2015_us-gaap_TypeOfArrangementAxis_incy_AgenusMember_y0Dg-8kaqEy_VnxO63h4KA" decimals="INF" format="ixt-sec:numwordsen" name="incy:NumberOfProgramTargets" scale="0" id="Narr_9PQh0UNZR066M6hOZwzvwg">three</ix:nonFraction> more targets were added. Targets may be designated profit-share programs, where all costs and profits are shared equally by us and Agenus, or royalty-bearing programs, where we are responsible for all costs associated with discovery, preclinical, clinical development and commercialization activities. The programs relating to GITR and OX40 and two of the undisclosed targets were profit-share programs until February 2017, while the other targets currently under collaboration are royalty-bearing programs. The Amended Agreement converted the programs relating to GITR and OX40 to royalty-bearing programs and removed from the collaboration the profit-share programs relating to the two undisclosed targets, with one reverting to us and one reverting to Agenus. &#160;Should any of those removed programs be successfully developed by a party, the other party will be eligible to receive the same milestone payments as the royalty-bearing programs and royalties at a <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_AgenusMember_rKJqPM2Kx0uzwD7Q93bGZw" decimals="2" format="ixt:numdotdecimal" name="incy:PercentageOfRoyaltyRatePayments" scale="-2" id="Narr_EACy4HDLhEe03SZyE6pzbQ">15</ix:nonFraction>% rate on global net sales. &#160;There are currently no profit-share programs. &#160;For each royalty-bearing product other than GITR and OX40, Agenus will be eligible to receive tiered royalties on global net sales ranging from <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2020_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_DevelopmentRegulatoryAndCommercializationMilestonesMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_incy_AgenusMember_NSPNOPBlrEe3WHqow3Mpyg" decimals="2" format="ixt:numdotdecimal" name="incy:PercentageOfRoyaltyRatePayments" scale="-2" id="Narr_pj52eE8pykCzSQw-MZD9yw">6</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2020_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_DevelopmentRegulatoryAndCommercializationMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_AgenusMember_7ArCsJGHDU6NWBPNa2r-7w" decimals="2" format="ixt:numdotdecimal" name="incy:PercentageOfRoyaltyRatePayments" scale="-2" id="Narr_xD8t7bj4b024o9KoiVRNLg">12</ix:nonFraction>%. &#160;For GITR and OX40, Agenus will be eligible to receive <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_AgenusMember_rKJqPM2Kx0uzwD7Q93bGZw" decimals="2" format="ixt:numdotdecimal" name="incy:PercentageOfRoyaltyRatePayments" scale="-2" id="Narr_YX400gHiNUyGqR7cgwTK2A">15</ix:nonFraction>% royalties on global net sales. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">In 2017 under the Amended Agreement, we paid Agenus $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2017_To_12_31_2017_incy_AchievementOfMilestoneAxis_incy_DevelopmentMilestonesMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_uSeThvtWXUGOcm74qPJaSA" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementUpfrontPaymentAmountPaid" scale="6" id="Narr_IkYENWJ69UeNv_P8r36_kg">20.0</ix:nonFraction> million in accelerated milestones relating to the clinical development of the GITR and OX40 programs, which was recorded in research and development expense. Agenus was initially eligible to receive up to an additional $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_2_28_2017_incy_AchievementOfMilestoneAxis_incy_DevelopmentRegulatoryAndCommercializationMilestonesMember_srt_RangeAxis_srt_MaximumMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_kP1dVDRyl0aHr25XhcLREg" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementAdditionalMilestonePayments" scale="6" id="Narr_ahTr2QZYg0-f8l36iZ8eFg">510.0</ix:nonFraction> million in future contingent development, regulatory and commercialization milestones across all programs in the collaboration. The agreement may be terminated by us for convenience upon 12 months&#8217; notice and may also be terminated under certain other circumstances, including material breach. In 2018, we paid Agenus a $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2018_incy_AchievementOfMilestoneAxis_incy_DevelopmentMilestonesMember_srt_ProductOrServiceAxis_incy_LG3ProgramMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_LEDpSv7x-UqhAEU0sms69Q" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementAdditionalMilestonePayments" scale="6" id="Narr_gOmR8o1OzES98QiGel4v_A">5.0</ix:nonFraction> million development milestone for the LAG-3 program and a $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2018_incy_AchievementOfMilestoneAxis_incy_DevelopmentMilestonesMember_srt_ProductOrServiceAxis_incy_TIM3ProgramMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_3cWnTNEGHkS-bqHYm75tQQ" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementAdditionalMilestonePayments" scale="6" id="Narr_hCmfWye3aUiaBDb8av3qwA">5.0</ix:nonFraction> million development milestone for the TIM-3 program, which were recorded in research and development expense.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the Amended Agreement, we also agreed to purchase <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_2_1_2017_To_2_1_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_tHZmzMoq7UOq_19LypjtHg" decimals="-5" format="ixt:numdotdecimal" name="incy:PurchaseOfCommonStockUnderStockPurchaseAgreementInShares" scale="6" id="Narr_mGeE21uNTU61Ru9DVGrrvw">10.0</ix:nonFraction> million shares of Agenus Inc. common stock for an aggregate purchase price of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_2_1_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_e1m5T-pYtEOP3IlBt9OmFQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="6" id="Narr_N5_Rs0REn0mt-5AyICsG2w">60.0</ix:nonFraction> million in cash, or $<ix:nonFraction unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A" contextRef="As_Of_2_1_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_e1m5T-pYtEOP3IlBt9OmFQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_0oCkqvkIGEicpuJnMyORkw">6.00</ix:nonFraction> per share. &#160;We completed the purchase of the shares on February 14, 2017, when the closing price on The Nasdaq Stock Market for Agenus Inc. shares was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A" contextRef="As_Of_2_14_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_dBlEvdYnr0a8IGYwmA0VRg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_oTVQgg6kM06PWi_0Mp8gqA">4.40</ix:nonFraction> per share. &#160;The shares we acquired were not registered under the Securities Act of 1933 on the purchase date and were subject to certain security specific restrictions for a period of time, and accordingly, we estimated a discount for lack of marketability on the shares on the issuance date of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_2_14_2017_To_2_14_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_imIGDtobsUmd4lo8UPrzlQ" decimals="-5" format="ixt:numdotdecimal" name="incy:FairValueInputsAmountOfDiscountForLackOfMarketability" scale="6" id="Narr_rDcLjV4BeUSF9uydrZ3ZzQ">4.5</ix:nonFraction> million, which resulted in a net fair value of the shares on the issuance date of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_2_14_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_dBlEvdYnr0a8IGYwmA0VRg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityFairValueDisclosure" scale="6" id="Narr_ZTOxT2wtjUGaJDDeHRg-vg">39.5</ix:nonFraction> million. Therefore, of the total consideration paid of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_2_14_2017_To_2_14_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_imIGDtobsUmd4lo8UPrzlQ" decimals="-5" format="ixt:numdotdecimal" name="incy:TotalConsiderationPaidUnderPurchaseAgreement" scale="6" id="Narr_VIIkMz11kESQS5dr3n1EaQ">60.0</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_GxCCmVblq0aKTFevJZTWYA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="6" id="Narr_eKZ96QhrEkyETXCY0EXKnA">39.5</ix:nonFraction> million was allocated to our stock purchase in Agenus Inc. and was recorded within long term investments and $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2017_To_3_31_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_4TeB7PMOikiSn1N2iwUlEQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_iJbQW_sIikCDyHGgl1G7ww">20.5</ix:nonFraction> million was allocated to research and development expense. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have concluded Agenus Inc. is not a VIE because it has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest. As of March 31, 2020, we owned approximately <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="As_Of_3_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_UX-Ls-ObqUaaxVRBpq4VvA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="Narr_G4yRaWp45k2-USlWwBRYLw">11</ix:nonFraction>% of the outstanding shares of Agenus Inc. common stock. We concluded that we have the ability to exercise significant influence, but not control, over Agenus Inc. based primarily on our ownership interest, the fact that we have been the largest Agenus stockholder since the date of our initial stock purchase, the level of intra-entity transactions between us and Agenus related to development expenses, as well as other qualitative factors. We have elected the fair value option to account for our long term investment in Agenus Inc. whereby the investment is marked to market through earnings in each reporting period. &#160;We believe the fair value option to be the most appropriate accounting method to account for securities in publicly held collaborators for which we have significant influence. For the three months ended March 31, 2020 and 2019, we recorded an unrealized loss of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_XFbZLyELLEuZAhhXTUaIyQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" sign="-" scale="6" id="Narr_D5WC63zPf02eUMIh-hKUdQ">28.8</ix:nonFraction> million and an unrealized gain of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_t6V1l4OIi0umobNraJpO-Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="Narr_K01tfiEoQ0i4Wd6h7WPU1A">10.5</ix:nonFraction> million, respectively, based on the change in fair value of Agenus Inc.&#8217;s common stock during these periods. The fair market value of our long term investment in Agenus Inc. at March 31, 2020 and December 31, 2019 was $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_UX-Ls-ObqUaaxVRBpq4VvA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="6" id="Narr_LPxrsrIV2EqQFfwlLb-Qmw">43.5</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_OmvX4naFCU2401ZLjrF4gQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="6" id="Narr_YLie-Q4qV0y68kE77-WmJw">72.3</ix:nonFraction> million, respectively. &#160;</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_xIYI6-e6KkOK_cK6DMNvmQ_cont4" continuedAt="Tb_xIYI6-e6KkOK_cK6DMNvmQ_cont5"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the twelve months ended December 31, 2019, Agenus reported within its Form 10-K total revenues of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_12_31_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_JsVzHcwF3UShcd4mtCEitg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationRevenue" scale="6" id="Narr_cpxSX8MJUEGRXRobNfHAOw">150.0</ix:nonFraction> million and net loss of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_12_31_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_JsVzHcwF3UShcd4mtCEitg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss" scale="6" id="Narr_2TyOUtFl4U23nzRYPhzeSg">111.6</ix:nonFraction> million within their consolidated financial statements.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses for the three months ended March 31, 2020 and 2019 also included $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_XFbZLyELLEuZAhhXTUaIyQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_Q5ZX1uuRh0-1hz9X0ptRSA">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_t6V1l4OIi0umobNraJpO-Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_yYVi6S63_UO6E8CZdCqnNQ">10.2</ix:nonFraction> million, respectively, of development costs incurred pursuant to the Agenus arrangement. &#160;At March 31, 2020 and December 31, 2019, a total of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_Gb1dDNbr-0mKUzuB4KREFg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="6" id="Narr_o6Nffxu22EyivKX6_HU6Sw">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_cPCZt8ELeUSjKmzshHEhQQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="6" id="Narr_UD3hABn-CEqMtV-0AHtwqw">1.6</ix:nonFraction> million, respectively, of such costs were included in accrued and other liabilities on the condensed consolidated balance sheets.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Merus</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2016, we entered into a Collaboration and License Agreement with Merus N.V. (&#8220;Merus&#8221;). Under this agreement, which became effective in January 2017, the parties have agreed to collaborate with respect to the research, discovery and development of bispecific antibodies utilizing Merus&#8217; technology platform. &#160;The collaboration encompasses up to <ix:nonFraction unitRef="Unit_Standard_item_4BIkJQxqZkOMHOIGydcttw" contextRef="Duration_1_1_2017_To_1_31_2017_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_7k2NhRIKp0uBjo2oHVvL-Q" decimals="INF" format="ixt-sec:numwordsen" name="incy:LicenseAgreementMaximumNumberOfIndependentPrograms" scale="0" id="Narr_suVvYg0fdkW5txIPLezVxg">eleven</ix:nonFraction> independent programs. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The most advanced collaboration program is MCLA-145, a bispecific antibody targeting PD-L1 and CD137, for which we received exclusive development and commercialization rights outside of the United States. Merus retained exclusive development and commercialization rights in the United States to MCLA-145. &#160;Each party will share equally the costs of mutually agreed global development activities for MCLA-145, and fund itself any independent development activities in its territory. &#160;Merus will be responsible for commercializing MCLA-145 in the United States and we will be responsible for commercializing it outside of the United States. &#160; &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to receiving rights to MCLA-145 outside of the United States, we received worldwide exclusive development and commercialization rights to up to <ix:nonFraction unitRef="Unit_Standard_item_4BIkJQxqZkOMHOIGydcttw" contextRef="Duration_1_1_2017_To_1_31_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_a6vIFrPYNUSTq51uQB6cnw" decimals="INF" format="ixt-sec:numwordsen" name="incy:LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms" scale="0" id="Narr_ZZyVEQ8Gz0y17Sr5h5Qlkg">ten</ix:nonFraction> additional programs. Of these ten additional programs, Merus retained the option, subject to certain conditions, to co-fund development of up to <ix:nonFraction unitRef="Unit_Standard_item_4BIkJQxqZkOMHOIGydcttw" contextRef="Duration_1_1_2017_To_1_31_2017_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_7k2NhRIKp0uBjo2oHVvL-Q" decimals="INF" format="ixt-sec:numwordsen" name="incy:LicenseAgreementNumberOfPreclinicalDiscoveryPrograms" scale="0" id="Narr_D3W-jJ4ejEmEDWnIJT-4tA">two</ix:nonFraction> such programs. If Merus exercises its co-funding option for a program, Merus would be responsible for funding <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2017_To_1_31_2017_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_7k2NhRIKp0uBjo2oHVvL-Q" decimals="2" format="ixt:numdotdecimal" name="incy:PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds" scale="-2" id="Narr_mMUV3hPSIkW4u7o2lG-gBw">35</ix:nonFraction>% of the associated future global development costs and, for certain of such programs, would be responsible for reimbursing us for certain development costs incurred prior to the option exercise. &#160;Merus will also have the right to participate in a specified proportion of detailing activities in the United States for <ix:nonFraction unitRef="Unit_Standard_item_4BIkJQxqZkOMHOIGydcttw" contextRef="Duration_1_1_2017_To_1_31_2017_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_7k2NhRIKp0uBjo2oHVvL-Q" decimals="INF" format="ixt-sec:numwordsen" name="incy:NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment" scale="0" id="Narr_5qO7gNerd0e4A3N3SdFwEg">one</ix:nonFraction> of those co-developed programs. All costs related to the co-funded collaboration programs are subject to joint research and development plans and overseen by a joint development committee, but we will have final determination as to such plans in cases of dispute. We will be responsible for all research, development and commercialization costs relating to all other programs. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2017, we paid Merus an upfront non-refundable payment of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_2_1_2017_To_2_28_2017_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_j9-fB82mM0aKB0lMVFtkDA" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementUpfrontPaymentAmountPaid" scale="6" id="Narr_4Xuw5X_MQUKIMyirjKljQQ">120.0</ix:nonFraction> million. For each program as to which Merus does not have commercialization or development co-funding rights, Merus will be eligible to receive up to $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_1_31_2017_incy_AchievementOfMilestoneAxis_incy_DevelopmentAndRegulatoryMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_3qBhaaUHQU-hsgEJZZLSGA" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementAdditionalMilestonePayments" scale="6" id="Narr_GrmYmPI8qU2BNWNgTwUyyw">100.0</ix:nonFraction> million in future contingent development and regulatory milestones, and up to $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_1_31_2017_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_wXhYzKmk30i4bB1talomPQ" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementAdditionalMilestonePayments" scale="6" id="Narr__skBZwhA2UGKkOwr7YzTuQ">250.0</ix:nonFraction> million in commercialization milestones as well as tiered royalties ranging from <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2017_To_1_31_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_jKF_MTXq-Em5r2YGQsjucw" decimals="2" format="ixt:numdotdecimal" name="incy:PercentageOfRoyaltyRatePayments" scale="-2" id="Narr_zrnGLFQZ-UWaeSKSBa72fw">6</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2017_To_1_31_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_a6vIFrPYNUSTq51uQB6cnw" decimals="2" format="ixt:numdotdecimal" name="incy:PercentageOfRoyaltyRatePayments" scale="-2" id="Narr_VekbS_0goEetCptlKjPWoA">10</ix:nonFraction>% of global net sales. For each program as to which Merus exercises its option to co-fund development, Merus will be eligible to receive a <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2017_To_1_31_2017_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_ziZW_6Itd0mRiuWAvHmhMA" decimals="2" format="ixt:numdotdecimal" name="incy:CollaborationAgreementProfitSharingPercentage" scale="-2" id="Narr_QuQDVgIY5U2oiKcismxeiw">50</ix:nonFraction>% share of profits (or sustain <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2017_To_1_31_2017_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_ziZW_6Itd0mRiuWAvHmhMA" decimals="2" format="ixt:numdotdecimal" name="incy:PercentageOfProfitsLosses" scale="-2" id="Narr_h1FMAOuWkUeDTRr0OXjW1A">50</ix:nonFraction>% of any losses) in the United States and be eligible to receive tiered royalties ranging from <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2017_To_1_31_2017_srt_RangeAxis_srt_MinimumMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_0jHvhxDIlEen-mp125RqxQ" decimals="2" format="ixt:numdotdecimal" name="incy:PercentageOfRoyaltyRatePayments" scale="-2" id="Narr_2jOYMhj56EKdePkrI5NUbg">6</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2017_To_1_31_2017_srt_RangeAxis_srt_MaximumMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_TmMtQTVRAEqEbpqiWMhMKg" decimals="2" format="ixt:numdotdecimal" name="incy:PercentageOfRoyaltyRatePayments" scale="-2" id="Narr_GWRgs_NJGkO_0c3t-xxP-A">10</ix:nonFraction>% of net sales of products outside of the United States. &#160;If Merus opts to cease co-funding a program as to which it exercised its co-development option, then Merus will no longer receive a share of profits in the United States but will be eligible to receive the same milestones from the co-funding termination date and the same tiered royalties described above with respect to programs where Merus does not have a right to co-fund development and, depending on the stage at which Merus chose to cease co-funding development costs, Merus will be eligible to receive additional royalties ranging up to <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2017_To_1_31_2017_srt_RangeAxis_srt_MaximumMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_TmMtQTVRAEqEbpqiWMhMKg" decimals="2" format="ixt:numdotdecimal" name="incy:PercentageOfNetSalesPertainingToAdditionalRoyalties" scale="-2" id="Narr_PElqf_jXR0OweZO6JnsFsQ">4</ix:nonFraction>% of net sales in the United States. &#160;For MCLA-145, we and Merus will each be eligible to receive tiered royalties on net sales in the other party&#8217;s territory at rates ranging from <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2017_To_1_31_2017_srt_RangeAxis_srt_MinimumMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_7nNpE5gl0kGtbk0copl0Ew" decimals="2" format="ixt:numdotdecimal" name="incy:PercentageOfRoyaltyRatePayments" scale="-2" id="Narr_5wk7L50Zs0yI0niH9-BHaw">6</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2017_To_1_31_2017_srt_RangeAxis_srt_MaximumMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_-UyvIh_1dUGHPh1Oi-HZjg" decimals="2" format="ixt:numdotdecimal" name="incy:PercentageOfRoyaltyRatePayments" scale="-2" id="Narr_e955cYo6EEuMFjzVQ4M8uA">10</ix:nonFraction>%. &#160; </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Merus agreement will continue on a program-by-program basis until we have no royalty payment obligations with respect to such program or, if earlier, the termination of the agreement or any program in accordance with the terms of the agreement. The agreement may be terminated in its entirety or on a program-by-program basis by us for convenience. &#160;The agreement may also be terminated by either party under certain other circumstances, including material breach, as set forth in the agreement. &#160;If the agreement is terminated with respect to one or more programs, all rights in the terminated programs revert to Merus, subject to payment to us of a reverse royalty of up to <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2017_To_1_31_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_a6vIFrPYNUSTq51uQB6cnw" decimals="2" format="ixt:numdotdecimal" name="incy:PercentageOfReverseRoyaltiesOnSaleOfFutureProducts" scale="-2" id="Narr_GMmOxSzi6k-56NCLpVE46w">4</ix:nonFraction>% on sales of future products, if Merus elects to pursue development and commercialization of products arising from the terminated programs. </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_xIYI6-e6KkOK_cK6DMNvmQ_cont5" continuedAt="Tb_xIYI6-e6KkOK_cK6DMNvmQ_cont6"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, in December 2016, we entered into a Share Subscription Agreement with Merus, pursuant to which we agreed to purchase <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_12_1_2016_To_12_31_2016_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_AHacTrqe70OBJPlyv84qXA" decimals="-5" format="ixt:numdotdecimal" name="incy:PurchaseOfCommonStockUnderStockPurchaseAgreementInShares" scale="6" id="Narr_PYmEOqtR_E-bjgqwGaCQMg">3.2</ix:nonFraction> million common shares of Merus for an aggregate purchase price of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2016_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_zhQ6u7Eorky9JUrK75lg6w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="6" id="Narr_BBaN2OjQc0mcgOhwt-X1Fw">80.0</ix:nonFraction> million in cash, or $<ix:nonFraction unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A" contextRef="As_Of_12_31_2016_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_zhQ6u7Eorky9JUrK75lg6w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_EyoEgetkg0a6XmlYWrckJg">25.00</ix:nonFraction> per share. &#160;We completed the purchase of the shares on January 23, 2017 when the closing price on The Nasdaq Stock Market for Merus shares was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A" contextRef="As_Of_1_23_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_KRP1zQuWsUCnd5bEiI4whg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_HZQGqByiM0SQbPbLVhqgLw">24.50</ix:nonFraction> per share. The shares we acquired were not registered under the Securities Act of 1933 on the purchase date and were subject to certain security specific restrictions for a period of time, and accordingly, we estimated a discount for lack of marketability on the shares on the issuance date of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_23_2017_To_1_23_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_0W47ULyywE66YQ7w30K3tQ" decimals="-5" format="ixt:numdotdecimal" name="incy:FairValueInputsAmountOfDiscountForLackOfMarketability" scale="6" id="Narr_F4MqbhngiEyldUxgkBLnkw">5.6</ix:nonFraction> million, which resulted in a net fair value of the shares on the issuance date of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_1_23_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_KRP1zQuWsUCnd5bEiI4whg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityFairValueDisclosure" scale="6" id="Narr_Vp3NB07miU2aBdM-b79jwg">72.8</ix:nonFraction> million. &#160;Of the total consideration paid of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_23_2017_To_1_23_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_0W47ULyywE66YQ7w30K3tQ" decimals="-5" format="ixt:numdotdecimal" name="incy:TotalConsiderationPaidUnderPurchaseAgreement" scale="6" id="Narr_0ztGzfHdVka3_8vwmaKqRQ">80.0</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_7XMbCpbDnEewpK0mRNy-0g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="6" id="Narr_FQfxeQBvpUSkWnhOE_tA_w">72.8</ix:nonFraction> million was allocated to our stock purchase in Merus and was recorded as a long term investment and $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2017_To_12_31_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_oWgSfS00vUW2MWLkfvZ1zg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_FIfzqowlLE-AFm2K5XMe6g">7.2</ix:nonFraction> million was allocated to research and development expense. The fair market value of our total long term investment in Merus at March 31, 2020 and December 31, 2019 was $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_Jr7vn9wY7EugrlmE7e-Utg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="Narr_zdUudgHKCEenPE0Zxis0fQ">38.7</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_enm1IIwTxE685YL-VEfceg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="Narr_iWzVTppIkkWQzoOWA9nILA">45.1</ix:nonFraction> million, respectively.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have concluded Merus is not a VIE because it has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest. As of March 31, 2020, we owned approximately <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="As_Of_3_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_Jr7vn9wY7EugrlmE7e-Utg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="Narr_Bz2JNq5PBE2WPkAgGkcc6w">11</ix:nonFraction>% of the outstanding common shares of Merus and conclude that we have the ability to exercise significant influence, but not control, over Merus based primarily on our ownership interest, the level of intra-entity transactions between us and Merus related to development expenses, as well as other qualitative factors. &#160;We have elected the fair value option to account for our long term investment in Merus whereby the investment is marked to market through earnings in each reporting period. &#160;We believe the fair value option to be the most appropriate accounting method to account for securities in publicly held collaborators for which we have significant influence. For the three months ended March 31, 2020 and 2019 we recorded an unrealized loss of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_4sLodCGvRUuTCXxu1AuBbA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" sign="-" scale="6" id="Narr_NlPJqkDKRE2ZmR2COrXWcA">6.3</ix:nonFraction> million and an unrealized gain of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_hK2vELdvC0qjgaQxW0SVXw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" sign="-" scale="6" id="Narr_NFKZ8uRCA0i5l8bKuO5rEA">2.5</ix:nonFraction> million, respectively, based on the change in fair value of Merus&#8217; common shares during these periods. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the twelve months ended December 31, 2019, Merus reported within its Form 10-K total revenues of approximately $<ix:nonFraction unitRef="Unit_Standard_EUR_4KUDkHZ-F0yLQi_l9X6Oxg" contextRef="Duration_1_1_2019_To_12_31_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_suFOYxNDt0-4KUvHJ2smxQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationRevenue" scale="6" id="Narr_tqyRIPBZ3EunKI5nFq2nWg">31.1</ix:nonFraction> million and net loss of approximately $<ix:nonFraction unitRef="Unit_Standard_EUR_4KUDkHZ-F0yLQi_l9X6Oxg" contextRef="Duration_1_1_2019_To_12_31_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_suFOYxNDt0-4KUvHJ2smxQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss" sign="-" scale="6" id="Narr_CaMIUiefv0-U1V21Ih4e6w">55.2</ix:nonFraction> million within their consolidated financial statements.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 12pt 0pt;">Research and development expenses for the three months ended March 31, 2020 and 2019 included $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_Y69YgRfz7EyDDBkJJ9glfg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_knadp7ffEkGuC6ML1ARwTw">2.3</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_vi_h8M1GhkeTPwj2SVyuYg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_MHlrHyRRLU6koUvzaGQjFQ">2.6</ix:nonFraction> million, respectively, of additional development costs incurred pursuant to the Merus agreement. At March 31, 2020 and December 31, 2019, a total of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_TDSLcpRho0W0O_zxs61WcQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="6" id="Narr_rfwwv8xx6Ei_9vFU79Pt7A">2.2</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_e8xNeuEtLkG3yuzAWXQPAQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="6" id="Narr_m7hdQ_LESkqf0DUmfQSn9A">1.6</ix:nonFraction> million, respectively, of such costs were included in accrued and other liabilities on the condensed consolidated balance sheets.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Calithera</span></p><p style="font-family:'Times New Roman';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">In January 2017, we entered into a Collaboration and License Agreement with Calithera Biosciences, Inc. (&#8220;Calithera&#8221;). Under this agreement, we received an exclusive, worldwide license to develop and commercialize small molecule arginase inhibitors, including CB-1158, which is currently in Phase I clinical trials, for hematology and oncology indications. We have agreed to co-fund <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2017_To_1_31_2017_us-gaap_TypeOfArrangementAxis_incy_CalitheraBiosciencesIncMember_k20QIDKWZ0Cx-yYlqJ-TBw" decimals="2" format="ixt:numdotdecimal" name="incy:LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded" scale="-2" id="Narr_2Pje8djG1kOxyEKz784q5g">70</ix:nonFraction>% of the global development costs for the development of the licensed products for hematology and oncology indications. Calithera will have the right to conduct certain clinical development under the collaboration, including combination studies of a licensed product with a proprietary compound of Calithera. We will be entitled to <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2017_To_1_31_2017_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_incy_CalitheraBiosciencesIncMember_HQYolQnSwkG5T9dK1t91Ow" decimals="2" format="ixt:numdotdecimal" name="incy:PercentageOfProfitsLosses" scale="-2" id="Narr_kJJA5BYUPEuevpyToIP2qg">60</ix:nonFraction>% of the profits and losses from net sales of licensed product in the United States, and Calithera will have the right to co-detail licensed products in the United States, and we have agreed to pay Calithera tiered royalties ranging from the low to mid-double digits on net sales of licensed products outside the United States. Calithera may opt out of its co-funding obligation, in which case the U.S. profit sharing will no longer be in effect, and we have agreed to pay Calithera tiered royalties ranging from the low to mid-double digits on net sales of licensed products both in the United States and outside the United States, and additional royalties to reimburse Calithera for previously incurred development costs.</p><p style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:24.5pt;margin:0pt;">In January 2017, we paid Calithera an upfront license fee of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2017_To_1_31_2017_us-gaap_TypeOfArrangementAxis_incy_CalitheraBiosciencesIncMember_k20QIDKWZ0Cx-yYlqJ-TBw" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementUpfrontPayment" scale="6" id="Narr_jcG0wmftVEWc1qintN5aVA">45.0</ix:nonFraction> million and have agreed to pay potential development, regulatory and sales milestone payments of over $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_1_31_2017_us-gaap_TypeOfArrangementAxis_incy_CalitheraBiosciencesIncMember_q6cjALmpG0eNfLyGFfZJcw" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementPotentialMilestonePaymentsWithProfitSharing" scale="6" id="Narr_eGsyH_39kE2iE9sYlu2RaA">430.0</ix:nonFraction> million if the profit share is in effect, or $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_1_31_2017_us-gaap_TypeOfArrangementAxis_incy_CalitheraBiosciencesIncMember_q6cjALmpG0eNfLyGFfZJcw" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementPotentialMilestonePaymentsWithoutProfitSharing" scale="6" id="Narr_GN_wucwFG0uAHf26Vgh_Nw">750.0</ix:nonFraction> million if the profit share terminates. In 2017, we paid Calithera a $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_3_1_2017_To_3_31_2017_us-gaap_TypeOfArrangementAxis_incy_CalitheraBiosciencesIncMember_Ms1l2DuiH0iX52Fe8ib4bw" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementMilestonePaymentAmountPaid" scale="6" id="Narr_cgVfRTBDVUuZoN3SXQTeNQ">12.0</ix:nonFraction> million milestone for the achievement of pharmacokinetic and pharmacodynamics goals for CB-1158 which was recorded in research and development expense.</p><p style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">The Calithera agreement will continue on a product-by-product and country-by-country basis for so long as we are developing or commercializing products in the United States (if the parties are sharing profits in the United States) and until we have no further royalty payment obligations, unless earlier terminated according to the terms of the agreement. The agreement may be terminated in its entirety or on a product-by-product and/or a country-by-country basis by us for </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_xIYI6-e6KkOK_cK6DMNvmQ_cont6" continuedAt="Tb_xIYI6-e6KkOK_cK6DMNvmQ_cont7"><p style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">convenience. The agreement may also be terminated by us for Calithera&#8217;s uncured material breach, by Calithera for our uncured material breach and by either party for bankruptcy or patent challenge. If the agreement is terminated early with respect to one or more products or countries, all rights in the terminated products and countries revert to Calithera.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, in January&#160;2017, we entered into a Stock Purchase Agreement with Calithera for the purchase of <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_1_1_2017_To_1_31_2017_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_RlWLiTnNKk-MYynvIhAMbA" decimals="-5" format="ixt:numdotdecimal" name="incy:PurchaseOfCommonStockUnderStockPurchaseAgreementInShares" scale="6" id="Narr_UhTZcX_Eh0uAw5MfgLF5SQ">1.7</ix:nonFraction> million common shares of Calithera for an aggregate purchase price of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_1_1_2017_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_0wbD4uybz0Kqy_sngxd94Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="6" id="Narr_HTzpXTXa_0q0X1sUfme1Dg">8.0</ix:nonFraction> million in cash, or $<ix:nonFraction unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A" contextRef="As_Of_1_1_2017_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_0wbD4uybz0Kqy_sngxd94Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_XJINWdUlVEWd89prapYYow">4.65</ix:nonFraction> per share. We completed the purchase of the shares on January 30, 2017 when the closing price on The Nasdaq Stock Market was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A" contextRef="As_Of_1_30_2017_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_V15b5Oo0-k2QDmXipNZJPg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_yTVwy4dP-0yuMmwqy6NtFA">6.75</ix:nonFraction> per share. The shares we acquired were registered under the Securities Act of 1933 on the purchase date and there were no security specific restrictions for these shares, and therefore the value of the 1.7 million shares acquired by us was $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_1_30_2017_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_V15b5Oo0-k2QDmXipNZJPg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="Narr_QtUcv06FwU-UaZWOhB2klA">11.6</ix:nonFraction> million. &#160;We paid total consideration of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_30_2017_To_1_30_2017_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_6yzhytojOUW72tF5DhREcQ" decimals="-5" format="ixt:numdotdecimal" name="incy:TotalConsiderationPaidUnderPurchaseAgreement" scale="6" id="Narr_W0WB-lozokuPYVz78OrPdg">53.0</ix:nonFraction> million to Calithera, composed of the $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_30_2017_To_1_30_2017_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_6yzhytojOUW72tF5DhREcQ" decimals="-5" format="ixt:numdotdecimal" name="incy:CollaborationAgreementUpfrontPayment" scale="6" id="Narr_tQoSOB5rqUCMNRjvUj0Vsw">45.0</ix:nonFraction> million upfront license fee and the $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_30_2017_To_1_30_2017_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_6yzhytojOUW72tF5DhREcQ" decimals="-5" format="ixt:numdotdecimal" name="incy:PurchasePriceOfCommonStockUnderStockPurchaseAgreement" scale="6" id="Narr_I67q72BM7EuscXY6TZqA_A">8.0</ix:nonFraction> million stock purchase price.&#160;&#160;Of the $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_30_2017_To_1_30_2017_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_6yzhytojOUW72tF5DhREcQ" decimals="-5" format="ixt:numdotdecimal" name="incy:TotalConsiderationPaidUnderPurchaseAgreement" scale="6" id="Narr_ZznVlwPcNUm0N90dUS8Bfg">53.0</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2017_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_3dQm43RaIU-3y4wKYTb_YA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="6" id="Narr_P4kcGLF-60GDUcrmSBk-GQ">11.6</ix:nonFraction> million was allocated to our stock purchase in Calithera and was recorded within long term investments and $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_wgLMqUpIOkW0LR2tv0blfQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_-1CROSA1xEOjvt9apSgtvw">41.4</ix:nonFraction> million was allocated to research and development expense. The fair market value of our long term investment in Calithera at March 31, 2020 and December 31, 2019 was $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_9FgpIjXW30il90Hlca16_w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="Narr_hVa36KlKjESxqo0HpTLw6w">7.6</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_kOKA_UdywE2p7qUAsKbRXg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="Narr_gqjnhNbqOEuANkBtS5myGQ">9.8</ix:nonFraction> million, respectively.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have concluded Calithera is not a VIE because it has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest. &#160;As of March 31, 2020, we owned approximately <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="As_Of_3_31_2020_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_9FgpIjXW30il90Hlca16_w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="Narr_l2ZgyYA2pE-kKwhqTv1gHA">3</ix:nonFraction>% of the outstanding shares of Calithera common stock and there are several other stockholders who hold larger positions of Calithera. As we do not hold a significant position of the voting shares of Calithera and lack the qualitative characteristics associated with the ability to exercise significant influence, our ownership interest does not meet the criteria to be accounted for as an equity method investment. We intend to hold the investment in Calithera for the foreseeable future and therefore, are accounting for our shares held in Calithera at fair value, and the investment is marked to market through earnings in each reporting period. Given our intent to hold the investment for the foreseeable future, we have classified the investment within long term investments on the accompanying condensed consolidated balance sheets. For the three months ended March 31, 2020 and 2019 we recorded an unrealized loss of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherComprehensiveIncomeMember_5oSPCzH0LUKKkaLwMadeGg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" sign="-" scale="6" id="Narr___dsjf-E8kyUIn04FtS0qg">2.2</ix:nonFraction> million and an unrealized gain of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherComprehensiveIncomeMember_9Lxk-PLyx0aRe3tPfUa9JQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" sign="-" scale="6" id="Narr_UljHbXfu70WurYjN9gmw9Q">4.7</ix:nonFraction> million, respectively, based on the change in fair value of Calithera&#8217;s common stock during these periods.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">Research and development expenses for the three months ended March 31, 2020 and 2019 also included $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_CalitheraBiosciencesIncMember_ZVATcnAIO0GBu8wTwLvFPg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_11i4yKevp0CV746R0Li4CA">2.5</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_TypeOfArrangementAxis_incy_CalitheraBiosciencesIncMember_gwhsiJOFE0CdmH4_ASRROw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_9niBNFM5_EihpU_IHBZSlw">4.6</ix:nonFraction> million, respectively, of additional development costs incurred pursuant to the Calithera agreement. At March 31, 2020 and December 31, 2019, a total of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_TypeOfArrangementAxis_incy_CalitheraBiosciencesIncMember_o_SL5702vkOgfJpisRbc3g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="6" id="Narr_S5nRQlypxUCXXZmUNfBmtg">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_CalitheraBiosciencesIncMember_ekerfwlyQkKKU2NodLZECQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="6" id="Narr_W9wDqTHlKEWtsl_aG4NdGg">1.1</ix:nonFraction> million, respectively, of such costs were included in accrued and other liabilities on the condensed consolidated balance sheets.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">MacroGenics</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 12pt 0pt;">In October 2017, we entered into a Global Collaboration and License Agreement with MacroGenics, Inc. (&#8220;MacroGenics&#8221;). Under this agreement, we received exclusive development and commercialization rights worldwide to MacroGenics&#8217; INCMGA0012 (formerly MGA012), an investigational monoclonal antibody that inhibits PD-1. Except as set forth in the succeeding sentence, we will have sole authority over and bear all costs and expenses in connection with the development and commercialization of INCMGA0012 in all indications, whether as a monotherapy or as part of a combination regimen.&#160; MacroGenics has retained the right to develop and commercialize, at its cost and expense, its pipeline assets in combination with INCMGA0012.&#160; In addition, MacroGenics has the right to manufacture a portion of both companies&#8217; global clinical and commercial supply needs of INCMGA0012. &#160;In 2017, we paid MacroGenics an upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_12_1_2017_To_12_31_2017_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_Pvqu3UdMtESm4jPlRmjNxw" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementUpfrontPaymentAmountPaid" scale="6" id="Narr__XjBP2fPOUmERu_bLB9Qfw">150.0</ix:nonFraction> million, which was recorded in research and development expense. MacroGenics was initially eligible to receive up to $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2017_incy_AchievementOfMilestoneAxis_incy_DevelopmentAndRegulatoryMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_1gx5QmF1QESvqesUmo91qw" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementAdditionalMilestonePayments" scale="6" id="Narr_8WNfm4R1t0KiIeEuuurYOQ">420.0</ix:nonFraction> million in future contingent development and regulatory milestones and up to $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2017_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_h51PWrAxiUSRzPvrkcOO8w" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementAdditionalMilestonePayments" scale="6" id="Narr_8prqU3EXTkK8K0Hu8PcydA">30.0</ix:nonFraction> million in sales milestones as well as tiered royalties ranging from <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_12_1_2017_To_12_31_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_LuJpKL3-sUqsR3zx1Ui6ug" decimals="2" format="ixt:numdotdecimal" name="incy:PercentageOfRoyaltyRatePayments" scale="-2" id="Narr_zypy9qixpEq7k8skcSCu9g">15</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_12_1_2017_To_12_31_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_Dn4atemmXECcuSaCHD3Xhw" decimals="2" format="ixt:numdotdecimal" name="incy:PercentageOfRoyaltyRatePayments" scale="-2" id="Narr_e9-HY3LgkkC6gaS7co6nGg">24</ix:nonFraction>% of global net sales. In 2018, we paid MacroGenics a $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_9_1_2018_To_9_30_2018_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_9FaYOW1DOUSCPsDwOUajaQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_TIL7G6tRBEK3wR1rINOftQ">10.0</ix:nonFraction> million and a $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_11_1_2018_To_11_30_2018_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_epQaBen2_U6nG4Y4rp6zig" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_RrGpmxkqlk6IAcqGmBZWKg">5.0</ix:nonFraction> million milestone for the achievement of certain clinical milestones as part of our collaboration and license agreement, which were recorded in research and development expense.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The MacroGenics agreement will continue until we are no longer commercializing, developing or manufacturing INCMGA0012 or, if earlier, the termination of the agreement in accordance with its terms.&#160; The agreement may be terminated in its entirety or on a licensed product by licensed product basis by us for convenience.&#160; The agreement may also be terminated by either party under certain other circumstances, including material breach, as set forth in the agreement.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_xIYI6-e6KkOK_cK6DMNvmQ_cont7" continuedAt="Tb_xIYI6-e6KkOK_cK6DMNvmQ_cont8"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses for the three months ended March 31, 2020 and 2019 also included $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_Bgm0Uqs6EEurpHztiTwV7A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_yYCjQnnDmEOOnP6Gf9MAKQ">16.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_fZaD2WqykkG-bcDt3R0hsg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_Siktk8uYxEyRcpAIQME8gw">9.4</ix:nonFraction> million, respectively, of additional development costs incurred pursuant to the MacroGenics agreement. At March 31, 2020 and December 31, 2019, a total of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_WXNGj9bwXUmUHfhHKe1dLw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="6" id="Narr_-G8Ii3ukzEerUHhXAjf0Jg">1.6</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_8PlbTBxq-kmWb2R31MsmkQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="6" id="Narr_o_xc25tjSkSML0jcpm5_jg">1.0</ix:nonFraction> million of such costs were included in accrued and other liabilities on the condensed consolidated balance sheets. &#160; </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Syros</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 12pt 0pt;">In January 2018, we entered into a target discovery, research collaboration and option agreement with Syros Pharmaceuticals, Inc. (&#8220;Syros&#8221;). Under this agreement, Syros will use its proprietary gene control platform to identify novel therapeutic targets with a focus in myeloproliferative neoplasms and we have received options to obtain exclusive worldwide rights to intellectual property resulting from the collaboration for up to <ix:nonFraction unitRef="Unit_Standard_item_4BIkJQxqZkOMHOIGydcttw" contextRef="Duration_1_1_2018_To_1_31_2018_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_e3Og2WQPREynUroSL3ThVw" decimals="INF" format="ixt-sec:numwordsen" name="incy:NumberOfProgramTargets" scale="0" id="Narr_fkHGoh5lq0-4W3ggchDhRA">seven</ix:nonFraction> validated targets. &#160;We will have exclusive worldwide rights to develop and commercialize any therapies under the collaboration that modulate those validated targets. &#160;We have agreed to pay Syros up to $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_1_31_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_7z6twVQHkkaobzJI5jhU7g" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementTargetSelectionAndOptionExerciseFeePayments" scale="6" id="Narr_y3D7U1F55U2yqTHyhf3Bzw">54.0</ix:nonFraction> million in target selection and option exercise fees should we decide to exercise all of our options under the agreement. For products resulting from the collaboration against each of the seven selected and validated targets, we have agreed to pay up to $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_1_31_2018_incy_AchievementOfMilestoneAxis_incy_DevelopmentAndRegulatoryMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_bojg3Cpm70KP1ASJ64IbcA" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementAdditionalMilestonePayments" scale="6" id="Narr_RH9v-LRj_02-guYnRyOI3w">50.0</ix:nonFraction> million in potential development and regulatory milestones and up to $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_1_31_2018_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_ggAKdTjZ60mONUG4Cc9HQg" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementAdditionalMilestonePayments" scale="6" id="Narr_2xjKJ76-SE2kOB7fuG5C3w">65.0</ix:nonFraction> million in potential sales milestones. Syros is also eligible to receive low single-digit royalties on net sales of products resulting from the collaboration. In January 2018, we paid Syros an upfront non-refundable (except in the event of a material breach of the agreement by Syros) payment of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2018_To_1_31_2018_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_e3Og2WQPREynUroSL3ThVw" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementUpfrontPaymentAmountPaid" scale="6" id="Narr_sHRo9_Se9kKTgBgP9UKmKA">10.0</ix:nonFraction> million, which was recorded in research and development expense. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, in January 2018, we entered into a Stock Purchase Agreement with Syros for the purchase of <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_1_1_2018_To_1_1_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_StockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_DgYpD_a5vUiEMdKdZb3MPA" decimals="-5" format="ixt:numdotdecimal" name="incy:PurchaseOfCommonStockUnderStockPurchaseAgreementInShares" scale="6" id="Narr_cRSCNBMmFUCo0RAhnHxBLg">0.8</ix:nonFraction> million common shares of Syros for an aggregate purchase price of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_1_1_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_StockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_h6YyQFHKjUOT_t4PglWApQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="6" id="Narr_PJf9aOQvu0mGKYX2bBF-FA">10.0</ix:nonFraction> million in cash, or $<ix:nonFraction unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A" contextRef="As_Of_1_1_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_StockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_h6YyQFHKjUOT_t4PglWApQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_cOOurfWBWEiiPR3wfoSgGQ">12.61</ix:nonFraction> per share. &#160;We agreed to not sell or otherwise transfer any of our Syros shares for a period, referred to as the Lock-Up Period, of <ix:nonNumeric contextRef="Duration_1_8_2018_To_1_8_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_StockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_omIR3ZvvjkKFbSUFw_JzGA" format="ixt-sec:durwordsen" name="incy:StockPurchaseAgreementLockUpPeriod" id="Narr_y6Ypw_rdc0isyyJL22DE7Q">12 months</ix:nonNumeric> after the closing date of the sale. We completed the purchase of the shares on January 8, 2018 when the closing price on The Nasdaq Stock Market was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A" contextRef="As_Of_1_8_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_StockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_q4yqPlQDMkKC2b9hPFXgEA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_4yvLY3ug1USXLCHtH9NLAw">9.77</ix:nonFraction> per share. The shares we acquired were not registered on the purchase date, and accordingly, we estimated a discount for lack of marketability on the shares of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_8_2018_To_1_8_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_StockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_omIR3ZvvjkKFbSUFw_JzGA" decimals="-5" format="ixt:numdotdecimal" name="incy:FairValueInputsAmountOfDiscountForLackOfMarketability" scale="6" id="Narr_1zK0TEHKQEyX37TkXTfDXw">0.1</ix:nonFraction> million, which resulted in a net fair value of the shares on the issuance date of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_1_8_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_StockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_q4yqPlQDMkKC2b9hPFXgEA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityFairValueDisclosure" scale="6" id="Narr_H0DlPBOy00Cbb5VX64izBQ">7.6</ix:nonFraction> million. Of the $10.0 million aggregate purchase price paid, $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_StockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_01Y2KuG7C02jQlyf-MJXhA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="6" id="Narr_cT5ojGegRECdDxjyXEDoUg">7.6</ix:nonFraction> million was allocated to our stock purchase in Syros and was recorded within long term investments and $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2018_To_12_31_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_StockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_iPk_0s54fkWZRS_3UlzhOA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_AicpL_LXdUKHLYlQjv9E4g">2.4</ix:nonFraction> million, representing premium paid on the purchase, was allocated to research and development expense. Also in January 2018, we entered into an Amended Stock Purchase Agreement with Syros for the purchase of an additional <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_1_1_2018_To_1_31_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmendedStockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_XLcYraNHWEaKYbjk95TcKg" decimals="-5" format="ixt:numdotdecimal" name="incy:PurchaseOfCommonStockUnderStockPurchaseAgreementInShares" scale="6" id="Narr_4goPrSK4A0CaNcDBKcqw-w">0.1</ix:nonFraction> million common shares of Syros for an aggregate purchase price of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_1_31_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmendedStockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_6YWfGDEPXE2CImLh9b1dmA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="6" id="Narr_wUNGghkvZUSAEWNL9aTHpA">1.4</ix:nonFraction> million in cash, or $<ix:nonFraction unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A" contextRef="As_Of_1_31_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmendedStockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_6YWfGDEPXE2CImLh9b1dmA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_LROHMuK4k0KmzAw9auUpdA">9.55</ix:nonFraction> per share. &#160;The shares were acquired in February 2018 and the $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmendedStockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_VTRtnBqUMkSsfHzFNQIj2A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="6" id="Narr_dFqJFwCKwEWTNfbp37EGQg">1.4</ix:nonFraction> million aggregate purchase price was recorded within long term investments on the condensed consolidated balance sheets. All acquired shares were subsequently registered under the Securities Act of 1933 in February 2018. The fair market value of our long term investment in Syros as of March 31, 2020 and December 31, 2019 was $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_AAhSlo2yskG8eSk5D_7vWA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="Narr_5tTjFqb2WEa71k6f3VU8Yw">5.6</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_2_qilDUt-02bEAeGgk-4HA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="Narr_XVw4g7HwX0aZEv9YsuJZrg">6.5</ix:nonFraction> million, respectively. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have concluded Syros is not a VIE because it has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest. &#160;As of March 31, 2020, we owned approximately <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="As_Of_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_AAhSlo2yskG8eSk5D_7vWA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="Narr_qht6vPtaSE-fA9dbKJvOqQ">2</ix:nonFraction>% of the outstanding shares of Syros common stock and there are several other stockholders who hold larger positions of Syros. &#160;As we do not hold a significant position of the voting shares of Syros and lack the qualitative characteristics associated with the ability to exercise significant influence, our ownership interest does not meet the criteria to be accounted for as an equity method investment. We intend to hold the investment in Syros for the foreseeable future and therefore, are accounting for our shares held in Syros at fair value, and the investment is marked to market through earnings in each reporting period. &#160;Given our intent to hold the investment for the foreseeable future, we have classified the investment within long term investments on the accompanying condensed consolidated balance sheets. For the three months ended March 31, 2020 and 2019, we recorded an unrealized loss of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_sIIh4iWJFk2a9UMIC24hHg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="Narr_uG5FsSPUe0OCdgJj5zMzZw">0.9</ix:nonFraction> million and an unrealized gain of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_6HXkrhkugk2ANaoLx9Ffjg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="Narr_6--BuzVkt0GGvfuvvvX0vg">3.3</ix:nonFraction> million, respectively, based on the change in fair market value of Syros&#8217; common stock during these periods. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Innovent </span></p><p style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In December 2018, we entered into a research collaboration and licensing agreement with Innovent. Under the terms of this agreement, Innovent received exclusive development and commercialization rights to our clinical-stage product candidates pemigatinib, itacitinib and parsaclisib in hematology and oncology in mainland China, Hong Kong, </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_xIYI6-e6KkOK_cK6DMNvmQ_cont8" continuedAt="Tb_xIYI6-e6KkOK_cK6DMNvmQ_cont9"><p style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Macau and Taiwan. In January 2019, we recognized an upfront payment under this agreement of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_1_31_2019_us-gaap_TypeOfArrangementAxis_incy_InnoventBiologicsIncMember_C_ENlXJVxkyNDvDNsqx1-Q" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" scale="6" id="Narr_4ZiP-bHLc0SY0Cps4HO2RA">40.0</ix:nonFraction> million upon our transfer of the functional intellectual property related to the clinical-stage product candidates to Innovent, which was recorded in milestone and contract revenues on the condensed consolidated statement of operations. The upfront milestone was recognized as revenue at a point in time upon our transfer of the licenses to Innovent for the right to use the functional intellectual property. In June 2019, we recognized the $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_6_1_2019_To_6_30_2019_incy_AchievementOfMilestoneAxis_incy_RegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_InnoventBiologicsIncMember_FsIzv8L_HEi55lLcoBwVbg" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" scale="6" id="Narr_dYos60qML0achxAyzO0uXA">20.0</ix:nonFraction>&#160;million milestone for the first related IND filing in China, which was recorded in milestone and contract revenues. &#160;In addition, we are eligible to receive up to an additional $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_12_1_2018_To_12_31_2018_incy_AchievementOfMilestoneAxis_incy_DevelopmentAndRegulatoryMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_InnoventBiologicsIncMember_REXXiwthXUuKAJa4ox8rdQ" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" scale="6" id="Narr_015bs0nTbkCSldghvMZQ4w">129.0</ix:nonFraction> million in potential development and regulatory milestones. We recognize development and regulatory milestones upon confirmation of achievement of the event, as development and regulatory approvals are events not controllable by us but rather development activities of Innovent and decisions made by regulatory agencies. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event of commercialization of the licensed molecule, we are eligible to receive up to $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_12_1_2018_To_12_31_2018_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_InnoventBiologicsIncMember_cY50RxpP-U6RWVnyPyfrmA" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" scale="6" id="Narr_0_JrkTFzhEyrsjXMBjAqNg">202.5</ix:nonFraction> million in potential sales milestones from Innovent. We will recognize sales milestones in the corresponding period of the product sale upon confirmation of net sales milestone threshold achievement by Innovent. We are also eligible to receive tiered royalties from the high-teens to the low-twenties on future sales of products resulting from the collaboration. We retain an option to assist in the promotion of the <ix:nonFraction unitRef="Unit_Standard_item_4BIkJQxqZkOMHOIGydcttw" contextRef="Duration_12_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_incy_InnoventBiologicsIncMember_dJHS72SJ40CyscATO6EB5Q" decimals="INF" format="ixt-sec:numwordsen" name="incy:NumberOfProductCandidates" scale="0" id="Narr_qGAqK-FhLkCSSsTw3rsKTA">three</ix:nonFraction> product candidates in the Innovent territories.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At March 31, 2020 and December 31, 2019, $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_InnoventBiologicsIncMember_ur26l_EwbEWNuQbgjhG5pw" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementReimbursableCosts" scale="6" id="Narr_8hCmlXX2pE-t-C97aDtz0Q">3.8</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_TypeOfArrangementAxis_incy_InnoventBiologicsIncMember_CDr03ADEikqqqKMjVIsLzw" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementReimbursableCosts" scale="6" id="Narr_C4C4SdpiHUujrszew5xJqQ">3.0</ix:nonFraction>&#160;million, respectively, of reimbursable costs were included in accounts receivable on the condensed consolidated balance sheets.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Zai Lab</span></p><p style="font-family:'Times New Roman';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">In July 2019, we entered into a collaboration and license agreement with Zai Lab. Under the terms of this agreement, Zai Lab received development and exclusive commercialization rights to INCMGA0012 in hematology and oncology in mainland China, Hong Kong, Macau and Taiwan. In August 2019, we recognized an upfront payment under this agreement of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_8_1_2019_To_8_31_2019_us-gaap_TypeOfArrangementAxis_incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember_fTLP0rPirE6Sgn7TSP_gGg" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" scale="6" id="Narr_S3AbOjVq4EWKW6EX5vLgng">17.5</ix:nonFraction> million upon our transfer of the functional intellectual property related to the licensed product candidate to Zai Lab, which was recorded in milestone and contract revenues. The upfront milestone was recognized as revenue at a point in time upon our transfer of the license to Zai Lab for the right to use the functional intellectual property.</p><p style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The agreement allows for Zai Lab to continue development of the licensed molecule and to submit the licensed molecule to authorities for regulatory approval within the agreement territory, upon which we are eligible for up to $22.5 million in potential development and regulatory milestones. We recognize development and regulatory milestones upon confirmation of achievement of the event, as development and regulatory approvals are events not controllable by us but rather development activities of Zai Lab and decisions made by regulatory agencies. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event of commercialization of the licensed molecule, we are eligible to receive up to $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_8_1_2019_To_8_31_2019_incy_AchievementOfMilestoneAxis_incy_DevelopmentRegulatoryAndCommercialMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember_2LertgtXmUSbLU3ewDQkAw" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementUpfrontPaymentAmountPaid" scale="6" id="Narr_s9TAGrS8Z0qAEahsW63WCA">37.5</ix:nonFraction> million in potential sales milestones from Zai Lab.  We will recognize sales milestones in the corresponding period of the product sale upon confirmation of net sales milestone threshold achievement by Zai Lab. We are also eligible to receive tiered royalties from the low to mid-twenties on future product sales resulting from the collaboration. We also retain an option to assist in the promotion of INCMGA0012 in Zai Lab&#8217;s licensed territories. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses for the three months ended March 31, 2020 were net of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember_71IYyLEOk0qtHTwC9gMr2g" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementResearchAndDevelopmentReimbursedCost" scale="6" id="Narr_MPGgToDIPEyYCzNvrJEXgA">0.2</ix:nonFraction> million of costs reimbursed by Zai Lab. At March 31, 2020, $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember_IqSk84yaxE-JJvKAc06yPg" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementReimbursableCosts" scale="6" id="Narr_6sgC37up50uaEIoAGbWqtA">0.2</ix:nonFraction> million of reimbursable costs were included in accounts receivable on the condensed consolidated balance sheet.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">MorphoSys</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In January 2020, we entered into a Collaboration and License Agreement with MorphoSys AG and MorphoSys US Inc., a wholly-owned subsidiary of MorphoSys AG (together with MorphoSys AG, &#8220;MorphoSys&#8221;), covering the worldwide development and commercialization of MOR208 (tafasitamab), an investigational Fc engineered monoclonal antibody directed against the target molecule CD19 that is currently in clinical development by MorphoSys. MorphoSys has exclusive worldwide development and commercialization rights to tafasitamab under a June 2010 collaboration and license agreement with Xencor, Inc. In December 2019, MorphoSys submitted a Biologics License Application to the FDA for tafasitamab for the treatment of relapsed or refractory diffuse large B cell lymphoma. &#160;The agreement became effective </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_xIYI6-e6KkOK_cK6DMNvmQ_cont9"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">in March 2020 after clearance by the German and Austrian antitrust authorities and expiration of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the agreement, we received exclusive commercialization rights outside of the United States, and MorphoSys and we have co-commercialization rights in the United States, with respect to tafasitamab. &#160;MorphoSys is responsible for leading the commercialization strategy and booking all revenue from sales of tafasitamab in the United States, and we and MorphoSys are both responsible for commercialization efforts in the United States and will share equally the profits and losses from the co-commercialization efforts. We will lead the commercialization strategy outside of the United States, and will be responsible for commercialization efforts and book all revenue from sales of tafasitamab outside of the United States, subject to our royalty payment obligations set forth below. We and MorphoSys have agreed to co-develop tafasitamab and to share development costs associated with global and U.S.-specific clinical trials, with Incyte responsible for <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2020_To_1_31_2020_dei_LegalEntityAxis_incy_IncyteMember_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_joVwB0DtIkOe9vuko8XrMQ" decimals="2" format="ixt:numdotdecimal" name="incy:LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded" scale="-2" id="Narr_1Emi9ZV6kkW8bolkAZ298Q">55</ix:nonFraction>% of such costs and MorphoSys responsible for <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2020_To_1_31_2020_srt_CounterpartyNameAxis_incy_MorphosysAgMember_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_6F3K0RN-oUSX6n5Ve-1LHA" decimals="2" format="ixt:numdotdecimal" name="incy:LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded" scale="-2" id="Narr_sZSgwdn4ckyi-7djbX2rcw">45</ix:nonFraction>% of such costs. &#160;Each company is responsible for funding any independent development activities, and we are responsible for funding development activities specific to territories outside of the United States. All development costs related to the collaboration are subject to a joint development plan. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2020, we paid MorphoSys an upfront non-refundable payment of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_3_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_rHTnGuemnUagNxNCaIIsSA" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementUpfrontPaymentAmountPaid" scale="6" id="Narr_LUk7eQTR5Eqq-oIkgxi3Sw">750.0</ix:nonFraction> million which was recorded in research and development expense on the condensed consolidated statement of operations for the three months ended March 31, 2020. MorphoSys is eligible to receive up to $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_1_31_2020_incy_AchievementOfMilestoneAxis_incy_DevelopmentAndRegulatoryMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_w44LObNwjk6l_m4tp62jQg" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementAdditionalMilestonePayments" scale="6" id="Narr_T3GBUaC5TUiwmNq9EGO3wQ">740.0</ix:nonFraction> million in future contingent development and regulatory milestones and up to $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_1_31_2020_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_738l7WGg-UO8nbsLnaCpFQ" decimals="-5" format="ixt:numdotdecimal" name="incy:LicenseAgreementAdditionalMilestonePayments" scale="6" id="Narr_9xCymaHox0CnAmef5v8-yg">315.0</ix:nonFraction> million in commercialization milestones as well as tiered royalties ranging from the mid-teens to mid-twenties of net sales outside of the United States. &#160;MorphoSys&#8217; right to receive royalties in any particular country will expire upon the last to occur of (a) the expiration of patent rights in that particular country, (b) a specified period of time after the first post-marketing authorization sale of a licensed product comprising tafasitamab in that country, and (c) the expiration of any regulatory exclusivity for that licensed product in that country.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, under the collaboration agreement and pursuant to a related purchase agreement, we agreed to purchase American Depositary Shares (&#8220;ADSs&#8221;), each representing <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="As_Of_1_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmericanDepositarySharesMember_zDA5FKw7iUSQ77Y1CYtdhA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="0" id="Narr_IWUcWCnlOEeJ2-XQTg-7XQ">0.25</ix:nonFraction> of an ordinary share of MorphoSys AG, for an aggregate purchase price of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_1_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmericanDepositarySharesMember_zDA5FKw7iUSQ77Y1CYtdhA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="6" id="Narr_8pxZAUe4hkqtlfj5F-Bj7g">150.0</ix:nonFraction> million or $<ix:nonFraction unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A" contextRef="As_Of_1_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmericanDepositarySharesMember_zDA5FKw7iUSQ77Y1CYtdhA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_hdvncp315EmABMpyWADZxg">41.33</ix:nonFraction> per ADS (such ADSs to be purchased, the &#8220;New ADSs&#8221;). We agreed, subject to limited exceptions, not to sell or otherwise transfer any of the New ADSs for an <span style="-sec-ix-hidden:Hidden_LxjukuDojEmG5LuismUbLw"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">18-month</span></span> period after the closing date of the sale. We completed the purchase of the ADSs on March 3, 2020 when the closing price on The Nasdaq Stock Market was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A" contextRef="As_Of_3_3_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmericanDepositarySharesMember_p8hX0lYkjECSDquP0kv7_A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_4pjLS3LTMkCObkhQTLOByA">27.65</ix:nonFraction> per ADS. The New ADSs were not registered under the Securities Act of 1933 on the purchase date, and accordingly, we estimated a discount for lack of marketability on the shares of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_3_3_2020_To_3_3_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmericanDepositarySharesMember_rB3V8pH9lUCWt7qCtdhL8g" decimals="-5" format="ixt:numdotdecimal" name="incy:FairValueInputsAmountOfDiscountForLackOfMarketability" scale="6" id="Narr_KCIPqqKgIE2agkxw5deDqw">4.9</ix:nonFraction> million, which resulted in a net fair value of the shares on the issuance date of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_3_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmericanDepositarySharesMember_p8hX0lYkjECSDquP0kv7_A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityFairValueDisclosure" scale="6" id="Narr_m9oywAO3VUa-2IY2oy4zpw">95.5</ix:nonFraction> million. Of the $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_1_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmericanDepositarySharesMember_zDA5FKw7iUSQ77Y1CYtdhA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="6" id="Narr_8EI6p9F3tk-QxjKatOtgQQ">150.0</ix:nonFraction> million aggregate purchase price paid, $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_3_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmericanDepositarySharesMember_p8hX0lYkjECSDquP0kv7_A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="6" id="Narr_GMCOqxZViEGDQ2DCdLCvQA">95.5</ix:nonFraction> million was allocated to our stock purchase in MorphoSys and was recorded within long term investments and $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_3_3_2020_To_3_3_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmericanDepositarySharesMember_rB3V8pH9lUCWt7qCtdhL8g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_Ktk3O-hwcUKS20ekYHV87Q">54.5</ix:nonFraction> million, representing the premium paid on the purchase, was allocated to research and development expense. &#160;The fair market value of our long term investment in MorphoSys as of March 31, 2020 was $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmericanDepositarySharesMember_1C9RFh6rfkulw5myLWBnDg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityFairValueDisclosure" scale="6" id="Narr_uqbY95zr7EiSC8i4DvQW-Q">85.6</ix:nonFraction> million. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have concluded MorphoSys is not a VIE because it has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest. &#160;As of March 31, 2020, we owned approximately <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="As_Of_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_GSawLGXUJUqNCpQXIs29TA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="Narr_jPSWUEvtUECNDatJ3UJoig">3</ix:nonFraction>% of the outstanding shares of MorphoSys common stock and there are several other stockholders who hold larger positions of MorphoSys. &#160;As we do not hold a significant position of the voting shares of MorphoSys and lack the qualitative characteristics associated with the ability to exercise significant influence, our ownership interest does not meet the criteria to be accounted for as an equity method investment. We intend to hold the investment in MorphoSys for the foreseeable future and therefore, are accounting for our shares held in MorphoSys at fair value, and the investment is marked to market through earnings in each reporting period. &#160;Given our intent to hold the investment for the foreseeable future, we have classified the investment within long term investments on the accompanying condensed consolidated balance sheets. For the three months ended March 31, 2020, we recorded an unrealized loss of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_-V355oZpTEGL8BHgB8JTrQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" sign="-" scale="6" id="Narr_T2wHeT0zgUGj_qRHqc2AdA">9.9</ix:nonFraction> million based on the change in fair market value of MorphoSys&#8217; common stock during these periods. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_-V355oZpTEGL8BHgB8JTrQ" decimals="2" format="ixt:numdotdecimal" name="incy:CollaborationAgreementProfitLossSharingRatio" scale="-2" id="Narr_BEOlahf2BEuKhOB_A68b8Q">50</ix:nonFraction>% share of the United States loss for the commercialization of tafasitamab was $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_-V355oZpTEGL8BHgB8JTrQ" decimals="-5" format="ixt:numdotdecimal" name="incy:CollaborationLossSharingExpense" scale="6" id="Narr_Rmvpj2MtZ0WmRbD-lRiYEg">2.1</ix:nonFraction> million for the three months ended March 31, 2020 and is recorded as collaboration loss sharing on the condensed consolidated statement of operations.  Research and development expenses for the three months ended March 31, 2020, includes $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_-V355oZpTEGL8BHgB8JTrQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_OvCuVd-dn0GOGZHAcIgAvQ">11.6</ix:nonFraction> million related to our <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2020_To_3_31_2020_dei_LegalEntityAxis_incy_IncyteMember_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_Hko43zDhUECuypoYAgazng" decimals="2" format="ixt:numdotdecimal" name="incy:LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded" scale="-2" id="Narr_02dud3ZSQEyFtewJDKhUaQ">55</ix:nonFraction>% share of the co-development costs for tafasitamab. &#160;At March 31, 2020, $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_-hgr7X57a0avQlFj1AvRPw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="6" id="Narr_0LIr3Iyb2kulFnXt6mkSLA">13.1</ix:nonFraction> million was included in accrued and other liabilities on the condensed consolidated balance sheet for amounts due to MorphoSys under the agreement.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_11f0cec7_cf6b_4d89_afc5_4b3c3b3ecfda"></a><a id="Tc_4T7kUWpsnkC83--pnbe-qg_1_2"></a><a id="Tc_sCMSpQohBE6Eq6lDUpT0cg_1_7"></a><a id="Tc_BDtOlCilWEyadnWbNPZCqQ_2_2"></a><a id="Tc_42WV9IcN00WBCbcTVymwig_3_2"></a><a id="Tc_TDZWyfGDxk2tc2OnUg8aiw_3_4"></a><a id="Tc_Kqu-whl2PkG01knxC9UtHQ_3_7"></a><a id="Tc_bSEQnU5Ax06XvlM0EncJQA_3_9"></a><a id="Tc_3azVICqmj0uOv53EH85fAQ_4_0"></a><a id="Tc_No0Pwps1y0Sp8GfngkNfHg_4_3"></a><a id="Tc_QbDZs1SBqku1gMiK78qhew_4_5"></a><a id="Tc_pqE3Q1h0UE2rGErk0NJl_Q_4_8"></a><a id="Tc_t3bwdGdZfkSv9DV2llc5Sw_4_10"></a><a id="Tc_qpUWAlMiVEiELE9dwR8ZmA_5_0"></a><a id="Tc_r6FbVJTpbkSH1lQrNPetYg_6_0"></a><a id="Tc_jcnwi3hqn0aW1uy-7XdquA_6_3"></a><a id="Tc_PyxIeiXmYUKT6PtJ4F9QwA_6_5"></a><a id="Tc_gHqNKREduUaxkNdqdwVlbw_6_8"></a><a id="Tc_LEwiKBWj_Ue6e3kTSRMSlg_6_10"></a><a id="Tc_-2Tz3JskGESP1uFfKIDm5A_7_0"></a><a id="_6514b019_682e_4686_89de_a13ad3d3e6fd"></a><a id="Tc_-I5BPp_4t0OZBh1da2Nj6A_1_2"></a><a id="Tc_M_g8YjoP80yB_KSgk9JnLw_2_2"></a><a id="Tc_GD8lunSxy0ODJWIZGjUiaA_3_4"></a><a id="Tc_ELx6TnGRQ0C_VVla2eCZBw_4_2"></a><a id="Tc_UMfVDWJK2kOYI9RWGMO27w_4_4"></a><a id="Tc_2mehSbGcmk2Xk7ju371Edg_5_0"></a><a id="Tc_jhl3O5qgS0iLEhRKufc_fw_5_4"></a><a id="Tc_CkxDywRswUOt3_EwB3nhKA_6_0"></a><a id="Tc_6BTJUnrGkEaHS0fZtB53oA_6_4"></a><a id="Tc_RX7fT4jgLUu8efHEGMWBKA_7_0"></a><a id="Tc_o27Q4BbOiku2caT-AuOpDg_7_4"></a><a id="Tc_vG5pdx-PS0q2ALpZucm1Qg_8_0"></a><a id="Tc_pXw0onscG02sJBfnrSdjVA_8_4"></a><a id="Tc_FHV-XLwopUy0SEJVG3i0Kw_9_0"></a><a id="Tc_uj0f_WE8HU-wtXhBIFwX0w_9_4"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_V2BHdt7kOEiXSIHBbPLdnw" continuedAt="Tb_V2BHdt7kOEiXSIHBbPLdnw_cont1" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">10.&#160;&#160;&#160;&#160; </b><b style="font-weight:bold;">Stock compensation</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We recorded $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_VcfFwxfZBkuV-rXd9139Jg">42.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_E6Bh__aCYkS-PxaxItMUKA">40.6</ix:nonFraction> million, respectively, of stock compensation expense on the condensed consolidated statements of operations for the three months ended March 31, 2020 and 2019.  Stock compensation expense included within our condensed consolidated statements of operations for the three months ended March 31, 2020 and 2019 included research and development expense of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_hdQWjmjVAUOoLAgOzPKlfg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_93-_Z5ysoUej5mG8XS8wnQ">28.7</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_HQ2dp39OO0S03M-igkKhPQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_upLOGI38jka6arGnecAadw">27.4</ix:nonFraction> million, respectively. Stock compensation expense included within our condensed consolidated statements of operations for the three months ended March 31, 2020 and 2019 also included selling, general and administrative expense of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ayQXfrU-kEqLMW5XKp3dOQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_xS2dZ8PrnEeoBkbv4UHwxQ">13.6</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember__KRsuuuxFUGHFrG9WcT73A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_AtjuMxS4NEunrOg5xIpKdw">13.0</ix:nonFraction> million, respectively. Stock compensation expense included within our condensed consolidated statements of operations for the three months ended March 31, 2020 and 2019 also included cost of product revenues of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_iAoPlqdY8EuohmWI9wvG1Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_m6fEQAT4DUimX9186ic4Mg"><ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_SYkDX7ewnEi-fA1QMyfsXw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_CuhkY1sJyUWQBH4nQI_GPA">0.2</ix:nonFraction></ix:nonFraction> million for each period. For the three months ended March 31, 2020 and 2019, we capitalized $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-5" format="ixt:numdotdecimal" name="incy:StockCompensationExpenseCapitalized" scale="6" id="Narr_4-juIC-dkUqX7FTQP3DHQQ">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-5" format="ixt:numdotdecimal" name="incy:StockCompensationExpenseCapitalized" scale="6" id="Narr_Jgx840j860eb6BoyUYwVvA">0.1</ix:nonFraction> million of stock compensation expense as part of the cost of an asset.</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="incy:ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="Tb_2oH7JsXj9UqXllMNo4R2jQ" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We utilized the <ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed" id="Narr_9QoDowqcl0GufNcPWWyGxQ">Black-Scholes valuation model</ix:nonNumeric> for estimating the fair value of the stock compensation granted, with the following weighted-average assumptions:</p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:99.53%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:55.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Employee Stock Options</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:23.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Employee Stock Purchase Plan</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:55.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:40.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Three Months&#160;Ended March&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:55.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#8194;&#8194;&#8194;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#8194;&#8194;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#8194;&#8194;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#8194;&#8194;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Average risk-free interest rates</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tgSRvrejHUqYFIu85rRsPg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_gnvtBwYRoke3j7jdAy9OpQ_4_2">1.56</ix:nonFraction> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;&#8194;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Cbj624ha3kmOoiQSEnwBlw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_-H4YpX7CLk6bqDCqnfKrxQ_4_4">2.51</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;&#8194;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_SVG1T8un0UuAR4xiq6ES-w" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_exI4qQIaLUKiVKMirLkcAQ_4_7">0.23</ix:nonFraction> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;&#8194;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_W9GbI2-s5ES4CTz48UruiA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_tU9nm2TnMEy8DTPki5OOeA_4_9">2.27</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;&#8194;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Average expected life (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tgSRvrejHUqYFIu85rRsPg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_umgKkYG2kUmm2VuDRgrkEg_5_2">4.65 </ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Cbj624ha3kmOoiQSEnwBlw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_SLaQg8UAGESwpRWBFp9kaw_5_4">5.33</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_SVG1T8un0UuAR4xiq6ES-w" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_0fOOP3OZx02ojNO25Nmddg_5_7">0.25 </ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_W9GbI2-s5ES4CTz48UruiA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_k_Wt0ozaOE2ShcC2CuPvvA_5_9">0.25</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Volatility</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tgSRvrejHUqYFIu85rRsPg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_dEPc4mzEMUGQx15I3DCSDQ_6_2">40</ix:nonFraction> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Cbj624ha3kmOoiQSEnwBlw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_zzMvPzHMaUCUR17ltSSCLQ_6_4">45</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_SVG1T8un0UuAR4xiq6ES-w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_OninVhEei0ODjZrirl2hkg_6_7">52</ix:nonFraction> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_W9GbI2-s5ES4CTz48UruiA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_cr7Vx1k290myb4edy3Ts-g_6_9">34</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Weighted-average fair value (in dollars)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tgSRvrejHUqYFIu85rRsPg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_xgtCUj1JDEKAKZp5PY__VA_7_2">28.43</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A" contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Cbj624ha3kmOoiQSEnwBlw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_YsF14GZzEkqrGuFpo0MHJA_7_4">31.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_SVG1T8un0UuAR4xiq6ES-w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_ujJJeNx3MUez2KdRSTQAWg_7_7">16.00</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A" contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_W9GbI2-s5ES4CTz48UruiA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_LWIcme8naUqDW4pZfrhfqg_7_9">13.31</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The risk-free interest rate is derived from the U.S. Federal Reserve rate in effect at the time of grant. The expected life calculation is based on the observed and expected time to the exercise of options by our employees based on historical exercise patterns for similar type options. Expected volatility is based on the historical volatility of our common stock over the period commensurate with the expected life of the options. A dividend yield of <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_CjqxRxKhvkGdTGYtLEzZBw">zero</ix:nonFraction> is assumed based on the fact that we have never paid cash dividends and have no present intention to pay cash dividends. Nonemployee awards are measured on the grant date by estimating the fair value of the equity instruments to be issued using the expected term, similar to our employee awards.</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_Md1qPoRkbEmHiPWUx0XN1A" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Option activity under our 2010 Amended and Restated Stock Incentive Plan (the &#8220;2010 Stock Plan&#8221;) was as follows:</p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:25.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares&#160;Subject&#160;to</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:25.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding&#160;Options</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Balance at December&#160;31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AzTpzCx2FEeghKSIssu86g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_WZmm9tSoXUW3p8ibA-wGMQ_5_2">12,632,657</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A" contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AzTpzCx2FEeghKSIssu86g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_NpB--Skm6kGjn-KoEvrFEA_5_5">81.42</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tgSRvrejHUqYFIu85rRsPg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="Tc_7_q0-o0ASUelW__OhjO10w_6_2">914,834</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tgSRvrejHUqYFIu85rRsPg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_yCb8RIPH00qOnEwrDPAB-w_6_5">80.12</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Options exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tgSRvrejHUqYFIu85rRsPg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_OtTLAnP86E6O_9SgNKif3A_7_2">688,202</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tgSRvrejHUqYFIu85rRsPg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_27RxsLhhwUO2SZw9_9wIug_7_5">26.83</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Options cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tgSRvrejHUqYFIu85rRsPg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_DPnh3a3EUkqCA48c6W7wtg_8_2">180,342</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tgSRvrejHUqYFIu85rRsPg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_rJhb0uXj9UOV8eEPFC4U5A_8_5">91.57</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Balance at March&#160;31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="As_Of_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_-W06vJqxfUKkm8FD3tX-XQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_5clZpMw55kyiZoqKYzLQ6A_9_2">12,678,947</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A" contextRef="As_Of_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_-W06vJqxfUKkm8FD3tX-XQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_uS2uD8HIoESZKfDzG5WF2w_9_5">84.14</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In July 2016, we revised the terms of our annual stock option grants to provide that new option grants would generally have a <span style="-sec-ix-hidden:Hidden_6RWKpuCFUEKpc6a3v7bZKw"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">10-year</span></span> term and vest over <ix:nonNumeric contextRef="Duration_7_1_2016_To_7_31_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_eVPwouvAqkSAUpm9iX0Giw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_8HyH_Zwzl0qg0MbeIURFgQ">four years</ix:nonNumeric>, with <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_7_1_2016_To_7_31_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_zIOfLPcoIE-WPja313LTug" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_NghHLQH4PUCTgmurMC2qHw">25</ix:nonFraction>% vesting after <ix:nonNumeric contextRef="Duration_7_1_2016_To_7_31_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_zIOfLPcoIE-WPja313LTug" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_atq8ZS7poEmLoUrpA41G5A">one year</ix:nonNumeric> and the remainder vesting in <span style="-sec-ix-hidden:Hidden_OR5-Cr_KuEOxFj4pvVNKEQ"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">36</span></span> equal monthly installments. Previously, our option grants generally had <span style="-sec-ix-hidden:Hidden_5i-HSeUv7Eq9b9ehfzeLfA"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">7-year</span></span> terms and vested over <ix:nonNumeric contextRef="Duration_1_1_2016_To_6_30_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_R2nXzmWcpEusNX2tgETvVg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_fqnWwwHf1Eq050tM8IvMVw">three years</ix:nonNumeric>, with <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2016_To_6_30_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_L9F2_6Qez0Ox5Fm8qYePbw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_ZOpQa9CnD0epLcjfEk_arg">33</ix:nonFraction>% vesting after <ix:nonNumeric contextRef="Duration_1_1_2016_To_6_30_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_L9F2_6Qez0Ox5Fm8qYePbw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_qAvhFKZYZ0GkugTzIz6Dpg">one year</ix:nonNumeric> and the remainder vesting in <span style="-sec-ix-hidden:Hidden_mWa7sHwgO02SjXEAYJrP4Q"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">24</span></span> equal monthly installments.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_4e75b77a_056b_4f83_acbf_8d1616a9e98c"></a><a id="Tc_rn8vHzCIpEOIGhLwDOjAOQ_1_2"></a><a id="Tc_uP_JB0NbkUCmLX4xIRC73Q_2_2"></a><a id="Tc_FTcbFXSBqU67BvT4r_0HWA_3_2"></a><a id="Tc_qSbAEJnhA026ozzHD025KQ_3_4"></a><a id="Tc_GPDakDMsekq-ZABJwVXu2g_4_0"></a><a id="Tc_dRLQRLVL-0asqjDyvEcNMw_4_4"></a><a id="Tc_7YUTpVqwiUyO_RLLtQ14QQ_5_0"></a><a id="Tc_7VquMlUA5EmzNn8W9LkxRQ_5_4"></a><a id="Tc_NCsGKTm4jUOVqcV-neR-OA_6_0"></a><a id="Tc_AHdtpZUFJ0qckcnPSecvKA_6_4"></a><a id="Tc_zPVhY93lyEWGIKaqfDrKwQ_7_0"></a><a id="Tc_VrWAnkpYx0usUCazXbOlZg_7_4"></a><a id="Tc_KF6S2ZZFz0SsfWDltwlYwA_8_0"></a><a id="Tc_k43vhpJDGEelFo41llbsyQ_8_4"></a><a id="Tc_ohab4-MqAUW7ztQKe_TYqw_9_0"></a><a id="Tc_nefAKBzKI0qJt3Lz54Z6og_9_4"></a><ix:continuation id="Tb_V2BHdt7kOEiXSIHBbPLdnw_cont1" continuedAt="Tb_V2BHdt7kOEiXSIHBbPLdnw_cont2"><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="incy:ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock" id="Tb_zUf_J-YsSESqBDYeFzVj8Q" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Restricted stock unit (&#8220;RSU&#8221;) and performance share (&#8220;PSU&#8221;) award activity under the 2010 Stock Plan was as follows:</p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:24.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares&#160;Subject&#160;to</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:24.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding&#160;Awards</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date Value</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Balance at December&#160;31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="Tc_7aWcJ4JWh0q1PfdreBM89A_4_2">2,602,376</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" scale="0" id="Tc_S217rlh7h0O7md8W9z_qpw_4_5">79.69</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">RSUs granted </p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_VmhuMJCx8kyw979O9O77sA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_V6dAhq49AUykVdhBuftilw_5_2">379,496</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_VmhuMJCx8kyw979O9O77sA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" scale="0" id="Tc_vwGB_JLP10ejUCBOc5S0pA_5_5">80.32</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">RSUs released</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_VmhuMJCx8kyw979O9O77sA" decimals="INF" format="ixt:numdotdecimal" name="incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" scale="0" id="Tc_cZZrfxKBwUS04aw-seTaJg_6_2">64,426</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_VmhuMJCx8kyw979O9O77sA" decimals="2" format="ixt:numdotdecimal" name="incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue" scale="0" id="Tc_JVGvyJAsEU2Y0jMO-8C51w_6_5">87.36</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">RSUs cancelled </p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_VmhuMJCx8kyw979O9O77sA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="Tc_ixmL9A60SkGmThStIG6j8Q_7_2">39,795</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_VmhuMJCx8kyw979O9O77sA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" scale="0" id="Tc_0Tedd2Y0SE27fBS0i6HHCg_7_5">80.31</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">PSUs cancelled</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_CUAHxIXboUW-AGQxTycjxQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="Tc_gFjakLtTrEGnFxW991oLIw_8_2">12,250</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_CUAHxIXboUW-AGQxTycjxQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" scale="0" id="Tc_AlZ4KouH-kqkqpKrS2VDdg_8_5">65.76</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Balance at March&#160;31, 2020</p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="Tc_pwlj1wDHCEC3qsmSAFBabA_9_2">2,865,401</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" scale="0" id="Tc_3anfuSsK_0ezs1yOv2DM0g_9_5">79.65</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January&#160;2014, we began granting RSUs and PSUs to our employees at the share price on the date of grant. &#160; Each RSU represents the right to acquire <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_1_1_2014_To_1_31_2014_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_a4J1xme2j0qJI7w67u-8Kw" decimals="INF" format="ixt-sec:numwordsen" name="incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits" scale="0" id="Narr_mfShpHQAQ0KX5-M8hshbcg">one</ix:nonFraction> share of our common stock.  Each RSU granted prior to July 2016 was subject to cliff vesting after <ix:nonNumeric contextRef="Duration_1_1_2016_To_6_30_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_yPcPm_5LjUyiK3NWPCSUmg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="Narr_1ycEo83lD06m0NHa27DavA">three years</ix:nonNumeric>. In July 2016, we revised the terms of our RSU grants to provide that the awards will vest <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_7_1_2016_To_7_31_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_2XwuCwQyq028NRrBWn-7FQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_n-6rzeEeS0CuoRmf4hbvEw">25</ix:nonFraction>% annually over <ix:nonNumeric contextRef="Duration_7_1_2016_To_7_31_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_2XwuCwQyq028NRrBWn-7FQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_uST1IjbMBEW-v7abbnSgTg">four years</ix:nonNumeric>. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2018, we granted <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_6_1_2018_To_6_30_2018_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_WKzuvMhbXkaBU9jbXYBPQw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_tpoe-oG6VUGM2ZW5m037-A">190,000</ix:nonFraction> RSUs and <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_6_1_2018_To_6_30_2018_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_vC6oKQwc_UO2IGuLtg5qng" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_HgqgzfwzREy8qiwOi0sUSw">446,500</ix:nonFraction> PSUs under long term incentive plans with performance and/or service-based milestones with graded and/or cliff vesting over <span style="-sec-ix-hidden:Hidden_w_7MzdT-j0OynAIorIKX9Q"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">three</span></span> to <ix:nonNumeric contextRef="Duration_6_1_2018_To_6_30_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_SZJ4LKIOuESQEpa0eW7EPw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="Narr_QD0gFy7810ifANskMJQScw">four years</ix:nonNumeric>. In April 2019, we granted an additional <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_4_1_2019_To_4_30_2019_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_incy_LongTermIncentivePlanOneMember_dDGsqWzkwEmzRXEky-0cyA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_KPm1jtVFQUWuRDjIdkDhMA">100,000</ix:nonFraction> PSUs under one of the existing long term incentive plans with performance based milestones and cliff vesting. For one of the existing long term incentive plans, under which <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_6_1_2018_To_6_30_2018_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_incy_LongTermIncentivePlanOneMember_jsEmMys8p0GNOaeQtFsmZQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_fNcfUadD-0Oo6UTUjXonCw">106,500</ix:nonFraction> PSUs were granted, the actual number of shares of our common stock into which each PSU may convert was subject to a multiplier of up to <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_6_1_2018_To_6_30_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_incy_LongTermIncentivePlanOneMember_DDOU9aUbe0qDsi2WsRXKrg" decimals="2" format="ixt:numdotdecimal" name="incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor" scale="-2" id="Narr_Cgqp__PZQ0yNfGXc76mZkg">267</ix:nonFraction>% based on the level at which the performance conditions were achieved. The actual number of shares of our common stock into which each PSU will convert is at a multiplier of <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_3_31_2019_To_3_31_2019_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_incy_LongTermIncentivePlanOneMember_10zMB4kxHUmiN5hoSzLWUw" decimals="2" format="ixt:numdotdecimal" name="incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor" scale="-2" id="Narr_JPDNr-p5CUiWBHIz3gv0Nw">142</ix:nonFraction>% based on the performance conditions being achieved as of March 31, 2019 and will continue to vest through June 2022. &#160;For an existing long term incentive plan, under which <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_6_1_2018_To_6_30_2018_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_incy_LongTermIncentivePlanTwoMember_GfdRdjchm0SNfn7rnmSnFA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_2A4VZ03MkEmL_V2mX24tlw">150,000</ix:nonFraction> PSUs were granted, the actual number of shares of our common stock into which each PSU may convert was subject to a multiplier of up to <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_6_1_2018_To_6_30_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_incy_LongTermIncentivePlanTwoMember_F_BDMjdwvUaazt5WAPM0pg" decimals="2" format="ixt:numdotdecimal" name="incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor" scale="-2" id="Narr_yu1Oeflgo0yDUXkaGoI-yA">100</ix:nonFraction>% if all performance conditions were achieved or <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_6_1_2018_To_6_30_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_incy_LongTermIncentivePlanTwoMember_0cnSLqNMKkOiYjDFx0hr1g" decimals="2" format="ixt:numdotdecimal" name="incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor" scale="-2" id="Narr_rgaXyoDTk0iEGrA3oo0ubg">0</ix:nonFraction>% if no performance conditions were achieved. The actual number of shares of our common stock into which each PSU will convert is at a multiplier of <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_12_31_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_incy_LongTermIncentivePlanTwoMember_g0CLhct2S0K4vHe7Em2Zuw" decimals="2" format="ixt:numdotdecimal" name="incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor" scale="-2" id="Narr_rFn8_P08mEyEvi2h5Qhmiw">100</ix:nonFraction>% based on the performance conditions being achieved as of December 31, 2019 and will cliff vest in June 2021. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Compensation expense for the performance-based awards is recorded over the estimated service period for each milestone when the performance conditions are deemed probable of achievement. For the period ended March 31, 2020, the stock compensation expense recorded during the period was for service-based awards and performance conditions deemed probable of achievement and/or achieved. For PSUs containing performance conditions which were not deemed probable of achievement at March 31, 2020, no stock compensation expense was recognized.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In July 2018, we granted <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_7_1_2018_To_7_31_2018_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_YelUbuNY80CUvf6lPtpuag" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_zGg-eihchEyykwQagECoNQ">77,243</ix:nonFraction> PSUs to executives with performance milestones and graded vesting over <ix:nonNumeric contextRef="Duration_7_1_2018_To_7_31_2018_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_YelUbuNY80CUvf6lPtpuag" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_MM_ImwwqLUmqOAWMWbZUXg">four years</ix:nonNumeric>. &#160;The shares of our common stock into which each PSU may convert is subject to a multiplier up to <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_7_1_2018_To_7_31_2018_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_YelUbuNY80CUvf6lPtpuag" decimals="2" format="ixt:numdotdecimal" name="incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageMultiplierForConversionOfUnitsIntoCommonStock" scale="-2" id="Narr_bi60a4BvoUqRtZTNCO-HXg">150</ix:nonFraction>% based on the level at which the performance condition is achieved. Compensation expense for the performance-based awards is recorded over the estimated service period when the performance condition is deemed probable of achievement. The actual number of shares of our common stock into which each PSU converted was at a multiplier of <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_AkK30_Ng-U2hTUpYkJOybQ" decimals="2" format="ixt:numdotdecimal" name="incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor" scale="-2" id="Narr_ZxX05KfiHUmUTGY2NbuBug">83</ix:nonFraction>% based on the performance condition being achieved as of December 31, 2018. &#160;These PSUs will continue to vest through July 2022. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In July 2019, we granted <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_7_1_2019_To_7_31_2019_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_TVxp6xaORUq6y8Ownz8CYg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_WcfcHOVW30KOcmMfb9KNPA">86,975</ix:nonFraction> PSUs to executives with a performance milestone and graded vesting over <ix:nonNumeric contextRef="Duration_7_1_2019_To_7_31_2019_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_TVxp6xaORUq6y8Ownz8CYg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_UmJ47S1_skuyaFIUPK_D-A">four years</ix:nonNumeric>. &#160;The shares of our common stock into which each PSU may convert is subject to a multiplier up to <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_7_1_2019_To_7_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_xd5AG2VWVEOzpz4FkpHdOg" decimals="2" format="ixt:numdotdecimal" name="incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor" scale="-2" id="Narr_ykatAncE10K8QDvf0MaNzA">125</ix:nonFraction>% based on the level at which the performance condition is achieved. Compensation expense for the performance-based awards is recorded over the estimated service period when the performance condition is deemed probable of achievement. The actual number of shares of our common stock into which each PSU will convert is at a multiplier of <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_12_31_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_R6qfbt0g7UGmt1ZGgohMYw" decimals="3" format="ixt:numdotdecimal" name="incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor" scale="-2" id="Narr_WvadR6pCBU-1ES1kuyLT-A">101.8</ix:nonFraction>% based on the performance condition being achieved as of December 31, 2019. &#160;These PSUs will continue to vest through July 2023.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_57c4b8f3_a9be_4df1_95bc_b8b83c48ac62"></a><a id="Tc_BPRMC4cu3EeTA3PVt1WX3g_1_2"></a><a id="Tc_KRGr4m--OUyk-FppggVxSQ_2_2"></a><a id="Tc_KPdmhC7dV0eW--9D_U9Pqw_3_0"></a><a id="Tc_hiX7v5zZEEOUVpf-UfZ2pw_4_0"></a><a id="Tc_Md7yrlJ-r0auiFDMI3qyJQ_5_0"></a><a id="Tc_GoqRtGy9j0Gqzvklg_uvOA_6_0"></a><ix:continuation id="Tb_V2BHdt7kOEiXSIHBbPLdnw_cont2"><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock" id="Tb_DPccJr7BQUCciC1EfIZsmQ" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our shares available for grant under the 2010 Stock Plan:</p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:81.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:15.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares Available</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:81.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:15.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for Grant</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Balance at December&#160;31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Tc_Il9tnnHmbUqlvWx5Z_R7bg_3_2">9,882,122</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Options, RSUs and PSUs granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="INF" format="ixt:numdotdecimal" name="incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted" scale="0" id="Tc_lm6IRX2F2k2DCQ8HoevzfA_4_2">1,673,826</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Options, RSUs and PSUs cancelled</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="INF" format="ixt:numdotdecimal" name="incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled" scale="0" id="Tc__bAdiqiFcUe2-xPURPS1PA_5_2">247,429</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Balance at March&#160;31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Tc_R7LIbVXEvEG3tyPgUnshNw_6_2">8,455,725</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Based on our historical experience of employee turnover, we have assumed an annualized forfeiture rate of <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="2" format="ixt:numdotdecimal" name="incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate" scale="-2" id="Narr_vjPhXL5h3U2gGJbBImbHIQ">5</ix:nonFraction>% for our options, RSUs and PSUs. Under the true-up provisions of the stock compensation guidance, we will record additional expense if the actual forfeiture rate is lower than we estimated, and will record a recovery of prior expense if the actual forfeiture is higher than we estimated.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Total compensation cost of options granted but not yet vested, as of March 31, 2020, was $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_-W06vJqxfUKkm8FD3tX-XQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="Narr_QZAHRB-EGE-_9EAK5Cjbuw">95.8</ix:nonFraction> million, which is expected to be recognized over the weighted average period of approximately <ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tgSRvrejHUqYFIu85rRsPg" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_wDNF09gHzkO9n66rS2Vbjg">1.4</ix:nonNumeric> years. Total compensation cost of RSUs granted but not yet vested, as of March 31, 2020, was $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_uJymqcnIC0WuSGRiCrl9yQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="Narr_1JcOo4pRS0q67gxGAD-BQA">93.3</ix:nonFraction> million, which is expected to be recognized over the weighted average period of approximately <ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_VmhuMJCx8kyw979O9O77sA" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_0vIfJHH7x0uM9aBBGaIeag">1.8</ix:nonNumeric> years. &#160;Total compensation cost of PSUs granted but not yet vested, as of March 31, 2020, was $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_y8PVaaJJd06F0gOHPbgysg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="Narr_d9k1fYDPVEmGqkTZAHWdtA">29.5</ix:nonFraction> million, which is expected to be recognized over the weighted average period of <ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_CUAHxIXboUW-AGQxTycjxQ" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_zLiEoCpNGE61M4m0myJefw">1.8</ix:nonNumeric> years, should the underlying performance conditions be deemed probable of achievement.</p></ix:continuation><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_780ff53e_b262_440a_a905_07a4aa2f8dae"></a><a id="Tc_Wl4UybyA2UWxWDbYGcJ_QA_1_2"></a><a id="Tc_-o6WCzMxGEKmsocLzeXJQQ_1_5"></a><a id="Tc_QkWPV5lpXEmmiRbE2_1p5g_2_2"></a><a id="Tc_ucS5KV38YEqJ1wFgxrOiIQ_2_5"></a><a id="Tc_L0RnWMjH4E21vZu1Uebkcg_3_0"></a><a id="Tc_u_1Hd591rkyODqcmdiP0hw_3_2"></a><a id="Tc_0weTydvCH0GehhTbtAtHJg_3_5"></a><a id="Tc_91XOQ6Qrt0yVdUnVLZR49w_4_0"></a><a id="Tc_Jale8MZEykin3mfslgrDMw_5_0"></a><a id="Tc__7uHAhjnPkugYLxdM7O4hQ_6_0"></a><a id="Tc_8yBmGIch8UeXXwdOJ922sw_7_0"></a><a id="Tc_CcurE3mW9kKxI7qBFgPLMw_8_0"></a><a id="Tc_JUZdpQgGfU6CiXP3S60VDA_9_0"></a><a id="Tc_2Sg3spF4tEyI8g14x_7L5Q_9_2"></a><a id="Tc_3zD5m83afkai8DZzU-FDHw_9_5"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="Tb_-ryyFvpuOUOasX4Y2GJ3Tg" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">11.&#160;&#160;&#160;&#160; </b><b style="font-weight:bold;">Accrued and other current liabilities</b></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_SKtNukAY9Ueh7d9bipX0ZQ" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accrued and other current liabilities consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:17.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31, </b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:17.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Royalties</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="Tc_HxonI-eD0Eu2ejxUVJy0wQ_3_3">73,045</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="Tc_IhftVFD_KkWRpZ0DG9k6Tg_3_6">73,221</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Clinical related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="incy:AccruedClinicalRelatedCostsCurrent" scale="3" id="Tc_X24BL7mMKkyAZqxYr1nq3Q_4_3">77,913</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="incy:AccruedClinicalRelatedCostsCurrent" scale="3" id="Tc_-JJVHkvD00-FwTGbibdhKg_4_6">88,710</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Sales allowances</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProvisionForLossOnContracts" scale="3" id="Tc_EzAPZ1ODwEGpi_5IGwvsvg_5_3">96,062</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProvisionForLossOnContracts" scale="3" id="Tc_wEt8KHapzkay_CdndiokGA_5_6">59,924</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConstructionPayableCurrent" scale="3" id="Tc_HC-dRC2TKUOfQW81KDBfuA_6_3">13,582</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConstructionPayableCurrent" scale="3" id="Tc_GVOBEv04-EKxdzDKxqNrug_6_6">12,732</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Operating lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_8NolupSH0kSTpQbCBZte4w_7_3">9,021</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_M4qhGyOjj0u3sqrmllv5eg_7_6">9,343</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_e4JXickss0Wn7dlTivRxng_8_3">60,411</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_1LIMs_SpUU-YZy51zEppZg_8_6">42,020</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Total accrued and other current liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_ef93hc-_6EmmNAfQowVskA_9_3">330,034</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_MSI8Ez8VkU6AykAG2QfwfQ_9_6">285,950</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><span style="background-color:#ffffff;font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_01eccf49_1cea_4991_a5a5_0c748b275522"></a><a id="Tc_Q9TzmlSRxkaOtpL8TRLHDw_1_6"></a><a id="Tc_Y__IUAojHECnwIX23_RWNQ_2_2"></a><a id="Tc_dpjs9FkZ_UWaYJIm0gDWeA_2_6"></a><a id="Tc_J1u_D3kl_02fVITsAAqvWA_2_9"></a><a id="Tc_AsKtZSvo1EmexfVvSAbUkg_3_0"></a><a id="Tc_a9J2u5lPS0WGX6ZBYl8VGQ_3_2"></a><a id="Tc_9R_W06_o-k2XIaC82LYBRA_3_4"></a><a id="Tc_xC0b6RAQJ0KbU0AENlKOTQ_3_6"></a><a id="Tc_mO8vEL_FFECkLK2J47YPoA_3_9"></a><a id="Tc_jI_T7iE9JUyCjndbclKEYQ_4_0"></a><a id="Tc_73S9MUr7HEKFIEtqGsdc4w_4_3"></a><a id="Tc_kmvNTAPS-EOGsND4u6B7bA_4_4"></a><a id="Tc_a21CtmBwmECo5kN9ezrgnw_4_6"></a><a id="Tc_MKtU62X3gUi39y5LaWEA8g_4_9"></a><a id="_8ec59dc6_b8a0_4107_83f8_058ff686ad6e"></a><a id="Tc_VA0rkrNDoE-fbwwDXiMlAw_1_2"></a><a id="Tc_cxTsYITFY0mORp5doxq15w_1_8"></a><a id="Tc_FodniDGYq0i7ipX16JUP-A_2_2"></a><a id="Tc_JRMSLjv5tk69mN16OlaKcA_2_8"></a><a id="Tc_1IAMEwlaSkqamr30V-4jHw_3_2"></a><a id="Tc_E8GsS5gTsUWFXiel7PsSCA_3_5"></a><a id="Tc_lHgKKDhdSkqoezPCgwwLkA_3_8"></a><a id="Tc_z-nfp2K7Z0yXoUJNqK_8WQ_3_11"></a><a id="Tc_fd4yUvveEky8GsIIrypSWQ_4_0"></a><a id="Tc_AKJmIIczxEGMIOGVbJc00Q_4_2"></a><a id="Tc_Uzcktxvawk-y7zRNDhWoJw_4_5"></a><a id="Tc_Ts8aUwuWG0S_El6Dbvv_5g_4_8"></a><a id="Tc_n3cKrQM_dUuoSn97selorw_4_11"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:DebtDisclosureTextBlock" id="Tb_WCQVUC3ZXUyOKGpkA-3ocw" continuedAt="Tb_WCQVUC3ZXUyOKGpkA-3ocw_cont1" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">12.&#160;&#160;&#160;&#160; </b><b style="font-weight:bold;">Debt</b></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="Tb_3Q4PoaONXky6BT-CO7SYdg" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The components of the convertible senior notes are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:56.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying&#160;Amount,</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:56.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Interest&#160;Rates</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:56.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Debt</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, 2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maturities</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">1.25% Convertible Senior Notes due 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="As_Of_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_mf1pSO_8xk-KJN_VOGoSlQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Tc_aaZduSSApEyf_WdUpas_7w_4_2">1.25</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_Zx-v_c4r70WwWX03gqsXyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebt" scale="3" id="Tc_zCT6kZHX1EqcQGIsnZC3ZQ_4_7">18,524</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_rppXeBwyn0KUPPFX6vCgDA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebt" scale="3" id="Tc_JCunXsjfhk2rsMHZ8j_MWQ_4_10">18,300</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="Tb_4DOZEC4OB0i9PIfcVNoylg" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The carrying amount and fair value of our convertible senior notes are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:59.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:18.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, 2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:18.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31, 2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:59.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:59.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="As_Of_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_mf1pSO_8xk-KJN_VOGoSlQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_WEDsMyVyVEKv-3q-S3-wZA"><ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_dUhGX9pGs0KEez2XYOKNtg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_fQsmjcAM20uA4NysFFKPQg">1.25</ix:nonFraction></ix:nonFraction>% Convertible Senior Notes due 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_Zx-v_c4r70WwWX03gqsXyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebt" scale="3" id="Tc_jVIuOkCwfUma9vJtvf-d5A_4_3">18,524</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_ByXHMCnwhUuLsKezaFFRag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebt" scale="3" id="Tc_oMMi-yNR10--AeNu7V4aFw_4_6">27,656</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_rppXeBwyn0KUPPFX6vCgDA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebt" scale="3" id="Tc_aTzwz-vIKUubk00WvWksaA_4_9">18,300</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_BIl-1RaM1EOPgs_KNzpbiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebt" scale="3" id="Tc_WIY_T_pyD0KrLBTTWMZlow_4_12">32,511</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fair value of the <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="As_Of_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_mf1pSO_8xk-KJN_VOGoSlQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_6oWsuqCgc0Sx-L1UnzNmlQ">1.25</ix:nonFraction>% Convertible Senior Notes due 2020 (the &#8220;2020 Notes&#8221;) is based on data from readily available pricing sources which utilize market observable inputs and other characteristics for similar types of instruments, and, therefore, is classified within Level 2 in the fair value hierarchy. </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_WCQVUC3ZXUyOKGpkA-3ocw_cont1"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to May 14, 2014, the 2020 Notes were not convertible except in connection with a make-whole fundamental change, as defined in the indenture. Beginning on, and including, May 15, 2014, the 2020 Notes are convertible prior to the close of business on the business day immediately preceding May 15, 2020 only under the following circumstances: (i) during any calendar quarter commencing after the calendar quarter ending on March 31, 2014 (and only during such calendar quarter), if the last reported sale price of our common stock for at least <span style="-sec-ix-hidden:Hidden_1LuKVsI460CF2sHZ2dlGqw"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">20</span></span> trading days (whether or not consecutive) during a period of <span style="-sec-ix-hidden:Hidden_Rv9y-6kA30urzn5y6CwGRg"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">30</span></span> consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member_MP4cDjTkq06lAGevzdzYBw" decimals="2" format="ixt:numdotdecimal" name="incy:DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" scale="-2" id="Narr_5ayzhQPlTUyaYd_5bH4oMg">130</ix:nonFraction>% of the conversion price for the 2020 Notes on each applicable trading day; (ii) during the <ix:nonFraction unitRef="Unit_Standard_item_4BIkJQxqZkOMHOIGydcttw" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member_MP4cDjTkq06lAGevzdzYBw" decimals="0" format="ixt-sec:numwordsen" name="incy:DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod" scale="0" id="Narr_igM1p09gF0STn8sH4e1gQw">five</ix:nonFraction> business day period after any <ix:nonFraction unitRef="Unit_Standard_item_4BIkJQxqZkOMHOIGydcttw" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member_MP4cDjTkq06lAGevzdzYBw" decimals="0" format="ixt-sec:numwordsen" name="incy:DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays" scale="0" id="Narr_I6eI5zuf30WRlNdWPlYhcw">five</ix:nonFraction> consecutive trading day period (the &#8220;measurement period&#8221;) in which the trading price per $<ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member_MP4cDjTkq06lAGevzdzYBw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="Narr_261ikMJJ2US31PgpDvO8sg">1,000</ix:nonFraction> principal amount of the 2020 Notes for each trading day of the measurement period was less than <ix:nonFraction unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member_MP4cDjTkq06lAGevzdzYBw" decimals="2" format="ixt:numdotdecimal" name="incy:DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum" scale="-2" id="Narr_SNZrATuSmUCTfpuzRctsYA">98</ix:nonFraction>% of the product of the last reported sale price of our common stock and the conversion rate for the 2020 Notes on each such trading day; or (iii) upon the occurrence of specified corporate events. On or after May 15, 2020 until the close of business on the <span style="-sec-ix-hidden:Hidden_LuZKOSV89k6ANKuV9BpZOg"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">second</span></span> scheduled trading day immediately preceding the relevant maturity date, the 2020 Notes are convertible at any time, regardless of the foregoing circumstances. Upon conversion we will pay or deliver, as the case may be, cash, shares of common stock or a combination of cash and shares of common stock, at our election.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April 1, 2020, the 2020 Notes became convertible through at least June 30, 2020, based on meeting the conversion criteria related to the sale price of our common stock during the calendar quarter ended March 31, 2020 as described in (i) above. The 2020 Notes are reflected in current liabilities on the condensed consolidated balance sheet as of March 31, 2020 due to their maturity date of November 15, 2020, unless earlier purchased or converted.</p></ix:continuation><a id="_c08cacc7_eb1d_4044_8899_313196a29d0c"></a><a id="Tc_g5oCOFZ0OEKie8lSzZQhiQ_1_2"></a><a id="Tc_t6r7V15tCEeHD1TSSnXCrw_2_2"></a><a id="Tc_sodNP1BIfUqqIybMZiVN5w_3_2"></a><a id="Tc_ta6zkzlMy0OWg4aIeb2JaQ_3_5"></a><a id="Tc_ao3Km_vbO0KAA-cFpq6b6g_4_0"></a><a id="Tc_vzaHh6BKh0uccBUJa_4R-Q_4_2"></a><a id="Tc_Yu6qW44N_0al5jGKLvKEtg_4_5"></a><a id="Tc_O9eDODUUhkSizrPZ3vaCnA_5_0"></a><a id="Tc_ymTAfgvrv0qECE9pMSB-fw_6_0"></a><a id="Tc_ZeWDZvHQrUib5imXfJROWg_7_0"></a><a id="Tc_Jwz6CKRp_U-w-zt3hMqalw_8_0"></a><a id="Tc_9AaKzRFqr0yNagayzvr0pQ_9_0"></a><a id="Tc_Je2LZ1Ku7EyoA9sHOemROg_9_2"></a><a id="Tc_CnbddpqnJUu2RJ-88-Aqsg_9_5"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="Tb_8P6vUBk8tkm4_t76K1Cacg" continuedAt="Tb_8P6vUBk8tkm4_t76K1Cacg_cont1" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">13. &#160;&#160;&#160;&#160;Employee benefit plans</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Defined Contribution Plans</i></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have a defined contribution plan qualified under Section&#160;401(k) of the Internal Revenue Code covering all U.S. employees and defined contribution plans for other Incyte employees in Europe and Japan. &#160;Employees may contribute a portion of their compensation, which is then matched by us, subject to certain limitations. Defined contribution expense for the three months ended March 31, 2020 and 2019 was $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="Narr_goz4G73YA0mSZM8vcIv35w">3.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="Narr_MCoDlmPyFE6HcBUsLbM2pQ">2.9</ix:nonFraction>&#160;million, respectively. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Defined Benefit Pension Plans</i><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have defined benefit pension plans for our employees in Europe which provide benefits to employees upon retirement, death or disability. The assets of the pension plans are held in collective investment accounts represented by the cash surrender value of an insurance policy and are classified as Level 2 within the fair value hierarchy.</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="Tb_8KC3_fQUikSCF85VwYTsxg" continuedAt="Tb_8KC3_fQUikSCF85VwYTsxg_cont1" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The net periodic benefit cost was as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:36.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months&#160;Ended</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:36.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, </b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:17.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:17.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Service cost</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanServiceCost" scale="3" id="Tc_2ihCKS1trkWbsnFCIyJR0g_4_3">1,457</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanServiceCost" scale="3" id="Tc_n7CORHVfyEmdxCWpsXtsYA_4_6">1,263</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Interest cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanInterestCost" scale="3" id="Tc_pgdqvRXkSkm2t9n7Jso4hg_5_3">46</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanInterestCost" scale="3" id="Tc_4T0STSRslEOu55rEjTTbVg_5_6">84</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Expected return on plan assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="3" id="Tc_oo8ULpsvpUSQ5NDY270n-A_6_3">30</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="3" id="Tc_3BuKBkri1Ua3R10svglmPg_6_6">60</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Amortization of prior service cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="3" id="Tc_Zv4SSz8Y7UiWvLVsXryeKg_7_3">54</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="3" id="Tc_DkX92oFHiUOcTfj-iVFsMw_7_6">45</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Amortization of actuarial losses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" sign="-" scale="3" id="Tc_wocyLkYy3EimIsTGnSTZFQ_8_3">167</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" sign="-" scale="3" id="Tc_vyseC3wuNkCl1P6sYMR1Sg_8_6">66</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Net periodic benefit cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="3" id="Tc_IYF5AmjpM0aOhu1ljN1p-Q_9_3">1,694</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="3" id="Tc_6wXqQwCGuUinNMx3Nybx5Q_9_6">1,398</ix:nonFraction></p></td></tr></table></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_6f9109b5_3e5f_4087_ac88_f092c10245b3"></a><a id="_6f9109b5_3e5f_4087_ac88_f092c10245b3_2"></a><a id="_6f9109b5_3e5f_4087_ac88_f092c10245b3_3"></a><ix:continuation id="Tb_8P6vUBk8tkm4_t76K1Cacg_cont1"><ix:continuation id="Tb_8KC3_fQUikSCF85VwYTsxg_cont1"></ix:continuation><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The components of net periodic benefit cost other than the service cost component are included in other income (expense), net on the condensed consolidated statements of operations. We expect to contribute a total of $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear" scale="6" id="Narr_mb7ewkLXrkWfnY6J4O8pDw">4.0</ix:nonFraction> million to the pension plans in 2020 inclusive of the amounts contributed to the plan during the current period. As of March 31, 2020 and December 31, 2019, $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" scale="6" id="Narr_EaVI9KL0nUWfVTE5IEDwDw">24.6</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" scale="6" id="Narr_DNL0DrwlM0271UnWBEipQA">24.1</ix:nonFraction> million, respectively, of accrued pension obligation is recorded in other long term liabilities on the condensed consolidated balance sheets.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_fWRSZPbDeE-N9HnvAoM_BA" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">14. &#160;&#160;&#160;&#160;Income taxes</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the three months ended March 31, 2020 and 2019, we recorded income tax expense of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="Narr_qZTr6wUZqEqsB5H7GyF4Ew">16.6</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="Narr_ksJ1jfl7NEGpy_cI1LZZ6w">1.8</ix:nonFraction> million, respectively. The change in tax expense for the three months ended March 31, 2020 was primarily driven by increased federal and state tax liabilities that are not fully sheltered by net operating losses or research and development tax credit carryforwards. The increase was also driven by reduced tax benefits for stock-based compensation in the current period. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2020, a full valuation allowance continues to be recorded against our U.S. and Swiss net deferred tax assets. Based upon our analysis of our historical operating results, as well as projections of our future taxable income (losses) during the periods in which the temporary differences will be recoverable, we believe the uncertainty regarding the realization of our U.S. and Swiss net deferred tax assets requires a full valuation allowance against such net assets as of March 31, 2020. When performing our assessment on projections of future taxable income (losses), we consider factors such as the likelihood of regulatory approval and commercial success of products currently under development, among other factors.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The balance of our unrecognized tax benefits (including penalties and interest) increased by approximately $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease" scale="6" id="Narr_ukMTgnb4g0KGzXPzMQUCJQ">0.1</ix:nonFraction> million during the three months ended March 31, 2020.  The overall net increase is primarily driven by unrecognized tax benefits related to current year operations and research and development tax credits offset by audit settlements in Wisconsin and Italy. After considering valuation allowance impacts, the change in unrecognized tax benefits resulted in a $<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" sign="-" scale="6" id="Narr_uHeoLA2HMkO8ZIlEGV4pNQ">0.2</ix:nonFraction> million decrease to noncurrent other liabilities on the condensed consolidated balance sheet. &#160; </p></ix:nonNumeric><a id="_872b110f_3fc2_46f6_96ed_905bbc0ecfcc"></a><a id="Tc_ibGVB8mBNUGkJE8vbtThsA_1_2"></a><a id="Tc_b_RNs92sLkWFtXjoTBOofw_2_2"></a><a id="Tc_bKxbvDfWtEy78QUiImA6qA_3_0"></a><a id="Tc_aqyisfKusU2VTvDdCu2qEg_3_3"></a><a id="Tc_6ceIH1cMPk6IG78jy_rSPg_3_5"></a><a id="Tc_t3_YRESERUmJwWnYpMwBAQ_4_0"></a><a id="Tc_j3cJ6Fj1nUqWZktBTUmuzw_5_0"></a><a id="Tc__SV_n2dW7Ue99qkjsEM7VA_5_2"></a><a id="Tc_yPm4VpA1y06MxgnqhEkmeQ_5_5"></a><a id="Tc_X0eqUfwxz0yRC0GWfJHi2g_6_0"></a><a id="Tc_3PVzhgo8yEGanUDSJjD1jg_8_0"></a><a id="Tc_T8PlyRKSEkm4BLLxxYu7Mg_8_2"></a><a id="Tc_T9L5gwB4pUuPil4FkRNgTw_8_5"></a><a id="Tc_Lm4N_t9jnUGv3vOOE5iIrQ_10_0"></a><a id="Tc_PbebKLbQ4U61gqEPwhpY4w_11_0"></a><a id="Tc_IZyku7ObB02u-IRiI57ckw_11_2"></a><a id="Tc_eEiMTo2pFEy4JSenx8Gl7Q_11_5"></a><a id="Tc_u8y2w2ot2k-H3rW55Ovfhg_12_0"></a><a id="Tc_07Qor0fzVU2vcSZ2gyK91g_14_0"></a><a id="Tc_olfiR8-EP0uct8Ctyzztlg_14_3"></a><a id="Tc_HL3HuQB7jEuw20yACrpL6A_16_0"></a><a id="Tc_cPxiWE5gr0Of8JHrmjsemg_18_0"></a><a id="Tc_JPC5uRwn6EyRNRNFLxIHVw_18_2"></a><a id="Tc_HR-jg-Kxb0WmK14Fy7hkCw_18_5"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:EarningsPerShareTextBlock" id="Tb_yln78x7XFUq9VsxsGHiJJA" continuedAt="Tb_yln78x7XFUq9VsxsGHiJJA_cont1" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">15.&#160;&#160;&#160;&#160;Net income (loss) per share</b></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_r7zNUJmfEEG81uZQWrxlpw" continuedAt="Tb_r7zNUJmfEEG81uZQWrxlpw_cont1" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net income (loss) per share was calculated as follows for the periods indicated below:</p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months&#160;Ended</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:76.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands, except per share data)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Basic Net Income (Loss) Per Share</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Basic net income (loss) per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_J3PqYvR9iEKYqhHFkuyokA_5_3">720,642</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="Tc_RbyKipYgEkmYrXar5q9Fxw_5_6">102,312</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted average common shares outstanding</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_OXO9O7y4Z0GvY5Hrfc91Ig_6_3">216,721</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_nq-we1EA60au4KZtgPOubQ_6_6">214,065</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Basic net income (loss) per share</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_E7MRbwR9fkKCAg_WgVypqQ_8_3">3.33</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" scale="0" id="Tc_VEwmLyg-skaKCPyykxHb7A_8_6">0.48</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Diluted Net Income (Loss) Per Share</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Diluted net income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" sign="-" scale="3" id="Tc_oq4OXnGatkGNmCY7QwUt_Q_11_3">720,642</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="Tc_H43W3hFOnECKDG1fJHUpHQ_11_6">102,312</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted average common shares outstanding</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_23muPSIWmEC9Pcf1FzxOlw_12_3">216,721</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_-e5LULyws0OyZnYGZ8SvfA_12_6">214,065</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Dilutive stock options and awards</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="Tc_8TtylQuRpUeZ7ROGFQgUpQ_14_6">2,996</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted average shares used to compute diluted net income (loss) per share </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="Tc__1WUm7TLjEOUM4rFowNuvg_16_3">216,721</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="Tc_azIHegAOrkWtNkzYB1svqg_16_6">217,061</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;">Diluted net income (loss) per share</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_NDL-VYcl6U--nRBZe8P1UA_18_3">3.33</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" scale="0" id="Tc_FfZRVKv09E6L8LwPToXidQ_18_6">0.47</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7e7c8ba7_e39b_483d_829e_17f974f3f009"></a><a id="Tc_hOfVWUbaIEK8xfBmLM8tIA_1_2"></a><a id="Tc_F6xVJvbuYEac78-JHJ1OlQ_2_2"></a><a id="Tc_Z9mXouF_YUa-015UX-2NZQ_3_2"></a><a id="Tc_4ZrfBlf1dUaL9JlHYmmRCA_3_4"></a><a id="Tc_skX9z7o-Y0iP8lQNaOQN0g_4_0"></a><a id="Tc_u0K-90XjzEmY_JNzSnhmPQ_5_0"></a><a id="Tc__gKf7A0ZyEaVGqeTAjI6hg_6_0"></a><ix:continuation id="Tb_yln78x7XFUq9VsxsGHiJJA_cont1"><ix:continuation id="Tb_r7zNUJmfEEG81uZQWrxlpw_cont1"></ix:continuation><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_xbq9chBYCkWIzBCRq2A_kQ" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The potential common shares that were excluded from the diluted net income (loss) per share computation are as follows:</p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:33.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months&#160;Ended</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:33.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:15.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Outstanding stock options and awards</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_ZCt4v5dz-02T3ZuSiZnehQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_1Vqv25wRuUmjwQjbKJLOzQ_4_2">15,544,348</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_3H_O8pHEdkix4PC8ZgQ7Mg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_XnUNunVR30m9HKYLYNPUWw_4_4">9,318,013</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Common shares issuable upon conversion of the 2020 Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_HcQZwZd8o0Wvrjt6JjzvDA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_soSQCPaiCUmUOZRa920_5w_5_2">368,939</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_2eLdjmLNS0eVWk19LxgYkw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_TAH0XXlnkE66yirHleQ87g_5_4">368,939</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Total potential common shares excluded from diluted net income (loss) per share computation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_XYIQrPAM70CNVzfBWFx_Pg_6_2">15,913,287</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA" contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc__ZGSvCw-k0KnkMSGkLZ6Eg_6_4">9,686,952</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="Tb_1kDO8w2B3UezXv-oRT-9Ng" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">16.&#160;&#160;&#160;&#160;Contingencies</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">In December 2018, we received a civil investigative demand from the U.S. Department of Justice (&#8220;DOJ&#8221;) for documents and information relating to our speaker programs and patient assistance programs, including our support of non-profit organizations that provide financial assistance to eligible patients. We have cooperated with this inquiry.&#160; In November 2019, the <i style="font-style:italic;">qui tam</i> complaint underlying the DOJ inquiry was unsealed (&#8220;Complaint&#8221;), at which time we learned that a former employee whom we had terminated had made certain allegations relating to the programs described above. &#160;We then became aware that the DOJ had not intervened in the <i style="font-style:italic;">qui tam</i> action, and, to our knowledge, the DOJ has not intervened to date. &#160;We filed an answer to the Complaint on January 22, 2020, and the action is proceeding. &#160;We cannot predict the outcome or the timing of the ultimate resolution of the investigation or <i style="font-style:italic;">qui tam</i> action, or reasonably estimate the possible range of loss, if any, that may result from these matters. &#160;Accordingly, no reserve has been made with respect to these matters as of March 31, 2020.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A" name="us-gaap:SubsequentEventsTextBlock" id="Tb_ZQaTrq-W_kmEPR2rZj-0jw" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">17.&#160;&#160;&#160;&#160;Subsequent event</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2020, the FDA approved PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement as detected by an FDA-approved test. PEMAZYRE is the first and only FDA-approved treatment for this indication, which was approved under accelerated approval based on overall response rate and duration of response. We have retained all rights to PEMAZYRE globally, other than those granted to Innovent Biologics, Inc. to develop and commercialize pemigatinib in hematology and oncology in mainland China, Hong Kong, Macau and Taiwan.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_68aff20d_86e4_43f8_911f_5292c100ca2a"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Item2ManagementsDiscussionandAnalysis_93"></a><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 2.&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following discussion of our financial condition and results of operations as of and for the three months ended March 31, 2020 should be read in conjunction with the unaudited condensed consolidated financial statements and notes to those statements included elsewhere in this Quarterly Report on Form&#160;10-Q and our audited consolidated financial statements as of and for the year ended December 31, 2019 included in our Annual Report on Form&#160;10-K for the year ended December 31, 2019 previously filed with the SEC.</i></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">This report contains forward-looking statements that involve risks and uncertainties. These statements relate to future periods, future events or our future operating or financial plans or performance. Often, these statements include the words &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;target,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;seek,&#8221; &#8220;estimate,&#8221; &#8220;potential,&#8221; or words of similar meaning, or future or conditional verbs such as &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;might,&#8221; or &#8220;may,&#8221; or the negative of these terms, and other similar expressions. These forward-looking statements include statements as to:</i></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;line-height:10pt;text-align:justify;">the discovery, development, formulation, manufacturing and commercialization of our compounds, our drug candidates and JAKAFI</i><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:10pt;text-align:justify;vertical-align:super;">&#174;</span><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;line-height:10pt;text-align:justify;">/JAKAVI</i><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:10pt;text-align:justify;vertical-align:super;">&#174;</span><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;line-height:10pt;text-align:justify;"> (ruxolitinib), PEMAZYRE</i><sup style="color:#000000;font-family:'Times New Roman';font-size:7.5pt;font-style:italic;font-weight:normal;line-height:100%;text-align:justify;top:0pt;vertical-align:top;">TM</sup><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;line-height:10pt;text-align:justify;"> (pemigatinib) and ICLUSIG</i><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:10pt;text-align:justify;vertical-align:super;">&#174;</span><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;line-height:10pt;text-align:justify;"> (ponatinib);</i></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;line-height:10pt;text-align:justify;">our plans to further develop our operations outside of the United States;</i></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">conducting clinical trials internally, with collaborators, or with clinical research organizations;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">our collaboration and strategic relationship strategy, and anticipated benefits and disadvantages of entering into collaboration agreements;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">our licensing, investment and commercialization strategies, including our plans to commercialize JAKAFI, PEMAZYRE and ICLUSIG;</i></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">the regulatory approval process, including obtaining U.S. Food and Drug Administration and other international health authorities approval for our products in the United States and abroad;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">the safety, effectiveness and potential benefits and indications of our drug candidates and other compounds under development;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">the timing and size of our clinical trials; the compounds expected to enter clinical trials; timing of clinical trial results;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">our ability to manage expansion of our drug discovery and development operations;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">future required expertise relating to clinical trials, manufacturing, sales and marketing;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">obtaining and terminating licenses to products, drug candidates or technology, or other intellectual property rights;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">the receipt from or payments pursuant to collaboration or license agreements resulting from milestones or royalties;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">plans to develop and commercialize products on our own;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">plans to use third-party manufacturers; </i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">plans for our manufacturing operations;</i></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;line-height:10pt;text-align:justify;">expected expenses and expenditure levels; expected uses of cash; expected revenues and sources of revenues, including milestone payments; expectations with respect to inventory;</i></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;line-height:10pt;text-align:justify;">expectations with respect to reimbursement for our products;</i></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;line-height:10pt;text-align:justify;">the expected impact of recent accounting pronouncements and changes in tax laws;</i></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">expected losses; fluctuation of losses; currency translation impact associated with collaboration royalties;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">our profitability; the adequacy of our capital resources to continue operations;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">the need to raise additional capital;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">the costs associated with resolving matters in litigation;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">our expectations regarding competition;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">expectations relating to our new European headquarters, including construction activities, and the anticipated completion date for our large molecule production facility;</i></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">our investments, including anticipated expenditures, losses and expenses; </i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">our patent prosecution and maintenance efforts; and</i></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">the potential effects of the COVID-19 pandemic and efforts undertaken or to be undertaken by us or applicable governmental authorities on local and global economic conditions, and on our business, results of operations and financial condition.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">These forward-looking statements reflect our current views with respect to future events, are based on assumptions and are subject to risks and uncertainties. These risks and uncertainties could cause actual results to differ materially from those projected and include, but are not limited to:</i></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">our ability to successfully commercialize JAKAFI, PEMAZYRE and ICLUSIG;</i></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;line-height:10pt;text-align:justify;">our ability to maintain at anticipated levels reimbursement for our products from government health administration authorities, private health insurers and other organizations;</i></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;line-height:10pt;text-align:justify;">our ability to establish and maintain effective sales, marketing and distribution capabilities;</i></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;line-height:10pt;text-align:justify;">the risk of reliance on other parties to manufacture our products, which could result in a short supply of our products, increased costs, and withdrawal of regulatory approval;</i></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;line-height:10pt;text-align:justify;">our ability to maintain regulatory approvals to market our products;</i></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;line-height:10pt;text-align:justify;">our ability to achieve a significant market share in order to achieve or maintain profitability;</i></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;line-height:10pt;text-align:justify;">the risk of civil or criminal penalties if we market our products in a manner that violates health care fraud and abuse and other applicable laws, rules&#160;and regulations;</i></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">our ability to discover, develop, formulate, manufacture and commercialize our drug candidates;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">the risk of unanticipated delays in, or discontinuations of, research and development efforts;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">the risk that previous preclinical testing or clinical trial results are not necessarily indicative of future clinical trial results;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">risks relating to the conduct of our clinical trials;</i></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">changing regulatory requirements;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">the risk of adverse safety findings;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">the risk that results of our clinical trials do not support submission of a marketing approval application for our drug candidates;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">the risk of significant delays or costs in obtaining regulatory approvals;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">risks relating to our reliance on third-party manufacturers, collaborators, and clinical research organizations;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">risks relating to the development of new products and their use by us and our current and potential collaborators;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">risks relating to our inability to control the development of out-licensed compounds or drug candidates;</i></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">risks relating to our collaborators&#8217; ability to develop and commercialize JAKAVI, OLUMIANT and the drug candidates licensed from us;</i></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">costs associated with prosecuting, maintaining, defending and enforcing patent claims and other intellectual property rights;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">our ability to maintain or obtain adequate product liability and other insurance coverage;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">the risk that our drug candidates may not obtain or maintain regulatory approval;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">the impact of technological advances and competition, including potential generic competition;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">our ability to compete against third parties with greater resources than ours;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">risks relating to changes in pricing and reimbursement in the markets in which we may compete;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">risks relating to governmental healthcare reform efforts, including efforts to control, set or cap pricing for our commercial drugs in the U.S and abroad;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">competition to develop and commercialize similar drug products;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">our ability to obtain and maintain patent protection and freedom to operate for our discoveries and to continue to be effective in expanding our patent coverage;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">the impact of changing laws on our patent portfolio;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">developments in and expenses relating to litigation;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">our ability to in-license drug candidates or other technology;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">unanticipated construction, other delays or changes in plans relating to our new European headquarters and large molecule production facility;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">our ability to integrate successfully acquired businesses, development programs or technology;</i></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">our ability to obtain additional capital when needed;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">fluctuations in net cash provided and used by operating, financing and investing activities;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">our ability to analyze the effects of new accounting pronouncements and apply new accounting rules;</i></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">our history of operating losses; </i></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">risks related to public health pandemics such as the COVID-19 pandemic; and</i></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">the risks set forth under &#8220;Risk Factors.&#8221;</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;white-space:pre-wrap;"> </i><i style="font-style:italic;">Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by federal securities laws, we undertake no obligation to update any forward-looking statements for any reason, even if new information becomes available or other events occur in the future.</i></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">In this report all references to &#8220;Incyte,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; or the &#8220;Company&#8221; mean Incyte Corporation and our subsidiaries, except where it is made clear that the term means only the parent company.</i></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Incyte and JAKAFI are our registered trademarks and PEMAZYRE is our trademark. We also refer to trademarks of other corporations and organizations in this Quarterly Report on Form&#160;10-Q.</i></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. Our global headquarters is located in Wilmington, Delaware. We conduct our European clinical development and commercial operations from our offices in Geneva, Switzerland, and Lausanne, Switzerland; and we conduct our Japanese operations from our office in Tokyo.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">COVID-19</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Effects of the COVID-19 Pandemic on Our Business</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2019, coronavirus disease of 2019, or COVID-19, was first reported in Wuhan, China. In March 2020, the World Health Organization declared COVID-19 a pandemic (&#8220;the COVID-19 Pandemic&#8221;) and certain governments, including the State of Delaware where our primary offices and laboratory spaces are located, enacted stay-at-home orders and sweeping restrictions to travel and business activity were initiated by corporations and governments. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We took aggressive, proactive actions early on to protect the health of our employees, and their families, including limiting the number of people permitted to be present in any particular meeting, curtailing most travel, encouraging videoconferencing whenever possible, establishing hand sanitizer stations throughout our locations, and posting signage instructing employees on the importance, and proper method, of handwashing. &#160;In addition, as the COVID-19 Pandemic worsened throughout March 2020, we voluntarily required almost all personnel across our global enterprise to work remotely and we restricted access to our sites to personnel who are required to perform critical business continuity activities. &#160;Since our voluntary shift to remote work, the State of Delaware, neighboring states, as well as many of the other countries in which we operate, have enacted stay-at-home orders or similar measures. In addition, the Trump Administration in the U.S. has recommended extensive social distancing measures be taken throughout the U.S. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">While we currently believe we are well-positioned to function in this virtual or remote fashion, the extent of the COVID-19 Pandemic&#8217;s effect on our operational and financial performance will depend on future developments, including the duration, spread and intensity of the pandemic, additional protective measures implemented by governmental authorities or by us to protect our employees, and effects of the pandemic and such protective measures on our suppliers, collaborators, services providers and healthcare organizations serving patients, all of which are uncertain and difficult to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">predict considering the rapidly evolving landscape. As a result, it is not currently possible to ascertain or predict the overall long-term impact of the COVID-19 Pandemic on our business. To date, we have not seen any material effect on our commercial operations, or our manufacturing supply chain, and we have increased manufacturing efforts of ruxolitinib to respond to the COVID-19 Pandemic and to pre-clinical and clinical study requests. We continue to anticipate that short-term effects may continue to emerge across different aspects of our global clinical trial programs. &#160;For example, while we expect ongoing monitoring of already-enrolled patients to continue, new patient recruitment in certain clinical studies may be impacted. We also expect the conduct of clinical trials may vary by disease state and by severity of disease, as well as by geography, as some regions are more adversely impacted. Our discovery laboratories have been staffed by essential personnel, and hence certain discovery programs may experience delays. Still, we caution that it remains relatively early in the COVID-19 Pandemic and we may not yet be able to assess its consequences accurately or fully at this time.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If the COVID-19 Pandemic continues to increase in severity or if overall or localized economic activity continues to contract for any appreciable length of time, we could experience a material adverse effect on our business, results of operations, financial condition and cash flows.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We intend to continue to actively monitor the situation and may take further actions altering our business operations that we determine are in the best interests of our employees, patients, partners, and stakeholders, or as required by federal, state, or local authorities. It is not clear what the potential effects any such alterations or modifications may have on our business, including the effects on our customers, employees, and future plans or prospects, or on our financial results for the remainder of fiscal 2020.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Clinical Trials to Address COVID-19</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2020, we announced the initiation of a Phase III clinical trial (RUXCOVID) to evaluate the efficacy and safety of ruxolitinib plus standard-of-care (SoC), compared to SoC therapy alone, in patients with COVID-19 associated cytokine storm. The SoC therapy is currently evolving and could be subject to change. We will sponsor this collaborative study in the United States and our collaboration partner Novartis International Pharmaceutical Ltd. will sponsor the study outside of the United States. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are also opening a second Phase III clinical trial in the United States to evaluate the efficacy and safety of ruxolitinib plus SoC, compared to SoC therapy alone, in COVID-19 patients on mechanical ventilation and who have acute respiratory distress syndrome (ARDS), a type of respiratory failure characterized by rapid onset of widespread inflammation in the lungs. The SoC therapy is currently evolving and could be subject to change.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have launched an Expanded Access Program in the United States to allow eligible patients with COVID-19 associated cytokine storm to receive ruxolitinib. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2020, our collaboration partner Eli Lilly and Company announced that it has entered into an agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to study baricitinib as an arm in NIAID&#39;s Adaptive COVID-19 Treatment Trial. The study will investigate the efficacy and safety of baricitinib as a potential treatment for hospitalized patients diagnosed with COVID-19 in the US, and Lilly is also planning an expansion to include Europe and Asia.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Marketed Indications - JAKAFI (ruxolitinib)</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">JAKAFI (ruxolitinib) is our first product to be approved for sale in the United States. It was approved by the U.S. Food and Drug Administration (FDA) in November 2011 for the treatment of adults with intermediate or high-risk myelofibrosis, in December 2014 for the treatment of adults with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea and in May 2019 <span style="background-color:#ffffff;">for the treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older</span>. Myelofibrosis and polycythemia vera are both myeloproliferative neoplasms (MPNs), a type of rare blood cancer, and GVHD is an adverse immune response to an allogeneic hematopoietic stem cell transplant (HSCT). Under our collaboration agreement with Novartis, Novartis received exclusive development and commercialization rights to ruxolitinib outside of the United States for all hematologic and oncologic indications and sells ruxolitinib outside of the United States under the name&#160;JAKAVI.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> </span>In 2003, we initiated a research and development program to explore the inhibition of enzymes called janus associated kinases (JAK). The JAK family is composed of four tyrosine kinases&#8212;JAK1, JAK2, JAK3 and Tyk2&#8212;that are involved in the signaling of a number of cytokines and growth factors. JAKs are central to a number of biologic processes, including the formation and development of blood cells and the regulation of immune functions. Dysregulation of the JAK-STAT signaling pathway has been associated with a number of diseases, including myeloproliferative neoplasms, other hematological malignancies, rheumatoid arthritis and other chronic inflammatory diseases. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have discovered multiple potent, selective and orally bioavailable JAK inhibitors that are selective for JAK1 or JAK1 and JAK2. JAKAFI is the most advanced compound in our JAK program. It is an oral&#160;JAK1 and JAK2 inhibitor.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">JAKAFI is marketed in the United States through our own specialty sales force and commercial team. JAKAFI was the first FDA-approved JAK inhibitor for any indication and was the first FDA-approved product in all three of its current indications. JAKAFI remains the first-line standard of care in MF and remains the only FDA-approved product for PV and steroid-refractory acute GVHD. The FDA has granted JAKAFI orphan drug status for MF, PV, ET, acute lymphoblastic leukemia (ALL) and GVHD.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To help ensure that all eligible patients have access to JAKAFI, we have established a patient assistance program called IncyteCARES (CARES stands for Connecting to Access, Reimbursement, Education and Support). IncyteCARES helps ensure that any patient with intermediate or high-risk MF, uncontrolled PV or steroid-refractory acute GVHD who meets certain eligibility criteria and is prescribed JAKAFI has access to the product regardless of ability to pay and has access to ongoing support and educational resources during treatment. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">JAKAFI is distributed primarily through a network of specialty pharmacy providers and wholesalers that allow for efficient delivery of the medication by mail directly to patients or direct delivery to the patient&#8217;s pharmacy. Our distribution process uses a model that is well-established and familiar to physicians who practice within the oncology field.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To further support appropriate use and future development of JAKAFI, our U.S. Medical Affairs department is responsible for providing appropriate scientific and medical education and information to physicians, preparing scientific presentations and publications, and overseeing the process for supporting investigator sponsored trials.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Myelofibrosis.</i> &#160;Myelofibrosis is a rare, life-threatening condition. MF, considered the most serious of the myeloproliferative neoplasms, can occur either as primary MF, or as secondary MF that develops in some patients who previously had polycythemia vera or essential thrombocythemia. We estimate there are between 16,000 and 18,500 patients with MF in the United States. Based on the modern prognostic scoring systems referred to as International Prognostic Scoring System and Dynamic International Prognostic Scoring System, we believe intermediate and high-risk patients represent 80%&#160; to 90%&#160; of all patients with MF in the United States and encompass patients over the age of 65, or patients who have or have ever had any of the following: anemia, constitutional symptoms, elevated white blood cell or blast counts, or platelet counts less than 100,000 per microliter of blood.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Most MF patients have enlarged spleens and many suffer from debilitating symptoms, including abdominal discomfort, pruritus (itching), night sweats and cachexia (involuntary weight loss). There were no FDA approved therapies for MF until the approval of JAKAFI. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA approval was based on results from two randomized Phase&#160;III trials (COMFORT-I and COMFORT-II), which demonstrated that patients treated with JAKAFI experienced significant reductions in splenomegaly (enlarged spleen). COMFORT-I also demonstrated improvements in symptoms. The most common hematologic adverse reactions in both trials were thrombocytopenia and anemia. These events rarely led to discontinuation of JAKAFI treatment. The most common non-hematologic adverse reactions were bruising, dizziness and headache.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In August 2014, the FDA approved supplemental labeling for JAKAFI to include Kaplan-Meier overall survival curves as well as additional safety and dosing information. The overall survival information is based on three-year data from COMFORT-I and II, and shows that at three years the probability of survival for patients treated with JAKAFI in COMFORT-I was 70% and for those patients originally randomized to placebo it was 61%. In COMFORT-II, at three years the probability of survival for patients treated with JAKAFI was 79% and for patients originally randomized to best </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">available therapy it was 59%. &#160;In December 2016, we announced an exploratory pooled analysis of data from the five-year follow-up of the COMFORT-I and COMFORT-II trials of patients treated with JAKAFI, which further supported previously published overall survival findings.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2016, we announced that JAKAFI had been included as a recommended treatment in the latest National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for myelofibrosis, underscoring the important and long-term clinical benefits seen in patients treated with JAKAFI.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2017, the FDA approved updated labeling for JAKAFI to include the addition of new patient-reported outcome (PRO) data from the COMFORT-I study, as well as updating the warning related to progressive multifocal leukoencephalopathy. An exploratory analysis of PRO data of patients with myelofibrosis receiving JAKAFI showed improvement in fatigue-related symptoms at Week 24. Fatigue response (defined as a reduction of 4.5 points or more from baseline in the PROMIS<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> Fatigue total score) was reported in 35% of patients treated with JAKAFI versus 14% of the patients treated with placebo.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Polycythemia Vera.</i> &#160;PV is a myeloproliferative neoplasm typically characterized by elevated hematocrit, the volume percentage of red blood cells in whole blood, which can lead to a thickening of the blood and an increased risk of blood clots, as well as an elevated white blood cell and platelet count. When phlebotomy can no longer control PV, chemotherapy such as hydroxyurea, or interferon, is utilized. Approximately 25,000 patients with PV in the United States are considered uncontrolled because they have an inadequate response to or are intolerant of hydroxyurea, the most commonly used chemotherapeutic agent for the treatment of PV.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2014, the FDA approved JAKAFI for the treatment of patients with PV who have had an inadequate response to or are intolerant of hydroxyurea. The approval of JAKAFI for PV was based on data from the pivotal Phase&#160;III RESPONSE trial. In this trial, patients treated with JAKAFI demonstrated superior hematocrit control and reductions in spleen volume compared to best available therapy. In addition, a greater proportion of patients treated with JAKAFI achieved complete hematologic remission&#8212;which was defined as achieving hematocrit control, and lowering platelet and white blood cell counts. In the RESPONSE trial, the most common hematologic adverse reactions (incidence &gt; 20%) were thrombocytopenia and anemia. The most common non-hematologic adverse events (incidence &gt;10%) were headache, abdominal pain, diarrhea, dizziness, fatigue, pruritus, dyspnea and muscle spasms.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2016, the FDA approved supplemental labeling for JAKAFI to include additional safety data as well as efficacy analyses from the RESPONSE trial to assess the durability of response in JAKAFI treated patients after 80 weeks. At this time, 83% patients were still on treatment, and 76% of the responders at 32 weeks maintained their response through 80 weeks.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2016, we announced data from the Phase III RESPONSE-2 study of JAKAFI in patients with inadequately controlled PV that was resistant to or intolerant of hydroxyurea who did not have an enlarged spleen. These data showed that JAKAFI was superior to best available therapy in maintaining hematocrit control (62.2% vs. 18.7%, respectively; P&lt;0.0001) without the need for phlebotomy.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2017, we announced that JAKAFI had been included as a recommended treatment in the latest NCCN Guidelines for patients with polycythemia vera who have had an inadequate response to first-line therapies, such as hydroxyurea.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Graft-versus-host disease.</i> GVHD is a condition that can occur after an allogeneic HSCT (the transfer of genetically dissimilar stem cells or tissue). In GVHD, the donated bone marrow or peripheral blood stem cells view the recipient&#8217;s body as foreign and attack various tissues. 12-month survival rates in patients with Grade III or IV steroid-refractory acute GVHD are 50% or less, and the incidence of steroid-refractory acute and chronic GVHD is approximately 3,000 per year in the United States.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In June 2016, we announced that the FDA granted Breakthrough Therapy designation for ruxolitinib in patients with acute GVHD. In May 2019, the FDA approved JAKAFI for the treatment of steroid-refractory acute GVHD in adult and pediatric patients 12 years and older. The approval was based on data from REACH1, an open-label, single-arm, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">multicenter study of JAKAFI in combination with corticosteroids in patients with steroid-refractory grade II-IV acute GVHD. The overall response rate (ORR) in patients refractory to steroids alone was 57% with a complete response (CR) rate of 31%. The most frequently reported adverse reactions among all study participants were infections (55%) and edema (51%), and the most common laboratory abnormalities were anemia (75%), thrombocytopenia (75%) and neutropenia (58%).</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have retained all development and commercialization rights to JAKAFI in the United States and are eligible to receive development and sales milestones as well as royalties from product sales outside the United States. We hold patents that cover the composition of matter and use of ruxolitinib which patents, including applicable extensions, expire in late 2027.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Marketed Indications - ICLUSIG (ponatinib)</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2016, we acquired the European operations of ARIAD Pharmaceuticals, Inc. (ARIAD) and obtained an exclusive license to develop and commercialize ICLUSIG (ponatinib) in Europe and other select countries. ICLUSIG is a kinase inhibitor. The primary target for ICLUSIG is BCR-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL).</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the European Union, ICLUSIG is approved for the treatment of adult patients with chronic phase, accelerated phase or blast phase CML who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation, or the treatment of adult patients with Ph+ ALL who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Marketed Indications - PEMAZYRE (pemigatinib)</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2020, we announced that the FDA approved PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement as detected by an FDA-approved test. PEMAZYRE is the first and only FDA-approved treatment for this indication, which was approved under accelerated approval based on overall response rate and duration of response (DOR). </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cholangiocarcinoma is a rare cancer that arises from the cells within the bile ducts. It is often diagnosed late (stages III and IV) and the prognosis is poor. The incidence of cholangiocarcinoma with FGFR2 fusions or rearrangements is increasing, and it is currently estimated that there are 2,000-3,000 patients in the U.S., Europe and Japan.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></span>The approval of PEMAZYRE was based on data from FIGHT-202, a multi-center, open-label, single-arm study evaluating PEMAZYRE as a treatment for adults with cholangiocarcinoma. In FIGHT-202, and in patients harboring FGFR2 fusions or rearrangements (Cohort A), PEMAZYRE monotherapy resulted in an overall response rate of 36% (primary endpoint), and median DOR of 9.1 months (secondary endpoint). Warnings and precautions included in the PEMAZYRE prescribing information include potential for eye problems such as dry or inflamed eyes, inflamed cornea, increased tears and a disorder of the retina; high levels of phosphate in the blood; and, for women who are pregnant, a risk of harm to the unborn baby or loss of pregnancy. FIGHT-302, a Phase III trial of pemigatinib for the first-line treatment of patients with cholangiocarcinoma and FGFR2 fusions or rearrangements, is ongoing.<span style="display:inline-block;width:8.96pt;"></span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></span>We have retained all rights to PEMAZYRE globally, other than those granted to Innovent Biologics, Inc. to develop and commercialize pemigatinib in hematology and oncology in mainland China, Hong Kong, Macau and Taiwan. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Clinical Programs in Oncology</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe that the future of cancer treatment lies in the use of targeted therapies, which aim to block the effects of cancer-causing mutations, and immune therapies, which seek to recruit the patient&#8217;s own immune system to tackle cancer. Our most advanced programs are detailed below. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">JAK Inhibition</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As part of our ongoing LIMBER (Leadership in MPNs BEyond Ruxolitinib) clinical development initiative, which is designed to improve and expand therapeutic options for patients with myeloproliferative neoplasms, we are evaluating combinations of ruxolitinib with other therapeutic modalities, as well as developing a once-a-day formulation of ruxolitinib for potential use as monotherapy and combination therapy. Based on positive Phase II data, we are preparing a pivotal trial program of ruxolitinib in combination with parsaclisib (PI3K&#948;). Additional Phase II trials combining ruxolitinib with investigational agents from our portfolio such as INCB53914 (PIM), INCB57643 (BET) and INCB00928 (ALK2) in patients with MF are either ongoing or in preparation. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As part of our development efforts to evaluate JAK inhibition in GVHD, the REACH clinical program is evaluating ruxolitinib in patients with steroid-refractory GVHD and includes REACH2, a Novartis-sponsored Phase III trial in steroid-refractory acute GVHD, and REACH3, a Phase III trial in steroid-refractory chronic GVHD that is co-sponsored by Incyte and Novartis. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2019, we and Novartis announced that REACH2 met its primary endpoint of superior ORR at Day 28 with ruxolitinib treatment compared to best available therapy. No new safety signals were observed, and the ruxolitinib safety profile in REACH2 was consistent with that seen in previously reported studies in steroid-refractory acute GVHD. In April 2020, we and Novartis announced that data from REACH2 were published in The New England Journal of Medicine. The result of REACH3 is expected to be available in the second half of 2020.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A second JAK inhibitor in development is itacitinib, which is a selective JAK1 inhibitor. In January 2020, we announced that in the pivotal Phase III GRAVITAS-301 trial in patients with steroid-na&#239;ve acute GVHD, itacitinib plus corticosteroids did not meet the primary endpoint of improving ORR at Day 28 compared to placebo plus corticosteroids. Itacitinib is also being evaluated in GRAVITAS-309, a pivotal Phase III trial of itacitinib in patients with steroid-na&#239;ve chronic GVHD. The FDA has granted itacitinib orphan drug status for GVHD.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">FGFR Inhibition</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pemigatinib is a potent and selective inhibitor of the fibroblast growth factor receptor (FGFR) isoforms 1, 2 and 3 with demonstrated activity in preclinical studies. The FGFR family of receptor tyrosine kinases can act as oncogenic drivers in a number of liquid and solid tumor types. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We initiated the FIGHT clinical program to evaluate pemigatinib across a spectrum of cancers that are driven by FGF/FGFR alterations. The program initially included three Phase II trials &#8211; FIGHT-201 in patients with bladder cancer, FIGHT-202 in patients with cholangiocarcinoma, and FIGHT-203 in patients with 8p11 myeloproliferative syndrome (8p11 MPN). Based on data generated from these ongoing trials, we have initiated additional trials, including FIGHT-205, which is evaluating pemigatinib plus pembrolizumab versus pemigatinib alone versus standard of care for metastatic or unresectable urothelial carcinoma in cisplatin-ineligible patients whose tumors express FGFR3 mutation or rearrangement, and FIGHT-207 which is a solid tumor-agnostic trial evaluating pemigatinib in patients with driver-alterations of FGF/FGFR.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2020, we announced the FDA approval of pemigatinib as PEMAZYRE for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement as detected by an FDA-approved test. Pemigatinib was previously granted Breakthrough Therapy designation by the FDA as a treatment for patients with previously treated, advanced/metastatic or unresectable FGFR2 translocated cholangiocarcinoma and has Breakthrough Therapy designation as a treatment for patients with myeloid/lymphoid neoplasms with FGFR1 rearrangement (8p11 MPN) who have relapsed or are refractory to initial chemotherapy. In January 2020, we announced that the Marketing Authorization Application (MAA) for pemigatinib as a treatment of adults with locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement that is relapsed or refractory after at least one line of systemic therapy had been validated by the European Medicines Agency (EMA).</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">CD19 antagonism</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2020, we and MorphoSys announced a collaboration and license agreement to further develop and commercialize MorphoSys&#39; proprietary anti-CD19 antibody tafasitamab (MOR208) globally. The agreement became effective March 2020. Tafasitamab is an Fc-engineered antibody against CD19 currently in clinical development for the treatment of B cell malignancies. We have rights to co-commercialize tafasitamab in the U.S. with MorphoSys, and we have exclusive development and commercialization rights outside of the U.S. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Tafasitamab is being investigated as a therapeutic option in B cell malignancies in a number of ongoing combination trials. An open-label Phase II combination trial (L-MIND) is investigating the safety and efficacy of tafasitamab in combination with lenalidomide in patients with relapsed or refractory diffuse large B cell lymphoma (r/r DLBCL), and the ongoing Phase III B-MIND trial is assessing the combination of tafasitamab and bendamustine versus rituximab and bendamustine in r/r DLBCL. First-MIND is a Phase Ib safety trial of tafasitamab as a first-line therapy for patients with DLBCL. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2020, the FDA accepted MorphoSys&#39; Biologics License Application (BLA) and granted Priority Review for tafasitamab in combination with lenalidomide for the treatment of r/r DLBCL, setting a Prescription Drug User Fee Act (PDUFA) date of August 30, 2020. In October 2017, based on interim data from L-MIND, the FDA granted Breakthrough Therapy designation for tafasitamab plus lenalidomide for the treatment of r/r DLBCL. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">PI3K-delta Inhibition</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The PI3K-delta pathway mediates oncogenic signaling in B cell malignancies. Parsaclisib is a PI3K-delta inhibitor that has demonstrated potency and selectivity in preclinical studies and has potential therapeutic utility in the treatment of patients with lymphoma. We initiated the CITADEL clinical program to evaluate parsaclisib in non-Hodgkin lymphomas, and we are currently running Phase II trials in follicular lymphoma, marginal zone lymphoma and mantle cell lymphoma.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">PD-1 Antagonism</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2017, we and MacroGenics, Inc. announced an exclusive global collaboration and license agreement for MacroGenics&#8217; retifanlimab (formerly INCMGA0012), an investigational monoclonal antibody that inhibits PD-1. Under this collaboration, we obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications. The molecule is currently being evaluated both as monotherapy and in combination therapy across various tumor types. Potentially registration-enabling trials in anal cancer, microsatellite instability-high (MSI-H) endometrial cancer and Merkel cell carcinoma are ongoing.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Preparations are ongoing to initiate the Phase III POD1UM-304 trial of retifanlimab in combination with platinum-based chemotherapy as a first-line treatment for patients with non-small cell lung cancer (NSCLC). The planned initiation of the Phase III POD1UM-301 trial of retifanlimab in combination with chemoradiation therapy (CRT) in participants with unresectable, Stage III NSCLC has been withdrawn.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Retifanlimab was recently granted Fast Track designation for the treatment of certain patients with advanced or metastatic MSI-H or DNA mismatch repair (dMMR) endometrial cancer and for the treatment of certain patients with locally advanced or metastatic squamous carcinoma of the anal canal.</p><table style="border-collapse:collapse;font-size:16pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:22.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:77.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:16.55pt;"><td style="background-color:#ffffff;vertical-align:top;width:22.22%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri';font-size:10pt;font-weight:bold;margin:0pt;"><b style="font-family:'Times New Roman';font-weight:bold;">&#160;</b></p></td><td style="background-color:#ffffff;vertical-align:top;width:77.77%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri';font-size:10pt;margin:0pt;"><b style="font-family:'Times New Roman';font-weight:bold;">Indication and status</b></p></td></tr><tr style="height:28.8pt;"><td style="background-color:#cceeff;vertical-align:top;width:22.22%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri';font-size:10pt;font-weight:bold;line-height:10pt;text-align:justify;margin:0pt;"><b style="font-family:'Times New Roman';font-weight:bold;">ruxolitinib <br />(JAK1/JAK2)</b></p></td><td style="background-color:#cceeff;vertical-align:top;width:77.77%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><span style="font-family:'Times New Roman';line-height:10pt;">Steroid-refractory chronic GVHD: Phase III (REACH3)</span><sup style="font-family:'Times New Roman';font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p><p style="font-family:'Calibri';font-size:10pt;line-height:10pt;margin:0pt 0pt 2pt 0pt;"><span style="font-family:'Times New Roman';">Refractory myelofibrosis: Phase III with parsaclisib (PI3K&#948;) in preparation; Phase II with INCB53914 (PIM) ongoing; Phase II with INCB57643 (BET) in preparation</span></p><p style="font-family:'Calibri';font-size:10pt;line-height:10pt;margin:0pt 0pt 2pt 0pt;"><span style="font-family:'Times New Roman';">Myelofibrosis: Phase II with INCB00928 (ALK2) in preparation</span></p><p style="font-family:'Calibri';font-size:10pt;line-height:10pt;margin:0pt 0pt 2pt 0pt;"><span style="font-family:'Times New Roman';visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:28.8pt;"><td style="background-color:auto;vertical-align:top;width:22.22%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri';font-size:10pt;font-weight:bold;line-height:10pt;text-align:justify;margin:0pt;"><b style="font-family:'Times New Roman';font-weight:bold;">Once-a-day ruxolitinib (JAK1/JAK2)</b></p><p style="font-family:'Calibri';font-size:10pt;font-weight:bold;line-height:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman';visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:top;width:77.77%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri';font-size:10pt;line-height:10pt;margin:0pt 0pt 2pt 0pt;"><span style="font-family:'Times New Roman';">Myelofibrosis and polycythemia vera: clinical pharmacology studies</span></p></td></tr><tr style="height:28.8pt;"><td style="background-color:#cceeff;vertical-align:top;width:22.22%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri';font-size:10pt;font-weight:bold;line-height:10pt;text-align:justify;margin:0pt;"><b style="font-family:'Times New Roman';font-weight:bold;">itacitinib (JAK1)</b></p></td><td style="background-color:#cceeff;vertical-align:top;width:77.77%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri';font-size:10pt;line-height:10pt;margin:0pt 0pt 2pt 0pt;"><span style="font-family:'Times New Roman';">Treatment-na&#239;ve chronic GVHD: Phase III (GRAVITAS-309)</span></p><p style="font-family:'Calibri';font-size:10pt;line-height:10pt;margin:0pt 0pt 2pt 0pt;"><span style="font-family:'Times New Roman';visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:28.8pt;"><td style="background-color:auto;vertical-align:top;width:22.22%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri';font-size:10pt;font-weight:bold;line-height:10pt;text-align:justify;margin:0pt;"><b style="font-family:'Times New Roman';font-weight:bold;">pemigatinib<br />(FGFR)</b></p></td><td style="background-color:auto;vertical-align:top;width:77.77%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri';font-size:10pt;line-height:10pt;margin:0pt 0pt 2pt 0pt;"><span style="font-family:'Times New Roman';">Cholangiocarcinoma: Phase II (FIGHT-202), Phase III (FIGHT-302); MAA under review</span></p><p style="font-family:'Calibri';font-size:10pt;line-height:10pt;margin:0pt 0pt 2pt 0pt;"><span style="font-family:'Times New Roman';">Bladder cancer: Phase II (FIGHT-201, FIGHT-205)</span></p><p style="font-family:'Calibri';font-size:10pt;line-height:10pt;margin:0pt 0pt 2pt 0pt;"><span style="font-family:'Times New Roman';">8p11 MPN: Phase II (FIGHT-203)</span></p><p style="font-family:'Calibri';font-size:10pt;line-height:10pt;margin:0pt 0pt 2pt 0pt;"><span style="font-family:'Times New Roman';">Tumor agnostic: Phase II (FIGHT-207)</span></p><p style="font-family:'Calibri';font-size:10pt;line-height:10pt;margin:0pt 0pt 2pt 0pt;"><span style="font-family:'Times New Roman';visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:28.8pt;"><td style="background-color:#cceeff;vertical-align:top;width:22.22%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri';font-size:10pt;font-weight:bold;line-height:10pt;text-align:justify;margin:0pt;"><b style="font-family:'Times New Roman';font-weight:bold;">tafasitamab (CD19)</b></p></td><td style="background-color:#cceeff;vertical-align:top;width:77.77%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri';font-size:10pt;line-height:10pt;margin:0pt 0pt 2pt 0pt;"><span style="font-family:'Times New Roman';">r/r DLBCL: Phase II (L-MIND); Phase III (B-MIND); BLA under review</span></p><p style="font-family:'Calibri';font-size:10pt;line-height:10pt;margin:0pt;"><span style="font-family:'Times New Roman';">1L DLBCL: Phase Ib (First-MIND)</span></p><p style="font-family:'Calibri';font-size:10pt;line-height:10pt;margin:0pt 0pt 2pt 0pt;"><span style="font-family:'Times New Roman';visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:28.8pt;"><td style="background-color:auto;vertical-align:top;width:22.22%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri';font-size:10pt;font-weight:bold;line-height:10pt;text-align:justify;margin:0pt;"><b style="font-family:'Times New Roman';font-weight:bold;">parsaclisib (PI3K&#948;)</b></p></td><td style="background-color:auto;vertical-align:top;width:77.77%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri';font-size:10pt;line-height:10pt;margin:0pt 0pt 2pt 0pt;"><span style="font-family:'Times New Roman';">Follicular lymphoma: Phase II (CITADEL-203)</span></p><p style="font-family:'Calibri';font-size:10pt;line-height:10pt;margin:0pt 0pt 2pt 0pt;"><span style="font-family:'Times New Roman';">Marginal zone lymphoma: Phase II (CITADEL-204)</span></p><p style="font-family:'Calibri';font-size:10pt;line-height:10pt;margin:0pt 0pt 2pt 0pt;"><span style="font-family:'Times New Roman';">Mantle cell lymphoma: Phase II (CITADEL-205)</span></p><p style="font-family:'Calibri';font-size:10pt;line-height:10pt;margin:0pt 0pt 2pt 0pt;"><span style="font-family:'Times New Roman';visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:28.8pt;"><td style="background-color:#cceeff;vertical-align:top;width:22.22%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt;"><b style="font-family:'Times New Roman';font-weight:bold;line-height:10pt;">retifanlimab (PD-1)</b><sup style="font-family:'Times New Roman';font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup></p></td><td style="background-color:#cceeff;vertical-align:top;width:77.77%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri';font-size:10pt;line-height:10pt;margin:0pt 0pt 2pt 0pt;"><span style="font-family:'Times New Roman';">MSI-high endometrial cancer: Phase II (POD1UM-101)</span></p><p style="font-family:'Calibri';font-size:10pt;line-height:10pt;margin:0pt 0pt 2pt 0pt;"><span style="font-family:'Times New Roman';">Merkel cell carcinoma: Phase II (POD1UM-201)</span></p><p style="font-family:'Calibri';font-size:10pt;line-height:10pt;margin:0pt;"><span style="font-family:'Times New Roman';">Anal cancer: Phase II (POD1UM-202)</span></p><p style="font-family:'Calibri';font-size:10pt;line-height:10pt;margin:0pt;"><span style="font-family:'Times New Roman';">NSCLC: Phase III (POD1UM-304) in preparation</span></p><p style="font-family:'Calibri';font-size:10pt;line-height:10pt;margin:0pt 0pt 2pt 0pt;"><span style="font-family:'Times New Roman';visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1.</sup> Clinical development of ruxolitinib in GVHD conducted in collaboration with Novartis.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2.</sup> Retifanlimab licensed from MacroGenics.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Earlier-Stage Programs</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We also have a number of other earlier-stage clinical programs, as detailed in the table below. We intend to describe these programs more fully if we obtain clinical proof-of-concept and establish that a program warrants further development in a specific indication or group of indications. Based on emerging data from the FGFR4 inhibitor program, development of INCB62079 has been discontinued because of insufficient efficacy in the target patient population.</p><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:27.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:48.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:23.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman';font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:16.55pt;"><td style="background-color:#ffffff;vertical-align:top;width:27.62%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri';font-size:10pt;font-weight:bold;margin:0pt;"><b style="font-family:'Times New Roman';font-weight:bold;">Modality</b></p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:72.37%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri';font-size:10pt;margin:0pt;"><b style="font-family:'Times New Roman';font-weight:bold;">Candidates</b></p></td></tr><tr style="height:21.6pt;"><td style="background-color:#cceeff;vertical-align:top;width:27.62%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri';font-size:10pt;font-weight:bold;margin:0pt;"><b style="font-family:'Times New Roman';font-weight:bold;">Small molecules</b></p></td><td colspan="2" style="background-color:#cceeff;vertical-align:top;width:72.37%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman';">INCB01158 (ARG)</span><sup style="font-family:'Times New Roman';font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup><span style="font-family:'Times New Roman';">, INCB81776 (AXL/MER), epacadostat (IDO1), INCB59872 (LSD1), INCB86550 (PD-L1)</span></p><p style="font-family:'Calibri';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman';"> </span><span style="font-family:'Times New Roman';visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:21.6pt;"><td style="background-color:#ffffff;vertical-align:top;width:27.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri';font-size:10pt;font-weight:bold;margin:0pt;"><b style="font-family:'Times New Roman';font-weight:bold;">Monoclonal antibodies</b><sup style="font-family:'Times New Roman';font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup></p></td><td colspan="2" style="background-color:#ffffff;vertical-align:top;width:72.37%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman';">INCAGN1876 (GITR), INCAGN2385 (LAG-3), INCAGN1949 (OX40), <br />INCAGN2390 (TIM-3) </span></p><p style="font-family:'Calibri';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman';visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:21.6pt;"><td style="background-color:#cceeff;vertical-align:top;width:27.62%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri';font-size:10pt;font-weight:bold;margin:0pt;"><b style="font-family:'Times New Roman';font-weight:bold;">Bispecific antibodies</b></p></td><td style="background-color:#cceeff;vertical-align:top;width:48.58%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman';">MCLA-145 (PD-L1xCD137)</span><sup style="font-family:'Times New Roman';font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">3</sup></p></td><td style="background-color:#cceeff;vertical-align:top;width:23.79%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman';visibility:hidden;">&#8203;</span></p></td></tr></table></div><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1.</sup> INCB01158 development in collaboration with Calithera Biosciences, Inc.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2.</sup> Discovery collaboration with Agenus Inc.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">3.</sup> MCLA-145 development in collaboration with Merus N.V.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Clinical Programs outside Oncology</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Ruxolitinib cream</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Atopic dermatitis. </i>Atopic dermatitis is a skin disorder that causes the skin to become red, scaly, and itchy. Onset can occur at any age, but is more common in infants and children. In the United States, we estimate that there are approximately 10 million diagnosed and treated adolescent and adult patients with mild to moderate atopic dermatitis.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2020, safety and efficacy data from the two Phase III trials in the TRuE-AD program evaluating ruxolitinib cream in mild-to-moderate atopic dermatitis were presented at the Revolutionizing Atopic Dermatitis (RAD) virtual symposium; both trials met their primary endpoints. The 44-week long-term safety and efficacy portion of both the TRuE-AD1 and TRuE-AD2 trials are ongoing.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Vitiligo.</i> Vitiligo is a long-term skin condition characterized by patches of the skin losing their pigment. It is estimated that vitiligo affects 0.5-2% of the US population and, therefore, there are at least 1.5 million patients in the United States with this disorder. There are no FDA approved treatments for repigmentation of vitiligo lesions.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2019, primary endpoint data after 6 months of therapy from the Phase II trial of ruxolitinib cream in patients with vitiligo showed a significant benefit over vehicle control, and a global, pivotal Phase III program was initiated in September 2019. In October 2019, updated data from the Phase II trial showed, after 12 months of therapy, additional improvement in the repigmentation of vitiligo lesions. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Other</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A Phase II trial of INCB54707, a JAK1 selective inhibitor, is ongoing in patients with hidradenitis suppurativa, an inflammatory skin disease. A Phase II trial of parsaclisib in patients with autoimmune hemolytic anemia, a rare red blood cell disorder, is also ongoing.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A Phase II trial of INCB00928 is in preparation for patients with fibrodysplasia ossificans progressiva, a disorder in which muscle tissue and connective tissue are gradually replaced by bone.</p><table style="border-collapse:collapse;font-size:16pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:23.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:76.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:16.55pt;"><td style="background-color:#ffffff;vertical-align:top;width:23.83%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri';font-size:10pt;font-weight:bold;margin:0pt;"><b style="font-family:'Times New Roman';font-weight:bold;">&#160;</b></p></td><td style="background-color:#ffffff;vertical-align:top;width:76.16%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri';font-size:10pt;margin:0pt;"><b style="font-family:'Times New Roman';font-weight:bold;">Indication and status</b></p></td></tr><tr style="height:33.25pt;"><td style="background-color:#cceeff;vertical-align:top;width:23.83%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri';font-size:10pt;font-weight:bold;margin:0pt;"><b style="font-family:'Times New Roman';font-weight:bold;line-height:10pt;">ruxolitinib cream</b><sup style="font-family:'Times New Roman';font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup><b style="font-family:'Times New Roman';font-weight:bold;line-height:10pt;"><br /></b><b style="font-family:'Times New Roman';font-weight:bold;line-height:10pt;">(JAK1/JAK2)</b></p></td><td style="background-color:#cceeff;vertical-align:top;width:76.16%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri';font-size:10pt;line-height:10pt;margin:0pt 0pt 2pt 0pt;"><span style="font-family:'Times New Roman';">Atopic dermatitis: Phase III (TRuE-AD1, TRuE-AD2; primary endpoints met)</span></p><p style="font-family:'Calibri';font-size:10pt;line-height:10pt;margin:0pt 0pt 2pt 0pt;"><span style="font-family:'Times New Roman';">Vitiligo: Phase III (TRuE-V1, TRuE-V2)</span></p></td></tr><tr style="height:18pt;"><td style="background-color:auto;vertical-align:top;width:23.83%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri';font-size:10pt;font-weight:bold;margin:0pt;"><b style="font-family:'Times New Roman';font-weight:bold;">INCB54707 (JAK1)</b></p></td><td style="background-color:auto;vertical-align:top;width:76.16%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri';font-size:10pt;line-height:10pt;margin:0pt 0pt 2pt 0pt;"><span style="font-family:'Times New Roman';">Hidradenitis suppurativa: Phase II</span></p><p style="font-family:'Calibri';font-size:10pt;line-height:10pt;margin:0pt 0pt 2pt 0pt;"><span style="font-family:'Times New Roman';visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:21.15pt;"><td style="background-color:#cceeff;vertical-align:top;width:23.83%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri';font-size:10pt;font-weight:bold;line-height:10pt;margin:0pt;"><b style="font-family:'Times New Roman';font-weight:bold;">parsaclisib (PI3K&#948;)</b></p></td><td style="background-color:#cceeff;vertical-align:top;width:76.16%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri';font-size:10pt;line-height:10pt;margin:0pt 0pt 2pt 0pt;"><span style="font-family:'Times New Roman';">Autoimmune hemolytic anemia: Phase II</span></p></td></tr><tr style="height:21.15pt;"><td style="background-color:auto;vertical-align:top;width:23.83%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri';font-size:10pt;font-weight:bold;line-height:10pt;margin:0pt;"><b style="font-family:'Times New Roman';font-weight:bold;">INCB00928 (ALK2)</b></p></td><td style="background-color:auto;vertical-align:top;width:76.16%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri';font-size:10pt;line-height:10pt;margin:0pt 0pt 2pt 0pt;"><span style="font-family:'Times New Roman';">Fibrodysplasia ossificans progressiva: Phase II in preparation</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1.</sup> Novartis&#8217; rights for ruxolitinib outside of the United States under our Collaboration and License Agreement with Novartis do not include topical administration.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Partnered Programs </b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Baricitinib</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We have a second JAK1 and JAK2 inhibitor, baricitinib, which is subject to our collaboration agreement with Lilly, in which Lilly received exclusive worldwide development and commercialization rights to the compound for inflammatory and autoimmune diseases. The Phase III program of baricitinib in patients with rheumatoid arthritis </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;">incorporated all three rheumatoid arthritis populations (methotrexate na&#239;ve, biologic na&#239;ve, and tumor necrosis factor (TNF) inhibitor inadequate responders); used event rates to fully power the baricitinib program for structural comparison and non-inferiority vs. adalimumab; and evaluated patient-reported outcomes. All four Phase III trials met their respective primary endpoints.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2016, Lilly submitted an NDA to the FDA and an MAA to the EMA for baricitinib as treatment for rheumatoid arthritis. In February 2017, we and Lilly announced that the European Commission approved baricitinib as OLUMIANT for the treatment of moderate-to-severe rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying antirheumatic drugs (DMARDs). In July 2017, Japan&#39;s Ministry of Health, Labor and Welfare (MHLW) granted marketing approval for OLUMIANT<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup>for the treatment of rheumatoid arthritis (including the prevention of structural injury of joints) in patients with inadequate response to standard-of-care therapies. In June 2018, the FDA approved the 2mg dose of OLUMIANT for the treatment of adults with moderately-to-severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) inhibitor therapies.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Rheumatoid Arthritis.</i> &#160;Rheumatoid arthritis is an autoimmune disease characterized by aberrant or abnormal immune mechanisms that lead to joint inflammation and swelling and, in some patients, the progressive destruction of joints. Rheumatoid arthritis can also affect connective tissue in the skin and organs of the body.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Current rheumatoid arthritis treatments include the use of non-steroidal anti-inflammatory drugs, disease-modifying anti-rheumatic drugs, such as methotrexate, and the newer biological response modifiers that target pro-inflammatory cytokines, such as tumor necrosis factor, implicated in the pathogenesis of rheumatoid arthritis. None of these approaches to treatment is curative; therefore, there remains an unmet need for new safe and effective treatment options for these patients. Rheumatoid arthritis is estimated to affect about 1%&#160;of the world&#8217;s population.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Atopic Dermatitis. </i>Atopic dermatitis (AtD) is a condition that makes the skin red and itchy and which is common in children but can occur at any age. Atopic dermatitis is long lasting and tends to flare periodically and then subside. Lilly has conducted a Phase&#160;IIa trial and a Phase III program to evaluate the safety and efficacy of baricitinib in patients with moderate-to-severe atopic dermatitis. The JAK-STAT pathway has been shown to play an essential role in the dysregulation of immune responses in atopic dermatitis. Therefore, we believe that inhibiting cytokine pathways dependent on JAK1 and JAK2 may lead to positive clinical outcomes in atopic dermatitis. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2019, we and Lilly announced that baricitinib met the primary endpoint in BREEZE-AD1 and BREEZE-AD2, two Phase III studies evaluating the efficacy and safety of baricitinib monotherapy for the treatment of adult patients with moderate to severe AtD and, in August 2019, we and Lilly announced that baricitinib met the primary endpoint in BREEZE-AD7, a Phase III study evaluating the efficacy and safety of baricitinib in combination with standard-of-care topical corticosteroids in patients with moderate to severe AtD. In January 2020, we and Lilly announced that baricitinib met the primary endpoint in both BREEZE-AD4 and BREEZE-AD5, the results of which complete the placebo-controlled data program intended to support global registrations. In January 2020, Lilly announced that baricitinib had been submitted for regulatory review in Europe as a treatment for patients with moderate to severe atopic dermatitis. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Systemic Lupus Erythematosus.</i> Systemic lupus erythematosus (SLE) is a chronic disease that causes inflammation. In addition to affecting the skin and joints, it can affect other organs in the body such as the kidneys, the tissue lining the lungs and heart, and the brain. Lilly has conducted a Phase&#160;II trial to evaluate the safety and efficacy of baricitinib in patients with SLE. Baricitinib&#8217;s activity profile suggests that it inhibits cytokines implicated in SLE such as type I interferon (IFN), type II IFN-&#947;, IL-6, and IL-23 as well as other cytokines that may have a role in SLE, including granulocyte macrophage colony stimulating factor (GM-CSF) and IL-12. The potential impact of baricitinib on the IFN pathway is highly relevant to SLE, as clinical and preclinical studies have established that this pathway is involved in the pathogenesis of SLE. Lilly is currently running a Phase III trial of baricitinib in patients with SLE.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Alopecia Areata</i>. Alopecia areata is an autoimmune disorder in which the immune system attacks the hair follicles, causing hair loss in patches. In March 2020, Lilly announced that baricitinib received Breakthrough Therapy designation for the treatment of alopecia areata, based on the positive Phase II results of Lilly&#8217;s adaptive Phase II/III study BRAVE-AA1. The Phase III portion of BRAVE-AA1 is ongoing. &#160;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Capmatinib</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Capmatinib is a potent and highly selective MET inhibitor. The investigational compound has demonstrated inhibitory activity in cell-based biochemical and functional assays that measure MET signaling and MET dependent cell proliferation, survival and migration. Under our agreement, Novartis received worldwide exclusive development and commercialization rights to capmatinib and certain back-up compounds in all indications. Capmatinib is being evaluated in patients with hepatocellular carcinoma, non-small cell lung cancer and other solid tumors, and may have potential utility as a combination agent.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">MET is a clinically validated receptor kinase cancer target. Abnormal MET activation in cancer correlates with poor prognosis. Dysregulation of the MET pathway triggers tumor growth, formation of new blood vessels that supply the tumor with nutrients, and causes cancer to spread to other organs. Dysregulation of the MET pathway is seen in many types of cancers, including lung, kidney, liver, stomach, breast and brain.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2019, we and Novartis announced positive updated results from the GEOMETRY mono-1 Phase II clinical trial of capmatinib in patients with advanced NSCLC harboring MET exon 14 skipping mutations. In December 2019, Novartis submitted the NDA seeking approval of capmatinib, and in February 2020 we and Novartis announced that the NDA had been accepted for Priority Review by the FDA. Capmatinib has also been granted Breakthrough Therapy designation by the FDA as a treatment for patients with metastatic NSCLC harboring MET exon-14 skipping mutations, both for treatment-naive patients and for patients previously treated with platinum-based chemotherapy. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">NSCLC is the most common type of lung cancer, impacting more than 2 million people per year. Approximately 3-4 percent of all patients with NSCLC whose tumors have a mutation that leads to MET exon 14 skipping. Though rare, this mutation is an indicator of especially poor prognosis and poor responses to standard therapies, including immunotherapy. There is currently no approved therapy designed to selectively target this mutation.</p><table style="border-collapse:collapse;font-size:16pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:19.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:80.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="background-color:#f2f2f2;vertical-align:top;width:19.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="background-color:#f2f2f2;vertical-align:top;width:80.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:16.55pt;"><td style="background-color:#ffffff;vertical-align:top;width:19.61%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri';font-size:10pt;font-weight:bold;margin:0pt;"><b style="font-family:'Times New Roman';font-weight:bold;">&#160;</b></p></td><td style="background-color:#ffffff;vertical-align:top;width:80.38%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri';font-size:10pt;margin:0pt;"><b style="font-family:'Times New Roman';font-weight:bold;">Indication and status</b></p></td></tr><tr style="height:28.8pt;"><td style="background-color:#cceeff;vertical-align:top;width:19.61%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt;"><b style="font-family:'Times New Roman';font-weight:bold;line-height:10pt;">baricitinib (JAK1/JAK2)</b><sup style="font-family:'Times New Roman';font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="background-color:#cceeff;vertical-align:top;width:80.38%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri';font-size:10pt;line-height:10pt;margin:0pt 0pt 2pt 0pt;"><span style="font-family:'Times New Roman';">Atopic dermatitis: Phase III (BREEZE-AD)</span></p><p style="font-family:'Calibri';font-size:10pt;line-height:10pt;margin:0pt 0pt 2pt 0pt;"><span style="font-family:'Times New Roman';">Systemic lupus erythematosus: Phase III</span></p><p style="font-family:'Calibri';font-size:10pt;line-height:10pt;margin:0pt 0pt 2pt 0pt;"><span style="font-family:'Times New Roman';">Severe alopecia areata: Phase III (BRAVE-AA1)</span></p><p style="font-family:'Calibri';font-size:10pt;line-height:10pt;margin:0pt 0pt 2pt 0pt;"><span style="font-family:'Times New Roman';visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:18.9pt;"><td style="background-color:#ffffff;vertical-align:top;width:19.61%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt;"><b style="font-family:'Times New Roman';font-weight:bold;line-height:10pt;">capmatinib (MET)</b><sup style="font-family:'Times New Roman';font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup></p></td><td style="background-color:#ffffff;vertical-align:top;width:80.38%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri';font-size:10pt;line-height:10pt;margin:0pt 0pt 2pt 0pt;"><span style="font-family:'Times New Roman';">NSCLC (with MET exon 14 skipping mutations): NDA by Novartis under Priority Review</span></p><p style="font-family:'Calibri';font-size:10pt;line-height:10pt;margin:0pt 0pt 2pt 0pt;"><span style="font-family:'Times New Roman';visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:6pt 0pt 6pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1.</sup> Baricitinib licensed to Lilly</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2.</sup> Capmatinib licensed to Novartis</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">License Agreements and Business Relationships</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:21.6pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:14.4pt;"></span>We establish business relationships, including collaborative arrangements with other companies and medical research institutions to assist in the clinical development and/or commercialization of certain of our drugs and drug candidates and to provide support for our research programs. We also evaluate opportunities for acquiring products or rights to products and technologies that are complementary to our business from other companies and medical research institutions.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></span>Below is a brief description of our significant business relationships and collaborations and related license agreements that expand our pipeline and provide us with certain rights to existing and potential new products and technologies. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Novartis</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In November 2009, we entered into a Collaboration and License Agreement with Novartis. Under the terms of the agreement, Novartis received exclusive development and commercialization rights outside of the United States to ruxolitinib and certain back-up compounds for hematologic and oncology indications, including all hematological </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">malignancies, solid tumors and myeloproliferative diseases. We retained exclusive development and commercialization rights to JAKAFI (ruxolitinib) in the United States and in certain other indications. Novartis also received worldwide exclusive development and commercialization rights to our MET inhibitor compound capmatinib and certain back-up compounds in all indications. We retained options to co-develop and to co-promote capmatinib in the United States.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under this agreement, we received an upfront payment and immediate milestone payment totaling $210.0&#160;million and were initially eligible to receive additional payments of up to approximately $1.2&#160;billion if defined development and commercialization milestones are achieved. We are also eligible to receive tiered, double-digit royalties ranging from the upper-teens to the mid-twenties percent on future ruxolitinib net sales outside of the United States, and tiered, worldwide royalties on future capmatinib net sales that range from 12% to 14%. In addition, Novartis has received reimbursement and pricing approval for ruxolitinib in a specified number of countries, and we are now obligated to pay to Novartis tiered royalties in the low single-digits on future ruxolitinib net sales within the United States. Each company is responsible for costs relating to the development and commercialization of ruxolitinib in its respective territories, with costs of collaborative studies shared equally. Novartis is also responsible for all costs relating to the development and commercialization of capmatinib.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2016, we amended this agreement to provide that Novartis has exclusive research, development and commercialization rights outside of the United States to ruxolitinib (excluding topical formulations) in the GVHD field. Under this amendment, we received a $5.0 million payment in exchange for the development and commercialization rights to ruxolitinib in GVHD outside of the United States and became eligible to receive up to $75.0 million of additional potential development and regulatory milestones relating to GVHD. &#160;In March 2017, we recognized a $25.0 million milestone for the first patient first visit in a GVHD study and in December 2017, we recognized a $40.0 million milestone for Novartis achieving annual net sales of a JAK licensed product of $600.0 million. In December 2018, we recognized a $60.0 million milestone for Novartis achieving annual net sales of a JAK licensed product of $900.0 million. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Novartis agreement will continue on a program-by-program basis until Novartis has no royalty payment obligations with respect to such program or, if earlier, the termination of the agreement or any program in accordance with the terms of the agreement. Royalties are payable by Novartis on a product-by-product and country-by-country basis until the latest to occur of (i)&#160;the expiration of the last valid claim of the licensed patent rights covering the licensed product in the relevant country, (ii)&#160;the expiration of regulatory exclusivity for the licensed product in such country and (iii)&#160;a specified period from first commercial sale in such country of the licensed product by Novartis or its affiliates or sublicensees. The agreement may be terminated in its entirety or on a program-by-program basis by Novartis for convenience. The agreement may also be terminated by either party under certain other circumstances, including material breach.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Lilly</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2009, we entered into a License, Development and Commercialization Agreement with Lilly. Under the terms of the agreement, Lilly received exclusive worldwide development and commercialization rights to baricitinib and certain back-up compounds for inflammatory and autoimmune diseases. We received an initial payment of $90.0&#160;million, and were initially eligible to receive additional payments of up to $665.0&#160;million based on the achievement of defined development, regulatory and commercialization milestones.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We retained options to co-develop our JAK1/JAK2 inhibitors with Lilly on a compound-by-compound and indication-by-indication basis. Lilly is responsible for all costs relating to the development and commercialization of the compounds unless we elect to co-develop any compounds or indications. If we elect to co-develop any compounds and/or indications, we would be responsible for funding 30% of the associated future global development costs from the initiation of a Phase IIb trial through regulatory approval, including post-launch studies required by a regulatory authority. We would receive an incremental royalty rate increase across all tiers resulting in effective royalty rates ranging up to the high twenties on potential future global net sales for compounds and/or indications that we elect to co-develop. &#160;For indications that we elect not to co-develop, we would receive tiered, double-digit royalty payments on future global net sales with rates ranging up to 20% if the product is successfully commercialized. If we have started co-development funding for any indication, we can at any time opt out and stop future co-development cost sharing. If we elect to do this, we would still be eligible for our base royalties plus an incremental pro-rated royalty commensurate with our contribution to the total co-development </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">cost for those indications for which we co-funded. &#160;We previously had retained an option to co-promote products in the United States but, in March 2016, we waived our co-promotion option as part of an amendment to the agreement. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In July 2010, we elected to co-develop baricitinib with Lilly in rheumatoid arthritis, and subsequently in several additional indications, and became responsible for funding 30% of the associated global development costs for such indications from the initiation of the Phase IIb trial through regulatory approval, including post-launch studies required by a regulatory authority. In April 2019, we elected to end additional co-funding of the development of baricitinib in all indications, effective as of January 1, 2019. Pursuant to the terms of the Lilly agreement, we will continue to receive base tiered royalties on global net sales of OLUMIANT in all indications, as well as pro-rated incremental royalties, as described above. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2016, we entered into an amendment to the agreement with Lilly that allows us to engage in the development and commercialization of ruxolitinib in the GVHD field. Upon execution of the amendment, we paid Lilly an upfront payment of $35.0 million and Lilly is eligible to receive up to $40.0 million in regulatory milestone payments relating to ruxolitinib in the GVHD field. &#160;In May 2019, the approval of JAKAFI in steroid-refractory acute GVHD triggered a $20.0 million milestone payment to Lilly.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2017, the European Commission announced the approval of baricitinib as OLUMIANT, triggering a $65.0 million milestone payment from Lilly. &#160;In July 2017, Japan&#39;s MHLW granted marketing approval for OLUMIANT, triggering a $15.0 million milestone payment from Lilly. &#160;In December 2017, we recognized a $30.0 million milestone payment for the first patient treated in the atopic dermatitis Phase III program for baricitinib. In June 2018, the FDA approved the 2mg dose of OLUMIANT, triggering a $100.0 million milestone payment from Lilly. In September 2018, we recognized a $20.0 million milestone payment for the first patient treated in the systemic lupus erythematosus Phase III program for baricitinib.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Lilly agreement will continue until Lilly no longer has any royalty payment obligations or, if earlier, the termination of the agreement in accordance with its terms. Royalties are payable by Lilly on a product-by-product and country-by-country basis until the latest to occur of (i)&#160;the expiration of the last valid claim of the licensed patent rights covering the licensed product in the relevant country, (ii)&#160;the expiration of regulatory exclusivity for the licensed product in such country and (iii)&#160;a specified period from first commercial sale in such country of the licensed product by Lilly or its affiliates or sublicensees. The agreement may be terminated by Lilly for convenience, and may also be terminated under certain other circumstances, including material breach.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Agenus</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2015, we entered into a License, Development and Commercialization Agreement with Agenus Inc. and its wholly-owned subsidiary, 4-Antibody AG (now known as Agenus Switzerland Inc.), which we collectively refer to as Agenus. Under this agreement, the parties have agreed to collaborate on the discovery of novel immuno-therapeutics using Agenus&#8217; antibody discovery platforms. In February 2017, we and Agenus amended this agreement.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Under the terms of this agreement, as amended, we received exclusive worldwide development and commercialization rights to four checkpoint modulators directed against GITR, OX40, LAG-3 and TIM-3. In addition to the initial four program targets, we and Agenus have the option to jointly nominate and pursue additional targets within the framework of the collaboration, and in November 2015, three more targets were added. Targets may be designated profit-share programs, where all costs and profits are shared equally by us and Agenus, or royalty-bearing programs, where we are responsible for all costs associated with discovery, preclinical, clinical development and commercialization activities. The programs relating to GITR and OX40 and two of the undisclosed targets were profit-share programs until February 2017, while the other targets currently under collaboration are royalty-bearing programs. &#160;The February 2017 amendment converted the programs relating to GITR and OX40 to royalty-bearing programs and removed from the collaboration the profit-share programs relating to the two undisclosed targets, with one reverting to us and one reverting to Agenus. &#160;Should any of those removed programs be successfully developed by a party, the other party will be eligible to receive the same milestone payments as the royalty-bearing programs and royalties at a 15% rate on global net sales. &#160;There are currently no profit-share programs. &#160;For each royalty-bearing product other than GITR and OX40, Agenus will be eligible to receive tiered royalties on global net sales ranging from 6% to 12%. &#160;For GITR and OX40, Agenus will be </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">eligible to receive 15% royalties on global net sales. Under the February 2017 amendment, we paid Agenus $20.0 million in accelerated milestones relating to the clinical development of the GITR and OX40 programs. &#160;Agenus is eligible to receive up to an additional $510.0 million in future contingent development, regulatory and commercialization milestones across all programs in the collaboration. &#160;The agreement may be terminated by us for convenience upon 12 months&#8217; notice and may also be terminated under certain other circumstances, including material breach.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Takeda (ARIAD) </span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2016, we acquired from ARIAD Pharmaceuticals, Inc. all of the outstanding shares of ARIAD Pharmaceuticals (Luxembourg) S.&#224;.r.l., the parent company of ARIAD&#8217;s European subsidiaries responsible for the development and commercialization of ICLUSIG in the European Union and other countries. &#160;We obtained an exclusive license to develop and commercialize ICLUSIG in Europe and other select countries. ARIAD was subsequently acquired by Takeda Pharmaceutical Company Limited in 2017. &#160;As such, Takeda will be eligible to receive from us tiered royalties on net sales of ICLUSIG in our territory and up to $135.0 million in potential future oncology development and regulatory approval milestone payments, together with additional milestone payments for non-oncology indications, if approved, in our territory. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Merus</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2016, we entered into a Collaboration and License Agreement with Merus N.V. Under this agreement, which became effective in January 2017, the parties have agreed to collaborate with respect to the research, discovery and development of bispecific antibodies utilizing Merus&#8217; technology platform. &#160;The collaboration encompasses up to eleven independent programs. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The most advanced collaboration program is MCLA-145, a bispecific antibody targeting PD-L1 and CD137, for which we received exclusive development and commercialization rights outside of the United States. Merus retained exclusive development and commercialization rights in the United States to MCLA-145. &#160;Each party will share equally the costs of mutually agreed global development activities for MCLA-145, and fund itself any independent development activities in its territory. &#160;Merus will be responsible for commercializing MCLA-145 in the United States and we will be responsible for commercializing it outside of the United States. &#160; &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to receiving rights to MCLA-145 outside of the United States, we received worldwide exclusive development and commercialization rights to up to ten additional programs. &#160;Of these ten additional programs, Merus retained the option, subject to certain conditions, to co-fund development of up to two such programs. &#160;If Merus exercises its co-funding option for a program, Merus would be responsible for funding 35% of the associated future global development costs and, for certain of such programs, would be responsible for reimbursing us for certain development costs incurred prior to the option exercise. &#160;Merus will also have the right to participate in a specified proportion of detailing activities in the United States for one of those co-developed programs. All costs related to the co-funded collaboration programs are subject to joint research and development plans and overseen by a joint development committee, but we will have final determination as to such plans in cases of dispute. &#160;We will be responsible for all research, development and commercialization costs relating to all other programs. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In February 2017, we paid Merus an upfront non-refundable payment of $120.0 million. For each program as to which Merus does not have commercialization or development co-funding rights, Merus will be eligible to receive up to $100.0 million in future contingent development and regulatory milestones, and up to $250.0 million in commercialization milestones as well as tiered royalties ranging from 6% to 10% of global net sales. &#160;For each program as to which Merus exercises its option to co-fund development, Merus will be eligible to receive a 50% share of profits (or sustain 50% of any losses) in the United States and be eligible to receive tiered royalties ranging from 6% to 10% of net sales of products outside of the United States. &#160;If Merus opts to cease co-funding a program as to which it exercised its co-development option, then Merus will no longer receive a share of profits in the United States but will be eligible to receive the same milestones from the co-funding termination date and the same tiered royalties described above with respect to programs where Merus does not have a right to co-fund development and, depending on the stage at which Merus chose to cease co-funding development costs, Merus will be eligible to receive additional royalties ranging up to 4% of net sales in the United </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">States. &#160;For MCLA-145, we and Merus will each be eligible to receive tiered royalties on net sales in the other party&#8217;s territory at rates ranging from 6% to 10%. &#160; </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Merus agreement will continue on a program-by-program basis until we have no royalty payment obligations with respect to such program or, if earlier, the termination of the agreement or any program in accordance with the terms of the agreement. &#160;The agreement may be terminated in its entirety or on a program-by-program basis by us for convenience. &#160;The agreement may also be terminated by either party under certain other circumstances, including material breach, as set forth in the agreement. &#160;If the agreement is terminated with respect to one or more programs, all rights in the terminated programs revert to Merus, subject to payment to us of a reverse royalty of up to 4% on sales of future products, if Merus elects to pursue development and commercialization of products arising from the terminated programs. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Calithera</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2017, we entered into a Collaboration and License Agreement with Calithera Biosciences, Inc. Under this agreement, we received an exclusive, worldwide license to develop and commercialize small molecule arginase inhibitors, including INCB01158 (CB-1158), which is currently in Phase I clinical trials, for hematology and oncology indications. We have agreed to co-fund 70% of the global development costs for the development of the licensed products for hematology and oncology indications. Calithera will have the right to conduct certain clinical development under the collaboration, including combination studies of a licensed product with a proprietary compound of Calithera. We will be entitled to 60% of the profits and losses from net sales of licensed product in the United States, and Calithera will have the right to co-detail licensed products in the United States, and we have agreed to pay Calithera tiered royalties ranging from the low to mid-double digits on net sales of licensed products outside the United States. Calithera may opt out of its co-funding obligation, in which case the U.S. profit sharing will no longer be in effect, and we have agreed to pay Calithera tiered royalties ranging from the low to mid-double digits on net sales of licensed products both in the United States and outside the United States, and additional royalties to reimburse Calithera for previously incurred development costs. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Calithera retains rights to certain arginase inhibitors that are not part of the collaboration for specific orphan indications outside of hematology and oncology, subject to our rights to negotiate a license for any such programs under specified circumstances if Calithera elects to out-license them.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2017, we paid Calithera an upfront license fee of $45.0 million and have agreed to pay potential development, regulatory and sales milestone payments of over $430.0 million if the profit share is in effect, or $750.0 million if the profit share terminates.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Calithera agreement will continue on a product-by-product and country-by-country basis for so long as we are developing or commercializing products in the United States (if the parties are sharing profits in the United States) and until we have no further royalty payment obligations, unless earlier terminated according to the terms of the agreement. The agreement may be terminated in its entirety or on a product-by-product and/or a country-by-country basis by us for convenience. The agreement may also be terminated by us for Calithera&#8217;s uncured material breach, by Calithera for our uncured material breach and by either party for bankruptcy or patent challenge. If the agreement is terminated early with respect to one or more products or countries, all rights in the terminated products and countries revert to Calithera.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">MacroGenics</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In October 2017, we entered into a Global Collaboration and License Agreement with MacroGenics. Under this agreement, we received exclusive development and commercialization rights worldwide to MacroGenics&#8217; INCMGA0012, an investigational monoclonal antibody that inhibits PD-1. Except as set forth in the succeeding sentence, we will have sole authority over and bear all costs and expenses in connection with the development and commercialization of INCMGA0012 in all indications, whether as a monotherapy or as part of a combination regimen.&#160; MacroGenics has retained the right to develop and commercialize, at its cost and expense, its pipeline assets in combination with INCMGA0012.&#160; In addition, MacroGenics has the right to manufacture a portion of both companies&#8217; global clinical and commercial supply needs of INCMGA0012. &#160;In 2017, we paid MacroGenics an upfront payment of $150.0 million and in 2018, we paid MacroGenics milestones totaling $15.0 million. &#160;MacroGenics will be eligible to receive up to an additional </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">$405.0 million in future contingent development and regulatory milestones, and up to $330.0 million in sales milestones as well as tiered royalties ranging from 15% to 24% of global net sales.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The MacroGenics agreement will continue until we are no longer commercializing, developing or manufacturing INCMGA0012 or, if earlier, the termination of the agreement in accordance with its terms.&#160; The agreement may be terminated in its entirety or on a licensed product by licensed product basis by us for convenience.&#160; The agreement may also be terminated by either party under certain other circumstances, including material breach, as set forth in the agreement.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Syros</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2018, we entered into a <span style="letter-spacing:-0.1pt;">target discovery, research collaboration and option agreement with Syros Pharmaceuticals, Inc. Under this agreement, Syros will use its proprietary gene control platform to identify novel therapeutic targets with a focus in myeloproliferative neoplasms and we have received</span> options to obtain exclusive worldwide rights to intellectual property resulting from the collaboration for up to seven <span style="letter-spacing:-0.1pt;">validated targets. &#160;We will have exclusive worldwide rights to develop and commercialize any therapies under the collaboration that modulate those</span> validated targets. &#160;<span style="letter-spacing:-0.1pt;">We paid Syros $2.5 million in cash for access to proprietary technology and $7.5 million in cash for research and development services. We have agreed to pay Syros up to</span> $54.0 million in target <span style="letter-spacing:-0.1pt;">selection and option</span> <span style="letter-spacing:0.1pt;">exercise fees should we decide to exercise all of our options under the agreement. For products resulting from the collaboration</span> against each of the seven selected and validated targets, we have agreed to pay up to $50.0 million in potential development and regulatory milestones and up to $65.0 million in potential sales milestones. Syros is also eligible to receive low single-digit royalties on net sales of products resulting from the collaboration.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Innovent</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2018, we entered into a research collaboration and licensing agreement with Innovent Biologics, Inc. Under the terms of this agreement, Innovent received exclusive development and commercialization rights to pemigatinib and our clinical-stage product candidates itacitinib and parsaclisib in hematology and oncology in mainland China, Hong Kong, Macau and Taiwan. In January 2019, we recognized an upfront payment under this agreement of $40.0 million upon our transfer of the intellectual property related to the clinical-stage product candidates to Innovent. In addition, we are eligible to receive $20.0 million in connection with the first related IND filing in China, up to an additional $129.0 million in potential development and regulatory milestones, and up to $202.5 million in potential sales milestones. We are also eligible to receive tiered royalties from the high-teens to the low-twenties on future sales of products resulting from the collaboration. We retain an option to assist in the promotion of the three product candidates in the Innovent territories. In June 2019, we recognized the $20.0 million milestone for the first related IND filing in China.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Zai Lab</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In July 2019, we entered into a collaboration and license agreement with a subsidiary of Zai Lab Limited. Under the terms of this agreement, Zai Lab received development and exclusive commercialization rights to INCMGA0012 in hematology and oncology in mainland China, Hong Kong, Macau and Taiwan. We recognized an upfront payment under this agreement of $17.5 million in August 2019 upon our transfer of technology related to the licensed product candidate to Zai Lab, and are eligible to receive an additional $60.0 million in potential development, regulatory and sales milestones, as well as tiered royalties from the low to mid-twenties. We also retain an option to assist in the promotion of INCMGA0012 in Zai Lab&#8217;s licensed territories. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">MorphoSys</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In January 2020, we entered into a Collaboration and License Agreement with MorphoSys AG and MorphoSys US Inc., a wholly-owned subsidiary of MorphoSys AG, covering the worldwide development and commercialization of MOR208 (tafasitamab), an investigational Fc engineered monoclonal antibody directed against the target molecule CD19 that is currently in clinical development by MorphoSys. MorphoSys has exclusive worldwide development and commercialization rights to tafasitamab under a June 2010 collaboration and license agreement with Xencor, Inc. In December 2019, MorphoSys submitted a Biologics License Application to the FDA for tafasitamab for the treatment of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">relapsed or refractory diffuse large B cell lymphoma. &#160;The agreement became effective in March 2020 after clearance by the German and Austrian antitrust authorities and expiration of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the agreement, we received exclusive commercialization rights outside of the United States, and MorphoSys and we have co-commercialization rights in the United States, with respect to tafasitamab. &#160;MorphoSys is responsible for leading the commercialization strategy and booking all revenue from sales of tafasitamab in the United States, and we and MorphoSys are both responsible for commercialization efforts in the United States and will share equally the profits and losses from the co-commercialization efforts. We will lead the commercialization strategy outside of the United States, and will be responsible for commercialization efforts and book all revenue from sales of tafasitamab outside of the United States, subject to our royalty payment obligations set forth below. We and MorphoSys have agreed to co-develop tafasitamab and to share development costs associated with global and U.S.-specific clinical trials, with Incyte responsible for 55% of such costs and MorphoSys responsible for 45% of such costs. &#160;Each company is responsible for funding any independent development activities, and we are responsible for funding development activities specific to territories outside of the United States. All development costs related to the collaboration are subject to a joint development plan. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2020, we paid MorphoSys an upfront non-refundable payment of $750.0 million. MorphoSys is eligible to receive up to $740.0 million in future contingent development and regulatory milestones and up to $315.0 million in commercialization milestones as well as tiered royalties ranging from the mid-teens to mid-twenties of net sales outside of the United States. &#160;MorphoSys&#8217; right to receive royalties in any particular country will expire upon the last to occur of (a) the expiration of patent rights in that particular country, (b) a specified period of time after the first post-marketing authorization sale of a licensed product comprising tafasitamab in that country, and (c) the expiration of any regulatory exclusivity for that licensed product in that country.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies and Significant Estimates</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates. We base our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances, the results of which form our basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates under different assumptions or conditions. We believe the following critical accounting policies reflect the more significant judgments and estimates used in the preparation of our condensed consolidated financial statements. See Note 2 of Notes to the Condensed Consolidated Financial Statements for a complete list of our significant accounting policies.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Revenue Recognition.</span> We recognize revenue only when we have satisfied a performance obligation through transferring control of the promised good or service to a customer. Control, in this instance, may mean the ability to prevent other entities from directing the use of, and receiving benefit from, a good or service. The standard indicates that an entity must determine at contract inception whether it will transfer control of a promised good or service over time or satisfy the performance obligation at a point in time through analysis of the following criteria: (i) the entity has a present right to payment, (ii) the customer has legal title, (iii) the customer has physical possession, (iv) the customer has the significant risks and rewards of ownership and (v) the customer has accepted the asset. We assess collectability based primarily on the customer&#8217;s payment history and on the creditworthiness of the customer.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Product Revenues</i></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our product revenues consist of U.S. sales of JAKAFI and European sales of ICLUSIG. &#160;Product revenues are recognized once we satisfy the performance obligation at a point in time under the revenue recognition criteria as described above. We recognize revenues for product received by our customers net of allowances for customer credits, including estimated rebates, chargebacks, discounts, returns, distribution service fees, patient assistance programs, and government rebates, such as Medicare Part D coverage gap reimbursements in the U.S. These sales allowances and accruals are recorded based on estimates which are described in detail below. &#160;Estimates are assessed as of the end of each reporting </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">period and are updated to reflect current information. &#160;We believe that our sales allowances and accruals are reasonable and appropriate based on current facts and circumstances.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Customer Credits:</i> Our customers are offered various forms of consideration, including allowances, service fees and prompt payment discounts. We expect our customers will earn prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized. Service fees are also deducted from total product sales as they are earned.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Rebates and Discounts:</i> &#160;We accrue rebates for mandated discounts under the Medicaid Drug Rebate Program in the U.S. and mandated discounts in Europe in markets where government-sponsored healthcare systems are the primary payers for healthcare. These accruals are based on statutory discount rates and expected utilization as well as historical data we have accumulated since product launch. Our estimates for expected utilization of rebates are based on data received from our customers. Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known prior quarters&#8217; unpaid rebates. If actual future rebates vary from estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Chargebacks: </i>Chargebacks are discounts that occur when certain contracted customers purchase directly from our wholesalers at a discounted price. The wholesalers, in turn, charges back to us the difference between the price initially paid by the wholesalers and the discounted price paid by the contracted customers. In addition to actual chargebacks received, we maintain an accrual for chargebacks based on the estimated contractual discounts on the inventory levels on hand in our distribution channel. &#160;If actual future chargebacks vary from these estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Medicare Part&#160;D Coverage Gap:</i> Medicare Part&#160;D prescription drug benefit mandates manufacturers to fund 70% of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for the expected Medicare Part&#160;D coverage gap are based on historical invoices received and in part from data received from our customers. Funding of the coverage gap is generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known prior quarters. If actual future funding varies from estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment. Additionally, beginning in January 2020, the amount of spending required by eligible patients in the Medicare Part D insurance coverage gap increased 30% due to the expiration of a provision in the Patient Protection and Affordable Care Act, which now results in a change in the True Out of Pocket (TrOOP) calculation methodology. The methodological change has resulted in an increase in required spending by patients and, in turn, an increase in manufacturers&#8217; contributions on behalf of patients in the Medicare Part D insurance coverage gap.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Co-payment Assistance:</i> &#160;Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Product Royalty Revenues</i></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Royalty revenues on commercial sales for JAKAVI by Novartis are estimated based on information provided by Novartis. Royalty revenues on commercial sales for OLUMIANT by Lilly are estimated based on information provided by Lilly. We exercise judgment in determining whether the information provided is sufficiently reliable for us to base our royalty revenue recognition thereon. If actual royalties vary from estimates, we may need to adjust the prior period, which would affect royalty revenue and receivable in the period of adjustment.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Milestone and Contract Revenues</i></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">At the inception of a contract, the transaction price reflects the amount of consideration we expect to be entitled to in exchange for transferring promised goods or services to our collaborator. We review our estimate of the transaction price each period, and make revisions to such estimates as necessary. Milestone and contract revenues from collaborative agreements with multiple performance obligations is determined based upon assessment of each distinct promised good or </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">service&#8217;s estimated fair value and recognized based upon the completion of the promised good or service to our collaborator. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our license agreements often include contractual milestones, which typically relate to the achievement of pre-specified development, regulatory and commercialization events outside of our control, such as regulatory approval of a compound, first patient dosing or achievement of sales-based thresholds. As such, milestones associated with our collaborations involve a substantial degree of uncertainty and risk that they may never be received. &#160;Given the uncertainty associated with achieving these milestones, constraints on the allocated consideration are assessed each reporting period. Revenues are recognized when achievement is probable, which may not be until achieved.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock Compensation.</span> &#160;Share-based payment transactions with employees, which include stock options, restricted stock units (RSUs) and performance shares (PSUs), are recognized as compensation expense over the requisite service period based on their estimated fair values at the date of grant as well as expected forfeiture rates based on actual experience. The stock compensation process requires significant judgment and the use of estimates, particularly surrounding Black-Scholes assumptions such as stock price volatility over the option term and expected option lives, as well as expected forfeiture rates and the probability of PSUs vesting. The fair value of stock options, which are subject to graded vesting, are recognized as compensation expense over the requisite service period using the accelerated attribution method. &#160;The fair value of RSUs that are subject to cliff vesting are recognized as compensation expense over the requisite service period using the straight-line attribution method, and the fair value of RSUs that are subject to graded vesting are recognized as compensation expense over the requisite service period using the accelerated attribution method. &#160;The fair value of PSUs are recognized as compensation expense beginning at the time in which the performance conditions are deemed probable of achievement. We assess the probability of achievement of performance conditions, including projected product revenues and clinical development milestones, as of the end of each reporting period. Once a performance condition is considered probable, we record compensation expense based on the portion of the service period elapsed to date with respect to that award, with a cumulative catch-up, net of estimated forfeitures, and recognize any remaining compensation expense, if any, over the remaining requisite service period using the straight-line attribution method for PSUs that are subject to cliff vesting and using the accelerated attribution method for PSUs that are subject to graded vesting.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes.</span> We account for income taxes using an asset and liability approach to financial accounting for income taxes. &#160;Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for years in which the basis differences are expected to reverse. We periodically assess the likelihood of the realization of deferred tax assets, and reduce the carrying amount of these deferred tax assets to an amount that is considered to be more-likely-than-not to be realizable. Our assessment considers recent cumulative earnings experience, projections of future taxable income (losses) and ongoing prudent and feasible tax planning strategies.&#160; When performing our assessment on projections of future taxable income (losses), we consider factors such as the likelihood of regulatory approval and commercial success of products currently under development, among other factors. &#160; Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our income tax provision in the period of such reversal.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We recognize the tax benefit from an uncertain tax position only if it is more-likely-than-not that the position will be sustained upon examination by the taxing authorities, including resolutions of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit that is recorded for these positions is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. We adjust the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Any interest and penalties on uncertain tax positions are included within the tax provision. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We record estimates and prepare and file tax returns in various jurisdictions across the U.S., Europe, and Asia based upon our interpretation of local tax laws and regulations. &#160;While we exercise significant judgment when applying complex tax laws and regulations in these various taxing jurisdictions, many of our tax returns are open to audit, and may be subject to future tax, interest, and penalty assessments. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe our estimates for the valuation allowances against certain deferred tax assets and the amount of benefits associated with uncertain tax positions recognized in our financial statements are appropriate based upon our assessment of the factors mentioned above. &#160; &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Acquisition-related contingent consideration. &#160;</span>Acquisition-related contingent consideration, which consists of our future royalty obligations to ARIAD/Takeda, was recorded on the acquisition date at the estimated fair value of the obligation, in accordance with the acquisition method of accounting. The fair value of the contingent consideration was determined using an income approach based on estimated ICLUSIG revenues in the European Union and other countries. As the fair value measurement is based on significant inputs that are unobservable in the market, this represents a Level 3 measurement.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fair value of the acquisition-related contingent consideration is remeasured each reporting period, with changes in fair value recorded in the consolidated statements of operations. The assumptions used to determine the fair value of the acquisition-related contingent consideration include projected ICLUSIG revenues and discount rates which, require significant judgement and are analyzed on a quarterly basis. While we use the best available information to prepare our projected ICLUSIG revenues and discount rate assumptions, actual ICLUSIG revenues and/or market conditions could differ significantly. &#160;Changes to one or multiple inputs could have a material impact on the amount of acquisition-related contingent consideration expense recorded during the reporting period. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recent Accounting Pronouncements</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2016-13, &#8220;Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.&#8221; This guidance applies to all entities and impacts how entities account for credit losses for financial assets measured at amortized cost and available for sale debt securities. ASU 2016-13 requires financial assets measured at amortized cost to be presented at the net amount expected to be collected. The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amounts. An entity must use judgment in determining the relevant information and estimation methods that are appropriate in its circumstances. &#160;For trade receivables, loans and held-to-maturity debt securities, entities will be required to estimate expected credit losses over the lifetime of the asset. &#160;For available-for-sale debt securities, entities will be required to recognize an allowance for credit losses rather than an other-than-temporary impairment that reduces the cost basis of the investment. Further, an entity will recognize any improvements in estimated credit losses on its available-for-sale debt securities immediately in earnings. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon adoption, we assessed each financial asset measured at amortized cost and each available for sale debt security held for the impact of the guidance as of January 1, 2020 and noted an insignificant impact due to the minimal credit risk associated with our financial assets subject to ASC 326. As such, it was concluded that a reserve for credit losses was de minimis on the adoption date. Financial assets will continue to be assessed on a quarterly basis in future periods.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2018, the FASB issued ASU No. 2018-13, &#8220;Fair Value Measurement (Topic 820): Disclosure Framework &#8211; Changes to the Disclosure Requirements for Fair Value Measurement,&#8221; which eliminates the required disclosure of the amount of and reason for transfers between Level 1 and Level 2 of the fair value hierarchy. The guidance also eliminates the required disclosure of the entity&#8217;s valuation process for Level 3 fair value measurements, however public entities are required to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. This guidance is effective for fiscal years beginning after December 15, 2019. We adopted this guidance for the period beginning January 1, 2020 and enhanced our disclosures in Note 4 to the condensed consolidated financial statements to comply with the standard. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2018, the FASB issued ASU No. 2018-14, &#8220;Compensation &#8211; Retirement Benefits &#8211; Defined Benefit Plans &#8211; General,&#8221; an update to Subtopic ASC 715-20. The guidance amended year-end disclosure requirements related to defined benefit pension plans, and does not affect interim disclosures. The guidance is effective for fiscal years ending after December 15, 2020 and is permitted for early adoption. The standard is to be applied on a retrospective basis. Incyte sponsors defined benefit plans for employees located in Europe. We are currently analyzing the impact of ASU No. 2018-14 on the condensed consolidated financial statements.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2018, the FASB issued ASU No. 2018-15, &#8220;Intangibles &#8211; Goodwill and Other &#8211; Internal-Use Software,&#8221; an update to Subtopic ASC 350-40. The guidance directs accounting for service contracts for cloud computing arrangements to follow guidance within ASC 350-40 to determine capitalization of implementation costs. The guidance is effective for fiscal years beginning after December 15, 2019 and may be applied on either a retrospective or prospective basis. We adopted this guidance for the period beginning January 1, 2020 on a prospective basis. New contracts for development of internal-use software were assessed and no qualifying contracts were identified during the period. We will continue to assess contracts and will disclose material, qualifying contracts if identified in future periods.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2018, the FASB issued ASU No. 2018-18, &#8220;Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606.&#8221; The guidance clarifies the interactions between Topic 808 and Topic 606, including clarifications on revenue recognition, unit of account, and reporting disclosure requirements. The guidance is effective for fiscal years beginning after December 15, 2019. We adopted this guidance for the period beginning January 1, 2020 on a retrospective to the date of our initial application of ASC 606, and noted that in assessment of our collaborative agreements, there was no material financial statement impact. Our collaborative arrangements and their associated accounting conclusions are described in detail within Note 9 to the condensed consolidated financial statements.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2019, the FASB issued ASU No. 2019-12, &#8220;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.&#8221; This guidance applies to all entities and aims to reduce the complexity of tax accounting standards while enhancing reporting disclosures. This guidance is effective for fiscal years beginning after December 15, 2020 and interim periods therein. Early adoption is permitted for any annual periods for which financial statements have not been issued and interim periods therein. We are currently analyzing the impact of ASU No. 2019-12 and do not anticipate the adoption of this ASU to have a material impact on our condensed consolidated financial statements. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We recorded net loss of $720.6 million and basic and diluted net loss per share of $3.33 for the three months ended March 31, 2020, as compared to net income of $102.3 million and basic net income per share of $0.48 and diluted net income per share of $0.47 in the corresponding period in 2019. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Revenues.</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:59.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;width:35.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Three Months&#160;Ended,</b></p></td><td style="background-color:auto;vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:59.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;width:35.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:59.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:59.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;width:35.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;millions)</b></p></td><td style="background-color:auto;vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">JAKAFI revenues, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 459.5</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 375.6</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">ICLUSIG revenues, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 27.2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20.6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total product revenues, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 486.7</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 396.2</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">JAKAVI product royalty revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 56.3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 45.6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">OLUMIANT product royalty revenues</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 25.5</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16.0</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total product royalty revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 81.8</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 61.6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Milestone and contract revenues</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 40.0</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 568.5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 497.8</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The increase in JAKAFI product revenues for the three months ended March 31, 2020 as compared to the corresponding period in 2019 was comprised of a volume increase of $81.6 million and a price increase of $2.3 million. Our product revenues may fluctuate from quarter to quarter due to our customers&#8217; purchasing patterns over the course of the year, including as a result of increased inventory building by customers in advance of expected or announced price increases. Product revenues are recorded net of estimated product returns, pricing discounts including rebates offered pursuant to mandatory federal and state government programs and chargebacks, prompt pay discounts and distribution fees and co-pay assistance. Our revenue recognition policies require estimates of the aforementioned sales allowances each period. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table provides a summary of activity with respect to our sales allowances and accruals (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:99.59%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:38.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Co-Pay</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:38.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Discounts&#160;and</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Government</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assistance</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:38.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Distribution</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Rebates&#160;and</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and&#160;Other</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Product</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:38.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Three Months&#160;Ended March&#160;31, 2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fees</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Chargebacks</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Discounts</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Returns</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:38.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Balance at January&#160;1, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,530</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 54,762</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 703</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,660</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 63,655</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Allowances for current period sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,791</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 97,129</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,241</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 249</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 117,410</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:38.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Allowances for prior period sales</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (157)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 91</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (541)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (607)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Credits/payments for current period sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (7,321)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (41,001)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,277)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (51,599)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:38.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Credits/payments for prior period sales</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (5,744)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (21,932)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (252)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (4)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (27,932)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Balance at March&#160;31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,099</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 89,049</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,415</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,364</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 100,927</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Government rebates and chargebacks are the most significant component of our sales allowances. Increases in certain government reimbursement rates are limited to a measure of inflation, and when the price of a drug increases faster than this measure of inflation it will result in a penalty adjustment factor that causes a larger sales allowance to those government related entities. We expect government rebates and chargebacks as a percentage of our gross product sales will continue to increase in connection with any future JAKAFI price increases greater than the rate of inflation, and any such increase in these government rebates and chargebacks will have a negative impact on our reported product revenues, net. We adjust our estimates for government rebates and chargebacks based on new information regarding actual rebates as it becomes available. &#160;Claims by third-party payors for rebates and chargebacks are frequently submitted after the period in which the related sales occurred, which may result in adjustments to prior period accrual balances in the period in which the new information becomes available. &#160;We also adjust our allowance for product returns based on new information regarding actual returns as it becomes available. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect our sales allowances to fluctuate from quarter to quarter as a result of the Medicare Part D Coverage Gap, the volume of purchases eligible for government mandated discounts and rebates as well as changes in discount percentages which are impacted by potential future price increases, rate of inflation, and other factors.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Product royalty revenues on commercial sales of JAKAVI by Novartis are based on net sales of licensed products in licensed territories as provided by Novartis. Product royalty revenues on commercial sales of OLUMIANT by Lilly are based on net sales of licensed products in licensed territories as provided by Lilly. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our milestone and contract revenues for the three months ended March 31, 2019, were derived from a $40.0 million payment under the Innovent research collaboration and licensing agreement.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cost of Product Revenues.</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:59.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;width:35.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Three Months&#160;Ended,</b></p></td><td style="background-color:auto;vertical-align:bottom;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:59.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;width:35.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:59.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:16.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:16.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:59.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;width:35.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;millions)</b></p></td><td style="background-color:auto;vertical-align:bottom;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Product costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3.4</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2.9</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Salary and benefits related</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0.8</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0.7</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Stock compensation </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0.2</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0.2</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Royalty expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 17.5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13.4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Amortization of definite-lived intangible assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5.4</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5.4</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total cost of product revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 27.3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22.6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">Cost of product revenues includes all JAKAFI and ICLUSIG related product costs, employee personnel costs, including stock compensation, for those employees dedicated to the production of our commercial products, low single-digit royalties to Novartis on all sales of JAKAFI in the United States and amortization of our licensed intellectual property rights for ICLUSIG using the straight-line method over the estimated useful life of 12.5 years. The increase in cost of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">product revenues for the three months ended March 31, 2020 as compared to the corresponding period in 2019 was due primarily to increased royalties to Novartis on all JAKAFI sales in the United States.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Operating Expenses.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research&#160;and&#160;development&#160;expenses</i></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:21.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Three Months&#160;Ended,</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;width:21.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:21.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;millions)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Salary and benefits related</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">68.1</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 63.0</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Stock compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">28.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 27.4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Clinical research and outside services</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">963.6</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 153.8</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Occupancy and all other costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">24.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 26.3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Total research and development expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,085.3</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 270.5</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">We account for research and development costs by natural expense line and not costs by project. The increase in salary and benefits related expense for the three months ended March 31, 2020 as compared to the corresponding period in 2019 was due primarily to increased development headcount to sustain our development pipeline. Stock compensation expense may fluctuate from period to period based on the number of awards granted, stock price volatility and expected award lives, as well as expected award forfeiture rates which are used to value equity-based compensation. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The increase in clinical research and outside services expense for the three months ended March 31, 2020 as compared to the corresponding period in 2019 was primarily due to upfront consideration related to our collaborative agreement with MorphoSys recorded during 2020. Research and development expenses include upfront and milestone expenses related to our collaborative agreements of $805.5 million and $0.3 million, respectively, for the three months ended March 31, 2020 and 2019. Research and development expenses for the three months ended March 31, 2020 and 2019 were net of&#160;$1.7 million and $4.0 million, respectively, of costs reimbursed by our collaborative partners. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">In addition to one-time expenses resulting from upfront fees in connection with the entry into any new or amended collaboration agreements and payment of milestones under those agreements, research and development expenses may fluctuate from period to period depending upon the stage of certain projects and the level of pre-clinical and clinical trial related activities. Many factors can affect the cost and timing of our clinical trials, including requests by regulatory agencies for more information, inconclusive results requiring additional clinical trials, slow patient enrollment, adverse side effects among patients, insufficient supplies for our clinical trials and real or perceived lack of effectiveness or safety of our investigational drugs in our clinical trials. In addition, the development of all of our products will be subject to extensive governmental regulation. These factors make it difficult for us to predict the timing and costs of the further development and approval of our products.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Selling, general and administrative expenses </i></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:21.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Three Months&#160;Ended,</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:21.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:21.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;millions)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Salary and benefits related</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">36.1</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 31.4</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Stock compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">13.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13.0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Other contract services and outside costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">61.4</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 79.6</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Total selling, general and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 111.1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 124.0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">The increase in salary and benefits related expense for the three months ended March 31, 2020 as compared to the corresponding period in 2019 was due primarily to increased headcount. This increased headcount was due primarily to the ongoing commercialization efforts related to JAKAFI for intermediate or high-risk myelofibrosis, uncontrolled polycythemia vera and GVHD as well as increased headcount related to our European operations. The decrease in other </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">contract services and outside costs for the three months ended March 31, 2020 as compared to the corresponding period in 2019 was due primarily to the timing of certain expenses. Stock compensation expense may fluctuate from period to period based on the number of awards granted, stock price volatility and expected award lives, as well as expected award forfeiture rates which are used to value equity-based compensation. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><i style="font-style:italic;">Change in fair value of acquisition-related contingent consideration</i></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Acquisition-related contingent consideration, which consists of our future royalty obligations to Takeda, was recorded on the acquisition date, June 1, 2016, at the estimated fair value of the obligation, in accordance with the acquisition method of accounting. The fair value of the acquisition-related contingent consideration is remeasured quarterly. &#160;The change in fair value of the acquisition-related contingent consideration for the three months ended March 31, 2020 and 2019 was $6.6 million and $6.7 million, respectively, which is recorded in change in fair value of acquisition-related contingent consideration on the condensed consolidated statements of operations. The change in fair value for the three months ended March 31, 2020 and 2019 was due primarily to the passage of time as there were no other significant changes in the key assumptions during the periods. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><i style="font-style:italic;">Collaboration loss sharing</i></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Under the collaboration and license agreement with MorphoSys, which was executed in March 2020, we and MorphoSys are both responsible for the commercialization efforts of tafasitamab in the United States and will share equally the profits and losses from the co-commercialization efforts. For the three months ended March 31, 2020, our 50% share of the costs for tafasitamab was $2.1 million as recorded in collaboration loss sharing on the condensed consolidated statement of operations. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other income (expense).</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Other income (expense), net. </i>Other income (expense), net for the three months ended March 31, 2020 and 2019 was $8.7 million and $9.4 million, respectively. The decrease in other income (expense), net primarily relates to lower interest income for the three months ended March 31, 2020.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Interest expense.</i>&#160;&#160;Interest expense for the three months ended March 31, 2020 and 2019 was $0.6 million and $0.3 million, respectively. Included in interest expense for the three months ended March 31, 2020 and 2019 was $0.2 million and $0.2 million, respectively, of non-cash charges to amortize the discounts on our convertible senior notes due November 2020.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;white-space:pre-wrap;"> </i><i style="font-style:italic;">Unrealized gain (loss) on long term investments. </i>Unrealized gains and losses on long term investments will fluctuate from period to period, based on the change in fair value of the securities we hold in our publicly held collaboration partners. The following table provides a summary of those unrealized gains and (losses): </p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:62.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:32.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Three Months&#160;Ended,</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:62.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:32.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:62.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:62.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:32.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;millions)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Agenus</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (28.8)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10.5</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Calithera</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2.2)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4.7</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Merus</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (6.3)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2.5</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">MorphoSys</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (9.9)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Syros</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (0.9)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3.3</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Total unrealized gain (loss) on long term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (48.1)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 21.0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><i style="font-style:italic;">Provision for income taxes. </i>The provision for income taxes for the three months ended March 31, 2020 and 2019 was $16.6 million and $1.8 million, respectively. The increase in provision for income taxes primarily relates to federal and state tax liabilities that are not fully sheltered by net operating losses or research and development tax credit carryforwards. &#160;The increase was also driven by reduced tax benefits for stock-based compensation in the current period. &#160;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Due to historical net losses, we had an accumulated deficit of $2.2&#160;billion as of March 31, 2020. We have funded our research and development operations through sales of equity securities, the issuance of convertible notes, cash received from customers, and collaborative arrangements. At March 31, 2020, we had available cash, cash equivalents and marketable securities of $1.3&#160;billion. Our cash and marketable securities balances are held in a variety of interest-bearing instruments, including money market accounts, and U.S. government debt securities. Available cash is invested in accordance with our investment policy&#8217;s primary objectives of liquidity, safety of principal and diversity of investments.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities for the three months ended March 31, 2020 was $683.4 million and net cash provided by operating activities for the three months ended March 31, 2019 was $155.7 million.&#160; The $839.1 million decrease in cash provided by operating activities was due primarily to cash outflows in March 2020 related to our collaboration and license agreement with MorphoSys and changes in working capital.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our investing activities, other than purchases, sales and maturities of marketable securities, have consisted predominantly of capital expenditures and purchases of long term investments. &#160;Net cash used in investing activities was $108.6 million for the three months ended March 31, 2020, which represented purchases of marketable securities of $147.4 million, capital expenditures of $39.3 million and purchases of long term equity investments of $95.5 million, offset in part by the sale and maturity of marketable securities of $173.6 million.&#160; Net cash used in investing activities was $24.6 million for the three months ended March 31, 2019, which represented purchases of marketable securities of $34.6 million, capital expenditures of $18.3 million, offset in part by the sale and maturity of marketable securities of $28.3 million. In the future, net cash used by investing activities may fluctuate significantly from period to period due to the timing of strategic equity investments, acquisitions, capital expenditures and maturities/sales and purchases of marketable securities.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities was $2.5 million and $4.5 million, respectively, for the three months ended March 31, 2020 and 2019, primarily representing proceeds from the issuance of common stock under our stock plans, offset in part by cash paid to ARIAD/Takeda for contingent consideration during the first quarter of 2020. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following summarizes our significant contractual obligations as of March 31, 2020 and the effect those obligations are expected to have on our liquidity and cash flow in future periods (in millions):</p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less&#160;Than</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Over</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1&#160;Year</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2&#160;-&#160;3</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">4&#160;-&#160;5</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">5&#160;Years</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Contractual Obligations:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Principal on convertible senior debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 19.1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 19.1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Interest on convertible senior debt</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0.2</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0.2</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Finance lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 43.8</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1.3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5.6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5.5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 31.4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Operating lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 26.6</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10.1</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9.2</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2.6</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4.7</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Other non-cancelable obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2.8</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1.4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1.4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Total contractual obligations</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 92.5</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 32.1</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16.2</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8.1</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 36.1</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:10pt 0pt 10pt 0pt;">We have entered into and may in the future seek to license additional rights relating to technologies or drug development candidates in connection with our drug discovery and development programs. Under these licenses, we may be required to pay upfront fees, milestone payments, and royalties on sales of future products, which are not reflected in the table above. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">In October 2019, we entered into an agreement with Wilmington Friends School Inc., to purchase property for $50.0 million to expand our global headquarters. Under that agreement, closing of the purchase is subject to certain standard closing conditions, including an initial diligence period and a subsequent approval period.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We believe that our cash flow from operations, together with our cash, cash equivalents and marketable securities, will be adequate to satisfy our capital needs for the foreseeable future. Our cash requirements depend on numerous factors, including our expenditures in connection with our drug discovery and development programs and commercialization operations; expenditures in connection with litigation or other legal proceedings; costs for future facility requirements; our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">receipt of any milestone or other payments under any collaborative agreements we may enter into, including the agreements with Novartis, Lilly, Innovent and Zai Lab; and expenditures in connection with strategic relationships and license agreements, including our agreements with Agenus, ARIAD/Takeda, Calithera, Lilly, MacroGenics, MorphoSys, Merus and Syros, strategic equity investments or potential acquisitions. To the extent we seek to augment our existing cash resources and cash flow from operations to satisfy our cash requirements for future acquisitions or other strategic purposes, we expect that additional funding can be obtained through equity or debt financings or from other sources. The sale of equity or additional convertible debt securities in the future may be dilutive to our stockholders, and may provide for rights, preferences or privileges senior to those of our holders of common stock. Debt financing arrangements may require us to pledge certain assets or enter into covenants that could restrict our operations or our ability to incur further indebtedness.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> </b><b style="font-weight:bold;">Off Balance Sheet Arrangements</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have no off-balance sheet arrangements other than those that are discussed above.</p><a id="_8e15e82f_bf35_471e_8296_29744289ec3a"></a><a id="Item3QuantitativeandQualitativeDisclosur"></a><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 3.&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our investments in marketable securities, which are composed primarily of U.S. government debt securities, are subject to default, changes in credit rating and changes in market value. These investments are also subject to interest rate risk and will decrease in value if market interest rates increase. As of March 31, 2020, marketable securities were $259.4&#160;million. Due to the nature of these investments, if market interest rates were to increase immediately and uniformly by 10% from levels as of March 31, 2020, the decline in fair value would not be material.</p><a id="_2f5ab4b2_9341_41c7_8256_69842b05cfdd"></a><a id="Item4ControlsandProcedures_75416"></a><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 4.&#160;&#160;</b> <b style="font-weight:bold;">Controls and Procedures</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Evaluation of disclosure controls and procedures.</span>&#160; We maintain &#8220;disclosure controls and procedures,&#8221; as such term is defined in Rule&#160;13a-15(e)&#160;under the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;), that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules&#160;and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Our disclosure controls and procedures have been designed to meet reasonable assurance standards. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on their evaluation as of the end of the period covered by this Quarterly Report on Form&#160;10-Q, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in internal control over financial reporting</span>.&#160;There were no changes in our internal control over financial reporting (as defined in Rules&#160;13a-15(f)&#160;and&#160;15d-15(f)&#160;under the Exchange Act) for the three months ended March 31, 2020, that materially affected or are reasonably likely to materially affect our internal control over financial reporting.</p><a id="_b2e04f52_14d0_4e30_8769_81f1ea3cd66b"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PARTIIOTHERINFORMATION_534946"></a><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART&#160;II:</b>&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">OTHER INFORMATION</b></p><a id="Item1ARiskFactors_692185"></a><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 1A.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Risk Factors</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">RISKS RELATING TO COMMERCIALIZATION OF OUR PRODUCTS</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We depend heavily on our lead product, JAKAFI (ruxolitinib), which is marketed as JAKAVI outside the United States. If we are unable to successfully commercialize JAKAFI in its approved indications or to successfully obtain regulatory approval for and commercialize ruxolitinib for the treatment of additional indications, or if we are significantly delayed or limited in doing so, our business may be materially harmed.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">JAKAFI is our first product marketed by us that is approved for sale in the United States. JAKAFI was approved by the U.S. Food and Drug Administration, or FDA, in November 2011 for the treatment of patients with intermediate or high-risk myelofibrosis, in December 2014 for the treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea, which we refer to as uncontrolled polycythemia vera, and in May 2019 for the treatment of steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older. Although we have received regulatory approval for these indications, such approval does not guarantee future revenues. While in June 2016 we acquired exclusive rights to develop and commercialize ICLUSIG in the European Union, or EU, and other countries, in June 2018 the FDA approved for sale OLUMIANT (baricitinib), which we exclusively licensed to Eli Lilly and Company, for the treatment of specified rheumatoid arthritis indications, and in April 2020, the FDA approved for sale PEMAZYRE for the treatment of specified cholangiocarcinoma indications, we anticipate that JAKAFI product sales will continue to contribute a significant percentage of our total revenues over the next several years.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The commercial success of JAKAFI and our ability to generate and maintain revenues from the sale of JAKAFI will depend on a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the number of patients with intermediate or high-risk myelofibrosis, uncontrolled polycythemia vera or steroid-refractory acute graft-versus-host disease who are diagnosed with the diseases and the number of such patients that may be treated with JAKAFI;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the acceptance of JAKAFI by patients and the healthcare community;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">whether physicians, patients and healthcare payors view JAKAFI as therapeutically effective and safe relative to cost and any alternative therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the ability to obtain and maintain sufficient coverage or reimbursement by third-party payors and pricing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the ability of our third-party manufacturers to manufacture JAKAFI in sufficient quantities that meet all applicable quality standards;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the ability of our company and our third-party providers to provide marketing and distribution support for JAKAFI;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the effects of the COVID-19 Pandemic, any associated quarantine, travel restriction, stay-at-home or shutdown orders, guidelines or practices, and any disruption in our supply chain for JAKAFI on our ability to provide marketing and distribution support for JAKAFI, our ability to produce sufficient quantities of JAKAFI that meet all applicable quality standards, patient demand (including new patient prescriptions) and other risks detailed further below under &#8220;&#8212;Other Risks Relating to our Business&#8212;Public health epidemics, such as the COVID-19 Pandemic, could adversely affect our business, results of operations, and financial condition&#8221;;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the label and promotional claims allowed by the FDA;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the maintenance of regulatory approval for the approved indications in the United States; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our ability to develop, obtain regulatory approval for and commercialize ruxolitinib in the United States for additional indications.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we are not able to maintain revenues from JAKAFI in the United States, or our revenues from JAKAFI decrease, our business may be materially harmed and we may need to delay other drug discovery, development and commercialization initiatives or even significantly curtail operations, and our ability to license or acquire new products to diversify our revenue base could be limited.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, our receipt of royalties under our collaboration agreements with Novartis for sales of JAKAVI outside the United States and with Lilly for worldwide sales of OLUMIANT will depend on factors similar to those listed above, with similar regulatory, pricing and reimbursement issues driven by applicable regulatory authorities and governmental and third-party payors affecting jurisdictions outside the United States.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to obtain, or maintain at anticipated levels, reimbursement for our products from government health administration authorities, private health insurers and other organizations, our pricing may be affected or our product sales, results of operations or financial condition could be harmed.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may not be able to sell our products on a profitable basis or our profitability may be reduced if we are required to sell our products at lower than anticipated prices or reimbursement is unavailable or limited in scope or amount. The costs of JAKAFI and ICLUSIG are not insignificant and the costs of PEMAZYRE are similarly expected not to be insignificant and almost all patients will require some form of third-party coverage to afford their cost. Our future revenues and profitability will be adversely affected if we cannot depend on government and other third-party payors to defray the cost of our products to the patient. Reimbursement systems in international markets vary significantly by country and by region, and reimbursement approvals must be obtained on a country-by-country basis. Reimbursement in the EU must be negotiated on a country-by-country basis and in many countries the product cannot be commercially launched until reimbursement is approved. The timing to complete the negotiation process in each country is highly uncertain, and in some countries, we expect that it may exceed 12 months. &#160;Risks related to pricing and reimbursement are described below under &#8220;&#8212;Other Risks Relating to our Business&#8212;Health care reform measures could impact the pricing and profitability of pharmaceuticals, and adversely affect the commercial viability of our or our collaborators&#8217; products and drug candidates. Our ability to generate revenues will be diminished if we or our collaborators are unable to obtain an adequate level of reimbursement from private insurers, government insurance programs or other third party payors of health care costs, which could be affected by current and potential healthcare reform legislation, and diminished revenues will harm our operating results and financial condition and could adversely affect our ability to conduct our research and development operations.&#8221; If government and other third-party payors refuse to provide coverage and reimbursement with respect to our products, determine to provide a lower level of coverage and reimbursement than anticipated, reduce previously approved levels of coverage and reimbursement, or delay reimbursement payments due to budgetary constraints relating to the COVID-19 Pandemic, then our pricing or reimbursement for our products may be affected and our product sales, results of operations or financial condition could be harmed.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We depend upon a limited number of specialty pharmacies and wholesalers for a significant portion of any revenues from JAKAFI, and the loss of, or significant reduction in sales to, any one of these specialty pharmacies or wholesalers could adversely affect our operations and financial condition.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We sell JAKAFI primarily to specialty pharmacies and wholesalers. Specialty pharmacies dispense JAKAFI to patients in fulfillment of prescriptions and wholesalers sell JAKAFI to hospitals and physician offices. We do not promote JAKAFI to specialty pharmacies or wholesalers, and they do not set or determine demand for JAKAFI. Our ability to successfully commercialize JAKAFI will depend, in part, on the extent to which we are able to provide adequate distribution of JAKAFI to patients. Although we have contracted with a number of specialty pharmacies and wholesalers, they are expected generally to carry a very limited inventory and may be reluctant to be part of our distribution network in the future if demand for the product does not increase. Further, it is possible that these specialty pharmacies and wholesalers could decide to change their policies or fees, or both, at some time in the future. This could result in their refusal to carry smaller volume products such as JAKAFI, or lower margins or the need to find alternative methods of distributing our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">product. Although we believe we can find alternative channels to distribute JAKAFI on relatively short notice, our revenue during that period of time may suffer and we may incur additional costs to replace any such specialty pharmacy or wholesaler. The loss of any large specialty pharmacy or wholesaler as part of our distribution network, a significant reduction in sales we make to specialty pharmacies or wholesalers, or any failure to pay for the products we have shipped to them could materially and adversely affect our results of operations and financial condition.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to establish and maintain effective sales, marketing and distribution capabilities, or to enter into agreements with third parties to do so, we will not be able to successfully commercialize our products.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under our collaboration and license agreement with Novartis, we have retained commercialization rights to JAKAFI in the United States. We have established commercial capabilities in the United States, but cannot guarantee that we will be able to enter into and maintain any marketing, distribution or third-party logistics agreements with third-party providers on acceptable terms, if at all. In connection with our June 2016 acquisition from ARIAD Pharmaceuticals, Inc. we licensed rights to develop and commercialize ICLUSIG in certain countries and we acquired the European sales, marketing and distribution operations of ARIAD. &#160;We may not be able to maintain those operations or retain their personnel or distribution arrangements. We may not be able to correctly judge the size and experience of the sales and marketing force and the scale of distribution capabilities necessary to successfully market and sell any new products. Establishing and maintaining sales, marketing and distribution capabilities are expensive and time-consuming. Competition for personnel with experience in sales and marketing can be high. Our expenses associated with building and maintaining the sales force and distribution capabilities may be disproportional compared to the revenues we may be able to generate on sales of our products.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To the extent that we are able to obtain marketing approval for ruxolitinib cream for dermatology indications such as atopic dermatitis and vitiligo, we will have to establish and maintain sales, marketing and distribution capabilities that will generally be separate from our existing capabilities for oncology indications, and we have no prior experience in commercializing products for dermatology indications. Successful commercialization of our drug candidates for dermatology indications, if approved, will require us to establish new physician and payor relationships, reimbursement strategies and governmental interactions. Our inability to commercialize successfully products in indications outside of oncology could harm our business and operating results.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to comply with applicable laws and regulations, we could lose our approval to market our products or be subject to other governmental enforcement activity.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We cannot guarantee that we will be able to maintain regulatory approval to market our products in the jurisdictions in which they are currently marketed. If we do not maintain our regulatory approval to market our products, in particular JAKAFI, our results of operations will be materially harmed. We and our collaborators, third-party manufacturers and suppliers are subject to rigorous and extensive regulation by the FDA and other federal and state agencies as well as foreign governmental agencies. These regulations continue to apply after product marketing approval, and cover, among other things, testing, manufacturing, quality control and assurance, labeling, advertising, promotion, risk mitigation, and adverse event reporting requirements.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The commercialization of our products is subject to post-regulatory approval product surveillance, and our products may have to be withdrawn from the market or subject to restrictions if previously unknown problems occur. Regulatory agencies may also require additional clinical trials or testing for our products, and our products may be recalled or may be subject to reformulation, additional studies, changes in labeling, warnings to the public and negative publicity. &#160;For example, from late 2013 through 2014, ICLUSIG was subject to review by the European Medicines Agency, or EMA, of the benefits and risks of ICLUSIG to better understand the nature, frequency and severity of events obstructing the arteries or veins, the potential mechanism that leads to these side effects and whether there needed to be a revision in the dosing recommendation, patient monitoring and a risk management plan for ICLUSIG. This review was completed in January 2015, with additional warnings in the product information but without any change in the approved indications. &#160;The EMA could take additional actions in the future that reduce the commercial potential of ICLUSIG.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Failure to comply with the laws and regulations administered by the FDA or other agencies could result in:</p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">administrative and judicial sanctions, including warning letters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">fines and other civil penalties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">suspension or withdrawal of regulatory approval to market or manufacture our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">interruption of production;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">operating restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">product recall or seizure;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">injunctions; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">criminal prosecution.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The occurrence of any such event may have a material adverse effect on our business.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If the use of our products harms patients, or is perceived to harm patients even when such harm is unrelated to our products, our regulatory approvals could be revoked or otherwise negatively impacted or we could be subject to costly and damaging product liability claims.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The testing of JAKAFI, ICLUSIG and PEMAZYRE, the manufacturing, marketing and sale of JAKAFI and PEMAZYRE and the marketing and sale of ICLUSIG expose us to product liability and other risks. Side effects and other problems experienced by patients from the use of our products<span style="font-style:italic;font-weight:bold;"> </span>could:</p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">lessen the frequency with which physicians decide to prescribe our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">encourage physicians to stop prescribing our products to their patients who previously had been prescribed our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">cause serious harm to patients that may give rise to product liability claims against us; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">result in our need to withdraw or recall our products from the marketplace.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If our products are used by a wide patient population, new risks and side effects may be discovered, the rate of known risks or side effects may increase, and risks previously viewed as less significant could be determined to be significant.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Previously unknown risks and adverse effects of our products may also be discovered in connection with unapproved, or off-label, uses of our products. We are prohibited by law from promoting or in any way supporting or encouraging the promotion of our products for off-label uses, but physicians are permitted to use products for off-label purposes. In addition, we are studying and expect to continue to study JAKAFI in diseases for potential additional indications in controlled clinical settings, and independent investigators are doing so as well. In the event of any new risks or adverse effects discovered as new patients are treated for intermediate or high-risk myelofibrosis, uncontrolled polycythemia vera or acute graft-versus-host disease and as JAKAFI is studied in or used by patients for off-label indications, regulatory authorities may delay or revoke their approvals, we may be required to conduct additional clinical trials, make changes in labeling of JAKAFI, reformulate JAKAFI or make changes and obtain new approvals. We may also experience a significant drop in the sales of JAKAFI, experience harm to our reputation and the reputation of JAKAFI in the marketplace or become subject to lawsuits, including class actions. Any of these results could decrease or prevent </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">sales of JAKAFI or substantially increase the costs and expenses of commercializing JAKAFI. Similar results could occur with respect to our commercialization of ICLUSIG and PEMAZYRE.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Patients who have been enrolled in our clinical trials or who may use our products in the future often have severe and advanced stages of disease and known as well as unknown significant pre-existing and potentially life-threatening health risks. During the course of treatment, patients may suffer adverse events, including death, for reasons that may or may not be related to our products. Such events could subject us to costly litigation, require us to pay substantial amounts of money to injured patients, delay, negatively impact or end our opportunity to receive or maintain regulatory approval to market our products, or require us to suspend or abandon our commercialization efforts. Even in a circumstance in which we do not believe that an adverse event is related to our products, the investigation into the circumstance may be time consuming or inconclusive. These investigations may interrupt our sales efforts, impact and limit the type of regulatory approvals our products receive or maintain, or delay the regulatory approval process in other countries.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Factors similar to those listed above also apply to our collaboration partner Novartis, to ICLUSIG for jurisdictions outside the United States, to our collaboration partner Lilly for all jurisdictions and to our collaboration partner Innovent for PEMAZYRE in the jurisdictions in which it has development and commercialization rights.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we market our products in a manner that violates various laws and regulations, we may be subject to civil or criminal penalties.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to FDA and related regulatory requirements, we are subject to health care &#8220;fraud and abuse&#8221; laws, such as the federal False Claims Act, the anti-kickback provisions of the federal Social Security Act, and other state and federal laws and regulations. Federal and state anti-kickback laws prohibit, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce, or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any health care item or service reimbursable under Medicare, Medicaid, or other federally- or state-financed health care programs. Federal false claims laws prohibit any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to get a false claim paid. Pharmaceutical companies have been prosecuted under these laws for a variety of alleged promotional and marketing activities.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although physicians are permitted, based on their medical judgment, to prescribe products for indications other than those approved by the FDA, manufacturers are prohibited from promoting their products for such off-label uses. We market JAKAFI for intermediate or high-risk myelofibrosis, uncontrolled polycythemia vera and acute graft-versus-host disease and provide promotional materials to physicians regarding the use of JAKAFI for these indications. Although we believe that our promotional materials for physicians do not constitute improper promotion of JAKAFI, the FDA or other agencies may disagree. If the FDA or another agency determines that our promotional materials or other activities constitute improper promotion of JAKAFI, it could request that we modify our promotional materials or other activities or subject us to regulatory enforcement actions, including the issuance of a warning letter, injunction, seizure, civil fine and criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action if they believe that the alleged improper promotion led to the submission and payment of claims for an unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement. Even if it is later determined we are not in violation of these laws, we may be faced with negative publicity, incur significant expenses defending our position and have to divert significant management resources from other matters. Similar risks will exist for our marketing of PEMAZYRE.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The European Union and member countries, as well as governmental authorities in other countries, impose similar strict restrictions on the promotion and marketing of drug products. &#160;The off-label promotion of medicinal products is prohibited in the EU and in other territories, and the EU also maintains strict controls on advertising and promotional materials. The promotion of medicinal products that are not subject to a marketing authorization is also prohibited in the EU. Violations of the rules governing the promotion of medicinal products in the EU and in other territories could be penalized by administrative measures, fines and imprisonment.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The majority of states also have statutes or regulations similar to the federal anti-kickback law and false claims laws, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">regardless of the payor. Numerous states and localities have enacted or are considering enacting legislation requiring pharmaceutical companies to establish marketing compliance programs, file periodic reports or make periodic public disclosures on sales, marketing, pricing, clinical trials, and other activities. Additionally, as part of the Patient Protection and Affordable Care Act, the federal government has enacted the Physician Payment Sunshine provisions. The Sunshine provisions and similar laws and regulations in other jurisdictions where we do business require manufacturers to publicly report certain payments or other transfers of value made to physicians and teaching hospitals. Many of these requirements are new and uncertain, and the penalties for failure to comply with these requirements are unclear. Nonetheless, if we are found not to be in full compliance with these laws, we could face enforcement action and fines and other penalties, which could be significant in amount or result in exclusion from federal healthcare programs such as Medicare and Medicaid. &#160;Any action initiated against us for violation of these laws, even if we successfully defend against it, could require the expenditure of significant resources and generate negative publicity, which could harm our business and operating results. See also &#8220;&#8212;Other Risks Relating to our Business&#8212;If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business&#8221; below.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Competition for our products could harm our business and result in a decrease in our revenue.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Present and potential competitors for JAKAFI could include major pharmaceutical and biotechnology companies, as well as specialty pharmaceutical firms. &#160;For example, in August 2019, Celgene Corporation, now a subsidiary of Bristol-Myers Squibb Company, announced that the FDA had approved INREBIC (fedratinib) for the treatment of myelofibrosis. See &#8220;&#8212;Other Risks Relating to our Business&#8212; We face significant competition for our drug discovery and development efforts, and if we do not compete effectively, our commercial opportunities will be reduced or eliminated&#8221; for a description of risks relating to this type of competition. &#160;In addition, JAKAFI could face competition from generic products. &#160;As a result of the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, in the United States, generic manufacturers may seek approval of a generic version of an innovative pharmaceutical by filing with the FDA an Abbreviated New Drug Application, or ANDA. The Hatch-Waxman Act provides significant incentives to generic manufacturers to challenge U.S. patents on successful innovative pharmaceutical products. &#160;In February 2016, we received a notice letter regarding an ANDA that requested approval to market a generic version of JAKAFI and purported to challenge patents covering ruxolitinib phosphate and its use that expire in 2028. The notice letter does not challenge the ruxolitinib composition of matter patent, which expires in December 2027. &#160;To date, to our knowledge, the FDA has taken no action with respect to this ANDA. Separately, in January 2018 the Patent Trial and Appeal Board (PTAB) of United States Patent and Trademark Office denied a petition challenging our patent covering deuterated ruxolitinib analogs and the PTAB subsequently denied Concert&#8217;s Request for Rehearing in May 2018. Nevertheless, Concert still has the right separately to challenge the validity of the patent in federal court. &#160;There can be no assurance that our patents will be upheld or that any litigation in which we might engage with any such generic manufacturer would be successful in protecting JAKAFI&#8217;s exclusivity. &#160;The entry of a generic version of JAKAFI could result in a decrease in JAKAFI sales and materially harm our business, operating results and financial condition.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">ICLUSIG currently competes with existing therapies that are approved for the treatment of patients with chronic myeloid leukemia, or CML, who are resistant or intolerant to prior tyrosine kinase inhibitor, or TKI, therapies, on the basis of, among other things, efficacy, cost, breadth of approved use and the safety and side-effect profile. In addition, generic versions of imatinib are available and, while we currently believe that generic versions of imatinib will not materially impact our commercialization of ICLUSIG, given ICLUSIG&#8217;s various indication statements globally that are currently focused on resistant or intolerant CML, we cannot be certain how physicians, payors, patients, regulatory authorities and other market participants will respond to the availability of generic versions of imatinib.&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Present and potential competitors for PEMAZYRE could include major pharmaceutical and biotechnology companies, as well as specialty pharmaceutical firms. &#160;&#160;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">OTHER RISKS RELATING TO OUR BUSINESS</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Public health epidemics, such as the COVID-19 Pandemic, could adversely affect our business, results of operations, and financial condition.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></span>Our global operations expose us to risks associated with public health epidemics, such as the COVID-19 Pandemic that has spread globally. &#160;The extent to which the COVID-19 Pandemic and the measures taken to limit COVID-19&#8217;s spread impact our operations and those of our suppliers, collaborators, service providers and healthcare organizations serving patients, as well as demand for our drug products, will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the outbreak and any future resurgence of the outbreak, additional or modified government actions, including any further restrictions or reopening of local, state or national social or economic activity, new information that may emerge concerning the severity of COVID-19 and the actions taken to contain COVID-19 or treat its impact, among others.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></span>As a result of the COVID-19 Pandemic, we may experience disruptions that could severely impact our business, results of operations and financial condition, including the following: </p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">To protect the health of our employees and their families, and our communities, in accordance with &#8211; and in some cases in advance or - direction from state and local government authorities, we have restricted access to our facilities to personnel and third parties who must perform critical activities that must be completed on-site, and requested that most of our personnel work remotely. In the event that governmental authorities were to further modify current restrictions, our employees conducting research and development activities may not be able to access our laboratory space, and our research and development activities may be significantly limited or curtailed, possibly for an extended period of time. &#160;These research and development activities could include completing Investigational New Drug (IND)/Clinical Trial Application (CTA)-enabling studies, our ability to select future development candidates, and initiation of additional clinical trials for our development programs. Having a significant portion of our employees work from home can strain our information technology infrastructure, which may affect our ability to operate effectively, may make us more susceptible to communications disruptions, and expose us to greater cybersecurity risks. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Our sales and marketing activities, including our interactions with healthcare professionals, have been limited and made more difficult by the work from home orders and travel restrictions, and we cannot predict the effects on patient demand or future sales if there are prolonged quarantines, work from home orders or travel restrictions. &#160;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Our clinical trials may be affected by delays in site initiation, patient screening, patient enrollment, and monitoring and data collection as a result of prioritization of hospital resources for the COVID-19 Pandemic, travel restrictions, and the inability to access sites for initiation and monitoring. In addition, some patients may be unable to comply with clinical trial protocols if quarantines or stay at home orders impede patient movement or interrupt health services, we may be unable to obtain blood samples for testing, and we may not be able to provide the trial drug candidate to patients. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Health regulatory agencies globally may experience disruptions in their operations as a result of the coronavirus pandemic. The FDA and comparable foreign regulatory agencies may have slower response times or be under-resourced to continue to monitor our clinical trials and, as a result, review, inspection, and other timelines may be materially delayed. If any of these disruptions occur, we cannot predict how long they may last. Our drug candidate application reviews and potential approvals could be impacted or delayed by these disruptions, if they occur. &#160;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">The outbreak and measures taken to limit the spread of the outbreak, especially if prolonged, could also disrupt our supply chain or limit our ability to obtain sufficient materials for our drug products and product candidates, which could adversely affect our revenues and clinical trial timelines. Currently, our supply chain for our drug products and product candidates depends on operations by us and by other companies in multiple countries around the world, and the effects of the COVID-19 Pandemic or any or all of these countries is uncertain and unpredictable and potential disruption is possible. And, for JAKAFI, while our strategy is to maintain a 24 month </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">stock of API, inclusive of finished product, ruxolitinib phosphate might be used by us either to make JAKAFI or for ruxolitinib drug candidates in clinical trials. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">The deterioration of worldwide credit and financial markets could result in losses on our holdings of cash and investments due to failures of financial institutions and other parties, and interruptions and delays in our ability to collect, or potential losses on, our accounts receivable. &#160; &#160; &#160;</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></span>Our collaborators could be affected by similar factors as those that have or could affect our business. The ultimate impact of the COVID-19 Pandemic or a similar health epidemic is highly uncertain and subject to change. &#160;We do not yet know the full extent of potential impacts or delays on our or our collaborators&#8217; businesses, our revenues, including milestone and royalty revenues from our collaborators, our and our collaborators&#8217; clinical trials, healthcare systems or the global economy as a whole. &#160;However, these effects could have a material adverse impact on our business, results of operations, and financial condition. <span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be unsuccessful in our efforts to discover and develop drug candidates and commercialize drug products.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our long-term success, revenue growth and diversification of revenues depends on our ability to obtain regulatory approval for new drug products and new indications for our existing drug products. &#160;Our ability to discover and develop drug candidates and to commercialize additional drug products and indications will depend on our ability to:</p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">hire and retain key employees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">identify high quality therapeutic targets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">identify potential drug candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">develop products internally or license drug candidates from others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">identify and enroll suitable human subjects, either in the United States or abroad, for our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">complete laboratory testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">commence, conduct and complete safe and effective clinical trials on humans;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">obtain and maintain necessary intellectual property rights to our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">obtain and maintain necessary regulatory approvals for our products, both in the United States and abroad;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">enter into arrangements with third parties to provide services or to manufacture our products on our behalf;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">deploy sales, marketing, distribution and manufacturing resources effectively or enter into arrangements with third parties to provide these functions in compliance with all applicable laws;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">obtain appropriate coverage and reimbursement levels for the cost of our products from governmental authorities, private health insurers and other third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">lease facilities at reasonable rates to support our growth; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">enter into arrangements with third parties to license and commercialize our products.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We may not be successful in discovering, developing, or commercializing additional drug products or our existing drug products in new indications. Discovery and development of drug candidates are expensive, uncertain and time-consuming, and we do not know if our efforts will lead to discovery of any drug candidates that can be successfully </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">developed and marketed. Of the compounds or biologics that we identify as potential drug products or that we may in-license from other companies, including potential products for which we are conducting clinical trials, only a few, if any, are likely to lead to successful drug development programs and commercialized drug products.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We depend heavily on the success of our most advanced drug candidates. We might not be able to commercialize any of our drug candidates successfully, and we may spend significant time and money attempting to do so.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have invested significant resources in the development of our most advanced drug candidates. Ruxolitinib is in Phase III clinical trials for the treatment of patients with steroid-refractory graft-versus-host disease and is in other clinical trials. Itacitinib is in Phase III clinical trials for the treatment of patients with chronic graft-versus-host disease. &#160;Further, we have a number of drug candidates in Phase I and Phase II clinical trials. Our ability to generate product revenues will depend on the successful development and eventual commercialization of our most advanced drug candidates. We, or our collaborators or licensees, may decide to discontinue development of any or all of our drug candidates at any time for commercial, scientific or other reasons. &#160;For example: in early 2016, we decided to discontinue the clinical trials of ruxolitinib in pancreatic cancer and solid tumors and itacitinib in pancreatic cancer; and, in April 2018, we along with Merck stopped the ECHO-301 study with epacadostat, and we also significantly downsized the epacadostat development program. In addition, in January 2020 we announced that itacitinib did not meet the primary endpoint in the Phase III clinical trial for the treatment of patients with acute graft-versus-host disease. &#160;If a product is developed but not approved or marketed, we may have spent significant amounts of time and money on it, which could adversely affect our operating results and financial condition as well as our business plans. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we or our collaborators are unable to obtain regulatory approval for our drug candidates in the United States and foreign jurisdictions, we or our collaborators will not be permitted to commercialize products resulting from our research.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In order to commercialize drug products in the United States, drug candidates will have to obtain regulatory approval from the FDA. Satisfaction of regulatory requirements typically takes many years. To obtain regulatory approval, we or our collaborators, as the case may be, must first show that our drug candidates are safe and effective for target indications through preclinical testing (animal testing) and clinical trials (human testing). Preclinical testing and clinical development are long, expensive and uncertain processes, and we do not know whether the FDA will allow us or our collaborators to undertake clinical trials of any drug candidates in addition to our compounds currently in clinical trials. If regulatory approval of a product is granted, this approval will be limited to those disease states and conditions for which the product is demonstrated through clinical trials to be safe and effective.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Completion of clinical trials may take several years and failure may occur at any stage of testing. The length of time required varies substantially according to the type, complexity, novelty and intended use of the drug candidate. Interim results of a preclinical test or clinical trial do not necessarily predict final results, and acceptable results in early clinical trials may not be repeated in later clinical trials. For example, a drug candidate that is successful at the preclinical level may cause harmful or dangerous side effects when tested at the clinical level. Our rate of commencement and completion of clinical trials may be delayed, and existing clinical trials with our drug candidates may be stopped, due to many potential factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the high degree of risk and uncertainty associated with drug development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our inability to formulate or manufacture sufficient quantities of materials for use in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">variability in the number and types of patients available for each study;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">difficulty in maintaining contact with patients after treatment, resulting in incomplete data;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">unforeseen safety issues or side effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">poor or unanticipated effectiveness of drug candidates during the clinical trials; or</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">government or regulatory delays.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Data obtained from clinical trials are susceptible to varying interpretation, which may delay, limit or prevent regulatory approval. Many companies in the pharmaceutical and biopharmaceutical industry, including our company, have suffered significant setbacks in advanced clinical trials, even after achieving promising results in earlier clinical trials. In addition, regulatory authorities may refuse or delay approval as a result of other factors, such as changes in regulatory policy during the period of product development and regulatory agency review. For example, the FDA has in the past required, and could in the future require, that we or our collaborators conduct additional trials of any of our drug candidates, which would result in delays. In April 2017, we and our collaborator Lilly announced that the FDA had issued a complete response letter for the New Drug Application, or NDA, of OLUMIANT as a once-daily oral medication for the treatment of moderate-to-severe rheumatoid arthritis. The letter indicated that additional clinical data were needed to determine the most appropriate doses and to further characterize safety concerns across treatment arms. In June 2018, after a resubmission of the NDA, the FDA approved the 2mg dose of OLUMIANT for the treatment of adults with moderately-to-severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor inhibitor therapies. &#160;The FDA did not at that time approve any higher dose of OLUMIANT and required a warning label in connection with its approval.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Compounds or biologics developed by us or with or by our collaborators and licensees may not prove to be safe and effective in clinical trials and may not meet all of the applicable regulatory requirements needed to receive marketing approval. For example, in January 2016, a Phase II trial that was evaluating ruxolitinib in combination with regorafenib in patients with relapsed or refractory metastatic colorectal cancer and high C-reactive protein was stopped early after a planned analysis of interim efficacy data determined that the likelihood of the trial meeting its efficacy endpoint was insufficient. &#160;In addition, in February 2016, we made a decision to discontinue our JANUS 1 study, our JANUS 2 study, our other studies of ruxolitinib in colorectal, breast and lung cancer, and our study of INCB39110 in pancreatic cancer after a planned analysis of interim efficacy data of JANUS 1 demonstrated that ruxolitinib plus capecitabine did not show a sufficient level of efficacy to warrant continuation. Also, in April 2018, we along with Merck announced that the ECHO-301 study had been stopped and we also significantly downsized the epacadostat development program and in January 2020 we stopped our Phase III trial of itacitinib for the treatment of acute graft-versus-host-disease. If clinical trials of any of our compounds or biologics are stopped for safety, efficacy or other reasons or fail to meet their respective endpoints, our overall development plans, business, prospects, expected operating results and financial condition could be materially harmed and the value of our company could be negatively affected. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Outside the United States, our and our collaborators&#8217; ability to market a product is contingent upon receiving a marketing authorization from the appropriate regulatory authorities. This foreign regulatory approval process typically includes all of the risks associated with the FDA approval process described above and may also include additional risks. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country and may require us to perform additional testing and expend additional resources. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other countries or by the FDA.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Health care reform measures could impact the pricing and profitability of pharmaceuticals, and adversely affect the commercial viability of our or our collaborators&#8217; products and drug candidates. Our ability to generate revenues will be diminished if we or our collaborators are unable to obtain an adequate level of reimbursement from private insurers, government insurance programs or other third-party payors of health care costs, which could be affected by current and potential healthcare reform legislation, and diminished revenues will harm our operating results and financial condition and could adversely affect our ability to conduct our research and development operations.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our ability to commercialize our current and any future approved products successfully will depend in part on the prices we are able to charge for our approved products and the extent to which adequate reimbursement levels for the cost of our products and related treatment are obtained from third-party payors, such as private insurers, government insurance programs, including Medicare and Medicaid, health maintenance organizations (HMOs) and other health care related organizations in the U.S. and abroad.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In recent years, through legislative and regulatory actions, the U.S. federal government has made substantial changes to various payment systems under the Medicare and other federal health care programs. Comprehensive reforms to the U.S. healthcare system were enacted, including changes to the methods for, and amounts of, Medicare reimbursement. While there is currently significant uncertainty regarding the implementation of some of these reforms or the scope of amended or additional reforms, the implementation of reforms could significantly reduce payments from Medicare and Medicaid. Reforms or other changes to these payment systems may change the availability, methods and rates of reimbursements from Medicare, private insurers and other third-party payors for our current and any future approved products. Some of these changes and proposed changes could result in reduced reimbursement rates or in eliminating dual sources of payment, which could reduce the price that we or any of our collaborators or licensees receive for any products in the future, and which would adversely affect our business strategy, operations and financial results. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, there has been an increasing legislative and enforcement interest in the United States with respect to drug pricing practices. This has resulted in several recent federal and state proposals to regulate prices of pharmaceutical products and other health care reforms, any of which could limit the prices that we can charge for our products and may further limit the commercial viability of our products and drug candidates. Specifically, there have been several federal congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, reform government program reimbursement methodologies for prescription drugs, allow importation of drugs into the U.S. from other countries and limit allowable prices for drugs to a function of an average international reference price that may be substantially lower than what we currently or would otherwise charge. In certain foreign markets, pricing or profitability of prescription pharmaceuticals is subject to government control. We expect that the health care reform measures that have been adopted in the United States and in foreign markets, and further reforms that may be adopted in the future, could result in more rigorous coverage criteria and additional downward pressure on the prices that we may receive for our approved products. If reimbursement for our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be materially harmed, including by our revenue potentially being materially adversely affected and our research and development efforts potentially being materially curtailed or, in some cases, ceasing. There may be future changes that result in reductions in current prices, coverage and reimbursement levels for our current or any future approved products, and we cannot predict the scope of any future changes or the impact that those changes would have on our operations.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The consequences of the COVID-19 Pandemic, including the economic effect on government budgets in the U.S. and elsewhere, may accelerate any of the healthcare reform efforts described above or result in future reform efforts, any of which could have adverse effects on our business, including higher costs for us, lower reimbursement rates for our products and lower demand for our products.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If third parties institute high co-payment amounts or other benefit limits for our products, the demand for our products and, accordingly, our revenues and results of operations, could be adversely affected. Our patient assistance programs have provided support for non-profit organizations that provide financial assistance to eligible patients or in some cases have provided our products without charge to patients who have no or limited insurance coverage through these charitable organizations. &#160;Substantial support in this manner could harm our profitability in the future. Further, those organizations&#8217; ability to provide assistance to patients is dependent on funding from external sources, and we cannot guarantee that such funding will be provided at adequate levels, or at all. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, if we become the subject of any governmental or other regulatory hearing or investigation with respect to the pricing of our products or other business practices, we could incur significant expenses and could be distracted from the operation of our business and execution of our business strategy. Any such hearing or investigation could also result in significant negative publicity and harm to our reputation, reduced market acceptance and demand, which could adversely affect our financial results and growth prospects. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Third-party payors are increasingly challenging the prices charged for medical products and services. Also, the trend toward managed health care in the United States, the organizations for which could control or significantly influence the purchase of health care services and products, as well as legislative and regulatory proposals to reform health care or reduce government insurance programs, may all result in lower prices for or rejection of our products. Adoption of our products by the medical community may be limited without adequate reimbursement for those products. Cost control </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">initiatives may decrease coverage and payment levels for our products and, in turn, the price that we will be able to charge for any product. Our products may not be considered cost-effective, and coverage and reimbursement may not be available or sufficient to allow us to sell our products on a profitable basis. We are unable to predict all changes to the coverage or reimbursement methodologies that will be applied by private or government payors to our current and any future approved products.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The continuing efforts of legislatures, health agencies and third-party payors to contain or reduce the costs of health care, any denial of private or government payor coverage or inadequate reimbursement for our drug candidates could materially and adversely affect our business strategy, operations, future revenues and profitability, and the future revenues and profitability of our potential customers, suppliers, collaborators and licensees and the availability of capital. &#160;The same risks apply to our compounds developed and marketed by our collaborators, and our future potential milestone and royalty revenues could be affected in a similar manner.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We depend on our collaborators and licensees for the future development and commercialization of some of our drug candidates. Conflicts may arise between our collaborators and licensees and us, or our collaborators and licensees may choose to terminate their agreements with us, which may adversely affect our business.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have licensed to Novartis rights to ruxolitinib outside of the United States and worldwide rights to our MET inhibitor compounds and licensed to Lilly worldwide rights to baricitinib. In addition, we have licensed to Innovent and to Zai Lab certain Asian rights to some of our clinical stage compounds. &#160;Under the terms of our agreements with these collaborators, we have no or limited control over the further clinical development of these drug candidates in the relevant territories and any revenues we may receive if these drug candidates receive regulatory approval and are commercialized in the relevant territories will depend primarily on the development and commercialization efforts of others. While OLUMIANT was approved by the European Commission in February 2017 for the treatment of moderate-to-severe rheumatoid arthritis in adult patients and by Japan&#8217;s Ministry of Health, Labor and Welfare in July 2017 for the treatment of rheumatoid arthritis in patients with inadequate response to standard-of-care therapies, the NDA for OLUMIANT for the treatment of moderate-to-severe rheumatoid arthritis was approved in June 2018, and only in the lower dosage tablet and with a warning label. &#160;Delays in any marketing approval by the FDA, European or other regulatory authorities, or any label modifications or restrictions in connection with any such approval, or the existence of other risks relating to approved drug products, including those described under &#8220;Risks Relating to Commercialization of Our Products,&#8221; could delay the receipt of and reduce resulting potential royalty and milestone revenue from baricitinib or any of our other out-licensed drug candidates. &#160; </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Conflicts may arise with our collaborators and licensees if they pursue alternative technologies or develop alternative products either on their own or in collaboration with others as a means for developing treatments for the diseases that we have targeted. Competing products and product opportunities may lead our collaborators and licensees to withdraw their support for our drug candidates. Any failure of our collaborators and licensees to perform their obligations under our agreements with them or otherwise to support our drug candidates could negatively impact the development of our drug candidates, lead to our loss of potential revenues from product sales and milestones and delay our achievement, if any, of profitability. Additionally, conflicts may arise if, among other things, there is a dispute about the achievement and payment of a milestone amount or the ownership of intellectual property that is developed during the course of a collaborative relationship.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our existing collaborative and license agreements can be terminated by our collaborators and licensees for convenience, among other circumstances. If any of our collaborators or licensees terminates its agreement with us, or terminates its rights with respect to certain indications or drug candidates, we may not be able to find a new collaborator for them, and our business could be adversely affected. Should an agreement be terminated before we have realized the benefits of the collaboration or license, our reputation could be harmed, we may not obtain revenues that we anticipated receiving, and our business could be adversely affected.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The success of our drug discovery and development efforts may depend on our ability to find suitable collaborators to fully exploit our capabilities. If we are unable to establish collaborations or if these future collaborations are unsuccessful in the development and commercialization of our drug candidates, our research, development and commercialization efforts may be unsuccessful, which could adversely affect our results of operations and financial condition.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An element of our business strategy is to enter into collaborative or license arrangements with other parties, under which we license our drug candidates to those parties for development and commercialization or under which we study our drug candidates in combination with other parties&#8217; compounds or biologics. For example, in addition to our Novartis, Lilly, Innovent and Zai Lab collaborations, we have entered into clinical study relationships with respect to several of our programs, including epacadostat, and are evaluating strategic relationships with respect to several of our other programs. However, because collaboration and license arrangements are complex to negotiate, we may not be successful in our attempts to establish these arrangements. Also, we may not have drug candidates that are desirable to other parties, or we may be unwilling to license a drug candidate to a particular party because such party interested in it is a competitor or for other reasons. The terms of any such arrangements that we establish may not be favorable to us. Alternatively, potential collaborators may decide against entering into an agreement with us because of our financial, regulatory or intellectual property position or for scientific, commercial or other reasons. If we are not able to establish collaboration or license arrangements, we may not be able to develop and commercialize a drug product, which could adversely affect our business and our revenues.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We will likely not be able to control the amount and timing of resources that our collaborators or licensees devote to our programs or drug candidates. If our collaborators or licensees prove difficult to work with, are less skilled than we originally expected, do not devote adequate resources to the program, are unable to obtain regulatory approval of our drug candidates, pursue alternative technologies or develop alternative products, or do not agree with our approach to development or manufacturing of the drug candidate, the relationship could be unsuccessful. Our collaborations with respect to epacadostat involved the study of our collaborators&#8217; drugs used in combination with epacadostat on a number of indications or tumor types, many of which were the same across multiple collaborations. We cannot assure you that potential conflicts will not arise or be alleged among these collaborations. If a business combination involving a collaborator or licensee and a third-party were to occur, the effect could be to terminate or cause delays in development of a drug candidate.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to enter into additional licensing agreements or if these arrangements are unsuccessful, our business and operations might be adversely affected.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In addition to establishing collaborative or license arrangements under which other parties license our drug candidates for development and commercialization or under which we study our drug candidates in combination with such parties&#8217; compounds or biologics, we may explore opportunities to develop our clinical pipeline by in-licensing drug candidates or therapeutics targets that fit within our focus on oncology, such as our collaborations with Agenus Inc., Calithera Biosciences, Inc., MacroGenics, Inc., Merus N.V., MorphoSys AG, and Syros Pharmaceuticals, Inc., or explore additional opportunities to further develop and commercialize existing drug candidates in specific jurisdictions, such as our June 2016 acquisition of the development and commercialization rights to ICLUSIG in certain countries. We may be unable to enter into any additional in-licensing agreements because suitable drug candidates that are within our expertise may not be available to us on terms that are acceptable to us or because competitors with greater resources seek to in-license the same drug candidates. Drug candidates that we would like to develop or commercialize may not be available to us because they are controlled by competitors who are unwilling to license the rights to the drug candidate to us. In addition, we may enter into license agreements that are unsuccessful and our business and operations might be adversely affected if we are unable to realize the expected economic benefits of a collaboration or other licensing arrangement, by the termination of a drug candidate and termination and winding down of the related license agreement, or due to other business or regulatory issues, including financial difficulties, that may adversely affect a licensor&#8217;s ability to continue to perform its obligations under an in-license agreement. For example, we may make or incur contractual obligations to make significant upfront payments in connection with licenses for late-stage drug candidates, such as we recently did in entering into a collaboration agreement with MorphoSys in January 2020, and if any of those drug candidates do not receive marketing approval as anticipated or we have to fund additional clinical trials before marketing approval can be obtained, we will have expended significant funds that might otherwise be applied for other uses or have to expend funds that were </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">not otherwise budgeted or anticipated in connection with the collaboration, and such developments could have a material adverse effect on our stock price and our ability to pursue other transactions. As discussed above under &#8220;We depend on our collaborators and licensees for the future development and commercialization of some of our drug candidates. Conflicts may arise between our collaborators and licensees and us, or our collaborators and licensees may choose to terminate their agreements with us, which may adversely affect our business,&#8221; conflicts or other issues may arise with our licensors. Those conflicts could result in delays in our plans to develop drug candidates or result in the expenditure of additional funds to resolve those conflicts that could have an adverse effect on our results of operations. We may also need to license drug delivery or other technology in order to continue to develop our drug candidates. If we are unable to enter into additional agreements to license drug candidates, drug delivery technology or other technology or if these arrangements are unsuccessful, our research and development efforts could be adversely affected.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if a drug candidate that we develop receives regulatory approval, we may decide not to commercialize it if we determine that commercialization of that product would require more money and time than we are willing to invest.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if any of our drug candidates receives regulatory approval, it could be subject to post-regulatory surveillance, and may have to be withdrawn from the market or subject to restrictions if previously unknown problems occur. Regulatory agencies may also require additional clinical trials or testing, and the drug product may be recalled or may be subject to reformulation, additional studies, changes in labeling, warnings to the public and negative publicity. As a result, we may not continue to commercialize a product even though it has obtained regulatory approval. Further, we may decide not to continue to commercialize a product if the market does not accept the product because it is too expensive or because third parties such as insurance companies or Medicare, have not approved it for substantial reimbursement. In addition, we may decide not to continue to commercialize a product if competitors develop and commercialize similar or superior products or have proprietary rights that preclude us from ultimately marketing our products.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Any approved drug product that we bring to the market may not gain market acceptance by physicians, patients, healthcare payors and others in the medical community.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if we or our collaborators are successful in gaining regulatory approval of any of our drug candidates in addition to JAKAFI, OLUMIANT and PEMAZYRE or acquire rights to approved drug products in addition to ICLUSIG, we may not generate significant product revenues if these drug products do not achieve an adequate level of acceptance. Physicians may not recommend our or our collaborators&#8217; drug products until longer-term clinical data or other factors demonstrate the safety and efficacy of our or our collaborators&#8217; drug products as compared to other alternative treatments. Even if the clinical safety and efficacy of our or our collaborators&#8217; drug products is established, physicians may elect not to prescribe these drug products for a variety of reasons, including the reimbursement policies of government and other third-party payors and the effectiveness of our or our collaborators&#8217; competitors in marketing their products.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Market acceptance of our drug products, if approved for commercial sale, will depend on a number of factors, including the following, and market acceptance of our collaborators&#8217; drug products will depend on similar factors:</p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the willingness and ability of patients and the healthcare community to use our drug products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the ability to manufacture our drug products in sufficient quantities that meet all applicable quality standards and to offer our drug products for sale at competitive prices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the perception of patients and the healthcare community, including third-party payors, regarding the safety, efficacy and benefits of our drug products compared to those of competing products or therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the label and promotional claims allowed by the FDA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the pricing and reimbursement of our drug products relative to existing treatments; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">marketing and distribution support for our drug products.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have limited capacity to conduct preclinical testing and clinical trials, and our resulting dependence on other parties could result in delays in and additional costs for our drug development efforts.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have limited internal resources and capacity to perform preclinical testing and clinical trials. As part of our development strategy, we often hire clinical research organizations, or CROs, to perform preclinical testing and clinical trials for drug candidates. If the CROs that we hire to perform our preclinical testing and clinical trials do not meet deadlines, do not follow proper procedures, or a conflict arises between us and our CROs, our preclinical testing and clinical trials may take longer than expected, may cost more, may be delayed or may be terminated. If we were forced to find a replacement entity to perform any of our preclinical testing or clinical trials, we may not be able to find a suitable entity on favorable terms, or at all. Even if we were able to find another company to perform a preclinical test or clinical trial, the delay in the test or trial may result in significant additional expenditures. Events such as these may result in delays in our obtaining regulatory approval for our drug candidates or our ability to commercialize our products and could result in increased expenditures that would adversely affect our operating results.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We face significant competition for our drug discovery and development efforts, and if we do not compete effectively, our commercial opportunities will be reduced or eliminated.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. Our drug discovery and development efforts may target diseases and conditions that are already subject to existing therapies or that are being developed by our competitors, many of which have substantially greater resources, larger research and development staffs and facilities, more experience in completing preclinical testing and clinical trials, and formulation, marketing and manufacturing capabilities. As a result of these resources, our competitors may develop drug products that render our products obsolete or noncompetitive by developing more effective drugs, developing their products more efficiently or pricing their products more competitively. Our ability to develop competitive products would be limited if our competitors succeeded in obtaining regulatory approvals for drug candidates more rapidly than we were able to or in obtaining patent protection or other intellectual property rights that limited our drug development efforts. Any drug products resulting from our research and development efforts, or from our joint efforts with collaborators or licensees, might not be able to compete successfully with our competitors&#8217; existing and future products, or obtain regulatory approval in the United States or elsewhere. The development of products or processes by our competitors with significant advantages over those that we are developing could harm our future revenues and profitability.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our reliance on other parties to manufacture our drug products and drug candidates could result in a short supply of the drugs, delays in clinical trials or drug development, increased costs, and withdrawal or denial of a regulatory authority&#8217;s approval.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not currently operate manufacturing facilities for clinical or commercial production of JAKAFI, PEMAZYRE and our other drug candidates or for ICLUSIG. We currently hire third parties to manufacture the raw materials, active pharmaceutical ingredient, or API, and finished drug product of JAKAFI, ICLUSIG, PEMAZYRE and our other drug candidates for clinical trials. &#160;In addition, we expect to continue to rely on third parties for the manufacture of commercial supplies of raw materials, API and finished drug product for any drugs that we successfully develop. We also hire third parties to package and label the finished product. The FDA requires that the raw materials, API and finished product for JAKAFI, PEMAZYRE and our other drug candidates be manufactured according to its current Good Manufacturing Practices regulations and regulatory authorities in other countries have similar requirements. There are only a limited number of manufacturers that comply with these requirements. Failure to comply with current Good Manufacturing Practices and the applicable regulatory requirements of other countries in the manufacture of our drug candidates and products could result in the FDA or a foreign regulatory authority halting our clinical trials, withdrawing or denying regulatory approval of our drug product, enforcing product recalls or other enforcement actions, which could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We may not be able to obtain sufficient quantities of our drug candidates or any drug products we may develop if our designated manufacturers do not have the capacity or capability to manufacture them according to our schedule and specifications. Manufacturers of pharmaceutical products often encounter difficulties in production, especially in scaling up initial production. These problems include difficulties with production costs and yields, quality control and assurance and shortages of qualified personnel. &#160;To the extent our supply chain involves parties in China or materials originating in </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">areas of China that are or could be affected by disease outbreaks such as the COVID-19 Pandemic in 2020, we could see disruptions to our supply chain. Currently, our supply chain for our drug products and product candidates depends on operations by us and by other companies in multiple countries around the world, and the effects of the COVID-19 Pandemic or any or all of these countries is uncertain and unpredictable and potential disruption is possible. And, for JAKAFI, while our strategy is to maintain a 24 months stock of API, inclusive of finished product, ruxolitinib phosphate might be used by us either to make JAKAFI or for ruxolitinib drug candidates in clinical trials. In addition, we may not be able to arrange for our drug candidates or any drug products that we may develop to be manufactured by one of these parties on reasonable terms, if at all. &#160;We generally have a single source or a limited number of suppliers that are qualified to supply each of the API and finished product of JAKAFI, ICLUSIG, PEMAZYRE and our other drug candidates and, in the case of JAKAFI, we only have a single source for its raw materials. If any of these suppliers were to become unable or unwilling to supply us with raw materials, API or finished product that complies with applicable regulatory requirements, we could incur significant delays in our clinical trials or interruption of commercial supply that could have a material adverse effect on our business. If we have promised delivery of a drug candidate or drug product and are unable to meet the delivery requirement due to manufacturing difficulties, our development programs could be delayed, we may have to expend additional sums in order to ensure that manufacturing capacity is available when we need it even if we do not use all of the manufacturing capacity, and our business and operating results could be harmed.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may not be able to adequately manage and oversee the manufacturers we choose, they may not perform as agreed or they may terminate their agreements with us. Foreign manufacturing approval processes typically include all of the risks associated with the FDA approval process for manufacturing and may also include additional risks.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A number of our collaborations involve the manufacture of antibodies. Either we or our collaborators have primary responsibility for manufacturing activities, and we are currently using third-party contract manufacturing organizations. Manufacturing antibodies and products containing antibodies is a more complex process than manufacturing small molecule drugs and subject to additional risks. The process of manufacturing antibodies and products containing antibodies is highly susceptible to product loss due to contamination, equipment failure or improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics, and difficulties in scaling up the production process. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our activities, and the activities of our collaborators, partners and third-party providers, are subject to extensive government regulation and oversight both in the United States and in foreign jurisdictions. The FDA and comparable agencies in other jurisdictions directly regulate many of our most critical business activities, including the conduct of preclinical and clinical studies, product manufacturing, advertising and promotion, product distribution, adverse event reporting and product risk management. States increasingly have been placing greater restrictions on the marketing practices of healthcare companies and have instituted pricing disclosure and other requirements for companies selling pharmaceuticals. In addition, pharmaceutical and biotechnology companies have been the target of lawsuits and investigations alleging violations of government regulations, including claims asserting submission of incorrect pricing information, improper promotion of pharmaceutical products, payments intended to influence the referral of federal or state healthcare business, submission of false claims for government reimbursement, antitrust violations, violations of the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act and similar anti-bribery or anti-corruption laws, or violations related to environmental matters. There is also enhanced scrutiny of company-sponsored patient assistance programs, including insurance premium and co-pay assistance programs and donations to third-party charities that provide such assistance. In December 2018, we received a civil investigative demand from the U.S. Department of Justice for documents and information relating to our speaker programs and patient assistance programs, including our support of non-profit organizations that provide financial assistance to eligible patients. Violations of governmental regulation by us, our vendors or donation recipients may be punishable by criminal and civil sanctions, including damages, fines and penalties and exclusion from participation in government programs, including Medicare and Medicaid. In addition to damages, fines and penalties for violation of laws and regulations, we could be required to repay amounts we received from government </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">payors, or pay additional rebates and interest if we are found to have miscalculated the pricing information we have submitted to the government. Actions taken by federal or local governments, legislative bodies and enforcement agencies with respect to these legal and regulatory compliance matters could also result in reduced demand for our products, reduced coverage of our products by health care payors, or both. We cannot ensure that our compliance controls, policies, and procedures will in every instance protect us from acts committed by our employees, collaborators, partners or third-party providers that would violate the laws or regulations of the jurisdictions in which we operate. Whether or not we have complied with the law, an investigation into alleged unlawful conduct could increase our expenses, damage our reputation, divert management time and attention and adversely affect our business. Risks relating to compliance with laws and regulations may be heightened as we continue to expand our global operations and enter new therapeutic areas with different patient populations, which due to different product distribution methods, marketing programs or patient assistance programs may result in additional regulatory burdens and obligations.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The illegal distribution and sale by third parties of counterfeit or unfit versions of our or our collaborators&#8217; products or stolen products could harm our business and reputation.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are aware that counterfeit versions of our products have been distributed or sold by entities not authorized by us using product packaging suggesting that the product was provided by us. If unauthorized third parties illegally distribute and sell counterfeit versions of our or our collaborators&#8217; products, those products may not meet our or our collaborators&#8217; rigorous manufacturing, distribution and handling standards. In addition, inventory that is stolen from warehouses, plants or while in-transit, and that is subsequently improperly stored and sold through unauthorized channels, may not meet our or our collaborators&#8217; distribution and handling standards. A patient who receives a counterfeit or unfit drug may suffer dangerous health consequences. &#160;Our reputation and business could suffer harm as a result of counterfeit or unfit drugs sold under our brand name and could result in lost sales for us and decreased revenues. If counterfeit or unfit drugs are sold under our or our collaborators&#8217; brand names, our reputation and business could suffer harm and we could experience decreased royalty revenues. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">As most of our drug discovery and development operations are conducted at our headquarters in Wilmington, Delaware, the loss of access to this facility would negatively impact our business.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our facility in Wilmington, Delaware is our headquarters and is also where we conduct most of our drug discovery, research, development and marketing activities. In addition, natural disasters, the effects of or measures taken to limit the effects of health epidemics such as the COVID-19 Pandemic, or actions of activists opposed to aspects of pharmaceutical research may disrupt our experiments or our ability to access or use our facility. The loss of access to or use of our Wilmington, Delaware facility, either on a temporary or permanent basis, would result in an interruption of our business and, consequently, would adversely affect our overall business.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We depend on key employees in a competitive market for skilled personnel, and the loss of the services of any of our key employees or our inability to attract and retain additional personnel would affect our ability to expand our drug discovery and development programs and achieve our objectives.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are highly dependent on the members of our executive management team and principal members of our commercial, development, medical, operations and scientific staff. We experience intense competition for qualified personnel. Our future success also depends in part on the continued service of our executive management team and key personnel and our ability to recruit, train and retain essential personnel for our drug discovery and development programs, and for our medical affairs and commercialization activities. If we lose the services of any of these people or if we are unable to recruit sufficient qualified personnel, our research and product development goals, and our commercialization efforts could be delayed or curtailed. We do not maintain &#8220;key person&#8221; insurance on any of our employees.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to manage our growth effectively, our ability to develop and commercialize products could suffer.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We expect that if our drug discovery efforts continue to generate drug candidates, our clinical drug candidates continue to progress in development, and we continue to build our development, medical and commercial organizations, we will require significant additional investment in personnel, management and resources. Our ability to achieve our research, development and commercialization objectives depends on our ability to respond effectively to these demands </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">and expand our internal organization, systems, controls and facilities to accommodate additional anticipated growth. If we are unable to manage our growth effectively, our business could be harmed and our ability to execute our business strategy could suffer.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may acquire businesses or assets, form joint ventures or make investments in other companies that may be unsuccessful, divert our management&#8217;s attention and harm our operating results and prospects.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As part of our business strategy, we may pursue additional acquisitions of what we believe to be complementary businesses or assets or seek to enter into joint ventures. We also may pursue strategic alliances in an effort to leverage our existing infrastructure and industry experience to expand our product offerings or distribution, or make investments in other companies. For example, in June 2016, we completed the acquisition of the European operations of ARIAD. The success of our acquisitions, joint ventures, strategic alliances and investments will depend on our ability to identify, negotiate, complete and, in the case of acquisitions, integrate those transactions and, if necessary, obtain satisfactory debt or equity financing to fund those transactions. &#160;We may not realize the anticipated benefits of any acquisition, joint venture, strategic alliance or investment. We may not be able to integrate acquisitions successfully into our existing business, achieve planned synergies or cost savings, maintain the key business relationships of businesses we acquire, or retain key personnel of an acquired business, and we could assume unknown or contingent liabilities or incur unanticipated expenses. Integration of acquired companies or businesses also may require management resources that otherwise would be available for ongoing development of our existing business. Any acquisitions or investments made by us also could result in significant write-offs or the incurrence of debt and contingent liabilities, any of which could harm our operating results. For example, as recently as the three months ended March 31, 2020, we recorded unrealized losses related to all of our investments in our collaboration partners,<i style="font-style:italic;"> </i>and we may in the future experience additional losses related to our investments. &#160;In addition, if we choose to issue shares of our stock as consideration for any acquisition, dilution to our stockholders could result.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risks associated with the expansion of our operations outside of the United States could adversely affect our business.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our acquisition of ARIAD&#8217;s European operations significantly expanded our operations in Europe, and we plan to continue to expand our operations and conduct certain development activities outside of the United States. &#160;For example, as part of our plans to expand our activities outside of the United States, we now conduct some of our drug development activities in Japan and are in the process of opening an office in China. International operations and business expansion plans are subject to numerous additional risks, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">multiple, conflicting and changing laws and regulations such as tax laws, privacy regulations, tariffs, export and import restrictions, employment, immigration and labor laws, regulatory requirements, and other governmental approvals, permits and licenses, compliance with which can increase in complexity as we enter into additional jurisdictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">difficulties in staffing and managing operations in diverse countries and difficulties in connection with assimilating and integrating any operations and personnel we might acquire &#160;into our company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">risks associated with obtaining and maintaining, or the failure to obtain or maintain, regulatory approvals for the sale or use of our products in various countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">complexities associated with managing government payor systems, multiple payor-reimbursement regimes or patient self-pay systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">financial risks, such as longer payment cycles, difficulty obtaining financing in foreign markets, difficulty enforcing contracts and intellectual property rights, difficulty collecting accounts receivable and exposure to foreign currency exchange rate fluctuations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">general political and economic conditions in the countries in which we operate, including terrorism and political unrest, curtailment of trade and other business restrictions, and uncertainties associated with the future relationship between the United Kingdom and the European Union; </span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">public health risks, such as the spread globally of COVID-19 in 2020, and related effects on supply chain, travel and employee health and availability; and</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">regulatory and compliance risks that relate to maintaining accurate information and control over activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act, its books and records provisions or its anti-bribery provisions, or similar anti-bribery or anti-corruption laws and regulations in other countries, such as the U.K. Anti-Bribery Act and the U.K. Criminal Finances Act, which may have similarly broad extraterritorial reach.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any of the risks described above, if encountered, could significantly increase our costs of operating internationally, prevent us from operating in certain jurisdictions, or otherwise significantly harm our future international expansion and operations, which could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If product liability lawsuits are brought against us, we could face substantial liabilities and may be required to limit commercialization of our products and our results of operations could be harmed.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to the risks described above under &#8220;&#8212;Risks Relating to Commercialization of Our Products&#8212;If the use of our products harms patients, or is perceived to harm patients even when such harm is unrelated to our products, our regulatory approvals could be revoked or otherwise negatively impacted or we could be subject to costly and damaging product liability claims,&#8221; the conduct of clinical trials of medical products that are intended for human use entails an inherent risk of product liability. If any product that we or any of our collaborators or licensees develops causes or is alleged to cause injury during clinical trials or commercialization, we may be held liable. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities, including substantial damages to be paid to the plaintiffs and legal costs, or we may be required to limit further development and commercialization of our products. Additionally, any product liability lawsuit could cause injury to our reputation, participants and investigators to withdraw from clinical trials, and potential collaborators or licensees to seek other partners, any of which could impact our results of operations.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our product liability insurance policy may not fully cover our potential liabilities. In addition, we may determine that we should increase our coverage, and this insurance may be prohibitively expensive to us or our collaborators or licensees and may not fully cover our potential liabilities. Since December 30, 2017, we elected to self-insure a portion of our exposure to product liability risks through our wholly-owned captive insurance subsidiary, in tandem with third-party insurance policies. Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the development or commercialization of our drug candidates and products, and if our liabilities from any such claims exceed our third-party insurance limits and self-insurance reserves, our results of operations, cash flows and financial condition could be adversely impacted.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Because our activities involve the use of hazardous materials, we may be subject to claims relating to improper handling, storage or disposal of these materials that could be time consuming and costly.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are subject to various environmental, health and safety laws and regulations governing, among other things, the use, handling, storage and disposal of regulated substances and the health and safety of our employees. Our research and development processes involve the controlled use of hazardous and radioactive materials and biological waste resulting in the production of hazardous waste products. We cannot completely eliminate the risk of accidental contamination or discharge and any resultant injury from these materials. If any injury or contamination results from our use or the use by our collaborators or licensees of these materials, we may be sued and our liability may exceed our insurance coverage and our total assets. Further, we may be required to indemnify our collaborators or licensees against all damages and other liabilities arising out of our development activities or products produced in connection with these collaborations or licenses. Compliance with the applicable environmental and workplace laws and regulations is expensive. Future changes to environmental, health, workplace and safety laws could cause us to incur additional expense or may restrict our operations or impair our research, development and production efforts.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> RISKS RELATING TO OUR FINANCIAL RESULTS</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may incur losses in the future, and we expect to continue to incur significant expenses to discover and develop drugs, which may make it difficult for us to achieve sustained profitability on a quarterly or annual basis in the future.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> </span>Due to historical net losses, we had an accumulated deficit of $2.2&#160;billion as of March 31, 2020. We intend to continue to spend significant amounts on our efforts to discover and develop drugs. As a result, we may incur losses in future periods as well. &#160;Our revenues, expenses and net income (loss) may fluctuate, even significantly, due to the risks described in these &#8220;Risk Factors&#8221; and factors discussed in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; as well as the timing of charges and expenses that we may take, including those relating to transactions such as acquisitions and the entry into collaborative agreements. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We anticipate that our drug discovery and development efforts and related expenditures will increase as we focus on the studies, including preclinical tests and clinical trials prior to seeking regulatory approval, that are required before we can sell a drug product.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The development of drug products will require us to spend significant funds on research, development, testing, obtaining regulatory approvals, manufacturing and marketing. To date, we do not have any drug products that have generated significant revenues other than from sales of JAKAFI and we cannot assure you that we will generate significant revenues from the drug candidates that we license or develop, including ICLUSIG and PEMAZYRE, for several years, if ever.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We cannot be certain whether or when we will achieve sustained or increased profitability on a quarterly or annual basis because of the factors discussed above and the significant uncertainties relating to our ability to generate commercially successful drug products. Even if we are successful in obtaining regulatory approvals for manufacturing and commercializing drug products in addition to JAKAFI, ICLUSIG and PEMAZYRE, we may incur losses if our drug products do not generate significant revenues. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may need additional capital in the future. If we are unable to generate sufficient funds from operations, the capital markets may not permit us to raise additional capital at the time that we require it, which could result in limitations on our research and development or commercialization efforts or the loss of certain of our rights in our technologies or drug candidates.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our future funding requirements will depend on many factors and we anticipate that we may need to raise additional capital to fund our business plan and research and development efforts going-forward.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additional factors that may affect our future funding requirements include:</p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the amount of revenues generated from our business activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">any changes in the breadth of our research and development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the results of research and development, preclinical testing and clinical trials conducted by us or our current or future collaborators or licensees, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our exercise of any co-development options with collaborators that may require us to fund future development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the acquisition of businesses, technologies, or drug candidates, or the licensing of technologies or drug candidates, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">costs for future facility requirements;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our ability to maintain and establish new corporate relationships and research collaborations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">competing technological and market developments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the time and costs involved in filing, prosecuting, defending and enforcing patent and intellectual property claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the receipt of contingent licensing or milestone fees or royalties on product sales from our current or future collaborative and license arrangements, if established; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the timing of regulatory approvals, if any.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we require additional capital at a time when investment in companies such as ours, or in the marketplace generally, is limited due to the then prevailing market or other conditions, we may have to scale back our operations, eliminate one or more of our research or development programs, or attempt to obtain funds by entering into an agreement with a collaborator or licensee that would result in terms that are not favorable to us or relinquishing our rights in certain of our proprietary technologies or drug candidates. If we are unable to raise funds at the time that we desire or at any time thereafter on acceptable terms, we may not be able to continue to develop our drug candidates. The sale of equity or additional convertible debt securities in the future may be dilutive to our stockholders and may provide for rights, preferences or privileges senior to those of our holders of common stock, and debt financing arrangements may require us to pledge certain assets or enter into covenants that could restrict our operations or our ability to incur further indebtedness.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our marketable securities and long term investments are subject to risks that could adversely affect our overall financial position.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We invest our cash in accordance with an established internal policy and customarily in instruments, money market funds, US government backed-funds and Treasury assets, which historically have been highly liquid and carried relatively low risk. In recent periods, similar types of investments and money market funds have experienced losses in value or liquidity issues that differ from their historical pattern.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Should a portion of our cash or marketable securities lose value or have their liquidity impaired, it could adversely affect our overall financial position by imperiling our ability to fund our operations and forcing us to seek additional financing sooner than we would otherwise. Such financing, if available, may not be available on commercially attractive terms.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As discussed under &#8220;Other Risks Relating to Our Business&#8212; We may acquire businesses or assets, form joint ventures or make investments in other companies that may be unsuccessful, divert our management&#8217;s attention and harm our operating results and prospects,&#8221; any investments that we may make in companies with which we have strategic alliances, such as Agenus and Merus, could result in our recognition of losses on those investments. In addition, to the extent we may seek to sell or otherwise monetize those investments, we may not be able to do so at our desired price or valuation levels, or at all, due to the limited liquidity of some or all of those investments.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any loss in value of our long term investments could adversely affect our financial position on the consolidated balance sheets and consolidated statements of operations.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our current revenues are derived from JAKAFI and ICLUSIG product sales, JAKAVI and OLUMIANT product royalties, collaborations and from licensing our intellectual property. If we are unable to achieve milestones, develop products or renew or enter into new collaborations, our revenues may decrease, and future milestone and royalty payments may not contribute significantly to revenues for several years, and may never result in revenues.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We derived substantially all of our revenues for the three months ended March 31, 2020 from JAKAFI and ICLUSIG<span style="font-style:italic;font-weight:bold;"> </span>product revenues, JAKAVI and OLUMIANT product royalties and our collaborations and licensing our intellectual property to others. We may be unable to successfully commercialize PEMAZYRE and receive significant </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">revenues from its sales. Future revenues from research and development collaborations depend upon continuation of the collaborations, the achievement of milestones and royalties we earn from any future products developed from our research. If we are unable to successfully achieve milestones or our collaborators fail to develop successful products, we will not earn the future revenues contemplated under our collaborative agreements. &#160;For example, delays in or other limitations with respect to the approval of baricitinib in the United States for the treatment of moderate-to-severe rheumatoid arthritis, or the failure to obtain such approval, as discussed under &#8220;&#8212;We depend on our collaborators and licensees for the future development and commercialization of some of our drug candidates. Conflicts may arise between our collaborators and licensees and us, or our collaborators and licensees may choose to terminate their agreements with us, which may adversely affect our business.&#8221; would affect potential future royalty and milestone and contract revenue. In addition, our revenues are subject to foreign currency exchange rate fluctuations due to the global nature of our operations. To the extent that our non-U.S. source revenues represent a more significant portion of our total revenues, these fluctuations could materially affect our operating results.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">RISKS RELATING TO INTELLECTUAL PROPERTY AND LEGAL MATTERS</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are subject to arbitration, litigation and infringement claims, they could be costly and disrupt our drug discovery and development efforts.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The technology that we use to make and develop our drug products, the technology that we incorporate in our products, and the products we are developing may be subject to claims that they infringe the patents or proprietary rights of others. The success of our drug discovery and development efforts will also depend on our ability to develop new compounds, drugs and technologies without infringing or misappropriating the proprietary rights of others. We are aware of patents and patent applications filed in certain countries claiming intellectual property relating to some of our drug discovery targets and drug candidates. While the validity of issued patents, patentability of pending patent applications and applicability of any of them to our programs are uncertain, if any of these patents are asserted against us or if we choose to license any of these patents, our ability to commercialize our products could be harmed or the potential return to us from any product that may be successfully commercialized could be diminished.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time we have received, and we may in the future receive, notices from third parties offering licenses to technology or alleging patent, trademark, or copyright infringement, claims regarding trade secrets or other contract claims. Receipt of these notices could result in significant costs as a result of the diversion of the attention of management from our drug discovery and development efforts. Parties sending these notices may have brought and in the future may bring litigation against us or seek arbitration relating to contract claims.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may be involved in future lawsuits or other legal proceedings alleging patent infringement or other intellectual property rights or contract violations. In addition, litigation or other legal proceedings may be necessary to:</p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">assert claims of infringement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">enforce our patents or trademarks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">protect our trade secrets or know-how; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">determine the enforceability, scope and validity of the proprietary rights of others.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may be unsuccessful in defending or pursuing these lawsuits, claims or other legal proceedings. Regardless of the outcome, litigation or other legal proceedings can be very costly and can divert management&#8217;s efforts. An adverse determination may subject us to significant liabilities or require us or our collaborators or licensees to seek licenses to other parties&#8217; patents or proprietary rights. We or our collaborators or licensees may also be restricted or prevented from manufacturing or selling a drug or other product that we or they develop. Further, we or our future collaborators or licensees may not be able to obtain any necessary licenses on acceptable terms, if at all. If we are unable to develop non-infringing technology or license technology on a timely basis or on reasonable terms, our business could be harmed.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be unable to adequately protect or enforce our proprietary information, which may result in its unauthorized use, a loss of revenue under a collaboration agreement or loss of sales to generic versions of our products or otherwise reduce our ability to compete in developing and commercializing products.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our business and competitive position depends in significant part upon our ability to protect our proprietary technology, including any drug products that we create. Despite our efforts to protect this information, unauthorized parties may attempt to obtain and use information that we regard as proprietary. For example, one of our collaborators may disclose proprietary information pertaining to our drug discovery efforts. In addition, while we have filed numerous patent applications with respect to ruxolitinib and our drug candidates in the United States and in foreign countries, our patent applications may fail to result in issued patents. In addition, because patent applications can take several years to issue as patents, there may be pending patent applications of others that may later issue as patents that cover some aspect of ruxolitinib and our drug candidates. Our existing patents and any future patents we may obtain may not be broad enough to protect our products or all of the potential uses of our products, or otherwise prevent others from developing competing products or technologies. In addition, our patents may be challenged and invalidated or may fail to provide us with any competitive advantages if, for example, others were first to invent or first to file&#160;a patent application for the technologies and products covered by our patents. &#160;As noted above under &#8220;&#8212;Risks Relating to Commercialization of Our Products&#8212;Competition for our products could potentially harm our business and result in a decrease in our revenue,&#8221; a potential generic drug company competitor has challenged certain patents relating to JAKAFI.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, when we do not control the prosecution, maintenance and enforcement of certain important intellectual property, such as a drug candidate in-licensed to us or subject to a collaboration with a third-party, the protection of the intellectual property rights may not be in our hands. If we do not control the intellectual property rights in-licensed to us with respect to a drug candidate and the entity that controls the intellectual property rights does not adequately protect those rights, our rights may be impaired, which may impact our ability to develop, market and commercialize the in-licensed drug candidate.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our means of protecting our proprietary rights may not be adequate, and our competitors may:</p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">independently develop substantially equivalent proprietary information, products and techniques;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">otherwise gain access to our proprietary information; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">design around patents issued to us or our other intellectual property.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We pursue a policy of having our employees, consultants and advisors execute proprietary information and invention agreements when they begin working for us. However, these agreements may not provide meaningful protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosure. If we fail to maintain trade secret and patent protection, our potential future revenues may be decreased.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If the effective term of our patents is decreased due to changes in the United States patent laws or if we need to refile some of our patent applications, the value of our patent portfolio and the revenues we derive from it may be decreased.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The value of our patents depends, in part, on their duration. A shorter period of patent protection could lessen the value of our rights under any patents that we obtain and may decrease the revenues we derive from our patents. The United States patent laws provide a term of patent protection of 20&#160;years from the earliest effective filing date of the patent application. Because the time from filing to issuance of biotechnology applications may be more than three years depending on the subject matter, a 20-year patent term from the filing date may result in substantially shorter patent protection.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Additionally, United States patent laws were amended in 2011 with the enactment of the America Invents Act and third parties are now able to challenge the validity of issued U.S. patents through various review proceedings; thus rendering the validity of U.S. patents more uncertain. We may be obligated to participate in review proceedings to determine the validity of our U.S. patents. We cannot predict the ultimate outcome of these proceedings, the conduct of which could result in substantial costs and diversion of our efforts and resources. If we are unsuccessful in these proceedings some or all of our claims in the patents may be narrowed or invalidated and the patent protection for our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">products and drug candidates in the United States could be substantially shortened. Further, if all of the patents covering one of our products are invalidated, the FDA could approve requests to manufacture a generic version of that product prior to the expiration date of those patents.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other changes in the United States patent laws or changes in the interpretation of patent laws could diminish the value of our patents or narrow the scope of our patent protection. For example, the Supreme Court of the United States resolved a split among the circuit courts of appeals regarding antitrust challenges to settlements of patent infringement lawsuits under the Hatch-Waxman Act between brand-name drug companies and generic drug companies. The Court rejected the &#8220;scope of the patent&#8221; test and ruled that settlements involving &#8220;reverse payments&#8221; from brand-name drug companies to generic drug companies should be analyzed under the rule of reason. This ruling may create uncertainty and make it more difficult to settle patent litigation if a company seeking to manufacture a generic version of one of our products challenges the patents covering that product prior to the expiration date of those patents.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">International patent protection is particularly uncertain and costly, and our involvement in opposition proceedings in foreign countries may result in the expenditure of substantial sums and management resources.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Biotechnology and pharmaceutical patent law outside the United States is even more uncertain and costly than in the United States and is currently undergoing review and revision in many countries. Further, the laws of some foreign countries may not protect our intellectual property rights to the same extent as United States laws. For example, certain countries do not grant patent claims that are directed to the treatment of humans. We have participated, and may in the future participate, in opposition proceedings to determine the validity of our foreign patents or our competitors&#8217; foreign patents, which could result in substantial costs and diversion of our efforts. Successful challenges to our patent or other intellectual property rights through these proceedings could result in a loss of rights in the relevant jurisdiction and allow third parties to use our proprietary technologies without a license from us or our collaborators, which may also result in loss of future royalty payments. In addition, successful challenges may jeopardize or delay our ability to enter into new collaborations or commercialize potential products, which could harm our business and results of operations.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">RISKS RELATING TO INFORMATION TECHNOLOGY AND DATA PRIVACY </b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Significant disruptions of information technology systems, breaches of data security, or unauthorized disclosures of sensitive data or personally identifiable information or individually identifiable health information could adversely affect our business,</span> <span style="font-style:italic;font-weight:bold;">and could</span> <span style="font-style:italic;font-weight:bold;">subject us to liability or reputational damage. </span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our business is increasingly dependent on critical, complex, and interdependent information technology (IT) systems, including Internet-based systems, some of which are managed or hosted by third parties, to support business processes as well as internal and external communications. The size and complexity of our IT systems make us potentially vulnerable to IT system breakdowns, malicious intrusion, and computer viruses, which may result in the impairment of our ability to operate our business effectively. &#160;In addition, having a significant portion of our employees work from home due to the COVID-19 Pandemic can strain our information technology infrastructure, which may affect our ability to operate effectively, may make us more susceptible to communications disruptions, and expose us to greater cybersecurity risks.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We are continuously evaluating and, where appropriate, enhancing our IT systems to address our planned growth, including to support our planned manufacturing operations. There are inherent costs and risks associated with implementing the enhancements to our IT systems, including potential delays in access to, or errors in, critical business and financial information, substantial capital expenditures, additional administrative time and operating expenses, retention of sufficiently skilled personnel to implement and operate the enhanced systems, demands on management time, and costs of delays or difficulties in transitioning to the enhanced systems, any of which could harm our business and results of operations. In addition, the implementation of enhancements to our IT systems may not result in productivity improvements at a level that outweighs the costs of implementation, or at all. &#160;In addition, our systems and the systems of our third-party providers and collaborators are potentially vulnerable to data security breaches which may expose sensitive data to unauthorized persons or to the public. Such data security breaches could lead to the loss of confidential information, trade secrets or other intellectual property, could lead to the public exposure of personal information (including personally identifiable information or individually identifiable health information) of our employees, clinical trial patients, customers, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">business partners, and others, could lead to potential identity theft, or could lead to reputational harm. &#160;Data security breaches could also result in loss of clinical trial data or damage to the integrity of that data. In addition, the increased use of social media by our employees and contractors could result in inadvertent disclosure of sensitive data or personal information, including but not limited to, confidential information, trade secrets and other intellectual property.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any such disruption or security breach, as well as any action by us or our employees or contractors that might be inconsistent with the rapidly evolving data privacy and security laws and regulations applicable within the United States and elsewhere where we conduct business, could result in enforcement actions by U.S. states, the U.S. Federal government or foreign governments, liability or sanctions under data privacy laws, including healthcare laws such as HIPAA, that protect certain types of sensitive information, regulatory penalties, other legal proceedings such as but not limited to private litigation, the incurrence of significant remediation costs, disruptions to our development programs, business operations and collaborations, diversion of management efforts and damage to our reputation, which could harm our business and operations. Because of the rapidly moving nature of technology and the increasing sophistication of cybersecurity threats, our measures to prevent, respond to and minimize such risks may be unsuccessful.&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the European Parliament and the Council of the European Union has adopted a comprehensive general data privacy regulation, known as the GDPR, which governs the collection and use of personal data in the European Union. The GDPR, which is wide-ranging in scope, imposes several requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals, the security and confidentiality of the personal data, data breach notification and the use of third party processors in connection with the processing of the personal data. The GDPR also imposes strict rules on the transfer of personal data out of the European Union to the United States, provides an enforcement authority and imposes large penalties for noncompliance, including the potential for fines of up to &#8364;20 million or 4% of the annual global revenues of the infringer, whichever is greater. &#160;The GDPR and other similar laws or regulations enacted in the United States or other jurisdictions associated with the enhanced protection of certain types of sensitive data, including healthcare data or other personal information, may increase our costs of doing business, and the differing requirements of these laws and regulations can complicate our compliance efforts.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Increasing use of social media could give rise to liability, breaches of data security, or reputational damage.</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We and our employees are increasingly utilizing social media tools as a means of communication both internally and externally. Despite our efforts to monitor evolving social media communication guidelines and comply with applicable rules, there is risk that the use of social media by us or our employees to communicate about our products or business may cause us to be found in violation of applicable requirements. In addition, our employees may knowingly or inadvertently make use of social media in ways that may not comply with our social media policy or other legal or contractual requirements, which may give rise to liability, lead to the loss of trade secrets or other intellectual property, or result in public exposure of personal information of our employees, clinical trial patients, customers, and others. Furthermore, negative posts or comments about us or our products in social media could seriously damage our reputation, brand image, and goodwill.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_0138975e_0bd5_41ea_92ce_626ecfd02db3"></a><a id="Item6Exhibits_714670"></a><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 6.</b>&#160;&#160;<b style="font-weight:bold;">Exhibits</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:9.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:87.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit<br />Number</b></p></td><td style="vertical-align:bottom;width:3.02%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description&#160;of&#160;Document</b></p></td></tr><tr><td style="vertical-align:top;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="background-color:#ffff00;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><span style="background-color:#ffff00;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">10.1&#8224;*</p></td><td style="vertical-align:bottom;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><a href="incy-20200331xex10d1.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Collaboration and License Agreement entered into as of January 12, 2020, by and among the Company, MorphoSys AG and MorphoSys US Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">10.2*</p></td><td style="vertical-align:bottom;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><a href="incy-20200331xex10d2.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Amendment, dated as of March 20, 2020, to Collaboration and License Agreement entered into as of November 24, 2009, by and between the Company and Novartis International Pharmaceutical Ltd.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">31.1*</p></td><td style="vertical-align:bottom;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><a href="incy-20200331xex31d1.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Rule&#160;13a-14(a)&#160;Certification of Chief Executive Officer</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">31.2*</p></td><td style="vertical-align:bottom;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><a href="incy-20200331xex31d2.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Rule&#160;13a-14(a)&#160;Certification of Chief Financial Officer</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">32.1**</p></td><td style="vertical-align:bottom;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><a href="incy-20200331xex32d1.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Statement of the Chief Executive Officer under Section&#160;906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section&#160;1350)</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">32.2**</p></td><td style="vertical-align:bottom;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><a href="incy-20200331xex32d2.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Statement of the Chief Financial Officer under Section&#160;906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section&#160;1350)</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">101.INS*</p></td><td style="vertical-align:bottom;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;">XBRL Instance Document</p></td></tr><tr><td style="vertical-align:top;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">101.SCH*</p></td><td style="vertical-align:bottom;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;">XBRL Taxonomy Extension Schema Document</p></td></tr><tr><td style="vertical-align:top;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">101.CAL*</p></td><td style="vertical-align:bottom;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;">XBRL Taxonomy Extension Calculation Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">101.LAB*</p></td><td style="vertical-align:bottom;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;">XBRL Taxonomy Extension Label Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">101.PRE*</p></td><td style="vertical-align:bottom;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;">XBRL Taxonomy Presentation Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">101.DEF*</p></td><td style="vertical-align:bottom;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;">XBRL Taxonomy Definition Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</p></td></tr></table><div style="font-family:'Times New Roman';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:3.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:96.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;">*</p></td><td style="vertical-align:top;width:96.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;">Filed herewith.</p></td></tr><tr><td style="vertical-align:top;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:96.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;">**</p></td><td style="vertical-align:top;width:96.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;">In accordance with Item 601(b)(32)(ii)&#160;of Regulation S-K and SEC Release No.&#160;34-47986, the certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Form&#160;10-Q and will not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Exchange Act. Such certifications will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#8224;</p></td><td style="vertical-align:top;width:96.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Portions of this exhibit have been omitted pursuant to Item 601(b)(10(iv) of Regulation S-K.</p></td></tr><tr><td style="vertical-align:top;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:96.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:96.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_e56922ee_afc6_44da_b16c_ee4492053c21"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="SIGNATURES_656357"></a><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:4.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:45.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">INCYTE CORPORATION</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Dated: May 5, 2020</p></td><td style="vertical-align:top;width:4.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">/s/&#160;HERV&#201; HOPPENOT</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Herv&#233; Hoppenot</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Chairman, President, and Chief Executive Officer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Dated: May 5, 2020</p></td><td style="vertical-align:top;width:4.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">/s/&#160;CHRISTIANA STAMOULIS</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Christiana Stamoulis</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">(Principal Financial Officer)</p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>incy-20200331xex10d1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.6.0.116-->
<!--Created on: 5/5/2020 2:06:28 PM-->
<html>
	<head>
		<title>
			incy_Ex_10_1
		</title>
	</head>
	<body><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt 0pt 6pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Exhibit 10.1</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;font-style:italic;">Certain identified information, marked by [***], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed.&nbsp; </font>

		</p>

		<p style="margin:0pt -6.9pt 0pt 0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">EXECUTION VERSION</font>

		</p>

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">COLLABORATION AND LICENSE AGREEMENT</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">This collaboration and license agreement ("</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Agreement</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">") is made and entered into effective as of </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">January 12, 2020 </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(the "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Execution Date</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"), by and between</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">MorphoSys AG</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">, a German stock corporation having a place of business at Semmelweisstrasse 7, 82152 Planegg, Germany ("</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">MorphoSys AG</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"), and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">MorphoSys US Inc</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">., a Delaware corporation, wholly-owned by MorphoSys AG, having its place of business at 470 Atlantic Avenue, 14</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;font-size:6pt;top:-4pt;position:relative;line-height:100%">th</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> floor. Boston, &nbsp;MA 02210, USA ("</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">MorphoSys Inc.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"), (both MorphoSys AG and MorphoSys Inc., subject to Section 18.7, "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">MorphoSys</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">")</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">and</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Incyte Corporation</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">, a Delaware corporation with its principal place of business at 1801 Augustine Cut-Off, Wilmington, Delaware 19803, USA ("</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">COMPANY</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">").</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">MorphoSys and COMPANY each may be referred to herein individually as a "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Party</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">," or collectively as the "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Parties</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">."</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">RECITALS</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">MorphoSys has in-licensed from Xencor and further developed a humanized monoclonal antibody specifically binding to the target CD19 called </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">MOR208 </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">tafasitamab </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(as further defined herein).&nbsp;&nbsp;MorphoSys controls certain patents and other intellectual property pertaining to MOR208 and methods and uses relating thereto, including its use for the treatment of B cell malignancies and has been performing clinical and manufacturing development of MOR208;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">MorphoSys and COMPANY desire to establish a global collaboration for the further development and worldwide commercialization of MOR208; and</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Under such global collaboration COMPANY will have the exclusive commercialization rights outside of the US, and MorphoSys and COMPANY will have co-commercialization rights in the US.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">In the internal relationship between MorphoSys AG and MorphoSys Inc., both companies have arranged by way of an inter-company agreement their interactions inter alia with regard to this Agreement. Pursuant to this inter-company agreement, either MorphoSys AG and MorphoSys Inc. will perform the obligations and assert rights under this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">In consideration of the foregoing premises, the mutual promises and covenants set forth in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, MorphoSys and COMPANY hereby agree as follows:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">1</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-indent: -35.45pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DEFINITIONS</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">When used in this Agreement, capitalized terms shall have the meanings as defined below and throughout the Agreement. Unless the context indicates otherwise, the singular shall include the plural and the plural shall include the singular.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">ADCC</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means antibody-dependent cell-mediated cytotoxicity, which is an immune response, in which an Antibody coats a target-bearing cell and engages Fc receptors on immune effector cells and thereby activates the immune effector cells to lyse the target-bearing cells.&nbsp;&nbsp;For clarity, this is not restricted to effects mediated by natural killer cells, but includes e.g., other effector cells as well.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Affiliate</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means with respect to a Party, any entity that, directly or indirectly, through one or more intermediaries, controls, is controlled by or is under common control with such Party.&nbsp;&nbsp;For this purpose, "control" means the ownership of fifty percent (50%) or more of the voting securities entitled to elect the directors or management of the entity, or the actual power to elect or direct the management or policies of the entity, whether by law, contract or otherwise.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">ALL</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means acute lymphoblastic leukemia (including any line of treatment, including first line, second line and third line, and including relapsed/refractory forms). For clarity, any of the above forms or lines of therapy to treat acute lymphoblastic leukemia can achieve the milestone events as set out in Section 8.2.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Antibody</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means whether in nucleic acid or protein form, individually and collectively, any antibody, whether naturally occurring, artificially produced, raised in an artificial system, designed de novo, or created through modification of another antibody or otherwise; any fragment or fusion of any of the foregoing; and any chemically modified versions of the foregoing antibodies (including versions that are conjugated with another chemical entity, such as a drug or toxin; pegylated versions (regardless of whether containing amino acid substitutions in order to achieve pegylation or otherwise modified versions to enable half-life extension or other desirable properties), including versions that are chemically or genetically fused to another molecular entity, such as multispecific antibodies, and cytokine fusions; and other chemically or biologically modified versions).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Approval</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means, for the purpose of Section 8.2 only, with respect to any Regulatory Approval, a final or a conditional approval or an approval under exceptional circumstances of a MAA.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Autoimmune Indication</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D; means the treatment or prophylaxis of any autoimmune disease or condition (i.e. any disease or condition that is caused by dis-or de-regulation of the immune system leading to tissue injury by a reaction to an endogenous antigen but that is not primarily a malignant neoplasia).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">BLA</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means a Biologic License Application (as defined in the US Federal Food, Drug and Cosmetics Act and the regulations promulgated thereunder (21 C.F.R. &#xA7;&#xA7; 600-680) in the</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">2</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">US, submitted to the FDA that must be approved prior to importing, marketing and selling a biological product.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Breaching Party</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" has the meaning described in Section 17.2(a).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Broader Anti-CD19 Patents</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means the Xencor Background Patents listed in </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT&nbsp;3A</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Business Day</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means any day other than </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> Saturday or Sunday or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> any other day on which banks in Munich, Germany, Geneva, Switzerland or New York, New York in the US, are permitted or required to be closed.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Buy-In Party</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D; has the meaning described in Section 7.6(b).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Candidate-Specific Patents</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means the Xencor Background Patents listed in </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT&nbsp;3B</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">CDC</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means complement-dependent cytotoxicity.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">CDR</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means a complementarity determining region of an antibody.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">CD19</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means CD19 (Cluster of Differentiation 19) protein, which includes human and other species homologues.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">CFR</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means the Code of Federal Regulations (i.e. the codification of the general and permanent rules published in the Federal Register) published by the Federal Government of the United States of America.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Change of Control</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means with respect to a Party: </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> the sale of all or substantially all of such Party&#x2019;s assets or business relating to this Agreement; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> a merger, reorganization or consolidation involving such Party in which the voting securities of such Party outstanding immediately prior thereto cease to represent at least fifty percent (50%) of the combined voting power of the surviving entity as a consequence of such merger, reorganization or consolidation; or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">a person or entity, or group of persons or entities, acting in concert (other than financial investment groups that do not have as a primary business the development and/or commercialization of pharmaceutical products or companion diagnostics) acquire more than fifty percent (50%) of the voting equity securities or management control of such Party.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Clearance</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means with respect to this Agreement, the expiration or termination of all applicable waiting periods and requests for information (and any extensions thereof) under the HSR Act and any other antitrust laws and regulations applicable to this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">CLL</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means Chronic Lymphocytic Leukaemia (including any line of treatment, including first line, second line and third line, and including relapsed/refractory forms). For clarity, any of the above forms or lines of therapy to treat Chronic Lymphocytic Leukaemia can achieve the milestone events as set out in Section 8.2.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Co-Commercialization</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means the joint performance of the Commercialization activities and Medical Affairs Activities by the Parties with respect to the Licensed Antibody(ies) or Product(s) in the Co-Commercialization Territory, as further detailed in Section&nbsp;5.3.</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">3</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 0.05pt;text-indent: -0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Co-Commercialization Budget</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means the annual budget for the Co-Commercialization, agreed upon by the Parties through the JCC and approved by the JSC, which budget may be amended and/or supplemented from time to time by consensual agreement of the JCC and approval by the JSC and shall cover at least the upcoming [***] months at all times. An initial outline of the Co-Commercialization Budget is attached hereto as </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT 15</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 0.05pt;text-indent: -0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Co-Commercialization Costs</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means [***] incurred by the Parties in support of Co-Commercialization of Product(s) in the Co-Commercialization Territory in accordance with the Co-Commercialization Budget [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 0.05pt;text-indent: -0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Co-Commercialization Plan</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means the plan for the Co-Commercialization activities, agreed upon by the Parties through the JCC and approved by the JSC, which plan may be amended and/or supplemented from time to time by consensual agreement of the JCC and approval by the JSC and shall cover at least the upcoming [***] months at all times. An initial outline of the Co-Commercialization Plan is attached hereto as </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT&nbsp;14</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 0.05pt;text-indent: -0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Co-Commercialization Territory</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means the US.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Combination Product</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> any Product which contains one or more active ingredients in addition to any of the Licensed Antibody and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> any product package which includes one or more additional tools or products (which are not Products) in addition to a Product. For clarity, a bi-specific or multi-specific Antibody shall not be regarded as a Combination Product in the absence of any additional clinically active component other than the bi-specific Licensed Antibody or multi-specific Licensed Antibody, respectively. For further clarity, the Parties acknowledge that a Product comprising any Licensed Antibody that is conjugated or otherwise bound to a toxin or any other clinically active component shall not be regarded as a Combination Product in the absence of any clinically active component other than the Licensed Antibody or the clinically active component to which the Licensed Antibody is conjugated.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Commercial FTE Rate</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means, with respect to FTE costs,[***] US Dollars (USD [***]) per year for Co-Commercialization-related FTEs. [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Commercial Manufacturing Costs</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means the costs and expenses incurred [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.31&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Commercialize</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" or "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Commercialization</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means all activities directed to the Pre-Launch, launch, market access, patient support, booking sales, named patients programs, compassionate use programs, marketing, promotion, advertising, Detailing, selling and Distribution of a Product in a country or region, including planning, forecasting, market research, market insight, importing, exporting, and post-marketing safety surveillance and reporting and Pricing Activities, including US Government Price Calculations and Reporting obligations.&nbsp;&nbsp;For clarity, "Commercialization" shall not include any activities covering Manufacturing or Development or Regulatory Activities.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.32&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Commercialization Costs</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means the costs and expenses incurred by a Party [***]the Commercialization of the Product [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.33&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Commercially Reasonable Efforts</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.34&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">COMPANY Annual Development Report</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means, for each calendar year, the written report that describes COMPANY&#x2019;s past and planned Development activities for Licensed</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">4</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Antibody or Product in the Field for that year, and covers other subject matter as called for in Section 3.14(a).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.35&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;COMPANY Commercialization Plan</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means the plan for the Commercialization activities conducted by the COMPANY in the COMPANY Territory and discussed by the Parties through the JCC and JSC, which plan shall cover at least the upcoming [***] months at all times and be in line with the overall strategic Product positioning, branding, core messaging, and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">overall medical congress strategy and global </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">medical education strategy with respect to the global Commercialization in the Territory.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.36&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">COMPANY Discretionary Manufacturing Activities</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means those activities, which are related to the transfer, developing and implementing of the Manufacturing process for the Manufacturing of Products from [***] to a COMPANY manufacturing site or a Third Party manufacturing site, as initiated by COMPANY, including activities like technology transfer, development of test methods, stability testing, formulation development, process development, quality assurance activities, quality control activities, qualification and validation activities, analytic process development, manufacturing process validation, scale-up, and all other activities, including CMC-related activities and including activities to obtain Regulatory Approval.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.37&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">COMPANY Discretionary Manufacturing Activity Costs</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means the costs and expenses incurred by a Party [***] COMPANY Discretionary Manufacturing Activities. [***]</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.38&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">COMPANY Foreground Patents</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means any Patent claiming a COMPANY Invention.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.39&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">COMPANY Funded Development Activities</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> Development activities of COMPANY or its Affiliates (or Sublicensee(s) or subcontractor(s)) in the Field that are </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">NOT</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> directly attributable to, or reasonably allocable to the performance of a Global Trial or a MorphoSys Trial, including any Trial that is solely designed or required to obtain and maintain Regulatory Approval in a certain jurisdiction of the COMPANY Territory, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> COMPANY Discretionary Manufacturing Activities, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> activities related to changes in the Manufacturing process and the Regulatory Materials that are requested solely by a Regulatory Authority within the COMPANY Territory, and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iv)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> Independent Trials-related activities performed by or on behalf of COMPANY or its Affiliates (or Sublicensee(s) or subcontractor(s)) in the Field.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.40&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">COMPANY Invention</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means an Invention that is conceived solely by employees of COMPANY or Sublicensee or any of their respective Affiliates, or by employees of a Third Party under an obligation of assignment to COMPANY or an Affiliate or Sublicensee of COMPANY.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.41&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">COMPANY Know-How</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means all Know-How that COMPANY or its Affiliate Controls during the Term that relates to any Product, Licensed Antibody or a method of Developing, Manufacturing, using (including methods of administration and dosing regimens) or testing of (or in the case of testing, of or for the presence of) any of the foregoing (or any article necessary or useful to practice or use (including those present during the practice or use of) any such Product, Licensed Antibody or method.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.42&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">COMPANY Territory</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means the whole world except the Co-Commercialization Territory.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.43&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">COMPANY Trial</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means [***].</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">5</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.44&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Competing Product</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means any </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.45&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Confidential Information</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" has the meaning set forth in Section 16.1.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.46&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Controlled</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" or "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Control</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means, with respect to any Know-How, Patent, Invention or other intellectual property right, possession (by means of ownership or license) by a Party, directly or through an Affiliate (other than pursuant to this Agreement), where the Party has the right to grant a license or sublicense as provided for in this Agreement. Any Patent, Know-How or other intellectual property right that is licensed or acquired by a Party following the Execution Date and that would otherwise be considered to be under the Control of a Party shall not be deemed to be under the Control of such Party if the application of such definition in the context of any licenses or sublicenses granted to the other Party under this Agreement would require the granting Party to make any additional payments or royalties to a Third Party in connection with such license or sublicense grants, unless the other Party agrees to pay the additional payments or royalties to the Third Party.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.47&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Cover</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means, with respect to a particular item and a particular Patent, that such Patent claims (as opposed to merely disclosing) directly or indirectly: </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> the composition of such item, any of its ingredients or formulations or any product containing or that is made using such item (by virtue of such product containing or being made using such item); </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> a method of making or using any of the foregoing things referred to in (a); and/or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> an item used or present in the manufacture of any of the foregoing things referred to in (a) (for example, with respect to a biologic, any vector, plasmid or cell line used to manufacture such product or item or any ingredient in either of them), in each case of (a), (b) and (c) that provides market exclusivity for the Product.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.48&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Cure Period</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D; has the meaning set forth in Section 17.2(a).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.49&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Data Protection Laws</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D; means all data protection and privacy legislation in force from time to time including but not limited to the EU General Data Protection Regulation 2016/679, as nationally implemented and supplemented in the countries of the European Region, the Health Insurance Portability and Accountability Act of 1996, and any other federal, state or national legislation relating to Personal Data and privacy, which is applicable to a Party relating to the processing of Personal Data.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.50&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Data Room</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means the virtual data room designated [***] hosted by [***] under [***] which was prepared by MorphoSys and was available to COMPANY from, [***] in its latest version of that later date.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.51&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Designated JDC Officers</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" has the meaning set forth in Section 9.5(e).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.52&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Detail</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" or "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Detailing</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means an interactive face-to-face visit by a Sales Representative with a Healthcare Professional or healthcare provider having prescribing authority and who is within the target audience, during which approved uses, safety, effectiveness, contraindications, side effects, warnings, or other relevant characteristics of a pharmaceutical or biological product are discussed in an effort to increase prescribing preferences of a pharmaceutical or biological product for its approved uses. Details shall not include: </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> activities conducted by medical support staff; or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> e-details, activities conducted at conventions or similar gatherings, or activities performed by market development specialists, managed care account directors, and other personnel not performing face-to-face sales calls or not specifically trained with respect to a pharmaceutical or biological product.</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">6</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.53&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Detailing Costs</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means [***]</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.54&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Develop</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" or "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Development</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means all activities covering research, non-clinical, preclinical and Trials (including Trial recruitment and Trial site engagement), toxicology testing, companion diagnostics development, statistical analysis and reporting, all the aforementioned regarding the Licensed Antibody and/or the Product in any country or jurisdiction in the world in the Field and being necessary or reasonably useful or requested or required by a Regulatory Authority or as a condition or in support of obtaining or maintaining any or all Regulatory Approvals for the Licensed Antibody and/or Product in any country or jurisdiction in the world in the Field. For clarity, "Develop" and "Development" shall include Post-Marketing Authorization Trials that are required by or committed to Regulatory Authorities but shall not include any activities covering Commercialization or Manufacture or other Regulatory Activities.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.55&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Development Activities</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means activities by or on behalf of the Parties or their Affiliates (or their Sublicensee(s) or subcontractor(s)) with respect to the Development of the Licensed Antibody or Product in the Field, which are </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Joint Development Activities or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&nbsp;Sole Funded Development Activities.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.56&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Development Costs</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means [***] Development Costs shall exclude Commercialization Costs, Medical Affairs Activities Costs and Regulatory Costs. [***]</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.57&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Development Data</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means all non-clinical, clinical, technical, biochemical, safety, and scientific data and information and other results, including relevant laboratory notebook information, screening data, Regulatory Data and synthesis schemes, including descriptions in any form, data and other information, including GMP and GDP-related quality information, generated by or resulting from or in connection with the conduct of Joint Development Activities ("</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Joint Development Data</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">") or in connection with the conduct of any Sole Funded Development Activity ("</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Sole Funded Development Data</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">").</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.58&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Development FTE Rate</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means, with respect to FTE costs, [***] US Dollars (USD [***]) per year for Development, Manufacture, and Regulatory Activities-related FTEs. [***]</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.59&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Development Plan</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means the plan for the Development of the Product in the Field in the Territory agreed upon by the Parties through the JDC and approved by the JSC, which plan may be amended and/or supplemented from time to time by consensual agreement of the JDC and approval by the JSC and shall cover at least the upcoming [***] months at all times.&nbsp;&nbsp;An initial outline of the Development Plan is provided in </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT&nbsp;6</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> ("</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Development Plan Outline</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">").</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.60&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Disclosing Party</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" has the meaning set forth in Section 16.1.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.61&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Disclosure Schedule</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" has the meaning set forth in Section&nbsp;13.2.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.62&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Dispute</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" has the meaning set forth in Section18.3(a).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.63&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Distribution</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means all activities with respect to the Product covering the </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> handling, storage and transportation to fulfil orders; and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> interactions with wholesalers, specialty pharmacies, distributors and group purchasing organizations</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.64&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Distribute</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" shall have the correlative meaning.</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">7</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.65&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Distributor</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means, for the purposes of the [***] definition and Net Sales definition, any Third Party that is not granted a sublicense hereunder, but that </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> has been granted the right to Distribute or resell any quantities of Product, which quantities are provided by a Party or its Affiliates or its Sublicensee(s); </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> pays the Party or its Affiliate or its Sublicensee(s) a transfer price and assumes responsibility to resell in its name; and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> does not pay the Party or its Affiliate or its Sublicensee(s) a royalty calculated as a percentage of sales or net sales, and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(d)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> does not pay the Party or its Affiliate or its Sublicensee(s) any other consideration in connection with Licensed Antibody or Product.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.66&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">DLBCL</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means Diffuse Large B Cell Lymphoma (including any line of treatment, including first line, second line and third line, and including relapsed/refractory "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">R/R</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" forms). For clarity, any of the above forms or lines of therapy to treat Diffuse Large B Cell Lymphoma can achieve the milestone events as set out in Section 8.2.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.67&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Drug Product</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means the Product in its final dosage form filled in its designated primary containers (e.g. vials) but not labelled and not packed in the final secondary packaging.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.68&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Early Access Program</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means a program that gives patients access to the Product in a certain country or territory prior to Marketing Authorization grant, or where applicable, prior to Pricing Approval, of the Product in such country or territory and outside the framework of a Trial.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.69&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Effective Date</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" shall mean the first (1</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;font-size:6pt;top:-4pt;position:relative;line-height:100%">st</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">) Business Day following the date on which Clearance occurs.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.70&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">EMA</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means the European Medicines Agency or any successor agency thereto in the EU.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.71&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">European Major Market</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.72&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">European Region</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" &nbsp;means [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.73&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">European Union</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" or "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">EU</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.74&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Execution Date</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" shall mean the date set forth in the Introductory Clause of this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.75&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Existing Product Marks</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means the Product Marks owned by MorphoSys and existing at the Execution Date, which are listed in </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT&nbsp;12</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.76&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">External Costs</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means [***] external expenses (including [***]) [***] excluding [***] paid by a Party or its Affiliates to Third Parties for [***] To the extent such services are not attributable solely to Product, then only the respective pro rata amount, which shall be agreed between the Parties in good faith, for Product shall be regarded as External Cost.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.77&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">FDA</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means the United States Food and Drug Administration or any successor agency thereto in the US.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.78&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Field</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means all human and non-human diagnostic, prophylactic, therapeutic and palliative uses.</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">8</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.79&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Filing</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means, with respect to any Regulatory Approval, the submission to the respective Regulatory Authority of all necessary Regulatory Materials to apply for such Regulatory Approval.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.80&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Finished Drug Product</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means the Drug Product finally labelled and packaged for end-user use, as required for a Trial or for Commercialization, as applicable.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.81&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">First Commercial Sale</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means, with respect to any Product and country, the first sale of such Product in a country by COMPANY or its Affiliates or Sublicensees to any Third Party (other than a Sublicensee).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.82&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">First Position Detail</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D; means a Detail in which the applicable pharmaceutical product is Detailed before any other product and the predominant portion of time is devoted to the Detailing of such pharmaceutical product.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.83&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">FL</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means follicular lymphoma (including any line of treatment, including first line, second line and third line, and including relapsed/refractory forms). For clarity, any of the above forms or lines of therapy to treat Follicular Lymphoma can achieve the milestone events as set out in Section 8.2.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.84&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">FTE</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means the equivalent of one (1) full-time person working over a twelve (12) month period [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.85&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">GAAP</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means Generally Accepted Accounting Principles and can comprise International Financial Reporting Standards (IFRS) or US-GAAP, consistently applied</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.86&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">GCP</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means all applicable Good Clinical Practice standards for the design, conduct, performance, monitoring, auditing, recording, analyses and reporting of clinical trials, including, as applicable, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> as set forth in European Commission Directive 2001/20/EC relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use, and brought into Law by European Commission Directive 2005/28/EC laying down the principles and detailed guidelines for good clinical practice for investigational medicinal products, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> regulation 536/2014 of the European Parliament and of the council of 16 April 2014 on clinical trials on medicinal products for human use, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Harmonised Tripartite Guideline for Good Clinical Practice (CPMP/ICH/135/95) and any further addenda thereto and any other guidelines for good clinical practice for trials on medicinal products in the EU, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iv)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> the Declaration of Helsinki (2004) as last amended at the 64th World Medical Association in October 2013 and any further amendments or clarifications thereto, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(v)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> US Code of Federal Regulations Title 21, Parts 50 (Protection of Human Subjects), 56 (Institutional Review Boards) and 312 (Investigational New Drug Application), as may be amended from time to time, and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(vi)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> the equivalent Laws in any relevant country, each as may be amended and applicable from time to time and in each case that provide for, among other things, assurance that the clinical data and reported results are credible and accurate and protect the rights, integrity, and confidentiality of trial subjects.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.87&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Germany Co-Detailing Agreement</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D; has the meaning set forth in Section 2.4(d).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.88&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Global Branding</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" has the meaning set forth in Section 5.6(a)(i)(1).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.89&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Global Brand Strategy</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" has the meaning set forth in Section 5.6(a)(i)(2).</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">9</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.90&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Global Product Mark</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" has the meaning set forth in Section&nbsp;5.6(a)(iii) and includes the Existing Product Marks.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.91&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Global Trial</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" would mean a </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Trial, other than a MorphoSys Trial, that is required to obtain and/or maintain Regulatory Approvals in at least the Co-Commercialization Territory and possibly also other country(ies) within the COMPANY Territory, or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&nbsp;an investigator initiated Trial, which is conducted in at least the Co-Commercialization Territory and possibly also other country(ies) within the COMPANY Territory or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&nbsp;an Early Access Program based on a MorphoSys Trial or a Trial under (i) above, which is conducted in at least the Co-Commercialization Territory and possibly also other country(ies) within the COMPANY Territory. If any activity under each of (i), (ii) and (iii) above is a Non-NDA Study, such activity to be subject to approval under Section 9.2(e).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.92&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">GLP</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means all applicable Good Laboratory Practice standards, including, as applicable, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> as set forth in European Commission Directive 2004/10/EC relating to the application of the principles of good laboratory practices, as may be amended from time to time, as well as the OECD Series on Principles of Good Laboratory Practice, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> the then-current good laboratory practice standards promulgated or endorsed by the FDA as defined in 21 C.F.R. Part 58, and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> the equivalent Laws in any relevant country, each as may be amended and applicable from time to time.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.93&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">GMP</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means all applicable Good Manufacturing Practices including, as applicable, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> the applicable part of quality assurance to ensure that products are consistently produced and controlled in accordance with the quality standards appropriate for their intended use, as defined in European Commission Directive 2003/94/EC laying down the principles and guidelines of good manufacturing practice, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> the principles detailed in the US Current Good Manufacturing Practices, 21 C.F.R. Sections 210, 211, 601 and 610, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> the Rules Governing Medicinal Products in the European Community, Volume IV Good Manufacturing Practice for Medicinal Products, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iv)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> the principles detailed in the ICH Q7A guidelines, and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(v)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> the equivalent Laws in any relevant country, each as may be amended and applicable from time to time.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.94&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Governmental Authority</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means any multinational, supra-national, federal, state, local, municipal or other governmental authority of any nature (including any Regulatory Authority and any governmental association, division, prefecture, subdivision, department, agency, bureau, branch, office, commission, committee, council, court or other tribunal, such as statutory health insurance funds and their associations), in each case having jurisdiction over the applicable subject matter.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.95&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Government Official</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D; &nbsp;means </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> any officer, employee of a government or any department, agency or instrument of a government; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> any person acting in an official capacity for or on behalf of a government or any department, agency, or instrument of a government, including, for example, a Healthcare Professional employed by a public hospital or healthcare system; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> any officer or employee of a company or business owned in whole or part by a government; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(d)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> any officer or employee of a public international organization such as the World Bank or United Nations; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(e)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> any political party, officer or employee of a political party ,or any person acting in an official capacity on behalf of a political party; and/or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(f)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> any candidate or relative of any candidate for political office.</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">10</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.96&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Healthcare Professional</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D; &nbsp;means any member of the medical, pharmacy or nursing professions or any other person who in the course of his or her professional activities may prescribe, purchase, supply or administer a medicinal product.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.97&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">HSR Act</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules promulgated thereunder.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.98&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">HSR Filing Date</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" has the meaning defined in Section&nbsp;18.21(a).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.99&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">IND</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means an Investigational New Drug Application (as defined in the US Federal Food, Drug and Cosmetics Act and the regulations promulgated thereunder (21 C.F.R. &#xA7;312) in the US, a clinical trial application in Europe, or a comparable application or filing in any other jurisdiction (i.e., a filing with a Regulatory Authority or Ethics Committee that must be made prior to commencing clinical testing in humans).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.100&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Independent Trial</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means a Trial, which has not been agreed by the Parties to be a Global Trial as Joint Development Activity in accordance with Section&nbsp;3.5. For clarity, an Independent Trial may be conducted in countries in either or both the Co-Commercialization Territory and the COMPANY Territory, provided that </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">such Independent Trial has been reviewed and discussed in the JDC, (ii) any Non-NDA Study is subject to approval under Section 9.2(e), and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> such Independent Trial has been included into the Development Plan.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.101&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Indication</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D; means, with respect to a Product, a separate and distinct disease or medical condition that such Product is intended to treat, cure, mitigate, control, prevent, diagnose, monitor or ameliorate, as set forth in the Market Authorization Application or label for such Product, as applicable, for which such Product has received Regulatory Approval from the applicable Regulatory Authority. For clarity, DLBCL, FL, MCL, MZL, ALL and CLL shall be separate Indications. For the purpose of Section 8.2 only, the use of a Product to treat an expanded set of patients or a sub-population of patients for a disease or medical condition, when such Product has already received Regulatory Approval in a different patient population or sub-population of patients with respect to such disease or medical condition or line of therapy, shall not constitute a separate Indication with respect to such Product, except as specifically outlined [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.102&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Initial Know-How Transfer</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D; has the meaning set forth in Section 3.1.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.103&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Invention</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means any invention, discovery, improvement, technology or other Know-How (in each case, whether patentable or not) that is not existing as of the Execution Date and is invented or generated under this Agreement during the Term.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.104&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">JCC</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" has the meaning set forth in Section 9.7(a).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.105&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">JDC</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" has the meaning set forth in Section 9.5(a).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.106&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">JMC</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" has the meaning set forth in Section 9.6(a).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.107&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Joint Development Activities</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> any Global Trial(s) or MorphoSys Trial(s), including Development Activities directly attributable to, or reasonably allocable to the performance of a Global Trial or a MorphoSys Trial, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">establishment and maintenance of the global safety database (or safety databases, as applicable) and, until obtaining of first Regulatory Approval for Product in Territory, pharmacovigilance activities for the Product, and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> Manufacturing Development Activities; in each case undertaken by or on behalf of a Party</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">11</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">or its Affiliates (or their Sublicensee(s) or subcontractors) with respect to the Licensed Antibody or Product in the Field and, for activities carried out after the Execution Date, consistent with the applicable Development Plan. For the avoidance of doubt, Manufacturing (other than commercial supply), distribution and clinical supply of Product, as well as any combination or comparator products, for Development Activities directly attributable to, or reasonably allocable to the performance of a Global Trial or a MorphoSys Trial shall be regarded as Joint Development Activities.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.108&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Joint Development Budget</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" shall mean the annual budget for all Joint Development Costs in the applicable Development Plan as agreed through the JDC and approved by the JSC, which budget may be amended and/or supplemented from time to time by consensual agreement of the JDC and approval by the JSC and shall cover at least the upcoming [***] months at all times.&nbsp;&nbsp;An initial outline of the Joint Development Budget is provided in </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT&nbsp;7</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.109&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Joint Development Costs</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means the Development Costs incurred by a Party or its Affiliates directly attributable to, or reasonably allocable to Joint Development Activities, provided that such costs and expenses are consistent with the applicable Development Plan (including the Joint Development Budget contained therein). "Joint Development Costs" shall [***]. For clarity, Joint Development Costs shall exclude Medical Affairs Activities Costs, Regulatory Costs and Commercialization Costs.&nbsp;&nbsp;For the avoidance of doubt, to the extent costs are partly directly attributable to the Joint Development Activities and partly attributable to other activities of COMPANY or MorphoSys (in particular Sole Funded Development Activities), such costs shall constitute "Joint Development Costs" on a pro rata basis, which calculation shall be agreed between the Parties in good faith.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.110&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Joint Foreground Patents</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D; means all Patents claiming Joint Inventions.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.111&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Joint Invention</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means an Invention that is conceived jointly by employees of, or persons under an obligation of assignment to, MorphoSys and COMPANY.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.112&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">JSC</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" or "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Joint Steering Committee</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" shall have the meaning set forth in Section&nbsp;9.2(a).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.113&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Know-How</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> all information, techniques, data, inventions, practices, methods, processes, knowledge, know-how, skill, experience, technical data, test results (including pharmacological, toxicological, clinical, analytical and quality control data, regulatory submissions, correspondence and communications, and marketing, distribution, pricing, cost, manufacturing, patent and legal data or descriptions), and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> compositions of matter, assays, cell lines, vectors, plasmids and other materials, including Development Data.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.114&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Labelling and Packaging</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means labelling and packaging of the Drug Product, including insertion of materials such as patient inserts, patient medication guides, professional inserts and any other written, printed or graphic materials accompanying the Product considered to be part of the Finished Drug Product, and its handling, storage, quality control, quality assurance, testing and related activities of the Product in connection with the foregoing.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.115&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Laws</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means all laws, statutes, rules, regulations, directives, decisions, ordinances, guidelines and other pronouncements of any Governmental Authority.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.116&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Licensed Antibody</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">the humanized monoclonal antibody designated by MorphoSys as "MOR208" or &#x201C;tafasitamab&#x201D; or &#x201C;XmAb5574&#x201D; the amino acid sequence of which</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">12</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">is disclosed in </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT&nbsp;1</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> and/or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">all derivative, follow-on and backup molecules thereof in all cases owned or Controlled by MorphoSys on the Execution Date or during the Term, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&nbsp;all derivative, follow-on and backup molecules, invented jointly with COMPANY at any time during the Term to the extent not forbidden by the Xencor Agreement and/or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(d)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> any other anti-CD19 monoclonal antibodies owned or Controlled by MorphoSys as of the Execution Date or during the Term. &#x201C;Licensed Antibody&#x201D; excludes XmAb5871 and all Antibodies in the XmAb5871 Program.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.117&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Losses</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" has the meaning set forth in Section&nbsp;14.1.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.118&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">MAA</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means a Marketing Authorization application in the form of a BLA in the US, a MAA in Europe, a JNDA in Japan or a comparable filing or filing serving to apply for Marketing Authorization in any other regulatory jurisdiction.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.119&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">M&amp;A Event</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" has the meaning set forth in Section 18.1.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.120&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Manufacturing</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" or "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Manufacture</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means all activities related to the manufacturing of the Licensed Antibody or a Product (both whether finished or not) or a Placebo thereof, or a combination or comparator product, or any ingredient thereof, including manufacturing for clinical use or commercial sale, in-process and lot release testing, release, certification, filling, Labelling and Packaging, quality assurance activities related to such aforementioned manufacturing of the Licensed Antibody, Product, combination or comparator product as well as handling and storage of the Licensed Antibody or Product or a Placebo thereof.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.121&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Manufacturing Development Activities</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means development of test methods, stability testing, formulation development, manufacturing development, process development, quality assurance activities, quality control activities, qualification and validation activities, development activities for analytical test methods, analytical testing, release testing, generation of reference materials, manufacturing process validation, scale-up, and all other activities, including CMC-related activities, necessary for or related to the development of Manufacture of Licensed Antibody, Placebo and Product for clinical or commercial use in the Field as far as directly allocable to or reasonably useful for the development of Manufacture for the supply for or Regulatory Approvals in any country worldwide.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.122&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Marketing Authorization</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means, with respect to a Product, the possession of all approvals (including supplements, amendments), licenses, registrations and authorizations of any national (e.g., the FDA), supra-national (e.g., the European Commission), regional, state or local regulatory agency, department, bureau, commission, council or other governmental authority, necessary for the manufacture, distribution, use and sale of such Product in a regulatory jurisdiction. For the avoidance of doubt, &#x201C;Marketing Authorization&#x201D; shall not include Pricing Approval.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.123&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Material Breach</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" has the meaning set forth in Section 17.2(a).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.124&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">MCL</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means Mantle Cell Lymphoma (including any line of treatment, including first line, second line and third line, and including relapsed/refractory forms). For clarity, any of the above forms or lines of therapy to treat Mantle Cell Lymphoma can achieve the milestone events as set out in Section 8.2.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.125&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Medical Affairs Activities</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means non-promotional activities designed to ensure or improve appropriate medical use of, conduct medical education of, or further research regarding, Licensed Antibody(ies) or Product(s), including by way of example: </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> activities of</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">13</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">medical science liaisons; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> the provision of grants or sponsorships to support continuing medical education, symposia, or Third Party research related to the Product; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> the development, publication and dissemination of publications relating to the Product and/or related disease or therapeutic indication; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iv)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&nbsp;medical information services provided in response to inquiries communicated via Sales Representatives or received by letter, phone call, email or other means of communication; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(v) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">presentation of relevant medical information to third-party payers, advocacy (including patient advocacy groups) and health policy groups; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(vi)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> the conduct of advisory board meetings and other meetings with Healthcare Professionals; and (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">vii</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">) Non-NDA Studies.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.126&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Medical Affairs Activities Costs</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means costs and expenses [***] the Medical Affairs Activities conducted pursuant to the Agreement and the Development Plan and Co-Commercialization Plan (as applicable) then in effect, incurred by a Party [***] Medical Affairs Activities in the Co-Commercialization Territory in accordance with the Joint Development Budget and Co-Commercialization Budget (as applicable), [***]. For the avoidance of doubt, to the extent costs are partly directly attributable to Medical Affairs Activities and partly attributable to other activities of COMPANY or MorphoSys (in particular Medical Affairs Activities for products controlled by COMPANY that are not Licensed Antibody or Product), such costs shall constitute &#x201C;Medical Affairs Activities Costs&#x201D; on a pro rata basis, which calculation shall be agreed between the Parties in good faith.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.127&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">MorphoSys Annual Development Report</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means, for each calendar year, the written report that describes MorphoSys&#x2019; past and planned Development activities for Licensed Antibody or Product in the Field for that year, and covers other subject matter as called for in Section 3.14(b).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.128&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">MorphoSys Background Patents</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> all patents and patent applications listed in </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT&nbsp;2</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">; &nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> all patent applications (including provisional and utility applications) claiming priority to or common priority with or based on any of the foregoing, including all divisionals, continuations, continuations-in-part, patents of addition and substitutions of any of the foregoing; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> all patents issuing on any of the foregoing, and all reissues, re-examinations, renewals and extensions of any of the foregoing, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(d)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> all counterparts to the foregoing in other countries; and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(e)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> all supplementary protection certificates, restoration or extension of patent term and other similar rights of MorphoSys and its Affiliates based on any of the foregoing.&nbsp;&nbsp;At the reasonable request of COMPANY, but no more than once per [***], MorphoSys shall provide COMPANY with an updated list of MorphoSys Background Patents and correct any typographical errors.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.129&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">MorphoSys Core Improvement Inventions</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means any and all Product Inventions, for which MorphoSys (or its Affiliate) has (meaning that it employs or has engaged as a consultant) at least one (1) person who would be a properly named inventor on the US Patent claiming such invention, that were invented in the course of MorphoSys&#x2019; or its Affiliate&#x2019;s Product activities during the Term, and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> relate to enhancing the antibody-dependent cytotoxic activity of an Fc in comparison to human wild type IgG1 antibodies, including, but not limited to, ADCC, CDC, and/or phagocytosis, and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> are not claimed in patents all of the claims of which are limited by CD19, any other target, or by CDR or specificity of the Antibody.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.130&nbsp;&nbsp;&nbsp;"MorphoSys Foreground Patents"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> means any Patent claiming a MorphoSys Invention.</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">14</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.131&nbsp;&nbsp;&nbsp;"MorphoSys Funded Development Activities"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> means Independent Trials-related activities performed by or on behalf of MorphoSys or its Affiliates (or Sublicensee(s) or subcontractor(s)) for Product.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.132&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">MorphoSys Invention</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means an Invention that is conceived solely by employees of MorphoSys or its Affiliates or of a Third Party under an obligation of assignment to MorphoSys or its Affiliates.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.133&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">MorphoSys Know-How</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means all Know-How that MorphoSys or its Affiliate Controls during the Term that relates in any way to any Product, Licensed Antibody or a method of Developing, Manufacturing, using (including methods of administration and dosing regimens) or testing of (or in the case of testing, of or for the presence of) any of the foregoing or any article necessary or reasonably useful to practice or use (including those present during the practice or use of) any such Product, Licensed Antibody or method.&nbsp;&nbsp;The MorphoSys Know-How includes all clinical data generated in clinical trials of Product by or for MorphoSys or its Affiliates. To avoid doubt, MorphoSys Know-How does not include Know-How relating to the manufacture of the Licensed Antibody and Product that is Controlled by [***] on the Execution Date. Without limiting the generality of the definition set forth in this Section, the MorphoSys Know-How on the Execution Date is listed in more detail in </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT&nbsp;4A</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> hereto.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.134&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">MorphoSys Patent</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means any MorphoSys Background Patent and MorphoSys Foreground Patent.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.135&nbsp;&nbsp;&nbsp;"MorphoSys Trial(s)"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> means the Trials outlined in </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT 8A</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">, [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.136&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">MZL</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means Marginal Zone Lymphoma (including any line of treatment, including first line, second line and third line, and including relapsed/refractory forms). For clarity, any of the above forms or lines of therapy to treat Marginal Zone Lymphoma can achieve the milestone events as set out in Section 8.2.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.137&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Net Sales</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means the gross amount invoiced by a Party or its Affiliates or any Sublicensee(s) for the sale of Product in the Territory, less any of the following applicable deductions related to such sale and included in the invoiced amounts:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">In the event that a Product is sold as part of a Combination Product, Net Sales of the Product, for the purpose of determining royalty payments, shall be determined by [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Net Sales excludes [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Net Sales includes [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Net Sales amounts shall be determined from the books and records of a Party and its Affiliates maintained in accordance with GAAP consistently applied [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.138&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">NHL</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means non-Hodgkins lymphoma, including but not limited to DLBCL, FL, marginal zone lymphoma and mantle cell lymphoma (including any line of treatment, including first line, second line and third line, and including relapsed/refractory forms).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.139&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Non-Breaching Party</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" has the meaning described in Section 17.2(a).</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">15</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.140&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Non-NDA Study</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D; means a Trial that is either </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> an investigator initiated trial, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> Early Access Program, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> interventional health economics and outcomes research (HEOR), </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(d)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> non-interventional retrospective or prospective study, or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(e)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> Post-Marketing Authorization Trial, in each case (a) through (e) above such Trial shall not be required by, or are a commitment to, Regulatory Authorities.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.141&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Other Licensee(s)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means any Third Party to whom Xencor or any of its Affiliates has granted a license or sublicense to research, develop, manufacture and/or commercialize any XmAb5871 Product.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.142&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Patent</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means any patent application or patent anywhere in the world, including all of the following kinds: provisional, utility, divisional, continuation, continuation-in-part, and substitution applications; and utility, re-issue, re-examination, renewal and extended patents, and patents of addition, and any supplementary protection certificates, restoration of patent terms and other similar rights.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.143&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Patent Challenge</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" has the meaning set forth in Section 11.20.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.144&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Personal Data&#x201D; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">means any information relating to an identified or identifiable natural person.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.145&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Pivotal Trial</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means a Trial (or &#x2013; in case of a multiphase clinical trial &#x2013; those parts of a clinical trial) intended and/or sufficient to provide affirmative evidence for a drug Marketing Authorization approval, including but not limited to a Phase 3 Trial.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.146&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Phase 1 Trial</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means, with respect to a Product, a Trial (or -- in case of a multi-phase clinical trial -- those parts of a clinical trial) in line with the provisions of 21CFR312, Section 21 (a).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.147&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Phase 2 Trial</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means, with respect to a Product, a Trial (or -- in case of a multi-phase clinical trial -- those parts of a clinical trial) in line with the provisions of 21CFR312, Section 21 (b).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.148&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Phase 3 Trial</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means, with respect to a Product, a Trial (or -- in case of a multi-phase clinical trial -- those parts of a clinical trial) in line with the provisions of 21CFR312, Section 21 (c).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.149&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Placebo</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D; means a substance or mixture of substances lacking presence of an active pharmaceutical ingredient, manufactured for purposes of control treatment in blinded clinical trials with Product.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.150&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">PMDA</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means the Pharmaceuticals and Medical Devices Agency in Japan or any successor agency thereto.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.151&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Post-Marketing Authorization Trial</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means with respect to Product, a Trial occurring after Marketing Authorization in a given Indication, including post-market requirement and commitment studies that are required of or agreed to by the Sponsor and that gather additional information about the Product's safety, efficacy, or optimal use within the Indication covered by the Marketing Authorization, including phase IV Trials and confirmatory Trials.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.152&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Pre-Launch</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means all activities undertaken prior to and in preparation for the launch of the Product in a given country or region.&nbsp;&nbsp;Pre-Launch shall include all activities directed to market research, advisory boards, medical education, disease-related public relations, sales</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">16</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">force training and other pre-launch activities prior to the First Commercial Sale of the Product in a given country or region.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.153&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Pre-Tax Profit (Loss)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means, for the purposes of this Agreement, for a given period of time, all Net Sales in the Co-Commercialization Territory during such period, less the sum of both Parties&#x2019; [***]. For sake of clarity, Pre-Tax Profit (Loss) shall be determined in accordance with GAAP consistently applied for all costs other than FTE Costs, which costs shall be determined as set forth in this Agreement, prior to application of any income taxes. In the event that there is overlap among any of those deductions (i)-(vii) and the deductions (a)-(e) under the Net Sales definition, each individual item shall only be deducted once in each Pre-Tax Profit (Loss) calculation.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.154&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Pre-Tax Profit (Loss) Share</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" has the meaning set forth in Section&nbsp;7.7.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.155&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Pricing Activities</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means activities by or on behalf of the Parties or their Affiliates (or their Sublicensee(s) or subcontractor(s)) with respect to (a)&nbsp;preparation, filing, obtaining and maintaining Pricing Approvals, (b)&nbsp;Pricing Materials, (c)&nbsp;calls and meetings with Governmental Authorities in relation to Pricing Approvals and/or Pricing Materials, all with respect to Licensed Antibody(ies) and/or Product(s).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.156&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Pricing Approval</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means the approval, agreement, determination or decision from a Governmental Authority or a private payer establishing the final net price and reimbursement for the Product for sale in a given country or regulatory jurisdiction, in such country or other regulatory jurisdiction prior to or subsequent to the marketing and sale of the Product in such country or regulatory jurisdiction.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.157&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Pricing Costs</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means [***] Pricing Activities in relation to the Product. [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.158&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Pricing Materials</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means applications, submissions, notifications, communications, correspondence, registrations and/or other filings submitted to, made to, received from or otherwise conducted with a Governmental Authority that are necessary in order to obtain and maintain Pricing Approvals in a particular country or regulatory jurisdiction.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.159&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Product</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means any product for use in the Field comprising or containing a Licensed Antibody, alone or in combination with one or more other active ingredients in all forms, in current and future formulations, dosage forms and strengths, and delivery modes, including any improvements to any of the foregoing.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.160&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Product Inventions</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means any and all patentable Inventions that constitute or relate in any way to </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> the Licensed Antibody, Product, Antibody in the XmAb5871 Program, or pharmaceutical composition containing any such Antibody, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> any method of making, using (including methods of administration and dosing regimens) or testing (in the case of testing, of or for the presence of) any of the foregoing, and/or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> any article necessary or useful to practice (including those present during the practice of) any method referred to in clause (b) (including cell lines, vectors and plasmids used in production).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.161&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Product Liability Expenses</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D; means [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.162&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Product Marks</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means the trademarks for use in connection with the Commercialization of the Product, including the trade dress, style of packaging, logos, internet domain names, trade names and other proprietary names for the Product used in connection</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">17</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">with the Commercialization of the Product. For clarity, Product Marks shall not include the corporate names and logos of COMPANY or MorphoSys.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.163&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Pro Rata Percentage</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means, in the context of costs, expenses, fees and payments sharing between the Parties under this Agreement, the following proportionate allocation:</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> with respect to COMPANY, fifty-five percent (55%), and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> with respect to MorphoSys, forty-five percent (45%). For clarity, for Co-Commercialization Costs in the Co-Commercialization Territory, the Pro Rata Percentage shall not apply but the principles set forth in Section 7.7 shall apply.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.164&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Regulatory Activities</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means activities by or on behalf of the Parties or their Affiliates (or their Sublicensee(s) or subcontractor(s)) with respect to </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> preparation, filing, obtaining and maintaining Regulatory Approvals </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&nbsp;Regulatory Materials, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&nbsp;calls and meetings with Regulatory Authorities, all with respect to Licensed Antibody(ies) and/or Product(s).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.165&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Regulatory Approvals</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means all necessary approvals (including INDs, Marketing Authorizations and, in each case any supplements and amendments thereto), licenses, registrations or authorizations of any Governmental Authority, necessary for the Development, Manufacture, distribution, use, promotion, importing, sale and commercialization of the Product in a given country or regulatory jurisdiction, except for Pricing Approvals.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.166&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Regulatory Authority</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means any Governmental Authority in any jurisdiction of the world involved in the granting of Marketing Authorization and/or authorizations for clinical trials for pharmaceutical products or medical devices (including regulated diagnostics).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.167&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Regulatory Costs</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means [***] Regulatory Activities. [***] Regulatory Costs shall exclude Development Costs, Commercialization Costs, Manufacturing costs and Medical Affairs Activities Costs.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.168&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Regulatory Data</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means any and all research data, pharmacology data, chemistry, manufacturing and control data, preclinical data, clinical data and all other documentation submitted, or required to be submitted, to Regulatory Authorities in association with obtaining or maintaining all Regulatory Approvals and Pricing Approval for the Product in the Territories (including relevant parts of any applicable Drug Master Files ("</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">DMFs</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"), Chemistry, Manufacturing and Control ("</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">CMC</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">") data, Common Technical Document ("</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">CTD</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">") or similar documentation).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.169&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Regulatory Materials</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means regulatory applications, submissions, notifications, communications, correspondence, registrations and/or other filings submitted to, made to, received from or otherwise conducted with a Regulatory Authority that are necessary in order to Develop, Manufacture, obtain and maintain Regulatory Approvals, market, sell or otherwise Commercialize the Product in a particular country or regulatory jurisdiction. Regulatory Materials include materials relating to pre-IND meetings, INDs, pre-MAA meetings, MAAs, presentations, responses, and applications for other Regulatory Approvals, excluding Pricing Materials.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.170&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">ROW Territory</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D; means the COMPANY Territory excluding the European Region and Japan.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.171&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Royalty Term</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" has the meaning set forth in Section&nbsp;8.3(c).</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">18</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.172&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Sales Representative</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means an authorized salesperson or agent who has been qualified by either Party under the Party&#x2019;s respective policies and procedures to sell a Product, whether employed or otherwise contracted by a Party.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.173&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Second Position Detail</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D; means a Detail in which the applicable pharmaceutical product is Detailed in the second position (i.e., no more than one other product is presented to or discussed with the Healthcare Professional before such Product) and the second most predominant portion of time is devoted to the Detailing of such pharmaceutical product.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.174&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Sole Funded Development Activities</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means either a MorphoSys Funded Development Activity and/or COMPANY Funded Development Activity.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.175&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Sole Funded Development Activity Budget</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D; has the meaning set forth in Section 3.5.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.176&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Sole Funded Development Activity Plan</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D; has the meaning set forth in Section 3.5.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.177&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Sponsor</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means the Party (or such Party's Affiliate or sublicensee) taking responsibility for the initiation and management, and/or financing of a Trial in accordance with applicable Laws. For the avoidance of doubt, the allocation of costs for Development activities in the internal relationship between the Parties under this Agreement shall not be decisive to determine which Party is the Sponsor of a Trial under this definition.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.178&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Sublicense Agreement</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means a sublicense or other right (including any option for a sublicense) for any Licensed Antibody, specifically excluding rights granted to Distributors.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.179&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Sublicensee</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means a Third Party to whom a Party (or its Affiliate) has granted a (sub)license, specifically excluding distributors and excluding contract manufacturing organizations with a right to Manufacture on behalf of a Party (or its Affiliate or its Sublicensee) only.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.180&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Supply Agreement</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" has the meaning set forth in Section 6.1.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.181&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Target</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means CD19.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.182&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Technology Transfer</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" has the meaning assigned to it in Section&nbsp;6.6(a).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.183&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Term</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" has the meaning assigned to it in Section 17.1(a).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.184&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Territory</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means, collectively, the Co-Commercialization Territory and the COMPANY Territory.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.185&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Third Party</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means any person or entity other than a Party or an Affiliate of a Party.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.186&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Third Party Patents</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means all Patents owned by any Third Party (other than Xencor or [***]) that a Party reasonably determines would be necessary for the research, development, manufacture (whether for development or Commercialization activities), use or Commercialization of any Licensed Antibody or Product.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.187&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Third Party Payments</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.188&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">TPP</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means the target product profile for the Product in the Field worldwide.</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">19</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.189&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Trial</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means any clinical study or clinical trial (including interventional clinical trials), Independent Trials and Sole Funded Development Activities in which the Product is administered or otherwise evaluated in humans (including any Post-Marketing Authorization Trial, Non-NDA Studies, paediatric trials) or any non-interventional, retrospective or observational studies related to the Product.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.190&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">US</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means the United States of America and its respective territories, districts, commonwealths and possessions (including Guam and Puerto Rico).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.191&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">US Dollar</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D; means U.S. Dollars and all references to &#x201C;dollars&#x201D; or &#x201C;$&#x201D; herein shall mean U.S. Dollars.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.192&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">US Government Price Calculations and Reporting</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D; has the meaning set forth in Section 4.5.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.193&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Valid Claim</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> a claim of an issued and unexpired patent which has not been found to be unpatentable, invalid or unenforceable by a court or other authority having jurisdiction, from which decision no appeal is taken or can be taken; and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> a claim of a pending application, which pending application </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">has not been pending for more than seven (7) years from the date of its earliest priority date, and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> which claim has not been finally abandoned. For the avoidance of doubt, any claim of an application which directly or indirectly claims priority to any application filed more than [***] years from the date of its earliest priority date shall not be a Valid Claim unless and until such claim becomes the claim of an issued and unexpired patent falling within subsection (i) of this Section.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.194&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Wild Type IgG 1</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means a monoclonal anti-CD19 Antibody, which has identical variable regions as XmAb5574 and XmAb5871 and a wild type IgG 1 backbone and the amino acid sequence of which is set forth in </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT 9D</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.195&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Xencor</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means XENCOR, INC., a Delaware corporation with its principal offices at 111 West Lemon Avenue, Monrovia, CA 91016.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.196&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Xencor Agreement</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means the collaboration and license agreement entered into by and between MorphoSys and Xencor on June 27, 2010, under which MorphoSys obtained an exclusive license to further develop and commercialize MOR208 worldwide. A redacted version of the Xencor Agreement was provided to COMPANY.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.197&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Xencor Agreement Effective Date</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means the effective date of the Xencor Agreement, i.e. 27 June 2010.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.198&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Xencor Agreement Term</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" shall mean the term of the Xencor Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.199&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Xencor Background Patents</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> all patents and patent applications listed in </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT 3</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">; &nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> all patent applications (including provisional and utility applications) claiming priority to or common priority with or based on any of the foregoing, including all divisionals, continuations, continuations-in-part, patents of addition and substitutions of any of the foregoing; all patents issuing on any of the foregoing, and all reissues, re-examinations, renewals and extensions of any of the foregoing, all counterparts to the foregoing in other countries; and all supplementary protection certificates, restoration or extension of patent term and other similar rights of MorphoSys and its Affiliates based on any of the foregoing; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> all Patents, for which Xencor (or its Affiliate) has (meaning that Xencor (or its Affiliate) employs or has engaged as a consultant) at least one (1) person who would be a properly named</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">20</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">inventor on the U.S. patent claiming such invention, that were invented in the course of Xencor&#x2019;s (or its Affiliate&#x2019;s) Product and/or Licensed Antibody and/or XmAb5871 Program activities and for which a Patent was filed before the Execution Date; including Xencor Patents filed before the Execution Date, and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(d)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> all Patents other than the Patents listed in </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT&nbsp;3</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> Controlled by Xencor or its Affiliate during the Xencor Agreement Term and claiming priority to a Patent in existence prior to the Execution Date that Cover Licensed Antibody and/or Product, all to the extent Controlled by MorphoSys on the Execution Date, but excluding after a Xencor Change of Control all Patents of the acquirer and/or the acquiring corporate family existing prior to or on the date of such Xencor Change of Control, claiming priority to such a Patent existing prior or on such date, or owned or controlled by such acquirer and/or the acquiring corporate family independently of Xencor (for clarity, in the case where Xencor is merged into another entity, the references here to "Xencor" and "independently of Xencor" mean to refer to "the merged entity" and "independently of the merged entity").&nbsp;&nbsp;For the avoidance of doubt, all Patents that qualified as Patents under (d) prior to the date of such Xencor Change of Control shall remain part of Xencor Background Patents during the Term.&nbsp;&nbsp;To avoid doubt, Xencor Background Patents exclude Patents on Xencor&#x2019;s technologies for protein and/or antibody design, such exclusion including Xencor&#x2019;s PDA&#xAE; technology.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.200&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Xencor Candidate Specific Product Invention Patents</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means Xencor Background Patents and Xencor Product Invention Patents, both solely related to a Product.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.201&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Xencor Change of Control</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> any acquisition, sale or merger of Xencor (or all or substantially all of its assets), regardless of the form of the transaction (specifically including stock sales, asset sales, and reverse transactions), or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> Xencor becoming Affiliated with any [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.202&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Xencor Foreground Patents</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means the Patents described in </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT&nbsp;5</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">, all to the extent Controlled by MorphoSys after the Execution Date during the Term.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.203&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Xencor Know-How</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means all unpatented Know-How that </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> is owned or Controlled by Xencor or its Affiliate as of the Xencor Agreement Effective Date, or owned or Controlled by Xencor or its Affiliate thereafter during the collaboration term of the Xencor Agreement, which is already expired, and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> is necessary or useful for Licensed Antibody, and/or Product development and/or commercialization (including Know-How relating to any method of making, using (including methods of administration and dosing regimens) or testing of (or in the case of testing, of or for the presence of) or Manufacturing of a Licensed Antibody and/or Product) or any article necessary or useful to practice (including those present during the practice of any such method) any of the foregoing; but specifically excluding computational protein design methods and drug discovery (but not development) methods and Know-How of an acquirer and/or the acquiring corporate family existing prior to or on the date of a Xencor Change of Control or independently of Xencor thereafter (for clarity, in the case where Xencor is merged into another entity, the references here to "Xencor" and "independently of Xencor" mean to refer to "the merged entity" and "independently of the merged entity"). Without limiting the generality of the definition set forth in this Section, the Xencor Know-How on the Execution Date is listed in more detail in </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT&nbsp;4B</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> hereto.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.204&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Xencor Payments</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means the royalty and milestone payments due by MorphoSys to Xencor under the Xencor Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.205&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Xencor Product Inventions</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means any and all Product Inventions, for which Xencor (or its Affiliate) has (meaning that it employs or has engaged as a consultant) at least one (1)</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">21</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">person who would be a properly named inventor on the US Patent claiming such invention, that were invented in the course of Xencor&#x2019;s (or its Affiliate&#x2019;s) Product and/or XmAb5871 Program activities during the Term.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.206&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Xencor Product Invention Patents</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means all Patents claiming Xencor Product Invention(s).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.207&nbsp;&nbsp;&nbsp;&#x201C;Xencor US Royalties&#x201D;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> means [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.208&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">XmAb5871</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means the monoclonal anti-CD19 Antibody that Xencor referred to as XmAb5871 as of the Xencor Agreement Effective Date, the amino acid sequence of which is set forth in </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT&nbsp;9A</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.209&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">XmAb5871 Product</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means any pharmaceutical composition containing any Antibody of the XmAb5871 Program.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.210&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">XmAb5871 Program</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">", "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">XmAb5871 Program Antibodies</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">", and "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">XmAb5871 Antibodies</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means all anti-CD19 Antibodies that do not contain any of the Fc variants in </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT&nbsp;9B</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> (as &#x201C;variant&#x201D; is defined in </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT&nbsp;9B</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">) and that both (1) (meaning either of (a) or (b)), and (2): </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(1)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> either of: </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> the Fc of such Antibody contains solely a variant listed in </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT&nbsp;9C</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> (as &#x201C;variant&#x201D; is defined in </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT&nbsp;9C</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">); </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:11pt;text-decoration:underline;">provided, however</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">, that such Antibody is not low- or afucosylated, unless such low- or afucosylated Antibody meets the definition of clause (b) below; or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> do not have reproducibly higher antibody-dependent cytotoxic activity (including ADCC, CDC, and/or phagocytosis) than XmAb5871 and Wild Type IgG 1, which shall be the case if both </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> such Antibody does not increase the Affinity Constant of Binding to FcgRI by more than a factor of [***] compared to Wild Type IgG 1, does not increase the Affinity Constant of Binding to FcgRIIIa by more than a factor of [***] compared to Wild Type IgG 1, does not have an absolute level of maximal lysis in a CDC activity assay (as set forth in </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT&nbsp;9E</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">) of more than [***] percent ([***]%) greater than the absolute level of maximal lysis of Wild Type IgG 1, and does have an Affinity Constant of Binding to FcgRIIb that is more than [***] times higher than XmAb5574, and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> such Antibody does not have an Affinity Constant of Binding to FcgRIIa 131 Arg that is higher than [***] of such Antibody&#x2019;s Affinity Constant of Binding to FcgRIIb, and does not have an Affinity Constant of Binding to FcgRIIa 131His that is more than [***] times higher than Wild Type IgG 1 AND </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(2)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> are not antibody-drug conjugates, unless such conjugate inhibits immune function and does not cause either directly or indirectly a cytotoxic effect on target cells. "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Affinity Constant of Binding</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means the affinity of an Antibody Fc to a Fcg receptor as determined using the protocol in </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT&nbsp;9E</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">. The Affinity Constant of Binding is increased, greater or higher if the K</font><sub style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">A</sub><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> value is nominally increased; as an example a K</font><sub style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">A</sub><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> of 10</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;font-size:6pt;top:-4pt;position:relative;line-height:100%">7</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> 1/M is increased, greater or higher than 10</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;font-size:6pt;top:-4pt;position:relative;line-height:100%">6</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> 1/M.</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-indent: -35.45pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LICENSES AND SUBLICENSES</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;License Grant from MorphoSys.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;Subject to the terms and conditions of this Agreement, and, with respect to Xencor Background Patents, Xencor Foreground Patents and Xencor Know-How, to the extent MorphoSys is entitled under the Xencor Agreement to grant the license rights under this Section 2.1, MorphoSys hereby grants to COMPANY:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">an </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> exclusive, royalty-bearing (in accordance with Section&nbsp;8.3), sublicense under the Xencor Background Patents and Xencor Know-How to research, have</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">22</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">researched, Develop, have Developed, make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, Commercialize, have Commercialized, import, have imported, export and have exported any Licensed Antibody and/or the Product(s) in the Field in the COMPANY Territory; and a </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">co-exclusive (together with MorphoSys and its Affiliates and Sublicensees, if any), chargeable (subject to the Pre-Tax Profit (Loss) Share in accordance with Section&nbsp;7.7) sublicense under the same, to do the same in the Co-Commercialization Territory solely in accordance with the Development Plan and the Co-Commercialization Plan;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">an </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> exclusive, royalty-bearing (in accordance with Section&nbsp;8.3) license under the MorphoSys Background Patents, MorphoSys Foreground Patents, MorphoSys Know-How and MorphoSys' interest in any Joint Foreground Patents to research, have researched, Develop, have Developed, make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, Commercialize, have Commercialized, import, have imported, export and have exported any Licensed Antibody and/or the Product(s) in the Field in the COMPANY Territory; and a </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">co-exclusive (together with MorphoSys and its Affiliates and Sublicensees, if any), chargeable (subject to the Pre-Tax Profit (Loss) Share in accordance with Section&nbsp;7.7) license under the same, to do the same in the Co-Commercialization Territory solely in accordance with the Development Plan and the Co-Commercialization Plan;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">an exclusive, royalty-bearing (in accordance with Section&nbsp;8.3), sublicense and license respectively to all rights to make and use all Xencor Know-How and all MorphoSys Know-How in the Field in the COMPANY Territory solely in order to practice the license of Section 2.1(a) and (b) (and specifically excluding all uses in support of activities outside the scope of the license in Section 2.1(a) and (b));</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">a &nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">non-exclusive, royalty-free sublicense under the Xencor Foreground Patents to research, have researched, Develop, have Developed, make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, Commercialize, have Commercialized, import, have imported, export and have exported Licensed Antibody and/or Product(s) in the Co-Commercialization Territory solely in accordance with the Co-Commercialization Plan and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> an exclusive, royalty-free sublicense to MorphoSys' non-exclusive license under the Xencor Foreground Patents, if any, to research, have researched, Develop, have Developed, make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, Commercialize and have Commercialized, import, have imported, export and have exported Licensed Antibody and/or Product(s) in the Field in the COMPANY Territory.&nbsp;&nbsp;To avoid doubt, the royalty-free nature of the license of this Section 2.1(d) shall not alter in any way the royalty-bearing nature of the license of Section 2.1(a), 2.1(b) or of Section 2.1(e), even if applying to the same Product; and</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">an </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> exclusive, royalty-bearing (in accordance with Section 8.3), license under the Existing Product Marks to research, have researched, Develop, have Developed, make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, Commercialize, have Commercialized, import, have imported, export and have exported the Licensed Antibody and/or the Product(s) in the Field in the COMPANY Territory; and a </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">co-exclusive (together with MorphoSys and its Affiliates and Sublicensees, if any), chargeable (subject to the Pre-Tax Profit (Loss) Share in accordance with Section&nbsp;7.7) license under the same, to do the same in the Co-</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">23</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Commercialization Territory solely in accordance with the Development Plan and the Co-Commercialization Plan.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Limitation.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The license grants under Section 2.1(a) to (d) do not include the right to research, have researched, Develop, have Developed, make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, Commercialize, have Commercialized, import, have imported, export and have exported any Antibody that is [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The license grants under Section 2.1(a) to (d) to make and have made Licensed Antibody and/or the Product(s) are subject to </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> the COMPANY's right to have independently Manufactured the Licensed Antibody and/or the Product(s) [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The license grants under Section 2.1(a) to (b) are exclusive in the COMPANY Territory, even as to MorphoSys and its Affiliates, to Commercialize the Product(s) in the Field in the COMPANY Territory; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:11pt;text-decoration:underline;">provided, however</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">, that MorphoSys retains the right to perform Development Activities and Non-NDA Studies subject to Section&nbsp;9.2(e)(ii)(4) worldwide pursuant to the Development Plan and this Agreement, including the continuation of MorphoSys Trials and the performance of Independent Trials.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The license grants under Section 2.1(a) to (d) do not include the right to use any Know-How or Patents developed or generated by MorphoSys, its Affiliates or licensees exclusively for use outside of the rights granted and activities contemplated under this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The licenses and sublicenses granted to COMPANY in Section 2.1 shall be sublicensable solely as provided in Section 2.5, but shall otherwise be non-assignable and non-transferable (except as explicitly permitted by Article&nbsp;17 &#x2013; Term and Termination &#x2013; or Section 18.1 &#x2013; Assignment).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">COMPANY shall not, and shall procure that its Affiliates and Sublicensees shall not, anywhere in the world, directly or indirectly, sue MorphoSys or its Affiliates and licensees based on a Patent Controlled by COMPANY or any of its Affiliates or Sublicensees as of the Execution Date that Covers a Licensed Antibody and/or a Product for infringement of such Patent due to MorphoSys', its Affiliates' or licensees' Development of Licensed Antibodies and/or Product(s) in the Field in the Territory as agreed under the Development Plan, or Commercialization of Licensed Antibodies and/or Product(s) in the Field in the Co-Commercialization Territory.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Acknowledgements and Obligations of COMPANY regarding Sublicense.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">COMPANY acknowledges and agrees that MorphoSys will notify Xencor promptly after the Execution Date of the sublicenses granted to COMPANY in Section&nbsp;2.1 and that MorphoSys will provide Xencor with a copy of this Agreement for the sole purpose of enabling Xencor to verify whether this Agreement is in accordance with the Xencor Agreement. The copy of this Agreement that MorphoSys will provide to Xencor will be redacted by MorphoSys with respect to development and commercial plans, and with respect to financial information. COMPANY acknowledges that under the Xencor Agreement, Xencor shall ensure that no information of such copy is disclosed to Xencor personnel other than Xencor officers, or to any Third Party</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">24</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">other than counsel to Xencor, except solely to the extent required by applicable Laws or to assert Xencor&#x2019;s rights under the Xencor Agreement (with any further redactions MorphoSys requests that are consistent with the legal requirement, or sufficient for Xencor to assert Xencor&#x2019;s rights under the Xencor Agreement, meaning, that &#x2013; with respect to the latter &#x2013; MorphoSys shall not expand such redactions in a way that limits Xencor&#x2019;s ability to assert its rights under the Xencor Agreement).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">2.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;License Grant from COMPANY.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">As consideration for all the rights granted by MorphoSys to COMPANY hereunder, subject to the terms and conditions of this Agreement, COMPANY hereby grants to MorphoSys:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">A co-exclusive (together with COMPANY), royalty-free, sublicensable (through one (1) or more tiers) license under the COMPANY Foreground Patents and the COMPANY Know-How and COMPANY's interest in any Joint Foreground Patents to research, have researched, Develop, have Developed, make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, Commercialize, have Commercialized, import, have imported, export and have exported the Licensed Antibody and/or the Product(s) in the Field in the Co-Commercialization Territory;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">a non-exclusive, royalty-free, sublicensable (through one (1) or more tiers) license under the COMPANY Foreground Patents and the COMPANY Know-How and COMPANY's interest in any Joint Foreground Patents, to perform Development Activities worldwide, solely in accordance with the Development Plan, including MorphoSys Funded Development Activities;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">a non-exclusive, royalty-free, sublicensable (through one (1) or more tiers) license under any COMPANY Foreground Patents that contain only claims that recite the sequence or make reference to the sequence of the CDRs or variable regions, or portions thereof (whether or not also providing for homology to such sequences), of Licensed Antibody and/or XmAb5871 and/or any and all Indications or applications thereof to research, have researched, Develop, have Developed, make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, Commercialize, have Commercialized, import, have imported, export and have exported XmAb5871 Program Antibodies worldwide for any and all fields and applications; and</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">an option for MorphoSys, [***] after a Marketing Authorization has been obtained by COMPANY for the EU and after launch of Product in Germany, to co-Detail the Product(s) in Germany in accordance with a Germany co-Detailing agreement with customary compliance and other provisions to govern any co-Detailing in Germany (the &#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Germany Co-Detailing Agreement</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;). Such option shall be exercisable by written notice by MorphoSys to COMPANY. Within [***] Business Days after COMPANY&#x2019;s receipt of such written notice by MorphoSys, COMPANY shall enable MorphoSys&#x2019; co-Detailing efforts by providing access to all necessary information, documentation and support required.&nbsp;&nbsp;Within [***] months after receipt of such information, documentation and support, the Parties shall enter into the Germany Co-Detailing Agreement, which shall include a co-Detailing plan that would be consistent with COMPANY&#x2019;s Commercialization Plan and strategy in the COMPANY Territory that allows MorphoSys to provide up to fifty percent (50%) of the FTEs of the Sales Representatives in Germany [***] months after agreement of such plan and as set forth in such plan, or within a timeframe otherwise mutually agreed between the Parties, the costs for MorphoSys&#x2019; co-Detailing activities to be fully borne by COMPANY, details to</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">25</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">be set forth in the Germany Co-Detailing Agreement, including the FTE rate.&nbsp;&nbsp;To the extent MorphoSys&#x2019; co-Detailing costs are partly directly attributable to co-Detailing activities and partly attributable to other activities of MorphoSys (in particular Commercialization activities for products controlled by MorphoSys that are not Licensed Antibody or Product), such costs shall constitute co-Detailing costs on a pro rata basis, which calculation shall be agreed between the Parties in good faith.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">2.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sublicenses by COMPANY. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">COMPANY shall be entitled to grant sublicenses under its licenses and sublicenses granted under Section 2.1, subject to all of the following and to any rights retained by MorphoSys under this Agreement:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notification/Approval of MorphoSys. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">With respect to the COMPANY Territory, COMPANY shall have the right to grant sublicenses without MorphoSys' prior approval, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:11pt;">provided, however,</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> that COMPANY shall promptly notify MorphoSys after granting a sublicense to any Third Party other than an Affiliate and shall provide MorphoSys with a copy of each such Sublicense Agreement with a Third Party within [***] calendar days for the sole purpose of verifying whether the Sublicense Agreement is in accordance with this Agreement.&nbsp;&nbsp;Such copy may be redacted as COMPANY may reasonably determine with respect to sensitive financial information and confidential information solely relating to matters or products other than Products or Licensed Antibody. MorphoSys shall ensure that no information of such copy is disclosed to any Third Party other than a counsel of MorphoSys, except solely to the extent required by applicable Laws (provided that MorphoSys shall provide COMPANY with notice sufficient to allow COMPANY to seek a protective order, and that MorphoSys shall only disclose such portion of such Sublicense Agreement as required) or to assert MorphoSys&#x2019; rights under this Agreement (with any further redactions COMPANY requests that are consistent with the legal requirement, or sufficient for MorphoSys to assert MorphoSys&#x2019; rights under this Agreement, meaning, that &#x2013; with respect to the latter &#x2013; COMPANY shall not expand such redactions in a way that limits MorphoSys&#x2019; ability to assert its rights hereunder). The preceding sentence does not limit the right of MorphoSys to notify Xencor of sublicenses granted by COMPANY and to provide Xencor with a copy of such Sublicense Agreement in accordance with Section 2.3 and Section 2.5(b), redacted as provided above. With respect to the Co-Commercialization Territory, any grant of a sublicense shall require the prior written approval of MorphoSys. For clarity, Sublicense Agreements of COMPANY with its Affiliates shall be consistent with this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consistency Requirement. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">COMPANY and its Sublicensees may only sublicense or further sublicense if the sublicense or further Sublicense Agreement is on terms consistent with this Agreement, including this Section 2.5. Further, COMPANY shall use Commercially Reasonable Efforts to obtain from each Sublicensee obligations in the Sublicense Agreement for the Sublicensee to comply with Section 17.7 as if the Sublicensee were COMPANY, on the same or better terms as provided for in Section 17.7 (or to avoid doubt, obligations in the Sublicense Agreement for the Sublicensee to provide the rights of Section 17.7 to COMPANY in case the Sublicense Agreement terminates, and for these to be passed on by COMPANY to MorphoSys, or if so requested, to Xencor in case this Agreement also terminates).&nbsp;&nbsp;In any event, COMPANY shall provide in each Sublicense Agreement that whatever rights (if any) and terms with respect to the subject matter of Section&nbsp;17.7 are granted to COMPANY in case such Sublicense terminates shall be passed on to</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">26</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">MorphoSys, or where provided under the Xencor Agreement and if so requested, to Xencor if this Agreement also terminates.&nbsp;&nbsp;Also in any event, COMPANY shall in each Sublicense Agreement obtain at a minimum the following: the co-Detailing option and the license to MorphoSys under COMPANY Foreground Patents as set forth under Section 2.4, including to the extent granted under those certain COMPANY Foreground Patents of the Sublicensee, shall survive in case the Sublicense Agreement terminates.&nbsp;&nbsp;In case the Sublicense Agreement terminates, there shall be a non-exclusive, royalty-free, irrevocable, sublicensable (through one (1) or more tiers without consent) license back to COMPANY under those certain COMPANY Foreground Patents as set forth under Section 2.4(b) to research, have researched, make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, Commercialize, have Commercialized, import, have imported, export and have exported Licensed Antibody and/or Products; which license shall be passed on to MorphoSys or, if so requested by MorphoSys, to Xencor if this Agreement also terminates.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Performance by Sublicensee(s).&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The activities and achievements of any Sublicensee(s) shall be counted towards each Party's performance under this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">2.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Registration of Licenses.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;Each Party and each Party's Sublicensees shall have the right to register &#x2013; to the extent possible under the respectively applicable Laws &#x2013; the licenses granted under Sections&nbsp;2.1 and 2.4 and sublicenses granted under such licenses in the respectively relevant registers. Upon the other Party's or the other Party's Sublicensee's request each Party shall provide to the other Party or the other Party's Sublicensee and execute all documents and instruments that may be required to perfect such registration of a license.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">2.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reservation of Rights; No Implied Licenses.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;No right, title or interest is granted by either Party whether expressly or by implication to or under any Patents or Know-How, other than those rights and licenses expressly granted in this Agreement. Each Party reserves to itself all rights not expressly granted under this Agreement. Subject to the covenants agreed by the Parties hereunder this Agreement shall not be deemed to restrict a Party from exploiting any of its rights not expressly granted to the other Party under this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">2.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Use of Patents and Know-How. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> Each Party hereby covenants that it (and its Affiliates and Sublicensees) shall not practice any Patents or Know-How (to avoid doubt, including any and all research materials provided during the Development Activities) licensed to the other Party under this Agreement, outside the scope of the licenses granted to the other Party under this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">2.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Coordination of Sublicenses and Rights of Other Licensees With This Agreement. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">COMPANY shall ensure that its agreements with Sublicensees and further Sublicensees are consistent with and impose obligations consistent with the applicable terms and conditions regarding Sublicensees set forth in this Agreement, including Sections 2.5, 2.8, 2.9, 2.10, 3.8, 3.15, 4.9, 8.3(d) to (g), and 14.2 (the Sublicensee shall make an equivalent indemnification of the MorphoSys Indemnitees), and 17.3. Subject to Section 2.5(b), COMPANY shall in particular require its Sublicensees to provide to COMPANY ownership of or a non-exclusive, sublicenseable (through one (1) or more tiers) license under Sublicensee&#x2019;s Product Invention Patents that contain only claims that recite the sequence or make reference to the sequence of the CDRs or variable regions, or portions thereof (whether or not also</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">27</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">providing for homology to such sequences) of Licensed Antibody and/or XmAb5871 and/or any and all indications or applications thereof, which license as sublicensed to COMPANY shall be free of additional payments (including royalties). Information provided by a Sublicensee (or of a Sublicensee provided by COMPANY) to MorphoSys under this Section 2.9 shall be treated as Confidential Information of COMPANY.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">2.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional Restrictions on Sublicensing.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> Notwithstanding each Party&#x2019;s sublicensing rights in this Article 2, neither Party shall be permitted to sublicense, except to Affiliates, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&nbsp;any of the Development Activities allocated to it under the Development Plan (other than any activities that are primarily operational in nature) related to a COMPANY Trial, MorphoSys Trial or Global Trial, and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&nbsp;any Co-Commercialization rights in the Co-Commercialization Territory; both (i) and (ii) without the other Party&#x2019;s prior written consent.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">2.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liability for Sublicensees. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">COMPANY shall monitor compliance with and enforce any Sublicense Agreements against its Sublicensees, and shall be jointly and severally liable for the operations, acts and omissions of any Sublicensee as if such operations, acts or omissions were carried out by COMPANY itself.</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-indent: -35.45pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TRANSFER AND DEVELOPMENT OF PRODUCTS</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transfer of Licensed Know How. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Within [***] Business Days after the Effective Date, MorphoSys shall provide COMPANY with electronic copies of the information contained in the Data Room regarding relevant MorphoSys Know-How and Xencor Know-How (the &#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Initial Know-How Transfer</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;).&nbsp;&nbsp;Thereafter, during the Term, to the extent there exists Xencor Know-How or MorphoSys Know-How that was not included in the Initial Know-How Transfer, and that is necessary or useful for COMPANY to conduct the Development, Manufacture and Commercialization activities under this Agreement, MorphoSys shall make available to COMPANY within reasonable time such additional Xencor Know-How or MorphoSys Know-How, including the MorphoSys Know-How and Xencor Know-How as set forth in </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT 4A</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT 4B</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">, as COMPANY shall reasonably request in writing.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Overview of Development; General Responsibilities.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Subject to the terms and conditions of this Agreement, the Parties shall collaborate with respect to the Development of the Licensed Antibody and the Product in the Field, as provided under this Agreement and as set forth in the Development Plan, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:11pt;text-decoration:underline;">provided however</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">, that MorphoSys shall be the Sponsor of [***], in both the Co-Commercialization Territory and the COMPANY Territory, and COMPANY shall be the Sponsor of [***] all as set forth in Section&nbsp;3.6 and Section&nbsp;3.7 below and in the Development Plan.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Development Plan.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The Parties shall conduct the Development Activities in accordance with the Development Plan and as further specified in this Agreement.&nbsp;&nbsp;The Development Plan shall set forth, among other things, the following Development Activities:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">preclinical studies, toxicology studies, pharmaco-economic studies and Trials evaluating the safety and/or efficacy including Phase 1 Trials, Phase 2 Trials, Phase 3 Trials, Pivotal Trials, in each case, together with all protocols, endpoints and investigators conducting such trials;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Non-NDA Studies and Post-Marketing Authorization Trials and studies;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">28</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">regulatory plans and other elements of obtaining and maintaining Regulatory Approvals;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">the Joint Development Budget and the qualification of each Development Activity as a Joint Development Activity, a Manufacturing Development Activity, a MorphoSys Funded Development Activity or a COMPANY Funded Development Activity (and within this qualification whether such COMPANY Funded Development Activity is a COMPANY Discretionary Manufacturing Activity);</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">the allocation of the Joint Development Activities to be conducted by each Party and the timeline for completing such Joint Development Activities;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">the plans and timeline for preparing the necessary Regulatory Materials/Pricing Materials and for obtaining and/or maintaining Regulatory Approvals/Pricing Approvals in the Territories;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">the Manufacturing Development Activities and other Manufacturing process development activities (including CMC related activities), as well as the plans, amounts and timelines for the Manufacture and supply of Product, Placebo, combination and comparator products necessary for the Development, taking into account the respective supply chain timelines and inventory of stock; and</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">the number of FTEs required for the performance of the Development Plan.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">For the avoidance of doubt, the Development Plan shall include also Trials and regulatory plans of the Parties with respect to Sole Funded Development Activities and shall not be limited to the Co-Commercialization Territory.&nbsp;&nbsp;The Initial Development Plan attached hereto as </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT 6</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> shall be updated in accordance with this Section 3.3 within [***] days of the Effective Date.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">3.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Updating and Amending Development Plan and Joint Development Budget.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;On or before [***] during the Term, the JDC shall submit to the JSC for approval the Development Plan (including the Joint Development Budget contained therein), which shall cover the Development Activities to be conducted during the upcoming [***] calendar years, including amendments to ongoing Development Activities, and the JDC shall, every [***] months, review, amend and update, as appropriate, the then-current Development Plan (including the Joint Development Budget) to reflect any changes, any current or forecast budget overruns, reprioritizations of, or additions to the Development Plan, always taking into account the Manufacturing capacities and commitments, and other Third Party-dependant factors. Once reviewed by the JDC pursuant to Section 9.5(c) and approved by the JSC (or otherwise decided upon pursuant to Sections 9.2(e) or 9.3), the amended Development Plan (including the Joint Development Budget contained therein) shall become effective and supersede the previous Development Plan and Joint Development Budget as of the date of such approval or at such other time as decided by the JSC (or otherwise decided upon pursuant to Section 9.2(e) or Section&nbsp;9.3).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">3.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;New Development Activities. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">From time to time during the Term, in accordance with the timelines set forth in Section 3.4, either Party may submit to the JDC an expansion of the Development Plan to cover new Development Activities (including proposals to make any Non-NDA Study a Joint Development Activity) that are not amending ongoing Joint Development Activity (e.g. a new Trial) and that are not yet included in the Development Plan with respect to the Product in the Territory in the Field for the JDC&#x2019;s review and referral for decision to the</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">29</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">JSC.&nbsp;&nbsp;The proposing Party shall provide a detailed proposal for such new Development Activity, including plans for design, budget, timelines, territorial scope, supply plan for Product (and Placebo, combination or comparator product, where applicable), proposed operational responsibilities of the Parties, technical feasibility, implications for future technical development in CMC and a rationale for conducting such Development activity either as Joint Development Activity or Sole Funded Development Activity, if applicable.&nbsp;&nbsp;Once reviewed by the JDC pursuant to Section 9.5(c) and approved by the JSC either as Joint Development Activity or as Sole Funded Development Activity, the updated Development Plan (including the Joint Development Budget contained therein) shall become effective and supersede the previous Development Plan and Joint Development Budget as of the date of such approval, always taking into account the Manufacturing capacities and commitments, and other Third Party-dependant factors. Notwithstanding the foregoing, no Party shall at any time be forced into any new &#x201C;Joint Development Activity&#x201D; that is not just amending an ongoing Joint Development Activity (e.g. a new Trial), i.e. if a Party rejects a submitted new Development activity as a Joint Development Activity, such new Development activity may only become a Sole Funded Development Activity, which shall then be subject to the &#x201C;buy-in&#x201D; option set forth in Section&nbsp;7.6(b).&nbsp;&nbsp;For the avoidance of doubt, any Trial described in this Section 3.5 that is solely designed or required to obtain and maintain Regulatory Approval in a jurisdiction of the COMPANY Territory shall always be regarded as COMPANY Funded Development Activity, and Development Data resulting from such Trial shall be used as set forth in Section 3.10(d).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">If a Party (the &#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Proposing Party</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;) submits to the JDC a proposed update to the Development Plan pursuant to this Section 3.5 to conduct a Trial that may support further Development or Regulatory Approval of a Product as a monotherapy or combination therapy in the COMPANY Territory and/or the Co-Commercialization Territory, and the JDC does not approve such proposed update as a Joint Development Activity within [***] days of presentation of such update to the JDC pursuant to this Section 3.5, then the Proposing Party shall have the right to conduct, fund and support the relevant proposed Trial as an Independent Trial, at its discretion and at its sole expense, and such study shall not be added to the Development Plan as a Joint Development Activity but as a Sole Funded Development Activity, subject to the following terms:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">At least [***] months prior to commencing the Sole Funded Development Activity, the Proposing Party shall submit to the other Party via the JDC a detailed protocol and timeline (the &#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Sole Funded Development Activity Plan</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;) and initial budget that outlines the anticipated Development Costs (the &#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Sole Funded Development Activity Budget</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;).&nbsp;&nbsp;The Proposing Party shall reasonably consider the comments provided by the non-Proposing Party&#x2019;s JDC representative with respect to such activities, including with respect to the design and conduct of applicable Trials and any safety or dosing concerns raised by the non-Proposing Party.&nbsp;&nbsp;If the non-Proposing Party reasonably believes that there are reasons stipulated in Section 9.2(e)(iv) or (v), and notifies this to the Proposing Party at least [***] months after the Proposing Party's submission of the detailed protocol and timeline, the Parties will refer the decision making to the JSC which will then be made pursuant to Section&nbsp;9.2(e) or Section&nbsp;9.3.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">3.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Specific MorphoSys Obligations regarding </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">and Development Activities.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;MorphoSys shall use Commercially Reasonable Efforts to continue to fulfil its responsibilities and conduct the Development Activities as Sponsor for [***], in accordance with applicable Laws, GCP and the Development Plan.&nbsp;&nbsp;Such conduct shall be made in close cooperation with COMPANY to the extent permitted by applicable Laws.&nbsp;&nbsp;In cases where the Parties may not</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">30</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">reach an agreement on any activities which are directly linked to MorphoSys&#x2019; responsibilities as a Sponsor of MorphoSys Trials as outlined in the Development Plan and applicable Laws, MorphoSys shall retain the right to act according to its own decision, provided that MorphoSys shall undertake all necessary efforts to take COMPANY&#x2019;s view into account, as far as legally feasible and subject to the final decision making authority provisions as set forth in Section&nbsp;9.2(e).&nbsp;&nbsp;Without limiting the foregoing, MorphoSys shall [***] in accordance with the protocol and the timelines outlined in the Development Plan.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">In addition to the obligations under Section 9.4 (Development Project Team) and Section 9.5 (Joint Development Committee), MorphoSys shall inform COMPANY regarding the status of [***], and MorphoSys&#x2019; Development Activities and other relevant on-going pre-clinical activities through progress reports submitted to the JDC meetings and once yearly in writing. Such reports shall include copies of any preliminary reports and final reports and other information or data reasonably requested by COMPANY if available at the time. MorphoSys' conduct of [***], shall be regarded as Joint Development Activities and is subject to the cost sharing under Section 7.1. During the conduct of [***], MorphoSys shall provide COMPANY with reasonable advance notice and a copy of briefing material and application dossiers of any meeting or substantive telephone conference with any Regulatory Authority relating to [***], and shall, upon COMPANY&#x2019;s request, permit COMPANY to participate in any such meeting or telephone conference, to the extent legally permitted.&nbsp;&nbsp;In addition, MorphoSys shall </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> furnish to COMPANY copies of all substantive correspondence that MorphoSys receives from any Regulatory Authority in connection with [***], </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> coordinate with COMPANY any substantive communication submitted to any Regulatory Authority in connection with the [***], and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> provide to COMPANY reasonably detailed minutes of any meetings or substantive telephone conferences relating to [***].&nbsp;&nbsp;Notwithstanding the above, MorphoSys shall not be required to share with COMPANY any information which MorphoSys is not permitted to share under applicable Laws.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">3.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Specific COMPANY Obligations regarding </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">and Development Activities.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;COMPANY shall use Commercially Reasonable Efforts to fulfil its responsibilities and conduct the Development Activities as Sponsor for [***] in accordance with applicable Laws, GCP and the Development Plan.&nbsp;&nbsp;Such conduct shall be made in close cooperation with MorphoSys to the extent permitted by applicable Laws.&nbsp;&nbsp;In cases where the Parties may not reach an agreement on any activities which are directly linked to COMPANY&#x2019;s responsibilities as a Sponsor of such Trial as outlined in the Development Plan and applicable Laws, COMPANY shall retain the right to act according to its own decision, provided that COMPANY shall undertake all necessary efforts to take MorphoSys&#x2019; view into account, as far as legally feasible and subject to the final decision making authority provisions as set forth in Section&nbsp;9.2(e).&nbsp;&nbsp;For clarity, for each MorphoSys Trial, MorphoSys shall have the deciding vote for the Trial design and for COMPANY Trial, COMPANY shall have the deciding vote for the Trial design.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">In addition to the obligations under Section 9.4 (Development Project Team) and Section 9.5 (Joint Development Committee), COMPANY shall inform MorphoSys regarding the status of [***] and COMPANY&#x2019;s Development Activities through progress reports submitted to the JDC meetings and once yearly in writing. Such reports shall include copies of any preliminary reports and final reports and other information or data reasonably requested by MorphoSys if available at the time. COMPANY&#x2019;s conduct of [***] shall be regarded as Joint Development Activities and is subject to the cost sharing under Section 7.1. During the conduct of [***], COMPANY shall provide MorphoSys with reasonable advance notice and a copy of briefing material and application dossiers of any meeting or substantive telephone conference with</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">31</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">any Regulatory Authority relating to [***], and shall, upon MorphoSys&#x2019; request, permit MorphoSys to participate in any such meeting or telephone conference, to the extent legally permitted.&nbsp;&nbsp;In addition, COMPANY shall </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> furnish to MorphoSys copies of all substantive correspondence that COMPANY receives from any Regulatory Authority in connection with [***], </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> coordinate with MorphoSys any substantive communication submitted to any Regulatory Authority in connection with [***], and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> provide to MorphoSys reasonably detailed minutes of any meetings or substantive telephone conferences relating to [***].&nbsp;&nbsp;Notwithstanding the above, COMPANY shall not be required to share with MorphoSys any information which COMPANY is not permitted to share under applicable Laws.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">3.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diligence.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Each Party shall use Commercially Reasonable Efforts </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> to Develop the Licensed Antibody and the Product(s) and to obtain and maintain Regulatory Approval for one (1) or more therapeutic, prophylactic or palliative Products in the Field in their respective Territory (i.e. MorphoSys in the Co-Commercialization Territory and COMPANY in the COMPANY Territory and the Co-Commercialization Territory), </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&nbsp;to collaborate with respect to the Development of the Licensed Antibody and the Product(s) in the Field in the Territory, and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> carry out the Joint Development Activities assigned to it under the Development Plan and in accordance with the Joint Development Budget and time frames set forth in the Development Plan. The Parties shall conduct the Development based on their respective experience, capabilities and capacity and as agreed to in the Development Plan; each Party shall utilize adequately skilled personnel to perform or oversee, as applicable, the Development and Manufacturing of the Product, in accordance with the terms of this Agreement. Neither Party shall be relieved of its diligence obligations under this Agreement by entering into Sublicense Agreements. The activities and achievements of any Sublicensee(s) shall be counted towards each Party's performance under this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">3.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Specific COMPANY Obligations. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Without limiting COMPANY's obligations in Section&nbsp;3.8 above, COMPANY shall in any case:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">use Commercially Reasonable Efforts to achieve the milestone events as set out in Section 8.2 for Indications in the Joint Development Plan;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">use Commercially Reasonable Efforts to develop, at least one (1) therapeutic, prophylactic or palliative Product in [***];</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">file an IND in [***] and perform a Trial in [***] with the intent to seek Regulatory Approval in [***]; both in a reasonable timeline;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">where available and commercially reasonable [***], conduct an Early Access Program for the Product in [***] in advance of the first Marketing Authorization of the Product in [***]; and</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">conduct Trials in accordance with all applicable Laws.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The Parties acknowledge and agree that any breach of this Section 3.9 by COMPANY may constitute a Material Breach of this Agreement giving rise to the termination right set forth in Section 17.2(a).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">3.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Development Data.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;All Development Data shall be owned and shared by the Parties as set forth in this Section 3.10:</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">32</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Joint Development Data shall be jointly owned by both Parties and shall be regarded as COMPANY Know-How and MorphoSys Know-How for all purposes under this Agreement and shall be regarded as the Confidential Information of both Parties. With respect to the data relating to a Party&#x2019;s proprietary molecule not otherwise subject to the licenses under this Agreement but included in Joint Development Data, the other Party may use such data solely in connection with the Development and Commercialization of the Product, and such data related to the proprietary molecule shall be considered the Confidential Information of the Party which owns such molecule.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Sole Funded Development Data shall be owned solely and exclusively by the Party generating such data, which shall be Confidential Information of such Party.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">With respect to Joint Development Data generated by or on behalf of a Party, its Affiliates or Sublicensees or sublicensees, as applicable, such Party shall promptly provide the other Party with copies of reports and summaries thereof, in each case as such reports and summaries become available to such Party, its Affiliates or Sublicensees or sublicensees.&nbsp;&nbsp;Each Party will share all Joint Development Data generated by it or on its behalf, its Affiliates or Sublicensees or sublicensees, as applicable with the other Party [***], and, subject to this Section 3.10, the Party receiving such Joint Development Data is entitled to disclose such Joint Development Data to its Affiliates and Sublicensees or sublicensees, as applicable only for use inside its Territory in accordance with the terms of this Agreement.&nbsp;&nbsp;Each Party shall ensure that its Affiliates and Sublicensees or sublicensees, as applicable, agree to the disclosure of Joint Development Data to the other Party, its Affiliates and Sublicensees or sublicensees, as applicable.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Each Party shall promptly provide the other Party with copies of relevant data, including safety data and medical data, from any Sole Funded Development Activity as such safety data and medical data becomes available to such Party, its Affiliates or Sublicensees or sublicensees and any other data required by Regulatory Authorities; provided, however, that such (i) safety data shall be for use in fulfilling each Party's pharmacovigilance responsibilities as set forth in Section 4.7(c) or as required by Regulatory Authorities, and (ii) medical data shall only be for use in responding to medical inquiries or as required by Regulatory Authorities, but the other Party, its Affiliates or Sublicensees or sublicensees shall not use such medical data in support of efficacy claims in any Regulatory Approval application, unless such Party has elected to the &#x201C;buy-in&#x201D; option set forth in Section&nbsp;7.6(b).&nbsp;&nbsp;Notwithstanding the foregoing, either Party shall be free to use any such Sole Funded Development Data that is in the public domain.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">3.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain Additional Restrictions.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Each Party agrees and acknowledges that it and its Affiliates and Sublicensees shall not conduct any Development or Regulatory Activities of the Product(s) except in accordance with a Development Plan established pursuant to this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">3.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Allocation of Operational Work Between the Parties.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The Parties shall discuss in good faith through the JDC the allocation of the activities to be performed under the Development Plan between the Parties, including for the MorphoSys Trials.</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">33</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">3.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Records.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;Each Party shall maintain current and accurate records of all work conducted by or on behalf of a Party and its Affiliates under the Development Plan, and all data and other information resulting from such work (which records shall include, as applicable, books, records, reports, research notes, charts, graphs, comments, computations, analyses, recordings, photographs, computer programs and documentation thereof (e.g., samples of materials and other graphic or written data generated in connection with such Development Activities).&nbsp;&nbsp;Such records shall properly reflect all work done and results achieved in the performance of such Development Activities in sufficient detail and in good scientific manner appropriate for regulatory and patent purposes. Such records shall be properly retained and archived according to applicable good pharmacovigilance practice, GLP, GCP and/or GMP standards.&nbsp;&nbsp;Each Party shall document such Development Activities, including Trials, to be conducted pursuant to the Development Plan, in formal written study reports upon completion of such activity according to applicable national and international (e.g</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:11pt;">.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">, ICH, GCP and GLP) guidelines and Manufacturing. All Trial activities and Development Activities should be documented by setting up, maintaining and controlling a trial master file according to ICH-GCP and subject to an audit plan to be agreed to by the Parties.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">3.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Progress Reports; Annual Development Report.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;COMPANY Annual Development Report.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">By [***], but subject to Section 3.15, COMPANY shall provide to MorphoSys the COMPANY Annual Development Report. The COMPANY Annual Development Report shall include in reasonable detail: </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> a summary of COMPANY&#x2019;s Development Activities in the previous year (including dosage, Trial design and Trial endpoints, protocols, clinical study reports, Product being tested, technical development and quality observations; material meetings, minutes, correspondence with Regulatory Authorities relating to Licensed Antibody and/or Product(s) in the COMPANY Territory; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">MAAs relating to Licensed Antibody and/or Product(s) in the COMPANY Territory planned for filing; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&nbsp;data reports; publications; conferences; all patent applications filed by COMPANY or an Affiliate relating to Licensed Antibody and/or Product(s); </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iv) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">COMPANY's Manufacturing activities, if any; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(v) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">actual patient and site recruitment and projections of the planned patient and site recruitment activities; and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(vi) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">a summary of COMPANY&#x2019;s planned Development Activities in the following [***] years, to the extent available. COMPANY shall further report to MorphoSys any material change to the COMPANY Annual Development Report, including any material change, within [***] calendar days after its occurrence. Within [***] calendar days after each submission of an annual report(s) to Regulatory Authorities, COMPANY shall also provide to MorphoSys such of its (or its Affiliate&#x2019;s) annual report(s) relating to Licensed Antibody or Product(s). With respect to annual reports to the Regulatory Authorities relating to Licensed Antibody or Product(s) submitted to the Regulatory Authorities by a Sublicensee, COMPANY shall use Commercially Reasonable Efforts to obtain such reports and the right from such Sublicensee to share such reports with MorphoSys. MorphoSys shall treat such COMPANY Annual Development Reports and such other annual report(s) to the Regulatory Authorities from COMPANY, its Affiliate or, if applicable, its Sublicensee as COMPANY&#x2019;s Confidential Information and shall not distribute such report(s) to any Third Party without prior written consent by COMPANY, except that, in derogation of Section 16, Xencor will be permitted to receive such reports from MorphoSys under appropriate confidentiality provisions. COMPANY shall, within [***] Business Days, notify MorphoSys in writing once it becomes aware that patient and/or site recruitment for [***] or any Global Trials, for which COMPANY is the Sponsor, is below the</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">34</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">projections in the latest COMPANY Annual Development Report. The Parties shall convene without undue delay and discuss in good faith potential measures and timeplans for implementation. Each Party shall have the right, but not the obligation, to intervene and provide support to the other Party in the implementation of the measures to drive patient and site recruitment for [***] and Global Trials as agreed between the Parties.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MorphoSys Annual Development Report. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> By [***], but subject to Section 3.15, MorphoSys shall provide to COMPANY the MorphoSys Annual Development Report. The MorphoSys Annual Development Report shall include in reasonable detail: </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> a summary of MorphoSys&#x2019; Development Activities in the previous calendar year (including dosage, Trial design and Trial endpoints, protocols, clinical study reports, Product being tested relating to Licensed Antibody and/or Product(s) in the Co-Commercialization Territory; material meetings, minutes, correspondence with Regulatory Authorities relating to Licensed Antibody and/or Product(s) in the Co-Commercialization Territory; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">BLAs relating to Licensed Antibody and/or Product(s) in the Co-Commercialization Territory planned for filing; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> data reports, publications, conferences, all patent applications filed by MorphoSys or an Affiliate relating to Licensed Antibody and/or Product(s); </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iv) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">MorphoSys&#x2019; Manufacturing activities, if any; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(v)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> actual patient and site recruitment and projections of the planned patient and site recruitment activities; and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(vi)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> a summary of MorphoSys&#x2019; planned Development Activities in the upcoming [***] calendar years, to the extent available. MorphoSys shall further summarize to COMPANY any material change to the information described in the MorphoSys Annual Development Report during the next regularly-scheduled JDC meeting. Within [***] calendar days after each submission of an annual report(s) to Regulatory Authorities, MorphoSys shall also provide to COMPANY such of its (or its Affiliates) annual report(s) relating to Licensed Antibody or Product(s). With respect to annual reports to the Regulatory Authorities relating to Licensed Antibody or Product(s) submitted to the Regulatory Authorities by a Sublicensee, MorphoSys shall use Commercially Reasonable Efforts to obtain such reports and the right from such Sublicensee to share such reports with COMPANY. COMPANY shall treat such MorphoSys Annual Development Reports and such other annual report(s) to the Regulatory Authorities from MorphoSys, its Affiliate or, if applicable, its Sublicensee as MorphoSys&#x2019; Confidential Information and shall not distribute such report(s) to any Third Party without prior written consent by MorphoSys. MorphoSys shall, within [***] Business Days, notify COMPANY in writing once it becomes aware that patient and/or site recruitment for Global Trials conducted in the Co-Commercialization Territory is below the projections in the latest MorphoSys Annual Development Report. The Parties shall convene without undue delay and discuss in good faith potential measures and timeplans for implementation. Each Party shall have the right, but not the obligation, to intervene and provide support to the other Party in the implementation of the measures to drive patient and site recruitment for [***] and Global Trials as agreed between the Parties.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">3.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Affiliate/Sublicensee Activities.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Each Party shall include such Party&#x2019;s and its respective Affiliates&#x2019; and Sublicensees&#x2019; accomplishments and activities (past and planned) in the relevant Annual Development Report with the same level of detail as if these had been achieved and conducted by such Party.</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">35</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">3.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Status Updates in the Territories by Both Parties. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Without limiting the foregoing obligations of each Party under Section 3.13, 3.14 and 3.15, each Party shall provide the JDC with reports detailing its respective Development Activities and Manufacturing under the Development Plan and the results thereof at least [***] prior to any JDC meeting, but in any event, on at least a calendar quarter basis.&nbsp;&nbsp;Without limiting the foregoing, each Party shall promptly, but in any event within [***] calendar days after receipt thereof, provide the other Party with copies of any material documents or correspondence received from any Regulatory Authority related to such Development Activities.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">3.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Compliance</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:11pt;">.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">In conducting any Development, Manufacture, Commercialization activities and Regulatory Activities under this Agreement, each of COMPANY and its Affiliates and Sublicensee(s), and MorphoSys and its Affiliates, shall: (a) use Commercially Reasonable Efforts to ensure that its employees, agents, clinical institutions and clinical investigators as well as any further entities actively involved in the conduct of development work (such as contract research organizations, contract manufacturing organizations, vendors, laboratories, etc.) comply with all applicable Laws with respect to Licensed Antibody and/or Products, including (as applicable): the Federal Food, Drug and Cosmetic Act, as amended (&#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">FFDCA&#x201D;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">), the Public Health Service Act (PHSA), the rules governing medicinal products in the European Union and including Directive 2001/83/EC and Regulation 726/2004/EC and applicable national legislation regulatory provisions regarding protection of human subjects, and, except to the extent contrary to applicable Law, the spirit and principles of the self-regulatory codes of The Pharmaceutical Research and Manufacturers of America (&#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">PhRMA</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;) and the European Federation of Pharmaceutical Industry and Associates (&#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">EFPIA</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;), the rules relating to financial disclosure by clinical investigators, Institutional Review Boards (IRB) and independent ethics committees, GCP, GLP, GMP and Good Distribution Practices, IND regulations, and any conditions imposed by a reviewing Governmental Authority or Ethics Committee/IRB, and comparable statutes and regulatory requirements in other jurisdictions; and (b) not, to the best of its knowledge, utilize, in conducting such studies, any person or entity that at such time is debarred by, or that, at such time, is under investigation by the FDA or other Governmental Authority for debarment, exclusion, or other sanction under the U.S. FFDCA, the U.S. Social Security Act, and comparable statutes and regulatory requirements in other jurisdictions.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">3.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Compensation for Commercial Impact</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 71.45pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">(a)&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">If MorphoSys conducts or supports a Trial as a MorphoSys Funded Development Activity in any one or more countries of the COMPANY Territory, which Trial </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:10.5pt;">(i)&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">enrolls at least </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">patients planned per protocol or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:10.5pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">&nbsp;enrolls less than </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;"> patients but cumulatively covers a total of at least </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;"> patients planned per protocol when taken together with other Trials conducted or supported as MorphoSys Funded Development Activities in </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">during the Term, and where in either of of (i) or (ii) such Trials target the same patient population for which a Product has, at the time such patients are enrolled, already received Regulatory Approval in any such countries and is being sold in any such countries; then, for </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;"> during which MorphoSys conducts or supports such Trial, MorphoSys shall compensate COMPANY for its lost profit due to lost Net Sales for such Product as calculated by COMPANY, taking into account, without limitation: </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">.&nbsp;&nbsp;In the event MorphoSys reasonably disagrees with the accuracy of the calculation provided by COMPANY, and the Finance Working Group cannot resolve the matter, MorphoSys shall have the right to refer the matter for determination by an Expert in accordance with Section 9.3, and the Expert shall decide the matter taking into consideration the above factors (A) through (F).&nbsp;&nbsp;For clarity, if a MorphoSys Funded Development</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">36</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 71.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">Activity studies a Product in a combination treatment regimen, it shall be subject to the foregoing provisions even though such Product may be approved only as a monotherapy or for use in a different combination.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 71.45pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">(b)&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">If a Party conducts or supports a Trial as Sole Funded Development Activity in the Co-Commercialization Territory, which Trial </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:10.5pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;"> enrolls at least </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;"> patients planned per protocol or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:10.5pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">&nbsp;enrolls less than </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;"> patients but cumulatively covers a total of at least </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;"> patients planned per protocol when taken together with other Trials conducted or supported as Sole Funded Development Activity in </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;"> during the Term; where in either of (i) or (ii) such Trial targets the same patient population for which a Product has, at the time such patients are enrolled, already received Regulatory Approval in the Co-Commercialization Territory and is being sold in the Co-Commercialization Territory, then, for </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;"> during which such Party conducts or supports such Trial, such Party will compensate the other Party for its loss under the Pre-Tax Profit (Loss) Share due to the conduct of such Trials as calculated by the Parties through the Finance Working Group, taking into account, without limitation: </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">.&nbsp;&nbsp;In the event the Parties cannot agree on the calculation, and the Finance Working Group cannot resolve the matter, either Party shall have the right to refer the matter for determination by an Expert in accordance with Section&nbsp;9.3, and the Expert shall decide the matter taking into consideration the above factors (A) through (D). For clarity, if a Sole Funded Development Activity studies a Product in a combination treatment regimen, it shall be subject to the foregoing provisions even though such Product may be approved only as a monotherapy or for use in a different combination.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-indent: -35.45pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;REGULATORY ACTIVITIES AND PRICING ACTIVITIES</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diligence; Ownership of Regulatory Approvals and Pricing Approvals.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General Regulatory Activities and Pricing Activities in COMPANY Territory.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">COMPANY shall be responsible for all Regulatory Activities and Pricing Activities and shall use Commercially Reasonable Efforts in preparing all Regulatory Materials and Pricing Materials necessary or desirable for obtaining and maintaining Regulatory Approvals and Pricing Approvals, as applicable, in the COMPANY Territory in the Field (including in connection with Labelling and Packaging for the Product in the COMPANY Territory) in accordance with the Development Plan and the COMPANY Commercialization Plan.&nbsp;&nbsp;MorphoSys shall have the right to review any essential Regulatory Materials and [***] related to the Licensed Antibody and Product and may provide advice to COMPANY on the proposed strategy and documentation for submission in the COMPANY Territory and COMPANY shall reasonably consider such comments in good faith in preparing such materials.&nbsp;&nbsp;COMPANY shall, subject to Section 4.1(c), prepare and submit such Regulatory Materials, MAAs and Pricing Materials, as applicable, to the applicable Governmental Authorities in the COMPANY Territory.&nbsp;&nbsp;Subject to Section 5.2(b), COMPANY shall use Commercially Reasonable Efforts toward obtaining and maintaining Regulatory Approvals and Pricing Approvals, as applicable, for Product as a therapeutic, prophylactic or palliative product in the countries and regulatory jurisdictions in the COMPANY Territory, in its own name, in a commercially reasonable time and manner.&nbsp;&nbsp;To the extent not prohibited by applicable Laws and feasible based on scheduling timelines, MorphoSys shall be entitled, [***], to attend key meetings and scheduled calls with the relevant Governmental Authorities</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">37</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">in the COMPANY Territory with respect to obtaining or maintaining the Regulatory Approvals and [***], as applicable, for the Product in the Field.&nbsp;&nbsp;COMPANY shall be responsible for and [***] the Product in the COMPANY Territory and, for clarity, shall [***] to the extent MorphoSys is performing [***] or supporting [***] as agreed between the Parties.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">For the avoidace of doubt, the exercise of MorphoSys&#x2019; rights to review materials and provide advice to COMPANY as described above shall </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Specific Regulatory Obligations in COMPANY Territory. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">COMPANY shall use Commercially Reasonable Efforts to file an MAA with [***] and with the Regulatory Authorities for [***] within [***] months after final tables, listings and figures of any Pivotal Trial in any indication becoming available from a Joint Development Activity, provided such Pivotal Trial has achieved COMPANY&#x2019;s target product profile (including Trial efficacy endpoints, therapeutic index, and commercial potential) and such MAA is reasonably believed by COMPANY to be sufficient for obtaining Regulatory Approval.&nbsp;&nbsp;For [***], COMPANY shall use Commercially Reasonable Efforts to generate Regulatory Data that is reasonably necessary to obtain Regulatory Approval in [***], as applicable, and shall use Commercially Reasonable Efforts to file an MAA in [***], as applicable, with the applicable Regulatory Authorities within [***] months after final tables, listings and figures of the Trials for generating such data are available, provided such Trial has achieved COMPANY&#x2019;s target product profile (including Trial efficacy endpoints, therapeutic index, and commercial potential) and such MAA is reasonably believed by COMPANY to be sufficient for obtaining Regulatory Approval in [***], as applicable. The Parties acknowledge and agree that any breach of this obligation by COMPANY may constitute a Material Breach of this Agreement giving rise to the termination right set forth in Section 17.2(a).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulatory Activities in the EU.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Without limiting COMPANY's rights and responsibility for preparation of Regulatory Materials and Pricing Materials under Section 4.1.(a) and the draft version of the transition plan attached hereto as </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT&nbsp;17</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">, MorphoSys shall use Commercially Reasonable Efforts to continue to </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> prepare Regulatory Materials for Product in the European Region and to prepare the MAA in the name of COMPANY or its designated Affiliate and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> be the primary contact point for the EMA, including leading the registration procedure and all meetings with rapporteurs, EMA and CHMP; for the first submission of a MAA in the European Region based on the L-MIND (MOR208C203) Trial, RE-MIND Trial and RE-MIND2 Trial until the grant of such Marketing Authorization for the EU. Such continuation shall be made in close cooperation and alignment with COMPANY and COMPANY representatives shall be permitted to attend key meetings and scheduled calls between MorphoSys and the Regulatory Authorities to the extent permitted by applicable Laws, and subject to Section 9.2(e)(ii).&nbsp;&nbsp;It is the shared objective of both Parties to file the EU MAA in COMPANY&#x2019;s (or its Affiliate&#x2019;s) name no later than [***] (assuming Regulatory Authority feedback is supportive).&nbsp;&nbsp;In the event that the Parties determine that it is not reasonably possible to file the EU MAA in COMPANY&#x2019;s name [***], the Chief Medical Officers (or equivalent functions) of both companies shall discuss in good faith the pros and cons of delaying the MAA filing (to file at a later date in COMPANY&#x2019;s name) or to file in MorphoSys&#x2019; name on or [***].&nbsp;&nbsp;In the event of disagreement, the matter shall be referred to the Parties&#x2019; Chief Executive Officers who shall discuss in good faith and shall reach agreement (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">without recourse to external Experts as described in Section 9.2(e)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">) whether to: </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> file the MAA with the EMA in the name of MorphoSys (or its Affiliate) on or before [***], or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> file the MAA with the EMA in the name of COMPANY</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">38</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(or its Affiliate) after [***].&nbsp;&nbsp;In the event that the Parties&#x2019; Chief Executive Officers agree on option (a) as the preferred course, MorphoSys will exercise Commercially Reasonable Efforts to transfer the MAA to COMPANY (or its designated Affiliate) as soon as possible after filing.&nbsp;&nbsp;COMPANY shall be responsible for preparing and submitting all future Marketing Authorizations in COMPANY Territory.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General Regulatory Activities and Pricing Activities in the Co-Commercialization Territory. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">MorphoSys shall be responsible for the preparation of all Regulatory Materials and Pricing Materials necessary or desirable for obtaining and maintaining Regulatory Approvals and Pricing Approvals, as applicable, in the Co-Commercialization Territory (including in connection with Labelling and Packaging for the Product in the Co-Commercialization Territory) in accordance with the Development Plan and the Co-Commercialization Plan.&nbsp;&nbsp;The Parties shall discuss and agree on </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">the regulatory strategy for filing and maintaining Regulatory Approvals in the Co-Commercialization Territory through the JDC and in alignment with the JCC and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">notwithstanding the provisions of Section 4.1, to the extent that [***] for sale of the Product in the Co-Commercialization Territory is/are required, the strategy for obtaining and maintaining [***] through the JCC.&nbsp;&nbsp;COMPANY shall have the right to attend meetings and scheduled calls with the relevant Governmental Authorities in the Co-Commercialization Territory and to participate in the preparation and review of any Regulatory Materials and [***].&nbsp;&nbsp;MorphoSys shall use good faith efforts to incorporate into any Regulatory Materials and [***] reasonable comments from COMPANY.&nbsp;&nbsp;MorphoSys shall submit such Regulatory Materials, MAAs and Pricing Materials, as applicable, to the applicable Governmental Authorities in the Co-Commercialization Territory. [***].&nbsp;&nbsp;Regulatory Activities in the Co-Commercialization Territory shall be subject to an audit plan to be agreed to by the Parties.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ownership of Regulatory Approvals and Pricing Approvals.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Subject to Section&nbsp;7.1 (Development Cost Sharing) or Section 7.6 (Buy-In), all Regulatory Approvals, and Pricing Approvals, if applicable, for the Product in the Co-Commercialization Territory shall be in the name of MorphoSys and MorphoSys shall own (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:11pt;">i.e.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">, hold the BLA and Marketing Authorization in its name) all right, title and interest in and to all such Regulatory Approvals, and Pricing Approvals, if applicable, as applicable, and all related Regulatory Materials and Pricing Materials. Subject to Section&nbsp;4.1(c) and Section 6.8, all Regulatory Approvals, and Pricing Approvals, if applicable, for the Product in the COMPANY Territory in the Field shall be in the name of COMPANY and COMPANY shall own (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:11pt;">i.e.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">, hold each applicable MAA and Marketing Authorization in its name) all right, title and interest in and to all such Regulatory Approvals, and Pricing Approvals, if applicable, and all related Regulatory Materials and Pricing Materials. The Parties shall, for the avoidance of doubt, also after receipt of Marketing Authorizations, exchange Regulatory Materials and [***] through the JDC or JCC, as applicable, and each Party may use the Regulatory Materials and [***] received from the other Party solely for maintaining Regulatory Approvals and [***], as applicable, in its respective Territory in accordance with this Agreement, provided such Party co-funded the relevant Trial in accordance with Section 7.1 or elected the buy-in in accordance with Section 7.6. Each Party shall reasonably cooperate with and provide reasonable assistance to the other Party in connection with all activities undertaken by such Party relating to obtaining and maintaining the Regulatory Approvals.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pricing Approvals.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Notwithstanding the provisions of Section 4.1, MorphoSys shall (to the extent permitted by applicable Laws) be solely responsible for and shall use</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">39</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Commercially Reasonable Efforts toward obtaining and maintaining Pricing Approval(s) in the Co-Commercialization Territory in its own name, in accordance with the Development Plan and the Co-Commercialization Plan.&nbsp;&nbsp;[***]. Notwithstanding the provisions of Section 4.1, to the extent that a given country or regulatory jurisdiction in the COMPANY Territory requires Pricing Approval for sale of the Product in such country or regulatory jurisdiction, COMPANY shall be solely responsible for and shall use Commercially Reasonable Efforts toward obtaining and maintaining such Pricing Approval in its own name following the receipt of the Marketing Authorization in such country or regulatory jurisdiction, subject to Section 9.7(c)(xiii).&nbsp;&nbsp;For clarity, COMPANY shall have the right to determine the timing of seeking Pricing Approval, including the right to sequence or defer seeking Pricing Approval in accordance with COMPANY&#x2019;S Commercialization strategy.&nbsp;&nbsp;[***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reporting and Review.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Each Party shall keep the other Party reasonably and regularly informed in connection with the preparation of all material Regulatory Materials and [***], Governmental Authority review of Regulatory Materials and Pricing Materials, Regulatory Approvals and Pricing Approvals, as applicable, with respect to the Product. Upon reasonable request, each Party shall provide the other Party, in a timely manner, with copies of all material notices, questions, and requests for information in tangible form which it receives from a Governmental Authority with respect to the Product; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:11pt;text-decoration:underline;">provided, however</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">, that such Party shall have the right to redact any information to the extent not related to the Product.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Price Reporting Obligations</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.&nbsp;&nbsp;Except as otherwise agreed by the Parties, MorphoSys shall be responsible for all federal and state government price reporting and disclosure obligations for Product sold in the Co-Commercialization Territory (&#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">US Government Price Calculations and Reporting</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;).&nbsp;&nbsp;US Government Price Calculations and Reporting may include, but shall not be limited to, any U.S. federal, state or other jurisdiction legal reporting or compliance obligation with respect to a Product under the applicable statutes, rules, and regulatory guidance relating to the Medicaid Rebate Program, the Medicare Program, the Public Health Service 340B Program, the Department of Veterans Affairs Master Agreement, the Federal Supply Schedule contract, and applicable state or other jurisdiction laws.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Strategy; Communications. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> The Parties agree to coordinate, through the JDC and JCC, as applicable, the regulatory strategy for filing and maintaining Regulatory Approvals and [***] in the Co-Commercialization Territory and the COMPANY Territory.&nbsp;&nbsp;The Parties shall generally cooperate in communicating with Regulatory Authorities having jurisdiction regarding the Product in the Territory and each Party shall keep the other Party informed of planned regulatory submissions and material communications, either on its own initiative in accordance with this Agreement or as a result of such a Regulatory Authority initiating contact with such Party in connection therewith.&nbsp;&nbsp;Each Party shall promptly provide, and cause its Affiliates, its Sublicensees, and distributors to provide, the other Party with copies of regulatory submissions to, and material communications with, any Regulatory Authorities.&nbsp;&nbsp;Notwithstanding the foregoing, except as may be required by applicable Laws, neither Party shall, with respect to the Product, communicate with any Regulatory Authority regarding the Product on a significant issue, unless consistent with the Development Plan or requested or permitted in writing to do so by the other Party, or unless so ordered by such Regulatory Authority, in which case such Party shall immediately notify the other Party of such order and shall, to the extent permitted by applicable Laws, take no further actions or communicate with such Regulatory Authority further until the Parties have agreed (in the case of the Co-Commercialization Territory), or discussed (in the case of the COMPANY Territory) as to how</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">40</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">to proceed.&nbsp;&nbsp;All communications with Regulatory Authorities regarding the Product shall be undertaken as provided for in this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">4.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pharmacovigilance.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MorphoSys Trials and COMPANY Trial. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">For the[***], MorphoSys shall be responsible for the collection, review, assessment, tracking and filing of information related to adverse events associated with the Product in accordance with applicable Laws and this Agreement and shall ensure that, in such Development of the Product, it will record, investigate, summarize, notify, report and review all adverse events in accordance with applicable Laws.&nbsp;&nbsp;For [***], COMPANY shall be responsible for the collection, review, assessment, tracking and filing of information related to adverse events associated with the Product in accordance with applicable Laws and this Agreement and shall ensure that, in such Development of the Product, it will record, investigate, summarize, notify, report and review all adverse events in accordance with applicable Laws.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exchange of Adverse Event Reports.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> Each Party shall keep the other Party informed of </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> any Serious Adverse Event (&#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">SAE</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;) within a reasonable period of time after such SAE is identified or reported and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> any Suspected Unexpected Serious Adverse Reaction (&#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">SUSAR</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;) as soon as reasonably possible after such SUSAR is identified or reported and in any event at the same time as any reporting of such SUSAR to any Regulatory Authority, independent of whether such SUSAR or SAE occurred under a Joint Development Activity or a Sole Funded Development Activity. The Parties shall cooperate in the preparation, review and submission of development safety update reports and periodic safety update reports. The costs of establishing and maintaining the global safety database for the Product shall be shared in accordance with the Pro Rata Percentage.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pharmacovigilance Agreement. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The safety representatives from each of the Parties shall meet and agree upon a written pharmacovigilance agreement for exchanging adverse event and other safety information relating to the Product within [***] days after the Effective Date (the &#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Pharmacovigilance Agreement</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;); </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:11pt;text-decoration:underline;">provided, however</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">, that during Development and Commercialization MorphoSys shall be responsible for maintaining the global safety database for the Product. Such written Pharmacovigilance Agreement shall ensure that adverse event and other safety information is exchanged, and pharmacovigilance obligations fulfilled, according to a schedule that will permit each Party (and its Affiliates, sublicensees or subcontractors) to comply with applicable Laws, current standards for pharmacovigilance practice and regulatory requirements. Each Party reserves the rights to qualify via an audit pharmacovigilance processes and systems. Details will be defined in the Pharmacovigilance Agreement.&nbsp;&nbsp;[***] shall be responsible for developing and maintaining core documents such as the Reference Safety Information section of the investigator brochure, aggregate safety reports (Periodic Adverse Drug Experience Report, Periodic Safety Update Reports, Development Safety Update Reports, etc.) and a core RMP; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:11pt;text-decoration:underline;">provided</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> that [***] shall provide [***] a right to review and comment on such materials, which comments [***] shall consider in good faith.&nbsp;&nbsp;[***] shall also be responsible for global signal management in the [***] and for signal reporting in the [***]. [***] shall be responsible for signal reporting in the [***].</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">41</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MorphoSys Obligations. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">For [***], (for which MorphoSys&#x2019; responsibilities are addressed in Section&nbsp;4.7(a) above), for which MorphoSys is the Sponsor, and for Commercialization, MorphoSys shall be responsible for the collection, review, assessment, tracking and filing of information related to adverse events associated with the Product in the COMPANY Territory or the Co-Commercialization Territory (whether or not Marketing Authorization has been achieved), in each case in accordance with applicable Laws and this Agreement, and MorphoSys shall ensure that, in the Development and Commercialization of the Product, it will record, investigate, summarize, notify, report and review all adverse events in accordance with applicable Laws, as further described in the Pharmacovigilance Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;COMPANY Obligations. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">For [***] (for which COMPANY&#x2019;s responsibilities are addressed in Section 4.7(a) above), for which COMPANY is the Sponsor, COMPANY shall be responsible for the collection, review, assessment, tracking and filing of information related to adverse events associated with the Product in the Co-Commercialization Territory or the COMPANY Territory (whether or not Marketing Authorization has been achieved), in each case in accordance with applicable Laws and this Agreement, and COMPANY shall ensure that, in the Development and Commercialization of the Product, it will record, investigate, summarize, notify, report and review all adverse events in accordance with applicable Laws, as further described in the Pharmacovigilance Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">4.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Governmental Authority Communications Received by a Party.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Each Party shall promptly inform the other Party of notification of any action by, or notification or other information (including any notice, audit notice, inspection notice, notice of initiation by Governmental Authorities of investigations, document or information requests, inspections, detentions, seizures or injunctions concerning the Product or this Agreement) which it receives (directly or indirectly) from any Governmental Authority in the Territory, whether in relation to the Co-Commercialization Territory or in the COMPANY Territory, which </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> raises any material concerns regarding the quality, safety or efficacy of the Product, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> indicates or suggests a potential material liability of either Party to Third Parties in connection with the Product, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> is reasonably likely to lead to a recall, market withdrawal or market notification with respect to the Product, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iv)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> relates to expedited exchange of individual case safety reports and periodic safety reports with respect to the Product, or product complaints, and which may have an adverse impact on Regulatory Approvals or the continued Commercialization of the Product or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(v) &nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">raises any material concerns regarding the compliance of either Party (or any of their respective Sublicensees, distributors, or subcontractors) with Laws related to the Product or this Agreement.&nbsp;&nbsp;MorphoSys shall be solely responsible for responding to any such communications relating to the Product in the Co-Commercialization Territory and COMPANY shall be solely responsible for responding to any such communications relating to the Product in the COMPANY Territory in the Field.&nbsp;&nbsp;Each Party shall reasonably cooperate with and assist the other Party in complying with regulatory obligations, including by providing to the other Party, within [***] Business Days (or such shorter period required by a Governmental Authority) after a request, such information and documentation which is in such Party&#x2019;s possession as may be necessary or reasonably helpful for the other Party to prepare a response to an inquiry from a Governmental Authority with respect to the Product.&nbsp;&nbsp;Each Party shall promptly provide, and ensure that its Affiliates and sublicensees provide the other Party with a copy of all material correspondence received from a Regulatory Authority specifically regarding the matters referred to above.</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">42</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">4.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recall, Withdrawal, or Market Notification of Product.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;In the event that any Governmental Authority suggests, threatens, recommends or initiates any action to remove the Product from the market whether in the Co-Commercialization Territory or in the COMPANY Territory (in whole or in part, including in clinical Trials), the Party receiving notice thereof shall notify the other Party of such communication promptly, but in no event later than [***], after receipt thereof.&nbsp;&nbsp;Notwithstanding the foregoing, in all cases MorphoSys shall determine whether to initiate any recall, withdrawal or market notification of the Product in the Co-Commercialization Territory, and COMPANY shall determine whether to initiate any such recall, withdrawal or market notification of the Product in the COMPANY Territory, including the scope of such recall or withdrawal (e.g., a full or partial recall, or a temporary or permanent recall) or market notification; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:11pt;text-decoration:underline;">provided, however</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">, that before MorphoSys or COMPANY (as the case may be) initiates a recall, withdrawal or market notification, the Parties shall promptly meet and discuss in good faith the reasons therefor and each Party shall take the other Party&#x2019;s comments under good faith consideration; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:11pt;text-decoration:underline;">further provided</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">, that such discussions shall not delay any action that MorphoSys or COMPANY (as the case may be) reasonably believes has to be taken in relation to any recall, withdrawal or market notification.&nbsp;&nbsp;In the event of any such recall, withdrawal or market notification, MorphoSys or COMPANY (as the case may be) shall determine the necessary actions to be taken, and shall implement such action, with the other Party providing reasonable input (which the first Party shall in good faith consider and incorporate into any recall, withdrawal or market notification strategy) and reasonably necessary assistance, to conduct such recall, withdrawal or market notification.&nbsp;&nbsp;Without limiting the foregoing, each Party shall have the right to propose that a Product recall, withdrawal or market notification should be initiated by the other Party, but such other Party shall make the final decision whether the recall, withdrawal or market notification will be initiated in its respective Territory.&nbsp;&nbsp;Each Party shall at all times utilize a batch tracing system which will enable it to identify, on a prompt basis, customers within its Territory who have been supplied with Product of any particular batch, and to recall such Product from such customers. Details of recalls&#x2019; management shall be dealt with in the Supply Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">4.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cost Allocation re Recall; Withdrawal or Market Notification.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">All direct costs and expenses associated with implementing a recall, withdrawal or market notification with respect to the Product in any territory shall be allocated between COMPANY and MorphoSys as follows:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-indent: -35.45pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;COMMERCIALIZATION OF PRODUCTS</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commercialization Efforts</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;JCC Oversight.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> The JCC shall oversee all Commercialization of Products in the Field, both in the Co-Commercialization Territory and in the COMPANY Territory.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commercialization Principles. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">It is the intent of the Parties that Commercialization of Products will be conducted in accordance with the following principles, and the JCC (or JSC, or the Executive Officers, or the Expert, as applicable) shall take into account and attempt to implement the following principles in its decision-making, including in the preparation, review and approval of the Co-Commercialization Plan and the COMPANY Commercialization Plan, and any updates to and amendments of such plans, and otherwise when allocating Commercialization responsibilities between the Parties in accordance with this Agreement:</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">43</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 85.05pt;text-indent: -49.6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">MorphoSys shall have the right, but not the obligation, to provide up to fifty percent (50%) of the overall Commercialization efforts (including but not limited to market access, patient support, marketing, sales and medical affairs functions) on an FTE basis for Co-Commercialization of the Product(s) in the Co-Commercialization Territory. By way of example, MorphoSys/COMPANY may provide [***]/[***]% of the Sales Representatives, [***]/[***]% of the market access FTEs and [***]/[***]% of the medical scientific liaison FTEs out of the 100% of FTEs determined to be required for each commercial function as set forth in the Co-Commercialization Plan.&nbsp;&nbsp;The JCC shall periodically (as determined by the JCC) review the efforts contributed by each Party (including any shortfall). At least [***] months prior to anticipated launch in the Co-Commercialization Territory, MorphoSys shall notify COMPANY of the level of Commercialization effort that MorphoSys will provide in the Co-Commercialization Territory following launch.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 85.05pt;text-indent: -49.6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The Co-Commercialization Plan shall include a meaningful role for both Parties. In allocating responsibilities between the Parties, the JCC (or the JSC, or the Executive Officers, or the Expert, if applicable) shall take into consideration each Party&#x2019;s expertise, capabilities, staffing and available resources to take on such activities, as well as the Parties&#x2019; intention to provide MorphoSys an opportunity to build and expand its expertise, capabilities, staffing and available resources in connection with performing Commercialization activities allocated to it.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 85.05pt;text-indent: -49.6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">To the extent efforts or costs for the Co-Commercialization activities cannot be attributed solely to the Co-Commercialization of the Product(s) hereunder but are incurred partly also for activities related to product(s) that are not the Product, then such efforts and costs shall only be taken into account on a pro rata basis, which shall be agreed between the Parties in good faith.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lead Parties. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">In collaboration with COMPANY, MorphoSys shall lead the strategic aspects of the Parties&#x2019; Commercialization of the Product in the Field in the Co-Commercialization Territory, as set forth in Section 5.3 and shall lead the overall strategic Product positioning, branding, core messaging, and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">overall medical congress strategy and global </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">medical education strategy with respect to global Commercialization in the Territory. In its role as lead Party with respect to such aspects in the Co-Commercialization Territory, MorphoSys shall be responsible for, amongst other things, setting the price. For operational efforts in the Co-Commercialization Territory, the Parties will distribute the responsibilities according to the outline of the Co-Commercialization Plan as set forth in </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT 14</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">. &nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Notwithstanding the foregoing, COMPANY shall lead the operational efforts regarding Medical Affairs Activities in the Territory. COMPANY shall lead the strategic and operational efforts to Commercialize the Product in the Field in the COMPANY Territory as set forth in Section 5.2, in alignment with the overall strategic Product positioning, branding, core messaging, and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">overall medical congress strategy and global </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">medical education strategy with respect to global Commercialization as set forth above.&nbsp;&nbsp;In its role as lead Party with respect to such aspects in the COMPANY Territory, COMPANY shall be responsible for among other things, setting the price. Notwithstanding anything in this Section, in case of disputes the final decision making shall be made in accordance with Section 9.2(e).</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">44</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Activities and Participation.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Each Party shall use Commercially Reasonable Efforts to execute and to perform, or cause to be performed, the activities assigned to it under the Co-Commercialization Plan and the COMPANY Commercialization Plan. The Parties shall reasonably cooperate to effectuate implementation of Commercialization of Products in the Field in the Co-Commercialization Territory as set forth in the Co-Commercialization Plan. Notwithstanding anything to the contrary contained herein, a Party or its Affiliate shall not be obligated to undertake or continue any Commercialization activities with respect to the Licensed Antibody or Products if such Party (or Affiliate) reasonably determines that performance of such Commercialization activity would violate applicable Law or if a Regulatory Authority determines that such Commercialization activities with respect to the Licensed Antibody or Product would pose an unacceptable safety risk to patients.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">With respect to activities allocated to COMPANY under the Co-Commercialization Plan, COMPANY agrees to reasonably cooperate as MorphoSys may request to provide MorphoSys an opportunity to observe and participate in COMPANY&#x2019;s and its Affiliates&#x2019; performance of such activities.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Within [***] months after commercial launch of a Product in the first of the European Major Markets, MorphoSys shall have the right to designate up to [***] representatives of MorphoSys (the "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">MorphoSys Representatives</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">") to participate in COMPANY&#x2019;s (or its Affiliates&#x2019;) strategic planning of Commercialization of Products in the COMPANY Territory [***]. It is the intent of the Parties that any such MorphoSys Representatives shall be an integral part of the team that brings the Products to market in the COMPANY Territory. COMPANY shall use Commercially Reasonable Efforts to inform and involve the MorphoSys Representatives in COMPANY&#x2019;s internal strategic discussions regarding the Commercialization of Products in the COMPANY Territory, including meetings of COMPANY&#x2019;s (or its Affiliates&#x2019;) designated brand value team or equivalent, and to keep the MorphoSys Representatives informed and involved in strategic discussions regarding implementation of Commercialization of Products in the COMPANY Territory.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subcontracting.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">If either Party (or its Affiliate) desires to subcontract any of its assigned Co-Commercialization activities, such Party shall first discuss it with the other Party and take into account and reasonably consider using the other Party for such subcontracted activities, taking into account (balanced with other factors) the capabilities of the other Party and potential impact on costs and profits, as a potential alternative to subcontracting such activities to a Third Party. In the event that any Commercialization activity allocated to a Party under the Co-</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">45</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Commercialization Plan is subcontracted to the other Party (as opposed to being allocated to such Party under the Co-Commercialization Plan), then the sub-contracting Party remains ultimately responsible under this Agreement for the conduct of such activities and the subcontractor Party shall conduct such activities under the management of, and as directed by, the sub-contracting Party, consistent with the terms of this Agreement and all applicable Laws.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Notwithstanding the foregoing, the subcontracting Party (or Party whose Affiliate enters into a subcontract) shall remain liable under this Agreement for the performance of all its obligations under this Agreement and shall be responsible and liable for compliance by its subcontractors with the applicable provisions of this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;COMPANY Territory.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">. Subject to the terms and conditions of this Agreement, applicable Law, Section 5.1 and the COMPANY Commercialization Plan as set forth in Section 5.2(e), COMPANY shall be solely responsible for the Commercialization of the Products in the COMPANY Territory in the Field during the Term, including:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">the setting of Product prices in the COMPANY Territory;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">subject to Section 5.6, the selection and protection of relevant trademarks in the COMPANY Territory; and</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">subject to Section 4, all Regulatory Activities in connection with any Commercialization of the Products in the COMPANY Territory.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Specific COMPANY Obligations. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">COMPANY shall use Commercially Reasonable Efforts to Commercialize at least one therapeutic, prophylactic or palliative Product in the Field in each country or jurisdiction in the COMPANY Territory in which COMPANY, its Affiliates and/or Sublicensees have received both Marketing Authorization and, if applicable, Pricing Approval for such Product(s).&nbsp;&nbsp;In particular, COMPANY shall use Commercially Reasonable Efforts to:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">obtain Regulatory Approvals and Pricing Approvals, and Commercialize the Product(s) in [***];</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">position the Product in First Line Detailing or Second Line Detailing in [***] after it has been launched;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">engage in outreach activities with the goal of covering up to [***] percent ([***]%) of patient potential in [***] after the Product(s) has/have been launched; and</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">not promote any Product together or in close connection with a product that competes targeting the same (or a subset of the same) patient population as the Product in [***], unless such product is to be used in combination with the Product.</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">46</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The Parties acknowledge and agree that any breach of this Section 5.2(b) with respect to obligations relating to [***] may constitute a Material Breach of this Agreement giving rise to the termination right set forth in Section&nbsp;17.2(a). For clarity, for purposes of this Section 5.2(b), with respect to [***], COMPANY&#x2019;s obligation to use Commercially Reasonable Efforts with respect to a given Product shall also take into account [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Booking Sales. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">COMPANY shall book all sales of Product(s) in the COMPANY Territory, and shall be responsible, among other things, in the COMPANY Territory for </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> receiving, accepting and filing orders for the Product, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> handling all returns of the Product, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> controlling invoicing, order processing and collection of accounts receivable for the sales of the Product, and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iv)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> warehousing and distributing of Product(s), all in accordance with GAAP. If MorphoSys receives any orders for a Product in or for the COMPANY Territory, it shall refer such orders to COMPANY.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cost of Commercialization and Medical Affairs Activities in the COMPANY Territory</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">. Subject to the terms and conditions of this Agreement, COMPANY shall be responsible for [***] in the COMPANY Territory.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;COMPANY Commercialization Plan</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.&nbsp;&nbsp;COMPANY will be solely responsible for developing a COMPANY Commercialization Plan that shall define the overall commercial strategy and detail the operational activities of COMPANY, its Affiliates and Sublicensees in the COMPANY Territory (and shall, for clarity, be consistent with the overall strategic Product positioning, branding, core messaging, and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">overall medical congress strategy and global </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">medical education strategy with respect to the global Commercialization in the Territory), including:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Regional go-to market models (e.g. Sales Representatives allocation, medical scientific liaisons allocation, other FTEs, spend);</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Country-specific market access and pricing strategy;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Regional marketing strategy, e.g. positioning, value proposition and core messaging;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Regional specific market insights and key performance indicators;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Regional medical activity plan and congresses; and</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(vi)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">the plans and timeline for preparing the necessary Pricing Materials and for obtaining and/or maintaining Pricing Approvals in the Territories.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Such COMPANY Commercialization Plan shall be presented to the JCC and approved by the JSC, within [***] calendar days after the Effective Date.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-indent:42.55pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;COMPANY Reports.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">In addition to sharing information on the Commercialization activities of COMPANY in the COMPANY Territory through the JCC, as set forth in Section 9.7(c), COMPANY shall provide to MorphoSys a verbal update on Commercialization activities in the COMPANY Territory for each JCC meeting and a written update on its Commercialization activities for the Product(s) in the COMPANY Territory on a regional or on a country-by-country basis no less than twice every calendar year. Moreover, COMPANY shall submit in writing to MorphoSys,</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">47</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">as long as existent through the JCC, and otherwise directly to MorphoSys, such other summary reports as MorphoSys may reasonably request from time to time during the Term with respect to material activities undertaken by COMPANY for the Product(s) in the Field in the COMPANY Territory, including general market conditions and general sales information.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Co-Commercialization Territory.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.&nbsp;&nbsp;Subject to the terms and conditions of this Agreement, the Co-Commercialization Plan and the Co-Commercialization Budget, the Parties shall be jointly responsible for the Co-Commercialization of the Product(s) in the Co-Commercialization Territory, in the Field, during the Term, including:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">US brand strategy, US go-to market model, positioning, value proposition and core messaging,</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">market access activities,</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">patient advocacy activities,</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">marketing and sales activities,</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">market insights activities,</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(vi)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Medical Affairs Activities,</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(vii)&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">congress and medical education activities,</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(viii)&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">subject to Section 5.6, the selection and protection of relevant trademarks in the Co-Commercialization Territory, and</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ix)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">subject to Section 4, all Regulatory Activities in connection with any such Co-Commercialization of the Product(s) in the Co-Commercialization Territory.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Co-Commercialization of the Product(s) will apply to all indications for which the Product(s) is/are planned to receive (according to the Development Plan and Co-Commercialization Plan) or has/have received Regulatory Approval and, if applicable, Pricing Approval, in the Co-Commercialization Territory, whether based on a Joint Development Activity or a Sole Funded Development Activity.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Specific Obligations. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The Parties shall use Commercially Reasonable Efforts to Commercialize at least one (1) therapeutic, prophylactic or palliative Product in the Field in the Co-Commercialization Territory as soon as Marketing Authorization and, if applicable, Pricing Approval for such Product have been received.&nbsp;&nbsp;In particular, the Parties shall use Commercially Reasonable Efforts to:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">position the Product in First Position Detail or Second Position Detail in the Co-Commercialization Territory,</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">ensure a minimum coverage of [***] percent ([***]%) of patient potential, and</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">48</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">not promote any Product together or in close connection with a product targeting the same (or a subset of the same) patient population as the Product in the Co-Commercialization Territory, unless such product is to be used in combination with the Product.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The Parties acknowledge and agree that any breach of this Section 5.3(b) may constitute a Material Breach of this Agreement giving rise to the termination right set forth in Section&nbsp;17.2(a).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Booking Sales. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">MorphoSys or its Affiliate shall book all sales of Product(s) in the Co-Commercialization Territory in accordance with the Co-Commercialization Plan, and shall be responsible, among other things, in the Co-Commercialization Territory for </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> receiving, accepting and filing orders for the Product, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> handling all returns of the Product, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> controlling invoicing, order processing and collection of accounts receivable for the sales of the Product, and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iv)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> warehousing and distributing of Product(s); whereby MorphoSys or its Affiliate shall be the contractual party to the final customer.&nbsp;&nbsp;The allocation of responsibilities and activities under Co-Commercialization Plan shall be made in a manner that permits MorphoSys or its Affiliate to book all sales of Product(s) in the Co-Commercialization Territory in accordance with GAAP. If COMPANY receives any orders for a Product in the Co-Commercialization Territory, it shall refer such orders to MorphoSys or its Affiliate.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre-Tax Profit (Loss) Share</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">. The Parties shall equally share the Pre-Tax Profit (Loss) of the Co-Commercialization in the Co-Commercialization Territory pursuant to Section 7.7.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Co-Commercialization Plan</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.&nbsp;&nbsp;The Parties will jointly develop and mutually agree through the JCC on a Co-Commercialization Plan and a Co-Commercialization Budget that shall define the overall commercial strategy and detail the operational activities, requirements and responsibilities of each Party. The initial Co-Commercialization Plan and Co-Commercialization Budget shall be approved by the JSC within [***] days after the Effective Date. The Co-Commercialization Plan shall be based on the Co-Commercialization Plan outline attached hereto as </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT&nbsp;14</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">, and the Co-Commercialization Budget shall be based on the Co-Commercialization Budget outline attached hereto as </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT 15</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">, and shall include, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:11pt;">inter alia,</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">the overall strategy and the operational details of engagement of, and relationships with, all stakeholders within the Co-Commercialization Territory, including Government Officials, patient access/advocacy groups, Healthcare Professionals, education providers, medical congress organizers, and pricing and access related groups,</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">alignment on external spend to support the overall strategy,</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">alignment on number of Commercial FTEs from each Party,</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">the specific overall responsibility of MorphoSys for Labelling and Packaging, Distribution and logistics services in the Co-Commercialization Territory, and</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">the specific overall responsibility of COMPANY for Medical Affairs Activities in cooperation with MorphoSys in the Territory.</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">49</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales Force</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">. Both Parties shall ensure that all Sales Representatives Detailing the Product in the Co-Commercialization Territory will be required to complete the same training and certification process. In particular, the Parties will be jointly responsible for the training of both Parties&#x2019; Sales Representatives and will prepare and implement a training program and training materials for such Sales Representatives, including Detail scripts.&nbsp;&nbsp;Without limiting the generality of the foregoing, each Party shall:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">be solely responsible for recruiting, hiring and maintaining its sales force of Sales Representatives, including determining incentive compensations, for the Commercialization of the Product in accordance with its standard procedures and the requirements of this Agreement;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">be responsible for the activities of its Sales Representatives, including compliance by its Sales Representatives with training and Detailing requirements and ensuring Sales Representatives have and maintain all credentials, licenses, or other governmental or institutional approvals necessary to engage in Detailing and related activities;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">ensure that any of its Sales Representatives involved in the Commercialization of the Product will not have any legal or regulatory disqualifications, bars or sanctions, including but not limited to any suspension or revocation of required credentials, licensing, or other governmental or institutional approvals necessary to engage in Detailing and related activities, or any record of debarment, exclusion, or other sanction under the U.S. Federal Food, Drug, and Cosmetic Act, the U.S. Social Security Act, and comparable statutes and regulatory requirements in other jurisdictions; and</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">maintain records and otherwise establish procedures to ensure compliance with all applicable Laws and professional requirements that apply to the Commercialization of the Product.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Detailing in the Co-Commercialization Territory.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> If either Party undertakes Detail calls promoting a product in addition to the Product, it shall comply with Section&nbsp;5.3(b), and will be reimbursed following an allocation key that depends on the number of products, including the Product, that a Sales Representative discusses in such Detail call ([***]).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">5.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Legal Compliance.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Each Party shall, and shall ensure that its Affiliates and sublicensees and subcontracting parties, in Commercializing the Product(s) in the Field, comply with all applicable Laws, including all applicable Regulatory Approvals for the Product in its respective Territory and have in place a compliance program consistent therewith.&nbsp;&nbsp;In addition, neither Party nor its Affiliates or sublicensees shall use in any capacity, in connection with its Commercialization of the Product hereunder, any person who has been debarred pursuant to Section 306 of the FD&amp;C Act, or who is the subject of a conviction described in such section, and each Party shall inform the other Party in writing immediately if it or any person who is performing services for each Party hereunder is debarred or is the subject of a conviction described in Section 306 (or similar Laws outside of the US), or if any action, suit, claim, investigation or legal administrative proceeding is pending or, to such Party&#x2019;s</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">50</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">knowledge, is threatened, relating to the debarment of such Party or any person used in any capacity by such Party in connection with its Commercialization of the Product(s) hereunder. Each Party shall be responsible for reporting its own expenditures in compliance with the Physician Payments Sunshine Act, subject to further agreement between the Parties as to any information exchange necessary to properly calculate and report spending on research and development which understanding shall be documented in the Co-Commercialization Plan.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">5.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Promotional Materials.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;COMPANY Territory.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The Parties will seek to align on and discuss core messages in promotional materials (including digital communications on websites) related to the Product for use in the COMPANY Territory in accordance with the Regulatory Approvals and applicable Laws.&nbsp;&nbsp;Such coordination by the Parties is intended to ensure that such promotional materials take into account the Global Brand Strategy for the Product.&nbsp;&nbsp;The Parties shall exchange samples of regional materials only (i.e. excluding any specific country related materials) in the English language of its promotional materials related to the Product for information and comment (and each Party shall consider any such comments in good faith) prior to distributing such promotional materials (for clarity, such samples need only be submitted for each different type of promotional material, as opposed to each item of promotional material needing to be submitted).&nbsp;&nbsp;To the extent either Party wants to include any trademarks Controlled by the other Party in the promotional materials or on the Product packaging or labelling, such Party may include, upon the other Party&#x2019;s prior written approval only, on a royalty-free basis such trademarks and shall comply with the other Party&#x2019;s then-current guidelines for trademark usage, a copy of which shall be requested from the Party intending to use the Controlled trademark; provided, however, that COMPANY shall be responsible for the finalization and use of promotional materials in the COMPANY Territory. For </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> any media release by COMPANY referencing the Product, COMPANY shall include the statement set forth in </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT 18</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> in the section containing background information on the Product; and for </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> any peer-reviewed publication COMPANY shall include the identical statement set forth in </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT 18</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> in e.g. the Materials and Methods section, the acknowledgements or the references at the discretion of the lead author and publisher. COMPANY shall own all right, title and interest in and to any promotional materials created by or on behalf of it hereunder relating to the Product in the COMPANY Territory.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Co-Commercialization Territory</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.&nbsp;&nbsp;The Parties shall develop promotional materials for use in the Co-Commercialization Territory by both Parties and their Affiliates that comply with each Party&#x2019;s applicable policies, SOPs, the Co-Commercialization Plan, and Applicable Laws and Regulatory Approvals. Copies of all promotional materials used by COMPANY and MorphoSys and their Affiliates in the Co-Commercialization Territory shall be archived by COMPANY and/or MorphoSys, as applicable, in accordance with applicable Laws. The promotional materials developed by the Parties shall be reviewed and approved by the JCC. The JCC shall establish and implement a review process to ensure that both Parties&#x2019; compliance officers and legal departments certify compliance of the promotional materials with applicable Laws and policies of the Parties.&nbsp;&nbsp;If the Parties cannot agree upon the content of a particular promotional material, the matter may be referred to the legal departments of the Parties, and then to the JCC for resolution, subject to the final approval of the Parties&#x2019; respective compliance officers and legal departments.&nbsp;&nbsp;If the</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">51</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Parties&#x2019; compliance officers or legal departments are unable to mutually approve the content of a particular promotional material in accordance with the immediately preceding sentence, then such promotional material shall include the content approved by the Party with the more conservative compliance or legal position regarding such content. The Parties shall jointly own all right, title and interest in and to any promotional materials created hereunder relating to the Product(s) in the Co-Commercialization Territory. Promotional material in the Co-Commercialization Territory shall include logos of MorphoSys and COMPANY (or the other entity marketing the Product) at equal size.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Use of Promotional Materials Exclusively for the Product. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The Parties will only use promotional materials, and any aspects thereof uniquely tied to the related Product, exclusively in connection with the Commercialization of such Product in the COMPANY Territory and in the Co-Commercialization Territory in the Field in accordance with the terms of this Agreement, and shall not use, or allow any other person to use, any such promotional materials except in accordance with this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">5.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product Marks</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-indent:35.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product Mark.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The Parties shall be jointly responsible for:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 134.7pt;text-indent: -21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(1)&nbsp;&nbsp;&nbsp;establishing a global branding for the Product, including identifying and selecting Product Marks and trademark standards for any Product Marks to be adopted as well as global look and feel of Products and Product packaging in the Territory ("</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Global Branding</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"). COMPANY and MorphoSys (and its Affiliates and sublicensees respectively) shall only use the Product Marks pursuant to the terms of this Agreement </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">to identify the Product(s) and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">in connection with the Commercialization of the Product(s), and COMPANY and MorphoSys shall not (and shall ensure that each of their Affiliates and sublicensees do not) use such Product Marks in the course of trade to identify, or otherwise in connection with, any other products, and</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 134.7pt;text-indent: -21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(2)&nbsp;&nbsp;&nbsp;aligning on a global brand strategy, which shall encompass Product positioning, alignment on core messages, discussing strategy related to commercial terms of sale, setting strategy for key opinion leader engagement ("</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Global Brand Strategy</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"). Such Global Brand Strategy may be updated from time to time by mutual agreement by the Parties. If the Parties do not mutually agree on the above, COMPANY shall have the right to decide on the brand strategy for the Product(s) in the COMPANY Territory, taking into account MorphoSys&#x2019; comments, and the Parties shall jointly decide on the brand strategy for the Product(s) in the Co-Commercialization Territory.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The Parties shall maintain, at all times, high quality standards for all materials, products and services for which the Product Marks are</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">52</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">used, which standards shall be no less than the standards of quality that have been maintained for the materials, products or services provided by the respective Party prior to the date of this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">To the extent permissible by Regulatory Authorities and applicable Law, COMPANY and MorphoSys shall use the same Product Mark in the COMPANY Territory and the Co-Commercialization Territory (a "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Global Product Mark</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">").&nbsp; Any Global Product Mark, which is not an Existing Product Mark, shall be co-owned by COMPANY and MorphoSys in all countries and regions in which such Global Product Mark is applied for, registered, or used.&nbsp; Where joint ownership is not possible or is impracticable under applicable Laws, the Parties shall discuss in good faith possible solutions. The Parties shall only use any Global Product Mark in the form as agreed upon between the Parties.&nbsp;&nbsp;Any Existing Product Mark shall be solely owned by MorphoSys in all countries and regions in which such Existing Product Mark is applied for, registered, or used and is subject to the license in Section&nbsp;2.1(e).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] shall have the obligation to prepare, file, prosecute and maintain the Global Product Marks in the [***], and [***] shall have the obligation to prepare, file, prosecute and maintain the Global Product Marks in the [***]. In the event that either Party intends not to prepare, file, prosecute, or maintain a Global Product Mark in [***], such Party shall provide reasonable prior written notice to the other Party of such intention (which notice shall, in any event, be given no later than [***] weeks prior to the next deadline for any action that may be taken with respect to such Global Product Mark in [***]), and the other Party shall thereupon have the option, in its sole discretion, to assume the control and direction of the preparation, filing, prosecution, and maintenance of such Global Product Mark in [***].&nbsp; Upon the continuing Party&#x2019;s written exercise of such option to the non-continuing Party, the continuing Party shall assume responsibility and full control for the preparation, filing, prosecution, and maintenance of any such Global Product Mark, and the continuing Party shall [***].&nbsp; The non-continuing Party shall assign to the continuing Party its interest in such Global Product Mark and shall execute such documents and perform such acts, [***], as may be reasonably necessary to permit the continuing Party to file such Global Product Mark application, and/or to prosecute and/or maintain such Global Product Mark.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Whether or not a Global Product Mark is adopted by the Parties, alternative Product Marks may need to be selected upon the Regulatory Authority&#x2019;s request, provided they are consistent with the Global Brand Strategy initially agreed between the Parties to the extent practicable. The use of an alternative Product Mark by a Party requires the prior written consent of the other Party, such consent not to be unreasonably withheld. If one of the Parties needs to use an alternative Product Mark instead of a Global Product Mark that has been adopted by the Parties, the Parties will enter into good faith negotiations on whether the application, registration and use of such alternative</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">53</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Product Mark is indeed feasible, in particular in view of the Global Brand Strategy agreed upon between the Parties.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(vi)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Any Product Marks, which are not Existing Product Marks and which are used exclusively within the COMPANY Territory shall be owned by COMPANY. &nbsp;COMPANY, [***], shall control the filing, prosecution, enforcement (subject to Section&nbsp;5.6(b)) and maintenance of the Product Marks used exclusively in the COMPANY Territory.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(vii)&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Any Product Marks used exclusively within the Co-Commercialization Territory shall be owned by MorphoSys.&nbsp; MorphoSys, [***], shall control the filing, prosecution, enforcement (subject to Section&nbsp;5.6(b)) and maintenance of the Product Marks used exclusively in the Co-Commercialization Territory.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Infringement of the Product Mark.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;In the event that either Party becomes aware of any infringement of the Product Marks by a Third Party including, but not limited to, the existence of conflicting trademarks or company names of Third Parties in the Territory, such Party shall promptly notify the other Party and the Parties shall consult with each other in good faith with respect thereto.&nbsp;&nbsp;Neither of the Parties is under an obligation to monitor the market for Third Party use of the Product Marks.&nbsp;&nbsp;Each Party shall, at its sole discretion, have the right to determine how to proceed with respect to such infringement [***], including by the institution of legal proceedings against such Third Party, [***].&nbsp;&nbsp;If a Party does not bring an action against such infringement of a Product Mark [***] within [***] calendar days after notification thereof to or by the respective Party, then the other Party shall have the right, but not the obligation, to bring, [***], an appropriate action [***] against any person or entity engaged in such infringement and [***]; whereby the latter Party shall not initiate such legal action without first conferring with the former Party and considering in good faith the former Party's reasons for not bringing any such action.&nbsp;&nbsp;If requested to do so, the Parties shall reasonably cooperate with any and all action initiated by the other Party, [***]. If an infringement of a Global Product Mark occurs [***], the Parties will consult fully with each other to agree on the requisite course of action.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Acknowledgments.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;Each Party acknowledges the sole ownership by the other Party and validity of all trademarks, trade dress, logos and slogans and related elements of a Global Brand Strategy (other than jointly owned Global Product Marks) owned by the other Party and used or intended to be used in connection with the Commercialization of the Product in the other Party&#x2019;s Territory, in accordance with this Agreement.&nbsp;&nbsp;Each Party agrees that it will not at any time during or after the Term assert or claim any interest in, or do anything which may adversely affect the validity or enforceability of, any copyright, trademark, trade dress, logo or slogan owned by the other Party and used or intended to be used on or in connection with the marketing or sale of the Product in accordance with this Agreement.&nbsp;&nbsp;Neither Party will register, seek to register or cause to be registered any copyrights, trademarks, trade dress, logos or slogans owned by the other Party and used or intended to be used on or in connection with the marketing or sale of the Product or any variation thereof, under any applicable Laws providing for registration of copyrights, trademarks, service marks, trade names or fictitious names (including as an Internet domain name) or similar Laws, in such other Party&#x2019;s Territory, without the other Party&#x2019;s prior written consent (in its sole discretion).&nbsp;&nbsp;Each Party agrees that all use of the other Party&#x2019;s trademarks, names and</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">54</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">logos will inure to the benefit of such other Party, including all goodwill in connection therewith.&nbsp;&nbsp;To the extent a Global Product Mark is used in the Co-Commercialization Territory and the COMPANY Territory, the Parties shall jointly own rights to any internet domain names incorporating the Global Product Mark or any variation or part of such Global Product Mark as its URL address or any part of such address under the country code top level domains corresponding to the countries of its respective Territory.&nbsp;&nbsp;With respect to generic top-level domains, the Parties shall jointly determine if the Global Product Mark shall be registered under the respective domains and which Party shall be entitled to register a respective domain name. Each Party shall be responsible for all costs incurred with respect to the Internet domain names registered by such Party.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sublicensee.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> Licenses granted by COMPANY to a Sublicensee or by MorphoSys to a sublicensee under a Product Mark or a Global Product Mark have to be consistent with this Section&nbsp;5.6 and shall impose on the Sublicensee or sublicensee respectively obligations at least as strict as the Parties&#x2019; obligations under this Section&nbsp;5.6. Except for licenses to Affiliates of either Party, licenses under a Global Product Mark shall not be granted by either Party without the prior written consent of the other Party, which shall not be unreasonably withheld.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">5.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Display of Trade Names/Logos. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">To the extent legally permitted by applicable Laws and compliant with Regulatory Approvals and each Party&#x2019;s applicable SOPs (in each case, as approved by the JCC), all Labelling and Packaging materials, labels and Promotional Materials relating to Products in the Field in the Co-Commercialization Territory shall display the then-current MorphoSys trade name/logo in a size equal to the size of the logo of COMPANY (or the other entity marketing the Product).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-indent: -35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MANUFACTURE OF PRODUCTS AND SUPPLY</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Supply of Product through MorphoSys.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Subject to COMPANY's right to [***], MorphoSys shall use Commercially Reasonable Efforts to source [***] </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> the demands of Licensed Antibody and Product for the conduct of the MorphoSys Trials pursuant to Section 6.2, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> to supply COMPANY with Drug Product for Development Activities other than MorphoSys Trials pursuant to Section 6.3, and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> to supply COMPANY with Drug Product for Commercialization pursuant to Section 6.4; all subject to [***]. The Parties shall use Commercially Reasonable Efforts to conclude within [***] after the Effective Date, a supply agreement (including a quality agreement to be concluded with [***] after the Effective Date) ("</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Supply Agreement</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"), for the clinical and commercial supply to COMPANY of the Drug Product and, where applicable, combination or comparator products.&nbsp;&nbsp;In any case COMPANY shall be responsible for Labelling and Packaging of the Product to be Commercialized in the COMPANY Territory and/or for COMPANY Funded Development Activities. At least [***] prior to the termination or expiration of [***] the Parties shall discuss in good faith either Party&#x2019;s responsibility and the source for further supply in the JMC.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-indent:0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Right of COMPANY to </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">As of the Effective Date, COMPANY shall have the right to [***]. Until such time, MorphoSys shall </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> continue to use Commercially Reasonable Efforts to source Drug Product [***] as set forth in Section 6.1(a) and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">55</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">consult with and, subject to confidentiality obligations [***]. At the request of either Party, the Parties agree to discuss in good faith the advantages and disadvantages of having COMPANY [***] for Commercialization in COMPANY Territory or for supply for Trials in the Territory. At the request of COMPANY to [***], subject to the obligations of MorphoSys [***], MorphoSys agrees that COMPANY may have Manufactured the Licensed Antibody or the Product(s) for Commercialization in the COMPANY Territory [***] and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(A)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> COMPANY shall take into account MorphoSys&#x2019; reasonable commercial interests (which for purposes of this Section shall mean [***], and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(B)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> MorphoSys shall use Commercially Reasonable Efforts to support COMPANY in its reasonable efforts to have such [***] to MorphoSys and COMPANY, respectively, shall be provided according to the following:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Unless otherwise agreed between the Parties, MorphoSys shall supply the Co-Commercialization Territory and MorphoSys Trials [***], COMPANY shall supply COMPANY Territory for Commercialization in the COMPANY Territory [***], and supply for COMPANY Funded Development Activities, COMPANY Trial and Global Trials to be agreed between the Parties;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Unless otherwise agreed between the Parties, MorphoSys shall use Commercially Reasonable Efforts to support COMPANY in obtaining Third Party licenses which may be needed for the Manufacture of Product on COMPANY&#x2019;s behalf, [***], if applicable, [***]; for clarity, all other costs of the direct supply under this Section 6.1(b) shall be borne by [***]; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:11pt;">provided that</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> MorphoSys shall use Commercially Reasonable Efforts to [***];</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The Parties shall cooperate and align in their negotiations [***] in order to [***]; in any case, the terms of [***] to MorphoSys or COMPANY under an [***] shall [***];</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The Parties shall [***];</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The Parties shall agree on a mechanism to share any Product-specific equipment, cell lines and resins used [***] to maximize efficiency;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(vi)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The Parties shall consult, cooperate and align on process improvements or changes to ensure that the Manufacturing processes do not diverge;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(vii)&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">In the event that the Manufacturing process needs to be changed for one or more countries, the Parties shall keep each other informed about such changes and secure access to such changed process for the other Party upon request; and</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(viii)&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The Parties shall aim to keep a common master dossier, and if not possible, consult, cooperate and align how to achieve creation and maintenance of the dossiers efficiently and to the benefit of both Parties.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Without limiting COMPANY's right to have Manufactured the Licensed Antibody or the Product(s) for Commercialization in the COMPANY Territory [***], the Parties will agree</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">56</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">in good faith on the details of the transition and implementation of the [***] the Supply Agreement. COMPANY will use Commercially Reasonable Efforts to support MorphoSys in its efforts to [***] in accordance with the above (i) to (viii).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical Supply for the MorphoSys Trials.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">MorphoSys shall use Commercially Reasonable Efforts to source and to supply the demands of GMP-compliant (if legally required) Licensed Antibody and Finished Drug Product, and if applicable Placebo, combination or comparator product(s) (including Labelling and Packaging) for the conduct of the MorphoSys Trials, subject to [***]. All costs related to such supply shall be regarded as [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical Supply for Further Clinical Development.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> MorphoSys shall use Commercially Reasonable Efforts to [***] the demands of GMP-compliant (if legally required) Drug Product and Placebo in accordance with the Development Plan and the Supply Agreement </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> for the conduct of Joint Development activities other than the MorphoSys Trials, including COMPANY Trial, and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> for the conduct of any Sole Funded Development Activity, provided that the supply for the purposes of (i) above shall have preference to the supply for the purposes of (ii) above, and provided further that MorphoSys&#x2019; above obligation to use Commercially Reasonable Efforts to source Drug Product shall no longer apply with respect to supply in the COMPANY Territory once COMPANY directly sources Product [***].&nbsp;&nbsp;Supply with Drug Product and Placebo for Joint Development Activities under this Section&nbsp;6.3 shall be regarded as [***], whereas Supply with Drug Product and Placebo for COMPANY Funded Development Activities will be [***]. Combination products Controlled by a Party and used for Joint Development Activities shall be provided by such Party [***]. Labelling and Packaging of the Drug Product for Global Trials that are Joint Development Activities shall be discussed in the JMC and the associated costs shall be regarded as [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">6.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commercial Supply. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">MorphoSys shall use Commercially Reasonable Efforts to source Drug Product [***] the demands of GMP-compliant Drug Product for Commercialization in the COMPANY Territory and the Co-Commercialization Territory, provided that MorphoSys&#x2019; above obligation to use Commercially Reasonable Efforts to source Drug Product shall no longer apply with respect to supply in the COMPANY Territory once COMPANY [***]. Supply of COMPANY with Drug Product for Commercialization in COMPANY Territory will be [***].&nbsp;&nbsp;Supply of COMPANY with Drug Product for Commercialization in the Co-Commercialization Territory will be [***]. In case of a Technology Transfer to the COMPANY or to another Third Party manufacturer under a COMPANY Discretionary Activity according to Section&nbsp;6.6(c), COMPANY shall use Commercially Reasonable Efforts to source Drug Product and to supply the Parties with GMP-compliant Drug Product for Commercialization in the Co-Commercialization Territory, if necessary according to the Co-Commercialization Plan. Supply in such a case will be [***], subject to a supply agreement to be mutually agreed between the Parties in good faith; in addition Section 6.6(c) shall apply with regard to [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">6.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Forecasting and Ordering.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">For the supply of Product through MorphoSys, COMPANY shall provide its forecasts in alignment with its capacity reservation plan, and submit binding orders for clinical and commercial demand of Drug Product, both with respect to the COMPANY Territory and the Co-Commercialization Territory, to MorphoSys in sufficient time before MorphoSys is required to submit its forecast and [***] so that MorphoSys can forward COMPANY's [***] for Manufacturing campaigns in accordance with the timelines of [***]. MorphoSys shall use Commercially Reasonable Efforts to supply COMPANY with Drug Product [***].</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">57</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">6.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Technology Transfer to COMPANY or Third Party.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">If after discussion in the JMC and decision of the JSC, and subject to COMPANY&#x2019;s final decision-making authority set forth in Section 9.2(e)(ii)(3), there will be a transfer of [***] ("</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Technology Transfer</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"), MorphoSys agrees to use Commercially Reasonable Efforts to </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> support the Technology Transfer to COMPANY or COMPANY Affiliate or a Third Party manufacturer, [***]. For any Technology Transfer or further technology transfer (for clarity, including transfers pursuant to Section 6.6(b) and 6.6(c) Sections 6.1(b)(ii), 6.1(b)(iii), 6.1(b)(vi) and 6.1(b)(vii) shall apply. Any other technology transfer than the Technology Transfer will be subject to the mutual agreement of the Parties, provided that such technology transfer [***].&nbsp;&nbsp;MorphoSys has not taken, and shall not take, any actions [***] described in this Section 6.6.&nbsp;&nbsp;No more than [***] time during any [***] month period, MorphoSys shall have the right to request and obtain, in accordance with the Supply Agreement, a technology transfer of the Manufacturing Process of the Product from COMPANY or any of its Affiliate or Third Party manufacturer, to MorphoSys, a MorphoSys Affiliate or any Third Party within a reasonable time after request, [***] if COMPANY desires at a later point in time to source Licensed Antibody or Drug Product from MORPHOSYS, a MorphoSys Affiliate or the Third Party.&nbsp;&nbsp;COMPANY&#x2019;s right to the Technology Transfer to a Third Party under this Section shall be conditioned upon COMPANY ensuring that the new applicable Third Party agreement shall provide for at least one (1) further technology transfer to MorphoSys, its Affiliates or Third Party manufacturer, and COMPANY using Commercially Reasonable Efforts to obtain the right to additional technology transfers.&nbsp;&nbsp;In order to facilitate such future technology transfer, [***], COMPANY shall </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(A)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> allow MorphoSys to be present in person during the performance of the key steps of the Technology Transfer, and in any case during the rendering of in-person advice and instructions [***] in the course of the Technology Transfer, and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(B)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> upon request of MorphoSys provide to MorphoSys access to the Manufacturing documentation.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Technology Transfer for Development or Commercial Supply for both Parties. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">If both Parties agree (for clarity, beyond the discussions in the JMC and the JSC where neither Party shall have the final say and, for clarity, this Section 6.6(b) shall not limit the right of COMPANY to pursue a Technology Transfer [***] pursuant to Section 6.6(a) or Section 9.2(e)(ii)) that a Technology Transfer or a further technology transfer to a Third Party for Development or Commercial supply will be pursued for supply of both Parties as provided under this Agreement, the Parties will discuss and agree on the Third Party manufacturer or COMPANY or COMPANY Affiliate to be the manufacturer as sole or second supplier of Product; except as otherwise agreed by the Parties, such agreed Technology Transfer or further technology transfer will be regarded as [***]. Supply by a Third Party manufacturer or by COMPANY or an Affiliate as manufacturer shall be charged as follows: if such supply is for the </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> Co-Commercialization in the Co-Commercialization Territory, the related costs [***] and/or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> Trials for the Co-Commercialization Territory and/or Global Trials, the related cost [***]. In addition, [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Technology Transfer for Development or Commercial Supply for COMPANY. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">If COMPANY requests to initiate a Technology Transfer or a further technology transfer in connection with the Development or Commercial supply in the COMPANY Territory, it shall bring this request to the JMC for discussion and decision by the JSC. If the JSC decides in accordance with Section 9.2(e)(ii)(3) that COMPANY</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">58</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">may pursue such transfer, COMPANY shall designate itself, an Affiliate or a Third Party manufacturer, in each case that is acceptable, in case of a Technology Transfer [***]; the activities relating to such requested Technology Transfer will be regarded as [***]. In case of such transfer, COMPANY shall ensure that, if MorphoSys desires at a later point in time to source Licensed Antibody or Drug Product from the COMPANY, COMPANY&#x2019;s Affiliate or its Third Party manufacturer, as the case may be, for the </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> Co-Commercialization in the Co-Commercialization Territory at [***] and/or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> Trials for the Co-Commercialization Territory and/or Global Trials at [***]; the cost for such respective supply shall [***] and COMPANY shall use Commercially Reasonable Efforts to ensure such supply to MorphoSys would be [***], for which COMPANY sources the Licensed Antibody or Drug Product from such manufacturer or Manufactures itself for the COMPANY Territory; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:11pt;text-decoration:underline;">provided, however</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">, that </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(A)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> the Parties will agree in good faith [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Supply after a Technology Transfer </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"> or after a further technology transfer. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">In case of a Technology Transfer or a further technology transfer to a Third Party manufacturer by either Party (the &#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Transferring Party</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;), the Transferring Party shall, through the JMC, keep the other Party (the &#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Non-Transferring Party</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;) closely informed regarding the negotiation and execution of the supply agreement between the Transferring Party and the Third Party manufacturer and shall reasonably consider the Non-Transferring Party's input thereto. The Transferring Party shall use Commercially Reasonable Efforts to ensure that, if the Non-Transferring Party is or will be supplied by the Transferring Party by use of such Third Party manufacturer, that the Non-Transferring Party shall receive the benefit of any rights and remedies with respect to damages and indemnification that are available to the Transferring Party in respect of such Third Party manufacturer's breach of representations or warranties or other obligations under such supply agreement, to the same extent as the Transferring Party.&nbsp;&nbsp;In case the Non-Transferring Party seeks to be supplied by the Transferring Party by use of the Transferring Party's Third Party manufacturer, the Parties will negotiate in good faith a supply agreement between the Parties, which supply agreement shall comply with and implement the principles for liability and indemnification as set out [***], as applicable, including if the Third Party manufacturer under such supply agreement is [***]. In case of a Technology Transfer or a further technology transfer not to a Third Party manufacturer but to either Party for such Party's own Manufacture and in case such Party also supplies the other Party, the Parties shall negotiate a supply agreement between the Parties for such supply, which supply agreement shall comply with and implement the principles for liability and indemnification as set out [***], as applicable.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">6.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"> Supply. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Subject to Section 6.4, except to the extent that </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> COMPANY sources product directly for the COMPANY Territory [***] pursuant to Section 6.1(b), or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">that COMPANY, any Affiliate of COMPANY, or a Third Party supplies the Product after a Technology Transfer pursuant to Section 6.6 above, MorphoSys and COMPANY shall and shall ensure that its Affiliates, Sublicensees and distributors source and purchase all of their clinical and commercial requirements of the Product for Development Activities, including for MorphoSys Funded Development Activities and COMPANY Funded Development Activities or for Commercialization via MorphoSys [***].&nbsp;&nbsp;Without limiting the foregoing, subject to Section 6.6(a) and (c), as of the Effective Date COMPANY shall have the right to identify and qualify a [***] manufacturer for eventual clinical and commercial supply for the COMPANY Territory following any Technology Transfer after reasonable consultation with MorphoSys, but in any</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">59</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">event at COMPANY&#x2019;S sole discretion.&nbsp;&nbsp;To the extent legally permissible, MorphoSys and its Affiliates shall not, and MorphoSys shall use Commercially Reasonable Efforts to ensure that its Sublicensees and distributors do not, supply any Third Party with the Licensed Antibody or Product for [***] supply of the COMPANY Territory.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">6.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CMC Data. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">In the case where MorphoSys sources Drug Product [***] and supplies the demands of Drug Product for Commercialization in the COMPANY Territory, the Co-Commercialization Territory, or Global Trials, MorphoSys will [***] to obtain [***] the CMC related sections of the dossier, as necessary to prepare Regulatory Materials for the European Union and, upon COMPANY's request and to the extent possible, also for any other jurisdictions in the COMPANY Territory. MorphoSys shall own and MorphoSys shall maintain the master dossier for the Co-Commercialization Territory and MorphoSys and COMPANY shall co-own and MorphoSys and COMPANY shall jointly maintain the master dossier for the COMPANY Territory, in each case to the extent legally possible, and Parties shall discuss in good faith whether the master dossier shall be co-owned at a certain point in time. Related CMC activities reasonably useful for the MorphoSys Trials and Global Trials will be regarded as [***]; related CMC activities not reasonably useful for the MorphoSys Trials and Global Trials will be regarded as [***]. Certain confidential CMC information that is not specific to the Licensed Antibody or Drug Product (e.g., manufacturing trade secrets) may be provided by [***] directly to Regulatory Authorities and may not be disclosed to [***]. For the avoidance of doubt, the Parties shall exchange CMC information through the JMC and each Party may use CMC information received from the other Party. In the case where more than one Party is responsible for supply, either under each Party&#x2019;s supply relationship [***] or under each Party&#x2019;s supply relationship with a Third Party manufacturer or COMPANY or COMPANY Affiliate, the Parties shall aim to keep a common master dossier, and if not possible consult, cooperate and align how to achieve creation and maintenance of the dossiers efficiently and to the benefit of both Parties.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-indent: -35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SHARING OF JOINT DEVELOPMENT COSTS AND PRE-TAX PROFIT (LOSS) SHARE</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">7.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Development Costs Sharing Principle.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Beginning as of the Execution Date the Parties shall share all Joint Development Costs set forth in the Development Plan in accordance with the Pro Rata Percentage as set forth in the applicable Development Plan. Joint Development Costs will be shared on a GAAP accrual basis, so that each Party can accurately report expenses in its financial statements. Each Party shall invoice the other Party&nbsp;&nbsp;by providing copies of all invoices received from Third Parties and records of the number of FTEs, in accordance with Section 7.8.&nbsp;&nbsp;ln order to ensure that the Parties have received sufficient funds, Development Costs will be shared once they are incurred and invoiced by a Party or invoiced by a Third Party.&nbsp;&nbsp;For the avoidance of doubt, Development activities carried out by MorphoSys prior to the Execution Date may not conform with the Development Plan inasmuch as the Development Plan first came into existence as of the Execution Date.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">7.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Development Costs not shared.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> All Development costs and Manufacturing costs for [***] Funded Development Activities shall be [***]. All Development costs and Manufacturing costs for [***] Funded Development Activities (including, for the avoidance of doubt, [***]), shall be [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">7.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Development and Co-Commercialization Budget Overruns.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;Each Party shall promptly inform the other Party upon determining that it is likely to exceed the budget amounts</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">60</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">set forth in the annual Joint Development Budget or in the Co-Commercialization Budget (each a &#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Budget</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;).&nbsp;&nbsp;To the extent that a Budget for a particular calendar year is exceeded by less than [***] percent ([***]%), each Party shall bear its share of such excess amount as set forth in Section 7.1 and Section 7.7(a), as applicable. To the extent that a Budget for a particular calendar year is exceeded by more than [***] percent ([***]%) (such excess over [***] percent ([***]%), the "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Excess Amount</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"), COMPANY shall fully bear its share of such Excess Amount; and COMPANY shall also initially (subject to the following) bear MorphoSys&#x2019; share if MorphoSys so requests the company to do so, subject to repayment as follows. COMPANY shall deduct such MorphoSys share of such Excess Amount (or parts of it, as applicable) from future milestone and/or royalties payments due to MorphoSys under this Agreement, provided that no milestone payment may be reduced by more than [***] percent ([***]%) and no royalty payments shall be reduced to represent less than [***] percent ([***]%) of Net Sales at any time.&nbsp;&nbsp;In the event that any portion of the Excess Amount of MorphoSys that was borne in accordance with the previous sentence by COMPANY remains outstanding and not reimbursed to COMPANY for [***] months or longer, then COMPANY may invoice MorphoSys for payment of such portion, plus interest on such amount at an annual rate of [***] percent ([***]%) from the date the payment to MorphoSys by the COMPANY was originally due, and MorphoSys shall pay to the COMPANY any such invoiced amount in accordance with Section 8.5.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">7.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Calculation of Development Costs Sharing, Forecasts and Currency.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Within [***] Business Days of the end of any calendar quarter, each Party shall submit a calculation of all Joint Development Costs (including accurate records and books of accounts containing all data reasonably required for the calculation and verification of FTEs used by each Party in accordance with GAAP and the Development Plan) in accordance with GAAP on an accrual basis, incurred by such Party which may be subject to a reimbursement or cost sharing under this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">In addition, each Party shall submit an updated forecast of the Joint Development Costs for the next [***] calendar quarters. Each Party shall be entitled to audit the cost calculations claimed by the other Party under this Section 7.4 and the audit provisions set forth in Section 8.3(g) shall apply mutatis mutandis to any such audit.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Joint Development Costs incurred in Euros or US dollars shall not be converted and shall be payable in Euros or US dollars, as the case may be, whereas Joint Development Costs incurred in other currencies than Euros or US dollars shall be converted to US dollars using [***].&nbsp;&nbsp;The Party incurring such Joint Development Costs shall provide to the other Party a true, accurate and complete report of the [***] exchange rate used in the calculation. All payments will be made without deduction of exchange, collection or other charges.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">7.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Development and Commercial FTE Costs</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.&nbsp;&nbsp;With respect to Development or Commercial-related FTE costs, which a Party is obligated to bear and then submit to the other Party for sharing or reimbursement, as the case may be, each Party shall calculate its costs using the relevant FTE Rate as set forth in Section 1.29 and Section&nbsp;1.58, respectively.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">7.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sole Funded Development Activities and Data Buy-In Mechanism.</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">61</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Responsibility for Sole Funded Development Activities. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Subject to Section&nbsp;3.5, each Party shall be fully responsible for its Sole Funded Development Activities.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sole Funded Development Data Buy-In Option. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Either Party (such Party, the &#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Buy-In Party</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;) shall have the right to use the other Party&#x2019;s Sole Funded Development Data the same way it may use Joint Development Data under this Agreement (including, for clarity, Sole Funded Development Data resulting from Non-NDA Studies that are Independent Trials), subject to the payment of </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">a buy-in fee constituting [***] incurred as of delivery of the buy-in notice (including internal and Out-of-Pocket Costs) for such Development activities that it would have otherwise been required to pay in accordance with the Pro Rata Percentage if such Development activities had been Joint Development Activities and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> its Pro Rata Percentage of Development Costs that are incurred after delivery of the buy-in notice whereby, with effect as of delivery of the buy-in notice, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(A) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">such Development Costs shall be considered part of Joint Development Costs, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(B)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> the respective Development activity shall be considered part of the Joint Development Plan, and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(C) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">budget overruns shall be considered Budget overruns as governed by Section 7.3.&nbsp; Such buy-in payment shall entitle the Buy-In Party to use only the Development Data of the Sole Funded Development Activity that the Buy-In Party elected to participate in and so paid for.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">7.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Co-Commercialization Costs &#x2013; Pre-Tax Profit (Loss) Share.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Principles. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The Parties shall share Pre-Tax Profit (Loss) as follows: </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&nbsp;MorphoSys shall be entitled to (and bear) fifty percent (50%) of Pre-Tax Profit (Loss); and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> COMPANY shall be entitled to (and bear) fifty percent (50%) of Pre-Tax Profit (Loss) ("</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Pre-Tax Profit (Loss) Share</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"). The Pre-Tax Profit (Loss) calculation shall exclude [***]. It is further understood that allowable costs to be deducted from Net Sales in the Co-Commercialization Territory as set forth in the Definitions of Pre-Tax Profit (Loss) and Pre-Tax Profit (Loss) Share shall include [***]. To the extent any Commercialization activity is conducted in the Co-Commercialization Territory (or an External Cost or Commercial FTE cost is incurred) in support of Product(s) but also in support of other products, services or efforts of a Party or are not solely attributable to Product(s), then the External Costs and Commercial FTE costs thereof shall be only included in the Pre-Tax Profit (Loss) calculation as allowable costs pro rata for Product.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Report of Costs under the Pre-Tax Profit (Loss) Share.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> The Parties shall furnish to each other a written report for [***] showing the [***]; in each case, solely to the extent incurred with respect to the Co-Commercialization Territory during such [***]. Such reports shall be furnished in reasonable detail for performing the Pre-Tax Profit (Loss) Share calculation. Such reports shall be due no later than [***] calendar days following the end of each [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Report on Net Sales in Co-Commercialization Territory and Reconciliation Calculation.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> MorphoSys shall compile and furnish to COMPANY a written report for each [***] showing the amount and calculation of the Net Sales for such [***] in the Co-Commercialization Territory. The report shall include gross sales and the calculation of Net Sales thereon, including the amount of any deductions provided for in the definition of Net Sales (broken down by category as enumerated in such definition).&nbsp;&nbsp;In addition, MorphoSys shall perform a reconciliation calculation to ensure that each</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">62</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Party bears and receives its share of Pre-Tax Profit (Loss) as set forth under this Agreement. Such report shall be due no later than [***] calendar days following the end of each [***] and such reconciliation calculation shall be due no later than [***] calendar days following the end of each [***].&nbsp;&nbsp;The reconciliation procedures shall also include for each Party to keep the other Party informed [***], on a regular ongoing basis, about forecasts of Net Sales of Product(s) in the Co-Commercialization Territory and forecasts of Pre-Tax Profit (Loss) in the Co-Commercialization Territory.&nbsp;&nbsp;In addition, taking into account the reasonable need of COMPANY to have such information for revenue forecasts and guidance, MorphoSys shall provide to COMPANY on a regular, ongoing basis, [***] estimates with regard to the Net Sales levels in the Co-Commercialization Territory.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reconciliation Payment. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The amounts resulting from the reconciliation calculation of the Pre-Tax Profit (Loss) Share under Section 7.7(c) shall be payable for each [***] after performance of such calculation as set forth in Section&nbsp;7.7(c) by MorphoSys or, as applicable, by COMPANY, within [***] calendar days of receipt of a respective undisputed invoice of the other Party.&nbsp;&nbsp;All items of the Pre-Tax Profit (Loss) Share being part of the reconciliation calculation in currencies other than US dollars shall be converted into US dollars by using the average closing exchange rate reported by Bloomberg for the respective quarter.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Audits. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Each Party shall be entitled to audit the cost reports and calculations of the Pre-Tax Profit (Loss) claimed by the other Party under this Section 7.7 and the audit provisions set forth in Section 8.3(f) shall apply mutatis mutandis to any such audit.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Record Keeping</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.&nbsp;&nbsp;MorphoSys shall keep and shall ensure that its Affiliates and Sublicensees keep, in accordance with GAAP, books and accounts of record in connection with the sales and other dispositions of Products in the Co-Commercialization Territory (including use in Trials, or provision on a compassionate use basis or as marketing samples) in sufficient detail to permit accurate determination of all figures necessary for verification of the Pre-Tax Profit (Loss) Share hereunder.&nbsp;&nbsp;MorphoSys and its Affiliates and Sublicensees shall maintain such records for a period of at least [***] years after the end of the [***] in which they were generated and make such records available upon request following the audit provisions set forth in Section 8.3 (g) which shall apply mutatis mutandis to any such audit.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">7.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Finance Working Group. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Within [***] calendar days after the Effective Date, each Party shall appoint two senior finance representatives who shall together form a joint working group (the "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Finance Working Group</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"), which shall report to the JSC. The Finance Working Group shall include individuals from each Party with expertise in the areas of accounting, cost allocation, budgeting and financial reporting. The Finance Working Group shall be responsible for: </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> coordinating and conducting the accounting, reporting, reconciliation and other related activities set forth in this Agreement, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> advising and providing support to the JSC, and the other committees if applicable, with respect to financial, accounting, budgeting, reporting and other issues that may arise in connection with the various plans and corresponding budgets for activities hereunder, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> reviewing relevant FTE costs and External Costs incurred by the Parties and their Affiliates hereunder, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iv)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> recommending for approval by the JSC any changes to reporting procedures, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(v)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> coordinating or performing the budgeting, consolidation, completion and review of the Pre-Tax Profit (Loss) Share in accordance with the reconciliation procedures set forth in Section 7.7 and as set forth in the Definitions of Pre-Tax Profit (Loss)</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">63</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">and Pre-Tax Profit (Loss) Share, including budgeting and calculation of allowable costs, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(vi)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> performing and reviewing calculations for the reconciliation of payments, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(vii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> reviewing and detailing the reconciliation methodology and Pre-Tax Profit (Loss) Share calculation and determination of allowable costs, and recommending for approval by the JSC any changes to such methodology, determination and details, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(viii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&nbsp;coordinating audits, and discussing and attempting to resolve discrepancies or issues arising from such audits. If the Finance Working Group does not approve such methodologies and costs brought forward by a Party or is unable to resolve any disputes or differences, the matter shall be brought to the JSC. For any Dispute unresolved by the JSC related to Commercial Manufacturing Costs in the COMPANY Territory referred to in Section 6.4, if the Executive Officers are also unable to resolve such Dispute, such Dispute shall be directly brought to the Expert for decision under Section 9.3. For the purpose of the reporting due under Sections&nbsp;7.4(a) and 7.7, each Party shall provide the actual number of their FTEs (per Trial and per function) having worked for such Party in performance of this Agreement to the extent such FTEs are to be included in defined costs to be allocated between the Parties under this Agreement. The Finance Working Group will agree on a process to provide each Party with all necessary information that is required to close each respective Party&#x2019;s books under the applicable GAAP.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-indent: -35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FINANCIAL TERMS</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;License Fee and Contribution.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Initial License Fee. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">COMPANY shall pay to MorphoSys a one-time, non-creditable, non-refundable, upfront and initial license fee of US dollar seven hundred fifty million (USD 750,000,000).&nbsp;&nbsp;This initial license fee shall be due on the Effective Date and payable by COMPANY within [***] Business Days after the Effective Date.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Contribution to Equity.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;COMPANY shall purchase from MorphoSys ordinary shares of MorphoSys in bearer form with no par value and a notional value attributable to each share of &#x20AC;1.00 in the form of American Depositary Shares against a total consideration of US dollar one hundred fifty million (USD 150,000,000), subject to the terms and conditions of </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT&nbsp;16</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">8.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Milestone Payments</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Development / Regulatory Milestones.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">COMPANY shall pay the following non-refundable and non-creditable milestone payments to MorphoSys, each due upon the first achievement of each milestone event indicated below (whether achieved by or on behalf of either Party or its Affiliate, Sublicensee or any other entity acting on behalf of any of them) with respect to the first Product achieving such milestone event. COMPANY shall notify MorphoSys upon achievement of any milestone event as set forth below and shall pay the applicable milestone payment within [***] calendar days of achievement of such milestone event:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td colspan="2" valign="top" style="border-right:1pt solid #000000 ;border-left:1pt solid #000000 ;width:100.00%;border-top:1.5pt solid #000000 ;border-bottom:1pt solid #000000 ;height:2.85pt;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Oncology: </font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Milestone event</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Milestone<br>payment (in US<br>dollars)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">64</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Total oncology development &amp; regulatory milestones</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">535 million</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="border-right:1pt solid #000000 ;border-left:1pt solid #000000 ;width:100.00%;border-top:1.5pt solid #000000 ;border-bottom:1pt solid #000000 ;height:2.85pt;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 3pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Autoimmune Indications**:</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Milestone event</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Milestone<br>payment (in US<br>dollars)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 5pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">65</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-left:1pt solid #000000 ;width:77.78%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Total autoimmune development &amp; regulatory milestones</font></p>
				</td>
				<td valign="middle" style="border-right:1pt solid #000000 ;width:22.22%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 5.4pt 0pt 5.4pt;height:2.85pt">
					<p style="margin:0pt 0pt 3pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">205 million</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">AutoImmune Indications Alternative Milestones***:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-left:1pt solid #000000 ;border-top:1pt solid #000000 ;width:78.04%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;border-top:1pt solid #000000 ;width:21.96%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:78.04%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:21.96%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:78.04%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:21.96%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:78.04%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:21.96%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:78.04%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:21.96%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:78.04%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:21.96%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:78.04%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:21.96%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:78.04%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:21.96%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:78.04%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:21.96%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:78.04%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:21.96%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:78.04%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:21.96%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:78.04%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:21.96%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:78.04%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:21.96%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:78.04%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:21.96%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:78.04%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:21.96%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;width:78.04%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;width:21.96%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">For each Regulatory Approval referred to in this table, &#x201C;Approval&#x201D; shall mean a final or a conditional approval or approval on exceptional circumstances.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Each milestone payment would be payable only upon first achievement of such milestone for the first Product and no amounts would be due for subsequent or repeated achievements of the same milestone by another Product.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">If any milestone event occurs without one of the preceding milestone events occurring in such country, the milestone payment to be made in such country with respect to the preceding milestone event would be paid at the same time as the payment for the</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">66</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">subsequent milestone event.&nbsp;&nbsp;For example, if there is a filing of the first MAA in the 1</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;font-size:6pt;top:-4pt;position:relative;line-height:100%">st</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> Autoimmune Indication, any Phase 1, Phase 2, or Phase 3 Trial milestones for such 1</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;font-size:6pt;top:-4pt;position:relative;line-height:100%">st</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> Autoimmune Indication, if not previously paid, shall be paid at the time of such first MAA filing.*COMPANY would pay [***] percent ([***]%), [***] percent ([***]%) and [***] percent ([***]%) of each European approval milestone upon achievement of Pricing Approval in each of the [***], respectively.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">**COMPANY would only pay these autoimmune milestones listed above if they are triggered based on a Trial that is a COMPANY Funded Development Activity.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">***COMPANY would only pay these autoimmune milestones listed above if they are triggered based on a Trial that is a Joint Development Activity, in both cases excluding any non-NDA Studies.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">For all purposes under this Section, whether an Indication is &#x201C;1</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;font-size:6pt;top:-4pt;position:relative;line-height:100%">st</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;, &#x201C;2</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;font-size:6pt;top:-4pt;position:relative;line-height:100%">nd</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;, &#x201C;3</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;font-size:6pt;top:-4pt;position:relative;line-height:100%">rd</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D; or &#x201C;4</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;font-size:6pt;top:-4pt;position:relative;line-height:100%">th</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D; (if applicable) for any given milestone event will be determined not based on which Indication started first in development, but on which indication first achieves the milestone event.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales Milestones.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">COMPANY shall notify MorphoSys upon achievement of any milestone event as set forth below and, within [***] calendar days of the first (1</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;font-size:6pt;top:-4pt;position:relative;line-height:100%">st</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">) occurrence of any of the following milestone events, COMPANY shall make the following one-time, non-creditable, non-refundable payments to MorphoSys based on Net Sales in any calendar year in the COMPANY Territory (across all Products and all indications) in accordance with the invoicing process outlined in Section 8.5:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-left:1pt solid #000000 ;border-top:1pt solid #000000 ;width:74.14%;background-color: #D9D9D9;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Milestone event (in US dollars) </font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;border-top:1pt solid #000000 ;width:25.86%;background-color: #D9D9D9;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Payment<br>(in US dollars)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:74.14%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:25.86%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:74.14%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:25.86%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:74.14%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:25.86%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:74.14%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:25.86%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:74.14%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:25.86%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;width:74.14%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Total Sales Milestones</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;width:25.86%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">315 million</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">For the avoidance of doubt, if more than one of the above Net Sales thresholds are achieved for the first time in the same calendar year, all such achieved milestone payments that were not previously paid will become due at such time.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Disputes on whether a development milestone event or a sales milestone event has occurred shall be settled according to Section 18.3(b).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">8.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Royalties from COMPANY.</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">67</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Royalties for Products in the European Region and Japan.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">In further consideration of the licenses granted by MorphoSys to COMPANY, COMPANY shall pay to MorphoSys tiered royalties on incremental annual Net Sales of Products in the European Region and Japan:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-left:1pt solid #000000 ;border-top:1pt solid #000000 ;width:81.00%;background-color: #D9D9D9;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Net Sales of Products in European Region and Japan in any calendar year (in US dollars)</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;border-top:1pt solid #000000 ;width:19.00%;background-color: #D9D9D9;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Royalty Rate</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:81.00%;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:19.00%;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:81.00%;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:19.00%;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:81.00%;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:19.00%;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:81.00%;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:19.00%;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:81.00%;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:19.00%;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;width:81.00%;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
				<td valign="middle" style="border-left:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;width:19.00%;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The royalty rates under this Section are incremental with respect to the annual Net Sales of Products. As an example, if Products achieve in any given calendar year [***] US dollar (USD [***]) in Net Sales in the COMPANY Territory, then a [***] percent ([***]%) royalty shall be paid on the first [***] dollars (USD [***]), a [***] percent ([***]%) royalty shall be paid on the next [***] dollars (USD [***]), and a [***] percent ([***]%) royalty shall be paid on the remaining [***] dollars (USD [***]).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Net Sales of Products in ROW Territory</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.&nbsp;&nbsp;In further consideration of the licenses granted by MorphoSys to COMPANY, COMPANY shall pay to MorphoSys a royalty of [***] percent ([***]%) of Net Sales of Products in the ROW Territory.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Royalty Term. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The royalties under Section 8.3 shall be paid by COMPANY to MorphoSys during the Royalty Term. "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Royalty Term</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means the time from [***] of a Product in a given country in the COMPANY Territory on a country-by-country and Product-by-Product basis and until the last to occur of: </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> the expiration of the last Valid Claim Covering such Product within the Xencor Background Patents, MorphoSys Background Patents, Joint Foreground Patents and MorphoSys Foreground Patents in such country, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] years after the first post-Marketing Authorization sale of such Product in such country and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> expiration of the regulatory exclusivity for such Product in such country. The royalties payable with respect to Net Sales of Products shall be reduced by [***] percent ([***]%) of the otherwise applicable rates, with respect to Net Sales of a Product in a country during any portion of the Royalty Term to the extent there is no such Valid Claim in such country; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:11pt;text-decoration:underline;">provided, however</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">, that, subject to Section 8.10, the royalty payments due in any calendar quarter during the Royalty Term shall in no case amount to less than [***] percent ([***]%) of Net Sales of Products in the COMPANY Territory. COMPANY has selected this royalty scheme from among other choices available to COMPANY as the most appropriate and convenient</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">68</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">approach to determine the value of the licenses granted by MorphoSys to COMPANY hereunder.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 36pt;text-indent: -0.55pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reporting of Net Sales and Monthly Forecast</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.&nbsp;&nbsp;Within [***] calendar days of the end of each calendar quarter for which royalties are due, COMPANY shall deliver to MorphoSys a written report setting forth the following information for such calendar quarter, on a Product-by-Product, country-by-country and COMPANY Territory-wide basis </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> Net Sales of each Product, gross sales associated therewith and the calculation of Net Sales thereon, including the amount of any deductions provided for in the definition of Net Sales (broken down by category as enumerated in such definition), and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> the royalties due hereunder for the sale of each such Product.&nbsp;&nbsp;No reports under this Section 8.3(d) shall be due for any such Product before the [***] of such Product or after the Royalty Term for such Product has expired in all countries in the COMPANY Territory.&nbsp;&nbsp;The total royalty due for the sale of all such Products during such calendar quarter shall be calculated in accordance with this Section 8.3. In addition, taking into account the reasonable need of MorphoSys to have such information for revenue forecasts and guidance, COMPANY shall provide to MorphoSys on a regular, ongoing basis, [***] estimates with regard to the Net Sales levels in [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Currency.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Royalties on Net Sales in Euros or US dollars shall not be converted and shall be payable in Euros or US dollars, as the case may be, whereas royalties on Net Sales in other currencies than US dollars or Euros shall be converted to US dollars or Euros using the average of the exchange rate as reported by [***] (or a successor entity) during the calendar quarter to which such payment pertains.&nbsp;&nbsp;With any payment in relation to which a currency conversion is performed to calculate the amount of payment due, each such invoice or report shall include the currency conversion and rate used as a separate line item. All payments will be made without deduction of exchange, collection or other charges.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Record Keeping.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">In accordance with GAAP, COMPANY shall keep and shall ensure that its Affiliates and Sublicensees keep books and accounts of record in connection with the sales and other dispositions of Products (including use in Trials, or provision on a compassionate use basis or as marketing samples) in sufficient detail to permit accurate determination of all figures necessary for verification of royalties or other payments to be paid hereunder.&nbsp;&nbsp;COMPANY and its Affiliates and Sublicensees shall maintain such records for a period of at least [***] years after the end of the calendar quarter in which they were generated and make such records available to MorphoSys or an independent certified public accounting firm reviewing such documents and records on behalf of Xencor and being selected by Xencor.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Audits.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Upon [***] calendar days prior notice from MorphoSys, COMPANY shall permit an independent certified public accounting firm selected by MorphoSys, to examine the relevant books and records of COMPANY and its Affiliates and Sublicensees as may be reasonably necessary to verify the amounts reported by COMPANY in accordance with Section 8.3(d) and the payment of royalties hereunder. An examination by MorphoSys under this Section 8.3(g) shall occur not more than once in any calendar year and shall be limited to the pertinent books and records for any calendar year ending not more than [***] years before the date of the request. The accounting firm shall be provided access to such books and records at COMPANY&#x2019;s or its Affiliates&#x2019; or Sublicensees&#x2019; facility(ies) where such books and records are</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">69</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">normally kept and such examination shall be conducted during COMPANY&#x2019;s or its Affiliates&#x2019; or Sublicensees&#x2019; facility(ies), normal business hours. COMPANY may require the accounting firm to sign a reasonably acceptable non-disclosure agreement before providing the accounting firm with access to COMPANY&#x2019;s or its Affiliates&#x2019; or Sublicensees&#x2019; facilities or records.&nbsp;&nbsp;Upon completion of the audit, the accounting firm shall provide both COMPANY and MorphoSys a written report disclosing any discrepancies in the reports submitted by COMPANY or the royalties paid by COMPANY, and, in each case, the specific details concerning any discrepancies. MorphoSys shall be entitled to report the results of any such audit to Xencor. If such accounting firm concludes that additional royalties were due to MorphoSys, then COMPANY will pay to MorphoSys the additional royalties within [***] calendar days of the date COMPANY receives such accountant&#x2019;s written report plus interest in the amount of [***] percentage point above the then-applicable rate on the deposit facility of the [***] per annum.&nbsp;&nbsp;Further, if the amount of such underpayments exceeds more than [***] percent ([***]%) of the amount that was properly payable to MorphoSys, then COMPANY shall reimburse MorphoSys for MorphoSys&#x2019; costs in connection with the audit (otherwise such audit shall be at MorphoSys&#x2019; cost).&nbsp;&nbsp;If such accounting firm concludes that COMPANY overpaid royalties to MorphoSys, then MorphoSys will refund such overpayments to COMPANY plus interest in the amount of [***] percentage point above the then-applicable rate on the deposit facility of the [***] per annum, within [***] calendar days of the date MorphoSys receives such accountant&#x2019;s report.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">8.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Third Party Licenses and Third Party Payments.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;If either Party determines that it may be desirable to obtain a license from a Third Party, such Party shall promptly notify the other Party of such determination in writing giving detailed reasoning and the Parties shall discuss, through the JSC, the necessity or usefulness to obtain such Third Party's license.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Third Party Payments.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Except as otherwise set forth in Section 11.15, in the event the Parties agree to seek a license from a Third Party, [***] shall have the first right to reasonably lead negotiations and conclude such license for the [***]. [***] shall have the right to participate in any such negotiation.&nbsp;&nbsp;In the event [***] seeks a license from a Third Party for the [***] shall have the first right to reasonably lead negotiations and conclude such license for the [***]. [***] shall have the right to participate in any such negotiation.&nbsp;&nbsp;Whichever Party negotiates such Third Party license shall keep the other Party informed and shall take due account of the other Party's interests, and such other Party shall provide any assistance reasonably requested.&nbsp;&nbsp;In the event the Parties agree during the Term to seek a Third Party license, the Parties shall [***] all Third Party Payments that are due on or after the Execution Date to Third Parties in relation to any Licensed Antibody or Products (i) in accordance with [***] if such license is worldwide and (ii) in accordance with [***] if such license is limited to the Co-Commercialization Territory.&nbsp;&nbsp;For the avoidance of doubt, this Section 8.4 does not apply for payments made which are [***].&nbsp;&nbsp;In the event the Parties disagree as to whether to seek a license from a Third Party but [***] has reasonably determined that it would be less burdensome and/or more efficient to Develop and Commercialize the Product in the [***] shall have the right to negotiate and conclude such license in its own name and for the [***], </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;text-decoration:underline;">provided that</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> [***] in the Field in the [***] and provided further that if [***] obtains a license from a Third Party in the [***] that is necessary for</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">70</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Commercialization of the Product in the form as existing on the Execution Date, in the [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Third Party Licenses under Issued Specific Composition Patents.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;If MorphoSys or COMPANY enter into any agreement with a Third Party for a license under an issued Patent which Covers the specific composition of matter of: (i) XmAb5574 due to and because of the sequence of its Fv or of its Fc variants, or of (ii) the Xencor High-ADCC/CDC Fc variants of any other Licensed Antibody which is under development or commercialization by MorphoSys or its Affiliate(s) or COMPANY or its Affiliate(s) due to and because of the sequence of such Xencor High-ADCC/CDC Fc variants ("</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Issued Specific Composition Patents</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">") to avoid doubt, an issued Patent will "Cover the specific composition" via a use claim if the scope of the use claims is limited to uses of such specific composition of matter due to and because of the sequence (meaning the Fv or Fc variants in the case of XmAb5574 and the Xencor High-ADCC/CDC Fc variants of such other Licensed Antibody) (and the foregoing specifically excluding Patents that apply due to any chemical modification thereto not present in the form thereof having been tested in the Xencor Phase 1 Trial), then [***] percent ([***]%) of the net sales royalties actually paid to the Third Party under such license with respect to Net Sales in any given calendar quarter in any given country may be offset against the royalty that would otherwise have been payable to MorphoSys with respect to such Net Sales in such calendar quarter; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:11pt;">provided, however</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">, that the foregoing reduction shall not reduce the royalty owed to MorphoSys in any given calendar quarter below [***] percent ([***]%) of Net Sales of Products in the COMPANY Territory.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payments under the Xencor Agreement</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.&nbsp;&nbsp;During the Term, MorphoSys shall be responsible for making the Xencor Payments to Xencor, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:11pt;text-decoration:underline;">provided, however</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">, that Xencor US Royalties shall be shared in accordance with the Pre-Tax Profit (Loss) Share.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">8.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General Payment Terms. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Unless otherwise specified, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">COMPANY shall make all payments under this Agreement, including the initial license fee and the milestone payments due to MorphoSys under this Agreement, in US dollars, and the royalty payments as set forth in Sections&nbsp;8.3(a) and (b), and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> both Parties shall make all payments to each other under the Pre-Tax Profit (Loss) Share reconciliation to each other in US dollars. All payments under this Agreement are exclusive of applicable statutory value-added tax (VAT), if any, which shall be listed separately on each invoice. All payments other than royalties due under this Agreement shall be made to the respective Party within [***] calendar days, unless otherwise set forth in this Agreement, following the receipt of an invoice, which shall in no case be sent prior to the respective due date. All royalty payments are due and payable within [***] calendar days upon receipt of an invoice from MorphoSys, which shall in no case be sent prior to the receipt of the Net Sales report provided by COMPANY pursuant to Section 8.3(d). Each payment under this Agreement shall be made by electronic transfer in immediately available funds via bank wire transfer to such bank account as the respective Party shall designate in writing to the other Party at least [***] calendar days before the payment is due. For the purpose of this Section 8.5, &#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">VAT</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D; means, in the EU, value-added tax calculated in accordance with Council Directive 2006/112/EC and, in a jurisdiction outside the EU, any equivalent tax. The Parties will cooperate in good faith to obtain any potential exemptions or reductions from VAT which may be levied on any payments and provide all necessary data and documents.</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">71</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">8.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Late Payment. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Unless otherwise set forth in this Agreement, all payments under this Agreement shall bear interest from the date due until paid at a rate equal to [***] percentage points above the then-applicable rate on the deposit facility of the [***] per annum.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">8.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Withholding Tax. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">If Laws, rules or regulations require withholding of income taxes or other taxes imposed upon payments by a Party (&#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Payer</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;) to the other Party (&#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Payee</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;), the Payer shall support the Payee in obtaining the benefit of any relevant tax treaties to minimize as far as reasonably possible any taxes which may be levied on any payments. If either Party is entitled under any applicable tax treaty to a reduction of the rate of, or the elimination of, applicable withholding tax, it may deliver to the other Party or the appropriate Governmental Authority (with the assistance of the other Party to the extent that this is reasonably required and is expressly requested in writing) the prescribed forms necessary to reduce the applicable rate of withholding or to relieve the other Party of its obligation to withhold tax, and the other Party shall apply the reduced rate of withholding tax, or dispense with withholding tax, as the case may be, provided that the other Party has received evidence of such delivery of all applicable forms (and, if necessary, its receipt of appropriate governmental authorization) at least [***] calendar days prior to the time that the payment is due.&nbsp;&nbsp;If, in accordance with the foregoing, a Party withholds any amount, it shall make timely payment to the proper taxing authority of the withheld amount, and send to the other Party proof of such payment within [***] days following such latter payment.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">8.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consistent Methodology. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">For the avoidance of doubt, all calculations hereunder shall be made in accordance with the applicable budgets, definitions and terms set forth in this Agreement, the applicable Exhibits, accounting policies and methodologies as agreed by the Finance Working Group and in accordance with GAAP.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">8.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Blocked Payments.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> In the event that, by reason of Laws in any country, it becomes impossible or illegal for a Party or its Affiliates to transfer, or have transferred on its behalf, payments to the other Party, such blocked Party shall promptly notify the other Party of the conditions preventing such transfer and such distribution fees or other payments shall be deposited in local currency in the relevant country to the credit of the receiving Party in a recognized banking institution within a period of [***] calendar days designated by the receiving Party.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">8.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Limitation to royalty deductions allowed.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> Notwithstanding anything to the contrary in this Agreement (except with respect to [***], the royalty payments due in any calendar quarter to MorphoSys under this Agreement shall never be reduced to less than [***] percent ([***]%) of the Net Sales in such calendar quarter, whether by application of deductions allowed hereunder or otherwise, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">provided that</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> in the event a deduction by COMPANY is disallowed in a particular calendar quarter by reason of this limitation (whether because of this Section 8.10 or other similar limitations in this Agreement), such disallowed deduction may be carried forward and deducted by COMPANY to the extent permissible in the next calendar quarter only.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-indent: -35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;GOVERNANCE</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">9.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General Committee Authority.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Each committee formed under this Agreement shall have solely the powers expressly assigned to it in this Agreement. No committee shall have any power to amend, modify, or waive compliance with this Agreement.</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">72</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">9.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Joint Steering Committee.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purpose of the Joint Steering Committee </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">("</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">JSC</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">")</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">. &nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The JSC shall have the authority to make decisions with respect to activities which have strategic importance to the Development, Manufacture or Commercialization of the Licensed Antibody and Product as well as unresolved disputes from the JDC, JMC and JCC pursuant to Sections 9.5(e), 9.6(e) or 9.7(e), respectively.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Formation and Composition of JSC.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;The Parties shall form the JSC shortly after the Execution Date to start planning prior to the Effective Date. Each Party shall initially appoint two (2) representatives to the JSC, with one (1) representative having knowledge, expertise or responsibility in the strategic research and development of products similar to the Product and the other representative having knowledge, expertise or responsibility in the strategic commercialization of products similar to the Products, both representatives being on senior management level.&nbsp;&nbsp;In addition to its JSC representatives, a Party may have other personnel attend JSC meetings for informational purposes. Each Party may replace its JSC representatives at any time upon written notice to the other Party. MorphoSys and COMPANY shall alternate on a yearly basis the chair of the JSC. The chairperson shall be responsible for administering JSC meetings, but shall have no additional powers or rights beyond those held by the other representatives on the JSC.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Specific Responsibilities of the JSC.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;In addition to its general responsibilities, the JSC shall in particular:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Discuss and decide upon the overall strategy for Developing, Commercializing and Manufacturing the Licensed Antibody and Product in both the Co-Commercialization Territory and the COMPANY Territory, including approval of the Development Plan, Joint Development Budget, the TPP, the overall strategy for seeking Regulatory Approvals and Pricing Approvals, the Co-Commercialization Plan, the Co-Commercialization Budget and including discussing and reviewing the COMPANY Commercialization Plan and approval of alignment of COMPANY Commercialization Plan with the overall strategic Product positioning, branding, core messaging, and overall medical congress strategy and global medical education strategy with respect to global Commercialization in the Territory;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Approve the COMPANY Commercialization Plan, the Co-Commercialization Plan and the Co-Commercialization Budget, and any updates and amendments thereto;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Approve additional Global Trials, including Independent Trials, and other material amendments of the Development Plan, including the determination of proposed new Development activities as either Joint Development Activity or Sole Funded Development Activity, subject to Section&nbsp;3.5;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Approve the strategic aspects of material Regulatory Activities and material Pricing Activities in the Territory;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">73</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Discuss and decide upon the overall global strategy for Commercializing the Product and material Pricing Activities in both the Co-Commercialization Territory and the COMPANY Territory;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(vi)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Discuss and decide responsibility for the Common Technical Document (CTD);</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(vii)&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Consider in good faith any reasonable concerns of a Party that a Sole Funded Development Activity or investigator initiated Trial might adversely affect in a material way the value proposition of Licensed Antibody or Product, by, as non-limiting examples, positioning Licensed Antibody or Product in a niche or addressing a significant number of patients that would otherwise be treated within the label of an already existing Regulatory Approval for Product;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(viii)&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Review and approve COMPANY&#x2019;s demand and sales forecasts for the COMPANY Territory and the Parties&#x2019; demand and sales forecast for the Co-Commercialization Territory and the respective timelines after reconciliation by the JMC;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ix)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Discuss and approve a potential Technology Transfer and the related supply chain strategy after discussion of the same in the JMC;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Discuss and review new in-license agreements for Third Party licenses in accordance with Section 8.4(a) and 8.4(b); and</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(xi)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Oversee the JDC, JMC, JCC and Finance Working Group (as defined in Section&nbsp;7.8), approve proposals, plans and Pre-Tax Profit (Loss) Share calculation methodology presented by these committees or group and decide upon issues, which these committees referred to the JSC pursuant to Section&nbsp;9.5(e), Section&nbsp;9.6(e), Section 9.7(e) or Section 7.8 and coordinate matters that affect more than one of such committees.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;JSC Meetings.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;The JSC shall meet at least [***], unless otherwise agreed between the JSC members. Either Party may also call a special meeting of the JSC (by videoconference or teleconference) with at least [***] calendar days prior written notice to the other Party in the event such Party reasonably believes that a significant strategic matter must be addressed prior to the next scheduled meeting.&nbsp;&nbsp;The JSC may meet in person, by videoconference or by teleconference.&nbsp;&nbsp;There shall be at least one (1) meeting in person per year. In-person JSC meetings shall be held at locations alternately selected by MorphoSys and by COMPANY.&nbsp;&nbsp;Meetings of the JSC shall be effective only if both JSC representatives of each Party are present or participating in such meeting.&nbsp;&nbsp;Each Party shall report to the JSC on all strategically important issues relating to the Development, Manufacture or Commercialization of Licensed Antibody or Product promptly after such issues arise.&nbsp;&nbsp;Each Party shall bear the expense of its respective JSC representatives&#x2019; participation in JSC meetings.&nbsp;&nbsp;The chairperson shall be responsible for preparing reasonably detailed written minutes of JSC meetings that reflect all decisions made at such meetings.&nbsp;&nbsp;The JSC chairperson shall send draft meeting minutes to each member of the JSC for review and approval within [***] Business Days after each JSC meeting.&nbsp;&nbsp;Minutes shall be deemed approved unless</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">74</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">one or more members of the JSC object to the accuracy of such minutes within [***] Business Days of receipt.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;JSC Decision-Making.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The JSC shall act and decide by consensus. Each Party shall have one (1) vote on behalf of that Party; the members of one Party can only cast one joint vote. The JSC shall use commercially reasonable efforts to resolve the matters within its roles and functions. If the JSC cannot reach consensus within [***] weeks on any issue that comes before the JSC for which the JSC is responsible under this Agreement, then the Parties shall immediately refer the matter to the chief executive officers or presidents (&#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Executive Officers</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;) for attempted resolution by good faith negotiations within [***] calendar days after such notice is received. If the Executive Officers are unable to resolve such dispute within [***] calendar days after such dispute is first referred to them, then:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Subject to Section 9.2(e) (iv), (v) and (vi), and Section 9.2(f), MorphoSys shall have the final decision making authority, if such dispute relates to any of the following:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 134.7pt;text-indent: -21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(1)&nbsp;&nbsp;&nbsp;any MorphoSys Trials (for clarity including [***], subject to Section&nbsp;3.7);</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 134.7pt;text-indent: -21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(2)&nbsp;&nbsp;&nbsp;strategic decisions related to Joint Development Activities in the Territory;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 134.7pt;text-indent: -21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(3)&nbsp;&nbsp;&nbsp;operational decisions related to Joint Development Activities in the Co-Commercialization Territory;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 134.7pt;text-indent: -21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(4)&nbsp;&nbsp;&nbsp;strategic and operational decisions related to Regulatory Activities in the Co-Commercialization Territory;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 134.7pt;text-indent: -21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(5)&nbsp;&nbsp;&nbsp;Manufacturing [***] (subject to Section&nbsp;9.2(e)(ii)(2);</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 134.7pt;text-indent: -21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(6)&nbsp;&nbsp;&nbsp;strategic and operational aspects of Commercialization of the Product (including, for clarity, Product pricing decisions) in the Co-Commercialization Territory and strategic aspects regarding Medical Affairs Activities in the Co-Commercialization Territory, except as set forth in Section&nbsp;9.2(e)(ii)(5);</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 134.7pt;text-indent: -21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(7)&nbsp;&nbsp;&nbsp;strategic Product positioning, branding, core messaging, and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">overall medical congress strategy and global </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">medical education strategy with respect to global Commercialization in the Territory;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 134.7pt;text-indent: -21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(8)&nbsp;&nbsp;&nbsp;MorphoSys Funded Development Activities, including amendments hereto;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 134.7pt;text-indent: -21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(9)&nbsp;&nbsp;&nbsp;MorphoSys&#x2019; compliance with any agreement existing on Execution Date, as amended, with a Third Party to which MorphoSys is the contractual party (including the Xencor Agreement and [***]);</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 134.7pt;text-indent: -21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(10)&nbsp;MorphoSys&#x2019; compliance with its responsibilities or legal obligations as the Sponsor of a Trial; and</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">75</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 134.7pt;text-indent: -21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(11)&nbsp;Non-NDA Studies in the Co-Commercialization Territory.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Subject to Section 9.2(e)(iii), (iv), (v) and (vi), and Section 9.2(f), COMPANY shall have the final decision making authority, if such dispute relates to any of the following:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 134.7pt;text-indent: -21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(1)&nbsp;&nbsp;&nbsp;COMPANY Trial;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 134.7pt;text-indent: -21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(2)&nbsp;&nbsp;&nbsp;operational decisions related to Joint Development Activities in the COMPANY Territory;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 134.7pt;text-indent: -21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(3)&nbsp;&nbsp;&nbsp;the Technology Transfer and further technology transfers;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 134.7pt;text-indent: -21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(4)&nbsp;&nbsp;&nbsp;Commercialization activities of the Product (including for clarity, Product pricing decisions) in the COMPANY Territory;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 134.7pt;text-indent: -21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(5)&nbsp;&nbsp;&nbsp;operational activities regarding Medical Affairs Activities in the Co-Commercialization Territory and strategic and operational activities regarding Medical Affairs Activities in the COMPANY Territory;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 134.7pt;text-indent: -21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(6)&nbsp;&nbsp;&nbsp;COMPANY Funded Development Activities, including amendments thereto;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 134.7pt;text-indent: -21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(7)&nbsp;&nbsp;&nbsp;strategic and operational decisions regarding Regulatory Activities in the COMPANY Territory; and</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 134.7pt;text-indent: -21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(8)&nbsp;&nbsp;&nbsp;COMPANY&#x2019;s compliance with its responsibilities or legal obligations as the Sponsor of a Trial; and</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 134.7pt;text-indent: -21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(9)&nbsp;&nbsp;&nbsp;Non-NDA Studies in the COMPANY Territory.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Subject to Section 9.2(e)(iv), (v) and (vi), and Section 9.2(f), MorphoSys shall have the final decision making authority, if any dispute relates to any issue for which each Party would otherwise have the final say according to the foregoing (i) and (ii) (i.e. overlap of final decisions);</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The respective Party shall not have the final decision making authority under each of (i), (ii) and (iii) above and the other Party shall have a veto right (and if such veto right is exercised, no action shall be taken with respect to the applicable decision), if the other Party reasonably believes and shows that the outcome of such Party's decision or its execution:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 134.7pt;text-indent: -21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(1)&nbsp;&nbsp;&nbsp;would materially amend any mutually agreed Joint Development Activity (including the MorphoSys Trials and COMPANY Trial) or mutually agreed Co-Commercialization Plan and Co-Commercialization Budget;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 134.7pt;text-indent: -21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(2)&nbsp;&nbsp;&nbsp;may result in a material safety issue for the Product;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">76</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 134.7pt;text-indent: -21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(3)&nbsp;&nbsp;&nbsp;would cause or oblige such other Party to violate Laws or breach agreements with Third Parties validly existing on Execution Date, in case of MorphoSys, in particular but not limited to, the [***];</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 134.7pt;text-indent: -21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(4)&nbsp;&nbsp;&nbsp;in case of a Technology Transfer or a further technology transfer, such transfer, would in any regard, adversely affect the supply of Product in, with respect to COMPANY, the COMPANY Territory, or with respect to either Party, the Co-Commercialization Territory, and Trials; an increase in the supply price [***], due to a Technology Transfer shall be deemed such an adverse effect, if COMPANY does not commit in writing to fully bear such [***];</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 134.7pt;text-indent: -21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(5)&nbsp;&nbsp;&nbsp;will increase the overall financial burden of such other Party by more than [***] percent ([***]%) in sharing Joint Development Costs pursuant Section 7.1 or Co-Commercialization Costs or Medical Affairs Activities Costs pursuant to Section 7.7.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The respective Party shall not have the final decision making authority under each of (i), (ii) and (iii) above and the other Party may refer the matter for determination by an Expert in accordance with Section&nbsp;9.3, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(y)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&nbsp;if such other Party reasonably believes and shows that the outcome of such Party's decision or its execution might adversely affect in a material way the Licensed Antibody and/or the Product or the Development, Regulatory Activities, Manufacture or Commercialization of the Licensed Antibody and/or the Product in the Co-Commercialization Territory or the COMPANY Territory, , or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(z) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">in the event a Party disputes the obligation to pay or to share compensation or the calculation made in accordance with Section&nbsp;3.18.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(vi)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Neither Party shall have the final decision making authority if the dispute was initially brought to the JSC&#x2019;s attention by the Finance Working Group and as such relates to a specific financial and/or accounting matter resulting from Section 7. Such dispute may be referred to an Expert in accordance with Section&nbsp;9.3, if it was not resolved by the JSC, nor by the Executive Officers.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Limitations to a Party's Decision Making Authority.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> Notwithstanding the foregoing provisions of Section 9.2(e), neither Party shall exercise its right to finally resolve a dispute hereunder in a manner that excuses such Party from any of its obligations specifically enumerated under this Agreement or in a manner that negates any consent rights or other rights specifically allocated to the other Party under this Agreement.&nbsp;&nbsp;In addition, in resolving a dispute hereunder each Party shall act in good faith and in a commercially reasonable manner.&nbsp;&nbsp;While a disputed matter remains unresolved, all previously agreed upon rights and obligations of each Party with respect to such disputed matter in the Development Plan shall continue to remain in effect.&nbsp;&nbsp;Nothing in this Section&nbsp;9.2(f), shall affect the right of a Party to exercise its rights or remedies for a breach of this Agreement by the other Party (in particular, but not limited to, firm obligations and obligations to use Commercially Reasonable Efforts, violations of payment obligations, breach of the other Party's intellectual property rights, violations of Confidentiality).</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">77</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">9.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Expert Decision. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">If a dispute remains unresolved pursuant to Section&nbsp;9.2(e)(v), on which neither Party has the deciding vote, then upon written request by either Party to the other Party, the Parties shall promptly negotiate in good faith to appoint an appropriate expert ("</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Expert</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">").&nbsp;&nbsp;If the Parties are unable to agree on an Expert by mutual written agreement within seven (7) calendar days after the receipt by a Party of the written request in the immediately preceding sentence, the Expert shall be appointed by the International Centre for Expertise of the International Chamber of Commerce (&#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">ICC</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;) under its rules of expertise; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:11pt;text-decoration:underline;">provided, however</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">, that initially, the Parties shall [***] the fees charged by ICC upon appointment of the Expert.&nbsp;&nbsp;The Parties will then promptly make available the same set of documents supporting their proposals to the mutually agreed Expert or the appointed Expert, as the case may be.&nbsp;&nbsp;Such Expert shall have the right to meet with the Parties, either alone or together, as necessary to make a determination. Each Party shall submit to such Expert and exchange with each other in advance of such Expert&#x2019;s review their last, best offers.&nbsp;&nbsp;Such Expert shall be limited to awarding only one or the other of the offers submitted.&nbsp;&nbsp;No later than [***] calendar days after the agreement or designation of such Expert, as the case may be, such Expert shall make a determination.&nbsp;&nbsp;Such Expert shall provide the Parties with a written statement setting forth the basis of the determination in connection therewith.&nbsp;&nbsp;The decision of such Expert shall be final and conclusive and binding on the Parties and their Affiliates and Sublicensees, absent manifest error. The costs of such Expert shall be borne [***].&nbsp;&nbsp;The Parties shall use their good faith efforts to expedite the processes set forth in Section 9.2(e) and this Section 9.3.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">9.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Development Project Team</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.&nbsp;&nbsp;As soon as reasonably practicable after the formation of the JDC, the JDC will establish a development project team (the &#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Development Project Team</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;) that will meet by teleconference (i) on a [***] basis for the first [***] months after establishment of the Development Project Team and (ii) at least [***] thereafter for such period agreed by the Parties, in each case to discuss the status, safety and efficacy data (if available) emerging from each MorphoSys Trial and any Global Trial that is a Joint Development Activity. The Development Project Team will consist of the lead clinician and clinical scientist for each applicable Trial and their respective counterparts from the Party not conducting such Clinical Study. Development Project Team members will have the right to join the weekly safety call with lead Trial investigators, and have contemporaneous access to any material safety data and all key efficacy data, including: (a) interim analyses, (b) first interpretable results, (c) draft tables, listings and figures, (d) final tables, listings and figures from such Trial.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">9.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Joint Development Committee.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purpose of the Joint Development Committee ("JDC").</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> The JDC shall govern and oversee the global Development Activities of Licensed Antibody and Products in the Territory in the Field, as long as a Product is in Development in any country of the Territory in the Field.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Formation and Composition of JDC.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The Parties shall form a JDC promptly after the Execution Date to start planning Development activities prior to the Effective Date. Each Party shall initially appoint three (3) representatives to the JDC, with each representative having knowledge, expertise or responsibility in the research, development and regulatory activities of products similar to the Products and the appropriate seniority. The JDC may change its size from time to time by mutual consent of its members; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:11pt;text-decoration:underline;">provided, however</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:11pt;">,</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> that the JDC shall consist at all times of an equal number of representatives of each of MorphoSys and COMPANY. In addition to its JDC representatives, a Party may have other personnel attend JDC meetings for informational purposes. Each Party may replace its JDC representatives at any time</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">78</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">upon written notice to the other Party. MorphoSys and COMPANY shall alternate on a yearly basis the chair of the JDC. The chairperson shall be responsible for administering JDC meetings, but shall have no additional powers or rights beyond those held by the other representatives on the JDC. The JDC may constitute working groups for addressing specific matters under its responsibility.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Specific Responsibilities of the JDC.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;In addition to its general responsibilities, the JDC shall in particular:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Manage and oversee the preparation and implementation of the Development Plan;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Review, discuss and approve non-material amendments to the Development Plan;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Every [***] months, review, discuss, amend, update and submit to the JSC for approval:&nbsp;&nbsp;the Development Plan (subject to Section 3.6), including the Joint Development Budget, the TPP, and any material amendments thereto; review and discuss proposals for new Development Activities pursuant to Section 3.5 and seek input from the JCC;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Decide upon which Party will be responsible for the performance of the various activities set forth in the Development Plan on the basis of each Party&#x2019;s respective experience, capabilities and capacity as set forth in Section 3.11, including which Party will be the Sponsor of a new Global Trial that is a Joint Development Activity;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Oversee the conduct and progress of all Trials required as set forth in the Development Plan, including compliance with Laws and applicable GLP, GCP and/or GMP standards, mitigation actions, e.g. clinical Trial liaison activities and medical scientific activities, in order to improve Trial recruitment and Trial site engagement and any Development Activities;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(vi)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Align with the Medical Affairs function with regards to Early Access Programs and investigator initiated Trials;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(vii)&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Review and discuss the progress of any Sole Funded Development Activity;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(viii)&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Coordinate and facilitate the exchange of information between the Parties under this Agreement regarding the strategy for implementing the Development Activities, including sharing and reviewing of Development Data created pursuant to this Agreement and establishing procedures for the efficient and prompt sharing of information and materials and Know-How reasonably necessary or useful for the Development of the Product in the Territory;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ix)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Coordinate and facilitate exchange by both Parties of Regulatory Data and Regulatory Materials in support of filings, facility inspections and Product launch in the Co-Commercialization Territory and the</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">79</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">COMPANY Territory; review, discuss and, with respect to Joint Development Activities only, approve the design of the Trial protocols and endpoints;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Discuss and agree on the regulatory strategy for filing and maintaining Regulatory Approvals in the Co-Commercialization Territory, in alignment with the JCC;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(xi)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Review and discuss the regulatory strategy for filing and maintaining Regulatory Approvals in the COMPANY Territory, in alignment with the JCC;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(xii)&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Review and discuss the contents of all submissions to Regulatory Authorities and Governmental Authorities in the Territory for Regulatory Approvals, Regulatory Materials and all necessary filing and registration activities related thereto;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(xiii)&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Discuss and agree on all matters related to the maintenance of each Party&#x2019;s safety database and the global safety database, as applicable;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(xiv)&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Review, discuss and oversee issues regarding pharmacovigilance and safety in both the Co-Commercialization Territory and the COMPANY Territory;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(xv)&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Review and provide comments to the JMC regarding Manufacturing Development Activities and discuss progress and issues concerning Manufacturing Development Activities;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(xvi)&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Review and discuss demand forecasts and timelines of Drug Product for supply of the Development Activities under the Supply Agreement and report such demand forecasts and timelines to the JMC;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(xvii)&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Discuss and agree the publication strategy for Development Data;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(xviii)&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Review and discuss subcontractors (e.g. contract research organizations, and vendors) and collaboration partners for Joint Development Activities (subject to qualification of such subcontractors in accordance with Laws, GMP and GDP), and report the proposed subcontractors to the JSC for approval; decide on thresholds for seeking the other Party&#x2019;s approval to engage such subcontractors and partners, and decide which Party (or the Parties) negotiates the respective agreements and signs such agreements with such subcontractor, with the other Party&#x2019;s prior approval;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(xix)&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Review results of subcontracted Joint Development Activities.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;JDC Meetings.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The JDC shall meet once per [***] unless otherwise agreed between the JDC members. Either Party may also call a special meeting of the JDC (by videoconference or teleconference) with at least [***] calendar days prior written notice to the other Party in the event such Party reasonably believes that a significant matter must be addressed prior to the next scheduled meeting.&nbsp;&nbsp;The JDC may meet in person, by videoconference or by teleconference.&nbsp;&nbsp;There shall be at least one (1)</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">80</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">meeting in person per year. In-person JDC meetings shall be held at locations alternately selected by MorphoSys and by COMPANY.&nbsp;&nbsp;Meetings of the JDC shall be effective only if all JDC representatives of each Party are present or participating in such meeting.&nbsp;&nbsp;Each Party shall report to the JDC on all material issues relating to the Development of any Licensed Antibody or Product promptly after such issues arise.&nbsp;&nbsp;Each Party shall bear the expense of its respective JDC representatives&#x2019; participation in JDC meetings.&nbsp;&nbsp;The chairperson shall be responsible for preparing reasonably detailed written minutes of JDC meetings that reflect all decisions made at such meetings.&nbsp;&nbsp;The JDC chairperson shall send draft meeting minutes to each member of the JDC for review and approval within [***] Business Days after each JDC meeting.&nbsp;&nbsp;Minutes shall be deemed approved unless one or more members of the JDC object to the accuracy of such minutes within [***] Business Days of receipt.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;JDC Decision-Making. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Subject to Section 9.5(c), the JDC shall have the authority to make decisions with respect to the Development of Licensed Antibodies and Products in the Territory in the Field. The JDC shall act by consensus. Each representative from each Party shall have one (1) vote on behalf of that Party. If the JDC cannot reach consensus within [***] Business Days on any issue that comes before the JDC for which the JDC is responsible, then the Parties shall immediately refer such matter to the Chief Development Officer at MorphoSys and the Chief Medical Officer at COMPANY ("</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Designated JDC Officers</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">") for resolution. In the event of a Dispute between COMPANY and MorphoSys that cannot be resolved within [***] Business Days by the Designated JDC Officers with respect to matters concerning the Development, the Designated JDC Officers shall refer the issue to the JSC which will decide upon the matter pursuant to Section 9.2(e).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">9.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Joint Manufacturing Committee.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purpose of the Joint Manufacturing Committee ("JMC").</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> The JMC shall discuss and shall have the authority to make decisions only as expressly set out in Section&nbsp;9.6(c) below.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Formation and Composition of JMC.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> The Parties shall form a JMC promptly after the Execution Date to start planning Development activities prior to the Effective Date. Each Party shall initially appoint two (2) representatives to the JMC, with each representative having knowledge, expertise or responsibility in the manufacturing of products similar to the Products and the appropriate seniority. The JMC may change its size from time to time by mutual consent of its members; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:11pt;text-decoration:underline;">provided, however</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:11pt;">,</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> that the JMC shall consist at all times of an equal number of representatives of each of MorphoSys and COMPANY. In addition to its JMC representatives, a Party may have other persons attend JMC meetings for informational purposes, including also representatives of [***] if appropriate. Each Party may replace its JMC representatives at any time upon written notice to the other Party. MorphoSys and COMPANY shall alternate on a yearly basis the chair of the JMC. The chairperson shall be responsible for administering JMC meetings, but shall have no additional powers or rights beyond those held by the other representatives on the JMC. The JMC may constitute working groups for addressing specific matters under its responsibility.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-indent:42.55pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Specific Responsibilities of the JMC. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The JMC shall in particular:</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">81</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Discuss and approve the Manufacturing Development Activities and discuss progress and issues concerning Manufacturing Development Activities and COMPANY Discretionary Manufacturing Development Activities, all in accordance with the Development Plan;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Oversee, discuss and approve the overall supply chain management and related regulatory strategy, forecasting procedures, as well as contingency plans;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Facilitate, to the extent permitted under this Agreement, exchange of CMC information;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Discuss the need and scope of a potential Technology Transfer and review potential Third Party manufacturers (and COMPANY as manufacturer) capabilities for provision of Drug Product, Drug Substance and analytical test methods, and oversee the Technology Transfer where agreed by the Parties through the JSC and [***];</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Review, discuss and reconcile demand and sales forecasts and timelines of Drug Product for supply of the Development Activities and Commercialization in the Territory after discussion of such demand and sales forecasts and timelines in the JDC and/or JCC, as the case may be, and report such reconciled demand and sales forecasts and timelines to the JSC for approval;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(vi)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Review and discuss any material issues and problems relating to the Manufacture of Products, including shortages, delays and non-compliances; discuss and approve remediation plans and corrective actions;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(vii)&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Review and discuss potential Third Party vendors for e.g. (a) Labelling and Packaging of the Drug Product and (b) Distribution of the Finished Drug Product; for Global Trials that are Joint Development Activities and for Co-Commercialization in the Co-Commercialization Territory, and report the proposed Third Party vendors to the JSC for approval. All Third Party vendors shall undergo successful qualification by the quality assurance function of the Party being responsible for contracting the Third Party; and</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(viii)&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Facilitate the involvement of the respective other Party in cases set out under Section 6.6(d).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;JMC Meetings.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;The JMC shall meet at least [***], unless otherwise agreed between the JMC members, and as needed for the forecasting mechanism under the [***]. Either Party may also call a special meeting of the JMC (by videoconference or teleconference) by at least [***] calendar days prior written notice to the other Party in the event such Party reasonably believes that a significant matter must be addressed prior to the next scheduled meeting.&nbsp;&nbsp;The JMC may meet in person, by videoconference, or by teleconference.&nbsp;&nbsp;There shall be at least one (1) meeting in person per year.&nbsp;&nbsp;In-person JMC meetings shall be held at locations alternately selected by MorphoSys and by COMPANY.&nbsp;&nbsp;Meetings of the JMC shall be effective only if both JMC representatives of each Party are present or participating in such</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">82</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">meeting.&nbsp;&nbsp;Each Party shall report to the JMC on all material issues relating to the Manufacturing of Products promptly after such issues arise.&nbsp;&nbsp;Each Party shall bear the expense of its respective JMC members&#x2019; participation in JMC meetings.&nbsp;&nbsp;The chairperson shall be responsible for preparing reasonably detailed written minutes of JMC meetings that reflect all decisions made at such meetings.&nbsp;&nbsp;The JMC chairperson shall send meeting minutes to each member of the JMC for review and approval within [***] Business Days after each JMC meeting.&nbsp;&nbsp;Minutes shall be deemed approved unless one or more members of the JMC object to the accuracy of such minutes within [***] Business Days of receipt.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;JMC Decision-Making.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The JMC shall act by consensus. Each representative from each Party shall have one (1) vote on behalf of that Party.&nbsp;&nbsp;If the JMC cannot reach consensus within [***] Business Days on any issue that comes before the JMC for which the JMC is responsible, then the Parties shall refer such matter to the relevant Chief Officers at MorphoSys and COMPANY ("</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Designated JMC Officers</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">") for resolution. In the event of a Dispute between COMPANY and MorphoSys that cannot be resolved within [***] Business Days by the Designated JMC Officers with respect to matters concerning the Manufacturing, the Designated JMC Officers shall refer the issue to the JSC which will decide upon the matter pursuant to Section 9.2(e).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">9.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Joint Commercialization Committee.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purpose of the Joint Commercialization Committee ("JCC").</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> The JCC shall govern and oversee the global Commercialization of Product in the Territory in the Field, as long as a Product is Commercialized in any country of the Territory in the Field.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Formation and Composition of JCC.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The Parties shall form a JCC within [***] calendar days following the Execution Date.&nbsp;&nbsp;Each Party shall initially appoint two (2) representatives to the JCC, with each representative having knowledge, expertise or responsibility in the commercialization of products similar to the Products and the appropriate seniority. The JCC may change its size from time to time by mutual consent of its members; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:11pt;text-decoration:underline;">provided, however</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:11pt;">,</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> that the JCC shall consist at all times of an equal number of representatives of each of MorphoSys and COMPANY.&nbsp;&nbsp;In addition to its JCC representatives, a Party may have other persons attend JCC meetings for informational purposes.&nbsp;&nbsp;Each Party may replace its JCC representatives at any time upon written notice to the other Party. The JCC shall be chaired by [***]. The chairperson shall be responsible for administering JCC meetings, but shall have no additional powers or rights beyond those held by the other representatives on the JCC. The JCC may constitute working groups for addressing specific matters under its responsibility.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Specific Responsibilities of the JCC.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">In combination with all the responsibilities of the JCC set forth in Article 5, the JCC shall in particular with respect to the Product in the Field</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Oversee and align on the overall global Commercialization strategy, in particular global market access, global marketing and global medical affairs strategies in the Territory;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">83</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Serve as a conduit for sharing information, knowledge and expertise relating to the Commercialization of the Product, and the principles of information-sharing with respect to Commercialization in Co-Commercialization Territory and in the COMPANY Territory shall be reciprocal;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Align, oversee and implement the Global Brand Strategy for Product(s) for use in the Field in the Territory;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Discuss and agree on the Co-Commercialization Plan and the Co-Commercialization Budget and any updates and amendments thereto;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Review and discuss the COMPANY Commercialization Plan and any updates and amendments thereto, whereby COMPANY shall consider in good faith any comments by MorphoSys with regards to the above;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(vi)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Share and discuss information on the Commercialization activities of COMPANY under this Agreement in the COMPANY Territory, including launch sequences, Pre-Launch and post-launch activities;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(vii)&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Review and discuss demand and sales forecasts and timelines of Drug Product for supply of the Commercialization in the Territory under the Supply Agreement and report such demand and sales forecasts and timelines to the JMC;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(viii)&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Review and provide comments to the JMC regarding supply chain management, forecasting procedures, and issues of material shortages;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ix)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Share and discuss information on competitor activities with relevance for the Commercialization of the Product;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Review and facilitate public relations and align on communication strategy related to Product enquiries;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(xi)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Review and discuss [***] in the Territory;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(xii)&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Discuss and agree on the [***] for the Co-Commercialization of the Product in the Co-Commercialization Territory, whereby MorphoSys shall have the final decision, in particular with respect to setting the price;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(xiii)&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Discuss and agree on the [***] for Commercialization of the Product in the COMPANY Territory, to the extent legally permitted, whereby COMPANY shall have the final decision, in particular with respect to setting the price;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(xiv)&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Discuss and agree on the strategy for receiving and maintaining [***] of the Product in European Major Markets, Canada, Australia, Israel, Japan, South Korea, Brazil, Argentina, Russia, India, China, Hong Kong and Mexico where applicable;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">84</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(xv)&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Oversee and align Medical Affairs Activities of each Party, subject to Section 5.1(c) and 5.3(e)(v), and align with the JDC with regards to Early Access Programs and investigator initiated Trials; and</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(xvi)&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Oversee and align marketing and sales activities, market access activities, patient advocacy activities, and market insight activities of the Parties, in the Co-Commercialization Territory.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;JCC Meetings.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;The JCC shall meet at least once per [***], unless otherwise agreed between the JCC members. Either Party may also call a special meeting of the JCC (by videoconference or teleconference) by at least [***] calendar days prior written notice to the other Party in the event such Party reasonably believes that a significant matter must be addressed prior to the next scheduled meeting.&nbsp;&nbsp;The JCC may meet in person, by videoconference, or by teleconference.&nbsp;&nbsp;There shall be at least one (1) meeting in person per year.&nbsp;&nbsp;In-person JCC meetings shall be held at locations alternately selected by MorphoSys and by COMPANY.&nbsp;&nbsp;Meetings of the JCC shall be effective only if both JCC representatives of each Party are present or participating in such meeting.&nbsp;&nbsp;Each Party shall report to the JCC on all material issues relating to the Commercialization of Products promptly after such issues arise.&nbsp;&nbsp;Each Party shall bear the expense of its respective JCC members&#x2019; participation in JCC meetings.&nbsp;&nbsp;The chairperson shall be responsible for preparing reasonably detailed written minutes of JCC meetings that reflect all discussions held at such meetings.&nbsp;&nbsp;The JCC chairperson shall send meeting minutes to each member of the JCC for review and approval within [***] Business Days after each JCC meeting.&nbsp;&nbsp;Minutes shall be deemed approved unless one or more members of the JCC object to the accuracy of such minutes within [***] Business Days of receipt.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;JCC Decision-Making.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The JCC shall act by consensus. Each representative from each Party shall have one (1) vote on behalf of that Party.&nbsp;&nbsp;If the JCC cannot reach consensus within [***] Business Days on any issue that comes before the JCC for which the JCC is responsible, then the Parties shall refer such matter to the relevant Chief Officers at MorphoSys and COMPANY ("</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Designated JCC Officers</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">") for resolution. In the event of a Dispute between COMPANY and MorphoSys that cannot be resolved within [***] Business Days by the Designated JCC Officers with respect to matters concerning the Commercialization, the Designated JCC Officers shall refer the issue to the JSC which will decide upon the matter pursuant to Section 9.2(e).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">9.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Compliance Subcommittee.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 70.85pt;text-indent: -35.4pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">Within </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">days after the Effective Date, the JSC will establish a joint compliance sub-committee of the JSC (the &#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:10.5pt;">Compliance Subcommittee</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">&#x201D;), and establish the roles and responsibilities, to facilitate the coordination</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> between the Parties with respect to each of its respective compliance obligations that relate to the Co-Commercialization and Co-Detailing in Germany, if applicable.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 70.85pt;text-indent: -35.4pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Each Party shall initially appoint two (2) representatives to the Compliance Subcommittee, with each representative having knowledge, expertise or responsibility in compliance and the appropriate seniority. The Compliance Subcommittee may change its size from time to time by mutual consent of its representatives; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:11pt;text-decoration:underline;">provided, however</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">, that the Compliance Subcommittee shall consist at all times of an equal number of representatives of each of MorphoSys</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">85</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 70.85pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">and COMPANY. In addition to its Compliance Subcommittee representatives, a Party may have other persons attend Compliance Subcommittee meetings for informational purposes, including representatives of [***] if appropriate. Each Party may replace its Compliance Subcommittee representatives at any time upon written notice to the other Party. The Compliance Subcommittee may establish working groups for addressing specific matters under its responsibility.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 70.85pt;text-indent: -35.4pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">Specific Responsibilities of the Compliance Subcommittee. The Compliance Subcommittee shall in particular:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 70.9pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At least </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">months prior to the first Regulatory Approval of a Product in the Co-Commercialization Territory or, if earlier, prior to the execution of a Co-Detailing plan pursuant to the MorphoSys Co-Detail option described in Section&nbsp;2.4(d), coordinate and exchange relevant information about those aspects of each Party&#x2019;s respective compliance programs that are necessary for each Party to adequately perform its activities under this Agreement in a manner consistent with Laws and the regulations, requirements, and best practices promulgated by applicable Regulatory Authorities;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 70.9pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Participate in the establishment and implementation of the review process of promotional materials pursuant to Section 5.5(b);</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 70.9pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Establish a process for the Parties to review and approve joint activities in the Co-Commercialization Territory and, if applicable, in Germany following the exercise of the MorphoSys co-Detail option described in Section 2.4(d);</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 70.9pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Resolve significant discrepancies between the Parties&#x2019; respective compliance policies, procedures, and systems which come to the attention of the Parties and relevant to each of the Parties to comply with its obligations under applicable Laws;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 70.9pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Manage compliance with any agreements and settlements with Governmental Authorities to which either of the Parties or their Affiliates engaged in Co-Commercialization of the Product are subject; and</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 70.9pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Perform other such duties as may be specifically delegated to the Compliance Subcommittee under this Agreement by the JSC.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 70.9pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Compliance Subcommittee Meetings.&nbsp;&nbsp;The Compliance Subcommittee shall meet at least once </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">(in person or by teleconference), unless otherwise agreed among the Compliance Subcommittee representatives. Each Party shall report to the Compliance Subcommittee on all material compliance issues that may impact performance of the other Party under this Agreement or is relevant to each of the Parties to comply with its obligations under applicable Laws promptly after such issues arise.&nbsp;&nbsp;Each Party shall bear the expense of its respective Compliance Subcommittee representatives&#x2019; participation in Compliance Subcommittee meetings.&nbsp;&nbsp;Minutes shall be deemed approved unless one or more representatives of the Compliance Subcommittee object to the accuracy of such minutes within </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">Business Days of receipt.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 71.45pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">(d)&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">Compliance Subcommittee Decision-Making.&nbsp;&nbsp;If the Compliance Subcommittee disagree on any important compliance matter, then the Parties shall refer such matter to the relevant Chief Officers at MorphoSys and COMPANY ("</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:10.5pt;">Designated</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">86</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 71.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:10.5pt;">Compliance Subcommittee Officers</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">") for resolution. In the event of a Dispute between COMPANY and MorphoSys that cannot be resolved within </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">Business Days by the Designated Compliance Subcommittee Officers, the Designated Compliance Subcommittee Officers shall refer the issue to the JSC, which will decide upon the matter pursuant to Section 9.2(e).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">9.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Discontinuation of a Committee.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Except as otherwise specifically stated in this Agreement, each committee formed under this Agreement shall continue to exist until the JSC agrees by consensus to disband such committee.&nbsp;&nbsp;Once the committee is disbanded as provided above, such committee shall have no further obligations under this Agreement and all decisions previously allocated to such committee shall thereafter be made by the JSC.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">9.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Alliance Managers. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Promptly after the Execution Date, each Party shall appoint a senior representative to act as a coordinator and alliance manager (the "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Alliance Manager</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">").&nbsp;&nbsp;Each Party may, at any time, replace its Alliance Manager with another suitably qualified individual, on written notice to the other Party.&nbsp;&nbsp;The Alliance Managers shall be primarily responsible for facilitating communications between the Parties and coordinating the Parties&#x2019; activities under this Agreement</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-indent: -35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;INVENTIONS</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">10.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ownership of COMPANY Inventions, MorphoSys Inventions and Joint Inventions.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MorphoSys Inventions and COMPANY Inventions.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> To the extent such Inventions do not belong to Xencor under the Xencor Agreement, as between the Parties, MorphoSys shall solely own, and it alone shall have the right to apply for, Patents for any MorphoSys Inventions and COMPANY shall solely own, and it alone shall have the right to apply for, Patents for any COMPANY Inventions.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Joint Inventions. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Subject to Section 10.1(c) below, Joint Inventions and Joint Foreground Patents shall be jointly owned by the Parties. MorphoSys and COMPANY shall each own an undivided one-half interest in any Joint Inventions and any Patents claiming such Joint Inventions, in each case without obligation to account to the other for the exploitation thereof within its respective own Territory and subject to the restrictions set forth in this Agreement. The Parties shall agree in good faith on the exploitation of Joint Inventions and Joint Foreground Patents for activities that are not related to the Licensed Antibody or Product.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MorphoSys Core Improvement Inventions. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">COMPANY acknowledges that MorphoSys is obliged to assign MorphoSys Core Improvement Inventions to Xencor under the Xencor Agreement and that consequently MorphoSys and COMPANY will assign their interests in any Joint Inventions which constitute MorphoSys Core Improvement Inventions to Xencor.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">10.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mutual Support.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> Each Party shall effectuate that the ownership rights of all Inventions that are developed, made or conceived under this Agreement shall vest in the respective Party or Parties in accordance with the ownership principles described in Section&nbsp;10.1.&nbsp;&nbsp;Each Party shall require any Affiliates, employees, consultants, Sublicensees or independent contractors performing an activity pursuant to this Agreement to assign all Inventions that are the subject</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">87</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">of patent applications claiming Inventions that are developed, made or conceived by such Affiliates, employees, consultants, Sublicensees or independent contractors to MorphoSys and/or COMPANY according to the ownership principles described in Section&nbsp;10.1.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">10.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disclosures; Disputes Regarding Inventions.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> Each Party shall promptly disclose to the other Party all Inventions made by it (meaning by its, its Affiliates' or its Sublicensee's employees, consultants, or independent contractors) under this Agreement, including Joint Inventions.&nbsp;&nbsp;Before filing an application, divisional or continuation of </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> a Candidate-Specific Patent, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> a MorphoSys Patent, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> a COMPANY Foreground Patent, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iv)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> a Joint Foreground Patent or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(v)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> Xencor Candidate Specific Product Invention Patent, the filing Party shall provide the other Party with a copy of any proposed patent application at least thirty (30) Business Days before filing such application. If the non-filing Party believes that the filing Party&#x2019;s proposed patent application discloses Confidential Information of the non-filing Party, the non-filing Party shall so notify the filing Party within [***] Business Days before filing of the application, and the filing Party shall amend its proposed application to comply with the confidentiality provisions of this Agreement. If the Parties disagree as to whether an Invention is a Joint Invention, a MorphoSys Invention or a COMPANY Invention, and are unable to reach agreement within [***] calendar days after commencing discussions, then the Parties shall agree on and nominate one external patent counsel to determine inventorship.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 70.9pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-indent: -35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PROSECUTION AND ENFORCEMENT OF INTELLECTUAL PROPERTY RIGHTS</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">11.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cooperation regarding Patent Prosecution and Patent Strategy.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The Parties shall, within [***] calendar days after the Execution Date, establish a routine intellectual property call. The intellectual property call shall provide a collaborative forum for the Parties to address intellectual property matters under this Agreement and shall </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> be the primary point of contact for the Parties regarding the exchange of information on filing, prosecution, maintenance, enforcement and defense matters of </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> Candidate-Specific Patents, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> MorphoSys Patents, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">COMPANY Foreground Patents, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iv)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> Joint Foreground Patents and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(v)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> Xencor Candidate Specific Product Invention Patents, as set forth in Article 11, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> review and discuss the overall strategy for obtaining, maintaining and enforcing patent protection and aligning the patenting strategy with other exclusivities available for the Product and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> discuss the selection of the Product Marks and the filing, prosecution, maintenance, enforcement and defense of such matters, subject to Section 5.6. The forum shall also be responsible for discussing prosecution strategy with the goal of achieving strong and robust Patents. The prosecuting Party shall consider in good faith the comments of the other Party with respect to strategies for filing and prosecuting such Patents. If the non-prosecuting Party fails to provide its comments reasonably in advance of the deadline for filing or otherwise responding to the patent authorities, the prosecuting Party shall be free to act without consideration of the non-prosecuting Party&#x2019;s comments. The Parties shall also strive to coordinate and align their activities under this Agreement in a professional and pro-active manner. In addition, each Party shall provide to the other Party all data, information and materials necessary to meet any disclosure obligations, e.g. to the USPTO under 37 CFR 1.56. Additionally, in the event either Party determines that it requires a license to Third Party IP to Commercialize the Product, such matter shall be discussed as well.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">11.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patent Prosecution of Xencor Background Patents.</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">88</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Xencor Background Patents.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Subject to Sections 11.2.(c) and 11.7 and if not specified differently below, [***] has the sole right in its sole discretion to perform the filing, prosecution and maintenance of the Xencor Background Patents on a worldwide basis.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Broader Anti-CD19 Patents.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] has the sole right in its sole discretion to perform the filing, prosecution and maintenance of the Broader Anti-CD19 Patents worldwide. With respect to the prosecution and maintenance costs, [***] bears [***] percent ([***]%), while [***] bears the remaining [***] percent ([***]%).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Candidate-Specific Patents. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] shall be solely responsible, in its own discretion, to perform the prosecution and maintenance of Candidate-Specific Patents in the [***] and [***] for the prosecution and maintenance [***] shall be [***], while [***] shall be solely responsible, in its own discretion, to perform the prosecution and maintenance of Candidate-Specific Patents [***] and shall be responsible for all of the [***] in the [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">11.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patent Prosecution of Xencor Foreground Patents.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MorphoSys Core Improvement Inventions.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Under the Xencor Agreement Xencor has the sole right in its sole discretion to perform the filing, prosecution and maintenance of the MorphoSys Core Improvement Inventions on a worldwide basis.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Xencor Foreground Patents.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;Under the Xencor Agreement, but subject to Section 11.6, Xencor is responsible to perform the filing, prosecution and maintenance of Xencor Foreground Patents on a worldwide basis.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">11.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patent Prosecution of MorphoSys Background Patents.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Initial Phase/Patent Filing. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] shall be responsible for drafting and filing of a MorphoSys Background Patent up to the stage of entry into the national/regional phases.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MorphoSys Background Patents in the Co-Commercialization Territory.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***], in the [***] shall have the right to prepare, file, prosecute (including any reissues, re-examinations, post-grant proceedings, requests for patent term extensions, supplementary protection certificates, interferences, derivation proceedings, supplemental examinations) and maintain the MorphoSys Background Patents.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MorphoSys Background Patents in the COMPANY Territory.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***], in the [***] shall have the right, to prepare, file, prosecute (including any reissues, re-examinations, post-grant proceedings, requests for patent term extensions, supplementary protection certificates, interferences, derivation proceedings, supplemental examinations) and maintain the MorphoSys Background Patents, provided that with respect to Patent family [***] (as specified in </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT&nbsp;2</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">) &nbsp;[***] shall align with the co-owner of Patent family [***] with respect to the prosecution and maintenance of such Patents in the [***].</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">11.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patent Prosecution of MorphoSys Foreground Patents.</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">89</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Initial Phase/Patent Filing. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] shall be responsible for drafting and filing of a MorphoSys Foreground Patent up to the stage of entry into the national/regional phases.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prosecution and Maintenance. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] shall have the right to prepare, file, prosecute (including any reissues, re-examinations, post-grant proceedings, requests for patent term extensions, supplementary protection certificates, interferences, derivation proceedings, supplemental examinations) and maintain the MorphoSys Foreground Patents in the [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">11.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patent Prosecution of COMPANY Foreground Patents.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Initial Phase/Patent Filing. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] shall be responsible for drafting and filing of a COMPANY Foreground Patent up to the stage of entry into the national/regional phases.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prosecution and Maintenance. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] shall have the right to prepare, file, prosecute (including any reissues, re-examinations, post-grant proceedings, requests for patent term extensions, supplementary protection certificates, interferences, derivation proceedings, supplemental examinations) and maintain the COMPANY Foreground Patents in the [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">11.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Xencor Candidate Specific Patents.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Initial Phase/Patent Filing of Xencor Candidate Specific Product Invention Patents. &nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] decide on the optimal strategy for drafting, filing, prosecution and maintenance of Xencor Candidate Specific Patents, including the content and the timing of a respective patent application.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;National/Regional Phases.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Upon entry into the national/regional phases, [***] shall have the right, to prepare, file, prosecute (including any reissues, re-examinations, post-grant proceedings, requests for patent term extensions, supplementary protection certificates, interferences, derivation proceedings, supplemental examinations) and maintain the Xencor Candidate Specific Patents in the [***] and [***] shall have the right, to prepare, file, prosecute (including any reissues, re-examinations, post-grant proceedings, requests for patent term extensions, supplementary protection certificates, interferences, derivation proceedings, supplemental examinations and defense of oppositions) and maintain the Xencor Candidate Specific Patents in the [***].&nbsp; [***] shall closely cooperate on all prosecutional matters.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">11.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patent Prosecution of Joint Foreground Patents.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Initial Phase/Patent Filing. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Each Party shall promptly disclose to the other in writing, and shall ensure that its Affiliates, or licensees and Sublicensees, and its and their employees, agents and contractors so disclose, the development, making, conception or reduction to practice of any Joint Inventions. [***] decide on the optimal strategy for drafting, filing, prosecution and maintenance of Joint Foreground Patents for Joint Inventions. Such decision shall include the content and the timing of a respective patent application for the respective Joint Invention.</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">90</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;National/Regional Phases.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Unless otherwise agreed, upon entry into the national/regional phases, [***] shall have the right, to prepare, file, prosecute (including any reissues, re-examinations, post-grant proceedings, requests for patent term extensions, supplementary protection certificates, interferences, derivation proceedings, supplemental examinations) and maintain Joint Foreground Patents in the [***] and [***] shall have the right, to prepare, file, prosecute (including any reissues, re-examinations, post-grant proceedings, requests for patent term extensions, supplementary protection certificates, interferences, derivation proceedings, supplemental examinations and defense of oppositions) and maintain Joint Foreground Patents in the [***].&nbsp;&nbsp;The Parties shall closely cooperate on all prosecutional matters.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">11.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Right to Take Over.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;In the event that [***] intends not to prepare, file, prosecute, or maintain (i) a Candidate-Specific Patent, (ii) a MorphoSys Patent, (iii) a COMPANY Foreground Patent, (iv) a Joint Foreground Patent or (vi) a Xencor Candidate Specific Product Invention Patent in any country or jurisdiction within its respective Territory, [***] shall provide reasonable prior written notice to [***] of such intention (which notice shall, in any event, be given no later than [***] weeks prior to the next deadline for any action that may be taken with respect to such Patent in the respective Territory), and [***] shall thereupon have the option, in its sole discretion, to assume the control and direction of the preparation, filing, prosecution, and maintenance of such Patent.&nbsp;&nbsp;Upon [***] written exercise of such option to [***] , [***] shall assume responsibility and full control for the preparation, filing, prosecution, and maintenance of any such Patent, and [***] shall [***].&nbsp;&nbsp;[***] shall assign to [***] its interest in such Patent and shall execute such documents and perform such acts, [***], as may be reasonably necessary to permit [***] to file such patent application, and/or to prosecute and/or maintain such Patent.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">In addition, and unless not agreed otherwise between the Parties, [***] shall prosecute, maintain and enforce the Xencor Background Patents and Xencor Foreground Patents in the event that that [***] abandons or does not enforce, its patent rights, to the extent permissible [***], provided that in the event that [***] intends not to prepare, file, prosecute, or maintain a Xencor Background Patents and Xencor Foreground Patents in any country or jurisdiction, [***] shall provide reasonable prior written notice to [***] of such intention and the procedure set forth under the first paragraph under this Section 11.9 shall apply accordingly.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">11.10&nbsp;&nbsp;&nbsp;Costs.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">From and after the Effective Date:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Before the entry of the national/regional phase the costs of drafting, filing, prosecution and maintenance of (i) a Candidate-Specific Patent, (ii) a MorphoSys Background Patent, (iii) a Joint Foreground Patent or (iv) Xencor Candidate Specific Product Invention Patent shall be [***]. Thereafter, the costs of prosecution and maintenance of (i) a Candidate-Specific Patent, (ii) a MorphoSys Background Patent, (iii) a Joint Foreground Patent or (iv) Xencor Candidate Specific Product Invention Patent in the [***] shall be [***] and the costs of prosecution and maintenance of (i) a Candidate-Specific Patent, (ii) a MorphoSys Background Patent, (iii) a Joint Foreground Patent or (iv) Xencor Candidate Specific Product Invention Patent [***] shall be [***], provided that with respect to Patent family [***] (as specified in </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT&nbsp;2</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">) &nbsp;[***] with respect to the drafting, filing, prosecution and maintenance of such Patents in the [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Before the entry of the national/regional phase the costs of drafting, filing, prosecution and maintenance of a MorphoSys Foreground Patent shall be [***].</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">91</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Thereafter, the costs of prosecution and maintenance of a MorphoSys Foreground Patent [***] shall be [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Before the entry of the national/regional phase the costs of drafting, filing, prosecution and maintenance of a COMPANY Foreground Patent shall be [***]. Thereafter, the costs of prosecution and maintenance of a COMPANY Foreground Patent [***] shall be [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Costs that are incurred [***] under this Section 11.10 shall be invoiced on a day-to-day basis, and paid as set forth in Section 8.5.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">11.11&nbsp;&nbsp;&nbsp;Patent&nbsp;Term Extensions.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The Parties shall mutually discuss in good faith on patent term extensions, whereas (a) [***] shall have the sole right in its sole discretion and at its sole expense to apply to extend the patent term of (i) a Candidate-Specific Patent, (ii) a MorphoSys Patent, (iii) a COMPANY Foreground Patent, (iv) a Joint Foreground Patent or (vi) a Xencor Candidate Specific Product Invention Patent with respect to a Product in the [***] and (b) [***] shall have the sole right in its sole discretion and at its sole expense to apply to extend the patent term of (i) a Candidate-Specific Patent, (ii) a MorphoSys Patent, (iii) a COMPANY Foreground Patent, (iv) a Joint Foreground Patent or (vi) a Xencor Candidate Specific Product Invention Patent with respect to a Product in the [***], subject to the procedures set forth in the Xencor Agreement and the patent term extension Laws or Supplemental Protection Certificate Laws. Upon the other Party's request each Party shall provide to the other Party and execute all documents and instruments that may be reasonably required to record or perfect an application for patent term extension of the respective other Party.&nbsp;&nbsp;With respect to clauses (i) and (vi) above, [***] will negotiate in good faith to reach mutual agreement with [***] on patent term extensions.&nbsp;&nbsp;If, following such negotiations the [***] are unable to agree on a strategy for patent term extensions, [***] shall assert its final decision-making authority rights in accordance with the Xencor Agreement, with the exception of [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">11.12&nbsp;&nbsp;&nbsp;Patent Enforcement.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notification. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Each Party shall promptly notify the other Party in writing if the notifying Party reasonably believes that any Xencor Background Patent, MorphoSys Patent, COMPANY Foreground Patent or any Joint Foreground Patent is being or has been infringed or misappropriated in any territory by a Third Party.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Enforcement in Co-Commercialization Territory.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] shall [***] with respect to the enforcement of any Candidate-Specific Patent, MorphoSys Patent, or any Joint Foreground Patent with respect to all past, present and future activities or conduct of a Third Party in the [***] that may constitute an infringement of the respective Candidate-Specific Patent, MorphoSys Patent, or Joint Foreground Patent.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Enforcement in COMPANY Territory.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] shall have the first right, but not the obligation, to enforce any Candidate-Specific Patent, MorphoSys Background Patent, COMPANY Foreground Patent or any Joint Foreground Patent&nbsp;&nbsp;with respect to all past, present and future activities or conduct of a Third Party in the [***] that may constitute an infringement of the respective Candidate-Specific Patent, MorphoSys Background Patent, COMPANY Foreground Patent or Joint Foreground Patent, provided that with respect to Patent family [***] (as specified in </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT&nbsp;2</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">) &nbsp;[***] shall cooperate with the co-owner of Patent family [***] with respect to the enforcement of such Patents in the [***].</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">92</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Coordination.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] does not require the consent of [***] to bring an enforcement action in the [***] and with respect to the [***], any enforcement action by [***] requires the consent of [***]. &nbsp;[***] shall reasonably consider [***] comments, if any, on any such enforcement activities, but for the avoidance of doubt, [***], as the case may be, shall control the litigation in all respects and shall make all decisions in its own discretion, subject only to the provisions regarding settlement provided below in Section&nbsp;11.13.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"> Back-up Right for Third Party Infringement of a Candidate-Specific Patent.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">If [***], do not bring action to prevent or abate Third Party Patent Infringement within [***] calendar days within their [***] after notification thereof to or by [***] pursuant to Section&nbsp;11.12(a), then [***] has the right, but not the obligation, to bring, [***], an appropriate action in the respective Territory against any person or entity engaged in such Third Party Patent Infringement of a Candidate-Specific Patent directly or contributorily; whereby [***] is obliged [***] not to initiate legal action without first conferring with [***] and considering in good faith [***] reasons for not bringing any such action. [***] acknowledge that [***] does not require the consent of [***], to bring such an enforcement action and that [***] to control the litigation in all respects and shall make all decisions in its own discretion, subject only to the provisions regarding settlement provided below in Section&nbsp;11.13.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Xencor Background Patents and Xencor Foreground Patents. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] acknowledge that with respect to any Infringement of any Xencor Background Patent which is not a Candidate-Specific Patent and Xencor Foreground Patent by Product activities within the scope of the license [***] ("</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Shared Patent Competitive Infringement</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"), [***] has the first right, but not the obligation, to enforce the Xencor Background Patents which are not Candidate-Specific Patents and Xencor Foreground Patents [***].&nbsp; [***] further acknowledge that [***] and that [***] shall keep [***] reasonably informed of [***] activities related to prevention or abatement of Shared Patent Competitive Infringement and considers [***] comments on any such activities.&nbsp;&nbsp;If [***] brings suit against a Third Party to enforce Xencor Background Patents which are not Candidate-Specific Patents and Xencor Foreground Patents against Shared Patent Competitive Infringement, [***], shall have the right, at [***] consent, to join the proceedings as a plaintiff, whereby, [***] shall have the right to join the proceedings in the [***] and [***] shall have the right to join the proceedings in the [***], and whereby the respective joining Party [***] depending on the extent of the respective joining Party's participation. If [***] does not bring action to prevent or abate Shared Patent Competitive Infringement within [***] calendar days (or initiate the exchange of patent lists within [***] calendar days of receiving notice of a Biosimilar application within the framework of the Biologics Price Competition and Innovation Act or any foreign equivalent), after notification thereof to or by [***] pursuant to Section&nbsp;11.12(a), then, [***], (i) [***] have the right, but not the obligation, to bring, [***], an appropriate action in the [***] against any person or entity engaged in such Shared Patent Competitive Infringement directly or contributorily and retain all related recoveries and (ii) [***] has the right, but not the obligation, to bring, [***], an appropriate action in the [***] against any person or entity engaged in such Shared Patent Competitive Infringement directly or contributorily [***]; &nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:11pt;text-decoration:underline;">provided, however</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">, &nbsp;[***] shall not initiate legal action without first conferring with [***] and considering in good faith [***] reasons for not bringing any such action.</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">93</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Infringement of MorphoSys Background Patents by Activities with respect to XmAb5871 Program Antibodies by Third Parties.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] acknowledge that as to the MorphoSys Background Patents, [***] shall have the right to enforce them against Third Party research, development, manufacture, use, sale, offer for sale, importation or exportation of XmAb5871 Program Antibodies ([***]). [***] agree that, [***] shall have the above right to enforce MorphoSys Background Patents in the Co-Commercialization Territory, while [***] shall have such right in the [***]. [***] undertakes to, as required [***], discuss with [***] in good faith any concerns [***] may have with respect to such enforcement for a period of not less than [***] calendar days before initiating the enforcement of a MorphoSys Background Patent in [***].&nbsp;&nbsp;Under [***] only has the right to enforce MorphoSys Background Patents against Third Party research, development, manufacture, use, sale, offer for sale, importation or exportation of XmAb5871 Program Antibodies ([***]) if [***] grants its withholdable consent for [***] to do so.&nbsp;&nbsp;[***] may request such consent and will meet and confer with [***] as to the proposed enforcement. [***] shall have the right to grant its withholdable consent for [***] and to meet and confer with [***] with regard to requests for consent of [***] which relate to the [***] while [***] shall have such right with regard to requests for consent of [***] which relate to the [***].&nbsp;&nbsp;If [***] elects to enforce, and [***], consents, then [***], shall cooperate by being joined in name as a party plaintiff ([***]) and under the [***] shall not knowingly take any position in the suit that would make any admission as to the unenforceability or invalidity of any MorphoSys Background Patent, unless [***], approves of such position or has already taken such position in litigation.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Participation of </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">with Respect to Infringement Suits.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] acknowledge (i) that [***] if [***] brings an action against infringement [***] bringing the action shall maintain control of the action and [***] shall be entitled to separate representation in such matter by counsel of its own choice [***], and [***] shall cooperate fully with [***] bringing such action including by being joined as a party plaintiff if necessary to obtain standing for such action ([***] of the [***], including [***] of [***] being joined), (ii) that [***] related to cooperation with [***] bringing the action will be [***] on an on-going basis, and (iii) [***] the above rights and obligations under (i), (ii) and (iii) shall apply to [***] with regard to [***] and to [***] with regard to [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other Xencor Background Patents. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Should any Xencor Background Patent not be covered by the above provisions under Sections&nbsp;11.12(b) to (g), then the following shall apply: To the extent that [***] or pursuant to applicable Laws has the right to enforce such Xencor Background Patent against activities infringing such Xencor Background Patent or to support such enforcement, e.g. by joining infringement proceedings, [***] shall have such right (but not the obligation) within [***] while [***] shall have such right (but not the obligation) within [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Right to Take Over. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">If [***] fails to institute or defend such litigation or otherwise take steps to remedy the infringement of a Candidate-Specific Patent, MorphoSys Patent, COMPANY Foreground Patent or any Joint Foreground Patent, within [***] calendar days (or any shorter period required by applicable Laws) of the date [***] has provided notice to [***] of such infringement or claim pursuant to Section 11.12(a), then [***] will have the right (but not the obligation), [***], to bring or defend any such suit, action or proceeding by counsel of its own choice. [***] elects not to take steps will have the right, [***], to be represented in any such action by counsel of its own choice. In case of nullity actions, opposition proceedings or other proceedings challenging the</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">94</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">validity of a Candidate-Specific Patent, MorphoSys Patent, COMPANY Foreground Patent or any Joint Foreground Patent [***] having the first right to defend such action pursuant to Sections&nbsp;11.12(b), 11.12(c),11.12(f), and 11.12(h) and above shall during the [***] calendar days period pursuant to sentence&nbsp;1 in any event carry out all steps and activities required to prevent that the respective Patent is invalidated or otherwise deteriorated by way of a default judgment or a similar decision of the responsible legal body following from the failure of [***] to carry out certain steps and/or activities required by the applicable Laws and procedural rules.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Enforcement of step in rights. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Notwithstanding anything to the contrary in the foregoing, to the extent that [***] has step in rights to enforce any Candidate-Specific Patent or other Xencor Background Patent, [***] shall not exercise such right with respect to any Candidate-Specific Patent or other Xencor Background Patent without [***] prior written consent, which consent shall not be unreasonably withheld.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">11.13&nbsp;&nbsp;&nbsp;Settlement.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-indent:0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] shall not settle a claim brought under Section 11.12 involving a Candidate-Specific Patent, a Xencor Background Patent, a MorphoSys Patent, a COMPANY Foreground Patent or a Joint Foreground Patent in a manner that would [***], or make any admission as to invalidity or unenforceability of any Candidate-Specific Patent, MorphoSys Patent, COMPANY Foreground Patent or Joint Foreground Patent in each case without the prior written consent of [***] (which consent shall not be unreasonably withheld, conditioned or delayed).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-indent:0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] shall not settle a claim brought under Section 11.12 involving a Candidate-Specific Patent, a MorphoSys Patent, a COMPANY Foreground Patent or a Joint Foreground Patent in a manner that would [***], or make any admission as to invalidity or unenforceability of any Candidate-Specific Patent, MorphoSys Patent, COMPANY Foreground Patent or Joint Foreground Patent in each case without the prior written consent of [***] (which consent shall not be unreasonably withheld, conditioned or delayed).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">11.14&nbsp;&nbsp;&nbsp;Allocation of Proceeds</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.&nbsp;&nbsp;Any settlements, damages or other monetary awards (a "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Recovery</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">") recovered pursuant to a suit, action or proceeding brought pursuant to Article&nbsp;11 will be allocated, [***]:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 70.85pt;text-indent: -35.4pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">[***]</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">11.15&nbsp;&nbsp;&nbsp;Infringement of Third-Party Rights.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 36pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">(a)&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">If the Development, Manufacture or Commercialization of the Product by either Party, its Affiliates, Sublicensees, as applicable, or other licensees becomes the subject of a Third Party&#x2019;s claim or assertion of infringement of a Patent relating to the Manufacture, use, sale, offer for sale or importation of a Product, the Party first having notice of the claim or assertion shall promptly notify the other Party, and the Parties shall promptly confer to consider the claim or assertion and the appropriate course of action.&nbsp;&nbsp;[***].&nbsp;&nbsp;In any event, the Parties shall reasonably assist one another and cooperate in any such litigation at the other Party&#x2019;s request and expense.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">95</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">11.16&nbsp;&nbsp;&nbsp;Patent Oppositions and Other Proceedings.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> If either Party desires to bring an opposition, action for declaratory judgment, nullity action, interference, re-examination or other attack upon the validity, title or enforceability of a Patent owned or controlled by a Third Party that covers or may cover the Manufacture, use for the Field or sale of any Product, such Party shall notify the other Party. The Parties shall closely cooperate on such oppositions and other proceedings.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">11.17&nbsp;&nbsp;&nbsp;Affiliates / Sublicensees. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">To the extent this Agreement provides for such rights of COMPANY, COMPANY may grant to its Affiliates or Sublicensees its rights to prosecute any Candidate-Specific Patent, MorphoSys Background Patent, COMPANY Foreground Patent, Xencor Candidate Specific Patents and/or any Joint Foreground Patent as set forth in Sections&nbsp;11.2&nbsp;(c), 11.4, 11.6, 11.7 and 11.8.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">11.18&nbsp;&nbsp;&nbsp;Compensation to Inventors. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">As between the Parties, only MorphoSys shall be responsible for any compensation and any other payments due to the inventors of any Patents owned or co-owned by MorphoSys and only COMPANY shall be responsible for any compensation and any other payments due to the inventors of any Patents owned or co-owned by COMPANY. With respect to Joint Patents, each Party shall be responsible for compensating its own inventors.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">11.19&nbsp;&nbsp;&nbsp;Patent Assistance. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Each Party shall do or procure to be done all such acts and things, and execute or procure the execution of all such documents, as the other Party may from time to time reasonably request to assist the other Party in the preparation, filing, prosecution, maintenance and enforcement activities described in this Article&nbsp;11.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">11.20&nbsp;&nbsp;&nbsp;Patent Challenges</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">. [***].</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-indent: -35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NON-COMPETE</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">12.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-Compete Obligation. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">During the Term, neither Party shall, and will ensure that its Affiliates and Sublicensees (and, with respect to Sublicensees, to the extent permitted by applicable Law) performing Commercialization related functions will not, directly or indirectly, clinically develop, have clinically developed, commercialize or have commercialized a Competing Product in the Field in the Territory; unless the Parties mutually agree on the terms and conditions to jointly Develop and Commercialize in their respective Territory such Competing Product. A breach of this Section 12.1 may constitute a Material Breach of this Agreement giving rise to the termination right set forth in Section 17.2(a); </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:11pt;text-decoration:underline;">provided that</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> in case of a Change of Control of a Party as set forth in Section 12.2, such Party shall not be regarded as being in Material Breach of this Agreement, if the Acquirer (as defined below) already develops or commercializes a Competing Product at the time of the Change of Control.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">12.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change of Control by Acquirer.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> In case a Party or any of its Affiliates undergoes a Change of Control, such Party will notify the other Party as reasonably possible in advance, however no later than upon effective date of such Change of Control.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-indent:0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The Third Party taking over control ("</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Acquirer</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">") shall confirm in writing within [***] Business Days after the effective date of the Change of Control to the other Party that it will continue to perform the Development and Commercialization of Licensed Antibody and/or Product under this Agreement according to the then-current</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">96</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Development Plan, Co-Commercialization Plan and COMPANY Commercialization Plan, including respective budgets.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-indent:0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">In case the Acquirer or any of its Affiliates directly or indirectly clinically develops, has clinically developed, commercializes or has commercialized a Competing Product, the acquiree ("</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Acquiree</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">") will indicate this fact in its abovementioned notification under 12.2(a) to the other Party. The Acquiree shall, and shall ensure that Acquirer shall as well, meet with the other Party within [***] months after closing the transaction of such Change of Control to discuss the Development and Commercialization plan of the Acquirer for Licensed Antibody and Products.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-indent:0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">In case such Acquirer or any of its Affiliates directly or indirectly clinically develops, has clinically developed, commercializes or has commercialized a Competing Product, the Acquirer shall confirm in its abovementioned notification under 12.2(a) to the other Party that it will (i) perform the Development in the Territory and Commercialization in the Territory of Licensed Antibody and/or Product according to a development and commercialization plan which is at least as strenuous as the last Development Plan for the Territory and the Co-Commercialization Plan for the Co-Commercialization Territory and the COMPANY Commercialization Plan for the COMPANY Territory (if applicable) of the Acquiree prior to the Change of Control and which provides for at least similar efforts for Licensed Antibody(ies) and Product(s) as for the development and commercialization of the Acquirer&#x2019;s Competing Product; (ii) devote at least as much effort to the Development and Commercialization of Licensed Antibody and/or Product as to the development and commercialization of the Competing Product; and (iii) within [***] days after the effective date of such Change of Control, set-up and maintain totally separate and distinct teams in all areas and on all levels below the Vice-President or General Manager level, as applicable, with appropriate firewalls and boundaries in place to prevent any sharing of any information that is related to the Product (including Development, Manufacture and Commercialization thereof) and the development, manufacture and commercialization of the Competing Product, including handle such Competing Product by a team of sales representatives and medical affairs representatives of such Party that is different from the teams that handle the Product(s). &nbsp;A breach of this Section&nbsp;may constitute a Material Breach of this Agreement giving rise to the termination right set forth in Section&nbsp;17.2(a).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 70.9pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-indent: -35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;REPRESENTATION AND WARRANTIES, COVENANTS</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">13.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reciprocal Representations and Warranties.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> Each Party represents and warrants to the other Party that:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">It is duly organized and validly existing under the Laws of its state or country of incorporation, and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">This Agreement is a legal and valid obligation binding upon its execution and enforceable against it in accordance with its terms and conditions;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The execution, delivery and performance of this Agreement by such Party has been duly authorized by all necessary corporate action, and the person executing this</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">97</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Agreement on behalf of such Party has been duly authorized to do so by all requisite corporate actions;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The execution, delivery and performance of this Agreement by it does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any material Law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">It has not granted, and shall not grant during the Term of the Agreement, any right to any Third Party which would conflict with the rights granted to the other Party hereunder.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">13.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MorphoSys Warranties</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.&nbsp;&nbsp;Except as disclosed in </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT&nbsp;19</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> ("</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Disclosure Schedule</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"), MorphoSys hereby warrants and represents to COMPANY as of the Execution Date that:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">MorphoSys has the right to grant the licenses under the Xencor Foreground Patents, Xencor Background Patents, Xencor Know-How, MorphoSys Patents, MorphoSys Know-How and MorphoSys' interest in any Joint Foreground Patents as set forth in this Agreement and for COMPANY&#x2019;s use in any Indication in the Field;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Xencor Background Patents listed on </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT&nbsp;3</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> and MorphoSys Background Patents listed on </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT&nbsp;2</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;text-decoration:underline;">,</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> save for the Patent family [***] (as specified in </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT&nbsp;2</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">) which is co-owned by MorphoSys, Xencor Know-How listed on </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT&nbsp;4B</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> and MorphoSys Know-How listed on </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT&nbsp;4A</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> are Controlled by MorphoSys free and clear of any liens, charges, and encumbrances or licenses in the Field, to the extent needed in order to grant the license as set forth in this Agreement;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">MorphoSys has not received from any Third Party any written notice stating any claim that any Patent right owned or controlled by such Third Party would be infringed by the Development, Manufacture, Commercialization of Licensed Antibody or Product;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">To MorphoSys&#x2019; Knowledge, the Xencor Background Patents,and the MorphoSys Patents which are granted Patents on the Execution Date are valid and enforceable and MorphoSys has complied with all applicable Laws in all material respects and duties of candor with respect to the filing, prosecution and maintenance of the Xencor Background Patents, and the MorphoSys Patents.&nbsp;&nbsp;MorphoSys has paid (with respect to the MorphoSys Patents for which it is responsible for prosecution and maintenance) and, to MorphoSys&#x2019; Knowledge, Xencor has paid (with respect to the Xencor Background Patents for which Xencor is responsible for prosecution and maintenance), all maintenance and annuity fees with respect to the MorphoSys Patents, Xencor Background Patents due as of the Effective Date.&nbsp;&nbsp;To MorphoSys&#x2019; Knowledge, no action or proceeding regarding inventorship of a MorphoSys Patent, or to MorphoSys&#x2019; knowledge, regarding inventorship of a Xencor Background Patent or Xencor Foreground Patent, has been brought or threatened in writing; "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">MorphoSys' Knowledge</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" means, when referring to the knowledge of MorphoSys, the actual knowledge of MorphoSys&#x2019; personnel with the following titles: [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">MorphoSys has provided to COMPANY in the Data Room true and correct partially-redacted copies of the [***] and the Xencor Agreement in their current form, which agreements are in full force and effect. MorphoSys is not in breach of either of</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">98</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">the Xencor Agreement or the [***].&nbsp;&nbsp;MorphoSys has not received any written notice of breach of the [***] or the Xencor Agreement.&nbsp;&nbsp;To MorphoSys&#x2019; Knowledge (i) Xencor is not in breach of the Xencor Agreement and (ii) [***]; and MorphoSys has not received any written notice of breach of the [***] or the Xencor Agreement.&nbsp;&nbsp;MorphoSys applied reasonable efforts to ensure that none of the redactions made to the [***] and the Xencor Agreement provided to COMPANY by MorphoSys contain provisions that would be reasonably considered material to COMPANY&#x2019;S assessment of the transaction underlying this Agreement or the terms of this Agreement;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">MorphoSys has complied with all applicable Law in all material respects in conducting the MorphoSys Trials;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The Development of any Licensed Antibody and/or the Product(s) by MorphoSys, or to MorphoSys&#x2019; Knowledge with respect to any subcontractors, as of the Effective Date has been carried out in all material respects in accordance with all applicable Laws and applicable GLP, GCP and/or GMP standards, and MorphoSys is not aware of any problems concerning the safety or efficacy of any Licensed Antibody and/or the Product(s) raised by any Regulatory Authority with respect thereto;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">MorphoSys and its Affiliates have complied with the Data Protection Laws in all material respects at all times in accessing, collecting, using or otherwise processing any Personal Data in connection with the Development of any Licensed Antibody and/or the Product(s), including by entering into appropriate contractual arrangements with any Third Parties, and to MorphoSys' Knowledge, no material claim, action, proceeding, suit, investigation or complaint: (a) is pending by or against MorphoSys or its Affiliates; or (b) has been threatened by or against MorphoSys or its Affiliates, alleging a violation or potential violation of any person&#x2019;s rights in relation to their Personal Data under Data Protection Laws; and</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">MorphoSys US Inc., a Delaware corporation, is a wholly owned subsidiary of MorphoSys AG.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">13.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;COMPANY Warranties.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> COMPANY hereby warrants, covenants and represents to MorphoSys as of the Execution Date that:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 42.55pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">COMPANY and its Affiliates do not own or Control any Competing Product;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 42.55pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Subject to the representations and indemnities expressly contained in this Agreement, COMPANY accepts the Licensed Antibody program in the condition it is in on the Execution Date, based upon its own inspection, examination and determination with respect thereto (including the due diligence investigation conducted by it), without reliance upon any express or implied representations or warranties of any nature of MorphoSys or any employee, advisor or other representative of MorphoSys.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">13.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional MorphoSys Covenant</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.&nbsp;&nbsp;MorphoSys agrees that, during the Term:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 70.85pt;text-indent: -35.4pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">it will not, and will cause its Affiliates not to </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> terminate, whether for convenience or otherwise, the Xencor Agreement without COMPANY&#x2019;s prior written consent; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> terminate, whether for convenience or otherwise, the [***] without COMPANY&#x2019;s prior written consent, which after the consummation of a successful Technology Transfer for Development and Commercial Supply in</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">99</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 70.85pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">the COMPANY Territory and the Co-Commercialization Territory pursuant to Section 6.6 shall not be unreasonably withheld, or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&nbsp;[***] or the Xencor Agreement in any manner that would materially adversely affect the rights granted to COMPANY hereunder without COMPANY&#x2019;s prior written consent; and</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 70.85pt;text-indent: -35.4pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">it will, and will cause its Affiliates to comply in all material respects with the terms of the Xencor Agreement and the [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">13.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DISCLAIMER OF WARRANTY.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN SECTIONS 13.1 TO 13.3, THE PATENTS AND KNOW-HOW PROVIDED BY EACH PARTY HEREUNDER ARE PROVIDED &#x201C;AS IS&#x201D; AND EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION THE WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES, IN ALL CASES WITH RESPECT TO THE PATENTS AND KNOW-HOW OR OTHERWISE WITH RESPECT TO THE ACTIVITIES UNDER THIS AGREEMENT.&nbsp;&nbsp;WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, EACH PARTY EXPRESSLY DOES NOT WARRANT (I) THE SUCCESS OF ACTIVITIES PERFORMED PURSUANT TO THIS AGREEMENT OR (II) THE SAFETY, EFFICACY OR USEFULNESS FOR ANY PURPOSE OF THE PATENTS OR KNOW-HOW IT PROVIDES UNDER THIS AGREEMENT OR THE SUBJECT MATTER OF THEM.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-indent: -35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;INDEMNIFICATION AND INSURANCE</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">14.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indemnification by MorphoSys.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 70.85pt;text-indent: -35.4pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General Indemnification by MorphoSys.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;MorphoSys shall defend, indemnify and hold harmless COMPANY, its Affiliates, and their respective directors, officers, employees and agents ("</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">COMPANY Indemnitees</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">") from and against any losses, damages, liabilities, fines, amounts paid in settlements, costs and expenses (including reasonable attorneys&#x2019; fees and expenses) (collectively, "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Losses</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">") in connection with any demand, claim, action or proceeding brought or initiated by a Third Party (each, a "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Third Party Claim</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">") to the extent arising from or occurring as a result of or in connection with </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&nbsp;MorphoSys&#x2019;, its Affiliates or its Sublicensees&#x2019; exercise of rights under this Agreement, including the Development, storage, handling, use, Commercialization, or importation of any Licensed Antibody or Product by MorphoSys or any of its Affiliates or Sublicensees in or for the Co-Commercialization Territory </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> any breach by MorphoSys of its representations, warranties, covenant or obligations under this Agreement, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> any Product in the Co-Commercialization Territory that MorphoSys expressly and deliberately decides not to withdraw, recall or provide any market notification in accordance with Section 4.9 although COMPANY and one or more competent Regulatory Authorities expressly recommended in writing to MorphoSys the withdrawal, recall or provision of any market notification with respect to such Product, or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iv)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> the gross negligence or wilful misconduct of any MorphoSys Indemnitee; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:11pt;text-decoration:underline;">provided, however</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">, &nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">with regards to (i) through (iv) above, excluding [***] (which, for clarity, shall be</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">100</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 70.85pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">governed solely by Section 14.1(b), (c) and (d), as applicable) and except to the extent that COMPANY has an indemnification obligation pursuant to Section 14.2 for such Loss and provided that COMPANY Indemnitees comply with the procedure set forth in Section 14.3 and except to the extent that such Losses are in connection with any demand, claim, action or proceeding brought by a Third Party relating to the Patent of a Third Party or relating to [***] as of the Execution Date under the [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 70.85pt;text-indent: -35.4pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indemnification by MorphoSys regarding </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 106.35pt;text-indent: -35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">Subject to the limitations set out in subsections 14.1(b)(ii), (iii) and (iv) below, MorphoSys shall indemnify and hold harmless COMPANY, its Affiliated Companies and its and its Affiliated Companies' Representatives from and against any third party (as each of Affiliated Companies and&nbsp;&nbsp;Affiliated Companies' Representatives&nbsp;&nbsp;is understood in the </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">) claim with respect to Licensed Antibody or Product </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">, &nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:10.5pt;">(A)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;"> to COMPANY for the COMPANY Territory or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:10.5pt;">(B)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">&nbsp;for Commercialization by the Parties in the Co-Commercialization Territory, in each case of (A) or (B), to the extent such third party claims are arising from </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:10.5pt;">(1) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">negligent or willful breach of </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;"> representations and warranties given in </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:10.5pt;">(2) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">negligent or willful non-compliance with its obligations under the </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">, or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:10.5pt;">(3)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;"> a Third Party patent holder asserting a claim that </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">use of its intellectual property rights in connection with </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">performance of its services </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">the Licensed Antibody or the Product infringes such Third Party&#x2019;s intellectual property rights, in each case of (1) through (3) above, except to the extent </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:10.5pt;">(I)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">&nbsp;COMPANY has contributed to such third party claims by COMPANY&#x2019;s, its Affiliated Companies or its Affiliated Companies' Representatives' negligent or wilful breach of its representations or warranties given under Sections 13.1 or 13.3, or by COMPANY&#x2019;s, its Affiliated Companies or its Affiliated Companies&#x2019; Representatives' negligent or wilful non-compliance with its obligations under this Agreement, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:10.5pt;">(II)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;"> such third party claims result from COMPANY&#x2019;s use of the rights or licences granted by MorphoSys hereunder not in accordance with this Agreement or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:10.5pt;">(III)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;"> COMPANY has an indemnification obligation pursuant to Section 14.2.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 106.3pt;text-indent: -35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The following shall apply to the above obligation of MorphoSys:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 134.7pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything to the contrary set forth in Section&nbsp;14.1(b)(i) above, MorphoSys&#x2019; indemnification obligations thereunder with respect to seeking indemnification from [***] shall be limited to MorphoSys being obligated to use diligent efforts to exercise its rights, to the extent available, under [***] provided that, in considering diligent efforts hereunder, MorphoSys shall take into account the interests of COMPANY to be remedied under this Section&nbsp;14.1(b).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 134.7pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MorphoSys&#x2019; indemnification and liability obligation under this Section 14.1(b) shall be limited to and shall in terms of scope and extent in no respect exceed [***]. Further, MorphoSys shall be entitled to defend itself against a claim brought under Section&nbsp;14.1(b), including by asserting the same defenses, which are available to and ultimately asserted by [***] against a</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">101</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 134.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">respective claim brought against [***]; the limitation periods applicable under the [***] for such claim under [***] shall apply for a claim brought under Section 14.1(b) of this Agreement against MorphoSys.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 134.7pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Without limiting the foregoing subsections 14.1(b)(ii)(1) and (2), MorphoSys&#x2019; obligations under Section 14.1(b)(i) shall always be subject to the following DISCLAIMER OF DAMAGES under (y) and subject to the following CAPS under (z):</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 155.95pt;text-indent: -21.25pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(y)&nbsp;&nbsp;&nbsp;EXCEPT FOR CASES OF WILLFUL MISCONDUCT AND SUCH CASES WHERE A LIMITATION OF LIABILITY OR A LIMITATION OF INDEMNIFICATION OBLIGATIONS IS NOT PERMITTED UNDER [***] LAW, FOR WHICH CASES THERE SHALL BE NO LIMITATION OF LIABILITY OR INDEMNIFICATION OBLIGATIONS, IN NO EVENT, EITHER DIRECTLY OR BY WAY OF INDEMNIFICATION, AND IRRESPECTIVE OF THE THEORY OF LIABILITY, OF WHETHER BREACH OF CONTRACT, TORT OR OTHERWISE, SHALL MORPHOSYS BE LIABLE AND/OR INDEMNIFY FOR ANY INCIDENTAL, INDIRECT, EXEMPLARY, SPECIAL, PUNITIVE, ENHANCED, OR CONSEQUENTIAL DAMAGES (THE AFOREMENTIONED TERMS TO BE INTERPRETED UNDER THE RESPECTIVE LAWS [***]) ARISING FROM, RELATED TO OR IN CONNECTION WITH THIS SECTION 14.1(b) INCLUDING, WITHOUT LIMITATION ANY CLAIMS FOR DAMAGES BY THIRD PARTIES, CLAIMS FOR DAMAGES BASED UPON LOST PROFITS, LOSS OF REPUTATION OR LOSS OF GOODWILL, EVEN IF MORPHOSYS HAS BEEN ADVISED OF THE POSSIBLITY OF SUCH DAMAGES. PROVIDED, HOWEVER, THAT THIS DISCLAIMER OF CONSEQUENTIAL DAMAGES SHALL NOT APPLY IF AND TO THE EXTENT MORPHOSYS IS OBLIGATED TO INDEMNIFY ONE OR MORE PARTIES UNDER SECTION 14.1(b)(i) FOR (A) THIRD PARTY CLAIMS FOR DAMAGES CAUSED BY A RECALL, (B) THIRD PARTY CLAIMS RELATING TO DEATH OR BODILY HARM CAUSED BY [***] PRODUCT OR (C) THIRD PARTY CLAIMS FOR BREACH OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS BY [***], (D) BREACH OF [***] CONFIDENTIALITY OBLIGATIONS ARISING UNDER [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 155.95pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">MORPHOSYS' OBLIGATION UNDER SECTION 14.1(b) SHALL, TO THE FULL EXTENT ALLOWABLE UNDER APPLICABLE LAW, NOT COVER ANY REMEDY, COMPENSATION OR INDEMNIFICATION FOR LOSS OF THE VALUE OF THE PRODUCT DUE TO A NEGLIGENT OR WILLFUL BREACH OF [***]).</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">102</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 155.95pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">ALL AFOREMENTIONED, TO THE FULL EXTENT ALLOWABLE UNDER APPLICABLE LAW, WILL BE SUBJECT TO THE OTHER LIMITATIONS, CAPS AND REQUIREMENTS SET OUT IN THIS SECTION 14.1(b)(ii).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 155.95pt;text-indent: -21.25pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(z)&nbsp;&nbsp;&nbsp;THE AFOREMENTIONED OBLIGATION OF MORPHOSYS UNDER SECTION 14.1(b) SHALL, TO THE FULL EXTENT ALLOWABLE UNDER [***] LAW, further BE SUBJECT TO THE LIMITATIONS AND CAPS WHICH APPLY TO MORPHOSYS', ITS AFFILIATED COMPANIES&#x2019; AND ITS OR ITS AFFILIATED COMPANIES' REPRESENTATIVES' CLAIMS AS SET FORTH IN [***], PROVIDED THAT IF AND TO THE EXTENT SUCH LIMITATIONS AND CAPS ARE MORE RESTRICTIVE THAN THOSE SET FORTH IN THIS SECTION 14.1(b)(ii) AND, IN CASE MORPHOSYS IS OBLIGATED TOWARDS COMPANY PURSUANT TO SECTION 14.1(b)(iii), IN ADDITION AS SET FORTH IN [***] AND ALL SUCH LIMITATIONS SHALL LIKEWISE APPLY MUTATIS MUTANDIS FOR MORPHOSYS' OBLIGATIONS UNDER THIS SECTION 14.1(b). THE AFOREMENTIONED PROVISIONS ARE SET OUT IN </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT 20</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> WHICH IS HEREBY INCORPORATED INTO, AND SHALL BE AN INTEGRAL PART OF, THIS SECTION 14.1(b).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 134.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(4) To be eligible to be indemnified pursuant to this Section&nbsp;14.1(b), [***] shall provide [***] with prompt notice of the third party claim giving rise to the indemnification obligation arising pursuant to this Section 14.1(b) and, to the extent legally possible, giving [***] the [***] ability to defend (with the reasonable cooperation of [***] or settle any such claim, provided, however, that [***] shall not enter into any settlement that admits fault, wrongdoing or damages without [***] written consent, such consent not to be unreasonably withheld or delayed. [***] shall have the right to participate, [***] and with counsel of its choice, in the defense of any claim or suit that has been assumed by the [***] subject to the relevant terms of [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 134.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(5) In the event that, on the one side, [***], and, on the other side, [***] are held jointly liable for any third party claims, the party which satisfies such third party may demand adjustment of advancements from the other party [***], provided, however, that [***] accepts that [***] shall (i) only be obligated to compensate within [***] and (ii) be entitled to demand from the other party or parties adjustments that exceed the limits of [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 106.3pt;text-indent: -35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">For the purpose of this Section 14.1(b) the term 'Affiliated Companies' and the term 'Representative' shall be defined and interpreted as under [***]. Except as explicitly set forth in Section 14.1(b)(i) or Section 14.1(b)(ii) above, Section 14.1(b) and EXHIBIT 20 shall be interpreted under [***] law [***] and in the same manner as interpreted in [***].</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">103</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 106.3pt;text-indent: -35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Subject to Section 11.15, if [***] determines that it may be desirable to obtain a license from a Third Party to settle a claim by Third Party patent holder asserting that [***] designated by [***], use of its intellectual property rights in connection with such [***] of its services when [***] infringes such Third Party&#x2019;s intellectual property rights, [***] shall promptly notify [***] of such determination in writing giving detailed reasoning and the Parties shall discuss, through the JSC, the necessity or usefulness to obtain such Third Party's license.&nbsp;&nbsp;[***] shall have the first right to reasonably lead negotiations and conclude such license for [***].&nbsp;&nbsp;[***] shall have the right to participate in any such negotiation. [***] shall keep [***] informed and shall take due account of [***] interests, and [***] shall provide any assistance reasonably requested. In case a license is concluded, [***] such Third Party Payments in accordance with [***] with respect to [***]. With respect to such Third Party Payments relating to the [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 106.3pt;text-indent: -35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">THE REMEDIES SET FORTH IN SECTION 14.1(b)(i), AND THE REMEDIES SET FORTH IN SECTION 11.15 WITH RESPECT TO [***] CLAIMS, CONSTITUTE COMPANY'S (AND ITS AFFILIATED COMPANIES' AND ITS AND ITS AFFILIATED COMPANIES REPRESENTATIVES') SOLE AND EXCLUSIVE REMEDY WITH RESPECT TO CLAIMS SUBJECT TO LIABILITY AND INDEMNIFICATION UNDER THIS SECTION 14.1(b) AND SECTION&nbsp;11.15.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 70.85pt;text-indent: -35.4pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liability/Indemnification for </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Product </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">. &nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Except in case of a [***], in which case this Section 14.1(c) shall not apply, MorphoSys shall </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(A)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> be liable for Losses or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(B)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> defend, indemnify and hold harmless COMPANY Indemnitees from and against any Losses in connection with any Third Party Claim, each with respect to Licensed Antibody or Product [***] for the Co-Commercialization Territory or the Company Territory to the extent arising from or occurring as a result of or in connection with </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***], or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> a Third Party patent holder asserting a claim that [***] infringe its rights, in each case of (i) through (iii) above, except to the extent any COMPANY Indemnity has contributed to Losses or Third Party claims by COMPANY's&#x2019; breach of COMPANY's representations or warranties given under Sections 13.1 or 13.2, or by COMPANY Indemnitees' negligent or wilful non-compliance with its obligations under this Agreement or [***] and further except to the extent that COMPANY has an indemnification obligation pursuant to Section 14.2 or under [***], provided however that all indemnification obligations set forth in this Section 14.1(c) shall be limited to and shall in terms of scope, extent and limitations in no respect exceed what MorphoSys and/or its Affiliates are entitled to claim, if any, from [***]. THE REMEDIES SET FORTH IN THIS SECTION 14.1(c) CONSTITUTE COMPANY'S (AND ITS AFFILIATES&#x2019;) SOLE AND EXCLUSIVE REMEDY WITH RESPECT TO CLAIMS SUBJECT TO THIS SECTION 14.1(c).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 70.85pt;text-indent: -35.4pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indemnification for </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Product.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Except in case of [***], in which case this Section 14.1(d) shall not apply, MorphoSys shall defend, indemnify and hold harmless, COMPANY Indemnitees from and against any Losses in connection</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">104</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 70.85pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">with any Third Party Claim with respect to Licensed Antibody or Product [***] to the extent arising from or occurring as a result of or in connection with (i) any of MorphoSys&#x2019; or its Affiliate's breach of MorphoSys&#x2019; or its Affiliate's representations and warranties [***] (ii) MorphoSys' or its Affiliate&#x2019;s non-compliance with its obligations [***], or (iii) a Third Party patent holder asserting a claim that MorphoSys' or its Affiliate's use of its intellectual property rights or [***] infringe its rights, in each case of (i) through (iii) above, except to the extent COMPANY has contributed to Third Party claims by any COMPANY&#x2019;s breach of its representations or warranties given under Sections 13.1 or 13.2 or, or by any COMPANY Indemnitees' non-compliance with its obligations under this Agreement or [***] and further except to the extent that Company has an indemnification obligation pursuant to Section 14.12.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">14.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indemnification by COMPANY.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 70.9pt;text-indent: -35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General Indemnification. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">COMPANY shall defend, indemnify and hold harmless MorphoSys, its Affiliates, and their respective directors, officers, employees, and agents ("</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">MorphoSys Indemnitees</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">") from and against any Losses in connection with any Third Party Claim to the extent arising from or occurring as a result of or in connection with: </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> COMPANY&#x2019;s, its Affiliates&#x2019; or its Sublicensees&#x2019; exercise of rights under this Agreement, including the Development, storage, handling, use, Commercialization, or importation of any Licensed Antibody or Product by COMPANY or any of its Affiliates or Sublicensees in or for the COMPANY Territory, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> COMPANY&#x2019;s, its Affiliates&#x2019; or Sublicensees&#x2019; exercise of the rights granted under this Agreement with respect to the Co-Commercialization Territory, including the Co-Commercialization of any Licensed Antibody or Product by COMPANY or any of its Affiliates or Sublicensees in or for the Co-Commercialization Territory, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> any breach by COMPANY of its representations, warranties, covenants or obligations under this Agreement, or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iv)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> the gross negligence or wilful misconduct of any COMPANY Indemnitee; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:11pt;text-decoration:underline;">provided, however</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">, &nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">with regards to (i) through (iv) above, excluding [***] (which, for clarity, shall be governed solely by Section 14.214.1(b) and (c)) and except to the extent that MorphoSys has an indemnification obligation pursuant to Section 14.1 for such Loss and provided that MorphoSys Indemnitees comply with the procedure set forth in Section 14.3.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 70.9pt;text-indent: -35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liability/Indemnification for </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Product </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">. &nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">COMPANY shall </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(A)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> be liable for Losses or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(B)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> defend, indemnify and hold harmless MorphoSys Indemnitees from and against any Losses in connection with any Third Party Claim, each with respect to Licensed Antibody or Product [***] to the extent arising from or occurring as a result of or in connection with </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***], or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> a Third Party patent holder asserting a claim that&nbsp;&nbsp;&nbsp;[***] infringe its rights, in each case of (i) &#x2013; (iii) above, except to the extent MorphoSys has contributed to Losses or Third Party claims by MorphoSys&#x2019; breach of its representations or warranties given under Sections 13.1 or 13.2, or by any MorphoSys Indemnity's non-compliance with its obligations under this Agreement or [***] and further except to the extent that MorphoSys has an indemnification obligation pursuant to Section 14.1 or [***];</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:11pt;text-decoration:underline;">provided, however</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> that all indemnification obligations set forth in this Section 14.2(b) shall be limited to and shall in terms of scope, extent and</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">105</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 70.9pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">limitations in no respect exceed what COMPANY and/or its Affiliates are entitled to claim, if any, from [***]. THE REMEDIES SET FORTH IN THIS SECTION 14.2(b) CONSTITUTE MORPHOSYS' (AND ITS AFFILIATES&#x2019;) SOLE AND EXCLUSIVE REMEDY WITH RESPECT TO CLAIMS SUBJECT TO THIS SECTION 14.2(b).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 70.85pt;text-indent: -35.4pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indemnification for </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Product. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">COMPANY shall defend, indemnify and hold harmless MorphoSys Indemnitees from and against any Losses in connection with any Third Party Claim with respect to Licensed Antibody or Product [***] to the extent arising from or occurring as a result of or in connection with (i) COMPANY&#x2019;s or its Affiliate's breach of COMPANY&#x2019;s or its Affiliate's representations and warranties in [***] (ii) COMPANY's or its Affiliate&#x2019;s non-compliance with its obligations under [***], or (iii) a Third Party patent holder asserting a claim that COMPANY's or its Affiliate's use of its intellectual property rights or [***], in each case of (i) &#x2013; (iii) above, except to the extent MorphoSys has contributed to Third Party claims by MorphoSys&#x2019; breach of its representations or warranties given under Sections 13.1 or 13.2, or by any MorphoSys Indemnity&#x2019;s non-compliance with its obligations under this Agreement or [***] and further except to the extent that MorphoSys has an indemnification obligation pursuant to Section 14.1.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">14.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indemnification Procedure. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Subject to the indemnification procedure for the indemnification in Section 14.2(b) as set out in Section 14.1(b)(ii), the following shall apply to all indemnification claims under this Agreement:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 70.85pt;text-indent: -35.4pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notice of Claim.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">All indemnification claims in respect of a Party, its Affiliates or their respective directors, officers, employees and agents (collectively, the "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Indemnitees</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">" and each an "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Indemnitee</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">") shall be made solely by such Party to this Agreement (the "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Indemnified Party</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"). The Indemnified Party shall give the indemnifying Party (the "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Indemnifying Party</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">") prompt written notice (an "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Indemnification Claim Notice</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">") of any Third Party Claim or discovery of fact upon which such Indemnified Party intends to base a request for indemnification under Section 14.1 or Section 14.2; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:11pt;text-decoration:underline;">provided, however</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:11pt;">,</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> that the failure to give such prompt written notice shall not relieve Indemnifying Party of its indemnification obligation under this Agreement except and only to the extent that the Indemnifying Party is actually prejudiced as a result of such failure.&nbsp;&nbsp;In no event shall the Indemnifying Party be liable for any Losses that result from any delay in providing such notice.&nbsp;&nbsp;Each Indemnification Claim Notice must contain a description of the Third Party Claim and the nature and amount of such Loss (to the extent that the nature and amount of such Loss are known at such time). The Indemnified Party shall furnish promptly to the Indemnifying Party copies of all papers and official documents received in respect of any Losses.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 70.9pt;text-indent: -35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Control of Defense.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;At its option, the Indemnifying Party may assume the defense of any Third Party Claim by giving written notice to the Indemnified Party within [***] calendar days after the Indemnifying Party&#x2019;s receipt of an Indemnification Claim Notice.&nbsp;&nbsp;Upon assuming the defense of a Third Party Claim, the Indemnifying Party may appoint as lead counsel in the defense of the Third Party Claim any legal counsel of its own choice.&nbsp;&nbsp;In the event the Indemnifying Party assumes the defense of a Third Party Claim, the</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">106</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 70.9pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Indemnified Party shall immediately deliver to the Indemnifying Party all original notices and documents (including court papers) received by any Indemnitee in connection with the Third Party Claim. Should the Indemnifying Party assume the defense of a Third Party Claim, the Indemnifying Party shall not be liable to the Indemnified Party or any other Indemnitee for any legal expenses subsequently incurred by such Indemnified Party or other Indemnitee in connection with the analysis, defense or settlement of the Third Party Claim.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 70.9pt;text-indent: -35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Right to Participate in Defense.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;Without limiting Section 14.3(b) above, any Indemnitee shall be entitled to participate in, but not control, the defense of such Third Party Claim and to employ counsel of its choice for such purpose; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:11pt;text-decoration:underline;">provided, however</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:11pt;text-decoration:underline;">,</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> that such employment shall be [***] unless (i) the employment thereof has been specifically authorized by the Indemnifying Party in writing, or (ii) the Indemnifying Party has failed to assume the defense and employ counsel in accordance with Section 14.3(b) (in which case the Indemnified Party shall control the defense).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 70.9pt;text-indent: -35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Settlement.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 70.9pt;text-indent: -35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cooperation.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;The Indemnified Party will, and shall cause each other Indemnitee to, cooperate in the defense or prosecution thereof and shall furnish such records, information and testimony, provide such witnesses and attend such conferences, discovery proceedings, hearings, trials and appeals as may be reasonably requested in connection with the defense or prosecution of any Third Party Claim.&nbsp;&nbsp;Such cooperation shall include access during normal business hours afforded to the Indemnifying Party to, and reasonable retention by the Indemnified Party of, records and information that are reasonably relevant to such Third Party Claim, and making Indemnitees and other employees and agents available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder, and the Indemnifying Party shall [***] the Indemnified Party for [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">14.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Expenses.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">14.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insurance.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;Each Party shall have and maintain such types and amounts of liability insurance, including by self-insurance, as is normal and customary in the industry generally for parties similarly situated, and shall upon request provide the other Party with a certificate of insurance in that regard, along with any amendments and revisions thereto.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-indent: -35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LIMITATION OF LIABILITY</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">15.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;EXCLUSION OF INDIRECT DAMAGES.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">IN NO EVENT SHALL EITHER PARTY BE LIABLE UNDER THIS AGREEMENT FOR ANY SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, HOWEVER CAUSED, ON ANY THEORY OF LIABILITY AND WHETHER OR NOT SUCH DAMAGES WERE FORESEEABLE AND WHETHER OR NOT SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, ARISING UNDER ANY CAUSE OF ACTION AND ARISING IN ANY WAY OUT OF THIS AGREEMENT.&nbsp;&nbsp;THE FOREGOING LIMITATIONS SHALL NOT APPLY TO AN AWARD OF ENHANCED DAMAGES AVAILABLE UNDER 3 U.S.C. &#xA7; 284 FOR WILFUL PATENT INFRINGEMENT. THIS LIMITATION OF LIABILITY DOES NOT APPLY IN CASES</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">107</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">OF (I) WILFUL MISCONDUCT OR GROSS NEGLIGENCE, (II) DEATH OR PERSONAL INJURY CAUSED BY A PARTY&#x2019;S OR ITS EMPLOYEES, AGENTS OR SUBCONTRACTORS NEGLIGENCE TO THE EXTENT SUCH EXCLUSION IS PROHIBITED BY APPLICABLE LAWS (III) BREACHES OF ARTICLE 16 (CONFIDENTIALITY), (IV) BREACHES OF ARTICLE 12 (NON-COMPETE), AND (V) A PARTY&#x2019;S INDEMNIFICATION OBLIGATIONS UNDER SECTIONS 14.1(a), (c) OR (d) OR 14.2; FOR CLARITY, FOR THE INDEMNIFICATION OBLIGATION UNDER SECTION 14.1(b) THE LIMITATIONS AND CAPS SET OUT IN SUCH SECTION 14.1(b) SHALL APPLY IN PLACE OF THIS SECTION 15.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">EXCLUSION OF LIABILITY </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">. &nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXCEPT FOR CASES OF WILLFUL MISCONDUCT OR SUCH CASES WHERE A LIMITATION OF LIABILITY IS NOT PERMITTED UNDER APPLICABLE LAW, SECTIONS 14.1(b), 14.1(c), 14.2(b), 11.15, OR 15.3 SHALL BE EACH PARTY&#x2019;S (AND ITS AFFILIATES&#x2019;) SOLE AND EXCLUSIVE REMEDY, AND EACH PARTY HEREBY DISCLAIMS ANY OTHER LIABILITY, IRRESPECTIVE OF THE THEORY OF LIABILITY, WHETHER BREACH OF CONTRACT, TORT OR OTHERWISE, IN CONNECTION WITH [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-indent: -35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CONFIDENTIALITY</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">16.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Definition.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">During the Term and subject to the terms and conditions of this Agreement, a Party or its Affiliates (a "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Disclosing Party</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">") may communicate to the other Party or its Affiliates (a "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Receiving Party</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">") confidential information in connection with this Agreement or the performance of its obligations, or the use of its rights hereunder, including scientific and Manufacturing information and plans, strategies, marketing, sales and business plans, pricing and financials, personnel matters, present or future products, sales, suppliers, customers, employees, investors or businesses (collectively, "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Confidential Information</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">").&nbsp;&nbsp;Without limiting the foregoing, "Confidential Information" is hereby deemed to include any information exchanged between the Parties pursuant to that certain Confidential Disclosure Agreement between the Parties dated as of [***] (&#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">CDA</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;), as amended on [***] (&#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">CDA Amendment</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;), which shall both be superseded by this Article 16, except (a) with respect to the non-solicitation provisions under Section 4 of the CDA Amendment and (b) with respect to the standstill provisions under Section 5 of the CDA Amendment; which shall all remain effective for the purposes of this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">16.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exclusions.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Notwithstanding the foregoing, information of a Disclosing Party shall not be deemed Confidential Information with respect to a Receiving Party for purposes of this Agreement if such information:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">was already known to the Receiving Party, as evidenced by their written records, other than under an obligation of confidentiality or non-use, at the time of disclosure to the Receiving Party or its Affiliates;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">was generally available or was otherwise part of the public domain at the time of its disclosure to the Receiving Party;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">became generally available or otherwise became part of the public domain after its disclosure to the Receiving Party, through no fault of or breach of its obligations under this Article 16 by the Receiving Party;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">was disclosed to the Receiving Party, other than under an obligation of confidentiality or non-use, by a Third Party who had no obligation to the Party that</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">108</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">controls such information and know-how not to disclose such information or know-how to others; or</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">was independently discovered or developed by the Receiving Party or its Affiliates, as evidenced by their written records, without the use of, and by personnel who had no access to, Confidential Information belonging to the Party that controls such information and know-how.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">16.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disclosure and Use Restriction. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> Except as expressly provided herein, the Parties agree that, during the Term and for [***] years thereafter, a Receiving Party shall keep completely confidential and shall not publish or otherwise disclose and shall not use for any purpose except for the purposes contemplated by this Agreement any Confidential Information of a Disclosing Party. In particular, a Party shall not use any Confidential Information disclosed in any governance committee hereunder for its other products, strategies, and for that purpose, COMPANY and MorphoSys shall ensure that the persons having access to MorphoSys Know-How, COMPANY Know-How, Development Data, Regulatory Materials, Pricing Materials and other Product-related information (e.g. governance committees members) shall not use Confidential Information of the other Party for any product (including any Competing Product) of the respective Party.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">16.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Authorized Disclosure.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;A Receiving Party may disclose Confidential Information of a Disclosing Party to the extent that such disclosure is:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">made in response to a valid order of a court of competent jurisdiction or other governmental or regulatory body of competent jurisdiction; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:11pt;text-decoration:underline;">provided, however</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:11pt;text-decoration:underline;">,</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> that such Receiving Party shall first have given notice to the Disclosing Party and given the Disclosing Party reasonable opportunity to quash such order and to obtain a protective order requiring that the Confidential Information and documents that are the subject of such order be held in confidence by such court or governmental or regulatory body or, if disclosed, be used only for the purposes for which the order was issued; and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:11pt;text-decoration:underline;">further provided</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> that if a disclosure order is not quashed or a protective order is not obtained, the Confidential Information disclosed in response to such court or governmental order shall be limited to that information which is legally required to be disclosed in response to such court or governmental order;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">otherwise required by Law; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:11pt;text-decoration:underline;">provided, however</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:11pt;text-decoration:underline;">,</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> subject to Section&nbsp;16.6, that the Disclosing Party shall provide the Receiving Party with notice of such disclosure in advance thereof to the extent practicable;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">made by such Party to regulatory authorities as required in connection with any regulatory filing or application; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:11pt;text-decoration:underline;">provided. however</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:11pt;text-decoration:underline;">,</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> that reasonable measures shall be taken to assure confidential treatment of such information;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">made by a Receiving Party, in connection with the performance of this Agreement, to directors, officers, employees, legal and financial advisors, consultants, representatives or agents who have a need to know such information, each of whom prior to disclosure must be bound by obligations of confidentiality and non-use at least similar in scope to those set forth in this Article 14;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">made by a Receiving Party on a need-to-know-basis to (i)&nbsp;existing or potential acquirers or merger candidates; (ii)&nbsp;existing or potential Sublicensees or existing or potential contractors (to the extent contemplated hereunder); (iii)&nbsp;investment bankers;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">109</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(iv)&nbsp;existing or potential investors, venture capital firms or other financial institutions or investors for purposes of obtaining financing; or to Affiliates or Sublicensees, each of whom prior to disclosure must be bound by obligations of confidentiality and non-use&nbsp;&nbsp;equivalent in scope to those set forth in this Article 16 or in accordance with applicable industry standards but for no less than five (5) years from disclosure;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">made by the Receiving Party with the prior written consent of the Disclosing Party.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">16.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Use of Name.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;Neither Party may make public use of the other Party&#x2019;s name except </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> in connection with announcements and other disclosures relating to this Agreement and the activities contemplated hereby as permitted in Section 16.6, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> as required by applicable Laws, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">as expressly permitted under this Agreement, and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iv)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> otherwise as agreed in writing by such other Party.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">16.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Press Releases and Publications</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Public Disclosures.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;The Parties have mutually agreed on a press release announcing the execution of this Agreement, which is attached hereto as </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT&nbsp;10</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.&nbsp;&nbsp;Subject to Section 16.7, for subsequent press releases and other written public disclosures relating to this Agreement or the Parties&#x2019; relationship hereunder (each, a "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Public Disclosure</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"), each Party shall submit to the other Party a draft of such Public Disclosures for review and comment by the other Party at least [***] full Business Days prior to the date on which such Party plans to release such Public Disclosure. In addition, and subject to the requirements of applicable securities and other Laws governing such disclosures, (i) COMPANY shall include the statement as set forth in </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT 18</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> in the section containing background information on the Product of each of COMPANY's Public Disclosures and each public announcements referencing the Licensed Antibody and/or Product(s), and (ii) each Party shall use good faith efforts to notify the other Party in advance of any significant public announcement regarding Licensed Antibody&#x2019;s and/or Products&#x2019; performance and achievements under this Agreement.&nbsp;&nbsp;In case of any disclosure after the Execution Date that is required by Laws as reasonably advised by the Disclosing Party&#x2019;s counsel, such Party will provide the other Party with prompt notice of the required disclosure, such other Party shall not be entitled to withhold consent, but the Parties shall work together in good faith to find a mutually acceptable manner in which to make the disclosure.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ad hoc Requirements.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;If a Party is unable to comply with the foregoing [***]-Business Day notice requirement because of a legal obligation or stock exchange requirement to make more rapid disclosure, such Party shall not be in breach of this Agreement but shall in that case give telephone and email notice to a senior executive of the other Party and provide a draft disclosure with as much notice as possible prior to the release of such Public Disclosure. The Parties however acknowledge that for so-called "ad hoc" announcements required under the German Securities Act, no prior notice may be possible.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Public Domain.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;A Party may publicly disclose, without regard to the preceding requirements of this Section 16.6, information that was previously disclosed in a Public Disclosure that was in compliance with such requirements.</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">110</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Milestone Reporting.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;Both Parties agree that as part of their corporate communications policy and standard practice, MorphoSys and/or COMPANY may announce the achievement of payment-bearing milestones under this Agreement and the related due amounts, and each Party shall be permitted to do so in accordance with applicable reporting standards.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Development Results.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;Each Party (and/or its Affiliates or Sublicensees) under this Agreement may wish to publish the results of research and development under this Agreement.&nbsp;&nbsp;In order to safeguard intellectual property rights, the Party (or Affiliate or Sublicensee) wishing to publish or otherwise publicly disclose the results of such research and development shall first submit a draft of each proposed manuscript or presentation or poster to the other Party for review, comment and consideration of appropriate patent action at least [***] weeks prior to any submission for publication or other public disclosure.&nbsp;&nbsp;Within [***] Business Days of receipt of the pre-publication materials, such other Party shall advise the Party seeking publication as to whether a patent application shall be prepared and filed or whether trade secret protection should be pursued and, if so, such other Party shall determine the appropriate timing and content of any such publications. Approval of a publication shall not be unreasonably withheld, conditioned or delayed.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">16.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Terms of Agreement.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;The Parties agree that the terms of this Agreement are confidential and shall not be disclosed by either Party to any Third Party (except to a Party&#x2019;s professional advisor and as permitted for Confidential Information under Sections 16.4&nbsp;and 16.6) without prior written permission of the other Party; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:11pt;text-decoration:underline;">provided, however</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">, that </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">either Party may make any filings of this Agreement required by Law or regulation in any country as set forth in Section 16.8; and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">that MorphoSys and COMPANY may disclose, without the other Party&#x2019;s prior written permission, to prospective investors that are under confidentiality obligations no less stringent than those hereunder the individual milestone amounts, royalty rate and royalty tiers payable under this Agreement; and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:11pt;text-decoration:underline;">further provided</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> that a Party may publicly disclose information that was previously disclosed in compliance with Section 16.7 and 16.8.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">16.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SEC Filings.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The Parties acknowledge that they may be obligated to make a filing (including to file a copy of this Agreement) with the United States Securities and Exchange Commission ("</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">SEC</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">") or other Governmental Authorities.&nbsp;&nbsp;Each Party shall be entitled to make such a required filing, provided that it shall (i) submit in connection with such filing a redacted copy of this Agreement in the form to be agreed between the Parties within [***] calendar days of the Execution Date (the "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Redacted Agreement</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"), (ii) request, and use Commercially Reasonable Efforts consistent with applicable Laws to obtain, confidential treatment of all terms redacted from this Agreement, as reflected in the Redacted Agreement, for a period of at least [***] years, (iii) promptly deliver to each other Party any written correspondence received by it or its representatives from such Governmental Authority with respect to such confidential treatment request and promptly advise each other Party of any other material communications between it or its representatives with such Governmental Authority with respect to such confidential treatment request, (iv) upon the written request of any other Party, if legally justifiable, request an appropriate extension of the term of the confidential treatment period, and (v) if such Governmental Authority requests any changes to the redactions set forth in the Redacted Agreement, use Commercially Reasonable Efforts consistent with applicable Laws to support the redactions in the Redacted Agreement as originally filed and not agree to any changes to the Redacted Agreement without, to the extent practical, first</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">111</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">discussing such changes with each other Party and taking each other Party&#x2019;s comments into consideration when deciding whether to agree to such changes. Each Party shall be responsible for its own legal and other external costs in connection with any such filing, registration or notification.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-indent: -35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TERM AND TERMINATION</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">17.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Term and Expiration</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Term</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">. The term of this Agreement shall commence as of the Execution Date and, unless earlier terminated in accordance with this Article 17 or under Section&nbsp;18.21(c), shall expire upon the payment of the last applicable payment under this Agreement (the "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Term</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">").</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Expiration</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">. Upon expiration of the Term, COMPANY shall retain the licenses granted in Section 2.1 as non-exclusive, irrevocable, perpetual, fully paid-up licenses and MorphoSys shall retain the licenses under Section 2.4 as irrevocable, perpetual, fully-paid-up licenses.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No relief from Existing Obligations</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">. Expiration or termination of this Agreement shall not relieve the Parties of any obligation accruing prior to such expiration or termination (including payment obligations).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">17.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Termination for Material Breach, Insolvency and Patent Challenge</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Termination for Breach</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.&nbsp;&nbsp;Any material failure by a Party ("</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Breaching Party</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">") to comply with any of its material obligations contained in this Agreement (such failure a "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Material Breach</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">") shall entitle the other Party ("</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Non-Breaching Party</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">") to give to the Breaching Party written notice specifying the nature of the Material Breach, requiring the Breaching Party to make good or otherwise cure such Material Breach. If such Material Breach is not cured within [***] calendar days after the receipt of notice pursuant to this Section (except for a Material Breach consisting of non-payment, in which case the cure period shall be [***] calendar days) (the &#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Cure Period</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;), the Non-Breaching Party shall be entitled to terminate with immediate effect (unless such Material Breach (excluding any payment breach), by its nature, cannot reasonably be cured within the Cure Period, and the Breaching Party has (i)&nbsp;notified the Non-Breaching Party of its plan for curing such Material Breach, (ii)&nbsp;commenced and sustained the required efforts to cure such Material Breach during the Cure Period, and (iii) ultimately does cure such Material Breach within [***] calendar days after the end of the Cure Period, or such longer period as may be agreed upon between the Parties)&nbsp;&nbsp;by providing a written notice pursuant to this Section 17.2 ("</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Termination Notice</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">") to the Breaching Party and without prejudice to any of its other rights conferred on it by this Agreement and other remedies available under applicable Laws.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Termination for Insolvency</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.&nbsp;&nbsp;A Party shall be entitled to terminate with immediate effect by providing a Termination Notice to the other Party and without prejudice to any of its other rights conferred on it by this Agreement and other remedies available under applicable Laws in case </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> of a Material Breach due to lack of financial resources of the other Party, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> filing for or institution of bankruptcy, reorganization, liquidation or receivership proceeding, or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> upon an assignment of a substantial</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">112</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">portion of the assets for the benefit of the other Party's creditors; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:11pt;text-decoration:underline;">provided, however</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">, that such termination (with immediate effect) shall remain effective only if such proceeding is not dismissed within [***] calendar days after the filing thereof.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">17.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Termination on Patent Challenge.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">In case of a Patent Challenge, in addition to any other remedies that MorphoSys may have, including those remedies set forth in Section 11.20, MorphoSys shall be entitled to terminate this Agreement with immediate effect by providing a Termination Notice to COMPANY. COMPANY shall include in all Sublicense Agreements provisions as set forth in Section 11.20 that COMPANY is permitted to terminate such Sublicense Agreement.&nbsp;&nbsp;If a Sublicensee directly, or indirectly through assistance granted to a Third Party, undertakes a Patent Challenge of any such Patent, then COMPANY upon receipt of notice from MorphoSys of such Patent Challenge shall immediately terminate the applicable Sublicense Agreement.&nbsp;&nbsp;If COMPANY fails to so terminate such Sublicense Agreement, MorphoSys may terminate this Agreement. Notwithstanding the above, COMPANY shall include provisions in all Sublicense Agreements that in case of a Patent Challenge by a Sublicensee allow for a termination of such Sublicense Agreement by COMPANY.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">17.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Termination of Entire Agreement or Country-by-Country Basis.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The Parties can exercise their respective termination rights as stipulated in Section 17.2 either with regard to the Agreement in its entirety or on a country-by-country basis, as the case may be, at their sole discretion. In the event of any termination on a country by country basis, Section 17.7 or 17.8 shall only apply to the countries which have been terminated.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">17.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Final Say after Notice of Termination.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">COMPANY shall no longer have the right to exercise its final say on the JSC pursuant to Section 9.2(e) for any purpose other than with respect to ongoing regulatory obligations, including to amend the Development Plan, after MorphoSys has filed a Termination Notice, and all decisions of matters where COMPANY had final decision making authority pursuant to Section 9.2(e) shall thereafter be taken by mutual agreement of the Parties.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">17.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Termination for Convenience</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.&nbsp;&nbsp;After the [***] anniversary of the Effective Date, COMPANY shall have the right for convenience to file a [***] prior written notice of termination of this Agreement to MorphoSys (such period, the &#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Notice Period</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;).&nbsp;&nbsp;During the Notice Period, COMPANY shall continue to fund Development Activities as provided under this Agreement. If any Trial(s) or other Development Activities with Licensed Antibody or Product will still be on-going at the end of the Notice Period, then MorphoSys shall notify COMPANY in writing at least [***] calendar days after delivery of the applicable termination notice, which of the following MorphoSys elects, on a Development Activity-by-Development Activity basis, and COMPANY shall (and ensure that its Affiliates or Sublicensees) comply with and carry out MorphoSys&#x2019; election: </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> COMPANY shall (and ensure that its Affiliates or Sublicensees) continue such on-going Trial(s) or Development Activities&nbsp;&nbsp;at MorphoSys&#x2019; costs, or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&nbsp;transfer sponsorship (if applicable) of such on-going Trial(s) or Development Activities to MorphoSys, or if so requested by MorphoSys, to Xencor on a reasonable timeline (such transfer to take place no later than the expiration of the Notice Period, to the extent practically possible) and [***] for such transfer and perform as stipulated in Section 17.8(k)(i); or&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(iii) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">COMPANY shall (and ensure that its Affiliates or Sublicensees) wind down or assist in the wind down the Trial(s) or Development Activities and shall be [***] associated with such wind-down, and shall continue to comply with all remaining obligations and commitments made to Regulatory Authorities by COMPANY and by Affiliates or Sublicensees (including if applicable, patient registries), to the extent the compliance with such obligations and commitments is required by</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">113</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">applicable Laws, at [***]. For clarity and unless requested otherwise by MorphoSys, during the Notice Period COMPANY shall continue performing Commercialization activities in the COMPANY Territory and Co-Commercialization activities in the Co-Commercialization Territory in accordance with the terms of this Agreement, including the Co-Commercialization Plan.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">In addition, COMPANY shall [***].&nbsp;&nbsp;If, prior to COMPANY&#x2019;s exercise of its right to terminate this Agreement under this Section 17.6, COMPANY has achieved [***] with respect to </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(y)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> any Product in [***], based on a [***], then MorphoSys shall pay COMPANY a [***] percent ([***]%) royalty on Net Sales of such Product sold by MorphoSys in the COMPANY Territory following the Notice Period during the Royalty Term or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(z)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> any Product in the Co-Commercialization Territory, based on [***], then MorphoSys shall pay COMPANY [***] percent ([***]%) royalty on Net Sales of such Product sold by MorphoSys in the Co-Commercialization Territory following the Notice Period during the Royalty Term.&nbsp;&nbsp;&nbsp;The provisions of Section 8.4 and 8.5 shall survive any termination of this Agreement pursuant to this Section 17.6.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">17.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consequences upon COMPANY's Termination Notice.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Upon Termination Notice by COMPANY under 17.2(a) (Material Breach by MorphoSys) or 17.2(b) (Insolvency of MorphoSys) the effects of termination shall apply as stipulated in this Section&nbsp;17.7, without prejudice to any of its other rights conferred on COMPANY by this Agreement and other remedies available under applicable Laws, except that the continuation of contribution by COMPANY under Section 17.7(h) shall in this case be limited to [***] calendar days.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Further, if COMPANY submits to MorphoSys a Termination Notice:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">provided that either Party has received [***] for a Product in country(ies) within the </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(y) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">COMPANY Territory based on [***], MorphoSys shall pay, as consideration for the assignments and transfers, and licenses or contributions as stipulated in this Section&nbsp;17.7, to COMPANY royalties on Net Sales of such Product in such country(ies) within the COMPANY Territory at the rate of [***] percent ([***]%) or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(z)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> Co-Commercialization Territory based on [***], MorphoSys shall pay, as consideration for the assignments and transfers, and licenses or contributions as stipulated in this Section&nbsp;17.7, to COMPANY royalties on Net Sales of such Product in the Co-Commercialization Territory at the rate of [***] percent ([***]%); Section 8.3 (b) &#x2013; (f) shall apply accordingly. For clarity, MorphoSys shall not be obligated to </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">pay any royalties to COMPANY in the COMPANY Territory in case of a termination before COMPANY has received [***] in any country of the COMPANY Territory based on [***] or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> pay any royalties to COMPANY in the Co-Commercialization Territory in case of a termination before MorphoSys has received [***] in the Co-Commercialization Territory based on [***], and this clause shall not be deemed to limit any other right or remedy of the COMPANY under this Agreement in the event of a termination of this Agreement by the COMPANY; and</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">COMPANY shall be entitled during a period of [***] calendar days following the effective date of termination of this Agreement to sell in</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">114</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">the COMPANY Territory any inventory of Products that remains on hand as of the effective date of the termination. COMPANY shall pay MorphoSys the royalties applicable to such sales in accordance with the terms and conditions of this Agreement. At any time within [***] calendar days after the effective date of termination with respect to any country(ies) in the COMPANY Territory, MorphoSys shall have the right, upon written notification to COMPANY, to purchase from COMPANY [***] any or all of the inventory of Products held by COMPANY as of the date of such notification.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-indent: -0.55pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Each of COMPANY&#x2019;s Third Party Sublicensees with respect to any affected Products in any affected country at such time shall continue to have the rights and license set forth in their Sublicense Agreements, subject to the continued performance of their obligations thereunder; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:11pt;text-decoration:underline;">provided, however</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">, that such Third Party Sublicensee agrees in writing that the Sublicense Agreements be transferred from COMPANY to MorphoSys so that MorphoSys is entitled to enforce all relevant terms and conditions of such Sublicense Agreement directly against such Third Party Sublicensee, except that MorphoSys shall not be bound to perform any duties or obligations set forth in any Sublicense Agreements that extend beyond the duties and obligations of MorphoSys set forth in this Agreement; and further provided that such Third Party Sublicensee is not then in breach of its Sublicense Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">17.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MorphoSys&#x2019; Rights upon MorphoSys&#x2019; Termination Notice and Effects of MorphoSys&#x2019; Termination</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.&nbsp;&nbsp;Upon a Termination Notice by MorphoSys under Section 17.2(a) (Material Breach by COMPANY), Section 17.2(b) (Insolvency of COMPANY), or Section 17.2(c) (Patent Challenge) or Section 17.6 (Termination for Convenience), COMPANY shall, subject to Section 17.4 or, if applicable, Section 17.6, transfer to MorphoSys the full MOR208 program, including the following:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;License Termination</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.&nbsp;&nbsp;The licenses granted by MorphoSys to COMPANY under Article 2 shall terminate and COMPANY, its Affiliates and Sublicensees, and all Third Parties working on behalf of any of the foregoing, shall immediately stop using all Xencor Know-How, MorphoSys Know-How, Licensed Antibodies and Products, and stop all activities covered by the Patents licensed to COMPANY under Section 2.1 and COMPANY shall transfer prosecution, maintenance and enforcement of such Patents to MorphoSys.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Termination of Co-Commercialization</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.&nbsp;&nbsp;The Co-Commercialization in the Co-Commercialization Territory and the Pre-Tax Profit (Loss) Share shall terminate. For clarity, MorphoSys may continue Commercialization in the Territory at its convenience and COMPANY shall cooperate to transfer all Commercialization activities ongoing by or on behalf of COMPANY, its Affiliates and Sublicensees to MorphoSys.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Return of Licensed Know-How; Transfer of Know-how</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">. Within [***] calendar days following such termination, COMPANY shall (and ensure that its Affiliates or Sublicensees) return to MorphoSys all then still existing Xencor Know-How, and MorphoSys Know-How received from MorphoSys as well as any Joint Development Data.&nbsp;&nbsp;COMPANY shall (and ensure that its Affiliates or Sublicensees) upon MorphoSys&#x2019; request (at no cost to MorphoSys) transfer to MorphoSys or its designee any COMPANY Know-How; such transfer shall be effected by the delivery of documents, to the extent such COMPANY Know-How is embodied in documents, and</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">115</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">to the extent that such Know-How is not fully embodied in documents, COMPANY shall (and ensure that its Affiliates or Sublicensees) make its employees and agents who have knowledge of such Know-How in addition to that embodied in documents available to MorphoSys for interviews and demonstrations to effect such transfer. Further, MorphoSys shall have the right to use COMPANY Funded Development Data the same way MorphoSys may use Joint Development Data under this Agreement, subject to the payment of a buy-in fee equivalent to [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Survival and Extension of Granted License. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The licenses granted to MorphoSys pursuant to Section 2.4 shall survive and become perpetual, irrevocable, royalty-free, and fully paid; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:11pt;text-decoration:underline;">provided, however</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">, that all such licenses shall, from the effect of the applicable termination notice, also grant MorphoSys the right to research, have researched, develop, have developed, make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported, export and have exported the Licensed Antibody and/or the Product(s) (i) inside the Field inside the Territory and (ii) in all other fields.&nbsp;&nbsp;COMPANY shall (and ensure that its Affiliates or Sublicensees) transfer prosecution, maintenance and enforcement of Patents licensed under Section 2.4 to MorphoSys. If COMPANY (or any Affiliate or Sublicensee) needs to make any payments specifically related to Licensed Antibody(ies) or Products to any Third Party for such Know-How of COMPANY or such technology claimed in a Patent Controlled by COMPANY, before COMPANY grants to MorphoSys such license, COMPANY shall first provide MorphoSys in writing with information about such payments, and MorphoSys shall request such license grant, and upon such request, MorphoSys shall commit to reimburse COMPANY (or Affiliate or Sublicensee) for such payments.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Contract Transfer and/or Assignment.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;To the extent requested by MorphoSys in writing within [***] calendar days following the applicable termination notice, COMPANY shall (and ensure that its Affiliates or Sublicensees) transfer and/or assign to MorphoSys or, if so requested by MorphoSys, to Xencor all or specific licenses, manufacturing agreements and other contracts specific to Licensed Antibody and Products (including clinical trial, Manufacturing agreements, sublicensing and Distribution agreements with respect thereto), to the extent such licenses and other contracts are in effect as of the date of such termination and such transfer and/or assignment is permitted under the contract. COMPANY shall (and ensure that its Affiliates or Sublicensees) provide copies for review, but only to the extent permitted under such contracts, to enable MorphoSys and/or Xencor to make such decision within [***] calendar days after the applicable termination notice. To the extent that any such agreement or contract is not assignable by COMPANY (or Affiliate or Sublicensee), upon the request of MorphoSys, COMPANY shall (and ensure that its Affiliates or Sublicensees) cooperate in good faith and use diligent efforts to allow MorphoSys or any Affiliate or Third Party designated by MorphoSys to obtain and to enjoy the benefits of such agreement in the form of a license or other right to the extent COMPANY (or Affiliate or Sublicensee) has the right and ability to do so.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Trademarks, Copyrights, other IP</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">. To the extent requested by MorphoSys in writing within [***] calendar days following the applicable termination notice, to the extent permitted by applicable Laws, COMPANY shall (and ensure that its Affiliates or Sublicensees) transfer or otherwise exclusively license any intellectual property rights to MorphoSys or, if so requested by MorphoSys, to Xencor to (i) all Product Marks</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">116</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">controlled by COMPANY (or Affiliate or Sublicensee) used in connection with the Commercialization of Licensed Antibody and/or Products in the Territory, (ii) to its part of the ownership in Global Product Marks and (iii) to its rights (including copyrights), title or interest in the promotional materials, package inserts and marketing materials, including marketing plans, for the Product used in the Territory, all (i), (ii) and (iii) including any goodwill associated therewith, and any registrations, applications and any internet domain name registrations and slogans, all to the extent related to the Product.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulatory and Data Transfer. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> To the extent requested by MorphoSys in writing within [***] calendar days following the applicable termination notice and to the full extent permitted by Laws, COMPANY shall (and ensure that its Affiliates or Sublicensees) take all actions reasonably necessary to transfer to MorphoSys, or if so requested by MorphoSys, to Xencor, all Development Data (including all raw clinical data, SAS datasets, trial master files, Regulatory Data and regulatory correspondence and minutes of meetings with Governmental Authorities), Commercialisation data, including market research data, INDs, MAAs, Marketing Authorizations, Pricing Approvals and other regulatory filings related to Licensed Antibody or Product that COMPANY or its Affiliates or Sublicensees holds as of the time of such termination, and any other documentation or data needed in accordance with International Conference of Harmonization E6 Good Clinical Practice: Consolidated Guidance), in each case of the foregoing to the extent reasonably required to support continued clinical and other Development and Commercialization. COMPANY shall (or ensure that its Affiliates or Sublicensees) appoint MorphoSys or a designated Third Party as COMPANY&#x2019;s agent for all Product-related matters involving regulatory authorities until all Marketing Authorizations and other regulatory filings and approvals have been transferred to MorphoSys or its designee, it being agreed that both Parties shall use reasonable and diligent efforts to have this transfer occur as rapidly as feasible. If the effective date of termination is after First Commercial Sale of a Product, then COMPANY (or ensure that its Affiliates or Sublicensees) shall appoint MorphoSys or a designated Third Party as its exclusive distributor of such Product and grant MorphoSys the right to appoint sub-distributors, until such time as all Marketing Authorizations have been transferred to MorphoSys or its designee it being agreed that both Parties shall use reasonable and diligent efforts to have this transfer occur as rapidly as feasible.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Continuation of COMPANY Ongoing Trials</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">. If any Trial(s) with Licensed Antibody or Product are on-going at the time of termination, then MorphoSys shall notify COMPANY in writing within [***] calendar days after the applicable termination notice, which of the following MorphoSys elects and COMPANY shall (and ensure that its Affiliates or Sublicensees) comply with and carry out MorphoSys&#x2019; election:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">COMPANY shall (and ensure that its Affiliates or Sublicensees) continue such on-going Trial(s) and/or transfer sponsorship (if applicable) of such on-going Trial(s) to MorphoSys, or if so requested by MorphoSys, to Xencor on a reasonable timeline and shall bear the costs as stipulated in Section&nbsp;17.8(i); or</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">COMPANY shall (and ensure that its Affiliates or Sublicensees) wind down the Trial and shall be fully and solely responsible for [***], and shall continue to comply with all remaining obligations and</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">117</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">commitments made to Regulatory Authorities by COMPANY and by Affiliates or Sublicensees (including if applicable, patient registries), to the extent the compliance with such obligations and commitments is required by applicable Laws, [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Continuation of Contribution.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> If this Agreement is terminated by MorphoSys in accordance with Section 17.2(a) (Material Breach by COMPANY), Section 17.2(b) (Insolvency of COMPANY), or Section 17.2(c) (Patent Challenge), and subject to the applicable termination notice, COMPANY shall continue to be responsible [***] until the earlier of </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&nbsp;MorphoSys has concluded an agreement with a Third Party subject to which such Third Party receives a license or licenses to </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(A)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> Develop and Commercialize the Product in the COMPANY Territory and Co-Commercialization Territory in the Field or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(B)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> to Commercialize the Product in the COMPANY Territory and Co-Commercialization Territory in the Field or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***] months after the applicable termination notice. If, within [***] months after the applicable termination notice, MorphoSys has entered into an agreement with a Third Party subject to which such Third Party receives a license to Develop and/or Commercialize the Product in the Field in the COMPANY Territory and Co-Commercialization Territory, under which good faith and arm&#x2019;s length agreement such Third Party is obligated to pay to MorphoSys upfront fees and near-term [***] milestone payments, with such payments being in the aggregate at least [***] times the amount of Joint Development Costs paid by COMPANY to MorphoSys under this Agreement, then, promptly following receipt by MorphoSys of at least such aggregate payments from such Third Party, MorphoSys will [***] of the amount of Joint Development Costs paid by COMPANY under this Section 17.8(i). Except as stipulated in this Section (i), MorphoSys shall not be obligated [***].</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Further Representations. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">COMPANY shall (and ensure that its Affiliates and Sublicensees) discontinue making any representation regarding its status as a licensee of MorphoSys for Licensed Antibody and Product and shall cease conducting all activities with respect to the Commercializing and Co-Commercializing all of the foregoing.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transition Assistance.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">To the extent reasonably permissible under the circumstances at the time, and to the extent requested by MorphoSys in writing [***] calendar days following the applicable termination notice, COMPANY shall (and ensure that its Affiliates and Sublicensees) provide such assistance as may be reasonably necessary to transfer and/or transition over a reasonable period of time to MorphoSys, or if so requested by MorphoSys, to Xencor any rights, items and contracts specified under 17.8(b), (d), (e), (f) and (g), including COMPANY Know-How, Product Marks, Global Product Marks, Development Data, Regulatory Data, Regulatory Materials, and Regulatory Approvals, (including contracts with contract research organisations, contract Manufacturing organisations and distributors) specific to Licensed Antibody or the Products with respect thereto, and provided that MorphoSys agrees to assume financial responsibility and all other obligations towards Third Parties under any licenses or contracts (other than the case where COMPANY has failed to obtain royalty-free</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">118</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">rights under those certain Xencor Patents licensed to MorphoSys under Section 2.4(b)).</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 113.4pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">In addition, to the extent that COMPANY or a COMPANY Affiliate is then manufacturing itself (respectively) Products and upon MorphoSys' request in writing within [***] calendar days after the applicable termination notice, COMPANY shall use Commercially Reasonable Efforts to (or ensure that its Affiliate) continue to manufacture Products for MorphoSys' or Xencor&#x2019;s use until the earlier of (i) [***] years and if reasonably required by MorphoSys to fully accomplish the technology transfer without supply interruption then [***] (for a total in that case of [***]) after the effective date of termination, and (ii) such time as MorphoSys has validated an alternative manufacturer (including [***]), and quantities of Product supplied by such manufacturer may legally be sold. Any such Product shall be supplied to MorphoSys and MorphoSys shall [***] COMPANY at COMPANY&#x2019;s (or its Affiliate&#x2019;s) [***], determined in accordance with GAAP.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Remaining Inventories.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> MorphoSys shall have the right to purchase from COMPANY (or its Affiliate) all of the inventory of Products held by COMPANY (or its Affiliate) as of the effective date of termination at [***], determined in accordance with GAAP.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Affiliates. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">COMPANY shall ensure that its Affiliates comply with Section 17.8 as if they were COMPANY.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">17.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Survival.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> Notwithstanding anything to the contrary contained herein, the following provisions shall survive any expiration or termination of this Agreement:&nbsp; Articles 1, 7 (with respect to wind down of activities and obligations thereunder), 10, 14, 15, 16, 17, 18 (other than Section 18.21), Sections: 2.7, 2.8, 3.12, 8.3(f), 8.3(g), 8.5, 8.6, 8.7, 8.9, 8.10, 11.4, 11.15, 13.5, and any other Section or clause, which by its nature should survive. Except as set forth in this Section 17.9 or otherwise expressly set forth herein, upon termination or expiration of this Agreement all other rights and obligations shall cease.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-indent: -35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MISCELLANEOUS</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">18.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assignment. &nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">MorphoSys interests in this Agreement shall be assignable to Xencor in case of termination of the Xencor Agreement. Without limiting the foregoing, neither this Agreement nor any right or obligation hereunder may be assigned or otherwise transferred by a Party to any Third Party without the prior written consent of the other Party; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:11pt;text-decoration:underline;">provided, however</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">, that each Party may, without such consent, assign this Agreement in its entirety </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(i) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">to such Party&#x2019;s Affiliate (for so long as the relationship of affiliation endures) or </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(ii)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">, subject to Section 12.3, if such Party merges with, or all or substantially all of its business or assets are acquired by another entity (whether by merger, sale of assets, sale of stock or otherwise), to the Party&#x2019;s merger partner or the Acquirer as part of such acquisition (each of (i) and (ii), an &#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">M&amp;A Event</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;). Each Party agrees that, notwithstanding any provisions of this Agreement to the contrary, if this Agreement is assigned by a Party in connection with an M&amp;A Event, such assignment shall not provide the non-assigning Party with rights or access to intellectual</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">119</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">property or technology of the merger partner or acquirer of the assigning Party existing prior to such M&amp;A Event. Any permitted assignment shall be binding on the successors of the assigning Party. In addition, notwithstanding anything express or implied in this Agreement, if MorphoSys and/or COMPANY becomes part of the corporate family of a larger pharmaceutical or biopharmaceutical company, then under no circumstances shall any entities in that family other than MorphoSys and/or COMPANY and its respective Affiliates prior to joining the corporate family, be deemed to be &#x201C;Affiliates&#x201D; of MorphoSys or COMPANY for purposes of the intellectual property definitions in this Agreement. Other than an assignment under the first sentence of this Section 18.1, any assignment or attempted assignment by either Party in violation of the terms of this Section shall be null and void.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">18.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Severability.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> If any provision of this Agreement is held to be illegal, invalid or unenforceable under any present or future Laws, and if the rights or obligations of either Party under this Agreement shall not be materially and adversely affected thereby, (i)&nbsp;such provision shall be fully severable, (ii) this Agreement shall be construed and enforced as if such illegal, invalid or unenforceable provision had never comprised a part hereof, (iii) the remaining provisions of this Agreement shall remain in full force and effect and shall not be affected by the illegal, invalid or unenforceable provision or by its severance here from, and (iv) in lieu of such illegal, invalid or unenforceable provision, there shall be added automatically as a part of this Agreement a legal, valid and enforceable provision as similar in terms to such illegal, invalid or unenforceable provision as may be possible and reasonably acceptable to the Parties herein.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">18.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Governing Law, Dispute Resolution.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Governing Law, Jurisdiction.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> This Agreement, and any disputes between the Parties related to or arising out of this Agreement (including the Parties&#x2019; relationship created hereby, the negotiations for and entry into this Agreement, its conclusion, binding effect, amendment, coverage, termination, or the performance or alleged non-performance of a Party of its obligations under this Agreement) (each a "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Dispute</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"), shall be governed by the Laws of [***], without regard to any choice of law principle that would require the application of the Law of another jurisdiction. The United Nations Convention on Contracts for International Sales of Goods (CISG) shall not apply to this Agreement. Notwithstanding the foregoing, the obligations under Section [***] shall be interpreted under [***] law except as otherwise specified in such Section.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dispute Resolution.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> The Parties recognize that disputes as to certain matters may from time to time arise which relate to either Party's rights and/or obligations hereunder. It is the intent and objective of the Parties to establish procedures to facilitate the resolution of such disputes in an expedient manner by mutual cooperation and without resort to litigation. Accordingly, subject to the specific resolution process set forth under Sections 9.2(e) and 9.3 for certain controversies, any Dispute, including any such Dispute involving Affiliates of any Party shall be resolved as set forth in </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT&nbsp;11</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Injunctive Relief.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> Notwithstanding the foregoing, nothing in this Section shall limit either Party&#x2019;s right to seek immediate temporary injunctive or other temporary equitable relief whenever the facts or circumstances would permit a Party to seek such relief in a court of competent jurisdiction.</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">120</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">18.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notices. &nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">All notices or other communications that are required or permitted hereunder shall be in writing and delivered personally, sent by facsimile (and promptly confirmed by personal delivery or overnight courier as provided herein), or sent by internationally-recognized overnight courier addressed as follows:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">If to MorphoSys, to:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 99.25pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">MorphoSys AG</font>
		</p>
		<p style="margin:0pt 0pt 0pt 99.25pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Semmelweisstrasse 7</font>
		</p>
		<p style="margin:0pt 0pt 0pt 99.25pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">82152 Planegg</font>
		</p>
		<p style="margin:0pt 0pt 0pt 99.25pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Germany</font>
		</p>
		<p style="margin:0pt 0pt 0pt 99.25pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Attention: CEO</font>
		</p>
		<p style="margin:0pt 0pt 0pt 99.25pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Facsimile: +49 89 899 27 5310</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">If to COMPANY, to:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 99pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 99pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Incyte Corporation</font>
		</p>
		<p style="margin:0pt 0pt 0pt 99pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">1801 Augustine Cut-Off</font>
		</p>
		<p style="margin:0pt 0pt 0pt 99pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Wilmington, DE 19803</font>
		</p>
		<p style="margin:0pt 0pt 0pt 99pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">USA</font>
		</p>
		<p style="margin:0pt 0pt 0pt 99pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Attention: CEO</font>
		</p>
		<p style="margin:0pt 0pt 0pt 99pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">With a copy to: General Counsel</font>
		</p>
		<p style="margin:0pt 0pt 0pt 99pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith. Any such communication shall be deemed to have been given when delivered. It is understood and agreed that this Section is not intended to govern the day-to-day business communications necessary between the Parties in performing their duties, in due course, under the terms of this Agreement.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">18.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Entire Agreement, Modifications.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">This Agreement, including the Exhibits attached hereto, each of which is hereby incorporated and made part of in this Agreement by reference, sets forth and constitutes the entire agreement and understanding between the Parties with respect to the subject matter hereof and supersedes all prior agreements, understanding, promises and representations, whether written or oral, with respect thereto, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:11pt;text-decoration:underline;">provided, however</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">, that the Confidential Disclosure Agreement between the Parties dated as of [***], shall remain partially in effect as set forth in Section&nbsp;16.1.&nbsp;&nbsp;Each Party confirms that it is not relying on any representations or warranties of the other Party except as specifically set forth herein.&nbsp;&nbsp;No amendment or modification of this Agreement shall be binding upon the Parties unless in writing and duly executed by authorized representatives of both Parties.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">18.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Force Majeure.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;Neither Party shall be liable for failure of or delay in performing obligations set forth in this Agreement, and neither shall be deemed in breach of its obligations, if such failure or delay is due to natural disasters or any causes beyond the reasonable control of such Party.&nbsp;&nbsp;In event of such force majeure, the Party affected thereby shall use reasonable efforts to cure or overcome the same and resume performance of its obligations hereunder.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">18.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Relationship of MorphoSys AG and MorphoSys Inc. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">With regard to the performance of this Agreement the following shall apply:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MorphoSys Obligations. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">In case this Agreement imposes an obligation on "MorphoSys" (for clarity, as being defined as MorphoSys AG and MorphoSys Inc.), the</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">121</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">respective MorphoSys Party which, at the sole discretion of MorphoSys, in the internal relationship between these MorphoSys Parties is responsible for this obligation, shall be obligated to fulfil such obligation; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">provided, however</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">, that MorphoSys Inc. may only perform obligations under this Agreement so long as it remains a subsidiary of MorphoSys AG. In case neither of MorphoSys AG or MorphoSys Inc. performs the respective obligation, COMPANY shall be entitled to enforce such right towards both MorphoSys Parties for performance of the respective obligation; however, COMPANY&#x2019;s rights and remedies for enforcement shall be without duplication and the respective obligations of MorphoSys will be deemed fulfilled if either MorphoSys AG or MorphoSys Inc. fulfilled the respective obligation.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;COMPANY's Obligation. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">In case this Agreement imposes an obligation on COMPANY, either MorphoSys AG or MorphoSys Inc. shall be entitled to enforce such right towards COMPANY; however, MorphoSys AG and MorphoSys Inc. can only claim performance once and the respective obligation will be deemed fulfilled if COMPANY has fulfilled the respective obligations towards either MorphoSys AG and MorphoSys Inc.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">18.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Relationship of the Parties.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">It is expressly agreed that the Parties&#x2019; relationship under this Agreement is strictly one of licensor-licensee, and that this Agreement does not create or constitute a partnership, joint venture or agency.&nbsp;&nbsp;Neither Party shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding (or purport to be binding) on the other.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">18.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mutual Duty of Good Faith.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The Parties undertake to be loyal to one another. Each Party shall inform the other immediately of all events that arise during the Term and that may affect its conduct.&nbsp;&nbsp;Both Parties undertake not to actively entice away the respective other Party&#x2019;s employees who are or were involved in the performance of any activities under this Agreement, prior to expiration of a blocking period of [***] months following the Execution Date; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:11pt;text-decoration:underline;">provided, however</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">, that the foregoing provision will not prevent any of the Parties from (i) employing or engaging any such person who contacts a Party on his or her own initiative without any direct or indirect solicitation by or encouragement from such Party, (ii) engaging in general solicitations not specifically targeted at such persons or employing or engaging any such person who contacts a Party&#x2019;s response to such general solicitation or (iii) employing or engaging any such person who no longer works for a Party at the time the other Party first commence employment discussions with such person.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">18.10&nbsp;&nbsp;&nbsp;Waiver.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;Any term or condition of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the Party waiving such term or condition.&nbsp;&nbsp;The waiver by either Party hereto of any right hereunder or of claims based on the failure to perform or a breach by the other Party shall not be deemed a waiver of any other right hereunder or of any other breach or failure by said other Party whether of a similar nature or otherwise.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">18.11&nbsp;&nbsp;&nbsp;No Benefit to Third Parties.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">This Agreement is for the sole benefit of the Parties hereto and their successors and permitted assigns, and it shall not be construed as conferring any rights on any other parties, except as expressly set forth in this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">18.12&nbsp;&nbsp;&nbsp;Further Assurance.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;Each Party shall duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">122</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">acts and things, including the filing of such assignments, agreements, documents and instruments, as may be necessary or as the other Party may reasonably request in connection with this Agreement and the performance thereunder, or to carry out more effectively the provisions and purposes, or to better assure and confirm unto such other Party its rights and remedies under this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">18.13&nbsp;&nbsp;&nbsp;English Language.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">This Agreement has been written and executed in the English language as used in the United States of America and shall be interpreted in accordance with the English language as used in the United States of America.&nbsp;&nbsp;Any translation by a Party into any other language shall not be an official version thereof, and in the event of any conflict in interpretation between the English version and such translation, the English version shall control.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">18.14&nbsp;&nbsp;&nbsp;No Drafting Party.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;This Agreement has been submitted to the scrutiny of, and has been negotiated by, both Parties and their counsel, and shall be given a fair and reasonable interpretation in accordance with its terms, without consideration or weight being given to any such terms having been drafted by any Party or its counsel.&nbsp;&nbsp;No rule of strict construction shall be applied against either Party.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">18.15&nbsp;&nbsp;&nbsp;Anti-Corruption and Bribery.&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Each Party shall, and its officers, directors, employees, agents, representatives, or any other person acting on its behalf (collectively its &#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Representatives</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;) shall, comply at all times with all applicable Laws combating bribery and corruption, including the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act, the bribery provisions in the German Criminal Code ("</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Anti-Bribery Laws</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">").&nbsp;&nbsp;Each Party further represents and warrants that neither it nor any of its Representatives has offered to pay, paid, or accepted, and undertakes that neither it nor any of its Representatives will offer, pay, or accept, any bribes (including any improper advantages, such as, but not limited to, cash or cash equivalents, improper gifts, excessive entertainment, lavish travel, substantial favors etc.) to or by any person (including, in particular, any Government Official or Healthcare Professional of any jurisdiction) to secure or retain a business advantage for such Party&#x2019;s own benefit, the benefit of the other Party under or in connection with this Agreement, or for the benefit of any other party. Each Party shall take appropriate steps, in particular maintain and effectively enforce internal policies and procedures, to ensure that Representatives will not breach any Anti-Bribery Laws. Each Party shall be responsible for any breach of Anti-Bribery Laws by its Representatives under or in connection with this Agreement. In addition, Each Party shall ensure that any person engaged by such Party for purposes of performing services or providing goods under or in connection with this Agreement does so only on the basis of a written contract which imposes on and secures from such person terms equivalent to those imposed on each Party in this and the foregoing paragraphs of this Section. Any material breach of any obligation under this Section by a Party or its Representatives may entitle the other Party to terminate this Agreement in accordance with Section 17.2(a) and claim any damages resulting from such breach.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">18.16&nbsp;&nbsp;&nbsp;Trade Controls.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> Each Party will perform all activities under this Agreement in compliance with all applicable Export Controls and Economic Sanctions Laws, including all applicable U.S. and EU laws, regulations, and orders imposing trade sanctions on countries (including their governments, residents, and entities organized under the laws of or operating from such countries), individuals, or entities and/or regulating the export, re-export, transfer, disclosure, or provision of commodities, software, technology, or services.</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">123</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">18.17&nbsp;&nbsp;&nbsp;Protection of Personal Data</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">. Each Party shall comply with all applicable Data Protection Laws. The Parties agree that the collection, processing and disclosure of personal data, including but not limited to personal data (as defined by privacy Laws) related to study participants (e.g. health and medical information), investigators and any study staff (e.g., name, hospital or clinic address and phone number, curriculum vitae) is subject to compliance with privacy Laws. Each Party undertakes to comply with the requirements set forth in applicable privacy Laws.&nbsp;&nbsp;Within [***] days from the Execution Date, and </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:11pt;">prior to</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> the processing of personal data, the Parties shall enter into a Data Processing Agreement in accordance with privacy Laws, in substantially the form attached hereto as </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT 13</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">,&nbsp;&nbsp;which shall be incorporated by reference herein, that establishes the Parties&#x2019; obligations to each other and with regard to the personal data to be processed including but not limited to Regulation (EU) 2016/679 and of the Council of 27 April 2016, on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, the EU general data protection regulation (GDPR) repealing Directive 95/46/EC.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">18.18&nbsp;&nbsp;&nbsp;Construction.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> Except where the context otherwise requires, wherever used, the use of any gender shall be applicable to all genders and the word "or" is used in the inclusive sense (and/or).&nbsp;&nbsp;The captions of this Agreement are for convenience of reference only and in no way define, describe, extend or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement.&nbsp;&nbsp;The term "including" as used herein means including, without limiting the generality of any description preceding such term. The word "any" means "any" unless otherwise clearly indicated by context.&nbsp;&nbsp;Unless the context requires otherwise, (i) any definition of or reference to any agreement, instrument or other document refer to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein or therein), (ii) any reference to any Laws refer to such Laws as from time to time enacted, repealed or amended, (iii) the words "herein", "hereof" and "hereunder", and words of similar import, refer to this Agreement in its entirety and not to any particular provision hereof, and (iv) all references herein to Sections and Exhibits, unless otherwise specifically provided, refer to the Sections and Exhibits of this Agreement. Definitions using the singular shall be applicable also to the plural and vice-versa. Headings are for convenience only.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">18.19&nbsp;&nbsp;&nbsp;Cumulative Remedies.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;Except to the extent otherwise expressly set forth in this Agreement, the rights and remedies of the Parties set forth herein or otherwise available at law or equity are cumulative and not alternative or exclusive.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">18.20&nbsp;&nbsp;&nbsp;Counterparts.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. If any signature is delivered by facsimile transmission or by e-mail delivery of a &#x201C;PDF&#x201D; format data file, such signature shall create a valid and binding obligation of the Party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or &#x201C;PDF&#x201D; signature page were an original thereof, provided that such facsimile or &#x201C;PDF&#x201D; signature is confirmed by an original signature.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">18.21&nbsp;&nbsp;&nbsp;Anti-Trust Filing</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Each of the Parties shall prepare and make appropriate filings under the HSR Act and other applicable antitrust regulations and laws in all required jurisdictions relating to the transaction contemplated by this Agreement as soon as reasonably practicable after the Execution Date (but not later than [***] Business Days, unless the</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">124</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Parties mutually agree otherwise) (&#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">HSR Filing Date</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;).&nbsp;&nbsp;The Parties agree to cooperate in the Clearance process and to furnish promptly to the FTC, the Antitrust Division of the DOJ and any other agency or authority requiring antitrust filing in any other jurisdiction, any information reasonably requested by them in connection with such filings.&nbsp;&nbsp;In the event a provision of this Agreement needs to be deleted or substantially revised in order to obtain Clearance of this transaction, the Parties will negotiate in good faith an amendment to this Agreement.&nbsp;&nbsp;Each Party shall bear its own expenses in connection with the Parties&#x2019; cooperation under this Section 18.21 except that COMPANY shall pay all filing fees due with respect to any filings under the HSR Act, in Germany and in Austria.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Other than the provisions of this Section 18.21 and Section&nbsp;16, the rights and obligations of the Parties under this Agreement shall not become effective until the Effective Date.&nbsp;&nbsp;Upon the occurrence of the Effective Date, all provisions of this Agreement shall become effective automatically without the need for further action by the Parties.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">In the event that Clearance is not obtained within [***] calendar days after the HSR Filing Date, or such other date as the Parties may mutually agree, this Agreement may be terminated by any Party on written notice to the other Party.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Upon the terms and subject to the conditions of this Agreement, each of the Parties shall (i) make promptly its respective filings and thereafter make any other required submissions, under the HSR Act and any other applicable Law with respect to this Agreement, if required, and (ii) use its best efforts to take, or cause to be taken, all appropriate action, and to do, or cause to be done, all things necessary, proper or advisable under applicable Laws to consummate and make effective this transaction, and the other transactions contemplated by this Agreement, including using its best efforts to obtain all permits, consents, approvals, authorizations, qualifications and orders of Governmental Authorities as are necessary for the consummation of the transactions contemplated by this Agreement and to fulfill the conditions to this Agreement; provided, that the term &#x201C;best efforts&#x201D; as used in this Section 18.21(d) shall not require any Party to (a) sell, divest (including through a license or a reversion of licensed or assigned rights), hold separate, transfer, or dispose of any portion of the assets, operations, rights, product lines, or businesses, or interests therein, of itself or any of its Affiliates (or consent to any of the foregoing actions), (b) restrain, restrict, prohibit or limit the ability of any Party to conduct its business or own its assets (or consent to any of the foregoing actions) or (c) litigate or otherwise formally oppose any determination (whether judicial or administrative in nature) by a Governmental Authority seeking to challenge the transactions contemplated by this Agreement or impose any of the restrictions referenced in clause (a) or (b) above.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">[END OF CONTRACT TERMS &#x2013; SIGNATURE PAGE TO FOLLOW ON NEXT PAGE]</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">125</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">IN WITNESS WHEREOF, and intending to be legally bound hereby, the Parties have caused this collaboration and license agreement to be executed by their respective duly authorized officers.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td colspan="2" valign="top" style="width:47.28%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">MorphoSys AG</font></p>
				</td>
				<td valign="top" style="width:02.22%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:50.50%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:47.28%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.22%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:50.50%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:06.66%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">By:</font></p>
				</td>
				<td valign="top" style="width:40.62%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.22%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:06.34%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">By:</font></p>
				</td>
				<td valign="top" style="width:44.16%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:06.66%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Name:</font></p>
				</td>
				<td valign="top" style="width:40.62%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.22%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:06.34%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Name:</font></p>
				</td>
				<td valign="top" style="width:44.16%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:06.66%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Title:</font></p>
				</td>
				<td valign="top" style="width:40.62%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.22%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:06.34%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Title:</font></p>
				</td>
				<td valign="top" style="width:44.16%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td colspan="2" valign="top" style="width:47.28%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">MorphoSys US Inc.</font></p>
				</td>
				<td valign="top" style="width:02.22%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:50.50%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:47.28%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.22%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:50.50%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:06.66%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">By:</font></p>
				</td>
				<td valign="top" style="width:40.62%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.22%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:06.34%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">By:</font></p>
				</td>
				<td valign="top" style="width:44.16%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:06.66%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Name:</font></p>
				</td>
				<td valign="top" style="width:40.62%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.22%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:06.34%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Name:</font></p>
				</td>
				<td valign="top" style="width:44.16%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:06.66%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Title:</font></p>
				</td>
				<td valign="top" style="width:40.62%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.22%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:06.34%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Title:</font></p>
				</td>
				<td valign="top" style="width:44.16%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td colspan="2" valign="top" style="width:47.28%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">INCYTE CORPORATION</font></p>
				</td>
				<td valign="top" style="width:02.22%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:50.50%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:47.28%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.22%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:50.50%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:06.66%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">By:</font></p>
				</td>
				<td valign="top" style="width:40.62%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.22%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:06.34%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">By:</font></p>
				</td>
				<td valign="top" style="width:44.16%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:06.66%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Name:</font></p>
				</td>
				<td valign="top" style="width:40.62%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.22%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:06.34%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Name:</font></p>
				</td>
				<td valign="top" style="width:44.16%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:06.66%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Title:</font></p>
				</td>
				<td valign="top" style="width:40.62%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.22%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:06.34%;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Title:</font></p>
				</td>
				<td valign="top" style="width:44.16%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">126</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">EXHIBITS to Collaboration and License Agreement:</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AMINO ACID SEQUENCE OF LICENSED ANTIBODY (MOR208)</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MORPHOSYS BACKGROUND PATENTS</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;XENCOR BACKGROUND PATENTS</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;KNOW-HOW</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;XENCOR FOREGROUND PATENTS</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DEVELOPMENT PLAN OUTLINE</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;JOINT DEVELOPMENT BUDGET OUTLINE</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 8A&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MORPHOSYS TRIALS OUTLINE</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 8B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;COMPANY TRIAL OUTLINE</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 8C&nbsp;&nbsp;&nbsp;&nbsp;COMPANY JAPAN TRIAL OUTLINE</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;XMAB5871</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PRESS RELEASE</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DISPUTE RESOLUTION PROCEDURE</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;EXISTING PRODUCT MARKS</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DATA PROCESSING AGREEMENT</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CO-COMMERCIALIZATION PLAN OUTLINE</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CO-COMMERCIALIZATION BUDGET OUTLINE</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CONTRIBUTION TO EQUITY AND SHARE ISSUANCE</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TRANSITION PLAN DRAFT</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;STATEMENT FOR COMPANY&#x2019;S MEDIA RELEASES AND PUBLICATIONS</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DISCLOSURE SCHEDULE</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADDITIONAL CAP RE OBLIGATION UNDER SECTION 14.1(B)(II)(3)(Z)</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;">127</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">EXHIBITS:</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AMINO ACID SEQUENCE OF LICENSED ANTIBODY (MOR208)</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MORPHOSYS BACKGROUND PATENTS</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;XENCOR BACKGROUND PATENTS</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;KNOW-HOW</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;XENCOR FOREGROUND PATENTS</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DEVELOPMENT PLAN OUTLINE</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;JOINT DEVELOPMENT BUDGET OUTLINE</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 8A&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MORPHOSYS TRIALS OUTLINE</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 8B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;COMPANY TRIAL(I) OUTLINE</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 8C&nbsp;&nbsp;&nbsp;&nbsp;COMPANY JAPAN TRIAL OUTLINE</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;XMAB5871</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PRESS RELEASE</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DISPUTE RESOLUTION PROCEDURE</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;EXISTING PRODUCT MARKS</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DATA PROCESSING AGREEMENT</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CO-COMMERCIALIZATION PLAN OUTLINE</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CO-COMMERCIALIZATION BUDGET OUTLINE</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CONTRIBUTION TO EQUITY AND SHARE ISSUANCE</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TRANSITION PLAN</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;STATEMENT FOR COMPANY&#x2019;S MEDIA RELEASES AND PUBLICATIONS</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DISCLOSURE SCHEDULE</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">EXHIBIT 20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADDITIONAL CAP RE OBLIGATION UNDER SECTION 14.1(B)(II)(3)(Z)</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">EXHIBIT 1</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">AMINO ACID SEQUENCE OF LICENSED ANTIBODY (MOR208)</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">EXHIBIT 2</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">MORPHOSYS BACKGROUND PATENTS</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">EXHIBIT 3</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">XENCOR BACKGROUND PATENTS</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">EXHIBIT 4</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">KNOW-HOW</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">EXHIBIT 5</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Xencor Foreground Patents</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">EXHIBIT 6</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">DEVELOPMENT PLAN OUTLINE</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">EXHIBIT 7</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">JOINT DEVELOPMENT BUDGET OUTLINE</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">[***]</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">EXHIBIT 8A</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">MORPHOSYS TRIALS OUTLINE</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">[***]</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">EXHIBIT 8B</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">COMPANY TRIAL(I) OUTLINE</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">[***]</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">EXHIBIT 8C</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">COMPANY JAPAN TRIAL OUTLINE</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">[***]</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">EXHIBIT 9</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">XMAB5871</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">[***]</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">EXHIBIT 10</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">PRESS RELEASE</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Media Release</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Planegg/Munich, Germany, and Wilmington, Delaware, U.S., January 12/13, 2020</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 14pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:14pt;">MorphoSys and Incyte Sign Global Collaboration and License Agreement for Tafasitamab</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:10.5pt;">MorphoSys and Incyte to co-commercialize tafasitamab in the U.S.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:10.5pt;">Incyte has exclusive commercialization rights outside of the U.S.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:10.5pt;">MorphoSys and Incyte to host joint conference call on January 13, 2020 at 7:00am PST / 4:00pm CET</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX &amp; TecDAX; NASDAQ: MOR) and Incyte Corporation (NASDAQ: INCY) announced today that the companies have entered into a collaboration and license agreement to further develop and commercialize MorphoSys&#x2019; proprietary anti-CD19 antibody tafasitamab (MOR208) globally. Tafasitamab is an Fc-engineered antibody against CD19 currently in clinical development for the treatment of B cell malignancies. MorphoSys and Incyte will co-commercialize tafasitamab in the U.S., while Incyte has exclusive commercialization rights outside of the U.S.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">&#x201C;The global partnership with Incyte is an important step towards unlocking the full potential of tafasitamab and achieving our goal of rapidly bringing tafasitamab to patients inside and outside of the U.S.,&#x201D; said Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys. &#x201C;The combination of our strong antibody and drug development expertise partnered with Incyte&#x2019;s well-established hematology-oncology experience and their commercial operations in key territories has the potential to significantly broaden the tafasitamab opportunity. We are pleased to work with Incyte to jointly improve the lives of patients suffering from DLBCL and other devastating diseases.&#x201D;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">&#x201C;Bringing together Incyte&#x2019;s expertise and MorphoSys&#x2018; commitment to innovation will allow us to make tafasitamab widely available to patients with cancer, upon approval,&#x201D; said Herv&#xE9; Hoppenot, CEO of Incyte. &#x201C;We look forward to collaborating closely with the team at MorphoSys and adding tafasitamab to our portfolio of oncology candidates as part of our committment to bringing new, advanced treatment options to patients and the clinical community around the world.&#x201D;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">Under the terms of the agreement, MorphoSys will receive an upfront payment of $750 million and, in addition, Incyte will make an equity investment into MorphoSys of $150 million in new American Depositary Shares (ADS) of MorphoSys at a premium to the share price at signing of the agreement. Depending on the achievement of certain developmental, regulatory and commercial milestones, MorphoSys will be eligible to receive milestone payments amounting to up to $1.1 billion. MorphoSys will also receive tiered royalties on ex-U.S. net sales of tafasitamab in a mid-teens to mid-twenties percentage range of net sales.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">In the U.S., MorphoSys and Incyte will co-commercialize tafasitamab, with MorphoSys leading the commercialization strategy and booking all revenues from sales of tafasitamab. Incyte and MorphoSys will be jointly responsible for commercialization activities in the U.S. and will share profits and losses on a 50:50 basis. Outside the U.S., Incyte will have exclusive commercialization rights, and will lead the commercialization strategy and book all revenues from sales of tafasitamab, paying MorphoSys royalties on ex-U.S. net sales.</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">Furthermore, the companies will share development costs associated with global and U.S.-specific trials at a rate of 55% (Incyte) to 45% (MorphoSys); Incyte will cover 100% of the future development costs for trials that are specific to ex-U.S. countries.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">Both parties have agreed to co-develop tafasitamab broadly in relapsed/refractory diffuse large B cell lymphoma (r/r DLBCL), frontline DLBCL as well as additional indications beyond DLBCL, such as follicular lymphoma (FL), marginal zone lymphoma (MZL) and chronic lymphocytic leukemia (CLL). Incyte will be responsible for initiating a combination study of its investigational PI3K-delta inhibitor parsaclisib and tafasitamab in r/r B cell malignancies. Further, Incyte will be responsible for leading any potential registration-enabling studies in CLL and a phase 3 trial in r/r FL/MZL. MorphoSys will continue to be responsible for its currently ongoing clinical trials of tafasitamab in non-Hodgkin lymphoma (NHL), CLL, r/r DLBCL and frontline DLBCL. The parties will share responsibility in starting additional global trials, and Incyte intends to pursue development in additional territories including Japan and China.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">MorphoSys recently submitted a Biologics License Application (BLA) for tafasitamab, in combination with lenalidomide, to the U.S. Food and Drug Administration (FDA) for the treatment of r/r DLBCL; the FDA decision regarding a potential approval is expected by mid-2020. The submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in r/r DLBCL is planned for mid-2020.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">The agreement between MorphoSys and Incyte, including the equity investment, is subject to clearance by the U.S. antitrust authorities under the Hart-Scott-Rodino Act as well as by the German and Austrian antitrust authorities, and will become effective as soon as these conditions have been met.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">MorphoSys and Incyte will host a joint conference call on January 13, 2020 at 7:00am PST/ 4:00pm CET.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:10.5pt;">Dial-in numbers for the conference call on Monday, January 13, 2020 at 7:00am PST; 3:00pm GMT; 10:00am EST; 04:00pm CET:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:22.50%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">For Germany:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:77.50%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">+49 69 201 744 220</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:22.50%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">For the U.K.:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:77.50%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">+44 203 009 2470</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:22.50%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">For the U.S.:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:77.50%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">+1 877 423 0830</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:22.50%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:77.50%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:22.50%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">Participant PIN:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:77.50%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">55656540#</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">Please dial in 10 minutes before the beginning of the conference.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">A live webcast will be made available at www.morphosys.com and at investor.incyte.com.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;text-decoration:underline;">About Tafasitamab</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">Tafasitamab is an investigational humanized Fc-engineered monoclonal antibody directed against CD19. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;"> engineered Fc domain, which is intended to lead to a significant potentiation of antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">cellular phagocytosis (ADCP), thus aiming to improve a key mechanism of tumor cell killing. MorphoSys is clinically investigating tafasitamab as a therapeutic option in B cell malignancies in a number of ongoing combination trials. An open-label phase 2 combination trial (L-MIND study) is investigating the safety and efficacy of tafasitamab in combination with lenalidomide in patients with relapsed/refractory DLBCL who are not eligible for high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT). Based on interim data from L-MIND, in October 2017 the U.S. FDA granted Breakthrough Therapy Designation for tafasitamab plus lenalidomide in this patient population. Re-MIND, the real-world data lenalidomide alone matched control cohort met its primary endpoint in October 2019, demonstrating clinical superiority of the tafasitamab/lenalidomide combination compared to lenalidomide alone. The ongoing phase 3 study B-MIND assesses the combination of tafasitamab and bendamustine versus rituximab and bendamustine in r/r DLBCL. In addition, tafasitamab is currently being investigated in patients with relapsed/refractory CLL/SLL after discontinuation of a prior Bruton tyrosine kinase (BTK) inhibitor therapy (e.g. ibrutinib) in combination with idelalisib or venetoclax.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;text-decoration:underline;">About MorphoSys</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">MorphoSys (FSE &amp; NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 28 are currently in clinical development. In 2017, Tremfya</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">, marketed by Janssen for the treatment of plaque psoriasis, became the first drug based on MorphoSys&#x2019;s antibody technology to receive regulatory approval. The Company&#x2019;s most advanced proprietary product candidate, tafasitamab (MOR208), has been granted U.S. FDA breakthrough therapy designation for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has approximately 405 employees. More information at https://www.morphosys.com.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">HuCAL</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">, HuCAL GOLD</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">, HuCAL PLATINUM</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">, CysDisplay</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">, RapMAT</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">, arYla</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">, Ylanthia</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">, 100 billion high potentials</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">, Slonomics</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">, Lanthio Pharma</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">, LanthioPep</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;"> and ENFORCER</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;font-size:5pt;top:-4pt;position:relative;line-height:100%">TM</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;"> are trademarks of the MorphoSys Group. Tremfya</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;"> is a trademark of Janssen Biotech, Inc. XmAb</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;"> is a trademark of Xencor, Inc.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;text-decoration:underline;">About Parsaclisib</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">Parsaclisib (INCB50465) is a highly selective and potent inhibitor of the phosphatidylinositol 3-kinase delta (PI3K&#x3B4;) isoform. PI3K&#x3B4; is an important target implicated in malignant B-cell growth, survival and proliferation, and its inhibition has potential as a mechanism to treat hematologic malignancies and a variety of B-cell mediated and antibody-driven diseases beyond oncology. The CITADEL&nbsp;(Clinical Investigation of TArgeted PI3K-DELta Inhibition in Lymphomas) clinical trial program is currently evaluating parsaclisib in several ongoing Phase 2 trials as a treatment for non-Hodgkin lymphomas (follicular, marginal zone and mantle cell). Parsaclisib is also being studied for patients with autoimmune hemolytic anemia and as part of a combination therapy for patients with  myeloproliferative neoplasms and non-Hodgkin lymphomas including diffuse large B-cell lymphoma.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;text-decoration:underline;">About Incyte Corporation</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">Incyte&nbsp;is a&nbsp;Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on&nbsp;Incyte, please visit Incyte.com and follow @Incyte.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:9pt;text-decoration:underline;">MorphoSys forward looking statements</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:9pt;">This communication contains certain forward-looking statements concerning the MorphoSys group of companies, including the expectations regarding the licensing agreement for tafasitamab, the further clinical development of tafasitamab</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">,</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:9pt;"> interactions with regulatory authorities and expectations regarding regulatory filings and possible approvals for tafasitamab as well as the potential future commercialization of tafasitamab. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:9pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:9pt;">results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are MorphoSys' expectations regarding the licensing agreement for tafasitamab, the further clinical development of tafasitamab, interactions with regulatory authorities and expectations regarding regulatory filings and possible approvals for tafasitamab as well as the potential future commercialization of tafasitamab, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys&#x2019;s Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:9pt;text-decoration:underline;">Incyte forward looking statements</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:9pt;">Except for the historical information set forth herein, the matters set forth in this press release contain predictions, estimates and other forward-looking statements, including without limitation statements regarding: whether the planned transaction will close within the expected timeframe or ever; whether tafasitamab will be approved for use in humans anywhere or will be commercialized anywhere successfully or at all; whether the MAA for tafacitinib will be submitted within the expected timeframe or at all; whether tafasitamab or parsaclisib will be effective in the treatment of the indications discussed in this press release; whether this collaboration will broaden the potential market for tafasitamab; and whether and when any of the milestone payments or royalties under this collaboration will ever be paid by Incyte. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: obtaining regulatory approval for this planned collaboration; research and development efforts related to the collaboration programs; the possibility that results of clinical trials may be unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; other market or economic factors, including other scientific developments; unanticipated delays; the effects of market competition; risks associated with relationships between collaboration partners; the impact of governmental actions regarding pricing, importation and reimbursement for pharmaceuticals; and such other risks detailed from time to time in each company&#x2019;s reports filed with the Securities and Exchange Commission, including Incyte&#x2019;s quarterly report on Form 10-Q for the quarter ended September 30, 2019 and MorphoSys&#x2019;s Annual Report on Form 20-F for the fiscal year ended December 31, 2018. Each party disclaims any intent or obligation to update these forward-looking statements.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:10.5pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:10.5pt;">For more information, please contact:</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:10.5pt;">MorphoSys AG</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">Dr. Sarah Fakih</font></p>
					<p style="margin:0pt 0pt 6pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">Vice President Corporate Communications &amp; IR<br>Tel: +49 (0) 89 / 899 27-26663</font></p>
					<p style="margin:0pt 0pt 6pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">Sarah.Fakih@morphosys.com</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">Dr. Julia Neugebauer</font></p>
					<p style="margin:0pt 0pt 6pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">Director Corporate Communications &amp; IR<br>Tel: +49 (0) 89 / 899 27-179</font></p>
					<p style="margin:0pt 0pt 6pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">Julia.Neugebauer@morphosys.com</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">Dr. Verena Kupas</font></p>
					<p style="margin:0pt 0pt 6pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">Associate Director Corporate Communications &amp; IR<br>Tel: +49 (0) 89 / 899 27-26814</font></p>
					<p style="margin:0pt 0pt 6pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">Verena.Kupas@morphosys.com</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:10.5pt;">Incyte Corporation</font>
		</p>
		<p style="margin:0pt 0pt 6pt 9pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">Catalina Loveman</font>
		</p>
		<p style="margin:0pt 0pt 6pt 9pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">Executive Director, Public Affairs</font>
		</p>
		<p style="margin:0pt 0pt 6pt 9pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">Tel: +1 302 498 6171</font>
		</p>
		<p style="margin:0pt 0pt 6pt 9pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">cloveman@incyte.com</font>
		</p>
		<p style="margin:0pt 0pt 6pt 9pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt 9pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">Dr. Michael Booth</font>
		</p>
		<p style="margin:0pt 0pt 6pt 9pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">Division Vice President, Investor Relations &amp; Corporate Responsibility</font>
		</p>
		<p style="margin:0pt 0pt 6pt 9pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">Tel: +1 302 498 5914</font>
		</p>
		<p style="margin:0pt 0pt 6pt 9pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">mbooth@incyte.com</font>
		</p>
		<p style="margin:0pt 0pt 6pt 9pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:10.5pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:10.5pt;">EXHIBIT 11</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:10.5pt;">Dispute Resolution Procedure</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any Dispute shall be brought to the attention of a senior management representative of each Party, who shall attempt to resolve the Dispute in good faith. If, however, the senior management representatives of the Parties are unable to resolve a Dispute, the CEOs or presidents (or their respective designee, provided the designee has authority to resolve the Dispute) of the Parties shall on the request of any of the Parties attempt in good faith to promptly resolve such Dispute within [***] calendar days. The limitation period with respect to claims relating to a dispute submitted to CEOs or presidents as provided for above is suspended by submission of the dispute until [***] after lapse of the aforementioned period of time.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">If the CEOs or presidents or permitted designees are unable to resolve such Dispute within such period, either Party may submit the Dispute to final and binding arbitration in accordance with the [***]; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:10.5pt;text-decoration:underline;">provided, however,</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;"> any dispute regarding the validity, scope or enforceability of patents licensed under this Agreement shall be submitted to a court of competent jurisdiction. The arbitration shall be conducted in the English language by [***] appointed in accordance with the [***], with the exception that the sole arbitrator or the President shall be nominated by the Parties. The place of arbitration is [***].</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">The costs of the arbitration as well as all reasonable out-of-pocket costs (including, without limitation, reasonable attorneys' fees and reasonable travel expenses) shall be borne [***].</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">Except as may be required by applicable Laws, neither Party, nor any Affiliate thereof, nor an arbitrator may disclose the existence, content or result of any arbitration held with respect to this Agreement without the prior written consent of both Parties.&nbsp;&nbsp;The Parties mutually agree that all information, documents, testimony, exhibits and other written, recorded, graphic or other information produced, exchanged or used in any way in any arbitration proceeding under this Section are designated as confidential and shall not be disclosed to anyone other than the Parties, their attorneys and advisors, and the arbitrators.&nbsp;&nbsp;Furthermore, any and all documents, materials or other information designated as confidential that are produced to or received by the other Party or any Affiliate as part of the arbitration proceeding shall be returned to the Party that produced or provided such materials within [***] calendar days of the conclusion of the arbitration, or such materials shall be certified in writing to have been destroyed within [***] calendar days of the conclusion of the arbitration; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:10.5pt;text-decoration:underline;">provided, however</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">, that the Parties and their counsel may retain copies of briefs and other papers filed with the arbitrators that contain or constitute such confidential material, so long as such briefs and other papers are maintained according to the confidentiality provisions of this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">By agreeing to arbitration neither Party intends to deprive any competent court having jurisdiction to issue a pre-arbitral injunction, pre-arbitral attachment or other order in aid of the arbitration proceedings and the enforcement of any award or injunction in aid of the arbitration proceedings.&nbsp;&nbsp;Without prejudice to such provisional remedies in aid of arbitration as may be available under the jurisdiction of a national court, the arbitration panel shall have full authority to grant provisional remedies and to award damages for failure of any Party to respect the arbitration panel&#x2019;s order to that effect.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">The arbitral tribunal shall [***].</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">If a Party fails to make the payment of any advance on costs fixed by the [***], and if the other Party makes the payment in lieu of the defaulting Party, the arbitral tribunal may, at the request of the paying Party, issue a separate award for reimbursement of the payment. Alternatively, the paying Party may ask the arbitral tribunal to order interim or conservatory measures, or it may, at its discretion, apply the competent state courts.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">EXHIBIT 12</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">EXISTING PRODUCT MARKS</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">[***]</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-weight:bold;font-size:11pt;">EXHIBIT 13</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">DATA PROCESSING AGREEMENT</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(JOINT CONTROLLER VERSION)</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">This Data Processing Agreement (&#x201C;</font><font style="display:inline;font-weight:bold;">DPA</font><font style="display:inline;">&#x201D;) is effective on &lt;&lt;Insert Effective Date&gt;&gt; (&#x201C;</font><font style="display:inline;font-weight:bold;">DPA Effective Date</font><font style="display:inline;">&#x201D;) and is between MorphoSys AG (&#x201C;</font><font style="display:inline;font-weight:bold;">MorphoSys</font><font style="display:inline;">&#x201D;), acting on its own behalf and as an agent for each MorphoSys Affiliate and &lt;&lt;Insert COMPANY Name &gt;&gt; (&#x201C;</font><font style="display:inline;font-weight:bold;">COMPANY</font><font style="display:inline;">&#x201D;) as an agent for each COMPANY Affiliate, each a &#x201C;</font><font style="display:inline;font-weight:bold;">Party</font><font style="display:inline;">&#x201D; and together, &#x201C;</font><font style="display:inline;font-weight:bold;">Parties</font><font style="display:inline;">&#x201D;.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10.5pt;">WHEREAS</font><font style="display:inline;font-size:10.5pt;">, the Parties entered into a separate collaboration and license agreement (the &#x201C;</font><font style="display:inline;font-weight:bold;font-size:10.5pt;">Agreement</font><font style="display:inline;font-size:10.5pt;">&#x201D;) effective as of &lt;&lt;Insert Agreement Effective Date&gt;&gt; for the further development and commercialization of tafasitamab worldwide.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10.5pt;">WHEREAS</font><font style="display:inline;font-size:10.5pt;">, this DPA is being entered into between the Parties to establish the data protection duties and obligations between them regarding Shared Personal Data (defined below), where the Parties are acting as Joint Controllers (defined below) and this DPA forms part of, and should be read in conjunction with, the Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10.5pt;">NOW THEREFORE</font><font style="display:inline;font-size:10.5pt;">, in consideration of the mutual obligations set out herein, the Parties hereby agree to the terms and conditions as follows:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-weight:bold;">DEFINITIONS.&nbsp; </font><font style="display:inline;">IN THIS DPA, THE FOLLOWING TERMS SHALL HAVE THE MEANINGS SET OUT BELOW.</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">"Agreement" </font><font style="display:inline;">means any existing agreement entered into between the Parties pursuant to which collaboration activities involve Shared Personal Data;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">&#x201C;Affiliate" </font><font style="display:inline;">means an entity that owns or controls, is owned or controlled by or is or under common control or ownership, where control is defined as the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of an entity, whether through ownership of voting securities, by contract or otherwise;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">"Controller",&nbsp;&nbsp;"Data Subject", &#x201C;Joint Controller&#x201D;, "Personal Data&#x201D;, "Process/Processing", "Processor", </font><font style="display:inline;">and</font><font style="display:inline;font-weight:bold;"> "Special Categories of Personal Data" </font><font style="display:inline;">shall have the same meaning as in the Data Protection Laws (and its derivatives) as may apply;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">"Data Protection Laws" </font><font style="display:inline;">means the EU General Data Protection Regulation 2016/679</font><font style="display:inline;font-weight:bold;"> (&#x201C;GDPR&#x201D;) </font><font style="display:inline;">(and its derivatives), Directive 2002/58/EC (as transposed into domestic legislation of each European Union Member State or Member State of the EEA)&nbsp;&nbsp;and any other applicable data protection laws, regulations, codes of practice, codes of conduct, guidance issued by any relevant Supervisory Authority in the relevant jurisdiction relating to the protection of natural persons with regard to Personal Data, privacy or Applicable Law&nbsp;&nbsp;amending, replacing or superseding any of the foregoing&nbsp;&nbsp;and in particular, following&nbsp;&nbsp;exit by the United Kingdom from the European Union, or, and to the extent applicable, the data protection or privacy laws of any other country including, without limitation, Switzerland;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">"EEA" </font><font style="display:inline;">means the European Economic Area;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">"Permitted Purposes" </font><font style="display:inline;">the purposes for which Processing of Shared Personal Data is permitted, as set out in Annex 1 to this DPA;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">"Personal Data Breach" </font><font style="display:inline;">means a breach of security leading to the accidental or unlawful destruction, loss, alteration, unauthorised disclosure of, or access to, Shared Personal Data transmitted, stored or otherwise Processed;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">&#x201C;Shared Personal Data&#x201D; </font><font style="display:inline;">means Personal Data that is provided by a Party and Processed by the other Party or any of each Party&#x2019;s Affiliates whereby each Party is acting as a Joint Controller of the Personal Data.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">"Standard Contractual Clauses" </font><font style="display:inline;">means the standard contractual clauses for the transfer of personal data to controllers established in third countries which do not ensure an adequate level of protection as set out in Commission Decision C(2004)5721; and</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">"Supervisory Authority" </font><font style="display:inline;">means (a) an independent public authority which is established by a European Union Member State or member of the EEA pursuant to Article 51 GDPR; and (b) any similar regulatory authority responsible for the enforcement of Data Protection Laws.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ROLES OF THE PARTIES.&nbsp; </font><font style="display:inline;">IN THE COURSE OF THE PARTIES&#x2019; PERFORMANCE OF WORK UNDER THE AGREEMENT, THE PARTIES ACKNOWLEDGE THAT EACH PROCESSES SHARED PERSONAL DATA AS JOINT CONTROLLERS.&nbsp;&nbsp;ACCORDINGLY, EACH PARTY HEREBY UNDERTAKES TO COMPLY WITH THE PROVISIONS SET OUT IN THIS DPA WITH RESPECT TO ITS PROCESSING OF SHARED PERSONAL DATA.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-weight:bold;">COMPLIANCE WITH LAW.&nbsp; </font><font style="display:inline;">EACH OF THE PARTIES SHALL COMPLY WITH ITS RESPECTIVE OBLIGATIONS UNDER APPLICABLE DATA PROTECTION LAWS IN RELATION TO ITS PROCESSING OF SHARED PERSONAL DATA PURSUANT TO THE AGREEMENT (INCLUDING THIS DPA).</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-weight:bold;">GENERAL OBLIGATIONS.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In respect of its Processing of Shared Personal Data as Joint Controllers, each Party shall undertake to:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 90pt;text-indent: -54pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">4.1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;not Process Shared Personal Data in a way that is incompatible with the Permitted Purposes;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 90pt;text-indent: -54pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">4.1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;not Process Shared Personal Data for longer than is necessary to carry out the Permitted Purposes (other than to comply with a requirement of EU, Member State or UK applicable laws to which the Parties are subject);</font>
		</p>
		<p style="margin:0pt 0pt 12pt 90pt;text-indent: -54pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">4.1.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;take all measures required pursuant to Article 32 of the GDPR, and, where the Personal Data is Processed in a jurisdiction other than in the EEA, shall comply with the obligations set out in the relevant schedule, to ensure the security of Processing of Shared Personal Data, including (where relevant) each of the technical and organisational measures listed in Annex 3;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 90pt;text-indent: -54pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">4.1.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ensure that persons authorized to process Shared Personal Data have undertaken appropriate training in relation to Data Protection Laws; committed themselves to confidentiality or are under an appropriate statutory obligation of confidentiality;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 90pt;text-indent: -54pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">4.1.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ensure that, in relation to any Processors appointed by a Party:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 144pt;text-indent: -54pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">4.1.5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;appropriate, documented due diligence is carried out on such Processor(s) prior to its appointment to ensure that, to the reasonable satisfaction of the respective Party, it is able to comply with (and that it will be in a position to ensure the the Party&#x2019;s compliance with) all relevant provisions of the Data Protection Laws; and</font>
		</p>
		<p style="margin:0pt 0pt 12pt 144pt;text-indent: -54pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">4.1.5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Party (or such Party&#x2019;s Affiliate, provided that the Party has express third party rights) has entered into a contract with the Processor which incorporates all necessary provisions of the Data Protection Laws.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Party shall co-operate with the other, to the extent reasonably requested, in relation to:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 108pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any requests from Data Subjects to exercise rights under applicable Data Protection Laws;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 108pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any other communication from a Data Subject concerning the Processing of Shared Personal Data; and</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 108pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any communication from a Supervisory Authority concerning either the Processing of Shared Personal Data, or compliance with the Data Protection Laws in relation to the Shared Personal Data.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PERSONAL DATA BREACH.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Party shall notify the other and the other Party&#x2019;s Affiliate (as applicable) as set forth in Section 9.3 below without undue delay upon becoming aware of or reasonably suspecting a Personal Data Breach.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of a Personal Data Breach, the Party and its Affiliate(s) shall not inform any third party without first obtaining the prior written consent of the other Party, and each Party&#x2019;s relevant Affiliate (if applicable), unless notification is required by EU or Member State law to which the Party or its Affiliate is subject, in which case the Party or its Affiliate shall to the extent permitted by such law inform the other Party or its Affiliate(s) of that legal requirement, provide a copy of the proposed notification and consider any comments made by the Party or its Affiliate(s) before notifying the Personal Data Breach.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Party shall co-operate with the other, to the extent reasonably requested, in relation to any notifications to Supervisory Authorities or to Data Subjects, which are required following a Personal Data Breach.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">5.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Parties acknowledge that they are Joint Controllers regarding the determination of the purposes and means of Processing of Shared Personal Data under the Agreement.&nbsp;&nbsp;This</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">DPA constitutes an arrangement setting out the respective responsibilities of the Parties, as Joint Controllers, for compliance with the obligations under applicable Data Protection Laws.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-weight:bold;">JOINT CONTROLLERS&#x2019; OBLIGATIONS.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As Joint Controllers, the Parties agree that they shall:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 90pt;text-indent: -54pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">6.1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each maintain a register of their processing activities in the context of the services provided or received under the Agreement.&nbsp;&nbsp;The register shall contain at least the required information under the applicable Data Protection Laws;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 90pt;text-indent: -54pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">6.1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Co-operate to ensure that Data Subjects are provided with all information regarding the Processing of the Shared Personal Data to which they are entitled under applicable Data Protection Laws;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 90pt;text-indent: -54pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">6.1.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except where an express request is made by a Data Subject to liaise directly with the other Party, be responsible for responding to all requests from Data Subjects to exercise rights under applicable Data Protection Laws (in relation to which the Party shall provide the other Party with reasonable assistance upon request). Notwithstanding the foregoing, a Party shall notify the other Party immediately upon receiving any such request always in accordance with Section 9.3 below, and shall take due account of the other Party&#x2019;s views when responding to a request on behalf of the Parties;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 90pt;text-indent: -54pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">6.1.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each its own retention periods in respect of the Shared Personal Data which it Processes. The Parties shall not Process Shared Personal Data for longer than is necessary to carry out the Permitted Purposes set out in Annex 1;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 90pt;text-indent: -54pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">6.1.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except where the Data Protection Laws or other applicable laws provide otherwise, be jointly and severally liable towards Data Subjects for all damages they have suffered in the framework of the Processing of Shared Personal Data under the Agreement. In the event that one of the Parties is addressed or subpoenaed in that regard that Party shall immediately inform the other Party thereof in accordance with Section 9.3 below.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-weight:bold;">ASSURANCE.&nbsp; </font><font style="display:inline;">IN ADDITION TO ANY AUDIT RIGHTS GRANTED PURSUANT TO THE AGREEMENT, A PARTY SHALL MAKE AVAILABLE TO THE OTHER PARTY ON REQUEST ALL INFORMATION NECESSARY TO DEMONSTRATE COMPLIANCE WITH THIS DPA AND THE APPLICABLE DATA PROTECTION LAWS.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-weight:bold;">INTERNATIONAL TRANSFERS</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A Party shall not (and shall ensure that each appointed Processor shall not) transfer Shared Personal Data outside of the EEA, Switzerland, or any other jurisdiction except in accordance with the applicable Data Protection Laws.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">8.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Without prejudice to the foregoing, each Party consents to the Processing of Shared Personal Data by the other Party in accordance with the following when Personal Data is transferred out of the EEA or Switzerland</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 90pt;text-indent: -22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">8.2.1 Processing of Shared Personal Data by a Party or its Processor(s) in a country which is considered an adequate country by the European Commission; or</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 90pt;text-indent: -22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">8.2.2 Processing of Shared Personal Data by a Party or its Processor(s) in third countries (countries not recognized as adequate per the European Commission) provided that: (a) a Party enters into Standard Contractual Clauses and the Standard Contractual Clauses shall come into effect on the commencement of an International Transfer among any Parties to the Standard Contractual Clauses; or</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 90pt;text-indent: -22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">8.2.3 A Party or its Processor(s) is Privacy Shield certified and maintain such accreditation.&nbsp;&nbsp;In the event a Party or its Processor(s) fails to maintain such accreditation, it shall notify the other party immediately and the Parties agree that they will enter into Standard Contractual Clauses or terminate Services and this DPA.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 90pt;text-indent: -22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&lt;&lt;PLACEHOLDER: Insert transfer language for jurisdictions outside of the EEA/Switzerland as applicable (Annex 4).&gt;&gt;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TERMINATION</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">9.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to Section 8.2, the Parties agree that this DPA shall terminate automatically upon termination of the Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">9.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any obligation imposed on either Party under this DPA in relation to the Processing of Shared Personal Data shall survive any termination or expiration of this DPA.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MISCELLANEOUS</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">10.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-weight:bold;">Governing Law.&nbsp; </font><font style="display:inline;">This DPA shall be governed by the governing law of the Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">10.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-weight:bold;">Entire Agreement; Order of Precedence.&nbsp; </font><font style="display:inline;">This DPA, together with all Annexes attached hereto and incorporated herein by reference, constitutes the final, complete and exclusive agreement of the Parties with respect to the subject matter hereof and supersedes all prior understanding and agreements relating to its subject matter.&nbsp;&nbsp;With regard to the subject matter of this DPA, in the event of inconsistencies between the provisions of this DPA and any other agreements (including but not limited to the Agreement) between the Parties, the provisions of this DPA shall prevail with regard to the Parties&#x2019; data protection obligations for Shared Personal Data of a Data Subject from a European Union Member State or member state of the EEA.&nbsp;&nbsp;In the event of any conflict or inconsistency between this DPA and the Standard Contractual Clauses (if entered into), the Standard Contractual Clauses shall prevail.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">10.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-weight:bold;">Notices.&nbsp; </font><font style="display:inline;">Any general notice to be given to a Party under or in connection with this DPA shall be in writing and shall be delivered (i) personally; (ii) by a globally recognized overnight courier; or (iii) by certified mail, postage prepaid, return receipt requested, or its equivalent.&nbsp;&nbsp;Such notices shall be deemed given upon receipt.</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">If any such notice is sent via Section 10.3, any such notice shall be sent to the Party at the applicable address set forth below or to such other address as to which the Party has given written notice thereof.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">In the event of notices to be provided by any Party where time is of the essence in accordance with this DPA as a result of: (a) Personal Data Breach; (b) Data Subject request; or (c) inquiry/communication from a Supervisory Authority, such notices to be given by a Party to the other Party shall be emailed to the email address set forth below.</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.10%;margin-left:0.25pt;">
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;width:50.00%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 10.5pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">If to COMPANY:</font></p>
					<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;text-decoration:underline;">General Notices</font><font style="display:inline;font-weight:bold;">:</font></p>
					<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Global Privacy Officer</font></p>
					<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">1801 Augustine Cut-off</font></p>
					<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Wilmington, Delaware 19803</font></p>
					<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">United States</font></p>
					<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">In the Event of </font><font style="display:inline;font-weight:bold;text-decoration:underline;">Personal Data Breach</font><font style="display:inline;font-weight:bold;">:</font></p>
					<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;text-decoration:underline;">cybersecurity@COMPANY.com</font></p>
					<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">In the Event of </font><font style="display:inline;font-weight:bold;text-decoration:underline;">Data Subject Rights Request/Inquiry from a Supervisory Authority</font><font style="display:inline;font-weight:bold;">:</font></p>
					<p style="margin:0pt 0pt 10.5pt 35.45pt;text-indent: -35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;text-decoration:underline;">privacy@COMPANY.com</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;width:50.00%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 10.5pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">If to MorphoSys AG:</font></p>
					<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;text-decoration:underline;">General Notices</font><font style="display:inline;font-weight:bold;">:</font></p>
					<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Data Protection Officer</font></p>
					<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Semmelweisstrasse 7</font></p>
					<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">82152 Planegg</font></p>
					<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Germany</font></p>
					<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">In the Event of </font><font style="display:inline;font-weight:bold;text-decoration:underline;">Personal Data Breach</font><font style="display:inline;font-weight:bold;">:</font></p>
					<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;text-decoration:underline;">datenschutz@morphosy.com</font></p>
					<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">In the Event of </font><font style="display:inline;font-weight:bold;text-decoration:underline;">Data Subject Rights Request/Inquiry from a Supervisory Authority</font><font style="display:inline;font-weight:bold;">:</font></p>
					<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;text-decoration:underline;">datenschutz@morphosy.com</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">10.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-weight:bold;">Costs of Compliance; Modification. </font><font style="display:inline;">Compliance by either Party with the provisions of this DPA or any amendments hereto will be at no additional cost to the other Party.&nbsp;&nbsp;If either Party wishes to vary any terms to this DPA or any Annexes attached hereto, no variation shall be valid or effective unless it is in writing and is duly signed or executed by each Party by their respective authorized representatives at no additional cost to the other Party.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">10.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-weight:bold;">Changes in Data Protection Laws.&nbsp; </font><font style="display:inline;">The Parties may notify each other in writing from time to time of any variations to this DPA which are required as a result of a change in Data Protection Laws including without limitation to the generality of the foregoing, any variations which are: (i) required as a result of any changes to United Kingdom Data Protection Laws following any exit of the United Kingdom from the European Union; or (ii) required to take account of any&nbsp;&nbsp;new data transfer mechanisms for the purposes of Section 7.&nbsp;&nbsp;&nbsp;Any such variations shall take effect on the date falling thirty (30) calendar days after the date such written notice is received by either Party.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">10.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-weight:bold;">Severance.&nbsp; </font><font style="display:inline;">Should any provision of this DPA be invalid or unenforceable, then the remainder of this DPA shall remain valid and in force. The invalid or unenforceable provision shall be either (i) amended as necessary to ensure its validity and enforceability, while preserving the Parties&#x2019; intentions as closely as possible or, if this is not possible, (ii) construed in a manner as if the invalid or unenforceable part had never been contained therein.</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">10.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-weight:bold;">Third party rights.&nbsp; </font><font style="display:inline;">Either Party&#x2019;s Affiliate(s) may enforce any term of this DPA which is expressly or implicitly intended to benefit it.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">IN WITNESS WHEREOF, the Parties hereto, by their authorized representatives, have executed this DPA, effective as of the Effective Date first written above.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td colspan="2" valign="top" style="width:48.34%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10.5pt;">&lt;&lt;Insert COMPANY Name&gt;&gt;</font></p>
				</td>
				<td valign="top" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:49.16%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10.5pt;">MorphoSys AG</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:48.34%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:49.16%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:48.34%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:49.16%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:05.84%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">By:</font></p>
				</td>
				<td valign="top" style="width:42.50%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.82%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">By:</font></p>
				</td>
				<td valign="top" style="width:43.34%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:05.84%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">Name:</font></p>
				</td>
				<td valign="top" style="width:42.50%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.82%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">Name:</font></p>
				</td>
				<td valign="top" style="width:43.34%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:05.84%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">Title:</font></p>
				</td>
				<td valign="top" style="width:42.50%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.82%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">Title:</font></p>
				</td>
				<td valign="top" style="width:43.34%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:05.84%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">Date:</font></p>
				</td>
				<td valign="top" style="width:42.50%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.82%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">Date:</font></p>
				</td>
				<td valign="top" style="width:43.34%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:05.84%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:42.50%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.82%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:43.34%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:05.84%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:42.50%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.82%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:43.34%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:48.34%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:49.16%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10.5pt;">MorphoSys AG</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:48.34%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:49.16%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:48.34%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:49.16%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:05.84%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:42.50%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.82%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">By:</font></p>
				</td>
				<td valign="top" style="width:43.34%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:05.84%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:42.50%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.82%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">Name:</font></p>
				</td>
				<td valign="top" style="width:43.34%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:05.84%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:42.50%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.82%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">Title:</font></p>
				</td>
				<td valign="top" style="width:43.34%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:05.84%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:42.50%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.82%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">Date:</font></p>
				</td>
				<td valign="top" style="width:43.34%;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">ANNEX 1: PERMITTED PURPOSES &amp; DETAILS OF PROCESSING SHARED PERSONAL DATA</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">A)&nbsp;&nbsp;&nbsp;Either Party may jointly Process the Shared Personal Data for the following purposes (the </font><font style="display:inline;font-weight:bold;">"Permitted Purposes"</font><font style="display:inline;">)</font>
		</p>
		<p style="margin:0pt 0pt 6pt 36pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Personal Data may be Processed by the Parties in furtherance of co-development activities established under the terms of the Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">B)&nbsp;&nbsp;&nbsp;This section includes certain Details of the Processing of Shared Personal Data as required by Article 28(3) GDPR.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">(1) Subject Matter and Duration of the Processing of Shared Personal Data:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">The subject matter and duration of the Processing of the Shared Personal Data are set out in this DPA.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">(2) The Nature and Purpose of the Processing of Shared Personal Data:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">The Parties are performing their respective activities under the terms of the Agreement, which involve the Processing of Shared Personal Data. The scope of the activities to be performed are set out in the Agreement, and the Shared Personal Data will be Processed by the Parties to in accordance with the terms of this DPA.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">(3) The Types of Shared Personal Data to be Processed:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic identification data (e.g. name, address, email, telephone, date of birth etc.)</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Medical/health data (e.g.&nbsp;&nbsp;blood type, urine test, x-rays, physical exams, known conditions, medical survey or questionnaire results, results of other procedures (specify) etc.)</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Genetic data (e.g. chromosomal, deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) data, other elements enabling equivalent information to be obtained etc.)</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Biometric data (e.g. iris or retina scan, facial image, fingerprint, full body scan, dactyloscopic data)</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial data (e.g. bank account number)</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Location data</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other sensitive data (e.g. race or ethnic origin)</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">(4) The categories of Data Subject to whom the Parties&#x2019; Personal Data relates:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pharmaceutical Trial Participants</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Trial Doctors and Medical Professionals</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Employees, agents, contractors, representatives, vendors of both COMPANY and MorphoSys</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">(5) The Obligations and Rights of the Parties and their respective Affiliates:</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">The obligations and rights of the Parties and their respective Affiliates are set out in this DPA.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(6) The Processing Operations Carried Out in Relation to the Shared Personal Data:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">The following Processing operations carried out in relation to the Shared Personal Data, for the Permitted Purposes of , the scope of which are set out in this Agreement are as follows:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 40.5pt;text-indent: -22.5pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Collecting and recording the data;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 40.5pt;text-indent: -22.5pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hosting the data;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 40.5pt;text-indent: -22.5pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Organizing the data;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 40.5pt;text-indent: -22.5pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adapting or altering the data;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 40.5pt;text-indent: -22.5pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consulting or retrieving the data;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 40.5pt;text-indent: -22.5pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disclosing or transferring the data</font>
		</p>
		<p style="margin:0pt 0pt 0pt 40.5pt;text-indent: -22.5pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">ANNEX 2: STANDARD CONTRACTUAL CLAUSES</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Between</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:50.00%;border-top:1pt solid #CCCCCC ;border-left:1pt solid #CCCCCC ;border-bottom:1pt solid #CCCCCC ;border-right:1pt solid #CCCCCC ;padding:0pt 1.5pt 0pt 1.5pt;">
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">..............................................................</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;border-top:1pt solid #CCCCCC ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #CCCCCC ;border-right:1pt solid #CCCCCC ;padding:0pt 1.5pt 0pt 1.5pt;">
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">(name)</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #CCCCCC ;border-bottom:1pt solid #CCCCCC ;border-right:1pt solid #CCCCCC ;padding:0pt 1.5pt 0pt 1.5pt;">
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">..............................................................</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #CCCCCC ;border-right:1pt solid #CCCCCC ;padding:0pt 1.5pt 0pt 1.5pt;">
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">(address and country of establishment)</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #CCCCCC ;border-bottom:1pt solid #CCCCCC ;border-right:1pt solid #CCCCCC ;padding:0pt 1.5pt 0pt 1.5pt;">
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">(hereinafter </font><font style="display:inline;font-weight:bold;">the data exporter</font><font style="display:inline;">)</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #CCCCCC ;border-right:1pt solid #CCCCCC ;padding:0pt 1.5pt 0pt 1.5pt;">
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">and</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 1.5pt 0pt 1.5pt;height:1.00pt">
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 1.5pt 0pt 1.5pt;height:1.00pt">
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;border-top:1pt solid #CCCCCC ;border-left:1pt solid #CCCCCC ;border-bottom:1pt solid #CCCCCC ;border-right:1pt solid #CCCCCC ;padding:0pt 1.5pt 0pt 1.5pt;">
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">..............................................................</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;border-top:1pt solid #CCCCCC ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #CCCCCC ;border-right:1pt solid #CCCCCC ;padding:0pt 1.5pt 0pt 1.5pt;">
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">(name)</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #CCCCCC ;border-bottom:1pt solid #CCCCCC ;border-right:1pt solid #CCCCCC ;padding:0pt 1.5pt 0pt 1.5pt;">
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">..............................................................</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #CCCCCC ;border-right:1pt solid #CCCCCC ;padding:0pt 1.5pt 0pt 1.5pt;">
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">(address and country of establishment)</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #CCCCCC ;border-bottom:1pt solid #CCCCCC ;border-right:1pt solid #CCCCCC ;padding:0pt 1.5pt 0pt 1.5pt;">
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">(hereinafter </font><font style="display:inline;font-weight:bold;"> data importer</font><font style="display:inline;">)</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #CCCCCC ;border-right:1pt solid #CCCCCC ;padding:0pt 1.5pt 0pt 1.5pt;">
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">each a </font><font style="display:inline;font-weight:bold;">party</font><font style="display:inline;">; together </font><font style="display:inline;font-weight:bold;">the parties</font><font style="display:inline;">.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">1. DEFINITIONS</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;For the purposes of the clauses:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(a)</font><font style="display:inline;">&nbsp;&nbsp;</font><font style="display:inline;font-weight:bold;">personal data</font><font style="display:inline;">, &nbsp;</font><font style="display:inline;font-weight:bold;">special categories of data/sensitive data</font><font style="display:inline;">, &nbsp;</font><font style="display:inline;font-weight:bold;">process/processing</font><font style="display:inline;">, &nbsp;</font><font style="display:inline;font-weight:bold;">controller</font><font style="display:inline;">, &nbsp;</font><font style="display:inline;font-weight:bold;">processor</font><font style="display:inline;">, &nbsp;</font><font style="display:inline;font-weight:bold;">data subject</font><font style="display:inline;"> and </font><font style="display:inline;font-weight:bold;">supervisory authority/authority</font><font style="display:inline;"> shall have the same meaning as in Directive 95/46/EC of 24 October 1995 (whereby </font><font style="display:inline;font-weight:bold;">the authority</font><font style="display:inline;"> shall mean the competent data protection authority in the territory in which the data exporter is established);</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(b)</font><font style="display:inline;">&nbsp;&nbsp;</font><font style="display:inline;font-weight:bold;">the data exporter</font><font style="display:inline;"> shall mean the controller who transfers the personal data;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(c)</font><font style="display:inline;">&nbsp;&nbsp;</font><font style="display:inline;font-weight:bold;">the data importer </font><font style="display:inline;">shall mean the controller who agrees to receive from the data exporter personal data for further processing in accordance with the terms of these clauses and who is not subject to a third country&#x2019;s system ensuring adequate protection;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(d)</font><font style="display:inline;">&nbsp;&nbsp;</font><font style="display:inline;font-weight:bold;">clauses</font><font style="display:inline;"> shall mean these contractual clauses, which are a free-standing document that does not incorporate commercial business terms established by the parties under separate commercial arrangements.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">The details of the transfer (as well as the personal data covered) are specified in </font><font style="display:inline;font-style:italic;">Annex B</font><font style="display:inline;">, which forms an integral part of the clauses.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">2.</font><font style="display:inline;">&nbsp;&nbsp;</font><font style="display:inline;font-weight:bold;">OBLIGATIONS OF THE DATA EXPORTER</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;The data exporter warrants and undertakes that:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(a)</font><font style="display:inline;">&nbsp;&nbsp;The personal data have been collected, processed and transferred in accordance with the laws applicable to the data exporter.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(b)</font><font style="display:inline;">&nbsp;&nbsp;It has used reasonable efforts to determine that the data importer is able to satisfy its legal obligations under these clauses.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(c)</font><font style="display:inline;">&nbsp;&nbsp;It will provide the data importer, when so requested, with copies of relevant data protection laws or references to them (where relevant, and not including legal advice) of the country in which the data exporter is established.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(d)</font><font style="display:inline;">&nbsp;&nbsp;It will respond to enquiries from data subjects and the authority concerning processing of the personal data by the data importer, unless the parties have agreed that the data importer will so respond, in which case the data exporter will still respond to the extent reasonably possible and with the information reasonably available to it if the data importer is unwilling or unable to respond. Responses will be made within a reasonable time.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(e)</font><font style="display:inline;">&nbsp;&nbsp;It will make available, upon request, a copy of the clauses to data subjects who are third party beneficiaries under </font><font style="display:inline;font-style:italic;">Clause 3</font><font style="display:inline;">, unless the clauses contain confidential information, in which case it may remove such information. Where information is removed, the data exporter shall inform data subjects in writing of the reason for removal and of their right to draw the removal to the attention of the authority. However, the data exporter shall abide by a decision of the authority regarding access to the full text of the clauses by data subjects, as long as data subjects have agreed to respect the confidentiality of the confidential information removed. The data exporter shall also provide a copy of the clauses to the authority where required.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">3.</font><font style="display:inline;">&nbsp;&nbsp;</font><font style="display:inline;font-weight:bold;">OBLIGATIONS OF THE DATA IMPORTER</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;The data importer warrants and undertakes that:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(a)</font><font style="display:inline;">&nbsp;&nbsp;It will have in place appropriate technical and organisational measures to protect the personal data against accidental or unlawful destruction or accidental loss, alteration, unauthorised disclosure or access, and which provide a level of security appropriate to the risk represented by the processing and the nature of the data to be protected.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(b)</font><font style="display:inline;">&nbsp;&nbsp;It will have in place procedures so that any third party it authorises to have access to the personal data, including processors, will respect and maintain the confidentiality and security of the personal data. Any person acting under the authority of the data importer, including a data processor, shall be obligated to process the personal data only on instructions from the data importer. This provision does not apply to persons authorised or required by law or regulation to have access to the personal data.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(c)</font><font style="display:inline;">&nbsp;&nbsp;It has no reason to believe, at the time of entering into these clauses, in the existence of any local laws that would have a substantial adverse effect on the guarantees provided for under these clauses, and it will inform the data exporter (which will pass such notification on to the authority where required) if it becomes aware of any such laws.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(d)</font><font style="display:inline;">&nbsp;&nbsp;It will process the personal data for purposes described in </font><font style="display:inline;font-style:italic;">Annex B</font><font style="display:inline;">, and has the legal authority to give the warranties and fulfil the undertakings set out in these clauses.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(e)</font><font style="display:inline;">&nbsp;&nbsp;It will identify to the data exporter a contact point within its organisation authorised to respond to enquiries concerning processing of the personal data, and will cooperate in good faith with the data exporter, the data subject and the authority concerning all such enquiries within a reasonable time. In case of legal dissolution of the data exporter, or if the parties have so agreed, the data importer will assume responsibility for compliance with the provisions of </font><font style="display:inline;font-style:italic;">Clause 1(e)</font><font style="display:inline;">.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(f)</font><font style="display:inline;">&nbsp;&nbsp;At the request of the data exporter, it will provide the data exporter with evidence of financial resources sufficient to fulfil its responsibilities under </font><font style="display:inline;font-style:italic;">Clause 3</font><font style="display:inline;"> (which may include insurance coverage).</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(g)</font><font style="display:inline;">&nbsp;&nbsp;Upon reasonable request of the data exporter, it will submit its data processing facilities, data files and documentation needed for processing to reviewing, auditing and/or certifying by the data exporter (or any independent or impartial inspection agents or auditors, selected by the data exporter and not</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">reasonably objected to by the data importer) to ascertain compliance with the warranties and undertakings in these clauses, with reasonable notice and during regular business hours. The request will be subject to any necessary consent or approval from a regulatory or supervisory authority within the country of the data importer, which consent or approval the data importer will attempt to obtain in a timely fashion.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(h)</font><font style="display:inline;">&nbsp;&nbsp;It will process the personal data, at its option, in accordance with:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(i)</font><font style="display:inline;">&nbsp;&nbsp;the data protection laws of the country in which the data exporter is established, or</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(ii)</font><font style="display:inline;">&nbsp;&nbsp;the relevant provisions of any Commission decision pursuant to Article 25(6) of Directive 95/46/EC, where the data importer complies with the relevant provisions of such an authorisation or decision and is based in a country to which such an authorisation or decision pertains, but is not covered by such authorisation or decision for the purposes of the transfer(s) of the personal data, or</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(iii)</font><font style="display:inline;">&nbsp;&nbsp;the data processing principles set forth in </font><font style="display:inline;font-style:italic;">Annex A</font><font style="display:inline;">.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:100.00%;border-top:1pt solid #CCCCCC ;border-left:1pt solid #CCCCCC ;border-bottom:1pt solid #CCCCCC ;border-right:1pt solid #CCCCCC ;padding:0pt 1.5pt 0pt 1.5pt;">
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">Data importer to indicate which option it selects:</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #CCCCCC ;border-bottom:1pt solid #CCCCCC ;border-right:1pt solid #CCCCCC ;padding:0pt 1.5pt 0pt 1.5pt;">
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-style:italic;">(iii)</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #CCCCCC ;border-bottom:1pt solid #CCCCCC ;border-right:1pt solid #CCCCCC ;padding:0pt 1.5pt 0pt 1.5pt;">
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">Initials of data importer:</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #CCCCCC ;border-bottom:1pt solid #CCCCCC ;border-right:1pt solid #CCCCCC ;padding:0pt 1.5pt 0pt 1.5pt;">
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">.............................</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(i)</font><font style="display:inline;">&nbsp;&nbsp;It will not disclose or transfer the personal data to a third party data controller located outside the European Economic Area (EEA) unless it notifies the data exporter about the transfer and</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(i)</font><font style="display:inline;">&nbsp;&nbsp;the third party data controller processes the personal data in accordance with a Commission decision finding that a third country provides adequate protection, or</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(ii)</font><font style="display:inline;">&nbsp;&nbsp;the third party data controller becomes a signatory to these clauses or another data transfer agreement approved by a competent authority in the EU, or</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(iii)</font><font style="display:inline;">&nbsp;&nbsp;data subjects have been given the opportunity to object, after having been informed of the purposes of the transfer, the categories of recipients and the fact that the countries to which data is exported may have different data protection standards, or</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(iv)</font><font style="display:inline;">&nbsp;&nbsp;with regard to onward transfers of sensitive data, data subjects have given their unambiguous consent to the onward transfer</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">4.</font><font style="display:inline;">&nbsp;&nbsp;</font><font style="display:inline;font-weight:bold;">LIABILITY AND THIRD PARTY RIGHTS</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(a)</font><font style="display:inline;">&nbsp;&nbsp;Each party shall be liable to the other parties for damages it causes by any breach of these clauses. Liability as between the parties is limited to actual damage suffered. Punitive damages (i.e. damages intended to punish a party for its outrageous conduct) are specifically excluded. Each party shall be liable to data subjects for damages it causes by any breach of third party rights under these clauses. This does not affect the liability of the data exporter under its data protection law.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(b)</font><font style="display:inline;">&nbsp;&nbsp;The parties agree that a data subject shall have the right to enforce as a third party beneficiary this clause and clauses </font><font style="display:inline;font-style:italic;">Clause 1(b)</font><font style="display:inline;">, &nbsp;</font><font style="display:inline;font-style:italic;">Clause 1(d)</font><font style="display:inline;">, &nbsp;</font><font style="display:inline;font-style:italic;">Clause 1(e)</font><font style="display:inline;">, &nbsp;</font><font style="display:inline;font-style:italic;">Clause 2(a)</font><font style="display:inline;">, &nbsp;</font><font style="display:inline;font-style:italic;">Clause 2(c)</font><font style="display:inline;">, &nbsp;</font><font style="display:inline;font-style:italic;">Clause 2(d)</font><font style="display:inline;">, &nbsp;</font><font style="display:inline;font-style:italic;">Clause 2(e)</font><font style="display:inline;">, &nbsp;</font><font style="display:inline;font-style:italic;">Clause 2(h)</font><font style="display:inline;">, &nbsp;</font><font style="display:inline;font-style:italic;">Clause 2(i)</font><font style="display:inline;">, &nbsp;</font><font style="display:inline;font-style:italic;">Clause 3(a)</font><font style="display:inline;">, &nbsp;</font><font style="display:inline;font-style:italic;">Clause 5</font><font style="display:inline;">, &nbsp;</font><font style="display:inline;font-style:italic;">Clause 6(d)</font><font style="display:inline;">and </font><font style="display:inline;font-style:italic;">Clause 7</font><font style="display:inline;"> against the data importer or the data exporter, for their respective breach of their contractual obligations, with regard to his personal data, and accept jurisdiction for this purpose in the data exporter&#x2019;s country of establishment. In cases involving allegations of breach by the data importer, the data subject must first request the data exporter</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">to take appropriate action to enforce his rights against the data importer; if the data exporter does not take such action within a reasonable period (which under normal circumstances would be one month), the data subject may then enforce his rights against the data importer directly. A data subject is entitled to proceed directly against a data exporter that has failed to use reasonable efforts to determine that the data importer is able to satisfy its legal obligations under these clauses (the data exporter shall have the burden to prove that it took reasonable efforts).</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">5.</font><font style="display:inline;">&nbsp;&nbsp;</font><font style="display:inline;font-weight:bold;">LAW APPLICABLE TO THE CLAUSES</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;These clauses shall be governed by the law of the country in which the data exporter is established, with the exception of the laws and regulations relating to processing of the personal data by the data importer under </font><font style="display:inline;font-style:italic;">Clause 2(h)</font><font style="display:inline;"> which shall apply only if so selected by the data importer under that clause.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">6.</font><font style="display:inline;">&nbsp;&nbsp;</font><font style="display:inline;font-weight:bold;">RESOLUTION OF DISPUTES WITH DATA SUBJECTS OR THE AUTHORITY</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(a)</font><font style="display:inline;">&nbsp;&nbsp;In the event of a dispute or claim brought by a data subject or the authority concerning the processing of the personal data against either or both of the parties, the parties will inform each other about any such disputes or claims, and will cooperate with a view to settling them amicably in a timely fashion.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(b)</font><font style="display:inline;">&nbsp;&nbsp;The parties agree to respond to any generally available non-binding mediation procedure initiated by a data subject or by the authority. If they do participate in the proceedings, the parties may elect to do so remotely (such as by telephone or other electronic means). The parties also agree to consider participating in any other arbitration, mediation or other dispute resolution proceedings developed for data protection disputes.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(c)</font><font style="display:inline;">&nbsp;&nbsp;Each party shall abide by a decision of a competent court of the data exporter&#x2019;s country of establishment or of the authority which is final and against which no further appeal is possible.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">7.</font><font style="display:inline;">&nbsp;&nbsp;</font><font style="display:inline;font-weight:bold;">TERMINATION</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(a)</font><font style="display:inline;">&nbsp;&nbsp;In the event that the data importer is in breach of its obligations under these clauses, then the data exporter may temporarily suspend the transfer of personal data to the data importer until the breach is repaired or the contract is terminated.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(b)</font><font style="display:inline;">&nbsp;&nbsp;In the event that:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(i)</font><font style="display:inline;">&nbsp;&nbsp;the transfer of personal data to the data importer has been temporarily suspended by the data exporter for longer than one month pursuant to </font><font style="display:inline;font-style:italic;">Clause 6(a)</font><font style="display:inline;">;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(ii)</font><font style="display:inline;">&nbsp;&nbsp;compliance by the data importer with these clauses would put it in breach of its legal or regulatory obligations in the country of import;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(iii)</font><font style="display:inline;">&nbsp;&nbsp;the data importer is in substantial or persistent breach of any warranties or undertakings given by it under these clauses;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(iv)</font><font style="display:inline;">&nbsp;&nbsp;a final decision against which no further appeal is possible of a competent court of the data exporter&#x2019;s country of establishment or of the authority rules that there has been a breach of the clauses by the data importer or the data exporter; or</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(v)</font><font style="display:inline;">&nbsp;&nbsp;a petition is presented for the administration or winding up of the data importer, whether in its personal or business capacity, which petition is not dismissed within the applicable period for such dismissal under applicable law; a winding up order is made; a receiver is appointed over any of its assets; a trustee in bankruptcy is appointed, if the data importer is an individual; a company voluntary arrangement is commenced by it; or any equivalent event in any jurisdiction occurs</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">then the data exporter, without prejudice to any other rights which it may have against the data importer, shall be entitled to terminate these clauses, in which case the authority shall be informed where required. In cases covered by </font><font style="display:inline;font-style:italic;">Clause 6.1(b)(i)</font><font style="display:inline;">, &nbsp;</font><font style="display:inline;font-style:italic;">Clause 6.1(b)(ii)</font><font style="display:inline;">, or </font><font style="display:inline;font-style:italic;">Clause 6.1(b)(iv)</font><font style="display:inline;"> above the data importer may also terminate these clauses.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(c)</font><font style="display:inline;">&nbsp;&nbsp;Either party may terminate these clauses if</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(i)</font><font style="display:inline;">&nbsp;&nbsp;any Commission positive adequacy decision under Article 25(6) of Directive 95/46/EC (or any superseding text) is issued in relation to the country (or a sector thereof) to which the data is transferred and processed by the data importer, or</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(ii)</font><font style="display:inline;">&nbsp;&nbsp;Directive 95/46/EC (or any superseding text) becomes directly applicable in such country.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(d)</font><font style="display:inline;">&nbsp;&nbsp;The parties agree that the termination of these clauses at any time, in any circumstances and for whatever reason (except for termination under </font><font style="display:inline;font-style:italic;">Clause 6(c)</font><font style="display:inline;"> does not exempt them from the obligations and/or conditions under the clauses as regards the processing of the personal data transferred.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">8.</font><font style="display:inline;">&nbsp;&nbsp;</font><font style="display:inline;font-weight:bold;">VARIATION OF THESE CLAUSES</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;The parties may not modify these clauses except to update any information in </font><font style="display:inline;font-style:italic;">Annex B</font><font style="display:inline;">, in which case they will inform the authority where required. This does not preclude the parties from adding additional commercial clauses where required.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">9.</font><font style="display:inline;">&nbsp;&nbsp;</font><font style="display:inline;font-weight:bold;">DESCRIPTION OF THE TRANSFER</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;The details of the transfer and of the personal data are specified in </font><font style="display:inline;font-style:italic;">Annex B</font><font style="display:inline;">. The parties agree that </font><font style="display:inline;font-style:italic;">Annex B</font><font style="display:inline;"> may contain confidential business information which they will not disclose to third parties, except as required by law or in response to a competent regulatory or government agency, or as required under </font><font style="display:inline;font-style:italic;">Clause 1(e)</font><font style="display:inline;">. The parties may execute additional annexes to cover additional transfers, which will be submitted to the authority where required. </font><font style="display:inline;font-style:italic;">Annex B</font><font style="display:inline;"> may, in the alternative, be drafted to cover multiple transfers.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Dated:.............................</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 1.5pt 0pt 1.5pt;height:1.00pt">
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 1.5pt 0pt 1.5pt;height:1.00pt">
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;border-top:1pt solid #CCCCCC ;border-left:1pt solid #CCCCCC ;border-bottom:1pt solid #CCCCCC ;border-right:1pt solid #CCCCCC ;padding:0pt 1.5pt 0pt 1.5pt;">
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">DATA EXPORTER</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;border-top:1pt solid #CCCCCC ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #CCCCCC ;border-right:1pt solid #CCCCCC ;padding:0pt 1.5pt 0pt 1.5pt;">
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">DATA IMPORTER</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #CCCCCC ;border-bottom:1pt solid #CCCCCC ;border-right:1pt solid #CCCCCC ;padding:0pt 1.5pt 0pt 1.5pt;">
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">..................................................</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">..................................................</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #CCCCCC ;border-right:1pt solid #CCCCCC ;padding:0pt 1.5pt 0pt 1.5pt;">
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">..................................................</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">..................................................</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">ANNEX A</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">DATA PROCESSING PRINCIPLES</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">1. Purpose limitation: Personal data may be processed and subsequently used or further communicated only for purposes described in </font><font style="display:inline;font-style:italic;">Annex B</font><font style="display:inline;"> or subsequently authorised by the data subject.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">2. Data quality and proportionality: Personal data must be accurate and, where necessary, kept up to date. The personal data must be adequate, relevant and not excessive in relation to the purposes for which they are transferred and further processed.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">3. Transparency: Data subjects must be provided with information necessary to ensure fair processing (such as information about the purposes of processing and about the transfer), unless such information has already been given by the data exporter.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">4. Security and confidentiality: Technical and organisational security measures must be taken by the data controller that are appropriate to the risks, such as against accidental or unlawful destruction or accidental loss, alteration, unauthorised disclosure or access, presented by the processing. Any person acting under the authority of the data controller, including a processor, must not process the data except on instructions from the data controller.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">5. Rights of access, rectification, deletion and objection: As provided in Article 12 of Directive 95/46/EC, data subjects must, whether directly or via a third party, be provided with the personal information about them that an organisation holds, except for requests which are manifestly abusive, based on unreasonable intervals or their number or repetitive or systematic nature, or for which access need not be granted under the law of the country of the data exporter. Provided that the authority has given its prior approval, access need also not be granted when doing so would be likely to seriously harm the interests of the data importer or other organisations dealing with the data importer and such interests are not overridden by the interests for fundamental rights and freedoms of the data subject. The sources of the personal data need not be identified when this is not possible by reasonable efforts, or where the rights of persons other than the individual would be violated. Data subjects must be able to have the personal information about them rectified, amended, or deleted where it is inaccurate or processed against these principles. If there are compelling grounds to doubt the legitimacy of the request, the organisation may require further justifications before proceeding to rectification, amendment or deletion. Notification of any rectification, amendment or deletion to third parties to whom the data have been disclosed need not be made when this involves a disproportionate effort. A data subject must also be able to object to the processing of the personal data relating to him if there are compelling legitimate grounds relating to his particular situation. The burden of proof for any refusal rests on the data importer, and the data subject may always challenge a refusal before the authority.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">6. Sensitive data: The data importer shall take such additional measures (e.g. relating to security) as are necessary to protect such sensitive data in accordance with its obligations under </font><font style="display:inline;font-style:italic;">Clause 2</font><font style="display:inline;">.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">7. Data used for marketing purposes: Where data are processed for the purposes of direct marketing, effective procedures should exist allowing the data subject at any time to &#x201C;opt-out&#x201D; from having his data used for such purposes.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">8. Automated decisions: For purposes hereof &#x201C;automated decision&#x201D; shall mean a decision by the data exporter or the data importer which produces legal effects concerning a data subject or significantly affects a data subject and which is based solely on automated processing of personal data intended to evaluate certain personal aspects relating to him, such as his performance at work, creditworthiness, reliability, conduct, etc. The data importer shall not make any automated decisions concerning data subjects, except when:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">(a) such decisions are made by the data importer in entering into or performing a contract with the data subject, and</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">(ii) (the data subject is given an opportunity to discuss the results of a relevant automated decision with a representative of the parties making such decision or otherwise to make representations to that parties.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">or</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">(b) where otherwise provided by the law of the data exporter.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">ANNEX B</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">DESCRIPTION OF THE TRANSFER</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">(To be completed by the parties)</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:100.00%;border-top:1pt solid #CCCCCC ;border-left:1pt solid #CCCCCC ;border-bottom:1pt solid #CCCCCC ;border-right:1pt solid #CCCCCC ;padding:0pt 1.5pt 0pt 1.5pt;">
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">Data subjects</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-style:italic;">See Annex 1</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #CCCCCC ;border-bottom:1pt solid #CCCCCC ;border-right:1pt solid #CCCCCC ;padding:0pt 1.5pt 0pt 1.5pt;height:42.20pt">
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">The personal data transferred concern the following categories of data subjects:</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #CCCCCC ;border-bottom:1pt solid #CCCCCC ;border-right:1pt solid #CCCCCC ;padding:0pt 1.5pt 0pt 1.5pt;">
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-style:italic;">See Annex 1</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt 0pt 0pt 1.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Contact points for data protection enquiries:</font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">See DPA</font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">ANNEX 3: TECHNICAL AND ORGANIZATIONAL SECURITY MEASURES</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10pt 18pt;text-indent: -18pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">(A)&nbsp;&nbsp;Data Processing</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">The Parties must assess and reduce the scope of data access and processing limited to what is strictly necessary for the performance of the Agreement.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10pt 18pt;text-indent: -18pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">(B)&nbsp;&nbsp;Confidentiality</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">The Parties shall ensure:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">1.&nbsp;&nbsp;&nbsp;&nbsp;Access to Personal Data stored or Processed is limited to members of its personnel on a strict need-to-know basis.&nbsp;&nbsp;For the avoidance of doubt, &#x201C;personnel&#x201D; includes employees, agents and contractors of Data Processor.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">2.&nbsp;&nbsp;&nbsp;&nbsp;Access to facilities where information systems are located is be limited to authorized personnel who are specifically identified.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">3.&nbsp;&nbsp;&nbsp;&nbsp;Relevant personnel who are authorized to grant, alter or cancel authorized access to data and resources have been appropriately identified.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">4.&nbsp;&nbsp;&nbsp;&nbsp;Authorization profiles are defined according to the roles and responsibilities of its personnel in order to restrict access to Personal Data to duly authorized users.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">5.&nbsp;&nbsp;&nbsp;&nbsp;Identification and authentication rules include things such as: (a) automated de-provisioning of access to personnel who are no longer with the respective Party; (b) personal users&#x2019; identifiers; (c) no default accounts; (d) no accounts are shared among users; (e) authentication methods based on strong password requirements; and/or (f) devices use officially recommended cryptographic mechanisms or biometric devices.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">(C)&nbsp;&nbsp;Backups</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">The Parties shall ensure:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">1.&nbsp;&nbsp;&nbsp;&nbsp;Backups are performed frequently, tested regularly and stored off-site.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">2.&nbsp;&nbsp;&nbsp;&nbsp;Backups are secure by either encrypting the backups themselves or encrypting data at the source, in either case storage is maintained at a secure location.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">(D)&nbsp;&nbsp;Encryption</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">The Parties shall ensure:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">1.&nbsp;&nbsp;&nbsp;&nbsp;Data "at rest" is protected and is encrypted with AES-256 or stronger.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">2.&nbsp;&nbsp;&nbsp;&nbsp;Data in transit is protected by the Parties e.g. through TLS (1.1 or higher) or hashing (SHA-2 or stronger).</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">3.&nbsp;&nbsp;&nbsp;&nbsp;Personal Data and Parties&#x2019; proprietary data that is transferred/uploaded to the provider is encrypted (according to specifications for &#x201C;data in transit&#x201D; above) and secure.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">(E)&nbsp;&nbsp;Security of Infrastructure and Applications</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">The Parties shall ensure:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">1.&nbsp;&nbsp;&nbsp;&nbsp;Software patches are applied routinely and promptly.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">2.&nbsp;&nbsp;&nbsp;&nbsp;It performs regular penetration testing, vulnerability management, and intrusion prevention.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">3.&nbsp;&nbsp;&nbsp;&nbsp;Applications, servers, storage, network devices, etc. are protected with complex passwords. In addition resources, exposed to external access must be protected by Multi-Factor authentication (MFA)</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">4.&nbsp;&nbsp;&nbsp;&nbsp;Critical firmware and software updates are installed after successful testing without delay.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">5.&nbsp;&nbsp;&nbsp;&nbsp;Users of the Parties' systems are required to notify the data privacy officer and/or the IT Service Desk immediately if information is lost or stolen in accordance with the Parties&#x2019; respective policies and the type of data impacted (ie: personal data or confidential/proprietary data).</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">6.&nbsp;&nbsp;&nbsp;&nbsp;It has dedicated points of contact responsible for dealing with reports of information security breaches or failures.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">7.&nbsp;&nbsp;&nbsp;&nbsp;Audit logs and records of security incidents are maintained, are subject to periodic review.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">(F)&nbsp;&nbsp;Development and Change Management Process</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">The Parties shall ensure:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">1.&nbsp;&nbsp;&nbsp;&nbsp;It follows standardized and documented procedures for coding, configuration management, patch installation, and change management for all systems (e.g. applications, servers, storage, network devices, etc.) involved in delivery of contracted services.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">(G)&nbsp;&nbsp;Availability</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">The Parties must:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">1.&nbsp;&nbsp;&nbsp;&nbsp;Design core IT infrastructure failsafe and redundant.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">2.&nbsp;&nbsp;&nbsp;&nbsp;Have disaster recovery and backup-and-restore processes in place.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">3.&nbsp;&nbsp;&nbsp;&nbsp;Have a business continuity plan that addresses the prompt restoration of the availability of and access to Parties&#x2019; Personal Data</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">(H)&nbsp;&nbsp;Audits and Standards</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">The Parties must:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">1.&nbsp;&nbsp;&nbsp;&nbsp;Review or audit its security operations by external security experts on a periodic basis.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">2.&nbsp;&nbsp;&nbsp;&nbsp;Comply with appropriate security standards.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">(I)&nbsp;&nbsp;&nbsp;&nbsp;Test and Development Environments</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">The Parties shall ensure that:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Only anonymized or dummy data are used in a non-production (e.g. test or development, training) environment and that these environments are secured to the same standard as production.</font>
		</p>
		<p style="margin:0pt 0pt 8pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">(J)&nbsp;&nbsp;&nbsp;Traceability and Logs</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">The Parties must:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">1.&nbsp;&nbsp;&nbsp;&nbsp;Set up a logging process that records the relevant events (end users, maintenance and administrative activities, unauthorized access to Personal Data, abusive use of Personal Data, abnormalities, events related to security, etc.) and allows for determinations of the origin of an incident and that these logs are available to the Parties for e.g. incident investigation.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">2.&nbsp;&nbsp;&nbsp;&nbsp;Collaborate in the event of a security incident and help each other to clarify the case, e.g. by secure exchange of relevant log data.Protect the logging equipment and the logged information against sabotage and unauthorized access.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt 22.5pt;text-indent: -22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">(K)&nbsp;&nbsp;&nbsp;&nbsp;Miscellaneous</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">The Parties must:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">1.&nbsp;&nbsp;&nbsp;&nbsp;Inform each other in case of a cyber security incident, data breach or any other critical incident which may disrupt joint operations.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">2.&nbsp;&nbsp;&nbsp;&nbsp;Have policies and procedures relevant to Personal Data and IT security in place.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">3.&nbsp;&nbsp;&nbsp;&nbsp;Have technical mechanisms and operational procedures in place to allow for the prompt retrieval, erasure, blocking and restriction of Parties&#x2019; Personal Data relating to a particular individual (i.e. an individual's personal data).</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">4.&nbsp;&nbsp;&nbsp;&nbsp;Perform phishing trainings for ongoing security awareness for internal users.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">5.&nbsp;&nbsp;&nbsp;&nbsp;Provide security awareness training for all personnel.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">&lt;&lt;PLACEHOLDER: ANNEX 4: TERMS AND CONDITIONS OF TRANSFER OF PERSONAL DATA SUBJECT TO &lt;&lt;INSERT COUNTRY&gt;&gt; DATA PROTECTION LAW&gt;&gt;</font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">EXHIBIT 14</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">CO-COMMERCIALIZATION PLAN OUTLINE</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">EXHIBIT 15</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">CO-COMMERCIALIZATION BUDGET OUTLINE</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">EXHIBIT 16</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">CONTRIBUTION TO EQUITY AND SHARE ISSUANCE</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">(the &#x201C;Purchase Agreement&#x201D;)</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-indent:14.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">A.&nbsp;&nbsp;COMPANY shall acquire a stake in the share capital of MorphoSys through the purchase from MorphoSys of new shares of MorphoSys in the form of American Depositary Shares (&#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">ADSs</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;), subject to the terms of the Agreement and the further terms and conditions of this </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT 16</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> (&#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Purchase Agreement</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;). &#x201C;MorphoSys&#x201D;, for the purpose of this </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT 16</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">, including its Annexes, shall mean MorphoSys AG only. In case of any conflicts or inconsistencies between the terms of the Agreement and this </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT 16</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">, the terms and conditions of this </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">EXHIBIT 16</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> shall prevail with respect to the subject matter hereof. As at the Execution Date, the registered share capital of MorphoSys amounts to &#x20AC;&nbsp;31,957,958, divided into 31,957,958 ordinary shares in bearer form with no par value and a notional value attributable to each share of &#x20AC;1.00 (the "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Existing Shares</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"). All Existing Shares of MorphoSys are admitted to trading on the regulated market (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:11pt;">regulierter Markt</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">) and to the sub-segment of the regulated market with additional obligations arising from admission (Prime Standard) on the Frankfurt Stock Exchange (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:11pt;">Frankfurter Wertpapierb&#xF6;rse</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">).</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-indent:14.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-indent:14.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">B. MorphoSys is party to the Amended and Restated Deposit Agreement dated April 18, 2018, among MorphoSys, The Bank of New York Mellon, as depositary (the &#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Depositary</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;) and the owners and holders of American Depositary Shares (the &#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Deposit Agreement</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;), pursuant to which the Depositary has issued ADSs representing one-quarter of an Existing Share. The ADSs are listed for quotation on the Nasdaq Global Market (the &#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Nasdaq Market</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;).</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-indent:14.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-indent:14.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">C. The management board (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:11pt;">Vorstand</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">) of MorphoSys has been authorised, until 30 April 2022, to increase, with the consent of the supervisory board (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:11pt;">Aufsichtsrat</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">) of MorphoSys, the share capital of MorphoSys by up to &#x20AC;&nbsp;2,915,977.00 (the "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Authorised Capital</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">") through the issuance of new no-par value bearer shares against cash contributions (the "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Authorisation</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"). The management board of MorphoSys is authorised to exclude, with the consent of the supervisory board of MorphoSys, the subscription rights of the shareholders, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:11pt;">inter alia</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">, in case of a capital increase</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">against contribution in cash, if the issue price of the newly issued shares is not significantly lower than the market price of the Existing Shares prevailing at the time of issuance and the number of shares issued does not exceed 10% of the share capital of MorphoSys, neither at the time when the Authorisation has become effective nor when it is used.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-indent:14.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-indent:14.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">D. The new shares of MorphoSys underlying the new ADSs to be purchased by COMPANY (the &#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">New ADSs</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;) shall be created by way of a capital increase against contribution in cash on the basis of the Authorisation and deposited with the Depositary who will deliver the New ADSs purchased by COMPANY to COMPANY. Each New ADS purchased by COMPANY will represent one-quarter of a New Share of MorphoSys.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-indent:14.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ISSUE AND SUBSCRIPTION OF NEW SHARES</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(a) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;text-decoration:underline;">Board Resolutions</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.&nbsp;&nbsp;To the extent permitted by law, the management board of MorphoSys shall, subject to the satisfaction of the conditions set forth in Section 9(b) hereof, within [***] Business Days after the Effective Date (the &#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Capital Increase Resolution Date</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;) resolve on an increase of the share capital of MorphoSys pursuant to the Authorisation with exclusion of subscription rights of the existing shareholders (the "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Capital Increase</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">") through the issuance of the Final Number of New Shares against cash consideration at the Purchase Price per New Share for the Aggregate Purchase Price admitting the COMPANY, or at the COMPANY&#x2019;s written request received by MorphoSys within [***] Business Days after the Execution Date, the German credit institution selected by MorphoSys to act as settlement agent (the &#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">German Settlement Agent</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;) to subscribe for the New Shares acting in its own name but for the account of COMPANY (the "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Management Board Resolution</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"; a draft of the resolution is attached hereto as </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Annex&nbsp;1</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">).</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Immediately after passing the Management Board Resolution, the management board of MorphoSys shall, to the extent permitted by law, ask the supervisory board of MorphoSys to approve the Capital Increase under the Authorisation as well as the issue of the New Shares at the Aggregate Purchase Price as resolved by the Management Board (the "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Supervisory Board Resolution</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">", a draft of the resolution is attached hereto as </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Annex 2</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">).</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-indent:14.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">&#x201C;Purchase Price&#x201D;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> shall mean a USD amount per New Share [***].</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-indent:14.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Market Price</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D; shall mean the closing market price of the ADSs as quoted on the Nasdaq Stock Market.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-indent:14.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">New Shares</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D; shall mean new ordinary shares of MorphoSys in bearer form with no par value and a notional value attributable to each share of &#x20AC;1.00, which shall carry the same rights and obligations as the Existing Shares, except that they shall carry dividend rights only from and including the fiscal year of MorphoSys in which they have been issued.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-indent:14.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-indent:14.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-indent:14.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-indent:14.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Final Number</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D; shall mean such number of New Shares that results of the division of (a) USD 150,000,000 by (b) the Purchase Price rounded down to the next full New Share.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-indent:14.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-indent:14.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Aggregate Purchase Price&#x201D;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> shall mean the result of the multiplication of (a) the Final Number of New Shares with (b) the Purchase Price.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">(b)&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;text-decoration:underline;">Payment of Aggregate Purchase Price; Subscription of New Shares.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;COMPANY shall, subject to the satisfaction of the conditions set forth in Section 9(a), immediately upon receipt of copies of the Management Board Resolution and the Supervisory Board Resolution by telefax or pdf-document attached to an email (such date, the &#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Subscription Date</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;) (i) effect payment of the Aggregate Purchase Price to an account of MorphoSys (the &#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Capital Increase Account</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;) maintained with the German Settlement Agent as notified by MorphoSys to COMPANY in due time prior to subscription and (ii) subscribe for, or, if COMPANY appointed the German Settlement Agent as set forth in Section 1 (a), cause the German Settlement Agent, acting in its own name but for the account of COMPANY, to immediately subscribe for, the New Shares by way of executing and delivering to MorphoSys a subscription certificate (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:11pt;">Zeichnungsschein</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">) (the &#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Subscription Certificate</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;) for the New Shares in the form attached as </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Annex 3</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> hereto, duly signed in duplicate form, and (iii) upon credit of the Aggregate Purchase Price to the Capital Increase Account cause the German Settlement Agent to deliver to MorphoSys a bank certificate (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:11pt;">Einzahlungsbest&#xE4;tigung</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">) in the form attached as </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Annex 4</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> hereto (the &#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Bank Certificate</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;) confirming such credit.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">(c)&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;text-decoration:underline;">Registration of Capital Increase.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;Without undue delay (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:11pt;">unverz&#xFC;glich</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">) upon receipt of the Subscription Certificate and Bank Certificate in accordance with Section 1 (b) above and provided the Management Board Resolution and the Supervisory Board Resolution have been passed in accordance with Section 1 (a) above, MorphoSys shall use its [***] efforts to effect the registration of the Capital Increase in the commercial register.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">(d)&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;text-decoration:underline;">Notification of German Settlement Agent.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;Without undue delay (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:11pt;">unverz&#xFC;glich</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">) upon the registration of the Capital Increase with the commercial register (the time of such registration referred to as the &#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Registration Time</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;), MorphoSys shall, by telefax or pdf-document attached to an email, with two original certified copies to follow promptly by courier, furnish the German Settlement Agent with a certified copy of the registration notice of the commercial register, a certified chronological excerpt from the commercial register and a certified copy of the articles of association of MorphoSys, each evidencing such Capital Increase.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">(e)&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;text-decoration:underline;">Delivery of Global Note.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> Without undue delay after Registration Time, MorphoSys shall deliver to the German Settlement Agent one global share certificate in the form set forth as </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Annex 5</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> hereto representing the New Shares. COMPANY shall cause the German Settlement Agent, acting in its own name, but for the account of COMPANY, to deliver such global share certificate to Clearstream Banking AG, Frankfurt am Main (&#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Clearstream</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;), and procure the New Shares to be credited to such securities account with a participant of Clearstream as the Depositary may designate to enable the delivery by the Depositary of the New ADSs in respect of the New Shares to COMPANY, as the case may be, by way of book-entry.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DELIVERY OF NEW ADSs</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Without undue delay after confirmation of receipt of the New Shares by the Depositary, MorphoSys shall instruct the Depositary to deliver four ADSs per New Share representing such New Share free of payment to a securities account of COMPANY as notified by COMPANY to MorphoSys or as the Depositary may otherwise require in due time prior to Registration Time. COMPANY shall take all steps necessary required by it to effect the delivery of the ADSs.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;REPRESENTATIONS REGARDING DELIVERY OF ADSs</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">COMPANY represents and warrants to MorphoSys that:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(a)&nbsp;COMPANY is acquiring the New ADSs for his own account as principal, not as a nominee or agent, for investment purposes only, and not with a view to, or for, resale, distribution or fractionalization thereof in whole or in part and no other person has a direct or indirect beneficial interest in the amount of ADSs COMPANY is acquiring. Further, COMPANY does not have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participations to such person or to any third person, with respect to the New ADSs COMPANY is acquiring.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(b)&nbsp;COMPANY understands that the New ADSs have not been, and will not be, registered under the U.S. Securities Act of 1933 (the &#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Securities Act</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;), and are being sold in reliance upon a specific exemption from the registration provisions of the Securities Act. COMPANY understands that the New ADSs are &#x201C;restricted securities&#x201D; under applicable U.S. federal and state securities laws and that, pursuant to these laws, COMPANY must hold the New ADSs indefinitely unless they are registered with the U.S. Securities and Exchange Commission and qualified by state authorities, or an exemption from such registration and qualification requirements is available. COMPANY acknowledges that MorphoSys has no obligation to register or qualify the ADSs.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(c)&nbsp;For so long as the New ADSs are &#x201C;restricted securities&#x201D; under the Securities Act the New ADSs will not be fungible with all other ADSs issued pursuant to the Deposit Agreement and will be subject to the following legend restricting transfer or surrender for the purpose of withdrawal:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201C;THE AMERICAN DEPOSITARY SHARES TO WHICH THIS CONFIRMATION RELATES AND THE ORDINARY SHARES (THE &#x201C;SHARES&#x201D;) OF MORPHOSYS AG (&#x201C;MORPHOSYS&#x201D;) REPRESENTED THEREBY MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OR IN A TRANSACTION THAT IS EXEMPT FROM, OR NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THAT</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">ACT, AS CONFIRMED BY AN OPINION OF COUNSEL THAT IS SATISFACTORY TO MORPHOSYS AND THE DEPOSITARY, AND IN ACCORDANCE WITH ANY OTHER APPLICABLE SECURITIES LAWS.&#x201D;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(d)&nbsp;So long as the above restriction applies, the New ADSs will not be eligible for settlement through the Depositary Trust Corporation.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;REPRESENTATIONS OF MORPHOSYS</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">MorphoSys represents and warrants to COMPANY each of the matters set forth in </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Annex 6</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> hereto.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IMPLEMENTATION OF CAPITAL INCREASE; CONSEQUENCES IN CASE OF FAILURE</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">If the registration of the Capital Increase with the commercial register has not been effected until [***] months after the Effective Date, 12:00 (Frankfurt time), at the election of COMPANY, (i) the Parties shall reinitiate such efforts for an additional [***]-month period, or (ii) the Subscription Certificate for the New Shares shall, in accordance with its terms, expire and MorphoSys shall without undue delay (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:11pt;">unverz&#xFC;glich</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">) repay the Aggregate Purchase Price. If COMPANY elects the option under (i) above, and the Capital Increase has not been effected within such additional [***]-month period, then the consequence under (ii) applies. Upon repayment to COMPANY of the foregoing amount, the Parties shall have no further obligation to each other with respect to the matters set forth in Section 8.1(b) of the Collaboration Agreement and this Purchase Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LISTING</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">MorphoSys undertakes to cause, without undue delay after Registration Time, the New Shares to be admitted to trading on the regulated market (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:11pt;">Regulierter Markt</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">) segment of the Frankfurt Stock Exchange and the sub-segment thereof with additional post-admission obligations (Prime Standard), or any successor thereof, and to use [***] efforts to maintain such listing.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;REMOVAL OF RESTRICTIVE LEGENDS</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">MorphoSys agrees that at such time as the New ADSs cease to be &#x201C;restricted securities&#x201D; such that any legend of the type set forth in Section&nbsp;3(c) is no longer</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">required, MorphoSys shall, no later than [***] Business Days following notice by COMPANY, use commercially reasonable efforts to cause the Depositary to remove any such legend (including by causing the delivery of any required instructions or legal opinions) and to facilitate any transfers of such New ADSs to an unrestricted depositary facility.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LOCK-UP</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(a)&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;text-decoration:underline;">Lock-up Period.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;COMPANY hereby undertakes to MorphoSys that for a period of eighteen (18) months following Registration Time (the "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Lock-Up Period</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"), it will not,</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 57.3pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">i.&nbsp;&nbsp;&nbsp;&nbsp;sell, transfer, pledge, encumber or otherwise dispose of (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:11pt;">verf&#xFC;gen &#xFC;ber</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">) (including the granting of any option over or the creation of any form of trust relationship in respect of) any New Shares or New ADSs;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 57.3pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">ii.&nbsp;&nbsp;&nbsp;&nbsp;enter into any agreement or transaction in respect of any voting rights or other rights attaching to any New Shares or New ADSs;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 57.3pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">iii.&nbsp;&nbsp;&nbsp;enter into any transaction (including derivative transactions) or carry out any other action that would be the economic equivalent of any of the above;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 57.3pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">in each case without the prior written consent of the management board of MorphoSys. The foregoing restrictions shall not apply to: (A) any transfers to COMPANY&#x2019;s Affiliates, (B) any transfers made following termination of the Collaboration Agreement pursuant to Section 17.2(a) thereof where MorphoSys is the Breaching Party and (C) any transfers in connection with or following a MorphoSys Change of Control; provided that in each transfer pursuant to clause (A), the transferee agrees to be bound in writing by the terms of this Purchase Agreement prior to such transfer.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(b)&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;text-decoration:underline;">Restriction on Sales following the Lock-Up Period.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;Following the end of the Lock-Up Period, COMPANY may only transfer, sell or otherwise dispose of, in any three (3)-month period, 25% of the aggregate number of New Shares or New ADSs subscribed to herein; provided that, notwithstanding the foregoing limitation, COMPANY may sell up to 50% of the aggregate number of New Shares or New ADSs subscribed to herein following the end of the Lock-Up Period in a sale to a single purchaser (but in the event that any such sale to a single purchaser exceeds 25% of the New Shares or New ADSs subscribed to herein, the number of New Shares or New ADSs that may be sold in any other transactions within three (3) months</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">of such sale to a single purchaser shall be reduced by such excess amount in order to ensure that sales within any three (3)-month period from the first sale to a single purchaser do not exceed in total 50% of the New Shares or New ADSs subscribed to herein (including the New Shares or New ADSs sold in the first sale to a single purchaser)). In the event COMPANY intends to sell more than 25% of the aggregate number of New Shares or New ADSs subscribed to herein in a single transaction, COMPANY shall notify and consult with MorphoSys about offering to sell such New Shares or New ADSs to certain investors of MorphoSys identified by MorphoSys.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CONDITIONS TO SUBSCRIPTION</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(a)&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;text-decoration:underline;">COMPANY Conditions</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">. &nbsp;COMPANY&#x2019;s obligations pursuant to Section 1(b) are subject to the fulfillment of the following conditions (unless waived in writing by COMPANY):</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;text-decoration:underline;">Representations and Warranties</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.&nbsp;&nbsp;The representations and warranties made by MorphoSys in Section 13.1 of the Agreement and Section&nbsp;4 hereof shall be true and correct as of the Execution Date and as of the Subscription Date as though made on and as of the Subscription Date, except to the extent such representations and warranties are specifically made as of a particular date, in which case such representations and warranties shall be true and correct as of such date; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;text-decoration:underline;">provided</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">, &nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;text-decoration:underline;">however</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">, that for purposes of this Section 9(a), all such representations and warranties of MorphoSys (other than Sections 1.1 and 1.2 in </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Annex 6</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> hereto) shall be deemed to be true and correct for purposes of this Section 9(a) unless the failure or failures of such representations and warranties to be so true and correct, without regard to any &#x201C;material&#x201D;, &#x201C;materiality&#x201D; or &#x201C;Material Adverse Effect&#x201D; qualifiers set forth therein, constitute a Material Adverse Effect.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">For purposes of this Purchase Agreement, &#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Material Adverse Effect</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D; means any change, event or occurrence (each, an &#x201C;Effect&#x201D;) that, individually or when taken together with all other Effects that have occurred prior to the date of determination of the occurrence of the Material Adverse Event, has had a material adverse effect on the business,</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">properties, management, financial position, stockholders&#x2019; equity or results of operations of MorphoSys and its subsidiaries taken as a whole or on the performance by MorphoSys of its obligations under this Purchase Agreement or the Agreement, except to the extent that any such Effect results from or arises out of: (A) changes in conditions in the United States, German or global economy or capital or financial markets generally, including changes in interest or exchange rates, (B) changes in general political, economic or business conditions in the United States and Germany thereof, (C) acts of war, sabotage or terrorism, or any escalation or worsening of any such acts of war, sabotage or terrorism, (D) earthquakes, hurricanes, floods or other natural disasters, (E) changes or prospective changes in any applicable Laws or regulations or applicable accounting regulations or principles or interpretation thereof or (F) the execution, delivery and announcement of this Agreement and any actions contemplated hereby or thereby, provided,&nbsp;&nbsp;however, that the Effects excluded in clauses (A), (B), (C) and (D) shall only be excluded to the extent such Effects are not disproportionately adverse on MorphoSys and its subsidiaries as compared to other companies operating in MorphoSys&#x2019;s industry.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;text-decoration:underline;">Covenants</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.&nbsp;&nbsp;All covenants and agreements contained in this Purchase Agreement to be performed or complied with by MorphoSys on or prior to the Subscription Date shall have been performed or complied with in all material respects.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;text-decoration:underline;">No Material Adverse Effect</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.&nbsp;&nbsp;From and after the Execution Date until the Subscription Date, there shall have occurred no event that has caused a Material Adverse Effect.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 72pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;text-decoration:underline;">MorphoSys&#x2019;s Conditions</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.&nbsp;&nbsp;MorphoSys&#x2019;s obligation to issue and sell the New ADSs is subject to the fulfillment of the following conditions (unless waived in writing by MorphoSys):</font>
		</p>
		<p style="margin:0pt 0pt 0pt 72pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;text-decoration:underline;">Representations and Warranties</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.&nbsp;&nbsp;The representations and warranties made by COMPANY in Section&nbsp;3 hereof and Section 13.1 of the Agreement shall be true and correct as&nbsp;of the Execution Date and as of the Subscription Date as though made on and as of the Subscription Date.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Annex 1 to EXHIBIT 16</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Management Board Resolution</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:47.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;"></font></p>
				</td>
				<td valign="top" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:45.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:47.78%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:45.64%;border-left:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;color:#C0C0C0;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#C0C0C0;font-size:11pt;">English convenience translation</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:47.78%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Niederschrift &#xFC;ber eine <br></font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"></font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Beschlussfassung</font></p>
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">des Vorstandes der MorphoSys AG ("Gesellschaft")</font></p>
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">vom [</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x2022;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">] 2020</font></p>
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">__________________________________</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:45.64%;border-left:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Minutes of a <br></font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"></font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">resolution of the</font></p>
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Management Board of MorphoSys AG ("Company")</font></p>
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">of [</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x2022;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">], 2020</font></p>
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">________________________________</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:47.78%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">I.</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:45.64%;border-left:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">I.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:47.78%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Aufgrund der von der Hauptversammlung am 17. Mai 2017 beschlossenen Erm&#xE4;chtigung ist der Vorstand nach &#xA7;&nbsp;5&nbsp;Abs. 6 der Satzung der Gesellschaft erm&#xE4;chtigt, mit Zustimmung des Aufsichtsrats bis zum 30.&nbsp;April 2022 (einschlie&#xDF;lich) das Grundkapital der Gesellschaft gegen Bareinlagen einmalig oder mehrmalig um bis zu &#x20AC;&nbsp;2.915.977,00 durch Ausgabe von bis zu 2.915.977 neuen und auf den Inhaber lautende St&#xFC;ckaktien zu erh&#xF6;hen (im Folgenden "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Genehmigtes Kapital 2017-I</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"). </font></p>
				</td>
				<td valign="top" style="width:03.28%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:45.64%;border-left:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Based on the authorization resolved by the general meeting on May 17, 2017 and &#xA7;&nbsp;5(6) of the articles of the Company, the management board, with the approval of the supervisory board, is authorized through and including April 30, 2022 to increase the registered share capital of the Company against cash contributions once or several times by up to &#x20AC;&nbsp;2,915,977.00 through the issuance of up to 2,915,977 new no par-value bearer shares (defined as "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Authorized Capital 2017-I</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">").</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:47.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Zugleich wurde der Vorstand erm&#xE4;chtigt, mit Zustimmung des Aufsichtsrats das Bezugsrecht der Aktion&#xE4;re unter anderem auszuschlie&#xDF;en, wenn die neuen Aktien zu einem Ausgabebetrag ausgegeben werden, der den B&#xF6;rsenpreis von Aktien gleicher Ausstattung nicht wesentlich unterschreitet und die gem&#xE4;&#xDF; oder in entsprechender Anwendung des &#xA7; 186 Abs. 3 Satz 4 AktG gegen Bareinlagen unter Ausschluss des Bezugsrechts w&#xE4;hrend der Laufzeit dieser Erm&#xE4;chtigung ausgegebenen Aktien insgesamt 10 % des Grundkapitals nicht &#xFC;berschreiten, und zwar weder zum Zeitpunkt des Wirksamwerdens noch zum Zeitpunkt der Aus&#xFC;bung dieser Erm&#xE4;chtigung.</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:45.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">At the same time, the management board was authorized to exclude the subscription rights of the shareholders with the approval of the supervisory board, inter alia, if the issue price for the new shares is not significantly below the stock exchange price of shares conferring identical rights, and the shares issued pursuant to Section 186 (3) sentence 4 German Stock Corporation Act (either applied directly or accordingly) against cash consideration and with exclusion of subscription rights during the term of this authorisation do not exceed, in total, 10 % of the registered share capital neither at the time when the authorization becomes effective nor at the time when it is used. </font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:47.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Weiter wurde der Vorstand erm&#xE4;chtigt, mit Zustimmung des Aufsichtsrats die weiteren</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:45.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Furthermore, the management board was authorized to determine the further</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:47.78%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Einzelheiten der Kapitalerh&#xF6;hung und ihrer Durchf&#xFC;hrung festzulegen.</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:03.28%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:45.64%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">details of the capital increase and its implementation with the approval of the supervisory board</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:12pt;">.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:47.78%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Die Gesellschaft hat mit [COMPANY] eine Kollaboration zu [</font><font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">] vereinbart. Im Zusammenhang mit dieser Kollaboration und zur St&#xE4;rkung der k&#xFC;nftigen strategischen Zusammenarbeit m&#xF6;chte [COMPANY] ein Eigenkapitalinvestment bei der Gesellschaft erbringen. [COMPANY] wird von der Gesellschaft [</font><font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">] neue auf den Inhaber lautende St&#xFC;ckaktien in Form von American Depositary Shares ("</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">ADS</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"), die jeweils ein Viertel einer auf den Inhaber lautenden St&#xFC;ckaktie der Gesellschaft vertreten, erwerben.</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:03.28%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:45.64%;border-left:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The Company has agreed on a collaboration with [COMPANY] regarding [</font><font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">]. In the context of this collaboration and in order to further strengthen the future strategic collaboration, [</font><font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">] wishes to make an equity investment in the Company. [COMPANY] shall purchase from the Company [</font><font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">] new no par-value bearer shares in the form of American Depositary Shares ("</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">ADS</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"), each representing one quarter of a no par-value bearer share of the Company. </font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:47.78%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Zur Schaffung der neuen Aktien der Gesellschaft die den ADS unterliegen, werden die nachfolgenden Beschl&#xFC;sse gefasst.</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.54%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:45.64%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The following resolutions are adopted for the creation of the new shares of the Company underlying the ADS.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:47.78%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">II.</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:03.28%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:45.64%;border-left:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">II.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:47.78%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Der Vorstand hat nach ordnungsgem&#xE4;&#xDF;er Beratung einstimmig entschieden, dass eine Ausgabe neuer Aktien an [COMPANY] aus dem Genehmigten Kapital 2017-I im Interesse der Gesellschaft und ihrer Aktion&#xE4;re liegt, um die langfristigen Ziele der Gesellschaft zu erreichen. Demgem&#xE4;&#xDF; hat der Vorstand am [</font><font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">] [To be completed: Procedure, e.g. physical meeting, conference call etc.] unter dem Vorbehalt der Zustimmung des Aufsichtsrats einstimmig wie folgt entschieden:</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:03.28%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:45.64%;border-left:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">After due consideration, the management board has unanimously decided that the issuance of new shares from the Authorised Capital 2017-I to [COMPANY] is in the best interest of the Company and its shareholders to achieve the Company's long-term goals. Therefore, on [</font><font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">] the management board, subject to the approval by the supervisory board, [To be completed: Procedure, e.g. physical meeting, conference call etc.] unanimously decided by way of passing a resolution by as follows:</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:47.78%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 23.05pt;text-indent: -23.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unter [teilweiser] Ausnutzung des Genehmigten Kapitals 2017-I (&#xA7; 5 Abs. 6 der Satzung) wird das eingetragene Grundkapital der Gesellschaft von derzeit &#x20AC;&nbsp;[31.957.958,00] um &#x20AC;&nbsp;[&#x2022;] auf &#x20AC; [&#x2022;] gegen Bareinlage durch Ausgabe von [&#x2022;] neuen auf den Inhaber lautende St&#xFC;ckaktien ("</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Neue Aktien</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">") erh&#xF6;ht ("</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Kapitalerh&#xF6;hung</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"). &nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:03.28%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:45.64%;border-left:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 22.7pt;text-indent: -22.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By [partially] utilizing the Authorized Capital 2017-I (&#xA7; 5(6) of the articles of the Company), the registered share capital of the Company from currently &#x20AC;&nbsp;[31,957,958.00] is increased by &#x20AC;&nbsp;[&#x2022;] to &#x20AC;&nbsp;[&#x2022;] against cash contributions by issuance of [&#x2022;] new no par-value bearer shares (the "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">New Shares</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">") (the "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Capital Increase</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">").</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:47.78%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 23.05pt;text-indent: -23.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:03.28%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:45.64%;border-left:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 22.7pt;text-indent: -22.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:47.78%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 22.7pt;text-indent: -22.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Die Neuen Aktien sind ab dem am&nbsp;&nbsp;1.&nbsp;Januar&nbsp;2020 beginnenden Gesch&#xE4;ftsjahr voll gewinnanteilsberechtigt.]</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:03.28%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:45.64%;border-left:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 22.7pt;text-indent: -22.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[The New Shares carry full dividend rights as of the financial year commenced on January&nbsp;1, 2020.]</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:47.78%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 22.7pt;text-indent: -22.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Der Ausgabebetrag betr&#xE4;gt &#x20AC;&nbsp;[&#x2022;] je Neuer Aktie. Der Gesamtausgabebetrag f&#xFC;r die insgesamt [&#x2022;] Neuen Aktien bel&#xE4;uft sich damit auf &#x20AC;&nbsp;[&#x2022;]. </font></p>
				</td>
				<td valign="top" style="width:03.28%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:45.64%;border-left:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 22.7pt;text-indent: -22.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The issue price is &#x20AC;&nbsp;[&#x2022;] per New Share. The total issue price for the [&#x2022;] New Shares amounts to &#x20AC;&nbsp;[&#x2022;].</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:47.78%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 22.7pt;text-indent: -22.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Das gesetzliche Bezugsrecht der Aktion&#xE4;re der Gesellschaft wird auf der Grundlage der Erm&#xE4;chtigung in &#xA7;&nbsp;5 Abs. 6 der Satzung ausgeschlossen. </font></p>
				</td>
				<td valign="top" style="width:03.28%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:45.64%;border-left:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 22.7pt;text-indent: -22.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the authorization in &#xA7;&nbsp;5(6) of the articles of the Company, the subscription rights of the Company's shareholders are excluded.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:47.78%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 22.7pt;text-indent: -22.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Zur Zeichnung der Neuen Aktien in eigenem Namen aber f&#xFC;r Rechnung von [COMPANY] wird [German Subscription Agent] zugelassen. </font></p>
				</td>
				<td valign="top" style="width:03.28%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:45.64%;border-left:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 22.7pt;text-indent: -22.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The New Shares will be subscribed for by [German Subscription Agent], acting in its own name but for the account of [COMPANY]. </font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:47.78%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 22.7pt;text-indent: -22.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Die Kosten der Kapitalerh&#xF6;hung werden von der Gesellschaft getragen.</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:45.64%;border-left:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 22.7pt;text-indent: -22.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The costs of the Capital Increase will be borne by the Company.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:47.78%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 28.35pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:45.64%;border-left:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 26.35pt;text-indent: -25.65pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:47.78%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:10.5pt;">III.</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:45.64%;border-left:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">III.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:47.78%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Diese Beschl&#xFC;sse bed&#xFC;rfen der Zustimmung des Aufsichtsrats der Gesellschaft.</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:45.64%;border-left:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 0.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">These resolutions require the consent of the Company&#x2019;s supervisory board.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:47.78%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:45.64%;border-left:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 0.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:47.78%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">IV.</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:45.64%;border-left:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">IV.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:47.78%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Als Vorsitzender des Vorstands stelle ich fest:</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:45.64%;border-left:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 0.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">As chairman of the management board, I hereby declare the following:</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:47.78%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 22.7pt;text-indent: -22.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;S&#xE4;mtliche Mitglieder des Vorstands haben unter Verzicht auf alle durch Gesetz oder Satzung vorgeschriebenen Form- und Fristerfordernisse f&#xFC;r das Fassen von Vorstandsbeschl&#xFC;ssen an der Beschlussfassung teilgenommen.</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:45.64%;border-left:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 22.7pt;text-indent: -22.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All management board members took part in the adoption of the resolutions and waived all requirements with regard to notice and form, whether imposed by law or by the articles of association, for the passing of management board resolutions. </font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:47.78%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 22.7pt;text-indent: -22.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;S&#xE4;mtliche Mitglieder des Vorstands haben den unter II. genannten Beschlussvorschl&#xE4;gen zugestimmt.</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:45.64%;border-left:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 22.7pt;text-indent: -22.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All management board members have approved the proposed resolutions under II. above. </font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:47.78%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 22.7pt;text-indent: -22.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Damit wurden die Beschl&#xFC;sse mit dem unter II. genannten Wortlaut gefasst.</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:45.64%;border-left:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 22.7pt;text-indent: -22.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Therefore, the resolutions were adopted with the wording stated under II. above. </font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:47.78%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Allein die deutsche Fassung dieses Beschlusses ist rechtlich bindend.</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.28%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:45.64%;border-left:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 0.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The German version of this resolution is legally binding only.</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 49.6pt;text-indent: -49.6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Planegg, den / this&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. [&#x2022;] 2020</font>
		</p>
		<p style="margin:0pt 0pt 12pt 49.6pt;text-indent: -49.6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:198.00pt;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:341.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:198.00pt;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Dr. Jean-Paul Kress</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:341.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:198.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Vorstandsvorsitzender</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:341.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Univers;font-weight:bold;font-size:11pt;">Annex 2 to EXHIBIT 16</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Univers;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Univers;font-weight:bold;font-size:11pt;">Supervisory Board Resolution</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:48.24%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.10%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.58%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:46.10%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;color:#C0C0C0;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#C0C0C0;font-size:11pt;">English convenience translation</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:48.24%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Niederschrift &#xFC;ber eine<br>Beschlussfassung</font></p>
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">des Aufsichtsrats der MorphoSys AG ("Gesellschaft")</font></p>
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">vom [&#x2022;] 2020</font></p>
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">__________________________________</font></p>
				</td>
				<td valign="top" style="width:03.10%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.58%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:46.10%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Minutes of a <br></font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"></font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">resolution of the</font></p>
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Supervisory Board of MorphoSys AG ("Company")</font></p>
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">of [&#x2022;], 2020</font></p>
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">________________________________</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:48.24%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">I.</font></p>
				</td>
				<td valign="top" style="width:03.10%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.58%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:46.10%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">I.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:48.24%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Aufgrund der von der Hauptversammlung am 17. Mai 2017 beschlossenen Erm&#xE4;chtigung und &#xA7;&nbsp;5 Abs. 6 der Satzung der Gesellschaft hat der Vorstand der Gesellschaft &#x2013; unter dem Vorbehalt der Zustimmung des Aufsichtsrats &#x2013; am [&#x2022;] 2020 den in der </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Anlage</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> dieser Niederschrift beigef&#xFC;gten Beschluss &#xFC;ber die Erh&#xF6;hung des eingetragenen Grundkapitals von gegenw&#xE4;rtig &#x20AC;&nbsp;[31.957.958,00] um &#x20AC;&nbsp;[</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x2022;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">] auf &#x20AC;&nbsp;[</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x2022;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">] gegen Bareinlage durch Ausgabe von [</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x2022;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">] &nbsp;neuen und auf den Inhaber lautenden St&#xFC;ckaktien mit einem anteiligen Betrag am Grundkapital von &#x20AC;&nbsp;[</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x2022;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">] je Aktie ("</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Neue Aktien</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">") zum Ausgabebetrag von &#x20AC;&nbsp;1,00 je Neuer Aktie gefasst ("</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Kapitalerh&#xF6;hung</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"). </font></p>
				</td>
				<td valign="top" style="width:03.10%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.58%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:46.10%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Based on the authorization resolved by&nbsp;&nbsp;the general meeting on May&nbsp;17, 2017 and &#xA7;&nbsp;5(6) of the articles of the Company, the management board of the Company, subject to the approval of the supervisory board, adopted on [&#x2022;], 2020 the enclosed resolution (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Annex</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">) regarding the increase of the registered share capital of the Company against cash contributions from currently &#x20AC;&nbsp;[31,957,958.00] by &#x20AC;&nbsp;[</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x2022;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">] to &#x20AC;&nbsp;[</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x2022;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">] by issuance of [</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x2022;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">] &nbsp;new no par-value bearer shares with a pro rata share in the share capital of &#x20AC;&nbsp;1.00 per share (the "</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">New Shares</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">") at an issue price of &#x20AC;&nbsp;[</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x2022;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">] per New Share ("</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Capital Increase</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">").</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:48.24%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Das gesetzliche Bezugsrecht der Aktion&#xE4;re wurde dabei auf der Grundlage der Erm&#xE4;chtigung in &#xA7;&nbsp;5 Abs. 6 der Satzung ausgeschlossen. Zur Zeichnung der Neuen Aktien wurde [German Subscription Agent] zugelassen. </font></p>
				</td>
				<td valign="top" style="width:03.10%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.58%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:46.10%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The subscription rights of the Company's shareholders were excluded in accordance with the authorization in &#xA7;&nbsp;5(6) of the articles of the Company. It was further resolved that the New Shares shall be subscribed by [German Subscription Agent]. &nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:48.24%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.10%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.58%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:46.10%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:48.24%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">II.</font></p>
				</td>
				<td valign="top" style="width:03.10%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.58%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:46.10%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">II.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:48.24%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Der Aufsichtsrat hat am [&#x2022;] 2020 im Wege des Umlaufbeschlussverfahrens per Email (&#xA7;&nbsp;10 Abs. 2 der Satzung) in Kenntnis des ihm als Anlage zu diesen Beschlussvorschl&#xE4;gen &#xFC;bermittelten Vorstandsbeschlusses vom [&#x2022;] 2020 &#xFC;ber folgende Beschlussvorschl&#xE4;ge abgestimmt:</font></p>
				</td>
				<td valign="top" style="width:03.10%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.58%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:46.10%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">On [&#x2022;], 2020, the supervisory board, having full knowledge of the management board resolution of [&#x2022;], 2020, which was forwarded to the supervisory board together with these resolution proposals, resolved by way of an email-vote (&#xA7;&nbsp;10(2) of the articles) as follows:</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:48.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;"></font></p>
				</td>
				<td valign="top" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:46.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:48.24%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 28.35pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Der Aufsichtsrat stimmt dem dieser Niederschrift als </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Anlage</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> beigef&#xFC;gten Beschluss des Vorstands vom [&#x2022;] 2020 vollumf&#xE4;nglich zu. </font></p>
				</td>
				<td valign="top" style="width:03.10%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.58%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:46.10%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 25.1pt;text-indent: -25.1pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The supervisory board approves the resolution of the management board of [&#x2022;], 2020, the minutes of which are attached as </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Annex</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> hereto, in full.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:48.24%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 28.35pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Auf der Grundlage der Erm&#xE4;chtigung in &#xA7; 5 Abs. 7 der Satzung wird die Satzung in &#xA7; 5 Abs. 1, Abs. 2 und Abs. 6 in Anpassung an die Kapitalerh&#xF6;hung aus dem Genehmigten Kapital 2017-I mit Wirkung vom Zeitpunkt der Eintragung der Durchf&#xFC;hrung der Kapitalerh&#xF6;hung im Handelsregister wie folgt neu gefasst: </font></p>
				</td>
				<td valign="top" style="width:03.10%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.58%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:46.10%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 26.35pt;text-indent: -26.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on the authorisation pursuant to &#xA7; 5(7) of the articles of the Company, with effect as of the date of the registration with the commercial register of the execution of the Capital Increase from the Authorized Capital 2017-I, &#xA7; 5(1), (2) and (6) of the articles shall be amended as follows:</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:48.24%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 28.35pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#xA7;&nbsp;5&nbsp;Abs.&nbsp;1 der Satzung erh&#xE4;lt folgende Fassung: </font></p>
				</td>
				<td valign="top" style="width:03.10%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.58%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:46.10%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 26.35pt;text-indent: -26.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#xA7; 5(1) of the articles is amended as follows:</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:48.24%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 65.5pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Das Grundkapital betr&#xE4;gt &#x20AC;&nbsp;[</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x2022;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">].</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:12pt;">"</font></p>
				</td>
				<td valign="top" style="width:03.10%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.58%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:46.10%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 61.1pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The registered share capital amounts to &#x20AC;&nbsp;[</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x2022;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">]."</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:48.24%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 28.35pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#xA7; 5 Abs. 2 der Satzung erh&#xE4;lt folgende Fassung: </font></p>
				</td>
				<td valign="top" style="width:03.10%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.58%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:46.10%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 26.35pt;text-indent: -26.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#xA7; 5(2) of the articles is amended as follows:</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:48.24%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 65.5pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Das Grundkapital ist eingeteilt in [</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x2022;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">] &nbsp;auf den Inhaber lautende nennwertlose St&#xFC;ckaktien."</font></p>
				</td>
				<td valign="top" style="width:03.10%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.58%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:46.10%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 61.1pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The share capital is divided into [</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x2022;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">] no-par-value bearer shares."</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:48.24%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 28.35pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Satz 1 von &#xA7;&nbsp;5&nbsp;Abs. 6 der Satzung wird wie folgt angepasst: </font></p>
				</td>
				<td valign="top" style="width:03.10%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.58%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:46.10%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 26.35pt;text-indent: -26.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sentence 1 of &#xA7; 5(6) of the articles is amended as follows:</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:48.24%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 61.7pt;text-indent: -35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Der Vorstand ist erm&#xE4;chtigt, mit Zustimmung des Aufsichtsrats bis zum 30. April 2022 (einschlie&#xDF;lich) das Grundkapital der Gesellschaft gegen Bareinlagen einmalig oder mehrmalig um insgesamt bis zu [&#x2022;] &#x20AC; durch Ausgabe von bis zu [&#x2022;] neuen und auf den Inhaber lautende St&#xFC;ckaktien zu erh&#xF6;hen (Genehmigtes Kapital 2017-&nbsp;I)."</font></p>
				</td>
				<td valign="top" style="width:03.10%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.58%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:46.10%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 61.7pt;text-indent: -35.45pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">"(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With the Supervisory Board&#xB4;s consent, the Management Board is authorized to increase the Company&#x2019;s share capital by issuing a maximum of [&#x2022;] new no-par value bearer shares against contribution in cash up to an amount of &#x20AC; [&#x2022;] on one or several occasions until and including the date of April 30, 2022 (Authorized Capital 2017-I)."</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:48.24%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 29.5pt;text-indent: -27pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Die &#xFC;brigen Satzungsbestimmungen bleiben unver&#xE4;ndert.</font></p>
				</td>
				<td valign="top" style="width:03.10%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.58%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:46.10%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 26.35pt;text-indent: -26.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The other provisions of the articles remain unchanged.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:48.24%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 29.5pt;text-indent: -27pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Die Mitglieder des Aufsichtsrats verzichten auf alle durch Gesetz und Satzung vorgeschriebenen Form-</font></p>
				</td>
				<td valign="top" style="width:03.10%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.58%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:46.10%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 26.35pt;text-indent: -26.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The supervisory board members waive all requirements with regard to notice and form, whether</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:48.24%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 28.1pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">und Fristerfordernisse f&#xFC;r das Fassen von Aufsichtsratsbeschl&#xFC;ssen in Bezug auf diese Beschlussfassung. </font></p>
				</td>
				<td valign="top" style="width:03.10%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.58%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:46.08%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 28.1pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">imposed by law or by the articles of association both with respect to this resolution. </font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:48.24%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 28.35pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.10%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.58%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:46.08%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 25.1pt;text-indent: -25.1pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:48.24%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">III.</font></p>
				</td>
				<td valign="top" style="width:03.10%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.58%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:46.08%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">III.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:48.24%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Als Vorsitzender des Aufsichtsrats stelle ich fest:</font></p>
				</td>
				<td valign="top" style="width:03.10%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.58%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:46.08%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 0.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">As chairman of the supervisory board, I hereby declare the following:</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:48.24%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 28.35pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;S&#xE4;mtliche Mitglieder des Aufsichtsrats haben unter Verzicht auf alle durch Gesetz oder Satzung vorgeschriebenen Form- und Fristerfordernisse f&#xFC;r das Fassen von Aufsichtsratsbeschl&#xFC;ssen an der Beschlussfassung teilgenommen. </font></p>
				</td>
				<td valign="top" style="width:03.10%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.58%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:46.08%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 19.25pt;text-indent: -19.25pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">1.&nbsp;&nbsp;&nbsp;&nbsp;All supervisory board members took part in the adoption of the resolutions and waived all requirements with regard to notice and form, whether imposed by law or by the articles of association, for the passing of supervisory board resolutions.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:48.24%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 28.35pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;S&#xE4;mtliche Mitglieder des Aufsichtsrats haben den unter II. genannten Beschlussvorschl&#xE4;gen zugestimmt.</font></p>
				</td>
				<td valign="top" style="width:03.10%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.58%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:46.08%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 19.25pt;text-indent: -19.25pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">2.&nbsp;&nbsp;&nbsp;&nbsp;All supervisory board members have approved the resolution proposals stated under II. above. </font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:48.24%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 28.35pt;text-indent: -28.35pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Damit wurden die Beschl&#xFC;sse mit dem unter II. genannten Wortlaut gefasst.</font></p>
				</td>
				<td valign="top" style="width:03.10%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.58%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:46.08%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 19.25pt;text-indent: -21.25pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Therefore, the resolutions were adopted with the wording stated under II. above. </font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:48.24%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Allein die deutsche Fassung dieser Beschl&#xFC;sse ist rechtlich bindend.</font></p>
				</td>
				<td valign="top" style="width:03.10%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.58%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:46.08%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 0.7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Only the German version of this resolution is legally binding.</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

			<font style="display:inline;font-size:8pt;">Confidential</font>

		</p>

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

			<font style="display:inline;font-size:8pt;">Supervisory Board Resolution &#x2013; Capital Increase</font>

		</p>

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 49.6pt;text-indent: -49.6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , den / this&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . [&#x2022;] 2020</font>
		</p>
		<p style="margin:0pt 0pt 12pt 49.6pt;text-indent: -49.6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:198.00pt;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:341.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:198.00pt;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Dr. Marc Cluzel</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:341.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:198.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Aufsichtsratsvorsitzender</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:341.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Anlage/Annex:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Beschluss des Vorstands vom&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . &nbsp;[&#x2022;] 2020 (Kopie) / </font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Resolution of the management board dated [&#x2022;] &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 (copy)</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Univers;font-weight:bold;font-size:11pt;">Annex 3 to EXHIBIT 16</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Univers;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Univers;font-weight:bold;font-size:11pt;">Subscription Certificate</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:48.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:46.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:48.00%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.26%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.46%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:46.30%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;color:#C0C0C0;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#C0C0C0;font-size:11pt;">English Convenience Translation</font></p>
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:48.00%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Zeichnungsschein</font></p>
				</td>
				<td valign="top" style="width:03.26%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.46%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:46.30%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Subscription Certificate</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:48.00%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Der Vorstand der MorphoSys AG, eingetragen im Handelsregister des Amtsgerichts M&#xFC;nchen unter HRB 121023 (die &#x201E;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Gesellschaft</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201C;) ist auf Grund der am 17. Mai 2017 von der ordentlichen Hauptversammlung der Gesellschaft beschlossenen Erm&#xE4;chtigung nach &#xA7; 5 Abs. (6) der Satzung der Gesellschaft erm&#xE4;chtigt, mit Zustimmung des Aufsichtsrats bis zum 30. April 2022 (einschlie&#xDF;lich) das Grundkapital der Gesellschaft gegen Bareinlagen einmalig oder mehrmalig um bis zu &#x20AC; 2.915.977,00 durch Ausgabe von bis zu 2.915.977 neuen und auf den Inhaber lautenden St&#xFC;ckaktien zu erh&#xF6;hen (Genehmigtes Kapital 2017-I). </font></p>
				</td>
				<td valign="top" style="width:03.26%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.46%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:46.30%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Based on the authorization resolved by the general meeting of MorphoSys AG registered in the commercial register of the local court of Munich under HRB 121023 (the "</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Company</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">") on May 17, 2017 and &#xA7;&nbsp;5(6) of the articles of the Company, the management board, with the approval of the supervisory board, is authorized through and including April 30, 2022 to increase the registered share capital of the Company against cash contributions once or several times by up to &#x20AC; 2,915,977.00 through the issuance of up to 2,915,977 new no par-value bearer shares (Authorized Capital 2017-I).</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:48.00%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Zugleich wurde der Vorstand erm&#xE4;chtigt, mit Zustimmung des Aufsichtsrats das Bezugsrecht der Aktion&#xE4;re auszuschlie&#xDF;en, wenn die neuen Aktien zu einem Ausgabebetrag ausgegeben werden, der den B&#xF6;rsenpreis von Aktien gleicher Ausstattung nicht wesentlich unterschreitet und die gem&#xE4;&#xDF; oder in entsprechender An-wendung des &#xA7; 186 Abs. 3 Satz 4 AktG gegen Bareinlagen unter Ausschluss des Bezugsrechts w&#xE4;hrend der Laufzeit dieser Erm&#xE4;chtigung ausgegebenen Aktien insgesamt 10% des Grundkapitals nicht &#xFC;berschreiten, und zwar weder zum Zeitpunkt des Wirksamwerdens noch zum Zeitpunkt der Aus&#xFC;bung dieser Erm&#xE4;chtigung. Weiter wurde der Vorstand erm&#xE4;chtigt, mit Zustimmung des Aufsichtsrats die weiteren Einzelheiten der Kapitalerh&#xF6;hung und ihrer Durchf&#xFC;hrung festzulegen.</font></p>
				</td>
				<td valign="top" style="width:03.26%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.46%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:46.30%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">At the same time, the management board was authorized to exclude the sub-scription rights of the shareholders with the approval of the supervisory board, inter alia, if the issue price for the new shares is not significantly below the stock exchange price of shares conferring identical rights, and the shares issued pursuant to Section 186 (3) sentence 4 German Stock Corporation Act (either applied directly or accordingly) against cash consideration and with exclusion of subscription rights during the term of this authorisation do not exceed, in total, 10 % of the registered share capital neither at the time when the authorization be-comes effective nor at the time when it is used. Furthermore, the management board was authorized to determine the further details of the capital increase and its implementation with the approval of the supervisory board.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:48.00%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Im Rahmen dieser Erm&#xE4;chtigung hat der Vorstand am [&#x25CF;]. 2020 mit Zustimmung des Aufsichtsrats vom [&#x25CF;]. 2020 beschlossen, unter [teilweiser]&nbsp;&nbsp;Ausnutzung des Genehmigten Kapitals 2017-I (&#xA7; 5 Abs. (6) der Satzung), das eingetragene&nbsp; </font></p>
				</td>
				<td valign="top" style="width:03.26%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.46%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:46.30%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Within this authorization and by [partially] utilizing the Authorized Capital 2017-I (</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#xA7;&nbsp;5(6) of the articles</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">) the management board resolved on [</font><font style="display:inline;font-family:Symbol;font-weight:bold;">&#xF0B7;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">] 2020 with approval of the supervisory board on [</font><font style="display:inline;font-family:Symbol;font-weight:bold;">&#xF0B7;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">] 2020</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> to increase the registered share capital of the</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:48.00%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Grundkapital der Gesellschaft von derzeit &#x20AC; [31.957.958,00] um &#x20AC; [&#x2022;] auf &#x20AC; [&#x2022;] gegen Bareinlage durch Ausgabe von [&#x2022;] neuen auf den Inhaber lautenden St&#xFC;ckaktien mit einem anteiligen Betrag am Grundkapital von &#x20AC; 1,00 je Aktie mit voller Gewinnanteilsberechtigung ab dem am 1. Januar 2020 beginnenden Gesch&#xE4;ftsjahr und unter Ausschluss des Bezugsrechts der Aktion&#xE4;re zu erh&#xF6;hen.</font></p>
				</td>
				<td valign="top" style="width:03.26%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.46%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:46.28%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 3pt;text-indent:0.2pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Company under exclusion of subscription rights of the Company's shareholders from currently &#x20AC; [31,957,958.00] by [</font><font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">]&nbsp;&#x20AC; to &#x20AC; &nbsp;[</font><font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">]&nbsp;against cash contribution by issuance of [</font><font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">] new no par-value bearer shares with a notional value in the registered share capital of 1.00&nbsp;&#x20AC; per share and carrying full dividend rights as of the financial year commenced on January 1, 2020. </font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:48.00%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Die neuen Aktien werden jeweils zum Ausgabebetrag von &#x20AC; [</font><font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">] je neuer Aktie ausgegeben.</font></p>
				</td>
				<td valign="top" style="width:03.26%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.46%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:46.28%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 3pt;text-indent:0.2pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">The new shares shall be issued at the issue price of &#x20AC; [</font><font style="display:inline;font-family:Symbol;font-weight:bold;">&#xF0B7;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">] per new share.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:48.00%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Zur Zeichnung der [&#x2022;] neuen Aktien zum Ausgabebetrag von &#x20AC; [</font><font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">] je neuer Aktie wurde ausschlie&#xDF;lich [German Subscription Agent] in eigenem Namen aber f&#xFC;r Rechnung von [COMPANY]&nbsp;&nbsp;zugelassen.</font></p>
				</td>
				<td valign="top" style="width:03.26%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.46%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:46.28%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">The [</font><font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">] new shares will be subscribed at the issue price of &#x20AC; &nbsp;[</font><font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">] per new share exclusively by [German Subscription Agent], acting in its own name but for the account of [COMPANY].</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:48.00%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Wir, die unterzeichnende&nbsp;&nbsp;[German Subscription Agent], zeichnen und &#xFC;bernehmen hiermit in eigenem Namen</font></p>
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[</font><font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">] St&#xFC;ck <br>(in Worten:[</font><font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">])</font></p>
					<p style="margin:0pt 0pt 11pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">neue auf den Inhaber lautende St&#xFC;ckaktien der MorphoSys AG mit einem anteiligen Betrag am Grundkapital von &#x20AC; 1,00&nbsp;je Aktie und mit voller Gewinnanteilsberechtigung ab dem am 1. Januar 2020 beginnenden Gesch&#xE4;ftsjahr, gegen Bareinlagen zu einem Ausgabebetrag von &#x20AC; [&#x2022;]&nbsp;&nbsp;je neuer Aktie und [COMPANY] zahlt auf diese Aktien den Ausgabebetrag in H&#xF6;he von rund &#x20AC; [&#x2022;] je neuer Aktie und damit den gesamten Ausgabebetrag in H&#xF6;he von insgesamt</font></p>
					<p style="margin:0pt 0pt 11pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x20AC; [</font><font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">]<br>(in Worten: [</font><font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">] Euro)</font></p>
					<p style="margin:0pt 0pt 11pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">auf das bei [German Subscription Agent], zins- und provisionsfrei gef&#xFC;hrte Sonderkonto der Gesellschaft mit der Bezeichnung &#x201E;[</font><font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">]&#x201C; ein.</font></p>
				</td>
				<td valign="top" style="width:03.26%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-indent:7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.46%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:46.28%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-indent:0.2pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">We, the undersigned&nbsp; [German Subscription Agent], hereby subscribe to and assume in our own name</font></p>
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[</font><font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">]<br>(in words [</font><font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">])</font></p>
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">new no par-value bearer shares of MorphoSys AG with a notional value in the registered share capital of 1.00 &#x20AC; per share and carrying full dividend rights as of the financial year commenced on January 1, 2020 against cash contribution at the issue price of &nbsp;&#x20AC; [</font><font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">] per new share and [COMPANY] pays on these shares the issue price of&nbsp;&nbsp;&#x20AC; [</font><font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">] per new share and thus the total issue price of</font></p>
					<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x20AC; [</font><font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">]<br>(in words:[</font><font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">] Euro).</font></p>
					<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">to the special account of the Company at [German Subscription Agent], free of interest and commis-sion with the name &#x201C;[</font><font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">]&#x201D;.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:48.00%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Die Zeichnung wird unverbindlich, wenn die Durchf&#xFC;hrung der Kapitalerh&#xF6;hung nicht bis zum&nbsp;[</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:11pt;text-decoration:underline;">Insert:</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:11pt;"> date [4] months after Effective Date</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">] (12:00 Uhr MEZ) in das Handelsregister der Gesellschaft</font></p>
				</td>
				<td valign="top" style="width:03.26%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-indent:7pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.46%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:46.28%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-indent:0.2pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The subscription&nbsp; will become null and void if the execution of the capital increase has not been registered with the commercial register of the Company until [</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:11pt;text-decoration:underline;">Insert</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:11pt;">: date [4] months after Effective</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:48.00%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">eingetragen worden ist.</font></p>
				</td>
				<td valign="top" style="width:03.26%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.46%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:46.28%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 3pt;text-indent:0.1pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:11pt;">Date</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">] (12:00 hrs CET).</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:48.00%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Die deutsche Fassung dieses Zeichnungsscheins ist alleine ma&#xDF;gebend.</font></p>
				</td>
				<td valign="top" style="width:03.26%;border-right:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.46%;border-left:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:46.28%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt 3.1pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">The German version of this subscription certificate is solely decisive. </font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[</font><font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">], den / this&nbsp;&nbsp;[</font><font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">]</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[</font><font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">]</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">_________________<br></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">[</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:11pt;">Name, function</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">]</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">__________________<br></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">[</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:11pt;">Name, function</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">]</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Univers;font-weight:bold;font-size:10.5pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Univers;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Univers;font-weight:bold;font-size:10.5pt;">Annex 4 to EXHIBIT 16</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Univers;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Univers;font-weight:bold;font-size:10.5pt;">Bank Confirmation</font>
		</p>
		<p style="margin:0pt 0pt 18pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
			<font style="display:inline;font-family:Univers;font-size:8pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 24pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;font-size:10.5pt;">[German Subscription Agent - letterhead]</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">1.&nbsp;Ausfertigung</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:10.5pt;">Best&#xE4;tigung</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:10.5pt;">Gem&#xE4;&#xDF; &#xA7;&#xA7; 203 Abs. 1. S. 1,&nbsp;188 Abs.&nbsp;2 i.V. mit &#xA7;&#xA7;&nbsp;36 Abs.&nbsp;2, 36a Abs.&nbsp;1, 37 Abs.&nbsp;1 AktG</font>
		</p>
		<p style="margin:0pt 0pt 36pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">(doppelt ausgestellt)</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">Zur Vorlage beim Amtsgericht M&#xFC;nchen &#x2013; Handelsregister &#x2013; best&#xE4;tigen wir hiermit hinsichtlich der von dem Vorstand der Gesellschaft am [&#x2022;] 2020 mit Zustimmung des Aufsichtsrats vom [&#x2022;] 2020 beschlossenen Kapitalerh&#xF6;hung &#xFC;ber insgesamt &#x20AC; [&#x2022;], dass wir heute der</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">MorphoSys AG</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">Planegg/Landkreis M&#xFC;nchen</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">den vollen Ausgabebetrag von &#x20AC;&nbsp;[&#x2022;] je neuer auf den Inhaber lautenden St&#xFC;ckaktie mit einem anteiligen Betrag am Grundkapital von &#x20AC;&nbsp;1,00 je Aktie der von der [German Subscription Agent] gezeichneten St&#xFC;ck [&#x2022;] neue Aktien, das sind insgesamt</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">&#x20AC;&nbsp;[&#x2022;]</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">(in Worten: Euro [&#x2022;])</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">auf einem bei uns gef&#xFC;hrten zins- und provisionsfreien &#x201E;[&#x2022;]&#x201C; der MorphoSys&nbsp;AG gutgeschrieben haben.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">Wir versichern, dass der eingezahlte Betrag vorbehaltlich der Eintragung der Durchf&#xFC;hrung der Kapitalerh&#xF6;hung in das Handelsregister endg&#xFC;ltig zur freien Verf&#xFC;gung des Vorstandes der MorphoSys AG steht.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">[&#x2022;], den [&#x2022;] 2020</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">[German Subscription Agent]</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">vertreten durch</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="border-bottom:1pt solid #000000 ;width:38.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:24.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-bottom:1pt solid #000000 ;width:37.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-top:1pt solid #000000 ;width:38.12%;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 36pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">[&#x2022;]</font></p>
				</td>
				<td valign="top" style="width:24.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 36pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-top:1pt solid #000000 ;width:37.84%;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 36pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">[&#x2022;]</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Univers;font-weight:bold;font-size:10.5pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Univers;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Univers;font-weight:bold;font-size:10.5pt;">Annex 5 to EXHIBIT 16</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Univers;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Univers;font-weight:bold;font-size:10.5pt;">Global Share Certificate</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:19.20%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:59.96%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 14pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:14pt;">MorphoSys AG</font></p>
				</td>
				<td valign="top" style="width:06.58%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">WKN</font></p>
				</td>
				<td valign="top" style="width:14.26%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">663 200</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:19.20%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:59.96%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<br><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:12pt;"></font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:12pt;">Planegg</font></p>
				</td>
				<td valign="top" style="width:06.58%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">ISIN</font></p>
				</td>
				<td valign="top" style="width:14.26%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">DE0006632003</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:19.20%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:59.96%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:20.84%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">Ordnungsnummer 22</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:19.20%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:59.96%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:12pt;">Globalurkunde</font></p>
				</td>
				<td colspan="2" valign="top" style="width:20.84%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:19.20%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:59.96%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:20.84%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:19.20%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:59.96%;padding:0pt;">
					<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">&#xFC;ber </font></p>
				</td>
				<td colspan="2" valign="top" style="width:20.84%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">[</font><font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">]&nbsp;&nbsp;auf den Inhaber lautende Stammaktien (St&#xFC;ckaktien)</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">St&#xFC;ckenummern [32.072.628] bis zu [</font><font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">]</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">Der Inhaber dieser Globalurkunde ist mit [</font><font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">]&nbsp;&nbsp;St&#xFC;ckaktien an der MorphoSys AG, Planegg, nach Ma&#xDF;gabe der Satzung als Aktion&#xE4;r</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">beteiligt.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">Die Anzahl der in dieser Globalurkunde verbrieften und begebenen Aktien ergibt sich aus der aktuellen EDV-basierten Depotdokumentation der</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">Clearstream&nbsp;Banking AG, Frankfurt am Main</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">Diese Globalurkunde ist ausschlie&#xDF;lich zur Verwahrung bei der Clearstream Banking AG, Frankfurt am Main, bestimmt.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">Zu dieser Globalurkunde wurde kein Globalgewinnanteilschein ausgefertigt.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">Die in dieser Globalurkunde verbrieften St&#xFC;ckaktien sind ab 1.&nbsp;Januar 2020 gewinnanteilsberechtigt.</font>
		</p>
		<p style="margin:0pt 0pt 18pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">Planegg, im [</font><font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">] 2020</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 50.00%;">
			<tr>
				<td valign="top" style="width:37.44%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:10.5pt;">MorphoSys AG</font></p>
				</td>
				<td valign="top" style="width:21.76%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:40.80%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.44%;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:21.76%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:40.80%;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.44%;border-top:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">Der Vorstand</font></p>
				</td>
				<td valign="top" style="width:21.76%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-size:10.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:40.80%;border-top:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">Der Vorstand</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:10.5pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:10.5pt;">Annex 6 to EXHIBIT 16</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Representations and Warranties of MorphoSys</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">MorphoSys hereby represents and warrants to COMPANY that:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Valid Issuance of New Shares and New ADS</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.&nbsp;&nbsp;&nbsp;MorphoSys has all requisite power and authority to issue and sell the New Shares and the New ADSs and to perform its obligations under and to carry out the other transactions contemplated by this Purchase Agreement. All of the New Shares and the New ADSs, when issued, delivered and paid for as contemplated herein, will have been duly authorized and will be validly issued, fully paid and non-assessable, free from any liens, encumbrances or restrictions on transfer, including pre-emptive rights, rights of first refusal or other similar rights, other than as arising pursuant to this Purchase Agreement, as a result of any action by COMPANY or under U.S. federal or state securities Laws.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"> No stop order</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.&nbsp;&nbsp;&nbsp;No stop order or suspension of trading of the Existing Shares or the ADSs has been imposed by the any Governmental Authority and remains in effect.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">1.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">No Conflicts</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.&nbsp;&nbsp;The execution, delivery and performance of this Purchase Agreement, the issuance and sale of the New ADSs or the New Shares and the consummation of the transactions contemplated by this Purchase Agreement&nbsp;&nbsp;will not (i) conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, or result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of MorphoSys pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which MorphoSys is a party, by which MorphoSys is bound or to which any of the property or assets of MorphoSys is subject, (ii) result in any violation of the provisions of the organizational documents of MorphoSys or (iii) result in the violation of any law or statute or any judgment, order, rule&nbsp;&nbsp;or regulation of any court or arbitrator or governmental or regulatory authority having jurisdiction over MorphoSys or any of its subsidiaries, except, in the case of clauses (i) and (iii) above, for any such conflict, breach, violation or default that would not, individually or in the aggregate, have a Material Adverse Effect.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">1.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">No Governmental Authority or Third Party Consents</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.&nbsp;&nbsp;To MorphoSys&#x2019; Knowledge, no consent, approval, authorization, order, regulatory license, registration or qualification of or with any court or arbitrator or governmental or regulatory authority is required for the execution, delivery and performance by MorphoSys of this Purchase Agreement or the issuance and sale of the New ADSs or the New Shares, except (i) such filings as may be required to be made with the SEC and with any state blue sky or other U.S or foreign securities regulatory authority, which filings shall be made in a timely manner in accordance with all applicable Laws, (ii) as required pursuant to the HSR Act or under any other applicable competition, merger control, antitrust or similar Law of any jurisdiction, (iii) the registration of the capital increase in relation to the New Shares with the commercial register and (iv) the admission to trading and introduction to trading of the New Shares by the Frankfurt Stock Exchange.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">1.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Litigation</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.&nbsp;&nbsp;To MorphoSys&#x2019; Knowledge, there are no legal, governmental or regulatory investigations, actions, suits or proceedings pending to which MorphoSys is a</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">party or to which any property of MorphoSys is subject that, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect; and no such investigations, actions, suits or proceedings are, to the Knowledge of MorphoSys, threatened or contemplated by any governmental or regulatory authority or others. For clarity, the aforementioned shall not cover proceedings before patent or trademark offices.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">1.6&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Regulatory Licenses and Other Rights; Compliance with Laws</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.&nbsp;&nbsp;MorphoSys and its subsidiaries, to MorphoSys&#x2019; Knowledge, possess or are in the process of obtaining all material regulatory licenses, certificates, permits and other authorizations issued by, and have made all declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory authorities that are necessary for the ownership or lease of their respective properties or the conduct of their respective businesses as described in MorphoSys SEC Documents, except where the failure to possess or make the same would not, individually or in the aggregate, have a Material Adverse Effect; and except as described in MorphoSys SEC Documents and except where any revocation would not, individually or in the aggregate, have a Material Adverse Effect, neither MorphoSys nor any of its subsidiaries has received notice of any revocation or modification of any such regulatory license, certificate, permit or authorization or has any reason to believe that any such license, certificate, permit or authorization will not be renewed.&nbsp;&nbsp;MorphoSys and its subsidiaries are, and at all times since April 19, 2018, have been, to MorphoSys&#x2019; Knowledge, in compliance in all material respects with all statutes, rules and regulations applicable to the ownership, packaging, processing, use, distribution, import, or export of any product manufactured or distributed by MorphoSys or its subsidiaries, except where such noncompliance would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">1.7&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">MorphoSys SEC Documents; Financial Statements; Nasdaq Market</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since April 19, 2018, MorphoSys has timely filed all required reports, schedules, forms, statements and other documents (including exhibits and all other information incorporated therein) required to be filed or furnished by it under the Securities Act and the Securities Exchange Act of 1934, as amended (the &#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Exchange Act</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;), and any required amendments to any of the foregoing, with the SEC (the &#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">MorphoSys SEC Documents</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&#x201D;).&nbsp;&nbsp;As of their respective filing dates, each of the MorphoSys SEC Documents complied in all material respects with the requirements of the Securities Act, the Exchange Act and the rules and regulations of the SEC promulgated thereunder applicable to such MorphoSys SEC Documents, and no MorphoSys SEC Documents when filed, declared effective or mailed, as applicable, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of the Execution Date, there are no outstanding or unresolved comments in comment letters received from the SEC or its staff.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The financial statements of MorphoSys filed with the SEC for the fiscal year ended December 31, 2018 and those it filed with the SEC for the quarterly periods ended March 31, 2019; June 30, 2019; and September 30, 2019 present fairly in all material respects the financial position of MorphoSys and its consolidated subsidiaries as of the dates indicated and the results of their operations and the changes in their cash flows for the periods specified; such financial statements have been prepared in conformity with IFRS applied on</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">a consistent basis throughout the periods covered thereby, except as otherwise disclosed therein and, in the case of unaudited, interim financial statements, subject to normal year-end audit adjustments and the exclusion of certain footnotes, and any supporting schedules included in MorphoSys SEC Documents present fairly the information required to be stated therein.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The ADSs are listed on the Nasdaq Market, and MorphoSys has taken no action designed to, or which is likely to have the effect of, terminating the registration of the ADSs under the Exchange Act or delisting the ADSs from the Nasdaq Market.&nbsp;&nbsp;MorphoSys has not received any notification that, and has no Knowledge that, the SEC or the Nasdaq Market is contemplating terminating such listing or registration.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">1.8&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Absence of Certain Changes</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.&nbsp;&nbsp;Except as disclosed in MorphoSys SEC Documents, since September 30, 2019, there has not been any material change in the capital stock, short-term debt or long-term debt of MorphoSys or any of its subsidiaries, or any dividend or distribution of any kind declared, set aside for payment, paid or made by MorphoSys on any class of capital stock, or any change, event or development that has had or would reasonably be expected to have a Material Adverse Effect.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">1.9&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Offering.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &nbsp;The offer, sale and issuance of the New ADSs to be issued in conformity with the terms of this Purchase Agreement constitute transactions which are exempt from the registration requirements of the Securities Act and from all applicable state registration or qualification requirements.&nbsp;&nbsp;Neither MorphoSys nor any person or entity acting on its behalf will take any action that would cause the loss of such exemption.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">1.10&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">No Integration</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.&nbsp;&nbsp;MorphoSys has not, directly or through any agent, sold, offered for sale, solicited offers to buy or otherwise negotiated in respect of, any security (as defined in the Securities Act), that is or will be integrated with the sale of the New ADSs in a manner that would require registration of the New ADSs under the Securities Act.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">1.11&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">No General Solicitation</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.&nbsp;&nbsp;Neither MorphoSys nor any person acting on behalf of MorphoSys has offered or sold any of the New ADSs or the New Shares by any form of general solicitation or general advertising.&nbsp;&nbsp;MorphoSys has offered the New ADSs for sale only to COMPANY.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">1.12&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Foreign Corrupt Practices</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.&nbsp;&nbsp;To MorphoSys&#x2019; Knowledge neither MorphoSys nor any agent or other person acting on behalf of MorphoSys, has, since April 19, 2018: (i) directly or indirectly used any funds for contributions, gifts, entertainment or other expenses related to foreign or domestic political activity which is unlawful in any material respect, (ii) made any payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds which is unlawful in any material respect, (iii) failed to disclose fully any contribution made by MorphoSys (or made by any person acting on its behalf of which MorphoSys is aware) which is in violation of law in any material respect or (iv) violated in any material respect any provision of the Foreign Corrupt Practices Act of 1977, as amended, or any applicable non-U.S. anti-bribery Law.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">1.13&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Regulation M Compliance</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.&nbsp;&nbsp;MorphoSys has not taken, directly or indirectly, any action designed to or that would reasonably be expected to cause or result in stabilization or manipulation of the price of the New ADSs to facilitate their sale or resale.</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">1.14&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Office of Foreign Assets Control</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.&nbsp;&nbsp;Neither MorphoSys nor, to MorphoSys&#x2019; Knowledge, any director, officer, agent, employee or Affiliate of MorphoSys is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">EXHIBIT 17</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">TRANSITION PLAN&nbsp;&nbsp;DRAFT</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">[***]</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">EXHIBIT 18</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">STATEMENT FOR COMPANY&#x2019;S MEDIA RELEASES AND PUBLICATIONS</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">[***]</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">EXHIBIT 19</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">DISCLOSURE SCHEDULE</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10.5pt;">[***]</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">CONFIDENTIAL</font>

		</p>

		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">EXHIBIT 20</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">ADDITIONAL CAP RE OBLIGATION UNDER SECTION 14.1(B)(II)(3)(Z)</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-size:10.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">[***]</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 14.1pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:avoid;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>incy-20200331xex10d2.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.6.0.116-->
<!--Created on: 5/5/2020 2:06:30 PM-->
<html>
	<head>
		<title>
			incy_Ex_10_2
		</title>
	</head>
	<body><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;line-height:100%;font-family:Calibri;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Exhibit 10.2</font>

		</p>

		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
		<p style="margin:0pt 0pt 12pt;text-align:right;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 12pt;">
			<font style="font-size: 12pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-style:italic;"><font style="display:inline;font-style:italic;;font-size: 12pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-style:italic;;font-size: 12pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-style:italic;;font-size: 12pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-style:italic;;font-size: 12pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-style:italic;;font-size: 12pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>EXECUTION VERSION</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:center;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 12pt;">
			<font style="display:inline;">AMENDMENT NO. 5</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:center;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 12pt;">
			<font style="display:inline;">TO</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:center;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 12pt;">
			<font style="display:inline;">COLLABORATION AND LICENSE AGREEMENT</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">THIS AMENDMENT NO. 5 TO COLLABORATION AND LICENSE AGREEMENT (this &#x201C;</font><font style="display:inline;text-decoration:underline;">Amendment No. 5</font><font style="display:inline;">&#x201D;) is entered into as of the 20th day of March, <a name="_cp_text_1_4"></a>2020 (the &#x201C;</font><font style="display:inline;text-decoration:underline;">Effective Date</font><font style="display:inline;">&#x201D;), by and between Incyte Corporation, a Delaware corporation having an office at 1801 Augustine Cut-Off, Wilmington, Delaware (&#x201C;</font><font style="display:inline;text-decoration:underline;">Incyte</font><font style="display:inline;">&#x201D;), and Novartis International Pharmaceutical AG, a company limited by shares organized under the laws of <a name="_cp_text_1_6"></a>Switzerland having an office at <a name="_cp_text_1_8"></a>Lichtstrasse 35, 4056 Basel, Switzerland (&#x201C;</font><font style="display:inline;text-decoration:underline;">Novartis</font><font style="display:inline;">&#x201D;). &nbsp; </font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">WHEREAS, Incyte and Novartis entered into that certain Collaboration and License Agreement dated as of November 24, 2009 (as amended to date, the &#x201C;</font><font style="display:inline;text-decoration:underline;">Original Agreement</font><font style="display:inline;">&#x201D;);</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">WHEREAS, Incyte and Novartis respectively wish to expand the scope of the Original Agreement to permit the Parties to Develop and Commercialize Non-Fixed Dose JAK Combination Regimens (as such term is defined herein) in the entire world;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">WHEREAS, Incyte and Novartis wish to amend the Original Agreement pursuant to and in accordance with the terms and conditions of this Amendment No. 5.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;line-height:100%;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:0pt;">
			<p style="line-height:100%;text-align:center;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;width:100%">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:normal;font-style:normal;text-transform:none;text-decoration:none;color:#000000;font-size:12pt;text-decoration:none;line-height:100%;text-align:center;display: inline;padding:0pt 1pt 0pt 0pt;">ARTICLE I</font>
			<a name="_Ref237928329"></a><br><font style="display:inline;"><br><br>Definitions</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:normal;font-style:normal;text-transform:none;text-decoration:none;color:#000000;font-size:12pt;text-decoration:none;text-align:justify;text-justify:inter-ideograph;line-height:100%;;;padding:0pt 20pt 0pt 0pt;"> 1.1</font>
			<font style="display:inline;text-decoration:underline;">Definitions</font><font style="display:inline;">.&nbsp;&nbsp;Capitalized terms used in this Amendment No. 5 but not defined herein shall have the meaning ascribed to them in the Original Agreement.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:0pt;">
			<p style="line-height:100%;text-align:center;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;width:100%">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:normal;font-style:normal;text-transform:none;text-decoration:none;color:#000000;font-size:12pt;text-decoration:none;line-height:100%;text-align:center;display: inline;padding:0pt 1pt 0pt 0pt;">ARTICLE II</font>
			<br><font style="display:inline;"><br><br>AMENDMENTS</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:normal;font-style:normal;text-transform:none;text-decoration:none;color:#000000;font-size:12pt;text-decoration:none;line-height:100%;;;padding:0pt 20pt 0pt 0pt;"> 2.1</font>
			<font style="display:inline;text-decoration:underline;">New Definitions</font><font style="display:inline;">.&nbsp; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:-9pt;"><p style="width:-9pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:63pt;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:normal;font-style:normal;text-transform:none;text-decoration:none;color:#000000;font-size:12pt;text-decoration:none;line-height:100%;;;padding:0pt 31pt 0pt 0pt;"> (a)</font>
			<font style="display:inline;color:#000000;">The Original Agreement is hereby amended to insert the following new definition into Article I immediately after Section 1.22:</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:108pt;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:normal;font-style:normal;text-transform:none;text-decoration:none;color:#000000;font-size:12pt;text-decoration:none;line-height:100%;;;padding:0pt 26pt 0pt 0pt;"> (i)</font>
			<font style="display:inline;color:#000000;">1.22A.<font style="display:inline;color:#000000;;font-size: 12pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;color:#000000;;font-size: 12pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>&#x201C;Controlled,&#x201D; solely for the purpose of this Amendment No. 5, means, with respect to any (a) material, document, item of information, method, data or other Know-How or (b) Patent Rights or other Intellectual Property Rights, the possession by a Party or its Affiliates, whether by </font></p></td></tr></table></div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"><div style="width:100%">

		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"><div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td valign="top" align="left" style="width: 100%;"><p style="margin:0pt 0pt 12pt 72pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;;"><font style="display:inline;color:#000000;">ownership or license (other than by licenses granted under this Agreement), of the ability to grant to another entity access, a license and/or a sublicense as provided herein</font><font style="display:inline;font-size:10pt;">&nbsp;</font><font style="display:inline;">without requiring the consent of a Third Party or violating the terms of any agreement or other arrangement with any Third Party</font><font style="display:inline;font-size:10pt;">,</font><font style="display:inline;color:#000000;"> in each case as of the Effective Date, or if any of the same are acquired or created after the Effective Date, at the date it is acquired or created by the relevant Party or its Affiliate.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:-9pt;"><p style="width:-9pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:63pt;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:normal;font-style:normal;text-transform:none;text-decoration:none;color:#000000;font-size:12pt;text-decoration:none;line-height:100%;;;padding:0pt 31pt 0pt 0pt;"> (b)</font>
			<font style="display:inline;color:#000000;">The Original Agreement is hereby amended to insert the following new definitions into Article I immediately after Section 1.43:</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 6pt 36pt;text-indent:72pt;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">1.43A &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;text-decoration:underline;">Incyte Combination Compound</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means a compound, other than a JAK Licensed Compound, Controlled by Incyte or any of its Affiliates in any single country or in any or all countries in the entire world.&#x201D; </font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:-9pt;"><p style="width:-9pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:63pt;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:normal;font-style:normal;text-transform:none;text-decoration:none;color:#000000;font-size:12pt;text-decoration:none;line-height:100%;;;padding:0pt 32pt 0pt 0pt;"> (c)</font>
			<font style="display:inline;color:#000000;">The Original Agreement is hereby amended such that Section 1.61 is deleted and replaced in its entirety with the following new definition:</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 6pt 36pt;text-indent:72pt;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">1.61<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;;font-size: 12pt;font-family:Arial,Helvetica,sans-serif;text-indent:0pt;margin-left:0pt;padding:0pt 57.6pt 0pt 0pt;"></font>&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;text-decoration:underline;">JAK Licensed Product</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means a product or product candidate that contains one or more JAK Licensed Compounds as the active ingredient, including all formulations and dosages of such JAK Licensed Compounds and all processes and delivery systems that incorporate such JAK Licensed Compounds.&nbsp;&nbsp;For the avoidance of doubt, only the JAK Licensed Compound component of a Non-Fixed Dose JAK Combination Regimen or a Combination Product is a JAK Licensed Product.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:-9pt;"><p style="width:-9pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:63pt;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:normal;font-style:normal;text-transform:none;text-decoration:none;color:#000000;font-size:12pt;text-decoration:none;line-height:100%;;;padding:0pt 31pt 0pt 0pt;"> (d)</font>
			<font style="display:inline;color:#000000;">The Original Agreement is hereby amended to insert the following new definition into Article I immediately after Section 1.18:</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 6pt 36pt;text-indent:72pt;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">1.18A<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;;font-size: 12pt;font-family:Arial,Helvetica,sans-serif;text-indent:0pt;margin-left:0pt;padding:0pt 54pt 0pt 0pt;"></font>&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;text-decoration:underline;">Combination Product</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means a product that contains a Licensed Product in combination with one or more active ingredients that is sold in a single fixed-dose finished dosage form. </font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:-9pt;"><p style="width:-9pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:63pt;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:normal;font-style:normal;text-transform:none;text-decoration:none;color:#000000;font-size:12pt;text-decoration:none;line-height:100%;;;padding:0pt 31pt 0pt 0pt;"> (e)</font>
			<font style="display:inline;color:#000000;">Section 1.73(d) of the Original Agreement is hereby deleted in its entirety and replaced with the following:</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 6pt 36pt;text-indent:72pt;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">1.73(d)<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;;font-size: 12pt;font-family:Arial,Helvetica,sans-serif;text-indent:0pt;margin-left:0pt;padding:0pt 46.8pt 0pt 0pt;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;;font-size: 12pt;font-family:Arial,Helvetica,sans-serif;text-indent:0pt;margin-left:0pt;padding:0pt 46.8pt 0pt 0pt;"></font>In the event the Licensed Product is sold as a component of a Combination Product, the Net Sales of the Licensed Product, for the purposes of determining royalty payments, shall be determined by multiplying the Net Sales (as defined above in this Section) of the Combination Product by the fraction, A/(A+B) where A is the weighted (by sales volume) average sale price in a particular country of the Licensed Product in the prior Calendar Year when sold separately in finished form and B is the weighted average sale price in that country in the prior Calendar Year of the other product(s) sold separately in finished form. &nbsp;In the event that such average sale price cannot be determined for both the Licensed Product and the other product(s) in combination, Net Sales for purposes of determining royalty payments shall be agreed by the Parties based on the relative value contributed by each component, such agreement not to be unreasonably withheld.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Calibri;font-size: 10pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">2</font>

		</p>

		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"><div style="width:100%">

		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"><p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:-9pt;"><p style="width:-9pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:63pt;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:normal;font-style:normal;text-transform:none;text-decoration:none;color:#000000;font-size:12pt;text-decoration:none;line-height:100%;;;padding:0pt 34pt 0pt 0pt;"> (f)</font>
			<font style="display:inline;color:#000000;">The Original Agreement is hereby amended to insert the following new definitions into Article I immediately after Section 1.73(d):</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 6pt 36pt;text-indent:72pt;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">1.73(e)<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;;font-size: 12pt;font-family:Arial,Helvetica,sans-serif;text-indent:0pt;margin-left:0pt;padding:0pt 46.8pt 0pt 0pt;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;;font-size: 12pt;font-family:Arial,Helvetica,sans-serif;text-indent:0pt;margin-left:0pt;padding:0pt 46.8pt 0pt 0pt;"></font>In the event the JAK Licensed Product is sold as a Non-Fixed Dose JAK Combination Regimen, wherein the JAK Licensed Product and the Novartis Combination Compound or the Incyte Combination Compound, as applicable, are sold in finished form as two products but at a single unit price, then the Net Sales of the JAK Licensed Product, for the purposes of determining royalty payments, shall be determined consistent with the method described in Section 1.73(d).</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:-9pt;"><p style="width:-9pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:63pt;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:normal;font-style:normal;text-transform:none;text-decoration:none;color:#000000;font-size:12pt;text-decoration:none;line-height:100%;;;padding:0pt 31pt 0pt 0pt;"> (g)</font>
			<font style="display:inline;color:#000000;">The Original Agreement is hereby amended to insert the following new definitions into Article I immediately after Section 1.73:</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 6pt 36pt;text-indent:72pt;border-bottom:1pt none #D9D9D9 ;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">1.73A.<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;;font-size: 12pt;font-family:Arial,Helvetica,sans-serif;text-indent:0pt;margin-left:0pt;padding:0pt 5.4pt 0pt 0pt;"></font>&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;text-decoration:underline;">Non-Fixed Dose JAK Combination Regimen</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means a combination therapy of two or more finished dosage forms (other than a Combination Product) that includes (i) in the case of Incyte, an Incyte Combination Compound (an &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;text-decoration:underline;">Incyte Non-Fixed Dose JAK Combination Regimen</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;) or (ii) in the case of Novartis, a Novartis Combination Compound (a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;text-decoration:underline;">Novartis Non-Fixed Dose JAK Combination Regimen</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;), in each case (a) administered in the protocol for a Clinical Trial in combination with a JAK Licensed Compound or JAK Licensed Product (other than a Combination Product) or (b) indicated for use in combination with a JAK Licensed Compound or JAK Licensed Product (other than a Combination Product). &nbsp; &nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt 36pt;text-indent:72pt;border-top:1pt none #D9D9D9 ;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">1.73B &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;text-decoration:underline;">Novartis Combination Compound</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means a compound, other than a JAK Licensed Compound, Controlled by Novartis or any of its Affiliates in any single country or in any or all countries in the entire world.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:normal;font-style:normal;text-transform:none;text-decoration:none;color:#000000;font-size:12pt;text-decoration:none;line-height:100%;;;padding:0pt 20pt 0pt 0pt;"> 2.2</font>
			<font style="display:inline;text-decoration:underline;">Rights Granted by Incyte to Novartis</font><font style="display:inline;">.&nbsp;&nbsp;The Original Agreement is hereby amended to insert the following new Section 2.1(c) and Section 2.1(d) immediately after Section 2.1(b):</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 6pt 36pt;text-indent:72pt;border-bottom:1pt none #D9D9D9 ;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;2.1(c)&nbsp;&nbsp;&nbsp;Subject to the terms of this Amendment No. 5, Incyte hereby grants Novartis, during the Term, a non-exclusive, non-transferable (except in accordance with Section 14.3), non-sublicensable (except to Affiliates and Subcontractors who are performing Development activities) license, under Incyte IP, to:</font>
		</p>
		<p style="margin:0pt 0pt 6pt 36pt;text-indent:72pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(i) conduct Clinical Trials with Novartis Non-Fixed Dose JAK Combination Regimens in the Incyte Territory and in the Novartis JAK Territory solely for the purposes of:</font>
		</p>
		<p style="margin:0pt 0pt 6pt 72pt;text-indent:72pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(x) using, offering for sale and selling JAK Licensed Products in, and importing JAK Licensed Compounds and JAK Licensed Products into, the Novartis JAK Territory in the JAK Field, and</font>
		</p>
		<p style="margin:0pt 0pt 6pt 72pt;text-indent:72pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(y) Commercializing Novartis Combination Compounds in accordance with its approved label as a component of a Novartis Non-Fixed Dose </font></p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Calibri;font-size: 10pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">3</font>

		</p>

		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"><div style="width:100%">

		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"><p style="margin:0pt 0pt 6pt 72pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">JAK Combination Regimen (i.e. label license) in the Incyte Territory in the JAK Field;</font>
		</p>
		<p style="margin:0pt 0pt 6pt 36pt;text-indent:72pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(ii) Commercialize Novartis Combination Compounds as a component of a Novartis Non-Fixed Dose JAK Combination Regimen (i.e. label license) in the Incyte Territory in the JAK Field wherein the license under this Section 2.1(c)(ii) shall be royalty free under any Valid Claim(s) Covering a treatment for an indication with a Novartis Non-Fixed Dose JAK Combination Regimen (but, for clarity, Novartis shall not Commercialize, sell or book sales of JAK Licensed Compounds, JAK Licensed Products or Combination Products in the Incyte Territory but may market, detail and promote the Novartis Non-Fixed Dose JAK Combination Regimen); and</font>
		</p>
		<p style="margin:0pt 0pt 6pt 36pt;text-indent:72pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(iii) subject to Incyte&#x2019;s election to seek Regulatory Approval of an Incyte Non-Fixed Dose JAK Combination Regimen in the Novartis JAK Territory pursuant to Section 4.8(d) of this Agreement, seek Regulatory Approval of JAK Licensed Product(s) as a component of an Incyte Non-Fixed Dose JAK Combination Regimen (label license) and Commercialize JAK Licensed Product(s) as a component of an Incyte Non-Fixed Dose JAK Combination Regimen (label license) in the Novartis JAK Territory in the JAK Field (but for clarity, Novartis shall not Commercialize an Incyte Combination Compound anywhere in the world).</font>
		</p>
		<p style="margin:0pt 0pt 6pt 36pt;text-indent:72pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">For the avoidance of doubt, Novartis may not, directly or indirectly, conduct Clinical Trials or other clinical studies, including any investigator initiated studies, utilizing JAK Licensed Compounds or JAK Licensed Products (other than Novartis Non-Fixed Dose JAK Combination Regimens) in the Incyte Territory without the prior approval of the JSC.</font>
		</p>
		<p style="margin:0pt 0pt 6pt 36pt;text-indent:72pt;border-top:1pt none #D9D9D9 ;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">2.1(d) Notwithstanding anything set forth in this Amendment or the Agreement, the license rights granted by Incyte to Novartis do not include any claims to any compound that is not a JAK2 Inhibitor Compound or a c-MET Inhibitor Compound.&nbsp; By way of example, in the event that a Combination Product is approved by a Regulatory Authority that includes a JAK Licensed Compound and an Incyte Combination Compound, nothing herein shall be deemed to give Novartis the right to research, Develop or Commercialize such Combination Product anywhere in the world; any such right would be the subject of an additional agreement between the Parties.&#x201D;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:normal;font-style:normal;text-transform:none;text-decoration:none;color:#000000;font-size:12pt;text-decoration:none;line-height:100%;;;padding:0pt 20pt 0pt 0pt;"> 2.3</font>
			<font style="display:inline;text-decoration:underline;">Rights Granted by Novartis to Incyte</font><font style="display:inline;">.&nbsp;&nbsp;The Original Agreement is hereby amended to insert the following new Section 2.2(c) and Section 2.2(d) immediately after Section 2.2(b):</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 6pt 36pt;text-indent:72pt;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;2.2(c)&nbsp;&nbsp;&nbsp;Subject to the terms of this Amendment No. 5, Novartis hereby grants Incyte, during the Term, a non-exclusive, non-transferable (except in accordance with Section 14.3), non-sublicensable (except to Affiliates and Subcontractors who are performing Development activities)&nbsp;license, under Novartis IP, to:</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Calibri;font-size: 10pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">4</font>

		</p>

		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"><div style="width:100%">

		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"><p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 6pt 36pt;text-indent:72pt;border-bottom:1pt none #D9D9D9 ;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(i) &nbsp;conduct Clinical Trials with Incyte Non-Fixed Dose JAK Combination Regimens in the Novartis JAK Territory and in the Incyte Territory solely for the purposes of:</font>
		</p>
		<p style="margin:0pt 0pt 6pt 72pt;text-indent:72pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(x) using, offering for sale and selling JAK Licensed Products in, and importing JAK Licensed Compounds and JAK Licensed Products into, the Incyte Territory in the JAK Field, and</font>
		</p>
		<p style="margin:0pt 0pt 6pt 72pt;text-indent:72pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(y) Commercializing Incyte Combination Compounds in accordance with its approved label as a component of an Incyte Non-Fixed Dose JAK Combination Regimen (i.e. label license) in the Novartis JAK Territory in the JAK Field;</font>
		</p>
		<p style="margin:0pt 0pt 6pt 36pt;text-indent:72pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(ii) Commercialize Incyte Combination Compounds as a component of an Incyte Non-Fixed Dose JAK Combination Regimen (i.e. label license) in the Novartis JAK Territory in the JAK Field </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;text-decoration:underline;">wherein the license under this Section 2.2(c)(ii) shall be royalty free under any Valid Claim(s) Covering a treatment for an indication with an Incyte Non-Fixed Dose JAK Combination Regimen</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;"> (but, for clarity, Incyte shall not Commercialize, sell or book sales of JAK Licensed Compounds, JAK Licensed Products, or Combination Products in the Novartis JAK Territory but may market, detail and promote the Incyte Non-Fixed Dose JAK Combination Regimen); and</font>
		</p>
		<p style="margin:0pt 0pt 6pt 36pt;text-indent:72pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(iii) subject to Novartis&#x2019; election to seek Regulatory Approval of a Novartis Non-Fixed Dose JAK Combination Regimen in the Incyte Territory pursuant to Section 4.8(d) of this Agreement, seek Regulatory Approval of JAK Licensed Products(s) as a component of a Novartis Non-Fixed Dose JAK Combination Regimen (label license) and Commercialize JAK Licensed Products as a component of a Novartis Non-Fixed Dose JAK Combination Regimen (label license) in the Incyte Territory in the JAK Field (but for clarity, Incyte shall not Commercialize a Novartis Combination Compound anywhere in the world).</font>
		</p>
		<p style="margin:0pt 0pt 6pt 36pt;text-indent:72pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">For the avoidance of doubt, Incyte may not, directly or indirectly, conduct Clinical Trials or other clinical studies, including any investigator initiated studies, utilizing JAK Licensed Compounds or JAK Licensed Products (other than Incyte Non-Fixed Dose JAK Combination Regimens) in the Novartis JAK Territory without the prior approval of the JSC.</font>
		</p>
		<p style="margin:0pt 0pt 6pt 36pt;text-indent:72pt;border-top:1pt none #D9D9D9 ;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">2.2(d)&nbsp;&nbsp;Notwithstanding anything set forth in this Amendment or the Agreement, the license rights granted by Novartis to Incyte do not include any claims to any compound that is not a JAK2 Inhibitor Compound.&nbsp; By way of example, in the event that a Combination Product is approved by a Regulatory Authority that includes a JAK Licensed Compound and a Novartis Combination Compound, nothing herein shall be deemed to give Incyte the right to research, Develop or Commercialize such Combination Product anywhere in the world; any such right would be the subject of an additional agreement between the Parties.&#x201D;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Calibri;font-size: 10pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">5</font>

		</p>

		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"><div style="width:100%">

		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"><p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:normal;font-style:normal;text-transform:none;text-decoration:none;color:#000000;font-size:12pt;text-decoration:none;line-height:100%;;;padding:0pt 20pt 0pt 0pt;"> 2.4</font>
			<font style="display:inline;text-decoration:underline;">Joint Program Team</font><font style="display:inline;">.&nbsp;&nbsp;The Original Agreement is hereby amended to add the following provision after Section 3.2(c)(ii):</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 6pt 36pt;text-indent:72pt;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;(iii) The JPT shall have responsibility for reviewing (A) high level safety data (e.g., of the type of detail set forth in an investigator&#x2019;s brochure) of the relevant Combination Compound and a high-level overview of proposed Clinical Trials (e.g., protocol synopsis) for any Non-Fixed Dose JAK Combination Regimen and (B) the key safety data of any ongoing Clinical Trial for any Non-Fixed Dose JAK Combination Regimen, such data to be provided as is relevant and would (1) reasonably be expected to be required by a relevant Regulatory Authority, (2) be shared between the Parties pursuant to the Pharmacovigilance Agreement, or (3) be set forth in an investigator&#x2019;s brochure.&#x201D;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:normal;font-style:normal;text-transform:none;text-decoration:none;color:#000000;font-size:12pt;text-decoration:none;line-height:100%;;;padding:0pt 20pt 0pt 0pt;"> 2.5</font>
			<font style="display:inline;text-decoration:underline;">Joint Commercialization Committee</font><font style="display:inline;">.&nbsp;&nbsp;The Original Agreement is hereby amended to add the following provisions after Section 3.2(d)(ii):</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 6pt 36pt;text-indent:72pt;border-bottom:1pt none #D9D9D9 ;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;(iii) Notwithstanding the provisions of this Section 3.2(d), if a Party has exercised its buy-in rights with respect to a Clinical Trial or Development activity under Section 4.3(c) of the Agreement or if a relevant Regulatory Authority has required a Party to amend its approved label to add a Combination Compound and, as a result, both Parties are promoting the same Non-Fixed Dose JAK Combination Regimen in the same country, the JCC shall have oversight in relation to a given (a) Novartis Non-Fixed Dose JAK Combination Regimen in the Incyte Territory, if Incyte has amended the approved label of a JAK Licensed Product in the Incyte Territory to include such Novartis Non-Fixed Dose JAK Combination Regimen or (B) Incyte</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Non-Fixed Dose JAK Combination Regimen</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">in the Novartis JAK Territory, if Novartis has amended the approved label of a JAK Licensed Product in the Novartis JAK Territory to include such Incyte Non-Fixed Dose JAK Combination Regimen.</font>
		</p>
		<p style="margin:0pt 0pt 6pt 36pt;text-indent:72pt;border-top:1pt none #D9D9D9 ;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(iv) Incyte shall not have final decision-making authority in relation to a Novartis Combination Compound in the Incyte Territory and Novartis shall not have final decision-making authority in relation to an Incyte Combination Compound in the Novartis Territory.&#x201D;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:normal;font-style:normal;text-transform:none;text-decoration:none;color:#000000;font-size:12pt;text-decoration:none;line-height:100%;;;padding:0pt 20pt 0pt 0pt;"> 2.6</font>
			<font style="display:inline;text-decoration:underline;">Development Activities of Non-Fixed Dose JAK Combination Regimen</font><font style="display:inline;">.&nbsp; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:-9pt;"><p style="width:-9pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:63pt;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:normal;font-style:normal;text-transform:none;text-decoration:none;color:#000000;font-size:12pt;text-decoration:none;line-height:100%;;;padding:0pt 31pt 0pt 0pt;"> (a)</font>
			<font style="display:inline;color:#000000;">The Original Agreement is hereby amended to add the following provision after Section 4.7:</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 6pt 36pt;text-indent:72pt;border-bottom:1pt none #D9D9D9 ;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;4.8 </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;text-decoration:underline;">Development Activities of Non-Fixed Dose JAK Combination Regimen.</font>
		</p>
		<p style="margin:0pt 0pt 6pt 36pt;text-indent:72pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(a) Notwithstanding anything to the contrary in the Original Agreement or Amendment No. 5, the Parties agree that (i) no more than 600 patients at any given time shall be enrolled in Clinical Trials of a Novartis Non-Fixed Dose JAK Combination Regimen in the Incyte Territory conducted or sponsored by Novartis and (ii) no more than 600 patients at any given time shall be enrolled in Clinical Trials of an Incyte Non-Fixed </font></p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Calibri;font-size: 10pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">6</font>

		</p>

		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"><div style="width:100%">

		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"><p style="margin:0pt 0pt 6pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Dose JAK Combination Regimen in the Novartis JAK Territory conducted or sponsored by Incyte, in each case, determined by reference to such Party&#x2019;s then current enrollment plan.</font>
		</p>
		<p style="margin:0pt 0pt 6pt 36pt;text-indent:72pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(b) Clinical Trials of a Non-Fixed Dose JAK Combination Regimen conducted (i) by Incyte in the Novartis JAK Territory or (ii) by Novartis in the Incyte Territory shall, in each case, only incorporate a JAK Licensed Product to the extent in the then-approved dosage range.&nbsp; </font>
		</p>
		<p style="margin:0pt 0pt 6pt 36pt;text-indent:72pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;(c)&nbsp;If a Party, having considered the safety information provided in Section 3.2(c)(iii) and (a) the Clinical Trial design for a Non-Fixed Dose JAK Combination Regimen or (b) data from an on-going Clinical Trial of a Non-Fixed Dose JAK Combination Regimen, reasonably believes that starting or continuing a Clinical Trial or clinical study of such Non-Fixed Dose JAK Combination Regimen is reasonably likely to have a material safety impact (such Party, the &#x201C;Concerned Party&#x201D;), then such Concerned Party shall present such concerns to the JPT in accordance with the provisions of Section 3.2(c)(iii) and the other Party shall consider such belief in good faith in determining how to proceed with further Development of such Non-Fixed Dose JAK Combination Regimen. &nbsp; &nbsp;The Parties agree that to the extent that (a) the protocol reviews by an applicable external institutional review board prior to initiation of a Clinical Trial, (b) the data review by an applicable independent data safety monitoring board after initiation of Clinical Trial, or (c) the FDA or equivalent Regulatory Authority, in each case, have identified and addressed the potential safety concerns or not raised any other objection, then the non-Concerned Party will have the right to initiate or continue a Clinical Trial (as the case may be) of a Non-Fixed Dose JAK Combination Regimen in the Concerned Party&#x2019;s Territory.&#x201D;</font>
		</p>
		<p style="margin:0pt 0pt 6pt 36pt;text-indent:72pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(d) (i) If Novartis seeks regulatory approval of a Novartis Combination Compound as a component of a Novartis Non-Fixed Dose JAK Combination Regimen in the Incyte Territory, Incyte shall have the right to seek regulatory approval of a JAK Licensed Product as a component of such Novartis Non-Fixed Dose JAK Combination Regimen in the Incyte Territory.&nbsp;&nbsp;(ii) If Incyte seeks regulatory approval of an Incyte Combination Compound as a component of an Incyte Non-Fixed Dose JAK Combination Regimen in the Novartis JAK Territory, Novartis shall have the right to seek regulatory approval of a JAK Licensed Product as a component of such Incyte Non-Fixed Dose JAK Combination Regimen in the Novartis JAK Territory.&nbsp; (iii) In each case of (i) and (ii), the Party that did not conduct the Clinical Trials or clinical studies of such Non-Fixed Dose JAK Combination Regimen (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;text-decoration:underline;">Non-Conducting Party</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;) and is seeking regulatory approval of a JAK Licensed Product as a component of such conducting Party&#x2019;s (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;text-decoration:underline;">Conducting Party</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;) Non-Fixed Dose JAK Combination Regimen in the Non-Conducting Party&#x2019;s Territory shall follow the provisions of Section 4.3(c) of the Original Agreement as if such Non-Conducting Party were a &#x201C;Buy-In Party,&#x201D; as defined therein, with all rights and responsibilities as set forth therein, including the obligation to make the payment set forth in such provision. &nbsp;A Conducting Party will only be required to share with the Non-Conducting Party the minimum level of data necessary to support a Regulatory Approval </font></p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Calibri;font-size: 10pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">7</font>

		</p>

		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"><div style="width:100%">

		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"><p style="margin:0pt 0pt 6pt 36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">on a country-by-country basis, as determined by the applicable Regulatory Authority and all safety information to comply with Regulatory Authorities and in accordance with the Pharmacovigilance Agreement.&nbsp; (iv) Notwithstanding item (iii), in the event that a Regulatory Authority requires that a Non-Conducting Party either (a) submit to the JAK Licensed Product NDA, or (b) include in the label for a JAK Licensed Product, in each case of (a) and (b), data from a Conducting Party&#x2019;s Clinical Trial or clinical study conducted pursuant to the rights granted under this Amendment No. 5, the Conducting Party hereby agrees to provide such data to the Non-Conducting Party and to allow the limited use of such data solely for such purpose without the requirement to make a payment to become a Buy-In Party; for clarity, in such event, the Non-Conducting Party may not use any such data for any other purpose unless it makes the payments as set forth in item (iii)&nbsp;&nbsp;For the avoidance of doubt, the Parties agree that any such data shared pursuant to this Section 4.8 is &#x201C;Confidential Information&#x201D; and the Parties agree that such Confidential Information will be used by the Receiving Party solely to exercise its rights as a &#x201C;Buy In Party&#x201D; or as set forth in item (iv) in this Section 4.8(d) and for no other purpose.</font>
		</p>
		<p style="margin:0pt 0pt 6pt 36pt;text-indent:72pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(e) Without the prior written consent of Incyte, Novartis will not conduct a Clinical Trial or clinical study in the Incyte Territory that evaluates a monotherapy arm of the JAK Licensed Product versus a monotherapy arm of a Novartis Combination Compound.&nbsp;&nbsp;Without the prior written consent of Novartis, Incyte will not conduct a Clinical Trial or clinical study in the Novartis Territory that evaluates a monotherapy arm of the JAK Licensed Product versus a monotherapy arm of an Incyte Combination Compound.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:72pt;border-top:1pt none #D9D9D9 ;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(f) For clarity, each Party has the right to pursue any mechanism of action for the Incyte Combination Compound and Novartis Combination Compound, as applicable, subject to such Incyte Combination Compound and Novartis Combination Compound, and actions by the Parties in connection therewith, being otherwise compliant with the terms of this Amendment No. 5 and the Agreement.&nbsp;&nbsp;For clarity, Section 2.6 of the agreement shall remain in full force and effect.&#x201D;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:normal;font-style:normal;text-transform:none;text-decoration:none;color:#000000;font-size:12pt;text-decoration:none;line-height:100%;;;padding:0pt 20pt 0pt 0pt;"> 2.7</font>
			<font style="display:inline;text-decoration:underline;">Clinical Supply of JAK Licensed Compounds for Non-Fixed Dose JAK Combination Regimens</font><font style="display:inline;">.&nbsp; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:-9pt;"><p style="width:-9pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:63pt;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:normal;font-style:normal;text-transform:none;text-decoration:none;color:#000000;font-size:12pt;text-decoration:none;line-height:100%;;;padding:0pt 31pt 0pt 0pt;"> (a)</font>
			<font style="display:inline;color:#000000;">The Original Agreement is hereby amended to add the following provision after Section 5.1(b):</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 6pt 36pt;text-indent:36pt;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;5.1(c) </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;text-decoration:underline;">Clinical Supply of JAK Licensed Product for Non-Fixed Dose JAK Combination Regimens.</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;"> &nbsp; &nbsp;Incyte agrees that it will acquire from Novartis or a Novartis distributor or sublicensee in the Novartis Territory commercial supply of JAK Licensed Product for use in Clinical Trials of Incyte Non-Fixed Dose JAK Combination Regimens in the Novartis Territory permitted pursuant to this Amendment No. 5, and Novartis agrees that it will acquire from Incyte or an Incyte distributor or sublicensee in the Incyte Territory commercial supply of JAK Licensed Product for use in Clinical Trials of Novartis Non-</font></p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Calibri;font-size: 10pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">8</font>

		</p>

		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"><div style="width:100%">

		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"><p style="margin:0pt 0pt 6pt 36pt;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Fixed Dose JAK Combination Regimens in the Incyte Territory permitted pursuant to this Amendment No. 5, in each case, on arm&#x2019;s length terms. &nbsp; &nbsp;In the event that Novartis or Incyte cannot acquire commercial supply for use in a particular Clinical Trial in accordance with the foregoing sentence, then the Party not conducting the Clinical Trial shall provide the other Party supply of JAK Licensed Product for such Clinical Trial at a price equal to that charged by the non-Conducting Party&#x2019;s distributors or sublicensees in the country in which the Clinical Trial is being conducted pursuant to the terms of a clinical supply agreement to be agreed between the Parties.&#x201D;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:normal;font-style:normal;text-transform:none;text-decoration:none;color:#000000;font-size:12pt;text-decoration:none;border-bottom:1pt none #D9D9D9;line-height:100%;;;padding:0pt 20pt 0pt 0pt;"> 2.8</font>
			<font style="display:inline;text-decoration:underline;">Non-Application of Certain Provisions</font><font style="display:inline;color:#000000;">.&nbsp; Notwithstanding anything to the contrary herein or in the Original Agreement, the Parties agree that the provisions of 3.2(b) (</font><font style="display:inline;font-style:italic;">Joint JAK Development Committee</font><font style="display:inline;color:#000000;">), 3.2(e) (</font><font style="display:inline;font-style:italic;">Joint Intellectual Property Committee</font><font style="display:inline;color:#000000;">), Section 3.3(b) (</font><font style="display:inline;font-style:italic;">Final Decision-Making</font><font style="display:inline;color:#000000;">), Section 4.2 (</font><font style="display:inline;font-style:italic;">Conduct of Development Activities</font><font style="display:inline;color:#000000;">), Section 4.3 (</font><font style="display:inline;font-style:italic;">Development Activity Proposals</font><font style="display:inline;color:#000000;">), Section 4.6 (</font><font style="display:inline;font-style:italic;">Development Reports</font><font style="display:inline;color:#000000;">), Section 6.1 (</font><font style="display:inline;font-style:italic;">Commercialization Diligence</font><font style="display:inline;color:#000000;">) and Section 6.5(a) (</font><font style="display:inline;font-style:italic;">Global Branding Strategy</font><font style="display:inline;color:#000000;">), and Article VII (</font><font style="display:inline;font-style:italic;">Intellectual Property Ownership, Protection and Related Matters</font><font style="display:inline;color:#000000;">) of the Original Agreement shall not apply to Non-Fixed Dose JAK Combination Regimens.<a name="_cp_text_1_17"></a></font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:normal;font-style:normal;text-transform:none;text-decoration:none;color:#000000;font-size:12pt;text-decoration:none;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;line-height:100%;;;padding:0pt 20pt 0pt 0pt;"> 2.9</font>
			<a name="_cp_blt_1_18"></a><a name="_cp_text_1_19"></a><font style="display:inline;text-decoration:underline;">Novartis Notice Address</font><font style="display:inline;">. Section 14.6 of the Original Agreement is hereby deleted in its entirety and replaced with the following:</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<a name="_cp_text_1_20"></a><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Notices to Novartis shall be addressed to: </font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:100%;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<a name="_cp_text_1_21"></a><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Novartis International Pharmaceutical AG</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Lichtstrasse 35</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">4056 Basel</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Switzerland</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Attention: Board of Directors</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">With copy to:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Novartis Pharma AG</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">P.O. Box</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">CH-4002 Basel</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Switzerland</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Attention: &nbsp;Head, Legal Department</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;Head of M&amp;A and BD&amp;L</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:100%;border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:0pt;">
			<p style="line-height:100%;text-align:center;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;width:100%">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:normal;font-style:normal;text-transform:none;text-decoration:none;color:#000000;font-size:12pt;text-decoration:none;line-height:100%;text-align:center;display: inline;padding:0pt 1pt 0pt 0pt;">ARTICLE III</font>
			<br><font style="display:inline;"><br><br>miscellaneous</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:normal;font-style:normal;text-transform:none;text-decoration:none;color:#000000;font-size:12pt;text-decoration:none;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9;line-height:100%;;;padding:0pt 20pt 0pt 0pt;"> 3.1</font>
			<font style="display:inline;text-decoration:underline;">Term of Amendment No. 5</font><font style="display:inline;">.&nbsp;&nbsp;This Amendment No. 5 shall continue in effect until the fifth anniversary of the Effective Date (the &#x201C;Amendment No. 5 Term&#x201D;), unless the Parties mutually agree in writing to extend the Amendment No. 5 Term prior to such date, at each Party&#x2019;s sole discretion.&nbsp; If the Parties fail to reach agreement to extend the term of this Amendment No. 5 </font></p></td></tr></table></div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Calibri;font-size: 10pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">9</font>

		</p>

		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"><div style="width:100%">

		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"><div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td valign="top" align="left" style="width: 100%;"><p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;;"><font style="display:inline;">by such time, (a) the terms of the Original Agreement and this Amendment No. 5 shall continue with respect to any Non-Fixed Dose JAK Combination Regimen for which FPFV has occurred, notwithstanding the Term and (b) the terms of the Original Agreement, as amended by amendments prior and subsequent to this Amendment No. 5 shall continue in effect, but the provisions of this Amendment No. 5 shall terminate, for any Non-Fixed Dose JAK Combination Regimen for which FPFV has not occurred. &nbsp; &nbsp;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:normal;font-style:normal;text-transform:none;text-decoration:none;color:#000000;font-size:12pt;text-decoration:none;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;line-height:100%;;;padding:0pt 20pt 0pt 0pt;"> 3.2</font>
			<font style="display:inline;text-decoration:underline;">Effect on Original Agreement</font><font style="display:inline;">.&nbsp;&nbsp;Except to the extent amended pursuant to this Amendment No. 5, the Original Agreement shall continue in full force and effect in accordance with its terms.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:36pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:normal;font-style:normal;text-transform:none;text-decoration:none;color:#000000;font-size:12pt;text-decoration:none;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;line-height:100%;;;padding:0pt 20pt 0pt 0pt;"> 3.3</font>
			<font style="display:inline;text-decoration:underline;">Miscellaneous Provisions</font><font style="display:inline;">.&nbsp;&nbsp;The following provisions of the Original Agreement shall apply to this Amendment No. 5 as if set forth herein in full:&nbsp;&nbsp; </font><font style="display:inline;text-decoration:underline;">Section 14.1</font><font style="display:inline;"> (Governing Law); </font><font style="display:inline;text-decoration:underline;">Section 14.2</font><font style="display:inline;"> (Consent to Jurisdiction); </font><font style="display:inline;text-decoration:underline;">Section 14.6</font><font style="display:inline;"> (Notices); </font><font style="display:inline;text-decoration:underline;">Section 14.11</font><font style="display:inline;"> (Headings); </font><font style="display:inline;text-decoration:underline;">Section 14.12</font><font style="display:inline;"> (No Implied Waivers; Rights Cumulative); </font><font style="display:inline;text-decoration:underline;">Section 14.13</font><font style="display:inline;"> (Severability); </font><font style="display:inline;text-decoration:underline;">Section 14.14</font><font style="display:inline;"> (Execution in Counterparts).</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 6pt;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">[THE REMAINDER OF THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK]<a name="_cp_text_2_32"></a><a name="_cp_text_1_34"></a></font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;font-family:Calibri;font-size: 11pt;">
			&nbsp;</p>

</div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">

<p style="margin:0pt 0pt 8pt;line-height:100%;font-family:Calibri;font-size: 11pt;">
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;font-family:Calibri;font-size: 11pt;">
			&nbsp;
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Calibri;font-size: 10pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">10</font>

		</p>

		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;line-height:100%;font-family:Calibri;font-size: 11pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">Exhibit 10.2</font>

		</p>

</div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"><p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">IN WITNESS WHEREOF, the Parties have caused their duly authorized officers to execute and acknowledge this Amendment No. 5 as of the date first written above.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:239.75pt;padding:0pt 6.9pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 12pt;">
						<a name="_Hlk246819951"></a><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">NOVARTIS INTERNATIONAL PHARMACEUTICAL AG</font></p>
				</td>
				<td valign="top" style="width:239.75pt;padding:0pt 6.9pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">INCYTE CORPORATION</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:239.75pt;height:58.50pt;padding:0pt 6.9pt;">
					<p style="margin:0pt;line-height:110%;text-align:left;border-bottom:1pt none #D9D9D9 ;text-decoration:none;font-family:Times New Roman,Times,serif;overflow: hidden;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt;line-height:110%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-decoration:none;font-family:Times New Roman,Times,serif;overflow: hidden;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt;line-height:110%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width: 90.00%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">By:&nbsp;&nbsp;_______________________________</font></p>
					<p style="margin:0pt;line-height:110%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-decoration:none;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;text-decoration:none;">Name:</font></p>
					<p style="margin:0pt;line-height:110%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-decoration:none;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;text-decoration:none;">Title:</font></p>
				</td>
				<td valign="top" style="width:239.75pt;height:58.50pt;padding:0pt 6.9pt;">
					<p style="margin:0pt;line-height:110%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-decoration:none;font-family:Times New Roman,Times,serif;overflow: hidden;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt;line-height:110%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-decoration:none;font-family:Times New Roman,Times,serif;overflow: hidden;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt;line-height:110%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width: 90.00%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">By:&nbsp;&nbsp;_______________________________</font></p>
					<p style="margin:0pt;line-height:110%;text-align:left;border-top:1pt none #D9D9D9 ;text-decoration:none;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;text-decoration:none;">Name:</font></p>
					<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Title:</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:12pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 50.00%;">
			<tr>
				<td valign="top" style="width:239.75pt;padding:0pt 6.9pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">NOVARTIS INTERNATIONAL PHARMACEUTICAL AG</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:239.75pt;height:58.50pt;padding:0pt 6.9pt;">
					<p style="margin:0pt;line-height:110%;text-align:left;border-bottom:1pt none #D9D9D9 ;text-decoration:none;font-family:Times New Roman,Times,serif;overflow: hidden;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt;line-height:110%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-decoration:none;font-family:Times New Roman,Times,serif;overflow: hidden;">
						<font style="display:inline;">&nbsp;</font></p>
					<p style="margin:0pt;line-height:110%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width: 90.00%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">By:&nbsp;&nbsp;_______________________________</font></p>
					<p style="margin:0pt;line-height:110%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-decoration:none;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;text-decoration:none;">Name:</font></p>
					<p style="margin:0pt;line-height:110%;text-align:left;border-top:1pt none #D9D9D9 ;text-decoration:none;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;text-decoration:none;">Title:</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 6pt 36pt;border-bottom:1pt none #D9D9D9 ;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;border-top:1pt none #D9D9D9 ;line-height:110%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt -22.5pt 8pt -18pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SIGNATURE PAGE TO AMENDMENT NO. 5 TO COLLABORATION AND LICENSE AGREEMENT</font>
		</p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 11pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;page-break-after:avoid;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>incy-20200331xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.6.0.116-->
<!--Created on: 5/5/2020 2:06:31 PM-->
<html>
	<head>
		<title>
			incy_Ex_31_1
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Exhibit&nbsp;31.1</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">CERTIFICATION</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">I, Herv&#xE9; Hoppenot, certify that:</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman,Times,serif;font-size:10pt;line-height:100%;;"> 1.</font>
			</p>
		</td><td style="width:10pt;"><p style="width:10pt;width:10pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">I have reviewed this quarterly report on Form&nbsp;10-Q of Incyte Corporation;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 28.8pt;text-indent: -28.8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman,Times,serif;font-size:10pt;line-height:100%;;"> 2.</font>
			</p>
		</td><td style="width:10pt;"><p style="width:10pt;width:10pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 28.8pt;text-indent: -28.8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman,Times,serif;font-size:10pt;line-height:100%;;"> 3.</font>
			</p>
		</td><td style="width:10pt;"><p style="width:10pt;width:10pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 28.8pt;text-indent: -28.8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman,Times,serif;font-size:10pt;line-height:100%;;"> 4.</font>
			</p>
		</td><td style="width:10pt;"><p style="width:10pt;width:10pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">The registrant&#x2019;s other certifying officer(s)&nbsp;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f)&nbsp;and 15d-15(f)) for the registrant and have:</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:28pt;"><p style="width:28pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman,Times,serif;font-size:10pt;line-height:100%;;"> a)</font>
			</p>
		</td><td style="width:10pt;"><p style="width:10pt;width:10pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 57.6pt;text-indent: -28.8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:28pt;"><p style="width:28pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman,Times,serif;font-size:10pt;line-height:100%;;"> b)</font>
			</p>
		</td><td style="width:10pt;"><p style="width:10pt;width:10pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 57.6pt;text-indent: -28.8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:28pt;"><p style="width:28pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman,Times,serif;font-size:10pt;line-height:100%;;"> c)</font>
			</p>
		</td><td style="width:10pt;"><p style="width:10pt;width:10pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 57.6pt;text-indent: -28.8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:28pt;"><p style="width:28pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman,Times,serif;font-size:10pt;line-height:100%;;"> d)</font>
			</p>
		</td><td style="width:10pt;"><p style="width:10pt;width:10pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter&nbsp;(the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman,Times,serif;font-size:10pt;line-height:100%;;"> 5.</font>
			</p>
		</td><td style="width:10pt;"><p style="width:10pt;width:10pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">The registrant&#x2019;s other certifying officer(s)&nbsp;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:28pt;"><p style="width:28pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman,Times,serif;font-size:10pt;line-height:100%;;"> a)</font>
			</p>
		</td><td style="width:10pt;"><p style="width:10pt;width:10pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 57.6pt;text-indent: -28.8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:28pt;"><p style="width:28pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman,Times,serif;font-size:10pt;line-height:100%;;"> b)</font>
			</p>
		</td><td style="width:10pt;"><p style="width:10pt;width:10pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Date: May&nbsp;5, 2020</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;border-bottom:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">/s/ HERV&#xC9; HOPPENOT</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Herv&#xE9; Hoppenot</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Chief Executive Officer</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:avoid;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>incy-20200331xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.6.0.116-->
<!--Created on: 5/5/2020 2:06:32 PM-->
<html>
	<head>
		<title>
			incy_Ex_31_2
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Exhibit&nbsp;31.2</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">CERTIFICATION</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">I, Christiana Stamoulis, certify that:</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman,Times,serif;line-height:100%;font-size:10pt;;"> 1.</font>
			</p>
		</td><td style="width:10pt;"><p style="width:10pt;width:10pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">I have reviewed this quarterly report on Form&nbsp;10-Q of Incyte Corporation;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 28.8pt;text-indent: -28.8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman,Times,serif;line-height:100%;font-size:10pt;;"> 2.</font>
			</p>
		</td><td style="width:10pt;"><p style="width:10pt;width:10pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 28.8pt;text-indent: -28.8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman,Times,serif;line-height:100%;font-size:10pt;;"> 3.</font>
			</p>
		</td><td style="width:10pt;"><p style="width:10pt;width:10pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 28.8pt;text-indent: -28.8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman,Times,serif;line-height:100%;font-size:10pt;;"> 4.</font>
			</p>
		</td><td style="width:10pt;"><p style="width:10pt;width:10pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">The registrant&#x2019;s other certifying officer(s)&nbsp;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f)&nbsp;and 15d-15(f)) for the registrant and have:</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:28pt;"><p style="width:28pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman,Times,serif;line-height:100%;font-size:10pt;;"> a)</font>
			</p>
		</td><td style="width:10pt;"><p style="width:10pt;width:10pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 57.6pt;text-indent: -28.8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:28pt;"><p style="width:28pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman,Times,serif;line-height:100%;font-size:10pt;;"> b)</font>
			</p>
		</td><td style="width:10pt;"><p style="width:10pt;width:10pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 57.6pt;text-indent: -28.8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:28pt;"><p style="width:28pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman,Times,serif;line-height:100%;font-size:10pt;;"> c)</font>
			</p>
		</td><td style="width:10pt;"><p style="width:10pt;width:10pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 57.6pt;text-indent: -28.8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:28pt;"><p style="width:28pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman,Times,serif;line-height:100%;font-size:10pt;;"> d)</font>
			</p>
		</td><td style="width:10pt;"><p style="width:10pt;width:10pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman,Times,serif;line-height:100%;font-size:10pt;;"> 5.</font>
			</p>
		</td><td style="width:10pt;"><p style="width:10pt;width:10pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">The registrant&#x2019;s other certifying officer(s)&nbsp;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 57.6pt;text-indent: -28.8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:28pt;"><p style="width:28pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman,Times,serif;line-height:100%;font-size:10pt;;"> a)</font>
			</p>
		</td><td style="width:10pt;"><p style="width:10pt;width:10pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 57.6pt;text-indent: -28.8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:28pt;"><p style="width:28pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman,Times,serif;line-height:100%;font-size:10pt;;"> b)</font>
			</p>
		</td><td style="width:10pt;"><p style="width:10pt;width:10pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Date:&nbsp;May&nbsp;5, 2020</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;border-bottom:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">/s/ CHRISTIANA STAMOULIS</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Christiana Stamoulis</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Chief Financial Officer</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:avoid;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>incy-20200331xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.6.0.116-->
<!--Created on: 5/5/2020 2:06:33 PM-->
<html>
	<head>
		<title>
			incy_Ex_32_1
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Exhibit&nbsp;32.1</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">STATEMENT PURSUANT TO</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">18 U.S.C. SECTION&nbsp;1350</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">With reference to the Quarterly Report of Incyte Corporation (the &#x201C;Company&#x201D;) on Form&nbsp;10-Q for the quarter ended March&nbsp;31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#x201C;Report&#x201D;),&nbsp;I, Herv&#xE9; Hoppenot, Chief Executive Officer of the Company, certify, for the purposes of 18 U.S.C. &#xA7; 1350, as adopted pursuant to &#xA7; 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">(1)&nbsp;&nbsp; the Report fully complies with the requirements of section 13(a)&nbsp;or 15(d)&nbsp;of the Securities Exchange Act of 1934; and</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">(2)&nbsp;&nbsp; the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">3</font></p>
				</td>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;border-bottom:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">/s/ HERV&#xC9; HOPPENOT</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Herv&#xE9; Hoppenot</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Chief Executive Officer</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">May&nbsp;5, 2020</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:avoid;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>incy-20200331xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.6.0.116-->
<!--Created on: 5/5/2020 2:06:34 PM-->
<html>
	<head>
		<title>
			incy_Ex_32_2
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Exhibit&nbsp;32.2</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">STATEMENT PURSUANT TO</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">18 U.S.C. SECTION&nbsp;1350</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">With reference to the Quarterly Report of Incyte Corporation (the &#x201C;Company&#x201D;) on Form&nbsp;10-Q for the quarter ended March 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#x201C;Report&#x201D;),&nbsp;I, Christiana Stamoulis, Chief Financial Officer of the Company, certify, for the purposes of 18 U.S.C. &#xA7; 1350, as adopted pursuant to &#xA7; 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">(1)&nbsp;&nbsp; the Report fully complies with the requirements of section 13(a)&nbsp;or 15(d)&nbsp;of the Securities Exchange Act of 1934; and</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">(2)&nbsp;&nbsp; the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;border-bottom:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">/s/ CHRISTIANA STAMOULIS</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Christiana Stamoulis</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Chief Financial Officer</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">May&nbsp;5, 2020</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:avoid;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>incy-20200505.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7401.38943 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/5/2020 8:06:59 PM-->
<!--Modified on: 5/5/2020 8:06:59 PM-->
<xsd:schema xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:attributeFormDefault="unqualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:incy="http://www.incyte.com/20200505" xmlns:link="http://www.xbrl.org/2003/linkbase" targetNamespace="http://www.incyte.com/20200505" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations" id="StatementCondensedConsolidatedStatementsOfOperations">
        <link:definition>00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome" id="StatementCondensedConsolidatedStatementsOfComprehensiveIncome">
        <link:definition>00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>00500 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails" id="DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails">
        <link:definition>40401 - Disclosure - Fair value of financial instruments - Fair value on a recurring basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsMarketableSecuritiesPortfolioDetails" id="DisclosureFairValueOfFinancialInstrumentsMarketableSecuritiesPortfolioDetails">
        <link:definition>40402 - Disclosure - Fair value of financial instruments - Marketable securities portfolio (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureInventoryCalc2" id="DisclosureInventoryCalc2">
        <link:definition>40502 - Disclosure - Inventory (Calc2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureInventoryDetails" id="DisclosureInventoryDetails">
        <link:definition>40601 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetails" id="DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetails">
        <link:definition>40701 - Disclosure - Property and equipment, net - Property and equipment, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetails" id="DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetails">
        <link:definition>40703 - Disclosure - Property and equipment, net - Lease and maturity of lease liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetailsCalc2" id="DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetailsCalc2">
        <link:definition>40704 - Disclosure - Property and equipment, net - Lease and maturity of lease liabilities (Details) (Calc2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwillDetails" id="DisclosureIntangibleAssetsAndGoodwillDetails">
        <link:definition>40801 - Disclosure - Intangible assets and goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesDetails" id="DisclosureAccruedAndOtherCurrentLiabilitiesDetails">
        <link:definition>41101 - Disclosure - Accrued and other current liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureEmployeeBenefitPlansPeriodicBenefitCostDetails" id="DisclosureEmployeeBenefitPlansPeriodicBenefitCostDetails">
        <link:definition>41302 - Disclosure - Employee benefit plans - Periodic Benefit Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" id="StatementCondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" id="StatementCondensedConsolidatedStatementsOfStockholdersEquity">
        <link:definition>00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical" id="StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical">
        <link:definition>00405 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" id="StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical">
        <link:definition>00505 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureOrganizationAndBusiness" id="DisclosureOrganizationAndBusiness">
        <link:definition>10101 - Disclosure - Organization and business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Summary of significant accounting policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureRevenues" id="DisclosureRevenues">
        <link:definition>10301 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureFairValueOfFinancialInstruments" id="DisclosureFairValueOfFinancialInstruments">
        <link:definition>10401 - Disclosure - Fair value of financial instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLosses" id="DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLosses">
        <link:definition>10501 - Disclosure - Concentration of credit risk and current expected credit losses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureInventory" id="DisclosureInventory">
        <link:definition>10601 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosurePropertyAndEquipmentNet" id="DisclosurePropertyAndEquipmentNet">
        <link:definition>10701 - Disclosure - Property and equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwill" id="DisclosureIntangibleAssetsAndGoodwill">
        <link:definition>10801 - Disclosure - Intangible assets and goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureLicenseAgreements" id="DisclosureLicenseAgreements">
        <link:definition>10901 - Disclosure - License agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureStockCompensation" id="DisclosureStockCompensation">
        <link:definition>11001 - Disclosure - Stock compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureAccruedAndOtherCurrentLiabilities" id="DisclosureAccruedAndOtherCurrentLiabilities">
        <link:definition>11101 - Disclosure - Accrued and other current liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureDebt" id="DisclosureDebt">
        <link:definition>11201 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureEmployeeBenefitPlans" id="DisclosureEmployeeBenefitPlans">
        <link:definition>11301 - Disclosure - Employee benefit plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11401 - Disclosure - Income taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureNetIncomeLossPerShare" id="DisclosureNetIncomeLossPerShare">
        <link:definition>11501 - Disclosure - Net income (loss) per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureContingencies" id="DisclosureContingencies">
        <link:definition>11601 - Disclosure - Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureSubsequentEvent" id="DisclosureSubsequentEvent">
        <link:definition>11701 - Disclosure - Subsequent event</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Summary of significant accounting policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsTables" id="DisclosureFairValueOfFinancialInstrumentsTables">
        <link:definition>30403 - Disclosure - Fair value of financial instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLossesTables" id="DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLossesTables">
        <link:definition>30503 - Disclosure - Concentration of credit risk and current expected credit losses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureInventoryTables" id="DisclosureInventoryTables">
        <link:definition>30603 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetTables" id="DisclosurePropertyAndEquipmentNetTables">
        <link:definition>30703 - Disclosure - Property and equipment, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwillTables" id="DisclosureIntangibleAssetsAndGoodwillTables">
        <link:definition>30803 - Disclosure - Intangible assets and goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureStockCompensationTables" id="DisclosureStockCompensationTables">
        <link:definition>31003 - Disclosure - Stock compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesTables" id="DisclosureAccruedAndOtherCurrentLiabilitiesTables">
        <link:definition>31103 - Disclosure - Accrued and other current liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureDebtTables" id="DisclosureDebtTables">
        <link:definition>31203 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureEmployeeBenefitPlansTables" id="DisclosureEmployeeBenefitPlansTables">
        <link:definition>31303 - Disclosure - Employee benefit plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureNetIncomeLossPerShareTables" id="DisclosureNetIncomeLossPerShareTables">
        <link:definition>31503 - Disclosure - Net income (loss) per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureOrganizationAndBusinessDetails" id="DisclosureOrganizationAndBusinessDetails">
        <link:definition>40101 - Disclosure - Organization and business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>40201 - Disclosure - Summary of significant accounting policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails">
        <link:definition>40202 - Disclosure - Summary of significant accounting policies - Revenue Recognition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails">
        <link:definition>40203 - Disclosure - Summary of significant accounting policies - Recent Accounting Pronouncements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureRevenuesDetails" id="DisclosureRevenuesDetails">
        <link:definition>40301 - Disclosure - Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLossesDetails" id="DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLossesDetails">
        <link:definition>40501 - Disclosure - Concentration of credit risk and current expected credit losses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetBuildingsAndConstructionDetails" id="DisclosurePropertyAndEquipmentNetBuildingsAndConstructionDetails">
        <link:definition>40702 - Disclosure - Property and equipment, net - Buildings and construction (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails" id="DisclosureLicenseAgreementsNovartisDetails">
        <link:definition>40901 - Disclosure - License agreements - Novartis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails" id="DisclosureLicenseAgreementsLillyDetails">
        <link:definition>40902 - Disclosure - License agreements - Lilly (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails" id="DisclosureLicenseAgreementsAgenusDetails">
        <link:definition>40903 - Disclosure - License agreements - Agenus (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails" id="DisclosureLicenseAgreementsMerusDetails">
        <link:definition>40904 - Disclosure - License agreements - Merus (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails" id="DisclosureLicenseAgreementsCalitheraDetails">
        <link:definition>40905 - Disclosure - License agreements - Calithera (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureLicenseAgreementsMacrogenicsDetails" id="DisclosureLicenseAgreementsMacrogenicsDetails">
        <link:definition>40906 - Disclosure - License agreements - MacroGenics (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureLicenseAgreementsSyrosDetails" id="DisclosureLicenseAgreementsSyrosDetails">
        <link:definition>40907 - Disclosure - License agreements - Syros (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureLicenseAgreementsInnoventDetails" id="DisclosureLicenseAgreementsInnoventDetails">
        <link:definition>40908 - Disclosure - License agreements - Innovent (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureLicenseAgreementsZaiLabDetails" id="DisclosureLicenseAgreementsZaiLabDetails">
        <link:definition>40909 - Disclosure - License agreements - Zai Lab (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails" id="DisclosureLicenseAgreementsMorphosysDetails">
        <link:definition>40910 - Disclosure - License agreements - MorphoSys (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureStockCompensationDetails" id="DisclosureStockCompensationDetails">
        <link:definition>41001 - Disclosure - Stock compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureStockCompensationOptionActivityDetails" id="DisclosureStockCompensationOptionActivityDetails">
        <link:definition>41002 - Disclosure - Stock compensation - Option activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuAwardActivityDetails" id="DisclosureStockCompensationRsuAndPsuAwardActivityDetails">
        <link:definition>41003 - Disclosure - Stock compensation - RSU and PSU award activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuDetails" id="DisclosureStockCompensationRsuAndPsuDetails">
        <link:definition>41004 - Disclosure - Stock compensation - RSU and PSU (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureStockCompensationSharesAvailableForGrantDetails" id="DisclosureStockCompensationSharesAvailableForGrantDetails">
        <link:definition>41005 - Disclosure - Stock compensation - Shares available for grant (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureDebtComponentsOfConvertibleNotesDetails" id="DisclosureDebtComponentsOfConvertibleNotesDetails">
        <link:definition>41201 - Disclosure - Debt - Components of convertible notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureDebtCarryingAmountAndFairValueDetails" id="DisclosureDebtCarryingAmountAndFairValueDetails">
        <link:definition>41202 - Disclosure - Debt - Carrying amount and Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureDebtNarrativeDetails" id="DisclosureDebtNarrativeDetails">
        <link:definition>41203 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureEmployeeBenefitPlansDefinedContributionPlanDetails" id="DisclosureEmployeeBenefitPlansDefinedContributionPlanDetails">
        <link:definition>41301 - Disclosure - Employee benefit plans - Defined Contribution Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureIncomeTaxesDetails" id="DisclosureIncomeTaxesDetails">
        <link:definition>41401 - Disclosure - Income taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureNetIncomeLossPerShareDetails" id="DisclosureNetIncomeLossPerShareDetails">
        <link:definition>41501 - Disclosure - Net income (loss) per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.incyte.com/role/DisclosureRevenuesTables" id="DisclosureRevenuesTables">
        <link:definition>30303 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="incy-20200505_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="incy-20200505_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="incy-20200505_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="incy-20200505_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://fasb.org/us-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="NovartisMember" id="incy_NovartisMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EliLillyMember" id="incy_EliLillyMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element id="incy_JAKAFIMember" name="JAKAFIMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="AchievementOfMilestoneAxis" id="incy_AchievementOfMilestoneAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PreSpecifiedEventsMember" id="incy_PreSpecifiedEventsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element id="incy_RegulatoryMilestonesMember" name="RegulatoryMilestonesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="CommercializationMilestonesMember" id="incy_CommercializationMilestonesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DevelopmentMilestonesMember" id="incy_DevelopmentMilestonesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PhasesOfArrangementsAxis" id="incy_PhasesOfArrangementsAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PhaseTwoBMember" id="incy_PhaseTwoBMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SalesRevenueGoodsServicesNetMember" id="incy_SalesRevenueGoodsServicesNetMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementsDisclosureAbstract" id="incy_LicenseAgreementsDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element id="incy_LicenseAgreementsTextBlock" name="LicenseAgreementsTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="incy_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" name="LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_LicenseAgreementUpfrontPaymentReceived" name="LicenseAgreementUpfrontPaymentReceived" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_LicenseAgreementReimbursableCosts" name="LicenseAgreementReimbursableCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_LicenseAgreementResearchAndDevelopmentReimbursedCost" name="LicenseAgreementResearchAndDevelopmentReimbursedCost" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds" name="PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="LicenseAgreementImmediateMilestonePaymentReceived" id="incy_LicenseAgreementImmediateMilestonePaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <element id="incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" name="LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="AchievementOfMilestoneDomain" id="incy_AchievementOfMilestoneDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PhasesOfArrangementsDomain" id="incy_PhasesOfArrangementsDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PhaseThreeMember" id="incy_PhaseThreeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element id="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="LitigationDisclosureAbstract" id="incy_LitigationDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ConcentrationOfCreditRiskAbstract" id="incy_ConcentrationOfCreditRiskAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CreditExposureLimitationNumberOfIssuerOtherThanUnitedStatesGovernmentGuaranteedSecurities" id="incy_CreditExposureLimitationNumberOfIssuerOtherThanUnitedStatesGovernmentGuaranteedSecurities" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CreditExposureLimitationNumberOfFinancialInvestmentOtherThanUnitedStatesGovernmentGuaranteedSecurities" id="incy_CreditExposureLimitationNumberOfFinancialInvestmentOtherThanUnitedStatesGovernmentGuaranteedSecurities" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="incy_InventoryFinishedGoodsUsefulLifeMaximum" name="InventoryFinishedGoodsUsefulLifeMaximum" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="ScheduleOfInventoryTableTextBlock" id="incy_ScheduleOfInventoryTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="InventoryNetCurrentAndNoncurrent" id="incy_InventoryNetCurrentAndNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="SchedulesOfConcentrationOfRiskByRiskFactorRelatedToSpecialtyPharmaceuticalCustomersTableTextBlock" id="incy_SchedulesOfConcentrationOfRiskByRiskFactorRelatedToSpecialtyPharmaceuticalCustomersTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CustomerAMember" id="incy_CustomerAMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CustomerABCAndDMember" id="incy_CustomerABCAndDMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CustomerBMember" id="incy_CustomerBMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CustomerCMember" id="incy_CustomerCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CustomerDMember" id="incy_CustomerDMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element id="incy_RoyaltyPaymentReceivable" name="RoyaltyPaymentReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member" id="incy_ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ConvertibleSeniorNotes1.25PercentDue2020Member" id="incy_ConvertibleSeniorNotes1.25PercentDue2020Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" id="incy_DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" id="incy_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" id="incy_DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <element id="incy_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod" name="DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays" name="DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum" id="incy_DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits" id="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageMultiplierForConversionOfUnitsIntoCommonStock" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageMultiplierForConversionOfUnitsIntoCommonStock" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_AgenusMember" name="AgenusMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_DevelopmentRegulatoryAndCommercializationMilestonesMember" name="DevelopmentRegulatoryAndCommercializationMilestonesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares" name="PurchaseOfCommonStockUnderStockPurchaseAgreementInShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_PurchasePriceOfCommonStockUnderStockPurchaseAgreement" name="PurchasePriceOfCommonStockUnderStockPurchaseAgreement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_StockPurchaseAgreementMember" name="StockPurchaseAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_RoyaltiesPayable" name="RoyaltiesPayable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock" name="ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_BuildingAndLeaseholdImprovementsMember" name="BuildingAndLeaseholdImprovementsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_PercentageOfRoyaltyRatePayments" name="PercentageOfRoyaltyRatePayments" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_TotalConsiderationPaidUnderPurchaseAgreement" name="TotalConsiderationPaidUnderPurchaseAgreement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_VariableInterestEntitiesAbstract" name="VariableInterestEntitiesAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_VariableInterestEntitiesNumber" name="VariableInterestEntitiesNumber" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_LicenseAgreementUpfrontPayment" name="LicenseAgreementUpfrontPayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_JakaviMember" name="JakaviMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_GvhdMember" name="GvhdMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_BusinessCombinationContingentConsiderationPolicyTextBlock" name="BusinessCombinationContingentConsiderationPolicyTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" name="FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems" name="FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_AriadPharmaceuticalsMember" name="AriadPharmaceuticalsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_ICLUSIGMember" name="ICLUSIGMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_FairValueInputsCashFlowsEstimatedPeriod" name="FairValueInputsCashFlowsEstimatedPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned" name="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_NumberOfProgramTargets" name="NumberOfProgramTargets" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue" nillable="true" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_DebtInstrumentConversionObligationNumberOfScheduledTradingDaysBeforeMaturity" name="DebtInstrumentConversionObligationNumberOfScheduledTradingDaysBeforeMaturity" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_PaymentOfContingentConsideration" name="PaymentOfContingentConsideration" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_DevelopmentAndRegulatoryMilestonesMember" name="DevelopmentAndRegulatoryMilestonesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_DevelopmentAndCommercializationMilestonesMember" name="DevelopmentAndCommercializationMilestonesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_CollaborationAgreementProfitSharingPercentage" name="CollaborationAgreementProfitSharingPercentage" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_LicenseAgreementMaximumNumberOfIndependentPrograms" name="LicenseAgreementMaximumNumberOfIndependentPrograms" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_LicenseAgreementNumberOfPreclinicalDiscoveryPrograms" name="LicenseAgreementNumberOfPreclinicalDiscoveryPrograms" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms" name="LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment" name="NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_PercentageOfProfitsLosses" name="PercentageOfProfitsLosses" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_PercentageOfNetSalesPertainingToAdditionalRoyalties" name="PercentageOfNetSalesPertainingToAdditionalRoyalties" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_PercentageOfReverseRoyaltiesOnSaleOfFutureProducts" name="PercentageOfReverseRoyaltiesOnSaleOfFutureProducts" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_MerusNVMember" name="MerusNVMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_LicenseAgreementUpfrontPaymentAmountPaid" name="LicenseAgreementUpfrontPaymentAmountPaid" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_LicenseAgreementAdditionalMilestonePayments" name="LicenseAgreementAdditionalMilestonePayments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded" name="LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_StockPurchaseAgreementLockUpPeriod" name="StockPurchaseAgreementLockUpPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_CalitheraBiosciencesIncMember" name="CalitheraBiosciencesIncMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_LicenseAgreementPotentialMilestonePaymentsWithProfitSharing" name="LicenseAgreementPotentialMilestonePaymentsWithProfitSharing" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_LicenseAgreementPotentialMilestonePaymentsWithoutProfitSharing" name="LicenseAgreementPotentialMilestonePaymentsWithoutProfitSharing" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_LicenseAgreementMilestonePaymentAmountPaid" name="LicenseAgreementMilestonePaymentAmountPaid" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_LongTermInvestmentPolicyTextBlock" name="LongTermInvestmentPolicyTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_FairValueInputsAmountOfDiscountForLackOfMarketability" name="FairValueInputsAmountOfDiscountForLackOfMarketability" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_CollaborationAgreementUpfrontPayment" name="CollaborationAgreementUpfrontPayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_PercentageOfMedicarePartDInsuranceCoverageGapRequiredToBeFundedByManufacturers" name="PercentageOfMedicarePartDInsuranceCoverageGapRequiredToBeFundedByManufacturers" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_MacrogenicsMember" name="MacrogenicsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_AdoptionOfAccountingStandardAdjustmentToRetainedEarnings" name="AdoptionOfAccountingStandardAdjustmentToRetainedEarnings" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_OfficeBuildingMorgesSwitzerlandMember" name="OfficeBuildingMorgesSwitzerlandMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_SyrosPharmaceuticalsIncMember" name="SyrosPharmaceuticalsIncMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_LicenseAgreementTargetSelectionAndOptionExerciseFeePayments" name="LicenseAgreementTargetSelectionAndOptionExerciseFeePayments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_AmendedStockPurchaseAgreementMember" name="AmendedStockPurchaseAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_CorporateAndGovernmentDebtSecuritiesMember" name="CorporateAndGovernmentDebtSecuritiesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_OlumiantRoyaltyMember" name="OlumiantRoyaltyMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember" name="LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_AccruedClinicalRelatedCostsCurrent" name="AccruedClinicalRelatedCostsCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_InnoventBiologicsIncMember" name="InnoventBiologicsIncMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_NumberOfProductCandidates" name="NumberOfProductCandidates" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_MilestoneAndContractRevenueMember" name="MilestoneAndContractRevenueMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_AccruedAndOtherCurrentLiabilityMember" name="AccruedAndOtherCurrentLiabilityMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_JakaviRoyaltyRevenuesMember" name="JakaviRoyaltyRevenuesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_StockCompensationExpenseCapitalized" name="StockCompensationExpenseCapitalized" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_OperatingLeaseRightOfUseAssetsMember" name="OperatingLeaseRightOfUseAssetsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_LesseeLeaseLiabilityTableTextBlock" name="LesseeLeaseLiabilityTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_OperatingAndFinanceLeaseLiability" name="OperatingAndFinanceLeaseLiability" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_CollaborationPartneraBAndCMember" name="CollaborationPartneraBAndCMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_FinanceLeaseLeaseIncentiveReceivable" name="FinanceLeaseLeaseIncentiveReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember" name="CollaborationAndLicenseAgreementWithZaiLabLtdMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_DevelopmentRegulatoryAndCommercialMilestonesMember" name="DevelopmentRegulatoryAndCommercialMilestonesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_MorphosysAgMember" name="MorphosysAgMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_IncyteMember" name="IncyteMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_CollaborationAgreementProfitLossSharingRatio" name="CollaborationAgreementProfitLossSharingRatio" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_AmericanDepositarySharesMember" name="AmericanDepositarySharesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_LG3ProgramMember" name="LG3ProgramMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_TIM3ProgramMember" name="TIM3ProgramMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_LongTermIncentivePlanOneMember" name="LongTermIncentivePlanOneMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_LongTermIncentivePlanTwoMember" name="LongTermIncentivePlanTwoMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_CollaborationLossSharingExpense" name="CollaborationLossSharingExpense" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_MedicarePartDInsuranceCoverageGapIncreaseInEligiblePatientSpendingPercentage" name="MedicarePartDInsuranceCoverageGapIncreaseInEligiblePatientSpendingPercentage" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="incy_CoronavirusAidReliefAndEconomicSecurityActFund" name="CoronavirusAidReliefAndEconomicSecurityActFund" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>incy-20200505_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7401.38943 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/5/2020 8:06:59 PM-->
<!--Modified on: 5/5/2020 8:06:59 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#StatementCondensedConsolidatedStatementsOfComprehensiveIncome" roleURI="http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails" roleURI="http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureFairValueOfFinancialInstrumentsMarketableSecuritiesPortfolioDetails" roleURI="http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsMarketableSecuritiesPortfolioDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureInventoryCalc2" roleURI="http://www.incyte.com/role/DisclosureInventoryCalc2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureInventoryDetails" roleURI="http://www.incyte.com/role/DisclosureInventoryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetails" roleURI="http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetails" roleURI="http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetailsCalc2" roleURI="http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetailsCalc2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureIntangibleAssetsAndGoodwillDetails" roleURI="http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwillDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureAccruedAndOtherCurrentLiabilitiesDetails" roleURI="http://www.incyte.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureEmployeeBenefitPlansPeriodicBenefitCostDetails" roleURI="http://www.incyte.com/role/DisclosureEmployeeBenefitPlansPeriodicBenefitCostDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <calculationLink xlink:role="http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637243060151322025" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_637243060151322025" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637243060151322025" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637243060151322025" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637243060151322025" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_637243060151322025" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637243060151322025" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_637243060151322025" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet_637243060151322025" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637243060151322025" xlink:to="us-gaap_AccountsReceivableNet_637243060151322025" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637243060151322025" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637243060151322025" xlink:to="us-gaap_InventoryNet_637243060151322025" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637243060151322025" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637243060151322025" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637243060151322025" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndInvestmentsNoncurrent_637243060151322025" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashAndInvestmentsNoncurrent_637243060151322025" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments_637243060151322025" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_LongTermInvestments_637243060151322025" order="3" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="us-gaap_InventoryNoncurrent_637243060151322025" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_InventoryNoncurrent_637243060151322025" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637243060151322025" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637243060151322025" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_637243060151332006" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_637243060151332006" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="us-gaap_OtherIntangibleAssetsNet_637243060151332006" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherIntangibleAssetsNet_637243060151332006" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_637243060151332006" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill_637243060151332006" order="8" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_637243060151332006" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_637243060151332006" order="9" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637243060151332006" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_637243060151332006" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637243060151332006" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637243060151332006" xlink:to="us-gaap_LiabilitiesCurrent_637243060151332006" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637243060151332006" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637243060151332006" xlink:to="us-gaap_AccountsPayableCurrent_637243060151332006" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_637243060151342020" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637243060151332006" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_637243060151342020" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_637243060151342020" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637243060151332006" xlink:to="us-gaap_InterestPayableCurrent_637243060151342020" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637243060151342020" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637243060151332006" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637243060151342020" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_637243060151342020" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637243060151332006" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_637243060151342020" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent_637243060151342020" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637243060151332006" xlink:to="us-gaap_ConvertibleDebtCurrent_637243060151342020" order="6" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_637243060151342020" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637243060151332006" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_637243060151342020" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_637243060151342020" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637243060151332006" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_637243060151342020" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_637243060151342020" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637243060151332006" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_637243060151342020" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637243060151352009" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637243060151332006" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637243060151352009" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637243060151352009" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_637243060151352009" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637243060151352009" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637243060151352009" xlink:to="us-gaap_PreferredStockValue_637243060151352009" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637243060151352009" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637243060151352009" xlink:to="us-gaap_CommonStockValue_637243060151352009" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_637243060151352009" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637243060151352009" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_637243060151352009" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637243060151352009" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637243060151352009" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637243060151352009" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637243060151352009" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637243060151352009" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637243060151352009" order="5" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_637243060151362008" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_637243060151362008" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637243060151362008" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_637243060151362008" xlink:to="us-gaap_OperatingIncomeLoss_637243060151362008" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637243060151362008" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637243060151362008" xlink:to="us-gaap_Revenues_637243060151362008" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_637243060151362008" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637243060151362008" xlink:to="us-gaap_CostsAndExpenses_637243060151362008" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_637243060151362008" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_637243060151362008" xlink:to="us-gaap_CostOfRevenue_637243060151362008" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637243060151362008" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_637243060151362008" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637243060151362008" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_637243060151362008" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_637243060151362008" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_637243060151362008" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_637243060151362008" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_637243060151362008" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_637243060151362008" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CollaborationLossSharingExpense" xlink:label="incy_CollaborationLossSharingExpense_637243060151372017" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_637243060151362008" xlink:to="incy_CollaborationLossSharingExpense_637243060151372017" order="5" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_637243060151372017" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_637243060151362008" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_637243060151372017" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_637243060151372017" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_637243060151362008" xlink:to="us-gaap_InterestExpense_637243060151372017" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_637243060151372017" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_637243060151362008" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_637243060151372017" order="4" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637243060151372017" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637243060151372017" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended" xlink:title="00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637243060151372017" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_637243060151372017" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_637243060151372017" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_637243060151372017" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_637243060151372017" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_637243060151372017" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_637243060151372017" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_637243060151382015" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_637243060151372017" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_637243060151382015" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_637243060151382015" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_637243060151372017" xlink:to="us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_637243060151382015" order="3" use="optional" weight="-1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00500 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637243060151392822" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637243060151392822" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637243060151392822" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637243060151392822" xlink:to="us-gaap_ProfitLoss_637243060151392822" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_637243060151392822" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637243060151392822" xlink:to="us-gaap_DepreciationDepletionAndAmortization_637243060151392822" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637243060151392822" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637243060151392822" xlink:to="us-gaap_ShareBasedCompensation_637243060151392822" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense_637243060151392822" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637243060151392822" xlink:to="us-gaap_OtherNoncashIncomeExpense_637243060151392822" order="4" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_637243060151392822" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637243060151392822" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_637243060151392822" order="5" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_637243060151392822" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637243060151392822" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_637243060151392822" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_637243060151392822" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637243060151392822" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_637243060151392822" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637243060151402018" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637243060151392822" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637243060151402018" order="8" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_637243060151402018" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637243060151392822" xlink:to="us-gaap_IncreaseDecreaseInInventories_637243060151402018" order="9" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637243060151402018" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637243060151392822" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637243060151402018" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_637243060151402018" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637243060151392822" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_637243060151402018" order="11" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637243060151402018" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637243060151402018" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_637243060151402018" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637243060151402018" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_637243060151402018" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_637243060151402018" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637243060151402018" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_637243060151402018" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_637243060151402018" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637243060151402018" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_637243060151402018" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireLongtermInvestments" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments_637243060151402018" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637243060151402018" xlink:to="us-gaap_PaymentsToAcquireLongtermInvestments_637243060151402018" order="4" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637243060151412012" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637243060151412012" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans_637243060151412012" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637243060151412012" xlink:to="us-gaap_ProceedsFromStockPlans_637243060151412012" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments_637243060151412012" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637243060151412012" xlink:to="us-gaap_FinanceLeasePrincipalPayments_637243060151412012" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PaymentOfContingentConsideration" xlink:label="incy_PaymentOfContingentConsideration_637243060151412012" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637243060151412012" xlink:to="incy_PaymentOfContingentConsideration_637243060151412012" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637243060151412012" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637243060151412012" order="4" use="optional" weight="1" priority="4" />
  </calculationLink>
  <calculationLink xlink:role="http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Fair value of financial instruments - Fair value on a recurring basis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637243060151412012" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637243060151412012" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_637243060151422018" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_637243060151422018" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments_637243060151422018" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_LongTermInvestments_637243060151422018" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_637243060151422018" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_637243060151422018" order="1" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsMarketableSecuritiesPortfolioDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Fair value of financial instruments - Marketable securities portfolio (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_637243060151422018" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_637243060151422018" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_637243060151422018" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_637243060151422018" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.incyte.com/role/DisclosureInventoryCalc2" xlink:type="extended" xlink:title="40502 - Disclosure - Inventory (Calc2)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_InventoryNetCurrentAndNoncurrent" xlink:label="incy_InventoryNetCurrentAndNoncurrent" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637243060151422018" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="incy_InventoryNetCurrentAndNoncurrent" xlink:to="us-gaap_InventoryNet_637243060151422018" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="us-gaap_InventoryNoncurrent_637243060151422018" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="incy_InventoryNetCurrentAndNoncurrent" xlink:to="us-gaap_InventoryNoncurrent_637243060151422018" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.incyte.com/role/DisclosureInventoryDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Inventory (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_InventoryNetCurrentAndNoncurrent" xlink:label="incy_InventoryNetCurrentAndNoncurrent_635493301753691683" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_637243060151432014" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="incy_InventoryNetCurrentAndNoncurrent_635493301753691683" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_637243060151432014" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_637243060151432014" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="incy_InventoryNetCurrentAndNoncurrent_635493301753691683" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_637243060151432014" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_637243060151432014" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="incy_InventoryNetCurrentAndNoncurrent_635493301753691683" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_637243060151432014" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Property and equipment, net - Property and equipment, net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_635470903437325758" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637243060151432014" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet_635470903437325758" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637243060151432014" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637243060151432014" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet_635470903437325758" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637243060151432014" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Property and equipment, net - Lease and maturity of lease liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_OperatingAndFinanceLeaseLiability" xlink:label="incy_OperatingAndFinanceLeaseLiability" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_637243060151432014" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="incy_OperatingAndFinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_637243060151432014" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637243060151432014" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="incy_OperatingAndFinanceLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637243060151432014" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_637243060151442017" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="incy_OperatingAndFinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_637243060151442017" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637243060151442017" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="incy_OperatingAndFinanceLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637243060151442017" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetailsCalc2" xlink:type="extended" xlink:title="40704 - Disclosure - Property and equipment, net - Lease and maturity of lease liabilities (Details) (Calc2)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability_637243060151442017" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiability_637243060151442017" order="1" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwillDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Intangible assets and goodwill (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_637243060151442017" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_637243060151442017" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_637243060151442017" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_637243060151442017" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.incyte.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Accrued and other current liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent_637243060151442017" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_637243060151442017" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AccruedClinicalRelatedCostsCurrent" xlink:label="incy_AccruedClinicalRelatedCostsCurrent_637243060151442017" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="incy_AccruedClinicalRelatedCostsCurrent_637243060151442017" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637243060151452017" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637243060151452017" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProvisionForLossOnContracts" xlink:label="us-gaap_ProvisionForLossOnContracts_637243060151452017" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_ProvisionForLossOnContracts_637243060151452017" order="4" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionPayableCurrent" xlink:label="us-gaap_ConstructionPayableCurrent_637243060151452017" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_ConstructionPayableCurrent_637243060151452017" order="5" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_637243060151452017" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_637243060151452017" order="6" use="optional" weight="1" priority="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.incyte.com/role/DisclosureEmployeeBenefitPlansPeriodicBenefitCostDetails" xlink:type="extended" xlink:title="41302 - Disclosure - Employee benefit plans - Periodic Benefit Cost (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost" xlink:label="us-gaap_DefinedBenefitPlanServiceCost_637243060151452017" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="us-gaap_DefinedBenefitPlanServiceCost_637243060151452017" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost" xlink:label="us-gaap_DefinedBenefitPlanInterestCost_637243060151452017" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="us-gaap_DefinedBenefitPlanInterestCost_637243060151452017" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:label="us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_637243060151452017" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_637243060151452017" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:label="us-gaap_DefinedBenefitPlanActuarialGainLoss_637243060151452017" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="us-gaap_DefinedBenefitPlanActuarialGainLoss_637243060151452017" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:label="us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_637243060151452017" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_637243060151452017" order="5" use="optional" weight="1" priority="2" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>incy-20200505_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7401.38943 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/5/2020 8:06:59 PM-->
<!--Modified on: 5/5/2020 8:06:59 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#StatementCondensedConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" roleURI="http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" roleURI="http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureRevenuesDetails" roleURI="http://www.incyte.com/role/DisclosureRevenuesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails" roleURI="http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureFairValueOfFinancialInstrumentsMarketableSecuritiesPortfolioDetails" roleURI="http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsMarketableSecuritiesPortfolioDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLossesDetails" roleURI="http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLossesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetails" roleURI="http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosurePropertyAndEquipmentNetBuildingsAndConstructionDetails" roleURI="http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetBuildingsAndConstructionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureIntangibleAssetsAndGoodwillDetails" roleURI="http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwillDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureLicenseAgreementsNovartisDetails" roleURI="http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureLicenseAgreementsLillyDetails" roleURI="http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureLicenseAgreementsAgenusDetails" roleURI="http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureLicenseAgreementsMerusDetails" roleURI="http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureLicenseAgreementsCalitheraDetails" roleURI="http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureLicenseAgreementsMacrogenicsDetails" roleURI="http://www.incyte.com/role/DisclosureLicenseAgreementsMacrogenicsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureLicenseAgreementsSyrosDetails" roleURI="http://www.incyte.com/role/DisclosureLicenseAgreementsSyrosDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureLicenseAgreementsInnoventDetails" roleURI="http://www.incyte.com/role/DisclosureLicenseAgreementsInnoventDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureLicenseAgreementsZaiLabDetails" roleURI="http://www.incyte.com/role/DisclosureLicenseAgreementsZaiLabDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureLicenseAgreementsMorphosysDetails" roleURI="http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureStockCompensationDetails" roleURI="http://www.incyte.com/role/DisclosureStockCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureStockCompensationOptionActivityDetails" roleURI="http://www.incyte.com/role/DisclosureStockCompensationOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureStockCompensationRsuAndPsuAwardActivityDetails" roleURI="http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuAwardActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureStockCompensationRsuAndPsuDetails" roleURI="http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureDebtComponentsOfConvertibleNotesDetails" roleURI="http://www.incyte.com/role/DisclosureDebtComponentsOfConvertibleNotesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureDebtCarryingAmountAndFairValueDetails" roleURI="http://www.incyte.com/role/DisclosureDebtCarryingAmountAndFairValueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureDebtNarrativeDetails" roleURI="http://www.incyte.com/role/DisclosureDebtNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureNetIncomeLossPerShareDetails" roleURI="http://www.incyte.com/role/DisclosureNetIncomeLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" xmlns="http://www.xbrl.org/2003/linkbase" />
  <definitionLink xlink:role="http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637243060151462019" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_637243060151462019" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_MilestoneAndContractRevenueMember" xlink:label="incy_MilestoneAndContractRevenueMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ProductsAndServicesDomain" xlink:to="incy_MilestoneAndContractRevenueMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostOfRevenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CollaborationLossSharingExpense" xlink:label="incy_CollaborationLossSharingExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="incy_CollaborationLossSharingExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637243060151512030" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_637243060151512030" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AdoptionOfAccountingStandardAdjustmentToRetainedEarnings" xlink:label="incy_AdoptionOfAccountingStandardAdjustmentToRetainedEarnings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="incy_AdoptionOfAccountingStandardAdjustmentToRetainedEarnings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="extended" xlink:title="00505 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637243060151532028" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_637243060151532028" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ConvertibleSeniorNotes1.25PercentDue2020Member" xlink:label="incy_ConvertibleSeniorNotes1.25PercentDue2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="incy_ConvertibleSeniorNotes1.25PercentDue2020Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of significant accounting policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_JAKAFIMember" xlink:label="incy_JAKAFIMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="incy_JAKAFIMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ICLUSIGMember" xlink:label="incy_ICLUSIGMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="incy_ICLUSIGMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ConcentrationOfCreditRiskAbstract" xlink:label="incy_ConcentrationOfCreditRiskAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="incy_ConcentrationOfCreditRiskAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CreditExposureLimitationNumberOfIssuerOtherThanUnitedStatesGovernmentGuaranteedSecurities" xlink:label="incy_CreditExposureLimitationNumberOfIssuerOtherThanUnitedStatesGovernmentGuaranteedSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="incy_ConcentrationOfCreditRiskAbstract" xlink:to="incy_CreditExposureLimitationNumberOfIssuerOtherThanUnitedStatesGovernmentGuaranteedSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CreditExposureLimitationNumberOfFinancialInvestmentOtherThanUnitedStatesGovernmentGuaranteedSecurities" xlink:label="incy_CreditExposureLimitationNumberOfFinancialInvestmentOtherThanUnitedStatesGovernmentGuaranteedSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="incy_ConcentrationOfCreditRiskAbstract" xlink:to="incy_CreditExposureLimitationNumberOfFinancialInvestmentOtherThanUnitedStatesGovernmentGuaranteedSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="us-gaap_InventoryNetAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryNetAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_InventoryFinishedGoodsUsefulLifeMaximum" xlink:label="incy_InventoryFinishedGoodsUsefulLifeMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="incy_InventoryFinishedGoodsUsefulLifeMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_VariableInterestEntitiesAbstract" xlink:label="incy_VariableInterestEntitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="incy_VariableInterestEntitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_VariableInterestEntitiesNumber" xlink:label="incy_VariableInterestEntitiesNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="incy_VariableInterestEntitiesAbstract" xlink:to="incy_VariableInterestEntitiesNumber" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of significant accounting policies - Revenue Recognition (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ICLUSIGMember" xlink:label="incy_ICLUSIGMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ProductMember" xlink:to="incy_ICLUSIGMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637243060151702043" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637243060151702043" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_MorphosysAgMember" xlink:label="incy_MorphosysAgMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="incy_MorphosysAgMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PercentageOfMedicarePartDInsuranceCoverageGapRequiredToBeFundedByManufacturers" xlink:label="incy_PercentageOfMedicarePartDInsuranceCoverageGapRequiredToBeFundedByManufacturers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="incy_PercentageOfMedicarePartDInsuranceCoverageGapRequiredToBeFundedByManufacturers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_MedicarePartDInsuranceCoverageGapIncreaseInEligiblePatientSpendingPercentage" xlink:label="incy_MedicarePartDInsuranceCoverageGapIncreaseInEligiblePatientSpendingPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="incy_MedicarePartDInsuranceCoverageGapIncreaseInEligiblePatientSpendingPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CollaborationAgreementProfitLossSharingRatio" xlink:label="incy_CollaborationAgreementProfitLossSharingRatio" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="incy_CollaborationAgreementProfitLossSharingRatio" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.incyte.com/role/DisclosureRevenuesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Revenues (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_JAKAFIMember" xlink:label="incy_JAKAFIMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ProductMember" xlink:to="incy_JAKAFIMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ICLUSIGMember" xlink:label="incy_ICLUSIGMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ProductMember" xlink:to="incy_ICLUSIGMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_JakaviRoyaltyRevenuesMember" xlink:label="incy_JakaviRoyaltyRevenuesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RoyaltyMember" xlink:to="incy_JakaviRoyaltyRevenuesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_OlumiantRoyaltyMember" xlink:label="incy_OlumiantRoyaltyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RoyaltyMember" xlink:to="incy_OlumiantRoyaltyMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_MilestoneAndContractRevenueMember" xlink:label="incy_MilestoneAndContractRevenueMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ProductsAndServicesDomain" xlink:to="incy_MilestoneAndContractRevenueMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Fair value of financial instruments - Fair value on a recurring basis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_637243060151722038" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_637243060151722038" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637243060151732039" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637243060151732039" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_637243060151732039" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_637243060151732039" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_637243060151742028" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_637243060151742028" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AriadPharmaceuticalsMember" xlink:label="incy_AriadPharmaceuticalsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="incy_AriadPharmaceuticalsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_BalanceSheetLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_637243060151742028" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_637243060151742028" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AccruedAndOtherCurrentLiabilityMember" xlink:label="incy_AccruedAndOtherCurrentLiabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="incy_AccruedAndOtherCurrentLiabilityMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_637243060151752029" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_637243060151752029" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputCapRateMember" xlink:label="us-gaap_MeasurementInputCapRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputCapRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_637243060151762029" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_637243060151762029" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilityMember" xlink:label="us-gaap_LiabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_LiabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LongTermInvestments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned" xlink:label="incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_FairValueInputsCashFlowsEstimatedPeriod" xlink:label="incy_FairValueInputsCashFlowsEstimatedPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="incy_FairValueInputsCashFlowsEstimatedPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsMarketableSecuritiesPortfolioDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Fair value of financial instruments - Marketable securities portfolio (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637243060151802040" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637243060151802040" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CorporateAndGovernmentDebtSecuritiesMember" xlink:label="incy_CorporateAndGovernmentDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="incy_CorporateAndGovernmentDebtSecuritiesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637243060151802040" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_637243060151802040" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtInstrumentTerm" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLossesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Concentration of credit risk and current expected credit losses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_637243060151812032" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_637243060151812032" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_SalesRevenueGoodsServicesNetMember" xlink:label="incy_SalesRevenueGoodsServicesNetMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="incy_SalesRevenueGoodsServicesNetMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_637243060151822043" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_637243060151822043" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CreditConcentrationRiskMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_MajorCustomersAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_637243060151822043" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_637243060151822043" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CollaborationPartneraBAndCMember" xlink:label="incy_CollaborationPartneraBAndCMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="incy_CollaborationPartneraBAndCMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CustomerAMember" xlink:label="incy_CustomerAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="incy_CustomerAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CustomerBMember" xlink:label="incy_CustomerBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="incy_CustomerBMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CustomerCMember" xlink:label="incy_CustomerCMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="incy_CustomerCMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CustomerDMember" xlink:label="incy_CustomerDMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="incy_CustomerDMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CustomerABCAndDMember" xlink:label="incy_CustomerABCAndDMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="incy_CustomerABCAndDMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Property and equipment, net - Property and equipment, net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637243060151842044" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637243060151842044" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LandMember" xlink:label="us-gaap_LandMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_BuildingAndLeaseholdImprovementsMember" xlink:label="incy_BuildingAndLeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="incy_BuildingAndLeaseholdImprovementsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_OperatingLeaseRightOfUseAssetsMember" xlink:label="incy_OperatingLeaseRightOfUseAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="incy_OperatingLeaseRightOfUseAssetsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetBuildingsAndConstructionDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Property and equipment, net - Buildings and construction (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealEstatePropertiesAxis" xlink:label="us-gaap_RealEstatePropertiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_RealEstatePropertiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealEstatePropertiesDomain" xlink:label="us-gaap_RealEstatePropertiesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RealEstatePropertiesAxis" xlink:to="us-gaap_RealEstatePropertiesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealEstatePropertiesDomain" xlink:label="us-gaap_RealEstatePropertiesDomain_637243060151862058" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_RealEstatePropertiesAxis" xlink:to="us-gaap_RealEstatePropertiesDomain_637243060151862058" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_OfficeBuildingMorgesSwitzerlandMember" xlink:label="incy_OfficeBuildingMorgesSwitzerlandMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RealEstatePropertiesDomain" xlink:to="incy_OfficeBuildingMorgesSwitzerlandMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember" xlink:label="incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RealEstatePropertiesDomain" xlink:to="incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:label="us-gaap_LesseeFinanceLeaseRenewalTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_LesseeFinanceLeaseRenewalTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_FinanceLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_FinanceLeaseLeaseIncentiveReceivable" xlink:label="incy_FinanceLeaseLeaseIncentiveReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="incy_FinanceLeaseLeaseIncentiveReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="us-gaap_ConstructionInProgressGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ConstructionInProgressGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireRealEstate" xlink:label="us-gaap_PaymentsToAcquireRealEstate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PaymentsToAcquireRealEstate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwillDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Intangible assets and goodwill (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:label="incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_637243060151892043" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_637243060151892043" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="us-gaap_GoodwillRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="us-gaap_GoodwillRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GoodwillRollForward" xlink:to="us-gaap_GoodwillPeriodIncreaseDecrease" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails" xlink:type="extended" xlink:title="40901 - Disclosure - License agreements - Novartis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_NovartisMember" xlink:label="incy_NovartisMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="incy_NovartisMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AchievementOfMilestoneAxis" xlink:label="incy_AchievementOfMilestoneAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="incy_AchievementOfMilestoneAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AchievementOfMilestoneDomain" xlink:label="incy_AchievementOfMilestoneDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="incy_AchievementOfMilestoneAxis" xlink:to="incy_AchievementOfMilestoneDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AchievementOfMilestoneDomain" xlink:label="incy_AchievementOfMilestoneDomain_637243060151912034" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="incy_AchievementOfMilestoneAxis" xlink:to="incy_AchievementOfMilestoneDomain_637243060151912034" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PreSpecifiedEventsMember" xlink:label="incy_PreSpecifiedEventsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="incy_AchievementOfMilestoneDomain" xlink:to="incy_PreSpecifiedEventsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DevelopmentMilestonesMember" xlink:label="incy_DevelopmentMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="incy_AchievementOfMilestoneDomain" xlink:to="incy_DevelopmentMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_RegulatoryMilestonesMember" xlink:label="incy_RegulatoryMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="incy_AchievementOfMilestoneDomain" xlink:to="incy_RegulatoryMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CommercializationMilestonesMember" xlink:label="incy_CommercializationMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="incy_AchievementOfMilestoneDomain" xlink:to="incy_CommercializationMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DevelopmentAndRegulatoryMilestonesMember" xlink:label="incy_DevelopmentAndRegulatoryMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="incy_AchievementOfMilestoneDomain" xlink:to="incy_DevelopmentAndRegulatoryMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DevelopmentAndCommercializationMilestonesMember" xlink:label="incy_DevelopmentAndCommercializationMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="incy_AchievementOfMilestoneDomain" xlink:to="incy_DevelopmentAndCommercializationMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_GvhdMember" xlink:label="incy_GvhdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="incy_GvhdMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_JAKAFIMember" xlink:label="incy_JAKAFIMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="incy_JAKAFIMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_JakaviMember" xlink:label="incy_JakaviMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ProductsAndServicesDomain" xlink:to="incy_JakaviMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PhasesOfArrangementsAxis" xlink:label="incy_PhasesOfArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="incy_PhasesOfArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PhasesOfArrangementsDomain" xlink:label="incy_PhasesOfArrangementsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="incy_PhasesOfArrangementsAxis" xlink:to="incy_PhasesOfArrangementsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PhasesOfArrangementsDomain" xlink:label="incy_PhasesOfArrangementsDomain_637243060151942038" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="incy_PhasesOfArrangementsAxis" xlink:to="incy_PhasesOfArrangementsDomain_637243060151942038" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PhaseThreeMember" xlink:label="incy_PhaseThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="incy_PhasesOfArrangementsDomain" xlink:to="incy_PhaseThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637243060151952040" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_637243060151952040" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="us-gaap_NonUsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="country_JP" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="country_US" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" xlink:label="incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementUpfrontPaymentReceived" xlink:label="incy_LicenseAgreementUpfrontPaymentReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_LicenseAgreementUpfrontPaymentReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementImmediateMilestonePaymentReceived" xlink:label="incy_LicenseAgreementImmediateMilestonePaymentReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_LicenseAgreementImmediateMilestonePaymentReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" xlink:label="incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PercentageOfRoyaltyRatePayments" xlink:label="incy_PercentageOfRoyaltyRatePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_PercentageOfRoyaltyRatePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:label="us-gaap_IncreaseDecreaseInRoyaltiesPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_IncreaseDecreaseInRoyaltiesPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_RoyaltiesPayable" xlink:label="incy_RoyaltiesPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_RoyaltiesPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementReimbursableCosts" xlink:label="incy_LicenseAgreementReimbursableCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_LicenseAgreementReimbursableCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementResearchAndDevelopmentReimbursedCost" xlink:label="incy_LicenseAgreementResearchAndDevelopmentReimbursedCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_LicenseAgreementResearchAndDevelopmentReimbursedCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_RoyaltyPaymentReceivable" xlink:label="incy_RoyaltyPaymentReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_RoyaltyPaymentReceivable" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails" xlink:type="extended" xlink:title="40902 - Disclosure - License agreements - Lilly (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_EliLillyMember" xlink:label="incy_EliLillyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="incy_EliLillyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AchievementOfMilestoneAxis" xlink:label="incy_AchievementOfMilestoneAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="incy_AchievementOfMilestoneAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AchievementOfMilestoneDomain" xlink:label="incy_AchievementOfMilestoneDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="incy_AchievementOfMilestoneAxis" xlink:to="incy_AchievementOfMilestoneDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PreSpecifiedEventsMember" xlink:label="incy_PreSpecifiedEventsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="incy_AchievementOfMilestoneDomain" xlink:to="incy_PreSpecifiedEventsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DevelopmentMilestonesMember" xlink:label="incy_DevelopmentMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="incy_AchievementOfMilestoneDomain" xlink:to="incy_DevelopmentMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_RegulatoryMilestonesMember" xlink:label="incy_RegulatoryMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="incy_AchievementOfMilestoneDomain" xlink:to="incy_RegulatoryMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CommercializationMilestonesMember" xlink:label="incy_CommercializationMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="incy_AchievementOfMilestoneDomain" xlink:to="incy_CommercializationMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DevelopmentAndCommercializationMilestonesMember" xlink:label="incy_DevelopmentAndCommercializationMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="incy_AchievementOfMilestoneDomain" xlink:to="incy_DevelopmentAndCommercializationMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_BalanceSheetLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="us-gaap_AccruedLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AccruedLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="country_JP" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_SegmentGeographicalDomain" xlink:to="us-gaap_NonUsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_GvhdMember" xlink:label="incy_GvhdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="incy_GvhdMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PhasesOfArrangementsAxis" xlink:label="incy_PhasesOfArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="incy_PhasesOfArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PhasesOfArrangementsDomain" xlink:label="incy_PhasesOfArrangementsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="incy_PhasesOfArrangementsAxis" xlink:to="incy_PhasesOfArrangementsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PhaseThreeMember" xlink:label="incy_PhaseThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="incy_PhasesOfArrangementsDomain" xlink:to="incy_PhaseThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PhaseTwoBMember" xlink:label="incy_PhaseTwoBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="incy_PhasesOfArrangementsDomain" xlink:to="incy_PhaseTwoBMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementUpfrontPaymentReceived" xlink:label="incy_LicenseAgreementUpfrontPaymentReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_LicenseAgreementUpfrontPaymentReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" xlink:label="incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" xlink:label="incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded" xlink:label="incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds" xlink:label="incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PercentageOfRoyaltyRatePayments" xlink:label="incy_PercentageOfRoyaltyRatePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_PercentageOfRoyaltyRatePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementResearchAndDevelopmentReimbursedCost" xlink:label="incy_LicenseAgreementResearchAndDevelopmentReimbursedCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_LicenseAgreementResearchAndDevelopmentReimbursedCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_RoyaltyPaymentReceivable" xlink:label="incy_RoyaltyPaymentReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_RoyaltyPaymentReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementUpfrontPaymentAmountPaid" xlink:label="incy_LicenseAgreementUpfrontPaymentAmountPaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_LicenseAgreementUpfrontPaymentAmountPaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementAdditionalMilestonePayments" xlink:label="incy_LicenseAgreementAdditionalMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_LicenseAgreementAdditionalMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementMilestonePaymentAmountPaid" xlink:label="incy_LicenseAgreementMilestonePaymentAmountPaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_LicenseAgreementMilestonePaymentAmountPaid" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails" xlink:type="extended" xlink:title="40903 - Disclosure - License agreements - Agenus (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_637243060152092050" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_637243060152092050" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AgenusMember" xlink:label="incy_AgenusMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="incy_AgenusMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_StockPurchaseAgreementMember" xlink:label="incy_StockPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="incy_StockPurchaseAgreementMember" priority="1" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="incy_AgenusMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AchievementOfMilestoneAxis" xlink:label="incy_AchievementOfMilestoneAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="incy_AchievementOfMilestoneAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AchievementOfMilestoneDomain" xlink:label="incy_AchievementOfMilestoneDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="incy_AchievementOfMilestoneAxis" xlink:to="incy_AchievementOfMilestoneDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DevelopmentRegulatoryAndCommercializationMilestonesMember" xlink:label="incy_DevelopmentRegulatoryAndCommercializationMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="incy_AchievementOfMilestoneDomain" xlink:to="incy_DevelopmentRegulatoryAndCommercializationMilestonesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DevelopmentMilestonesMember" xlink:label="incy_DevelopmentMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="incy_AchievementOfMilestoneDomain" xlink:to="incy_DevelopmentMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LG3ProgramMember" xlink:label="incy_LG3ProgramMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="incy_LG3ProgramMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_TIM3ProgramMember" xlink:label="incy_TIM3ProgramMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="incy_TIM3ProgramMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="us-gaap_AccruedLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AccruedLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_NumberOfProgramTargets" xlink:label="incy_NumberOfProgramTargets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_NumberOfProgramTargets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PercentageOfRoyaltyRatePayments" xlink:label="incy_PercentageOfRoyaltyRatePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_PercentageOfRoyaltyRatePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementUpfrontPaymentAmountPaid" xlink:label="incy_LicenseAgreementUpfrontPaymentAmountPaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_LicenseAgreementUpfrontPaymentAmountPaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementAdditionalMilestonePayments" xlink:label="incy_LicenseAgreementAdditionalMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_LicenseAgreementAdditionalMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares" xlink:label="incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_FairValueInputsAmountOfDiscountForLackOfMarketability" xlink:label="incy_FairValueInputsAmountOfDiscountForLackOfMarketability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_FairValueInputsAmountOfDiscountForLackOfMarketability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="us-gaap_EquityFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EquityFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_TotalConsiderationPaidUnderPurchaseAgreement" xlink:label="incy_TotalConsiderationPaidUnderPurchaseAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_TotalConsiderationPaidUnderPurchaseAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LongTermInvestments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue" xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss" xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails" xlink:type="extended" xlink:title="40904 - Disclosure - License agreements - Merus (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_MerusNVMember" xlink:label="incy_MerusNVMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="incy_MerusNVMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="incy_MerusNVMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_StockPurchaseAgreementMember" xlink:label="incy_StockPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="incy_StockPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AchievementOfMilestoneAxis" xlink:label="incy_AchievementOfMilestoneAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="incy_AchievementOfMilestoneAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AchievementOfMilestoneDomain" xlink:label="incy_AchievementOfMilestoneDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="incy_AchievementOfMilestoneAxis" xlink:to="incy_AchievementOfMilestoneDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DevelopmentAndRegulatoryMilestonesMember" xlink:label="incy_DevelopmentAndRegulatoryMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="incy_AchievementOfMilestoneDomain" xlink:to="incy_DevelopmentAndRegulatoryMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CommercializationMilestonesMember" xlink:label="incy_CommercializationMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="incy_AchievementOfMilestoneDomain" xlink:to="incy_CommercializationMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="country_US" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="us-gaap_NonUsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="us-gaap_AccruedLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AccruedLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementMaximumNumberOfIndependentPrograms" xlink:label="incy_LicenseAgreementMaximumNumberOfIndependentPrograms" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_LicenseAgreementMaximumNumberOfIndependentPrograms" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementNumberOfPreclinicalDiscoveryPrograms" xlink:label="incy_LicenseAgreementNumberOfPreclinicalDiscoveryPrograms" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_LicenseAgreementNumberOfPreclinicalDiscoveryPrograms" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms" xlink:label="incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment" xlink:label="incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds" xlink:label="incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementUpfrontPaymentAmountPaid" xlink:label="incy_LicenseAgreementUpfrontPaymentAmountPaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_LicenseAgreementUpfrontPaymentAmountPaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementAdditionalMilestonePayments" xlink:label="incy_LicenseAgreementAdditionalMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_LicenseAgreementAdditionalMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PercentageOfRoyaltyRatePayments" xlink:label="incy_PercentageOfRoyaltyRatePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_PercentageOfRoyaltyRatePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CollaborationAgreementProfitSharingPercentage" xlink:label="incy_CollaborationAgreementProfitSharingPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_CollaborationAgreementProfitSharingPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PercentageOfProfitsLosses" xlink:label="incy_PercentageOfProfitsLosses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_PercentageOfProfitsLosses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PercentageOfNetSalesPertainingToAdditionalRoyalties" xlink:label="incy_PercentageOfNetSalesPertainingToAdditionalRoyalties" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_PercentageOfNetSalesPertainingToAdditionalRoyalties" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PercentageOfReverseRoyaltiesOnSaleOfFutureProducts" xlink:label="incy_PercentageOfReverseRoyaltiesOnSaleOfFutureProducts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_PercentageOfReverseRoyaltiesOnSaleOfFutureProducts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares" xlink:label="incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_StockPurchaseAgreementLockUpPeriod" xlink:label="incy_StockPurchaseAgreementLockUpPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_StockPurchaseAgreementLockUpPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_FairValueInputsAmountOfDiscountForLackOfMarketability" xlink:label="incy_FairValueInputsAmountOfDiscountForLackOfMarketability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_FairValueInputsAmountOfDiscountForLackOfMarketability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="us-gaap_EquityFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EquityFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_TotalConsiderationPaidUnderPurchaseAgreement" xlink:label="incy_TotalConsiderationPaidUnderPurchaseAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_TotalConsiderationPaidUnderPurchaseAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LongTermInvestments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue" xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss" xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LiabilitiesCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails" xlink:type="extended" xlink:title="40905 - Disclosure - License agreements - Calithera (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CalitheraBiosciencesIncMember" xlink:label="incy_CalitheraBiosciencesIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="incy_CalitheraBiosciencesIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="incy_CalitheraBiosciencesIncMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_StockPurchaseAgreementMember" xlink:label="incy_StockPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="incy_StockPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="country_US" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637243060152432062" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_637243060152432062" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeMember" xlink:label="us-gaap_OtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="us-gaap_AccruedLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AccruedLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded" xlink:label="incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PercentageOfProfitsLosses" xlink:label="incy_PercentageOfProfitsLosses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_PercentageOfProfitsLosses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementUpfrontPayment" xlink:label="incy_LicenseAgreementUpfrontPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_LicenseAgreementUpfrontPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementPotentialMilestonePaymentsWithProfitSharing" xlink:label="incy_LicenseAgreementPotentialMilestonePaymentsWithProfitSharing" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_LicenseAgreementPotentialMilestonePaymentsWithProfitSharing" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementPotentialMilestonePaymentsWithoutProfitSharing" xlink:label="incy_LicenseAgreementPotentialMilestonePaymentsWithoutProfitSharing" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_LicenseAgreementPotentialMilestonePaymentsWithoutProfitSharing" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementMilestonePaymentAmountPaid" xlink:label="incy_LicenseAgreementMilestonePaymentAmountPaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_LicenseAgreementMilestonePaymentAmountPaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares" xlink:label="incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="us-gaap_EquityFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EquityFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_TotalConsiderationPaidUnderPurchaseAgreement" xlink:label="incy_TotalConsiderationPaidUnderPurchaseAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_TotalConsiderationPaidUnderPurchaseAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CollaborationAgreementUpfrontPayment" xlink:label="incy_CollaborationAgreementUpfrontPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_CollaborationAgreementUpfrontPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PurchasePriceOfCommonStockUnderStockPurchaseAgreement" xlink:label="incy_PurchasePriceOfCommonStockUnderStockPurchaseAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_PurchasePriceOfCommonStockUnderStockPurchaseAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LongTermInvestments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.incyte.com/role/DisclosureLicenseAgreementsMacrogenicsDetails" xlink:type="extended" xlink:title="40906 - Disclosure - License agreements - MacroGenics (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_MacrogenicsMember" xlink:label="incy_MacrogenicsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="incy_MacrogenicsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AchievementOfMilestoneAxis" xlink:label="incy_AchievementOfMilestoneAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="incy_AchievementOfMilestoneAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AchievementOfMilestoneDomain" xlink:label="incy_AchievementOfMilestoneDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="incy_AchievementOfMilestoneAxis" xlink:to="incy_AchievementOfMilestoneDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DevelopmentAndRegulatoryMilestonesMember" xlink:label="incy_DevelopmentAndRegulatoryMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="incy_AchievementOfMilestoneDomain" xlink:to="incy_DevelopmentAndRegulatoryMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CommercializationMilestonesMember" xlink:label="incy_CommercializationMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="incy_AchievementOfMilestoneDomain" xlink:to="incy_CommercializationMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="us-gaap_AccruedLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AccruedLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementUpfrontPaymentAmountPaid" xlink:label="incy_LicenseAgreementUpfrontPaymentAmountPaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_LicenseAgreementUpfrontPaymentAmountPaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementAdditionalMilestonePayments" xlink:label="incy_LicenseAgreementAdditionalMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_LicenseAgreementAdditionalMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PercentageOfRoyaltyRatePayments" xlink:label="incy_PercentageOfRoyaltyRatePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_PercentageOfRoyaltyRatePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.incyte.com/role/DisclosureLicenseAgreementsSyrosDetails" xlink:type="extended" xlink:title="40907 - Disclosure - License agreements - Syros (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_SyrosPharmaceuticalsIncMember" xlink:label="incy_SyrosPharmaceuticalsIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="incy_SyrosPharmaceuticalsIncMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AchievementOfMilestoneAxis" xlink:label="incy_AchievementOfMilestoneAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="incy_AchievementOfMilestoneAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AchievementOfMilestoneDomain" xlink:label="incy_AchievementOfMilestoneDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="incy_AchievementOfMilestoneAxis" xlink:to="incy_AchievementOfMilestoneDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DevelopmentAndRegulatoryMilestonesMember" xlink:label="incy_DevelopmentAndRegulatoryMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="incy_AchievementOfMilestoneDomain" xlink:to="incy_DevelopmentAndRegulatoryMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CommercializationMilestonesMember" xlink:label="incy_CommercializationMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="incy_AchievementOfMilestoneDomain" xlink:to="incy_CommercializationMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_StockPurchaseAgreementMember" xlink:label="incy_StockPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="incy_StockPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AmendedStockPurchaseAgreementMember" xlink:label="incy_AmendedStockPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="incy_AmendedStockPurchaseAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_NumberOfProgramTargets" xlink:label="incy_NumberOfProgramTargets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_NumberOfProgramTargets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementTargetSelectionAndOptionExerciseFeePayments" xlink:label="incy_LicenseAgreementTargetSelectionAndOptionExerciseFeePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_LicenseAgreementTargetSelectionAndOptionExerciseFeePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementAdditionalMilestonePayments" xlink:label="incy_LicenseAgreementAdditionalMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_LicenseAgreementAdditionalMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementUpfrontPaymentAmountPaid" xlink:label="incy_LicenseAgreementUpfrontPaymentAmountPaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_LicenseAgreementUpfrontPaymentAmountPaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares" xlink:label="incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_StockPurchaseAgreementLockUpPeriod" xlink:label="incy_StockPurchaseAgreementLockUpPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_StockPurchaseAgreementLockUpPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_FairValueInputsAmountOfDiscountForLackOfMarketability" xlink:label="incy_FairValueInputsAmountOfDiscountForLackOfMarketability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_FairValueInputsAmountOfDiscountForLackOfMarketability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="us-gaap_EquityFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EquityFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LongTermInvestments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.incyte.com/role/DisclosureLicenseAgreementsInnoventDetails" xlink:type="extended" xlink:title="40908 - Disclosure - License agreements - Innovent (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_InnoventBiologicsIncMember" xlink:label="incy_InnoventBiologicsIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="incy_InnoventBiologicsIncMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AchievementOfMilestoneAxis" xlink:label="incy_AchievementOfMilestoneAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="incy_AchievementOfMilestoneAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AchievementOfMilestoneDomain" xlink:label="incy_AchievementOfMilestoneDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="incy_AchievementOfMilestoneAxis" xlink:to="incy_AchievementOfMilestoneDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_RegulatoryMilestonesMember" xlink:label="incy_RegulatoryMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="incy_AchievementOfMilestoneDomain" xlink:to="incy_RegulatoryMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DevelopmentAndRegulatoryMilestonesMember" xlink:label="incy_DevelopmentAndRegulatoryMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="incy_AchievementOfMilestoneDomain" xlink:to="incy_DevelopmentAndRegulatoryMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CommercializationMilestonesMember" xlink:label="incy_CommercializationMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="incy_AchievementOfMilestoneDomain" xlink:to="incy_CommercializationMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" xlink:label="incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" xlink:label="incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementUpfrontPaymentAmountPaid" xlink:label="incy_LicenseAgreementUpfrontPaymentAmountPaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_LicenseAgreementUpfrontPaymentAmountPaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementMilestonePaymentAmountPaid" xlink:label="incy_LicenseAgreementMilestonePaymentAmountPaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_LicenseAgreementMilestonePaymentAmountPaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementResearchAndDevelopmentReimbursedCost" xlink:label="incy_LicenseAgreementResearchAndDevelopmentReimbursedCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_LicenseAgreementResearchAndDevelopmentReimbursedCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementReimbursableCosts" xlink:label="incy_LicenseAgreementReimbursableCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_LicenseAgreementReimbursableCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_NumberOfProductCandidates" xlink:label="incy_NumberOfProductCandidates" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="incy_NumberOfProductCandidates" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.incyte.com/role/DisclosureLicenseAgreementsZaiLabDetails" xlink:type="extended" xlink:title="40909 - Disclosure - License agreements - Zai Lab (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember" xlink:label="incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AchievementOfMilestoneAxis" xlink:label="incy_AchievementOfMilestoneAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="incy_AchievementOfMilestoneAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AchievementOfMilestoneDomain" xlink:label="incy_AchievementOfMilestoneDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="incy_AchievementOfMilestoneAxis" xlink:to="incy_AchievementOfMilestoneDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DevelopmentRegulatoryAndCommercialMilestonesMember" xlink:label="incy_DevelopmentRegulatoryAndCommercialMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="incy_AchievementOfMilestoneDomain" xlink:to="incy_DevelopmentRegulatoryAndCommercialMilestonesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" xlink:label="incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementUpfrontPaymentAmountPaid" xlink:label="incy_LicenseAgreementUpfrontPaymentAmountPaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="incy_LicenseAgreementUpfrontPaymentAmountPaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementResearchAndDevelopmentReimbursedCost" xlink:label="incy_LicenseAgreementResearchAndDevelopmentReimbursedCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="incy_LicenseAgreementResearchAndDevelopmentReimbursedCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementReimbursableCosts" xlink:label="incy_LicenseAgreementReimbursableCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="incy_LicenseAgreementReimbursableCosts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails" xlink:type="extended" xlink:title="40910 - Disclosure - License agreements - MorphoSys (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_MorphosysAgMember" xlink:label="incy_MorphosysAgMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="incy_MorphosysAgMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637243060152622081" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_637243060152622081" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_IncyteMember" xlink:label="incy_IncyteMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="incy_IncyteMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637243060152622081" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637243060152622081" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="incy_MorphosysAgMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AchievementOfMilestoneAxis" xlink:label="incy_AchievementOfMilestoneAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="incy_AchievementOfMilestoneAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AchievementOfMilestoneDomain" xlink:label="incy_AchievementOfMilestoneDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="incy_AchievementOfMilestoneAxis" xlink:to="incy_AchievementOfMilestoneDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DevelopmentAndRegulatoryMilestonesMember" xlink:label="incy_DevelopmentAndRegulatoryMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="incy_AchievementOfMilestoneDomain" xlink:to="incy_DevelopmentAndRegulatoryMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CommercializationMilestonesMember" xlink:label="incy_CommercializationMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="incy_AchievementOfMilestoneDomain" xlink:to="incy_CommercializationMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_StatementTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AmericanDepositarySharesMember" xlink:label="incy_AmericanDepositarySharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="incy_AmericanDepositarySharesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="us-gaap_AccruedLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AccruedLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded" xlink:label="incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementUpfrontPaymentAmountPaid" xlink:label="incy_LicenseAgreementUpfrontPaymentAmountPaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="incy_LicenseAgreementUpfrontPaymentAmountPaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementAdditionalMilestonePayments" xlink:label="incy_LicenseAgreementAdditionalMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="incy_LicenseAgreementAdditionalMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_StockPurchaseAgreementLockUpPeriod" xlink:label="incy_StockPurchaseAgreementLockUpPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="incy_StockPurchaseAgreementLockUpPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_FairValueInputsAmountOfDiscountForLackOfMarketability" xlink:label="incy_FairValueInputsAmountOfDiscountForLackOfMarketability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="incy_FairValueInputsAmountOfDiscountForLackOfMarketability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="us-gaap_EquityFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermInvestments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CollaborationAgreementProfitLossSharingRatio" xlink:label="incy_CollaborationAgreementProfitLossSharingRatio" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="incy_CollaborationAgreementProfitLossSharingRatio" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CollaborationLossSharingExpense" xlink:label="incy_CollaborationLossSharingExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="incy_CollaborationLossSharingExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.incyte.com/role/DisclosureStockCompensationDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Stock compensation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637243060152692083" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637243060152692083" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637243060152692083" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637243060152692083" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_StockCompensationExpenseCapitalized" xlink:label="incy_StockCompensationExpenseCapitalized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="incy_StockCompensationExpenseCapitalized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.incyte.com/role/DisclosureStockCompensationOptionActivityDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Stock compensation - Option activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_637243060152742087" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_637243060152742087" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuAwardActivityDetails" xlink:type="extended" xlink:title="41003 - Disclosure - Stock compensation - RSU and PSU award activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuDetails" xlink:type="extended" xlink:title="41004 - Disclosure - Stock compensation - RSU and PSU (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637243060152832090" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_637243060152832090" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LongTermIncentivePlanOneMember" xlink:label="incy_LongTermIncentivePlanOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="incy_LongTermIncentivePlanOneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LongTermIncentivePlanTwoMember" xlink:label="incy_LongTermIncentivePlanTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="incy_LongTermIncentivePlanTwoMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageMultiplierForConversionOfUnitsIntoCommonStock" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageMultiplierForConversionOfUnitsIntoCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageMultiplierForConversionOfUnitsIntoCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.incyte.com/role/DisclosureDebtComponentsOfConvertibleNotesDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Debt - Components of convertible notes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ConvertibleSeniorNotes1.25PercentDue2020Member" xlink:label="incy_ConvertibleSeniorNotes1.25PercentDue2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="incy_ConvertibleSeniorNotes1.25PercentDue2020Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConvertibleDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.incyte.com/role/DisclosureDebtCarryingAmountAndFairValueDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Debt - Carrying amount and Fair Value (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ConvertibleSeniorNotes1.25PercentDue2020Member" xlink:label="incy_ConvertibleSeniorNotes1.25PercentDue2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="incy_ConvertibleSeniorNotes1.25PercentDue2020Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConvertibleDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.incyte.com/role/DisclosureDebtNarrativeDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Debt - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member" xlink:label="incy_ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="incy_ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xlink:label="incy_DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="incy_DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" xlink:label="incy_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="incy_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" xlink:label="incy_DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="incy_DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod" xlink:label="incy_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="incy_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays" xlink:label="incy_DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="incy_DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum" xlink:label="incy_DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="incy_DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DebtInstrumentConversionObligationNumberOfScheduledTradingDaysBeforeMaturity" xlink:label="incy_DebtInstrumentConversionObligationNumberOfScheduledTradingDaysBeforeMaturity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="incy_DebtInstrumentConversionObligationNumberOfScheduledTradingDaysBeforeMaturity" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.incyte.com/role/DisclosureNetIncomeLossPerShareDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Net income (loss) per share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_637243060152912077" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_637243060152912077" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ConvertibleSeniorNotes1.25PercentDue2020Member" xlink:label="incy_ConvertibleSeniorNotes1.25PercentDue2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="incy_ConvertibleSeniorNotes1.25PercentDue2020Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasicAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="us-gaap_EarningsPerShareDilutedAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareDilutedAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>incy-20200505_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7401.38943 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/5/2020 8:06:59 PM-->
<!--Modified on: 5/5/2020 8:06:59 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Quarterly Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONDENSED CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Consolidated Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ASSETS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities-available-for-sale (amortized cost $258,622; allowance for credit losses $0)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories - current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndInvestmentsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:to="us-gaap_RestrictedCashAndInvestmentsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndInvestmentsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash and Investments, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndInvestmentsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash and investments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long term investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long term investments (Note 6)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="us-gaap_InventoryNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNoncurrent" xlink:to="us-gaap_InventoryNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories-noncurrent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance lease right-of-use assets, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="us-gaap_OtherIntangibleAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIntangibleAssetsNet" xlink:to="us-gaap_OtherIntangibleAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIntangibleAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Intangible Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIntangibleAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other intangible assets, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LIABILITIES AND STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued and other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total accrued and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance lease liabilities, current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtCurrent" xlink:to="us-gaap_ConvertibleDebtCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Debt, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible senior notes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Contingent Consideration, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition-related contingent consideration</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Contingent Consideration, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition-related contingent consideration</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance lease liabilities, noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, $0.001 par value; 5,000,000 shares authorized; none issued or outstanding as of March 31, 2020 and December 31, 2019</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.001 par value; 400,000,000 shares authorized; 216,952,325 and 216,177,830 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Amortized Cost, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities-amortized cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Allowance for Credit Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities-allowance for credit losses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total revenues</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Costs and Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Costs and expenses:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of product revenues (including definite-lived intangible amortization)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, general and administrative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of acquisition-related contingent consideration</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CollaborationLossSharingExpense" xlink:label="incy_CollaborationLossSharingExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_CollaborationLossSharingExpense" xlink:to="incy_CollaborationLossSharingExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_CollaborationLossSharingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The expense recognized during the reporting period for collaboration loss sharing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_CollaborationLossSharingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Loss Sharing Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_CollaborationLossSharingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration loss sharing</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Costs and Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total costs and expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (loss) from operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expense), net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Securities, FV-NI, Unrealized Gain (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized loss (gain) on long term investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized gain (loss) on long term investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized gain (loss) on long term investments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (loss) before provision for income taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax (benefit) expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net (loss) income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net income (loss)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic and Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net income (loss) per share:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic net income (loss) per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted net income (loss) per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares used in computing net income (loss) per share:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average common shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares used to compute diluted net income (loss) per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive loss:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency translation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized gain on marketable securities, net of tax</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined benefit pension obligations, net of tax</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive income (loss)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of shares of Common Stock upon exercise of stock options and settlement of employee restricted stock units</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Issued for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of shares of Common Stock for services rendered</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock compensation</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AdoptionOfAccountingStandardAdjustmentToRetainedEarnings" xlink:label="incy_AdoptionOfAccountingStandardAdjustmentToRetainedEarnings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_AdoptionOfAccountingStandardAdjustmentToRetainedEarnings" xlink:to="incy_AdoptionOfAccountingStandardAdjustmentToRetainedEarnings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_AdoptionOfAccountingStandardAdjustmentToRetainedEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase (decrease) in retained earnings due to the adjustment of prepaid tax assets from adoption of new accounting standard.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_AdoptionOfAccountingStandardAdjustmentToRetainedEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adoption of Accounting Standard Adjustment To Retained Earnings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_AdoptionOfAccountingStandardAdjustmentToRetainedEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adoption of ASU No. 2016-02</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of shares of Common Stock upon exercise of stock options and restricted stock units</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Issued for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of shares of Common Stock for services rendered</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net income (loss)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net income to net cash provided by operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Noncash Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued and other liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash (used in) provided by operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from investing activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireLongtermInvestments" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireLongtermInvestments" xlink:to="us-gaap_PaymentsToAcquireLongtermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Long-term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of long term investments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Productive Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital expenditures</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Sale and Maturity of Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale and maturities of marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock under stock plans</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Principal Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of finance lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for financing lease liabilities in financing cash flows</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PaymentOfContingentConsideration" xlink:label="incy_PaymentOfContingentConsideration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_PaymentOfContingentConsideration" xlink:to="incy_PaymentOfContingentConsideration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_PaymentOfContingentConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash outflow with regard to the contingent consideration during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_PaymentOfContingentConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of Contingent Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="incy_PaymentOfContingentConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of contingent consideration</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency translation change</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of exchange rates on cash, cash equivalents, restricted cash and investments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net (decrease) increase in cash, cash equivalents, restricted cash and investments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents, restricted cash and investments at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents, restricted cash and investments at beginning of period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Schedule of Cash Flow Information</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes Paid, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes paid</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Expenditures Incurred but Not yet Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unpaid purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leased assets obtained in exchange for new operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leased assets obtained in exchange for new finance lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rate of debt (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization and business</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization and business</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of significant accounting policies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of significant accounting policies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of financial instruments.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of financial instruments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of credit risk and current expected credit losses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of credit risk and current expected credit losses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets and goodwill</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill and Intangible Assets Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets and goodwill</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementsDisclosureAbstract" xlink:label="incy_LicenseAgreementsDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_LicenseAgreementsDisclosureAbstract" xlink:to="incy_LicenseAgreementsDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_LicenseAgreementsDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreements</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementsTextBlock" xlink:label="incy_LicenseAgreementsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_LicenseAgreementsTextBlock" xlink:to="incy_LicenseAgreementsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_LicenseAgreementsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This element may be used to describe all significant license agreements of the reporting entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_LicenseAgreementsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreements [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_LicenseAgreementsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee benefit plans</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pension and Other Postretirement Benefits Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee benefit plans</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net income (loss) per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net income (loss) per share</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LitigationDisclosureAbstract" xlink:label="incy_LitigationDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_LitigationDisclosureAbstract" xlink:to="incy_LitigationDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_LitigationDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingencies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="us-gaap_LegalMattersAndContingenciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Matters and Contingencies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingencies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent event</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent event</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of presentation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidation, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principles of Consolidation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Translation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentrations of Credit Risk</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:label="us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:to="us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Loss, Financial Instrument [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Expected Credit Losses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities-Available-for-Sale</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and Other Accounts Receivable, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="us-gaap_ConsolidationVariableInterestEntityPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Interest Entities</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LongTermInvestmentPolicyTextBlock" xlink:label="incy_LongTermInvestmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_LongTermInvestmentPolicyTextBlock" xlink:to="incy_LongTermInvestmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_LongTermInvestmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for long term investments in financial asset.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_LongTermInvestmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Investment [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_LongTermInvestmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Investments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Accounting</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Intangible Assets, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of Long-Lived Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing Costs Related to Long-term Debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue From Contract With Customer Policy Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Compensation and Long-term Incentive Plans</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_BusinessCombinationContingentConsiderationPolicyTextBlock" xlink:label="incy_BusinessCombinationContingentConsiderationPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_BusinessCombinationContingentConsiderationPolicyTextBlock" xlink:to="incy_BusinessCombinationContingentConsiderationPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_BusinessCombinationContingentConsiderationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for acquisition related contingent consideration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_BusinessCombinationContingentConsiderationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination Contingent Consideration [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_BusinessCombinationContingentConsiderationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition-Related Contingent Consideration</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement, Accounting Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration loss sharing</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disaggregation of Revenue [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of disaggregated revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of fair value of assets measured on recurring basis</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of fair value of liabilities measured on recurring basis</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of roll forward of Level 3 liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of marketable securities portfolio</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_SchedulesOfConcentrationOfRiskByRiskFactorRelatedToSpecialtyPharmaceuticalCustomersTableTextBlock" xlink:label="incy_SchedulesOfConcentrationOfRiskByRiskFactorRelatedToSpecialtyPharmaceuticalCustomersTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_SchedulesOfConcentrationOfRiskByRiskFactorRelatedToSpecialtyPharmaceuticalCustomersTableTextBlock" xlink:to="incy_SchedulesOfConcentrationOfRiskByRiskFactorRelatedToSpecialtyPharmaceuticalCustomersTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_SchedulesOfConcentrationOfRiskByRiskFactorRelatedToSpecialtyPharmaceuticalCustomersTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark, related to the specialty pharmaceutical customers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_SchedulesOfConcentrationOfRiskByRiskFactorRelatedToSpecialtyPharmaceuticalCustomersTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedules of Concentration of Risk by Risk Factor Related to Specialty Pharmaceutical Customers [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_SchedulesOfConcentrationOfRiskByRiskFactorRelatedToSpecialtyPharmaceuticalCustomersTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of concentration of credit risk related to specialty pharmacy customers</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ScheduleOfInventoryTableTextBlock" xlink:label="incy_ScheduleOfInventoryTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_ScheduleOfInventoryTableTextBlock" xlink:to="incy_ScheduleOfInventoryTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_ScheduleOfInventoryTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of carrying amount of inventories as of the balance sheet date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_ScheduleOfInventoryTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Inventory [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_ScheduleOfInventoryTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of inventory</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LesseeLeaseLiabilityTableTextBlock" xlink:label="incy_LesseeLeaseLiabilityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_LesseeLeaseLiabilityTableTextBlock" xlink:to="incy_LesseeLeaseLiabilityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_LesseeLeaseLiabilityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure of lease liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_LesseeLeaseLiabilityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease Liability [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_LesseeLeaseLiabilityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of lease liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of finite-lived intangible assets, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of estimated aggregate amortization expense</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="incy_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="incy_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock options plan and employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share Based Payment Award, Stock Options and Employee Stock Purchase Plan Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of valuation assumptions used for valuation of fair value of stock compensation granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of option activity under the 2010 Stock Plan</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock" xlink:label="incy_ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock" xlink:to="incy_ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure represents the schedule of share based compensation other than stock options activity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of RSU award and PSU activity under the 2010 Stock Plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Nonvested Share Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of shares available for grant</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accrued and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-term Debt Instruments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of components of convertible notes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of carrying amount and fair value of convertible notes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:label="us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Net Benefit Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of net periodic benefit cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of calculation of net income (loss) per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of antidilutive securities excluded from the computation of earnings per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:label="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:to="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization and Business</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of operating segments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Products and Services [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Products And Services [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Products and Services [Domain]</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_JAKAFIMember" xlink:label="incy_JAKAFIMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_JAKAFIMember" xlink:to="incy_JAKAFIMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_JAKAFIMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to JAKAFI (ruxolitinib), an oral Janus associate kinase (JAK) inhibitor sold within the United State of America.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_JAKAFIMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">J A K A F I [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_JAKAFIMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">JAKAFI</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ICLUSIGMember" xlink:label="incy_ICLUSIGMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_ICLUSIGMember" xlink:to="incy_ICLUSIGMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_ICLUSIGMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to ICLUSIG, a kinase inhibitor.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_ICLUSIGMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">I C L U S I G [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_ICLUSIGMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICLUSIG</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ConcentrationOfCreditRiskAbstract" xlink:label="incy_ConcentrationOfCreditRiskAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_ConcentrationOfCreditRiskAbstract" xlink:to="incy_ConcentrationOfCreditRiskAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_ConcentrationOfCreditRiskAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of Credit Risk [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_ConcentrationOfCreditRiskAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentrations of Credit Risk</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CreditExposureLimitationNumberOfIssuerOtherThanUnitedStatesGovernmentGuaranteedSecurities" xlink:label="incy_CreditExposureLimitationNumberOfIssuerOtherThanUnitedStatesGovernmentGuaranteedSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_CreditExposureLimitationNumberOfIssuerOtherThanUnitedStatesGovernmentGuaranteedSecurities" xlink:to="incy_CreditExposureLimitationNumberOfIssuerOtherThanUnitedStatesGovernmentGuaranteedSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_CreditExposureLimitationNumberOfIssuerOtherThanUnitedStatesGovernmentGuaranteedSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of issuer to which entity limits the amount of credit exposure other than US Government guaranteed securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_CreditExposureLimitationNumberOfIssuerOtherThanUnitedStatesGovernmentGuaranteedSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Exposure Limitation Number of Issuer Other than United States Government Guaranteed Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_CreditExposureLimitationNumberOfIssuerOtherThanUnitedStatesGovernmentGuaranteedSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of issuer to which company limits the amount of credit exposure other than US Government guaranteed securities</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CreditExposureLimitationNumberOfFinancialInvestmentOtherThanUnitedStatesGovernmentGuaranteedSecurities" xlink:label="incy_CreditExposureLimitationNumberOfFinancialInvestmentOtherThanUnitedStatesGovernmentGuaranteedSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_CreditExposureLimitationNumberOfFinancialInvestmentOtherThanUnitedStatesGovernmentGuaranteedSecurities" xlink:to="incy_CreditExposureLimitationNumberOfFinancialInvestmentOtherThanUnitedStatesGovernmentGuaranteedSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_CreditExposureLimitationNumberOfFinancialInvestmentOtherThanUnitedStatesGovernmentGuaranteedSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of financial investment to which entity limits the amount of credit exposure other than US Government guaranteed securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_CreditExposureLimitationNumberOfFinancialInvestmentOtherThanUnitedStatesGovernmentGuaranteedSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Exposure Limitation, Number of Financial Investment Other than United States Government Guaranteed Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_CreditExposureLimitationNumberOfFinancialInvestmentOtherThanUnitedStatesGovernmentGuaranteedSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of financial investment to which company limits the amount of credit exposure other than US Government guaranteed securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="us-gaap_InventoryNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_InventoryFinishedGoodsUsefulLifeMaximum" xlink:label="incy_InventoryFinishedGoodsUsefulLifeMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_InventoryFinishedGoodsUsefulLifeMaximum" xlink:to="incy_InventoryFinishedGoodsUsefulLifeMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_InventoryFinishedGoodsUsefulLifeMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the maximum useful life of merchandise or goods held by the entity that are readily available for sale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_InventoryFinishedGoodsUsefulLifeMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Finished Goods Useful Life Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_InventoryFinishedGoodsUsefulLifeMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shelf life for finished goods inventory, maximum</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_VariableInterestEntitiesAbstract" xlink:label="incy_VariableInterestEntitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_VariableInterestEntitiesAbstract" xlink:to="incy_VariableInterestEntitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_VariableInterestEntitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_VariableInterestEntitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Interest Entities Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_VariableInterestEntitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Interest Entities</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_VariableInterestEntitiesNumber" xlink:label="incy_VariableInterestEntitiesNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_VariableInterestEntitiesNumber" xlink:to="incy_VariableInterestEntitiesNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_VariableInterestEntitiesNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of Variable Interest Entities as on date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_VariableInterestEntitiesNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Interest Entities Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_VariableInterestEntitiesNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of entities in which variable interest held</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disaggregation of Revenue [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognition</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PercentageOfMedicarePartDInsuranceCoverageGapRequiredToBeFundedByManufacturers" xlink:label="incy_PercentageOfMedicarePartDInsuranceCoverageGapRequiredToBeFundedByManufacturers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_PercentageOfMedicarePartDInsuranceCoverageGapRequiredToBeFundedByManufacturers" xlink:to="incy_PercentageOfMedicarePartDInsuranceCoverageGapRequiredToBeFundedByManufacturers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_PercentageOfMedicarePartDInsuranceCoverageGapRequiredToBeFundedByManufacturers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of Medicare Part D insurance coverage gap mandate to be funded by manufacturers for prescription drugs sold to eligible patients.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_PercentageOfMedicarePartDInsuranceCoverageGapRequiredToBeFundedByManufacturers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Medicare Part D Insurance Coverage Gap Required To Be Funded By Manufacturers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_PercentageOfMedicarePartDInsuranceCoverageGapRequiredToBeFundedByManufacturers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Medicare Part D insurance coverage gap mandate to be funded by manufacturers</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_MedicarePartDInsuranceCoverageGapIncreaseInEligiblePatientSpendingPercentage" xlink:label="incy_MedicarePartDInsuranceCoverageGapIncreaseInEligiblePatientSpendingPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_MedicarePartDInsuranceCoverageGapIncreaseInEligiblePatientSpendingPercentage" xlink:to="incy_MedicarePartDInsuranceCoverageGapIncreaseInEligiblePatientSpendingPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_MedicarePartDInsuranceCoverageGapIncreaseInEligiblePatientSpendingPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the Medicare Part D insurance coverage gap percent increase for required patient spending.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_MedicarePartDInsuranceCoverageGapIncreaseInEligiblePatientSpendingPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Medicare Part D Insurance Coverage Gap, Increase in Eligible Patient Spending, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_MedicarePartDInsuranceCoverageGapIncreaseInEligiblePatientSpendingPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in required patient spending in the Medicare Part D insurance coverage gap (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Remaining Amortization Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization period</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CollaborationAgreementProfitLossSharingRatio" xlink:label="incy_CollaborationAgreementProfitLossSharingRatio" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_CollaborationAgreementProfitLossSharingRatio" xlink:to="incy_CollaborationAgreementProfitLossSharingRatio_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_CollaborationAgreementProfitLossSharingRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ratio of sharing profit and losses under the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_CollaborationAgreementProfitLossSharingRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement Profit Loss Sharing Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_CollaborationAgreementProfitLossSharingRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit (loss) sharing ratio</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements and Changes in Accounting Principles [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CoronavirusAidReliefAndEconomicSecurityActFund" xlink:label="incy_CoronavirusAidReliefAndEconomicSecurityActFund" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_CoronavirusAidReliefAndEconomicSecurityActFund" xlink:to="incy_CoronavirusAidReliefAndEconomicSecurityActFund_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_CoronavirusAidReliefAndEconomicSecurityActFund_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the Coronavirus Aid, Relief, and Economic Security (CARES) Act funding in the US.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_CoronavirusAidReliefAndEconomicSecurityActFund_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Coronavirus Aid, Relief, and Economic Security Act Fund</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_CoronavirusAidReliefAndEconomicSecurityActFund_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Coronavirus Aid, Relief, and Economic Security (CARES) Act</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disaggregation of Revenue [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer, Excluding Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of financial instruments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available-for-sale Securities, Debt Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt securities (government)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated Fair Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Contingent Consideration, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition-related contingent consideration</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Liabilities Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Roll forward of Level 3 liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning of the period</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned" xlink:label="incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned" xlink:to="incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of decrease in the value of a contingent consideration liability attributable to consideration earned by the acquiree in a business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Contingent Consideration Arrangements, Change In Amount Of Contingent Consideration Liability, Consideration Earned</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration earned during the period but not yet paid</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of contingent consideration</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_FairValueInputsCashFlowsEstimatedPeriod" xlink:label="incy_FairValueInputsCashFlowsEstimatedPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_FairValueInputsCashFlowsEstimatedPeriod" xlink:to="incy_FairValueInputsCashFlowsEstimatedPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_FairValueInputsCashFlowsEstimatedPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of time used to measure cash flows to find the present value of an amount to be paid or received in the future as an input to measure fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_FairValueInputsCashFlowsEstimatedPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Inputs Cash Flows Estimated Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_FairValueInputsCashFlowsEstimatedPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Projected cash flows period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Contingent Consideration, Liability, Measurement Input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation input (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Available-for-sale Securities [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of marketable security portfolio</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available-for-sale Debt Securities, Amortized Cost Basis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortized Cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Unrealized Gains</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual maturity dates</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Benchmark [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Benchmark [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Benchmark [Domain]</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_SalesRevenueGoodsServicesNetMember" xlink:label="incy_SalesRevenueGoodsServicesNetMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_SalesRevenueGoodsServicesNetMember" xlink:to="incy_SalesRevenueGoodsServicesNetMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_SalesRevenueGoodsServicesNetMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate revenue during the period from the sale of goods and services in the normal course of business, after deducting returns, allowances and discounts, when it serves as a benchmark in a concentration of risk calculation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_SalesRevenueGoodsServicesNetMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales Revenue Goods Services Net [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_SalesRevenueGoodsServicesNetMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Product Revenues</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer Concentration Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer Concentration Risk</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditConcentrationRiskMember" xlink:to="us-gaap_CreditConcentrationRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditConcentrationRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Concentration Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CreditConcentrationRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Concentration Risk</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Name Of Major Customer [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer [Domain]</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CollaborationPartneraBAndCMember" xlink:label="incy_CollaborationPartneraBAndCMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_CollaborationPartneraBAndCMember" xlink:to="incy_CollaborationPartneraBAndCMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_CollaborationPartneraBAndCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to both the Collaboration partners A, B and C.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_CollaborationPartneraBAndCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Partnera B And C [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_CollaborationPartneraBAndCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Partner A, B, C and D</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CustomerAMember" xlink:label="incy_CustomerAMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_CustomerAMember" xlink:to="incy_CustomerAMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_CustomerAMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the customer A.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_CustomerAMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer A [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_CustomerAMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer A</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CustomerBMember" xlink:label="incy_CustomerBMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_CustomerBMember" xlink:to="incy_CustomerBMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_CustomerBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the customer B.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_CustomerBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer B [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_CustomerBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer B</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CustomerCMember" xlink:label="incy_CustomerCMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_CustomerCMember" xlink:to="incy_CustomerCMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_CustomerCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the customer C.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_CustomerCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer C [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_CustomerCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer C</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CustomerDMember" xlink:label="incy_CustomerDMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_CustomerDMember" xlink:to="incy_CustomerDMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_CustomerDMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the customer D.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_CustomerDMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer D [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_CustomerDMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer D</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CustomerABCAndDMember" xlink:label="incy_CustomerABCAndDMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_CustomerABCAndDMember" xlink:to="incy_CustomerABCAndDMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_CustomerABCAndDMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the customers A, B, C and D.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_CustomerABCAndDMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer A B C And D [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_CustomerABCAndDMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer A, B, C and D</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of risk</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of concentration risk</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Raw Materials, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Raw materials</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Work in Process, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Work-in-process</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Finished Goods, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finished goods</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_InventoryNetCurrentAndNoncurrent" xlink:label="incy_InventoryNetCurrentAndNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_InventoryNetCurrentAndNoncurrent" xlink:to="incy_InventoryNetCurrentAndNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_InventoryNetCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the aggregate carrying amount of current and noncurrent portion, net of valuation reserves and allowances, as of the balance sheet date of inventories.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_InventoryNetCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Net Current and Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="incy_InventoryNetCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total inventories</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property Plant And Equipment Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Laboratory equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LandMember" xlink:label="us-gaap_LandMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandMember" xlink:to="us-gaap_LandMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LandMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Land [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LandMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Land</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_BuildingAndLeaseholdImprovementsMember" xlink:label="incy_BuildingAndLeaseholdImprovementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_BuildingAndLeaseholdImprovementsMember" xlink:to="incy_BuildingAndLeaseholdImprovementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_BuildingAndLeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to building and leasehold improvements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_BuildingAndLeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Building And Leasehold Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_BuildingAndLeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Building and leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_OperatingLeaseRightOfUseAssetsMember" xlink:label="incy_OperatingLeaseRightOfUseAssetsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_OperatingLeaseRightOfUseAssetsMember" xlink:to="incy_OperatingLeaseRightOfUseAssetsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_OperatingLeaseRightOfUseAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual agreement that stipulates the lessee pay the lessor for use of an asset under operating lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_OperatingLeaseRightOfUseAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Right Of Use Assets [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_OperatingLeaseRightOfUseAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Costs for architectural and engineering studies and initial ground preparation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less accumulated depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealEstatePropertiesAxis" xlink:label="us-gaap_RealEstatePropertiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealEstatePropertiesAxis" xlink:to="us-gaap_RealEstatePropertiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RealEstatePropertiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Real Estate Property Ownership [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealEstatePropertiesDomain" xlink:label="us-gaap_RealEstatePropertiesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealEstatePropertiesDomain" xlink:to="us-gaap_RealEstatePropertiesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RealEstatePropertiesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Real Estate Properties [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RealEstatePropertiesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Real Estate Properties [Domain]</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_OfficeBuildingMorgesSwitzerlandMember" xlink:label="incy_OfficeBuildingMorgesSwitzerlandMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_OfficeBuildingMorgesSwitzerlandMember" xlink:to="incy_OfficeBuildingMorgesSwitzerlandMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_OfficeBuildingMorgesSwitzerlandMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to the office building located in Morges, Switzerland.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_OfficeBuildingMorgesSwitzerlandMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office Building Morges Switzerland [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_OfficeBuildingMorgesSwitzerlandMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office Building in Morges, Switzerland</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember" xlink:label="incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember" xlink:to="incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to land located with Y-PARC, Switzerland's largest technology park in Yverdon.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Land Located Within Y Parc Switzerlands Largest Technology Park In Yverdon [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Land in Y-PARC, Switzerland's largest technology park, Yverdon</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Finance Lease, Term of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial lease term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Finance Lease, Existence of Option to Extend [true false]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options to extend</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:label="us-gaap_LesseeFinanceLeaseRenewalTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:to="us-gaap_LesseeFinanceLeaseRenewalTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeFinanceLeaseRenewalTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Finance Lease, Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeFinanceLeaseRenewalTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Renewal term of agreement to rent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Square Footage of Laboratory and Office Purchased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Square footage</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Present value of lease liabilities</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_FinanceLeaseLeaseIncentiveReceivable" xlink:label="incy_FinanceLeaseLeaseIncentiveReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_FinanceLeaseLeaseIncentiveReceivable" xlink:to="incy_FinanceLeaseLeaseIncentiveReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_FinanceLeaseLeaseIncentiveReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of lease incentive receivable from landlord under finance leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_FinanceLeaseLeaseIncentiveReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Lease Incentive Receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="us-gaap_ConstructionInProgressGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressGross" xlink:to="us-gaap_ConstructionInProgressGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Construction in Progress, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConstructionInProgressGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Site preparation, design and construction costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireRealEstate" xlink:label="us-gaap_PaymentsToAcquireRealEstate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireRealEstate" xlink:to="us-gaap_PaymentsToAcquireRealEstate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireRealEstate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Real Estate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToAcquireRealEstate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_AssetsAndLiabilitiesLesseeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Lease Obligations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfResidualValueGuarantee" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfResidualValueGuarantee" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfResidualValueGuarantee" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfResidualValueGuarantee_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfResidualValueGuarantee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Existence of Residual Value Guarantee [true false]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Existence of Option to Extend [true false]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities, current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities, noncurrent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_OperatingAndFinanceLeaseLiability" xlink:label="incy_OperatingAndFinanceLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_OperatingAndFinanceLeaseLiability" xlink:to="incy_OperatingAndFinanceLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_OperatingAndFinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Present value of lessee's discounted obligation for lease payments from operating and finance lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_OperatingAndFinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating And Finance Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="incy_OperatingAndFinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Interest Payment on Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for financing lease liabilities in operating cash flows</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Payment, Due [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturity of our finance lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Payment, Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease cash payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average lease term, finance leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average lease term, operating leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average discount rate, operating leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average discount rate, finance leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense related to our operating leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Right-of-Use Asset, Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization on our finance lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense on finance lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Rent Expense, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rent expense</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:label="incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:to="incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represent Finite lived and indefinite lived intangible assets by major class.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite Lived And Indefinite Lived Intangible Assets By Major Class [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite Lived Intangible Assets Major Class Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntellectualPropertyMember" xlink:to="us-gaap_IntellectualPropertyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntellectualPropertyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intellectual Property [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntellectualPropertyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensed IP</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represent Finite Lived And Indefinite Lived Intangible Assets By Major Class.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite Lived And Indefinite Lived Intangible Assets By Major Class [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Useful Lives (Years)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-lived intangible assets:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Carrying Amount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Accumulated Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Amortization</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Carrying Amount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization Expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remainder of 2020</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Amortization Expense, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Amortization Expense, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Amortization Expense, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Amortization Expense, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Amortization Expense, after Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereafter</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="us-gaap_GoodwillRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillRollForward" xlink:to="us-gaap_GoodwillRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes to carrying amount of goodwill</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillPeriodIncreaseDecrease" xlink:to="us-gaap_GoodwillPeriodIncreaseDecrease_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes to the carry amount of goodwill</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements And Nonarrangement Transactions [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_NovartisMember" xlink:label="incy_NovartisMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_NovartisMember" xlink:to="incy_NovartisMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_NovartisMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents details pertaining to Novartis with whom we have entered into a Collaboration and License Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_NovartisMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Novartis [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_NovartisMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Novartis</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_GvhdMember" xlink:label="incy_GvhdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_GvhdMember" xlink:to="incy_GvhdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_GvhdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to GVHD, an Graft-Versus-Host Disease field.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_GvhdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gvhd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_GvhdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">GVHD</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_JakaviMember" xlink:label="incy_JakaviMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_JakaviMember" xlink:to="incy_JakaviMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_JakaviMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to JAKAVI (ruxolitinib), an oral Janus associate kinase (JAK) inhibitor sold outside the United State of America.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_JakaviMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Jakavi [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_JakaviMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">JAKAVI</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AchievementOfMilestoneAxis" xlink:label="incy_AchievementOfMilestoneAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_AchievementOfMilestoneAxis" xlink:to="incy_AchievementOfMilestoneAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_AchievementOfMilestoneAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information by different categories of achievement of milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_AchievementOfMilestoneAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Achievement of Milestone [Axis]</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AchievementOfMilestoneDomain" xlink:label="incy_AchievementOfMilestoneDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_AchievementOfMilestoneDomain" xlink:to="incy_AchievementOfMilestoneDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_AchievementOfMilestoneDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Different categories of achievement of milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_AchievementOfMilestoneDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Achievement Of Milestone [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_AchievementOfMilestoneDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Achievement of Milestone [Domain]</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PreSpecifiedEventsMember" xlink:label="incy_PreSpecifiedEventsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_PreSpecifiedEventsMember" xlink:to="incy_PreSpecifiedEventsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_PreSpecifiedEventsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to certain pre-specified events on the basis of which certain milestones are achieved.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_PreSpecifiedEventsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre Specified Events [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_PreSpecifiedEventsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-specified Events</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DevelopmentMilestonesMember" xlink:label="incy_DevelopmentMilestonesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_DevelopmentMilestonesMember" xlink:to="incy_DevelopmentMilestonesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_DevelopmentMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to certain development events on the basis of which certain milestones are achieved.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_DevelopmentMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_DevelopmentMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development Milestones</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_RegulatoryMilestonesMember" xlink:label="incy_RegulatoryMilestonesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_RegulatoryMilestonesMember" xlink:to="incy_RegulatoryMilestonesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_RegulatoryMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to certain regulatory events on the basis of which certain milestones are achieved.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_RegulatoryMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Regulatory Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_RegulatoryMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Regulatory Milestones</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CommercializationMilestonesMember" xlink:label="incy_CommercializationMilestonesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_CommercializationMilestonesMember" xlink:to="incy_CommercializationMilestonesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_CommercializationMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to certain commercialized events on the basis of which certain milestones are achieved.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_CommercializationMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercialization Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_CommercializationMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercialization Milestones</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Geographical [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonUsMember" xlink:to="us-gaap_NonUsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonUsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non Us [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonUsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-U.S.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EuropeMember" xlink:to="srt_EuropeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EuropeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Europe [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_EuropeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Europe</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="country_JP" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_JP" xlink:to="country_JP_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_JP_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">J [P]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_JP_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">JAPAN</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="country_US" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U [S]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_US_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreements</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" xlink:label="incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" xlink:to="incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the upfront and immediate milestone payment received under the license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Upfront Payment and Immediate Milestone Payment to be Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront and immediate milestone payment to be received under license agreement</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementUpfrontPaymentReceived" xlink:label="incy_LicenseAgreementUpfrontPaymentReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_LicenseAgreementUpfrontPaymentReceived" xlink:to="incy_LicenseAgreementUpfrontPaymentReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_LicenseAgreementUpfrontPaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the upfront payment received under the license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_LicenseAgreementUpfrontPaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Upfront Payment Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_LicenseAgreementUpfrontPaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront payment received under license agreement</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementImmediateMilestonePaymentReceived" xlink:label="incy_LicenseAgreementImmediateMilestonePaymentReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_LicenseAgreementImmediateMilestonePaymentReceived" xlink:to="incy_LicenseAgreementImmediateMilestonePaymentReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_LicenseAgreementImmediateMilestonePaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the immediate milestone payment received under the license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_LicenseAgreementImmediateMilestonePaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Immediate Milestone Payment Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_LicenseAgreementImmediateMilestonePaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Immediate milestone payment received under license agreement</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" xlink:label="incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" xlink:to="incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the earning recognized and the payment received for the achievement of a predefined milestone under the license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Amount Recognized and Received for Achievement of a Predefined Milestone</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount recognized and received for the achievement of a predefined milestone</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PercentageOfRoyaltyRatePayments" xlink:label="incy_PercentageOfRoyaltyRatePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_PercentageOfRoyaltyRatePayments" xlink:to="incy_PercentageOfRoyaltyRatePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_PercentageOfRoyaltyRatePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents range of tiered, double-digit royalty payments on future global sales if product is successfully commercialized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_PercentageOfRoyaltyRatePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Royalty Rate Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_PercentageOfRoyaltyRatePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty payments on future global net sales (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:label="us-gaap_IncreaseDecreaseInRoyaltiesPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:to="us-gaap_IncreaseDecreaseInRoyaltiesPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInRoyaltiesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Royalties Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInRoyaltiesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalties payable on net sales</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_RoyaltiesPayable" xlink:label="incy_RoyaltiesPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_RoyaltiesPayable" xlink:to="incy_RoyaltiesPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_RoyaltiesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of royalties payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_RoyaltiesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalties Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_RoyaltiesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalties payable</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementReimbursableCosts" xlink:label="incy_LicenseAgreementReimbursableCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_LicenseAgreementReimbursableCosts" xlink:to="incy_LicenseAgreementReimbursableCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_LicenseAgreementReimbursableCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents reimbursable costs pertaining to license agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_LicenseAgreementReimbursableCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Reimbursable Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_LicenseAgreementReimbursableCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reimbursable costs included in accounts receivable</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementResearchAndDevelopmentReimbursedCost" xlink:label="incy_LicenseAgreementResearchAndDevelopmentReimbursedCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_LicenseAgreementResearchAndDevelopmentReimbursedCost" xlink:to="incy_LicenseAgreementResearchAndDevelopmentReimbursedCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_LicenseAgreementResearchAndDevelopmentReimbursedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents reimbursed costs pertaining to research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_LicenseAgreementResearchAndDevelopmentReimbursedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Research and Development Reimbursed Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_LicenseAgreementResearchAndDevelopmentReimbursedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenses reimbursed</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_RoyaltyPaymentReceivable" xlink:label="incy_RoyaltyPaymentReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_RoyaltyPaymentReceivable" xlink:to="incy_RoyaltyPaymentReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_RoyaltyPaymentReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the royalty payment receivable under the license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_RoyaltyPaymentReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Payment Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_RoyaltyPaymentReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product royalties in accounts receivable</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_EliLillyMember" xlink:label="incy_EliLillyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_EliLillyMember" xlink:to="incy_EliLillyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_EliLillyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents details pertaining to Eli Lilly with whom we have entered into a License, Development and Commercialization Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_EliLillyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eli Lilly [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_EliLillyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eli Lilly</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PhasesOfArrangementsAxis" xlink:label="incy_PhasesOfArrangementsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_PhasesOfArrangementsAxis" xlink:to="incy_PhasesOfArrangementsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_PhasesOfArrangementsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information by phases of arrangements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_PhasesOfArrangementsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Phases of Arrangements [Axis]</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PhasesOfArrangementsDomain" xlink:label="incy_PhasesOfArrangementsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_PhasesOfArrangementsDomain" xlink:to="incy_PhasesOfArrangementsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_PhasesOfArrangementsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Different phases of arrangements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_PhasesOfArrangementsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Phases Of Arrangements [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_PhasesOfArrangementsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Phases of Arrangements [Domain]</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PhaseThreeMember" xlink:label="incy_PhaseThreeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_PhaseThreeMember" xlink:to="incy_PhaseThreeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_PhaseThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the Phase III of the arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_PhaseThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Phase Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_PhaseThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Phase III</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PhaseTwoBMember" xlink:label="incy_PhaseTwoBMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_PhaseTwoBMember" xlink:to="incy_PhaseTwoBMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_PhaseTwoBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to phase IIb of the arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_PhaseTwoBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Phase Two B [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_PhaseTwoBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Phase IIB</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded" xlink:label="incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded" xlink:to="incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of future global development costs funded under the license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement Percentage of Future Global Development Costs Funded</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Funding of future development costs (as a percent)</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds" xlink:label="incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds" xlink:to="incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of associated future global development costs from the initiation of a Phase IIb trial provided the entity elects to co-develop any compounds and/or indications.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Funding on Cost on Possible Election of Co-development of Compounds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Associated future global development costs from the initiation of a Phase IIb trial, if elected to co-develop (as a percentage)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Associated future global development costs , if elected to co-develop (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities and Other Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued and other liabilities</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementUpfrontPaymentAmountPaid" xlink:label="incy_LicenseAgreementUpfrontPaymentAmountPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_LicenseAgreementUpfrontPaymentAmountPaid" xlink:to="incy_LicenseAgreementUpfrontPaymentAmountPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_LicenseAgreementUpfrontPaymentAmountPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of the upfront payment made under the license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_LicenseAgreementUpfrontPaymentAmountPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement Upfront Payment Amount Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_LicenseAgreementUpfrontPaymentAmountPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront payment under license agreement</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementAdditionalMilestonePayments" xlink:label="incy_LicenseAgreementAdditionalMilestonePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_LicenseAgreementAdditionalMilestonePayments" xlink:to="incy_LicenseAgreementAdditionalMilestonePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_LicenseAgreementAdditionalMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the additional milestone payments to be made under the license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_LicenseAgreementAdditionalMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement Additional Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_LicenseAgreementAdditionalMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional milestone payments under the license agreement</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementMilestonePaymentAmountPaid" xlink:label="incy_LicenseAgreementMilestonePaymentAmountPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_LicenseAgreementMilestonePaymentAmountPaid" xlink:to="incy_LicenseAgreementMilestonePaymentAmountPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_LicenseAgreementMilestonePaymentAmountPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of the milestone payment made under the license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_LicenseAgreementMilestonePaymentAmountPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement Milestone Payment Amount Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_LicenseAgreementMilestonePaymentAmountPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payment made under license agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment, Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Method Investee Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AgenusMember" xlink:label="incy_AgenusMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_AgenusMember" xlink:to="incy_AgenusMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_AgenusMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents details pertaining to Agenus with whom we have entered into a License, Development and Commercialization Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_AgenusMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agenus [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_AgenusMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agenus</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_StockPurchaseAgreementMember" xlink:label="incy_StockPurchaseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_StockPurchaseAgreementMember" xlink:to="incy_StockPurchaseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_StockPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents stock purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_StockPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_StockPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock purchase agreement</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DevelopmentRegulatoryAndCommercializationMilestonesMember" xlink:label="incy_DevelopmentRegulatoryAndCommercializationMilestonesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_DevelopmentRegulatoryAndCommercializationMilestonesMember" xlink:to="incy_DevelopmentRegulatoryAndCommercializationMilestonesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_DevelopmentRegulatoryAndCommercializationMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents development regulatory and commercialization milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_DevelopmentRegulatoryAndCommercializationMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development Regulatory And Commercialization Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_DevelopmentRegulatoryAndCommercializationMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development, Regulatory and Commercialization Milestones</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="us-gaap_AccruedLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesMember" xlink:to="us-gaap_AccruedLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued and other liabilities</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_NumberOfProgramTargets" xlink:label="incy_NumberOfProgramTargets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_NumberOfProgramTargets" xlink:to="incy_NumberOfProgramTargets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_NumberOfProgramTargets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of program targets identified.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_NumberOfProgramTargets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Program Targets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_NumberOfProgramTargets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of program targets</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares" xlink:label="incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares" xlink:to="incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the purchase of common stock under Stock Purchase Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of common stock under stock purchase agreement in shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of common stock under Stock Purchase Agreement (in shares )</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Method Investment, Aggregate Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase price of common stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Per share price</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_FairValueInputsAmountOfDiscountForLackOfMarketability" xlink:label="incy_FairValueInputsAmountOfDiscountForLackOfMarketability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_FairValueInputsAmountOfDiscountForLackOfMarketability" xlink:to="incy_FairValueInputsAmountOfDiscountForLackOfMarketability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_FairValueInputsAmountOfDiscountForLackOfMarketability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustment to the amount of discount used to measure fair value for lack of ability to convert business interests into cash quickly..</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_FairValueInputsAmountOfDiscountForLackOfMarketability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Inputs, Amount of Discount for Lack of Marketability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_FairValueInputsAmountOfDiscountForLackOfMarketability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discount for lack of marketability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="us-gaap_EquityFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityFairValueDisclosure" xlink:to="us-gaap_EquityFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of shares on the issuance date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of shares</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_TotalConsiderationPaidUnderPurchaseAgreement" xlink:label="incy_TotalConsiderationPaidUnderPurchaseAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_TotalConsiderationPaidUnderPurchaseAgreement" xlink:to="incy_TotalConsiderationPaidUnderPurchaseAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_TotalConsiderationPaidUnderPurchaseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of the total consideration paid under purchase agreement during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_TotalConsiderationPaidUnderPurchaseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Consideration Paid Under Purchase Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_TotalConsiderationPaidUnderPurchaseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total consideration paid</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Method Investment, Ownership Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership percentage (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue" xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue" xlink:to="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Method Investment, Summarized Financial Information, Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total revenues</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss" xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss" xlink:to="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Method Investment, Summarized Financial Information, Net Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net income (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_MerusNVMember" xlink:label="incy_MerusNVMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_MerusNVMember" xlink:to="incy_MerusNVMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_MerusNVMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Merus N. V.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_MerusNVMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Merus N V [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_MerusNVMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Merus</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DevelopmentAndRegulatoryMilestonesMember" xlink:label="incy_DevelopmentAndRegulatoryMilestonesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_DevelopmentAndRegulatoryMilestonesMember" xlink:to="incy_DevelopmentAndRegulatoryMilestonesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_DevelopmentAndRegulatoryMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to certain development and regulatory events on the basis of which certain milestones are achieved.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_DevelopmentAndRegulatoryMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development And Regulatory Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_DevelopmentAndRegulatoryMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development and Regulatory Milestones</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementMaximumNumberOfIndependentPrograms" xlink:label="incy_LicenseAgreementMaximumNumberOfIndependentPrograms" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_LicenseAgreementMaximumNumberOfIndependentPrograms" xlink:to="incy_LicenseAgreementMaximumNumberOfIndependentPrograms_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_LicenseAgreementMaximumNumberOfIndependentPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the maximum number of independent programs encompassed under the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_LicenseAgreementMaximumNumberOfIndependentPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Maximum Number Of Independent Programs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_LicenseAgreementMaximumNumberOfIndependentPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of independent programs</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementNumberOfPreclinicalDiscoveryPrograms" xlink:label="incy_LicenseAgreementNumberOfPreclinicalDiscoveryPrograms" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_LicenseAgreementNumberOfPreclinicalDiscoveryPrograms" xlink:to="incy_LicenseAgreementNumberOfPreclinicalDiscoveryPrograms_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_LicenseAgreementNumberOfPreclinicalDiscoveryPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of preclinical immuno-oncology discovery programs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_LicenseAgreementNumberOfPreclinicalDiscoveryPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Number of Preclinical Discovery Programs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_LicenseAgreementNumberOfPreclinicalDiscoveryPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of preclinical discovery programs</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms" xlink:label="incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms" xlink:to="incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of additional preclinical discovery programs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Number of Additional Preclinical Discovery Programs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of additional preclinical discovery programs</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment" xlink:label="incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment" xlink:to="incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of programs in which the resulting products are co-funded for development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Programs Under Which The Resulting Products Are Co-Funded For Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of programs under the resulting products are co-funded for development</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CollaborationAgreementProfitSharingPercentage" xlink:label="incy_CollaborationAgreementProfitSharingPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_CollaborationAgreementProfitSharingPercentage" xlink:to="incy_CollaborationAgreementProfitSharingPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_CollaborationAgreementProfitSharingPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of profits and losses shared under the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_CollaborationAgreementProfitSharingPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement Profit Sharing Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_CollaborationAgreementProfitSharingPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit sharing (as a percent)</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PercentageOfProfitsLosses" xlink:label="incy_PercentageOfProfitsLosses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_PercentageOfProfitsLosses" xlink:to="incy_PercentageOfProfitsLosses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_PercentageOfProfitsLosses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of profits (losses).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_PercentageOfProfitsLosses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Profits (Losses)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_PercentageOfProfitsLosses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of profit (losses)</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PercentageOfNetSalesPertainingToAdditionalRoyalties" xlink:label="incy_PercentageOfNetSalesPertainingToAdditionalRoyalties" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_PercentageOfNetSalesPertainingToAdditionalRoyalties" xlink:to="incy_PercentageOfNetSalesPertainingToAdditionalRoyalties_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_PercentageOfNetSalesPertainingToAdditionalRoyalties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of net sales attributable to additional royalties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_PercentageOfNetSalesPertainingToAdditionalRoyalties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Net Sales Pertaining to Additional Royalties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_PercentageOfNetSalesPertainingToAdditionalRoyalties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of additional royalties</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PercentageOfReverseRoyaltiesOnSaleOfFutureProducts" xlink:label="incy_PercentageOfReverseRoyaltiesOnSaleOfFutureProducts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_PercentageOfReverseRoyaltiesOnSaleOfFutureProducts" xlink:to="incy_PercentageOfReverseRoyaltiesOnSaleOfFutureProducts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_PercentageOfReverseRoyaltiesOnSaleOfFutureProducts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of reverse royalties on sale of future products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_PercentageOfReverseRoyaltiesOnSaleOfFutureProducts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Reverse Royalties On Sale of Future Products</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_PercentageOfReverseRoyaltiesOnSaleOfFutureProducts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of reverse royalty</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_StockPurchaseAgreementLockUpPeriod" xlink:label="incy_StockPurchaseAgreementLockUpPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_StockPurchaseAgreementLockUpPeriod" xlink:to="incy_StockPurchaseAgreementLockUpPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_StockPurchaseAgreementLockUpPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the period of time that the company will not sell or otherwise transfer any of the equity method shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_StockPurchaseAgreementLockUpPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Purchase Agreement Lock Up Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_StockPurchaseAgreementLockUpPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lock-up period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair market value of our long term investments</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CalitheraBiosciencesIncMember" xlink:label="incy_CalitheraBiosciencesIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_CalitheraBiosciencesIncMember" xlink:to="incy_CalitheraBiosciencesIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_CalitheraBiosciencesIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents details pertaining to our long-term investment in Calithera Biosciences, Inc with whom we have entered into a License and Commercialization Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_CalitheraBiosciencesIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Calithera Biosciences Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_CalitheraBiosciencesIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Calithera</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeMember" xlink:label="us-gaap_OtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeMember" xlink:to="us-gaap_OtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementUpfrontPayment" xlink:label="incy_LicenseAgreementUpfrontPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_LicenseAgreementUpfrontPayment" xlink:to="incy_LicenseAgreementUpfrontPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_LicenseAgreementUpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the upfront payment under the license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_LicenseAgreementUpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement Upfront Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_LicenseAgreementUpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront payment made under license agreement</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementPotentialMilestonePaymentsWithProfitSharing" xlink:label="incy_LicenseAgreementPotentialMilestonePaymentsWithProfitSharing" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_LicenseAgreementPotentialMilestonePaymentsWithProfitSharing" xlink:to="incy_LicenseAgreementPotentialMilestonePaymentsWithProfitSharing_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_LicenseAgreementPotentialMilestonePaymentsWithProfitSharing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the potential milestone payments to be made under the license agreement with profit sharing in effect.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_LicenseAgreementPotentialMilestonePaymentsWithProfitSharing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement Potential Milestone Payments with Profit Sharing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_LicenseAgreementPotentialMilestonePaymentsWithProfitSharing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potential milestone payments to be made with profit sharing in effect</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementPotentialMilestonePaymentsWithoutProfitSharing" xlink:label="incy_LicenseAgreementPotentialMilestonePaymentsWithoutProfitSharing" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_LicenseAgreementPotentialMilestonePaymentsWithoutProfitSharing" xlink:to="incy_LicenseAgreementPotentialMilestonePaymentsWithoutProfitSharing_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_LicenseAgreementPotentialMilestonePaymentsWithoutProfitSharing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the potential milestone payments to be made under the license agreement if profit sharing is terminated.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_LicenseAgreementPotentialMilestonePaymentsWithoutProfitSharing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement Potential Milestone Payments Without Profit Sharing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_LicenseAgreementPotentialMilestonePaymentsWithoutProfitSharing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potential milestone payments to be made with profit sharing terminated</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CollaborationAgreementUpfrontPayment" xlink:label="incy_CollaborationAgreementUpfrontPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_CollaborationAgreementUpfrontPayment" xlink:to="incy_CollaborationAgreementUpfrontPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_CollaborationAgreementUpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represent information pertaining to collaboration agreement upfront payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_CollaborationAgreementUpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement Upfront Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_CollaborationAgreementUpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront license fees</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PurchasePriceOfCommonStockUnderStockPurchaseAgreement" xlink:label="incy_PurchasePriceOfCommonStockUnderStockPurchaseAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_PurchasePriceOfCommonStockUnderStockPurchaseAgreement" xlink:to="incy_PurchasePriceOfCommonStockUnderStockPurchaseAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_PurchasePriceOfCommonStockUnderStockPurchaseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the purchase price of common stock under Stock Purchase Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_PurchasePriceOfCommonStockUnderStockPurchaseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase price of common stock under stock purchase agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="incy_PurchasePriceOfCommonStockUnderStockPurchaseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock purchase price</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_MacrogenicsMember" xlink:label="incy_MacrogenicsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_MacrogenicsMember" xlink:to="incy_MacrogenicsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_MacrogenicsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents details pertaining to MacroGenics with whom we have entered into an exclusive global collaboration and license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_MacrogenicsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Macrogenics [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_MacrogenicsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">MacroGenics</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementTargetSelectionAndOptionExerciseFeePayments" xlink:label="incy_LicenseAgreementTargetSelectionAndOptionExerciseFeePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_LicenseAgreementTargetSelectionAndOptionExerciseFeePayments" xlink:to="incy_LicenseAgreementTargetSelectionAndOptionExerciseFeePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_LicenseAgreementTargetSelectionAndOptionExerciseFeePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the target selection and option exercise fee payments to be made under the license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_LicenseAgreementTargetSelectionAndOptionExerciseFeePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement Target Selection and Option Exercise Fee Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_LicenseAgreementTargetSelectionAndOptionExerciseFeePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Target selection and option exercise fee payment</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_NumberOfProductCandidates" xlink:label="incy_NumberOfProductCandidates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_NumberOfProductCandidates" xlink:to="incy_NumberOfProductCandidates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_NumberOfProductCandidates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of clinical-stage product candidates .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_NumberOfProductCandidates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Product Candidates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_NumberOfProductCandidates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product candidates</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Award [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units R S U [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units (RSUs)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance Stock Units (PSUs)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale Of Stock Name Of Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling General And Administrative Expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General and Administrative Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Compensation Plans</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock compensation expense</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_StockCompensationExpenseCapitalized" xlink:label="incy_StockCompensationExpenseCapitalized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_StockCompensationExpenseCapitalized" xlink:to="incy_StockCompensationExpenseCapitalized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_StockCompensationExpenseCapitalized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of stock compensation expenses capitalized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_StockCompensationExpenseCapitalized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Compensation Expense Capitalized</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate" xlink:to="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the expected annualized forfeiture rate for options granted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions Expected Annualized Forfeiture Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assumed annualized forfeiture rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average fair value assumptions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Method Used</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation method</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Average risk-free interest rates (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Average expected life (in years)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Volatility (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average fair value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividend yield (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Aggregate Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation cost for nonvested option (in dollars)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period of recognition of the unrecognized compensation cost of nonvested awards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Award Tranche One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting after one year</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Award Tranche Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remainder vesting</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Subject to Outstanding Options, Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the end of the period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the beginning of the period (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercised (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options cancelled (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Subject to Outstanding Options, Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the end of the period (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the beginning of the period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercised (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options cancelled (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Termination period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of units vesting at the end of each calendar year (as a percent)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting Percentage</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the end of the period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the beginning of the period (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">outstanding (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:to="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of shares of employee compensation programs, other than options, released during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Released In Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Released (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancelled (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Intrinsic Value, Amount Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the end of the period (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the beginning of the period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue" xlink:to="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Per share weighted average intrinsic value of equity-based compensation awards released. Excludes stock and unit options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Released Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Released (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Intrinsic Value, Amount Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancelled (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits" xlink:to="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of shares awarded for each restricted share units.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement by Share Based Payment Award Number of Shares Per Restricted Stock Units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares awarded for each RSU (in shares)</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageMultiplierForConversionOfUnitsIntoCommonStock" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageMultiplierForConversionOfUnitsIntoCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageMultiplierForConversionOfUnitsIntoCommonStock" xlink:to="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageMultiplierForConversionOfUnitsIntoCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageMultiplierForConversionOfUnitsIntoCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the multiplier expressed as a percentage used for conversion of PSU into actual number of shares of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageMultiplierForConversionOfUnitsIntoCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement by Share Based Payment Award, Percentage Multiplier for Conversion of Units Into Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageMultiplierForConversionOfUnitsIntoCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Multiplier conversion rate of units into common stock (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Service period</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor" xlink:to="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation arrangement by share-based payment award, equity instruments other than options, conversion multiplying factor.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based payment Award, Equity Instruments Other than Options, Conversion Multiplying Factor</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Multiplying factor</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" xlink:to="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Available For Grant</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the end of the period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the beginning of the period (in shares)</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted" xlink:to="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares granted under an established share-based compensation plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement by Share Based Payment Award Number of Shares Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options, RSUs and PSUs granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled" xlink:to="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares canceled under an established share-based compensation plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement by Share Based Payment Award Number of Shares Canceled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options, RSUs and PSUs cancelled (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued and Other Current Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Royalties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalties</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AccruedClinicalRelatedCostsCurrent" xlink:label="incy_AccruedClinicalRelatedCostsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_AccruedClinicalRelatedCostsCurrent" xlink:to="incy_AccruedClinicalRelatedCostsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_AccruedClinicalRelatedCostsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical related costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_AccruedClinicalRelatedCostsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Clinical Related Costs Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_AccruedClinicalRelatedCostsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clinical related costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProvisionForLossOnContracts" xlink:label="us-gaap_ProvisionForLossOnContracts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForLossOnContracts" xlink:to="us-gaap_ProvisionForLossOnContracts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForLossOnContracts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for Loss on Contracts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProvisionForLossOnContracts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales allowances</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionPayableCurrent" xlink:label="us-gaap_ConstructionPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionPayableCurrent" xlink:to="us-gaap_ConstructionPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Construction Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConstructionPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Construction in progress</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-term Debt Instruments [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ConvertibleSeniorNotes1.25PercentDue2020Member" xlink:label="incy_ConvertibleSeniorNotes1.25PercentDue2020Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_ConvertibleSeniorNotes1.25PercentDue2020Member" xlink:to="incy_ConvertibleSeniorNotes1.25PercentDue2020Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_ConvertibleSeniorNotes1.25PercentDue2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents a contractual arrangement to borrow and repay the amount under convertible senior notes at an interest rate of 1.25 percent, which are due in 2020.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_ConvertibleSeniorNotes1.25PercentDue2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Senior Notes1.25 Percent Due2020 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_ConvertibleSeniorNotes1.25PercentDue2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Senior Notes 1.25 Percent Due 2020</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Basis [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Portion At Fair Value Fair Value Disclosure [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Portion at Fair Value Measurement [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying Reported Amount Fair Value Disclosure [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying Amount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Notes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible senior notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible senior notes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimate Of Fair Value Fair Value Disclosure [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member" xlink:label="incy_ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member" xlink:to="incy_ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">A contractual arrangement to borrow and repay the amount under convertible senior notes at an interest rate of 0.375 percent, which are due in 2018 and 1.25 percent, which are due in 2020.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Senior Notes0.375 Percent Due2018 And Convertible Senior Notes1.25 Percent Due2020 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Senior Notes 0.375 Percent Due 2018 and Convertible Senior Notes 1.25 Percent Due 2020</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xlink:label="incy_DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xlink:to="incy_DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of trading days within a period of 30 consecutive trading days the price of the entity's common stock must exceed the applicable conversion price in order for the debt instruments to be convertible.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Conversion Obligation Common Stock Closing Sales Price Number of Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of days within 30 consecutive trading days in which the price of the entity's common stock must exceed the conversion price for the notes to be converted</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" xlink:label="incy_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" xlink:to="incy_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of consecutive trading days during which the closing price of the entity's common stock must exceed the applicable conversion price for at least 20 days in order for the debt instruments to be convertible.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Conversion Obligation Number of Consecutive Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of consecutive trading days during which the closing price of the entity's common stock must exceed the conversion price for at least 20 days in order for the notes to be convertible</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" xlink:label="incy_DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" xlink:to="incy_DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of the closing sales price of the common stock for at least 20 days within 30 consecutive trading days that the closing sales price of the common stock must exceed the conversion price in order for the debt instruments to be convertible.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Conversion Obligation Common Stock Closing Sales Price as Percentage of Conversion Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the closing sales price of common stock that the conversion price must exceed in order for the notes to be convertible (as a percent)</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod" xlink:label="incy_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod" xlink:to="incy_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of consecutive business days immediately after any five consecutive trading day period during the debt instrument measurement period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Conversion Obligation Number of Consecutive Business Days after Consecutive Trading Day Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of consecutive business days immediately after any five consecutive trading day period during the note measurement period</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays" xlink:label="incy_DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays" xlink:to="incy_DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of consecutive trading days prior to the five consecutive business days during the debt instrument measurement period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Conversion Obligation Period of Consecutive Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of consecutive trading days before five consecutive business days during the note measurement period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Convertible, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion ratio, principal amount of note</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum" xlink:label="incy_DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum" xlink:to="incy_DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the maximum percentage of the trading price of each debt instrument to the product of the last reported sale price of common stock and the conversion rate of the debt instrument that the trading price must be less than in order for the debt instruments to be convertible.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Conversion Obligation Trading Price as Percentage of Product of Last Reported Common Stock Sale Price and Conversion Rate Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the trading price to the product of the last reported sale price of the common stock and the conversion rate, maximum (as a percent)</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DebtInstrumentConversionObligationNumberOfScheduledTradingDaysBeforeMaturity" xlink:label="incy_DebtInstrumentConversionObligationNumberOfScheduledTradingDaysBeforeMaturity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_DebtInstrumentConversionObligationNumberOfScheduledTradingDaysBeforeMaturity" xlink:to="incy_DebtInstrumentConversionObligationNumberOfScheduledTradingDaysBeforeMaturity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_DebtInstrumentConversionObligationNumberOfScheduledTradingDaysBeforeMaturity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of trading days prior to maturity at which Notes are convertible regardless of other circumstances.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_DebtInstrumentConversionObligationNumberOfScheduledTradingDaysBeforeMaturity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Conversion Obligation Number Of Scheduled Trading Days Before Maturity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_DebtInstrumentConversionObligationNumberOfScheduledTradingDaysBeforeMaturity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of scheduled trading days preceding relevant maturity date at which Notes are convertible regardless of other circumstances</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan Disclosure [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Cost Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined contribution expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Defined Benefit Plans Disclosures [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan Disclosure [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Pension Plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost" xlink:label="us-gaap_DefinedBenefitPlanServiceCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanServiceCost" xlink:to="us-gaap_DefinedBenefitPlanServiceCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanServiceCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Service Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DefinedBenefitPlanServiceCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employer Service cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost" xlink:label="us-gaap_DefinedBenefitPlanInterestCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanInterestCost" xlink:to="us-gaap_DefinedBenefitPlanInterestCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanInterestCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Interest Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DefinedBenefitPlanInterestCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:label="us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Expected Return on Plan Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected return on plan assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:label="us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of prior service cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:label="us-gaap_DefinedBenefitPlanActuarialGainLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:to="us-gaap_DefinedBenefitPlanActuarialGainLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanActuarialGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Actuarial Gain (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DefinedBenefitPlanActuarialGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of actuarial losses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Net Periodic Benefit Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net periodic benefit cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList" xlink:label="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList" xlink:to="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Excluding Service Cost, Statement of Income or Comprehensive Income [Extensible List]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Location of costs excluding the service component</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan, Expected Contributions in Current Fiscal Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected contributions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" xlink:label="us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" xlink:to="us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Pension Plan, Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued pension obligation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:to="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in unrecognized tax benefits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Noncurrent Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) noncurrent other liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasicLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net income per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic Net Income (Loss) Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic net income (loss) per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="us-gaap_EarningsPerShareDilutedAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDilutedAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted Net Income (Loss) Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Available to Common Stockholders, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted net income (loss)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dilutive stock options and awards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted, Other Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Anti-dilutive securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potential common shares excluded from diluted net income (loss) per share computation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product revenues, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyMember" xlink:to="us-gaap_RoyaltyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product royalty revenues</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_MilestoneAndContractRevenueMember" xlink:label="incy_MilestoneAndContractRevenueMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_MilestoneAndContractRevenueMember" xlink:to="incy_MilestoneAndContractRevenueMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_MilestoneAndContractRevenueMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to milestone and contract revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_MilestoneAndContractRevenueMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone And Contract Revenue [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_MilestoneAndContractRevenueMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone and contract revenues</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_MorphosysAgMember" xlink:label="incy_MorphosysAgMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_MorphosysAgMember" xlink:to="incy_MorphosysAgMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_MorphosysAgMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents member information pertaining to MorphoSys AG.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_MorphosysAgMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Morphosys Ag [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_MorphosysAgMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">MorphoSys AG</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_JakaviRoyaltyRevenuesMember" xlink:label="incy_JakaviRoyaltyRevenuesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_JakaviRoyaltyRevenuesMember" xlink:to="incy_JakaviRoyaltyRevenuesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_JakaviRoyaltyRevenuesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to JAKAVI royalty revenues, an oral Janus associate kinase (JAK) inhibitor sold within the United State of America.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_JakaviRoyaltyRevenuesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Jakavi Royalty Revenues [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_JakaviRoyaltyRevenuesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">JAKAVI Royalty Revenues</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_OlumiantRoyaltyMember" xlink:label="incy_OlumiantRoyaltyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_OlumiantRoyaltyMember" xlink:to="incy_OlumiantRoyaltyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_OlumiantRoyaltyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to OLUMIANT royalty revenues, a treatment of adults with moderately-to-severely active rheumatoid arthritis.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_OlumiantRoyaltyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Olumiant Royalty [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_OlumiantRoyaltyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OLUMIANT Royalty Revenues</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Frequency [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements Recurring [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recurring</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Hierarchy [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Inputs Level1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Inputs Level2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 2</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Inputs Level3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 3</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition Acquiree [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition, Acquiree [Domain]</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AriadPharmaceuticalsMember" xlink:label="incy_AriadPharmaceuticalsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_AriadPharmaceuticalsMember" xlink:to="incy_AriadPharmaceuticalsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_AriadPharmaceuticalsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to ARIAD Pharmaceuticals.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_AriadPharmaceuticalsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ariad Pharmaceuticals [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_AriadPharmaceuticalsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ARIAD</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AccruedAndOtherCurrentLiabilityMember" xlink:label="incy_AccruedAndOtherCurrentLiabilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_AccruedAndOtherCurrentLiabilityMember" xlink:to="incy_AccruedAndOtherCurrentLiabilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_AccruedAndOtherCurrentLiabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Primary financial statement caption encompassing accrued and other current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_AccruedAndOtherCurrentLiabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued And Other Current Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_AccruedAndOtherCurrentLiabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Discount Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discount rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputCapRateMember" xlink:label="us-gaap_MeasurementInputCapRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputCapRateMember" xlink:to="us-gaap_MeasurementInputCapRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputCapRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Cap Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputCapRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Average Cost of Capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value by Liability Class [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilityMember" xlink:label="us-gaap_LiabilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilityMember" xlink:to="us-gaap_LiabilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments [Domain]</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CorporateAndGovernmentDebtSecuritiesMember" xlink:label="incy_CorporateAndGovernmentDebtSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_CorporateAndGovernmentDebtSecuritiesMember" xlink:to="incy_CorporateAndGovernmentDebtSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_CorporateAndGovernmentDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt securities issued by government or corporate business, banks and other entities with a promise of repayment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_CorporateAndGovernmentDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate And Government Debt Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_CorporateAndGovernmentDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt securities (government)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Construction In Progress [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Construction in Progress</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DevelopmentAndCommercializationMilestonesMember" xlink:label="incy_DevelopmentAndCommercializationMilestonesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_DevelopmentAndCommercializationMilestonesMember" xlink:to="incy_DevelopmentAndCommercializationMilestonesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_DevelopmentAndCommercializationMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to certain development and commercialization events on the basis of which certain milestones are achieved.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_DevelopmentAndCommercializationMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development And Commercialization Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_DevelopmentAndCommercializationMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development and Commercialization Milestones</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LG3ProgramMember" xlink:label="incy_LG3ProgramMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_LG3ProgramMember" xlink:to="incy_LG3ProgramMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_LG3ProgramMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to LAG-3 program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_LG3ProgramMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">L G3 Program [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_LG3ProgramMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LAG-3 program</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_TIM3ProgramMember" xlink:label="incy_TIM3ProgramMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_TIM3ProgramMember" xlink:to="incy_TIM3ProgramMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_TIM3ProgramMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to TIM-3 program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_TIM3ProgramMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">T I M3 Program [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_TIM3ProgramMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TIM-3 program</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_SyrosPharmaceuticalsIncMember" xlink:label="incy_SyrosPharmaceuticalsIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_SyrosPharmaceuticalsIncMember" xlink:to="incy_SyrosPharmaceuticalsIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_SyrosPharmaceuticalsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents details pertaining to Syros Pharmaceuticals, Inc with whom we have entered into a target discovery, research collaboration and option agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_SyrosPharmaceuticalsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Syros Pharmaceuticals Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_SyrosPharmaceuticalsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Syros Pharmaceuticals, Inc.</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AmendedStockPurchaseAgreementMember" xlink:label="incy_AmendedStockPurchaseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_AmendedStockPurchaseAgreementMember" xlink:to="incy_AmendedStockPurchaseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_AmendedStockPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents amended stock purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_AmendedStockPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amended Stock Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_AmendedStockPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amended stock purchase agreement</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_InnoventBiologicsIncMember" xlink:label="incy_InnoventBiologicsIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_InnoventBiologicsIncMember" xlink:to="incy_InnoventBiologicsIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_InnoventBiologicsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents details pertaining to Innovent Biologics, Inc with whom we have entered into a research collaboration and licensing agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_InnoventBiologicsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Innovent Biologics Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_InnoventBiologicsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Innovent</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember" xlink:label="incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember" xlink:to="incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the collaboration and license agreement with Zai Lab Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration And License Agreement With Zai Lab Ltd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Zai Lab Ltd</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DevelopmentRegulatoryAndCommercialMilestonesMember" xlink:label="incy_DevelopmentRegulatoryAndCommercialMilestonesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_DevelopmentRegulatoryAndCommercialMilestonesMember" xlink:to="incy_DevelopmentRegulatoryAndCommercialMilestonesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_DevelopmentRegulatoryAndCommercialMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to certain development and regulatory events on the basis of which certain milestones are achieved.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_DevelopmentRegulatoryAndCommercialMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development Regulatory And Commercial Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_DevelopmentRegulatoryAndCommercialMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development Regulatory And Commercial Milestones</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_IncyteMember" xlink:label="incy_IncyteMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_IncyteMember" xlink:to="incy_IncyteMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_IncyteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents member information pertaining to Incyte.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_IncyteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incyte [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_IncyteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incyte</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repurchase Agreement Counterparty Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AmericanDepositarySharesMember" xlink:label="incy_AmericanDepositarySharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_AmericanDepositarySharesMember" xlink:to="incy_AmericanDepositarySharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_AmericanDepositarySharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents American Depositary Shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_AmericanDepositarySharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">American Depositary Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_AmericanDepositarySharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ADSs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost Of Sales [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of product revenues</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LongTermIncentivePlanOneMember" xlink:label="incy_LongTermIncentivePlanOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_LongTermIncentivePlanOneMember" xlink:to="incy_LongTermIncentivePlanOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_LongTermIncentivePlanOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to one of the existing long term incentive plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_LongTermIncentivePlanOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Incentive Plan One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_LongTermIncentivePlanOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long term incentive plan - 1</label>
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LongTermIncentivePlanTwoMember" xlink:label="incy_LongTermIncentivePlanTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="incy_LongTermIncentivePlanTwoMember" xlink:to="incy_LongTermIncentivePlanTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="incy_LongTermIncentivePlanTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to one of the existing long term incentive plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="incy_LongTermIncentivePlanTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Incentive Plan Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="incy_LongTermIncentivePlanTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long term incentive plan - 2</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>incy-20200505_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7401.38943 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/5/2020 8:06:59 PM-->
<!--Modified on: 5/5/2020 8:06:59 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.incyte.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#StatementCondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#StatementCondensedConsolidatedStatementsOfComprehensiveIncome" roleURI="http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#StatementCondensedConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical" roleURI="http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" roleURI="http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureOrganizationAndBusiness" roleURI="http://www.incyte.com/role/DisclosureOrganizationAndBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureRevenues" roleURI="http://www.incyte.com/role/DisclosureRevenues" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureFairValueOfFinancialInstruments" roleURI="http://www.incyte.com/role/DisclosureFairValueOfFinancialInstruments" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLosses" roleURI="http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLosses" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureInventory" roleURI="http://www.incyte.com/role/DisclosureInventory" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosurePropertyAndEquipmentNet" roleURI="http://www.incyte.com/role/DisclosurePropertyAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureIntangibleAssetsAndGoodwill" roleURI="http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureLicenseAgreements" roleURI="http://www.incyte.com/role/DisclosureLicenseAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureStockCompensation" roleURI="http://www.incyte.com/role/DisclosureStockCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureAccruedAndOtherCurrentLiabilities" roleURI="http://www.incyte.com/role/DisclosureAccruedAndOtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureDebt" roleURI="http://www.incyte.com/role/DisclosureDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureEmployeeBenefitPlans" roleURI="http://www.incyte.com/role/DisclosureEmployeeBenefitPlans" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureIncomeTaxes" roleURI="http://www.incyte.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureNetIncomeLossPerShare" roleURI="http://www.incyte.com/role/DisclosureNetIncomeLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureContingencies" roleURI="http://www.incyte.com/role/DisclosureContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureSubsequentEvent" roleURI="http://www.incyte.com/role/DisclosureSubsequentEvent" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureRevenuesTables" roleURI="http://www.incyte.com/role/DisclosureRevenuesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureFairValueOfFinancialInstrumentsTables" roleURI="http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLossesTables" roleURI="http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLossesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureInventoryTables" roleURI="http://www.incyte.com/role/DisclosureInventoryTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosurePropertyAndEquipmentNetTables" roleURI="http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureIntangibleAssetsAndGoodwillTables" roleURI="http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwillTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureStockCompensationTables" roleURI="http://www.incyte.com/role/DisclosureStockCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureAccruedAndOtherCurrentLiabilitiesTables" roleURI="http://www.incyte.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureDebtTables" roleURI="http://www.incyte.com/role/DisclosureDebtTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureEmployeeBenefitPlansTables" roleURI="http://www.incyte.com/role/DisclosureEmployeeBenefitPlansTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureNetIncomeLossPerShareTables" roleURI="http://www.incyte.com/role/DisclosureNetIncomeLossPerShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureOrganizationAndBusinessDetails" roleURI="http://www.incyte.com/role/DisclosureOrganizationAndBusinessDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" roleURI="http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" roleURI="http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureRevenuesDetails" roleURI="http://www.incyte.com/role/DisclosureRevenuesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails" roleURI="http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureFairValueOfFinancialInstrumentsMarketableSecuritiesPortfolioDetails" roleURI="http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsMarketableSecuritiesPortfolioDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLossesDetails" roleURI="http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLossesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureInventoryDetails" roleURI="http://www.incyte.com/role/DisclosureInventoryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetails" roleURI="http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosurePropertyAndEquipmentNetBuildingsAndConstructionDetails" roleURI="http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetBuildingsAndConstructionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetails" roleURI="http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureIntangibleAssetsAndGoodwillDetails" roleURI="http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwillDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureLicenseAgreementsNovartisDetails" roleURI="http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureLicenseAgreementsLillyDetails" roleURI="http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureLicenseAgreementsAgenusDetails" roleURI="http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureLicenseAgreementsMerusDetails" roleURI="http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureLicenseAgreementsCalitheraDetails" roleURI="http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureLicenseAgreementsMacrogenicsDetails" roleURI="http://www.incyte.com/role/DisclosureLicenseAgreementsMacrogenicsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureLicenseAgreementsSyrosDetails" roleURI="http://www.incyte.com/role/DisclosureLicenseAgreementsSyrosDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureLicenseAgreementsInnoventDetails" roleURI="http://www.incyte.com/role/DisclosureLicenseAgreementsInnoventDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureLicenseAgreementsZaiLabDetails" roleURI="http://www.incyte.com/role/DisclosureLicenseAgreementsZaiLabDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureLicenseAgreementsMorphosysDetails" roleURI="http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureStockCompensationDetails" roleURI="http://www.incyte.com/role/DisclosureStockCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureStockCompensationOptionActivityDetails" roleURI="http://www.incyte.com/role/DisclosureStockCompensationOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureStockCompensationRsuAndPsuAwardActivityDetails" roleURI="http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuAwardActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureStockCompensationRsuAndPsuDetails" roleURI="http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureStockCompensationSharesAvailableForGrantDetails" roleURI="http://www.incyte.com/role/DisclosureStockCompensationSharesAvailableForGrantDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureAccruedAndOtherCurrentLiabilitiesDetails" roleURI="http://www.incyte.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureDebtComponentsOfConvertibleNotesDetails" roleURI="http://www.incyte.com/role/DisclosureDebtComponentsOfConvertibleNotesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureDebtCarryingAmountAndFairValueDetails" roleURI="http://www.incyte.com/role/DisclosureDebtCarryingAmountAndFairValueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureDebtNarrativeDetails" roleURI="http://www.incyte.com/role/DisclosureDebtNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureEmployeeBenefitPlansDefinedContributionPlanDetails" roleURI="http://www.incyte.com/role/DisclosureEmployeeBenefitPlansDefinedContributionPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureEmployeeBenefitPlansPeriodicBenefitCostDetails" roleURI="http://www.incyte.com/role/DisclosureEmployeeBenefitPlansPeriodicBenefitCostDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureIncomeTaxesDetails" roleURI="http://www.incyte.com/role/DisclosureIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="incy-20200505.xsd#DisclosureNetIncomeLossPerShareDetails" roleURI="http://www.incyte.com/role/DisclosureNetIncomeLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.incyte.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637243060152972084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_637243060152972084" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_637243060152972084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_637243060152972084" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637243060152972084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_637243060152972084" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637243060152972084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637243060152972084" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637243060152972084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_637243060152972084" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637243060152972084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_637243060152972084" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637243060152972084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637243060152972084" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637243060152972084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637243060152972084" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637243060152972084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637243060152972084" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637243060152972084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637243060152972084" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637243060152972084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_637243060152972084" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637243060152982096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_637243060152982096" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637243060152982096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_637243060152982096" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637243060152982096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_637243060152982096" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637243060152982096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_637243060152982096" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637243060152982096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_637243060152982096" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637243060152982096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_637243060152982096" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637243060152982096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_637243060152982096" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637243060152982096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_637243060152982096" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637243060152982096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_637243060152982096" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637243060152982096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_637243060152982096" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637243060152982096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637243060152982096" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637243060152992078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_637243060152992078" order="23" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637243060152992078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_637243060152992078" order="24" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637243060152992078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_637243060152992078" order="25" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637243060152992078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_637243060152992078" order="26" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637243060152992078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_637243060152992078" order="27" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637243060152992078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637243060152992078" order="28" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637243060152992078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_637243060152992078" order="29" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637243060153002088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_637243060153002088" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637243060153002088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637243060153002088" xlink:to="us-gaap_AssetsCurrentAbstract_637243060153002088" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637243060153002088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637243060153002088" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637243060153002088" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_637243060153002088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637243060153002088" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_637243060153002088" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet_637243060153002088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637243060153002088" xlink:to="us-gaap_AccountsReceivableNet_637243060153002088" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637243060153002088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637243060153002088" xlink:to="us-gaap_InventoryNet_637243060153002088" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637243060153002088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637243060153002088" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637243060153002088" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637243060153002088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637243060153002088" xlink:to="us-gaap_AssetsCurrent_637243060153002088" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndInvestmentsNoncurrent_637243060153002088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637243060153002088" xlink:to="us-gaap_RestrictedCashAndInvestmentsNoncurrent_637243060153002088" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments_637243060153002088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637243060153002088" xlink:to="us-gaap_LongTermInvestments_637243060153002088" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="us-gaap_InventoryNoncurrent_637243060153002088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637243060153002088" xlink:to="us-gaap_InventoryNoncurrent_637243060153002088" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637243060153002088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637243060153002088" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637243060153002088" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_637243060153002088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637243060153002088" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_637243060153002088" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="us-gaap_OtherIntangibleAssetsNet_637243060153012090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637243060153002088" xlink:to="us-gaap_OtherIntangibleAssetsNet_637243060153012090" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_637243060153012090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637243060153002088" xlink:to="us-gaap_Goodwill_637243060153012090" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_637243060153012090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637243060153002088" xlink:to="us-gaap_OtherAssetsNoncurrent_637243060153012090" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637243060153012090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637243060153002088" xlink:to="us-gaap_Assets_637243060153012090" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637243060153012090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637243060153012090" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637243060153012090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637243060153012090" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637243060153012090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637243060153012090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637243060153012090" xlink:to="us-gaap_AccountsPayableCurrent_637243060153012090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_637243060153012090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637243060153012090" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_637243060153012090" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_637243060153012090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637243060153012090" xlink:to="us-gaap_InterestPayableCurrent_637243060153012090" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637243060153012090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637243060153012090" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637243060153012090" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_637243060153022090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637243060153012090" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_637243060153022090" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent_637243060153022090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637243060153012090" xlink:to="us-gaap_ConvertibleDebtCurrent_637243060153022090" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_637243060153022090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637243060153012090" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_637243060153022090" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637243060153022090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637243060153012090" xlink:to="us-gaap_LiabilitiesCurrent_637243060153022090" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_637243060153022090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637243060153012090" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_637243060153022090" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_637243060153022090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637243060153012090" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_637243060153022090" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637243060153022090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637243060153012090" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637243060153022090" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637243060153022090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637243060153012090" xlink:to="us-gaap_Liabilities_637243060153022090" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_637243060153032704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637243060153012090" xlink:to="us-gaap_StockholdersEquityAbstract_637243060153032704" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637243060153032704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637243060153032704" xlink:to="us-gaap_PreferredStockValue_637243060153032704" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637243060153032704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637243060153032704" xlink:to="us-gaap_CommonStockValue_637243060153032704" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_637243060153042096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637243060153032704" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_637243060153042096" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637243060153042096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637243060153032704" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637243060153042096" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637243060153042096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637243060153032704" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637243060153042096" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637243060153042096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637243060153032704" xlink:to="us-gaap_StockholdersEquity_637243060153042096" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637243060153042096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637243060153012090" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637243060153042096" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_637243060153042096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_637243060153042096" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_637243060153052096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_637243060153052096" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_637243060153052096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_637243060153052096" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_637243060153052096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_637243060153052096" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_637243060153052096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_637243060153052096" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_637243060153052096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_637243060153052096" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637243060153052096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637243060153052096" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637243060153052096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_637243060153052096" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637243060153052096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_637243060153052096" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637243060153052096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_637243060153052096" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637243060153052096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable_637243060153052096" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637243060153052096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153052096" xlink:to="srt_ProductOrServiceAxis_637243060153052096" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637243060153052096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637243060153052096" xlink:to="srt_ProductsAndServicesDomain_637243060153052096" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_637243060153052096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637243060153052096" xlink:to="us-gaap_ProductMember_637243060153052096" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember_637243060153062093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637243060153052096" xlink:to="us-gaap_RoyaltyMember_637243060153062093" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_MilestoneAndContractRevenueMember" xlink:label="incy_MilestoneAndContractRevenueMember_637243060153062093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637243060153052096" xlink:to="incy_MilestoneAndContractRevenueMember_637243060153062093" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637243060153062093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153052096" xlink:to="us-gaap_StatementLineItems_637243060153062093" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract_637243060153062093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637243060153062093" xlink:to="us-gaap_RevenuesAbstract_637243060153062093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637243060153062093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_637243060153062093" xlink:to="us-gaap_Revenues_637243060153062093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract_637243060153062093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637243060153062093" xlink:to="us-gaap_CostsAndExpensesAbstract_637243060153062093" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_637243060153062093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_637243060153062093" xlink:to="us-gaap_CostOfRevenue_637243060153062093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637243060153062093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_637243060153062093" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637243060153062093" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_637243060153062093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_637243060153062093" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_637243060153062093" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_637243060153062093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_637243060153062093" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_637243060153062093" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CollaborationLossSharingExpense" xlink:label="incy_CollaborationLossSharingExpense_637243060153062093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_637243060153062093" xlink:to="incy_CollaborationLossSharingExpense_637243060153062093" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_637243060153062093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_637243060153062093" xlink:to="us-gaap_CostsAndExpenses_637243060153062093" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637243060153062093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637243060153062093" xlink:to="us-gaap_OperatingIncomeLoss_637243060153062093" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_637243060153072086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637243060153062093" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_637243060153072086" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_637243060153072086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637243060153062093" xlink:to="us-gaap_InterestExpense_637243060153072086" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_637243060153072086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637243060153062093" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_637243060153072086" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_637243060153072086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637243060153062093" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_637243060153072086" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637243060153072086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637243060153062093" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637243060153072086" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637243060153072086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637243060153062093" xlink:to="us-gaap_NetIncomeLoss_637243060153072086" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637243060153072086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637243060153062093" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637243060153072086" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_637243060153072086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637243060153072086" xlink:to="us-gaap_EarningsPerShareBasic_637243060153072086" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_637243060153072086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637243060153072086" xlink:to="us-gaap_EarningsPerShareDiluted_637243060153072086" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637243060153082095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637243060153062093" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637243060153082095" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637243060153082095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637243060153082095" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637243060153082095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637243060153082095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637243060153082095" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637243060153082095" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended" xlink:title="00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637243060153082095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss_637243060153082095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_637243060153082095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_637243060153082095" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_637243060153082095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_637243060153082095" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_637243060153082095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_637243060153082095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_637243060153082095" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_637243060153082095" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_637243060153082095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_637243060153082095" xlink:to="us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_637243060153082095" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_637243060153082095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_637243060153082095" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_637243060153082095" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_637243060153082095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_637243060153082095" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637243060153092096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_637243060153092096" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637243060153092096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153092096" xlink:to="us-gaap_StatementEquityComponentsAxis_637243060153092096" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637243060153092096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637243060153092096" xlink:to="us-gaap_CommonStockMember_637243060153092096" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637243060153092096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637243060153092096" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637243060153092096" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_637243060153092096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637243060153092096" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_637243060153092096" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637243060153092096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637243060153092096" xlink:to="us-gaap_RetainedEarningsMember_637243060153092096" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637243060153092096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637243060153092096" xlink:to="us-gaap_EquityComponentDomain_637243060153092096" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637243060153092096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153092096" xlink:to="us-gaap_StatementLineItems_637243060153092096" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637243060153092096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637243060153092096" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637243060153092096" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637243060153092096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637243060153092096" xlink:to="us-gaap_StockholdersEquity_637243060153092096" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_637243060153092096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637243060153092096" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_637243060153092096" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_637243060153092096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637243060153092096" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_637243060153092096" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637243060153092096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637243060153092096" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637243060153092096" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AdoptionOfAccountingStandardAdjustmentToRetainedEarnings" xlink:label="incy_AdoptionOfAccountingStandardAdjustmentToRetainedEarnings_637243060153102095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637243060153092096" xlink:to="incy_AdoptionOfAccountingStandardAdjustmentToRetainedEarnings_637243060153102095" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_637243060153102095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637243060153092096" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_637243060153102095" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637243060153102095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637243060153092096" xlink:to="us-gaap_NetIncomeLoss_637243060153102095" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637243060153102095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637243060153092096" xlink:to="us-gaap_StockholdersEquity_637243060153102095" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="extended" xlink:title="00405 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_637243060153102095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_637243060153102095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_637243060153102095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_637243060153102095" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00500 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637243060153102095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637243060153102095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637243060153102095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637243060153102095" xlink:to="us-gaap_ProfitLoss_637243060153102095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637243060153112102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637243060153102095" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637243060153112102" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_637243060153112102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637243060153112102" xlink:to="us-gaap_DepreciationDepletionAndAmortization_637243060153112102" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637243060153112102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637243060153112102" xlink:to="us-gaap_ShareBasedCompensation_637243060153112102" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense_637243060153112102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637243060153112102" xlink:to="us-gaap_OtherNoncashIncomeExpense_637243060153112102" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_637243060153112102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637243060153112102" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_637243060153112102" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_637243060153112102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637243060153112102" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_637243060153112102" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637243060153112102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637243060153112102" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637243060153112102" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_637243060153112102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637243060153112102" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_637243060153112102" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637243060153112102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637243060153112102" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637243060153112102" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_637243060153112102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637243060153112102" xlink:to="us-gaap_IncreaseDecreaseInInventories_637243060153112102" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637243060153112102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637243060153112102" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637243060153112102" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_637243060153112102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637243060153112102" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_637243060153112102" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637243060153112102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637243060153102095" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637243060153112102" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637243060153122087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637243060153122087" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireLongtermInvestments" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments_637243060153122087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637243060153122087" xlink:to="us-gaap_PaymentsToAcquireLongtermInvestments_637243060153122087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_637243060153122087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637243060153122087" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_637243060153122087" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_637243060153122087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637243060153122087" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_637243060153122087" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_637243060153122087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637243060153122087" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_637243060153122087" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637243060153122087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637243060153122087" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637243060153122087" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637243060153122087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637243060153122087" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans_637243060153122087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637243060153122087" xlink:to="us-gaap_ProceedsFromStockPlans_637243060153122087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments_637243060153122087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637243060153122087" xlink:to="us-gaap_FinanceLeasePrincipalPayments_637243060153122087" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PaymentOfContingentConsideration" xlink:label="incy_PaymentOfContingentConsideration_637243060153122087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637243060153122087" xlink:to="incy_PaymentOfContingentConsideration_637243060153122087" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637243060153132090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637243060153122087" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637243060153132090" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637243060153132090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637243060153122087" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637243060153132090" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637243060153132090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637243060153122087" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637243060153132090" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637243060153132090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637243060153122087" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637243060153132090" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6372430601531320901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637243060153122087" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6372430601531320901" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_637243060153132090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_637243060153132090" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet_637243060153132090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637243060153132090" xlink:to="us-gaap_IncomeTaxesPaidNet_637243060153132090" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_637243060153132090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637243060153132090" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_637243060153132090" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637243060153132090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637243060153132090" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637243060153132090" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_637243060153142089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637243060153132090" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_637243060153142089" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="extended" xlink:title="00505 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637243060153142089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable_637243060153142089" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637243060153142089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153142089" xlink:to="us-gaap_DebtInstrumentAxis_637243060153142089" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637243060153142089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637243060153142089" xlink:to="us-gaap_DebtInstrumentNameDomain_637243060153142089" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ConvertibleSeniorNotes1.25PercentDue2020Member" xlink:label="incy_ConvertibleSeniorNotes1.25PercentDue2020Member_637243060153142089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637243060153142089" xlink:to="incy_ConvertibleSeniorNotes1.25PercentDue2020Member_637243060153142089" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637243060153142089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153142089" xlink:to="us-gaap_StatementLineItems_637243060153142089" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637243060153142089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637243060153142089" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637243060153142089" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureOrganizationAndBusiness" xlink:type="extended" xlink:title="10101 - Disclosure - Organization and business" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_637243060153153280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_637243060153153280" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Summary of significant accounting policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_637243060153153280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_637243060153153280" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureRevenues" xlink:type="extended" xlink:title="10301 - Disclosure - Revenues" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_637243060153153280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_637243060153153280" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureFairValueOfFinancialInstruments" xlink:type="extended" xlink:title="10401 - Disclosure - Fair value of financial instruments" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_637243060153153280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_637243060153153280" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLosses" xlink:type="extended" xlink:title="10501 - Disclosure - Concentration of credit risk and current expected credit losses" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_637243060153153280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_637243060153153280" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureInventory" xlink:type="extended" xlink:title="10601 - Disclosure - Inventory" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock_637243060153162104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock_637243060153162104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosurePropertyAndEquipmentNet" xlink:type="extended" xlink:title="10701 - Disclosure - Property and equipment, net" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_637243060153162104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_637243060153162104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwill" xlink:type="extended" xlink:title="10801 - Disclosure - Intangible assets and goodwill" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_637243060153162104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_637243060153162104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureLicenseAgreements" xlink:type="extended" xlink:title="10901 - Disclosure - License agreements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementsDisclosureAbstract" xlink:label="incy_LicenseAgreementsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementsTextBlock" xlink:label="incy_LicenseAgreementsTextBlock_637243060153162104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_LicenseAgreementsDisclosureAbstract" xlink:to="incy_LicenseAgreementsTextBlock_637243060153162104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureStockCompensation" xlink:type="extended" xlink:title="11001 - Disclosure - Stock compensation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637243060153162104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637243060153162104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureAccruedAndOtherCurrentLiabilities" xlink:type="extended" xlink:title="11101 - Disclosure - Accrued and other current liabilities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_637243060153172100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_637243060153172100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureDebt" xlink:type="extended" xlink:title="11201 - Disclosure - Debt" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_637243060153172100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock_637243060153172100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureEmployeeBenefitPlans" xlink:type="extended" xlink:title="11301 - Disclosure - Employee benefit plans" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_637243060153172100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_637243060153172100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11401 - Disclosure - Income taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_637243060153172100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_637243060153172100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureNetIncomeLossPerShare" xlink:type="extended" xlink:title="11501 - Disclosure - Net income (loss) per share" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_637243060153172100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_637243060153172100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureContingencies" xlink:type="extended" xlink:title="11601 - Disclosure - Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LitigationDisclosureAbstract" xlink:label="incy_LitigationDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock_637243060153172100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_LitigationDisclosureAbstract" xlink:to="us-gaap_LegalMattersAndContingenciesTextBlock_637243060153172100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureSubsequentEvent" xlink:type="extended" xlink:title="11701 - Disclosure - Subsequent event" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_637243060153182100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_637243060153182100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Summary of significant accounting policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637243060153182100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637243060153182100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock_637243060153182100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock_637243060153182100" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_637243060153182100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_637243060153182100" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_637243060153182100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_637243060153182100" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_637243060153182100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_637243060153182100" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:label="us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_637243060153182100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_637243060153182100" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637243060153182100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637243060153182100" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy_637243060153182100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy_637243060153182100" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_637243060153182100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_637243060153182100" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock_637243060153182100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock_637243060153182100" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy_637243060153192099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationVariableInterestEntityPolicy_637243060153192099" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LongTermInvestmentPolicyTextBlock" xlink:label="incy_LongTermInvestmentPolicyTextBlock_637243060153192099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="incy_LongTermInvestmentPolicyTextBlock_637243060153192099" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_637243060153192099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_637243060153192099" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_637243060153192099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_637243060153192099" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_637243060153192099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_637243060153192099" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_637243060153192099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_637243060153192099" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_637243060153192099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_637243060153192099" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_637243060153192099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_637243060153192099" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock_637243060153192099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock_637243060153192099" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_637243060153192099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_637243060153192099" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_637243060153192099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_637243060153192099" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_637243060153202090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_637243060153202090" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_637243060153202090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_637243060153202090" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637243060153202090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637243060153202090" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_BusinessCombinationContingentConsiderationPolicyTextBlock" xlink:label="incy_BusinessCombinationContingentConsiderationPolicyTextBlock_637243060153202090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="incy_BusinessCombinationContingentConsiderationPolicyTextBlock_637243060153202090" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_637243060153202090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy_637243060153202090" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637243060153202090" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637243060153202090" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureRevenuesTables" xlink:type="extended" xlink:title="30303 - Disclosure - Revenues (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_637243060153212103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_637243060153212103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsTables" xlink:type="extended" xlink:title="30403 - Disclosure - Fair value of financial instruments (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_637243060153212103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_637243060153212103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_637243060153212103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_637243060153212103" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_637243060153212103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_637243060153212103" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_637243060153212103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_637243060153212103" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLossesTables" xlink:type="extended" xlink:title="30503 - Disclosure - Concentration of credit risk and current expected credit losses (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_SchedulesOfConcentrationOfRiskByRiskFactorRelatedToSpecialtyPharmaceuticalCustomersTableTextBlock" xlink:label="incy_SchedulesOfConcentrationOfRiskByRiskFactorRelatedToSpecialtyPharmaceuticalCustomersTableTextBlock_637243060153212103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="incy_SchedulesOfConcentrationOfRiskByRiskFactorRelatedToSpecialtyPharmaceuticalCustomersTableTextBlock_637243060153212103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureInventoryTables" xlink:type="extended" xlink:title="30603 - Disclosure - Inventory (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ScheduleOfInventoryTableTextBlock" xlink:label="incy_ScheduleOfInventoryTableTextBlock_637243060153212103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="incy_ScheduleOfInventoryTableTextBlock_637243060153212103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetTables" xlink:type="extended" xlink:title="30703 - Disclosure - Property and equipment, net (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_637243060153222101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_637243060153222101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LesseeLeaseLiabilityTableTextBlock" xlink:label="incy_LesseeLeaseLiabilityTableTextBlock_637243060153222101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="incy_LesseeLeaseLiabilityTableTextBlock_637243060153222101" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwillTables" xlink:type="extended" xlink:title="30803 - Disclosure - Intangible assets and goodwill (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_637243060153222101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_637243060153222101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_637243060153222101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_637243060153222101" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureStockCompensationTables" xlink:type="extended" xlink:title="31003 - Disclosure - Stock compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="incy_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_637243060153222101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="incy_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_637243060153222101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637243060153222101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637243060153222101" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock" xlink:label="incy_ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock_637243060153222101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="incy_ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock_637243060153222101" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_637243060153222101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_637243060153222101" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesTables" xlink:type="extended" xlink:title="31103 - Disclosure - Accrued and other current liabilities (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_637243060153232100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_637243060153232100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureDebtTables" xlink:type="extended" xlink:title="31203 - Disclosure - Debt (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_637243060153232100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_637243060153232100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_637243060153232100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_637243060153232100" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureEmployeeBenefitPlansTables" xlink:type="extended" xlink:title="31303 - Disclosure - Employee benefit plans (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:label="us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_637243060153232100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_637243060153232100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureNetIncomeLossPerShareTables" xlink:type="extended" xlink:title="31503 - Disclosure - Net income (loss) per share (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_637243060153232100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_637243060153232100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637243060153232100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637243060153232100" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureOrganizationAndBusinessDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Organization and business (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:label="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_637243060153242100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_637243060153242100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_637243060153242100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_637243060153242100" xlink:to="us-gaap_NumberOfOperatingSegments_637243060153242100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of significant accounting policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_636147313702158168" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637243060153242100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_636147313702158168" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637243060153242100" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637243060153242100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637243060153242100" xlink:to="srt_ProductOrServiceAxis_637243060153242100" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637243060153242100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637243060153242100" xlink:to="srt_ProductsAndServicesDomain_637243060153242100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_JAKAFIMember" xlink:label="incy_JAKAFIMember_637243060153242100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637243060153242100" xlink:to="incy_JAKAFIMember_637243060153242100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ICLUSIGMember" xlink:label="incy_ICLUSIGMember_637243060153242100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637243060153242100" xlink:to="incy_ICLUSIGMember_637243060153242100" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637243060153242100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637243060153242100" xlink:to="us-gaap_StatementLineItems_637243060153242100" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ConcentrationOfCreditRiskAbstract" xlink:label="incy_ConcentrationOfCreditRiskAbstract_637243060153242100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637243060153242100" xlink:to="incy_ConcentrationOfCreditRiskAbstract_637243060153242100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CreditExposureLimitationNumberOfIssuerOtherThanUnitedStatesGovernmentGuaranteedSecurities" xlink:label="incy_CreditExposureLimitationNumberOfIssuerOtherThanUnitedStatesGovernmentGuaranteedSecurities_637243060153242100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_ConcentrationOfCreditRiskAbstract_637243060153242100" xlink:to="incy_CreditExposureLimitationNumberOfIssuerOtherThanUnitedStatesGovernmentGuaranteedSecurities_637243060153242100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CreditExposureLimitationNumberOfFinancialInvestmentOtherThanUnitedStatesGovernmentGuaranteedSecurities" xlink:label="incy_CreditExposureLimitationNumberOfFinancialInvestmentOtherThanUnitedStatesGovernmentGuaranteedSecurities_637243060153242100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_ConcentrationOfCreditRiskAbstract_637243060153242100" xlink:to="incy_CreditExposureLimitationNumberOfFinancialInvestmentOtherThanUnitedStatesGovernmentGuaranteedSecurities_637243060153242100" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="us-gaap_InventoryNetAbstract_637243060153242100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637243060153242100" xlink:to="us-gaap_InventoryNetAbstract_637243060153242100" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_InventoryFinishedGoodsUsefulLifeMaximum" xlink:label="incy_InventoryFinishedGoodsUsefulLifeMaximum_637243060153252100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract_637243060153242100" xlink:to="incy_InventoryFinishedGoodsUsefulLifeMaximum_637243060153252100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_VariableInterestEntitiesAbstract" xlink:label="incy_VariableInterestEntitiesAbstract_637243060153252100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637243060153242100" xlink:to="incy_VariableInterestEntitiesAbstract_637243060153252100" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_VariableInterestEntitiesNumber" xlink:label="incy_VariableInterestEntitiesNumber_637243060153252100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_VariableInterestEntitiesAbstract_637243060153252100" xlink:to="incy_VariableInterestEntitiesNumber_637243060153252100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of significant accounting policies - Revenue Recognition (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_636898937997957154" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637243060153252100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_636898937997957154" xlink:to="us-gaap_StatementTable_637243060153252100" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637243060153252100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153252100" xlink:to="srt_ProductOrServiceAxis_637243060153252100" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637243060153252100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637243060153252100" xlink:to="srt_ProductsAndServicesDomain_637243060153252100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_637243060153252100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637243060153252100" xlink:to="us-gaap_ProductMember_637243060153252100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ICLUSIGMember" xlink:label="incy_ICLUSIGMember_637243060153252100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductMember_637243060153252100" xlink:to="incy_ICLUSIGMember_637243060153252100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637243060153312105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153252100" xlink:to="us-gaap_TypeOfArrangementAxis_637243060153312105" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637243060153312105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637243060153312105" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637243060153312105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_MorphosysAgMember" xlink:label="incy_MorphosysAgMember_637243060153312105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637243060153312105" xlink:to="incy_MorphosysAgMember_637243060153312105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_637243060153312105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153252100" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_637243060153312105" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PercentageOfMedicarePartDInsuranceCoverageGapRequiredToBeFundedByManufacturers" xlink:label="incy_PercentageOfMedicarePartDInsuranceCoverageGapRequiredToBeFundedByManufacturers_637243060153312105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_637243060153312105" xlink:to="incy_PercentageOfMedicarePartDInsuranceCoverageGapRequiredToBeFundedByManufacturers_637243060153312105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_MedicarePartDInsuranceCoverageGapIncreaseInEligiblePatientSpendingPercentage" xlink:label="incy_MedicarePartDInsuranceCoverageGapIncreaseInEligiblePatientSpendingPercentage_637243060153312105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_637243060153312105" xlink:to="incy_MedicarePartDInsuranceCoverageGapIncreaseInEligiblePatientSpendingPercentage_637243060153312105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_637243060153322106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_637243060153312105" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_637243060153322106" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CollaborationAgreementProfitLossSharingRatio" xlink:label="incy_CollaborationAgreementProfitLossSharingRatio_637243060153322106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_637243060153312105" xlink:to="incy_CollaborationAgreementProfitLossSharingRatio_637243060153322106" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" xlink:type="extended" xlink:title="40203 - Disclosure - Summary of significant accounting policies - Recent Accounting Pronouncements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_637243060153322106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_637243060153322106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CoronavirusAidReliefAndEconomicSecurityActFund" xlink:label="incy_CoronavirusAidReliefAndEconomicSecurityActFund_637243060153322106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_637243060153322106" xlink:to="incy_CoronavirusAidReliefAndEconomicSecurityActFund_637243060153322106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureRevenuesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Revenues (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable_637243060153322106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable_637243060153322106" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637243060153322106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_637243060153322106" xlink:to="srt_ProductOrServiceAxis_637243060153322106" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637243060153322106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637243060153322106" xlink:to="srt_ProductsAndServicesDomain_637243060153322106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_637243060153332114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637243060153322106" xlink:to="us-gaap_ProductMember_637243060153332114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_JAKAFIMember" xlink:label="incy_JAKAFIMember_637243060153332114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductMember_637243060153332114" xlink:to="incy_JAKAFIMember_637243060153332114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ICLUSIGMember" xlink:label="incy_ICLUSIGMember_637243060153332114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductMember_637243060153332114" xlink:to="incy_ICLUSIGMember_637243060153332114" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember_637243060153332114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637243060153322106" xlink:to="us-gaap_RoyaltyMember_637243060153332114" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_JakaviRoyaltyRevenuesMember" xlink:label="incy_JakaviRoyaltyRevenuesMember_637243060153332114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RoyaltyMember_637243060153332114" xlink:to="incy_JakaviRoyaltyRevenuesMember_637243060153332114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_OlumiantRoyaltyMember" xlink:label="incy_OlumiantRoyaltyMember_637243060153332114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RoyaltyMember_637243060153332114" xlink:to="incy_OlumiantRoyaltyMember_637243060153332114" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_MilestoneAndContractRevenueMember" xlink:label="incy_MilestoneAndContractRevenueMember_637243060153332114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637243060153322106" xlink:to="incy_MilestoneAndContractRevenueMember_637243060153332114" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_637243060153332114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_637243060153322106" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_637243060153332114" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637243060153332114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_637243060153332114" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637243060153332114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Fair value of financial instruments - Fair value on a recurring basis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637243060153332114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637243060153332114" order="1" use="optional" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_637243060153332114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637243060153332114" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_637243060153332114" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_637243060153342106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_637243060153332114" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_637243060153342106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_637243060153342106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_637243060153342106" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_637243060153342106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637243060153342106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637243060153332114" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637243060153342106" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637243060153342106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637243060153342106" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637243060153342106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_637243060153342106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637243060153342106" xlink:to="us-gaap_FairValueInputsLevel1Member_637243060153342106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_637243060153342106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637243060153342106" xlink:to="us-gaap_FairValueInputsLevel2Member_637243060153342106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_637243060153342106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637243060153342106" xlink:to="us-gaap_FairValueInputsLevel3Member_637243060153342106" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_637243060153342106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637243060153332114" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_637243060153342106" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_637243060153342106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis_637243060153342106" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_637243060153342106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_637243060153342106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember_637243060153342106" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_637243060153342106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_637243060153342106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637243060153332114" xlink:to="us-gaap_BusinessAcquisitionAxis_637243060153342106" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_637243060153342106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_637243060153342106" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_637243060153342106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AriadPharmaceuticalsMember" xlink:label="incy_AriadPharmaceuticalsMember_637243060153342106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_637243060153342106" xlink:to="incy_AriadPharmaceuticalsMember_637243060153342106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_637243060153342106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637243060153332114" xlink:to="us-gaap_BalanceSheetLocationAxis_637243060153342106" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_637243060153352101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis_637243060153342106" xlink:to="us-gaap_BalanceSheetLocationDomain_637243060153352101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AccruedAndOtherCurrentLiabilityMember" xlink:label="incy_AccruedAndOtherCurrentLiabilityMember_637243060153352101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_637243060153352101" xlink:to="incy_AccruedAndOtherCurrentLiabilityMember_637243060153352101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_637243060153352101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637243060153332114" xlink:to="us-gaap_MeasurementInputTypeAxis_637243060153352101" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_637243060153352101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_637243060153352101" xlink:to="us-gaap_MeasurementInputTypeDomain_637243060153352101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember_637243060153352101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637243060153352101" xlink:to="us-gaap_MeasurementInputDiscountRateMember_637243060153352101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputCapRateMember" xlink:label="us-gaap_MeasurementInputCapRateMember_637243060153352101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637243060153352101" xlink:to="us-gaap_MeasurementInputCapRateMember_637243060153352101" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis_637243060153352101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637243060153332114" xlink:to="us-gaap_FairValueByLiabilityClassAxis_637243060153352101" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_637243060153352101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis_637243060153352101" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_637243060153352101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilityMember" xlink:label="us-gaap_LiabilityMember_637243060153352101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_637243060153352101" xlink:to="us-gaap_LiabilityMember_637243060153352101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637243060153352101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637243060153332114" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637243060153352101" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637243060153362101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637243060153352101" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637243060153362101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_637243060153362101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637243060153352101" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_637243060153362101" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments_637243060153362101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637243060153352101" xlink:to="us-gaap_LongTermInvestments_637243060153362101" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_637243060153362101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637243060153352101" xlink:to="us-gaap_AssetsFairValueDisclosure_637243060153362101" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_637243060153362101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637243060153352101" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_637243060153362101" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_637243060153362101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637243060153352101" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_637243060153362101" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_637243060153362101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637243060153352101" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_637243060153362101" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_637243060153362101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_637243060153362101" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_637243060153362101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned" xlink:label="incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned_637243060153372097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_637243060153362101" xlink:to="incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned_637243060153372097" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_637243060153372097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_637243060153362101" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_637243060153372097" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_637243060153372097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_637243060153362101" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_637243060153372097" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_FairValueInputsCashFlowsEstimatedPeriod" xlink:label="incy_FairValueInputsCashFlowsEstimatedPeriod_637243060153372097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_637243060153362101" xlink:to="incy_FairValueInputsCashFlowsEstimatedPeriod_637243060153372097" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_637243060153372097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_637243060153362101" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_637243060153372097" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsMarketableSecuritiesPortfolioDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Fair value of financial instruments - Marketable securities portfolio (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637243060153382106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_StatementTable_637243060153382106" order="1" use="optional" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_637243060153382106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153382106" xlink:to="us-gaap_FinancialInstrumentAxis_637243060153382106" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637243060153382106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_637243060153382106" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637243060153382106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CorporateAndGovernmentDebtSecuritiesMember" xlink:label="incy_CorporateAndGovernmentDebtSecuritiesMember_637243060153382106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637243060153382106" xlink:to="incy_CorporateAndGovernmentDebtSecuritiesMember_637243060153382106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637243060153382106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153382106" xlink:to="srt_RangeAxis_637243060153382106" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637243060153382106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637243060153382106" xlink:to="srt_RangeMember_637243060153382106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637243060153382106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637243060153382106" xlink:to="srt_MinimumMember_637243060153382106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637243060153382106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637243060153382106" xlink:to="srt_MaximumMember_637243060153382106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_637243060153382106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153382106" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_637243060153382106" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_637243060153382106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_637243060153382106" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_637243060153382106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_637243060153382106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_637243060153382106" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_637243060153382106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_637243060153382106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_637243060153382106" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_637243060153382106" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm_637243060153382106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_637243060153382106" xlink:to="us-gaap_DebtInstrumentTerm_637243060153382106" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLossesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Concentration of credit risk and current expected credit losses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable_637243060153392105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_ConcentrationRiskTable_637243060153392105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_637243060153392105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_637243060153392105" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_637243060153392105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_637243060153392105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_637243060153392105" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_637243060153392105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_SalesRevenueGoodsServicesNetMember" xlink:label="incy_SalesRevenueGoodsServicesNetMember_637243060153392105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_637243060153392105" xlink:to="incy_SalesRevenueGoodsServicesNetMember_637243060153392105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember_637243060153392105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_637243060153392105" xlink:to="us-gaap_AccountsReceivableMember_637243060153392105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_637243060153392105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_637243060153392105" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_637243060153392105" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_637243060153392105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_637243060153392105" xlink:to="us-gaap_ConcentrationRiskTypeDomain_637243060153392105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember_637243060153392105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain_637243060153392105" xlink:to="us-gaap_CustomerConcentrationRiskMember_637243060153392105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember_637243060153392105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain_637243060153392105" xlink:to="us-gaap_CreditConcentrationRiskMember_637243060153392105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_637243060153392105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_637243060153392105" xlink:to="srt_MajorCustomersAxis_637243060153392105" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_637243060153392105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis_637243060153392105" xlink:to="srt_NameOfMajorCustomerDomain_637243060153392105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CollaborationPartneraBAndCMember" xlink:label="incy_CollaborationPartneraBAndCMember_637243060153392105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_637243060153392105" xlink:to="incy_CollaborationPartneraBAndCMember_637243060153392105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CustomerAMember" xlink:label="incy_CustomerAMember_637243060153392105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_637243060153392105" xlink:to="incy_CustomerAMember_637243060153392105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CustomerBMember" xlink:label="incy_CustomerBMember_637243060153402105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_637243060153392105" xlink:to="incy_CustomerBMember_637243060153402105" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CustomerCMember" xlink:label="incy_CustomerCMember_637243060153402105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_637243060153392105" xlink:to="incy_CustomerCMember_637243060153402105" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CustomerDMember" xlink:label="incy_CustomerDMember_637243060153402105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_637243060153392105" xlink:to="incy_CustomerDMember_637243060153402105" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CustomerABCAndDMember" xlink:label="incy_CustomerABCAndDMember_637243060153402105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_637243060153392105" xlink:to="incy_CustomerABCAndDMember_637243060153402105" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems_637243060153402105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_637243060153392105" xlink:to="us-gaap_ConcentrationRiskLineItems_637243060153402105" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1_637243060153402105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_637243060153402105" xlink:to="us-gaap_ConcentrationRiskPercentage1_637243060153402105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureInventoryDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Inventory (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract_635493301753535682" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_637243060153402105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_635493301753535682" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_637243060153402105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_637243060153402105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_635493301753535682" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_637243060153402105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_637243060153402105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_635493301753535682" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_637243060153402105" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_InventoryNetCurrentAndNoncurrent" xlink:label="incy_InventoryNetCurrentAndNoncurrent_637243060153412106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_635493301753535682" xlink:to="incy_InventoryNetCurrentAndNoncurrent_637243060153412106" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637243060153412106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_635493301753535682" xlink:to="us-gaap_InventoryNet_637243060153412106" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="us-gaap_InventoryNoncurrent_637243060153412106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_635493301753535682" xlink:to="us-gaap_InventoryNoncurrent_637243060153412106" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Property and equipment, net - Property and equipment, net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_635470903437165758" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637243060153412106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_635470903437165758" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637243060153412106" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637243060153422112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637243060153412106" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637243060153422112" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637243060153422112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637243060153422112" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637243060153422112" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember_637243060153422112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637243060153422112" xlink:to="us-gaap_OfficeEquipmentMember_637243060153422112" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_637243060153422112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637243060153422112" xlink:to="us-gaap_EquipmentMember_637243060153422112" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_637243060153422112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637243060153422112" xlink:to="us-gaap_ComputerEquipmentMember_637243060153422112" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LandMember" xlink:label="us-gaap_LandMember_637243060153422112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637243060153422112" xlink:to="us-gaap_LandMember_637243060153422112" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_BuildingAndLeaseholdImprovementsMember" xlink:label="incy_BuildingAndLeaseholdImprovementsMember_637243060153422112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637243060153422112" xlink:to="incy_BuildingAndLeaseholdImprovementsMember_637243060153422112" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_OperatingLeaseRightOfUseAssetsMember" xlink:label="incy_OperatingLeaseRightOfUseAssetsMember_637243060153422112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637243060153422112" xlink:to="incy_OperatingLeaseRightOfUseAssetsMember_637243060153422112" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember_637243060153422112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637243060153422112" xlink:to="us-gaap_ConstructionInProgressMember_637243060153422112" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_637243060153422112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637243060153412106" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_637243060153422112" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637243060153422112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637243060153422112" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637243060153422112" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637243060153422112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637243060153422112" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637243060153422112" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637243060153422112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637243060153422112" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637243060153422112" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetBuildingsAndConstructionDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Property and equipment, net - Buildings and construction (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_635780793131919605" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637243060153432107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_635780793131919605" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637243060153432107" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealEstatePropertiesAxis" xlink:label="us-gaap_RealEstatePropertiesAxis_637243060153432107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637243060153432107" xlink:to="us-gaap_RealEstatePropertiesAxis_637243060153432107" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealEstatePropertiesDomain" xlink:label="us-gaap_RealEstatePropertiesDomain_637243060153432107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RealEstatePropertiesAxis_637243060153432107" xlink:to="us-gaap_RealEstatePropertiesDomain_637243060153432107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_OfficeBuildingMorgesSwitzerlandMember" xlink:label="incy_OfficeBuildingMorgesSwitzerlandMember_637243060153432107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RealEstatePropertiesDomain_637243060153432107" xlink:to="incy_OfficeBuildingMorgesSwitzerlandMember_637243060153432107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember" xlink:label="incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember_637243060153432107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RealEstatePropertiesDomain_637243060153432107" xlink:to="incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember_637243060153432107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637243060153432107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637243060153432107" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637243060153432107" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637243060153432107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637243060153432107" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637243060153432107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember_637243060153432107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637243060153432107" xlink:to="us-gaap_ConstructionInProgressMember_637243060153432107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_637243060153432107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637243060153432107" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_637243060153432107" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1_637243060153432107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637243060153432107" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1_637243060153432107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend_637243060153432107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637243060153432107" xlink:to="us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend_637243060153432107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:label="us-gaap_LesseeFinanceLeaseRenewalTerm1_637243060153432107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637243060153432107" xlink:to="us-gaap_LesseeFinanceLeaseRenewalTerm1_637243060153432107" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty_637243060153442110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637243060153432107" xlink:to="us-gaap_AreaOfRealEstateProperty_637243060153442110" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability_637243060153442110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637243060153432107" xlink:to="us-gaap_FinanceLeaseLiability_637243060153442110" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_637243060153442110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637243060153432107" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_637243060153442110" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_FinanceLeaseLeaseIncentiveReceivable" xlink:label="incy_FinanceLeaseLeaseIncentiveReceivable_637243060153442110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637243060153432107" xlink:to="incy_FinanceLeaseLeaseIncentiveReceivable_637243060153442110" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="us-gaap_ConstructionInProgressGross_637243060153442110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637243060153432107" xlink:to="us-gaap_ConstructionInProgressGross_637243060153442110" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireRealEstate" xlink:label="us-gaap_PaymentsToAcquireRealEstate_637243060153442110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637243060153432107" xlink:to="us-gaap_PaymentsToAcquireRealEstate_637243060153442110" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637243060153442110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637243060153432107" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637243060153442110" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Property and equipment, net - Lease and maturity of lease liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract_637243060153442110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_AssetsAndLiabilitiesLesseeAbstract_637243060153442110" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfResidualValueGuarantee" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfResidualValueGuarantee_637243060153442110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_637243060153442110" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfResidualValueGuarantee_637243060153442110" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_637243060153452109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_637243060153442110" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_637243060153452109" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637243060153452109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_637243060153442110" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637243060153452109" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_637243060153452109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent_637243060153452109" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_637243060153452109" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_637243060153452109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_637243060153442110" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_637243060153452109" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_637243060153452109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent_637243060153452109" xlink:to="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_637243060153452109" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637243060153452109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_637243060153442110" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637243060153452109" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_637243060153452109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent_637243060153452109" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_637243060153452109" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_637243060153452109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_637243060153442110" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_637243060153452109" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_637243060153452109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent_637243060153452109" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_637243060153452109" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_OperatingAndFinanceLeaseLiability" xlink:label="incy_OperatingAndFinanceLeaseLiability_637243060153452109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_637243060153442110" xlink:to="incy_OperatingAndFinanceLeaseLiability_637243060153452109" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_637243060153452109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_637243060153442110" xlink:to="us-gaap_OperatingLeasePayments_637243060153452109" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_637243060153452109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_637243060153442110" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_637243060153452109" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments_637243060153452109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_637243060153442110" xlink:to="us-gaap_FinanceLeasePrincipalPayments_637243060153452109" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_637243060153452109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_637243060153452109" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_637243060153462104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_637243060153452109" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_637243060153462104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability_637243060153462104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_637243060153452109" xlink:to="us-gaap_FinanceLeaseLiability_637243060153462104" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_637243060153462104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_637243060153462104" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_637243060153462104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_637243060153462104" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_637243060153462104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_637243060153462104" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_637243060153462104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_637243060153462104" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_637243060153462104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_OperatingLeaseCost_637243060153462104" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_637243060153462104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_637243060153462104" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense_637243060153462104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_FinanceLeaseInterestExpense_637243060153462104" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense_637243060153462104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_OperatingLeaseExpense_637243060153462104" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwillDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Intangible assets and goodwill (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_636023854814065284" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:label="incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_637243060153472104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_636023854814065284" xlink:to="incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_637243060153472104" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_637243060153472104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_637243060153472104" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_637243060153472104" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_637243060153472104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_637243060153472104" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_637243060153472104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember_637243060153472104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_637243060153472104" xlink:to="us-gaap_IntellectualPropertyMember_637243060153472104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems_637243060153472104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_637243060153472104" xlink:to="incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems_637243060153472104" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_637243060153472104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems_637243060153472104" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_637243060153472104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_637243060153472104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems_637243060153472104" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_637243060153472104" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_637243060153472104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_637243060153472104" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_637243060153472104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_637243060153472104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_637243060153472104" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_637243060153472104" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_637243060153472104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_637243060153472104" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_637243060153472104" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_637243060153482112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems_637243060153472104" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_637243060153482112" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_637243060153482112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_637243060153482112" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_637243060153482112" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_637243060153482112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_637243060153482112" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_637243060153482112" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_637243060153482112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_637243060153482112" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_637243060153482112" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_637243060153482112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_637243060153482112" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_637243060153482112" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_637243060153482112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_637243060153482112" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_637243060153482112" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_637243060153482112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_637243060153482112" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_637243060153482112" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="us-gaap_GoodwillRollForward_637243060153482112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems_637243060153472104" xlink:to="us-gaap_GoodwillRollForward_637243060153482112" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease_637243060153482112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillRollForward_637243060153482112" xlink:to="us-gaap_GoodwillPeriodIncreaseDecrease_637243060153482112" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails" xlink:type="extended" xlink:title="40901 - Disclosure - License agreements - Novartis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementsDisclosureAbstract" xlink:label="incy_LicenseAgreementsDisclosureAbstract_635470902700425758" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637243060153492111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_LicenseAgreementsDisclosureAbstract_635470902700425758" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637243060153492111" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637243060153492111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637243060153492111" xlink:to="us-gaap_TypeOfArrangementAxis_637243060153492111" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637243060153492111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637243060153492111" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637243060153492111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_NovartisMember" xlink:label="incy_NovartisMember_637243060153492111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637243060153492111" xlink:to="incy_NovartisMember_637243060153492111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637243060153492111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637243060153492111" xlink:to="srt_ProductOrServiceAxis_637243060153492111" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637243060153492111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637243060153492111" xlink:to="srt_ProductsAndServicesDomain_637243060153492111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_GvhdMember" xlink:label="incy_GvhdMember_637243060153492111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637243060153492111" xlink:to="incy_GvhdMember_637243060153492111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_JAKAFIMember" xlink:label="incy_JAKAFIMember_637243060153492111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637243060153492111" xlink:to="incy_JAKAFIMember_637243060153492111" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_JakaviMember" xlink:label="incy_JakaviMember_637243060153492111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637243060153492111" xlink:to="incy_JakaviMember_637243060153492111" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AchievementOfMilestoneAxis" xlink:label="incy_AchievementOfMilestoneAxis_637243060153492111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637243060153492111" xlink:to="incy_AchievementOfMilestoneAxis_637243060153492111" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AchievementOfMilestoneDomain" xlink:label="incy_AchievementOfMilestoneDomain_637243060153492111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_AchievementOfMilestoneAxis_637243060153492111" xlink:to="incy_AchievementOfMilestoneDomain_637243060153492111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PreSpecifiedEventsMember" xlink:label="incy_PreSpecifiedEventsMember_637243060153492111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_AchievementOfMilestoneDomain_637243060153492111" xlink:to="incy_PreSpecifiedEventsMember_637243060153492111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DevelopmentMilestonesMember" xlink:label="incy_DevelopmentMilestonesMember_637243060153502109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_AchievementOfMilestoneDomain_637243060153492111" xlink:to="incy_DevelopmentMilestonesMember_637243060153502109" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_RegulatoryMilestonesMember" xlink:label="incy_RegulatoryMilestonesMember_637243060153502109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_AchievementOfMilestoneDomain_637243060153492111" xlink:to="incy_RegulatoryMilestonesMember_637243060153502109" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CommercializationMilestonesMember" xlink:label="incy_CommercializationMilestonesMember_637243060153502109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_AchievementOfMilestoneDomain_637243060153492111" xlink:to="incy_CommercializationMilestonesMember_637243060153502109" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DevelopmentAndRegulatoryMilestonesMember" xlink:label="incy_DevelopmentAndRegulatoryMilestonesMember_637243060153502109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_AchievementOfMilestoneDomain_637243060153492111" xlink:to="incy_DevelopmentAndRegulatoryMilestonesMember_637243060153502109" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DevelopmentAndCommercializationMilestonesMember" xlink:label="incy_DevelopmentAndCommercializationMilestonesMember_637243060153502109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_AchievementOfMilestoneDomain_637243060153492111" xlink:to="incy_DevelopmentAndCommercializationMilestonesMember_637243060153502109" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637243060153502109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637243060153492111" xlink:to="srt_RangeAxis_637243060153502109" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637243060153502109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637243060153502109" xlink:to="srt_RangeMember_637243060153502109" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637243060153513186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637243060153502109" xlink:to="srt_MinimumMember_637243060153513186" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637243060153513186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637243060153502109" xlink:to="srt_MaximumMember_637243060153513186" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PhasesOfArrangementsAxis" xlink:label="incy_PhasesOfArrangementsAxis_637243060153513186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637243060153492111" xlink:to="incy_PhasesOfArrangementsAxis_637243060153513186" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PhasesOfArrangementsDomain" xlink:label="incy_PhasesOfArrangementsDomain_637243060153513186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_PhasesOfArrangementsAxis_637243060153513186" xlink:to="incy_PhasesOfArrangementsDomain_637243060153513186" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PhaseThreeMember" xlink:label="incy_PhaseThreeMember_637243060153513186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_PhasesOfArrangementsDomain_637243060153513186" xlink:to="incy_PhaseThreeMember_637243060153513186" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637243060153513186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637243060153492111" xlink:to="srt_StatementGeographicalAxis_637243060153513186" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637243060153513186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637243060153513186" xlink:to="srt_SegmentGeographicalDomain_637243060153513186" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember_637243060153513186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637243060153513186" xlink:to="us-gaap_NonUsMember_637243060153513186" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember_637243060153522115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637243060153513186" xlink:to="srt_EuropeMember_637243060153522115" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="country_JP_637243060153522115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637243060153513186" xlink:to="country_JP_637243060153522115" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="country_US_637243060153522115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637243060153513186" xlink:to="country_US_637243060153522115" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_637243060153522115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637243060153492111" xlink:to="us-gaap_RelatedPartyTransactionLineItems_637243060153522115" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" xlink:label="incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived_637243060153522115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153522115" xlink:to="incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived_637243060153522115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementUpfrontPaymentReceived" xlink:label="incy_LicenseAgreementUpfrontPaymentReceived_637243060153522115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153522115" xlink:to="incy_LicenseAgreementUpfrontPaymentReceived_637243060153522115" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementImmediateMilestonePaymentReceived" xlink:label="incy_LicenseAgreementImmediateMilestonePaymentReceived_637243060153522115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153522115" xlink:to="incy_LicenseAgreementImmediateMilestonePaymentReceived_637243060153522115" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" xlink:label="incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone_637243060153522115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153522115" xlink:to="incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone_637243060153522115" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637243060153532109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153522115" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637243060153532109" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PercentageOfRoyaltyRatePayments" xlink:label="incy_PercentageOfRoyaltyRatePayments_637243060153532109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153522115" xlink:to="incy_PercentageOfRoyaltyRatePayments_637243060153532109" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:label="us-gaap_IncreaseDecreaseInRoyaltiesPayable_637243060153544828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153522115" xlink:to="us-gaap_IncreaseDecreaseInRoyaltiesPayable_637243060153544828" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_RoyaltiesPayable" xlink:label="incy_RoyaltiesPayable_637243060153544828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153522115" xlink:to="incy_RoyaltiesPayable_637243060153544828" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementReimbursableCosts" xlink:label="incy_LicenseAgreementReimbursableCosts_637243060153544828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153522115" xlink:to="incy_LicenseAgreementReimbursableCosts_637243060153544828" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementResearchAndDevelopmentReimbursedCost" xlink:label="incy_LicenseAgreementResearchAndDevelopmentReimbursedCost_637243060153554785" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153522115" xlink:to="incy_LicenseAgreementResearchAndDevelopmentReimbursedCost_637243060153554785" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_RoyaltyPaymentReceivable" xlink:label="incy_RoyaltyPaymentReceivable_637243060153554785" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153522115" xlink:to="incy_RoyaltyPaymentReceivable_637243060153554785" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails" xlink:type="extended" xlink:title="40902 - Disclosure - License agreements - Lilly (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementsDisclosureAbstract" xlink:label="incy_LicenseAgreementsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637243060153562823" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_LicenseAgreementsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637243060153562823" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637243060153562823" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637243060153562823" xlink:to="us-gaap_TypeOfArrangementAxis_637243060153562823" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637243060153562823" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637243060153562823" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637243060153562823" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_EliLillyMember" xlink:label="incy_EliLillyMember_637243060153562823" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637243060153562823" xlink:to="incy_EliLillyMember_637243060153562823" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637243060153562823" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637243060153562823" xlink:to="srt_ProductOrServiceAxis_637243060153562823" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637243060153562823" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637243060153562823" xlink:to="srt_ProductsAndServicesDomain_637243060153562823" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_GvhdMember" xlink:label="incy_GvhdMember_637243060153562823" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637243060153562823" xlink:to="incy_GvhdMember_637243060153562823" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_637243060153562823" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637243060153562823" xlink:to="us-gaap_BalanceSheetLocationAxis_637243060153562823" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_637243060153572111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis_637243060153562823" xlink:to="us-gaap_BalanceSheetLocationDomain_637243060153572111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="us-gaap_AccruedLiabilitiesMember_637243060153572111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_637243060153572111" xlink:to="us-gaap_AccruedLiabilitiesMember_637243060153572111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AchievementOfMilestoneAxis" xlink:label="incy_AchievementOfMilestoneAxis_637243060153572111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637243060153562823" xlink:to="incy_AchievementOfMilestoneAxis_637243060153572111" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AchievementOfMilestoneDomain" xlink:label="incy_AchievementOfMilestoneDomain_637243060153572111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_AchievementOfMilestoneAxis_637243060153572111" xlink:to="incy_AchievementOfMilestoneDomain_637243060153572111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PreSpecifiedEventsMember" xlink:label="incy_PreSpecifiedEventsMember_637243060153572111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_AchievementOfMilestoneDomain_637243060153572111" xlink:to="incy_PreSpecifiedEventsMember_637243060153572111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DevelopmentMilestonesMember" xlink:label="incy_DevelopmentMilestonesMember_637243060153572111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_AchievementOfMilestoneDomain_637243060153572111" xlink:to="incy_DevelopmentMilestonesMember_637243060153572111" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_RegulatoryMilestonesMember" xlink:label="incy_RegulatoryMilestonesMember_637243060153572111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_AchievementOfMilestoneDomain_637243060153572111" xlink:to="incy_RegulatoryMilestonesMember_637243060153572111" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CommercializationMilestonesMember" xlink:label="incy_CommercializationMilestonesMember_637243060153572111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_AchievementOfMilestoneDomain_637243060153572111" xlink:to="incy_CommercializationMilestonesMember_637243060153572111" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DevelopmentAndCommercializationMilestonesMember" xlink:label="incy_DevelopmentAndCommercializationMilestonesMember_637243060153572111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_AchievementOfMilestoneDomain_637243060153572111" xlink:to="incy_DevelopmentAndCommercializationMilestonesMember_637243060153572111" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PhasesOfArrangementsAxis" xlink:label="incy_PhasesOfArrangementsAxis_637243060153572111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637243060153562823" xlink:to="incy_PhasesOfArrangementsAxis_637243060153572111" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PhasesOfArrangementsDomain" xlink:label="incy_PhasesOfArrangementsDomain_637243060153572111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_PhasesOfArrangementsAxis_637243060153572111" xlink:to="incy_PhasesOfArrangementsDomain_637243060153572111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PhaseThreeMember" xlink:label="incy_PhaseThreeMember_637243060153582112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_PhasesOfArrangementsDomain_637243060153572111" xlink:to="incy_PhaseThreeMember_637243060153582112" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PhaseTwoBMember" xlink:label="incy_PhaseTwoBMember_637243060153582112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_PhasesOfArrangementsDomain_637243060153572111" xlink:to="incy_PhaseTwoBMember_637243060153582112" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637243060153582112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637243060153562823" xlink:to="srt_RangeAxis_637243060153582112" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637243060153582112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637243060153582112" xlink:to="srt_RangeMember_637243060153582112" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637243060153582112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637243060153582112" xlink:to="srt_MaximumMember_637243060153582112" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637243060153582112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637243060153562823" xlink:to="srt_StatementGeographicalAxis_637243060153582112" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637243060153582112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637243060153582112" xlink:to="srt_SegmentGeographicalDomain_637243060153582112" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="country_JP_637243060153582112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637243060153582112" xlink:to="country_JP_637243060153582112" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember_637243060153582112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637243060153582112" xlink:to="srt_EuropeMember_637243060153582112" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember_637243060153592109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637243060153582112" xlink:to="us-gaap_NonUsMember_637243060153592109" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_637243060153592109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637243060153562823" xlink:to="us-gaap_RelatedPartyTransactionLineItems_637243060153592109" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementUpfrontPaymentReceived" xlink:label="incy_LicenseAgreementUpfrontPaymentReceived_637243060153592109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153592109" xlink:to="incy_LicenseAgreementUpfrontPaymentReceived_637243060153592109" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" xlink:label="incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived_637243060153592109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153592109" xlink:to="incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived_637243060153592109" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" xlink:label="incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone_637243060153592109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153592109" xlink:to="incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone_637243060153592109" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded" xlink:label="incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded_637243060153592109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153592109" xlink:to="incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded_637243060153592109" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds" xlink:label="incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds_637243060153592109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153592109" xlink:to="incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds_637243060153592109" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PercentageOfRoyaltyRatePayments" xlink:label="incy_PercentageOfRoyaltyRatePayments_637243060153592109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153592109" xlink:to="incy_PercentageOfRoyaltyRatePayments_637243060153592109" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementResearchAndDevelopmentReimbursedCost" xlink:label="incy_LicenseAgreementResearchAndDevelopmentReimbursedCost_637243060153602109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153592109" xlink:to="incy_LicenseAgreementResearchAndDevelopmentReimbursedCost_637243060153602109" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637243060153602109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153592109" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637243060153602109" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_637243060153602109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153592109" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_637243060153602109" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637243060153602109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153592109" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637243060153602109" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_RoyaltyPaymentReceivable" xlink:label="incy_RoyaltyPaymentReceivable_637243060153602109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153592109" xlink:to="incy_RoyaltyPaymentReceivable_637243060153602109" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementUpfrontPaymentAmountPaid" xlink:label="incy_LicenseAgreementUpfrontPaymentAmountPaid_637243060153602109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153592109" xlink:to="incy_LicenseAgreementUpfrontPaymentAmountPaid_637243060153602109" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementAdditionalMilestonePayments" xlink:label="incy_LicenseAgreementAdditionalMilestonePayments_637243060153612109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153592109" xlink:to="incy_LicenseAgreementAdditionalMilestonePayments_637243060153612109" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementMilestonePaymentAmountPaid" xlink:label="incy_LicenseAgreementMilestonePaymentAmountPaid_637243060153612109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153592109" xlink:to="incy_LicenseAgreementMilestonePaymentAmountPaid_637243060153612109" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails" xlink:type="extended" xlink:title="40903 - Disclosure - License agreements - Agenus (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementsDisclosureAbstract" xlink:label="incy_LicenseAgreementsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637243060153612109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_LicenseAgreementsDisclosureAbstract" xlink:to="us-gaap_StatementTable_637243060153612109" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_637243060153622129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153612109" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_637243060153622129" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_637243060153622129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_637243060153622129" xlink:to="srt_EquityMethodInvesteeNameDomain_637243060153622129" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AgenusMember" xlink:label="incy_AgenusMember_637243060153622129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain_637243060153622129" xlink:to="incy_AgenusMember_637243060153622129" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637243060153622129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153612109" xlink:to="us-gaap_TypeOfArrangementAxis_637243060153622129" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637243060153622129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637243060153622129" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637243060153622129" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_StockPurchaseAgreementMember" xlink:label="incy_StockPurchaseAgreementMember_637243060153622129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637243060153622129" xlink:to="incy_StockPurchaseAgreementMember_637243060153622129" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AgenusMember" xlink:label="incy_AgenusMember_6372430601536221291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637243060153622129" xlink:to="incy_AgenusMember_6372430601536221291" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AchievementOfMilestoneAxis" xlink:label="incy_AchievementOfMilestoneAxis_637243060153622129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153612109" xlink:to="incy_AchievementOfMilestoneAxis_637243060153622129" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AchievementOfMilestoneDomain" xlink:label="incy_AchievementOfMilestoneDomain_637243060153622129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_AchievementOfMilestoneAxis_637243060153622129" xlink:to="incy_AchievementOfMilestoneDomain_637243060153622129" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DevelopmentRegulatoryAndCommercializationMilestonesMember" xlink:label="incy_DevelopmentRegulatoryAndCommercializationMilestonesMember_637243060153622129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_AchievementOfMilestoneDomain_637243060153622129" xlink:to="incy_DevelopmentRegulatoryAndCommercializationMilestonesMember_637243060153622129" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DevelopmentMilestonesMember" xlink:label="incy_DevelopmentMilestonesMember_637243060153622129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_AchievementOfMilestoneDomain_637243060153622129" xlink:to="incy_DevelopmentMilestonesMember_637243060153622129" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637243060153622129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153612109" xlink:to="srt_ProductOrServiceAxis_637243060153622129" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637243060153622129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637243060153622129" xlink:to="srt_ProductsAndServicesDomain_637243060153622129" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LG3ProgramMember" xlink:label="incy_LG3ProgramMember_637243060153632116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637243060153622129" xlink:to="incy_LG3ProgramMember_637243060153632116" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_TIM3ProgramMember" xlink:label="incy_TIM3ProgramMember_637243060153632116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637243060153622129" xlink:to="incy_TIM3ProgramMember_637243060153632116" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637243060153632116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153612109" xlink:to="srt_RangeAxis_637243060153632116" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637243060153632116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637243060153632116" xlink:to="srt_RangeMember_637243060153632116" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637243060153632116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637243060153632116" xlink:to="srt_MinimumMember_637243060153632116" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637243060153632116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637243060153632116" xlink:to="srt_MaximumMember_637243060153632116" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_637243060153632116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153612109" xlink:to="us-gaap_BalanceSheetLocationAxis_637243060153632116" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_637243060153632116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis_637243060153632116" xlink:to="us-gaap_BalanceSheetLocationDomain_637243060153632116" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="us-gaap_AccruedLiabilitiesMember_637243060153632116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_637243060153632116" xlink:to="us-gaap_AccruedLiabilitiesMember_637243060153632116" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_637243060153632116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153612109" xlink:to="us-gaap_RelatedPartyTransactionLineItems_637243060153632116" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_NumberOfProgramTargets" xlink:label="incy_NumberOfProgramTargets_637243060153632116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153632116" xlink:to="incy_NumberOfProgramTargets_637243060153632116" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PercentageOfRoyaltyRatePayments" xlink:label="incy_PercentageOfRoyaltyRatePayments_637243060153642112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153632116" xlink:to="incy_PercentageOfRoyaltyRatePayments_637243060153642112" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementUpfrontPaymentAmountPaid" xlink:label="incy_LicenseAgreementUpfrontPaymentAmountPaid_637243060153642112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153632116" xlink:to="incy_LicenseAgreementUpfrontPaymentAmountPaid_637243060153642112" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementAdditionalMilestonePayments" xlink:label="incy_LicenseAgreementAdditionalMilestonePayments_637243060153642112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153632116" xlink:to="incy_LicenseAgreementAdditionalMilestonePayments_637243060153642112" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares" xlink:label="incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares_637243060153642112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153632116" xlink:to="incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares_637243060153642112" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost_637243060153642112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153632116" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost_637243060153642112" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_637243060153642112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153632116" xlink:to="us-gaap_SharePrice_637243060153642112" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_FairValueInputsAmountOfDiscountForLackOfMarketability" xlink:label="incy_FairValueInputsAmountOfDiscountForLackOfMarketability_637243060153642112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153632116" xlink:to="incy_FairValueInputsAmountOfDiscountForLackOfMarketability_637243060153642112" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="us-gaap_EquityFairValueDisclosure_637243060153652110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153632116" xlink:to="us-gaap_EquityFairValueDisclosure_637243060153652110" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_TotalConsiderationPaidUnderPurchaseAgreement" xlink:label="incy_TotalConsiderationPaidUnderPurchaseAgreement_637243060153652110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153632116" xlink:to="incy_TotalConsiderationPaidUnderPurchaseAgreement_637243060153652110" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments_637243060153652110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153632116" xlink:to="us-gaap_LongTermInvestments_637243060153652110" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637243060153652110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153632116" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637243060153652110" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_637243060153652110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153632116" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_637243060153652110" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_637243060153652110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153632116" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_637243060153652110" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue" xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue_637243060153652110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153632116" xlink:to="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue_637243060153652110" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss" xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss_637243060153662109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153632116" xlink:to="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss_637243060153662109" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637243060153662109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153632116" xlink:to="us-gaap_AssetsCurrent_637243060153662109" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637243060153662109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153632116" xlink:to="us-gaap_LiabilitiesCurrent_637243060153662109" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_637243060153662109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153632116" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_637243060153662109" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails" xlink:type="extended" xlink:title="40904 - Disclosure - License agreements - Merus (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementsDisclosureAbstract" xlink:label="incy_LicenseAgreementsDisclosureAbstract_636270014959921014" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637243060153672124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_LicenseAgreementsDisclosureAbstract_636270014959921014" xlink:to="us-gaap_StatementTable_637243060153672124" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_637243060153672124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153672124" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_637243060153672124" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_637243060153672124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_637243060153672124" xlink:to="srt_EquityMethodInvesteeNameDomain_637243060153672124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_MerusNVMember" xlink:label="incy_MerusNVMember_637243060153672124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain_637243060153672124" xlink:to="incy_MerusNVMember_637243060153672124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637243060153672124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153672124" xlink:to="us-gaap_TypeOfArrangementAxis_637243060153672124" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637243060153672124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637243060153672124" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637243060153672124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_MerusNVMember" xlink:label="incy_MerusNVMember_6372430601536721241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637243060153672124" xlink:to="incy_MerusNVMember_6372430601536721241" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_StockPurchaseAgreementMember" xlink:label="incy_StockPurchaseAgreementMember_637243060153672124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637243060153672124" xlink:to="incy_StockPurchaseAgreementMember_637243060153672124" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637243060153672124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153672124" xlink:to="srt_RangeAxis_637243060153672124" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637243060153672124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637243060153672124" xlink:to="srt_RangeMember_637243060153672124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637243060153672124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637243060153672124" xlink:to="srt_MinimumMember_637243060153672124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637243060153672124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637243060153672124" xlink:to="srt_MaximumMember_637243060153672124" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AchievementOfMilestoneAxis" xlink:label="incy_AchievementOfMilestoneAxis_637243060153672124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153672124" xlink:to="incy_AchievementOfMilestoneAxis_637243060153672124" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AchievementOfMilestoneDomain" xlink:label="incy_AchievementOfMilestoneDomain_637243060153672124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_AchievementOfMilestoneAxis_637243060153672124" xlink:to="incy_AchievementOfMilestoneDomain_637243060153672124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DevelopmentAndRegulatoryMilestonesMember" xlink:label="incy_DevelopmentAndRegulatoryMilestonesMember_637243060153682116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_AchievementOfMilestoneDomain_637243060153672124" xlink:to="incy_DevelopmentAndRegulatoryMilestonesMember_637243060153682116" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CommercializationMilestonesMember" xlink:label="incy_CommercializationMilestonesMember_637243060153682116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_AchievementOfMilestoneDomain_637243060153672124" xlink:to="incy_CommercializationMilestonesMember_637243060153682116" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637243060153682116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153672124" xlink:to="srt_StatementGeographicalAxis_637243060153682116" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637243060153682116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637243060153682116" xlink:to="srt_SegmentGeographicalDomain_637243060153682116" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="country_US_637243060153682116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637243060153682116" xlink:to="country_US_637243060153682116" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember_637243060153682116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637243060153682116" xlink:to="us-gaap_NonUsMember_637243060153682116" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_637243060153682116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153672124" xlink:to="us-gaap_BalanceSheetLocationAxis_637243060153682116" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_637243060153682116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis_637243060153682116" xlink:to="us-gaap_BalanceSheetLocationDomain_637243060153682116" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="us-gaap_AccruedLiabilitiesMember_637243060153682116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_637243060153682116" xlink:to="us-gaap_AccruedLiabilitiesMember_637243060153682116" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_637243060153682116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153672124" xlink:to="us-gaap_RelatedPartyTransactionLineItems_637243060153682116" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementMaximumNumberOfIndependentPrograms" xlink:label="incy_LicenseAgreementMaximumNumberOfIndependentPrograms_637243060153692115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153682116" xlink:to="incy_LicenseAgreementMaximumNumberOfIndependentPrograms_637243060153692115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementNumberOfPreclinicalDiscoveryPrograms" xlink:label="incy_LicenseAgreementNumberOfPreclinicalDiscoveryPrograms_637243060153692115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153682116" xlink:to="incy_LicenseAgreementNumberOfPreclinicalDiscoveryPrograms_637243060153692115" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms" xlink:label="incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms_637243060153692115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153682116" xlink:to="incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms_637243060153692115" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment" xlink:label="incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment_637243060153692115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153682116" xlink:to="incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment_637243060153692115" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds" xlink:label="incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds_637243060153692115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153682116" xlink:to="incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds_637243060153692115" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementUpfrontPaymentAmountPaid" xlink:label="incy_LicenseAgreementUpfrontPaymentAmountPaid_637243060153692115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153682116" xlink:to="incy_LicenseAgreementUpfrontPaymentAmountPaid_637243060153692115" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementAdditionalMilestonePayments" xlink:label="incy_LicenseAgreementAdditionalMilestonePayments_637243060153692115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153682116" xlink:to="incy_LicenseAgreementAdditionalMilestonePayments_637243060153692115" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PercentageOfRoyaltyRatePayments" xlink:label="incy_PercentageOfRoyaltyRatePayments_637243060153692115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153682116" xlink:to="incy_PercentageOfRoyaltyRatePayments_637243060153692115" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CollaborationAgreementProfitSharingPercentage" xlink:label="incy_CollaborationAgreementProfitSharingPercentage_637243060153702113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153682116" xlink:to="incy_CollaborationAgreementProfitSharingPercentage_637243060153702113" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PercentageOfProfitsLosses" xlink:label="incy_PercentageOfProfitsLosses_637243060153702113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153682116" xlink:to="incy_PercentageOfProfitsLosses_637243060153702113" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PercentageOfNetSalesPertainingToAdditionalRoyalties" xlink:label="incy_PercentageOfNetSalesPertainingToAdditionalRoyalties_637243060153702113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153682116" xlink:to="incy_PercentageOfNetSalesPertainingToAdditionalRoyalties_637243060153702113" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PercentageOfReverseRoyaltiesOnSaleOfFutureProducts" xlink:label="incy_PercentageOfReverseRoyaltiesOnSaleOfFutureProducts_637243060153702113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153682116" xlink:to="incy_PercentageOfReverseRoyaltiesOnSaleOfFutureProducts_637243060153702113" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares" xlink:label="incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares_637243060153702113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153682116" xlink:to="incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares_637243060153702113" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost_637243060153702113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153682116" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost_637243060153702113" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_637243060153702113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153682116" xlink:to="us-gaap_SharePrice_637243060153702113" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_StockPurchaseAgreementLockUpPeriod" xlink:label="incy_StockPurchaseAgreementLockUpPeriod_637243060153712116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153682116" xlink:to="incy_StockPurchaseAgreementLockUpPeriod_637243060153712116" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_FairValueInputsAmountOfDiscountForLackOfMarketability" xlink:label="incy_FairValueInputsAmountOfDiscountForLackOfMarketability_637243060153712116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153682116" xlink:to="incy_FairValueInputsAmountOfDiscountForLackOfMarketability_637243060153712116" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="us-gaap_EquityFairValueDisclosure_637243060153712116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153682116" xlink:to="us-gaap_EquityFairValueDisclosure_637243060153712116" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_TotalConsiderationPaidUnderPurchaseAgreement" xlink:label="incy_TotalConsiderationPaidUnderPurchaseAgreement_637243060153712116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153682116" xlink:to="incy_TotalConsiderationPaidUnderPurchaseAgreement_637243060153712116" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments_637243060153712116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153682116" xlink:to="us-gaap_LongTermInvestments_637243060153712116" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637243060153712116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153682116" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637243060153712116" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_637243060153722113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153682116" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_637243060153722113" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure_637243060153722113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153682116" xlink:to="us-gaap_InvestmentsFairValueDisclosure_637243060153722113" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_637243060153722113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153682116" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_637243060153722113" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_637243060153722113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153682116" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_637243060153722113" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue" xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue_637243060153732126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153682116" xlink:to="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue_637243060153732126" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss" xlink:label="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss_637243060153732126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153682116" xlink:to="us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss_637243060153732126" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637243060153732126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153682116" xlink:to="us-gaap_AssetsCurrent_637243060153732126" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637243060153732126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153682116" xlink:to="us-gaap_LiabilitiesCurrent_637243060153732126" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails" xlink:type="extended" xlink:title="40905 - Disclosure - License agreements - Calithera (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementsDisclosureAbstract" xlink:label="incy_LicenseAgreementsDisclosureAbstract_636270894910994819" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637243060153742132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_LicenseAgreementsDisclosureAbstract_636270894910994819" xlink:to="us-gaap_StatementTable_637243060153742132" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_637243060153742132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153742132" xlink:to="us-gaap_FinancialInstrumentAxis_637243060153742132" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637243060153742132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_637243060153742132" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637243060153742132" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CalitheraBiosciencesIncMember" xlink:label="incy_CalitheraBiosciencesIncMember_637243060153742132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637243060153742132" xlink:to="incy_CalitheraBiosciencesIncMember_637243060153742132" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637243060153742132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153742132" xlink:to="us-gaap_TypeOfArrangementAxis_637243060153742132" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637243060153742132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637243060153742132" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637243060153742132" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CalitheraBiosciencesIncMember" xlink:label="incy_CalitheraBiosciencesIncMember_6372430601537421321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637243060153742132" xlink:to="incy_CalitheraBiosciencesIncMember_6372430601537421321" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_StockPurchaseAgreementMember" xlink:label="incy_StockPurchaseAgreementMember_637243060153752124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637243060153742132" xlink:to="incy_StockPurchaseAgreementMember_637243060153752124" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637243060153752124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153742132" xlink:to="srt_StatementGeographicalAxis_637243060153752124" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637243060153752124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637243060153752124" xlink:to="srt_SegmentGeographicalDomain_637243060153752124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="country_US_637243060153752124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637243060153752124" xlink:to="country_US_637243060153752124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637243060153752124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153742132" xlink:to="us-gaap_IncomeStatementLocationAxis_637243060153752124" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637243060153752124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637243060153752124" xlink:to="us-gaap_IncomeStatementLocationDomain_637243060153752124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeMember" xlink:label="us-gaap_OtherComprehensiveIncomeMember_637243060153752124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637243060153752124" xlink:to="us-gaap_OtherComprehensiveIncomeMember_637243060153752124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_637243060153752124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153742132" xlink:to="us-gaap_BalanceSheetLocationAxis_637243060153752124" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_637243060153752124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis_637243060153752124" xlink:to="us-gaap_BalanceSheetLocationDomain_637243060153752124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="us-gaap_AccruedLiabilitiesMember_637243060153752124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_637243060153752124" xlink:to="us-gaap_AccruedLiabilitiesMember_637243060153752124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_637243060153752124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153742132" xlink:to="us-gaap_RelatedPartyTransactionLineItems_637243060153752124" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded" xlink:label="incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded_637243060153752124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153752124" xlink:to="incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded_637243060153752124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PercentageOfProfitsLosses" xlink:label="incy_PercentageOfProfitsLosses_637243060153762119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153752124" xlink:to="incy_PercentageOfProfitsLosses_637243060153762119" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementUpfrontPayment" xlink:label="incy_LicenseAgreementUpfrontPayment_637243060153762119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153752124" xlink:to="incy_LicenseAgreementUpfrontPayment_637243060153762119" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementPotentialMilestonePaymentsWithProfitSharing" xlink:label="incy_LicenseAgreementPotentialMilestonePaymentsWithProfitSharing_637243060153762119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153752124" xlink:to="incy_LicenseAgreementPotentialMilestonePaymentsWithProfitSharing_637243060153762119" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementPotentialMilestonePaymentsWithoutProfitSharing" xlink:label="incy_LicenseAgreementPotentialMilestonePaymentsWithoutProfitSharing_637243060153762119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153752124" xlink:to="incy_LicenseAgreementPotentialMilestonePaymentsWithoutProfitSharing_637243060153762119" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementMilestonePaymentAmountPaid" xlink:label="incy_LicenseAgreementMilestonePaymentAmountPaid_637243060153762119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153752124" xlink:to="incy_LicenseAgreementMilestonePaymentAmountPaid_637243060153762119" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares" xlink:label="incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares_637243060153762119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153752124" xlink:to="incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares_637243060153762119" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost_637243060153762119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153752124" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost_637243060153762119" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_637243060153762119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153752124" xlink:to="us-gaap_SharePrice_637243060153762119" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure_637243060153762119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153752124" xlink:to="us-gaap_InvestmentsFairValueDisclosure_637243060153762119" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="us-gaap_EquityFairValueDisclosure_637243060153772116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153752124" xlink:to="us-gaap_EquityFairValueDisclosure_637243060153772116" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_TotalConsiderationPaidUnderPurchaseAgreement" xlink:label="incy_TotalConsiderationPaidUnderPurchaseAgreement_637243060153772116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153752124" xlink:to="incy_TotalConsiderationPaidUnderPurchaseAgreement_637243060153772116" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CollaborationAgreementUpfrontPayment" xlink:label="incy_CollaborationAgreementUpfrontPayment_637243060153772116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153752124" xlink:to="incy_CollaborationAgreementUpfrontPayment_637243060153772116" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PurchasePriceOfCommonStockUnderStockPurchaseAgreement" xlink:label="incy_PurchasePriceOfCommonStockUnderStockPurchaseAgreement_637243060153772116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153752124" xlink:to="incy_PurchasePriceOfCommonStockUnderStockPurchaseAgreement_637243060153772116" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments_637243060153772116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153752124" xlink:to="us-gaap_LongTermInvestments_637243060153772116" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637243060153772116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153752124" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637243060153772116" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_637243060153772116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153752124" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_637243060153772116" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637243060153782118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153752124" xlink:to="us-gaap_NetIncomeLoss_637243060153782118" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_637243060153782118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153752124" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_637243060153782118" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_637243060153782118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153752124" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_637243060153782118" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureLicenseAgreementsMacrogenicsDetails" xlink:type="extended" xlink:title="40906 - Disclosure - License agreements - MacroGenics (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementsDisclosureAbstract" xlink:label="incy_LicenseAgreementsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637243060153782118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_LicenseAgreementsDisclosureAbstract" xlink:to="us-gaap_StatementTable_637243060153782118" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AchievementOfMilestoneAxis" xlink:label="incy_AchievementOfMilestoneAxis_637243060153782118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153782118" xlink:to="incy_AchievementOfMilestoneAxis_637243060153782118" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AchievementOfMilestoneDomain" xlink:label="incy_AchievementOfMilestoneDomain_637243060153782118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_AchievementOfMilestoneAxis_637243060153782118" xlink:to="incy_AchievementOfMilestoneDomain_637243060153782118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DevelopmentAndRegulatoryMilestonesMember" xlink:label="incy_DevelopmentAndRegulatoryMilestonesMember_637243060153792127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_AchievementOfMilestoneDomain_637243060153782118" xlink:to="incy_DevelopmentAndRegulatoryMilestonesMember_637243060153792127" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CommercializationMilestonesMember" xlink:label="incy_CommercializationMilestonesMember_637243060153792127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_AchievementOfMilestoneDomain_637243060153782118" xlink:to="incy_CommercializationMilestonesMember_637243060153792127" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637243060153792127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153782118" xlink:to="srt_RangeAxis_637243060153792127" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637243060153792127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637243060153792127" xlink:to="srt_RangeMember_637243060153792127" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637243060153792127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637243060153792127" xlink:to="srt_MinimumMember_637243060153792127" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637243060153792127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637243060153792127" xlink:to="srt_MaximumMember_637243060153792127" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637243060153792127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153782118" xlink:to="us-gaap_TypeOfArrangementAxis_637243060153792127" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637243060153792127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637243060153792127" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637243060153792127" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_MacrogenicsMember" xlink:label="incy_MacrogenicsMember_637243060153792127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637243060153792127" xlink:to="incy_MacrogenicsMember_637243060153792127" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_637243060153792127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153782118" xlink:to="us-gaap_BalanceSheetLocationAxis_637243060153792127" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_637243060153792127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis_637243060153792127" xlink:to="us-gaap_BalanceSheetLocationDomain_637243060153792127" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="us-gaap_AccruedLiabilitiesMember_637243060153792127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_637243060153792127" xlink:to="us-gaap_AccruedLiabilitiesMember_637243060153792127" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_637243060153792127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153782118" xlink:to="us-gaap_RelatedPartyTransactionLineItems_637243060153792127" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementUpfrontPaymentAmountPaid" xlink:label="incy_LicenseAgreementUpfrontPaymentAmountPaid_637243060153802125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153792127" xlink:to="incy_LicenseAgreementUpfrontPaymentAmountPaid_637243060153802125" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementAdditionalMilestonePayments" xlink:label="incy_LicenseAgreementAdditionalMilestonePayments_637243060153802125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153792127" xlink:to="incy_LicenseAgreementAdditionalMilestonePayments_637243060153802125" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PercentageOfRoyaltyRatePayments" xlink:label="incy_PercentageOfRoyaltyRatePayments_637243060153802125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153792127" xlink:to="incy_PercentageOfRoyaltyRatePayments_637243060153802125" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637243060153802125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153792127" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637243060153802125" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_637243060153802125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153792127" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_637243060153802125" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureLicenseAgreementsSyrosDetails" xlink:type="extended" xlink:title="40907 - Disclosure - License agreements - Syros (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementsDisclosureAbstract" xlink:label="incy_LicenseAgreementsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637243060153812134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_LicenseAgreementsDisclosureAbstract" xlink:to="us-gaap_StatementTable_637243060153812134" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637243060153812134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153812134" xlink:to="us-gaap_TypeOfArrangementAxis_637243060153812134" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637243060153812134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637243060153812134" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637243060153812134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_SyrosPharmaceuticalsIncMember" xlink:label="incy_SyrosPharmaceuticalsIncMember_637243060153812134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637243060153812134" xlink:to="incy_SyrosPharmaceuticalsIncMember_637243060153812134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AchievementOfMilestoneAxis" xlink:label="incy_AchievementOfMilestoneAxis_637243060153812134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153812134" xlink:to="incy_AchievementOfMilestoneAxis_637243060153812134" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AchievementOfMilestoneDomain" xlink:label="incy_AchievementOfMilestoneDomain_637243060153812134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_AchievementOfMilestoneAxis_637243060153812134" xlink:to="incy_AchievementOfMilestoneDomain_637243060153812134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DevelopmentAndRegulatoryMilestonesMember" xlink:label="incy_DevelopmentAndRegulatoryMilestonesMember_637243060153812134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_AchievementOfMilestoneDomain_637243060153812134" xlink:to="incy_DevelopmentAndRegulatoryMilestonesMember_637243060153812134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CommercializationMilestonesMember" xlink:label="incy_CommercializationMilestonesMember_637243060153812134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_AchievementOfMilestoneDomain_637243060153812134" xlink:to="incy_CommercializationMilestonesMember_637243060153812134" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637243060153812134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153812134" xlink:to="srt_RangeAxis_637243060153812134" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637243060153812134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637243060153812134" xlink:to="srt_RangeMember_637243060153812134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637243060153822130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637243060153812134" xlink:to="srt_MaximumMember_637243060153822130" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_637243060153822130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153812134" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_637243060153822130" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_637243060153822130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_637243060153822130" xlink:to="srt_EquityMethodInvesteeNameDomain_637243060153822130" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_StockPurchaseAgreementMember" xlink:label="incy_StockPurchaseAgreementMember_637243060153822130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain_637243060153822130" xlink:to="incy_StockPurchaseAgreementMember_637243060153822130" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AmendedStockPurchaseAgreementMember" xlink:label="incy_AmendedStockPurchaseAgreementMember_637243060153822130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain_637243060153822130" xlink:to="incy_AmendedStockPurchaseAgreementMember_637243060153822130" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_637243060153822130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153812134" xlink:to="us-gaap_RelatedPartyTransactionLineItems_637243060153822130" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_NumberOfProgramTargets" xlink:label="incy_NumberOfProgramTargets_637243060153822130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153822130" xlink:to="incy_NumberOfProgramTargets_637243060153822130" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementTargetSelectionAndOptionExerciseFeePayments" xlink:label="incy_LicenseAgreementTargetSelectionAndOptionExerciseFeePayments_637243060153822130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153822130" xlink:to="incy_LicenseAgreementTargetSelectionAndOptionExerciseFeePayments_637243060153822130" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementAdditionalMilestonePayments" xlink:label="incy_LicenseAgreementAdditionalMilestonePayments_637243060153822130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153822130" xlink:to="incy_LicenseAgreementAdditionalMilestonePayments_637243060153822130" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementUpfrontPaymentAmountPaid" xlink:label="incy_LicenseAgreementUpfrontPaymentAmountPaid_637243060153822130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153822130" xlink:to="incy_LicenseAgreementUpfrontPaymentAmountPaid_637243060153822130" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares" xlink:label="incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares_637243060153832124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153822130" xlink:to="incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares_637243060153832124" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost_637243060153832124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153822130" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost_637243060153832124" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_637243060153832124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153822130" xlink:to="us-gaap_SharePrice_637243060153832124" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_StockPurchaseAgreementLockUpPeriod" xlink:label="incy_StockPurchaseAgreementLockUpPeriod_637243060153832124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153822130" xlink:to="incy_StockPurchaseAgreementLockUpPeriod_637243060153832124" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_FairValueInputsAmountOfDiscountForLackOfMarketability" xlink:label="incy_FairValueInputsAmountOfDiscountForLackOfMarketability_637243060153832124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153822130" xlink:to="incy_FairValueInputsAmountOfDiscountForLackOfMarketability_637243060153832124" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="us-gaap_EquityFairValueDisclosure_637243060153832124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153822130" xlink:to="us-gaap_EquityFairValueDisclosure_637243060153832124" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments_637243060153832124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153822130" xlink:to="us-gaap_LongTermInvestments_637243060153832124" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure_637243060153832124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153822130" xlink:to="us-gaap_InvestmentsFairValueDisclosure_637243060153832124" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637243060153842123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153822130" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637243060153842123" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_637243060153842123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153822130" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_637243060153842123" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_637243060153842123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153822130" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_637243060153842123" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureLicenseAgreementsInnoventDetails" xlink:type="extended" xlink:title="40908 - Disclosure - License agreements - Innovent (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementsDisclosureAbstract" xlink:label="incy_LicenseAgreementsDisclosureAbstract_636838402884106950" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637243060153842123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_LicenseAgreementsDisclosureAbstract_636838402884106950" xlink:to="us-gaap_StatementTable_637243060153842123" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637243060153842123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153842123" xlink:to="us-gaap_TypeOfArrangementAxis_637243060153842123" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637243060153842123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637243060153842123" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637243060153842123" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_InnoventBiologicsIncMember" xlink:label="incy_InnoventBiologicsIncMember_637243060153842123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637243060153842123" xlink:to="incy_InnoventBiologicsIncMember_637243060153842123" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AchievementOfMilestoneAxis" xlink:label="incy_AchievementOfMilestoneAxis_637243060153852133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153842123" xlink:to="incy_AchievementOfMilestoneAxis_637243060153852133" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AchievementOfMilestoneDomain" xlink:label="incy_AchievementOfMilestoneDomain_637243060153852133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_AchievementOfMilestoneAxis_637243060153852133" xlink:to="incy_AchievementOfMilestoneDomain_637243060153852133" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_RegulatoryMilestonesMember" xlink:label="incy_RegulatoryMilestonesMember_637243060153852133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_AchievementOfMilestoneDomain_637243060153852133" xlink:to="incy_RegulatoryMilestonesMember_637243060153852133" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DevelopmentAndRegulatoryMilestonesMember" xlink:label="incy_DevelopmentAndRegulatoryMilestonesMember_637243060153852133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_AchievementOfMilestoneDomain_637243060153852133" xlink:to="incy_DevelopmentAndRegulatoryMilestonesMember_637243060153852133" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CommercializationMilestonesMember" xlink:label="incy_CommercializationMilestonesMember_637243060153852133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_AchievementOfMilestoneDomain_637243060153852133" xlink:to="incy_CommercializationMilestonesMember_637243060153852133" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637243060153852133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153842123" xlink:to="srt_RangeAxis_637243060153852133" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637243060153852133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637243060153852133" xlink:to="srt_RangeMember_637243060153852133" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637243060153852133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637243060153852133" xlink:to="srt_MaximumMember_637243060153852133" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_637243060153852133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153842123" xlink:to="us-gaap_RelatedPartyTransactionLineItems_637243060153852133" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" xlink:label="incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived_637243060153852133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153852133" xlink:to="incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived_637243060153852133" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone" xlink:label="incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone_637243060153862135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153852133" xlink:to="incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone_637243060153862135" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementUpfrontPaymentAmountPaid" xlink:label="incy_LicenseAgreementUpfrontPaymentAmountPaid_637243060153862135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153852133" xlink:to="incy_LicenseAgreementUpfrontPaymentAmountPaid_637243060153862135" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementMilestonePaymentAmountPaid" xlink:label="incy_LicenseAgreementMilestonePaymentAmountPaid_637243060153873823" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153852133" xlink:to="incy_LicenseAgreementMilestonePaymentAmountPaid_637243060153873823" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementResearchAndDevelopmentReimbursedCost" xlink:label="incy_LicenseAgreementResearchAndDevelopmentReimbursedCost_637243060153942122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153852133" xlink:to="incy_LicenseAgreementResearchAndDevelopmentReimbursedCost_637243060153942122" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementReimbursableCosts" xlink:label="incy_LicenseAgreementReimbursableCosts_637243060153942122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153852133" xlink:to="incy_LicenseAgreementReimbursableCosts_637243060153942122" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_NumberOfProductCandidates" xlink:label="incy_NumberOfProductCandidates_637243060153942122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637243060153852133" xlink:to="incy_NumberOfProductCandidates_637243060153942122" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureLicenseAgreementsZaiLabDetails" xlink:type="extended" xlink:title="40909 - Disclosure - License agreements - Zai Lab (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementsDisclosureAbstract" xlink:label="incy_LicenseAgreementsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637243060153952143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_LicenseAgreementsDisclosureAbstract" xlink:to="us-gaap_StatementTable_637243060153952143" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637243060153952143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153952143" xlink:to="us-gaap_TypeOfArrangementAxis_637243060153952143" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637243060153952143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637243060153952143" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637243060153952143" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember" xlink:label="incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember_637243060153952143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637243060153952143" xlink:to="incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember_637243060153952143" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AchievementOfMilestoneAxis" xlink:label="incy_AchievementOfMilestoneAxis_637243060153952143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153952143" xlink:to="incy_AchievementOfMilestoneAxis_637243060153952143" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AchievementOfMilestoneDomain" xlink:label="incy_AchievementOfMilestoneDomain_637243060153952143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_AchievementOfMilestoneAxis_637243060153952143" xlink:to="incy_AchievementOfMilestoneDomain_637243060153952143" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DevelopmentRegulatoryAndCommercialMilestonesMember" xlink:label="incy_DevelopmentRegulatoryAndCommercialMilestonesMember_637243060153952143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_AchievementOfMilestoneDomain_637243060153952143" xlink:to="incy_DevelopmentRegulatoryAndCommercialMilestonesMember_637243060153952143" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637243060153952143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153952143" xlink:to="us-gaap_StatementLineItems_637243060153952143" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived" xlink:label="incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived_637243060153952143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637243060153952143" xlink:to="incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived_637243060153952143" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementUpfrontPaymentAmountPaid" xlink:label="incy_LicenseAgreementUpfrontPaymentAmountPaid_637243060153952143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637243060153952143" xlink:to="incy_LicenseAgreementUpfrontPaymentAmountPaid_637243060153952143" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementResearchAndDevelopmentReimbursedCost" xlink:label="incy_LicenseAgreementResearchAndDevelopmentReimbursedCost_637243060153952143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637243060153952143" xlink:to="incy_LicenseAgreementResearchAndDevelopmentReimbursedCost_637243060153952143" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementReimbursableCosts" xlink:label="incy_LicenseAgreementReimbursableCosts_637243060153952143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637243060153952143" xlink:to="incy_LicenseAgreementReimbursableCosts_637243060153952143" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails" xlink:type="extended" xlink:title="40910 - Disclosure - License agreements - MorphoSys (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementsDisclosureAbstract" xlink:label="incy_LicenseAgreementsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637243060153962129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_LicenseAgreementsDisclosureAbstract" xlink:to="us-gaap_StatementTable_637243060153962129" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637243060153962129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153962129" xlink:to="us-gaap_TypeOfArrangementAxis_637243060153962129" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637243060153962129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637243060153962129" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637243060153962129" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_MorphosysAgMember" xlink:label="incy_MorphosysAgMember_637243060153962129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637243060153962129" xlink:to="incy_MorphosysAgMember_637243060153962129" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_637243060153962129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153962129" xlink:to="dei_LegalEntityAxis_637243060153962129" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637243060153962129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_637243060153962129" xlink:to="dei_EntityDomain_637243060153962129" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_IncyteMember" xlink:label="incy_IncyteMember_637243060153962129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_637243060153962129" xlink:to="incy_IncyteMember_637243060153962129" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637243060153962129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153962129" xlink:to="srt_CounterpartyNameAxis_637243060153962129" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637243060153962129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637243060153962129" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637243060153962129" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_MorphosysAgMember" xlink:label="incy_MorphosysAgMember_6372430601539621291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637243060153962129" xlink:to="incy_MorphosysAgMember_6372430601539621291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AchievementOfMilestoneAxis" xlink:label="incy_AchievementOfMilestoneAxis_637243060153962129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153962129" xlink:to="incy_AchievementOfMilestoneAxis_637243060153962129" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AchievementOfMilestoneDomain" xlink:label="incy_AchievementOfMilestoneDomain_637243060153972135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_AchievementOfMilestoneAxis_637243060153962129" xlink:to="incy_AchievementOfMilestoneDomain_637243060153972135" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DevelopmentAndRegulatoryMilestonesMember" xlink:label="incy_DevelopmentAndRegulatoryMilestonesMember_637243060153972135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_AchievementOfMilestoneDomain_637243060153972135" xlink:to="incy_DevelopmentAndRegulatoryMilestonesMember_637243060153972135" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CommercializationMilestonesMember" xlink:label="incy_CommercializationMilestonesMember_637243060153972135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_AchievementOfMilestoneDomain_637243060153972135" xlink:to="incy_CommercializationMilestonesMember_637243060153972135" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637243060153972135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153962129" xlink:to="srt_RangeAxis_637243060153972135" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637243060153972135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637243060153972135" xlink:to="srt_RangeMember_637243060153972135" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637243060153972135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637243060153972135" xlink:to="srt_MaximumMember_637243060153972135" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_637243060153972135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153962129" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_637243060153972135" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_637243060153972135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_637243060153972135" xlink:to="srt_EquityMethodInvesteeNameDomain_637243060153972135" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AmericanDepositarySharesMember" xlink:label="incy_AmericanDepositarySharesMember_637243060153972135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain_637243060153972135" xlink:to="incy_AmericanDepositarySharesMember_637243060153972135" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_637243060153972135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153962129" xlink:to="us-gaap_BalanceSheetLocationAxis_637243060153972135" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_637243060153972135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis_637243060153972135" xlink:to="us-gaap_BalanceSheetLocationDomain_637243060153972135" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="us-gaap_AccruedLiabilitiesMember_637243060153982125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_637243060153972135" xlink:to="us-gaap_AccruedLiabilitiesMember_637243060153982125" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637243060153982125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637243060153962129" xlink:to="us-gaap_StatementLineItems_637243060153982125" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded" xlink:label="incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded_637243060153982125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637243060153982125" xlink:to="incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded_637243060153982125" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementUpfrontPaymentAmountPaid" xlink:label="incy_LicenseAgreementUpfrontPaymentAmountPaid_637243060153982125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637243060153982125" xlink:to="incy_LicenseAgreementUpfrontPaymentAmountPaid_637243060153982125" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LicenseAgreementAdditionalMilestonePayments" xlink:label="incy_LicenseAgreementAdditionalMilestonePayments_637243060153982125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637243060153982125" xlink:to="incy_LicenseAgreementAdditionalMilestonePayments_637243060153982125" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_637243060153982125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637243060153982125" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_637243060153982125" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_637243060153982125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637243060153982125" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_637243060153982125" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost_637243060153982125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637243060153982125" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost_637243060153982125" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_637243060153982125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637243060153982125" xlink:to="us-gaap_SharePrice_637243060153982125" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_StockPurchaseAgreementLockUpPeriod" xlink:label="incy_StockPurchaseAgreementLockUpPeriod_637243060153992126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637243060153982125" xlink:to="incy_StockPurchaseAgreementLockUpPeriod_637243060153992126" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_FairValueInputsAmountOfDiscountForLackOfMarketability" xlink:label="incy_FairValueInputsAmountOfDiscountForLackOfMarketability_637243060153992126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637243060153982125" xlink:to="incy_FairValueInputsAmountOfDiscountForLackOfMarketability_637243060153992126" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="us-gaap_EquityFairValueDisclosure_637243060153992126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637243060153982125" xlink:to="us-gaap_EquityFairValueDisclosure_637243060153992126" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments_637243060153992126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637243060153982125" xlink:to="us-gaap_LongTermInvestments_637243060153992126" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637243060153992126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637243060153982125" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637243060153992126" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_637243060153992126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637243060153982125" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_637243060153992126" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CollaborationAgreementProfitLossSharingRatio" xlink:label="incy_CollaborationAgreementProfitLossSharingRatio_637243060153992126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637243060153982125" xlink:to="incy_CollaborationAgreementProfitLossSharingRatio_637243060153992126" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_CollaborationLossSharingExpense" xlink:label="incy_CollaborationLossSharingExpense_637243060154002125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637243060153982125" xlink:to="incy_CollaborationLossSharingExpense_637243060154002125" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureStockCompensationDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Stock compensation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_635470907758075758" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637243060154002125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_635470907758075758" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637243060154002125" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637243060154002125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637243060154002125" xlink:to="us-gaap_AwardTypeAxis_637243060154002125" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637243060154002125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637243060154002125" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637243060154002125" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637243060154002125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637243060154002125" xlink:to="us-gaap_EmployeeStockOptionMember_637243060154002125" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_637243060154002125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637243060154002125" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_637243060154002125" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember_637243060154002125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637243060154002125" xlink:to="us-gaap_PerformanceSharesMember_637243060154002125" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637243060154002125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637243060154002125" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637243060154002125" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637243060154002125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637243060154002125" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637243060154002125" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember_637243060154012137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637243060154002125" xlink:to="us-gaap_EmployeeStockMember_637243060154012137" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637243060154012137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637243060154002125" xlink:to="us-gaap_IncomeStatementLocationAxis_637243060154012137" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637243060154012137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637243060154012137" xlink:to="us-gaap_IncomeStatementLocationDomain_637243060154012137" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637243060154012137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637243060154012137" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637243060154012137" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_637243060154012137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637243060154012137" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_637243060154012137" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember_637243060154012137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637243060154012137" xlink:to="us-gaap_CostOfSalesMember_637243060154012137" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637243060154012137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637243060154002125" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637243060154012137" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637243060154012137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637243060154012137" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637243060154012137" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_StockCompensationExpenseCapitalized" xlink:label="incy_StockCompensationExpenseCapitalized_637243060154012137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637243060154012137" xlink:to="incy_StockCompensationExpenseCapitalized_637243060154012137" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate_637243060154012137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637243060154012137" xlink:to="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate_637243060154012137" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637243060154012137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637243060154012137" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637243060154012137" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed_637243060154012137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637243060154012137" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed_637243060154012137" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637243060154022130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637243060154012137" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637243060154022130" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637243060154022130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637243060154012137" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637243060154022130" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637243060154022130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637243060154012137" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637243060154022130" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637243060154022130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637243060154012137" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637243060154022130" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637243060154022130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637243060154012137" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637243060154022130" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_637243060154022130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637243060154012137" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_637243060154022130" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_637243060154022130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_637243060154022130" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_637243060154022130" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637243060154022130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_637243060154022130" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637243060154022130" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureStockCompensationOptionActivityDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Stock compensation - Option activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637243060154032128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637243060154032128" order="1" use="optional" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637243060154032128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637243060154032128" xlink:to="us-gaap_AwardTypeAxis_637243060154032128" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637243060154032128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637243060154032128" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637243060154032128" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637243060154032128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637243060154032128" xlink:to="us-gaap_EmployeeStockOptionMember_637243060154032128" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_637243060154032128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637243060154032128" xlink:to="us-gaap_VestingAxis_637243060154032128" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_637243060154032128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_637243060154032128" xlink:to="us-gaap_VestingDomain_637243060154032128" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_637243060154032128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637243060154032128" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_637243060154032128" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_637243060154032128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637243060154032128" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_637243060154032128" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637243060154032128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637243060154032128" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637243060154032128" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637243060154032128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637243060154032128" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637243060154032128" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637243060154032128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637243060154032128" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637243060154032128" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_637243060154042137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637243060154032128" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_637243060154042137" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637243060154042137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637243060154032128" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637243060154042137" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637243060154042137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637243060154032128" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637243060154042137" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637243060154042137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637243060154032128" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637243060154042137" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637243060154042137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637243060154032128" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637243060154042137" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637243060154042137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637243060154042137" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637243060154042137" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637243060154042137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637243060154042137" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637243060154042137" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637243060154042137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637243060154042137" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637243060154042137" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_637243060154042137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637243060154042137" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_637243060154042137" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6372430601540421371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637243060154042137" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6372430601540421371" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637243060154042137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637243060154042137" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637243060154042137" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637243060154052132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637243060154042137" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637243060154052132" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637243060154052132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637243060154042137" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637243060154052132" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuAwardActivityDetails" xlink:type="extended" xlink:title="41003 - Disclosure - Stock compensation - RSU and PSU award activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637243060154052132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637243060154052132" order="1" use="optional" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637243060154052132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637243060154052132" xlink:to="us-gaap_AwardTypeAxis_637243060154052132" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637243060154052132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637243060154052132" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637243060154052132" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_637243060154052132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637243060154052132" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_637243060154052132" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember_637243060154052132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637243060154052132" xlink:to="us-gaap_PerformanceSharesMember_637243060154052132" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637243060154052132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637243060154052132" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637243060154052132" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637243060154052132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637243060154052132" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637243060154052132" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_637243060154062141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637243060154052132" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_637243060154062141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637243060154062141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637243060154052132" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637243060154062141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_637243060154062141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637243060154052132" xlink:to="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_637243060154062141" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_637243060154062141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637243060154052132" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_637243060154062141" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_6372430601540621411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637243060154052132" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_6372430601540621411" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637243060154062141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637243060154052132" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637243060154062141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_637243060154062141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637243060154062141" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_637243060154062141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_637243060154062141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637243060154062141" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_637243060154062141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue_637243060154062141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637243060154062141" xlink:to="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue_637243060154062141" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_637243060154072132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637243060154062141" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_637243060154072132" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_637243060154072132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637243060154062141" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_637243060154072132" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuDetails" xlink:type="extended" xlink:title="41004 - Disclosure - Stock compensation - RSU and PSU (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637243060154072132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637243060154072132" order="1" use="optional" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637243060154072132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637243060154072132" xlink:to="us-gaap_AwardTypeAxis_637243060154072132" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637243060154072132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637243060154072132" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637243060154072132" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637243060154072132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637243060154072132" xlink:to="us-gaap_EmployeeStockOptionMember_637243060154072132" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_637243060154082548" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637243060154072132" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_637243060154082548" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember_637243060154082548" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637243060154072132" xlink:to="us-gaap_PerformanceSharesMember_637243060154082548" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637243060154082548" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637243060154072132" xlink:to="us-gaap_PlanNameAxis_637243060154082548" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637243060154082548" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637243060154082548" xlink:to="us-gaap_PlanNameDomain_637243060154082548" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LongTermIncentivePlanOneMember" xlink:label="incy_LongTermIncentivePlanOneMember_637243060154082548" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637243060154082548" xlink:to="incy_LongTermIncentivePlanOneMember_637243060154082548" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_LongTermIncentivePlanTwoMember" xlink:label="incy_LongTermIncentivePlanTwoMember_637243060154082548" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637243060154082548" xlink:to="incy_LongTermIncentivePlanTwoMember_637243060154082548" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637243060154082548" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637243060154072132" xlink:to="srt_RangeAxis_637243060154082548" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637243060154082548" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637243060154082548" xlink:to="srt_RangeMember_637243060154082548" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637243060154082548" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637243060154082548" xlink:to="srt_MinimumMember_637243060154082548" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637243060154082548" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637243060154082548" xlink:to="srt_MaximumMember_637243060154082548" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637243060154082548" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637243060154072132" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637243060154082548" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits_637243060154082548" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637243060154082548" xlink:to="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits_637243060154082548" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637243060154082548" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637243060154082548" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637243060154082548" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637243060154092139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637243060154082548" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637243060154092139" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637243060154092139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637243060154082548" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637243060154092139" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageMultiplierForConversionOfUnitsIntoCommonStock" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageMultiplierForConversionOfUnitsIntoCommonStock_637243060154092139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637243060154082548" xlink:to="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageMultiplierForConversionOfUnitsIntoCommonStock_637243060154092139" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637243060154092139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637243060154082548" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637243060154092139" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_637243060154092139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637243060154082548" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_637243060154092139" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor_637243060154092139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637243060154082548" xlink:to="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor_637243060154092139" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureStockCompensationSharesAvailableForGrantDetails" xlink:type="extended" xlink:title="41005 - Disclosure - Stock compensation - Shares available for grant (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_637243060154102148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_637243060154102148" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_637243060154102148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_637243060154102148" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_637243060154102148" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted_637243060154102148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_637243060154102148" xlink:to="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted_637243060154102148" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled" xlink:label="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled_637243060154102148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_637243060154102148" xlink:to="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled_637243060154102148" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6372430601541021481" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_637243060154102148" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6372430601541021481" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Accrued and other current liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_637243060154102148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_637243060154102148" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent_637243060154102148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_637243060154102148" xlink:to="us-gaap_AccruedRoyaltiesCurrent_637243060154102148" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_AccruedClinicalRelatedCostsCurrent" xlink:label="incy_AccruedClinicalRelatedCostsCurrent_637243060154102148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_637243060154102148" xlink:to="incy_AccruedClinicalRelatedCostsCurrent_637243060154102148" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProvisionForLossOnContracts" xlink:label="us-gaap_ProvisionForLossOnContracts_637243060154102148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_637243060154102148" xlink:to="us-gaap_ProvisionForLossOnContracts_637243060154102148" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionPayableCurrent" xlink:label="us-gaap_ConstructionPayableCurrent_637243060154102148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_637243060154102148" xlink:to="us-gaap_ConstructionPayableCurrent_637243060154102148" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637243060154102148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_637243060154102148" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637243060154102148" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_637243060154102148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_637243060154102148" xlink:to="us-gaap_OtherLiabilitiesCurrent_637243060154102148" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637243060154102148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_637243060154102148" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637243060154102148" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureDebtComponentsOfConvertibleNotesDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Debt - Components of convertible notes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_635470905655245758" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_637243060154112141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_635470905655245758" xlink:to="us-gaap_DebtInstrumentTable_637243060154112141" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637243060154112141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637243060154112141" xlink:to="us-gaap_DebtInstrumentAxis_637243060154112141" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637243060154112141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637243060154112141" xlink:to="us-gaap_DebtInstrumentNameDomain_637243060154112141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ConvertibleSeniorNotes1.25PercentDue2020Member" xlink:label="incy_ConvertibleSeniorNotes1.25PercentDue2020Member_637243060154112141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637243060154112141" xlink:to="incy_ConvertibleSeniorNotes1.25PercentDue2020Member_637243060154112141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_637243060154112141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637243060154112141" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_637243060154112141" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_637243060154112141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis_637243060154112141" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_637243060154112141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_637243060154112141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember_637243060154112141" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember_637243060154112141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_637243060154112141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637243060154112141" xlink:to="us-gaap_DebtInstrumentLineItems_637243060154112141" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637243060154112141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637243060154112141" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637243060154112141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt_637243060154112141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637243060154112141" xlink:to="us-gaap_ConvertibleDebt_637243060154112141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureDebtCarryingAmountAndFairValueDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Debt - Carrying amount and Fair Value (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_636601741179429601" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_637243060154122142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_636601741179429601" xlink:to="us-gaap_DebtInstrumentTable_637243060154122142" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637243060154122142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637243060154122142" xlink:to="us-gaap_DebtInstrumentAxis_637243060154122142" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637243060154122142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637243060154122142" xlink:to="us-gaap_DebtInstrumentNameDomain_637243060154122142" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ConvertibleSeniorNotes1.25PercentDue2020Member" xlink:label="incy_ConvertibleSeniorNotes1.25PercentDue2020Member_637243060154122142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637243060154122142" xlink:to="incy_ConvertibleSeniorNotes1.25PercentDue2020Member_637243060154122142" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_637243060154122142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637243060154122142" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_637243060154122142" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_637243060154122142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis_637243060154122142" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_637243060154122142" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_637243060154122142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember_637243060154122142" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember_637243060154122142" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_637243060154122142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember_637243060154122142" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_637243060154122142" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_637243060154122142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637243060154122142" xlink:to="us-gaap_DebtInstrumentLineItems_637243060154122142" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637243060154122142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637243060154122142" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637243060154122142" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt_637243060154122142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637243060154122142" xlink:to="us-gaap_ConvertibleDebt_637243060154122142" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureDebtNarrativeDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Debt - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_636601749673987136" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_637243060154132142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_636601749673987136" xlink:to="us-gaap_DebtInstrumentTable_637243060154132142" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637243060154132142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637243060154132142" xlink:to="us-gaap_DebtInstrumentAxis_637243060154132142" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637243060154132142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637243060154132142" xlink:to="us-gaap_DebtInstrumentNameDomain_637243060154132142" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member" xlink:label="incy_ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member_637243060154132142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637243060154132142" xlink:to="incy_ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member_637243060154132142" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_637243060154132142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637243060154132142" xlink:to="us-gaap_DebtInstrumentLineItems_637243060154132142" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637243060154132142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637243060154132142" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637243060154132142" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xlink:label="incy_DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays_637243060154132142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637243060154132142" xlink:to="incy_DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays_637243060154132142" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" xlink:label="incy_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays_637243060154132142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637243060154132142" xlink:to="incy_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays_637243060154132142" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" xlink:label="incy_DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice_637243060154132142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637243060154132142" xlink:to="incy_DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice_637243060154132142" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod" xlink:label="incy_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod_637243060154132142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637243060154132142" xlink:to="incy_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod_637243060154132142" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays" xlink:label="incy_DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays_637243060154132142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637243060154132142" xlink:to="incy_DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays_637243060154132142" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_637243060154132142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637243060154132142" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1_637243060154132142" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum" xlink:label="incy_DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum_637243060154142140" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637243060154132142" xlink:to="incy_DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum_637243060154142140" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_DebtInstrumentConversionObligationNumberOfScheduledTradingDaysBeforeMaturity" xlink:label="incy_DebtInstrumentConversionObligationNumberOfScheduledTradingDaysBeforeMaturity_637243060154142140" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637243060154132142" xlink:to="incy_DebtInstrumentConversionObligationNumberOfScheduledTradingDaysBeforeMaturity_637243060154142140" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureEmployeeBenefitPlansDefinedContributionPlanDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Employee benefit plans - Defined Contribution Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_637243060154142140" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_637243060154142140" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureEmployeeBenefitPlansPeriodicBenefitCostDetails" xlink:type="extended" xlink:title="41302 - Disclosure - Employee benefit plans - Periodic Benefit Cost (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_636205060842055100" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost" xlink:label="us-gaap_DefinedBenefitPlanServiceCost_637243060154142140" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract_636205060842055100" xlink:to="us-gaap_DefinedBenefitPlanServiceCost_637243060154142140" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost" xlink:label="us-gaap_DefinedBenefitPlanInterestCost_637243060154142140" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract_636205060842055100" xlink:to="us-gaap_DefinedBenefitPlanInterestCost_637243060154142140" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:label="us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_637243060154142140" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract_636205060842055100" xlink:to="us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_637243060154142140" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:label="us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_637243060154142140" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract_636205060842055100" xlink:to="us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_637243060154142140" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:label="us-gaap_DefinedBenefitPlanActuarialGainLoss_637243060154142140" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract_636205060842055100" xlink:to="us-gaap_DefinedBenefitPlanActuarialGainLoss_637243060154142140" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_637243060154152144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract_636205060842055100" xlink:to="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_637243060154152144" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList" xlink:label="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList_637243060154152144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract_636205060842055100" xlink:to="us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList_637243060154152144" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear_637243060154152144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract_636205060842055100" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear_637243060154152144" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" xlink:label="us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities_637243060154152144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract_636205060842055100" xlink:to="us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities_637243060154152144" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Income taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_636131594159388021" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637243060154152144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_636131594159388021" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637243060154152144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_637243060154152144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_636131594159388021" xlink:to="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_637243060154152144" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637243060154152144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_636131594159388021" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637243060154152144" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.incyte.com/role/DisclosureNetIncomeLossPerShareDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Net income (loss) per share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_635840497867226885" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637243060154152144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_635840497867226885" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637243060154152144" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637243060154152144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637243060154152144" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637243060154152144" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_637243060154152144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637243060154152144" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_637243060154152144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637243060154152144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637243060154152144" xlink:to="us-gaap_EmployeeStockOptionMember_637243060154152144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="incy-20200505.xsd#incy_ConvertibleSeniorNotes1.25PercentDue2020Member" xlink:label="incy_ConvertibleSeniorNotes1.25PercentDue2020Member_637243060154152144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637243060154152144" xlink:to="incy_ConvertibleSeniorNotes1.25PercentDue2020Member_637243060154152144" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems_637243060154152144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637243060154152144" xlink:to="us-gaap_EarningsPerShareBasicLineItems_637243060154152144" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract_637243060154152144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems_637243060154152144" xlink:to="us-gaap_EarningsPerShareBasicAbstract_637243060154152144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637243060154152144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_637243060154152144" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637243060154152144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637243060154152144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_637243060154152144" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637243060154152144" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_637243060154152144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_637243060154152144" xlink:to="us-gaap_EarningsPerShareBasic_637243060154152144" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="us-gaap_EarningsPerShareDilutedAbstract_637243060154152144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems_637243060154152144" xlink:to="us-gaap_EarningsPerShareDilutedAbstract_637243060154152144" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_637243060154152144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract_637243060154152144" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_637243060154152144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6372430601541521441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract_637243060154152144" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6372430601541521441" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_637243060154152144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract_637243060154152144" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_637243060154152144" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637243060154152144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract_637243060154152144" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637243060154152144" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_637243060154152144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract_637243060154152144" xlink:to="us-gaap_EarningsPerShareDiluted_637243060154152144" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_637243060154152144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems_637243060154152144" xlink:to="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_637243060154152144" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637243060154152144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_637243060154152144" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637243060154152144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6781470304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License agreements - Zai Lab (Details) - Zai Lab Ltd - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived', window );">Upfront and immediate milestone payment to be received under license agreement</a></td>
<td class="nump">$ 17.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementResearchAndDevelopmentReimbursedCost', window );">Research and development expenses reimbursed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementReimbursableCosts', window );">Reimbursable costs included in accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember', window );">Development Regulatory And Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementUpfrontPaymentAmountPaid', window );">Upfront payment under license agreement</a></td>
<td class="nump">$ 37.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementReimbursableCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents reimbursable costs pertaining to license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementReimbursableCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementResearchAndDevelopmentReimbursedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents reimbursed costs pertaining to research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementResearchAndDevelopmentReimbursedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementUpfrontPaymentAmountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of the upfront payment made under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementUpfrontPaymentAmountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the upfront and immediate milestone payment received under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_DevelopmentRegulatoryAndCommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_DevelopmentRegulatoryAndCommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6664850944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock compensation - RSU and PSU award activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Jul. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares Subject to Outstanding Options, Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Outstanding at the beginning of the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,602,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Outstanding at the end of the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,865,401<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Shares Subject to Outstanding Options, Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Outstanding at the beginning of the period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Outstanding at the end of the period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79.65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares Subject to Outstanding Options, Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,000<span></span>
</td>
<td class="nump">379,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod', window );">Released (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64,426)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,795)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Shares Subject to Outstanding Options, Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue', window );">Released (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue', window );">Cancelled (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80.31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Stock Units (PSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares Subject to Outstanding Options, Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">86,975<span></span>
</td>
<td class="nump">77,243<span></span>
</td>
<td class="nump">446,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,250)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Shares Subject to Outstanding Options, Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue', window );">Cancelled (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65.76<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares of employee compensation programs, other than options, released during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share weighted average intrinsic value of equity-based compensation awards released. Excludes stock and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of award forfeited under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of award granted under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6643014000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Components of convertible notes (Details) - Convertible Senior Notes 1.25 Percent Due 2020 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate of debt (as a percent)</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=incy_ConvertibleSeniorNotes1.25PercentDue2020Member', window );">Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible senior notes</a></td>
<td class="nump">$ 18,524<span></span>
</td>
<td class="nump">$ 18,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=incy_ConvertibleSeniorNotes1.25PercentDue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=incy_ConvertibleSeniorNotes1.25PercentDue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6781459168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 1,275<span></span>
</td>
<td class="nump">$ 1,275<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">11,228<span></span>
</td>
<td class="nump">8,634<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">9,714<span></span>
</td>
<td class="nump">6,596<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_InventoryNetCurrentAndNoncurrent', window );">Total inventories</a></td>
<td class="nump">22,217<span></span>
</td>
<td class="nump">16,505<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories - current</a></td>
<td class="nump">13,977<span></span>
</td>
<td class="nump">11,400<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventories-noncurrent</a></td>
<td class="nump">$ 8,240<span></span>
</td>
<td class="nump">$ 5,105<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size:9pt;">The condensed consolidated balance sheet at December 31, 2019 has been derived from the audited consolidated financial statements at that date.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_InventoryNetCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate carrying amount of current and noncurrent portion, net of valuation reserves and allowances, as of the balance sheet date of inventories.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_InventoryNetCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6798088528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 568,507<span></span>
</td>
<td class="nump">$ 497,857<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenues, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">486,727<span></span>
</td>
<td class="nump">396,249<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=incy_JAKAFIMember', window );">JAKAFI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">459,479<span></span>
</td>
<td class="nump">375,611<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=incy_ICLUSIGMember', window );">ICLUSIG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">27,248<span></span>
</td>
<td class="nump">20,638<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Product royalty revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">81,780<span></span>
</td>
<td class="nump">61,608<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=incy_JakaviRoyaltyRevenuesMember', window );">JAKAVI Royalty Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">56,333<span></span>
</td>
<td class="nump">45,571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=incy_OlumiantRoyaltyMember', window );">OLUMIANT Royalty Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 25,447<span></span>
</td>
<td class="nump">16,037<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=incy_MilestoneAndContractRevenueMember', window );">Milestone and contract revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=incy_JAKAFIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=incy_JAKAFIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=incy_ICLUSIGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=incy_ICLUSIGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=incy_JakaviRoyaltyRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=incy_JakaviRoyaltyRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=incy_OlumiantRoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=incy_OlumiantRoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=incy_MilestoneAndContractRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=incy_MilestoneAndContractRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6786395280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee benefit plans<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee benefit plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee benefit plans</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">13. &#160;&#160;&#160;&#160;Employee benefit plans</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Defined Contribution Plans</i></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have a defined contribution plan qualified under Section&#160;401(k) of the Internal Revenue Code covering all U.S. employees and defined contribution plans for other Incyte employees in Europe and Japan. &#160;Employees may contribute a portion of their compensation, which is then matched by us, subject to certain limitations. Defined contribution expense for the three months ended March 31, 2020 and 2019 was $3.3&#160;million and $2.9&#160;million, respectively. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Defined Benefit Pension Plans</i><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have defined benefit pension plans for our employees in Europe which provide benefits to employees upon retirement, death or disability. The assets of the pension plans are held in collective investment accounts represented by the cash surrender value of an insurance policy and are classified as Level 2 within the fair value hierarchy.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The net periodic benefit cost was as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:36.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months&#160;Ended</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:36.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, </b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:17.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:17.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Service cost</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,457</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,263</p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Interest cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 84</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Expected return on plan assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (30)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (60)</p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Amortization of prior service cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 45</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Amortization of actuarial losses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 167</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 66</p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Net periodic benefit cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,694</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,398</p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The components of net periodic benefit cost other than the service cost component are included in other income (expense), net on the condensed consolidated statements of operations. We expect to contribute a total of $4.0 million to the pension plans in 2020 inclusive of the amounts contributed to the plan during the current period. As of March 31, 2020 and December 31, 2019, $24.6 million and $24.1 million, respectively, of accrued pension obligation is recorded in other long term liabilities on the condensed consolidated balance sheets.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6786395280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent event<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent event</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">17.&#160;&#160;&#160;&#160;Subsequent event</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2020, the FDA approved PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement as detected by an FDA-approved test. PEMAZYRE is the first and only FDA-approved treatment for this indication, which was approved under accelerated approval based on overall response rate and duration of response. We have retained all rights to PEMAZYRE globally, other than those granted to Innovent Biologics, Inc. to develop and commercialize pemigatinib in hematology and oncology in mainland China, Hong Kong, Macau and Taiwan.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6799173296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee benefit plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee benefit plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Schedule of net periodic benefit cost</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The net periodic benefit cost was as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:36.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months&#160;Ended</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:36.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, </b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:17.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:17.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Service cost</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,457</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,263</p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Interest cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 84</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Expected return on plan assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (30)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (60)</p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Amortization of prior service cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 45</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Amortization of actuarial losses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 167</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 66</p></td></tr><tr><td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Net periodic benefit cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,694</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,398</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6786460320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets and goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible assets and goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of finite-lived intangible assets, net</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The components of intangible assets were as follows (in thousands, except for useful life):</p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100.55%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:23.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:23.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="color:#0000ff;font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:30.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at March&#160;31, 2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:30.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at December&#160;31, 2019</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:23.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="color:#0000ff;font-size:14pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:23.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average Useful</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:23.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Lives (Years)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td colspan="3" style="background-color:auto;vertical-align:bottom;width:35.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Finite-lived intangible assets:</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:23.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Licensed IP</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;">12.5</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 271,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 82,556</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 188,444</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 271,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 77,172</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 193,828</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of estimated aggregate amortization expense</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Estimated aggregate amortization expense based on the current carrying value of amortizable intangible assets is as follows (in thousands):</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100.01%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:40.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:40.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remainder of</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:40.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Thereafter</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:40.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Amortization expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,152</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,536</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,536</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,536</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,536</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 86,148</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6781401664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and business</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.&#160;&#160;&#160;&#160; </b><b style="font-weight:bold;">Organization and business</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Incyte Corporation (including its subsidiaries, &#8220;Incyte,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a biopharmaceutical company focused on developing and commercializing proprietary therapeutics. Our portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products JAKAFI&#174; (ruxolitinib), and ICLUSIG&#174; (ponatinib). Our operations are treated as one operating segment.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6797908992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentration of credit risk and current expected credit losses<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Concentration of credit risk and current expected credit losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">Concentration of credit risk and current expected credit losses</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">5.&#160;&#160;&#160;&#160; </b><b style="font-weight:bold;">Concentration of credit risk and current expected credit losses</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">In November 2009, we entered into a collaboration and license agreement with Novartis. In December 2009, we entered into a license, development and commercialization agreement with Lilly. In December 2018, we entered into a research collaboration and licensing agreement with Innovent Biologics, Inc. (&#8220;Innovent&#8221;). In July 2019, we entered into a collaboration and license agreement with Zai Lab (Shanghai) Co., Ltd., a subsidiary of Zai Lab Limited (collectively, &#8220;Zai Lab&#8221;). The above collaboration partners comprised, in aggregate, 24% and 30% of the accounts receivable balance as of March 31, 2020 and December 31, 2019, respectively. &#160;For further information relating these collaboration and license agreements,<b style="font-weight:bold;"> </b>refer to Note 9 to the condensed consolidated financial statements.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2011, we began commercialization and distribution of JAKAFI to a number of customers. Our product revenues are concentrated in a number of these customers that are specialty pharmacies and wholesalers. The concentration of credit risk related to our JAKAFI product revenues is as follows:</p><p style="font-family:'Times New Roman';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:26.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percentage&#160;of&#160;Total&#160;Net</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:26.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Product&#160;Revenues&#160;for&#160;the</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:26.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months&#160;Ended</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:26.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Customer A</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Customer B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Customer C</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Customer D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are exposed to risks associated with extending credit to customers related to the sale of products. Customers A, B, C and D comprised, in aggregate, 40% and 39% of the accounts receivable balance as of March 31, 2020 and December 31, 2019, respectively. The concentration of credit risk relating to ICLUSIG product revenues or accounts receivable is not significant.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We assessed our collaborative and customer receivable assets as of March 31, 2020 according to our accounting policy for applying reserves for expected credit losses, noting minimal history of uncollectible receivables and the </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">continued perceived creditworthiness of our third party sales relationships, upon which the expected credit losses were considered de minimis. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6658740384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementsDisclosureAbstract', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementsTextBlock', window );">License agreements</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">9.&#160;&#160;&#160;&#160;License agreements</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Novartis</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2009, we entered into a Collaboration and License Agreement with Novartis. Under the terms of the agreement, Novartis received exclusive development and commercialization rights outside of the United States to our JAK inhibitor ruxolitinib and certain back-up compounds for hematologic and oncology indications, including all hematological malignancies, solid tumors and myeloproliferative diseases. We retained exclusive development and commercialization rights to JAKAFI (ruxolitinib) in the United States and in certain other indications. &#160;Novartis also received worldwide exclusive development and commercialization rights to our MET inhibitor compound capmatinib and certain back-up compounds in all indications. We retained options to co-develop and to co-promote capmatinib in the United States.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Under this agreement, we received an upfront payment and immediate milestone payment totaling $210.0&#160;million and were initially eligible to receive up to $1.2&#160;billion in milestone payments across multiple indications upon the achievement of pre-specified events, including up to $174.0&#160;million for the achievement of development milestones, up to $495.0&#160;million for the achievement of regulatory milestones and up to $500.0&#160;million for the achievement of commercialization milestones. In April 2016, we amended this agreement to provide that Novartis has exclusive research, development and commercialization rights outside of the United States to ruxolitinib (excluding topical formulations) in the graft-versus-host-disease (&#8220;GVHD&#8221;) field. We became eligible to receive up to $75.0 million of additional potential development and regulatory milestones relating to GVHD.  We recognize development and regulatory milestones upon confirmation of achievement of the event, as development and regulatory approvals are events not controllable by us but rather development activities of Novartis and decisions made by regulatory agencies. We recognize sales milestones in the corresponding period of the product sale upon confirmation of net sales milestone threshold achievement by Novartis. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Exclusive of the upfront payment of $150.0 million received in 2009 and the immediate milestone of $60.0 million earned in 2010, we have recognized and received in the aggregate $132.0 million for the achievement of development milestones, $215.0 million for the achievement of regulatory milestones and $120.0 million for the achievement of sales milestones through March 31, 2020. In 2018, we recognized a $60.0 million sales milestone for Novartis achieving annual net sales of a JAK licensed product of $900.0 million. In 2017, we recognized a $40.0 million sales milestone for Novartis achieving annual net sales of a JAK licensed product of $600.0 million and a $25.0 million development milestone based on the formal initiation by Novartis of a Phase III clinical trial evaluating ruxolitinib in GVHD. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We also are eligible to receive tiered, double-digit royalties ranging from the upper-teens to the mid-twenties on future JAKAVI net sales outside of the United States, and tiered, worldwide royalties on future capmatinib net sales that range from 12% to 14%. Since the achievement of the $60.0 million regulatory milestone related to reimbursement of JAKAVI in Europe in September 2014, we are obligated to pay to Novartis tiered royalties in the low single-digits on future JAKAFI net sales within the United States. During the three months ended March 31, 2020 and 2019, such royalties payable to Novartis on net sales within the United States totaled $17.5 million and $13.4 million, respectively, and are reflected in cost of product revenues on the condensed consolidated statements of operations. At March 31, 2020 and December 31, 2019, $56.3 million and $50.2 million, respectively, of accrued royalties payable to Novartis were included in accrued and other current liabilities on the condensed consolidated balance sheets. Each company is responsible for costs relating to the development and commercialization of ruxolitinib in its respective territories, with costs of </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">collaborative studies shared equally. Novartis is also responsible for all costs relating to the development and commercialization of capmatinib.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Novartis agreement will continue on a program-by-program basis until Novartis has no royalty payment obligations with respect to such program or, if earlier, the termination of the agreement or any program in accordance with the terms of the agreement. Royalties are payable by Novartis on a product-by-product and country-by-country basis until the latest to occur of (i)&#160;the expiration of the last valid claim of the licensed patent rights covering the licensed product in the relevant country, (ii)&#160;the expiration of regulatory exclusivity for the licensed product in such country and (iii)&#160;a specified period from first commercial sale in such country of the licensed product by Novartis or its affiliates or sublicensees. The agreement may be terminated in its entirety or on a program-by-program basis by Novartis for convenience. The agreement may also be terminated by either party under certain other circumstances, including material breach.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Reimbursable costs incurred after the effective date of the agreement with Novartis are recorded net against the related research and development expenses. At March 31, 2020 and December 31, 2019, $0.1&#160;million and $0.4&#160;million, respectively, of reimbursable costs were included in accounts receivable on the condensed consolidated balance sheets. Research and development expenses for the three months ended March 31, 2020 and 2019 were net of $0.3 million and $0.6 million, respectively, of costs reimbursed by Novartis.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Milestone and contract revenue under the Novartis agreement for the three months ended March 31, 2020 and 2019 was $0.0 million for each period.  Product royalty revenue related to Novartis net sales of JAKAVI outside of the United States for the three months ended March 31, 2020 and 2019 was $56.3 million and $45.6 million, respectively. &#160;At March 31, 2020 and December 31, 2019, $56.3 million and $65.0 million, respectively, of product royalties were included in accounts receivable on the condensed consolidated balance sheets.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Lilly - Baricitinib</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2009, we entered into a License, Development and Commercialization Agreement with Lilly. Under the terms of the agreement, Lilly received exclusive worldwide development and commercialization rights to our JAK inhibitor baricitinib, and certain back-up compounds for inflammatory and autoimmune diseases. We received an upfront payment of $90.0&#160;million, and were initially eligible to receive up to $665.0&#160;million in substantive milestone payments across multiple indications upon the achievement of pre-specified events, including up to $150.0&#160;million for the achievement of development milestones, up to $365.0&#160;million for the achievement of regulatory milestones and up to $150.0&#160;million for the achievement of commercialization milestones. Exclusive of the upfront payment of $90.0 million received in 2009, we have recognized and received, in aggregate, $149.0 million for the achievement of development milestones and $235.0 million for the achievement of regulatory milestones through March 31, 2020. We recognize development and regulatory milestones upon confirmation of achievement of the event, as development and regulatory approvals are events not controllable by us but rather development activities of Lilly and decisions made by regulatory agencies. We recognize sales milestones in the corresponding period of the product sale upon confirmation of net sales milestone threshold achievement by Lilly.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2016, Lilly submitted an NDA to the FDA and a Marketing Authorization Application (MAA) to the European Medicines Agency for baricitinib as treatment for rheumatoid arthritis. In February 2017, we and Lilly announced that the European Commission approved baricitinib as OLUMIANT for the treatment of moderate-to-severe rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying antirheumatic drugs. In July 2017, Japan's Ministry of Health, Labor and Welfare granted marketing approval for OLUMIANT<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup>for the treatment of rheumatoid arthritis in patients with inadequate response to standard-of-care therapies. &#160;In June 2018, the FDA approved the 2mg dose of OLUMIANT for the treatment of adults with moderately-to-severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor inhibitor therapies.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In 2018, we recognized a $20.0 million development milestone for the first patient treated in the systemic lupus erythematosus Phase III program for baricitinib and a $100.0 million regulatory milestone for the FDA approval of the 2mg dose of OLUMIANT (baricitinib) for the treatment of adults with moderately-to-severely active rheumatoid arthritis. In 2017, we recognized a $30.0 million development milestone for the first patient treated in the atopic dermatitis Phase </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">III program for baricitinib, $15.0 million regulatory milestone for the approval of baricitinib for the treatment of rheumatoid arthritis by Japan&#8217;s Ministry of Health, Labor and Welfare and a $65.0 million regulatory milestone for the approval of baricitinib for the treatment of moderate-to-severe rheumatoid arthritis in adult patients by the European Commission.  </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We retained options to co-develop our JAK1/JAK2 inhibitors with Lilly on a compound-by-compound and indication-by-indication basis. Lilly is responsible for all costs relating to the development and commercialization of the compounds unless we elect to co-develop any compounds or indications. If we elect to co-develop any compounds and/or indications, we would be responsible for funding 30% of the associated future global development costs from the initiation of a Phase IIb trial through regulatory approval, including post-launch studies required by a regulatory authority. We would receive an incremental royalty rate increase across all tiers resulting in effective royalty rates ranging up to the high twenties on potential future global net sales for compounds and/or indications that we elect to co-develop. &#160;For indications that we elect not to co-develop, we would receive tiered, double-digit royalty payments on future global net sales with rates ranging up to 20% if the product is successfully commercialized. &#160;If we have started co-development funding for any indication, we can at any time opt out and stop future co-development cost sharing. If we elect to do this we would still be eligible for our base royalties plus an incremental pro-rated royalty commensurate with our contribution to the total co-development cost for those indications for which we co-funded. &#160;We previously had retained an option to co-promote products in the United States but, in March 2016, we waived our co-promotion option as part of an amendment to the agreement. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In July&#160;2010, we elected to co-develop baricitinib with Lilly in rheumatoid arthritis and became responsible for funding 30% of the associated future global development costs for this indication from the initiation of the Phase IIb trial through regulatory approval, including post-launch studies required by a regulatory authority. &#160;We subsequently elected to co-develop baricitinib with Lilly in psoriatic arthritis, atopic dermatitis, alopecia areata, systemic lupus erythematosus and axial spondyloarthritis and were responsible for funding 30% of future global development costs for those indications through regulatory approval, including post-launch studies required by a regulatory authority. In April 2019, we elected to end additional co-funding of the development of baricitinib effective as of January 1, 2019. We will continue to receive royalties on global net sales of OLUMIANT, pursuant to the terms in the Lilly agreement, as described above.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Lilly agreement will continue until Lilly no longer has any royalty payment obligations or, if earlier, the termination of the agreement in accordance with its terms. Royalties are payable by Lilly on a product-by-product and country-by-country basis until the latest to occur of (i) the expiration of the last valid claim of the licensed patent rights covering the licensed product in the relevant country, (ii) the expiration of regulatory exclusivity for the licensed product in such country and (iii) a specified period from first commercial sale in such country of the licensed product by Lilly or its affiliates or sublicensees. The agreement may be terminated by Lilly for convenience, and may also be terminated under certain other circumstances, including material breach.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Milestone and contract revenue under the Lilly agreement for the three months ended March 31, 2020 and 2019 was $0.0 million for each period.  Product royalty revenue related to Lilly global net sales of OLUMIANT for the three months ended March 31, 2020 and 2019 was $25.4 million and $16.0 million, respectively. &#160;At March 31, 2020 and December 31, 2019, $25.4 million and $23.6 million, respectively, of product royalties were included in accounts receivable on the condensed consolidated balance sheets. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Lilly - Ruxolitinib</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">In March 2016, we entered into an amendment to the agreement with Lilly that amended the non-compete provision of the agreement to allow us to engage in the development and commercialization of ruxolitinib in the GVHD field. Upon execution of the amendment, we paid Lilly an upfront payment of $35.0 million and Lilly is eligible to receive up to $40.0 million in regulatory milestone payments relating to ruxolitinib in the GVHD field. &#160;In May 2019, the approval of JAKAFI in steroid-refractory acute GVHD triggered a $20.0 million milestone payment to Lilly. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Agenus</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In January 2015, we entered into a License, Development and Commercialization Agreement with Agenus Inc. and its wholly-owned subsidiary, 4-Antibody AG (now known as Agenus Switzerland Inc.), which we collectively refer </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">to as Agenus. Under this agreement, the parties have agreed to collaborate on the discovery of novel immuno-therapeutics using Agenus&#8217; antibody discovery platforms. The agreement became effective on February 18, 2015, upon the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Upon closing of the agreement, we paid Agenus total consideration of $60.0 million. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2017, we and Agenus amended this agreement (the &#8220;Amended Agreement&#8221;). Under the terms of the Amended Agreement, we received exclusive worldwide development and commercialization rights to four checkpoint modulators directed against GITR, OX40, LAG-3 and TIM-3. In addition to the initial four program targets, we and Agenus have the option to jointly nominate and pursue additional targets within the framework of the collaboration, and in November 2015, three more targets were added. Targets may be designated profit-share programs, where all costs and profits are shared equally by us and Agenus, or royalty-bearing programs, where we are responsible for all costs associated with discovery, preclinical, clinical development and commercialization activities. The programs relating to GITR and OX40 and two of the undisclosed targets were profit-share programs until February 2017, while the other targets currently under collaboration are royalty-bearing programs. The Amended Agreement converted the programs relating to GITR and OX40 to royalty-bearing programs and removed from the collaboration the profit-share programs relating to the two undisclosed targets, with one reverting to us and one reverting to Agenus. &#160;Should any of those removed programs be successfully developed by a party, the other party will be eligible to receive the same milestone payments as the royalty-bearing programs and royalties at a 15% rate on global net sales. &#160;There are currently no profit-share programs. &#160;For each royalty-bearing product other than GITR and OX40, Agenus will be eligible to receive tiered royalties on global net sales ranging from 6% to 12%. &#160;For GITR and OX40, Agenus will be eligible to receive 15% royalties on global net sales. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">In 2017 under the Amended Agreement, we paid Agenus $20.0 million in accelerated milestones relating to the clinical development of the GITR and OX40 programs, which was recorded in research and development expense. Agenus was initially eligible to receive up to an additional $510.0 million in future contingent development, regulatory and commercialization milestones across all programs in the collaboration. The agreement may be terminated by us for convenience upon 12 months&#8217; notice and may also be terminated under certain other circumstances, including material breach. In 2018, we paid Agenus a $5.0 million development milestone for the LAG-3 program and a $5.0 million development milestone for the TIM-3 program, which were recorded in research and development expense.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the Amended Agreement, we also agreed to purchase 10.0 million shares of Agenus Inc. common stock for an aggregate purchase price of $60.0 million in cash, or $6.00 per share. &#160;We completed the purchase of the shares on February 14, 2017, when the closing price on The Nasdaq Stock Market for Agenus Inc. shares was $4.40 per share. &#160;The shares we acquired were not registered under the Securities Act of 1933 on the purchase date and were subject to certain security specific restrictions for a period of time, and accordingly, we estimated a discount for lack of marketability on the shares on the issuance date of $4.5 million, which resulted in a net fair value of the shares on the issuance date of $39.5 million. Therefore, of the total consideration paid of $60.0 million, $39.5 million was allocated to our stock purchase in Agenus Inc. and was recorded within long term investments and $20.5 million was allocated to research and development expense. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have concluded Agenus Inc. is not a VIE because it has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest. As of March 31, 2020, we owned approximately 11% of the outstanding shares of Agenus Inc. common stock. We concluded that we have the ability to exercise significant influence, but not control, over Agenus Inc. based primarily on our ownership interest, the fact that we have been the largest Agenus stockholder since the date of our initial stock purchase, the level of intra-entity transactions between us and Agenus related to development expenses, as well as other qualitative factors. We have elected the fair value option to account for our long term investment in Agenus Inc. whereby the investment is marked to market through earnings in each reporting period. &#160;We believe the fair value option to be the most appropriate accounting method to account for securities in publicly held collaborators for which we have significant influence. For the three months ended March 31, 2020 and 2019, we recorded an unrealized loss of $28.8 million and an unrealized gain of $10.5 million, respectively, based on the change in fair value of Agenus Inc.&#8217;s common stock during these periods. The fair market value of our long term investment in Agenus Inc. at March 31, 2020 and December 31, 2019 was $43.5 million and $72.3 million, respectively. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the twelve months ended December 31, 2019, Agenus reported within its Form 10-K total revenues of approximately $150.0 million and net loss of approximately $111.6 million within their consolidated financial statements.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses for the three months ended March 31, 2020 and 2019 also included $0.1 million and $10.2 million, respectively, of development costs incurred pursuant to the Agenus arrangement. &#160;At March 31, 2020 and December 31, 2019, a total of $1.4 million and $1.6 million, respectively, of such costs were included in accrued and other liabilities on the condensed consolidated balance sheets.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Merus</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2016, we entered into a Collaboration and License Agreement with Merus N.V. (&#8220;Merus&#8221;). Under this agreement, which became effective in January 2017, the parties have agreed to collaborate with respect to the research, discovery and development of bispecific antibodies utilizing Merus&#8217; technology platform. &#160;The collaboration encompasses up to eleven independent programs. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The most advanced collaboration program is MCLA-145, a bispecific antibody targeting PD-L1 and CD137, for which we received exclusive development and commercialization rights outside of the United States. Merus retained exclusive development and commercialization rights in the United States to MCLA-145. &#160;Each party will share equally the costs of mutually agreed global development activities for MCLA-145, and fund itself any independent development activities in its territory. &#160;Merus will be responsible for commercializing MCLA-145 in the United States and we will be responsible for commercializing it outside of the United States. &#160; &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to receiving rights to MCLA-145 outside of the United States, we received worldwide exclusive development and commercialization rights to up to ten additional programs. Of these ten additional programs, Merus retained the option, subject to certain conditions, to co-fund development of up to two such programs. If Merus exercises its co-funding option for a program, Merus would be responsible for funding 35% of the associated future global development costs and, for certain of such programs, would be responsible for reimbursing us for certain development costs incurred prior to the option exercise. &#160;Merus will also have the right to participate in a specified proportion of detailing activities in the United States for one of those co-developed programs. All costs related to the co-funded collaboration programs are subject to joint research and development plans and overseen by a joint development committee, but we will have final determination as to such plans in cases of dispute. We will be responsible for all research, development and commercialization costs relating to all other programs. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2017, we paid Merus an upfront non-refundable payment of $120.0 million. For each program as to which Merus does not have commercialization or development co-funding rights, Merus will be eligible to receive up to $100.0 million in future contingent development and regulatory milestones, and up to $250.0 million in commercialization milestones as well as tiered royalties ranging from 6% to 10% of global net sales. For each program as to which Merus exercises its option to co-fund development, Merus will be eligible to receive a 50% share of profits (or sustain 50% of any losses) in the United States and be eligible to receive tiered royalties ranging from 6% to 10% of net sales of products outside of the United States. &#160;If Merus opts to cease co-funding a program as to which it exercised its co-development option, then Merus will no longer receive a share of profits in the United States but will be eligible to receive the same milestones from the co-funding termination date and the same tiered royalties described above with respect to programs where Merus does not have a right to co-fund development and, depending on the stage at which Merus chose to cease co-funding development costs, Merus will be eligible to receive additional royalties ranging up to 4% of net sales in the United States. &#160;For MCLA-145, we and Merus will each be eligible to receive tiered royalties on net sales in the other party&#8217;s territory at rates ranging from 6% to 10%. &#160; </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Merus agreement will continue on a program-by-program basis until we have no royalty payment obligations with respect to such program or, if earlier, the termination of the agreement or any program in accordance with the terms of the agreement. The agreement may be terminated in its entirety or on a program-by-program basis by us for convenience. &#160;The agreement may also be terminated by either party under certain other circumstances, including material breach, as set forth in the agreement. &#160;If the agreement is terminated with respect to one or more programs, all rights in the terminated programs revert to Merus, subject to payment to us of a reverse royalty of up to 4% on sales of future products, if Merus elects to pursue development and commercialization of products arising from the terminated programs. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, in December 2016, we entered into a Share Subscription Agreement with Merus, pursuant to which we agreed to purchase 3.2 million common shares of Merus for an aggregate purchase price of $80.0 million in cash, or $25.00 per share. &#160;We completed the purchase of the shares on January 23, 2017 when the closing price on The Nasdaq Stock Market for Merus shares was $24.50 per share. The shares we acquired were not registered under the Securities Act of 1933 on the purchase date and were subject to certain security specific restrictions for a period of time, and accordingly, we estimated a discount for lack of marketability on the shares on the issuance date of $5.6 million, which resulted in a net fair value of the shares on the issuance date of $72.8 million. &#160;Of the total consideration paid of $80.0 million, $72.8 million was allocated to our stock purchase in Merus and was recorded as a long term investment and $7.2 million was allocated to research and development expense. The fair market value of our total long term investment in Merus at March 31, 2020 and December 31, 2019 was $38.7 million and $45.1 million, respectively.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have concluded Merus is not a VIE because it has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest. As of March 31, 2020, we owned approximately 11% of the outstanding common shares of Merus and conclude that we have the ability to exercise significant influence, but not control, over Merus based primarily on our ownership interest, the level of intra-entity transactions between us and Merus related to development expenses, as well as other qualitative factors. &#160;We have elected the fair value option to account for our long term investment in Merus whereby the investment is marked to market through earnings in each reporting period. &#160;We believe the fair value option to be the most appropriate accounting method to account for securities in publicly held collaborators for which we have significant influence. For the three months ended March 31, 2020 and 2019 we recorded an unrealized loss of $6.3 million and an unrealized gain of $2.5 million, respectively, based on the change in fair value of Merus&#8217; common shares during these periods. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the twelve months ended December 31, 2019, Merus reported within its Form 10-K total revenues of approximately $31.1 million and net loss of approximately $55.2 million within their consolidated financial statements.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 12pt 0pt;">Research and development expenses for the three months ended March 31, 2020 and 2019 included $2.3 million and $2.6 million, respectively, of additional development costs incurred pursuant to the Merus agreement. At March 31, 2020 and December 31, 2019, a total of $2.2 million and $1.6 million, respectively, of such costs were included in accrued and other liabilities on the condensed consolidated balance sheets.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Calithera</span></p><p style="font-family:'Times New Roman';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">In January 2017, we entered into a Collaboration and License Agreement with Calithera Biosciences, Inc. (&#8220;Calithera&#8221;). Under this agreement, we received an exclusive, worldwide license to develop and commercialize small molecule arginase inhibitors, including CB-1158, which is currently in Phase I clinical trials, for hematology and oncology indications. We have agreed to co-fund 70% of the global development costs for the development of the licensed products for hematology and oncology indications. Calithera will have the right to conduct certain clinical development under the collaboration, including combination studies of a licensed product with a proprietary compound of Calithera. We will be entitled to 60% of the profits and losses from net sales of licensed product in the United States, and Calithera will have the right to co-detail licensed products in the United States, and we have agreed to pay Calithera tiered royalties ranging from the low to mid-double digits on net sales of licensed products outside the United States. Calithera may opt out of its co-funding obligation, in which case the U.S. profit sharing will no longer be in effect, and we have agreed to pay Calithera tiered royalties ranging from the low to mid-double digits on net sales of licensed products both in the United States and outside the United States, and additional royalties to reimburse Calithera for previously incurred development costs.</p><p style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:24.5pt;margin:0pt;">In January 2017, we paid Calithera an upfront license fee of $45.0 million and have agreed to pay potential development, regulatory and sales milestone payments of over $430.0 million if the profit share is in effect, or $750.0 million if the profit share terminates. In 2017, we paid Calithera a $12.0 million milestone for the achievement of pharmacokinetic and pharmacodynamics goals for CB-1158 which was recorded in research and development expense.</p><p style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">The Calithera agreement will continue on a product-by-product and country-by-country basis for so long as we are developing or commercializing products in the United States (if the parties are sharing profits in the United States) and until we have no further royalty payment obligations, unless earlier terminated according to the terms of the agreement. The agreement may be terminated in its entirety or on a product-by-product and/or a country-by-country basis by us for </p><p style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">convenience. The agreement may also be terminated by us for Calithera&#8217;s uncured material breach, by Calithera for our uncured material breach and by either party for bankruptcy or patent challenge. If the agreement is terminated early with respect to one or more products or countries, all rights in the terminated products and countries revert to Calithera.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, in January&#160;2017, we entered into a Stock Purchase Agreement with Calithera for the purchase of 1.7 million common shares of Calithera for an aggregate purchase price of $8.0 million in cash, or $4.65 per share. We completed the purchase of the shares on January 30, 2017 when the closing price on The Nasdaq Stock Market was $6.75 per share. The shares we acquired were registered under the Securities Act of 1933 on the purchase date and there were no security specific restrictions for these shares, and therefore the value of the 1.7 million shares acquired by us was $11.6 million. &#160;We paid total consideration of $53.0 million to Calithera, composed of the $45.0 million upfront license fee and the $8.0 million stock purchase price.&#160;&#160;Of the $53.0 million, $11.6 million was allocated to our stock purchase in Calithera and was recorded within long term investments and $41.4 million was allocated to research and development expense. The fair market value of our long term investment in Calithera at March 31, 2020 and December 31, 2019 was $7.6 million and $9.8 million, respectively.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have concluded Calithera is not a VIE because it has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest. &#160;As of March 31, 2020, we owned approximately 3% of the outstanding shares of Calithera common stock and there are several other stockholders who hold larger positions of Calithera. As we do not hold a significant position of the voting shares of Calithera and lack the qualitative characteristics associated with the ability to exercise significant influence, our ownership interest does not meet the criteria to be accounted for as an equity method investment. We intend to hold the investment in Calithera for the foreseeable future and therefore, are accounting for our shares held in Calithera at fair value, and the investment is marked to market through earnings in each reporting period. Given our intent to hold the investment for the foreseeable future, we have classified the investment within long term investments on the accompanying condensed consolidated balance sheets. For the three months ended March 31, 2020 and 2019 we recorded an unrealized loss of $2.2 million and an unrealized gain of $4.7 million, respectively, based on the change in fair value of Calithera&#8217;s common stock during these periods.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">Research and development expenses for the three months ended March 31, 2020 and 2019 also included $2.5 million and $4.6 million, respectively, of additional development costs incurred pursuant to the Calithera agreement. At March 31, 2020 and December 31, 2019, a total of $1.3 million and $1.1 million, respectively, of such costs were included in accrued and other liabilities on the condensed consolidated balance sheets.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">MacroGenics</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 12pt 0pt;">In October 2017, we entered into a Global Collaboration and License Agreement with MacroGenics, Inc. (&#8220;MacroGenics&#8221;). Under this agreement, we received exclusive development and commercialization rights worldwide to MacroGenics&#8217; INCMGA0012 (formerly MGA012), an investigational monoclonal antibody that inhibits PD-1. Except as set forth in the succeeding sentence, we will have sole authority over and bear all costs and expenses in connection with the development and commercialization of INCMGA0012 in all indications, whether as a monotherapy or as part of a combination regimen.&#160; MacroGenics has retained the right to develop and commercialize, at its cost and expense, its pipeline assets in combination with INCMGA0012.&#160; In addition, MacroGenics has the right to manufacture a portion of both companies&#8217; global clinical and commercial supply needs of INCMGA0012. &#160;In 2017, we paid MacroGenics an upfront payment of $150.0 million, which was recorded in research and development expense. MacroGenics was initially eligible to receive up to $420.0 million in future contingent development and regulatory milestones and up to $30.0 million in sales milestones as well as tiered royalties ranging from 15% to 24% of global net sales. In 2018, we paid MacroGenics a $10.0 million and a $5.0 million milestone for the achievement of certain clinical milestones as part of our collaboration and license agreement, which were recorded in research and development expense.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The MacroGenics agreement will continue until we are no longer commercializing, developing or manufacturing INCMGA0012 or, if earlier, the termination of the agreement in accordance with its terms.&#160; The agreement may be terminated in its entirety or on a licensed product by licensed product basis by us for convenience.&#160; The agreement may also be terminated by either party under certain other circumstances, including material breach, as set forth in the agreement.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses for the three months ended March 31, 2020 and 2019 also included $16.4 million and $9.4 million, respectively, of additional development costs incurred pursuant to the MacroGenics agreement. At March 31, 2020 and December 31, 2019, a total of $1.6 million and $1.0 million of such costs were included in accrued and other liabilities on the condensed consolidated balance sheets. &#160; </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Syros</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 12pt 0pt;">In January 2018, we entered into a target discovery, research collaboration and option agreement with Syros Pharmaceuticals, Inc. (&#8220;Syros&#8221;). Under this agreement, Syros will use its proprietary gene control platform to identify novel therapeutic targets with a focus in myeloproliferative neoplasms and we have received options to obtain exclusive worldwide rights to intellectual property resulting from the collaboration for up to seven validated targets. &#160;We will have exclusive worldwide rights to develop and commercialize any therapies under the collaboration that modulate those validated targets. &#160;We have agreed to pay Syros up to $54.0 million in target selection and option exercise fees should we decide to exercise all of our options under the agreement. For products resulting from the collaboration against each of the seven selected and validated targets, we have agreed to pay up to $50.0 million in potential development and regulatory milestones and up to $65.0 million in potential sales milestones. Syros is also eligible to receive low single-digit royalties on net sales of products resulting from the collaboration. In January 2018, we paid Syros an upfront non-refundable (except in the event of a material breach of the agreement by Syros) payment of $10.0 million, which was recorded in research and development expense. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, in January 2018, we entered into a Stock Purchase Agreement with Syros for the purchase of 0.8 million common shares of Syros for an aggregate purchase price of $10.0 million in cash, or $12.61 per share. &#160;We agreed to not sell or otherwise transfer any of our Syros shares for a period, referred to as the Lock-Up Period, of 12 months after the closing date of the sale. We completed the purchase of the shares on January 8, 2018 when the closing price on The Nasdaq Stock Market was $9.77 per share. The shares we acquired were not registered on the purchase date, and accordingly, we estimated a discount for lack of marketability on the shares of $0.1 million, which resulted in a net fair value of the shares on the issuance date of $7.6 million. Of the $10.0 million aggregate purchase price paid, $7.6 million was allocated to our stock purchase in Syros and was recorded within long term investments and $2.4 million, representing premium paid on the purchase, was allocated to research and development expense. Also in January 2018, we entered into an Amended Stock Purchase Agreement with Syros for the purchase of an additional 0.1 million common shares of Syros for an aggregate purchase price of $1.4 million in cash, or $9.55 per share. &#160;The shares were acquired in February 2018 and the $1.4 million aggregate purchase price was recorded within long term investments on the condensed consolidated balance sheets. All acquired shares were subsequently registered under the Securities Act of 1933 in February 2018. The fair market value of our long term investment in Syros as of March 31, 2020 and December 31, 2019 was $5.6 million and $6.5 million, respectively. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have concluded Syros is not a VIE because it has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest. &#160;As of March 31, 2020, we owned approximately 2% of the outstanding shares of Syros common stock and there are several other stockholders who hold larger positions of Syros. &#160;As we do not hold a significant position of the voting shares of Syros and lack the qualitative characteristics associated with the ability to exercise significant influence, our ownership interest does not meet the criteria to be accounted for as an equity method investment. We intend to hold the investment in Syros for the foreseeable future and therefore, are accounting for our shares held in Syros at fair value, and the investment is marked to market through earnings in each reporting period. &#160;Given our intent to hold the investment for the foreseeable future, we have classified the investment within long term investments on the accompanying condensed consolidated balance sheets. For the three months ended March 31, 2020 and 2019, we recorded an unrealized loss of $0.9 million and an unrealized gain of $3.3 million, respectively, based on the change in fair market value of Syros&#8217; common stock during these periods. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Innovent </span></p><p style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In December 2018, we entered into a research collaboration and licensing agreement with Innovent. Under the terms of this agreement, Innovent received exclusive development and commercialization rights to our clinical-stage product candidates pemigatinib, itacitinib and parsaclisib in hematology and oncology in mainland China, Hong Kong, </p><p style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Macau and Taiwan. In January 2019, we recognized an upfront payment under this agreement of $40.0 million upon our transfer of the functional intellectual property related to the clinical-stage product candidates to Innovent, which was recorded in milestone and contract revenues on the condensed consolidated statement of operations. The upfront milestone was recognized as revenue at a point in time upon our transfer of the licenses to Innovent for the right to use the functional intellectual property. In June 2019, we recognized the $20.0&#160;million milestone for the first related IND filing in China, which was recorded in milestone and contract revenues. &#160;In addition, we are eligible to receive up to an additional $129.0 million in potential development and regulatory milestones. We recognize development and regulatory milestones upon confirmation of achievement of the event, as development and regulatory approvals are events not controllable by us but rather development activities of Innovent and decisions made by regulatory agencies. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event of commercialization of the licensed molecule, we are eligible to receive up to $202.5 million in potential sales milestones from Innovent. We will recognize sales milestones in the corresponding period of the product sale upon confirmation of net sales milestone threshold achievement by Innovent. We are also eligible to receive tiered royalties from the high-teens to the low-twenties on future sales of products resulting from the collaboration. We retain an option to assist in the promotion of the three product candidates in the Innovent territories.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At March 31, 2020 and December 31, 2019, $3.8 million and $3.0&#160;million, respectively, of reimbursable costs were included in accounts receivable on the condensed consolidated balance sheets.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Zai Lab</span></p><p style="font-family:'Times New Roman';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">In July 2019, we entered into a collaboration and license agreement with Zai Lab. Under the terms of this agreement, Zai Lab received development and exclusive commercialization rights to INCMGA0012 in hematology and oncology in mainland China, Hong Kong, Macau and Taiwan. In August 2019, we recognized an upfront payment under this agreement of $17.5 million upon our transfer of the functional intellectual property related to the licensed product candidate to Zai Lab, which was recorded in milestone and contract revenues. The upfront milestone was recognized as revenue at a point in time upon our transfer of the license to Zai Lab for the right to use the functional intellectual property.</p><p style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The agreement allows for Zai Lab to continue development of the licensed molecule and to submit the licensed molecule to authorities for regulatory approval within the agreement territory, upon which we are eligible for up to $22.5 million in potential development and regulatory milestones. We recognize development and regulatory milestones upon confirmation of achievement of the event, as development and regulatory approvals are events not controllable by us but rather development activities of Zai Lab and decisions made by regulatory agencies. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event of commercialization of the licensed molecule, we are eligible to receive up to $37.5 million in potential sales milestones from Zai Lab.  We will recognize sales milestones in the corresponding period of the product sale upon confirmation of net sales milestone threshold achievement by Zai Lab. We are also eligible to receive tiered royalties from the low to mid-twenties on future product sales resulting from the collaboration. We also retain an option to assist in the promotion of INCMGA0012 in Zai Lab&#8217;s licensed territories. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses for the three months ended March 31, 2020 were net of $0.2 million of costs reimbursed by Zai Lab. At March 31, 2020, $0.2 million of reimbursable costs were included in accounts receivable on the condensed consolidated balance sheet.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">MorphoSys</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In January 2020, we entered into a Collaboration and License Agreement with MorphoSys AG and MorphoSys US Inc., a wholly-owned subsidiary of MorphoSys AG (together with MorphoSys AG, &#8220;MorphoSys&#8221;), covering the worldwide development and commercialization of MOR208 (tafasitamab), an investigational Fc engineered monoclonal antibody directed against the target molecule CD19 that is currently in clinical development by MorphoSys. MorphoSys has exclusive worldwide development and commercialization rights to tafasitamab under a June 2010 collaboration and license agreement with Xencor, Inc. In December 2019, MorphoSys submitted a Biologics License Application to the FDA for tafasitamab for the treatment of relapsed or refractory diffuse large B cell lymphoma. &#160;The agreement became effective </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">in March 2020 after clearance by the German and Austrian antitrust authorities and expiration of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the agreement, we received exclusive commercialization rights outside of the United States, and MorphoSys and we have co-commercialization rights in the United States, with respect to tafasitamab. &#160;MorphoSys is responsible for leading the commercialization strategy and booking all revenue from sales of tafasitamab in the United States, and we and MorphoSys are both responsible for commercialization efforts in the United States and will share equally the profits and losses from the co-commercialization efforts. We will lead the commercialization strategy outside of the United States, and will be responsible for commercialization efforts and book all revenue from sales of tafasitamab outside of the United States, subject to our royalty payment obligations set forth below. We and MorphoSys have agreed to co-develop tafasitamab and to share development costs associated with global and U.S.-specific clinical trials, with Incyte responsible for 55% of such costs and MorphoSys responsible for 45% of such costs. &#160;Each company is responsible for funding any independent development activities, and we are responsible for funding development activities specific to territories outside of the United States. All development costs related to the collaboration are subject to a joint development plan. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2020, we paid MorphoSys an upfront non-refundable payment of $750.0 million which was recorded in research and development expense on the condensed consolidated statement of operations for the three months ended March 31, 2020. MorphoSys is eligible to receive up to $740.0 million in future contingent development and regulatory milestones and up to $315.0 million in commercialization milestones as well as tiered royalties ranging from the mid-teens to mid-twenties of net sales outside of the United States. &#160;MorphoSys&#8217; right to receive royalties in any particular country will expire upon the last to occur of (a) the expiration of patent rights in that particular country, (b) a specified period of time after the first post-marketing authorization sale of a licensed product comprising tafasitamab in that country, and (c) the expiration of any regulatory exclusivity for that licensed product in that country.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, under the collaboration agreement and pursuant to a related purchase agreement, we agreed to purchase American Depositary Shares (&#8220;ADSs&#8221;), each representing 0.25 of an ordinary share of MorphoSys AG, for an aggregate purchase price of $150.0 million or $41.33 per ADS (such ADSs to be purchased, the &#8220;New ADSs&#8221;). We agreed, subject to limited exceptions, not to sell or otherwise transfer any of the New ADSs for an <span style="-sec-ix-hidden:Hidden_LxjukuDojEmG5LuismUbLw"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">18-month</span></span> period after the closing date of the sale. We completed the purchase of the ADSs on March 3, 2020 when the closing price on The Nasdaq Stock Market was $27.65 per ADS. The New ADSs were not registered under the Securities Act of 1933 on the purchase date, and accordingly, we estimated a discount for lack of marketability on the shares of $4.9 million, which resulted in a net fair value of the shares on the issuance date of $95.5 million. Of the $150.0 million aggregate purchase price paid, $95.5 million was allocated to our stock purchase in MorphoSys and was recorded within long term investments and $54.5 million, representing the premium paid on the purchase, was allocated to research and development expense. &#160;The fair market value of our long term investment in MorphoSys as of March 31, 2020 was $85.6 million. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have concluded MorphoSys is not a VIE because it has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest. &#160;As of March 31, 2020, we owned approximately 3% of the outstanding shares of MorphoSys common stock and there are several other stockholders who hold larger positions of MorphoSys. &#160;As we do not hold a significant position of the voting shares of MorphoSys and lack the qualitative characteristics associated with the ability to exercise significant influence, our ownership interest does not meet the criteria to be accounted for as an equity method investment. We intend to hold the investment in MorphoSys for the foreseeable future and therefore, are accounting for our shares held in MorphoSys at fair value, and the investment is marked to market through earnings in each reporting period. &#160;Given our intent to hold the investment for the foreseeable future, we have classified the investment within long term investments on the accompanying condensed consolidated balance sheets. For the three months ended March 31, 2020, we recorded an unrealized loss of $9.9 million based on the change in fair market value of MorphoSys&#8217; common stock during these periods. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our 50% share of the United States loss for the commercialization of tafasitamab was $2.1 million for the three months ended March 31, 2020 and is recorded as collaboration loss sharing on the condensed consolidated statement of operations.  Research and development expenses for the three months ended March 31, 2020, includes $11.6 million related to our 55% share of the co-development costs for tafasitamab. &#160;At March 31, 2020, $13.1 million was included in accrued and other liabilities on the condensed consolidated balance sheet for amounts due to MorphoSys under the agreement.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element may be used to describe all significant license agreements of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>25
<FILENAME>0001558370-20-005185-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-20-005185-xbrl.zip
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M?/'H\5UHM-&GL_.CC_^UT56[OS/BV[Y7H-8V\QQ($<W 65N ,1\4<B(+]-5
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MH90JA"MB0LXZV)A(F\#[(+G#%#=%@<%4>P.#2E/8BE'+"##D)%_5)?9@#)@
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M=L@?>WN )1M*/X9Q\B>RL1JE<1?$-Y0EI<'LX*[]]OB(_>H,G@-Y+3CT!0>
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M3C+"M>11F0A8(%BLQN#I0DX=8MRAS'M)M))X X1G>R3QX&4'HDA1NL$H!9$
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M2FO-9+48>'^H?%11<F*X9:#P_?=ZFD1W&L'JB\E1)K?V)I5!X^R7S6V6S:X
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M46I:V9\3:W$DX=YV:5A*,R8&"&VONA"U/_4'S",PLV!#P))D;CA?82-V_*M
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M].'+IWO,OX=]8*N"PD0BCB4H<X>%L[]S$.GVR^Q:N7 EPUW+Q.7&1>)88EC
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M,YC6&L#=FLL.WXC\*U%:<!N%C[SM=SQG<O/:0*5)R=6JR/T77C.)S2.#T&B
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M]VJ+@IK+8"^SLA'/-BD7PPDQ<?"K#@9/G_[+'F<OMB@:N3P#3J$1:G]E#I[
M'"RI4W2 6O'Z!*BX':(_M.IZ>75YZAESU NB.>3 &ZCK9([(\E:VV^?[S\VY
M=%ZOGIUZWF)<N-]$8E?PN%NDC;\34>R_;8?>V![5S$O3>T@/J+P]&9GK0=[M
M76%ZH/8/V@JVN"ZC33ET1"=2YQ6%4TM>UN_TXS%(\!I2'%H$2]V6FOTH>)F
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M9 $GPN[!@&V\1>,.O30[:>X65W)'TEQ3G1-9FPQ&(D5>.L?5A[0"S/9_;RJ
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M8TL^^ E>=?OIW2$5_4!3T3\-J>@A%3VDHH=4]&-S [79C,4#VC[8Q0@+*ZK
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MQ8;'Y2US/);I*>OB7!A3=S5IFT;E[J8PP<U5@G%S44!:%.8\IP#?Y2H$7!X
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M2S/*!H5^6,*T4. @TKB9:7\C)R-[7X')]4]I,4&U/!UYQ^8DL+G? _T,?<L
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MGR?2U='-[4?O!.RUN/A*B?&P5BVQ[#0YMY: 93(U/#BF)@9GZP6Z5E/NF+-
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M96S\^[ H YKN7J'I?AG0= .:;D#3/7J>O$=I/=Q*Q/ZF*']OG.1WEUC!P1B
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M: .LY>WG;/6=AQ9G#R>__-./0WYYR"\/^>7]YI<?9(NS>VKV:RO:L6+$;#2
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MY:/.( -%<=#O=X3V<CU)WFF>SZ)Y HM^A,5=.'=YR-&Q85E&.!IPY0L*VG#
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MN'AUTCWY5GB)W0L1[JCO9@RF[N!\",#%N)Z=2^572@C;W6I=:86ZG['#&C&
MH&QBKR5FJEC"^'V>C9^.S%5X$A^CHK\5XEGN!-T(>>63A:5E(Z(1ZDD11_,4
MPYEP])=F6E<-)G-5D]\9)J<'<2CKL,^DGAYTEITSF6'2J/KF.F-6+QL>37O
M$[?W;7UY3U7%S2\J%A-LJJ3,&: 8UFS#XV$7V1VE"\LMNH<&2C,TXKTL/Q%6
M2R'3H=>,456<@CF6D4F8<(_OQ';^!B7TK0QMM SV3S0SR8Q:2-NT*1/W\:1)
M7!;I&"1=(U:?8^+;-"5'/HRIWXTGAR!2I"&]/*RXRD.H+%'MJ6)$8O]+RK)>
M>OADD2^$:*.0%(LKF\$53?AW\Y3+[.VZ.H)&6EJ3V7J;K2]DCZNONDHFS6I2
MJV'MEUUB\QT-EM+?GU_2+4&>/6G>).Z\M4R;3$"CLQ_EK6LF?Z!)L4;]E>;!
MH;(Z[0R[I#T##";J2\\K^I=!MA29B]9%:54&&-3>]5%9O^^L,^A22V<DI5',
MF<E?)91ULPJJ]%5+LE/7#>(E-(:K[E$BTU.Z,!M&Q\:)F^X?> <&"NX'K6CZ
M[C0<JKL<JK?8A!/,6-)SL)ADA/>:Q8)""3-8F(ND[LSL4P>G&\HG4:P(SPE!
M8JR)6378>\0_4]I("#=B[\3#;]:$G%>DORX?WYVD2[,4NS385-JLD\ZL"IU(
M;ZFS72T\&T3LW?VN."F);"WAJR]%E>FCDP#QC.AOG"^Q [[3!7+$8W8Q4]L;
MW_7,+&:4-LPSTR@>I,DN+0O)IN%B-PHLCZ?2@J[UELB+T!'W+;U^-D&.*;K.
M^4+EKV3F% P Q08E$D<Y3:UGV) O6@PGK/W\RPR9G"&3<YA,SO,ADS-D<H9,
MSI#)>;R9G*8=B/8X1M[ +$DM'8:J3H2_B'-"3)-NJVQ;K''P&7;Q&6XEX7+<
M!*G;(#[:Y6BW=L9LI76LNY!BM+J$#$W;WFR*"RHW8__C*&!3=<ZQ(Y6DN *S
M;G2$$4Q&+4$9RJA"Q8W&/S^/)D='73&'-LRH]5XW2>OT&$6\2\8/*=V;)75'
MEJ%V$L3&FA3)T)T5W1O'7S[D8N++TY.]S^;8BM4L562@*X"V%SX^UR)I4^)A
M8J8YNKC)!:INB;6F6X9=<DSDRUE:S%P"0ZJEXH[>F[&$8"BLPS(*FV"^2+F*
M2K&_(ITO@N-A$%FR9-HH_YC4DX I)'-7FF.Y0E0RYB;F;9+<;B@SQF?J1:78
MT_@W87XVS#E@RJ#*@_3I7S*]C? -&%>2&<X:::9EGN&+".0%2_PI6*XG5T(E
MK64('MS18JSJ3EMTP<JY)[9![EJ)!6/'H^X42R >HMI4ZU6><-44%<<NI!"N
MD1+FI!.\AF^IWC8.(O:.\,J&X&:YX339I+ =^3C1$MRO*<%)& *3#!1K>_YC
MFBP,HI2B68)D#.BEL_Q8%E!;0@^S ,O3@SD2UHWN#%,X[WZCA*E'2BO1R_E\
M@+ IKXJ46BSP"_.X[6NKMA:YHXS@<@[?#2R8%I<&_1VC=H615UHP;9H>. Z2
M@ZTVDR%MLGP540[O,D^+LJ*=C9L3%L?%;S'/$6P_RPDNA8MJ@S4O_ULI21#&
M@+N5=_SGDCV!@31%QK,ZHXB#\.9=. P5@YWFV,X"7Y+Y[#(>+&6&^%7M+'21
M;\<NUTOQY+8(=@5C\^FT+DJ[T*V@JU5*F$M;MU03YA]U$0F%IY&,7Q6$R=0,
M1_DU>4&.'5TM\_'M_^16"EUQY4JS/-3I'IC4P02/@GL.JS9+.7M/*6YWT,92
M*#@#!89=KHF.AK*6\$\86M":VBR,8TA,>KS^D4@DYO<5CP_\N@L<<>3-YJYQ
MD[E*?09\HX:)<>UZKE*Q:>V&3A)Y94QLI_;H.7-I(PH/:ZK:FDO3="H:F]6%
M<.WS^2*&#$*T0!2HM2+U)10CS"6:"?8Q([*CBLK7V=G&'%PR.P<90),^F<_%
M)E'K7EAG(I'$?#[G>D\DPK?\2E8J.H2" +<D$E=?,3Z1>M;-DQI1*_=%R]"Y
MW(+\%?922$F_,X(L=BU1["<TWPDA0'-.MENL63A%9;QMY[A9*F]KF@0K<YX4
M:6"NQ,[L7+?X63GW:LD/@@0=6>C=KR_XZRB8#3'6"[ !8.1PB[J4SU0/&00B
M9M%[E.L,K-Q9CGXK7784-7IYQLYDV;9AK?'1N[F[T[2C;DS/T2[;V^*&VZE>
MU9="S1A/Q.X5U7M,$.Z:VQR2F?<LF?EB2&8.R<PAF7GODYD#8^LU'"<VQLCJ
M2S,B6V'PU\1D9I[Z7J"!TQYVN<=(A-Q &V)59_OYL$"I%UUG_98=T@JNMJB#
ML*&7? 'Y4ME2\YT[VS86AD[!CEY1@Q@A$>V,2#0M2?@ <\ ; <E@VJ$U]?7S
MG^"1D&GL6JWJG]KOV"9E]"IWK9OF1%NSBA;80D'&38T*&5EL>W#YWTA3 7RL
MBL(U>R[R?__9"&.>@D 4Z10?^"1XX*9I]D'2=-X[>ZK1@W,F_-NJ@=HW]+G3
M1G]8"N$MV$=P'DO2O@4M[FXM9CG,71**F7JFM0.\.,HN"[W4+Q2TR!U"2V%H
M:7;IT-*))WS::UCI3WY(&<%D9E58:(>*(U(#D1BWK^RB"Q0UE?4KV\JC<U]P
M[#OG.K\FP!=T9#.WJ2#TZ1+;+]H89V.,>D2:V4T%U*F/%':/JU!-86/)*?U+
M[73'=Z-_9;=MQ^C&R 2,3+"XJQ9V6N'U%)47Z"8=C(C]=7;F^O4'1;F-7J=&
M7,/[O+NCD#4'E3R@&X$\D-<R>>W+W;?P&QX$I2LI(/(7ZLP?_D2#9+_,T($)
M0FF9Q5K*0T1TNMKR6,9VV8*]K7:W=)'"WE$42J'KI@E1*)==?8VP] KD[D_;
M8Y1)+!UYI:KUIS:DCN2R@X1;T[@[3LPF5?3.$ Y9!_I!I9N)*M7G0EP_4$R4
M2N]P$81X78Y-^L0VJ*/8Z?PJA.X/Z#R]$;1E\&X.&75'W_@F%,_/X\L:$/S?
M#\=_?7UW_/K+U\]OHX_OHD^?/[[Y^OK+273\UYOHY.NG3W_^WT&Q\_P^W7U2
M_T!/(5D\H$UY2RSD)_4*>Q-Z'F-0>D5>GYZU@7-[/"Y//)I.5#/B"RP,1K+P
M71PA_B!9(/>(JY]^.\=>KV3[E7E=3*7@^R$U8<;#"7,9&1/XB!<QBX[A%)OD
MLW7 1VWK?,$0Y;P4GX=^2K_P(:YIE<6ZCGX>/XL?5%MA DR1V%L[@*RM-T5]
M&DS8&VX;24B18W1@F,M&I=1WG+_G\6TP--^-26R;>MUS].)WLD05KE9@.U]:
MD9\=-S[(.G?U"0!E/L7_EC+S&+%YDU34AEY>R%/'ZBRIH\CR7SO'F9XC49O-
MCSDZ,(&OZ'>7EM\K]U#L]0S<B1IPBU=C^8]EAKV>MYHHD!OX4<S@MZ )+-QG
MDF8N^DF(U +=(T=$%D+-F/0"W9\&@6]'#*[/ VKD\WG%M4RK&'(7)146[-,V
MD"_?U00PZ%8MX^C8AD18B@(:#@YSNM<WWU>IAP7P]>TH:3>=D0Y;Z.KO%ED$
M@YKH ,6WF-<%_5"645[\'Q]>7]L0$P_BQ_&/#]4VNSQ,_3,90,I=!4'8-]_/
M(773 0S+8]<_N*GMMU%ZR^GS%:RI!8?5$2O6MD(/>J@G>SW2A;+$6#J#W8WK
M0'O+ 5@BNSUJC>I,D7_!2?\47N/P]M#DZ/:A,_K. \SG <%\?AI@/@/,9X#Y
M##"?QQ:.U$=L4*E'+IQRYK'\B'L?L1.M,[IB:AU7KEH&\?6M1*UV;KB^!NN'
M.OT;HCF:G2=9A0UZA/JO5)_ S<'D0P?/VH%LM71'+.#F;>=.'#MQA:@VD&-
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M#7IZ]Q<OZ.F]UM,!W'.Q)= )[',/3M?7"L"SIQNQSPW,J^Q 60;&^)P7?GK
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MI6F"3MB8%!*^(040,)/DA@:D-%!/"X4QVURJN':=M[PT[TY&OKX[2(U*SS&
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MX^PX<*G[39$KW3M/S_6>R/LMV!T6O\<]^W.#B:1:W.FT+N+IROC+VGA88PK
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M?@?85O31>UQW1NY;?+Y3D=TD'VL\LD2^ *)M<6JF$?5_FN,'>ZF\$DPX_.=
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M^(NF._CM^$M$E>5QD<!9 \>*)O1@SFH$[1Z<'EC<#,LE/"8M_?9 ^"#=BUS
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M%<#O?TP5+$?LAGR\D&99D6Q1_LN-H(PBJ=354H8A&(H&=$1;#*P<WY0D3OU
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M-3&%B @"\/CR.Y/.) "V6E$B\,V,]"6XHYM>K3653C_]]0$Q@=P(@Z+W;AY
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MJ7HW)9_5).UO00EY&_(V? .B;::8CU9C##FI46+6:MBYJ38CB 5W;V8;:*Q
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ML%AH];"Y!/3)*)T)Q9VAW"G10/_O_^_'R]]>_/YG+G85&CG4I$0&6,WVB[E
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M7G?_,UQU>O9W\+EWVOMZ= !OVSWMV8M8]^S_V1T$_0'_<? GW=#YK0SQ\.]
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MM7QY-)XALFP2+:;8'"]+D_,Q95C@R4*#:_JSR&J4.^KQJ/@OS>+7U#V';JM
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M'!^!^=4_^I^OIV*O' 0?P)YB0T@#- =X-=(\]+Z<'![_W2-S!VYY1E\,OGZ
MAYZ=@I5S?.H^CXD<>D'O/V1%D+EDC5LP(DY.CS^#/74F#P6+H;]/QLEA]]L
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M,#[= K3AQ>7).7L!=&CD%G8SCL0O+17EU@ON/>TX; \.UY:'T/A@:A^=Q6
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M&L.'\ZO,^S>28PE68Q:!39*AU(,=;PZRBV@L4Z O1C@%V52F2'W);/!DDVO
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M<)S5%SE/K/&R):P;5*0 NEA=IU)F+?>D3*]S4S=77=XX[IE'(9A@PMF]P,\
M+5UT(6$BS [<E5G#=:ZZEO^DQ:,('N7]<F5?K:$[95U(9W[UVQK@ _49M-B$
MI;_95NTU@31J&8X\5%8%1M (V!"-T0G]JZN@#7MA6KKS"*XM<]=T2E>]#7:6
M5*YW2F!1[^QQ[O(:[AJ6RY%\K*=;G><;OMC+*_AR?/KRM_>X14'69V4TKXFQ
MW2;7_G3 $W5IF9L:6U+&_1![Y*RNW9RW/9S\ ^\4W<SQI2:Q,!ACIZPZ+)<2
MXG>N46?)-JR^I[KV-",6#<I7P/TGIFN8K@?/%)6UAC7T6'F1SH,%M6'&KZ1&
M]=])>K7[.;UR?1S[6;F&7I]MVJZ4JD.\,V4)+69^E((EQ-/%[!P%'9M3?</*
MS'D]_"HEZ&8WPH;+I>MF&*!W"_<E^Y&K-<G^T+0@#G&8#XMYWI"FNK3=77C[
M4:?7I,2VN4MK4W)KYLC%<CO)U.Y9] -%&XE%=P[3/.\$@XLH4^6]W)C[1DXJ
MXSXU#LC+S\<,'S2<)571'Z7I7%$*'_TG4[(-WRPM6M$\04--K&4UQKIJJ-TS
M]]JK\E05BXRVBU&K6M."":@7%KZF3\&9W&CGRF_- 36;(2QSQI9K<6Y<(Y_Q
M'/@8129[2H2/1>D>GI43RN_,JC^W6?H2=60$!R:F*K%8!\[(_X'M4'CU]@=1
M$7FJY(XOU^ 12-4;W*] <@>DX/ FH--@:R+3!#QQK!!^I+@"08_0"H[/Y&"S
MPCK2(P>P2S,S3D<+"<WXU?9TK_(CR,F?T>%/(";GU^OC!3:82ETW"]RF?7^V
MM.^;-NW;IGW;M.]/G_9M^R#<)?%;XL/1D6#W>,;0+W>S;SBH[VC84"]4XNJ=
MS:?IM1)? 70F>M97%Y(H^@Y#FJKQN<U!VD'ZM/ </:\;JU,1Y1E#$R(JA\6Z
MC-45/WZL9FF2%YG.%:6:Q=TSB<!9T\4RR[.X> /$9^JY^HAQB7'%8*0?Y!&F
MI+V4./I^^/-Z,[,6KUG)C)FN[0C='"ZN=V%F)F#Y(9G1)9KHA:G1:MTQWQT;
MW]@=&U!A+U+)8G@>MU<NT8Q/$NH3-VUOTQS<E1BC)_EU1+DO]UY7RI,Q#S5*
M9\2),5=(D@L.?I:IRU3BVU*8O3O)E-#YLLZ81_&X3:\ZZ56>5^SLJA=&D@GD
M8%J@R9J4G=$T3WEIRP@:K78RE8/]B US227I/_&EQZQ(Y!OY"[] G2R?(EM;
MB,I'_H9_P04(TY4/L-H^A-&BATCL?]%47TL?HN]L/HYGV'I'ON8_\';J!_Z+
MQ(:^X;^E@V^5:Q6N^Y?4STBP& GO=F)$V6"-#7WS,48HB_.!'Y9#G+7N?<"@
M^ G^(+]/G_U6@>5*-+L<PG[MA\X"I\'$CE!]FT&5QM0)P-<?YZ8%N=,,.I<>
MY\+MF*FI+JVIS#\#FBSA;:ZA(6X"V1!!FF/:!@=-=^-"C2X2<';.KS'B&<_X
MO+9-)F /9>ETJEQ(4EBN:"'I+Y6FNCNL;*%,XBPO=/[;)XG0H 9NX)(0?H1C
MGT.LUV9^9IFO<LA(=S;B>(P[ !XA7T]A'/I2KJQ:#LPVR%LWG@U!0RMO@9L7
MU\RY'F-[D/L'N;KQ04XB&($Z/G/X3%'Y=$WAWMX&#XU TA">G5Y/#EN6WY7Q
MUS5.E_O2?S)G7.Q8#D2&:W/>DJ[.C*(R1RCJU&0Q@662*A4+I;&T""-92:OH
M:I6;EX)T^45'L)"H'.&M</V"+PV/),.;1T9?(#<Y,9 *CX(S.!]>AW"T(JVP
ME/K&0MW[8!;)=%-K0FRZRTMYU3))KUT@+O=RVT)I!T.9IY8AO#>6#:U_1^D<
M,TH3*D9#_POT.ZA:ZH)2HAXN#4=*EV460L:(D2@[87I^+Y$??>S1+TWWB+70
MOTLWREYP5G6D38.JR.W(H\>K/6N><;JO@[I=JN8%$4Q&GIPV+O#GSKO6Y@1A
M5L[3=(Q]JX1L'9W0,?P2G7,4.+#2^/2GGD]>>J%BA[C6 ><=HCK,0SHLHIAE
ME%;TGY23#-*5T<+[HG)I(H'OR+W5!Z_A\K>\;':5UCM3+R+7GJ;(Q! N+4@Z
MQ]C*JSUD_4-V<DOD,YRP8P73]1U%.)U?,RPXE!7LGVPT8_E0)VR3BAM>5^EZ
M[NLTUKN"*#+5#SC@<O#R0=_J;<.5'P7X>'"@8$,<4-8P-)!Y@6K?^@2'?Z&;
MAN/7; -?<,4?/GO69OJ>:J;O;9OI:S-];::OS?0]-S/-M7!&=:&T%:8OAGJ9
M[2M))/IHRBRK\$ 7>E:.U+JE8EXH-N0X+)@%:+W,P3<P7=>O$L5M=N WGZ;I
M,"J9##J*:W\NQHGKLQLS$MUJ+"4*=*I/V08J8-W,4GP'>,1,B@]R[" R^@[Z
M'$/(*I-0 IJGB@Q YT+[//LUK!DV3-0T3WKD>DI+DT#V7-R1V; O9N^,)AGZ
M8M1;S.G60E$#7!6!=2.##7<\T3T;Q8RTW4RT=9<EJ@ /ACJQ)YAS]'[(08)I
M>D[O03"ZDHEL L3."[:^D.\+G=\"R&FZXE#H"/.[9R;=O,E0X\.X0-K1-\4O
M=:[0_?@_E/&02@*4<-,]ZSH _:9RZ@WIXJ!OVYR+]TLE3>\H)DH51%<VJ#B&
M"\)@T!W0OW)% 2VJ@II%>4'9J2D&.AWQH'OB)#C=6N'A&$],L:):YA;F>U$P
MR]M,D7*2P.,GK**@8!\\Q>G A'5.5KOGO%@\OK*F,]E$^;Y_= !C_-+MXG^-
M+I1[_U=KI),L'M'G<PP"@@KUR&O-N^!*XF"7I:+<MHM>5WO!MRYI'74!.S9W
MHJ54I5P3+;6*E4>HT21RZF7TZI17D^Q5B92@3ZHVDO-EG]A\E10E?XZR69KH
M$[3W%M8$VU%HH3CA9FN@N9"X.IW&8YJ(3XN8[M\)*>R+-7*:=\PKU*EH;"/N
MIH,542K,*?EJ*Z>-4-IE<669NUJ4CO]*/!@FYB:;$W0$85O\$*(;)W3#A[!J
ME2)V @PQ5:F-+NQJX=&]A./D,IU>EGH<1T[[L07,PI1NT23 RZ65A,4(MM.J
MVZF"7H;$QL()^(7)*4B!+CJ%IE2+IQACL4X#0$(MU81F!8@4YTX :#1:8+ ?
M5- \'C-S]03NA,W\*)^\FN\BUL'QCY1-M?) G)(<A94U$+9_U^:\B608CLB;
MR0<ARG1L"UNW<P8FS2ITESAQ2Q$4^MGY8KCKW @T&0N+)3F(\N62<W-Q>&AI
M:.TYSYZ[N%4"V>54U]O@.'%ZA.8;C6V7.QRO[F",&<5RWV)]/GI'8VT?C^:6
MQ7=/M:W=I/C!6@VW))=K[*,')T#?<!-EC5"[6]O@^V\.[+9^C71&/R]JZ*3+
M3-+OI3=O*][KB/>CX7"]0Z/A0G<3]AL&,ZZ7/DJGBIP)DFXT%\C\=JB)[] R
MN&6 ;1.$6TH0OFL3A&V"L$T0_O0)PI8!]@[I0=OA'BL^\*AV0LU.=-@C!TW(
M!%T29'5"WB5"K#D<]1R5I*03QYW+]8B*[8781E/94O9-A< =?9S;Z&8=B*HM
M<+NU.[9&<".U+6HV"HOO5WH'8$1+<^A4<U;EH/Q#DLZ):>Q79]X(B.\:U$/E
M&> <6N&X)&VE*)O&S/RRU68M\2:;M93($PFC"W."FD9AJL:!!K.CX06'G9GG
M6%*%_%)(7W(?26PP^-MN-]3=:.,;2>U4TCK* R[<O,>YUQ?'%N1MNVO0AXU.
M'C+-/;TY0^C)!F>-==0,/KZX08D%-F+WXL<WNX%;9X?Z@EQ+"G51\>(&5 9<
M[.RM?Q&9Z I1T36KMY:;4&IC>)2EXHTHF]ET*9Y%A5M$47DE.%&]%FO(TN^E
MJA;S28;2,=&<#0F<-KLX]7J%$+-0I(ERBB:M%6<*3SF_)6\=G<.(SHG4LH!!
M1GDA-RLH!$.7S)!@'(^T*A_"/D4SL>K<-53]8=>R)6 F(R0HV!S9H6UB@59V
M7O@F!>8W]?"D&$4/V[P6%7279]450\)R22^UR2W?S'D9Q_+ 8.U>T&/NZJ6=
M AEVMK+#7FLUUZC)?VYI-1^EFC8$?*PY0F@$39)O%.!UL\!PF:^Q@SET8WC.
MHN\:E9AYKX#^7)2QPX>EEO#I@K(+1B\JG[ <(\9+BS#=0+)"F LRO</G&D;E
MT%*6VQ64@:JZ'K.D0_6=ROB95MY]>?]^<R97S'\Q,0_62X,T@ =VFVE]ABFD
MA\Z0EN&@!CQ&R,R<W4VG,#C.1HL9KW#N8@9"%^&Y-KATRZ7K56VGZY/Y=#?"
MBZH,V9B&:C5\U$T"\R9 Q*6?F;7M% E?<>N,+VEB*9B,"V6;8O@U[Z9XFHR$
M(2+.Q_@?C$I@0UZ"GI]W7*1GF;(S]&'X82TX/ZR@7RO05>\#'7X15@TW]*BQ
M=*$/[-<O1CK?5%4;/&J:G4>)@%?AI^8"OVK?NTHP4Q;?U5G!%.!C^^O+^?E]
M_&8;3GDZMU-!#R3/%[#^DQAY83 .98(Z7&RL.=L9=^BUL4FOX,#-2VSNO,HH
M%946TC1M.WPC& ^;W00@O<(Q>YV"P7F0]BM2ENWR/+4IVC9%NZ44[?LV1=NF
M:-L4;9NB?;XI6JENU!9WBIZPRNA0%ANPK@]*4[>EEWNOP?SKM+[88X?S]2VY
M;34_[A<\1>8/6],;YXS1]@FRP/M1TTFP(\8JL7]TK"%KB.J,]/QJJ(;N&<WM
MNVE$D6LB,^!8G5I/J6>+&):6D'2\]*A];\=0QYB3\VJ&(,I&QW$@M4E49"_A
M%[Z&3WFJP$>KJZTJ$QL)<'+$D(9<MZLU#(C&;\1Y9;K!.6(E:<=DBSGS&^-B
M\@!VJ-8)[HSU>Q36A:G0A6!T26?=]K6AI<3TBEG\E EX85*!AOF2J92U$4>H
MF>3,]=)X$'SS_X<TL](]QO2;Y5>,>;+HR=ZMT-&>JG.2A"$SC>Z!^W7MU^\8
M9*JYF=\!I(:ED2?0P%B*:C793KF T'S5T0#7L>(9K"_[^]3MGK0!1%^/3F\9
M,#\U(.&^-"T&,=HHOF0UFW=]L^6*V'1NWG*Y[A[+>FN[Q'Y%*YRW%<[9#833
M1@ZWF+%9$KYT4?5N&I *(4EPX$LGMM,V:)U+@];?U^-QWZBR.4H+7#D,,&NN
M#S2L3/TV1^TR;O\6T9[&0%W,]7=.6)S"C#EW&BX1N%\CIW:<F:+UPN^QYV?#
M_^"7UPTG\^!%&+P+=LKI-5LJ@NEPFX8K-RBVC;;!%GCQ&_S_:_C_-_#_;^'_
MW\'_O_?BD4:"W^^]?&'A=_D?X+7 U2_WWH?!J[T7+\, ?(Z=28?_]YS^]PW^
MYRW^YQW^YW?\#SWRQ=YK^B\]]Q5>YY?UZX=R\SWB.V<0!6AFW&TP5POJUI<N
MIF,]L5Z.O=)YV=F)OY=)]S!GFF/C3/,KO:1,[NDN3^:M707Y:,/"3B-UK^NT
M39X^(:5_+^$![]V,+_M(W_A>5-[[O?6/N2_]P7[O\+![U#O^.FB/#)F_%RML
M TL,'FP\.N#F3IG4*J\V?K<>DL,V;%.'R/"EZ4/*IX+2%]G>[M3<$=W3:3SC
M.$"I.W"B8M'EWB 2-TM)ZM"HJ, <$#JWR@-58U]MNJ0)B.T7H%I-]P'M0C.]
M5PQWP:!%H8C,+)=."T0S1D.E'[5M2IPV)02"Y[F$)0F=F 23;N<$FM.$[B4H
M?L+L&^#O9PINL&7@^28M<N++T3-CHP4VWD9!F3P-IBD:<D(D@APT>!)C]3>:
M2G(U2KY*QF!6<#N-;6-\-RI%#F36V$$O]UXQ5?#""I?*S@6Y17@'3?&_&*(Y
M7' 44%QH%*HA-AD'TRE@MGHE]/?1R"GY27A3H_S!$W:N+A3]/92G92$UHZ&5
MR)EI2_^=%^GHNZ=S;%%2:<GY5D19F#"G,E[4Y7$0G8IF,V0$"7XA*) =VEP2
M3-2!-[1' [[]_GV?&$LEX<O_CF9P:@4]C$ULLFB#WNW@3P2F6N6B$1"@<T(,
M"I<=(=>GJ9J^)0<I9&>W7!=D#A/GS*BAM83Y]^8BM-@?Z8E@P;$:'81/3])D
MER_",=OS1YOC**DCQ <13Z5#J_WP( 3WSBWI]5,"3/S> B9:P$0+F/CI 1/;
M)[W^2;UVU]0P[2HHT&D2K.+R52VW2%MMN@RG=)JK'W'.K,[D2FHGP+,6.#%I
M66LK9@-XM<.8[1KIW@,W^?_9>_>V-G(M7_BKZ&'..P=FC /DGIS=SSC@)-Y-
M@,'.3O?,,W^4R[)=G7*5=UT@GD__KHND4I4+L D07S27-."R2EI:6EK7WT*U
M($[2&U[<%*7H?XUZQ'YBY4ZD?.$)AT#GG "D&\TU1M(1!N[N64;@!E-T&E,?
M(-X"U5K'8^J-O63B^3+/""D4ANH'<>6/&)6 .2J4.+;OH[B2*:[@'=%!K>/#
M.I:M7UMXAF^</X7A$0+<)#38X1&S;7_%'$:L6Q[V%10#)-9 U55K;;P82>NP
MY1(6:QYH_4US&#B5:1'UJ^ND,I!#F L[:.<VJRG.BT7C_Q7,5&3<<Q]#-,0U
MG&S9Z_RF>=@@PEK?1F8']IQ,*RP*FK'RVACU^"J(PY(G")U#Z=QK#'-'><A(
M45=Q,' !)NTM/+HCP(3N'-51ZK$1$TKF5(TU%:A8-'-_$%+J!98"4.('\DX>
MJ6:E7E'\P:/*5+'7,*<X"8-MJ.P8$SA/RWX_XJ82W]759I9K$C7NOL(@\P9
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M*H;ZXOTE@=\?-6%,L4ZINLUP1AA0QA;F7F*'%3Q[L*/P&^ACWJRB_92@_.9
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MNVB'XM1%_8/V<J*%J+K<&NB\ L.0#3[5! I>8>M[\QZ6\K-BUTL-Q@]VDTK
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MD(%73&: 2H<8!#?DLA01F7DO(:9*D'?0:(\$D%3@S>MK785>0(LC7C:-&Q1
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MR*<?>+2 [@I\&RPZ2"P^%S%\3'-$,HGO$H2 3)(@BQ,63RG1J=@=H&L*/!S
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M2?F#<*,0I I+6U35J()N4GJFS<%C&<XK@!41K7F5*K:I6_=U@I*:L%U3A0&
MKC0CT&Q*]RR5=I)C<3L"YN#@"N E#,N5.1JY!M%]""TBQ@ZB\@=AX=NP$6H6
M>'!0<A,&-3(F0XSQ,S::!;=:Q<>DJAXF%)I< 14@::Z]F?[1IM(4[66I"N[-
M)=:5C">!NHQNMRH)E1[H,B3A'R@UA,^G N?2&\8W731#9()8X2%XD7TS-)15
M8L0!P]XCRA'5H&N0L8(CRK3_R$A:6/W4X$7AUQ%!IZ"QQA5(ZXEVR\)X^Q ]
M3!%6,&"0:H]KKKG8TMGFF-O"\*]*5XOJ1KXE,LN3J$ 7X%%I)F86I( J$X2T
MQV*)-QM'>@((01SFMF5B38GP5"M#%GH'=J$>!LQ,R)O*=AJ#K.;.O4#++(EG
M!4;'?>>Q5EKJXT(E%XJ8L9OY4,"Q 1T2Y%.HT.L(BP;4U8#]!OTDD$-;G$R]
M*:+:5' 'K*/%K]*H-HAZ!>(O"S(VBPG+P#H=FD- 1XY%B*AZ7LJ/W?1F/$H3
MA 5AN&+61Q43*98PPZ..391.&8)K6!':6W'YRU6\_#^HVTU[3BR!5KKI&=1A
MP! O<IIP.YZ99>^P"03B X>RC1_\2I"F.;JVP-3>5^_ >_2O//)5@:O] 5P@
MGC^>:! )F@7%NNBV"P:WBU]SIK25IX%_Z$HA;"U"8M$O7VS0TDWU3>D8,.N_
M0$7VR8QGTU]S.:'B8%,(F5HOJ*CC2N'RKKP@)!U+W]>R3$%R;'*W&$+Q!$HW
MYB?K12 ]6,"3%$=TIK+/CYJQU\^1:!8K^@R\"5B>#" YA+DA.*0BH+K"XD(#
MJYM&@3;"^T8RP<L4ALQ6'/?A/8_[$UF)YK!E2=#/D168<[;'&!NMHCSNX$GG
M,X8'C^3MQ/O.YI("!#.R;'!5 +"F!$+TH]!CE3.(P/^'<YHMCIF6!L4&4H',
MC8=;#CVPPJCC%IMZ62W7@ AK"*736!$"-;+U=7T%I!(T:-*E2=0,206W 9N*
M;S/\:"L$WHDHA!*J:=@C,R1G^OV&^9&2SU<':C@3K0G)Y(IQMB;22T&^J>X#
MF5D0(=&"[0.J&/=O TMXIK%KU9U'H$4LC^\%6W3_P.SATO''PZ?)G%IF8C\7
M,3YT>5,N;\KE3:W,7FU,WM33R-8GOP8>0MJ:G*FC#5]FI]OKG'T2%Y?G)U^/
M>^)+Z_+W[E+E7J30B><OFR]>KIY^_$!Y9:NPE'MIV:0;K]""G3;GM#FGS3EM
M;H7VRFESJZW-+::F/=^Z2^[)T][MC=CY[:35:Z'6>-SN=E&!;'VZ;+>_M,]Z
MJSC_-:/M[M_/.V<]<7Q^UKL\/SUM7XI_M"^[G?.SO55<P/KJU:HQ\HF7>5Q[
MD5(?M"+%9I?#.\<+N\(K9^2BM< 7@7[TEI/W>YA86/3TB"/QKV'V'O^_@W[<
M3+3-9S!G^:\C^!#^_P&F61EYR5F3Z[UH>F#CV_[LW,Q8RTVI06T4L D$-]3"
M_K]].?;"(>?:I)2P-=)M$ZA,PIIVD08##U?VX/C\RT7K[$]QAFU;'FH+U*#+
MTKUN&7I^9A$-_KLG?FZ*%(-8:H(JU#JB%C"-!WA]()=C@Q5JL+#YPO0V94V[
M([Y];E^V6]U%.6 ^IZA()Z);C9*Z*"_=!-O*'5>X^R<ENEOM+7=QH)]AQYK9
MF4OC?HLK#G4A_[E]847\%)?3#9>!:6VBVG7:O8"0''?UOA37<1(.P,I;N&YG
MA9CPGL K*[2")SE&J/3 I4]W-MZ2I<.DKW'[M,&?98H :UBPH1IJ8I)3G*ED
MVT%NDOR*7CBI/=;$*E;ICCU\W85,4DK.(0UL=R"'E&'7!WZ]WL."1>S 5BTD
M5!<['(Z_8Y&(.(8E)G#H,56O,H3*CU*KQ>19D]7:4/F_<1X..('5HP11/R[2
MI3#9D(7._?+W5I"Q-L@??L<9.3O_)GIX3CZ>7[;O>U*8(;!@*+%ZQDJ5,%_B
M=.RZB)ER=D=&S;;XM[[)KN>L4:"5:O9KM];&3+006#==M//%JNW*0Z 'BN?F
MY 01)M:^$_O/5^LP[?QVV+Q?4M7]TZPJ1EO[8^>LT^N<GW753!9)/M_YK7,&
MQZ+318G8P ,B/IZ?GIY_0Q=.KWWYI2NZGUNGI^)SZQ]M^OA+NW4&'\+?VSUQ
M_K4G/K3A\855@T=FMWN$8ESLQ<5>7.QE-?9J8V(OCVB>V+4]*W'WU4C4':,@
M[RQV"TVDQXV8N3*2%'ICV-YIC4SS),TQP1\^YX[V%:L?S6)N2AI$5P1A4&=Q
M;-PV:)>&<?TMN1M(>=/S-[Z.4I5#C/85MM8E/RI7\OG:ZJ(T;$PHIH>YK -=
M#)2K3<]0:<LU]KT=!U-MU>G/ NQ&RS:;EYKFPU)UCAT0:B]WWD;$"/ZM83*G
MXVLNN>!/:%[4K9F12Q+IEY3V J\&U>YI'&)[XI23S-72&U8/; +?*6:.SUW%
MQ*JI:7K;P-736CR_J.&Y#E*Y<<RU4QC:.PU;?]TAZ[W++;5W"C]OU3S7+JZ&
MV"D=0_OO'(1Y5@1C=HJ_QO#>Q?@9MO=^2K78Z4XENL;$,9R>49PH_BC-=\%#
M9=4G$1X%A@OPH"GGA0+!T+$G[4?!VG.Q2P$53,N'_;MB3*4]749%Z?F;QUUU
MA%A*?!&DR%?Q2<)YU2XE:[Q+;CB./P*WO7KVJF@-M"2/F%#/IY.+R\)ON]!4
M:W>VH=#)T95[='!P].SEFV?M8^""%!$EHG0:I_HV',03K+WW12A'01H:IP1%
M>-IY$D^!%N)KA'_^PGVLNU2Z :*I_#O+Q':[52H.HN 88EZ1#+0P$:K^OI P
M$A)#U!2!#09\6J8H# /&.E!_4N O#3'* \9RH2H91EZ(L PXE%=XHW?SJ4RH
MCGXF6J:B+]# 7.JI4LV@#8C%6 AFEO#FR,MRY(<I'>%4@RJ@)Q*_4#K96)T)
MN^+3?=,J 4*4B 1W",.%)!+A82C.B 7H^ XNC+=PPQ 9:P2B<%2E<\ -X0,?
M2)@TE..G\AQH1YFN<X)=Q7+_W^$18 /5NQWWL+3M6-W3T$6.##U!%3S%7C9J
M';A4G<^+Q[TUX&?$"%BQG24S<0=22A?^^+\R">'MFR>@X*@L+X_TUK3A ,03
M;#L ANGFT>;"0(E=Y F*JT5%-YU7]16*7+$Z;R5C !_61@M <30 9@VJX5<.
M6#A6K2B2/\2AP4PYN6AM),TM<GQ(\ I83M\7??H2DEAIM'#VI6=C&WB^3] &
M7LC:/8B&81XR8D:N*MI#4-AA![!X4<F!/%+%V'AO*5@5KJRFVD,8%#877M&H
MWUJZ]/3.(@@_FQQ&M=;L(3=/RFC5HHXN)JUBB3VN$!;MNL!"@L3;5Q67XHUA
MZ'H+1$P)5+2H?C<F9\H&'@Q0/(;O+,)VWES@SD!LVK-=*M2V#GN[ YH7XLD,
M>.5 $(PA'8=HL2ZOZJ9Z,-\:S.?!3 X G:0A$WBJB4LW/^*)QD7@U 1W-3Q?
M0"/CK1_0EJ)4'L0$E20C.LR8>320_\Q1FPPQQX!5/Z-0E$4R-G%3R*(G8&'1
M#\>[H.V^V'OY^NB0<H4V;\/KE-FE=GK7PR V^CXDH;0BJ 7W+RK@+GAS@O(F
MTLF^PR"8\.^%*5!RK+50-07E]^6A0$.'L[EV^WLD!5+0^D!KU08 +K"84*(;
MHX32<&(%H:3.VEONP*]@E['R[A\]6(#P\ORTW17G'RD>=]&Z['7:]XCYM<7Q
M^=?+;KLRD!;AXJ)]^?'\\DOK[)@>^79^^;OX>G;2OJ2G37IWP_ZR:!W_?G;^
M[;1]\@FCA:V>:+>./^NT\#8%$R_;)SAV]_RL=2HH:[S5%=4$YVZ)6*WCX_/+
MD\[9I],_&VI$>-^? L/Y'_[D6?5:O\/XO7/*=SS]4WSK]#[SU"[/_]'!9.DB
M9&G%//FYRW;WHGW<PZ]W>ET[C1U67C?G=>;-G=^>_^)8-6U1ASB+R'_:^K84
M_Q(+E-E6A:GMS<>=5!O;^0?P\(?3SJ<6!<@5'[<N8!;'K0^G;:&K%WKX\/D9
MSJB+;'+9/J6O+,X9X@(.U=?6&3%3Z:2(W<[9\>G7$PJM*_;;6YJ1UB(9XL4O
M9K!/[;/V)6R(M>?K?6)?- ^7I5PG,DA5<,&BCW$!*[HNBZYA:^[LQ::P3D;H
M//&BF4D%![\]F./@ER]6C^#+DWS^7]2/%=EO<%N 8DQPIMH6"R)$V0'#&;4E
M V\X[U!9@29@JQ%!=YDS+G/&9<ZXS)D-NWR.'DJ#NO,*0I,<@6\UL#5<0I'$
MQ[V$\"Y]+X$?-++X_$TD=FU4[)A0XL(9WUV>QE37AG[[:V/.[_#U=SNR2-$F
MD\A3S?9/.:U@;W,W_OG/;SEI9JBG:8B_ MF^SJ/S_$C[?-"Q0\'"4K%%-<Y2
MN(5)>RD#MA:LH-MZM%L-I3;:G$'NY)I\^6IH-_7'<I!3E#+6KD;R=^H(!:9C
MW*G8-HI0I=CEI>DW[ D=]. T?'\<P58R'GR<C+PH2#7^K"%GB.C]@R*T]'QS
MV?'%S[.CV35$?U=A=^4=_%^&B)_>)I\H9<98'!'*BB2>)MQS(?$"RJ )=-R?
M89?K_(GO*0]-]:X9RTF*=$J5Y[N$V(VAC41C$GOE-R+R94X.SH)[54:#/<;F
M,L3+!V6(1G7G"&I9)WBE5NN?(C:UO,5Y^.+%JA.WQHM!U%[>"K6XM>C2@8'7
M'),@8:V2\VWH8L<^""AV8]7!RY!^-]U37400Q3PS.T$7N2V*<0]5=-AJ?8,R
M,QUZI81+JVF?AL8EDU>W%[.OAUTNU2,X6O@+MVZ@ZP9TCD SBW4?F"X310R2
MQ@M,IZ@]U?Q'72Q56/[ZW+OE U'KSF]+*YY%?X]=W7;CIF!PJ4>CU0]B1ET:
MY0]L2)>J:..4_D[V#K B?5XN\39IMH671#.OCH%%?@PZ:D)A:.KL8O3:Q79_
M4[VS2^]QN^H!]./]>"JIPKY0YQC7H9QG9F3"3*-D8Q9'6>@O)] 98/+PX,WJ
M4WHW^"DL?,Z$)**EG-]GIU9S%?8/K-U/I3HH6F<IS*E:H;:Y]+XOP>W<QLDD
M1Q. R$54]TITIYX_,HETE\6[K8][9C.L#<V7)[KJH#)/Z/I\7XOBJC?+8H1O
M<&E*20VX.<V^HHGB<W6#KG,DJ>;6?_E@L;IR'/3#)89IUYE82)NEM>^YFS**
M<=I6^IQNTF,ET]6H2I3N7\CQ/9T_-8R3##4;T];N;?,YPUN8%&RX U#5!U:>
MB7P:(]*5CSU-1]1Y@G+]J?>$N9BIY[/*QQ-U>:3KOHM+ZSL=]D+)*]UUI)8L
M#4N!U84<9@-W3;]/],!RKSZR;FWU5F_9,$BP?4@_4^Z,6WLX5IB'L_OKDC"-
MK6-Q53"TN0IS<T/4N8E+M2P.+(<AF-WMKW/E(J%W/>^CY;(\FP;<4)QN3=+Y
M5'&FE\K;OL14*ZN117-J:DONCVD*BJHUJ:ES6T%T Y,CE"/J_F2\TL8F(9-B
M:NHTT(BF0IL2:11 !T& Z#Y@U*%13+R!M#L&UT^C+['^0PD%HT%LX)%;VHW]
MN"8&[96]DZ0]UVD;5.*7&">B5K8;BGF]Q.H3:VIT-E1N+NW\[=GA&O][%%^'
M<C"2QMJ?$?WF@9K*?<L'$M%P@JB$L6/*0O (<C;L0JY_J[5< =M4GG.0KD)
M<X7FX)(I7#*%2Z9PR13K=%MA,G?1Z9>1<),$VX=3R )L)P8 SG7+/A.,,/4)
MH*9EJL+?RCMHW) 5.;S!MV!'M1=RQVVFE_G5+\X!GBLI,)4-/Y,5O":D7]IM
MT:IE\5+V#:,5&D6.E/3-3/Y]]3#)OV31Z$[AE HUPKP176$5)#KO@0P(&Z-(
M]Q%'"FAIA(T[ U]:U9KDQ/$EB+#! DJN+-ZO[2LU,32*O;3H9!IPD U-:];
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MP9 ]+%N^J5"Y(5JJP)Z+JK^T?H=/_]'JG%*MM'K\'-'TU7/G6"G]GU_;W9[
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M,Q7L78ZV^KS?+ #&4"R1>EF0#F<B@*^&<@0L:/=X8^.\Y+5R++-^_E9@F>L
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MG'GDXR;/QSC+O)JJ5[!A^0?>=W?U?<_.^4PF^)HIW.CWJ=]J[A@=K$D(66U
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M$<?!-4M47G0MR\H^,YKFXJLL6Q7S>J?K._7IR Z2);2MCOP8" "W9 R;$_2
MJ$X+G=DU*6 ',+>O4)8*V<@9:7&;N!AA_0>.&YDE:!G$OGDCMYTHT N"@^9W
M$?9X=I$FG/V&2 ,/<Z+IH>83$:/,\4!S[M\P5ED&FS>#L6.I;*LC?]84EQ+8
MDF9E9I([L;(KV1NA;&3$^3 :.H$;.RI7.]:W^M)!^LK)$EL)%C>8L)]#S]/]
MEY#GF"T-%8L".?<C;@A-EUF_OEZ/AL4@9$!GSF20(D1?G$1I3P.;&5=Y88SM
M43 Q6W5T2 -#D*JT?#P3?)_$RW/P-#7RG.B;HA7<*'9,[1$1B"PK]LQ3T4U
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MU#[- O-K!F0S!7W'9Q:KN[2BLAC!I$._.$IMH) B&X=IU)-Q>5V9N74L?:C
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M5Y^0&9[F8OT"P56$5)Q-S,V9PSMQS](<&PYW,XU7:"M:JSUY/G=/.HH8%98
M 5/!BN"'ZJ,HQ1U0[!R+_H-AK,O8W@@L6C(K4)Y2:CS6DJCJN7S]9X];$ (C
M"X98]Z<+E'"7534J"OZ;MP+S[[/ )VT1RYC7;_.3%,5P76\?'PB4Y*0>[3NB
ME. 7??I"?\"<<.003)L?(@I1S ^0^]-S]R401S_.$5B J/".,:C3$Z U#?&
MVBT\ 5;OK\ G]@;[,(QK%YD 5E:' UA?EYAN)*G#.Q40]J*;<<*;[_;@5;T1
MPD?XA.?2=4-X-Q"P?M#*9'G\HF(TN+HB_:HFIVOOI*!WOW-Z/])Q;/7MBF_;
M?'U;[2!7T[-!*PFB1P&*-D0"XD7V52/QR&/H-ZV.#P8PED3NI"29K\6:BT9@
M%U2U*EV"OI$!<3N-(=!5UR+ 3RP)/R8L7,3J%,/NL#Y%K<+5TWK CFFUP:!
M%=AW7.HPCQP]0;N&7T]*,L*Y6-Y967K:.RWPSK8B@3"P[+/B.S>??9)^_01.
M(BKA3_" JKBW L:%#]11UYAZK?;ETZ/G+PC'@32LY4LG:[5F\[GGJ4+ZH:0^
M1C/+%TT5*&C2(FRA9!2%Z7 DKCY=BKW#YB&NW<@= GO<IQ^=>$3XM)<?6T^/
MS(7=W\F5G6_N%\T^I#^UCID9P<:Y3-"/S9F5RL]M9%C^-1U[H:-P/Q1$&98
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M*L)UQ-?+4U6H..5G(3_'LF*_:AMD:?%VU\IV'4BJ/(.(? M>(Y/(R0GOA60
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M%%#MC1MD7?EF(0SRG(&&'@'!GN.[N[)AQ,R[8?CC*1!A=/-X"W4>$<#AT9H
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M."&)"GIXZB6DPN SE4)>,)E0 4>L/ Q/N7W7B4A')R%,G0VS)HA*TL%CL!J
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MUHC)5RM?6&"K0PEF$5;)B;_0:TRS(5;+DN4UZ/6 E<8%^35Q(E@S?#_:)W_
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M8Z7 #?KN-0*Z]34&FI,9;@,7F$0/!B%NP*A!)[F/7F]*PV?&<Z.X$3=&6LA
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M#$_IW9] R_LE$1*, 6EF5>9\N?*5A6,_E*"% R4?_(7>8FJPL5H65A*[^7K
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M-OV@:E/Z*4T0IP*KZV<(3FIO8WY>G\"S\6E2TD[ !(%]-^!XBK_DJ-QS%.%
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MWIP"<6HBI:8.D2B8/-30 >N"*[X[YN&;/E;""68*XQI"^7X;(G!Z(_%9]ZJ
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M:AVY,,IJ67D7PXNUP;C@E9*8THU@Z1!X*\4N[B_W&5I:.Y-CCE.Y:JPOE2R
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M-%R<RK9YYC94S0XL"-7L> &<A6; \YJ 1Q8U&)F!@M]M9@V3;37^PZ9_2Q;
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M)0  .WP! !@   !I;F-Y+3(P,C P,S,Q>&5X,3!D,BYH=&WM/6MOVTB2G^>
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M?@^B =Z&=?>E)1@'^CUL-%D[ND-*!1(\B\*=JWZ_QOZ0SA >#G&X>+"M%2%
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MWUDZ\Z$\Z>N1$67M,HEG2\ZT.(\TD[4$OX]0FUP?0$F^F[*6=*8I3EIC*6V
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M:)TPR, 4>_",81)043Y80+$W-@+>H*P?LJ7=?(,Z;S6K,JJI9TX0QHF\JBD
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MSQ3RJC<_+BQR0'S0S6%&\%!R,,4<#4H#F*AD;(I>T5T;E3ORM[.SM$Z$BD5
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M(4">I-@(5U\- 6!,9=>M,D-6I_ )ZCM"01G/G\B)HAB$7-=*<M+SJ@R8=63
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MQU3;K0<?2QPIN!EH*]@$N&./"%%0VI51($ SLZX)"5: ]1"IFR3044[;ST?
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M 14#7RGJ-H<9E6#0C[+UGT U7LA78W6X0*@%QUS5@C>AU&OEUNW^BS-N-]2
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MIQ*4.26+,7U3%=/)%/Z[OWV83HS1G3$:WS[VI@,@Z-!MBFY?+$$="Z!ASW0
M*X\EK0MS%HMBO"^:X=T?W8\?;W\&NL$OM\;@ ?Z^[9!OC#Q1BSM;O-3NUIN"
MQ2A?-D2Y-_G9N!N.?NUZ=0+;&Z9,6RA7TCO"Y"_$=NEH=L<XS)V,V -8(4J]
M,5";U_R1FB[L"/@<%OQ,W5"',-M'?'?LBNS@[1GL/@#[36WP!W(TGI&E(6;&
M+*C38)M*$U3<((8,*C>>L';C![_^OW2&TM!0[HG\ CI\LND$=0LMI&HLI#.#
M?B^:&4LEEF4&\Z:9P6SJ-E18N;$*:N\,IMQ@!OP91!5RW8>FOTEBGWA;#.-E
M&L:PO/&#YM !40Y$3C=,O2\&XUUZ$(Z T?6+,CC&4L!NQEGWN'7[A\M6..0\
M4"?G<0YFS9@4 _L^#6S SR#<,FC \7\,3IV2MYTA-#6$(26*PK-[XN"\LQ[-
M]),A(T_,UO-0/9NHSJ_,/"[JF8>N1K]:^E7CC&OKI_:F]LY4]F\JF5/P;IB6
M&<W;/1M--_^7S_\.X7,&:]F>4M11@.TG(:P79MNY*X+2$L6P_YBU1@AX&D0S
MU2#/?;;=(%".8\\TI4LM &/D+*CLPPX61"^?%RJ7*\3T_#R-J<]9(RF0MV%Z
MS+OQO1ZTM\N5+=:47E,.37#&-N%J3"43%C/]9WVA\A:#-4L7PWR1WFL%_(TG
MCYFQPAIP*/<K,?Q:#*RFPSL7;S_<'OR/$R]W8(H;\)F02RV CVT5RF*?Z=D5
M^DP#!M&?V%L];D:$70=6X\#DF."8MZ . ^%J1RGCI<M"EI=-0I;&#[%*NH[9
M.-0Q<83Y92%LBTJ%BV9G73?FD<&A&/.WS8(?D^FH_X^?1\.;V\?)?QNW__MY
M,/V]PWUWN-?N]'78E5E$Q5&@W"*ZD6'G0="M#".'2UEXM)$];,*CG1547:B/
MY)QP]J=N,BS*KEW%.%6I%7D>61&.L+]*[["BC/3"[<EGU4&4!]'$72Z)7,,@
MR^:<S<"@8?ULFL*%)2^?CZ'7F; K32)6L50Q@&_2 /I\T8FE-IP-$K(V5C[O
M#M$\1!_I,^5N&K/P>3$J%VE4@I*=SAN&^VN&\DL0:I;7T8&7!QZL+DR0U4N9
MA$6%I!9S'IGZ G.1[_Z[?5U1$Q8?WKNA4"K=OYJR*0;[,@UVK"+$V]3L# EU
MZ5DO<"M2O[J P-85=H90&OK/C?F7@%44[._47C-<5S$ 5P))O3!]!U*#L%B-
M>%@)6+4#81U>>7@-F8E;Y]Y<4IJY!DD3%&-SE<;&9V&0D$>'1^X^"WU8F+$/
M&HN&+@H("O$X/\O8/2$+PXSPZ/!H'!ZN'1<NP:MI0+B#, _"&_J46B3H9\5
M9+@=L%2GYSKA]BI!]1(<,AP-V:'S#IG\11D>^IJ2U_1P%7U5C$.&.\$K;#A8
MNM-^GO9A\^$I"C?R8RHG"R)I$H=LHF)$,O;\P,9@'BH_X#;^+P9L80R%S#J
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MKVSI+H,1N3IYP>@:M.I MDD;MU_\HU/%+L)<VJ_OV4N+%#;N@3K^M9^P(7F
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M>=#"YGS0T+'_6%>W,&TVI&]['9/2)<QX^+A?0)>4K*XT)I&U2W!VJ+H2WUY
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M$ETD["I($XS::1,*<*9S[8NE)*%"JN'6U8&\AO,;H3_8%CIB(5?- ,22);<
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MM]']56T:>@WKV,".J[8@H4U+;<5Q=QRSWW,(R&;6S0XSL2%LWL:(\!_["7I
M^-EW49.[.&Y?K9KEEUZ8I5A@<!=XZ7#:K@ZK16-)-JQ7CEN@K)TL$"$AK5KD
M5_A+_7[2["KV_0(])931*,Q(GN1$)OY3@.ZB!,5Z$?!D_JU&P-,.R'^V?0RB
MR<#=]C((:3=]B8.GW&Q5+(IH9Y;L8O$K$R((EV(5A!.E+I!\<35A,0%@!U(F
M2QJ?PR\.)#"*;U1\91@+E.(LR(6IZP&%9#K-)K#C=R<?5Z>PBQ316OQ@$=T6
M((3LR"QKL[#I,@=@U%PY/LYRP\Z6M\BA"TJV #NQ'POF,6DM.)&@BI.:E",
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M[3W]<#F\1S-7SNNV 6_D9(/"X+WQ6AJU8E[^^C[7SRHTY-__/U!+ P04
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MI0B3Y!OH_TU$G^$K!0X_ H?O?@\<_F?^YVOOB8:_(=#RT_V55J$?:[3R3L*
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MEL3/O!.SD'?>#MY!_8,OE_TXS<@_??^[?UW]_OOO_XUX(5\K0QDOPAM#[;2
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M^H''Q8,7PGV)CUX&8KW=;OH P@ ZV,%AJ&F.,BWT(X(9- ;K,ORZC>0H%\;
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M_IJNH^ 3#X($[L 89,OOZH,\FHU4KM]5:^F .)K-Y!Y\8Q\L#;.WXBC#3VC
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M!Y:P?XZ=LN>(;9@OMN<J_N0 Z9""@[B1".W>*.^>Q27FB#_6+S737$&2BL1
M<4YISV66>UWUS_>Y"40#/A1PFX:'@/-;D:=#1J(XXRO-'9.'?W\@[[RO!)[Y
MX@\TV:W(NR?E3R]QR(TH5N:Y:E04>_^M?+L.EYK>^4K[@+VP@$8!_#WX2APV
MGFT2+EW"M7N7?B6/Z-_1KX31Q$D-Y&39QVEV!D62P3!0]#UAOM#3V=D,>N=3
MARPA+!'2DEQ<(N1=$9E.*A=9;A47#B,_*L06F\FD%)PHDCN?,RSYNWDI+7H"
M!.#YU<<GSQED0/MJ)K#GA",*#=POU=0O0<U55OL2> B_=&V06R6,=')AWWC-
M^TE#J2Y@"69!.6M VYC5L(:SD.]&RN(<.I$:,LZ30!9F.D0!3<3\@@//M\70
MQ!E-O,JJY76$C/&/6Z\_B$U 'BF4367(UH700-I+7.F,5=7B4B:A>ZXVY)*1
M2QHE>L74GT@8K,U/8E%T(>,R'RU7BD!',)]W96(5_NX?/A%//)R"&?D=_#8)
M$MJ>]-W$$:S2:"#,.7""9T@$*0*.,TKSQ,V$PB(F:;T4L1%()<-\#8QXWC6/
M;:IK!7)_AGC%4RZQW!0+2 Q(LO;]Y$ #Y7%K3Q0Q(+ 8!#$U1C-Z=/5>!'(8
M*V$#-7)FM6?C^ !C5I-XN4E@/B)G<?# '#824;SGKJP"#U6OHC1+Q.2Z,XN/
M4<?% $67\LT H>NU"&#H%-Z&]]>KPQ*%'T)<F,4BL*R+(V$!^9CLA2:9N&00
MQ1D.)+C(G_R(+!EBR[\XN2]S9Z2GUNHWR[##8S'X8M&DS5!D@<$B4,NFGC;"
MN9!')LS)#P++BRY5*AT1[0O 0&SV/7Y^"/:MG^:AA- ;FIW3B&Y8)LJ:]=W(
MZ>B]&-@S,H-FZZ:MZR*@RDP#*YLUE,.'9"7+Z,T%+#SPGF+C?9K9[!%Q>^QI
MPN* ^9"/0AC&YTPQ0,-Q 7=(-.9#Q446'B"W03^HZ$MM,= QR$S-4-*+U"*@
M99A&-D*KX$PX:[DUO!(I 'U9SU/R1SBO<6<QWPM]*)V>7T4";&)YN70H5?,5
M()7<4\: 3NLH8P'8A+W0*FW9Y6>X[,CG@*(^]&Y_R/($+<=F[;'-;(_18C#-
MMG$UV]:6N"P"":TK:V4;7!%*R5-("K'(1E:$+P5K1E:$,(K2W)YJ;B79(:V9
M&T[^_;K):6%R#!!,GV$M?4\A12,7JJJXR<THKH:G\C-PB;QQNG[B:W#/SW3?
MVTB:V('5ALEJ&#J&(&:XM*+7X%"5!$G)?D7JY60OBY</E1"DD(+\4LCA"ON<
MVNXV>?:BXGT<S+"+VJP.*QL>=D\TN=W<[D4AUNBY4%ICP+;VR &F4]5:44)=
M8\3 T"WSX#*#@C)$=TF[C&E'E01GT#4N=4TUNKI8T^DS1@%F=<[Y.KLCC^*^
MAFA>5;7W11SCO568,GW:R2 ^.![2)%-B@?]V' ?\3Y K+3CXV6WR0),7YM/U
M9W8\3+4T0^K778J!_^K:(/333E%'^",0E6>R.6&83W+:;MP0CE,+.=['.X\=
MOU[H:HO?(?4J'GGE:4/<KMDB[VC_7-?\4U*?>;4SDZ:>B:8C7J+]:?WG]8>K
MCQ3F8T<:-GV.-)ZTJI2/N=0/L;_&:I1UJ"?=5V^G6+2)DYU<&<.\@[N2R/X0
M$\F1O$L.GV.X7QNQ)Y$?@<2)%Y(_>=$!\E:GL<\@,\2O+()7^N]XKZ\XT2U[
M8I!'/XW#@+RR;,LBL77X*1*Y'1XRZ -[O#N:,-^;^=V556/^B:S)G_E_'\@5
M^472=)%_P*Y.@IA%2+FZN/[T</63'E..&V &E49E2E2I?8H=5IJ%G117<I90
M,B4'C1(N9H8!N\I?D0MR33Z1!XX#/[E$ LMJ26H6L>"H.LF%*/P!U4DTYS#&
MG3!CAK'2)8YT]D XU>\I^%"?/"GA(WG("CZNCCI<Z)X>*6\S2@75R\][<4IS
M#4FY!,MB _@J30_\W^*%NIS8B7E=^E/\0I,(QIV?#IY("<0_*0^4&\TV(3/4
MJ#"UD2LTF8H3]AG.](I;F"V)XG+E^0<3(E5EY&1..YD83[:MJ@CE9;-HKI^:
MXN+3 ZDT(,^E"LKECIDG7'B_BQQ#"]%()1NISJ6D>.16,;&RG$U5:U="*C>7
M7(Q':"U^HW5W42\QFL3?9QP?/_"U302EZZY$7@60::;!TAKG)8^<=LUO/(S:
M8;OT,=6R%:P/L)M"/E&"30KXWW"X1?(UZ<?>E3+XEL*22MHO:BA&\FW<&$8)
MLE':SFV?LNKC#<TZ;@5KFB(=,TT45&_L-+5#N-]D).[@G<^"Z$H\#75]A79:
M'6V>]10TH7)&NJ7!3W$<I)]2NCF$UVQ#/WJ?V>ZP:]RZ-NZ*-,Z&&* Z.3+K
MAWUVV%<-2].[G20+N<LY(SXN;<0)\XY";O4H8"G_-2'/( O9TC" DN]5Q0 8
MG#+BB<2B7L#"MZ/,=*D7SEV)>2X[5C68"T9$<"*2%0%>)&?FXCAK)C,\<*?8
M2+>!+WQ3V$)Z#*L&@UVS*48@YL]>PL#3KOA,",I+B!<1?"+4=B!FT <S1IJJ
M7()C5P?LJ&@L_U#_C;[QYL6GR34J&)"" RE8D(*' SQRJ/8,D".7?WWT+GLL
M$6[JZG:"C6R^5*@YDM[ZMEI+O'HIB2,2>-G<DZB);=&BLN2 "* LJ5QM$-%"
M51;EFT(OA3E880Z8:;O;SWG/TJ)*HKB/<4_Y+.Y KUE$KS*ZTSVV-.B&%.SZ
M*J[N^73U0;S_8RSZ4*>O,Q U$B0+\@LP(8*+HXVAR97/"4ZS:6Z0_&PN!?G2
MWX^?(P9<+$ZU[F@"-[:\9WJ[^4@#YGL)O?.2[/U5E!X2C\?R!6R(\\]_\O;W
M].\'EM#@,3ZG'Z#81G#^]M&+#AL^LSPDW!6:$-\Z!Z3H-J$YRZF?7?+8IXH3
M:6MI:KDOI0/$+>0C("!YS^<8N8C$SV4DS]Z>[+PH$+5*8_)$R4;("7M].U52
M6=:3\_(3)FM]!<GA.97O5:#B:<ADS>H]-QW(,_.T%=GW4HE#;D^_B%(F4@A%
MN%2D$(L\QN2<$BD9.7\C-=D<3)#Q&M>REUL<Q#KM=!7Y">7Z7$67>>S<R=!Y
MV-,(*OQ6:C9])Y;I8Q[ IC!E.7S9)(Y]\)I$5TM#EV$8YR,<Y+(4DHIQ*2F
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MC-V\D/&)]JUSQ.Y>V&/83.U:'+=WP1S+AI(/]NZ</FDZ)W$ZCW2HN<.03FC
MLIX!W=$'>SB;J%P+YK8.F$/92.[![BRH(PQC-UK/_0#IO^*D )14\P"ZL1'2
MX&Q7JGJ/=-P"8?AU"#IZ^'#Q3OK&V]';34VKQC5;5UO$WM>I8N&$VH9(?;%;
MWL%;UYPRY.P4M$GEH$Z69M.JVJG<B"/0BSCDM&(YF-QY21;1Q#N'(LKZ U"#
M/DACK9?*Y>%G5P?L1Y_&\@_.%D#S5&5P=KF!8TLQ-=G3)./N*DY 8_(49UMQ
MKED3A^RE/"E9K\BY+#$^\S'CY.:I*UQPX-JN05N71XQN5!=?]8IK#M_V>YM@
ME@/EN@6[3IJ@AJIFA2IDJG^.'H@TXDZ*.P Y?C&"KN?&%LL:EU.!M5/8F$RK
M"<#@O!L,SA<%!N<=8'"^+# X%G<^,#AW! :V-"[#YAP#&-C7:@(P:%O5G#19
M AAHURSUSY<"!K.N2&I@,/NJP[+&U0D/!C"PK]4$8/"^&PS>+PH,WG> P?ME
M@<&QN/.!P7M'8&!+XS)LWF,  _M:3;%G<'ZQC@(#2#ANN 1@:%3N=!=!;;44
MD&@6>C:H2.N;6:ZV%ZP:0=ED..>*P2XE"AR92LNQNY$374Z][LA,V-H!*2J9
M*]MZ,_5Z 0D&#82V^<S_VG7:P-GTS1^F(8K4.UE_P'NFWYD:I]YE:=':H'!K
MO"KMEQ2Q36+;B]D5J>@C"5F;"E>T\F)NBOINX_<J>N&BQ,G;O??ZT>-68EX(
MCRIO-_=4/H_5V,NH(_)8-E=>C>CN7HCCNH?P0YV]9+$BG DIN:S$(V+N_P4G
M-X$^@P5 [5U!&D%L_R5.?KV*[I+8IVF_X&[MN93H[E:_,;SUW980WP;26PAP
MX ()$W(^V$)\0B, Z3,6G>TE<011_H%%+-W20.1'Z!7EK3V7$N7=ZC=&N;[;
M$J+<0'H+45YPD4E!L 7YA#8H%1>9:2SNM)?"<WDO#DG"?UE'P0UW=_E+T]:?
M01^DL=I+Y7(KOJL#]EUY8_DM;-##-KQ7IESRO21Y@PWZO$(RK#DE3[&Q&Y4B
MB)(2HL1F)$/ZI:PIF= B.Q+O4:526D&V)*C=S!D^>2'\C? (X;TA"RQ\PG*U
M&4UG/@&8W. E X& %XI)*R;S%A281^]'8*]^L>YF.WPN!P=0;W=<%=#R\N\'
MMH<P[$S#8M83*8(.4%^=[1AT0SS;Z2/]X!VZG,>*""XBJ$L^*QPI6[1VZ$S=
M8M9SJ;[?GLK%H-L2?=]BHI."1^[Z:]7U,21YF=,&K?'O//'+[6;#?%K*U9H=
M0M<6>92WJJC&=6-#Q)'<+N]0OY54E7AUF_1A4B5I0=9= )J%WN*"SB#<EA-H
MMKT/2VS9UNM:/D:%Y2R"R+J(=_L#MX%9A.E;(X^T#C7K-T<:FR*.O"Z)A]\7
MD731#'.3*XH@(*_Y%+@U!FL-D(?=J3)JI%6?(@ZN!B&'(S]?W;B-(,O:6#R:
M.3^P,&#1,U]H7E/.8!N'P=5NG\0O% (RU;^*,.Z)-%@&J%\>UIAUPWYDTU,+
MRR\K$@JE)?(,,;DD8B,B+&0A3!%FYM.5F6Q3L!';4"4CHG)R^?YB;BOHOWZ+
MD'>[IXGP/*'2/7O>9K>;3RE=IREM SS#?ICAKH_J)=B9=,(.=;UT&''1NRP7
MZCTG5'@NR;9>1M*,[46%8'EX'5+.EY*]]U;^&B>$8R,YR((_7D0\$(T<HH!/
MD.-"?!D=,V/A+,8KF4@8)((-I/GCC(CDY!()9[:!^)I) FS.XLT9>(7P!XQG
MT=<=K]6,.B)%S?[*&QW&72_@%5L/X2<YAD+PL&U&$PC=:74$%U&'FR%:O45Y
M^[[&*CHM-<1K2AN%M^BQQ-"N"S[1Z;)@@BR@[2I^K/'S9!J_T.0I=JKS19SR
MF1E,77FL;5E&^?PW@0DPX%GTS(&2BDJ8:78(6'[!DD4L8[P-MPN?WY)]0O>>
M?!_HM 3A82>FZ,%[V+#PF1"(_QQ2^(%;;KV#^Z/_D"E3=5;5? L6R2/'4=N&
M/"J):(4V8FRVKN+0P%8$(:HD*U+*(H)9E69%CK!_58="NQCXH[1F)*Z!!VT8
MB,:HUWRE3SS%LH$BCKQ\KLCA#@WOJ1=>IAD7,;<%A^Z6V\8MS9&C59>B*OKH
MVB)&DTZ1AV_J\_%;4BYCGMR^0C[W+=L[OSS<I'?KG>'6#@OT8?T-87WKA?FQ
MI;NP#9X,\U2WEX#QZ#OFH$5<9"P.=SYR66CZ\,JR?] DU%VWZ-41:5SV5[XZ
M:S'IA?ZPI9<2$QXKP]E*+&_3EB?,PH$IK$&)E&Q%%-GF/EF9Q5+YA>+RE%7R
M4=5V>K+BQ ;-7[]%\(-[.M?2U_["LBV+_GK'H4/AE5Y[P#][I/XVBL/X^8TW
M^/4J^NL+38(XTJ.C-<J8X=.N^4I\M4,6.P!;UG+2E*H"?@I0YA)NR5_/[M;W
M%[6X_&W*VPF)25:*# 6D1#J67.J9L1N)D<7MQEP.(@4A?X5Z2[YJP)3DPI!*
M&FCT*[DJ[>=R$,!D3#!@'Q=<%09T>'M9W"?YP"+(4"!N*#S29'>[*6ZDZ))3
MFO1#.DKT5KUV!;JK$^*EL+GL8S8I*16)<$3&"\%D18 -W$TJ&#FZ2CVY^E?Y
MZ92\@\,%VF$*[,O/+,TH_^UV<[N'\?0QOOS,_Q 8VZN-PN*"O=,<[6&O[;XH
M .C6PC(4E P!#R1+F,M)IN27+#E0LO'"E+IZ;S&CB22Y%/2G@B(FM+BG$7WU
M0H!(\SG 4:?%84*3TNTPH/985.0W"FXYV',>8OS'$LY6]2X4S/()CG)W.R9-
M6:YFO)624 \R_!V=!KSISKGUS9%'<9>BM5L@FK:(([=3Y*&^^_#W@Y=0\B&.
MBWSKU]5#=UC-YAN?=UR;+>]Q,CK-$\%3Z[^1^KL+5!6<KIGWQ$*FC5)=6^0A
MVJJB&I^-#1$'9[N\([*IJJ-H2=A- $ZI8_5@)<PI-R1-G.NZZS2*WLF-;)$Q
M5*!LI[XCCHYJ*L#_KD0%#?;"IST^92_>4TB/M._3#RG,]%:]/-0QZ83]R*:7
M#H,SFT+>W#))KG1A5O#A,]V"$8%O1)S,A'$2Y&\0-SF>B6YS/\>>Q3S'B"WL
M4S(B%2>G!:C2+#GXX$8BU3]?JJ1IV[.<]AY(L:"'ND?5IW3-$4\_3*0>\22Y
MI)U7KA#4G;["F5+A!Y91]4')B@0T9<_R;K6O6L.'ARL.W]AY;R*QP6.\]O]^
M8 FM%D<:L[7W0![)!NK6GM;IFR..9!.I!\] <]JP)Y53)\I53D?OZ:94.-^Q
MX-',?(=#KGSA#QE0JLF^W)!</Z7BR%&WYV'2$7G8FBM?VZ#K[(4XB'L(/WA4
M]O8,:@S(&>;M4\B>/7F(]$O!8YJ#,X/U\PSJ7]M8.]L\,:LG]U"."N_YW"$X
M>.'/L.S_Z<#G%%%&=>/S4%K((6"4B4Z/W7H20@P4X_09>TAWE"_GZ$R^8$X$
M=U*R;SV;1Q-V/2ZVF--8=IB97FXQ)+#<L)KH@DM[./6ZXC)C@82:D<K=[HO&
MJFK&G9 'BIG2M=H)K3T0AX*AX)92KBEG5*NBW)>CN@ISZ8WFU,J=QBNB*>6&
M!<8>8#<!=AEN-_EQHQ?>Q2D#1!9HG+*GD/=*AP%>+_*+AL;^AC0'47/:BX7;
M 2I.",PK4LH#$Y12(E*(1'ZIA"(@E<-Y2N.9O*WPMD8<>7#;-6+G?9TO*; M
M*VC[1M R@UJ#EMJJSGWZ(0]%8]4-!E T%9X'C(P6B^ZV#7E3EQL>N!R91/N&
M^7FD51]1L$\U2Q_(8>D ,LE<?0CY)8,2DAE[)="BQO?&29/%@+=)'WFX6S=E
MY^S]"PMU^SK:G\//'N9=Y6W646#R*L6X$](@ZZ?T:54;70_L-\;-%;#XZ $.
MRWZ;DH"E/EPCIP&)R]LK(@FXG+_NB\MJXB)Y5;T&+F'6[I&[JF0SF<VJB0!4
M]*JAQ=1/@.+,"YN6,3-I_@C\[;R+F6+-4EQ5-)I,*HV1HIZ9DOI%0=$2\:#?
M(;"UJ7I!&</F@C4M+[QTRV&8!0*58_W^ HX%QA4?2[AYLUS_VZC/&]K6SLCC
MMY\1=/-^?4_$\=U3 4LS]H)3$?:$3UP0O<V=T!!U2-CHG^["0Z$*,7SHM@GC
M5R10H=Q++M#R_:'K+GXO @N"##-C=&T7-/=>"'08*F%_P9]S6Q'.#L'%_1EM
M\M'+#@FW :P)N2KU)1V^R47YG2FVZ+/15.^V0'1H4KQS"U'ILS D:!1]VOB?
M=T4_F_+JFMZ7TX?FM9*;P/X+A0*Y-%AS>/2>Z3W=R;S2XL.VG'>]B2PHZ,V-
MHH. ;@H+ 80>BEB"AX(CR5F2DF>^!^@NB=[,ABDMX>66D"@".?961[E$L&P1
M#H:3 620 \I0P^@W'!<-*H-5L;9)B1A89C=.*[0<;75B!9?W^0G:/21#I(EO
M>E_2B,R2P:7%,,;@TD!CJ>#2ILITX%)P)<"6KW0D8X3P,H5Y3N"E..TFB; &
M'H1IF=*9XTMO(LC199A1#-="RT*6@8I,M1;"A"HSFZ8+4W NB"YBP^O:>4/D
MR*!73C^S@%:(([Q%6&NS Z"*8>BWHMWEYSV-4BK+A/)XS&)Q@H%S3+\'T+C=
M?$JIR,JDEJ@W@+7VWLACM:<9=,-W2U?$4=U7 TL#MF!U%F_..#,BN*V(RL_]
M2#VE,51B<"GD]& S*>QSX+]X(D\:#IPH+HWDX-;CFDG58T%XH%&WZW)4WGPA
M<:^3VO8UJ)R^^]BVK7"I(<V'?+BACN^BPG&BJ[8(UK5%'KNM*NJGWOCCM5U>
M2Q/P5%3@*@-U16XHBNFX+76%<K09A<85T6 9O68O?%T?!5=10#?57S@V<&'A
M^95,=WK^]M'[KSBY"/FH_MA27F,<1:1A:M%<:DF.$>2P/[VRI-WPB,GKJA,I
M"!_(7F!K2=2N+F3)_\A*:?(9*WEZ(SL0B/@@T?QU/%Q:+K>7X"8>:%42Y'^L
M9) KH)2<OQ$A!A%RD%^$)&[?99L8;/V9Z=XZ]:. %+5&F.-HH6#:'?%$9(@6
MXV+H3!<N3T?A CQQ1DMEEQMO1]_'<%&AOWTU5)8;-6UF,8R<)A++C)Y63:R,
M0J<1I(8/<"6_2+Z.:FF[L8X.7U;FYID/9&"K(0RIGQV\L*AL^I'NGFBBL6EK
M!^30T:VLBA+ZUH@!P4#H,;M2!6E2T":_2.J.(GQ"=:^9#^MZ'LAW&-;VURRB
M5QG='<^,[5%%&KR6S39^G5^2_&+7^J<:6EOOCUB_+F6];\]Z-M;\( T1XLP,
MT5B,>'6\C>2P'INL-!>TS$N/+G1]2NGF$%ZSC>Y<921)I)AOTV"UZFXCZ"&>
M]%E1:_#E@YQYCO!GH6[U<W*I4@I!0 IG)>-<6DYOD!>:DG=_I5Z2?H5R_^F&
M9MU9*\PZ(T>@?D8PW&12>B)&E9X*3+5IPGE-G:)BS$;2!*;0''_] 244M!5P
M-^BVW/#7EG+OZK/,D+=3X[PKV*<K[6Z6AF9:[045<N$ER9M(L[F#9Q0HHWKM
M^X?=0=PS-[NZW9_0<B._PSB&6*"ALDQTZ%)F*KQ0^.*X[SVW@4P-@ )5^%QI
MT 1KT6BA*&V^/%@F"JB"3[@<<):Q:DJ]89FSA)G!AT-V2*@*-?EMVN$; B8D
MEQO_Q@8S1(=.>LO$#G.U)D26^J.QZM[Z!Y;Z7DA@1XZ4&201;TI,;\PF.Z'$
MJP8CR,0^ 4V@Y@I\L?"]#IC2F5->+GKU-9_IXL>0[#*QK+=VDRV/&M&LE$66
M^"FA#1V,S6;'FD7@TLY2H RT?WR-K9BVHO5%P=61B88#5$[HBX&D8WWF!2$Q
ME^+LEP ZMBS%D>6[12$+9]_R)'\@M2\/750SC<07(/5E(4Q-(Q<8 P(L!F6L
M6(OCS/=+PID/W/363)@3^^)01C72.) !2E\4QM04<@ QP'\I"&/%5AQ@?E@4
MP/"V]BPHB7UY *,8:23 \+9?%L"H"KD &-YG,0!CPU8<8/YY*0"SWG K6D69
M8XI?%-0TFFLXWM3(?3&@TZS5O,CC@0S+PA^[9GO<TH0**[B#HI_B.'AE87@?
MA^&'.'GUDD!CJ>:6R*&C13T5$AJ:(0[U-FD'7QW-:9)?@"K)R3HZ>9Y"P8LM
M[T=3R&KL%]=@/'$-!LYDGG..[@/QCB8LYECD)Y!)[CV5_W882MMI(>'9KG13
MI#;W6$#0=@@^-GY%[0#.@!0<R+N"Q\E3KWF#>2+%E;C.ME3&-JK ?O"W-#B$
M]'9S+Q.KWWE)]O:8>%'J^3"W2,_?:I\T)%D<2PLY#(PRD8H.@P@A!HUQ^@P-
MJ8(KQ$].G0CR1.6\@GQF]8^=)P!\Y QN-^LD 4R W!4MJ?YT;9''2JN*:BPT
M-D3LZ^WR#EYC<:K@QPI=D0WT)H[./.5OJF<[S\RG")NNHX#+JHBJ2MJ:2:L_
M%>2N/] LM00-_4@@#I>AF@R^D*OP$[EBZAR/ LAITBZGIND&EQ$Y^31)OV[B
M%S[^LF8X:&Z!--1;U"D3:]4_QIXD2R/MZ(17*0EHYK$P)9"4+J]WRQ=!!3_R
MRK(M>=W&._)*R=9[H82*L@_BY7],/'(1AUS0.)';LN"W>4HZLGY.J/#<F5-B
M6;95:0HW<#2E2A;!XZ>7;: 'CMJGF$'C5(T2,*J/L(-%@Z06@()%FSC9R3"O
M@\5//__Q_8J'/ODI\3;9V<_<E?D@^L<XS: BI=@^VC :!C/C@$4S "F7\6]3
M%?YE68S[/WF_>B],'_E'GV.._295RNA7/\0>_XVR3HH ?UK_>?WS%7F7'#['
M4.\I8D]?"43@\X*0_,F+#BFD!XI]YF64_,HBL:7,>WW%B6[9$^/N1M(X#$A\
MR%(64+$+^PD.50/RD$$G6'WO:,)\;V88L6I-2<PEE-A51WSO%N%D[6\9?1&S
MQMO-1Q;2-(LCVK#_UMT:,]1TJUD"C[XI=A@RD-PR*#V]D8!M-GQYPI?+W.GH
M<YPPF@)V>)4P\.NN$&?N?+T3&F5=5[$D/F(CLE>4-A;X,&F_O$@]+=K1V7B9
MT6JIY,3[14:E)>75N+RMQ:63LB/S*AR;*#P"BNX2^K"G/N,+S.#R!48$_5JD
MI2UF".I2L80?74/LT-,I]Z1K%U_^1GC3L[00@U A!Y2TA94()\<$8+UNF;\M
MNU1X1;R$%F@V]S['9.;CA$E)F4C2+I<N4RJJ?/62M$6,>L^=(HSW$ ,E%K;
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M(>TW8Y]8M9(?L@\P;CC, &9!49U;E"/&P@Z*-D2S%/#EDC3<UE.T)> EDKJ
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M&[J3AQU4E9=6.6E!S3C)).<D!M;AX@*%A;PP;);E5=TK$*DL;W5&?KSPX(5
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M10;7XF2O.KK"ZY]%%KV5OA>_>:IOA/ _OC@R-+C^?EXZOE\*T5W/0^6IOO'
M__B"!X.+[.LEBA:X8_T:A3^2-^)TZ 3T=E'[=-]X$0=1\&-DG9V+Z WY/H^6
M\D-5(!?CX=DY:#:XWUZ08&3EG<]"PN62G-6$[O?,^WJZ3DCV*3)_IT_ &(7Z
M1I(TEH(T(^OU? IRX\6NX_\=.1'=!8+V:'\(DD)0T&)D'5_X:VP_]0;_IF[P
MISS9'U)D !2<&%GE5S\T\Z018Z7T;%]YX4$HF#&YZ$<D;HU_&\S0S_]$]!G
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M1V:9YS .CFDAPN@\=\_OJ:D=R3@=TO)4;KP63GL<'/^-6[H40JWA,PRU>&*
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MLGEV[R3$#A_3N8S,9.LY(,DI,0VL, Y=S]U;S]D/1VXM;:)JQP'FLO#&"YS
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MMPB\N><Z>U'\\'Q ;O@;[P]_^6O(;>EX^Z*!LWG38)6_JB_C(3_JW4XKHQ?
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MCT:GQMD3I&'WW%D$&53J7F[O^=SM/60/>6+0>CP\RL?T,\EGXX&0#85Q,<K
MZ-<L<I_I9L:V< T;D'O#%I'[O( =N:_\=W@$,KZK2B$?1Y]);!Q^L6<D<G'
M'-E 9$3LW3C8"!WCSJBEJ0XA\"I%D1C##*0P>VH0J0ZABH'!9LV1NPQ22\30
M170X".)H- (T0JGU^K>JL\"'-1$V">>3KME?G&B!ZF_,U#\)CM]&5.UL8DA
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M$N5I,,Q*4++/HPRXSK+C21.:#DAX6"!;S<\H>O=<<B-V7@,N)GF)XOH_,>.
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MM'?:-NR!P;;=RM@U>ZA\E'"OSRN.A "@QQ:@8Y]#<6APJ000"0$ _>),[JM
M!7:H#L3%H'CIA7ZX\%QV& 3ZT^ (5T':SJZW)'JHE.L)@'""Y[A]ZN*;@+,B
M ()!HIK87(@Q!DZHK5 NY('H=7^8Y#+HV:%7$B=4<KN/;M%WXENA-GY)QV!T
MB[X3WPRN!@=IP-$M^C:WXD.Q(KJ%05KX%JYA _) :B2Z!00"&=]5I9"/ R:)
M,.^J]JU+;852ZYT152M>SJV88':+)PHS#Z/?O4/U$EZB)^0B[QTUN6PD6#,X
M_322PL[L2Z-I>GEW-O-DQ;C"14".8-.U2 ;R)HPJ<]U'C #-L;%G&].(B*_=
M&ZJ6/L66[E.(?T$1:C!1+]+/='^ATE(!28'7L101)'BW3Y6CF%ZZBO/LZ-ST
M88P.DB7AP\HH(RB0>K_%)^0M7]?X.V8UUQD;UU.QV@69@([M$TUC0\"Z*RLL
MGPP765\09$*Q&O8*'8@P1% KNO"J5P6E^#:SM9M<.<',FV&#\>+^5!^VDG4Y
MM%JON8X,^%?^7\?#WR'K77DAY%V)ZQ[@RBUTKNRG)^4%;@''P#TI)=TF"T@"
MOG;2^P,0W29-4BA!QSZ'XM ^W2;I7F@0Z!=G<E\%*K ;/]*@GNS[F.DP<O(0
M<+N=W1]>\I:-MG?)C'76+UT-.(FHH'G/)T"-6:"J1XL')@0M2(T63< )>&"J
M.AK0YH%I?&8F:7,AQA@XH;;"R@90X6^&>YNM1Y*DNYY@+7T0 X/.'3DHPF]<
M)(I7;3QOA?T'P<BBU=1?$)?!0Q?0?@6@>&=3J-^30&/?8,'AK;528</MY4F^
MN7,\:T32&'HO8VGK.+FS2 HB.+LY\._P].8^C%9O8?P12Q[@C(9"!SA9]<\?
M\><1#I0CG-/Q:'QAUQ%.#NE@CG ,4BA!1Z,C''$J#_<(!P#]XDPJ/L+AZ\/H
M]M]F.)TLZ+M[>P^!HU<%13OS+3'0QGDE]<9%+Q$C][=%^/[[#'E9!X%_V.T7
M\*_^<8<6CG\=X-G11TW'7O,$.,*ENG-10#HB6S3B)_O.VE.6W3^#84;4R%5:
MN%",-S!JR""R9&$%"=K^'11'7(OO](-<(,89:GYK]HILLJ%H1;PI&6G"ZQX#
MPVFC'E$*%;!KZFBUFZ%C%PDUP[=P63#L2A%5Y;<=6..M6O>$=62.T';,-)BG
MCN#RJ<<+J&_]<1-PC*W=WL1ANS@S=_>RB<V%&&/@A-H*.P_5!91X!G4[U+="
M#54&'83JZCWQS> :#\[69:@NDQPW7@ZQH3!NOO8F5)=)6O@6KF$#<@]J(E07
M" (9WU6ED(^CQR0^NV]HMO;1=%Z?"V?_MP@Q=IC:5 =&(HV[7N7H&3?4#?36
MM,^G;E.Q"X#A6PMU564TL(3Q3H6VAL:S1L]U@B]H%<9>XD0?65)Z^L2:70*4
M#!KPM+N4E@=KG&DU#AJ7CN\$+GI^0XCDFLXHH[O;T!X'HX=6'C=2Z!BA*0P[
MW=3!J.WN^07 \2I%D1C#D+MS15Y8KANM\;=Z61IPC]+O\QZOFN@<MR* 8A#J
M]!LAM40,RN[' 1! HUY>$%=.][F!^W';%*;3^<TZ64?HJQ^^.GYIVS=UNK]9
ME]W-60[9<C7"Y9E-V<ZL3H,1/N_!U5X,LT8B4G![>0]N,IMYV7?N7@(5NN#$
M*&ZI)&01P[KLIF;.8"9G>2\UI :R#O<*E5+H+M6X!2)HA!=6M%N=W<AD@;O:
M!;9PS15LB9*VJ48>;&<'#_)K3K*;^ACAD96VUMP\8 ^-'$Q:0]NJFCT^)Z'[
M_7'77_0.__(;&<*\L'81P2]5M<@%MLAISUAN Y2QM0"'^AO'B_[F^&MT&ZS6
M29RMA:9S<O^8_'031G>.^WTZOW>B[RC)-M ^ZM30J")+!*(.>ZZ9"QB:43D?
MV-AH>[6=.0NH>;[_:FD&L=B.&K94Q3N*7L,:79R:T<5=&"Q>4+3<3GYH"XJ:
M)^W1@BBX0@5 =B55I2"L"S9T_7-%-F<H:F"6L4<7\C +A;3=JJ3U$X8TLG]\
MATTR3=Y05/J5\"%G35E[--,<;J$=(!N:0M' -R<^43CW$K+'0A9C7K!X(G^O
MOT<@7K[_JE #N5"&GOA>(QW**.&J'TI$BI2-<3P<]G"+HC'*@G+-VY+Z0KJE
M*_:K<$D@9OXB,I'<1L/A:#>26UKCP"U5J3]ZFYKA<PMC.B^;)$_SE)Z%IYM8
MY -GQ:$7)0Z<FDJQZ$Z.SX87P[.SD_/AV0G^7T,[EAO7XO1C+YTTON463CGF
MS^7']IGBY/B'$\V8,>=4U0^N,](@@)J]5:WFHWIY&)GDIM^*W\)PRZT\ TX1
M>LFJF>MRK0&*X.9&V0(-9H^^$U#O=>A\%3BY\>FGG-5T81A+G$BOERL__$#9
M=&J:@F"Z%%.?!Z>>SI10L_<K921+E/2$\,#ON7AFD,+^%GA)_/3\C:DF9IE/
M1;4Q%,Q0 =*J>D31/(R6V>T ZD4WSM.?2FIF(@T>D$;F9>O7V)MYY#*@DTY>
M21-B3,*IS\/34<<3<CG+Z J$JD 1VZ\G#6@Z+P7W9<^[N07A:42*LQK.FT&V
M9%93F<J)SXSK.M71>'1T9E@+S;CDS' 98"U1P6W@ADNTW9WGWZ]FE("GBHY'
M$5G;4*<A@*3 '#689<#)098>88(9>"WI)Y@.';R5,*]D7X3"H%G2!<;^@>49
M^;C.Q5<4H,CQL1$FLZ47>.0()?'>46X']J)7J@XK1=3> I;LEI S.3R*XUD>
M6S)[SUDI"S&4MFQR\*9NM)G;'2]Z1.N*P8FK\VT3/2;4D)71R+FXGU:.9O5F
M8GL*BQ6&IT ]BJ@Y0F]N'^-3+-95MAH05\[*2[(+N=2[;.QBAR>35I91-&GR
M=3F,-K;>YM;.)([7RQ163&Q"SM\F0;#.;'(31G/DD>@S3[B!U4JNRP\X5/$:
MM['6."&&+FXIM2I>D&5WX$,_7'QPW$X[>//AM133QK5DIJK4?)GMOL5[LQ7-
M;[-'_2U%J;EY<"QN?'8-L$D\>?'WFPBA6Y+$#,5)S;RJL_=621MCTH:?S<2D
M[2W9HMW>F& ;[U5FODHNEX]8+47+"S^;"+N)=&?T0]_#9EGM;Z&/JR'A6+H:
M3NK?_-E:NAE0)*Q_Z,N2[&I"_!4_F,2W01;HZ@_D+=[('L@[BIP%2O_X!5MP
M8VO53:C95WPV)_7-22$3&J)>]JIIL7JF+]Z[-T/!K.OQJ/Q>>YJ/T3TP8=-:
MTAXV?K\H>O?R&R3[MBP"G&YOD/."#;2N]W#UK,=TC!"TO8U$)F2IAS!+/);=
MM(I?PL3QRW\G3D4/8?)WE#PA-UP$-<?-VM\'3NQZ--A0Z\HLJC5'R)%E;2";
M+-Z$4?XK\AQM2ZK;C_AL+>;,W$UFE0ZC3&5+I(F;X E?\B$;<VHL$'/JUT'V
MCH&3O^0S"E6+2C]#3@F[KQZ-1^-SLSVC&@EU$%\JMQ5CAE!T4F>&G&K;!9L"
MH 6]S-5XRG*M(<"VR;0<MD2> J ]OA8:["NI,HPEGB.:(D\!4$]G2F!,^86,
M9(F2_H;7+UZP8(QTI2?@J:7C<8YG"[A16_(O9PY/E6? <<VS/94M^X<#BOA3
M=>,&@!O)-&!?H9>H :HPI/KZMG@/1C@O/\*6PMG4<"#"8>.UR1.S#S>F <BL
MZTF*)A,>NI]D[N S72=QX@0SDA0D]/V;,")_U.375?\R> K7HSCUWED2]K1[
MA&]BL8>U_#R@^7OL$;F\]K0*GV%>19I?I4><SXD3)5#<5]2Z=7;BQ5MEZ+C'
M=PTA-  !VW9SWMZQ[LE>YFT<K]'LRYKDM<KPIZ:*2QN=\?5/%+D>XT*M=$6?
M^JWH5XW]VD["+S*-!JEWS R,2ELRLPTTH;N+KGG3I\Y5]M.B!FY[_8C3$$[Z
MV1" S-8_&T$7YE5T+2*;K5\'UHP&D]G,RTPA?H="ZSOM:1Q=[]?(FU71))Z6
MX[MO(:7V.Y2=*XG%=/,Q\EQ=MU,%WVY/,VFL7JU#B;3M#W@[B'H0(W+-5TF;
M4O<%G^U*J<>A&OM;N=G4UJ:%V8PV+*F/^&Q;.MI6>PJTQA7M:_.JV5LQT< D
M/^.SB>EH8BI(T! "R*8=N%ZMM$:?;<JH\:W>S'OE&_5UUZC7/U=>E#[,/]!1
M4?_G,$-K$MJLJRA."FVO#NHTC7F!*?=)SJS&#$NJZ!559DXP,^-/W6LW<"[]
M,^O6)TTZB[+1GLC &6/3N41V"^9$2?6[/IN"RB% VM)YFSC7/1QT&/'D*5Z3
MVZCX?U.+-(Q\<B04^>3I^=L SSX'C^2_Y'6?05!45/H9!$7X1@J 'K,W05"J
M?9Y]05  :$$O<_M*X5N#RC;(=4J?XIX D!N??I7;N)*&L>0VTQ.>3D8>"1J<
M3H&^!5X2XWD/+SL\O0PX%76FB'TQRAM*:Y!/Z4R6:B2&%RGS,%HZ01[TD9T,
MG/+TIZR:F>CS=GRWM^,A*+/C69HF$VKQ.^V5=J'>CX>@<3V:TWJ$R;.GUK'_
MO&?:?RB"&U__<XT!W 9X)K5.NRSM-W(D7EWE\70\.N[YJ;^$7!6VE;86[\"M
MNF_.,_N63-Y0]/+F!)W<OY=\_6<[4M*.5%@=EALU.1G";0/7>S(\25L&^8U&
M"STA'Y%"E(;1\=L_VP5I%Q",_ADF0,ZHN3<LM2$9^(+/QM3-("-F>,WA!OK6
MH'J[WOEL0R9,KMVYN6_KG7Y$*NCSH-/USIF\635'*NC;D,(=J#?)UFZ#)/*"
MV'.U9-1N^AWV-)W&BNYRVB;#P@'',5"T]V*XR;$^YK/=&=R3$V]\>G;HI,/Q
M&-RA8[0@(]_PV7!,;-J)MA<]D0N@IMAKNWN376,W.D91OZ3*\EF/O1%Z,4#)
M\: UA(%UD\)>+<$^6QH@%KH+;V#B=I_LA;YCZ0M]GS?X/F_P=7"##T"?V9L;
M?&>6W^ #H 6]S.TKA6^-SQM\NNZ/ ) ;G_X&TRM5AK'D!I^FS.4 U-.9$O9%
M*&<D2Y2D^2[H^?CD&'K&.7V*DC>4UGU^>^Z"'K:L9$QD2;[9PDZ,27CY$7AJ
MZ7@.SC4&HZ,Q?,PA-)-FM1L ='/-3V>,@<CXE(-R[GL7!HL7%"UO Q*8S'M'
M!,LT0+7]O$ )L'0RN-DY!&T L%?LOOP()=G=E+"5739 F#$9XB@I=<SX7[N=
M,O[5/Y[(R%0S\%;^!H[5KD9<OA484S"U0ZTXF[5M=^>O8!CE6[B&#<@=;7/R
M[KW 6ZZ75/HJ?X='(..[JA3R<?291.<GF\3RW_M,(A<'S$'1WD!%!S0L:S:A
M(H^G-H&*5#OA9E?/<EY(E.FZW4NE+K=";X2G8#V*VEEB&#"JUEA$)GUF7_EF
M?*W=I 473?\0Y-^].6&%/_G,GS*\P*/YQ2')7*<5M5Z%,.64Y:>5XR&MUGK7
M/\F/M'Y:K/#A*K*%?1C3XL83 =7SW.U@<+_V$V_E>RBZ":,KXH<=Q;B.Z3R=
M(]T&28BK7H9!.F]2.O-M^ V'ITDX9E;D>Z_H!B;T.RZ (PT>0K,!86%%B0DM
MFE8_(6S6V$O0,XK>/1?IG%]3WO79%O2;$U9:PLXOZV^'UWS4_< KE!O'+7U9
M-S?V&1]R>,T F*T5I2GD.+IV>(TQVV^=O#N>3XXG\#0S'2)E+S6>"%UJS%XV
M<(JW#>9A-%B0]WW><>SLCJ/JCI6B('K^!]VOJS3<T7 \,KWWK.Y6HQ'3P?19
MZ&X.7#V:VC.?ZFDPYW5@U&U$BPKGQTWL##&8G-X#]=062&T77ON&3UVK/T9G
MF;;MZ2$GJ+7TI2V],KXBMXY\K3HN7O$I9/5"9MI6ZTFAH<N']DY6#,49/+S9
MBH+$!1 "+TU<-UJCV228I7LW5^N(4'SG.:^>[R4>BN6V*D;#T>Y61?Z&--Q2
M2-XQ<+.7#/SM6_JR08$U0W018WNEN!R?M_O +&'$2R+CHT1Q3CH'"+<<F)%9
M@JR*AT,C@)8LWW/P3^&'XY>@L[6P^S0X!32CE"H-(;Q:'6:/%,W[<T!7^$G/
M=?SR5ED]\X*EK%- &]Q6ANV(PG>/'.C@J=%=&,?3X"H,4D-2(S#02UBGEJ:8
MM:ZQ##E%8,3D7- E4/*1F#VHT M8JQ-)R#9&5)[BY8]#O)7O2!3WPJ(?;*FP
M"UDKEP:PM3HHFI(,647N&Y.FE?JG[16)!%X;G?&H=I1=UUJK$#G$JOS6PL3Q
M3>QP?4&O"=D-#(/40VF>^20E'AYK'\)$=H-KO+_!15Z _[-]QR"<#]SM6P8!
M>4U?=K@(FM+V(,>UIO9A+*.3X[/AQ?#D].1D?'QR=G)NIBL@G[?U3F/%_*YY
MLMH81N9S^$@8>[_-BP($%82Y^M&,*'_[#X)D3X0 'G54<("9XP;NHST.G$4J
M%SP2.0B-[RE3=@U+0^<S"O 8G@Z@H]_&)_F=JB]K1$K1@\#)U0"<?@Z+.YN(
M"J!KW5HVM*%XXWA1FMOF\N,>KVKQR):>TSJQ%S,Z?$XIX,*1Z?V;( 4<QC6,
M4JLG&UB;'[93&W8D:/$:P*F@"9<UF\LM+6!\=%&TO^Q$$;E.\H16V"!H-EF&
MZR"1E9-D+> DU58,-7O2"BQBB<2JO?8=)RX;Y6EPDE&U$F$CM"3$?!7R;8"_
M!\7)DY.@YX0< G/C/XE7 %PH;+IY8I$&;N-<M[0$(-:AGX.6G[),%B+H5#E.
MU&XYGW2TY9P/H]GP.0EFVQ%4<L-Y3-MPSM\P<-)7I Z6Y"6#]"V'M=]\BO5S
MAO5S=G$\OL _0Q@L6NTWCW%+,)TM4MS8#?:;<X" =RU;[#<#84^$ /G]9OC,
M*=IO!L<BE8NF^\T\*@]ZOQD<_1P6%>XWZ].%\3EX!_O-X(0CT_LW0?JYWPRS
M^VC"I<+]9BBCBS7[S0 DU58,BO>;[9+8=9QX2R=!TWGC[DJFB@,05VMS6)*,
M1L-)!@"]J%KCLA%^GF2TV] ')Q0VW>I.,BQ>12DXR>B]+$30*1H^JAFA:A(M
MZ#W+>,!3-(=D-)4]NCBB'%UL*CS$4XJ+T[.CB_.ST9&A^.X*3RF.8+1A06,W
M.*4X K_7W>*4 @A[(@3(GU+ 9T[1*04X%JE<-#VEX%$)\I1B^-O1666G?70^
M"6:Z3C14O VXK#CJ$#K]T&8F&^?X&O8,P(FJ^8C#1FCEME&'>P;@A,*F6]V>
M <C^A#+P53&6\F>]^MXBI:J4/NL*3]"]8/'L^"A^C#P7%2$77R)GAO_PQ?FH
MS2.L_"66"*U#X\"*8]58C 5<$G0'N6NR_=!:>^PZ#TMJ#6QA?&M=2\\V*:46
M+N)-D-+I']7W<<S7'98$U9I)0[@M<UW=Y1J; \4Q:8N3.?ZFVF9:FYFQFY<>
MEE)U&$M#K*^.])J!4CLTL^L\++4UL(6&T&#F5["EG9ZMF9Z(B6CI-H7+6R(H
M-;BUYKKL;L60MY&:Z<-C%,[6;C*=WSEX59][KI5F'V3:D14KMA=SBZ%[YZ>W
M7"^;]6D:/ZC*XS'F<=A'_0(UI(;$EAU/)9_=-S1;^VA6&C@NT3R,,.YD35IF
MNUDCO_[#4FA+N^2"N^AK)M7KY<H//Q"Z1 &:>\FC[P3Q%_Q30!ICD$3>ZSJ=
MV.#?RSFE'.T'<"S>-7C-7C98D;>EWBKI"P?E-P[(*_OBME+)@A/,GE#B97<
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M2;:L6<I__L7U2E#N7__WG__O*?IG_:^GI[__?PAZTH:%;N-)MJ7 !);_)+E
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MWOGXY#Q5<(''C^=F0\YI8XNF\+P:U##:]JKDQ[@E TDS!2.R&]56Z7A^>XJ
M77?-!'YL.V*@'DR48)B@P>HK1 ?,:(R*!<Y0T6BB*(+GLV@&S:9EQH<</3_I
M"M0G"^6P4Z!GC29=5*5B>T)&T(7O-MD+ 'NUV<)0)N]S4KT,:P@79#"'&X:-
M<[/]@]5Z[&C)@0'D/:5> )'[!)J"'[B:'QZ0MA&,ZPS;S^5UG&S5@WZ^X(R9
M6,6C'S*9Q)JV"![3EM@"!'^F+;F(H-:+G*HU67??TJ9CV"$ :R P3OR>+6%
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ML7)MQFX/@4M$>-I'LF*6L6%(1SM%<Z@YK7$MN8<+/]3-@:._?U+AS1S]=]Q
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M\M7<TL:_&[C#W!!J>! CSCA!6/:[!6>&]>>)XV["W>$;EJ5=F_=F- !)L(K
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MN1(G\'S;!.X>RW=?%8_T6"2HL3ANWMO5/+T0%H EJ:;@ZGO%+8(!O"Z8 RL
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M<-T3>\&JNP3I3-0^5C4?<OEM5C4GF>%TT5CX79T-'0,:>\*@WTZG7#Y6-?\
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M8(9?+3T<&4B)566)1=X^31^H.X4Z07)M!5B:M'MH,&R5IWEQ,>1,KC)1*W6
MR(V'SGLO\H[I^D#?"?110O2$&A]!KMF>I(&H(R^*R+<OL'FVD27@* 9@E$G-
MT;RN*&42N]Z15"2>I7':4!F?\<A&[)4#(YKP)MIJ E^U(Q=Z#CS_)0;;_Q:
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M0FM>5<FFF#@=G_B-I%^%Z$M5.'%]KV:KM_&#S#A^)2U^N,OTLR G*X+4<V>
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M?&PBAF:!'9QB/NXP&G7KV^;!5S$&X\_B6F2>6_P5X\6S#4U^^B]X_<^N1?Q
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M8T ,FCZ$>$P&FP\6]1&'U_1QZ OB\!,KU0(:P-%AR_G]N:?F:&IL[CNN#P]
M/3L&1@3>/T[\-?P;Z@^8,,(KWN\P+]7^ )3!-4*6F:%$8S0A410YE%B6("29
M8C$%8T8:L!5?'RRF*"(Q]#TC)\Q\-U]7.SUVPI\\ "V/BLL5LYW6L%RF7N@X
MQ5:WKXQ/'8!F#5TCRD2?Q!9+8S HJ/TQVX?/)"-_6/E"@Y+$ TVA\[2+GJ?A
M#^PMCRRC?:+VB?4%/,SB:($O>N9^ZS6.O)SXV.'\FEP.!Y5GDH"1(N9#*$2
MFJ]A.SP$W1Q%!]</=B9:\N'TM>C@$]V"YW&_$[M!KVYYXI^YY1D\1M64_7GK
M;Q\\T8&7LE__YOF*>'"K_-<_;=W;W?4')O,DIIBRZWXRHGI!W+(?N!*?7QC(
M(Z<SSK],Y?GY_WQD?F/_'3GPE'?7/?YR__Z3>/I]+DUUGS>LK94)[%4: \[R
M:J(#F#Q[U"<N?7PR7'PAU?U"ZKSAD[\0.B>$\ 5C4ONPQ 8GAH'D>8KI8ZO,
M(M'.-#;&9K%M;MJI7*+::H!G8^^>(N\N1H"-"1I8QV/_>L P/#:7G=@2MLB$
MMUYB04^$)QWQY=RN2]LGUSE"OYW%<L.SI+UPV\FV)U:;JB6RS_';H2!C:8IH
MFQEM6H*L1GS :O"^PSGX*!0+_3JE$TJYBV1S/D)>V(O1YYLGL'"ZK&SG/7H\
MP8B4-7!$:I6U"W OR _VHCW18E795>7%#OHQ6)U!\W:ZO5Q.?[A/Y[T</H59
M$Z/-"]$:7$+]#):35SRR^=9$N1T,+!5FCFFQX2:F3#2P]C-8&6,UT8)T0!A&
M/KAJ\Q>^OT4YD=W82#<U-2:;)A@![ZG"X/3"UV%HVK-C0VT_ #QX'YU^NI%I
M.X<W,O?1ZH,@]R-WP0@V5-KP1F9,!;\%M@T<.G<T10LL'9R(!3?IW=A?X*$
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M#C+20ID4YKWB7&AMTD8.M^>Y3!<\>/\8]W]_%:K9$QE6 8$!?:U@AK7GY3E
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MX"Q] V\&YZ/BSKRQ8-=V8^ D8OM9(-_EMKY+1%(V+ZUG4/0/P>%N]20CK">
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MQL*FFM2&,5UE$8 /6"L,\SE/XKX-DDA$:=*V%4P'UO5P-4NWG9AE>R@P$ZG
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MM^"^"_8\7VV8Z7YA9K2<?+V<SV^WM70 =MBD"*?B&/.Y.CLHGA 6ZPNE _Q
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MM'AMV66TD6X!LVZH6> [+S:'? 1P8 _!W )6WAEUL;?MN;L4<']$U!4SP,-
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M:ZC/BS/1M]33RM9O?[4]GF8>6&^N=+75OWXL^8_2@S@$;4YY#C^WCQC_0#I
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M+3\*?7#DW]5_,W6)!P1Q")8SG4(2+>4!_D;/_H5#&E0\H.L5G+JV-R,D=E$
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M>,I9E.],] 6&)=2E,&[-QX:I-7'GVX]X6,K9(PXZCM!T-\5+YW?*1; ]+_-
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M3B?A*HK ./'!U&YOX*8%Y6V\_%&*YVSR'):>+^J.[T(!]*?M,40\T*+SP3_
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M>0G38;X^]!X8OE&#PH^C E#YP.8]D.2> 6L>A&,&&:P]OS2PX0,9[<+4U&_
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M8I-$J=6\LT;B1:E4SUEHF\DT#38E95N31I7FDNY]?OR%)"-O:22MGHUD46C
M!T!TN+":M-7VJ($M<HQ".6:SX\S03.7>+M<ZT=O8HVFBQ"(UIK6ATWQGKCI
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MFM.--E#S[9U.@"IB_UL("F@V:MF>4BA2:#D_(H:$H8Y*&3]W-1Y/O1#Q]T&
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M<S7SUVOL@^)',6-P EX4=$R"\L.0%KH!6_LW#B\Q!VC1F. ZC\P3[Y$!5"D
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M0O!C,,<QP'4O[S6'%T!N<'E\D)SB1'.MX@-YM<G,^137/K&'WP%+J_Q4-S*
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M29;69T-NM!Y%EH($'<JCI_>FS+0SFD9&)*$6";D_+Z\<-CE,'%^IDDQZF.N
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MEN,XD S7-UTP[C*]Y9^"YW3 HS5I2WJ8F!:5M3HEYU6U-V:XKP?@$2.&S6I
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M1:'J<^<Y])<',88_.H85VP<9=$]*CE#]Y#V,U=B;P0C=.<RNO/D;AW]F_Q3
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MJM"?)[#9>,A6%TV,;K1^6DC\X2:G\IVH44N0F!":1'MYHQQ2*;#)^*TIA#9
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M8#6P7Q+;^S><U7#F&U#/*HKZ4AQ8)+"(/%HG<#(HW 3] PM.WI[2MWQ]076
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M'T$/\3/GHFP\J('R[N)T=D/DYOCHJBT2M7U#(8*>*MBH&OSW_2=IG"I/V-$
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M_S,.>ZS]8/<5B-,S=W</V,T^/W&EV7GO?VQC:P\/NR,Y>X9*=\5\"%Y$A]@
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M-3MB-;F(U>RT0/B7U<WM%@CNL![P+1Z\5QN';>)%RL/XU$*X?"+U^561OU,
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M-YD5&?V'S%XB;6"KVD"89KQBGPW._G*\URRG;B[:=>7ZKI"\.#Y2'!Q9!<I
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M: ]=24-,@Q.'3>.G80L+Z\%0!-^J:LYC/=Y\!0M#*1&PD1CP$4)M)IF:"C^
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M4\E6*\=3/,54)K'L(0F.<1O-5I<&?%^DGH;WS:>39/MYD#DSC-I3X>CT>C_
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M#@69,W5N(A2D_/F@76=LUA]^L6F=GU$1(5J$:(N(1A+>GR&)_YAUJ<-1@'P
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MZVI-]/$<)$'+>]925K^)%H'!Z19BK#U@"2HTKI.9,,'_V/KP\0,9EZ(H6PN
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M/KL,0#^>)F,Z7/'J$V(NT"9H*RH%U&*:N4,7;A47#=*M\R\7O9VC;5VE((V
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MZ50FXN)$B(@2S5R!9Z:[UFRD>X>-T,H3=Q 4V6[K].*;5&+9^ [X"SLTUD)
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M+CQ5FW:[^UAM>O%Q5?7,=UDQ@_X?=0\/#V#-__/IE_/W%]LMQY^XGCN(L<W
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M]JJT:=GSPV2LM++W:&;I[4RQ9*CU!YI37W!CJ[9*3FHXC;(N>X<[ASBUDB:
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M*XAR>"3G28BQV$53&P,?%FQ@#G_9SM8"*\6:+_2M$>0%XZ/H6) ]P\].;7<
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M)TGU_U*EY&+3Z^'D=%NK0JZR'I6EW13;$?6BSH;R5O\';HXFK5+&U%2%3?2
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M\>&6P49KV[[P:-4+:\9'ZW^!] Z7"Q^QOJIKD_R?TS"(\/UF_CJZ0G&>I<'
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MJ-;EMN)%XC="?!OC_OEMK5OPK_H?61*0NF%Q<9$_ H25Z@#? 5F&\$F<@/(
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MB-0U;)35\?#1USG$I,#=K4&?=WC[?^VR!K19N9LEG/#"-RSV,,NUW_4A %5
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M/@<CL6A;VA"0N&6BXE=PIV*=T@;H9"P!8*'98M&M._"+7.Y#/R"#%O2!&+O
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M>=;RY=UD#8B+#4XL"@Y9M]ZP:Y61:8GK+HOWKBQ6=9V;Y(D["UD6-.N=>LK
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M&Y1WU2<8B_Z[%@/&X'''S1NA94C<I NJ*Q?9AJVP0G0NX8)Z)/1^YBG$%RC
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M +N"&*PD&"P^DBCS'H4S(UP7N9V90G7Y3N/0,FA!&12;PH1O>W%;R<;:%Y)
MBZ.P$HTB_2(>XDW&"TFR7B%@J-C*EAVT#(W-^7  ( JS)E=W12IKS-JW8EJ:
M!NTQ%$]2FJ)21]Y)%\Z44;#]3*#UQ18W!+8H=OPW<=!;(W3[NSPI>EFT!'5'
MD"GFJUEEOKP+*8SVLM6&U_A;<_6U%EO?>OIK!_:XAY-9U[F.1+OZ:PTP12<H
MI%Y#]P%U>CV,Y&.T;:>3)[->5V.:A&K=5$NZ4[%>L+^-S;RA#9.<\" 6M(=C
MZ.E(!Z2B31$^6K!8HA7;&#1::=+D+RBF2P;'B?B+C ,1=2.'4 8H-:#9&O:N
ML5N5]1A]8?W"DP]-F@=9/Y[!$7*8-BZP]&/7E1XZ(\X;'5T_QAZ,GTBMD8ZV
M2F_9G\*@SNA2@+[12&ML+LY,+H1ULM$J_!CTA3530=XIN-T0S",5]%N[7Q^Y
MRMT2_&A?J2(!."*O0JS0W+]M]',#/@'TA%\N=+0!TPNX?\L0_!K]HOP,H1!1
M^,7#H01=9L92W2Z<C4<I ?]-2+%V!#]O1@>9.%,,163X?^@,DW=>MW[F5L(-
M.C$T3>V!-^0&Q#H?PUX([1;B0 %:PR3_K!!;,]Q*0-@A1!ZC%L-$*)F4)*K6
M-0U!C[@P>X"^A#)"HP.M;D*4'&./!H0CU5U#T<A(RI>ME,,P<AV,IY)9.XBI
MKD,Q58J-;'"6_%.OD_<\F@X#*'R,HUG:,?I=2K&092>9 @S*I0)QT[K.<$J3
MT'N,0K  JYADQ<?,PK^CA->_:@7+:66<)1*3H[$D!YT@HP;\ABC$X@R45\_C
M8K^M[Q&H@/91F(+&J#%T#SDL;1"@>>2O%/G -507!&UZ DJC$#+A(W$<AE]S
M+[)LAU.6;<JR?2I9-O9)J!A)!"\AA\Z2'[NU(\# -HS/+>M%)OBJC-1=^68/
M'JY689B5HB/T)S: _9PTB7-1P\<^KSR"-34XP@A84T1CWU XETXF#10+ >%K
M?3F#_X. JF'125GS;+YZ"$?K1_2FP\**(,V,;Y\<^U*,<I?:00)(14G'):^;
M>BO%3OB48YJP27SS'$GF W'#F A%@I7"]$@/\/I:;.RW'2*[5LX$[EA]C_Q!
M*MU8)8SB_7A]&0>GSPDMC3,Q'J%5$S^Q7X_N+A&[W,EQ>"1Q/TXM#.MKP#U=
M.I[1=Y:5'8=W>CXS&3@X2Y)2?SK+:9:\S.+ZC1! 9;/$L5KKC9LD_O;.!)J[
MR[V@2&./A<?A#8;;45>()8?W)C5S:)<H]J-!K3B[JK3L:Q[O'08V2M!?&'$T
M=5I#A('B-S&896@] @RU4_:030/UL=QOE,W2")^RGIEQZ$<KJC.E@4A:@FIY
M-7*QE$9]21Y]CHD<7[5,=-[K+SGQNLY[.,+L _G'8#@X^/I%XP0)&Q..A>2G
M>U,ZU 4B<&,%]1[SQ"P%KPI&G+QUDJ;ZX.&A^U&#/<@W8;2"!)48XYZ4@9GS
MC;^,8LQ5#BH !Y#';*:U$[E.Q RW@N$,=93*W*P9$PPT-O4.YYWZB/51ZNFB
M(P[7(PL%8!X$F-#B;SVC])J#['&-!'$.;KF6F8<2493YLQ2C$@^BKW;Q.?,"
M%=2J4D1N4<21,SV8::,/6!;-NAW%)07*'7>G.,GXZ,'ALS1Y[DJ\@V J-1O)
ME*8@*,^Q>+";@]E0(/HE,-RWH'NV=7GP<H>JX2UP^7Q.<PA X*,0K^J.$AP^
M2H412&S1\=&EDQ_??/?MR?/D"Q!L=&N+^9<^0>-+0\B%M"%AOM(??)LQ'$U7
M*Z[I'G(CQ0FT E;Z8$V^UY<,D--I<:GY82X,N$&S(RZP,"4>>)458%H'IN,!
ME11C! FM-YHS''D8J4@E"6&LLI]N"AZ\5BR8?>GI1^7,$0L252)*H-8AB8S6
M62]B<MP2&"M=1K&E7B#%7N.H]F@@!=5=930*X9V#*_T&#$=-PA\OZ->'SYX^
M2HD^=07"U5<CX5/_EFT7JX.?L]_@GK(=-CY41A<:FSI43N3<^U!M06%?_3*F
M"PJ=- H/KN KK';B"S3?H15+,'@J^#E/G!S/YUA^3[H4Y0D1X9CAY)G(<&['
M/[XX9HNOOQM-3+0]@P#=6UA'ZR==#';&LPG+TB%Z[$^SMS.L,F+3K3(J^H)-
M]8\46.-[-V\4W_8)*2,I:4%=P\/$)%1NLB2X$]B@8LU2B-_E8X5)HX0W7=94
M==](>5#8G6Z,KB)I=S,@8X/6YDKSV@A[3%.0<2U@=A2D7&$[1T_Y .)-^$&2
MX64<U#(#..JUC^RB+*+HK"Q);1)^$9GF+X!>%.^$5W[EPXMU@G,D?!D+,GCI
M\E.7&M'84K2_PF$7F6F[,"6.=+>9E][*?(V2(M06EOBI^C5TX1AF 3V:S0;L
MC>3;&@XM^>+UN^-OO\3M1)=(?X7??]=D.'RS>9^\H@FL('FJ@MC 7VREF0^
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M(NPXM39>)*-L>-Y#Z)4[BL?A:TN^XMJ2$=#0Y(>"$C-Q/4?8<LXV>IYD =;
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MC8C(O5.%1Z679J&Y5D,*#H.[_0T^YQ;Y[,'$9G>/S4QE$6;Z$->IF#.\]RB
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M8U_A45TK0SL;GKM9$9?8>"T7 X<"HVQ3,':X/8O0MKWPX[RY._H:J#[<(!C
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M[HW ECTL58)5:/9 *[M:NHC^@AD?A]17N 3#C7V*!\\)^9WN?#ILW?=.LGD
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M&C:OLD%&BT.+]"9UH8SQ=>LBC5(2X? ZT=6DS4\F]'(R/Y]5YF:$G[0L)MF
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MBTY?OSTX/WK_6W1^'!W_<1J].7I_\/[PZ."M^\W9'V_/S_[VE\$=QTQ?@:2
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M[B5!I"_$7EC&<\$N"[L';CHF?L YM'[\,^'I@(38"=28@3NH\KH$B.O[Q/\
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M_']02P$"% ,4    "  F@:50&]]M])C0 @"*YQL &               @ $
M    :6YC>2TR,#(P,#,S,7AE>#$P9#$N:'1M4$L! A0#%     @ )H&E4 />
M@DBI)0  .WP! !@              ( !SM " &EN8WDM,C R,# S,S%X97@Q
M,&0R+FAT;5!+ 0(4 Q0    ( ":!I5#GN1#^P0@  "I)   8
M  "  :WV @!I;F-Y+3(P,C P,S,Q>&5X,S%D,2YH=&U02P$"% ,4    "  F
M@:50+'.V-L8(  #A20  &               @ &D_P( :6YC>2TR,#(P,#,S
M,7AE>#,Q9#(N:'1M4$L! A0#%     @ )H&E4,U!P<GB!   3AT  !@
M         ( !H @# &EN8WDM,C R,# S,S%X97@S,F0Q+FAT;5!+ 0(4 Q0
M   ( ":!I5",P\50V@0  ,,<   8              "  ;@- P!I;F-Y+3(P
M,C P,S,Q>&5X,S)D,BYH=&U02P$"% ,4    "  F@:50='-? UL9    *0$
M$0              @ '($@, :6YC>2TR,#(P,#4P-2YX<V102P$"% ,4
M"  F@:50IS2&*&$1  !7_0  %0              @ %2+ , :6YC>2TR,#(P
M,#4P-5]C86PN>&UL4$L! A0#%     @ )H&E4#>:\P4_0   .1T% !4
M         ( !YCT# &EN8WDM,C R,# U,#5?9&5F+GAM;%!+ 0(4 Q0    (
M ":!I5 5[]-T.J   ,E'"@ 5              "  5A^ P!I;F-Y+3(P,C P
M-3 U7VQA8BYX;6Q02P$"% ,4    "  F@:509[9R+XYP   ?VP@ %0
M        @ '%'@0 :6YC>2TR,#(P,#4P-5]P<F4N>&UL4$L! A0#%     @
M)H&E4%8>:6R:CP, T?0A !4              ( !AH\$ &EN8WDM,C R,# U
@,#5X,3!Q+FAT;5!+!08     #  , #(#  !3'P@    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6786672912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee benefit plans - Defined Contribution Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee benefit plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contribution expense</a></td>
<td class="nump">$ 3.3<span></span>
</td>
<td class="nump">$ 2.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6800165552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 568,507<span></span>
</td>
<td class="nump">$ 497,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of product revenues (including definite-lived intangible amortization)</a></td>
<td class="nump">27,319<span></span>
</td>
<td class="nump">22,588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,085,287<span></span>
</td>
<td class="nump">270,545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">111,148<span></span>
</td>
<td class="nump">123,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of acquisition-related contingent consideration</a></td>
<td class="nump">6,627<span></span>
</td>
<td class="nump">6,671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_CollaborationLossSharingExpense', window );">Collaboration loss sharing</a></td>
<td class="nump">2,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">1,232,511<span></span>
</td>
<td class="nump">423,787<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(664,004)<span></span>
</td>
<td class="nump">74,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">8,662<span></span>
</td>
<td class="nump">9,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(602)<span></span>
</td>
<td class="num">(335)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) on long term investments</a></td>
<td class="num">(48,132)<span></span>
</td>
<td class="nump">20,989<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before provision for income taxes</a></td>
<td class="num">(704,076)<span></span>
</td>
<td class="nump">104,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">16,566<span></span>
</td>
<td class="nump">1,785<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (720,642)<span></span>
</td>
<td class="nump">$ 102,312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net income (loss) per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="num">$ (3.33)<span></span>
</td>
<td class="nump">$ 0.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="num">$ (3.33)<span></span>
</td>
<td class="nump">$ 0.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Shares used in computing net income (loss) per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="nump">216,721<span></span>
</td>
<td class="nump">214,065<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="nump">216,721<span></span>
</td>
<td class="nump">217,061<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenues, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 486,727<span></span>
</td>
<td class="nump">$ 396,249<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Product royalty revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 81,780<span></span>
</td>
<td class="nump">61,608<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=incy_MilestoneAndContractRevenueMember', window );">Milestone and contract revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_CollaborationLossSharingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expense recognized during the reporting period for collaboration loss sharing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_CollaborationLossSharingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=incy_MilestoneAndContractRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=incy_MilestoneAndContractRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6803030720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License agreements - Novartis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">125 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Jan. 31, 2010</div></th>
<th class="th"><div>Dec. 31, 2009</div></th>
<th class="th"><div>Nov. 30, 2009</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 568,507<span></span>
</td>
<td class="nump">$ 497,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=incy_JAKAFIMember', window );">JAKAFI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">459,479<span></span>
</td>
<td class="nump">375,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_NovartisMember', window );">Novartis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived', window );">Upfront and immediate milestone payment to be received under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementUpfrontPaymentReceived', window );">Upfront payment received under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementImmediateMilestonePaymentReceived', window );">Immediate milestone payment received under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementReimbursableCosts', window );">Reimbursable costs included in accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementResearchAndDevelopmentReimbursedCost', window );">Research and development expenses reimbursed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_RoyaltyPaymentReceivable', window );">Product royalties in accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,300<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_NovartisMember', window );">Novartis | Pre-specified Events | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived', window );">Upfront and immediate milestone payment to be received under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_NovartisMember', window );">Novartis | Development Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone', window );">Amount recognized and received for the achievement of a predefined milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_NovartisMember', window );">Novartis | Development Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived', window );">Upfront and immediate milestone payment to be received under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_NovartisMember', window );">Novartis | Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone', window );">Amount recognized and received for the achievement of a predefined milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_NovartisMember', window );">Novartis | Regulatory Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived', window );">Upfront and immediate milestone payment to be received under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">495,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_NovartisMember', window );">Novartis | Commercialization Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone', window );">Amount recognized and received for the achievement of a predefined milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_NovartisMember', window );">Novartis | Commercialization Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived', window );">Upfront and immediate milestone payment to be received under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_NovartisMember', window );">Novartis | Development and Commercialization Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_NovartisMember', window );">Novartis | GVHD | Development Milestones | Phase III</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone', window );">Amount recognized and received for the achievement of a predefined milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_NovartisMember', window );">Novartis | GVHD | Development and Regulatory Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived', window );">Upfront and immediate milestone payment to be received under license agreement</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_NovartisMember', window );">Novartis | JAKAFI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRoyaltiesPayable', window );">Royalties payable on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500<span></span>
</td>
<td class="nump">13,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_RoyaltiesPayable', window );">Royalties payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,300<span></span>
</td>
<td class="nump">$ 50,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_NovartisMember', window );">Novartis | JAKAVI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,300<span></span>
</td>
<td class="nump">$ 45,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_NovartisMember', window );">Novartis | JAKAVI | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_PercentageOfRoyaltyRatePayments', window );">Royalty payments on future global net sales (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_NovartisMember', window );">Novartis | JAKAVI | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_PercentageOfRoyaltyRatePayments', window );">Royalty payments on future global net sales (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_NovartisMember', window );">Novartis | JAKAVI | Regulatory Milestones | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone', window );">Amount recognized and received for the achievement of a predefined milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_NovartisMember', window );">Novartis | JAKAVI | Commercialization Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone', window );">Amount recognized and received for the achievement of a predefined milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the earning recognized and the payment received for the achievement of a predefined milestone under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementImmediateMilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the immediate milestone payment received under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementImmediateMilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementReimbursableCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents reimbursable costs pertaining to license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementReimbursableCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementResearchAndDevelopmentReimbursedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents reimbursed costs pertaining to research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementResearchAndDevelopmentReimbursedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the upfront and immediate milestone payment received under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the upfront payment received under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_PercentageOfRoyaltyRatePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents range of tiered, double-digit royalty payments on future global sales if product is successfully commercialized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_PercentageOfRoyaltyRatePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_RoyaltiesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of royalties payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_RoyaltiesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_RoyaltyPaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the royalty payment receivable under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_RoyaltyPaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRoyaltiesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for compensation payments related to the use of copyrights, patents, trade names, licenses, technology. Royalty payments are also paid by the lease holders for oil, gas, and mineral extraction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRoyaltiesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=incy_JAKAFIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=incy_JAKAFIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=incy_NovartisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=incy_NovartisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_PreSpecifiedEventsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_PreSpecifiedEventsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_DevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_DevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_DevelopmentAndCommercializationMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_DevelopmentAndCommercializationMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=incy_GvhdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=incy_GvhdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_PhasesOfArrangementsAxis=incy_PhaseThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_PhasesOfArrangementsAxis=incy_PhaseThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=incy_JakaviMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=incy_JakaviMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795752896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">$ (720,642)<span></span>
</td>
<td class="nump">$ 102,312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">13,098<span></span>
</td>
<td class="nump">13,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">42,513<span></span>
</td>
<td class="nump">40,592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other, net</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized loss (gain) on long term investments</a></td>
<td class="nump">48,132<span></span>
</td>
<td class="num">(20,989)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of acquisition-related contingent consideration</a></td>
<td class="nump">6,627<span></span>
</td>
<td class="nump">6,671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(42,713)<span></span>
</td>
<td class="nump">63,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(16,701)<span></span>
</td>
<td class="nump">5,559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(5,712)<span></span>
</td>
<td class="num">(600)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(22,710)<span></span>
</td>
<td class="num">(33,464)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued and other liabilities</a></td>
<td class="nump">14,546<span></span>
</td>
<td class="num">(21,930)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(683,417)<span></span>
</td>
<td class="nump">155,663<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLongtermInvestments', window );">Purchase of long term investments</a></td>
<td class="num">(95,468)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Capital expenditures</a></td>
<td class="num">(39,265)<span></span>
</td>
<td class="num">(18,267)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(147,403)<span></span>
</td>
<td class="num">(34,574)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sale and maturities of marketable securities</a></td>
<td class="nump">173,576<span></span>
</td>
<td class="nump">28,278<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(108,560)<span></span>
</td>
<td class="num">(24,563)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of common stock under stock plans</a></td>
<td class="nump">14,619<span></span>
</td>
<td class="nump">15,481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of finance lease liabilities</a></td>
<td class="num">(187)<span></span>
</td>
<td class="num">(195)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_PaymentOfContingentConsideration', window );">Payment of contingent consideration</a></td>
<td class="num">(11,933)<span></span>
</td>
<td class="num">(10,799)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">2,499<span></span>
</td>
<td class="nump">4,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rates on cash, cash equivalents, restricted cash and investments</a></td>
<td class="nump">1,560<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents, restricted cash and investments</a></td>
<td class="num">(787,918)<span></span>
</td>
<td class="nump">135,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, restricted cash and investments at beginning of period</a></td>
<td class="nump">1,833,707<span></span>
</td>
<td class="nump">1,164,986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, restricted cash and investments at end of period</a></td>
<td class="nump">1,045,789<span></span>
</td>
<td class="nump">1,300,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Schedule of Cash Flow Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid</a></td>
<td class="nump">855<span></span>
</td>
<td class="nump">448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Unpaid purchases of property and equipment</a></td>
<td class="nump">13,582<span></span>
</td>
<td class="nump">8,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Leased assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">$ 1,984<span></span>
</td>
<td class="nump">932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Leased assets obtained in exchange for new finance lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 645<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_PaymentOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow with regard to the contingent consideration during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_PaymentOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireLongtermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireLongtermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6799126912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License agreements - Calithera (Details) - USD ($)<br> $ / shares in Units, $ in Thousands, shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Jan. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 133,657<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,085,287<span></span>
</td>
<td class="nump">$ 270,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(720,642)<span></span>
</td>
<td class="nump">102,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) on long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48,132)<span></span>
</td>
<td class="nump">20,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_CalitheraBiosciencesIncMember', window );">Calithera</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded', window );">Funding of future development costs (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementUpfrontPayment', window );">Upfront payment made under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementPotentialMilestonePaymentsWithProfitSharing', window );">Potential milestone payments to be made with profit sharing in effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementPotentialMilestonePaymentsWithoutProfitSharing', window );">Potential milestone payments to be made with profit sharing terminated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementMilestonePaymentAmountPaid', window );">Milestone payment made under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_CalitheraBiosciencesIncMember', window );">Calithera | Accrued and other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued and other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_CalitheraBiosciencesIncMember', window );">Calithera | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_PercentageOfProfitsLosses', window );">Percentage of profit (losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=incy_CalitheraBiosciencesIncMember', window );">Calithera | Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) on long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,200)<span></span>
</td>
<td class="num">$ (4,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=incy_CalitheraBiosciencesIncMember', window );">Calithera | Calithera | Accrued and other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued and other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=incy_CalitheraBiosciencesIncMember', window );">Calithera | Stock purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares', window );">Purchase of common stock under Stock Purchase Agreement (in shares )</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Purchase price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 8,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Per share price</a></td>
<td class="nump">$ 6.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 4.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Fair market value of our long term investments</a></td>
<td class="nump">$ 11,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,800<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_TotalConsiderationPaidUnderPurchaseAgreement', window );">Total consideration paid</a></td>
<td class="nump">53,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_CollaborationAgreementUpfrontPayment', window );">Upfront license fees</a></td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_PurchasePriceOfCommonStockUnderStockPurchaseAgreement', window );">Stock purchase price</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="10"></td></tr>
<tr><td colspan="10"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size:9pt;">The condensed consolidated balance sheet at December 31, 2019 has been derived from the audited consolidated financial statements at that date.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_CollaborationAgreementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent information pertaining to collaboration agreement upfront payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_CollaborationAgreementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementMilestonePaymentAmountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of the milestone payment made under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementMilestonePaymentAmountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of future global development costs funded under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementPotentialMilestonePaymentsWithProfitSharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the potential milestone payments to be made under the license agreement with profit sharing in effect.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementPotentialMilestonePaymentsWithProfitSharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementPotentialMilestonePaymentsWithoutProfitSharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the potential milestone payments to be made under the license agreement if profit sharing is terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementPotentialMilestonePaymentsWithoutProfitSharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the upfront payment under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_PercentageOfProfitsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of profits (losses).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_PercentageOfProfitsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the purchase of common stock under Stock Purchase Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_PurchasePriceOfCommonStockUnderStockPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the purchase price of common stock under Stock Purchase Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_PurchasePriceOfCommonStockUnderStockPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_TotalConsiderationPaidUnderPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of the total consideration paid under purchase agreement during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_TotalConsiderationPaidUnderPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=incy_CalitheraBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=incy_CalitheraBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=incy_CalitheraBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=incy_CalitheraBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=incy_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=incy_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6786578624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of components of convertible notes</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The components of the convertible senior notes are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:56.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying&#160;Amount,</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:56.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Interest&#160;Rates</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:56.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Debt</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, 2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maturities</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">1.25% Convertible Senior Notes due 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.25</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,524</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,300</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Schedule of carrying amount and fair value of convertible notes</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The carrying amount and fair value of our convertible senior notes are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:59.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:18.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, 2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:18.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31, 2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:59.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:59.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">1.25% Convertible Senior Notes due 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,524</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,656</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,300</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,511</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6786479568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment, net consists of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri';">&#160;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Office equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,285</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,303</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 72,352</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 70,510</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Computer equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 60,077</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59,069</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Land</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,227</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,203</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Building and leasehold improvements</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 208,276</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 208,293</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Operating lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,641</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,672</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Construction in progress</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 153,508</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 116,387</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 538,366</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 499,437</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Less accumulated depreciation and amortization</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (128,332)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (121,870)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 410,034</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 377,567</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LesseeLeaseLiabilityTableTextBlock', window );">Summary of lease liability</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are the lessee of several contracts, including those to secure fleet vehicles, buildings and equipment. Our lease agreements do not contain any material residual value guarantees or restrictive covenants. Some of our building leases include options to renew and the exercise of these options is at our discretion. Our current operating lease liabilities are reflected in accrued and other current liabilities and our noncurrent operating lease liabilities are reflected in other liabilities on the condensed consolidated balance sheets and are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:71.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri';">&#160;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Current</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="-sec-ix-hidden:Hidden_DXWVUeF4QEyCGxw9FL_y3g"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Operating lease liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,343</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="-sec-ix-hidden:Hidden_fgS4bxuAUka7K61E668xgw"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Finance lease liabilities</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 910</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 664</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="-sec-ix-hidden:Hidden_DZPOj2yYtU-8JCIk7usOfw"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Operating lease liabilities</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,151</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,854</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="-sec-ix-hidden:Hidden_T_UTUYhcFUKgazgt2tP-VA"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Finance lease liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,959</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,918</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Total lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 53,041</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 53,779</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LesseeLeaseLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LesseeLeaseLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6967357008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">10.&#160;&#160;&#160;&#160; </b><b style="font-weight:bold;">Stock compensation</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We recorded $42.5&#160;million and $40.6 million, respectively, of stock compensation expense on the condensed consolidated statements of operations for the three months ended March 31, 2020 and 2019.  Stock compensation expense included within our condensed consolidated statements of operations for the three months ended March 31, 2020 and 2019 included research and development expense of $28.7 million and $27.4 million, respectively. Stock compensation expense included within our condensed consolidated statements of operations for the three months ended March 31, 2020 and 2019 also included selling, general and administrative expense of $13.6 million and $13.0 million, respectively. Stock compensation expense included within our condensed consolidated statements of operations for the three months ended March 31, 2020 and 2019 also included cost of product revenues of $0.2 million for each period. For the three months ended March 31, 2020 and 2019, we capitalized $0.2 million and $0.1 million of stock compensation expense as part of the cost of an asset.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We utilized the Black-Scholes valuation model for estimating the fair value of the stock compensation granted, with the following weighted-average assumptions:</p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:99.53%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:55.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Employee Stock Options</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:23.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Employee Stock Purchase Plan</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:55.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:40.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Three Months&#160;Ended March&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:55.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#8194;&#8194;&#8194;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#8194;&#8194;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#8194;&#8194;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#8194;&#8194;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Average risk-free interest rates</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.56 </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;&#8194;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.51</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;&#8194;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.23 </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;&#8194;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.27</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;&#8194;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Average expected life (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4.65 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.25 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Volatility</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">40 </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">45</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">52 </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">34</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Weighted-average fair value (in dollars)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">28.43 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">31.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">16.00 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">13.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The risk-free interest rate is derived from the U.S. Federal Reserve rate in effect at the time of grant. The expected life calculation is based on the observed and expected time to the exercise of options by our employees based on historical exercise patterns for similar type options. Expected volatility is based on the historical volatility of our common stock over the period commensurate with the expected life of the options. A dividend yield of zero is assumed based on the fact that we have never paid cash dividends and have no present intention to pay cash dividends. Nonemployee awards are measured on the grant date by estimating the fair value of the equity instruments to be issued using the expected term, similar to our employee awards.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Option activity under our 2010 Amended and Restated Stock Incentive Plan (the &#8220;2010 Stock Plan&#8221;) was as follows:</p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:25.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares&#160;Subject&#160;to</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:25.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding&#160;Options</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Balance at December&#160;31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,632,657</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81.42</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 914,834</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80.12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Options exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (688,202)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26.83</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Options cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (180,342)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 91.57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Balance at March&#160;31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,678,947</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84.14</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In July 2016, we revised the terms of our annual stock option grants to provide that new option grants would generally have a <span style="-sec-ix-hidden:Hidden_6RWKpuCFUEKpc6a3v7bZKw"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">10-year</span></span> term and vest over four years, with 25% vesting after one year and the remainder vesting in <span style="-sec-ix-hidden:Hidden_OR5-Cr_KuEOxFj4pvVNKEQ"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">36</span></span> equal monthly installments. Previously, our option grants generally had <span style="-sec-ix-hidden:Hidden_5i-HSeUv7Eq9b9ehfzeLfA"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">7-year</span></span> terms and vested over three years, with 33% vesting after one year and the remainder vesting in <span style="-sec-ix-hidden:Hidden_mWa7sHwgO02SjXEAYJrP4Q"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">24</span></span> equal monthly installments.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Restricted stock unit (&#8220;RSU&#8221;) and performance share (&#8220;PSU&#8221;) award activity under the 2010 Stock Plan was as follows:</p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:24.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares&#160;Subject&#160;to</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:24.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding&#160;Awards</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date Value</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Balance at December&#160;31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,602,376</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79.69</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">RSUs granted </p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 379,496</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80.32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">RSUs released</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (64,426)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 87.36</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">RSUs cancelled </p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (39,795)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">PSUs cancelled</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (12,250)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65.76</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Balance at March&#160;31, 2020</p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,865,401</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January&#160;2014, we began granting RSUs and PSUs to our employees at the share price on the date of grant. &#160; Each RSU represents the right to acquire one share of our common stock.  Each RSU granted prior to July 2016 was subject to cliff vesting after three years. In July 2016, we revised the terms of our RSU grants to provide that the awards will vest 25% annually over four years. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2018, we granted 190,000 RSUs and 446,500 PSUs under long term incentive plans with performance and/or service-based milestones with graded and/or cliff vesting over <span style="-sec-ix-hidden:Hidden_w_7MzdT-j0OynAIorIKX9Q"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">three</span></span> to four years. In April 2019, we granted an additional 100,000 PSUs under one of the existing long term incentive plans with performance based milestones and cliff vesting. For one of the existing long term incentive plans, under which 106,500 PSUs were granted, the actual number of shares of our common stock into which each PSU may convert was subject to a multiplier of up to 267% based on the level at which the performance conditions were achieved. The actual number of shares of our common stock into which each PSU will convert is at a multiplier of 142% based on the performance conditions being achieved as of March 31, 2019 and will continue to vest through June 2022. &#160;For an existing long term incentive plan, under which 150,000 PSUs were granted, the actual number of shares of our common stock into which each PSU may convert was subject to a multiplier of up to 100% if all performance conditions were achieved or 0% if no performance conditions were achieved. The actual number of shares of our common stock into which each PSU will convert is at a multiplier of 100% based on the performance conditions being achieved as of December 31, 2019 and will cliff vest in June 2021. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Compensation expense for the performance-based awards is recorded over the estimated service period for each milestone when the performance conditions are deemed probable of achievement. For the period ended March 31, 2020, the stock compensation expense recorded during the period was for service-based awards and performance conditions deemed probable of achievement and/or achieved. For PSUs containing performance conditions which were not deemed probable of achievement at March 31, 2020, no stock compensation expense was recognized.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In July 2018, we granted 77,243 PSUs to executives with performance milestones and graded vesting over four years. &#160;The shares of our common stock into which each PSU may convert is subject to a multiplier up to 150% based on the level at which the performance condition is achieved. Compensation expense for the performance-based awards is recorded over the estimated service period when the performance condition is deemed probable of achievement. The actual number of shares of our common stock into which each PSU converted was at a multiplier of 83% based on the performance condition being achieved as of December 31, 2018. &#160;These PSUs will continue to vest through July 2022. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In July 2019, we granted 86,975 PSUs to executives with a performance milestone and graded vesting over four years. &#160;The shares of our common stock into which each PSU may convert is subject to a multiplier up to 125% based on the level at which the performance condition is achieved. Compensation expense for the performance-based awards is recorded over the estimated service period when the performance condition is deemed probable of achievement. The actual number of shares of our common stock into which each PSU will convert is at a multiplier of 101.8% based on the performance condition being achieved as of December 31, 2019. &#160;These PSUs will continue to vest through July 2023.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our shares available for grant under the 2010 Stock Plan:</p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:81.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:15.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares Available</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:81.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:15.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for Grant</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Balance at December&#160;31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,882,122</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Options, RSUs and PSUs granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (1,673,826)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Options, RSUs and PSUs cancelled</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 247,429</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Balance at March&#160;31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,455,725</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Based on our historical experience of employee turnover, we have assumed an annualized forfeiture rate of 5% for our options, RSUs and PSUs. Under the true-up provisions of the stock compensation guidance, we will record additional expense if the actual forfeiture rate is lower than we estimated, and will record a recovery of prior expense if the actual forfeiture is higher than we estimated.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Total compensation cost of options granted but not yet vested, as of March 31, 2020, was $95.8 million, which is expected to be recognized over the weighted average period of approximately 1.4 years. Total compensation cost of RSUs granted but not yet vested, as of March 31, 2020, was $93.3 million, which is expected to be recognized over the weighted average period of approximately 1.8 years. &#160;Total compensation cost of PSUs granted but not yet vested, as of March 31, 2020, was $29.5 million, which is expected to be recognized over the weighted average period of 1.8 years, should the underlying performance conditions be deemed probable of achievement.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6800142768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2.&#160;&#160;&#160;&#160; </b><b style="font-weight:bold;">Summary of significant accounting policies</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Basis of presentation</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. The condensed consolidated balance sheet as of March 31, 2020, the condensed consolidated statements of operations, comprehensive income (loss), stockholders&#8217; equity, and cash flows for the three months ended March 31, 2020 and 2019, are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which we consider necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. &#160;The condensed consolidated balance sheet at December 31, 2019 has been derived from our audited consolidated financial statements.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although we believe that the disclosures in these financial statements are adequate to make the information presented not misleading, certain information and footnote information normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) have been condensed or omitted pursuant to the rules&#160;and regulations of the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Results for any interim period are not necessarily indicative of results for any future interim period or for the entire year. The accompanying financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form&#160;10-K for the year ended December 31, 2019.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Principles of Consolidation.</i> &#160;The condensed consolidated financial statements include the accounts of Incyte Corporation and our wholly owned subsidiaries. All inter-company accounts, transactions, and profits have been eliminated in consolidation.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Foreign Currency Translation</i>. Operations in non-U.S. entities are recorded in the functional currency of each entity. For financial reporting purposes, the functional currency of an entity is determined by a review of the source of an entity's most predominant cash flows. The results of operations for any non-U.S. dollar functional currency entities are translated from functional currencies into U.S. dollars using the average currency rate during each month. Assets and liabilities are translated using currency rates at the end of the period. Adjustments resulting from translating the financial statements of our foreign entities that use their local currency as the functional currency into U.S. dollars are reflected as a component of other comprehensive income (loss). Transaction gains and losses are recorded in other income (expense), net, in the condensed consolidated statements of operations.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Use of Estimates.</i> &#160;The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Concentrations of Credit Risk.</i> &#160;Cash, cash equivalents, marketable securities, and trade receivables are financial instruments which potentially subject us to concentrations of credit risk. The estimated fair value of financial instruments approximates the carrying value based on available market information. We primarily invest our excess available funds in debt securities and, by policy, limit the amount of credit exposure to any one issuer and to any one type of investment, </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">other than securities issued or guaranteed by the U.S. government and money market funds that meet certain guidelines. Our receivables mainly relate to our product sales of JAKAFI, ICLUSIG and collaborative agreements with pharmaceutical companies. We have not experienced any significant credit losses on cash, cash equivalents, marketable securities, or trade receivables to date and do not require collateral on receivables.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Current Expected Credit Losses. &#160;</i>Effective January 1, 2020, financial assets measured at amortized cost are assessed for future expected credit losses under guidance within ASC 326, Financial Instruments &#8211; Credit Losses, to determine if application of an expected credit losses reserve is necessary. On a quarterly basis, receivables that resulted from revenue transactions within the scope of ASC 606 and recognized on an amortized cost basis are reviewed on a customer-level basis to analyze expectations of future collections based upon past history of collections, payment, aging of receivables and viability of the customer to continue payment, as well as estimates of future economic conditions. Receivables generally consist of two types: receivables from collaborative agreements, including milestones, reimbursements for agreed-upon activities and sales royalties; and receivables from customer product sales. Collaborative agreement receivables are closely monitored relationships with select, reputable industry peers. Collection of receivables is assessed within each collaborative partnership on a quarterly basis, including evaluation of each entity&#8217;s credit quality, financial health and past history of payment. Customer product sales receivables are independently evaluated on a monthly basis, on which unusual items or aged receivables are closely monitored for signs of credit deterioration, or indications of payment refusal. Customer product sales are with specialty pharmaceutical distributors, wholesalers, and certain public and private institutions, some of which whose financial obligations are funded by various government agencies. These receivables are assessed for signs of credit deterioration and in the Company&#8217;s sales history and future expectations of economic conditions, there are minimal instances of bad debts or uncollected receivables. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Cash and Cash Equivalents.</i> &#160;Cash and cash equivalents are held in banks or in custodial accounts with banks. Cash equivalents are defined as all liquid investments and money market funds with maturity from date of purchase of 90 days or less that are readily convertible into cash.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Marketable Securities&#8212;Available-for-Sale.</i> &#160;Our marketable securities consist of investments in U.S. government debt securities that are classified as available-for-sale. Available-for-sale securities are carried at fair value, based on quoted market prices and observable inputs, with unrealized gains and losses, net of tax, reported as a separate component of stockholders&#8217; equity. We classify marketable securities that are available for use in current operations as current assets on the condensed consolidated balance sheets. Realized gains and losses and declines in value judged to be other than temporary for available-for-sale securities are included in other income (expense), net on the condensed consolidated statements of operations. &#160;The cost of securities sold is based on the specific identification method.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Accounts Receivable.</i> &#160;As of March 31, 2020 and December 31, 2019, we had a de minimis allowance for doubtful accounts. We provide an allowance for doubtful accounts based on experience and specifically identified risks. Accounts receivable are carried at fair value and charged off against the allowance for doubtful accounts when we determine that recovery is unlikely and we cease collection efforts.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Inventory.</i> &#160;Inventories are determined at the lower of cost and net realizable value with cost determined under the specific identification method and may consist of raw materials, work in process and finished goods. JAKAFI and <span style="-sec-ix-hidden:Hidden_Z0f1rDx3zUCCp3VLdTAwTg"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ICLUSIG</span></span> raw materials and work-in-process inventory are not subject to expiration and the shelf life of finished goods inventory is 36 months from the start of manufacturing of the finished goods. We evaluate for potential excess inventory by analyzing current and future product demand relative to the remaining product shelf life. We build demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance and patient usage. We classify inventory as current on the condensed consolidated balance sheets when we expect inventory to be consumed for commercial use within the next twelve months.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Variable Interest Entities</i>. We perform an initial and ongoing evaluation of the entities with which we have variable interests, such as equity ownership, in order to<i style="font-style:italic;"> </i>identify entities (i) that do not have sufficient equity investment at risk to permit the entity to finance its activities without additional subordinated financial support or (ii) in which the equity investors lack an essential characteristic of a controlling financial interest as variable interest entities (&#8220;VIE&#8221; or &#8220;VIEs&#8221;). If an entity is identified as a VIE, we perform an assessment to determine whether we have both (i) the power to direct activities that most significantly impact the VIE&#8217;s economic performance and (ii) have the obligation to absorb losses from </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">or the right to receive benefits of the VIE that could potentially be significant to the VIE. If both of these criteria are satisfied, we are identified as the primary beneficiary of the VIE. &#160;As of March 31, 2020, there were no entities in which we held a variable interest which we determined to be VIEs.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Long Term Investments.</i> Our long term investments consist of equity investments in common stock of publicly-held companies with whom we have entered into collaboration and license agreements. We classify all of our equity investments in common stock of publicly-held companies as long term investments on our condensed consolidated balance sheets. Our equity investments are accounted for at fair value using readily determinable pricing available on a securities exchange on our condensed consolidated balance sheets. All changes in fair value are reported in the condensed consolidated statements of operations as an unrealized gain (loss) on long term investments. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In assessing whether we exercise significant influence over any of the companies in which we hold equity investments, we consider the nature and magnitude of our investment, any voting and protective rights we hold, any participation in the governance of the other company, and other relevant factors such as the presence of a collaboration or other business relationship. Currently, none of our equity investments in publicly-held companies are considered relationships in which we are able to assert control. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Property and Equipment, net.</i> &#160;Property and equipment, net is stated at cost, less accumulated depreciation and amortization. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets. Leasehold improvements are amortized over the shorter of the estimated useful life of the assets or lease term.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Lease Accounting.</i> &#160;Accounting Standard Codification (&#8220;ASC&#8221;) 842, Leases, was adopted for the fiscal year beginning on January 1, 2019. All leases with a lease term greater than 12 months, regardless of lease type classification, are recorded as an obligation on the balance sheet with a corresponding right-of-use asset. Both finance and operating leases are reflected as liabilities on the commencement date of the lease based on the present value of the lease payments to be made over the lease term. Current operating lease liabilities are reflected in accrued and other current liabilities and noncurrent operating lease liabilities are reflected in other liabilities on the condensed consolidated balance sheet. Right-of-use assets are valued at the initial measurement of the lease liability, plus any initial direct costs or rent prepayments, minus lease incentives and any deferred lease payments. Operating lease right-of-use assets are recorded in property and equipment, net on the condensed consolidated balance sheet and lease cost is recognized on a straight-line basis. For finance leases, expense is recognized as separate amortization and interest expense, with higher interest expense in the earlier periods of a lease. Leases with an initial term of 12 months or less are not recorded on the balance sheet and we recognize lease expense for these leases on a straight-line basis over the term of the lease. In determining whether a contract contains a lease, asset and service agreements are assessed at onset and upon modification for criteria of specifically identified assets, control and economic benefit. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Other Intangible Assets, net.</i> Other intangible assets, net consist of licensed intellectual property rights acquired in business combinations, which are reported at acquisition date fair value, less accumulated amortization. Intangible assets with finite lives are amortized over their estimated useful lives using the straight-line method.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Impairment of Long-Lived Assets.</i> &#160;Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. &#160;If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset. &#160;If the expected cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash flows.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Goodwill.</i> &#160;Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. &#160;Goodwill is not amortized but is tested for impairment at the reporting unit level at least annually as of October 1 or when a triggering event occurs that could indicate a potential impairment by assessing qualitative factors or performing a quantitative analysis in determining whether it is more likely than not that the fair value of net assets are below their carrying amounts. &#160;A reporting unit is the same as, or one level below, an operating segment. Our operations are currently comprised of a single, entity wide reporting </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">unit. We completed our most recent annual impairment assessment as of October 1, 2019 and determined that the carrying value of our goodwill was not impaired. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Income Taxes.</i> &#160;We account for income taxes using the asset and liability approach which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and amounts reportable for income tax purposes. &#160;<span style="background-color:#ffffff;">Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized. </span>The primary factors used to assess the likelihood of realization are our recent history of cumulative earnings or losses, expected reversals of taxable temporary timing differences, forecasts of future taxable income and available tax planning strategies that could be implemented to realize the deferred tax assets. &#160;Upon evaluating and weighting both positive and negative evidence, we concluded that we should continue to maintain the valuation allowance on the majority of our deferred tax assets as of March 31, 2020. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We recognize the tax benefit from an uncertain tax position only if it is more-likely-than-not that the position will be sustained upon examination by the taxing authorities, including resolutions of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit that is recorded for these positions is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. We adjust the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Any interest and penalties on uncertain tax positions are included within the tax provision.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Coronavirus Aid, Relief, and Economic Security (CARES) Act was signed into law in March 2020 to provide an estimated $2.2 trillion designed to stimulate the U.S. economy during the COVID-19 pandemic. &#160;The Act includes tax relief, government loans, grants and investments for entities in affected industries, which has related accounting and financial reporting impacts. &#160;Disclosure for certain income tax accounting measures are required in the period of enactment and disclosure for government loans, investments, grants, and revenue recognition are required in future periods as federal agencies establish rules and procedures to implement the CARES Act. &#160;During the three months ended March 31, 2020, we have not sought any financial relief under the CARES Act and have determined the income tax provision implications to be immaterial. We have further described the expected impact and risks of COVID-19 on our business in the overview to Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations and in Item 1A. Risk Factors.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Financing Costs Related to Long-term Debt.</i> &#160;Costs associated with obtaining long-term debt are deferred and amortized over the term of the related debt using the effective interest method. Such costs are presented as a direct deduction from the carrying amount of the long-term debt liability, consistent with debt discounts, on the condensed consolidated balance sheets.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Net Income (Loss) Per Share.</i> &#160;Our basic and diluted net income (loss) per share is calculated by dividing the net income (loss) by the weighted average number of shares of common stock outstanding during all periods presented. Options to purchase stock, restricted stock units, performance stock units and shares issuable upon the conversion of convertible debt are included in diluted earnings per share calculations, unless the effects are anti-dilutive.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Accumulated Other Comprehensive Income (Loss).</i> &#160;Accumulated other comprehensive income (loss) consists of unrealized gains or losses on marketable securities that are classified as available-for-sale, foreign currency translation gains or losses and defined benefit pension obligations.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Revenue Recognition.</i> &#160;Revenue-generating contracts are assessed under ASC 606, <i style="font-style:italic;">Revenue from contracts with customers</i>, to identify distinct performance obligations, determine the transaction price of the contract and allocate the transaction price to each of the distinct performance obligations. Revenue is recognized when we have satisfied a performance obligation through transferring control of the promised good or service to a customer. Control, in this instance, may mean the ability to prevent other entities from directing the use of, and receiving benefit from, a good or service. We determine at contract inception whether we will transfer control of a promised good or service over time or satisfy the performance obligation at a point in time through analysis of the following criteria: (i) the entity has a present right to payment, (ii) the customer has legal title, (iii) the customer has physical possession, (iv) the customer has the significant </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">risks and rewards of ownership and (v) the customer has accepted the asset. We assess collectability based primarily on the customer&#8217;s payment history and on the creditworthiness of the customer.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration:underline;text-decoration-color:#000000;">Product Revenues</i></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our product revenues consist of U.S. sales of JAKAFI and European sales of ICLUSIG. &#160;Product revenues are recognized once we satisfy the performance obligation at a point in time under the revenue recognition criteria as described above. We sell JAKAFI to our customers in the U.S., which include specialty pharmacies and wholesalers.&#160;We sell ICLUSIG to our customers in the European Union and certain other jurisdictions, which include retail pharmacies, hospital pharmacies and distributors. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We recognize revenues for product received by our customers net of allowances for customer credits, including estimated rebates, chargebacks, discounts, returns, distribution service fees, patient assistance programs, and government rebates, such as Medicare Part D coverage gap reimbursements in the U.S. Product shipping and handling costs are included in cost of product revenues. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Customer Credits:</i> &#160;Our customers are offered various forms of consideration, including allowances, service fees and prompt payment discounts. We expect our customers will earn prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized. Service fees are also deducted from total product sales as they are earned.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Rebates and Discounts:</i> &#160;Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program in the U.S. and mandated discounts in Europe in markets where government-sponsored healthcare systems are the primary payers for healthcare. Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or legal requirements with public sector benefit providers. The accrual for rebates is based on statutory discount rates and expected utilization as well as historical data we have accumulated since product launches. Our estimates for expected utilization of rebates are based on data received from our customers. Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known prior quarters&#8217; unpaid rebates. If actual future rebates vary from estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Chargebacks: &#160;</i>Chargebacks are discounts that occur when certain contracted customers, which currently consist primarily of group purchasing organizations, Public Health Service institutions, non-profit clinics, and Federal government entities purchasing via the Federal Supply Schedule, purchase directly from our wholesalers. Contracted customers generally purchase the product at a discounted price. The wholesalers, in turn, charges back to us the difference between the price initially paid by the wholesalers and the discounted price paid by the contracted customers. In addition to actual chargebacks received we maintain an accrual for chargebacks based on the estimated contractual discounts on the inventory levels on hand in our distribution channel. &#160;If actual future chargebacks vary from these estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Medicare Part&#160;D Coverage Gap:</i> &#160;Medicare Part&#160;D prescription drug benefit mandates manufacturers to fund 70% of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for the expected Medicare Part&#160;D coverage gap are based on historical invoices received and in part from data received from our customers. Funding of the coverage gap is generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known prior quarters. If actual future funding varies from estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment. &#160;Additionally, beginning in January 2020, the amount of spending required by eligible patients in the Medicare Part D insurance coverage gap increased 30% due to the expiration of a provision in the Patient Protection and Affordable Care Act, which now results in a change in the True Out of Pocket (TrOOP) calculation methodology. The methodological change has resulted in an increase in required spending by patients and, in turn, an increase in manufacturers&#8217; contributions on behalf of patients in the Medicare Part D insurance coverage gap.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Co-payment Assistance:</i> &#160;Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration:underline;text-decoration-color:#000000;">Product Royalty Revenues</i></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Royalty revenues on commercial sales for ruxolitinib (marketed as JAKAVI<span style="vertical-align:super;">&#174;</span> outside the United States) by Novartis Pharmaceutical International&#160;Ltd. (&#8220;Novartis&#8221;) are based on net sales of licensed products in licensed territories as provided by Novartis. &#160;Royalty revenues on commercial sales for baricitinib (marketed as OLUMIANT) by Eli Lilly and Company (&#8220;Lilly&#8221;) are based on net sales of licensed products in licensed territories as provided by Lilly. We recognize royalty revenues in the period the sales occur.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration:underline;text-decoration-color:#000000;">Milestone and Contract Revenues</i></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our license agreements, which fall within the scope of ASC 606, Revenue from Contracts with Customers, include distinct drug compound out-licensing, collection of upfront payments, milestones or royalty revenues from a counterparty, and provision of commercially available products to suppliers. Our agreements often include contractual milestones, which typically relate to the achievement of pre-specified development, regulatory and commercialization events outside of our control, such as regulatory approval of a compound, first patient dosing or achievement of sales-based thresholds. For such cases, we believe that revenue related to these events should not be recognized until the milestone has been achieved. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Some contracts form collaborative arrangements of various types with third-parties. We assess whether the nature of the arrangement is within the scope of ASC 808, Collaborative Arrangements, in conjunction with the revenue recognition guidance in ASC 606 to determine the nature of the performance obligations and associated transaction prices. A collaborative relationship may exist when we participate in an activity or process with another party, such as performance of research and development services or the exchange of intellectual property for use in clinical trials, when both parties share in the risks and rewards that result from the activity and participate and govern contract activities through a joint steering committee. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The regulatory review and approval process, which includes preclinical testing and clinical trials of each drug candidate, is lengthy, expensive and uncertain. Securing approval by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) requires the submission of extensive preclinical and clinical data and supporting information to the FDA for each indication to establish a drug candidate&#8217;s safety and efficacy. The approval process takes many years, requires the expenditure of substantial resources, involves post-marketing surveillance and may involve ongoing requirements for post-marketing studies. Before commencing clinical investigations of a drug candidate in humans, we must submit an Investigational New Drug application (&#8220;IND&#8221;), which must be reviewed by the FDA.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The steps generally required before a drug may be marketed in the United States include preclinical laboratory tests, animal studies and formulation studies, submission to the FDA of an IND for human clinical testing, performance of adequate and well-controlled clinical trials in three phases, as described below, to establish the safety and efficacy of the drug for each indication, submission of a new drug application (&#8220;NDA&#8221;) or biologics license application (&#8220;BLA&#8221;) to the FDA for review and FDA approval of the NDA or BLA.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Similar requirements exist within foreign regulatory agencies as well. The time required satisfying the FDA requirements or similar requirements of foreign regulatory agencies may vary substantially based on the type, complexity and novelty of the product or the targeted disease.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Preclinical testing includes laboratory evaluation of product pharmacology, drug metabolism, and toxicity, which includes animal studies, to assess potential safety and efficacy as well as product chemistry, stability, formulation, development, and testing. The results of the preclinical tests, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND. The FDA may raise safety concerns or questions about the conduct of the clinical trials included in the IND, and any of these concerns or questions must be resolved before clinical trials can proceed. We cannot be sure that submission of an IND will result in the FDA allowing clinical trials to commence. Clinical </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">trials involve the administration of the investigational drug or the marketed drug to human subjects under the supervision of qualified investigators and in accordance with good clinical practices regulations covering the protection of human subjects. Clinical trials typically are conducted in three sequential phases, but the phases may overlap or be combined. Phase&#160;I usually involves the initial introduction of the investigational drug into healthy volunteers to evaluate its safety, dosage tolerance, absorption, metabolism, distribution and excretion. Phase&#160;II usually involves clinical trials in a limited patient population to evaluate dosage tolerance and optimal dosage, identify possible adverse effects and safety risks, and evaluate and gain preliminary evidence of the efficacy of the drug for specific indications. Phase&#160;III clinical trials usually further evaluate clinical efficacy and safety by testing the drug in its final form in an expanded patient population, providing statistical evidence of efficacy and safety, and providing an adequate basis for labeling. We cannot guarantee that Phase&#160;I, Phase&#160;II or Phase&#160;III testing will be completed successfully within any specified period of time, if at all. Furthermore, we, the institutional review board for a trial, or the FDA may suspend clinical trials at any time on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Generally, the milestone events contained in our collaboration agreements coincide with the progression of our drugs from development, to regulatory approval and then to commercialization. The process of successfully discovering a new development candidate, having it approved and successfully commercialized is highly uncertain. As such, the milestone payments we may earn from our partners involve a significant degree of risk to achieve. Therefore, as a drug candidate progresses through the stages of its life-cycle, the value of the drug candidate generally increases.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration:underline;text-decoration-color:#000000;">Cost of Product Revenues</i></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cost of product revenues includes all JAKAFI related product costs as well as ICLUSIG related product costs. In addition, cost of product revenues include low single-digit royalties under our collaboration and license agreement to Novartis on all future sales of JAKAFI in the United States and the amortization of our licensed intellectual property for ICLUSIG using the straight-line method over the estimated useful life of 12.5 years from the date of acquisition on June 1, 2016 of all of the outstanding shares of ARIAD Pharmaceuticals (Luxembourg) S.&#224;.r.l. (since renamed Incyte Biosciences Luxembourg S.&#224;.r.l.) from ARIAD Pharmaceuticals, Inc. (&#8220;ARIAD&#8221;). Cost of product revenues also includes employee personnel costs, including stock compensation, for those employees dedicated to the production of our commercial products.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Development Costs.</i> &#160;Our policy is to expense research and development costs as incurred, including amounts funded by research and development collaborations. Research and development expenses are comprised of costs we incur in performing research and development activities, including salary and benefits; stock-based compensation expense; outsourced services and other direct expenses, including clinical trial and pharmaceutical development costs; collaboration payments; expenses associated with drug supplies that are not being capitalized; and infrastructure costs, including facilities costs and depreciation expense. If a collaboration is a cost-sharing arrangement in which both we and our collaborator perform development work and share costs, we also recognize, as research and development expense in the period when our collaborator incurs development expenses, our portion of the co-development expenses that we are obligated to reimburse. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We often contract with clinical research organizations (&#8220;CROs&#8221;) to facilitate, coordinate and perform agreed upon research and development of a new drug. To ensure that research and development costs are expensed as incurred, we record monthly accruals for clinical trials and preclinical testing costs based on the work performed under the contract. These CRO contracts typically call for the payment of fees for services at the initiation of the contract and/or upon the achievement of certain clinical trial milestones. In the event that we prepay CRO fees, we record the prepayment as a prepaid asset and amortize the asset into research and development expense over the period of time the contracted research and development services are performed. Most professional fees, including project and clinical management, data management, monitoring, and medical writing fees are incurred throughout the contract period. These professional fees are expensed based on their percentage of completion at a particular date. Our CRO contracts generally include pass through fees. Pass through fees include, but are not limited to, regulatory expenses, investigator fees, travel costs, and other miscellaneous costs, including shipping and printing fees. We expense the costs of pass through fees under our CRO contracts as they are incurred, based on the best information available to us at the time. The estimates of the pass through fees incurred are based on the amount of work completed for the clinical trial and are monitored through correspondence with the CROs, internal reviews and a review of contractual terms. The factors utilized to derive the estimates include the </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">number of patients enrolled, duration of the clinical trial, estimated patient attrition, screening rate and length of the dosing regimen. CRO fees incurred to set up the clinical trial are expensed during the setup period. Under our clinical trial collaboration agreements we may be reimbursed for certain development costs incurred. Such costs are recorded as a reduction of research and development expense in the period in which the related expense is incurred. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Stock Compensation.</i> &#160;Share-based payment transactions with employees, which include stock options, restricted stock units (&#8220;RSUs&#8221;) and performance shares (&#8220;PSUs&#8221;), are recognized as compensation expense over the requisite service period based on their estimated fair values as well as expected forfeiture rates. &#160;The stock compensation process requires significant judgment and the use of estimates, particularly surrounding Black-Scholes assumptions such as stock price volatility over the option term and expected option lives, as well as expected forfeiture rates and the probability of PSUs vesting. &#160;The fair value of stock options, which are subject to graded vesting, are recognized as compensation expense over the requisite service period using the accelerated attribution method. &#160;The fair value of RSUs that are subject to cliff vesting are recognized as compensation expense over the requisite service period using the straight-line attribution method, and the fair value of RSUs that are subject to graded vesting are recognized as compensation expense over the requisite service period using the accelerated attribution method. &#160;The fair value of PSUs are recognized as compensation expense beginning at the time in which the performance conditions are deemed probable of achievement, which we assess as of the end of each reporting period. Once a performance condition is considered probable, we record compensation expense based on the portion of the service period elapsed to date with respect to that award, with a cumulative catch-up, net of estimated forfeitures, and recognize any remaining compensation expense, if any, over the remaining requisite service period using the straight-line attribution method for PSUs that are subject to cliff vesting and using the accelerated attribution method for PSUs that are subject to graded vesting. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Long Term Incentive Plans.</i> We have long term incentive plans which provide eligible employees with the opportunity to receive performance and service-based incentive compensation, which may be comprised of cash, stock options, restricted stock units and/or performance shares. The payment of cash and the grant or vesting of equity may be contingent upon the achievement of pre-determined regulatory, sales and internal performance milestones. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Acquisition-Related Contingent Consideration.</i> Acquisition-related contingent consideration consists of our future royalty obligations on future net sales of ICLUSIG to Takeda Pharmaceutical Company Limited, which acquired ARIAD (&#8220;Takeda&#8221;). Acquisition-related contingent consideration was recorded on the acquisition date of June 1, 2016 at the estimated fair value of the obligation, in accordance with the acquisition method of accounting. &#160;The fair value measurement is based on significant inputs that are unobservable in the market and thus represents a Level 3 measurement. The fair value of the acquisition-related contingent consideration is remeasured each reporting period, with changes in fair value recorded in the condensed consolidated statements of operations.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><i style="font-style:italic;">Collaboration loss sharing.</i> &#160;Under collaboration and license agreements with shared commercialization efforts, we record our share of the losses from the co-commercialization efforts in collaboration loss sharing on the condensed consolidated statement of operations. For the three months ended March 31, 2020, collaboration loss sharing represents our 50% share of the United States loss for commercialization of tafasitamab under our agreement with MorphoSys. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recent Accounting Pronouncements</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2016-13, &#8220;Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.&#8221; This guidance applies to all entities and impacts how entities account for credit losses for financial assets measured at amortized cost and available for sale debt securities. ASU 2016-13 requires financial assets measured at amortized cost to be presented at the net amount expected to be collected. The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amounts. An entity must use judgment in determining the relevant information and estimation methods that are appropriate in its circumstances. &#160;For trade receivables, loans and held-to-maturity debt securities, entities will be required to estimate expected credit losses over the lifetime of the asset. &#160;For available-for-sale debt securities, entities will be required to recognize an allowance for credit losses rather than an other-than-temporary impairment that reduces the cost basis of the investment. Further, an entity will recognize any improvements in estimated credit losses on its available-for-sale debt securities immediately in earnings. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon adoption, we assessed each financial asset measured at amortized cost and each available for sale debt security held for the impact of the guidance as of January 1, 2020 and noted an insignificant impact due to the minimal credit risk associated with our financial assets subject to ASC 326. As such, it was concluded that a reserve for credit losses was de minimis on the adoption date. Financial assets will continue to be assessed on a quarterly basis in future periods.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2018, the FASB issued ASU No. 2018-13, &#8220;Fair Value Measurement (Topic 820): Disclosure Framework &#8211; Changes to the Disclosure Requirements for Fair Value Measurement,&#8221; which eliminates the required disclosure of the amount of and reason for transfers between Level 1 and Level 2 of the fair value hierarchy. The guidance also eliminates the required disclosure of the entity&#8217;s valuation process for Level 3 fair value measurements, however public entities are required to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. This guidance is effective for fiscal years beginning after December 15, 2019. We adopted this guidance for the period beginning January 1, 2020 and enhanced our disclosures in Note 4 to the condensed consolidated financial statements to comply with the standard. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2018, the FASB issued ASU No. 2018-14, &#8220;Compensation &#8211; Retirement Benefits &#8211; Defined Benefit Plans &#8211; General,&#8221; an update to Subtopic ASC 715-20. The guidance amended year-end disclosure requirements related to defined benefit pension plans, and does not affect interim disclosures. The guidance is effective for fiscal years ending after December 15, 2020 and is permitted for early adoption. The standard is to be applied on a retrospective basis. Incyte sponsors defined benefit plans for employees located in Europe. We are currently analyzing the impact of ASU No. 2018-14 on the condensed consolidated financial statements.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2018, the FASB issued ASU No. 2018-15, &#8220;Intangibles &#8211; Goodwill and Other &#8211; Internal-Use Software,&#8221; an update to Subtopic ASC 350-40. The guidance directs accounting for service contracts for cloud computing arrangements to follow guidance within ASC 350-40 to determine capitalization of implementation costs. The guidance is effective for fiscal years beginning after December 15, 2019 and may be applied on either a retrospective or prospective basis. We adopted this guidance for the period beginning January 1, 2020 on a prospective basis. New contracts for development of internal-use software were assessed and no qualifying contracts were identified during the period. We will continue to assess contracts and will disclose material, qualifying contracts if identified in future periods.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2018, the FASB issued ASU No. 2018-18, &#8220;Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606.&#8221; The guidance clarifies the interactions between Topic 808 and Topic 606, including clarifications on revenue recognition, unit of account, and reporting disclosure requirements. The guidance is effective for fiscal years beginning after December 15, 2019. We adopted this guidance for the period beginning January 1, 2020 on a retrospective to the date of our initial application of ASC 606, and noted that in assessment of our collaborative agreements, there was no material financial statement impact. Our collaborative arrangements and their associated accounting conclusions are described in detail within Note 9 to the condensed consolidated financial statements.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2019, the FASB issued ASU No. 2019-12, &#8220;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.&#8221; This guidance applies to all entities and aims to reduce the complexity of tax accounting standards while enhancing reporting disclosures. This guidance is effective for fiscal years beginning after December 15, 2020 and interim periods therein. Early adoption is permitted for any annual periods for which financial statements have not been issued and interim periods therein. We are currently analyzing the impact of ASU No. 2019-12 and do not anticipate the adoption of this ASU to have a material impact on our condensed consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6967323744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">6.</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;"> Inventory</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our inventory balance consists of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,275</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,275</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Work-in-process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,228</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,634</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,714</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,596</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,217</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,505</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Inventories-current</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,977</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,400</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Inventories-noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,240</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,105</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Inventories, stated at the lower of cost and net realizable value, consist of raw materials, work in process and finished goods. At March 31, 2020, $14.0 million of inventory was classified as current on the condensed consolidated balance sheet as we expect this inventory to be consumed for commercial use within the next twelve months. At March 31, 2020, $8.2 million of inventory was classified as noncurrent on the condensed consolidated balance sheets as we did not expect this inventory to be consumed for commercial use within the next twelve months. &#160;We obtain some inventory components from a limited number of suppliers due to technology, availability, price, quality or other considerations. The loss of a supplier, the deterioration of our relationship with a supplier, or any unilateral violation of the contractual terms under which we are supplied components by a supplier could adversely affect our total revenues and gross margins.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6952203632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net income (loss) per share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic Net Income (Loss) Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Basic net income (loss) per share</a></td>
<td class="num">$ (720,642)<span></span>
</td>
<td class="nump">$ 102,312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding</a></td>
<td class="nump">216,721,000<span></span>
</td>
<td class="nump">214,065,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income (loss) per share</a></td>
<td class="num">$ (3.33)<span></span>
</td>
<td class="nump">$ 0.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted Net Income (Loss) Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Diluted net income (loss)</a></td>
<td class="num">$ (720,642)<span></span>
</td>
<td class="nump">$ 102,312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding</a></td>
<td class="nump">216,721,000<span></span>
</td>
<td class="nump">214,065,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive stock options and awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,996,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares used to compute diluted net income (loss) per share</a></td>
<td class="nump">216,721,000<span></span>
</td>
<td class="nump">217,061,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income (loss) per share</a></td>
<td class="num">$ (3.33)<span></span>
</td>
<td class="nump">$ 0.47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Anti-dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential common shares excluded from diluted net income (loss) per share computation</a></td>
<td class="nump">15,913,287<span></span>
</td>
<td class="nump">9,686,952<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Anti-dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential common shares excluded from diluted net income (loss) per share computation</a></td>
<td class="nump">15,544,348<span></span>
</td>
<td class="nump">9,318,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=incy_ConvertibleSeniorNotes1.25PercentDue2020Member', window );">Convertible Senior Notes 1.25 Percent Due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Anti-dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential common shares excluded from diluted net income (loss) per share computation</a></td>
<td class="nump">368,939<span></span>
</td>
<td class="nump">368,939<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1500-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=incy_ConvertibleSeniorNotes1.25PercentDue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=incy_ConvertibleSeniorNotes1.25PercentDue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6634203248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details) - Convertible Senior Notes 0.375 Percent Due 2018 and Convertible Senior Notes 1.25 Percent Due 2020<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>item</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays', window );">Number of days within 30 consecutive trading days in which the price of the entity's common stock must exceed the conversion price for the notes to be converted</a></td>
<td class="text">20 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays', window );">Number of consecutive trading days during which the closing price of the entity's common stock must exceed the conversion price for at least 20 days in order for the notes to be convertible</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice', window );">Percentage of the closing sales price of common stock that the conversion price must exceed in order for the notes to be convertible (as a percent)</a></td>
<td class="nump">130.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod', window );">Number of consecutive business days immediately after any five consecutive trading day period during the note measurement period</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays', window );">Number of consecutive trading days before five consecutive business days during the note measurement period</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Conversion ratio, principal amount of note</a></td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum', window );">Percentage of the trading price to the product of the last reported sale price of the common stock and the conversion rate, maximum (as a percent)</a></td>
<td class="nump">98.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_DebtInstrumentConversionObligationNumberOfScheduledTradingDaysBeforeMaturity', window );">Number of scheduled trading days preceding relevant maturity date at which Notes are convertible regardless of other circumstances</a></td>
<td class="text">2 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of the closing sales price of the common stock for at least 20 days within 30 consecutive trading days that the closing sales price of the common stock must exceed the conversion price in order for the debt instruments to be convertible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of trading days within a period of 30 consecutive trading days the price of the entity's common stock must exceed the applicable conversion price in order for the debt instruments to be convertible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of consecutive business days immediately after any five consecutive trading day period during the debt instrument measurement period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of consecutive trading days during which the closing price of the entity's common stock must exceed the applicable conversion price for at least 20 days in order for the debt instruments to be convertible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_DebtInstrumentConversionObligationNumberOfScheduledTradingDaysBeforeMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of trading days prior to maturity at which Notes are convertible regardless of other circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_DebtInstrumentConversionObligationNumberOfScheduledTradingDaysBeforeMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of consecutive trading days prior to the five consecutive business days during the debt instrument measurement period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum percentage of the trading price of each debt instrument to the product of the last reported sale price of common stock and the conversion rate of the debt instrument that the trading price must be less than in order for the debt instruments to be convertible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=incy_ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=incy_ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>39
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "incy-20200505x10q.htm": {
   "axisCustom": 2,
   "axisStandard": 29,
   "contextCount": 325,
   "dts": {
    "calculationLink": {
     "local": [
      "incy-20200505_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "incy-20200505_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "incy-20200505x10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "incy-20200505_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "incy-20200505_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "incy-20200505.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd"
     ]
    }
   },
   "elementCount": 609,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 23,
    "http://www.incyte.com/20200505": 5,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 33
   },
   "keyCustom": 75,
   "keyStandard": 364,
   "memberCustom": 51,
   "memberStandard": 41,
   "nsprefix": "incy",
   "nsuri": "http://www.incyte.com/20200505",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.incyte.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - Organization and business",
     "role": "http://www.incyte.com/role/DisclosureOrganizationAndBusiness",
     "shortName": "Organization and business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Summary of significant accounting policies",
     "role": "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of significant accounting policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Revenues",
     "role": "http://www.incyte.com/role/DisclosureRevenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Fair value of financial instruments",
     "role": "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstruments",
     "shortName": "Fair value of financial instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Concentration of credit risk and current expected credit losses",
     "role": "http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLosses",
     "shortName": "Concentration of credit risk and current expected credit losses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Inventory",
     "role": "http://www.incyte.com/role/DisclosureInventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Property and equipment, net",
     "role": "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNet",
     "shortName": "Property and equipment, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Intangible assets and goodwill",
     "role": "http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwill",
     "shortName": "Intangible assets and goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "incy:LicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - License agreements",
     "role": "http://www.incyte.com/role/DisclosureLicenseAgreements",
     "shortName": "License agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "incy:LicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - Stock compensation",
     "role": "http://www.incyte.com/role/DisclosureStockCompensation",
     "shortName": "Stock compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - Accrued and other current liabilities",
     "role": "http://www.incyte.com/role/DisclosureAccruedAndOtherCurrentLiabilities",
     "shortName": "Accrued and other current liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - Debt",
     "role": "http://www.incyte.com/role/DisclosureDebt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11301 - Disclosure - Employee benefit plans",
     "role": "http://www.incyte.com/role/DisclosureEmployeeBenefitPlans",
     "shortName": "Employee benefit plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11401 - Disclosure - Income taxes",
     "role": "http://www.incyte.com/role/DisclosureIncomeTaxes",
     "shortName": "Income taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11501 - Disclosure - Net income (loss) per share",
     "role": "http://www.incyte.com/role/DisclosureNetIncomeLossPerShare",
     "shortName": "Net income (loss) per share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11601 - Disclosure - Contingencies",
     "role": "http://www.incyte.com/role/DisclosureContingencies",
     "shortName": "Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11701 - Disclosure - Subsequent event",
     "role": "http://www.incyte.com/role/DisclosureSubsequentEvent",
     "shortName": "Subsequent event",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - Summary of significant accounting policies (Policies)",
     "role": "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of significant accounting policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - Revenues (Tables)",
     "role": "http://www.incyte.com/role/DisclosureRevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - Fair value of financial instruments (Tables)",
     "role": "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsTables",
     "shortName": "Fair value of financial instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "incy:SchedulesOfConcentrationOfRiskByRiskFactorRelatedToSpecialtyPharmaceuticalCustomersTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - Concentration of credit risk and current expected credit losses (Tables)",
     "role": "http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLossesTables",
     "shortName": "Concentration of credit risk and current expected credit losses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "incy:SchedulesOfConcentrationOfRiskByRiskFactorRelatedToSpecialtyPharmaceuticalCustomersTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "incy:ScheduleOfInventoryTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - Inventory (Tables)",
     "role": "http://www.incyte.com/role/DisclosureInventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "incy:ScheduleOfInventoryTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30703 - Disclosure - Property and equipment, net (Tables)",
     "role": "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetTables",
     "shortName": "Property and equipment, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30803 - Disclosure - Intangible assets and goodwill (Tables)",
     "role": "http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwillTables",
     "shortName": "Intangible assets and goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "incy:ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31003 - Disclosure - Stock compensation (Tables)",
     "role": "http://www.incyte.com/role/DisclosureStockCompensationTables",
     "shortName": "Stock compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "incy:ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31103 - Disclosure - Accrued and other current liabilities (Tables)",
     "role": "http://www.incyte.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesTables",
     "shortName": "Accrued and other current liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31203 - Disclosure - Debt (Tables)",
     "role": "http://www.incyte.com/role/DisclosureDebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31303 - Disclosure - Employee benefit plans (Tables)",
     "role": "http://www.incyte.com/role/DisclosureEmployeeBenefitPlansTables",
     "shortName": "Employee benefit plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31503 - Disclosure - Net income (loss) per share (Tables)",
     "role": "http://www.incyte.com/role/DisclosureNetIncomeLossPerShareTables",
     "shortName": "Net income (loss) per share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_segment_jI2Df57rGUiaWugJ41i_Hg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - Organization and business (Details)",
     "role": "http://www.incyte.com/role/DisclosureOrganizationAndBusinessDetails",
     "shortName": "Organization and business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_segment_jI2Df57rGUiaWugJ41i_Hg",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "incy:CreditExposureLimitationNumberOfIssuerOtherThanUnitedStatesGovernmentGuaranteedSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_issuer_ywviBYfRh0KpQHOu97pP7g",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - Summary of significant accounting policies (Details)",
     "role": "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
     "shortName": "Summary of significant accounting policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "incy:CreditExposureLimitationNumberOfIssuerOtherThanUnitedStatesGovernmentGuaranteedSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_issuer_ywviBYfRh0KpQHOu97pP7g",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "incy:PercentageOfMedicarePartDInsuranceCoverageGapRequiredToBeFundedByManufacturers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40202 - Disclosure - Summary of significant accounting policies - Revenue Recognition (Details)",
     "role": "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails",
     "shortName": "Summary of significant accounting policies - Revenue Recognition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "incy:PercentageOfMedicarePartDInsuranceCoverageGapRequiredToBeFundedByManufacturers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_3_1_2020_To_3_31_2020_PdzkVcZmpESGdHSRd_l9Vw",
      "decimals": "-11",
      "first": true,
      "lang": null,
      "name": "incy:CoronavirusAidReliefAndEconomicSecurityActFund",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40203 - Disclosure - Summary of significant accounting policies - Recent Accounting Pronouncements (Details)",
     "role": "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails",
     "shortName": "Summary of significant accounting policies - Recent Accounting Pronouncements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_3_1_2020_To_3_31_2020_PdzkVcZmpESGdHSRd_l9Vw",
      "decimals": "-11",
      "first": true,
      "lang": null,
      "name": "incy:CoronavirusAidReliefAndEconomicSecurityActFund",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Revenues (Details)",
     "role": "http://www.incyte.com/role/DisclosureRevenuesDetails",
     "shortName": "Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_iqotuIRBdEWR4e6oAi-V5w",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermInvestments",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Fair value of financial instruments - Fair value on a recurring basis (Details)",
     "role": "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails",
     "shortName": "Fair value of financial instruments - Fair value on a recurring basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_6_1_2016_To_6_1_2016_us-gaap_BusinessAcquisitionAxis_incy_AriadPharmaceuticalsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_LiabilityMember_-BGrwF-qIkuMeVQ7qNEL5Q",
      "decimals": null,
      "lang": "en-US",
      "name": "incy:FairValueInputsCashFlowsEstimatedPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "As_Of_3_31_2020_us-gaap_FinancialInstrumentAxis_incy_CorporateAndGovernmentDebtSecuritiesMember__EpAzA1tU0628uub7apmQQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40402 - Disclosure - Fair value of financial instruments - Marketable securities portfolio (Details)",
     "role": "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsMarketableSecuritiesPortfolioDetails",
     "shortName": "Fair value of financial instruments - Marketable securities portfolio (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "As_Of_3_31_2020_us-gaap_FinancialInstrumentAxis_incy_CorporateAndGovernmentDebtSecuritiesMember__EpAzA1tU0628uub7apmQQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "incy:SchedulesOfConcentrationOfRiskByRiskFactorRelatedToSpecialtyPharmaceuticalCustomersTableTextBlock",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_srt_MajorCustomersAxis_incy_CustomerAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_incy_SalesRevenueGoodsServicesNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Fqdfsibh4kKYy4vq1H2Aew",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Concentration of credit risk and current expected credit losses (Details)",
     "role": "http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLossesDetails",
     "shortName": "Concentration of credit risk and current expected credit losses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "incy:SchedulesOfConcentrationOfRiskByRiskFactorRelatedToSpecialtyPharmaceuticalCustomersTableTextBlock",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_srt_MajorCustomersAxis_incy_CustomerAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_incy_SalesRevenueGoodsServicesNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Fqdfsibh4kKYy4vq1H2Aew",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "incy:ScheduleOfInventoryTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Inventory (Details)",
     "role": "http://www.incyte.com/role/DisclosureInventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "incy:ScheduleOfInventoryTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Property and equipment, net - Property and equipment, net (Details)",
     "role": "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetails",
     "shortName": "Property and equipment, net - Property and equipment, net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40702 - Disclosure - Property and equipment, net - Buildings and construction (Details)",
     "role": "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetBuildingsAndConstructionDetails",
     "shortName": "Property and equipment, net - Buildings and construction (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "As_Of_2_28_2018_us-gaap_RealEstatePropertiesAxis_incy_OfficeBuildingMorgesSwitzerlandMember_sv07bVwxFk-3b4wTy2XUvQ",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeaseTermOfContract1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "role": "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "incy:LesseeLeaseLiabilityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseExistenceOfResidualValueGuarantee",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40703 - Disclosure - Property and equipment, net - Lease and maturity of lease liabilities (Details)",
     "role": "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetails",
     "shortName": "Property and equipment, net - Lease and maturity of lease liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "incy:LesseeLeaseLiabilityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseExistenceOfResidualValueGuarantee",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Intangible assets and goodwill (Details)",
     "role": "http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwillDetails",
     "shortName": "Intangible assets and goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - License agreements - Novartis (Details)",
     "role": "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails",
     "shortName": "License agreements - Novartis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "incy:LicenseAgreementsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_11_1_2009_To_11_30_2009_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_A9wnHAKOPUiEb-WirPUvYA",
      "decimals": "-5",
      "lang": null,
      "name": "incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40902 - Disclosure - License agreements - Lilly (Details)",
     "role": "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
     "shortName": "License agreements - Lilly (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_12_1_2009_To_12_31_2009_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_F7owIWcWcESiFzYW1Mzbig",
      "decimals": "-5",
      "lang": null,
      "name": "incy:LicenseAgreementUpfrontPaymentReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermInvestments",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40903 - Disclosure - License agreements - Agenus (Details)",
     "role": "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails",
     "shortName": "License agreements - Agenus (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_11_1_2015_To_11_30_2015_us-gaap_TypeOfArrangementAxis_incy_AgenusMember_y0Dg-8kaqEy_VnxO63h4KA",
      "decimals": "INF",
      "lang": null,
      "name": "incy:NumberOfProgramTargets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_4BIkJQxqZkOMHOIGydcttw",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermInvestments",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40904 - Disclosure - License agreements - Merus (Details)",
     "role": "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails",
     "shortName": "License agreements - Merus (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2017_To_1_31_2017_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_7k2NhRIKp0uBjo2oHVvL-Q",
      "decimals": "INF",
      "lang": null,
      "name": "incy:LicenseAgreementMaximumNumberOfIndependentPrograms",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_4BIkJQxqZkOMHOIGydcttw",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermInvestments",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40905 - Disclosure - License agreements - Calithera (Details)",
     "role": "http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails",
     "shortName": "License agreements - Calithera (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2017_To_1_31_2017_us-gaap_TypeOfArrangementAxis_incy_CalitheraBiosciencesIncMember_k20QIDKWZ0Cx-yYlqJ-TBw",
      "decimals": "2",
      "lang": null,
      "name": "incy:LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40906 - Disclosure - License agreements - MacroGenics (Details)",
     "role": "http://www.incyte.com/role/DisclosureLicenseAgreementsMacrogenicsDetails",
     "shortName": "License agreements - MacroGenics (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_12_1_2017_To_12_31_2017_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_Pvqu3UdMtESm4jPlRmjNxw",
      "decimals": "-5",
      "lang": null,
      "name": "incy:LicenseAgreementUpfrontPaymentAmountPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermInvestments",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40907 - Disclosure - License agreements - Syros (Details)",
     "role": "http://www.incyte.com/role/DisclosureLicenseAgreementsSyrosDetails",
     "shortName": "License agreements - Syros (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2018_To_1_31_2018_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_e3Og2WQPREynUroSL3ThVw",
      "decimals": "INF",
      "lang": null,
      "name": "incy:NumberOfProgramTargets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_4BIkJQxqZkOMHOIGydcttw",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2019_To_1_31_2019_us-gaap_TypeOfArrangementAxis_incy_InnoventBiologicsIncMember_C_ENlXJVxkyNDvDNsqx1-Q",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40908 - Disclosure - License agreements - Innovent (Details)",
     "role": "http://www.incyte.com/role/DisclosureLicenseAgreementsInnoventDetails",
     "shortName": "License agreements - Innovent (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2019_To_1_31_2019_us-gaap_TypeOfArrangementAxis_incy_InnoventBiologicsIncMember_C_ENlXJVxkyNDvDNsqx1-Q",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mHv5WMXrp0O8iRpfgdj6oA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mHv5WMXrp0O8iRpfgdj6oA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_8_1_2019_To_8_31_2019_us-gaap_TypeOfArrangementAxis_incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember_fTLP0rPirE6Sgn7TSP_gGg",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40909 - Disclosure - License agreements - Zai Lab (Details)",
     "role": "http://www.incyte.com/role/DisclosureLicenseAgreementsZaiLabDetails",
     "shortName": "License agreements - Zai Lab (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_8_1_2019_To_8_31_2019_us-gaap_TypeOfArrangementAxis_incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember_fTLP0rPirE6Sgn7TSP_gGg",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40910 - Disclosure - License agreements - MorphoSys (Details)",
     "role": "http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails",
     "shortName": "License agreements - MorphoSys (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "As_Of_1_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmericanDepositarySharesMember_zDA5FKw7iUSQ77Y1CYtdhA",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - Stock compensation (Details)",
     "role": "http://www.incyte.com/role/DisclosureStockCompensationDetails",
     "shortName": "Stock compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": "-5",
      "lang": null,
      "name": "incy:StockCompensationExpenseCapitalized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AzTpzCx2FEeghKSIssu86g",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41002 - Disclosure - Stock compensation - Option activity (Details)",
     "role": "http://www.incyte.com/role/DisclosureStockCompensationOptionActivityDetails",
     "shortName": "Stock compensation - Option activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AzTpzCx2FEeghKSIssu86g",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "incy:ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41003 - Disclosure - Stock compensation - RSU and PSU award activity (Details)",
     "role": "http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuAwardActivityDetails",
     "shortName": "Stock compensation - RSU and PSU award activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "incy:ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41004 - Disclosure - Stock compensation - RSU and PSU (Details)",
     "role": "http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuDetails",
     "shortName": "Stock compensation - RSU and PSU (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2014_To_1_31_2014_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_a4J1xme2j0qJI7w67u-8Kw",
      "decimals": "INF",
      "lang": null,
      "name": "incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41005 - Disclosure - Stock compensation - Shares available for grant (Details)",
     "role": "http://www.incyte.com/role/DisclosureStockCompensationSharesAvailableForGrantDetails",
     "shortName": "Stock compensation - Shares available for grant (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedRoyaltiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - Accrued and other current liabilities (Details)",
     "role": "http://www.incyte.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesDetails",
     "shortName": "Accrued and other current liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedRoyaltiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "As_Of_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_mf1pSO_8xk-KJN_VOGoSlQ",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unitRef": "Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - Debt - Components of convertible notes (Details)",
     "role": "http://www.incyte.com/role/DisclosureDebtComponentsOfConvertibleNotesDetails",
     "shortName": "Debt - Components of convertible notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "As_Of_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_mf1pSO_8xk-KJN_VOGoSlQ",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unitRef": "Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41202 - Disclosure - Debt - Carrying amount and Fair Value (Details)",
     "role": "http://www.incyte.com/role/DisclosureDebtCarryingAmountAndFairValueDetails",
     "shortName": "Debt - Carrying amount and Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "As_Of_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_ByXHMCnwhUuLsKezaFFRag",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ConvertibleDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00405 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "role": "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member_MP4cDjTkq06lAGevzdzYBw",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "incy:DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41203 - Disclosure - Debt - Narrative (Details)",
     "role": "http://www.incyte.com/role/DisclosureDebtNarrativeDetails",
     "shortName": "Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member_MP4cDjTkq06lAGevzdzYBw",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "incy:DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41301 - Disclosure - Employee benefit plans - Defined Contribution Plan (Details)",
     "role": "http://www.incyte.com/role/DisclosureEmployeeBenefitPlansDefinedContributionPlanDetails",
     "shortName": "Employee benefit plans - Defined Contribution Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41302 - Disclosure - Employee benefit plans - Periodic Benefit Cost (Details)",
     "role": "http://www.incyte.com/role/DisclosureEmployeeBenefitPlansPeriodicBenefitCostDetails",
     "shortName": "Employee benefit plans - Periodic Benefit Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41401 - Disclosure - Income taxes (Details)",
     "role": "http://www.incyte.com/role/DisclosureIncomeTaxesDetails",
     "shortName": "Income taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41501 - Disclosure - Net income (loss) per share (Details)",
     "role": "http://www.incyte.com/role/DisclosureNetIncomeLossPerShareDetails",
     "shortName": "Net income (loss) per share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00500 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20200505x10q.htm",
      "contextRef": "As_Of_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_mf1pSO_8xk-KJN_VOGoSlQ",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unitRef": "Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00505 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)",
     "role": "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    }
   },
   "segmentCount": 99,
   "tag": {
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "J [P]",
        "terseLabel": "JAPAN"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "U [S]",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "incy_AccruedAndOtherCurrentLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing accrued and other current liabilities.",
        "label": "Accrued And Other Current Liability [Member]",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "AccruedAndOtherCurrentLiabilityMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_AccruedClinicalRelatedCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.incyte.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical related costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Clinical Related Costs Current",
        "terseLabel": "Clinical related costs"
       }
      }
     },
     "localname": "AccruedClinicalRelatedCostsCurrent",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_AchievementOfMilestoneAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information by different categories of achievement of milestones.",
        "label": "Achievement of Milestone [Axis]"
       }
      }
     },
     "localname": "AchievementOfMilestoneAxis",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsInnoventDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMacrogenicsDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsSyrosDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "incy_AchievementOfMilestoneDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Different categories of achievement of milestones.",
        "label": "Achievement Of Milestone [Domain]",
        "terseLabel": "Achievement of Milestone [Domain]"
       }
      }
     },
     "localname": "AchievementOfMilestoneDomain",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsInnoventDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMacrogenicsDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsSyrosDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_AdoptionOfAccountingStandardAdjustmentToRetainedEarnings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in retained earnings due to the adjustment of prepaid tax assets from adoption of new accounting standard.",
        "label": "Adoption of Accounting Standard Adjustment To Retained Earnings",
        "terseLabel": "Adoption of ASU No. 2016-02"
       }
      }
     },
     "localname": "AdoptionOfAccountingStandardAdjustmentToRetainedEarnings",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_AgenusMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents details pertaining to Agenus with whom we have entered into a License, Development and Commercialization Agreement.",
        "label": "Agenus [Member]",
        "terseLabel": "Agenus"
       }
      }
     },
     "localname": "AgenusMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_AmendedStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents amended stock purchase agreement.",
        "label": "Amended Stock Purchase Agreement [Member]",
        "terseLabel": "Amended stock purchase agreement"
       }
      }
     },
     "localname": "AmendedStockPurchaseAgreementMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsSyrosDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_AmericanDepositarySharesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents American Depositary Shares.",
        "label": "American Depositary Shares [Member]",
        "terseLabel": "ADSs"
       }
      }
     },
     "localname": "AmericanDepositarySharesMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_AriadPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to ARIAD Pharmaceuticals.",
        "label": "Ariad Pharmaceuticals [Member]",
        "terseLabel": "ARIAD"
       }
      }
     },
     "localname": "AriadPharmaceuticalsMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_BuildingAndLeaseholdImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information relating to building and leasehold improvements.",
        "label": "Building And Leasehold Improvements [Member]",
        "terseLabel": "Building and leasehold improvements"
       }
      }
     },
     "localname": "BuildingAndLeaseholdImprovementsMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in the value of a contingent consideration liability attributable to consideration earned by the acquiree in a business combination.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change In Amount Of Contingent Consideration Liability, Consideration Earned",
        "negatedLabel": "Contingent consideration earned during the period but not yet paid"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_BusinessCombinationContingentConsiderationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for acquisition related contingent consideration.",
        "label": "Business Combination Contingent Consideration [Policy Text Block]",
        "terseLabel": "Acquisition-Related Contingent Consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationPolicyTextBlock",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "incy_CalitheraBiosciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents details pertaining to our long-term investment in Calithera Biosciences, Inc with whom we have entered into a License and Commercialization Agreement.",
        "label": "Calithera Biosciences Inc [Member]",
        "terseLabel": "Calithera"
       }
      }
     },
     "localname": "CalitheraBiosciencesIncMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_CollaborationAgreementProfitLossSharingRatio": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ratio of sharing profit and losses under the collaboration agreement.",
        "label": "Collaboration Agreement Profit Loss Sharing Ratio",
        "terseLabel": "Profit (loss) sharing ratio"
       }
      }
     },
     "localname": "CollaborationAgreementProfitLossSharingRatio",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails",
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "incy_CollaborationAgreementProfitSharingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the percentage of profits and losses shared under the collaboration agreement.",
        "label": "Collaboration Agreement Profit Sharing Percentage",
        "terseLabel": "Profit sharing (as a percent)"
       }
      }
     },
     "localname": "CollaborationAgreementProfitSharingPercentage",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "incy_CollaborationAgreementUpfrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represent information pertaining to collaboration agreement upfront payment.",
        "label": "Collaboration Agreement Upfront Payment",
        "terseLabel": "Upfront license fees"
       }
      }
     },
     "localname": "CollaborationAgreementUpfrontPayment",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the collaboration and license agreement with Zai Lab Ltd.",
        "label": "Collaboration And License Agreement With Zai Lab Ltd [Member]",
        "terseLabel": "Zai Lab Ltd"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementWithZaiLabLtdMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_CollaborationLossSharingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The expense recognized during the reporting period for collaboration loss sharing.",
        "label": "Collaboration Loss Sharing Expense",
        "terseLabel": "Collaboration loss sharing"
       }
      }
     },
     "localname": "CollaborationLossSharingExpense",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails",
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_CollaborationPartneraBAndCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to both the Collaboration partners A, B and C.",
        "label": "Collaboration Partnera B And C [Member]",
        "terseLabel": "Collaboration Partner A, B, C and D"
       }
      }
     },
     "localname": "CollaborationPartneraBAndCMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_CommercializationMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to certain commercialized events on the basis of which certain milestones are achieved.",
        "label": "Commercialization Milestones [Member]",
        "terseLabel": "Commercialization Milestones"
       }
      }
     },
     "localname": "CommercializationMilestonesMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsInnoventDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMacrogenicsDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsSyrosDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_ConcentrationOfCreditRiskAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Concentration of Credit Risk [Abstract]",
        "terseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationOfCreditRiskAbstract",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "incy_ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A contractual arrangement to borrow and repay the amount under convertible senior notes at an interest rate of 0.375 percent, which are due in 2018 and 1.25 percent, which are due in 2020.",
        "label": "Convertible Senior Notes0.375 Percent Due2018 And Convertible Senior Notes1.25 Percent Due2020 [Member]",
        "terseLabel": "Convertible Senior Notes 0.375 Percent Due 2018 and Convertible Senior Notes 1.25 Percent Due 2020"
       }
      }
     },
     "localname": "ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_ConvertibleSeniorNotes1.25PercentDue2020Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents a contractual arrangement to borrow and repay the amount under convertible senior notes at an interest rate of 1.25 percent, which are due in 2020.",
        "label": "Convertible Senior Notes1.25 Percent Due2020 [Member]",
        "terseLabel": "Convertible Senior Notes 1.25 Percent Due 2020"
       }
      }
     },
     "localname": "ConvertibleSeniorNotes1.25PercentDue2020Member",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureDebtCarryingAmountAndFairValueDetails",
      "http://www.incyte.com/role/DisclosureDebtComponentsOfConvertibleNotesDetails",
      "http://www.incyte.com/role/DisclosureNetIncomeLossPerShareDetails",
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_CoronavirusAidReliefAndEconomicSecurityActFund": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the Coronavirus Aid, Relief, and Economic Security (CARES) Act funding in the US.",
        "label": "Coronavirus Aid, Relief, and Economic Security Act Fund",
        "terseLabel": "Coronavirus Aid, Relief, and Economic Security (CARES) Act"
       }
      }
     },
     "localname": "CoronavirusAidReliefAndEconomicSecurityActFund",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_CorporateAndGovernmentDebtSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by government or corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate And Government Debt Securities [Member]",
        "terseLabel": "Debt securities (government)"
       }
      }
     },
     "localname": "CorporateAndGovernmentDebtSecuritiesMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsMarketableSecuritiesPortfolioDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_CreditExposureLimitationNumberOfFinancialInvestmentOtherThanUnitedStatesGovernmentGuaranteedSecurities": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of financial investment to which entity limits the amount of credit exposure other than US Government guaranteed securities.",
        "label": "Credit Exposure Limitation, Number of Financial Investment Other than United States Government Guaranteed Securities",
        "terseLabel": "Number of financial investment to which company limits the amount of credit exposure other than US Government guaranteed securities"
       }
      }
     },
     "localname": "CreditExposureLimitationNumberOfFinancialInvestmentOtherThanUnitedStatesGovernmentGuaranteedSecurities",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "incy_CreditExposureLimitationNumberOfIssuerOtherThanUnitedStatesGovernmentGuaranteedSecurities": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of issuer to which entity limits the amount of credit exposure other than US Government guaranteed securities.",
        "label": "Credit Exposure Limitation Number of Issuer Other than United States Government Guaranteed Securities",
        "terseLabel": "Number of issuer to which company limits the amount of credit exposure other than US Government guaranteed securities"
       }
      }
     },
     "localname": "CreditExposureLimitationNumberOfIssuerOtherThanUnitedStatesGovernmentGuaranteedSecurities",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "incy_CustomerABCAndDMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to the customers A, B, C and D.",
        "label": "Customer A B C And D [Member]",
        "terseLabel": "Customer A, B, C and D"
       }
      }
     },
     "localname": "CustomerABCAndDMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_CustomerAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to the customer A.",
        "label": "Customer A [Member]",
        "terseLabel": "Customer A"
       }
      }
     },
     "localname": "CustomerAMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_CustomerBMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to the customer B.",
        "label": "Customer B [Member]",
        "terseLabel": "Customer B"
       }
      }
     },
     "localname": "CustomerBMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_CustomerCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to the customer C.",
        "label": "Customer C [Member]",
        "terseLabel": "Customer C"
       }
      }
     },
     "localname": "CustomerCMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_CustomerDMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to the customer D.",
        "label": "Customer D [Member]",
        "terseLabel": "Customer D"
       }
      }
     },
     "localname": "CustomerDMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the percentage of the closing sales price of the common stock for at least 20 days within 30 consecutive trading days that the closing sales price of the common stock must exceed the conversion price in order for the debt instruments to be convertible.",
        "label": "Debt Instrument Conversion Obligation Common Stock Closing Sales Price as Percentage of Conversion Price",
        "terseLabel": "Percentage of the closing sales price of common stock that the conversion price must exceed in order for the notes to be convertible (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "incy_DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of trading days within a period of 30 consecutive trading days the price of the entity's common stock must exceed the applicable conversion price in order for the debt instruments to be convertible.",
        "label": "Debt Instrument Conversion Obligation Common Stock Closing Sales Price Number of Trading Days",
        "terseLabel": "Number of days within 30 consecutive trading days in which the price of the entity's common stock must exceed the conversion price for the notes to be converted"
       }
      }
     },
     "localname": "DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "incy_DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of consecutive business days immediately after any five consecutive trading day period during the debt instrument measurement period.",
        "label": "Debt Instrument Conversion Obligation Number of Consecutive Business Days after Consecutive Trading Day Period",
        "terseLabel": "Number of consecutive business days immediately after any five consecutive trading day period during the note measurement period"
       }
      }
     },
     "localname": "DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "incy_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of consecutive trading days during which the closing price of the entity's common stock must exceed the applicable conversion price for at least 20 days in order for the debt instruments to be convertible.",
        "label": "Debt Instrument Conversion Obligation Number of Consecutive Trading Days",
        "terseLabel": "Number of consecutive trading days during which the closing price of the entity's common stock must exceed the conversion price for at least 20 days in order for the notes to be convertible"
       }
      }
     },
     "localname": "DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "incy_DebtInstrumentConversionObligationNumberOfScheduledTradingDaysBeforeMaturity": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of trading days prior to maturity at which Notes are convertible regardless of other circumstances.",
        "label": "Debt Instrument Conversion Obligation Number Of Scheduled Trading Days Before Maturity",
        "terseLabel": "Number of scheduled trading days preceding relevant maturity date at which Notes are convertible regardless of other circumstances"
       }
      }
     },
     "localname": "DebtInstrumentConversionObligationNumberOfScheduledTradingDaysBeforeMaturity",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "incy_DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of consecutive trading days prior to the five consecutive business days during the debt instrument measurement period.",
        "label": "Debt Instrument Conversion Obligation Period of Consecutive Trading Days",
        "terseLabel": "Number of consecutive trading days before five consecutive business days during the note measurement period"
       }
      }
     },
     "localname": "DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "incy_DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the maximum percentage of the trading price of each debt instrument to the product of the last reported sale price of common stock and the conversion rate of the debt instrument that the trading price must be less than in order for the debt instruments to be convertible.",
        "label": "Debt Instrument Conversion Obligation Trading Price as Percentage of Product of Last Reported Common Stock Sale Price and Conversion Rate Maximum",
        "terseLabel": "Percentage of the trading price to the product of the last reported sale price of the common stock and the conversion rate, maximum (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "incy_DevelopmentAndCommercializationMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to certain development and commercialization events on the basis of which certain milestones are achieved.",
        "label": "Development And Commercialization Milestones [Member]",
        "terseLabel": "Development and Commercialization Milestones"
       }
      }
     },
     "localname": "DevelopmentAndCommercializationMilestonesMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_DevelopmentAndRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to certain development and regulatory events on the basis of which certain milestones are achieved.",
        "label": "Development And Regulatory Milestones [Member]",
        "terseLabel": "Development and Regulatory Milestones"
       }
      }
     },
     "localname": "DevelopmentAndRegulatoryMilestonesMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsInnoventDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMacrogenicsDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsSyrosDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_DevelopmentMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to certain development events on the basis of which certain milestones are achieved.",
        "label": "Development Milestones [Member]",
        "terseLabel": "Development Milestones"
       }
      }
     },
     "localname": "DevelopmentMilestonesMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_DevelopmentRegulatoryAndCommercialMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to certain development and regulatory events on the basis of which certain milestones are achieved.",
        "label": "Development Regulatory And Commercial Milestones [Member]",
        "terseLabel": "Development Regulatory And Commercial Milestones"
       }
      }
     },
     "localname": "DevelopmentRegulatoryAndCommercialMilestonesMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_DevelopmentRegulatoryAndCommercializationMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents development regulatory and commercialization milestones.",
        "label": "Development Regulatory And Commercialization Milestones [Member]",
        "terseLabel": "Development, Regulatory and Commercialization Milestones"
       }
      }
     },
     "localname": "DevelopmentRegulatoryAndCommercializationMilestonesMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_EliLillyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents details pertaining to Eli Lilly with whom we have entered into a License, Development and Commercialization Agreement.",
        "label": "Eli Lilly [Member]",
        "terseLabel": "Eli Lilly"
       }
      }
     },
     "localname": "EliLillyMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_FairValueInputsAmountOfDiscountForLackOfMarketability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adjustment to the amount of discount used to measure fair value for lack of ability to convert business interests into cash quickly..",
        "label": "Fair Value Inputs, Amount of Discount for Lack of Marketability",
        "terseLabel": "Discount for lack of marketability"
       }
      }
     },
     "localname": "FairValueInputsAmountOfDiscountForLackOfMarketability",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsSyrosDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_FairValueInputsCashFlowsEstimatedPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period of time used to measure cash flows to find the present value of an amount to be paid or received in the future as an input to measure fair value.",
        "label": "Fair Value Inputs Cash Flows Estimated Period",
        "terseLabel": "Projected cash flows period"
       }
      }
     },
     "localname": "FairValueInputsCashFlowsEstimatedPeriod",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "incy_FinanceLeaseLeaseIncentiveReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of lease incentive receivable from landlord under finance leases.",
        "label": "Finance Lease, Lease Incentive Receivable"
       }
      }
     },
     "localname": "FinanceLeaseLeaseIncentiveReceivable",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetBuildingsAndConstructionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represent Finite Lived And Indefinite Lived Intangible Assets By Major Class.",
        "label": "Finite Lived And Indefinite Lived Intangible Assets By Major Class [Line Items]",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represent Finite lived and indefinite lived intangible assets by major class.",
        "label": "Finite Lived And Indefinite Lived Intangible Assets By Major Class [Table]"
       }
      }
     },
     "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "incy_GvhdMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to GVHD, an Graft-Versus-Host Disease field.",
        "label": "Gvhd [Member]",
        "terseLabel": "GVHD"
       }
      }
     },
     "localname": "GvhdMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_ICLUSIGMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to ICLUSIG, a kinase inhibitor.",
        "label": "I C L U S I G [Member]",
        "terseLabel": "ICLUSIG"
       }
      }
     },
     "localname": "ICLUSIGMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureRevenuesDetails",
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_IncyteMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents member information pertaining to Incyte.",
        "label": "Incyte [Member]",
        "terseLabel": "Incyte"
       }
      }
     },
     "localname": "IncyteMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_InnoventBiologicsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents details pertaining to Innovent Biologics, Inc with whom we have entered into a research collaboration and licensing agreement.",
        "label": "Innovent Biologics Inc [Member]",
        "terseLabel": "Innovent"
       }
      }
     },
     "localname": "InnoventBiologicsIncMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsInnoventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_InventoryFinishedGoodsUsefulLifeMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the maximum useful life of merchandise or goods held by the entity that are readily available for sale.",
        "label": "Inventory Finished Goods Useful Life Maximum",
        "terseLabel": "Shelf life for finished goods inventory, maximum"
       }
      }
     },
     "localname": "InventoryFinishedGoodsUsefulLifeMaximum",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "incy_InventoryNetCurrentAndNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.incyte.com/role/DisclosureInventoryCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.incyte.com/role/DisclosureInventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the aggregate carrying amount of current and noncurrent portion, net of valuation reserves and allowances, as of the balance sheet date of inventories.",
        "label": "Inventory Net Current and Noncurrent",
        "totalLabel": "Total inventories"
       }
      }
     },
     "localname": "InventoryNetCurrentAndNoncurrent",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_JAKAFIMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to JAKAFI (ruxolitinib), an oral Janus associate kinase (JAK) inhibitor sold within the United State of America.",
        "label": "J A K A F I [Member]",
        "terseLabel": "JAKAFI"
       }
      }
     },
     "localname": "JAKAFIMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails",
      "http://www.incyte.com/role/DisclosureRevenuesDetails",
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_JakaviMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to JAKAVI (ruxolitinib), an oral Janus associate kinase (JAK) inhibitor sold outside the United State of America.",
        "label": "Jakavi [Member]",
        "terseLabel": "JAKAVI"
       }
      }
     },
     "localname": "JakaviMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_JakaviRoyaltyRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to JAKAVI royalty revenues, an oral Janus associate kinase (JAK) inhibitor sold within the United State of America.",
        "label": "Jakavi Royalty Revenues [Member]",
        "terseLabel": "JAKAVI Royalty Revenues"
       }
      }
     },
     "localname": "JakaviRoyaltyRevenuesMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_LG3ProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to LAG-3 program.",
        "label": "L G3 Program [Member]",
        "terseLabel": "LAG-3 program"
       }
      }
     },
     "localname": "LG3ProgramMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to land located with Y-PARC, Switzerland's largest technology park in Yverdon.",
        "label": "Land Located Within Y Parc Switzerlands Largest Technology Park In Yverdon [Member]",
        "terseLabel": "Land in Y-PARC, Switzerland's largest technology park, Yverdon"
       }
      }
     },
     "localname": "LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetBuildingsAndConstructionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_LesseeLeaseLiabilityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The tabular disclosure of lease liability.",
        "label": "Lessee, Lease Liability [Table Text Block]",
        "terseLabel": "Summary of lease liability"
       }
      }
     },
     "localname": "LesseeLeaseLiabilityTableTextBlock",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "incy_LicenseAgreementAdditionalMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the additional milestone payments to be made under the license agreement.",
        "label": "License Agreement Additional Milestone Payments",
        "terseLabel": "Additional milestone payments under the license agreement"
       }
      }
     },
     "localname": "LicenseAgreementAdditionalMilestonePayments",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMacrogenicsDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsSyrosDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the earning recognized and the payment received for the achievement of a predefined milestone under the license agreement.",
        "label": "License Agreement, Amount Recognized and Received for Achievement of a Predefined Milestone",
        "terseLabel": "Amount recognized and received for the achievement of a predefined milestone"
       }
      }
     },
     "localname": "LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsInnoventDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_LicenseAgreementImmediateMilestonePaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the immediate milestone payment received under the license agreement.",
        "label": "License Agreement, Immediate Milestone Payment Received",
        "terseLabel": "Immediate milestone payment received under license agreement"
       }
      }
     },
     "localname": "LicenseAgreementImmediateMilestonePaymentReceived",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_LicenseAgreementMaximumNumberOfIndependentPrograms": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the maximum number of independent programs encompassed under the collaboration agreement.",
        "label": "License Agreement, Maximum Number Of Independent Programs",
        "terseLabel": "Number of independent programs"
       }
      }
     },
     "localname": "LicenseAgreementMaximumNumberOfIndependentPrograms",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "incy_LicenseAgreementMilestonePaymentAmountPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the amount of the milestone payment made under the license agreement.",
        "label": "License Agreement Milestone Payment Amount Paid",
        "terseLabel": "Milestone payment made under license agreement"
       }
      }
     },
     "localname": "LicenseAgreementMilestonePaymentAmountPaid",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsInnoventDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of additional preclinical discovery programs.",
        "label": "License Agreement, Number of Additional Preclinical Discovery Programs",
        "terseLabel": "Number of additional preclinical discovery programs"
       }
      }
     },
     "localname": "LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "incy_LicenseAgreementNumberOfPreclinicalDiscoveryPrograms": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of preclinical immuno-oncology discovery programs.",
        "label": "License Agreement, Number of Preclinical Discovery Programs",
        "terseLabel": "Number of preclinical discovery programs"
       }
      }
     },
     "localname": "LicenseAgreementNumberOfPreclinicalDiscoveryPrograms",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the percentage of future global development costs funded under the license agreement.",
        "label": "License Agreement Percentage of Future Global Development Costs Funded",
        "terseLabel": "Funding of future development costs (as a percent)"
       }
      }
     },
     "localname": "LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "incy_LicenseAgreementPotentialMilestonePaymentsWithProfitSharing": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the potential milestone payments to be made under the license agreement with profit sharing in effect.",
        "label": "License Agreement Potential Milestone Payments with Profit Sharing",
        "terseLabel": "Potential milestone payments to be made with profit sharing in effect"
       }
      }
     },
     "localname": "LicenseAgreementPotentialMilestonePaymentsWithProfitSharing",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_LicenseAgreementPotentialMilestonePaymentsWithoutProfitSharing": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the potential milestone payments to be made under the license agreement if profit sharing is terminated.",
        "label": "License Agreement Potential Milestone Payments Without Profit Sharing",
        "terseLabel": "Potential milestone payments to be made with profit sharing terminated"
       }
      }
     },
     "localname": "LicenseAgreementPotentialMilestonePaymentsWithoutProfitSharing",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_LicenseAgreementReimbursableCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents reimbursable costs pertaining to license agreements.",
        "label": "License Agreement, Reimbursable Costs",
        "terseLabel": "Reimbursable costs included in accounts receivable"
       }
      }
     },
     "localname": "LicenseAgreementReimbursableCosts",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsInnoventDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_LicenseAgreementResearchAndDevelopmentReimbursedCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents reimbursed costs pertaining to research and development expenses.",
        "label": "License Agreement, Research and Development Reimbursed Cost",
        "terseLabel": "Research and development expenses reimbursed"
       }
      }
     },
     "localname": "LicenseAgreementResearchAndDevelopmentReimbursedCost",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsInnoventDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_LicenseAgreementTargetSelectionAndOptionExerciseFeePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the target selection and option exercise fee payments to be made under the license agreement.",
        "label": "License Agreement Target Selection and Option Exercise Fee Payments",
        "terseLabel": "Target selection and option exercise fee payment"
       }
      }
     },
     "localname": "LicenseAgreementTargetSelectionAndOptionExerciseFeePayments",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsSyrosDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_LicenseAgreementUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the upfront payment under the license agreement.",
        "label": "License Agreement Upfront Payment",
        "terseLabel": "Upfront payment made under license agreement"
       }
      }
     },
     "localname": "LicenseAgreementUpfrontPayment",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_LicenseAgreementUpfrontPaymentAmountPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the amount of the upfront payment made under the license agreement.",
        "label": "License Agreement Upfront Payment Amount Paid",
        "terseLabel": "Upfront payment under license agreement"
       }
      }
     },
     "localname": "LicenseAgreementUpfrontPaymentAmountPaid",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsInnoventDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMacrogenicsDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsSyrosDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the upfront and immediate milestone payment received under the license agreement.",
        "label": "License Agreement, Upfront Payment and Immediate Milestone Payment to be Received",
        "terseLabel": "Upfront and immediate milestone payment to be received under license agreement"
       }
      }
     },
     "localname": "LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsInnoventDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_LicenseAgreementUpfrontPaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the upfront payment received under the license agreement.",
        "label": "License Agreement, Upfront Payment Received",
        "terseLabel": "Upfront payment received under license agreement"
       }
      }
     },
     "localname": "LicenseAgreementUpfrontPaymentReceived",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_LicenseAgreementsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "License agreements"
       }
      }
     },
     "localname": "LicenseAgreementsDisclosureAbstract",
     "nsuri": "http://www.incyte.com/20200505",
     "xbrltype": "stringItemType"
    },
    "incy_LicenseAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element may be used to describe all significant license agreements of the reporting entity.",
        "label": "License Agreements [Text Block]",
        "terseLabel": "License agreements"
       }
      }
     },
     "localname": "LicenseAgreementsTextBlock",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "incy_LitigationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Contingencies"
       }
      }
     },
     "localname": "LitigationDisclosureAbstract",
     "nsuri": "http://www.incyte.com/20200505",
     "xbrltype": "stringItemType"
    },
    "incy_LongTermIncentivePlanOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to one of the existing long term incentive plan.",
        "label": "Long Term Incentive Plan One [Member]",
        "terseLabel": "Long term incentive plan - 1"
       }
      }
     },
     "localname": "LongTermIncentivePlanOneMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_LongTermIncentivePlanTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to one of the existing long term incentive plan.",
        "label": "Long Term Incentive Plan Two [Member]",
        "terseLabel": "Long term incentive plan - 2"
       }
      }
     },
     "localname": "LongTermIncentivePlanTwoMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_LongTermInvestmentPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for long term investments in financial asset.",
        "label": "Long Term Investment [Policy Text Block]",
        "terseLabel": "Long Term Investments"
       }
      }
     },
     "localname": "LongTermInvestmentPolicyTextBlock",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "incy_MacrogenicsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents details pertaining to MacroGenics with whom we have entered into an exclusive global collaboration and license agreement.",
        "label": "Macrogenics [Member]",
        "terseLabel": "MacroGenics"
       }
      }
     },
     "localname": "MacrogenicsMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMacrogenicsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_MedicarePartDInsuranceCoverageGapIncreaseInEligiblePatientSpendingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the Medicare Part D insurance coverage gap percent increase for required patient spending.",
        "label": "Medicare Part D Insurance Coverage Gap, Increase in Eligible Patient Spending, Percentage",
        "terseLabel": "Increase in required patient spending in the Medicare Part D insurance coverage gap (as a percent)"
       }
      }
     },
     "localname": "MedicarePartDInsuranceCoverageGapIncreaseInEligiblePatientSpendingPercentage",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "incy_MerusNVMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to Merus N. V.",
        "label": "Merus N V [Member]",
        "terseLabel": "Merus"
       }
      }
     },
     "localname": "MerusNVMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_MilestoneAndContractRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to milestone and contract revenues.",
        "label": "Milestone And Contract Revenue [Member]",
        "terseLabel": "Milestone and contract revenues"
       }
      }
     },
     "localname": "MilestoneAndContractRevenueMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureRevenuesDetails",
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_MorphosysAgMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents member information pertaining to MorphoSys AG.",
        "label": "Morphosys Ag [Member]",
        "terseLabel": "MorphoSys AG"
       }
      }
     },
     "localname": "MorphosysAgMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails",
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_NovartisMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents details pertaining to Novartis with whom we have entered into a Collaboration and License Agreement.",
        "label": "Novartis [Member]",
        "terseLabel": "Novartis"
       }
      }
     },
     "localname": "NovartisMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_NumberOfProductCandidates": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of clinical-stage product candidates .",
        "label": "Number of Product Candidates",
        "terseLabel": "Product candidates"
       }
      }
     },
     "localname": "NumberOfProductCandidates",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsInnoventDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "incy_NumberOfProgramTargets": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of program targets identified.",
        "label": "Number Of Program Targets",
        "terseLabel": "Number of program targets"
       }
      }
     },
     "localname": "NumberOfProgramTargets",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsSyrosDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of programs in which the resulting products are co-funded for development.",
        "label": "Number of Programs Under Which The Resulting Products Are Co-Funded For Development",
        "terseLabel": "Number of programs under the resulting products are co-funded for development"
       }
      }
     },
     "localname": "NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "incy_OfficeBuildingMorgesSwitzerlandMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information relating to the office building located in Morges, Switzerland.",
        "label": "Office Building Morges Switzerland [Member]",
        "terseLabel": "Office Building in Morges, Switzerland"
       }
      }
     },
     "localname": "OfficeBuildingMorgesSwitzerlandMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetBuildingsAndConstructionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_OlumiantRoyaltyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to OLUMIANT royalty revenues, a treatment of adults with moderately-to-severely active rheumatoid arthritis.",
        "label": "Olumiant Royalty [Member]",
        "terseLabel": "OLUMIANT Royalty Revenues"
       }
      }
     },
     "localname": "OlumiantRoyaltyMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_OperatingAndFinanceLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating and finance lease.",
        "label": "Operating And Finance Lease Liability",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseLiability",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_OperatingLeaseRightOfUseAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual agreement that stipulates the lessee pay the lessor for use of an asset under operating lease.",
        "label": "Operating Lease Right Of Use Assets [Member]",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetsMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_PaymentOfContingentConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow with regard to the contingent consideration during the period.",
        "label": "Payment of Contingent Consideration",
        "negatedLabel": "Payment of contingent consideration"
       }
      }
     },
     "localname": "PaymentOfContingentConsideration",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the percentage of associated future global development costs from the initiation of a Phase IIb trial provided the entity elects to co-develop any compounds and/or indications.",
        "label": "Percentage Funding on Cost on Possible Election of Co-development of Compounds",
        "terseLabel": "Associated future global development costs from the initiation of a Phase IIb trial, if elected to co-develop (as a percentage)",
        "verboseLabel": "Associated future global development costs , if elected to co-develop (as a percent)"
       }
      }
     },
     "localname": "PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "incy_PercentageOfMedicarePartDInsuranceCoverageGapRequiredToBeFundedByManufacturers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the percentage of Medicare Part D insurance coverage gap mandate to be funded by manufacturers for prescription drugs sold to eligible patients.",
        "label": "Percentage Of Medicare Part D Insurance Coverage Gap Required To Be Funded By Manufacturers",
        "terseLabel": "Percentage of Medicare Part D insurance coverage gap mandate to be funded by manufacturers"
       }
      }
     },
     "localname": "PercentageOfMedicarePartDInsuranceCoverageGapRequiredToBeFundedByManufacturers",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "incy_PercentageOfNetSalesPertainingToAdditionalRoyalties": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the percentage of net sales attributable to additional royalties.",
        "label": "Percentage of Net Sales Pertaining to Additional Royalties",
        "terseLabel": "Percentage of additional royalties"
       }
      }
     },
     "localname": "PercentageOfNetSalesPertainingToAdditionalRoyalties",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "incy_PercentageOfProfitsLosses": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the percentage of profits (losses).",
        "label": "Percentage of Profits (Losses)",
        "terseLabel": "Percentage of profit (losses)"
       }
      }
     },
     "localname": "PercentageOfProfitsLosses",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "incy_PercentageOfReverseRoyaltiesOnSaleOfFutureProducts": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the percentage of reverse royalties on sale of future products.",
        "label": "Percentage of Reverse Royalties On Sale of Future Products",
        "terseLabel": "Percentage of reverse royalty"
       }
      }
     },
     "localname": "PercentageOfReverseRoyaltiesOnSaleOfFutureProducts",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "incy_PercentageOfRoyaltyRatePayments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents range of tiered, double-digit royalty payments on future global sales if product is successfully commercialized.",
        "label": "Percentage Of Royalty Rate Payments",
        "terseLabel": "Royalty payments on future global net sales (as a percent)"
       }
      }
     },
     "localname": "PercentageOfRoyaltyRatePayments",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMacrogenicsDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "incy_PhaseThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to the Phase III of the arrangement.",
        "label": "Phase Three [Member]",
        "terseLabel": "Phase III"
       }
      }
     },
     "localname": "PhaseThreeMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_PhaseTwoBMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to phase IIb of the arrangement.",
        "label": "Phase Two B [Member]",
        "terseLabel": "Phase IIB"
       }
      }
     },
     "localname": "PhaseTwoBMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_PhasesOfArrangementsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by phases of arrangements.",
        "label": "Phases of Arrangements [Axis]"
       }
      }
     },
     "localname": "PhasesOfArrangementsAxis",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "incy_PhasesOfArrangementsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Different phases of arrangements.",
        "label": "Phases Of Arrangements [Domain]",
        "terseLabel": "Phases of Arrangements [Domain]"
       }
      }
     },
     "localname": "PhasesOfArrangementsDomain",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_PreSpecifiedEventsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to certain pre-specified events on the basis of which certain milestones are achieved.",
        "label": "Pre Specified Events [Member]",
        "terseLabel": "Pre-specified Events"
       }
      }
     },
     "localname": "PreSpecifiedEventsMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the purchase of common stock under Stock Purchase Agreement.",
        "label": "Purchase of common stock under stock purchase agreement in shares",
        "terseLabel": "Purchase of common stock under Stock Purchase Agreement (in shares )"
       }
      }
     },
     "localname": "PurchaseOfCommonStockUnderStockPurchaseAgreementInShares",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsSyrosDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "incy_PurchasePriceOfCommonStockUnderStockPurchaseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the purchase price of common stock under Stock Purchase Agreement.",
        "label": "Purchase price of common stock under stock purchase agreement",
        "verboseLabel": "Stock purchase price"
       }
      }
     },
     "localname": "PurchasePriceOfCommonStockUnderStockPurchaseAgreement",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_RegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to certain regulatory events on the basis of which certain milestones are achieved.",
        "label": "Regulatory Milestones [Member]",
        "terseLabel": "Regulatory Milestones"
       }
      }
     },
     "localname": "RegulatoryMilestonesMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsInnoventDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_RoyaltiesPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the amount of royalties payable.",
        "label": "Royalties Payable",
        "terseLabel": "Royalties payable"
       }
      }
     },
     "localname": "RoyaltiesPayable",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_RoyaltyPaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the royalty payment receivable under the license agreement.",
        "label": "Royalty Payment Receivable",
        "terseLabel": "Product royalties in accounts receivable"
       }
      }
     },
     "localname": "RoyaltyPaymentReceivable",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_SalesRevenueGoodsServicesNetMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate revenue during the period from the sale of goods and services in the normal course of business, after deducting returns, allowances and discounts, when it serves as a benchmark in a concentration of risk calculation.",
        "label": "Sales Revenue Goods Services Net [Member]",
        "terseLabel": "Net Product Revenues"
       }
      }
     },
     "localname": "SalesRevenueGoodsServicesNetMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_ScheduleOfInventoryTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of carrying amount of inventories as of the balance sheet date.",
        "label": "Schedule of Inventory [Table Text Block]",
        "terseLabel": "Schedule of inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryTableTextBlock",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureInventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "incy_ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure represents the schedule of share based compensation other than stock options activity.",
        "label": "Schedule of RSU award and PSU activity under the 2010 Stock Plan"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "incy_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock options plan and employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share Based Payment Award, Stock Options and Employee Stock Purchase Plan Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of valuation assumptions used for valuation of fair value of stock compensation granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "incy_SchedulesOfConcentrationOfRiskByRiskFactorRelatedToSpecialtyPharmaceuticalCustomersTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark, related to the specialty pharmaceutical customers.",
        "label": "Schedules of Concentration of Risk by Risk Factor Related to Specialty Pharmaceutical Customers [Table Text Block]",
        "terseLabel": "Schedule of concentration of credit risk related to specialty pharmacy customers"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorRelatedToSpecialtyPharmaceuticalCustomersTableTextBlock",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLossesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, equity instruments other than options, conversion multiplying factor.",
        "label": "Share-based Compensation Arrangement by Share-based payment Award, Equity Instruments Other than Options, Conversion Multiplying Factor",
        "terseLabel": "Multiplying factor"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of shares of employee compensation programs, other than options, released during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Released In Period",
        "negatedLabel": "Released (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share weighted average intrinsic value of equity-based compensation awards released. Excludes stock and unit options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Released Intrinsic Value",
        "terseLabel": "Released (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the expected annualized forfeiture rate for options granted.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions Expected Annualized Forfeiture Rate",
        "terseLabel": "Assumed annualized forfeiture rate (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares canceled under an established share-based compensation plan.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Number of Shares Canceled",
        "terseLabel": "Options, RSUs and PSUs cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationSharesAvailableForGrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares granted under an established share-based compensation plan.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Number of Shares Granted",
        "negatedLabel": "Options, RSUs and PSUs granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationSharesAvailableForGrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of shares awarded for each restricted share units.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Number of Shares Per Restricted Stock Units",
        "terseLabel": "Number of shares awarded for each RSU (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageMultiplierForConversionOfUnitsIntoCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the multiplier expressed as a percentage used for conversion of PSU into actual number of shares of common stock.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award, Percentage Multiplier for Conversion of Units Into Common Stock",
        "terseLabel": "Multiplier conversion rate of units into common stock (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageMultiplierForConversionOfUnitsIntoCommonStock",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "No definition available.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant [Roll Forward]",
        "terseLabel": "Shares Available For Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationSharesAvailableForGrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "incy_StockCompensationExpenseCapitalized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the amount of stock compensation expenses capitalized.",
        "label": "Stock Compensation Expense Capitalized"
       }
      }
     },
     "localname": "StockCompensationExpenseCapitalized",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_StockPurchaseAgreementLockUpPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the period of time that the company will not sell or otherwise transfer any of the equity method shares.",
        "label": "Stock Purchase Agreement Lock Up Period",
        "terseLabel": "Lock-up period"
       }
      }
     },
     "localname": "StockPurchaseAgreementLockUpPeriod",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsSyrosDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "incy_StockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents stock purchase agreement.",
        "label": "Stock Purchase Agreement [Member]",
        "terseLabel": "Stock purchase agreement"
       }
      }
     },
     "localname": "StockPurchaseAgreementMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsSyrosDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_SyrosPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents details pertaining to Syros Pharmaceuticals, Inc with whom we have entered into a target discovery, research collaboration and option agreement.",
        "label": "Syros Pharmaceuticals Inc [Member]",
        "terseLabel": "Syros Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "SyrosPharmaceuticalsIncMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsSyrosDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_TIM3ProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to TIM-3 program.",
        "label": "T I M3 Program [Member]",
        "terseLabel": "TIM-3 program"
       }
      }
     },
     "localname": "TIM3ProgramMember",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "incy_TotalConsiderationPaidUnderPurchaseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the amount of the total consideration paid under purchase agreement during the period.",
        "label": "Total Consideration Paid Under Purchase Agreement",
        "terseLabel": "Total consideration paid"
       }
      }
     },
     "localname": "TotalConsiderationPaidUnderPurchaseAgreement",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "incy_VariableInterestEntitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "n/a",
        "label": "Variable Interest Entities Abstract",
        "terseLabel": "Variable Interest Entities"
       }
      }
     },
     "localname": "VariableInterestEntitiesAbstract",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "incy_VariableInterestEntitiesNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of Variable Interest Entities as on date.",
        "label": "Variable Interest Entities Number",
        "terseLabel": "Number of entities in which variable interest held"
       }
      }
     },
     "localname": "VariableInterestEntitiesNumber",
     "nsuri": "http://www.incyte.com/20200505",
     "presentation": [
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r49",
      "r94"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity Method Investee Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsSyrosDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r137",
      "r207",
      "r210",
      "r391"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsMarketableSecuritiesPortfolioDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsInnoventDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMacrogenicsDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsSyrosDetails",
      "http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsMarketableSecuritiesPortfolioDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMacrogenicsDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails",
      "http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Name Of Major Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r135",
      "r207",
      "r208",
      "r388",
      "r389"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Products and Services [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails",
      "http://www.incyte.com/role/DisclosureRevenuesDetails",
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails",
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Products And Services [Domain]",
        "terseLabel": "Products and Services [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails",
      "http://www.incyte.com/role/DisclosureRevenuesDetails",
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails",
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsMarketableSecuritiesPortfolioDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsInnoventDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMacrogenicsDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsSyrosDetails",
      "http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsMarketableSecuritiesPortfolioDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsInnoventDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMacrogenicsDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsSyrosDetails",
      "http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Repurchase Agreement Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsSyrosDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r136",
      "r207",
      "r209",
      "r390",
      "r393",
      "r395"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Summary of significant accounting policies"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "verboseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureAccruedAndOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r19",
      "r379"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, Net",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued and other liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMacrogenicsDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.incyte.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued and other current liabilities",
        "totalLabel": "Total accrued and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesDetails",
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]",
        "terseLabel": "Accrued and Other Current Liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.",
        "label": "Accrued Liabilities [Member]",
        "terseLabel": "Accrued and other liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMacrogenicsDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r38"
     ],
     "calculation": {
      "http://www.incyte.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r34",
      "r190"
     ],
     "calculation": {
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r53",
      "r54",
      "r55"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r52",
      "r55",
      "r56",
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "verboseLabel": "Weighted Average Useful Lives (Years)"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r233",
      "r235",
      "r267",
      "r268"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r235",
      "r262",
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Stock compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationDetails",
      "http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potential common shares excluded from diluted net income (loss) per share computation"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Square Footage of Laboratory and Office Purchased",
        "terseLabel": "Square footage"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetBuildingsAndConstructionDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsInnoventDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMacrogenicsDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsSyrosDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsZaiLabDetails",
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r132",
      "r367",
      "r380"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsAndLiabilitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Capital Lease Obligations [Abstract]",
        "verboseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r48"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "terseLabel": "Current assets",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r308"
     ],
     "calculation": {
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r151"
     ],
     "calculation": {
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsMarketableSecuritiesPortfolioDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Net Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsMarketableSecuritiesPortfolioDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r148",
      "r164"
     ],
     "calculation": {
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsMarketableSecuritiesPortfolioDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available-for-sale Debt Securities, Amortized Cost Basis",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsMarketableSecuritiesPortfolioDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r145",
      "r149",
      "r164"
     ],
     "calculation": {
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsMarketableSecuritiesPortfolioDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available-for-sale Securities, Debt Securities",
        "terseLabel": "Debt securities (government)",
        "verboseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails",
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsMarketableSecuritiesPortfolioDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r147",
      "r164"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Marketable securities-available-for-sale (amortized cost $258,622; allowance for credit losses $0)"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r237",
      "r264"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationDetails",
      "http://www.incyte.com/role/DisclosureStockCompensationOptionActivityDetails",
      "http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuAwardActivityDetails",
      "http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMacrogenicsDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r305",
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMacrogenicsDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r280",
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r79",
      "r287"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in fair value of acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r283",
      "r284",
      "r286"
     ],
     "calculation": {
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "verboseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r283",
      "r285"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Valuation input (as a percent)"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r283",
      "r285"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r85",
      "r86",
      "r87"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Unpaid purchases of property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r322",
      "r323"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Carrying Reported Amount Fair Value Disclosure [Member]",
        "terseLabel": "Carrying Amount"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureDebtCarryingAmountAndFairValueDetails",
      "http://www.incyte.com/role/DisclosureDebtComponentsOfConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r30",
      "r82"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r11",
      "r83",
      "r89"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r77",
      "r82",
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, restricted cash and investments at end of period",
        "periodStartLabel": "Cash, cash equivalents, restricted cash and investments at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r77",
      "r329"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents, restricted cash and investments"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaboration loss sharing"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r18",
      "r198"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.001 par value; 400,000,000 shares authorized; 216,952,325 and 216,177,830 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Employee benefit plans"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r59",
      "r61",
      "r62"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r120",
      "r121",
      "r324",
      "r325"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r120",
      "r121",
      "r324",
      "r325",
      "r392"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r120",
      "r121",
      "r324",
      "r325",
      "r392"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r115",
      "r377"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.",
        "label": "Concentration Risk Disclosure [Text Block]",
        "verboseLabel": "Concentration of credit risk and current expected credit losses"
       }
      }
     },
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLosses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration of risk"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r120",
      "r121",
      "r324",
      "r325"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percentage of concentration risk"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLossesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r118",
      "r120",
      "r121",
      "r122",
      "r324",
      "r326"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r120",
      "r121",
      "r324",
      "r325"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r89",
      "r292",
      "r302",
      "r303"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "auth_ref": [
      "r89",
      "r297",
      "r298",
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "terseLabel": "Variable Interest Entities"
       }
      }
     },
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r189"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Site preparation, design and construction costs"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetBuildingsAndConstructionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction In Progress [Member]",
        "terseLabel": "Construction in Progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetBuildingsAndConstructionDetails",
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionPayableCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.incyte.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Construction Payable, Current",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r16",
      "r370",
      "r382"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible Debt",
        "totalLabel": "Convertible senior notes",
        "verboseLabel": "Convertible senior notes"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureDebtCarryingAmountAndFairValueDetails",
      "http://www.incyte.com/role/DisclosureDebtComponentsOfConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Convertible Debt, Current",
        "terseLabel": "Convertible senior notes"
       }
      }
     },
     "localname": "ConvertibleDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of product revenues (including definite-lived intangible amortization)"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost Of Sales [Member]",
        "terseLabel": "Cost of product revenues"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditConcentrationRiskMember": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement.",
        "label": "Credit Concentration Risk [Member]",
        "terseLabel": "Credit Concentration Risk"
       }
      }
     },
     "localname": "CreditConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditLossFinancialInstrumentPolicyTextBlock": {
     "auth_ref": [
      "r157",
      "r159",
      "r161",
      "r162",
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status.",
        "label": "Credit Loss, Financial Instrument [Policy Text Block]",
        "terseLabel": "Current Expected Credit Losses"
       }
      }
     },
     "localname": "CreditLossFinancialInstrumentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r368",
      "r370",
      "r378"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureDebtCarryingAmountAndFairValueDetails",
      "http://www.incyte.com/role/DisclosureDebtComponentsOfConvertibleNotesDetails",
      "http://www.incyte.com/role/DisclosureDebtNarrativeDetails",
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r41",
      "r199",
      "r200",
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Conversion ratio, principal amount of note"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate of debt (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureDebtCarryingAmountAndFairValueDetails",
      "http://www.incyte.com/role/DisclosureDebtComponentsOfConvertibleNotesDetails",
      "http://www.incyte.com/role/DisclosureDebtNarrativeDetails",
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Convertible Notes"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureDebtCarryingAmountAndFairValueDetails",
      "http://www.incyte.com/role/DisclosureDebtComponentsOfConvertibleNotesDetails",
      "http://www.incyte.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureDebtCarryingAmountAndFairValueDetails",
      "http://www.incyte.com/role/DisclosureDebtComponentsOfConvertibleNotesDetails",
      "http://www.incyte.com/role/DisclosureDebtNarrativeDetails",
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r42",
      "r95",
      "r199",
      "r201",
      "r202",
      "r203",
      "r332",
      "r333",
      "r335",
      "r376"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureDebtCarryingAmountAndFairValueDetails",
      "http://www.incyte.com/role/DisclosureDebtComponentsOfConvertibleNotesDetails",
      "http://www.incyte.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "verboseLabel": "Contractual maturity dates"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsMarketableSecuritiesPortfolioDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtPolicyTextBlock": {
     "auth_ref": [
      "r89",
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.",
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Financing Costs Related to Long-term Debt"
       }
      }
     },
     "localname": "DebtPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r150",
      "r164",
      "r167",
      "r168"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss",
        "terseLabel": "Marketable securities-allowance for credit losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": {
     "auth_ref": [
      "r164"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Amortized Cost, Current",
        "terseLabel": "Marketable securities-amortized cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Summary of marketable securities portfolio"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities": {
     "auth_ref": [
      "r212",
      "r216",
      "r369",
      "r381"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension plan. Excludes other postretirement benefit plan.",
        "label": "Defined Benefit Pension Plan, Liabilities",
        "terseLabel": "Accrued pension obligation"
       }
      }
     },
     "localname": "DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureEmployeeBenefitPlansPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActuarialGainLoss": {
     "auth_ref": [
      "r215"
     ],
     "calculation": {
      "http://www.incyte.com/role/DisclosureEmployeeBenefitPlansPeriodicBenefitCostDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.",
        "label": "Defined Benefit Plan, Actuarial Gain (Loss)",
        "negatedLabel": "Amortization of actuarial losses"
       }
      }
     },
     "localname": "DefinedBenefitPlanActuarialGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureEmployeeBenefitPlansPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r223",
      "r228",
      "r230"
     ],
     "calculation": {
      "http://www.incyte.com/role/DisclosureEmployeeBenefitPlansPeriodicBenefitCostDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "verboseLabel": "Amortization of prior service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureEmployeeBenefitPlansPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear": {
     "auth_ref": [
      "r229"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of contributions received and expected to be received by defined benefit plan from employer in current fiscal year.",
        "label": "Defined Benefit Plan, Expected Contributions in Current Fiscal Year",
        "verboseLabel": "Expected contributions"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureEmployeeBenefitPlansPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r222",
      "r227",
      "r230"
     ],
     "calculation": {
      "http://www.incyte.com/role/DisclosureEmployeeBenefitPlansPeriodicBenefitCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return on Plan Assets",
        "negatedLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureEmployeeBenefitPlansPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r214",
      "r221",
      "r226",
      "r230"
     ],
     "calculation": {
      "http://www.incyte.com/role/DisclosureEmployeeBenefitPlansPeriodicBenefitCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "verboseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureEmployeeBenefitPlansPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r219",
      "r224",
      "r230"
     ],
     "calculation": {
      "http://www.incyte.com/role/DisclosureEmployeeBenefitPlansPeriodicBenefitCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost",
        "totalLabel": "Net periodic benefit cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureEmployeeBenefitPlansPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList": {
     "auth_ref": [
      "r219",
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates line item in statement of income or comprehensive income that includes components of net periodic benefit cost (credit), excluding service cost component, for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Excluding Service Cost, Statement of Income or Comprehensive Income [Extensible List]",
        "terseLabel": "Location of costs excluding the service component"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureEmployeeBenefitPlansPeriodicBenefitCostDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r213",
      "r220",
      "r225",
      "r230"
     ],
     "calculation": {
      "http://www.incyte.com/role/DisclosureEmployeeBenefitPlansPeriodicBenefitCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "verboseLabel": "Employer Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureEmployeeBenefitPlansPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r231"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost Recognized",
        "terseLabel": "Defined contribution expense"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureEmployeeBenefitPlansDefinedContributionPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r80",
      "r130"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Revenues",
        "verboseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureRevenuesDetails",
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of disaggregated revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureRevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stock compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net income (loss) per share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r67",
      "r98",
      "r102",
      "r104",
      "r105",
      "r106",
      "r110",
      "r373",
      "r387"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic",
        "verboseLabel": "Basic net income (loss) per share"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureNetIncomeLossPerShareDetails",
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Basic Net Income (Loss) Per Share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "verboseLabel": "Net income (loss) per share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "terseLabel": "Net income per share"
       }
      }
     },
     "localname": "EarningsPerShareBasicLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r67",
      "r98",
      "r102",
      "r104",
      "r105",
      "r106",
      "r110",
      "r373",
      "r387"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted",
        "verboseLabel": "Diluted net income (loss) per share"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureNetIncomeLossPerShareDetails",
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Diluted Net Income (Loss) Per Share"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Anti-dilutive securities"
       }
      }
     },
     "localname": "EarningsPerShareDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r89",
      "r107",
      "r108",
      "r109"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Income (Loss) Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net income (loss) per share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureNetIncomeLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r329"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Foreign currency translation change",
        "terseLabel": "Effect of exchange rates on cash, cash equivalents, restricted cash and investments"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Employee Service Share-based Compensation, Aggregate Disclosures [Abstract]",
        "terseLabel": "Unrecognized compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r263"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized",
        "terseLabel": "Unrecognized compensation cost for nonvested option (in dollars)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Vesting period of recognition of the unrecognized compensation cost of nonvested awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureNetIncomeLossPerShareDetails",
      "http://www.incyte.com/role/DisclosureStockCompensationDetails",
      "http://www.incyte.com/role/DisclosureStockCompensationOptionActivityDetails",
      "http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityFairValueDisclosure": {
     "auth_ref": [
      "r308"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of the entity's equity.",
        "label": "Equity, Fair Value Disclosure",
        "terseLabel": "Fair value of shares on the issuance date",
        "verboseLabel": "Fair value of shares"
       }
      }
     },
     "localname": "EquityFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsSyrosDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "auth_ref": [
      "r31"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Aggregate Cost",
        "verboseLabel": "Purchase price of common stock"
       }
      }
     },
     "localname": "EquityMethodInvestmentAggregateCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsSyrosDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Ownership percentage (as a percent)"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsSyrosDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r91",
      "r154",
      "r156",
      "r327"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) reported by an equity method investment of the entity.",
        "label": "Equity Method Investment, Summarized Financial Information, Net Income (Loss)",
        "terseLabel": "Net income (loss)",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue": {
     "auth_ref": [
      "r0",
      "r156"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue from sale of product and rendering of service reported by equity method investee.",
        "label": "Equity Method Investment, Summarized Financial Information, Revenue",
        "terseLabel": "Total revenues"
       }
      }
     },
     "localname": "EquityMethodInvestmentSummarizedFinancialInformationRevenue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r153"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "negatedLabel": "Unrealized loss (gain) on long term investments",
        "terseLabel": "Unrealized gain (loss) on long term investments",
        "verboseLabel": "Unrealized gain (loss) on long term investments"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsSyrosDetails",
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate Of Fair Value Fair Value Disclosure [Member]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureDebtCarryingAmountAndFairValueDetails",
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair value of financial instruments"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r308",
      "r309",
      "r310",
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r308",
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of fair value of assets measured on recurring basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r217",
      "r218",
      "r230",
      "r309",
      "r361"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value, Hierarchy [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r316",
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r308",
      "r318"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureDebtCarryingAmountAndFairValueDetails",
      "http://www.incyte.com/role/DisclosureDebtComponentsOfConvertibleNotesDetails",
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r308",
      "r309",
      "r312",
      "r313",
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair value of financial instruments."
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair value of financial instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r217",
      "r218",
      "r230",
      "r309",
      "r362"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r217",
      "r218",
      "r230",
      "r309",
      "r363"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r217",
      "r218",
      "r230",
      "r309",
      "r364"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r308",
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of fair value of liabilities measured on recurring basis"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Roll forward of Level 3 liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r314",
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of roll forward of Level 3 liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r315"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Change in fair value of contingent consideration"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r314"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance at the end of the period",
        "periodStartLabel": "Balance at the beginning of the period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r316",
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value Measurements Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r339",
      "r347",
      "r354"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest expense on finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r342",
      "r349"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease, Interest Payment on Liability",
        "terseLabel": "Cash paid for financing lease liabilities in operating cash flows"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Finance Lease, Liability, Payment, Due [Abstract]",
        "verboseLabel": "Maturity of our finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r337",
      "r353"
     ],
     "calculation": {
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetailsCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Financing lease liabilities",
        "verboseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetBuildingsAndConstructionDetails",
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "incy_OperatingAndFinanceLeaseLiability",
       "weight": 1.0
      },
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Finance lease liabilities",
        "verboseLabel": "Finance lease liabilities, current"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetails",
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.",
        "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "incy_OperatingAndFinanceLeaseLiability",
       "weight": 1.0
      },
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Finance lease liabilities, noncurrent",
        "verboseLabel": "Finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetails",
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability.",
        "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r353"
     ],
     "calculation": {
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Payment, Due",
        "totalLabel": "Total lease cash payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r341",
      "r349"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Payment of finance lease liabilities",
        "terseLabel": "Cash paid for financing lease liabilities in financing cash flows"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetails",
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r336"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under finance lease.",
        "label": "Finance Lease, Right-of-Use Asset",
        "terseLabel": "Finance lease right-of-use assets, net"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetBuildingsAndConstructionDetails",
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r339",
      "r347",
      "r354"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization on our finance lease right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r352",
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate, finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r351",
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average lease term, finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r160",
      "r163",
      "r165",
      "r166",
      "r169",
      "r170"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsMarketableSecuritiesPortfolioDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r184"
     ],
     "calculation": {
      "http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwillDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2020"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r185"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r185"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r185"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r185"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r180",
      "r182",
      "r184",
      "r186",
      "r366"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Amortization Expense"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r184",
      "r366"
     ],
     "calculation": {
      "http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r180",
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite Lived Intangible Assets Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r184"
     ],
     "calculation": {
      "http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "terseLabel": "Finite-lived intangible assets:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "terseLabel": "Amortization period"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r89",
      "r328",
      "r330"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r177",
      "r178"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Intangible assets and goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible assets and goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r89",
      "r179"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillPeriodIncreaseDecrease": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Period Increase (Decrease)",
        "terseLabel": "Changes to the carry amount of goodwill"
       }
      }
     },
     "localname": "GoodwillPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Changes to carrying amount of goodwill"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r89",
      "r188",
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest",
        "totalLabel": "Income (loss) before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/DisclosureStockCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/DisclosureStockCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r92",
      "r131",
      "r277"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes",
        "verboseLabel": "Income tax (benefit) expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureIncomeTaxesDetails",
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r63",
      "r89",
      "r271",
      "r272",
      "r274",
      "r275",
      "r276",
      "r278",
      "r394"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Increase (decrease) noncurrent other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInRoyaltiesPayable": {
     "auth_ref": [
      "r79"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the obligations due for compensation payments related to the use of copyrights, patents, trade names, licenses, technology. Royalty payments are also paid by the lease holders for oil, gas, and mineral extraction.",
        "label": "Increase (Decrease) in Royalties Payable",
        "terseLabel": "Royalties payable on net sales"
       }
      }
     },
     "localname": "IncreaseDecreaseInRoyaltiesPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r103",
      "r108"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "verboseLabel": "Dilutive stock options and awards"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r89",
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Other Intangible Assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntellectualPropertyMember": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights.",
        "label": "Intellectual Property [Member]",
        "terseLabel": "Licensed IP"
       }
      }
     },
     "localname": "IntellectualPropertyMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r64",
      "r129",
      "r331",
      "r334",
      "r374"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r38"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Interest payable"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureInventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r25",
      "r175"
     ],
     "calculation": {
      "http://www.incyte.com/role/DisclosureInventoryDetails": {
       "order": 3.0,
       "parentTag": "incy_InventoryNetCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r45",
      "r172"
     ],
     "calculation": {
      "http://www.incyte.com/role/DisclosureInventoryCalc2": {
       "order": 1.0,
       "parentTag": "incy_InventoryNetCurrentAndNoncurrent",
       "weight": 1.0
      },
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "verboseLabel": "Inventories - current"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureInventoryDetails",
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory, Net [Abstract]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.incyte.com/role/DisclosureInventoryCalc2": {
       "order": 2.0,
       "parentTag": "incy_InventoryNetCurrentAndNoncurrent",
       "weight": 1.0
      },
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "terseLabel": "Inventory",
        "verboseLabel": "Inventories-noncurrent"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureInventoryDetails",
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r10",
      "r46",
      "r89",
      "r112",
      "r173",
      "r174"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r27",
      "r175"
     ],
     "calculation": {
      "http://www.incyte.com/role/DisclosureInventoryDetails": {
       "order": 1.0,
       "parentTag": "incy_InventoryNetCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r26",
      "r175"
     ],
     "calculation": {
      "http://www.incyte.com/role/DisclosureInventoryDetails": {
       "order": 2.0,
       "parentTag": "incy_InventoryNetCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Fair market value of our long term investments"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsSyrosDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend finance lease.",
        "label": "Lessee, Finance Lease, Existence of Option to Extend [true false]",
        "terseLabel": "Options to extend"
       }
      }
     },
     "localname": "LesseeFinanceLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetBuildingsAndConstructionDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeFinanceLeaseRenewalTerm1": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Renewal Term",
        "terseLabel": "Renewal term of agreement to rent"
       }
      }
     },
     "localname": "LesseeFinanceLeaseRenewalTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetBuildingsAndConstructionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeFinanceLeaseTermOfContract1": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Term of Contract",
        "terseLabel": "Initial lease term"
       }
      }
     },
     "localname": "LesseeFinanceLeaseTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetBuildingsAndConstructionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lease, Policy [Policy Text Block]",
        "terseLabel": "Lease Accounting"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease.",
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfResidualValueGuarantee": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates (true false) whether lessee provided residual value guarantee for operating lease.",
        "label": "Lessee, Operating Lease, Existence of Residual Value Guarantee [true false]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfResidualValueGuarantee",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r24",
      "r371",
      "r384"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "terseLabel": "Current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liability [Member]",
        "terseLabel": "Contingent Consideration"
       }
      }
     },
     "localname": "LiabilityMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term Investments",
        "terseLabel": "Long term investments",
        "verboseLabel": "Long term investments (Note 6)"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsSyrosDetails",
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities-Available-for-Sale"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MeasurementInputCapRateMember": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using ratio of net operating income produced by asset to its capital cost.",
        "label": "Measurement Input Cap Rate [Member]",
        "terseLabel": "Average Cost of Capital"
       }
      }
     },
     "localname": "MeasurementInputCapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input Discount Rate [Member]",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r77",
      "r78",
      "r81"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "totalLabel": "Net cash (used in) provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r57",
      "r60",
      "r66",
      "r81",
      "r108",
      "r372",
      "r386"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income",
        "totalLabel": "Net (loss) income",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome",
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r98",
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Basic net income (loss) per share"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r100",
      "r101"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Diluted net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non Us [Member]",
        "terseLabel": "Non-U.S."
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureOrganizationAndBusinessDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income (loss) from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r348",
      "r354"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Expense related to our operating leases"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r340"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Leases, Rent Expense, Net",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.incyte.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "incy_OperatingAndFinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Operating lease liabilities, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesDetails",
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "incy_OperatingAndFinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r343",
      "r349"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r352",
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate, operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r351",
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average lease term, operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization and business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r1",
      "r97",
      "r126",
      "r304"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "verboseLabel": "Organization and business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureOrganizationAndBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 9.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets, net"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r290",
      "r291",
      "r295"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r58",
      "r61",
      "r290",
      "r291",
      "r295"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income",
        "totalLabel": "Other comprehensive income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome",
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "verboseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r51",
      "r53"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax",
        "negatedLabel": "Defined benefit pension obligations, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which reported facts about other comprehensive income have been included.",
        "label": "Other Comprehensive Income [Member]",
        "terseLabel": "Other Comprehensive Income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r50",
      "r53"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax",
        "terseLabel": "Unrealized gain on marketable securities, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIntangibleAssetsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.",
        "label": "Other Intangible Assets, Net",
        "terseLabel": "Other intangible assets, net"
       }
      }
     },
     "localname": "OtherIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r38"
     ],
     "calculation": {
      "http://www.incyte.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquireLongtermInvestments": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.",
        "label": "Payments to Acquire Long-term Investments",
        "negatedLabel": "Purchase of long term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireLongtermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r146"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "negatedLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireRealEstate": {
     "auth_ref": [
      "r73"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow from the acquisition of a piece of land, anything permanently fixed to it, including buildings, structures on it and so forth; includes real estate intended to generate income for the owner; excludes real estate acquired for use by the owner.",
        "label": "Payments to Acquire Real Estate",
        "terseLabel": "Purchase price"
       }
      }
     },
     "localname": "PaymentsToAcquireRealEstate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetBuildingsAndConstructionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for pension and other postretirement benefits.",
        "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]",
        "verboseLabel": "Employee benefit plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureEmployeeBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Stock Units (PSUs)"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationDetails",
      "http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuAwardActivityDetails",
      "http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r237",
      "r264"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion At Fair Value Fair Value Disclosure [Member]",
        "terseLabel": "Portion at Fair Value Measurement [Member]"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureDebtCarryingAmountAndFairValueDetails",
      "http://www.incyte.com/role/DisclosureDebtComponentsOfConvertibleNotesDetails",
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock, $0.001 par value; 5,000,000 shares authorized; none issued or outstanding as of March 31, 2020 and December 31, 2019"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r28",
      "r29"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Sale and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuance of common stock under stock plans"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product revenues, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureRevenuesDetails",
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails",
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r57",
      "r60",
      "r76",
      "r132",
      "r134",
      "r290",
      "r293",
      "r294",
      "r300",
      "r301"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r34",
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetBuildingsAndConstructionDetails",
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r33",
      "r189"
     ],
     "calculation": {
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and Equipment, gross",
        "verboseLabel": "Costs for architectural and engineering studies and initial ground preparation"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetBuildingsAndConstructionDetails",
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetBuildingsAndConstructionDetails",
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r12",
      "r13",
      "r191",
      "r385"
     ],
     "calculation": {
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetails",
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r32",
      "r89",
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r12",
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r12",
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetBuildingsAndConstructionDetails",
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProvisionForLossOnContracts": {
     "auth_ref": [
      "r205"
     ],
     "calculation": {
      "http://www.incyte.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cumulative provision for contract losses not offset against related costs accumulated on the balance sheet.",
        "label": "Provision for Loss on Contracts",
        "terseLabel": "Sales allowances"
       }
      }
     },
     "localname": "ProvisionForLossOnContracts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RealEstatePropertiesAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by ownership of the property.",
        "label": "Real Estate Property Ownership [Axis]"
       }
      }
     },
     "localname": "RealEstatePropertiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetBuildingsAndConstructionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RealEstatePropertiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents categories of ownership of real estate properties.",
        "label": "Real Estate Properties [Domain]",
        "terseLabel": "Real Estate Properties [Domain]"
       }
      }
     },
     "localname": "RealEstatePropertiesDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetBuildingsAndConstructionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "License agreements"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsInnoventDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMacrogenicsDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsSyrosDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r270",
      "r396"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMacrogenicsDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsSyrosDetails",
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r89",
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndInvestmentsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.",
        "label": "Restricted Cash and Investments, Noncurrent",
        "terseLabel": "Restricted cash and investments"
       }
      }
     },
     "localname": "RestrictedCashAndInvestmentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units R S U [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationDetails",
      "http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuAwardActivityDetails",
      "http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r21",
      "r204",
      "r383"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r206",
      "r207"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenues",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails",
      "http://www.incyte.com/role/DisclosureRevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r90",
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue From Contract With Customer Policy Text Block",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureRevenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r65",
      "r127",
      "r128",
      "r133"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues.",
        "terseLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r350",
      "r354"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Leased assets obtained in exchange for new finance lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r350",
      "r354"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Leased assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Concentration of credit risk and current expected credit losses"
       }
      }
     },
     "localname": "RisksAndUncertaintiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Product royalty revenues"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureRevenuesDetails",
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued and other current liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of antidilutive securities excluded from the computation of earnings per share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureNetIncomeLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Available-for-sale Securities [Line Items]",
        "terseLabel": "Summary of marketable security portfolio"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsMarketableSecuritiesPortfolioDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of carrying amount and fair value of convertible notes"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r42",
      "r95",
      "r199",
      "r201",
      "r202",
      "r203",
      "r332",
      "r333",
      "r335",
      "r376"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of components of convertible notes"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of calculation of net income (loss) per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureNetIncomeLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r180",
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of finite-lived intangible assets, net"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "verboseLabel": "Schedule of net periodic benefit cost"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureEmployeeBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested shares.",
        "label": "Schedule of Nonvested Share Activity [Table Text Block]",
        "terseLabel": "Summary of shares available for grant"
       }
      }
     },
     "localname": "ScheduleOfNonvestedShareActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r34",
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetBuildingsAndConstructionDetails",
      "http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetails",
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r93",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r237",
      "r264"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationDetails",
      "http://www.incyte.com/role/DisclosureStockCompensationOptionActivityDetails",
      "http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuAwardActivityDetails",
      "http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r242",
      "r253",
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]",
        "terseLabel": "Schedule of option activity under the 2010 Stock Plan"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of estimated aggregate amortization expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]",
        "terseLabel": "Organization and Business"
       }
      }
     },
     "localname": "SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureOrganizationAndBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r70",
      "r171"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling General And Administrative Expenses [Member]",
        "terseLabel": "Selling, General and Administrative Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period",
        "terseLabel": "Service period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationOptionActivityDetails",
      "http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average intrinsic value of award forfeited under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Intrinsic Value, Amount Per Share",
        "terseLabel": "Cancelled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "outstanding (in shares)",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuAwardActivityDetails",
      "http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average intrinsic value of award granted under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Intrinsic Value, Amount Per Share",
        "periodEndLabel": "Outstanding at the end of the period (in dollars per share)",
        "periodStartLabel": "Outstanding at the beginning of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Weighted-average fair value assumptions"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Volatility (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of method used to estimate fair value of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Method Used",
        "terseLabel": "Valuation method"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Average risk-free interest rates (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Stock compensation",
        "verboseLabel": "Stock Compensation Plans"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationDetails",
      "http://www.incyte.com/role/DisclosureStockCompensationOptionActivityDetails",
      "http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuAwardActivityDetails",
      "http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r243",
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "periodEndLabel": "Outstanding at the end of the period (in shares)",
        "periodStartLabel": "Outstanding at the beginning of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "periodEndLabel": "Outstanding at the end of the period (in shares)",
        "periodStartLabel": "Outstanding at the beginning of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationSharesAvailableForGrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "verboseLabel": "Shares Subject to Outstanding Options, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationOptionActivityDetails",
      "http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r244",
      "r264"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at the end of the period (in shares)",
        "periodStartLabel": "Outstanding at the beginning of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares Subject to Outstanding Options, Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationOptionActivityDetails",
      "http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at the end of the period (in dollars per share)",
        "periodStartLabel": "Outstanding at the beginning of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r234",
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationDetails",
      "http://www.incyte.com/role/DisclosureStockCompensationOptionActivityDetails",
      "http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuAwardActivityDetails",
      "http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options cancelled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share Based Compensation Award Tranche One [Member]",
        "terseLabel": "Vesting after one year"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share Based Compensation Award Tranche Two [Member]",
        "terseLabel": "Remainder vesting"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r89",
      "r237",
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]",
        "terseLabel": "Stock Compensation and Long-term Incentive Plans"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Per share price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsSyrosDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Percentage of units vesting at the end of each calendar year (as a percent)",
        "verboseLabel": "Vesting Percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationOptionActivityDetails",
      "http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "verboseLabel": "Termination period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r257",
      "r265"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Average expected life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of significant accounting policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r44",
      "r198"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement",
        "verboseLabel": "Condensed Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsZaiLabDetails",
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical",
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CONDENSED CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsMarketableSecuritiesPortfolioDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsInnoventDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMacrogenicsDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsSyrosDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsZaiLabDetails",
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails",
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical",
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Issuance of shares of Common Stock for services rendered"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r17",
      "r18",
      "r198",
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures",
        "terseLabel": "Issuance of shares of Common Stock upon exercise of stock options and restricted stock units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r17",
      "r18",
      "r198",
      "r204",
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Issuance of shares of Common Stock for services rendered"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r17",
      "r18",
      "r204",
      "r236",
      "r254"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures",
        "terseLabel": "Issuance of shares of Common Stock upon exercise of stock options and settlement of employee restricted stock units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r18",
      "r22",
      "r23",
      "r143"
     ],
     "calculation": {
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balances",
        "periodStartLabel": "Balances",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent event"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "verboseLabel": "Subsequent event"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureSubsequentEvent"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Schedule of Cash Flow Information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r144"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Trade and Other Accounts Receivable, Policy [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsMarketableSecuritiesPortfolioDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsInnoventDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMacrogenicsDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsSyrosDetails",
      "http://www.incyte.com/role/DisclosureLicenseAgreementsZaiLabDetails",
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.",
        "label": "Unrecognized Tax Benefits, Period Increase (Decrease)",
        "terseLabel": "Increase in unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r113",
      "r114",
      "r116",
      "r117",
      "r123",
      "r124",
      "r125"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureStockCompensationOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r101",
      "r106"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "positiveLabel": "Weighted average shares used to compute diluted net income (loss) per share",
        "verboseLabel": "Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureNetIncomeLossPerShareDetails",
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "Shares used in computing net income (loss) per share:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r99",
      "r106"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "positiveLabel": "Weighted average common shares outstanding",
        "verboseLabel": "Basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.incyte.com/role/DisclosureNetIncomeLossPerShareDetails",
      "http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1377-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1500-109256"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e4975-111524"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=SL6953423-111524"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5212-111524"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5033-111524"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5093-111524"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26626-111562"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=116654751&loc=SL75117546-209714"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33912-111571"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919260-210447"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919272-210447"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "35",
   "Topic": "605",
   "URI": "http://asc.fasb.org/extlink&oid=68068069&loc=d3e57777-111642"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "30",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "44",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5558-128473"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2AA",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=SL6759068-111685"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5728-111685"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=SL6759159-111685"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-02)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-03)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13467-108611"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13476-108611"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918631-209977"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62652-112803"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r397": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r398": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r399": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r401": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r402": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6800893312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License agreements - Lilly (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">124 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Jul. 31, 2010</div></th>
<th class="th"><div>Dec. 31, 2009</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,085,287<span></span>
</td>
<td class="nump">$ 270,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">568,507<span></span>
</td>
<td class="nump">497,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_EliLillyMember', window );">Eli Lilly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementUpfrontPaymentReceived', window );">Upfront payment received under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_RoyaltyPaymentReceivable', window );">Product royalties in accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,400<span></span>
</td>
<td class="nump">$ 23,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_EliLillyMember', window );">Eli Lilly | Phase IIB</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds', window );">Associated future global development costs from the initiation of a Phase IIb trial, if elected to co-develop (as a percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_EliLillyMember', window );">Eli Lilly | Pre-specified Events | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived', window );">Upfront and immediate milestone payment to be received under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">665,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_EliLillyMember', window );">Eli Lilly | Development Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone', window );">Amount recognized and received for the achievement of a predefined milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">149,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_EliLillyMember', window );">Eli Lilly | Development Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived', window );">Upfront and immediate milestone payment to be received under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_EliLillyMember', window );">Eli Lilly | Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone', window );">Amount recognized and received for the achievement of a predefined milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 235,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_EliLillyMember', window );">Eli Lilly | Regulatory Milestones | JAPAN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone', window );">Amount recognized and received for the achievement of a predefined milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_EliLillyMember', window );">Eli Lilly | Regulatory Milestones | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone', window );">Amount recognized and received for the achievement of a predefined milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_EliLillyMember', window );">Eli Lilly | Regulatory Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived', window );">Upfront and immediate milestone payment to be received under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_EliLillyMember', window );">Eli Lilly | Commercialization Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,400<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_EliLillyMember', window );">Eli Lilly | Commercialization Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived', window );">Upfront and immediate milestone payment to be received under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_PercentageOfRoyaltyRatePayments', window );">Royalty payments on future global net sales (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_EliLillyMember', window );">Eli Lilly | Development and Commercialization Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_EliLillyMember', window );">Eli Lilly | GVHD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementUpfrontPaymentAmountPaid', window );">Upfront payment under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementAdditionalMilestonePayments', window );">Additional milestone payments under the license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_EliLillyMember', window );">Eli Lilly | GVHD | Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementMilestonePaymentAmountPaid', window );">Milestone payment made under license agreement</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementAdditionalMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the additional milestone payments to be made under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementAdditionalMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the earning recognized and the payment received for the achievement of a predefined milestone under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementMilestonePaymentAmountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of the milestone payment made under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementMilestonePaymentAmountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementUpfrontPaymentAmountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of the upfront payment made under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementUpfrontPaymentAmountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the upfront and immediate milestone payment received under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the upfront payment received under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of associated future global development costs from the initiation of a Phase IIb trial provided the entity elects to co-develop any compounds and/or indications.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_PercentageOfRoyaltyRatePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents range of tiered, double-digit royalty payments on future global sales if product is successfully commercialized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_PercentageOfRoyaltyRatePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_RoyaltyPaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the royalty payment receivable under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_RoyaltyPaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=incy_EliLillyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=incy_EliLillyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_PhasesOfArrangementsAxis=incy_PhaseTwoBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_PhasesOfArrangementsAxis=incy_PhaseTwoBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_PreSpecifiedEventsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_PreSpecifiedEventsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_DevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_DevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_DevelopmentAndCommercializationMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_DevelopmentAndCommercializationMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=incy_GvhdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=incy_GvhdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6799020560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License agreements - MacroGenics (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,085,287<span></span>
</td>
<td class="nump">$ 270,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MacrogenicsMember', window );">MacroGenics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementUpfrontPaymentAmountPaid', window );">Upfront payment under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,400<span></span>
</td>
<td class="nump">$ 9,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MacrogenicsMember', window );">MacroGenics | Accrued and other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued and other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | MacroGenics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_PercentageOfRoyaltyRatePayments', window );">Royalty payments on future global net sales (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | MacroGenics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_PercentageOfRoyaltyRatePayments', window );">Royalty payments on future global net sales (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember', window );">Development and Regulatory Milestones | Maximum | MacroGenics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementAdditionalMilestonePayments', window );">Additional milestone payments under the license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember', window );">Commercialization Milestones | Maximum | MacroGenics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementAdditionalMilestonePayments', window );">Additional milestone payments under the license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementAdditionalMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the additional milestone payments to be made under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementAdditionalMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementUpfrontPaymentAmountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of the upfront payment made under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementUpfrontPaymentAmountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_PercentageOfRoyaltyRatePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents range of tiered, double-digit royalty payments on future global sales if product is successfully commercialized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_PercentageOfRoyaltyRatePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=incy_MacrogenicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=incy_MacrogenicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6604337600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=incy_ConvertibleSeniorNotes1.25PercentDue2020Member', window );">Convertible Senior Notes 1.25 Percent Due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate of debt (as a percent)</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=incy_ConvertibleSeniorNotes1.25PercentDue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=incy_ConvertibleSeniorNotes1.25PercentDue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6797888704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Apr. 28, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-12400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INCYTE CORP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3136539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1801 Augustine Cut-Off<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Wilmington<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">498-6700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INCY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,373,454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000879169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6796896160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (720,642)<span></span>
</td>
<td class="nump">$ 102,312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation</a></td>
<td class="nump">1,560<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on marketable securities, net of tax</a></td>
<td class="nump">654<span></span>
</td>
<td class="nump">681<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Defined benefit pension obligations, net of tax</a></td>
<td class="nump">221<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="nump">2,435<span></span>
</td>
<td class="nump">918<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="num">$ (718,207)<span></span>
</td>
<td class="nump">$ 103,230<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6643181872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Carrying amount and Fair Value (Details) - Convertible Senior Notes 1.25 Percent Due 2020 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate of debt (as a percent)</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=incy_ConvertibleSeniorNotes1.25PercentDue2020Member', window );">Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible senior notes</a></td>
<td class="nump">$ 18,524<span></span>
</td>
<td class="nump">$ 18,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=incy_ConvertibleSeniorNotes1.25PercentDue2020Member', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible senior notes</a></td>
<td class="nump">$ 27,656<span></span>
</td>
<td class="nump">$ 32,511<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=incy_ConvertibleSeniorNotes1.25PercentDue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=incy_ConvertibleSeniorNotes1.25PercentDue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6800722368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License agreements - MorphoSys (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th"><div>Mar. 03, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) on long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (48,132)<span></span>
</td>
<td class="nump">$ 20,989<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">$ 133,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,085,287<span></span>
</td>
<td class="nump">$ 270,545<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_CollaborationLossSharingExpense', window );">Collaboration loss sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_AmericanDepositarySharesMember', window );">ADSs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity Method Investment, Aggregate Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Per share price</a></td>
<td class="nump">$ 27.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_StockPurchaseAgreementLockUpPeriod', window );">Lock-up period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_FairValueInputsAmountOfDiscountForLackOfMarketability', window );">Discount for lack of marketability</a></td>
<td class="nump">$ 4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Fair value of shares</a></td>
<td class="nump">95,500<span></span>
</td>
<td class="nump">85,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long term investments</a></td>
<td class="nump">95,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 54,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MorphosysAgMember', window );">MorphoSys AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementUpfrontPaymentAmountPaid', window );">Upfront payment under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) on long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_CollaborationAgreementProfitLossSharingRatio', window );">Profit (loss) sharing ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_CollaborationLossSharingExpense', window );">Collaboration loss sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MorphosysAgMember', window );">MorphoSys AG | Accrued and other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued and other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MorphosysAgMember', window );">MorphoSys AG | Development and Regulatory Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementAdditionalMilestonePayments', window );">Additional milestone payments under the license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 740,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MorphosysAgMember', window );">MorphoSys AG | Commercialization Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementAdditionalMilestonePayments', window );">Additional milestone payments under the license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 315,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MorphosysAgMember', window );">MorphoSys AG | MorphoSys AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded', window );">Funding of future development costs (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MorphosysAgMember', window );">MorphoSys AG | Incyte</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded', window );">Funding of future development costs (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size:9pt;">The condensed consolidated balance sheet at December 31, 2019 has been derived from the audited consolidated financial statements at that date.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_CollaborationAgreementProfitLossSharingRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio of sharing profit and losses under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_CollaborationAgreementProfitLossSharingRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_CollaborationLossSharingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expense recognized during the reporting period for collaboration loss sharing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_CollaborationLossSharingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_FairValueInputsAmountOfDiscountForLackOfMarketability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to the amount of discount used to measure fair value for lack of ability to convert business interests into cash quickly..</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_FairValueInputsAmountOfDiscountForLackOfMarketability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementAdditionalMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the additional milestone payments to be made under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementAdditionalMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of future global development costs funded under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementUpfrontPaymentAmountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of the upfront payment made under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementUpfrontPaymentAmountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_StockPurchaseAgreementLockUpPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the period of time that the company will not sell or otherwise transfer any of the equity method shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_StockPurchaseAgreementLockUpPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of the entity's equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_AmericanDepositarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_AmericanDepositarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=incy_MorphosysAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=incy_MorphosysAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=incy_MorphosysAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=incy_MorphosysAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=incy_IncyteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=incy_IncyteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>incy-20200505x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:incy="http://www.incyte.com/20200505"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="incy-20200505.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e2R-5xzxfUC6nZUl8PL1YA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7twDsd2JDEOndz5YGwcBzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fEwSRBjO_Ui2kpLBrnNHdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2hQ7NTSBMUWmxGpMp6-_0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Hj6IUMCWb02gJP3m4OeDnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_xkbc2Y822UqXDVbR6a7_LQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__tiHxydERESGTR76ARwl7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_h7i3Ro_OZUmCp9mkSGukFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4IpabeHWGEeyws0bt-_LIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_-bO_iV0lbkSyipE07mBbnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_OfMjHRm8vkyNOUMTG5Sgug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vUipIgfa4km0rtW5tdmA4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_S1joOk6fhkO10LOQZpl6lQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_XMlG1LUJy0Scx4eCJMw_Og">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AsudZYg1cEuP3-a7_igGEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mHv5WMXrp0O8iRpfgdj6oA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JPMoYCXuZU2eJZVVkKRx5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_YuWnGWZBFEycAhcGmFa2fQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AzTpzCx2FEeghKSIssu86g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_SVG1T8un0UuAR4xiq6ES-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Cbj624ha3kmOoiQSEnwBlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_W9GbI2-s5ES4CTz48UruiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2019_To_4_30_2019_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_incy_LongTermIncentivePlanOneMember_dDGsqWzkwEmzRXEky-0cyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">incy:LongTermIncentivePlanOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2018_To_6_30_2018_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_incy_LongTermIncentivePlanTwoMember_GfdRdjchm0SNfn7rnmSnFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">incy:LongTermIncentivePlanTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2018_To_6_30_2018_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_incy_LongTermIncentivePlanOneMember_jsEmMys8p0GNOaeQtFsmZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">incy:LongTermIncentivePlanOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2018_To_6_30_2018_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_WKzuvMhbXkaBU9jbXYBPQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2018_To_6_30_2018_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_vC6oKQwc_UO2IGuLtg5qng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_7_31_2019_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_TVxp6xaORUq6y8Ownz8CYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2016_To_7_31_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember__akggGl53kSTF7JP7JfRbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-01</startDate>
            <endDate>2016-07-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2016_To_7_31_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_zIOfLPcoIE-WPja313LTug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-01</startDate>
            <endDate>2016-07-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2016_To_7_31_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_2XwuCwQyq028NRrBWn-7FQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-01</startDate>
            <endDate>2016-07-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2016_To_7_31_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_eVPwouvAqkSAUpm9iX0Giw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-01</startDate>
            <endDate>2016-07-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2016_To_6_30_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_D0lxLn0JWU2EcDQaGVWl7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2016_To_6_30_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_L9F2_6Qez0Ox5Fm8qYePbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2016_To_6_30_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_R2nXzmWcpEusNX2tgETvVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2018_To_6_30_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_GfsaK8p46UWIkVJ17vp0wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2018_To_6_30_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_SZJ4LKIOuESQEpa0eW7EPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2016_To_6_30_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_yPcPm_5LjUyiK3NWPCSUmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_incy_JakaviMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_GNv-lY-ZsUCHv1M3VoVXPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JakaviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_DevelopmentAndCommercializationMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_3WbzHyKMakilo4AxBzCjyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndCommercializationMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_DevelopmentAndCommercializationMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_y0tgn3-jJkylj0qNlXf4Ug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndCommercializationMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_uP4dhWDKFEyFnudcYGBOSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_Ndda4EOg1kixjWN0CSTfeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_iqotuIRBdEWR4e6oAi-V5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_incy_OlumiantRoyaltyMember_ub66w40qPUKCwKGhu43JRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:OlumiantRoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_incy_JakaviRoyaltyRevenuesMember_zns3wnT-Jk-Ya594Fpdi2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JakaviRoyaltyRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_incy_JakaviMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_b36l365IDEWlJXt_MSsqIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JakaviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_incy_AchievementOfMilestoneAxis_incy_DevelopmentAndCommercializationMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_RxSzkAad5ES3uONix4NATw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndCommercializationMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_incy_AchievementOfMilestoneAxis_incy_DevelopmentAndCommercializationMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_d2Q6vESwZE6zC2NO5BBD8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndCommercializationMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_-8oLxMS1UkuCYQQOT0HLxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_801prtYWj0OCkCXY8rQvyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_zIkoXlOLU0qoXHFNAsPMOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_incy_OlumiantRoyaltyMember_hSkSbP1pFEi6wsQTwl0CLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:OlumiantRoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_incy_MilestoneAndContractRevenueMember_VtUC1dCVcEWIzn5Q-dz-vg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:MilestoneAndContractRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_incy_JakaviRoyaltyRevenuesMember_gEBfS3KRGEK69j70qm4oIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JakaviRoyaltyRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_incy_JAKAFIMember_J80BHp4_KUeJ-iOOK_2ieg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JAKAFIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_incy_ICLUSIGMember_zX4IHXitz0maYHqKIsHnOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:ICLUSIGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_Y69YgRfz7EyDDBkJJ9glfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_Bgm0Uqs6EEurpHztiTwV7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_CalitheraBiosciencesIncMember_ZVATcnAIO0GBu8wTwLvFPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_vi_h8M1GhkeTPwj2SVyuYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_fZaD2WqykkG-bcDt3R0hsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_us-gaap_TypeOfArrangementAxis_incy_CalitheraBiosciencesIncMember_gwhsiJOFE0CdmH4_ASRROw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2018_To_11_30_2018_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_epQaBen2_U6nG4Y4rp6zig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2018_To_9_30_2018_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_9FaYOW1DOUSCPsDwOUajaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_StockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_iPk_0s54fkWZRS_3UlzhOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_12_31_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_oWgSfS00vUW2MWLkfvZ1zg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_wgLMqUpIOkW0LR2tv0blfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_3_31_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_4TeB7PMOikiSn1N2iwUlEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_us-gaap_RealEstatePropertiesAxis_incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember_vZQPIl3GOUCQvPfbSWPEeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RealEstatePropertiesAxis">incy:LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_OpaZX17-qki74dlsTGJgWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember_-A59uhU7lE2X3hkgLlOppQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_Uc4T8OoznUaWUBZFbSY_iQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_X2RaDJKM2UKzTQvrCqAeaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_Os6xIsQTJkSi8T8XKdZa9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_incy_OperatingLeaseRightOfUseAssetsMember_OnCRjgugL0CS9Eac1n0YMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">incy:OperatingLeaseRightOfUseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_incy_BuildingAndLeaseholdImprovementsMember_ip5R7-17nEmNlOU8G0fwCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">incy:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_Fz8X3N5MXEKKKq7aHQVBHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember_U4SkB6IAZkiT0rKLLkS3fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_VmJWm_2dZ0KLxA_TYtgIWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_H7HrVzI_zk64zWsiLLAWBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_BhUGXoa_EEGIKABq8Fc4Hg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_incy_OperatingLeaseRightOfUseAssetsMember_acMKMXWO1UmpzV7l3A0xFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">incy:OperatingLeaseRightOfUseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_incy_BuildingAndLeaseholdImprovementsMember_nfb1lKsHeUq_kOC7b4Hp-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">incy:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_1_2018_To_7_31_2018_us-gaap_RealEstatePropertiesAxis_incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember_cI046B97zkCNRFIvPRRTaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RealEstatePropertiesAxis">incy:LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1-7nj5ASlkiVwC_JguIJwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_A8RojBoxM0mFmINTN2EuXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HPSBbAExTU2JCIrpO-YFvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_OmvX4naFCU2401ZLjrF4gQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_StockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_01Y2KuG7C02jQlyf-MJXhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmendedStockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_VTRtnBqUMkSsfHzFNQIj2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AmendedStockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_7XMbCpbDnEewpK0mRNy-0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2017_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_3dQm43RaIU-3y4wKYTb_YA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_GxCCmVblq0aKTFevJZTWYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-03-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_RealEstatePropertiesAxis_incy_OfficeBuildingMorgesSwitzerlandMember_hyf9S0MCgUaWtQ2fty1E5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RealEstatePropertiesAxis">incy:OfficeBuildingMorgesSwitzerlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_enm1IIwTxE685YL-VEfceg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_kOKA_UdywE2p7qUAsKbRXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_2_qilDUt-02bEAeGgk-4HA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_30_2017_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_V15b5Oo0-k2QDmXipNZJPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-01-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_incy_JAKAFIMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_28xwnjC9e0Sh55l-kRb2nQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JAKAFIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_incy_JAKAFIMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_BdI492nuSkutSDrwULb1hw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JAKAFIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_UHqTF8VUAUCGTkb1EXExuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_eOfQkKzKrUOycC233zEEKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_bwDrZo3Tr0aCPMmzLzjjyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_RmAbn78EhEiQanXoFkVVRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_4sLodCGvRUuTCXxu1AuBbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherComprehensiveIncomeMember_5oSPCzH0LUKKkaLwMadeGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_sIIh4iWJFk2a9UMIC24hHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_XFbZLyELLEuZAhhXTUaIyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_hK2vELdvC0qjgaQxW0SVXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherComprehensiveIncomeMember_9Lxk-PLyx0aRe3tPfUa9JQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_6HXkrhkugk2ANaoLx9Ffjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_t6V1l4OIi0umobNraJpO-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_suFOYxNDt0-4KUvHJ2smxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_JsVzHcwF3UShcd4mtCEitg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_Jr7vn9wY7EugrlmE7e-Utg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_9FgpIjXW30il90Hlca16_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_AAhSlo2yskG8eSk5D_7vWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_GSawLGXUJUqNCpQXIs29TA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_UX-Ls-ObqUaaxVRBpq4VvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmericanDepositarySharesMember_zDA5FKw7iUSQ77Y1CYtdhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmendedStockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_6YWfGDEPXE2CImLh9b1dmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AmendedStockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-31</instant>
        </period>
    </context>
    <context id="As_Of_1_1_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_StockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_h6YyQFHKjUOT_t4PglWApQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="As_Of_2_1_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_e1m5T-pYtEOP3IlBt9OmFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-02-01</instant>
        </period>
    </context>
    <context id="As_Of_1_1_2017_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_0wbD4uybz0Kqy_sngxd94Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-01-01</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2016_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_zhQ6u7Eorky9JUrK75lg6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmericanDepositarySharesMember_1C9RFh6rfkulw5myLWBnDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_3_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmericanDepositarySharesMember_p8hX0lYkjECSDquP0kv7_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-03</instant>
        </period>
    </context>
    <context id="As_Of_1_8_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_StockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_q4yqPlQDMkKC2b9hPFXgEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-08</instant>
        </period>
    </context>
    <context id="As_Of_2_14_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_dBlEvdYnr0a8IGYwmA0VRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-02-14</instant>
        </period>
    </context>
    <context id="As_Of_1_23_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_KRP1zQuWsUCnd5bEiI4whg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-01-23</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_CUAHxIXboUW-AGQxTycjxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tgSRvrejHUqYFIu85rRsPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_uJymqcnIC0WuSGRiCrl9yQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_y8PVaaJJd06F0gOHPbgysg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_-W06vJqxfUKkm8FD3tX-XQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_incy_CorporateAndGovernmentDebtSecuritiesMember__FioQn-7xkq2Ihn7ogju8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">incy:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_incy_CorporateAndGovernmentDebtSecuritiesMember_ZlCggm6Ff0Wzf5NwRBQL8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">incy:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_mf1pSO_8xk-KJN_VOGoSlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">incy:ConvertibleSeniorNotes1.25PercentDue2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_dUhGX9pGs0KEez2XYOKNtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">incy:ConvertibleSeniorNotes1.25PercentDue2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_ByXHMCnwhUuLsKezaFFRag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">incy:ConvertibleSeniorNotes1.25PercentDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_Zx-v_c4r70WwWX03gqsXyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">incy:ConvertibleSeniorNotes1.25PercentDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_BIl-1RaM1EOPgs_KNzpbiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">incy:ConvertibleSeniorNotes1.25PercentDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_rppXeBwyn0KUPPFX6vCgDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">incy:ConvertibleSeniorNotes1.25PercentDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_RealEstatePropertiesAxis_incy_OfficeBuildingMorgesSwitzerlandMember_KrB3YVMc5UW_hq4utsVGBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RealEstatePropertiesAxis">incy:OfficeBuildingMorgesSwitzerlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_srt_MajorCustomersAxis_incy_CustomerDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_incy_SalesRevenueGoodsServicesNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_jdQZkwbreEeOVODBdtyWjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">incy:SalesRevenueGoodsServicesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_srt_MajorCustomersAxis_incy_CustomerCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_incy_SalesRevenueGoodsServicesNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_-RMVb1Fvokicsqve2ojFBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">incy:SalesRevenueGoodsServicesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_srt_MajorCustomersAxis_incy_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_incy_SalesRevenueGoodsServicesNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_sJWHbHVE3k67_lQw54yY_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">incy:SalesRevenueGoodsServicesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_srt_MajorCustomersAxis_incy_CustomerAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_incy_SalesRevenueGoodsServicesNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Fqdfsibh4kKYy4vq1H2Aew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">incy:SalesRevenueGoodsServicesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_srt_MajorCustomersAxis_incy_CustomerABCAndDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_aIRqd3JLu0iLl9imB6WWgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerABCAndDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_srt_MajorCustomersAxis_incy_CollaborationPartneraBAndCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_qEwDHoxU_kykVFnagpQ7eg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CollaborationPartneraBAndCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_MajorCustomersAxis_incy_CustomerABCAndDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_nrSCSBku-kmb34bhbBHQUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerABCAndDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_MajorCustomersAxis_incy_CollaborationPartneraBAndCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_GNwwFEEnHkOgZF7ymHUW2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CollaborationPartneraBAndCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_srt_MajorCustomersAxis_incy_CustomerDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_incy_SalesRevenueGoodsServicesNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_AYtvU5JiEE2vyJD2GOHIpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">incy:SalesRevenueGoodsServicesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_srt_MajorCustomersAxis_incy_CustomerCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_incy_SalesRevenueGoodsServicesNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_eOhzoKcIP0OkJVjjz8gMLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">incy:SalesRevenueGoodsServicesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_srt_MajorCustomersAxis_incy_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_incy_SalesRevenueGoodsServicesNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_guuZvSOjo0u0KsbTuzRxeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">incy:SalesRevenueGoodsServicesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_srt_MajorCustomersAxis_incy_CustomerAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_incy_SalesRevenueGoodsServicesNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_f3XjwLwtRkSypl-ZsaWVPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">incy:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">incy:SalesRevenueGoodsServicesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2019_dMCk6SsWm0OpwCR3K8OhEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_9ClNYpZejEWe3kBT1B-jvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_BusinessAcquisitionAxis_incy_AriadPharmaceuticalsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_LiabilityMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputCapRateMember_W3i3GxnCAEexsivT7-_BCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">incy:AriadPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputCapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_6_1_2016_us-gaap_BusinessAcquisitionAxis_incy_AriadPharmaceuticalsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_LiabilityMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_hQh32X0nE0CI4sShb6FASg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">incy:AriadPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-06-01</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_aaFIoA90rESC-8Dh21XUzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wmT2dRGShkmAkpk-MnUNQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_FinancialInstrumentAxis_incy_CorporateAndGovernmentDebtSecuritiesMember__EpAzA1tU0628uub7apmQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">incy:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FinancialInstrumentAxis_incy_CorporateAndGovernmentDebtSecuritiesMember_BpEuHfSwDE-2bwHlTacRhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">incy:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fokaHHGN_US8Vn_P7eshvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_O7zFu8UChUGSYYKQwC_Jgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vzfnNpXOk0-u4q-eKRYLuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_rGtntt3PoUmQLgQUufOvRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_YPDANAjNxES2dszn1Xx1jA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_SgUaszookkqnrXkDEDnurA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_2_28_2018_us-gaap_RealEstatePropertiesAxis_incy_OfficeBuildingMorgesSwitzerlandMember_sv07bVwxFk-3b4wTy2XUvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RealEstatePropertiesAxis">incy:OfficeBuildingMorgesSwitzerlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-28</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_ZCt4v5dz-02T3ZuSiZnehQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_HcQZwZd8o0Wvrjt6JjzvDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">incy:ConvertibleSeniorNotes1.25PercentDue2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_3H_O8pHEdkix4PC8ZgQ7Mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_2eLdjmLNS0eVWk19LxgYkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">incy:ConvertibleSeniorNotes1.25PercentDue2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ayQXfrU-kEqLMW5XKp3dOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_hdQWjmjVAUOoLAgOzPKlfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_SYkDX7ewnEi-fA1QMyfsXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember__KRsuuuxFUGHFrG9WcT73A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_HQ2dp39OO0S03M-igkKhPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_iAoPlqdY8EuohmWI9wvG1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_w-vcv_NpWkCA4qcaHLsFbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fWoGq7r2vk2UCLk0trvcdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_-OdiLY_HUEi_z6wHQe3vIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_-hgr7X57a0avQlFj1AvRPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_TDSLcpRho0W0O_zxs61WcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_WXNGj9bwXUmUHfhHKe1dLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_TypeOfArrangementAxis_incy_CalitheraBiosciencesIncMember_o_SL5702vkOgfJpisRbc3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_Gb1dDNbr-0mKUzuB4KREFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_CalitheraBiosciencesIncMember_ekerfwlyQkKKU2NodLZECQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_e8xNeuEtLkG3yuzAWXQPAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_8PlbTBxq-kmWb2R31MsmkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_cPCZt8ELeUSjKmzshHEhQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_1_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmericanDepositarySharesMember_y989uIAWJUij4EiffRDHoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2018_To_7_31_2018_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_YelUbuNY80CUvf6lPtpuag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2014_To_1_31_2014_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_a4J1xme2j0qJI7w67u-8Kw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_VmhuMJCx8kyw979O9O77sA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_12_31_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_incy_LongTermIncentivePlanTwoMember_g0CLhct2S0K4vHe7Em2Zuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">incy:LongTermIncentivePlanTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-31</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_31_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_R6qfbt0g7UGmt1ZGgohMYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-31</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_7_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_xd5AG2VWVEOzpz4FkpHdOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="Duration_3_31_2019_To_3_31_2019_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_incy_LongTermIncentivePlanOneMember_10zMB4kxHUmiN5hoSzLWUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">incy:LongTermIncentivePlanOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-31</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2018_To_6_30_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_incy_LongTermIncentivePlanTwoMember_0cnSLqNMKkOiYjDFx0hr1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">incy:LongTermIncentivePlanTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2018_To_6_30_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_incy_LongTermIncentivePlanTwoMember_F_BDMjdwvUaazt5WAPM0pg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">incy:LongTermIncentivePlanTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2018_To_6_30_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_incy_LongTermIncentivePlanOneMember_DDOU9aUbe0qDsi2WsRXKrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">incy:LongTermIncentivePlanOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_AkK30_Ng-U2hTUpYkJOybQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_8g5N0q7JO0mkbsolYzXxgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_pOoZGDkfJUy5oibDwCrC8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_srt_ProductOrServiceAxis_incy_JAKAFIMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_mfwS80yn5ESSYPVY2L68BQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JAKAFIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_srt_ProductOrServiceAxis_incy_JAKAFIMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_2-_MOs2yjU-WWrny5byzXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JAKAFIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_1_31_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmendedStockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_XLcYraNHWEaKYbjk95TcKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AmendedStockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_1_1_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_StockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_DgYpD_a5vUiEMdKdZb3MPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-01</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2017_To_2_1_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_tHZmzMoq7UOq_19LypjtHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-01</startDate>
            <endDate>2017-02-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_1_31_2017_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_RlWLiTnNKk-MYynvIhAMbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-01-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2016_To_12_31_2016_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_AHacTrqe70OBJPlyv84qXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_incy_JakaviMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_3GwL6JL350ydhcQXwwZPzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JakaviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_incy_JakaviMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_AVkAZtSlqUSKsew2Ua_8jg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JakaviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_DevelopmentRegulatoryAndCommercializationMilestonesMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_incy_AgenusMember_NSPNOPBlrEe3WHqow3Mpyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:AgenusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentRegulatoryAndCommercializationMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_DevelopmentRegulatoryAndCommercializationMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_AgenusMember_7ArCsJGHDU6NWBPNa2r-7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:AgenusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentRegulatoryAndCommercializationMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_kBoYI7PVIk6voJvkwi61Vw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_AgenusMember_rKJqPM2Kx0uzwD7Q93bGZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:AgenusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2017_To_12_31_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_LuJpKL3-sUqsR3zx1Ui6ug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2017_To_12_31_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_Dn4atemmXECcuSaCHD3Xhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_1_31_2017_srt_RangeAxis_srt_MinimumMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_7nNpE5gl0kGtbk0copl0Ew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_1_31_2017_srt_RangeAxis_srt_MinimumMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_0jHvhxDIlEen-mp125RqxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_1_31_2017_srt_RangeAxis_srt_MaximumMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_-UyvIh_1dUGHPh1Oi-HZjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_1_31_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_jKF_MTXq-Em5r2YGQsjucw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_1_31_2017_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_incy_CalitheraBiosciencesIncMember_HQYolQnSwkG5T9dK1t91Ow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_1_31_2017_srt_RangeAxis_srt_MaximumMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_TmMtQTVRAEqEbpqiWMhMKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_incy_PhasesOfArrangementsAxis_incy_PhaseTwoBMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_hx8Gg9ss0k26kPkVIwC0gQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:PhasesOfArrangementsAxis">incy:PhaseTwoBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2010_To_7_31_2010_incy_PhasesOfArrangementsAxis_incy_PhaseTwoBMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_NfiO75iKBky-zhPH0mFJsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:PhasesOfArrangementsAxis">incy:PhaseTwoBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-07-01</startDate>
            <endDate>2010-07-31</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2015_To_11_30_2015_us-gaap_TypeOfArrangementAxis_incy_AgenusMember_y0Dg-8kaqEy_VnxO63h4KA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:AgenusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-11-01</startDate>
            <endDate>2015-11-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2015_To_1_31_2015_us-gaap_TypeOfArrangementAxis_incy_AgenusMember_1GF_BNYkFkelmcMuY5Dozw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:AgenusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-01-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_incy_InnoventBiologicsIncMember_dJHS72SJ40CyscATO6EB5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:InnoventBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2009_To_12_31_2009_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_1SaePKedd0OWp_iIJJVHXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-12-01</startDate>
            <endDate>2009-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2009_To_12_31_2009_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_F7owIWcWcESiFzYW1Mzbig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-12-01</startDate>
            <endDate>2009-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2019_To_8_31_2019_us-gaap_TypeOfArrangementAxis_incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember_fTLP0rPirE6Sgn7TSP_gGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:CollaborationAndLicenseAgreementWithZaiLabLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_1_31_2019_us-gaap_TypeOfArrangementAxis_incy_InnoventBiologicsIncMember_C_ENlXJVxkyNDvDNsqx1-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:InnoventBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2018_To_12_31_2018_incy_AchievementOfMilestoneAxis_incy_DevelopmentAndRegulatoryMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_InnoventBiologicsIncMember_REXXiwthXUuKAJa4ox8rdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:InnoventBiologicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2018_To_12_31_2018_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_InnoventBiologicsIncMember_cY50RxpP-U6RWVnyPyfrmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:InnoventBiologicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2016_To_4_30_2016_incy_AchievementOfMilestoneAxis_incy_DevelopmentAndRegulatoryMilestonesMember_srt_ProductOrServiceAxis_incy_GvhdMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_ZRB_EBm4DkyNeZO2LH5-Dg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:GvhdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-01</startDate>
            <endDate>2016-04-30</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2009_To_12_31_2009_incy_AchievementOfMilestoneAxis_incy_RegulatoryMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_QW2Dt4PfxUSmygcBR82y9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-12-01</startDate>
            <endDate>2009-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2009_To_12_31_2009_incy_AchievementOfMilestoneAxis_incy_PreSpecifiedEventsMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_4-WVfL6AnEGN9XUCN2Qzkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:PreSpecifiedEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-12-01</startDate>
            <endDate>2009-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2009_To_12_31_2009_incy_AchievementOfMilestoneAxis_incy_DevelopmentMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_hql1KJZ8iU62EhDjjNk-sA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-12-01</startDate>
            <endDate>2009-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2009_To_12_31_2009_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_2tauCzcC80iBzbGQiJbcgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-12-01</startDate>
            <endDate>2009-12-31</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2009_To_11_30_2009_incy_AchievementOfMilestoneAxis_incy_RegulatoryMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_zksZlxX7L0aZmXvNApJ4Eg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-11-01</startDate>
            <endDate>2009-11-30</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2009_To_11_30_2009_incy_AchievementOfMilestoneAxis_incy_PreSpecifiedEventsMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember__tZTD8Vmu0GW3hPdg82qeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:PreSpecifiedEventsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-11-01</startDate>
            <endDate>2009-11-30</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2009_To_11_30_2009_incy_AchievementOfMilestoneAxis_incy_DevelopmentMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_wtKKfm2jZ0yM-1dlYFTMnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-11-01</startDate>
            <endDate>2009-11-30</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2009_To_11_30_2009_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_MJwI5aFJqEO8pUKY2yAKBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-11-01</startDate>
            <endDate>2009-11-30</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2009_To_11_30_2009_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_A9wnHAKOPUiEb-WirPUvYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-11-01</startDate>
            <endDate>2009-11-30</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_rHTnGuemnUagNxNCaIIsSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2019_To_8_31_2019_incy_AchievementOfMilestoneAxis_incy_DevelopmentRegulatoryAndCommercialMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember_2LertgtXmUSbLU3ewDQkAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:CollaborationAndLicenseAgreementWithZaiLabLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentRegulatoryAndCommercialMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_1_31_2018_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_e3Og2WQPREynUroSL3ThVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2017_To_12_31_2017_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_Pvqu3UdMtESm4jPlRmjNxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2017_To_2_28_2017_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_j9-fB82mM0aKB0lMVFtkDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-01</startDate>
            <endDate>2017-02-28</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_12_31_2017_incy_AchievementOfMilestoneAxis_incy_DevelopmentMilestonesMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_uSeThvtWXUGOcm74qPJaSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2016_To_3_31_2016_srt_ProductOrServiceAxis_incy_GvhdMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_Vfkt7ZI1EUi8hMQs6ojgVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:GvhdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_1_31_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_7z6twVQHkkaobzJI5jhU7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_Bx9b-kfxkUS7NmglDo36lw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember_71IYyLEOk0qtHTwC9gMr2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:CollaborationAndLicenseAgreementWithZaiLabLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_VI1jInirZE-TkdoXTr7aBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_ZvhiClZSVke50DoQFEthjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_InnoventBiologicsIncMember_ur26l_EwbEWNuQbgjhG5pw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:InnoventBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember_IqSk84yaxE-JJvKAc06yPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:CollaborationAndLicenseAgreementWithZaiLabLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_QXsD9niNL0WfkNO0BEluBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_TypeOfArrangementAxis_incy_InnoventBiologicsIncMember_CDr03ADEikqqqKMjVIsLzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:InnoventBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2017_us-gaap_TypeOfArrangementAxis_incy_CalitheraBiosciencesIncMember_q6cjALmpG0eNfLyGFfZJcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-01-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_dei_LegalEntityAxis_incy_IncyteMember_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_Hko43zDhUECuypoYAgazng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">incy:IncyteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_1_31_2020_srt_CounterpartyNameAxis_incy_MorphosysAgMember_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_6F3K0RN-oUSX6n5Ve-1LHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">incy:MorphosysAgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_1_31_2020_dei_LegalEntityAxis_incy_IncyteMember_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_joVwB0DtIkOe9vuko8XrMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">incy:IncyteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_1_31_2017_us-gaap_TypeOfArrangementAxis_incy_CalitheraBiosciencesIncMember_k20QIDKWZ0Cx-yYlqJ-TBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_1_31_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_a6vIFrPYNUSTq51uQB6cnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-01-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2019_To_5_31_2019_incy_AchievementOfMilestoneAxis_incy_RegulatoryMilestonesMember_srt_ProductOrServiceAxis_incy_GvhdMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_wl45rQuyWUeKj9KE8YrNQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:GvhdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2017_To_3_31_2017_us-gaap_TypeOfArrangementAxis_incy_CalitheraBiosciencesIncMember_Ms1l2DuiH0iX52Fe8ib4bw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_1_31_2017_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_7k2NhRIKp0uBjo2oHVvL-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2010_To_1_31_2010_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_D9O6EwtrQ063PpAtibslDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-01-01</startDate>
            <endDate>2010-01-31</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2019_To_6_30_2019_incy_AchievementOfMilestoneAxis_incy_RegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_InnoventBiologicsIncMember_FsIzv8L_HEi55lLcoBwVbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:InnoventBiologicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_ProductOrServiceAxis_incy_JakaviMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_VTtBfVOpYEyYEfKARlTg8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JakaviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_incy_AchievementOfMilestoneAxis_incy_RegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_IgQggmnvRkCC-yAC7hkMdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_incy_AchievementOfMilestoneAxis_incy_DevelopmentMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_4R2bbsjbu02S1SWTGCefdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_12_31_2017_incy_AchievementOfMilestoneAxis_incy_DevelopmentMilestonesMember_incy_PhasesOfArrangementsAxis_incy_PhaseThreeMember_srt_ProductOrServiceAxis_incy_GvhdMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_PHAppsJyCU6_gL715nvt8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:GvhdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:PhasesOfArrangementsAxis">incy:PhaseThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_12_31_2017_incy_AchievementOfMilestoneAxis_incy_RegulatoryMilestonesMember_srt_StatementGeographicalAxis_srt_EuropeMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_X2hC_LIgGkysVkbfF6pqAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_12_31_2017_incy_AchievementOfMilestoneAxis_incy_RegulatoryMilestonesMember_srt_StatementGeographicalAxis_country_JP_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_uTR5OD0KnkKmPCLLZ5hQIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_12_31_2017_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_ProductOrServiceAxis_incy_JakaviMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_5B46pCgC4U6TcjzvVo1wJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JakaviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_12_31_2017_incy_AchievementOfMilestoneAxis_incy_DevelopmentMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_54PH53-4h0mdJxINNUsslA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2014_To_9_30_2014_incy_AchievementOfMilestoneAxis_incy_RegulatoryMilestonesMember_srt_ProductOrServiceAxis_incy_JakaviMember_srt_StatementGeographicalAxis_srt_EuropeMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_-D5iCFjOtEOHLfhUWXsfAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JakaviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-09-01</startDate>
            <endDate>2014-09-30</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2009_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_RegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_POZKRL4X4UeOibd7iQ44iQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-12-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2009_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_DevelopmentMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_lSHmlJZy7kyXkEGNGXcb4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-12-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2009_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_RegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_Y2Gx6SWIbEqR4hwAGpSZ5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-11-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2009_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_DevelopmentMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_9-Pn4E2E_kSLd-r3M4EQbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-11-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2009_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_C1OZWHg3g0uldVYjrprkFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-11-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_1_31_2020_incy_AchievementOfMilestoneAxis_incy_DevelopmentAndRegulatoryMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_w44LObNwjk6l_m4tp62jQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2020_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_738l7WGg-UO8nbsLnaCpFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_incy_AchievementOfMilestoneAxis_incy_DevelopmentMilestonesMember_srt_ProductOrServiceAxis_incy_TIM3ProgramMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_3cWnTNEGHkS-bqHYm75tQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:TIM3ProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_incy_AchievementOfMilestoneAxis_incy_DevelopmentMilestonesMember_srt_ProductOrServiceAxis_incy_LG3ProgramMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_LEDpSv7x-UqhAEU0sms69Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:LG3ProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2018_incy_AchievementOfMilestoneAxis_incy_DevelopmentAndRegulatoryMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_bojg3Cpm70KP1ASJ64IbcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2018_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_ggAKdTjZ60mONUG4Cc9HQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2017_incy_AchievementOfMilestoneAxis_incy_DevelopmentAndRegulatoryMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_1gx5QmF1QESvqesUmo91qw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2017_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_h51PWrAxiUSRzPvrkcOO8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MacrogenicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="As_Of_2_28_2017_incy_AchievementOfMilestoneAxis_incy_DevelopmentRegulatoryAndCommercializationMilestonesMember_srt_RangeAxis_srt_MaximumMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_kP1dVDRyl0aHr25XhcLREg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentRegulatoryAndCommercializationMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-02-28</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2017_incy_AchievementOfMilestoneAxis_incy_DevelopmentAndRegulatoryMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_3qBhaaUHQU-hsgEJZZLSGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-01-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2017_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_wXhYzKmk30i4bB1talomPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="incy:AchievementOfMilestoneAxis">incy:CommercializationMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-01-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2016_srt_ProductOrServiceAxis_incy_GvhdMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_Sd04Ae5b5U6RhSen8O3xGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:GvhdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:EliLillyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-03-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_incy_JAKAFIMember__fw2KcDlhEK50BfPWrKV_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:JAKAFIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_incy_ICLUSIGMember_YO1pSkx-YU6EMn97oz0Vig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">incy:ICLUSIGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2019_us-gaap_RealEstatePropertiesAxis_incy_OfficeBuildingMorgesSwitzerlandMember_cTCu8-DdLUWDnNq9pv0w3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RealEstatePropertiesAxis">incy:OfficeBuildingMorgesSwitzerlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="Duration_6_1_2016_To_6_1_2016_us-gaap_BusinessAcquisitionAxis_incy_AriadPharmaceuticalsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_LiabilityMember_-BGrwF-qIkuMeVQ7qNEL5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">incy:AriadPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-06-01</startDate>
            <endDate>2016-06-01</endDate>
        </period>
    </context>
    <context id="Duration_3_3_2020_To_3_3_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmericanDepositarySharesMember_rB3V8pH9lUCWt7qCtdhL8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-03</startDate>
            <endDate>2020-03-03</endDate>
        </period>
    </context>
    <context id="Duration_1_8_2018_To_1_8_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_StockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_omIR3ZvvjkKFbSUFw_JzGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:SyrosPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-08</startDate>
            <endDate>2018-01-08</endDate>
        </period>
    </context>
    <context id="Duration_2_14_2017_To_2_14_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_imIGDtobsUmd4lo8UPrzlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:AgenusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-14</startDate>
            <endDate>2017-02-14</endDate>
        </period>
    </context>
    <context id="Duration_1_23_2017_To_1_23_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_0W47ULyywE66YQ7w30K3tQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">incy:MerusNVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-23</startDate>
            <endDate>2017-01-23</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member_MP4cDjTkq06lAGevzdzYBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">incy:ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2020_To_3_31_2020_PdzkVcZmpESGdHSRd_l9Vw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_30_2017_To_1_30_2017_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_6yzhytojOUW72tF5DhREcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">incy:CalitheraBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-30</startDate>
            <endDate>2017-01-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_1_31_2017_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_ziZW_6Itd0mRiuWAvHmhMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MerusNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_-V355oZpTEGL8BHgB8JTrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">incy:MorphosysAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_XgR3Kyb9BUuL8DSnhdbM0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_BalanceSheetLocationAxis_incy_AccruedAndOtherCurrentLiabilityMember_us-gaap_BusinessAcquisitionAxis_incy_AriadPharmaceuticalsMember_eNBdRdYCsk2AT0YapnXIQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">incy:AccruedAndOtherCurrentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">incy:AriadPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_BalanceSheetLocationAxis_incy_AccruedAndOtherCurrentLiabilityMember_us-gaap_BusinessAcquisitionAxis_incy_AriadPharmaceuticalsMember_Rx_uiVSjYEmmn41tyR4osA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">incy:AccruedAndOtherCurrentLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">incy:AriadPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_DbVOFfn2yECjfpwbXtOkuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_4_28_2020__qchIpXJpESyCkG1opGDWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
        </entity>
        <period>
            <instant>2020-04-28</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_segment_jI2Df57rGUiaWugJ41i_Hg">
        <measure>incy:segment</measure>
    </unit>
    <unit id="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_instrument_X67SygLtqEeZMZZtTj-6RQ">
        <measure>incy:instrument</measure>
    </unit>
    <unit id="Unit_Standard_issuer_ywviBYfRh0KpQHOu97pP7g">
        <measure>incy:issuer</measure>
    </unit>
    <unit id="Unit_Standard_item_4BIkJQxqZkOMHOIGydcttw">
        <measure>incy:item</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_sqft_EcjTExigKk28_NSPhmR_FQ">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Unit_Standard_EUR_4KUDkHZ-F0yLQi_l9X6Oxg">
        <measure>iso4217:EUR</measure>
    </unit>
    <incy:DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member_MP4cDjTkq06lAGevzdzYBw"
      id="Hidden_1LuKVsI460CF2sHZ2dlGqw">P20D</incy:DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays>
    <incy:DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member_MP4cDjTkq06lAGevzdzYBw"
      id="Hidden_Rv9y-6kA30urzn5y6CwGRg">P30D</incy:DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      id="Hidden_IJ-VJlHxY0CEZeshYZ-_Zg"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      id="Hidden_00WskpThfUe7BGq8TEau6Q"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="INF"
      id="Hidden_7OOuLSkz1keOYZ2bBUlh2Q"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">216952325</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="INF"
      id="Hidden_H-VABGyQBEqLMEDhcDPfAg"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="INF"
      id="Hidden_0-39tUcKG0i1Uu34pUXyLg"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">0</us-gaap:PreferredStockSharesOutstanding>
    <incy:DebtInstrumentConversionObligationNumberOfScheduledTradingDaysBeforeMaturity
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member_MP4cDjTkq06lAGevzdzYBw"
      id="Hidden_LuZKOSV89k6ANKuV9BpZOg">P2D</incy:DebtInstrumentConversionObligationNumberOfScheduledTradingDaysBeforeMaturity>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_7_1_2016_To_7_31_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_eVPwouvAqkSAUpm9iX0Giw"
      id="Hidden_6RWKpuCFUEKpc6a3v7bZKw">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2016_To_6_30_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_R2nXzmWcpEusNX2tgETvVg"
      id="Hidden_5i-HSeUv7Eq9b9ehfzeLfA">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_1_2016_To_7_31_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember__akggGl53kSTF7JP7JfRbA"
      id="Hidden_OR5-Cr_KuEOxFj4pvVNKEQ">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2016_To_6_30_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_D0lxLn0JWU2EcDQaGVWl7Q"
      id="Hidden_mWa7sHwgO02SjXEAYJrP4Q">P24M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      id="Hidden_DXWVUeF4QEyCGxw9FL_y3g">us-gaap:AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      id="Hidden_YKRv1wQ5MU6qRbBLux7YLQ">us-gaap:AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      id="Hidden_fgS4bxuAUka7K61E668xgw">us-gaap:FinanceLeaseLiabilityCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      id="Hidden_JdEmJ1TRLEuX3trAlTt_1Q">us-gaap:FinanceLeaseLiabilityCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      id="Hidden_DZPOj2yYtU-8JCIk7usOfw">us-gaap:OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      id="Hidden_vm-xD2amQkygzKbNU_aQ2w">us-gaap:OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      id="Hidden_T_UTUYhcFUKgazgt2tP-VA">us-gaap:FinanceLeaseLiabilityNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      id="Hidden_kmiwLnkoB0igxckkueRbJQ">us-gaap:FinanceLeaseLiabilityNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      id="Hidden_GM3GSp9hq06a9WD9qcF_iA">us-gaap:OtherNonoperatingIncomeExpense</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Hidden_imtwPvcDJU-u5c1IWdvgmQ">us-gaap:OtherNonoperatingIncomeExpense</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tc_tuye0J3LB0K9tt9PPfsxnw_2_1">0000879169</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tc_qdv24iowAUWrFPBQbD9_1g_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tc_qhsuMhkhdEiS96dgmoWyMg_4_1">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tc_Ip7b-32qOEacMHZPp2erfQ_5_1">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tc_QAtdvl1bdEWk9q8E8J5MQQ_6_1">false</dei:AmendmentFlag>
    <incy:InventoryFinishedGoodsUsefulLifeMaximum
      contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_incy_ICLUSIGMember_YO1pSkx-YU6EMn97oz0Vig"
      id="Hidden_Z0f1rDx3zUCCp3VLdTAwTg">P36M</incy:InventoryFinishedGoodsUsefulLifeMaximum>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Hidden_GNLsXbAN4UCKMgqU4Rhibg"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">258622000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="INF"
      id="Hidden_n5eXxN5QFkGcxSpRYcUebQ"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">216177830</us-gaap:CommonStockSharesOutstanding>
    <incy:StockPurchaseAgreementLockUpPeriod
      contextRef="Duration_1_1_2020_To_1_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmericanDepositarySharesMember_y989uIAWJUij4EiffRDHoQ"
      id="Hidden_LxjukuDojEmG5LuismUbLw">P18M</incy:StockPurchaseAgreementLockUpPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="Duration_6_1_2018_To_6_30_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_GfsaK8p46UWIkVJ17vp0wg"
      id="Hidden_w_7MzdT-j0OynAIorIKX9Q">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:DebtInstrumentTerm
      contextRef="Duration_1_1_2020_To_3_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_incy_CorporateAndGovernmentDebtSecuritiesMember__FioQn-7xkq2Ihn7ogju8g"
      id="Hidden_wxfFNirtIkK2gW_Xg1C_gw">P12M</us-gaap:DebtInstrumentTerm>
    <dei:DocumentType
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Narr_gu_d017hq0mss4rZF2ln_Q">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Narr_w8YCPza3mkqBr-enLt48Rw">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Narr_LMV4xUpzekeQpVV10YavEg">2020-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Narr_kT2aYn05bEmv8yRN_1qTOg">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Narr_75Bn7-_7dEGMMfr8cBiYPw">001-12400</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Narr_sVvaknkCO0qBw88ef2K0yg">INCYTE CORP</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tc_EX_o2ULuA02oJRxGYvt79A_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tc_PB1_a3BZg0Cjs3Ar10-cLA_1_2">94-3136539</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Narr_tfF5wn9yqk6hOA4VmDDaoQ">1801 Augustine Cut-Off</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Narr_Vq-rLobz00G-3shb6DP0hw">Wilmington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Narr_afwbFSGwKUOP81diH2070w">DE</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tc_2wjOYxf95Eq3dPHmT9xkUA_4_2">19803</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Narr_wyNbCPUAvkOz5Ew__XSMVg">302</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Narr_bfU6JdWSBkuiRRU_WWHm0A">498-6700</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tc_0wDq-TDQykyqzRyTBG-NSQ_3_0">Common Stock, $.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tc_jdK3Y9AzbEa0C42TlDejKQ_3_2">INCY</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tc_DaczpX5gh02BnZrU4wFoIQ_3_3">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Narr_DMfoB8LzXEaS0HVDIQWKBg">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Narr_0q3guYXfBUWXfkLEkxnfrQ">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Narr_bbC9_KsHdEK9U_HRAK6owQ">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Narr_TXSFOr7XUUm0f1f2SCi7Dg">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Narr_nnkix5uG6U-B6-yaLefmUQ">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Narr__IsjIRowV0iMPyY_d5FHuA">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_4_28_2020__qchIpXJpESyCkG1opGDWA"
      decimals="INF"
      id="Narr_MJlnNGm9uUeeOD7Guif_ag"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">217373454</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_e5RHz7blWE-x-1Hi0oC9Kw_5_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1043241000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_1R6JqLKHeUKe5p6pBSqHQw_5_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1832684000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Narr_bjJj1lBz4024CsZtNZuDng"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_BSuXgp4u8UO4APyQ0UjXUA_6_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">259351000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_Fu1im2pBBUiJ7wkCrYnA3A_6_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">284870000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNet
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_fq5GIWcmokCNWc2_uylf2w_7_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">351522000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc__Q4cAi7CLEqE685HxQZrBA_7_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">308809000</us-gaap:AccountsReceivableNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_uLg1lMVr30yiKmGSCtckzQ_8_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">13977000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_XhrcmoFpvUStqrhrIbji6A_8_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">11400000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_q4-SKzILMkuz_SpJejoCDQ_9_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">48078000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_gwKKyn1Wr0WkIPsoFWzsyg_9_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">43725000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_U4oarbLW1U6KpBASOWjCXw_10_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1716169000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc__MmdO33ZVUeSQzItX2z2Jg_10_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">2481488000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_j8e5pg7OkUS0Qhpw0RFAcg_12_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">2548000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_vcYuBQQlAE631jPaw96jNg_12_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1023000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <us-gaap:LongTermInvestments
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_HASaQSqiikq4TTHhFOLxkw_13_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">180993000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_ntl_TJoRok2kvgilDz5AQQ_13_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">133657000</us-gaap:LongTermInvestments>
    <us-gaap:InventoryNoncurrent
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_gW0lge5_mk2jAyfxk23WQA_14_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">8240000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_tegNf856j0G9fqa17Rp90Q_14_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">5105000</us-gaap:InventoryNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_xZhops2Pj0i9A3cdUGk4Gg_15_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">410034000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_02jLG0GJmU2xrTW1J5qO1g_15_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">377567000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc__PrjYcWpnES--hQk1FU0RA_16_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">28622000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_MA46kpgz80e5rQC71pZaow_16_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">29058000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OtherIntangibleAssetsNet
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_Zr9K-gTEzEyuxY6R95YgTA_17_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">188444000</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:OtherIntangibleAssetsNet
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_gv7DZ6WyZEymq5cyVQQwbA_17_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">193828000</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_ji4xP8lnyEGBg4mWLo44xg_18_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">155593000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_UKZZluQUzkylaZpeYQ7Ubg_18_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">155593000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_YnXWNdLrbkKP3M6gU__l2Q_19_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">61779000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_ln4GC3egGUipgSru4CVulQ_19_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">49431000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_bhJVu9QL1UqEi2hYHTJ5Pg_20_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">2752422000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_BUeeFiw5Ckut-I6C_gVPRQ_20_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">3426750000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_77ckIicxGkiDCahn_Yw7tA_24_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">60937000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_a5ohNrB_5EyyFWGwZ6Bp_Q_24_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">83647000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_4EoZVKwF5UeBKH818FH3ug_25_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">57779000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_iiNzPQ3oRkGjQm8ezmHxFw_25_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">90706000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_vG5WS98oUE-jHnftPqUDUg_26_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">89000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_d7F91iwAoUOZJlHXIhwhvA_26_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">29000</us-gaap:InterestPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_B5RAh36Dp02784kXdeF75A_27_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">330034000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_zdRH3cfB0EmnrBFFKDc9dg_27_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">285950000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_U6BKx7lVikC6_QGw_t8NAg_28_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">910000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_Ub3Aii55Skqo4R4y6lscqg_28_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">664000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_ZOi6aNOl7k2wTXGVyWhhTw_29_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">18524000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_XUvA6ZO9nUaVao0bSM54wA_29_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">18300000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_VT2_2SldbEucCwIrddUsfg_30_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">35139000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_DLg7M2GV3E-urgYITOjCRg_30_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">34044000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_bG0YgFGSdEmMzumZvkZ2wQ_31_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">503412000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_AcvH1yHODkm7W7kMpvCnWA_31_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">513340000</us-gaap:LiabilitiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_j6cxKVlQC0SJdP_7D95Mew_33_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">239861000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_wUmYM7gVikiUMMpr1iCtvQ_33_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">242956000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_CiWxNZnkSEGOVf-98TZCZg_34_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">31959000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_gAYiIHyfn0e7WfvlHupmLg_34_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">31918000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_kYuQzJLrm0i1XcDcrRd1gA_35_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">39469000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_9NYaJZa-M0C39_pKeh_zIA_35_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">40130000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_vZJVYDwJGUKVp5YBcTSryQ_36_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">814701000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_YrbwcyBevUmVYnmfBmOVBA_36_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">828344000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="INF"
      id="Narr_zg0yTVfS8UyWShECY8whlw"
      unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="INF"
      id="Narr_WzjrGstRtEGB5v5gWjzpmQ"
      unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="INF"
      id="Narr_7xz9usLbgki_MQB9RhTRvw"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="INF"
      id="Narr_eCu9Xhv2mESdU1i1XtE7xA"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="INF"
      id="Narr_7uyG4sA_2EO5LAPk423VMg"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="INF"
      id="Narr_Wh3d_onWMUe7g4RQDW8ndQ"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="INF"
      id="Narr_YTRUJ-UyEkiCyqpKVzRh7A"
      unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="INF"
      id="Narr_pdHAOpQ_E02Z1LhXTK6yvg"
      unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="INF"
      id="Narr_Hboohi-kBUu-OcOcw3rtlQ"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="INF"
      id="Narr_lDdjUlsfcUap18LtbFEZ6A"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="INF"
      id="Narr_fgg0vJ0XSEe6yPNA_ezLbg"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">216952325</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="INF"
      id="Narr_Ao-m-fC8MEiJRMmQQx8ZSA"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">216177830</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_GmERVU19fUCG-RP4PB_SNw_40_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">217000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_XhCxSyAePU2EM_yM-GM1VA_40_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">216000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_0h8iCd4euUmQkIJOeZK9OQ_41_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">4102011000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_c8L6yPRPEUC8H_B5VSapDQ_41_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">4044490000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_nzEScCTEQEikBWL5vipvPg_42_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-13107000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_PlsYpJAIuE6KJU9P-Jf3Yw_42_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-15542000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_X6UmmjW1kEmLdNcV5k5eBQ_43_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-2151400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_ljSkJ9leEUupHlFP7dQgdA_43_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-1430758000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_3Sx3FSrBRUaIpW85w9WxGg_44_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1937721000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_OF2q213bxkis1OQGk_1quw_44_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">2598406000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_q6b5VUlY3k-llQZuvQlELw_45_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">2752422000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_pGJuowBCK02IV8uC5OqDug_45_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">3426750000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_iqotuIRBdEWR4e6oAi-V5w"
      decimals="-3"
      id="Tc_ZI4uk79OXU-CTrv6qBfnOA_5_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">486727000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_zIkoXlOLU0qoXHFNAsPMOg"
      decimals="-3"
      id="Tc_-gAM2Gl5SkOiXW2jaeRunQ_5_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">396249000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_Ndda4EOg1kixjWN0CSTfeQ"
      decimals="-3"
      id="Tc_sBvR26CP_EyLa6Y62Ed2kA_6_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">81780000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_801prtYWj0OCkCXY8rQvyg"
      decimals="-3"
      id="Tc_sKyFmXBInkiXpPoK9EtKAA_6_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">61608000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_incy_MilestoneAndContractRevenueMember_VtUC1dCVcEWIzn5Q-dz-vg"
      decimals="-3"
      id="Tc_E2xffwJAE0WihR3ABHK9XQ_7_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">40000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_2wPBMtERtkO9zSgpmjRHtg_9_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">568507000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_-Geduf195EeeoYKZNh842A_9_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">497857000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_VP9SblXhsUez6f0g1Zj8pQ_12_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">27319000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_B4L0rVOscUmqedxpOAruJA_12_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">22588000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_WBhwXH1u3UOQxW9S6kiUQA_13_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1085287000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_0M9R93Hes0uc5fY9dMr0lQ_13_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">270545000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_96DqryCa5UCo6g0dx82NIg_14_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">111148000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_11yiVEejUUyKG4eK8poETg_14_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">123983000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_Ux-WgDTSu0CpIQZGIFPq2A_15_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">6627000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_vRl7xOnTo0SKqHnBMBvQ6A_15_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">6671000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <incy:CollaborationLossSharingExpense
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_jpvlZZl1oU6K85qtuvCDhQ_16_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">2130000</incy:CollaborationLossSharingExpense>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_KifjCghf0UetZUYzUGskkQ_18_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1232511000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_zJ5z-8hhh0WfSizx52S3-A_18_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">423787000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_D43chYnqW06S5mlNqts-uA_20_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-664004000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_WkL3coVPF0Or0s4oTNX9cw_20_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">74070000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_vXG5yNGBAE-7ho7QPz5fSg_21_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">8662000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_jcsgeCBL5ECN6sUQkW0wgw_21_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">9373000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_nj8YJCIH1kGPXPY1Kin3Iw_22_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">602000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_bbfUU9c0TEmZmPUgwiIajA_22_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">335000</us-gaap:InterestExpense>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_EzcxWgg7xUCMpj45IVKCMg_23_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-48132000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_1n8Q-sE8aEyr2JUsMV5P9g_23_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">20989000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_5eN1kK8pj0qk2MMXx-UuNw_25_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-704076000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_D8Uc9JS5kUqoHQdjhWWzIg_25_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">104097000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_KXJV_Z5gdUuJ4L08milWYA_27_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">16566000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_ESNB1Fov3UiZVNdriSVs4g_27_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1785000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_4KuhkhhSD02S0DLV2nt7Rg_29_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-720642000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_4KtvoXJgPUyC9VX96TSpkA_29_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">102312000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="2"
      id="Tc_s7No8CJl10KK6uOb8TKQdA_32_3"
      unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A">-3.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="2"
      id="Tc_tfWPTyodnEOBbi4TvZkdtQ_32_6"
      unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A">0.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="2"
      id="Tc_s0-HiNeBfUaMA8MUmSQ3GA_33_3"
      unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A">-3.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="2"
      id="Tc_XhWJayICN0SHBRu_vU5PjA_33_6"
      unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A">0.47</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_9sRGfeTxhkq9elF0mos5kA_36_3"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">216721000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_HANQlCYImkSrHPLHHzzOCA_36_6"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">214065000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_E4AYa1RT1EaiS1T1sLnW6g_37_3"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">216721000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_Dv7ZSUqfSkav1afuHM2CyA_37_6"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">217061000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_ZURr9iImD0q6Y0gqRqDtww_4_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-720642000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_uAG0Ko_ALEet_iWNAhsUYQ_4_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">102312000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_ozvFCqT3CEOdKuRwaehyDg_7_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1560000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_sCN29q2eskmZHymJocx1Vw_7_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">126000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_JYmVHRZhuUqzkP-7akNT-Q_8_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">654000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_v0w3gdR4NkaGeszPNfeecQ_8_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">681000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_iwgkzrpsSE2eW6tgRjYq3g_9_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-221000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_immEMLX510SFW3oenaHXuw_9_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-111000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_pTOEngn02UuyXsdWoE8MWg_10_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">2435000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_Uv9Tbr-k60mViT5EqKMSxQ_10_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">918000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_Vrw3uJ9fOkq8oBIGrwEu3w_12_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-718207000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_ejdnnfxhyk22uPGLUIFYZg_12_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">103230000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mHv5WMXrp0O8iRpfgdj6oA"
      decimals="-3"
      id="Tc_guu-NkFa0E6wtTZ_oKXczA_5_2"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">213000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JPMoYCXuZU2eJZVVkKRx5A"
      decimals="-3"
      id="Tc_ra8eCIvTCkul1cq59TGB5g_5_5"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">3813678000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_YuWnGWZBFEycAhcGmFa2fQ"
      decimals="-3"
      id="Tc_Eo1RCftGxEWqeg5KbMqHew_5_8"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-10165000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AsudZYg1cEuP3-a7_igGEA"
      decimals="-3"
      id="Tc_aABhOQCWbkqiJl5io0VVgw_5_11"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-1877759000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_9ClNYpZejEWe3kBT1B-jvg"
      decimals="-3"
      id="Tc_wJX9NzpWL0ODIbfJeVCQkg_5_14"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1925967000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="INF"
      id="Narr_lkdrcxD-SUm8oCvv9XhWLQ"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">1044745</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7twDsd2JDEOndz5YGwcBzA"
      decimals="-3"
      id="Tc_2pNgKkCIIEeD4clhP9cgTg_6_2"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fWoGq7r2vk2UCLk0trvcdw"
      decimals="-3"
      id="Tc_qml5Djh0wEqVaqwEQgqxsg_6_5"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">15480000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_nMpLRtpHSk-8R-AHbIJdTw_6_14"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">15481000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="INF"
      id="Narr_JB_gfo0SMU-bUFe5WMV3iQ"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">1200</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fWoGq7r2vk2UCLk0trvcdw"
      decimals="-3"
      id="Tc_iaq63_elqEOv12vG_nzTcw_7_5"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">104000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_ZY5BpqVqA0q9dsb9S3M8lg_7_14"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">104000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fWoGq7r2vk2UCLk0trvcdw"
      decimals="-3"
      id="Tc_DLwsXI1nbkOJWfqNvwIIPA_8_5"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">40690000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_qSGdEBJlqUKNFyEkSi6X8g_8_14"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">40690000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <incy:AdoptionOfAccountingStandardAdjustmentToRetainedEarnings
      contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_DbVOFfn2yECjfpwbXtOkuQ"
      decimals="-3"
      id="Tc_Qg4Tl9BTSEGs4BMFSF5DwQ_9_11"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">95000</incy:AdoptionOfAccountingStandardAdjustmentToRetainedEarnings>
    <incy:AdoptionOfAccountingStandardAdjustmentToRetainedEarnings
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_rMRGnrn9PEq_pcDu2yHJRg_9_14"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">95000</incy:AdoptionOfAccountingStandardAdjustmentToRetainedEarnings>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_A8RojBoxM0mFmINTN2EuXg"
      decimals="-3"
      id="Tc_HxQIhA8VEk2Z09gSbIgXqQ_10_8"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">918000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_9BZkRKjfHUiHnrMkc0cLqA_10_14"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">918000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_DbVOFfn2yECjfpwbXtOkuQ"
      decimals="-3"
      id="Tc_R0EspgGsDUGnwBVPnb8o7w_11_11"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">102312000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_VuPit3WYD0y8YaZFfB5QyA_11_14"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">102312000</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vUipIgfa4km0rtW5tdmA4w"
      decimals="-3"
      id="Tc_REu-mZT-1kqUj6jxNSJr9A_12_2"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">214000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_S1joOk6fhkO10LOQZpl6lQ"
      decimals="-3"
      id="Tc_yJKBQuWQa0KagZGlld8zpw_12_5"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">3869952000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_XMlG1LUJy0Scx4eCJMw_Og"
      decimals="-3"
      id="Tc_F15j2VmILUaPNSPdtErsQw_12_8"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-9247000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_OfMjHRm8vkyNOUMTG5Sgug"
      decimals="-3"
      id="Tc_2PpbkBG9o0GTHhR3eAK56w_12_11"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-1775352000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2019_dMCk6SsWm0OpwCR3K8OhEw"
      decimals="-3"
      id="Tc_xBARIAe1f0GaBZIrV2u7hA_12_14"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">2085567000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_h7i3Ro_OZUmCp9mkSGukFg"
      decimals="-3"
      id="Tc_esZPbSOol0y1J9na_kPaTw_5_2"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">216000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4IpabeHWGEeyws0bt-_LIw"
      decimals="-3"
      id="Tc_Hyke_xD8DUCSD6vvjkQY6w_5_5"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">4044490000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_-bO_iV0lbkSyipE07mBbnA"
      decimals="-3"
      id="Tc_oxvONU2UpkOpjUw1GHxX7Q_5_8"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-15542000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__tiHxydERESGTR76ARwl7w"
      decimals="-3"
      id="Tc_7Rv5E81PSEqrokNGiqliWA_5_11"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-1430758000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_VW1M5710KUCopAC2UNPdRg_5_14"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">2598406000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="INF"
      id="Narr_e3kCZoxSRkqX0FC51yxkvg"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">772538</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e2R-5xzxfUC6nZUl8PL1YA"
      decimals="-3"
      id="Tc_PfTsuv2QOkCtfOm3icmaYQ_6_2"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_w-vcv_NpWkCA4qcaHLsFbw"
      decimals="-3"
      id="Tc_sRB5JZOlPUuJmZi-Mb-K_g_6_5"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">14618000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_AdTCz-COyU6SdKuhQH5Jlg_6_14"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">14619000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="INF"
      id="Narr_AAG71Dk3s0yzhONwd93-Yg"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">1957</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_w-vcv_NpWkCA4qcaHLsFbw"
      decimals="-3"
      id="Tc_vSZAhmwf0EyMhMAE7J71cg_7_5"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">145000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_QZF4kGqe4UesTrb2Wmf3Fg_7_14"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">145000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_w-vcv_NpWkCA4qcaHLsFbw"
      decimals="-3"
      id="Tc_lA3L52C0E0-l5yE5Zsn9XA_8_5"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">42758000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_dftJkawjW0K6s72gHYOaMQ_8_14"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">42758000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1-7nj5ASlkiVwC_JguIJwg"
      decimals="-3"
      id="Tc_dwVy0Cjsu0CX-Qhy6195xw_9_8"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">2435000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_WefEiQG4f0muYLI2uChKLA_9_14"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">2435000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HPSBbAExTU2JCIrpO-YFvQ"
      decimals="-3"
      id="Tc_6s_sEUx8-UWtDd9EA4H92w_10_11"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-720642000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_W8Fl6rvweE6TrwZqEtcYxg_10_14"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-720642000</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2hQ7NTSBMUWmxGpMp6-_0w"
      decimals="-3"
      id="Tc_moUcuyCNAEKkQD55aVi10Q_11_2"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">217000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Hj6IUMCWb02gJP3m4OeDnw"
      decimals="-3"
      id="Tc_vAU1LBeSj0ii4rGRy_Gf4Q_11_5"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">4102011000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_xkbc2Y822UqXDVbR6a7_LQ"
      decimals="-3"
      id="Tc_pRDfTMTNBkiLecLDXq1kuA_11_8"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-13107000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fEwSRBjO_Ui2kpLBrnNHdg"
      decimals="-3"
      id="Tc_xyc2KREVcUeE2UNVegWwVQ_11_11"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-2151400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_rg_PuBArQEyRqAXjyNg3mg_11_14"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1937721000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_5RcMJ5QfwESUtMvDlQttbg_5_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-720642000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_vNDgyJKXjE2jF_1GMjoIyg_5_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">102312000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_2OwlOeMmvE2urWFqvHn3PA_7_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">13098000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_HBNsDmfpkkmwV-o_GOG_EQ_7_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">13891000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_LNjew6gQREG2KjH6TGd4Og_8_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">42513000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_F3apIExXukSie6-0xoD0GA_8_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">40592000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_omyrR9eNBUq7kW8SHB42fQ_9_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-145000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_XtaxqCjMaUOhVWx-uFENYw_9_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-104000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_xOSizPbz0EmhgpB7E-02kA_10_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-48132000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_6Pn9k0slS0mIIBh1mg2Mvw_10_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">20989000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_rmsM3budd0eEPrJoQ0iURw_11_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">6627000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_PGKRrRH1REeiOxVYz5Q5HA_11_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">6671000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_qrEQBFCW80GVMjxx33lahg_13_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">42713000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_twzlzVRqPkWZ88vQA7wrSw_13_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-63517000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_LN74uHylfk6BQ6E5Gmcq_g_14_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">16701000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_ppICXiaN0Em7_SCdS_lU9g_14_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-5559000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_kA0NR-g-e0Ogv7csIlolzw_15_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">5712000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_Jwh0EYn2PEu6XPUfe4ofyg_15_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">600000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_jZxWtoOvhkCyWoMbYn43mw_16_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-22710000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_MivBTRLm90eag5qJTnN9vg_16_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-33464000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_t353DsD1s0-7dUUI26YNRw_17_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">14546000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_ys37dmjHfkuh-YsfH3o2Cg_17_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-21930000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_H4RjT8G1DUaR4_sn20h-BQ_18_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-683417000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_8WGmeOjzlE2kZcXRbOcs2A_18_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">155663000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireLongtermInvestments
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_ZN502eLsJ0-nqUTb1NHCiA_20_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">95468000</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_6sbbG7LHZ0uqL90EKDwAAA_21_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">39265000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_bS-8XlKu1EGuY8gMLa47hA_21_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">18267000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_vg7p7RfDyE-IfG7DYFSr5g_22_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">147403000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_zD3NG6nBB0Cyqm9OtTWuCQ_22_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">34574000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_LOtx6ugHgEyurYtzlNKEIQ_23_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">173576000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_qlfqhYGSHEGXAsi4kAMJyg_23_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">28278000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_Sd1p8DdEIUOPlbeaKZwdfg_24_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-108560000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_IvR6CUgpQ0enO9YbxS4KqQ_24_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-24563000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockPlans
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_zwVaGrzpyEqnmgM-JKwd-w_26_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">14619000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_vXBHuW-N_k-j1rMYFvRXiA_26_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">15481000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_ssxNGG0jV0G0HQqzcogfeA_27_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">187000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_xwMM1-mW8ku6s7J_O5iz_w_27_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">195000</us-gaap:FinanceLeasePrincipalPayments>
    <incy:PaymentOfContingentConsideration
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_YK4e0RAq20S90GcFXk9U_A_28_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">11933000</incy:PaymentOfContingentConsideration>
    <incy:PaymentOfContingentConsideration
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_hT3vHtXXckWY3nLSgQXnig_28_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">10799000</incy:PaymentOfContingentConsideration>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_7bt3TDUqD0CH9nX503Zd9A_29_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">2499000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_fKHjXpM1M0i2ca_dyB1Hnw_29_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">4487000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_Gip1H5v-7EahIuHSFhtXmA_30_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1560000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_gAYFDfbNYUKQPKDKe6OrtQ_30_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">126000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_7jhceT7Ff0WCj62g2yMg8g_31_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-787918000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_Ms3EzN_1AUOwxaLhitTaxA_31_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">135713000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_v6Zqmdon-kiq1xt41fBX-w_32_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1833707000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2018_9ClNYpZejEWe3kBT1B-jvg"
      decimals="-3"
      id="Tc_IbA1u2tsaEyX3jWLYZ4COg_32_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1164986000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_v3OkoTtiHEO2Y4IFJat2Qg_33_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1045789000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_3_31_2019_dMCk6SsWm0OpwCR3K8OhEw"
      decimals="-3"
      id="Tc_4yNpv5-jFkCqefU-jN9Rkw_33_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1300699000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_zmGdCZKtG0G_KfDk15BFaQ_35_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">855000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_OLS8KdsYyE6BAetd8qFrZA_35_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">448000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_0UXUEho_mkOymR5hjdRCgg_36_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">13582000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_1QssCok2s0WGBBsXbsV6mQ_36_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">8414000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_5kwyEjqWGkWzQcDJfwC5wg_37_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1984000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_kJSg3Bi-xUiUi7Sz5KQQUA_37_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">932000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_ZMZ09IHWsk6AIdFTdmCtlw_38_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">645000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_Eup-VL3trEOb1J8RCWTQeA">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;1.&#160;&#160;&#160;&#160; &lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Organization and business&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Incyte Corporation (including its subsidiaries, &#x201c;Incyte,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; or &#x201c;our&#x201d;) is a biopharmaceutical company focused on developing and commercializing proprietary therapeutics. Our portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products JAKAFI&#xae; (ruxolitinib), and ICLUSIG&#xae; (ponatinib). Our operations are treated as one operating segment.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="INF"
      id="Narr_25m1gSJGCku2n4yBcTiGHA"
      unitRef="Unit_Standard_segment_jI2Df57rGUiaWugJ41i_Hg">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_ceHk9ALov02Yy0bhzaPPug">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2.&#160;&#160;&#160;&#160; &lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Summary of significant accounting policies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Basis of presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. The condensed consolidated balance sheet as of March 31, 2020, the condensed consolidated statements of operations, comprehensive income (loss), stockholders&#x2019; equity, and cash flows for the three months ended March 31, 2020 and 2019, are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which we consider necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. &#160;The condensed consolidated balance sheet at December 31, 2019 has been derived from our audited consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Although we believe that the disclosures in these financial statements are adequate to make the information presented not misleading, certain information and footnote information normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;) have been condensed or omitted pursuant to the rules&#160;and regulations of the Securities and Exchange Commission.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Results for any interim period are not necessarily indicative of results for any future interim period or for the entire year. The accompanying financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form&#160;10-K for the year ended December 31, 2019.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Principles of Consolidation.&lt;/i&gt; &#160;The condensed consolidated financial statements include the accounts of Incyte Corporation and our wholly owned subsidiaries. All inter-company accounts, transactions, and profits have been eliminated in consolidation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Foreign Currency Translation&lt;/i&gt;. Operations in non-U.S. entities are recorded in the functional currency of each entity. For financial reporting purposes, the functional currency of an entity is determined by a review of the source of an entity's most predominant cash flows. The results of operations for any non-U.S. dollar functional currency entities are translated from functional currencies into U.S. dollars using the average currency rate during each month. Assets and liabilities are translated using currency rates at the end of the period. Adjustments resulting from translating the financial statements of our foreign entities that use their local currency as the functional currency into U.S. dollars are reflected as a component of other comprehensive income (loss). Transaction gains and losses are recorded in other income (expense), net, in the condensed consolidated statements of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Use of Estimates.&lt;/i&gt; &#160;The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Concentrations of Credit Risk.&lt;/i&gt; &#160;Cash, cash equivalents, marketable securities, and trade receivables are financial instruments which potentially subject us to concentrations of credit risk. The estimated fair value of financial instruments approximates the carrying value based on available market information. We primarily invest our excess available funds in debt securities and, by policy, limit the amount of credit exposure to any one issuer and to any one type of investment, &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;other than securities issued or guaranteed by the U.S. government and money market funds that meet certain guidelines. Our receivables mainly relate to our product sales of JAKAFI, ICLUSIG and collaborative agreements with pharmaceutical companies. We have not experienced any significant credit losses on cash, cash equivalents, marketable securities, or trade receivables to date and do not require collateral on receivables.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Current Expected Credit Losses. &#160;&lt;/i&gt;Effective January 1, 2020, financial assets measured at amortized cost are assessed for future expected credit losses under guidance within ASC 326, Financial Instruments &#x2013; Credit Losses, to determine if application of an expected credit losses reserve is necessary. On a quarterly basis, receivables that resulted from revenue transactions within the scope of ASC 606 and recognized on an amortized cost basis are reviewed on a customer-level basis to analyze expectations of future collections based upon past history of collections, payment, aging of receivables and viability of the customer to continue payment, as well as estimates of future economic conditions. Receivables generally consist of two types: receivables from collaborative agreements, including milestones, reimbursements for agreed-upon activities and sales royalties; and receivables from customer product sales. Collaborative agreement receivables are closely monitored relationships with select, reputable industry peers. Collection of receivables is assessed within each collaborative partnership on a quarterly basis, including evaluation of each entity&#x2019;s credit quality, financial health and past history of payment. Customer product sales receivables are independently evaluated on a monthly basis, on which unusual items or aged receivables are closely monitored for signs of credit deterioration, or indications of payment refusal. Customer product sales are with specialty pharmaceutical distributors, wholesalers, and certain public and private institutions, some of which whose financial obligations are funded by various government agencies. These receivables are assessed for signs of credit deterioration and in the Company&#x2019;s sales history and future expectations of economic conditions, there are minimal instances of bad debts or uncollected receivables. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Cash and Cash Equivalents.&lt;/i&gt; &#160;Cash and cash equivalents are held in banks or in custodial accounts with banks. Cash equivalents are defined as all liquid investments and money market funds with maturity from date of purchase of 90 days or less that are readily convertible into cash.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Marketable Securities&#x2014;Available-for-Sale.&lt;/i&gt; &#160;Our marketable securities consist of investments in U.S. government debt securities that are classified as available-for-sale. Available-for-sale securities are carried at fair value, based on quoted market prices and observable inputs, with unrealized gains and losses, net of tax, reported as a separate component of stockholders&#x2019; equity. We classify marketable securities that are available for use in current operations as current assets on the condensed consolidated balance sheets. Realized gains and losses and declines in value judged to be other than temporary for available-for-sale securities are included in other income (expense), net on the condensed consolidated statements of operations. &#160;The cost of securities sold is based on the specific identification method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Accounts Receivable.&lt;/i&gt; &#160;As of March 31, 2020 and December 31, 2019, we had a de minimis allowance for doubtful accounts. We provide an allowance for doubtful accounts based on experience and specifically identified risks. Accounts receivable are carried at fair value and charged off against the allowance for doubtful accounts when we determine that recovery is unlikely and we cease collection efforts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Inventory.&lt;/i&gt; &#160;Inventories are determined at the lower of cost and net realizable value with cost determined under the specific identification method and may consist of raw materials, work in process and finished goods. JAKAFI and &lt;span style="-sec-ix-hidden:Hidden_Z0f1rDx3zUCCp3VLdTAwTg"&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;ICLUSIG&lt;/span&gt;&lt;/span&gt; raw materials and work-in-process inventory are not subject to expiration and the shelf life of finished goods inventory is 36 months from the start of manufacturing of the finished goods. We evaluate for potential excess inventory by analyzing current and future product demand relative to the remaining product shelf life. We build demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance and patient usage. We classify inventory as current on the condensed consolidated balance sheets when we expect inventory to be consumed for commercial use within the next twelve months.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Variable Interest Entities&lt;/i&gt;. We perform an initial and ongoing evaluation of the entities with which we have variable interests, such as equity ownership, in order to&lt;i style="font-style:italic;"&gt; &lt;/i&gt;identify entities (i) that do not have sufficient equity investment at risk to permit the entity to finance its activities without additional subordinated financial support or (ii) in which the equity investors lack an essential characteristic of a controlling financial interest as variable interest entities (&#x201c;VIE&#x201d; or &#x201c;VIEs&#x201d;). If an entity is identified as a VIE, we perform an assessment to determine whether we have both (i) the power to direct activities that most significantly impact the VIE&#x2019;s economic performance and (ii) have the obligation to absorb losses from &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;or the right to receive benefits of the VIE that could potentially be significant to the VIE. If both of these criteria are satisfied, we are identified as the primary beneficiary of the VIE. &#160;As of March 31, 2020, there were no entities in which we held a variable interest which we determined to be VIEs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Long Term Investments.&lt;/i&gt; Our long term investments consist of equity investments in common stock of publicly-held companies with whom we have entered into collaboration and license agreements. We classify all of our equity investments in common stock of publicly-held companies as long term investments on our condensed consolidated balance sheets. Our equity investments are accounted for at fair value using readily determinable pricing available on a securities exchange on our condensed consolidated balance sheets. All changes in fair value are reported in the condensed consolidated statements of operations as an unrealized gain (loss) on long term investments. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In assessing whether we exercise significant influence over any of the companies in which we hold equity investments, we consider the nature and magnitude of our investment, any voting and protective rights we hold, any participation in the governance of the other company, and other relevant factors such as the presence of a collaboration or other business relationship. Currently, none of our equity investments in publicly-held companies are considered relationships in which we are able to assert control. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Property and Equipment, net.&lt;/i&gt; &#160;Property and equipment, net is stated at cost, less accumulated depreciation and amortization. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets. Leasehold improvements are amortized over the shorter of the estimated useful life of the assets or lease term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Lease Accounting.&lt;/i&gt; &#160;Accounting Standard Codification (&#x201c;ASC&#x201d;) 842, Leases, was adopted for the fiscal year beginning on January 1, 2019. All leases with a lease term greater than 12 months, regardless of lease type classification, are recorded as an obligation on the balance sheet with a corresponding right-of-use asset. Both finance and operating leases are reflected as liabilities on the commencement date of the lease based on the present value of the lease payments to be made over the lease term. Current operating lease liabilities are reflected in accrued and other current liabilities and noncurrent operating lease liabilities are reflected in other liabilities on the condensed consolidated balance sheet. Right-of-use assets are valued at the initial measurement of the lease liability, plus any initial direct costs or rent prepayments, minus lease incentives and any deferred lease payments. Operating lease right-of-use assets are recorded in property and equipment, net on the condensed consolidated balance sheet and lease cost is recognized on a straight-line basis. For finance leases, expense is recognized as separate amortization and interest expense, with higher interest expense in the earlier periods of a lease. Leases with an initial term of 12 months or less are not recorded on the balance sheet and we recognize lease expense for these leases on a straight-line basis over the term of the lease. In determining whether a contract contains a lease, asset and service agreements are assessed at onset and upon modification for criteria of specifically identified assets, control and economic benefit. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Other Intangible Assets, net.&lt;/i&gt; Other intangible assets, net consist of licensed intellectual property rights acquired in business combinations, which are reported at acquisition date fair value, less accumulated amortization. Intangible assets with finite lives are amortized over their estimated useful lives using the straight-line method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Impairment of Long-Lived Assets.&lt;/i&gt; &#160;Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. &#160;If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset. &#160;If the expected cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash flows.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Goodwill.&lt;/i&gt; &#160;Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. &#160;Goodwill is not amortized but is tested for impairment at the reporting unit level at least annually as of October 1 or when a triggering event occurs that could indicate a potential impairment by assessing qualitative factors or performing a quantitative analysis in determining whether it is more likely than not that the fair value of net assets are below their carrying amounts. &#160;A reporting unit is the same as, or one level below, an operating segment. Our operations are currently comprised of a single, entity wide reporting &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;unit. We completed our most recent annual impairment assessment as of October 1, 2019 and determined that the carrying value of our goodwill was not impaired. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Income Taxes.&lt;/i&gt; &#160;We account for income taxes using the asset and liability approach which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and amounts reportable for income tax purposes. &#160;&lt;span style="background-color:#ffffff;"&gt;Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized. &lt;/span&gt;The primary factors used to assess the likelihood of realization are our recent history of cumulative earnings or losses, expected reversals of taxable temporary timing differences, forecasts of future taxable income and available tax planning strategies that could be implemented to realize the deferred tax assets. &#160;Upon evaluating and weighting both positive and negative evidence, we concluded that we should continue to maintain the valuation allowance on the majority of our deferred tax assets as of March 31, 2020. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We recognize the tax benefit from an uncertain tax position only if it is more-likely-than-not that the position will be sustained upon examination by the taxing authorities, including resolutions of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit that is recorded for these positions is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. We adjust the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Any interest and penalties on uncertain tax positions are included within the tax provision.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Coronavirus Aid, Relief, and Economic Security (CARES) Act was signed into law in March 2020 to provide an estimated $2.2 trillion designed to stimulate the U.S. economy during the COVID-19 pandemic. &#160;The Act includes tax relief, government loans, grants and investments for entities in affected industries, which has related accounting and financial reporting impacts. &#160;Disclosure for certain income tax accounting measures are required in the period of enactment and disclosure for government loans, investments, grants, and revenue recognition are required in future periods as federal agencies establish rules and procedures to implement the CARES Act. &#160;During the three months ended March 31, 2020, we have not sought any financial relief under the CARES Act and have determined the income tax provision implications to be immaterial. We have further described the expected impact and risks of COVID-19 on our business in the overview to Item 2. Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations and in Item 1A. Risk Factors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Financing Costs Related to Long-term Debt.&lt;/i&gt; &#160;Costs associated with obtaining long-term debt are deferred and amortized over the term of the related debt using the effective interest method. Such costs are presented as a direct deduction from the carrying amount of the long-term debt liability, consistent with debt discounts, on the condensed consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Net Income (Loss) Per Share.&lt;/i&gt; &#160;Our basic and diluted net income (loss) per share is calculated by dividing the net income (loss) by the weighted average number of shares of common stock outstanding during all periods presented. Options to purchase stock, restricted stock units, performance stock units and shares issuable upon the conversion of convertible debt are included in diluted earnings per share calculations, unless the effects are anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Accumulated Other Comprehensive Income (Loss).&lt;/i&gt; &#160;Accumulated other comprehensive income (loss) consists of unrealized gains or losses on marketable securities that are classified as available-for-sale, foreign currency translation gains or losses and defined benefit pension obligations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Revenue Recognition.&lt;/i&gt; &#160;Revenue-generating contracts are assessed under ASC 606, &lt;i style="font-style:italic;"&gt;Revenue from contracts with customers&lt;/i&gt;, to identify distinct performance obligations, determine the transaction price of the contract and allocate the transaction price to each of the distinct performance obligations. Revenue is recognized when we have satisfied a performance obligation through transferring control of the promised good or service to a customer. Control, in this instance, may mean the ability to prevent other entities from directing the use of, and receiving benefit from, a good or service. We determine at contract inception whether we will transfer control of a promised good or service over time or satisfy the performance obligation at a point in time through analysis of the following criteria: (i) the entity has a present right to payment, (ii) the customer has legal title, (iii) the customer has physical possession, (iv) the customer has the significant &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;risks and rewards of ownership and (v) the customer has accepted the asset. We assess collectability based primarily on the customer&#x2019;s payment history and on the creditworthiness of the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;text-decoration:underline;text-decoration-color:#000000;"&gt;Product Revenues&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Our product revenues consist of U.S. sales of JAKAFI and European sales of ICLUSIG. &#160;Product revenues are recognized once we satisfy the performance obligation at a point in time under the revenue recognition criteria as described above. We sell JAKAFI to our customers in the U.S., which include specialty pharmacies and wholesalers.&#160;We sell ICLUSIG to our customers in the European Union and certain other jurisdictions, which include retail pharmacies, hospital pharmacies and distributors. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We recognize revenues for product received by our customers net of allowances for customer credits, including estimated rebates, chargebacks, discounts, returns, distribution service fees, patient assistance programs, and government rebates, such as Medicare Part D coverage gap reimbursements in the U.S. Product shipping and handling costs are included in cost of product revenues. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Customer Credits:&lt;/i&gt; &#160;Our customers are offered various forms of consideration, including allowances, service fees and prompt payment discounts. We expect our customers will earn prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized. Service fees are also deducted from total product sales as they are earned.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Rebates and Discounts:&lt;/i&gt; &#160;Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program in the U.S. and mandated discounts in Europe in markets where government-sponsored healthcare systems are the primary payers for healthcare. Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or legal requirements with public sector benefit providers. The accrual for rebates is based on statutory discount rates and expected utilization as well as historical data we have accumulated since product launches. Our estimates for expected utilization of rebates are based on data received from our customers. Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#x2019;s activity, plus an accrual balance for known prior quarters&#x2019; unpaid rebates. If actual future rebates vary from estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Chargebacks: &#160;&lt;/i&gt;Chargebacks are discounts that occur when certain contracted customers, which currently consist primarily of group purchasing organizations, Public Health Service institutions, non-profit clinics, and Federal government entities purchasing via the Federal Supply Schedule, purchase directly from our wholesalers. Contracted customers generally purchase the product at a discounted price. The wholesalers, in turn, charges back to us the difference between the price initially paid by the wholesalers and the discounted price paid by the contracted customers. In addition to actual chargebacks received we maintain an accrual for chargebacks based on the estimated contractual discounts on the inventory levels on hand in our distribution channel. &#160;If actual future chargebacks vary from these estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Medicare Part&#160;D Coverage Gap:&lt;/i&gt; &#160;Medicare Part&#160;D prescription drug benefit mandates manufacturers to fund 70% of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for the expected Medicare Part&#160;D coverage gap are based on historical invoices received and in part from data received from our customers. Funding of the coverage gap is generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#x2019;s activity, plus an accrual balance for known prior quarters. If actual future funding varies from estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment. &#160;Additionally, beginning in January 2020, the amount of spending required by eligible patients in the Medicare Part D insurance coverage gap increased 30% due to the expiration of a provision in the Patient Protection and Affordable Care Act, which now results in a change in the True Out of Pocket (TrOOP) calculation methodology. The methodological change has resulted in an increase in required spending by patients and, in turn, an increase in manufacturers&#x2019; contributions on behalf of patients in the Medicare Part D insurance coverage gap.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Co-payment Assistance:&lt;/i&gt; &#160;Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;text-decoration:underline;text-decoration-color:#000000;"&gt;Product Royalty Revenues&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Royalty revenues on commercial sales for ruxolitinib (marketed as JAKAVI&lt;span style="vertical-align:super;"&gt;&#xae;&lt;/span&gt; outside the United States) by Novartis Pharmaceutical International&#160;Ltd. (&#x201c;Novartis&#x201d;) are based on net sales of licensed products in licensed territories as provided by Novartis. &#160;Royalty revenues on commercial sales for baricitinib (marketed as OLUMIANT) by Eli Lilly and Company (&#x201c;Lilly&#x201d;) are based on net sales of licensed products in licensed territories as provided by Lilly. We recognize royalty revenues in the period the sales occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;text-decoration:underline;text-decoration-color:#000000;"&gt;Milestone and Contract Revenues&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Our license agreements, which fall within the scope of ASC 606, Revenue from Contracts with Customers, include distinct drug compound out-licensing, collection of upfront payments, milestones or royalty revenues from a counterparty, and provision of commercially available products to suppliers. Our agreements often include contractual milestones, which typically relate to the achievement of pre-specified development, regulatory and commercialization events outside of our control, such as regulatory approval of a compound, first patient dosing or achievement of sales-based thresholds. For such cases, we believe that revenue related to these events should not be recognized until the milestone has been achieved. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Some contracts form collaborative arrangements of various types with third-parties. We assess whether the nature of the arrangement is within the scope of ASC 808, Collaborative Arrangements, in conjunction with the revenue recognition guidance in ASC 606 to determine the nature of the performance obligations and associated transaction prices. A collaborative relationship may exist when we participate in an activity or process with another party, such as performance of research and development services or the exchange of intellectual property for use in clinical trials, when both parties share in the risks and rewards that result from the activity and participate and govern contract activities through a joint steering committee. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The regulatory review and approval process, which includes preclinical testing and clinical trials of each drug candidate, is lengthy, expensive and uncertain. Securing approval by the U.S. Food and Drug Administration (the &#x201c;FDA&#x201d;) requires the submission of extensive preclinical and clinical data and supporting information to the FDA for each indication to establish a drug candidate&#x2019;s safety and efficacy. The approval process takes many years, requires the expenditure of substantial resources, involves post-marketing surveillance and may involve ongoing requirements for post-marketing studies. Before commencing clinical investigations of a drug candidate in humans, we must submit an Investigational New Drug application (&#x201c;IND&#x201d;), which must be reviewed by the FDA.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The steps generally required before a drug may be marketed in the United States include preclinical laboratory tests, animal studies and formulation studies, submission to the FDA of an IND for human clinical testing, performance of adequate and well-controlled clinical trials in three phases, as described below, to establish the safety and efficacy of the drug for each indication, submission of a new drug application (&#x201c;NDA&#x201d;) or biologics license application (&#x201c;BLA&#x201d;) to the FDA for review and FDA approval of the NDA or BLA.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Similar requirements exist within foreign regulatory agencies as well. The time required satisfying the FDA requirements or similar requirements of foreign regulatory agencies may vary substantially based on the type, complexity and novelty of the product or the targeted disease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Preclinical testing includes laboratory evaluation of product pharmacology, drug metabolism, and toxicity, which includes animal studies, to assess potential safety and efficacy as well as product chemistry, stability, formulation, development, and testing. The results of the preclinical tests, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND. The FDA may raise safety concerns or questions about the conduct of the clinical trials included in the IND, and any of these concerns or questions must be resolved before clinical trials can proceed. We cannot be sure that submission of an IND will result in the FDA allowing clinical trials to commence. Clinical &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;trials involve the administration of the investigational drug or the marketed drug to human subjects under the supervision of qualified investigators and in accordance with good clinical practices regulations covering the protection of human subjects. Clinical trials typically are conducted in three sequential phases, but the phases may overlap or be combined. Phase&#160;I usually involves the initial introduction of the investigational drug into healthy volunteers to evaluate its safety, dosage tolerance, absorption, metabolism, distribution and excretion. Phase&#160;II usually involves clinical trials in a limited patient population to evaluate dosage tolerance and optimal dosage, identify possible adverse effects and safety risks, and evaluate and gain preliminary evidence of the efficacy of the drug for specific indications. Phase&#160;III clinical trials usually further evaluate clinical efficacy and safety by testing the drug in its final form in an expanded patient population, providing statistical evidence of efficacy and safety, and providing an adequate basis for labeling. We cannot guarantee that Phase&#160;I, Phase&#160;II or Phase&#160;III testing will be completed successfully within any specified period of time, if at all. Furthermore, we, the institutional review board for a trial, or the FDA may suspend clinical trials at any time on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Generally, the milestone events contained in our collaboration agreements coincide with the progression of our drugs from development, to regulatory approval and then to commercialization. The process of successfully discovering a new development candidate, having it approved and successfully commercialized is highly uncertain. As such, the milestone payments we may earn from our partners involve a significant degree of risk to achieve. Therefore, as a drug candidate progresses through the stages of its life-cycle, the value of the drug candidate generally increases.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;text-decoration:underline;text-decoration-color:#000000;"&gt;Cost of Product Revenues&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cost of product revenues includes all JAKAFI related product costs as well as ICLUSIG related product costs. In addition, cost of product revenues include low single-digit royalties under our collaboration and license agreement to Novartis on all future sales of JAKAFI in the United States and the amortization of our licensed intellectual property for ICLUSIG using the straight-line method over the estimated useful life of 12.5 years from the date of acquisition on June 1, 2016 of all of the outstanding shares of ARIAD Pharmaceuticals (Luxembourg) S.&#xe0;.r.l. (since renamed Incyte Biosciences Luxembourg S.&#xe0;.r.l.) from ARIAD Pharmaceuticals, Inc. (&#x201c;ARIAD&#x201d;). Cost of product revenues also includes employee personnel costs, including stock compensation, for those employees dedicated to the production of our commercial products.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Research and Development Costs.&lt;/i&gt; &#160;Our policy is to expense research and development costs as incurred, including amounts funded by research and development collaborations. Research and development expenses are comprised of costs we incur in performing research and development activities, including salary and benefits; stock-based compensation expense; outsourced services and other direct expenses, including clinical trial and pharmaceutical development costs; collaboration payments; expenses associated with drug supplies that are not being capitalized; and infrastructure costs, including facilities costs and depreciation expense. If a collaboration is a cost-sharing arrangement in which both we and our collaborator perform development work and share costs, we also recognize, as research and development expense in the period when our collaborator incurs development expenses, our portion of the co-development expenses that we are obligated to reimburse. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;We often contract with clinical research organizations (&#x201c;CROs&#x201d;) to facilitate, coordinate and perform agreed upon research and development of a new drug. To ensure that research and development costs are expensed as incurred, we record monthly accruals for clinical trials and preclinical testing costs based on the work performed under the contract. These CRO contracts typically call for the payment of fees for services at the initiation of the contract and/or upon the achievement of certain clinical trial milestones. In the event that we prepay CRO fees, we record the prepayment as a prepaid asset and amortize the asset into research and development expense over the period of time the contracted research and development services are performed. Most professional fees, including project and clinical management, data management, monitoring, and medical writing fees are incurred throughout the contract period. These professional fees are expensed based on their percentage of completion at a particular date. Our CRO contracts generally include pass through fees. Pass through fees include, but are not limited to, regulatory expenses, investigator fees, travel costs, and other miscellaneous costs, including shipping and printing fees. We expense the costs of pass through fees under our CRO contracts as they are incurred, based on the best information available to us at the time. The estimates of the pass through fees incurred are based on the amount of work completed for the clinical trial and are monitored through correspondence with the CROs, internal reviews and a review of contractual terms. The factors utilized to derive the estimates include the &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;number of patients enrolled, duration of the clinical trial, estimated patient attrition, screening rate and length of the dosing regimen. CRO fees incurred to set up the clinical trial are expensed during the setup period. Under our clinical trial collaboration agreements we may be reimbursed for certain development costs incurred. Such costs are recorded as a reduction of research and development expense in the period in which the related expense is incurred. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Stock Compensation.&lt;/i&gt; &#160;Share-based payment transactions with employees, which include stock options, restricted stock units (&#x201c;RSUs&#x201d;) and performance shares (&#x201c;PSUs&#x201d;), are recognized as compensation expense over the requisite service period based on their estimated fair values as well as expected forfeiture rates. &#160;The stock compensation process requires significant judgment and the use of estimates, particularly surrounding Black-Scholes assumptions such as stock price volatility over the option term and expected option lives, as well as expected forfeiture rates and the probability of PSUs vesting. &#160;The fair value of stock options, which are subject to graded vesting, are recognized as compensation expense over the requisite service period using the accelerated attribution method. &#160;The fair value of RSUs that are subject to cliff vesting are recognized as compensation expense over the requisite service period using the straight-line attribution method, and the fair value of RSUs that are subject to graded vesting are recognized as compensation expense over the requisite service period using the accelerated attribution method. &#160;The fair value of PSUs are recognized as compensation expense beginning at the time in which the performance conditions are deemed probable of achievement, which we assess as of the end of each reporting period. Once a performance condition is considered probable, we record compensation expense based on the portion of the service period elapsed to date with respect to that award, with a cumulative catch-up, net of estimated forfeitures, and recognize any remaining compensation expense, if any, over the remaining requisite service period using the straight-line attribution method for PSUs that are subject to cliff vesting and using the accelerated attribution method for PSUs that are subject to graded vesting. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Long Term Incentive Plans.&lt;/i&gt; We have long term incentive plans which provide eligible employees with the opportunity to receive performance and service-based incentive compensation, which may be comprised of cash, stock options, restricted stock units and/or performance shares. The payment of cash and the grant or vesting of equity may be contingent upon the achievement of pre-determined regulatory, sales and internal performance milestones. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Acquisition-Related Contingent Consideration.&lt;/i&gt; Acquisition-related contingent consideration consists of our future royalty obligations on future net sales of ICLUSIG to Takeda Pharmaceutical Company Limited, which acquired ARIAD (&#x201c;Takeda&#x201d;). Acquisition-related contingent consideration was recorded on the acquisition date of June 1, 2016 at the estimated fair value of the obligation, in accordance with the acquisition method of accounting. &#160;The fair value measurement is based on significant inputs that are unobservable in the market and thus represents a Level 3 measurement. The fair value of the acquisition-related contingent consideration is remeasured each reporting period, with changes in fair value recorded in the condensed consolidated statements of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Collaboration loss sharing.&lt;/i&gt; &#160;Under collaboration and license agreements with shared commercialization efforts, we record our share of the losses from the co-commercialization efforts in collaboration loss sharing on the condensed consolidated statement of operations. For the three months ended March 31, 2020, collaboration loss sharing represents our 50% share of the United States loss for commercialization of tafasitamab under our agreement with MorphoSys. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU No. 2016-13, &#x201c;Financial Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.&#x201d; This guidance applies to all entities and impacts how entities account for credit losses for financial assets measured at amortized cost and available for sale debt securities. ASU 2016-13 requires financial assets measured at amortized cost to be presented at the net amount expected to be collected. The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amounts. An entity must use judgment in determining the relevant information and estimation methods that are appropriate in its circumstances. &#160;For trade receivables, loans and held-to-maturity debt securities, entities will be required to estimate expected credit losses over the lifetime of the asset. &#160;For available-for-sale debt securities, entities will be required to recognize an allowance for credit losses rather than an other-than-temporary impairment that reduces the cost basis of the investment. Further, an entity will recognize any improvements in estimated credit losses on its available-for-sale debt securities immediately in earnings. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Upon adoption, we assessed each financial asset measured at amortized cost and each available for sale debt security held for the impact of the guidance as of January 1, 2020 and noted an insignificant impact due to the minimal credit risk associated with our financial assets subject to ASC 326. As such, it was concluded that a reserve for credit losses was de minimis on the adoption date. Financial assets will continue to be assessed on a quarterly basis in future periods.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In August 2018, the FASB issued ASU No. 2018-13, &#x201c;Fair Value Measurement (Topic 820): Disclosure Framework &#x2013; Changes to the Disclosure Requirements for Fair Value Measurement,&#x201d; which eliminates the required disclosure of the amount of and reason for transfers between Level 1 and Level 2 of the fair value hierarchy. The guidance also eliminates the required disclosure of the entity&#x2019;s valuation process for Level 3 fair value measurements, however public entities are required to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. This guidance is effective for fiscal years beginning after December 15, 2019. We adopted this guidance for the period beginning January 1, 2020 and enhanced our disclosures in Note 4 to the condensed consolidated financial statements to comply with the standard. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In August 2018, the FASB issued ASU No. 2018-14, &#x201c;Compensation &#x2013; Retirement Benefits &#x2013; Defined Benefit Plans &#x2013; General,&#x201d; an update to Subtopic ASC 715-20. The guidance amended year-end disclosure requirements related to defined benefit pension plans, and does not affect interim disclosures. The guidance is effective for fiscal years ending after December 15, 2020 and is permitted for early adoption. The standard is to be applied on a retrospective basis. Incyte sponsors defined benefit plans for employees located in Europe. We are currently analyzing the impact of ASU No. 2018-14 on the condensed consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In August 2018, the FASB issued ASU No. 2018-15, &#x201c;Intangibles &#x2013; Goodwill and Other &#x2013; Internal-Use Software,&#x201d; an update to Subtopic ASC 350-40. The guidance directs accounting for service contracts for cloud computing arrangements to follow guidance within ASC 350-40 to determine capitalization of implementation costs. The guidance is effective for fiscal years beginning after December 15, 2019 and may be applied on either a retrospective or prospective basis. We adopted this guidance for the period beginning January 1, 2020 on a prospective basis. New contracts for development of internal-use software were assessed and no qualifying contracts were identified during the period. We will continue to assess contracts and will disclose material, qualifying contracts if identified in future periods.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2018, the FASB issued ASU No. 2018-18, &#x201c;Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606.&#x201d; The guidance clarifies the interactions between Topic 808 and Topic 606, including clarifications on revenue recognition, unit of account, and reporting disclosure requirements. The guidance is effective for fiscal years beginning after December 15, 2019. We adopted this guidance for the period beginning January 1, 2020 on a retrospective to the date of our initial application of ASC 606, and noted that in assessment of our collaborative agreements, there was no material financial statement impact. Our collaborative arrangements and their associated accounting conclusions are described in detail within Note 9 to the condensed consolidated financial statements.&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In December 2019, the FASB issued ASU No. 2019-12, &#x201c;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.&#x201d; This guidance applies to all entities and aims to reduce the complexity of tax accounting standards while enhancing reporting disclosures. This guidance is effective for fiscal years beginning after December 15, 2020 and interim periods therein. Early adoption is permitted for any annual periods for which financial statements have not been issued and interim periods therein. We are currently analyzing the impact of ASU No. 2019-12 and do not anticipate the adoption of this ASU to have a material impact on our condensed consolidated financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_7CXqmB3Ki0yW8DKuYSn3Mw">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Basis of presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. The condensed consolidated balance sheet as of March 31, 2020, the condensed consolidated statements of operations, comprehensive income (loss), stockholders&#x2019; equity, and cash flows for the three months ended March 31, 2020 and 2019, are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which we consider necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. &#160;The condensed consolidated balance sheet at December 31, 2019 has been derived from our audited consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Although we believe that the disclosures in these financial statements are adequate to make the information presented not misleading, certain information and footnote information normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;) have been condensed or omitted pursuant to the rules&#160;and regulations of the Securities and Exchange Commission.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Results for any interim period are not necessarily indicative of results for any future interim period or for the entire year. The accompanying financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form&#160;10-K for the year ended December 31, 2019.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_mSdAWLLrM0i4axJ-Roizkw">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Principles of Consolidation.&lt;/i&gt; &#160;The condensed consolidated financial statements include the accounts of Incyte Corporation and our wholly owned subsidiaries. All inter-company accounts, transactions, and profits have been eliminated in consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_M-0fqDR43U6wEawDluwqsA">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Foreign Currency Translation&lt;/i&gt;. Operations in non-U.S. entities are recorded in the functional currency of each entity. For financial reporting purposes, the functional currency of an entity is determined by a review of the source of an entity's most predominant cash flows. The results of operations for any non-U.S. dollar functional currency entities are translated from functional currencies into U.S. dollars using the average currency rate during each month. Assets and liabilities are translated using currency rates at the end of the period. Adjustments resulting from translating the financial statements of our foreign entities that use their local currency as the functional currency into U.S. dollars are reflected as a component of other comprehensive income (loss). Transaction gains and losses are recorded in other income (expense), net, in the condensed consolidated statements of operations.&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb__N3tnyEeqEq3BSYoDXMVUQ">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Use of Estimates.&lt;/i&gt; &#160;The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_UYyDh7Nr0EKuCpOwyI01xg">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Concentrations of Credit Risk.&lt;/i&gt; &#160;Cash, cash equivalents, marketable securities, and trade receivables are financial instruments which potentially subject us to concentrations of credit risk. The estimated fair value of financial instruments approximates the carrying value based on available market information. We primarily invest our excess available funds in debt securities and, by policy, limit the amount of credit exposure to any one issuer and to any one type of investment, &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;other than securities issued or guaranteed by the U.S. government and money market funds that meet certain guidelines. Our receivables mainly relate to our product sales of JAKAFI, ICLUSIG and collaborative agreements with pharmaceutical companies. We have not experienced any significant credit losses on cash, cash equivalents, marketable securities, or trade receivables to date and do not require collateral on receivables.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <incy:CreditExposureLimitationNumberOfIssuerOtherThanUnitedStatesGovernmentGuaranteedSecurities
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="INF"
      id="Narr_uREjfAOSNEiWfHjLutxBVQ"
      unitRef="Unit_Standard_issuer_ywviBYfRh0KpQHOu97pP7g">1</incy:CreditExposureLimitationNumberOfIssuerOtherThanUnitedStatesGovernmentGuaranteedSecurities>
    <incy:CreditExposureLimitationNumberOfFinancialInvestmentOtherThanUnitedStatesGovernmentGuaranteedSecurities
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="INF"
      id="Narr_MtLKlSfGqkWmDYE6zaBfxQ"
      unitRef="Unit_Standard_instrument_X67SygLtqEeZMZZtTj-6RQ">1</incy:CreditExposureLimitationNumberOfFinancialInvestmentOtherThanUnitedStatesGovernmentGuaranteedSecurities>
    <us-gaap:CreditLossFinancialInstrumentPolicyTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_6OdjJAzYAEGC3oyOxuhbUg">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Current Expected Credit Losses. &#160;&lt;/i&gt;Effective January 1, 2020, financial assets measured at amortized cost are assessed for future expected credit losses under guidance within ASC 326, Financial Instruments &#x2013; Credit Losses, to determine if application of an expected credit losses reserve is necessary. On a quarterly basis, receivables that resulted from revenue transactions within the scope of ASC 606 and recognized on an amortized cost basis are reviewed on a customer-level basis to analyze expectations of future collections based upon past history of collections, payment, aging of receivables and viability of the customer to continue payment, as well as estimates of future economic conditions. Receivables generally consist of two types: receivables from collaborative agreements, including milestones, reimbursements for agreed-upon activities and sales royalties; and receivables from customer product sales. Collaborative agreement receivables are closely monitored relationships with select, reputable industry peers. Collection of receivables is assessed within each collaborative partnership on a quarterly basis, including evaluation of each entity&#x2019;s credit quality, financial health and past history of payment. Customer product sales receivables are independently evaluated on a monthly basis, on which unusual items or aged receivables are closely monitored for signs of credit deterioration, or indications of payment refusal. Customer product sales are with specialty pharmaceutical distributors, wholesalers, and certain public and private institutions, some of which whose financial obligations are funded by various government agencies. These receivables are assessed for signs of credit deterioration and in the Company&#x2019;s sales history and future expectations of economic conditions, there are minimal instances of bad debts or uncollected receivables. &#160;&lt;/p&gt;</us-gaap:CreditLossFinancialInstrumentPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_ShUyp13Iu0qyI1bnoRwOog">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Cash and Cash Equivalents.&lt;/i&gt; &#160;Cash and cash equivalents are held in banks or in custodial accounts with banks. Cash equivalents are defined as all liquid investments and money market funds with maturity from date of purchase of 90 days or less that are readily convertible into cash.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_MYdnr5HIs0y0tvntCCVjAQ">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Marketable Securities&#x2014;Available-for-Sale.&lt;/i&gt; &#160;Our marketable securities consist of investments in U.S. government debt securities that are classified as available-for-sale. Available-for-sale securities are carried at fair value, based on quoted market prices and observable inputs, with unrealized gains and losses, net of tax, reported as a separate component of stockholders&#x2019; equity. We classify marketable securities that are available for use in current operations as current assets on the condensed consolidated balance sheets. Realized gains and losses and declines in value judged to be other than temporary for available-for-sale securities are included in other income (expense), net on the condensed consolidated statements of operations. &#160;The cost of securities sold is based on the specific identification method.&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_mUb693giEU65kKl_kq1L1w">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Accounts Receivable.&lt;/i&gt; &#160;As of March 31, 2020 and December 31, 2019, we had a de minimis allowance for doubtful accounts. We provide an allowance for doubtful accounts based on experience and specifically identified risks. Accounts receivable are carried at fair value and charged off against the allowance for doubtful accounts when we determine that recovery is unlikely and we cease collection efforts.&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_RUL53fsni0m51seQf2LQ6A">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Inventory.&lt;/i&gt; &#160;Inventories are determined at the lower of cost and net realizable value with cost determined under the specific identification method and may consist of raw materials, work in process and finished goods. JAKAFI and &lt;span style="-sec-ix-hidden:Hidden_Z0f1rDx3zUCCp3VLdTAwTg"&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;ICLUSIG&lt;/span&gt;&lt;/span&gt; raw materials and work-in-process inventory are not subject to expiration and the shelf life of finished goods inventory is 36 months from the start of manufacturing of the finished goods. We evaluate for potential excess inventory by analyzing current and future product demand relative to the remaining product shelf life. We build demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance and patient usage. We classify inventory as current on the condensed consolidated balance sheets when we expect inventory to be consumed for commercial use within the next twelve months.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <incy:InventoryFinishedGoodsUsefulLifeMaximum
      contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_incy_JAKAFIMember__fw2KcDlhEK50BfPWrKV_w"
      id="Narr_025DmrSdN0Gsf_wvU4Iy8w">P36M</incy:InventoryFinishedGoodsUsefulLifeMaximum>
    <us-gaap:ConsolidationVariableInterestEntityPolicy
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_gQmXOQGAIUG41XGO_OnExw">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Variable Interest Entities&lt;/i&gt;. We perform an initial and ongoing evaluation of the entities with which we have variable interests, such as equity ownership, in order to&lt;i style="font-style:italic;"&gt; &lt;/i&gt;identify entities (i) that do not have sufficient equity investment at risk to permit the entity to finance its activities without additional subordinated financial support or (ii) in which the equity investors lack an essential characteristic of a controlling financial interest as variable interest entities (&#x201c;VIE&#x201d; or &#x201c;VIEs&#x201d;). If an entity is identified as a VIE, we perform an assessment to determine whether we have both (i) the power to direct activities that most significantly impact the VIE&#x2019;s economic performance and (ii) have the obligation to absorb losses from &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;or the right to receive benefits of the VIE that could potentially be significant to the VIE. If both of these criteria are satisfied, we are identified as the primary beneficiary of the VIE. &#160;As of March 31, 2020, there were no entities in which we held a variable interest which we determined to be VIEs.&lt;/p&gt;</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <incy:VariableInterestEntitiesNumber
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="INF"
      id="Narr_CDa7Ur6MG0W8ebe35V0fXQ"
      unitRef="Unit_Standard_item_4BIkJQxqZkOMHOIGydcttw">0</incy:VariableInterestEntitiesNumber>
    <incy:LongTermInvestmentPolicyTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_wGUeknXW4kKKkolpHSKgvA">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Long Term Investments.&lt;/i&gt; Our long term investments consist of equity investments in common stock of publicly-held companies with whom we have entered into collaboration and license agreements. We classify all of our equity investments in common stock of publicly-held companies as long term investments on our condensed consolidated balance sheets. Our equity investments are accounted for at fair value using readily determinable pricing available on a securities exchange on our condensed consolidated balance sheets. All changes in fair value are reported in the condensed consolidated statements of operations as an unrealized gain (loss) on long term investments. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In assessing whether we exercise significant influence over any of the companies in which we hold equity investments, we consider the nature and magnitude of our investment, any voting and protective rights we hold, any participation in the governance of the other company, and other relevant factors such as the presence of a collaboration or other business relationship. Currently, none of our equity investments in publicly-held companies are considered relationships in which we are able to assert control. &lt;/p&gt;</incy:LongTermInvestmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_vPZjA_50wkSa7nNUC99elQ">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Property and Equipment, net.&lt;/i&gt; &#160;Property and equipment, net is stated at cost, less accumulated depreciation and amortization. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets. Leasehold improvements are amortized over the shorter of the estimated useful life of the assets or lease term.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_uHtKJmzhFEm9lOtt0XRJCA">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Lease Accounting.&lt;/i&gt; &#160;Accounting Standard Codification (&#x201c;ASC&#x201d;) 842, Leases, was adopted for the fiscal year beginning on January 1, 2019. All leases with a lease term greater than 12 months, regardless of lease type classification, are recorded as an obligation on the balance sheet with a corresponding right-of-use asset. Both finance and operating leases are reflected as liabilities on the commencement date of the lease based on the present value of the lease payments to be made over the lease term. Current operating lease liabilities are reflected in accrued and other current liabilities and noncurrent operating lease liabilities are reflected in other liabilities on the condensed consolidated balance sheet. Right-of-use assets are valued at the initial measurement of the lease liability, plus any initial direct costs or rent prepayments, minus lease incentives and any deferred lease payments. Operating lease right-of-use assets are recorded in property and equipment, net on the condensed consolidated balance sheet and lease cost is recognized on a straight-line basis. For finance leases, expense is recognized as separate amortization and interest expense, with higher interest expense in the earlier periods of a lease. Leases with an initial term of 12 months or less are not recorded on the balance sheet and we recognize lease expense for these leases on a straight-line basis over the term of the lease. In determining whether a contract contains a lease, asset and service agreements are assessed at onset and upon modification for criteria of specifically identified assets, control and economic benefit. &lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_6LfRNSCdb06zWBpPlVz2QQ">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Other Intangible Assets, net.&lt;/i&gt; Other intangible assets, net consist of licensed intellectual property rights acquired in business combinations, which are reported at acquisition date fair value, less accumulated amortization. Intangible assets with finite lives are amortized over their estimated useful lives using the straight-line method.&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_-RVoqKVyF0O3NN_QtqqDfw">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Impairment of Long-Lived Assets.&lt;/i&gt; &#160;Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. &#160;If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset. &#160;If the expected cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash flows.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_1GF5gMUFC06JE5Ffcitqdw">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Goodwill.&lt;/i&gt; &#160;Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. &#160;Goodwill is not amortized but is tested for impairment at the reporting unit level at least annually as of October 1 or when a triggering event occurs that could indicate a potential impairment by assessing qualitative factors or performing a quantitative analysis in determining whether it is more likely than not that the fair value of net assets are below their carrying amounts. &#160;A reporting unit is the same as, or one level below, an operating segment. Our operations are currently comprised of a single, entity wide reporting &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;unit. We completed our most recent annual impairment assessment as of October 1, 2019 and determined that the carrying value of our goodwill was not impaired. &lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_VgSWBnQE0U6WS-jIf1hZ-A">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Income Taxes.&lt;/i&gt; &#160;We account for income taxes using the asset and liability approach which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and amounts reportable for income tax purposes. &#160;&lt;span style="background-color:#ffffff;"&gt;Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized. &lt;/span&gt;The primary factors used to assess the likelihood of realization are our recent history of cumulative earnings or losses, expected reversals of taxable temporary timing differences, forecasts of future taxable income and available tax planning strategies that could be implemented to realize the deferred tax assets. &#160;Upon evaluating and weighting both positive and negative evidence, we concluded that we should continue to maintain the valuation allowance on the majority of our deferred tax assets as of March 31, 2020. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We recognize the tax benefit from an uncertain tax position only if it is more-likely-than-not that the position will be sustained upon examination by the taxing authorities, including resolutions of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit that is recorded for these positions is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. We adjust the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Any interest and penalties on uncertain tax positions are included within the tax provision.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Coronavirus Aid, Relief, and Economic Security (CARES) Act was signed into law in March 2020 to provide an estimated $2.2 trillion designed to stimulate the U.S. economy during the COVID-19 pandemic. &#160;The Act includes tax relief, government loans, grants and investments for entities in affected industries, which has related accounting and financial reporting impacts. &#160;Disclosure for certain income tax accounting measures are required in the period of enactment and disclosure for government loans, investments, grants, and revenue recognition are required in future periods as federal agencies establish rules and procedures to implement the CARES Act. &#160;During the three months ended March 31, 2020, we have not sought any financial relief under the CARES Act and have determined the income tax provision implications to be immaterial. We have further described the expected impact and risks of COVID-19 on our business in the overview to Item 2. Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations and in Item 1A. Risk Factors.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <incy:CoronavirusAidReliefAndEconomicSecurityActFund
      contextRef="Duration_3_1_2020_To_3_31_2020_PdzkVcZmpESGdHSRd_l9Vw"
      decimals="-11"
      id="Narr_Dv53azv0CkWlF_2opX7w8Q"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">2200000000000</incy:CoronavirusAidReliefAndEconomicSecurityActFund>
    <us-gaap:DebtPolicyTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_vXiiBWyTWk2mAtxYsrgqAg">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Financing Costs Related to Long-term Debt.&lt;/i&gt; &#160;Costs associated with obtaining long-term debt are deferred and amortized over the term of the related debt using the effective interest method. Such costs are presented as a direct deduction from the carrying amount of the long-term debt liability, consistent with debt discounts, on the condensed consolidated balance sheets.&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_vZa0JQw0skyhflfGQlj3-Q">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Net Income (Loss) Per Share.&lt;/i&gt; &#160;Our basic and diluted net income (loss) per share is calculated by dividing the net income (loss) by the weighted average number of shares of common stock outstanding during all periods presented. Options to purchase stock, restricted stock units, performance stock units and shares issuable upon the conversion of convertible debt are included in diluted earnings per share calculations, unless the effects are anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_tivhvdlwXkKwMiG80KVcwg">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Accumulated Other Comprehensive Income (Loss).&lt;/i&gt; &#160;Accumulated other comprehensive income (loss) consists of unrealized gains or losses on marketable securities that are classified as available-for-sale, foreign currency translation gains or losses and defined benefit pension obligations.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_5VrHyiZUNUyYUYQvauuyhg">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Revenue Recognition.&lt;/i&gt; &#160;Revenue-generating contracts are assessed under ASC 606, &lt;i style="font-style:italic;"&gt;Revenue from contracts with customers&lt;/i&gt;, to identify distinct performance obligations, determine the transaction price of the contract and allocate the transaction price to each of the distinct performance obligations. Revenue is recognized when we have satisfied a performance obligation through transferring control of the promised good or service to a customer. Control, in this instance, may mean the ability to prevent other entities from directing the use of, and receiving benefit from, a good or service. We determine at contract inception whether we will transfer control of a promised good or service over time or satisfy the performance obligation at a point in time through analysis of the following criteria: (i) the entity has a present right to payment, (ii) the customer has legal title, (iii) the customer has physical possession, (iv) the customer has the significant &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;risks and rewards of ownership and (v) the customer has accepted the asset. We assess collectability based primarily on the customer&#x2019;s payment history and on the creditworthiness of the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;text-decoration:underline;text-decoration-color:#000000;"&gt;Product Revenues&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Our product revenues consist of U.S. sales of JAKAFI and European sales of ICLUSIG. &#160;Product revenues are recognized once we satisfy the performance obligation at a point in time under the revenue recognition criteria as described above. We sell JAKAFI to our customers in the U.S., which include specialty pharmacies and wholesalers.&#160;We sell ICLUSIG to our customers in the European Union and certain other jurisdictions, which include retail pharmacies, hospital pharmacies and distributors. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We recognize revenues for product received by our customers net of allowances for customer credits, including estimated rebates, chargebacks, discounts, returns, distribution service fees, patient assistance programs, and government rebates, such as Medicare Part D coverage gap reimbursements in the U.S. Product shipping and handling costs are included in cost of product revenues. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Customer Credits:&lt;/i&gt; &#160;Our customers are offered various forms of consideration, including allowances, service fees and prompt payment discounts. We expect our customers will earn prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized. Service fees are also deducted from total product sales as they are earned.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Rebates and Discounts:&lt;/i&gt; &#160;Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program in the U.S. and mandated discounts in Europe in markets where government-sponsored healthcare systems are the primary payers for healthcare. Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or legal requirements with public sector benefit providers. The accrual for rebates is based on statutory discount rates and expected utilization as well as historical data we have accumulated since product launches. Our estimates for expected utilization of rebates are based on data received from our customers. Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#x2019;s activity, plus an accrual balance for known prior quarters&#x2019; unpaid rebates. If actual future rebates vary from estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Chargebacks: &#160;&lt;/i&gt;Chargebacks are discounts that occur when certain contracted customers, which currently consist primarily of group purchasing organizations, Public Health Service institutions, non-profit clinics, and Federal government entities purchasing via the Federal Supply Schedule, purchase directly from our wholesalers. Contracted customers generally purchase the product at a discounted price. The wholesalers, in turn, charges back to us the difference between the price initially paid by the wholesalers and the discounted price paid by the contracted customers. In addition to actual chargebacks received we maintain an accrual for chargebacks based on the estimated contractual discounts on the inventory levels on hand in our distribution channel. &#160;If actual future chargebacks vary from these estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Medicare Part&#160;D Coverage Gap:&lt;/i&gt; &#160;Medicare Part&#160;D prescription drug benefit mandates manufacturers to fund 70% of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for the expected Medicare Part&#160;D coverage gap are based on historical invoices received and in part from data received from our customers. Funding of the coverage gap is generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#x2019;s activity, plus an accrual balance for known prior quarters. If actual future funding varies from estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment. &#160;Additionally, beginning in January 2020, the amount of spending required by eligible patients in the Medicare Part D insurance coverage gap increased 30% due to the expiration of a provision in the Patient Protection and Affordable Care Act, which now results in a change in the True Out of Pocket (TrOOP) calculation methodology. The methodological change has resulted in an increase in required spending by patients and, in turn, an increase in manufacturers&#x2019; contributions on behalf of patients in the Medicare Part D insurance coverage gap.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Co-payment Assistance:&lt;/i&gt; &#160;Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;text-decoration:underline;text-decoration-color:#000000;"&gt;Product Royalty Revenues&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Royalty revenues on commercial sales for ruxolitinib (marketed as JAKAVI&lt;span style="vertical-align:super;"&gt;&#xae;&lt;/span&gt; outside the United States) by Novartis Pharmaceutical International&#160;Ltd. (&#x201c;Novartis&#x201d;) are based on net sales of licensed products in licensed territories as provided by Novartis. &#160;Royalty revenues on commercial sales for baricitinib (marketed as OLUMIANT) by Eli Lilly and Company (&#x201c;Lilly&#x201d;) are based on net sales of licensed products in licensed territories as provided by Lilly. We recognize royalty revenues in the period the sales occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;text-decoration:underline;text-decoration-color:#000000;"&gt;Milestone and Contract Revenues&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Our license agreements, which fall within the scope of ASC 606, Revenue from Contracts with Customers, include distinct drug compound out-licensing, collection of upfront payments, milestones or royalty revenues from a counterparty, and provision of commercially available products to suppliers. Our agreements often include contractual milestones, which typically relate to the achievement of pre-specified development, regulatory and commercialization events outside of our control, such as regulatory approval of a compound, first patient dosing or achievement of sales-based thresholds. For such cases, we believe that revenue related to these events should not be recognized until the milestone has been achieved. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Some contracts form collaborative arrangements of various types with third-parties. We assess whether the nature of the arrangement is within the scope of ASC 808, Collaborative Arrangements, in conjunction with the revenue recognition guidance in ASC 606 to determine the nature of the performance obligations and associated transaction prices. A collaborative relationship may exist when we participate in an activity or process with another party, such as performance of research and development services or the exchange of intellectual property for use in clinical trials, when both parties share in the risks and rewards that result from the activity and participate and govern contract activities through a joint steering committee. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The regulatory review and approval process, which includes preclinical testing and clinical trials of each drug candidate, is lengthy, expensive and uncertain. Securing approval by the U.S. Food and Drug Administration (the &#x201c;FDA&#x201d;) requires the submission of extensive preclinical and clinical data and supporting information to the FDA for each indication to establish a drug candidate&#x2019;s safety and efficacy. The approval process takes many years, requires the expenditure of substantial resources, involves post-marketing surveillance and may involve ongoing requirements for post-marketing studies. Before commencing clinical investigations of a drug candidate in humans, we must submit an Investigational New Drug application (&#x201c;IND&#x201d;), which must be reviewed by the FDA.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The steps generally required before a drug may be marketed in the United States include preclinical laboratory tests, animal studies and formulation studies, submission to the FDA of an IND for human clinical testing, performance of adequate and well-controlled clinical trials in three phases, as described below, to establish the safety and efficacy of the drug for each indication, submission of a new drug application (&#x201c;NDA&#x201d;) or biologics license application (&#x201c;BLA&#x201d;) to the FDA for review and FDA approval of the NDA or BLA.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Similar requirements exist within foreign regulatory agencies as well. The time required satisfying the FDA requirements or similar requirements of foreign regulatory agencies may vary substantially based on the type, complexity and novelty of the product or the targeted disease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Preclinical testing includes laboratory evaluation of product pharmacology, drug metabolism, and toxicity, which includes animal studies, to assess potential safety and efficacy as well as product chemistry, stability, formulation, development, and testing. The results of the preclinical tests, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND. The FDA may raise safety concerns or questions about the conduct of the clinical trials included in the IND, and any of these concerns or questions must be resolved before clinical trials can proceed. We cannot be sure that submission of an IND will result in the FDA allowing clinical trials to commence. Clinical &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;trials involve the administration of the investigational drug or the marketed drug to human subjects under the supervision of qualified investigators and in accordance with good clinical practices regulations covering the protection of human subjects. Clinical trials typically are conducted in three sequential phases, but the phases may overlap or be combined. Phase&#160;I usually involves the initial introduction of the investigational drug into healthy volunteers to evaluate its safety, dosage tolerance, absorption, metabolism, distribution and excretion. Phase&#160;II usually involves clinical trials in a limited patient population to evaluate dosage tolerance and optimal dosage, identify possible adverse effects and safety risks, and evaluate and gain preliminary evidence of the efficacy of the drug for specific indications. Phase&#160;III clinical trials usually further evaluate clinical efficacy and safety by testing the drug in its final form in an expanded patient population, providing statistical evidence of efficacy and safety, and providing an adequate basis for labeling. We cannot guarantee that Phase&#160;I, Phase&#160;II or Phase&#160;III testing will be completed successfully within any specified period of time, if at all. Furthermore, we, the institutional review board for a trial, or the FDA may suspend clinical trials at any time on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Generally, the milestone events contained in our collaboration agreements coincide with the progression of our drugs from development, to regulatory approval and then to commercialization. The process of successfully discovering a new development candidate, having it approved and successfully commercialized is highly uncertain. As such, the milestone payments we may earn from our partners involve a significant degree of risk to achieve. Therefore, as a drug candidate progresses through the stages of its life-cycle, the value of the drug candidate generally increases.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;text-decoration:underline;text-decoration-color:#000000;"&gt;Cost of Product Revenues&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cost of product revenues includes all JAKAFI related product costs as well as ICLUSIG related product costs. In addition, cost of product revenues include low single-digit royalties under our collaboration and license agreement to Novartis on all future sales of JAKAFI in the United States and the amortization of our licensed intellectual property for ICLUSIG using the straight-line method over the estimated useful life of 12.5 years from the date of acquisition on June 1, 2016 of all of the outstanding shares of ARIAD Pharmaceuticals (Luxembourg) S.&#xe0;.r.l. (since renamed Incyte Biosciences Luxembourg S.&#xe0;.r.l.) from ARIAD Pharmaceuticals, Inc. (&#x201c;ARIAD&#x201d;). Cost of product revenues also includes employee personnel costs, including stock compensation, for those employees dedicated to the production of our commercial products.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <incy:PercentageOfMedicarePartDInsuranceCoverageGapRequiredToBeFundedByManufacturers
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="2"
      id="Narr_xRG934HPpU-hyC3bSVqvaw"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.70</incy:PercentageOfMedicarePartDInsuranceCoverageGapRequiredToBeFundedByManufacturers>
    <incy:MedicarePartDInsuranceCoverageGapIncreaseInEligiblePatientSpendingPercentage
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="2"
      id="Narr_KmkYAY19dUSX4IyAcC0Qaw"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.30</incy:MedicarePartDInsuranceCoverageGapIncreaseInEligiblePatientSpendingPercentage>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_incy_ICLUSIGMember_YO1pSkx-YU6EMn97oz0Vig"
      id="Narr_jR2vfVnv7EypiUVZxfrowg">P12Y6M</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_fV2BpZF8QEuYbvImQQ0a9w">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Research and Development Costs.&lt;/i&gt; &#160;Our policy is to expense research and development costs as incurred, including amounts funded by research and development collaborations. Research and development expenses are comprised of costs we incur in performing research and development activities, including salary and benefits; stock-based compensation expense; outsourced services and other direct expenses, including clinical trial and pharmaceutical development costs; collaboration payments; expenses associated with drug supplies that are not being capitalized; and infrastructure costs, including facilities costs and depreciation expense. If a collaboration is a cost-sharing arrangement in which both we and our collaborator perform development work and share costs, we also recognize, as research and development expense in the period when our collaborator incurs development expenses, our portion of the co-development expenses that we are obligated to reimburse. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;We often contract with clinical research organizations (&#x201c;CROs&#x201d;) to facilitate, coordinate and perform agreed upon research and development of a new drug. To ensure that research and development costs are expensed as incurred, we record monthly accruals for clinical trials and preclinical testing costs based on the work performed under the contract. These CRO contracts typically call for the payment of fees for services at the initiation of the contract and/or upon the achievement of certain clinical trial milestones. In the event that we prepay CRO fees, we record the prepayment as a prepaid asset and amortize the asset into research and development expense over the period of time the contracted research and development services are performed. Most professional fees, including project and clinical management, data management, monitoring, and medical writing fees are incurred throughout the contract period. These professional fees are expensed based on their percentage of completion at a particular date. Our CRO contracts generally include pass through fees. Pass through fees include, but are not limited to, regulatory expenses, investigator fees, travel costs, and other miscellaneous costs, including shipping and printing fees. We expense the costs of pass through fees under our CRO contracts as they are incurred, based on the best information available to us at the time. The estimates of the pass through fees incurred are based on the amount of work completed for the clinical trial and are monitored through correspondence with the CROs, internal reviews and a review of contractual terms. The factors utilized to derive the estimates include the &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;number of patients enrolled, duration of the clinical trial, estimated patient attrition, screening rate and length of the dosing regimen. CRO fees incurred to set up the clinical trial are expensed during the setup period. Under our clinical trial collaboration agreements we may be reimbursed for certain development costs incurred. Such costs are recorded as a reduction of research and development expense in the period in which the related expense is incurred. &lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_bimWwQ--PU2sh3WV6FQGnQ">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Stock Compensation.&lt;/i&gt; &#160;Share-based payment transactions with employees, which include stock options, restricted stock units (&#x201c;RSUs&#x201d;) and performance shares (&#x201c;PSUs&#x201d;), are recognized as compensation expense over the requisite service period based on their estimated fair values as well as expected forfeiture rates. &#160;The stock compensation process requires significant judgment and the use of estimates, particularly surrounding Black-Scholes assumptions such as stock price volatility over the option term and expected option lives, as well as expected forfeiture rates and the probability of PSUs vesting. &#160;The fair value of stock options, which are subject to graded vesting, are recognized as compensation expense over the requisite service period using the accelerated attribution method. &#160;The fair value of RSUs that are subject to cliff vesting are recognized as compensation expense over the requisite service period using the straight-line attribution method, and the fair value of RSUs that are subject to graded vesting are recognized as compensation expense over the requisite service period using the accelerated attribution method. &#160;The fair value of PSUs are recognized as compensation expense beginning at the time in which the performance conditions are deemed probable of achievement, which we assess as of the end of each reporting period. Once a performance condition is considered probable, we record compensation expense based on the portion of the service period elapsed to date with respect to that award, with a cumulative catch-up, net of estimated forfeitures, and recognize any remaining compensation expense, if any, over the remaining requisite service period using the straight-line attribution method for PSUs that are subject to cliff vesting and using the accelerated attribution method for PSUs that are subject to graded vesting. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Long Term Incentive Plans.&lt;/i&gt; We have long term incentive plans which provide eligible employees with the opportunity to receive performance and service-based incentive compensation, which may be comprised of cash, stock options, restricted stock units and/or performance shares. The payment of cash and the grant or vesting of equity may be contingent upon the achievement of pre-determined regulatory, sales and internal performance milestones. &lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <incy:BusinessCombinationContingentConsiderationPolicyTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_qWqT-3KrzUicEv7HNNp0_g">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Acquisition-Related Contingent Consideration.&lt;/i&gt; Acquisition-related contingent consideration consists of our future royalty obligations on future net sales of ICLUSIG to Takeda Pharmaceutical Company Limited, which acquired ARIAD (&#x201c;Takeda&#x201d;). Acquisition-related contingent consideration was recorded on the acquisition date of June 1, 2016 at the estimated fair value of the obligation, in accordance with the acquisition method of accounting. &#160;The fair value measurement is based on significant inputs that are unobservable in the market and thus represents a Level 3 measurement. The fair value of the acquisition-related contingent consideration is remeasured each reporting period, with changes in fair value recorded in the condensed consolidated statements of operations.&lt;/p&gt;</incy:BusinessCombinationContingentConsiderationPolicyTextBlock>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_DHMNWZ0wHU2uVF0XzCHBpg">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Collaboration loss sharing.&lt;/i&gt; &#160;Under collaboration and license agreements with shared commercialization efforts, we record our share of the losses from the co-commercialization efforts in collaboration loss sharing on the condensed consolidated statement of operations. For the three months ended March 31, 2020, collaboration loss sharing represents our 50% share of the United States loss for commercialization of tafasitamab under our agreement with MorphoSys. &lt;/p&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <incy:CollaborationAgreementProfitLossSharingRatio
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_-V355oZpTEGL8BHgB8JTrQ"
      decimals="2"
      id="Narr_0aThop117kqcgRmgrsnQ2w"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.50</incy:CollaborationAgreementProfitLossSharingRatio>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_IMIsj86Ga02hSIlBKsMwIw">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU No. 2016-13, &#x201c;Financial Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.&#x201d; This guidance applies to all entities and impacts how entities account for credit losses for financial assets measured at amortized cost and available for sale debt securities. ASU 2016-13 requires financial assets measured at amortized cost to be presented at the net amount expected to be collected. The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amounts. An entity must use judgment in determining the relevant information and estimation methods that are appropriate in its circumstances. &#160;For trade receivables, loans and held-to-maturity debt securities, entities will be required to estimate expected credit losses over the lifetime of the asset. &#160;For available-for-sale debt securities, entities will be required to recognize an allowance for credit losses rather than an other-than-temporary impairment that reduces the cost basis of the investment. Further, an entity will recognize any improvements in estimated credit losses on its available-for-sale debt securities immediately in earnings. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Upon adoption, we assessed each financial asset measured at amortized cost and each available for sale debt security held for the impact of the guidance as of January 1, 2020 and noted an insignificant impact due to the minimal credit risk associated with our financial assets subject to ASC 326. As such, it was concluded that a reserve for credit losses was de minimis on the adoption date. Financial assets will continue to be assessed on a quarterly basis in future periods.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In August 2018, the FASB issued ASU No. 2018-13, &#x201c;Fair Value Measurement (Topic 820): Disclosure Framework &#x2013; Changes to the Disclosure Requirements for Fair Value Measurement,&#x201d; which eliminates the required disclosure of the amount of and reason for transfers between Level 1 and Level 2 of the fair value hierarchy. The guidance also eliminates the required disclosure of the entity&#x2019;s valuation process for Level 3 fair value measurements, however public entities are required to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. This guidance is effective for fiscal years beginning after December 15, 2019. We adopted this guidance for the period beginning January 1, 2020 and enhanced our disclosures in Note 4 to the condensed consolidated financial statements to comply with the standard. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In August 2018, the FASB issued ASU No. 2018-14, &#x201c;Compensation &#x2013; Retirement Benefits &#x2013; Defined Benefit Plans &#x2013; General,&#x201d; an update to Subtopic ASC 715-20. The guidance amended year-end disclosure requirements related to defined benefit pension plans, and does not affect interim disclosures. The guidance is effective for fiscal years ending after December 15, 2020 and is permitted for early adoption. The standard is to be applied on a retrospective basis. Incyte sponsors defined benefit plans for employees located in Europe. We are currently analyzing the impact of ASU No. 2018-14 on the condensed consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In August 2018, the FASB issued ASU No. 2018-15, &#x201c;Intangibles &#x2013; Goodwill and Other &#x2013; Internal-Use Software,&#x201d; an update to Subtopic ASC 350-40. The guidance directs accounting for service contracts for cloud computing arrangements to follow guidance within ASC 350-40 to determine capitalization of implementation costs. The guidance is effective for fiscal years beginning after December 15, 2019 and may be applied on either a retrospective or prospective basis. We adopted this guidance for the period beginning January 1, 2020 on a prospective basis. New contracts for development of internal-use software were assessed and no qualifying contracts were identified during the period. We will continue to assess contracts and will disclose material, qualifying contracts if identified in future periods.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2018, the FASB issued ASU No. 2018-18, &#x201c;Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606.&#x201d; The guidance clarifies the interactions between Topic 808 and Topic 606, including clarifications on revenue recognition, unit of account, and reporting disclosure requirements. The guidance is effective for fiscal years beginning after December 15, 2019. We adopted this guidance for the period beginning January 1, 2020 on a retrospective to the date of our initial application of ASC 606, and noted that in assessment of our collaborative agreements, there was no material financial statement impact. Our collaborative arrangements and their associated accounting conclusions are described in detail within Note 9 to the condensed consolidated financial statements.&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In December 2019, the FASB issued ASU No. 2019-12, &#x201c;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.&#x201d; This guidance applies to all entities and aims to reduce the complexity of tax accounting standards while enhancing reporting disclosures. This guidance is effective for fiscal years beginning after December 15, 2020 and interim periods therein. Early adoption is permitted for any annual periods for which financial statements have not been issued and interim periods therein. We are currently analyzing the impact of ASU No. 2019-12 and do not anticipate the adoption of this ASU to have a material impact on our condensed consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_qzMuaNkmKk2LKRg7eSxwWA">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;3.&#160;&#160;&#160;&#160; &lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Revenues&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As discussed in Note 2, revenues are recognized under guidance within ASC 606 and ASC 808. The following table presents our disaggregated revenue for the periods presented (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:41.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:41.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:18.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;JAKAFI revenues, net&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 459,479&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 375,611&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;ICLUSIG revenues, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,248&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,638&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Total product revenues, net&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 486,727&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 396,249&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;JAKAVI product royalty revenues&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 56,333&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 45,571&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;OLUMIANT product royalty revenues&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,447&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,037&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Total product royalty revenues&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 81,780&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 61,608&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Milestone and contract revenues&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Total revenues&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.33%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 568,507&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.5%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 497,857&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;For further information on our revenue-generating contracts,&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;refer to Note 9 to the condensed consolidated financial statements.&lt;b style="font-weight:bold;"&gt; &#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_YLoH4GilP0unUigK-RBqEw">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As discussed in Note 2, revenues are recognized under guidance within ASC 606 and ASC 808. The following table presents our disaggregated revenue for the periods presented (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:41.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:41.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:18.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;JAKAFI revenues, net&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 459,479&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 375,611&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;ICLUSIG revenues, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,248&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,638&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Total product revenues, net&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 486,727&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 396,249&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;JAKAVI product royalty revenues&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 56,333&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 45,571&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;OLUMIANT product royalty revenues&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,447&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,037&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Total product royalty revenues&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 81,780&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 61,608&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Milestone and contract revenues&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Total revenues&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.33%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 568,507&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.5%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 497,857&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_incy_JAKAFIMember__fw2KcDlhEK50BfPWrKV_w"
      decimals="-3"
      id="Tc_S7lmze4xy0KhBGes3cM04Q_4_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">459479000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_incy_JAKAFIMember_J80BHp4_KUeJ-iOOK_2ieg"
      decimals="-3"
      id="Tc_f2ALsaAONU-yDZ625XEzcQ_4_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">375611000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_incy_ICLUSIGMember_YO1pSkx-YU6EMn97oz0Vig"
      decimals="-3"
      id="Tc_q6SEB--3CUCXo2B72etujA_5_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">27248000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_incy_ICLUSIGMember_zX4IHXitz0maYHqKIsHnOw"
      decimals="-3"
      id="Tc_hs0Jw3_g8kSU9DLhPtYnXQ_5_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">20638000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_iqotuIRBdEWR4e6oAi-V5w"
      decimals="-3"
      id="Tc_YS9V3JmnEUaVmCEFXUCs7w_6_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">486727000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember_zIkoXlOLU0qoXHFNAsPMOg"
      decimals="-3"
      id="Tc_qeD8eVL-Hk65u_XaWHGbMQ_6_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">396249000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_incy_JakaviRoyaltyRevenuesMember_zns3wnT-Jk-Ya594Fpdi2w"
      decimals="-3"
      id="Tc_jyzPIO-iLUKVU1ajB7RVmQ_7_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">56333000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_incy_JakaviRoyaltyRevenuesMember_gEBfS3KRGEK69j70qm4oIA"
      decimals="-3"
      id="Tc_ow5EecjhJUKqYD0-8fmKMg_7_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">45571000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_incy_OlumiantRoyaltyMember_ub66w40qPUKCwKGhu43JRQ"
      decimals="-3"
      id="Tc_adeJOFt0SECQrU9eDRhPMA_8_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">25447000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_incy_OlumiantRoyaltyMember_hSkSbP1pFEi6wsQTwl0CLg"
      decimals="-3"
      id="Tc_O3Wyubj7JU-NERyABaTmkw_8_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">16037000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_Ndda4EOg1kixjWN0CSTfeQ"
      decimals="-3"
      id="Tc_2pOUytN1Y0ynBsX75_HjEQ_9_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">81780000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember_801prtYWj0OCkCXY8rQvyg"
      decimals="-3"
      id="Tc_z7MaWhraWkKM-yivOpC3ng_9_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">61608000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_incy_MilestoneAndContractRevenueMember_VtUC1dCVcEWIzn5Q-dz-vg"
      decimals="-3"
      id="Tc_x0FWE9MNsEGf__nlN_OtSw_10_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">40000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_kETovZVSfkODMLLJ86f5Zg_11_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">568507000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_W4O0zZ6ORkaYIPkYaisrlg_11_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">497857000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_ECL-M6bHlEW6mxbvpuHI1w">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;4.&#160;&#160;&#160;&#160; &lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Fair value of financial instruments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;FASB accounting guidance defines fair value as the price that would be received to sell an asset or paid to transfer a liability (&#x201c;the exit price&#x201d;) in an orderly transaction between market participants at the measurement date. The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value we use quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of us. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;Level&#160;1&#x2014;Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;Level&#160;2&#x2014;Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;Level&#160;3&#x2014;Valuations based on inputs that are unobservable and models that are significant to the overall fair value measurement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recurring Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Our marketable securities consist of investments in U.S. government debt securities that are classified as available-for-sale. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At March 31, 2020 and December 31, 2019, our Level 2 U.S. government debt securities were valued using readily available pricing sources which utilize market observable inputs, including the current interest rate and other characteristics for similar types of investments. Our long term investments classified as Level 1 were valued using their respective closing stock prices on The Nasdaq Stock Market. &#160;We did not experience any transfers of financial instruments between the fair value hierarchy levels during the three months ended March 31, 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following fair value hierarchy table presents information about each major category of our financial assets measured at fair value on a recurring basis (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:39.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurement&#160;at&#160;Reporting&#160;Date&#160;Using:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&#160;for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Identical&#160;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;as&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,043,241&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,043,241&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Debt securities (government)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 259,351&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 259,351&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Long term investments (Note 9)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 180,993&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 180,993&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,224,234&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 259,351&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,483,585&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:39.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurement&#160;at&#160;Reporting&#160;Date&#160;Using:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&#160;for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Identical&#160;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;as&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31, 2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,832,684&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,832,684&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Debt securities (government)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 284,870&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 284,870&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Long term investments (Note 9)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 133,657&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 133,657&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,966,341&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 284,870&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,251,211&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following fair value hierarchy table presents information about each major category of our financial liabilities measured at fair value on a recurring basis as (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:39.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurement&#160;at&#160;Reporting&#160;Date&#160;Using:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&#160;for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Identical&#160;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;as&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Acquisition-related contingent consideration&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 275,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 275,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 275,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 275,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100.5%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:39.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurement&#160;at&#160;Reporting&#160;Date&#160;Using:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&#160;for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Identical&#160;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;as&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31, 2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Acquisition-related contingent consideration&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 277,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 277,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 277,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 277,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following is a rollforward of our Level 3 liabilities (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:82.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:82.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:82.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Balance at January 1, &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 277,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:82.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Contingent consideration earned during the period but not yet paid&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,627)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:82.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Change in fair value of contingent consideration&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,627&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:82.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Balance at March&#160;31, &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 275,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The fair value of the contingent consideration was determined on the date of acquisition, June 1, 2016, using an income approach based on estimated ICLUSIG revenues in the European Union and other countries for the approved third line treatment over 18 years, and discounted to present value at a rate of 10%. The fair value of the contingent consideration is remeasured each reporting period, with changes in fair value recorded in the consolidated statements of operations. The valuation inputs utilized to estimate the fair value of the contingent consideration as of March 31, 2020 included a weighted average cost of capital of 10% and updated projections of future ICLUSIG revenues in the European Union and other &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;countries for the approved third line treatment. The change in fair value of the contingent consideration during the three months ended March 31, 2020 was due primarily to the passage of time as there were no other significant changes in the key assumptions during the period. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We make payments to Takeda quarterly based on the royalties or any additional milestone payments earned in the previous quarter. At March 31, 2020 and December 31, 2019, contingent consideration earned but not yet paid was $8.6 million and $23.0 million, respectively, and was included in accrued and other current liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt; The following is a summary of our marketable security portfolio for the periods presented (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:99.15%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;March&#160;31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Debt securities (government)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 258,622&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 729&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 259,351&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Debt securities (government)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 284,795&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 75&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 284,870&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Our available-for-sale debt securities generally have contractual maturity dates of between &lt;span style="-sec-ix-hidden:Hidden_wxfFNirtIkK2gW_Xg1C_gw"&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;12&lt;/span&gt;&lt;/span&gt; to 18 months. Debt security assets were assessed for risk of expected credit losses per our accounting policy as described in Note 2. As of March 31, 2020 and December 31, 2019, the available-for-sale debt securities were held in US-government backed funds and Treasury assets and were assessed on an individual security basis to have a de minimis risk of credit loss.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_e0BJCr3UUEiNQ7WMNuCxsw">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following fair value hierarchy table presents information about each major category of our financial assets measured at fair value on a recurring basis (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:39.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurement&#160;at&#160;Reporting&#160;Date&#160;Using:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&#160;for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Identical&#160;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;as&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,043,241&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,043,241&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Debt securities (government)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 259,351&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 259,351&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Long term investments (Note 9)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 180,993&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 180,993&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,224,234&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 259,351&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,483,585&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:39.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurement&#160;at&#160;Reporting&#160;Date&#160;Using:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&#160;for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Identical&#160;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;as&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31, 2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,832,684&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,832,684&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Debt securities (government)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 284,870&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 284,870&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Long term investments (Note 9)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 133,657&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 133,657&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,966,341&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 284,870&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,251,211&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_3_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_O7zFu8UChUGSYYKQwC_Jgg"
      decimals="-3"
      id="Tc_o1f7Atu6UUaUIzc6w58ILQ_6_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1043241000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_3_31_2020_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vzfnNpXOk0-u4q-eKRYLuQ"
      decimals="-3"
      id="Tc_MvBALrDCJEGCTfXKYTkKkQ_6_12"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1043241000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_3_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fokaHHGN_US8Vn_P7eshvg"
      decimals="-3"
      id="Tc_QPNDWiHI60KGb3Z3rkbJCw_7_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">259351000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_3_31_2020_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vzfnNpXOk0-u4q-eKRYLuQ"
      decimals="-3"
      id="Tc_0KjG0qu1sEqiqQivz2aDCA_7_12"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">259351000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:LongTermInvestments
      contextRef="As_Of_3_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_O7zFu8UChUGSYYKQwC_Jgg"
      decimals="-3"
      id="Tc_dDBa9fejMEiwIWS0wI3Fmg_8_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">180993000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="As_Of_3_31_2020_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vzfnNpXOk0-u4q-eKRYLuQ"
      decimals="-3"
      id="Tc_vP-eo9W2gEmoOaiU3mpm6w_8_12"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">180993000</us-gaap:LongTermInvestments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_3_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_O7zFu8UChUGSYYKQwC_Jgg"
      decimals="-3"
      id="Tc_Ewt30lk5REqo3V-s0NHuAw_9_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1224234000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_3_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fokaHHGN_US8Vn_P7eshvg"
      decimals="-3"
      id="Tc_2EERXIfG1ki6t5ILQiWqxQ_9_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">259351000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_3_31_2020_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vzfnNpXOk0-u4q-eKRYLuQ"
      decimals="-3"
      id="Tc_ZNYNJR5GJUO3hEzmn4OKVw_9_12"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1483585000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_YPDANAjNxES2dszn1Xx1jA"
      decimals="-3"
      id="Tc_bQyoQY-OVkmfBssii2qZYw_6_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1832684000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_SgUaszookkqnrXkDEDnurA"
      decimals="-3"
      id="Tc_CTLYd5Bfo06j6RcYJbzmxQ_6_12"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1832684000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_rGtntt3PoUmQLgQUufOvRw"
      decimals="-3"
      id="Tc_OFoZ8I36AUO-bA73ZUd_wA_7_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">284870000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_SgUaszookkqnrXkDEDnurA"
      decimals="-3"
      id="Tc_BAObm2k2f0a5sAFO5GBW1w_7_12"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">284870000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:LongTermInvestments
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_YPDANAjNxES2dszn1Xx1jA"
      decimals="-3"
      id="Tc_XrNySBMzu06i9AUKbjOySw_8_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">133657000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_SgUaszookkqnrXkDEDnurA"
      decimals="-3"
      id="Tc_QA5AOZh8D0O0DTt63gj0bQ_8_12"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">133657000</us-gaap:LongTermInvestments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_YPDANAjNxES2dszn1Xx1jA"
      decimals="-3"
      id="Tc_-85Y8msAFEG2aBYtAdUp_A_9_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1966341000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_rGtntt3PoUmQLgQUufOvRw"
      decimals="-3"
      id="Tc_eHDFV3rcoUSpRHzenpx8wQ_9_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">284870000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_SgUaszookkqnrXkDEDnurA"
      decimals="-3"
      id="Tc_YwvHxBKFTEm3Ax1nkHwP6A_9_12"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">2251211000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_FxVno3y70kGulolTBBjHSw">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following fair value hierarchy table presents information about each major category of our financial liabilities measured at fair value on a recurring basis as (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:39.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurement&#160;at&#160;Reporting&#160;Date&#160;Using:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&#160;for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Identical&#160;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;as&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Acquisition-related contingent consideration&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 275,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 275,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 275,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 275,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100.5%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:39.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurement&#160;at&#160;Reporting&#160;Date&#160;Using:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&#160;for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Identical&#160;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;as&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31, 2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Acquisition-related contingent consideration&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 277,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 277,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 277,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 277,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="As_Of_3_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_aaFIoA90rESC-8Dh21XUzg"
      decimals="-3"
      id="Tc_XMtSR7qK8U26vYglz5qvEQ_6_9"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">275000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="As_Of_3_31_2020_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vzfnNpXOk0-u4q-eKRYLuQ"
      decimals="-3"
      id="Tc_aDdrHTwzB02ginhBrTKngA_6_12"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">275000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="As_Of_3_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_aaFIoA90rESC-8Dh21XUzg"
      decimals="-3"
      id="Tc_A4VptjMi1UeHFgR0qE0YXw_7_9"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">275000000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="As_Of_3_31_2020_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vzfnNpXOk0-u4q-eKRYLuQ"
      decimals="-3"
      id="Tc_sSuZWZEOKkCkyWCzIf4eAw_7_12"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">275000000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wmT2dRGShkmAkpk-MnUNQA"
      decimals="-3"
      id="Tc_wON2cM2ynE-9FNV7WPNrYA_6_9"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">277000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_SgUaszookkqnrXkDEDnurA"
      decimals="-3"
      id="Tc_3Jh_Y42QjE-CD2KOCzM92Q_6_12"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">277000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wmT2dRGShkmAkpk-MnUNQA"
      decimals="-3"
      id="Tc_8_1jJJBB30GjmFNbc18tOQ_7_9"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">277000000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_SgUaszookkqnrXkDEDnurA"
      decimals="-3"
      id="Tc_Jr17SYVS60uKbt0lhH-l2w_7_12"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">277000000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_5d1Z2AbRi0enPDo73q9ezg">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following is a rollforward of our Level 3 liabilities (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:82.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:82.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:82.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Balance at January 1, &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 277,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:82.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Contingent consideration earned during the period but not yet paid&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,627)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:82.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Change in fair value of contingent consideration&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,627&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:82.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Balance at March&#160;31, &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 275,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_RmAbn78EhEiQanXoFkVVRw"
      decimals="-3"
      id="Tc_FgosX-pzKEqy1Mg-NE_wug_2_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">277000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <incy:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_XgR3Kyb9BUuL8DSnhdbM0A"
      decimals="-3"
      id="Tc_Kz2tS0gw_0SgjA40JXR0-w_3_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">8627000</incy:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_XgR3Kyb9BUuL8DSnhdbM0A"
      decimals="-3"
      id="Tc_i62_Tr-ekkmorxTiWm7xxg_4_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">6627000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_3_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_bwDrZo3Tr0aCPMmzLzjjyw"
      decimals="-3"
      id="Tc_MiJK9F_3u0KYZHtfUPck0g_5_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">275000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <incy:FairValueInputsCashFlowsEstimatedPeriod
      contextRef="Duration_6_1_2016_To_6_1_2016_us-gaap_BusinessAcquisitionAxis_incy_AriadPharmaceuticalsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_LiabilityMember_-BGrwF-qIkuMeVQ7qNEL5Q"
      id="Narr_sEDdpBWtvU2NZyh80lWpBw">P18Y</incy:FairValueInputsCashFlowsEstimatedPeriod>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="As_Of_6_1_2016_us-gaap_BusinessAcquisitionAxis_incy_AriadPharmaceuticalsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_LiabilityMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_hQh32X0nE0CI4sShb6FASg"
      decimals="2"
      id="Narr_zIXBUPkSOE6nre9LRbMIGg"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.10</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="As_Of_3_31_2020_us-gaap_BusinessAcquisitionAxis_incy_AriadPharmaceuticalsMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_LiabilityMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputCapRateMember_W3i3GxnCAEexsivT7-_BCA"
      decimals="2"
      id="Narr_3T8ppZcdTECs182Bfzwysg"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.10</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <incy:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_BalanceSheetLocationAxis_incy_AccruedAndOtherCurrentLiabilityMember_us-gaap_BusinessAcquisitionAxis_incy_AriadPharmaceuticalsMember_eNBdRdYCsk2AT0YapnXIQg"
      decimals="-5"
      id="Narr_Ml7kqkM_KEiCsL_0Ed2f4g"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">8600000</incy:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned>
    <incy:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_BalanceSheetLocationAxis_incy_AccruedAndOtherCurrentLiabilityMember_us-gaap_BusinessAcquisitionAxis_incy_AriadPharmaceuticalsMember_Rx_uiVSjYEmmn41tyR4osA"
      decimals="-5"
      id="Narr_nhtgfjojt0u0C2lgM12uIA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">23000000.0</incy:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_BC7xIo3obkiReNUud7sBAg">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt; The following is a summary of our marketable security portfolio for the periods presented (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:99.15%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;March&#160;31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Debt securities (government)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 258,622&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 729&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 259,351&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Debt securities (government)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 284,795&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 75&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 284,870&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_3_31_2020_us-gaap_FinancialInstrumentAxis_incy_CorporateAndGovernmentDebtSecuritiesMember__EpAzA1tU0628uub7apmQQ"
      decimals="-3"
      id="Tc_PGDjAQzSzU-d3o22_WwIqg_5_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">258622000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_3_31_2020_us-gaap_FinancialInstrumentAxis_incy_CorporateAndGovernmentDebtSecuritiesMember__EpAzA1tU0628uub7apmQQ"
      decimals="-3"
      id="Tc_LOe26LIEpUe-xc6sbD66mg_5_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">729000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_3_31_2020_us-gaap_FinancialInstrumentAxis_incy_CorporateAndGovernmentDebtSecuritiesMember__EpAzA1tU0628uub7apmQQ"
      decimals="-3"
      id="Tc_QOPjvCIH706rzpCdvfaJnw_5_12"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">259351000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2019_us-gaap_FinancialInstrumentAxis_incy_CorporateAndGovernmentDebtSecuritiesMember_BpEuHfSwDE-2bwHlTacRhg"
      decimals="-3"
      id="Tc_1XbgrmHgF0uNycWSUiZdYQ_8_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">284795000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2019_us-gaap_FinancialInstrumentAxis_incy_CorporateAndGovernmentDebtSecuritiesMember_BpEuHfSwDE-2bwHlTacRhg"
      decimals="-3"
      id="Tc_BnPE6ah4TUu9kEPVYfYiRw_8_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">75000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2019_us-gaap_FinancialInstrumentAxis_incy_CorporateAndGovernmentDebtSecuritiesMember_BpEuHfSwDE-2bwHlTacRhg"
      decimals="-3"
      id="Tc_rxevMPTe_kK-XD58eS1Z-A_8_12"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">284870000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtInstrumentTerm
      contextRef="Duration_1_1_2020_To_3_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_incy_CorporateAndGovernmentDebtSecuritiesMember_ZlCggm6Ff0Wzf5NwRBQL8Q"
      id="Narr_H2kQyC91X0mpf0-JNGyq5g">P18M</us-gaap:DebtInstrumentTerm>
    <us-gaap:ConcentrationRiskDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_9qTWZAkxLE-SlBh1u1p4Cg">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;5.&#160;&#160;&#160;&#160; &lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Concentration of credit risk and current expected credit losses&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"&gt;In November 2009, we entered into a collaboration and license agreement with Novartis. In December 2009, we entered into a license, development and commercialization agreement with Lilly. In December 2018, we entered into a research collaboration and licensing agreement with Innovent Biologics, Inc. (&#x201c;Innovent&#x201d;). In July 2019, we entered into a collaboration and license agreement with Zai Lab (Shanghai) Co., Ltd., a subsidiary of Zai Lab Limited (collectively, &#x201c;Zai Lab&#x201d;). The above collaboration partners comprised, in aggregate, 24% and 30% of the accounts receivable balance as of March 31, 2020 and December 31, 2019, respectively. &#160;For further information relating these collaboration and license agreements,&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;refer to Note 9 to the condensed consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2011, we began commercialization and distribution of JAKAFI to a number of customers. Our product revenues are concentrated in a number of these customers that are specialty pharmacies and wholesalers. The concentration of credit risk related to our JAKAFI product revenues is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:26.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Percentage&#160;of&#160;Total&#160;Net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:26.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Product&#160;Revenues&#160;for&#160;the&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:26.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:26.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Customer A&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Customer B&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Customer C&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Customer D&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We are exposed to risks associated with extending credit to customers related to the sale of products. Customers A, B, C and D comprised, in aggregate, 40% and 39% of the accounts receivable balance as of March 31, 2020 and December 31, 2019, respectively. The concentration of credit risk relating to ICLUSIG product revenues or accounts receivable is not significant.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;We assessed our collaborative and customer receivable assets as of March 31, 2020 according to our accounting policy for applying reserves for expected credit losses, noting minimal history of uncollectible receivables and the &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;continued perceived creditworthiness of our third party sales relationships, upon which the expected credit losses were considered de minimis. &lt;/p&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2020_To_3_31_2020_srt_MajorCustomersAxis_incy_CollaborationPartneraBAndCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_qEwDHoxU_kykVFnagpQ7eg"
      decimals="2"
      id="Narr_8UzJKz-GpkurFyioHOs0wg"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_MajorCustomersAxis_incy_CollaborationPartneraBAndCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_GNwwFEEnHkOgZF7ymHUW2g"
      decimals="2"
      id="Narr_d7Se6nSDxUOt36gJl_seaw"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.30</us-gaap:ConcentrationRiskPercentage1>
    <incy:SchedulesOfConcentrationOfRiskByRiskFactorRelatedToSpecialtyPharmaceuticalCustomersTableTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_pbKr_AITL0GxJe2R84JeGA">&lt;p style="font-family:'Times New Roman';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:26.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Percentage&#160;of&#160;Total&#160;Net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:26.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Product&#160;Revenues&#160;for&#160;the&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:26.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:26.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Customer A&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Customer B&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Customer C&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Customer D&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</incy:SchedulesOfConcentrationOfRiskByRiskFactorRelatedToSpecialtyPharmaceuticalCustomersTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2020_To_3_31_2020_srt_MajorCustomersAxis_incy_CustomerAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_incy_SalesRevenueGoodsServicesNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Fqdfsibh4kKYy4vq1H2Aew"
      decimals="2"
      id="Tc_Hh3ibm1l9kqouxpK_VQp8g_6_2"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2019_To_3_31_2019_srt_MajorCustomersAxis_incy_CustomerAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_incy_SalesRevenueGoodsServicesNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_f3XjwLwtRkSypl-ZsaWVPQ"
      decimals="2"
      id="Tc_SUTUt6CKQ0O6sMw9Aqbz5w_6_4"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2020_To_3_31_2020_srt_MajorCustomersAxis_incy_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_incy_SalesRevenueGoodsServicesNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_sJWHbHVE3k67_lQw54yY_A"
      decimals="2"
      id="Tc_nZ0JSZbeREqUi80mRHNgrA_7_2"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2019_To_3_31_2019_srt_MajorCustomersAxis_incy_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_incy_SalesRevenueGoodsServicesNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_guuZvSOjo0u0KsbTuzRxeQ"
      decimals="2"
      id="Tc_oiBTnfin2kiBF_TVzQmQmg_7_4"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2020_To_3_31_2020_srt_MajorCustomersAxis_incy_CustomerCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_incy_SalesRevenueGoodsServicesNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_-RMVb1Fvokicsqve2ojFBA"
      decimals="2"
      id="Tc_h1MVYpXmNkCzwTaELts0ug_8_2"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2019_To_3_31_2019_srt_MajorCustomersAxis_incy_CustomerCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_incy_SalesRevenueGoodsServicesNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_eOhzoKcIP0OkJVjjz8gMLA"
      decimals="2"
      id="Tc_3mdDKuDiMkarwBKFGFcprQ_8_4"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2020_To_3_31_2020_srt_MajorCustomersAxis_incy_CustomerDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_incy_SalesRevenueGoodsServicesNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_jdQZkwbreEeOVODBdtyWjQ"
      decimals="2"
      id="Tc_J7UEYxconk-LYZf9bJ3M_Q_9_2"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2019_To_3_31_2019_srt_MajorCustomersAxis_incy_CustomerDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_incy_SalesRevenueGoodsServicesNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_AYtvU5JiEE2vyJD2GOHIpA"
      decimals="2"
      id="Tc_NfByhtmHakePY_-UH8Y0PA_9_4"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2020_To_3_31_2020_srt_MajorCustomersAxis_incy_CustomerABCAndDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_aIRqd3JLu0iLl9imB6WWgQ"
      decimals="2"
      id="Narr_hRbAIzykB0mDztZ2dHSiig"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.40</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_MajorCustomersAxis_incy_CustomerABCAndDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_nrSCSBku-kmb34bhbBHQUg"
      decimals="2"
      id="Narr_VTz4OQ3cu0aeJqMFJSfe-Q"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.39</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_ptGI0irUz0Gj4VZUNSAbhQ">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;6.&lt;/b&gt;&#160;&#160;&#160;&#160;&lt;b style="font-weight:bold;"&gt; Inventory&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Our inventory balance consists of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,275&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,275&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Work-in-process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,228&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,634&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,714&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,596&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,217&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,505&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Inventories-current&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,977&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,400&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Inventories-noncurrent&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,240&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,105&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Inventories, stated at the lower of cost and net realizable value, consist of raw materials, work in process and finished goods. At March 31, 2020, $14.0 million of inventory was classified as current on the condensed consolidated balance sheet as we expect this inventory to be consumed for commercial use within the next twelve months. At March 31, 2020, $8.2 million of inventory was classified as noncurrent on the condensed consolidated balance sheets as we did not expect this inventory to be consumed for commercial use within the next twelve months. &#160;We obtain some inventory components from a limited number of suppliers due to technology, availability, price, quality or other considerations. The loss of a supplier, the deterioration of our relationship with a supplier, or any unilateral violation of the contractual terms under which we are supplied components by a supplier could adversely affect our total revenues and gross margins.&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <incy:ScheduleOfInventoryTableTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_20JSw3cNREKZp4VG2bvjvg">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Our inventory balance consists of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,275&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,275&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Work-in-process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,228&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,634&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,714&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,596&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,217&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,505&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Inventories-current&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,977&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,400&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Inventories-noncurrent&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,240&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,105&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</incy:ScheduleOfInventoryTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_qLz5WnT7CUys28lIc483GA_3_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1275000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_yQev0iTdMUyHtfNf6UePvw_3_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1275000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_9UxcJXvMcEOc_9g_W8zIcg_4_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">11228000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_JhU6lI5UsUqsVwmVg6QYaA_4_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">8634000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_Rn7000cMBUCzA12fxM4DPQ_5_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">9714000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_HD3nmf04LESuyjqc1i8O9A_5_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">6596000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <incy:InventoryNetCurrentAndNoncurrent
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_wgZQqG6K_kqyyFHhXn3A_Q_6_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">22217000</incy:InventoryNetCurrentAndNoncurrent>
    <incy:InventoryNetCurrentAndNoncurrent
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_JNMLKT5lUEqXu_P0lkpO5w_6_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">16505000</incy:InventoryNetCurrentAndNoncurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_7NkncYMprkmWPK0k433qSg_7_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">13977000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_1w8xptrMSEWR-RS3YvoE6w_7_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">11400000</us-gaap:InventoryNet>
    <us-gaap:InventoryNoncurrent
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_Qulo5VSsYkSeU4FCtBLhTA_8_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">8240000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_W_R-X6Cn90uiD8qKRQrbvw_8_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">5105000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-5"
      id="Narr_gDAU37xqrE2t1zzFXNdSmg"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">14000000.0</us-gaap:InventoryNet>
    <us-gaap:InventoryNoncurrent
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-5"
      id="Narr_8F9iRmNPKU-qNDugjS7VXw"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">8200000</us-gaap:InventoryNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_lKn_S-EQKkm-4WMXNVQyPw">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;7.&#160;&#160;&#160;&#160;Property and equipment, net&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment, net consists of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Office equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,285&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,303&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 72,352&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 70,510&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 60,077&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59,069&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Land&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,227&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,203&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Building and leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 208,276&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 208,293&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Operating lease right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,641&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,672&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 153,508&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 116,387&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 538,366&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 499,437&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Less accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (128,332)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (121,870)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 410,034&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 377,567&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In February 2018, we signed an agreement to rent a building in Morges, Switzerland for an initial term of 15 years plus one year of free rent, with multiple options to extend for an additional 20 years. The building will serve as our new European headquarters and will consist of approximately 100,000 square feet of office space. This building will allow for consolidation of our European operations that are currently located in Geneva and Lausanne, Switzerland. Building permits were granted by the local government authorities in September 2018 and construction activity began immediately thereafter. In June 2019, we obtained control of the Morges building to begin our construction activity. At that time, we determined the lease to be a finance lease and recorded a lease liability of $31.1 million and a finance lease right-of-use asset of $29.1 million, net of a lease incentive from our landlord of $2.0 million. As of March 31, 2020, we have capitalized approximately $18.2 million in on site preparation, design and construction costs. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In July 2018, we signed an agreement to purchase land located in Yverdon, Switzerland. The land was purchased, in cash, for approximately $4.8 million. Upon this parcel, we are constructing a large molecule production facility. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Construction activity commenced in July 2018 and as of March 31, 2020, we have capitalized approximately $102.8 million in costs for construction, ground preparation and architectural and engineering studies. We currently anticipate the facility will be completed in the second half of 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We are the lessee of several contracts, including those to secure fleet vehicles, buildings and equipment. Our lease agreements do not contain any material residual value guarantees or restrictive covenants. Some of our building leases include options to renew and the exercise of these options is at our discretion. Our current operating lease liabilities are reflected in accrued and other current liabilities and our noncurrent operating lease liabilities are reflected in other liabilities on the condensed consolidated balance sheets and are as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:71.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:71.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:71.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_DXWVUeF4QEyCGxw9FL_y3g"&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,343&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:71.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_fgS4bxuAUka7K61E668xgw"&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Finance lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 910&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 664&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Noncurrent&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:71.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_DZPOj2yYtU-8JCIk7usOfw"&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,151&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,854&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_T_UTUYhcFUKgazgt2tP-VA"&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Finance lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,959&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,918&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:71.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Total lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 53,041&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 53,779&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;The cash paid for amounts included in the measurement of our operating lease liabilities as of March 31, 2020 and 2019 was $3.2 million and $2.8 million, respectively, in operating cash flows. The cash paid for amounts included in the measurement of our finance lease liabilities as of March 31, 2020 and 2019 was $0.2 million in financing cash flows. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;As of March 31, 2020, our finance and operating leases had a weighted average lease term of approximately 15.4 and 3.1 years, respectively. The discount rate of our leases is an approximation of an estimated incremental borrowing rate and is dependent upon the term and economics of each agreement. The weighted average discount rate of our finance and operating leases is approximately 3.6% and 4.4%, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;For the three months ended March 31, 2020, we incurred approximately $3.2 million of expense related to our operating leases, approximately $0.6 million of amortization on our finance lease right-of-use assets and approximately $0.3 million of interest expense on our finance lease liabilities. For the three months ended March 31, 2019, we incurred approximately $3.6 million of expense related to our operating leases, approximately $0.2 million of amortization on our finance lease right-of-use assets and a de minimis amount of interest expense on our finance lease liabilities. Rent expense for the three months ended March 31, 2020 and 2019 was approximately $3.5 million and $3.3 million, respectively. For the three months ended March 31, 2020 and 2019, the cost of our short term leases with a term less than 12 months was de minimis. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_R0EKuOUAWkCLTIoy6MNvyQ">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment, net consists of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Office equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,285&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,303&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 72,352&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 70,510&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 60,077&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59,069&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Land&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,227&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,203&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Building and leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 208,276&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 208,293&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Operating lease right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,641&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,672&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 153,508&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 116,387&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 538,366&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 499,437&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Less accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (128,332)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (121,870)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 410,034&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 377,567&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_3_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_OpaZX17-qki74dlsTGJgWg"
      decimals="-3"
      id="Tc_h1q5ZQiHB0qfdnNPT_b9BQ_3_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">15285000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_Fz8X3N5MXEKKKq7aHQVBHw"
      decimals="-3"
      id="Tc_CVEY325EREmlv3r9ka1P7g_3_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">15303000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_3_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_Uc4T8OoznUaWUBZFbSY_iQ"
      decimals="-3"
      id="Tc_xZA22gqqH0uMVn4hfm1euQ_4_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">72352000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_VmJWm_2dZ0KLxA_TYtgIWg"
      decimals="-3"
      id="Tc_mvdt72EZvk2r7V27937m7g_4_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">70510000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_3_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_Os6xIsQTJkSi8T8XKdZa9g"
      decimals="-3"
      id="Tc_1Sr6ILdegkSBiRXPugQG8g_5_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">60077000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_BhUGXoa_EEGIKABq8Fc4Hg"
      decimals="-3"
      id="Tc_ZidGNiUDlE6DodOhz9UxHA_5_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">59069000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_3_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember_-A59uhU7lE2X3hkgLlOppQ"
      decimals="-3"
      id="Tc_Uwyj_AjsDkSpzDrLcr0aMA_6_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">10227000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember_U4SkB6IAZkiT0rKLLkS3fw"
      decimals="-3"
      id="Tc_nAFwRKFHmUmU3gyIuAdkhw_6_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">10203000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_3_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_incy_BuildingAndLeaseholdImprovementsMember_ip5R7-17nEmNlOU8G0fwCg"
      decimals="-3"
      id="Tc_q_VozUHe1UqJ4eO7kqqPag_7_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">208276000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_incy_BuildingAndLeaseholdImprovementsMember_nfb1lKsHeUq_kOC7b4Hp-w"
      decimals="-3"
      id="Tc_59GjttQVYE-M2wh7MYUg-A_7_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">208293000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_3_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_incy_OperatingLeaseRightOfUseAssetsMember_OnCRjgugL0CS9Eac1n0YMw"
      decimals="-3"
      id="Tc_w_CShMHKVEiwrwpnMDJ2gg_8_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">18641000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_incy_OperatingLeaseRightOfUseAssetsMember_acMKMXWO1UmpzV7l3A0xFQ"
      decimals="-3"
      id="Tc_XCvUrmyYLEykyPi2elXcYQ_8_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">19672000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_3_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_X2RaDJKM2UKzTQvrCqAeaw"
      decimals="-3"
      id="Tc_xxta-WwNuEy9J7GCjFxCig_9_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">153508000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_H7HrVzI_zk64zWsiLLAWBQ"
      decimals="-3"
      id="Tc_GpZ8cOoZEkO0Ou9KB4fCJQ_9_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">116387000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_sK9ziIA5NkKjtRc_W2c-9g_10_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">538366000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_vmuMUGMS0k-5ay2wGKWFBw_10_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">499437000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_DJgrBePoLUioqMh7WtKeZQ_11_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">128332000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_fXFD5MExa0WAX9kFRWpPGw_11_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">121870000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_2B5fQkkl60iAaVeHvvhwiA_12_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">410034000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_wfHGENShUU-nHxB8B-IhkQ_12_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">377567000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:LesseeFinanceLeaseTermOfContract1
      contextRef="As_Of_2_28_2018_us-gaap_RealEstatePropertiesAxis_incy_OfficeBuildingMorgesSwitzerlandMember_sv07bVwxFk-3b4wTy2XUvQ"
      id="Narr_cEhS6YND00CgBgCv9HNWbQ">P15Y</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <us-gaap:LesseeFinanceLeaseExistenceOfOptionToExtend
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_RealEstatePropertiesAxis_incy_OfficeBuildingMorgesSwitzerlandMember_hyf9S0MCgUaWtQ2fty1E5g"
      id="Narr_GNI8tGCF4k631LxD3IdcVg">true</us-gaap:LesseeFinanceLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeFinanceLeaseRenewalTerm1
      contextRef="As_Of_2_28_2018_us-gaap_RealEstatePropertiesAxis_incy_OfficeBuildingMorgesSwitzerlandMember_sv07bVwxFk-3b4wTy2XUvQ"
      id="Narr_x44hpv4YmEewHdCOunwvTA">P20Y</us-gaap:LesseeFinanceLeaseRenewalTerm1>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="As_Of_2_28_2018_us-gaap_RealEstatePropertiesAxis_incy_OfficeBuildingMorgesSwitzerlandMember_sv07bVwxFk-3b4wTy2XUvQ"
      decimals="0"
      id="Narr_5HmyOvkc3EaxqRnVnCOhpw"
      unitRef="Unit_Standard_sqft_EcjTExigKk28_NSPhmR_FQ">100000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:FinanceLeaseLiability
      contextRef="As_Of_6_30_2019_us-gaap_RealEstatePropertiesAxis_incy_OfficeBuildingMorgesSwitzerlandMember_cTCu8-DdLUWDnNq9pv0w3g"
      decimals="-5"
      id="Narr_w25g0szbV0y5XX4vKovfHw"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">31100000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="As_Of_6_30_2019_us-gaap_RealEstatePropertiesAxis_incy_OfficeBuildingMorgesSwitzerlandMember_cTCu8-DdLUWDnNq9pv0w3g"
      decimals="-5"
      id="Narr_p4agxveGiUKzi9ghmBmybQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">29100000</us-gaap:FinanceLeaseRightOfUseAsset>
    <incy:FinanceLeaseLeaseIncentiveReceivable
      contextRef="As_Of_6_30_2019_us-gaap_RealEstatePropertiesAxis_incy_OfficeBuildingMorgesSwitzerlandMember_cTCu8-DdLUWDnNq9pv0w3g"
      decimals="-5"
      id="Narr_C1JiSwbwNUCYhOC-9k_quQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">2000000.0</incy:FinanceLeaseLeaseIncentiveReceivable>
    <us-gaap:ConstructionInProgressGross
      contextRef="As_Of_3_31_2020_us-gaap_RealEstatePropertiesAxis_incy_OfficeBuildingMorgesSwitzerlandMember_KrB3YVMc5UW_hq4utsVGBg"
      decimals="-5"
      id="Narr_ulB-KUFzB0WC2CSizSTxlA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">18200000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PaymentsToAcquireRealEstate
      contextRef="Duration_7_1_2018_To_7_31_2018_us-gaap_RealEstatePropertiesAxis_incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember_cI046B97zkCNRFIvPRRTaw"
      decimals="-5"
      id="Narr_POusVYbSlkC8Vhhk5BkwCw"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">4800000</us-gaap:PaymentsToAcquireRealEstate>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_3_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_us-gaap_RealEstatePropertiesAxis_incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember_vZQPIl3GOUCQvPfbSWPEeA"
      decimals="-5"
      id="Narr_SmAy3InoKEaqn6zyT5uVKQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">102800000</us-gaap:PropertyPlantAndEquipmentGross>
    <incy:LesseeLeaseLiabilityTableTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_vgICce07DEGtfBen6aU_fQ">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We are the lessee of several contracts, including those to secure fleet vehicles, buildings and equipment. Our lease agreements do not contain any material residual value guarantees or restrictive covenants. Some of our building leases include options to renew and the exercise of these options is at our discretion. Our current operating lease liabilities are reflected in accrued and other current liabilities and our noncurrent operating lease liabilities are reflected in other liabilities on the condensed consolidated balance sheets and are as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:71.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:71.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:71.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_DXWVUeF4QEyCGxw9FL_y3g"&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,343&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:71.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_fgS4bxuAUka7K61E668xgw"&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Finance lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 910&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 664&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Noncurrent&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:71.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_DZPOj2yYtU-8JCIk7usOfw"&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,151&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,854&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_T_UTUYhcFUKgazgt2tP-VA"&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Finance lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,959&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,918&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:71.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Total lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 53,041&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 53,779&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</incy:LesseeLeaseLiabilityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseExistenceOfResidualValueGuarantee
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Narr_2t4PnkTtck-AQysH7jyHcQ">false</us-gaap:LesseeOperatingLeaseExistenceOfResidualValueGuarantee>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Narr_CBxw0IsJ60qJZhlG5E_G2Q">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_WfVAxHpbrkOwJ-5kv3x9zQ_4_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">9021000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_-pP9g-Py-k-KKfG2x9a2UQ_4_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">9343000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_Q6uEYoDs80aSVXxloqI1Ug_5_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">910000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_RJfM-9RwI0CYYhZuYOF48Q_5_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">664000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_18mg9Q7MqkOAUFciOuJ1SA_7_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">11151000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_4zZnMtfzN0WYtlm1xRaoDA_7_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">11854000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_uodjNssHY0C9n7yP04m3Eg_8_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">31959000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_RQB7GPERgU6AWW_jtNJEsg_8_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">31918000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <incy:OperatingAndFinanceLeaseLiability
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_H-uzBx0Y30alPGMDMyzS-w_9_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">53041000</incy:OperatingAndFinanceLeaseLiability>
    <incy:OperatingAndFinanceLeaseLiability
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_AwAVARM5z0-vjPo6tnmWRw_9_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">53779000</incy:OperatingAndFinanceLeaseLiability>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-5"
      id="Narr_NUYqyqGBKUC6obAvUX60LQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">3200000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-5"
      id="Narr_s2fOSQfkNUm5wBiBwOhK8g"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">2800000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-5"
      id="Narr_234Ew5_k5Uq26E9CdLSxzQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">200000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-5"
      id="Narr_ztP93M-FH02sZQ9wXqzdzQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">200000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      id="Narr_gFnm7IWH3kWTYbcAaA6jtw">P15Y4M24D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      id="Narr_5rPs-2NHdkeqVulD9Mzy5g">P3Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="3"
      id="Narr_gwrxRwOaM0iAuEBRHiNf4g"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.036</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="3"
      id="Narr_FcEsAkP3w02AwZy6CkUjpw"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.044</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-5"
      id="Narr_TwxJp7ipLUaNeHxob97rSw"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">3200000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-5"
      id="Narr_X7riq-_Us02KzNP-Ot2JGA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">600000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-5"
      id="Narr_BeFGj5TvqUaRuB6nlv0_jg"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">300000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-5"
      id="Narr_EzVh5pf1OkC7l22nomXIDg"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">3600000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-5"
      id="Narr_MqKlh1gAGkmk8NST-toAgA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">200000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-5"
      id="Narr_3ionoq0rX0uArtXQbLbrLQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">3500000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-5"
      id="Narr_DhLlVDdLNEKM4bfc6EK_8w"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">3300000</us-gaap:OperatingLeaseExpense>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_zne9P99wWUq0PaiV-8a3Nw">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;8.&#160;&#160;&#160;&#160;Intangible assets and goodwill&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Intangible Assets, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The components of intangible assets were as follows (in thousands, except for useful life):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100.55%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:23.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:23.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0000ff;font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:30.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance at March&#160;31, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:30.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance at December&#160;31, 2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:23.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0000ff;font-size:14pt;font-weight:bold;text-decoration:underline;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:23.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average Useful&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accumulated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accumulated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:23.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Lives (Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:auto;vertical-align:bottom;width:35.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Finite-lived intangible assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:23.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Licensed IP&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;12.5&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 271,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 82,556&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 188,444&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 271,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 77,172&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 193,828&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Estimated aggregate amortization expense based on the current carrying value of amortizable intangible assets is as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100.01%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:40.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remainder of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:40.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Thereafter&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:40.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Amortization expense&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,152&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,536&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,536&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,536&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,536&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 86,148&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;There were no changes to the carrying amount of goodwill for the three months ended March 31, 2020.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_AIjQ4uM3Y0u5W41LTyRLgQ">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The components of intangible assets were as follows (in thousands, except for useful life):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100.55%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:23.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:23.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0000ff;font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:30.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance at March&#160;31, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:30.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance at December&#160;31, 2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:23.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0000ff;font-size:14pt;font-weight:bold;text-decoration:underline;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:23.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average Useful&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accumulated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accumulated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:23.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Lives (Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:auto;vertical-align:bottom;width:35.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Finite-lived intangible assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:23.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Licensed IP&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;12.5&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 271,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 82,556&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 188,444&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 271,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 77,172&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 193,828&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_-OdiLY_HUEi_z6wHQe3vIQ"
      id="Tc_YI11P3-tOUe4DrYWlbyccg_6_2">P12Y6M</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_3_31_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_UHqTF8VUAUCGTkb1EXExuw"
      decimals="-3"
      id="Tc_Ir-cfB9mC0WZVMsHvKbGmA_6_5"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">271000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_3_31_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_UHqTF8VUAUCGTkb1EXExuw"
      decimals="-3"
      id="Tc_SikwbJosAEGcqwgGdFAHjA_6_8"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">82556000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_3_31_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_UHqTF8VUAUCGTkb1EXExuw"
      decimals="-3"
      id="Tc_CqajxChtskSeMTfRrcvKew_6_11"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">188444000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_eOfQkKzKrUOycC233zEEKQ"
      decimals="-3"
      id="Tc_o63Cb9ueAkCD17lsV8aNmA_6_14"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">271000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_eOfQkKzKrUOycC233zEEKQ"
      decimals="-3"
      id="Tc_UlG75idZJUK5RjybW6lvqQ_6_17"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">77172000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2019_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_eOfQkKzKrUOycC233zEEKQ"
      decimals="-3"
      id="Tc_xNFtRJB89E68ULTuBJoYSw_6_20"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">193828000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_WB4bu1UHZ02FT8cOlyPO1A">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Estimated aggregate amortization expense based on the current carrying value of amortizable intangible assets is as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100.01%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:40.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remainder of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:40.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Thereafter&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:40.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Amortization expense&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,152&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,536&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,536&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,536&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,536&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 86,148&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_RXodCQeDjEGW8RpGSbiTXA_3_2"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">16152000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_0swbum2ck06ghvNIDxf_dQ_3_5"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">21536000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_irpwwdUVtEGzTWyWkQen8A_3_8"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">21536000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_ibImQnpc5E-Z0M9PN6Le7g_3_11"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">21536000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_FMVgp_reckiYTKmQLU-XHQ_3_14"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">21536000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_A7Vvu-CKDUegsO9J97Ikwg_3_17"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">86148000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-5"
      id="Narr_9RANwHvxNkWHGYvfYShMSg"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">0</us-gaap:GoodwillPeriodIncreaseDecrease>
    <incy:LicenseAgreementsTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_xIYI6-e6KkOK_cK6DMNvmQ">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;9.&#160;&#160;&#160;&#160;License agreements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Novartis&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2009, we entered into a Collaboration and License Agreement with Novartis. Under the terms of the agreement, Novartis received exclusive development and commercialization rights outside of the United States to our JAK inhibitor ruxolitinib and certain back-up compounds for hematologic and oncology indications, including all hematological malignancies, solid tumors and myeloproliferative diseases. We retained exclusive development and commercialization rights to JAKAFI (ruxolitinib) in the United States and in certain other indications. &#160;Novartis also received worldwide exclusive development and commercialization rights to our MET inhibitor compound capmatinib and certain back-up compounds in all indications. We retained options to co-develop and to co-promote capmatinib in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;Under this agreement, we received an upfront payment and immediate milestone payment totaling $210.0&#160;million and were initially eligible to receive up to $1.2&#160;billion in milestone payments across multiple indications upon the achievement of pre-specified events, including up to $174.0&#160;million for the achievement of development milestones, up to $495.0&#160;million for the achievement of regulatory milestones and up to $500.0&#160;million for the achievement of commercialization milestones. In April 2016, we amended this agreement to provide that Novartis has exclusive research, development and commercialization rights outside of the United States to ruxolitinib (excluding topical formulations) in the graft-versus-host-disease (&#x201c;GVHD&#x201d;) field. We became eligible to receive up to $75.0 million of additional potential development and regulatory milestones relating to GVHD.  We recognize development and regulatory milestones upon confirmation of achievement of the event, as development and regulatory approvals are events not controllable by us but rather development activities of Novartis and decisions made by regulatory agencies. We recognize sales milestones in the corresponding period of the product sale upon confirmation of net sales milestone threshold achievement by Novartis. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;Exclusive of the upfront payment of $150.0 million received in 2009 and the immediate milestone of $60.0 million earned in 2010, we have recognized and received in the aggregate $132.0 million for the achievement of development milestones, $215.0 million for the achievement of regulatory milestones and $120.0 million for the achievement of sales milestones through March 31, 2020. In 2018, we recognized a $60.0 million sales milestone for Novartis achieving annual net sales of a JAK licensed product of $900.0 million. In 2017, we recognized a $40.0 million sales milestone for Novartis achieving annual net sales of a JAK licensed product of $600.0 million and a $25.0 million development milestone based on the formal initiation by Novartis of a Phase III clinical trial evaluating ruxolitinib in GVHD. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;We also are eligible to receive tiered, double-digit royalties ranging from the upper-teens to the mid-twenties on future JAKAVI net sales outside of the United States, and tiered, worldwide royalties on future capmatinib net sales that range from 12% to 14%. Since the achievement of the $60.0 million regulatory milestone related to reimbursement of JAKAVI in Europe in September 2014, we are obligated to pay to Novartis tiered royalties in the low single-digits on future JAKAFI net sales within the United States. During the three months ended March 31, 2020 and 2019, such royalties payable to Novartis on net sales within the United States totaled $17.5 million and $13.4 million, respectively, and are reflected in cost of product revenues on the condensed consolidated statements of operations. At March 31, 2020 and December 31, 2019, $56.3 million and $50.2 million, respectively, of accrued royalties payable to Novartis were included in accrued and other current liabilities on the condensed consolidated balance sheets. Each company is responsible for costs relating to the development and commercialization of ruxolitinib in its respective territories, with costs of &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;collaborative studies shared equally. Novartis is also responsible for all costs relating to the development and commercialization of capmatinib.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;The Novartis agreement will continue on a program-by-program basis until Novartis has no royalty payment obligations with respect to such program or, if earlier, the termination of the agreement or any program in accordance with the terms of the agreement. Royalties are payable by Novartis on a product-by-product and country-by-country basis until the latest to occur of (i)&#160;the expiration of the last valid claim of the licensed patent rights covering the licensed product in the relevant country, (ii)&#160;the expiration of regulatory exclusivity for the licensed product in such country and (iii)&#160;a specified period from first commercial sale in such country of the licensed product by Novartis or its affiliates or sublicensees. The agreement may be terminated in its entirety or on a program-by-program basis by Novartis for convenience. The agreement may also be terminated by either party under certain other circumstances, including material breach.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Reimbursable costs incurred after the effective date of the agreement with Novartis are recorded net against the related research and development expenses. At March 31, 2020 and December 31, 2019, $0.1&#160;million and $0.4&#160;million, respectively, of reimbursable costs were included in accounts receivable on the condensed consolidated balance sheets. Research and development expenses for the three months ended March 31, 2020 and 2019 were net of $0.3 million and $0.6 million, respectively, of costs reimbursed by Novartis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Milestone and contract revenue under the Novartis agreement for the three months ended March 31, 2020 and 2019 was $0.0 million for each period.  Product royalty revenue related to Novartis net sales of JAKAVI outside of the United States for the three months ended March 31, 2020 and 2019 was $56.3 million and $45.6 million, respectively. &#160;At March 31, 2020 and December 31, 2019, $56.3 million and $65.0 million, respectively, of product royalties were included in accounts receivable on the condensed consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Lilly - Baricitinib&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In December&#160;2009, we entered into a License, Development and Commercialization Agreement with Lilly. Under the terms of the agreement, Lilly received exclusive worldwide development and commercialization rights to our JAK inhibitor baricitinib, and certain back-up compounds for inflammatory and autoimmune diseases. We received an upfront payment of $90.0&#160;million, and were initially eligible to receive up to $665.0&#160;million in substantive milestone payments across multiple indications upon the achievement of pre-specified events, including up to $150.0&#160;million for the achievement of development milestones, up to $365.0&#160;million for the achievement of regulatory milestones and up to $150.0&#160;million for the achievement of commercialization milestones. Exclusive of the upfront payment of $90.0 million received in 2009, we have recognized and received, in aggregate, $149.0 million for the achievement of development milestones and $235.0 million for the achievement of regulatory milestones through March 31, 2020. We recognize development and regulatory milestones upon confirmation of achievement of the event, as development and regulatory approvals are events not controllable by us but rather development activities of Lilly and decisions made by regulatory agencies. We recognize sales milestones in the corresponding period of the product sale upon confirmation of net sales milestone threshold achievement by Lilly.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In January 2016, Lilly submitted an NDA to the FDA and a Marketing Authorization Application (MAA) to the European Medicines Agency for baricitinib as treatment for rheumatoid arthritis. In February 2017, we and Lilly announced that the European Commission approved baricitinib as OLUMIANT for the treatment of moderate-to-severe rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying antirheumatic drugs. In July 2017, Japan's Ministry of Health, Labor and Welfare granted marketing approval for OLUMIANT&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt; &lt;/sup&gt;for the treatment of rheumatoid arthritis in patients with inadequate response to standard-of-care therapies. &#160;In June 2018, the FDA approved the 2mg dose of OLUMIANT for the treatment of adults with moderately-to-severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor inhibitor therapies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In 2018, we recognized a $20.0 million development milestone for the first patient treated in the systemic lupus erythematosus Phase III program for baricitinib and a $100.0 million regulatory milestone for the FDA approval of the 2mg dose of OLUMIANT (baricitinib) for the treatment of adults with moderately-to-severely active rheumatoid arthritis. In 2017, we recognized a $30.0 million development milestone for the first patient treated in the atopic dermatitis Phase &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;III program for baricitinib, $15.0 million regulatory milestone for the approval of baricitinib for the treatment of rheumatoid arthritis by Japan&#x2019;s Ministry of Health, Labor and Welfare and a $65.0 million regulatory milestone for the approval of baricitinib for the treatment of moderate-to-severe rheumatoid arthritis in adult patients by the European Commission.  &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We retained options to co-develop our JAK1/JAK2 inhibitors with Lilly on a compound-by-compound and indication-by-indication basis. Lilly is responsible for all costs relating to the development and commercialization of the compounds unless we elect to co-develop any compounds or indications. If we elect to co-develop any compounds and/or indications, we would be responsible for funding 30% of the associated future global development costs from the initiation of a Phase IIb trial through regulatory approval, including post-launch studies required by a regulatory authority. We would receive an incremental royalty rate increase across all tiers resulting in effective royalty rates ranging up to the high twenties on potential future global net sales for compounds and/or indications that we elect to co-develop. &#160;For indications that we elect not to co-develop, we would receive tiered, double-digit royalty payments on future global net sales with rates ranging up to 20% if the product is successfully commercialized. &#160;If we have started co-development funding for any indication, we can at any time opt out and stop future co-development cost sharing. If we elect to do this we would still be eligible for our base royalties plus an incremental pro-rated royalty commensurate with our contribution to the total co-development cost for those indications for which we co-funded. &#160;We previously had retained an option to co-promote products in the United States but, in March 2016, we waived our co-promotion option as part of an amendment to the agreement. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In July&#160;2010, we elected to co-develop baricitinib with Lilly in rheumatoid arthritis and became responsible for funding 30% of the associated future global development costs for this indication from the initiation of the Phase IIb trial through regulatory approval, including post-launch studies required by a regulatory authority. &#160;We subsequently elected to co-develop baricitinib with Lilly in psoriatic arthritis, atopic dermatitis, alopecia areata, systemic lupus erythematosus and axial spondyloarthritis and were responsible for funding 30% of future global development costs for those indications through regulatory approval, including post-launch studies required by a regulatory authority. In April 2019, we elected to end additional co-funding of the development of baricitinib effective as of January 1, 2019. We will continue to receive royalties on global net sales of OLUMIANT, pursuant to the terms in the Lilly agreement, as described above.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Lilly agreement will continue until Lilly no longer has any royalty payment obligations or, if earlier, the termination of the agreement in accordance with its terms. Royalties are payable by Lilly on a product-by-product and country-by-country basis until the latest to occur of (i) the expiration of the last valid claim of the licensed patent rights covering the licensed product in the relevant country, (ii) the expiration of regulatory exclusivity for the licensed product in such country and (iii) a specified period from first commercial sale in such country of the licensed product by Lilly or its affiliates or sublicensees. The agreement may be terminated by Lilly for convenience, and may also be terminated under certain other circumstances, including material breach.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Milestone and contract revenue under the Lilly agreement for the three months ended March 31, 2020 and 2019 was $0.0 million for each period.  Product royalty revenue related to Lilly global net sales of OLUMIANT for the three months ended March 31, 2020 and 2019 was $25.4 million and $16.0 million, respectively. &#160;At March 31, 2020 and December 31, 2019, $25.4 million and $23.6 million, respectively, of product royalties were included in accounts receivable on the condensed consolidated balance sheets. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Lilly - Ruxolitinib&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;In March 2016, we entered into an amendment to the agreement with Lilly that amended the non-compete provision of the agreement to allow us to engage in the development and commercialization of ruxolitinib in the GVHD field. Upon execution of the amendment, we paid Lilly an upfront payment of $35.0 million and Lilly is eligible to receive up to $40.0 million in regulatory milestone payments relating to ruxolitinib in the GVHD field. &#160;In May 2019, the approval of JAKAFI in steroid-refractory acute GVHD triggered a $20.0 million milestone payment to Lilly. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Agenus&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In January 2015, we entered into a License, Development and Commercialization Agreement with Agenus Inc. and its wholly-owned subsidiary, 4-Antibody AG (now known as Agenus Switzerland Inc.), which we collectively refer &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;to as Agenus. Under this agreement, the parties have agreed to collaborate on the discovery of novel immuno-therapeutics using Agenus&#x2019; antibody discovery platforms. The agreement became effective on February 18, 2015, upon the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Upon closing of the agreement, we paid Agenus total consideration of $60.0 million. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In February 2017, we and Agenus amended this agreement (the &#x201c;Amended Agreement&#x201d;). Under the terms of the Amended Agreement, we received exclusive worldwide development and commercialization rights to four checkpoint modulators directed against GITR, OX40, LAG-3 and TIM-3. In addition to the initial four program targets, we and Agenus have the option to jointly nominate and pursue additional targets within the framework of the collaboration, and in November 2015, three more targets were added. Targets may be designated profit-share programs, where all costs and profits are shared equally by us and Agenus, or royalty-bearing programs, where we are responsible for all costs associated with discovery, preclinical, clinical development and commercialization activities. The programs relating to GITR and OX40 and two of the undisclosed targets were profit-share programs until February 2017, while the other targets currently under collaboration are royalty-bearing programs. The Amended Agreement converted the programs relating to GITR and OX40 to royalty-bearing programs and removed from the collaboration the profit-share programs relating to the two undisclosed targets, with one reverting to us and one reverting to Agenus. &#160;Should any of those removed programs be successfully developed by a party, the other party will be eligible to receive the same milestone payments as the royalty-bearing programs and royalties at a 15% rate on global net sales. &#160;There are currently no profit-share programs. &#160;For each royalty-bearing product other than GITR and OX40, Agenus will be eligible to receive tiered royalties on global net sales ranging from 6% to 12%. &#160;For GITR and OX40, Agenus will be eligible to receive 15% royalties on global net sales. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;In 2017 under the Amended Agreement, we paid Agenus $20.0 million in accelerated milestones relating to the clinical development of the GITR and OX40 programs, which was recorded in research and development expense. Agenus was initially eligible to receive up to an additional $510.0 million in future contingent development, regulatory and commercialization milestones across all programs in the collaboration. The agreement may be terminated by us for convenience upon 12 months&#x2019; notice and may also be terminated under certain other circumstances, including material breach. In 2018, we paid Agenus a $5.0 million development milestone for the LAG-3 program and a $5.0 million development milestone for the TIM-3 program, which were recorded in research and development expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the Amended Agreement, we also agreed to purchase 10.0 million shares of Agenus Inc. common stock for an aggregate purchase price of $60.0 million in cash, or $6.00 per share. &#160;We completed the purchase of the shares on February 14, 2017, when the closing price on The Nasdaq Stock Market for Agenus Inc. shares was $4.40 per share. &#160;The shares we acquired were not registered under the Securities Act of 1933 on the purchase date and were subject to certain security specific restrictions for a period of time, and accordingly, we estimated a discount for lack of marketability on the shares on the issuance date of $4.5 million, which resulted in a net fair value of the shares on the issuance date of $39.5 million. Therefore, of the total consideration paid of $60.0 million, $39.5 million was allocated to our stock purchase in Agenus Inc. and was recorded within long term investments and $20.5 million was allocated to research and development expense. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We have concluded Agenus Inc. is not a VIE because it has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest. As of March 31, 2020, we owned approximately 11% of the outstanding shares of Agenus Inc. common stock. We concluded that we have the ability to exercise significant influence, but not control, over Agenus Inc. based primarily on our ownership interest, the fact that we have been the largest Agenus stockholder since the date of our initial stock purchase, the level of intra-entity transactions between us and Agenus related to development expenses, as well as other qualitative factors. We have elected the fair value option to account for our long term investment in Agenus Inc. whereby the investment is marked to market through earnings in each reporting period. &#160;We believe the fair value option to be the most appropriate accounting method to account for securities in publicly held collaborators for which we have significant influence. For the three months ended March 31, 2020 and 2019, we recorded an unrealized loss of $28.8 million and an unrealized gain of $10.5 million, respectively, based on the change in fair value of Agenus Inc.&#x2019;s common stock during these periods. The fair market value of our long term investment in Agenus Inc. at March 31, 2020 and December 31, 2019 was $43.5 million and $72.3 million, respectively. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For the twelve months ended December 31, 2019, Agenus reported within its Form 10-K total revenues of approximately $150.0 million and net loss of approximately $111.6 million within their consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development expenses for the three months ended March 31, 2020 and 2019 also included $0.1 million and $10.2 million, respectively, of development costs incurred pursuant to the Agenus arrangement. &#160;At March 31, 2020 and December 31, 2019, a total of $1.4 million and $1.6 million, respectively, of such costs were included in accrued and other liabilities on the condensed consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Merus&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In December 2016, we entered into a Collaboration and License Agreement with Merus N.V. (&#x201c;Merus&#x201d;). Under this agreement, which became effective in January 2017, the parties have agreed to collaborate with respect to the research, discovery and development of bispecific antibodies utilizing Merus&#x2019; technology platform. &#160;The collaboration encompasses up to eleven independent programs. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The most advanced collaboration program is MCLA-145, a bispecific antibody targeting PD-L1 and CD137, for which we received exclusive development and commercialization rights outside of the United States. Merus retained exclusive development and commercialization rights in the United States to MCLA-145. &#160;Each party will share equally the costs of mutually agreed global development activities for MCLA-145, and fund itself any independent development activities in its territory. &#160;Merus will be responsible for commercializing MCLA-145 in the United States and we will be responsible for commercializing it outside of the United States. &#160; &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In addition to receiving rights to MCLA-145 outside of the United States, we received worldwide exclusive development and commercialization rights to up to ten additional programs. Of these ten additional programs, Merus retained the option, subject to certain conditions, to co-fund development of up to two such programs. If Merus exercises its co-funding option for a program, Merus would be responsible for funding 35% of the associated future global development costs and, for certain of such programs, would be responsible for reimbursing us for certain development costs incurred prior to the option exercise. &#160;Merus will also have the right to participate in a specified proportion of detailing activities in the United States for one of those co-developed programs. All costs related to the co-funded collaboration programs are subject to joint research and development plans and overseen by a joint development committee, but we will have final determination as to such plans in cases of dispute. We will be responsible for all research, development and commercialization costs relating to all other programs. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In February 2017, we paid Merus an upfront non-refundable payment of $120.0 million. For each program as to which Merus does not have commercialization or development co-funding rights, Merus will be eligible to receive up to $100.0 million in future contingent development and regulatory milestones, and up to $250.0 million in commercialization milestones as well as tiered royalties ranging from 6% to 10% of global net sales. For each program as to which Merus exercises its option to co-fund development, Merus will be eligible to receive a 50% share of profits (or sustain 50% of any losses) in the United States and be eligible to receive tiered royalties ranging from 6% to 10% of net sales of products outside of the United States. &#160;If Merus opts to cease co-funding a program as to which it exercised its co-development option, then Merus will no longer receive a share of profits in the United States but will be eligible to receive the same milestones from the co-funding termination date and the same tiered royalties described above with respect to programs where Merus does not have a right to co-fund development and, depending on the stage at which Merus chose to cease co-funding development costs, Merus will be eligible to receive additional royalties ranging up to 4% of net sales in the United States. &#160;For MCLA-145, we and Merus will each be eligible to receive tiered royalties on net sales in the other party&#x2019;s territory at rates ranging from 6% to 10%. &#160; &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Merus agreement will continue on a program-by-program basis until we have no royalty payment obligations with respect to such program or, if earlier, the termination of the agreement or any program in accordance with the terms of the agreement. The agreement may be terminated in its entirety or on a program-by-program basis by us for convenience. &#160;The agreement may also be terminated by either party under certain other circumstances, including material breach, as set forth in the agreement. &#160;If the agreement is terminated with respect to one or more programs, all rights in the terminated programs revert to Merus, subject to payment to us of a reverse royalty of up to 4% on sales of future products, if Merus elects to pursue development and commercialization of products arising from the terminated programs. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In addition, in December 2016, we entered into a Share Subscription Agreement with Merus, pursuant to which we agreed to purchase 3.2 million common shares of Merus for an aggregate purchase price of $80.0 million in cash, or $25.00 per share. &#160;We completed the purchase of the shares on January 23, 2017 when the closing price on The Nasdaq Stock Market for Merus shares was $24.50 per share. The shares we acquired were not registered under the Securities Act of 1933 on the purchase date and were subject to certain security specific restrictions for a period of time, and accordingly, we estimated a discount for lack of marketability on the shares on the issuance date of $5.6 million, which resulted in a net fair value of the shares on the issuance date of $72.8 million. &#160;Of the total consideration paid of $80.0 million, $72.8 million was allocated to our stock purchase in Merus and was recorded as a long term investment and $7.2 million was allocated to research and development expense. The fair market value of our total long term investment in Merus at March 31, 2020 and December 31, 2019 was $38.7 million and $45.1 million, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We have concluded Merus is not a VIE because it has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest. As of March 31, 2020, we owned approximately 11% of the outstanding common shares of Merus and conclude that we have the ability to exercise significant influence, but not control, over Merus based primarily on our ownership interest, the level of intra-entity transactions between us and Merus related to development expenses, as well as other qualitative factors. &#160;We have elected the fair value option to account for our long term investment in Merus whereby the investment is marked to market through earnings in each reporting period. &#160;We believe the fair value option to be the most appropriate accounting method to account for securities in publicly held collaborators for which we have significant influence. For the three months ended March 31, 2020 and 2019 we recorded an unrealized loss of $6.3 million and an unrealized gain of $2.5 million, respectively, based on the change in fair value of Merus&#x2019; common shares during these periods. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For the twelve months ended December 31, 2019, Merus reported within its Form 10-K total revenues of approximately $31.1 million and net loss of approximately $55.2 million within their consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 12pt 0pt;"&gt;Research and development expenses for the three months ended March 31, 2020 and 2019 included $2.3 million and $2.6 million, respectively, of additional development costs incurred pursuant to the Merus agreement. At March 31, 2020 and December 31, 2019, a total of $2.2 million and $1.6 million, respectively, of such costs were included in accrued and other liabilities on the condensed consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Calithera&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In January 2017, we entered into a Collaboration and License Agreement with Calithera Biosciences, Inc. (&#x201c;Calithera&#x201d;). Under this agreement, we received an exclusive, worldwide license to develop and commercialize small molecule arginase inhibitors, including CB-1158, which is currently in Phase I clinical trials, for hematology and oncology indications. We have agreed to co-fund 70% of the global development costs for the development of the licensed products for hematology and oncology indications. Calithera will have the right to conduct certain clinical development under the collaboration, including combination studies of a licensed product with a proprietary compound of Calithera. We will be entitled to 60% of the profits and losses from net sales of licensed product in the United States, and Calithera will have the right to co-detail licensed products in the United States, and we have agreed to pay Calithera tiered royalties ranging from the low to mid-double digits on net sales of licensed products outside the United States. Calithera may opt out of its co-funding obligation, in which case the U.S. profit sharing will no longer be in effect, and we have agreed to pay Calithera tiered royalties ranging from the low to mid-double digits on net sales of licensed products both in the United States and outside the United States, and additional royalties to reimburse Calithera for previously incurred development costs.&lt;/p&gt;&lt;p style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:24.5pt;margin:0pt;"&gt;In January 2017, we paid Calithera an upfront license fee of $45.0 million and have agreed to pay potential development, regulatory and sales milestone payments of over $430.0 million if the profit share is in effect, or $750.0 million if the profit share terminates. In 2017, we paid Calithera a $12.0 million milestone for the achievement of pharmacokinetic and pharmacodynamics goals for CB-1158 which was recorded in research and development expense.&lt;/p&gt;&lt;p style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"&gt;The Calithera agreement will continue on a product-by-product and country-by-country basis for so long as we are developing or commercializing products in the United States (if the parties are sharing profits in the United States) and until we have no further royalty payment obligations, unless earlier terminated according to the terms of the agreement. The agreement may be terminated in its entirety or on a product-by-product and/or a country-by-country basis by us for &lt;/p&gt;&lt;p style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;convenience. The agreement may also be terminated by us for Calithera&#x2019;s uncured material breach, by Calithera for our uncured material breach and by either party for bankruptcy or patent challenge. If the agreement is terminated early with respect to one or more products or countries, all rights in the terminated products and countries revert to Calithera.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In addition, in January&#160;2017, we entered into a Stock Purchase Agreement with Calithera for the purchase of 1.7 million common shares of Calithera for an aggregate purchase price of $8.0 million in cash, or $4.65 per share. We completed the purchase of the shares on January 30, 2017 when the closing price on The Nasdaq Stock Market was $6.75 per share. The shares we acquired were registered under the Securities Act of 1933 on the purchase date and there were no security specific restrictions for these shares, and therefore the value of the 1.7 million shares acquired by us was $11.6 million. &#160;We paid total consideration of $53.0 million to Calithera, composed of the $45.0 million upfront license fee and the $8.0 million stock purchase price.&#160;&#160;Of the $53.0 million, $11.6 million was allocated to our stock purchase in Calithera and was recorded within long term investments and $41.4 million was allocated to research and development expense. The fair market value of our long term investment in Calithera at March 31, 2020 and December 31, 2019 was $7.6 million and $9.8 million, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We have concluded Calithera is not a VIE because it has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest. &#160;As of March 31, 2020, we owned approximately 3% of the outstanding shares of Calithera common stock and there are several other stockholders who hold larger positions of Calithera. As we do not hold a significant position of the voting shares of Calithera and lack the qualitative characteristics associated with the ability to exercise significant influence, our ownership interest does not meet the criteria to be accounted for as an equity method investment. We intend to hold the investment in Calithera for the foreseeable future and therefore, are accounting for our shares held in Calithera at fair value, and the investment is marked to market through earnings in each reporting period. Given our intent to hold the investment for the foreseeable future, we have classified the investment within long term investments on the accompanying condensed consolidated balance sheets. For the three months ended March 31, 2020 and 2019 we recorded an unrealized loss of $2.2 million and an unrealized gain of $4.7 million, respectively, based on the change in fair value of Calithera&#x2019;s common stock during these periods.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 0pt 0pt;"&gt;Research and development expenses for the three months ended March 31, 2020 and 2019 also included $2.5 million and $4.6 million, respectively, of additional development costs incurred pursuant to the Calithera agreement. At March 31, 2020 and December 31, 2019, a total of $1.3 million and $1.1 million, respectively, of such costs were included in accrued and other liabilities on the condensed consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;MacroGenics&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 12pt 0pt;"&gt;In October 2017, we entered into a Global Collaboration and License Agreement with MacroGenics, Inc. (&#x201c;MacroGenics&#x201d;). Under this agreement, we received exclusive development and commercialization rights worldwide to MacroGenics&#x2019; INCMGA0012 (formerly MGA012), an investigational monoclonal antibody that inhibits PD-1. Except as set forth in the succeeding sentence, we will have sole authority over and bear all costs and expenses in connection with the development and commercialization of INCMGA0012 in all indications, whether as a monotherapy or as part of a combination regimen.&#160; MacroGenics has retained the right to develop and commercialize, at its cost and expense, its pipeline assets in combination with INCMGA0012.&#160; In addition, MacroGenics has the right to manufacture a portion of both companies&#x2019; global clinical and commercial supply needs of INCMGA0012. &#160;In 2017, we paid MacroGenics an upfront payment of $150.0 million, which was recorded in research and development expense. MacroGenics was initially eligible to receive up to $420.0 million in future contingent development and regulatory milestones and up to $30.0 million in sales milestones as well as tiered royalties ranging from 15% to 24% of global net sales. In 2018, we paid MacroGenics a $10.0 million and a $5.0 million milestone for the achievement of certain clinical milestones as part of our collaboration and license agreement, which were recorded in research and development expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The MacroGenics agreement will continue until we are no longer commercializing, developing or manufacturing INCMGA0012 or, if earlier, the termination of the agreement in accordance with its terms.&#160; The agreement may be terminated in its entirety or on a licensed product by licensed product basis by us for convenience.&#160; The agreement may also be terminated by either party under certain other circumstances, including material breach, as set forth in the agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development expenses for the three months ended March 31, 2020 and 2019 also included $16.4 million and $9.4 million, respectively, of additional development costs incurred pursuant to the MacroGenics agreement. At March 31, 2020 and December 31, 2019, a total of $1.6 million and $1.0 million of such costs were included in accrued and other liabilities on the condensed consolidated balance sheets. &#160; &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Syros&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 12pt 0pt;"&gt;In January 2018, we entered into a target discovery, research collaboration and option agreement with Syros Pharmaceuticals, Inc. (&#x201c;Syros&#x201d;). Under this agreement, Syros will use its proprietary gene control platform to identify novel therapeutic targets with a focus in myeloproliferative neoplasms and we have received options to obtain exclusive worldwide rights to intellectual property resulting from the collaboration for up to seven validated targets. &#160;We will have exclusive worldwide rights to develop and commercialize any therapies under the collaboration that modulate those validated targets. &#160;We have agreed to pay Syros up to $54.0 million in target selection and option exercise fees should we decide to exercise all of our options under the agreement. For products resulting from the collaboration against each of the seven selected and validated targets, we have agreed to pay up to $50.0 million in potential development and regulatory milestones and up to $65.0 million in potential sales milestones. Syros is also eligible to receive low single-digit royalties on net sales of products resulting from the collaboration. In January 2018, we paid Syros an upfront non-refundable (except in the event of a material breach of the agreement by Syros) payment of $10.0 million, which was recorded in research and development expense. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In addition, in January 2018, we entered into a Stock Purchase Agreement with Syros for the purchase of 0.8 million common shares of Syros for an aggregate purchase price of $10.0 million in cash, or $12.61 per share. &#160;We agreed to not sell or otherwise transfer any of our Syros shares for a period, referred to as the Lock-Up Period, of 12 months after the closing date of the sale. We completed the purchase of the shares on January 8, 2018 when the closing price on The Nasdaq Stock Market was $9.77 per share. The shares we acquired were not registered on the purchase date, and accordingly, we estimated a discount for lack of marketability on the shares of $0.1 million, which resulted in a net fair value of the shares on the issuance date of $7.6 million. Of the $10.0 million aggregate purchase price paid, $7.6 million was allocated to our stock purchase in Syros and was recorded within long term investments and $2.4 million, representing premium paid on the purchase, was allocated to research and development expense. Also in January 2018, we entered into an Amended Stock Purchase Agreement with Syros for the purchase of an additional 0.1 million common shares of Syros for an aggregate purchase price of $1.4 million in cash, or $9.55 per share. &#160;The shares were acquired in February 2018 and the $1.4 million aggregate purchase price was recorded within long term investments on the condensed consolidated balance sheets. All acquired shares were subsequently registered under the Securities Act of 1933 in February 2018. The fair market value of our long term investment in Syros as of March 31, 2020 and December 31, 2019 was $5.6 million and $6.5 million, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We have concluded Syros is not a VIE because it has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest. &#160;As of March 31, 2020, we owned approximately 2% of the outstanding shares of Syros common stock and there are several other stockholders who hold larger positions of Syros. &#160;As we do not hold a significant position of the voting shares of Syros and lack the qualitative characteristics associated with the ability to exercise significant influence, our ownership interest does not meet the criteria to be accounted for as an equity method investment. We intend to hold the investment in Syros for the foreseeable future and therefore, are accounting for our shares held in Syros at fair value, and the investment is marked to market through earnings in each reporting period. &#160;Given our intent to hold the investment for the foreseeable future, we have classified the investment within long term investments on the accompanying condensed consolidated balance sheets. For the three months ended March 31, 2020 and 2019, we recorded an unrealized loss of $0.9 million and an unrealized gain of $3.3 million, respectively, based on the change in fair market value of Syros&#x2019; common stock during these periods. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Innovent &lt;/span&gt;&lt;/p&gt;&lt;p style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In December 2018, we entered into a research collaboration and licensing agreement with Innovent. Under the terms of this agreement, Innovent received exclusive development and commercialization rights to our clinical-stage product candidates pemigatinib, itacitinib and parsaclisib in hematology and oncology in mainland China, Hong Kong, &lt;/p&gt;&lt;p style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Macau and Taiwan. In January 2019, we recognized an upfront payment under this agreement of $40.0 million upon our transfer of the functional intellectual property related to the clinical-stage product candidates to Innovent, which was recorded in milestone and contract revenues on the condensed consolidated statement of operations. The upfront milestone was recognized as revenue at a point in time upon our transfer of the licenses to Innovent for the right to use the functional intellectual property. In June 2019, we recognized the $20.0&#160;million milestone for the first related IND filing in China, which was recorded in milestone and contract revenues. &#160;In addition, we are eligible to receive up to an additional $129.0 million in potential development and regulatory milestones. We recognize development and regulatory milestones upon confirmation of achievement of the event, as development and regulatory approvals are events not controllable by us but rather development activities of Innovent and decisions made by regulatory agencies. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In the event of commercialization of the licensed molecule, we are eligible to receive up to $202.5 million in potential sales milestones from Innovent. We will recognize sales milestones in the corresponding period of the product sale upon confirmation of net sales milestone threshold achievement by Innovent. We are also eligible to receive tiered royalties from the high-teens to the low-twenties on future sales of products resulting from the collaboration. We retain an option to assist in the promotion of the three product candidates in the Innovent territories.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At March 31, 2020 and December 31, 2019, $3.8 million and $3.0&#160;million, respectively, of reimbursable costs were included in accounts receivable on the condensed consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Zai Lab&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In July 2019, we entered into a collaboration and license agreement with Zai Lab. Under the terms of this agreement, Zai Lab received development and exclusive commercialization rights to INCMGA0012 in hematology and oncology in mainland China, Hong Kong, Macau and Taiwan. In August 2019, we recognized an upfront payment under this agreement of $17.5 million upon our transfer of the functional intellectual property related to the licensed product candidate to Zai Lab, which was recorded in milestone and contract revenues. The upfront milestone was recognized as revenue at a point in time upon our transfer of the license to Zai Lab for the right to use the functional intellectual property.&lt;/p&gt;&lt;p style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The agreement allows for Zai Lab to continue development of the licensed molecule and to submit the licensed molecule to authorities for regulatory approval within the agreement territory, upon which we are eligible for up to $22.5 million in potential development and regulatory milestones. We recognize development and regulatory milestones upon confirmation of achievement of the event, as development and regulatory approvals are events not controllable by us but rather development activities of Zai Lab and decisions made by regulatory agencies. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In the event of commercialization of the licensed molecule, we are eligible to receive up to $37.5 million in potential sales milestones from Zai Lab.  We will recognize sales milestones in the corresponding period of the product sale upon confirmation of net sales milestone threshold achievement by Zai Lab. We are also eligible to receive tiered royalties from the low to mid-twenties on future product sales resulting from the collaboration. We also retain an option to assist in the promotion of INCMGA0012 in Zai Lab&#x2019;s licensed territories. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development expenses for the three months ended March 31, 2020 were net of $0.2 million of costs reimbursed by Zai Lab. At March 31, 2020, $0.2 million of reimbursable costs were included in accounts receivable on the condensed consolidated balance sheet.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;MorphoSys&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In January 2020, we entered into a Collaboration and License Agreement with MorphoSys AG and MorphoSys US Inc., a wholly-owned subsidiary of MorphoSys AG (together with MorphoSys AG, &#x201c;MorphoSys&#x201d;), covering the worldwide development and commercialization of MOR208 (tafasitamab), an investigational Fc engineered monoclonal antibody directed against the target molecule CD19 that is currently in clinical development by MorphoSys. MorphoSys has exclusive worldwide development and commercialization rights to tafasitamab under a June 2010 collaboration and license agreement with Xencor, Inc. In December 2019, MorphoSys submitted a Biologics License Application to the FDA for tafasitamab for the treatment of relapsed or refractory diffuse large B cell lymphoma. &#160;The agreement became effective &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;in March 2020 after clearance by the German and Austrian antitrust authorities and expiration of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the terms of the agreement, we received exclusive commercialization rights outside of the United States, and MorphoSys and we have co-commercialization rights in the United States, with respect to tafasitamab. &#160;MorphoSys is responsible for leading the commercialization strategy and booking all revenue from sales of tafasitamab in the United States, and we and MorphoSys are both responsible for commercialization efforts in the United States and will share equally the profits and losses from the co-commercialization efforts. We will lead the commercialization strategy outside of the United States, and will be responsible for commercialization efforts and book all revenue from sales of tafasitamab outside of the United States, subject to our royalty payment obligations set forth below. We and MorphoSys have agreed to co-develop tafasitamab and to share development costs associated with global and U.S.-specific clinical trials, with Incyte responsible for 55% of such costs and MorphoSys responsible for 45% of such costs. &#160;Each company is responsible for funding any independent development activities, and we are responsible for funding development activities specific to territories outside of the United States. All development costs related to the collaboration are subject to a joint development plan. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In March 2020, we paid MorphoSys an upfront non-refundable payment of $750.0 million which was recorded in research and development expense on the condensed consolidated statement of operations for the three months ended March 31, 2020. MorphoSys is eligible to receive up to $740.0 million in future contingent development and regulatory milestones and up to $315.0 million in commercialization milestones as well as tiered royalties ranging from the mid-teens to mid-twenties of net sales outside of the United States. &#160;MorphoSys&#x2019; right to receive royalties in any particular country will expire upon the last to occur of (a) the expiration of patent rights in that particular country, (b) a specified period of time after the first post-marketing authorization sale of a licensed product comprising tafasitamab in that country, and (c) the expiration of any regulatory exclusivity for that licensed product in that country.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In addition, under the collaboration agreement and pursuant to a related purchase agreement, we agreed to purchase American Depositary Shares (&#x201c;ADSs&#x201d;), each representing 0.25 of an ordinary share of MorphoSys AG, for an aggregate purchase price of $150.0 million or $41.33 per ADS (such ADSs to be purchased, the &#x201c;New ADSs&#x201d;). We agreed, subject to limited exceptions, not to sell or otherwise transfer any of the New ADSs for an &lt;span style="-sec-ix-hidden:Hidden_LxjukuDojEmG5LuismUbLw"&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;18-month&lt;/span&gt;&lt;/span&gt; period after the closing date of the sale. We completed the purchase of the ADSs on March 3, 2020 when the closing price on The Nasdaq Stock Market was $27.65 per ADS. The New ADSs were not registered under the Securities Act of 1933 on the purchase date, and accordingly, we estimated a discount for lack of marketability on the shares of $4.9 million, which resulted in a net fair value of the shares on the issuance date of $95.5 million. Of the $150.0 million aggregate purchase price paid, $95.5 million was allocated to our stock purchase in MorphoSys and was recorded within long term investments and $54.5 million, representing the premium paid on the purchase, was allocated to research and development expense. &#160;The fair market value of our long term investment in MorphoSys as of March 31, 2020 was $85.6 million. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We have concluded MorphoSys is not a VIE because it has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest. &#160;As of March 31, 2020, we owned approximately 3% of the outstanding shares of MorphoSys common stock and there are several other stockholders who hold larger positions of MorphoSys. &#160;As we do not hold a significant position of the voting shares of MorphoSys and lack the qualitative characteristics associated with the ability to exercise significant influence, our ownership interest does not meet the criteria to be accounted for as an equity method investment. We intend to hold the investment in MorphoSys for the foreseeable future and therefore, are accounting for our shares held in MorphoSys at fair value, and the investment is marked to market through earnings in each reporting period. &#160;Given our intent to hold the investment for the foreseeable future, we have classified the investment within long term investments on the accompanying condensed consolidated balance sheets. For the three months ended March 31, 2020, we recorded an unrealized loss of $9.9 million based on the change in fair market value of MorphoSys&#x2019; common stock during these periods. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Our 50% share of the United States loss for the commercialization of tafasitamab was $2.1 million for the three months ended March 31, 2020 and is recorded as collaboration loss sharing on the condensed consolidated statement of operations.  Research and development expenses for the three months ended March 31, 2020, includes $11.6 million related to our 55% share of the co-development costs for tafasitamab. &#160;At March 31, 2020, $13.1 million was included in accrued and other liabilities on the condensed consolidated balance sheet for amounts due to MorphoSys under the agreement.&lt;/p&gt;</incy:LicenseAgreementsTextBlock>
    <incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived
      contextRef="Duration_11_1_2009_To_11_30_2009_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_A9wnHAKOPUiEb-WirPUvYA"
      decimals="-5"
      id="Narr_KL44N3jMaESjrEzQUULtgg"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">210000000.0</incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived>
    <incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived
      contextRef="Duration_11_1_2009_To_11_30_2009_incy_AchievementOfMilestoneAxis_incy_PreSpecifiedEventsMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember__tZTD8Vmu0GW3hPdg82qeQ"
      decimals="-8"
      id="Narr_sR1R5mHcyUuCBhvkz8yTnw"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1200000000</incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived>
    <incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived
      contextRef="Duration_11_1_2009_To_11_30_2009_incy_AchievementOfMilestoneAxis_incy_DevelopmentMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_wtKKfm2jZ0yM-1dlYFTMnA"
      decimals="-5"
      id="Narr_RSue9WjEvkm1FbVe1dgx9g"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">174000000.0</incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived>
    <incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived
      contextRef="Duration_11_1_2009_To_11_30_2009_incy_AchievementOfMilestoneAxis_incy_RegulatoryMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_zksZlxX7L0aZmXvNApJ4Eg"
      decimals="-5"
      id="Narr_VEmmE2BP40mNtbzVF7QeFQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">495000000.0</incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived>
    <incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived
      contextRef="Duration_11_1_2009_To_11_30_2009_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_MJwI5aFJqEO8pUKY2yAKBw"
      decimals="-5"
      id="Narr_HU1lfSNKz0uzgxLxtRRvbA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">500000000.0</incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived>
    <incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived
      contextRef="Duration_4_1_2016_To_4_30_2016_incy_AchievementOfMilestoneAxis_incy_DevelopmentAndRegulatoryMilestonesMember_srt_ProductOrServiceAxis_incy_GvhdMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_ZRB_EBm4DkyNeZO2LH5-Dg"
      decimals="-5"
      id="Narr_RJvDT_bHUkKQeyY-9uhPzA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">75000000.0</incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived>
    <incy:LicenseAgreementUpfrontPaymentReceived
      contextRef="Duration_12_1_2009_To_12_31_2009_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_1SaePKedd0OWp_iIJJVHXw"
      decimals="-5"
      id="Narr_X4zRlAFxuk2HI1RUTkW4XA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">150000000.0</incy:LicenseAgreementUpfrontPaymentReceived>
    <incy:LicenseAgreementImmediateMilestonePaymentReceived
      contextRef="Duration_1_1_2010_To_1_31_2010_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_D9O6EwtrQ063PpAtibslDA"
      decimals="-5"
      id="Narr_wN418WNr_EmeDr2PQKG0Pg"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">60000000.0</incy:LicenseAgreementImmediateMilestonePaymentReceived>
    <incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone
      contextRef="Duration_11_1_2009_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_DevelopmentMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_9-Pn4E2E_kSLd-r3M4EQbQ"
      decimals="-5"
      id="Narr_M1awvsqpmU-oQ_pR9fNHRg"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">132000000.0</incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone>
    <incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone
      contextRef="Duration_11_1_2009_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_RegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_Y2Gx6SWIbEqR4hwAGpSZ5Q"
      decimals="-5"
      id="Narr_5G66E0pUeUOVX8wl3p5oCA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">215000000.0</incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone>
    <incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone
      contextRef="Duration_11_1_2009_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_C1OZWHg3g0uldVYjrprkFA"
      decimals="-5"
      id="Narr_4c8k4HHFYkKJMjDYTb4C1g"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">120000000.0</incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone>
    <incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone
      contextRef="Duration_1_1_2018_To_12_31_2018_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_ProductOrServiceAxis_incy_JakaviMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_VTtBfVOpYEyYEfKARlTg8A"
      decimals="-5"
      id="Narr_rVkUh5UAoEShgJH_O0KxaA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">60000000.0</incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2018_To_12_31_2018_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_ProductOrServiceAxis_incy_JakaviMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_VTtBfVOpYEyYEfKARlTg8A"
      decimals="-5"
      id="Narr_rLQquxlUyUmzQzljSsfHrA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">900000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone
      contextRef="Duration_1_1_2017_To_12_31_2017_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_ProductOrServiceAxis_incy_JakaviMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_5B46pCgC4U6TcjzvVo1wJA"
      decimals="-5"
      id="Narr_nQqhreZyrUuu0Z9X97_FXA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">40000000.0</incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2017_To_12_31_2017_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_ProductOrServiceAxis_incy_JakaviMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_5B46pCgC4U6TcjzvVo1wJA"
      decimals="-5"
      id="Narr_FMFkV60afkqIzOds3RkXJA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">600000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone
      contextRef="Duration_1_1_2017_To_12_31_2017_incy_AchievementOfMilestoneAxis_incy_DevelopmentMilestonesMember_incy_PhasesOfArrangementsAxis_incy_PhaseThreeMember_srt_ProductOrServiceAxis_incy_GvhdMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_PHAppsJyCU6_gL715nvt8w"
      decimals="-5"
      id="Narr_ohzdwc0bHUqh7c9b2PrByw"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">25000000.0</incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone>
    <incy:PercentageOfRoyaltyRatePayments
      contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_incy_JakaviMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_3GwL6JL350ydhcQXwwZPzQ"
      decimals="2"
      id="Narr_Bl_cNQsWJk2tLhthkpIA8Q"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.12</incy:PercentageOfRoyaltyRatePayments>
    <incy:PercentageOfRoyaltyRatePayments
      contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_incy_JakaviMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_AVkAZtSlqUSKsew2Ua_8jg"
      decimals="2"
      id="Narr_Iqn-9J_VEEO4_71ZKjz0KQ"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.14</incy:PercentageOfRoyaltyRatePayments>
    <incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone
      contextRef="Duration_9_1_2014_To_9_30_2014_incy_AchievementOfMilestoneAxis_incy_RegulatoryMilestonesMember_srt_ProductOrServiceAxis_incy_JakaviMember_srt_StatementGeographicalAxis_srt_EuropeMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_-D5iCFjOtEOHLfhUWXsfAA"
      decimals="-5"
      id="Narr_z0Bq5hBm6UWdT-7ra4V41A"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">60000000.0</incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone>
    <us-gaap:IncreaseDecreaseInRoyaltiesPayable
      contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_incy_JAKAFIMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_28xwnjC9e0Sh55l-kRb2nQ"
      decimals="-5"
      id="Narr__yZpQNEubEi-KMNbzwS0vg"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">17500000</us-gaap:IncreaseDecreaseInRoyaltiesPayable>
    <us-gaap:IncreaseDecreaseInRoyaltiesPayable
      contextRef="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_incy_JAKAFIMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_BdI492nuSkutSDrwULb1hw"
      decimals="-5"
      id="Narr_E0P-9AAlgUiMwXUfcZPWCg"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">13400000</us-gaap:IncreaseDecreaseInRoyaltiesPayable>
    <incy:RoyaltiesPayable
      contextRef="As_Of_3_31_2020_srt_ProductOrServiceAxis_incy_JAKAFIMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_mfwS80yn5ESSYPVY2L68BQ"
      decimals="-5"
      id="Narr_3pZBYG1WEEOmzG26_3_HbA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">56300000</incy:RoyaltiesPayable>
    <incy:RoyaltiesPayable
      contextRef="As_Of_12_31_2019_srt_ProductOrServiceAxis_incy_JAKAFIMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_2-_MOs2yjU-WWrny5byzXQ"
      decimals="-5"
      id="Narr_dQRVapZD5EiijfbgBaet7g"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">50200000</incy:RoyaltiesPayable>
    <incy:LicenseAgreementReimbursableCosts
      contextRef="As_Of_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_ZvhiClZSVke50DoQFEthjg"
      decimals="-5"
      id="Narr_SfuH9qyINkiVEdx8Dn2GAg"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">100000</incy:LicenseAgreementReimbursableCosts>
    <incy:LicenseAgreementReimbursableCosts
      contextRef="As_Of_12_31_2019_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_QXsD9niNL0WfkNO0BEluBQ"
      decimals="-5"
      id="Narr_lYxJbQLeREWFRge8VkfFuA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">400000</incy:LicenseAgreementReimbursableCosts>
    <incy:LicenseAgreementResearchAndDevelopmentReimbursedCost
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_Bx9b-kfxkUS7NmglDo36lw"
      decimals="-5"
      id="Narr_bN5GOrm90kG8h9J8AkI8IQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">300000</incy:LicenseAgreementResearchAndDevelopmentReimbursedCost>
    <incy:LicenseAgreementResearchAndDevelopmentReimbursedCost
      contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_VI1jInirZE-TkdoXTr7aBw"
      decimals="-5"
      id="Narr_OlnQCZamo0mIVYKlb7jEjw"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">600000</incy:LicenseAgreementResearchAndDevelopmentReimbursedCost>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2019_To_3_31_2019_incy_AchievementOfMilestoneAxis_incy_DevelopmentAndCommercializationMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_RxSzkAad5ES3uONix4NATw"
      decimals="-5"
      id="Narr_JoakQhgslUi3mF_Vt1XU4Q"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">0.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_DevelopmentAndCommercializationMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_3WbzHyKMakilo4AxBzCjyw"
      decimals="-5"
      id="Narr_dj2vIdz0e0WTjSd6ZdeCsA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">0.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_3_31_2020_srt_ProductOrServiceAxis_incy_JakaviMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_GNv-lY-ZsUCHv1M3VoVXPg"
      decimals="-5"
      id="Narr_z26UerTDaEmz3R3jMIMn7Q"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">56300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2019_To_3_31_2019_srt_ProductOrServiceAxis_incy_JakaviMember_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_b36l365IDEWlJXt_MSsqIA"
      decimals="-5"
      id="Narr_g9Fhkp0lZ0-VC-PIj9GFwQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">45600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <incy:RoyaltyPaymentReceivable
      contextRef="As_Of_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_ZvhiClZSVke50DoQFEthjg"
      decimals="-5"
      id="Narr_PrXFeURJAUqRrXpnkP5Xyg"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">56300000</incy:RoyaltyPaymentReceivable>
    <incy:RoyaltyPaymentReceivable
      contextRef="As_Of_12_31_2019_us-gaap_TypeOfArrangementAxis_incy_NovartisMember_QXsD9niNL0WfkNO0BEluBQ"
      decimals="-5"
      id="Narr_-31DzUhKu0-FZvxpdtJq8A"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">65000000.0</incy:RoyaltyPaymentReceivable>
    <incy:LicenseAgreementUpfrontPaymentReceived
      contextRef="Duration_12_1_2009_To_12_31_2009_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_F7owIWcWcESiFzYW1Mzbig"
      decimals="-5"
      id="Narr_VQRo3_HBUkG2Tfz89xSiNw"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">90000000.0</incy:LicenseAgreementUpfrontPaymentReceived>
    <incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived
      contextRef="Duration_12_1_2009_To_12_31_2009_incy_AchievementOfMilestoneAxis_incy_PreSpecifiedEventsMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_4-WVfL6AnEGN9XUCN2Qzkg"
      decimals="-5"
      id="Narr_NPWXfXpk8UO-itY6RnIq7g"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">665000000.0</incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived>
    <incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived
      contextRef="Duration_12_1_2009_To_12_31_2009_incy_AchievementOfMilestoneAxis_incy_DevelopmentMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_hql1KJZ8iU62EhDjjNk-sA"
      decimals="-5"
      id="Narr_R8NbGupiZk2udmcKdeSPJQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">150000000.0</incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived>
    <incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived
      contextRef="Duration_12_1_2009_To_12_31_2009_incy_AchievementOfMilestoneAxis_incy_RegulatoryMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_QW2Dt4PfxUSmygcBR82y9w"
      decimals="-5"
      id="Narr_6t1bLlE7MkC5XgTG26jVJA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">365000000.0</incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived>
    <incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived
      contextRef="Duration_12_1_2009_To_12_31_2009_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_2tauCzcC80iBzbGQiJbcgQ"
      decimals="-5"
      id="Narr_VOdnEhDrZEeNGyZ2fW0Gww"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">150000000.0</incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived>
    <incy:LicenseAgreementUpfrontPaymentReceived
      contextRef="Duration_12_1_2009_To_12_31_2009_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_F7owIWcWcESiFzYW1Mzbig"
      decimals="-5"
      id="Narr_hwmgSmlxj0KkjRGL2S-W4w"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">90000000.0</incy:LicenseAgreementUpfrontPaymentReceived>
    <incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone
      contextRef="Duration_12_1_2009_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_DevelopmentMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_lSHmlJZy7kyXkEGNGXcb4w"
      decimals="-5"
      id="Narr_WKYCSoKS50uQGIkBhiuOWg"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">149000000.0</incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone>
    <incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone
      contextRef="Duration_12_1_2009_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_RegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_POZKRL4X4UeOibd7iQ44iQ"
      decimals="-5"
      id="Narr_ac8unAAq10a4ibFIRsQdlQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">235000000.0</incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone>
    <incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone
      contextRef="Duration_1_1_2018_To_12_31_2018_incy_AchievementOfMilestoneAxis_incy_DevelopmentMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_4R2bbsjbu02S1SWTGCefdA"
      decimals="-5"
      id="Narr_y3rN8QKb1E-uIF2psouH_g"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">20000000.0</incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone>
    <incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone
      contextRef="Duration_1_1_2018_To_12_31_2018_incy_AchievementOfMilestoneAxis_incy_RegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_IgQggmnvRkCC-yAC7hkMdA"
      decimals="-5"
      id="Narr_2hBQ0OnWME670FjaqRzRsA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">100000000.0</incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone>
    <incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone
      contextRef="Duration_1_1_2017_To_12_31_2017_incy_AchievementOfMilestoneAxis_incy_DevelopmentMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_54PH53-4h0mdJxINNUsslA"
      decimals="-5"
      id="Narr_H6tXFqDT3USx4pHQVgBrGQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">30000000.0</incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone>
    <incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone
      contextRef="Duration_1_1_2017_To_12_31_2017_incy_AchievementOfMilestoneAxis_incy_RegulatoryMilestonesMember_srt_StatementGeographicalAxis_country_JP_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_uTR5OD0KnkKmPCLLZ5hQIQ"
      decimals="-5"
      id="Narr_xrZDPPApxkOdbBNeF2R4pQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">15000000.0</incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone>
    <incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone
      contextRef="Duration_1_1_2017_To_12_31_2017_incy_AchievementOfMilestoneAxis_incy_RegulatoryMilestonesMember_srt_StatementGeographicalAxis_srt_EuropeMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_X2hC_LIgGkysVkbfF6pqAA"
      decimals="-5"
      id="Narr_XqG49d90YEC-pPuuQBmbeQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">65000000.0</incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone>
    <incy:PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds
      contextRef="Duration_1_1_2020_To_3_31_2020_incy_PhasesOfArrangementsAxis_incy_PhaseTwoBMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_hx8Gg9ss0k26kPkVIwC0gQ"
      decimals="2"
      id="Narr_7wBw9OJl40yFj4LzReJ6IA"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.30</incy:PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds>
    <incy:PercentageOfRoyaltyRatePayments
      contextRef="Duration_1_1_2020_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_kBoYI7PVIk6voJvkwi61Vw"
      decimals="2"
      id="Narr_-tQYyj-JAUO11doXgmgk8Q"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.20</incy:PercentageOfRoyaltyRatePayments>
    <incy:PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds
      contextRef="Duration_7_1_2010_To_7_31_2010_incy_PhasesOfArrangementsAxis_incy_PhaseTwoBMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_NfiO75iKBky-zhPH0mFJsw"
      decimals="2"
      id="Narr_K_84_hGv_E2brbQFleeIlg"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.30</incy:PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds>
    <incy:PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds
      contextRef="Duration_7_1_2010_To_7_31_2010_incy_PhasesOfArrangementsAxis_incy_PhaseTwoBMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_NfiO75iKBky-zhPH0mFJsw"
      decimals="2"
      id="Narr_aMqfQleCREWz44GyjFhj9Q"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.30</incy:PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2019_To_3_31_2019_incy_AchievementOfMilestoneAxis_incy_DevelopmentAndCommercializationMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_d2Q6vESwZE6zC2NO5BBD8Q"
      decimals="-5"
      id="Narr_7BFSTZOGUUeA3PzWefW4Xw"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">0.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_DevelopmentAndCommercializationMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_y0tgn3-jJkylj0qNlXf4Ug"
      decimals="-5"
      id="Narr_d5otEmegjEmgxcJLtQ7acA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">0.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_uP4dhWDKFEyFnudcYGBOSA"
      decimals="-5"
      id="Narr_T54hTr-PY0O-vQujtClDHw"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">25400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2019_To_3_31_2019_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_-8oLxMS1UkuCYQQOT0HLxA"
      decimals="-5"
      id="Narr_LdZNTHK-pUe3UHp-aN9a-A"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">16000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <incy:RoyaltyPaymentReceivable
      contextRef="As_Of_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_8g5N0q7JO0mkbsolYzXxgg"
      decimals="-5"
      id="Narr_Fyck6QOEwEOZCoN3zopcPg"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">25400000</incy:RoyaltyPaymentReceivable>
    <incy:RoyaltyPaymentReceivable
      contextRef="As_Of_12_31_2019_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_pOoZGDkfJUy5oibDwCrC8w"
      decimals="-5"
      id="Narr_svqN8hQnO0u1etsZMX0NfQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">23600000</incy:RoyaltyPaymentReceivable>
    <incy:LicenseAgreementUpfrontPaymentAmountPaid
      contextRef="Duration_3_1_2016_To_3_31_2016_srt_ProductOrServiceAxis_incy_GvhdMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_Vfkt7ZI1EUi8hMQs6ojgVA"
      decimals="-5"
      id="Narr_RWJqIfgh50qK9nlQFjHprA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">35000000.0</incy:LicenseAgreementUpfrontPaymentAmountPaid>
    <incy:LicenseAgreementAdditionalMilestonePayments
      contextRef="As_Of_3_31_2016_srt_ProductOrServiceAxis_incy_GvhdMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_Sd04Ae5b5U6RhSen8O3xGw"
      decimals="-5"
      id="Narr_pO6nBpz3DUS2fYNIpUjMIQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">40000000.0</incy:LicenseAgreementAdditionalMilestonePayments>
    <incy:LicenseAgreementMilestonePaymentAmountPaid
      contextRef="Duration_5_1_2019_To_5_31_2019_incy_AchievementOfMilestoneAxis_incy_RegulatoryMilestonesMember_srt_ProductOrServiceAxis_incy_GvhdMember_us-gaap_TypeOfArrangementAxis_incy_EliLillyMember_wl45rQuyWUeKj9KE8YrNQg"
      decimals="-5"
      id="Narr_S4FJqBo6o0GL5V9yQjmcfQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">20000000.0</incy:LicenseAgreementMilestonePaymentAmountPaid>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="As_Of_2_1_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_e1m5T-pYtEOP3IlBt9OmFQ"
      decimals="-5"
      id="Narr_pZICHV_8dEym0OCq6yM-QQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">60000000.0</us-gaap:EquityMethodInvestmentAggregateCost>
    <incy:NumberOfProgramTargets
      contextRef="Duration_1_1_2015_To_1_31_2015_us-gaap_TypeOfArrangementAxis_incy_AgenusMember_1GF_BNYkFkelmcMuY5Dozw"
      decimals="INF"
      id="Narr_Lvr_NwYMEEqI7WNNHvB1UA"
      unitRef="Unit_Standard_item_4BIkJQxqZkOMHOIGydcttw">4</incy:NumberOfProgramTargets>
    <incy:NumberOfProgramTargets
      contextRef="Duration_11_1_2015_To_11_30_2015_us-gaap_TypeOfArrangementAxis_incy_AgenusMember_y0Dg-8kaqEy_VnxO63h4KA"
      decimals="INF"
      id="Narr_9PQh0UNZR066M6hOZwzvwg"
      unitRef="Unit_Standard_item_4BIkJQxqZkOMHOIGydcttw">3</incy:NumberOfProgramTargets>
    <incy:PercentageOfRoyaltyRatePayments
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_AgenusMember_rKJqPM2Kx0uzwD7Q93bGZw"
      decimals="2"
      id="Narr_EACy4HDLhEe03SZyE6pzbQ"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.15</incy:PercentageOfRoyaltyRatePayments>
    <incy:PercentageOfRoyaltyRatePayments
      contextRef="Duration_1_1_2020_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_DevelopmentRegulatoryAndCommercializationMilestonesMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_incy_AgenusMember_NSPNOPBlrEe3WHqow3Mpyg"
      decimals="2"
      id="Narr_pj52eE8pykCzSQw-MZD9yw"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.06</incy:PercentageOfRoyaltyRatePayments>
    <incy:PercentageOfRoyaltyRatePayments
      contextRef="Duration_1_1_2020_To_3_31_2020_incy_AchievementOfMilestoneAxis_incy_DevelopmentRegulatoryAndCommercializationMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_AgenusMember_7ArCsJGHDU6NWBPNa2r-7w"
      decimals="2"
      id="Narr_xD8t7bj4b024o9KoiVRNLg"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.12</incy:PercentageOfRoyaltyRatePayments>
    <incy:PercentageOfRoyaltyRatePayments
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_AgenusMember_rKJqPM2Kx0uzwD7Q93bGZw"
      decimals="2"
      id="Narr_YX400gHiNUyGqR7cgwTK2A"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.15</incy:PercentageOfRoyaltyRatePayments>
    <incy:LicenseAgreementUpfrontPaymentAmountPaid
      contextRef="Duration_1_1_2017_To_12_31_2017_incy_AchievementOfMilestoneAxis_incy_DevelopmentMilestonesMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_uSeThvtWXUGOcm74qPJaSA"
      decimals="-5"
      id="Narr_IkYENWJ69UeNv_P8r36_kg"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">20000000.0</incy:LicenseAgreementUpfrontPaymentAmountPaid>
    <incy:LicenseAgreementAdditionalMilestonePayments
      contextRef="As_Of_2_28_2017_incy_AchievementOfMilestoneAxis_incy_DevelopmentRegulatoryAndCommercializationMilestonesMember_srt_RangeAxis_srt_MaximumMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_kP1dVDRyl0aHr25XhcLREg"
      decimals="-5"
      id="Narr_ahTr2QZYg0-f8l36iZ8eFg"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">510000000.0</incy:LicenseAgreementAdditionalMilestonePayments>
    <incy:LicenseAgreementAdditionalMilestonePayments
      contextRef="As_Of_12_31_2018_incy_AchievementOfMilestoneAxis_incy_DevelopmentMilestonesMember_srt_ProductOrServiceAxis_incy_LG3ProgramMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_LEDpSv7x-UqhAEU0sms69Q"
      decimals="-5"
      id="Narr_gOmR8o1OzES98QiGel4v_A"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">5000000.0</incy:LicenseAgreementAdditionalMilestonePayments>
    <incy:LicenseAgreementAdditionalMilestonePayments
      contextRef="As_Of_12_31_2018_incy_AchievementOfMilestoneAxis_incy_DevelopmentMilestonesMember_srt_ProductOrServiceAxis_incy_TIM3ProgramMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_3cWnTNEGHkS-bqHYm75tQQ"
      decimals="-5"
      id="Narr_hCmfWye3aUiaBDb8av3qwA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">5000000.0</incy:LicenseAgreementAdditionalMilestonePayments>
    <incy:PurchaseOfCommonStockUnderStockPurchaseAgreementInShares
      contextRef="Duration_2_1_2017_To_2_1_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_tHZmzMoq7UOq_19LypjtHg"
      decimals="-5"
      id="Narr_mGeE21uNTU61Ru9DVGrrvw"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">10000000.0</incy:PurchaseOfCommonStockUnderStockPurchaseAgreementInShares>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="As_Of_2_1_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_e1m5T-pYtEOP3IlBt9OmFQ"
      decimals="-5"
      id="Narr_N5_Rs0REn0mt-5AyICsG2w"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">60000000.0</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:SharePrice
      contextRef="As_Of_2_1_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_e1m5T-pYtEOP3IlBt9OmFQ"
      decimals="2"
      id="Narr_0oCkqvkIGEicpuJnMyORkw"
      unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A">6.00</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="As_Of_2_14_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_dBlEvdYnr0a8IGYwmA0VRg"
      decimals="2"
      id="Narr_oTVQgg6kM06PWi_0Mp8gqA"
      unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A">4.40</us-gaap:SharePrice>
    <incy:FairValueInputsAmountOfDiscountForLackOfMarketability
      contextRef="Duration_2_14_2017_To_2_14_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_imIGDtobsUmd4lo8UPrzlQ"
      decimals="-5"
      id="Narr_rDcLjV4BeUSF9uydrZ3ZzQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">4500000</incy:FairValueInputsAmountOfDiscountForLackOfMarketability>
    <us-gaap:EquityFairValueDisclosure
      contextRef="As_Of_2_14_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_dBlEvdYnr0a8IGYwmA0VRg"
      decimals="-5"
      id="Narr_ZTOxT2wtjUGaJDDeHRg-vg"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">39500000</us-gaap:EquityFairValueDisclosure>
    <incy:TotalConsiderationPaidUnderPurchaseAgreement
      contextRef="Duration_2_14_2017_To_2_14_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_imIGDtobsUmd4lo8UPrzlQ"
      decimals="-5"
      id="Narr_VIIkMz11kESQS5dr3n1EaQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">60000000.0</incy:TotalConsiderationPaidUnderPurchaseAgreement>
    <us-gaap:LongTermInvestments
      contextRef="As_Of_3_31_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_GxCCmVblq0aKTFevJZTWYA"
      decimals="-5"
      id="Narr_eKZ96QhrEkyETXCY0EXKnA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">39500000</us-gaap:LongTermInvestments>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2017_To_3_31_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_4TeB7PMOikiSn1N2iwUlEQ"
      decimals="-5"
      id="Narr_iJbQW_sIikCDyHGgl1G7ww"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">20500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="As_Of_3_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_UX-Ls-ObqUaaxVRBpq4VvA"
      decimals="2"
      id="Narr_G4yRaWp45k2-USlWwBRYLw"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.11</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_XFbZLyELLEuZAhhXTUaIyQ"
      decimals="-5"
      id="Narr_D5WC63zPf02eUMIh-hKUdQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-28800000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="Duration_1_1_2019_To_3_31_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_t6V1l4OIi0umobNraJpO-Q"
      decimals="-5"
      id="Narr_K01tfiEoQ0i4Wd6h7WPU1A"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">10500000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:LongTermInvestments
      contextRef="As_Of_3_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_UX-Ls-ObqUaaxVRBpq4VvA"
      decimals="-5"
      id="Narr_LPxrsrIV2EqQFfwlLb-Qmw"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">43500000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="As_Of_12_31_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_OmvX4naFCU2401ZLjrF4gQ"
      decimals="-5"
      id="Narr_YLie-Q4qV0y68kE77-WmJw"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">72300000</us-gaap:LongTermInvestments>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationRevenue
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_JsVzHcwF3UShcd4mtCEitg"
      decimals="-5"
      id="Narr_cpxSX8MJUEGRXRobNfHAOw"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">150000000.0</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationRevenue>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_JsVzHcwF3UShcd4mtCEitg"
      decimals="-5"
      id="Narr_2TyOUtFl4U23nzRYPhzeSg"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">111600000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_3_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_XFbZLyELLEuZAhhXTUaIyQ"
      decimals="-5"
      id="Narr_Q5ZX1uuRh0-1hz9X0ptRSA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2019_To_3_31_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_t6V1l4OIi0umobNraJpO-Q"
      decimals="-5"
      id="Narr_yYVi6S63_UO6E8CZdCqnNQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">10200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="As_Of_3_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_Gb1dDNbr-0mKUzuB4KREFg"
      decimals="-5"
      id="Narr_o6Nffxu22EyivKX6_HU6Sw"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1400000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="As_Of_12_31_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AgenusMember_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_cPCZt8ELeUSjKmzshHEhQQ"
      decimals="-5"
      id="Narr_UD3hABn-CEqMtV-0AHtwqw"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1600000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <incy:LicenseAgreementMaximumNumberOfIndependentPrograms
      contextRef="Duration_1_1_2017_To_1_31_2017_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_7k2NhRIKp0uBjo2oHVvL-Q"
      decimals="INF"
      id="Narr_suVvYg0fdkW5txIPLezVxg"
      unitRef="Unit_Standard_item_4BIkJQxqZkOMHOIGydcttw">11</incy:LicenseAgreementMaximumNumberOfIndependentPrograms>
    <incy:LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms
      contextRef="Duration_1_1_2017_To_1_31_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_a6vIFrPYNUSTq51uQB6cnw"
      decimals="INF"
      id="Narr_ZZyVEQ8Gz0y17Sr5h5Qlkg"
      unitRef="Unit_Standard_item_4BIkJQxqZkOMHOIGydcttw">10</incy:LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms>
    <incy:LicenseAgreementNumberOfPreclinicalDiscoveryPrograms
      contextRef="Duration_1_1_2017_To_1_31_2017_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_7k2NhRIKp0uBjo2oHVvL-Q"
      decimals="INF"
      id="Narr_D3W-jJ4ejEmEDWnIJT-4tA"
      unitRef="Unit_Standard_item_4BIkJQxqZkOMHOIGydcttw">2</incy:LicenseAgreementNumberOfPreclinicalDiscoveryPrograms>
    <incy:PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds
      contextRef="Duration_1_1_2017_To_1_31_2017_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_7k2NhRIKp0uBjo2oHVvL-Q"
      decimals="2"
      id="Narr_mMUV3hPSIkW4u7o2lG-gBw"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.35</incy:PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds>
    <incy:NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment
      contextRef="Duration_1_1_2017_To_1_31_2017_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_7k2NhRIKp0uBjo2oHVvL-Q"
      decimals="INF"
      id="Narr_5qO7gNerd0e4A3N3SdFwEg"
      unitRef="Unit_Standard_item_4BIkJQxqZkOMHOIGydcttw">1</incy:NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment>
    <incy:LicenseAgreementUpfrontPaymentAmountPaid
      contextRef="Duration_2_1_2017_To_2_28_2017_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_j9-fB82mM0aKB0lMVFtkDA"
      decimals="-5"
      id="Narr_4Xuw5X_MQUKIMyirjKljQQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">120000000.0</incy:LicenseAgreementUpfrontPaymentAmountPaid>
    <incy:LicenseAgreementAdditionalMilestonePayments
      contextRef="As_Of_1_31_2017_incy_AchievementOfMilestoneAxis_incy_DevelopmentAndRegulatoryMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_3qBhaaUHQU-hsgEJZZLSGA"
      decimals="-5"
      id="Narr_GrmYmPI8qU2BNWNgTwUyyw"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">100000000.0</incy:LicenseAgreementAdditionalMilestonePayments>
    <incy:LicenseAgreementAdditionalMilestonePayments
      contextRef="As_Of_1_31_2017_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_wXhYzKmk30i4bB1talomPQ"
      decimals="-5"
      id="Narr__skBZwhA2UGKkOwr7YzTuQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">250000000.0</incy:LicenseAgreementAdditionalMilestonePayments>
    <incy:PercentageOfRoyaltyRatePayments
      contextRef="Duration_1_1_2017_To_1_31_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_jKF_MTXq-Em5r2YGQsjucw"
      decimals="2"
      id="Narr_zrnGLFQZ-UWaeSKSBa72fw"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.06</incy:PercentageOfRoyaltyRatePayments>
    <incy:PercentageOfRoyaltyRatePayments
      contextRef="Duration_1_1_2017_To_1_31_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_a6vIFrPYNUSTq51uQB6cnw"
      decimals="2"
      id="Narr_VekbS_0goEetCptlKjPWoA"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.10</incy:PercentageOfRoyaltyRatePayments>
    <incy:CollaborationAgreementProfitSharingPercentage
      contextRef="Duration_1_1_2017_To_1_31_2017_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_ziZW_6Itd0mRiuWAvHmhMA"
      decimals="2"
      id="Narr_QuQDVgIY5U2oiKcismxeiw"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.50</incy:CollaborationAgreementProfitSharingPercentage>
    <incy:PercentageOfProfitsLosses
      contextRef="Duration_1_1_2017_To_1_31_2017_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_ziZW_6Itd0mRiuWAvHmhMA"
      decimals="2"
      id="Narr_h1FMAOuWkUeDTRr0OXjW1A"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.50</incy:PercentageOfProfitsLosses>
    <incy:PercentageOfRoyaltyRatePayments
      contextRef="Duration_1_1_2017_To_1_31_2017_srt_RangeAxis_srt_MinimumMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_0jHvhxDIlEen-mp125RqxQ"
      decimals="2"
      id="Narr_2jOYMhj56EKdePkrI5NUbg"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.06</incy:PercentageOfRoyaltyRatePayments>
    <incy:PercentageOfRoyaltyRatePayments
      contextRef="Duration_1_1_2017_To_1_31_2017_srt_RangeAxis_srt_MaximumMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_TmMtQTVRAEqEbpqiWMhMKg"
      decimals="2"
      id="Narr_GWRgs_NJGkO_0c3t-xxP-A"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.10</incy:PercentageOfRoyaltyRatePayments>
    <incy:PercentageOfNetSalesPertainingToAdditionalRoyalties
      contextRef="Duration_1_1_2017_To_1_31_2017_srt_RangeAxis_srt_MaximumMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_TmMtQTVRAEqEbpqiWMhMKg"
      decimals="2"
      id="Narr_PElqf_jXR0OweZO6JnsFsQ"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.04</incy:PercentageOfNetSalesPertainingToAdditionalRoyalties>
    <incy:PercentageOfRoyaltyRatePayments
      contextRef="Duration_1_1_2017_To_1_31_2017_srt_RangeAxis_srt_MinimumMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_7nNpE5gl0kGtbk0copl0Ew"
      decimals="2"
      id="Narr_5wk7L50Zs0yI0niH9-BHaw"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.06</incy:PercentageOfRoyaltyRatePayments>
    <incy:PercentageOfRoyaltyRatePayments
      contextRef="Duration_1_1_2017_To_1_31_2017_srt_RangeAxis_srt_MaximumMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_-UyvIh_1dUGHPh1Oi-HZjg"
      decimals="2"
      id="Narr_e955cYo6EEuMFjzVQ4M8uA"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.10</incy:PercentageOfRoyaltyRatePayments>
    <incy:PercentageOfReverseRoyaltiesOnSaleOfFutureProducts
      contextRef="Duration_1_1_2017_To_1_31_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_a6vIFrPYNUSTq51uQB6cnw"
      decimals="2"
      id="Narr_GMmOxSzi6k-56NCLpVE46w"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.04</incy:PercentageOfReverseRoyaltiesOnSaleOfFutureProducts>
    <incy:PurchaseOfCommonStockUnderStockPurchaseAgreementInShares
      contextRef="Duration_12_1_2016_To_12_31_2016_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_AHacTrqe70OBJPlyv84qXA"
      decimals="-5"
      id="Narr_PYmEOqtR_E-bjgqwGaCQMg"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">3200000</incy:PurchaseOfCommonStockUnderStockPurchaseAgreementInShares>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="As_Of_12_31_2016_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_zhQ6u7Eorky9JUrK75lg6w"
      decimals="-5"
      id="Narr_BBaN2OjQc0mcgOhwt-X1Fw"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">80000000.0</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2016_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_zhQ6u7Eorky9JUrK75lg6w"
      decimals="2"
      id="Narr_EyoEgetkg0a6XmlYWrckJg"
      unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A">25.00</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="As_Of_1_23_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_KRP1zQuWsUCnd5bEiI4whg"
      decimals="2"
      id="Narr_HZQGqByiM0SQbPbLVhqgLw"
      unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A">24.50</us-gaap:SharePrice>
    <incy:FairValueInputsAmountOfDiscountForLackOfMarketability
      contextRef="Duration_1_23_2017_To_1_23_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_0W47ULyywE66YQ7w30K3tQ"
      decimals="-5"
      id="Narr_F4MqbhngiEyldUxgkBLnkw"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">5600000</incy:FairValueInputsAmountOfDiscountForLackOfMarketability>
    <us-gaap:EquityFairValueDisclosure
      contextRef="As_Of_1_23_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_KRP1zQuWsUCnd5bEiI4whg"
      decimals="-5"
      id="Narr_Vp3NB07miU2aBdM-b79jwg"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">72800000</us-gaap:EquityFairValueDisclosure>
    <incy:TotalConsiderationPaidUnderPurchaseAgreement
      contextRef="Duration_1_23_2017_To_1_23_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_0W47ULyywE66YQ7w30K3tQ"
      decimals="-5"
      id="Narr_0ztGzfHdVka3_8vwmaKqRQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">80000000.0</incy:TotalConsiderationPaidUnderPurchaseAgreement>
    <us-gaap:LongTermInvestments
      contextRef="As_Of_12_31_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_7XMbCpbDnEewpK0mRNy-0g"
      decimals="-5"
      id="Narr_FQfxeQBvpUSkWnhOE_tA_w"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">72800000</us-gaap:LongTermInvestments>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2017_To_12_31_2017_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_oWgSfS00vUW2MWLkfvZ1zg"
      decimals="-5"
      id="Narr_FIfzqowlLE-AFm2K5XMe6g"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">7200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_3_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_Jr7vn9wY7EugrlmE7e-Utg"
      decimals="-5"
      id="Narr_zdUudgHKCEenPE0Zxis0fQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">38700000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_enm1IIwTxE685YL-VEfceg"
      decimals="-5"
      id="Narr_iWzVTppIkkWQzoOWA9nILA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">45100000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="As_Of_3_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_Jr7vn9wY7EugrlmE7e-Utg"
      decimals="2"
      id="Narr_Bz2JNq5PBE2WPkAgGkcc6w"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.11</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_4sLodCGvRUuTCXxu1AuBbA"
      decimals="-5"
      id="Narr_NlPJqkDKRE2ZmR2COrXWcA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-6300000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="Duration_1_1_2019_To_3_31_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_hK2vELdvC0qjgaQxW0SVXw"
      decimals="-5"
      id="Narr_NFKZ8uRCA0i5l8bKuO5rEA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-2500000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationRevenue
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_suFOYxNDt0-4KUvHJ2smxQ"
      decimals="-5"
      id="Narr_tqyRIPBZ3EunKI5nFq2nWg"
      unitRef="Unit_Standard_EUR_4KUDkHZ-F0yLQi_l9X6Oxg">31100000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationRevenue>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_MerusNVMember_suFOYxNDt0-4KUvHJ2smxQ"
      decimals="-5"
      id="Narr_CaMIUiefv0-U1V21Ih4e6w"
      unitRef="Unit_Standard_EUR_4KUDkHZ-F0yLQi_l9X6Oxg">-55200000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_Y69YgRfz7EyDDBkJJ9glfg"
      decimals="-5"
      id="Narr_knadp7ffEkGuC6ML1ARwTw"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">2300000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_vi_h8M1GhkeTPwj2SVyuYg"
      decimals="-5"
      id="Narr_MHlrHyRRLU6koUvzaGQjFQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">2600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="As_Of_3_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_TDSLcpRho0W0O_zxs61WcQ"
      decimals="-5"
      id="Narr_rfwwv8xx6Ei_9vFU79Pt7A"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">2200000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="As_Of_12_31_2019_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_TypeOfArrangementAxis_incy_MerusNVMember_e8xNeuEtLkG3yuzAWXQPAQ"
      decimals="-5"
      id="Narr_m7hdQ_LESkqf0DUmfQSn9A"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1600000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <incy:LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded
      contextRef="Duration_1_1_2017_To_1_31_2017_us-gaap_TypeOfArrangementAxis_incy_CalitheraBiosciencesIncMember_k20QIDKWZ0Cx-yYlqJ-TBw"
      decimals="2"
      id="Narr_2Pje8djG1kOxyEKz784q5g"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.70</incy:LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded>
    <incy:PercentageOfProfitsLosses
      contextRef="Duration_1_1_2017_To_1_31_2017_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_incy_CalitheraBiosciencesIncMember_HQYolQnSwkG5T9dK1t91Ow"
      decimals="2"
      id="Narr_kJJA5BYUPEuevpyToIP2qg"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.60</incy:PercentageOfProfitsLosses>
    <incy:LicenseAgreementUpfrontPayment
      contextRef="Duration_1_1_2017_To_1_31_2017_us-gaap_TypeOfArrangementAxis_incy_CalitheraBiosciencesIncMember_k20QIDKWZ0Cx-yYlqJ-TBw"
      decimals="-5"
      id="Narr_jcG0wmftVEWc1qintN5aVA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">45000000.0</incy:LicenseAgreementUpfrontPayment>
    <incy:LicenseAgreementPotentialMilestonePaymentsWithProfitSharing
      contextRef="As_Of_1_31_2017_us-gaap_TypeOfArrangementAxis_incy_CalitheraBiosciencesIncMember_q6cjALmpG0eNfLyGFfZJcw"
      decimals="-5"
      id="Narr_eGsyH_39kE2iE9sYlu2RaA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">430000000.0</incy:LicenseAgreementPotentialMilestonePaymentsWithProfitSharing>
    <incy:LicenseAgreementPotentialMilestonePaymentsWithoutProfitSharing
      contextRef="As_Of_1_31_2017_us-gaap_TypeOfArrangementAxis_incy_CalitheraBiosciencesIncMember_q6cjALmpG0eNfLyGFfZJcw"
      decimals="-5"
      id="Narr_GN_wucwFG0uAHf26Vgh_Nw"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">750000000.0</incy:LicenseAgreementPotentialMilestonePaymentsWithoutProfitSharing>
    <incy:LicenseAgreementMilestonePaymentAmountPaid
      contextRef="Duration_3_1_2017_To_3_31_2017_us-gaap_TypeOfArrangementAxis_incy_CalitheraBiosciencesIncMember_Ms1l2DuiH0iX52Fe8ib4bw"
      decimals="-5"
      id="Narr_cgVfRTBDVUuZoN3SXQTeNQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">12000000.0</incy:LicenseAgreementMilestonePaymentAmountPaid>
    <incy:PurchaseOfCommonStockUnderStockPurchaseAgreementInShares
      contextRef="Duration_1_1_2017_To_1_31_2017_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_RlWLiTnNKk-MYynvIhAMbA"
      decimals="-5"
      id="Narr_UhTZcX_Eh0uAw5MfgLF5SQ"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">1700000</incy:PurchaseOfCommonStockUnderStockPurchaseAgreementInShares>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="As_Of_1_1_2017_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_0wbD4uybz0Kqy_sngxd94Q"
      decimals="-5"
      id="Narr_HTzpXTXa_0q0X1sUfme1Dg"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">8000000.0</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:SharePrice
      contextRef="As_Of_1_1_2017_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_0wbD4uybz0Kqy_sngxd94Q"
      decimals="2"
      id="Narr_XJINWdUlVEWd89prapYYow"
      unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A">4.65</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="As_Of_1_30_2017_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_V15b5Oo0-k2QDmXipNZJPg"
      decimals="2"
      id="Narr_yTVwy4dP-0yuMmwqy6NtFA"
      unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A">6.75</us-gaap:SharePrice>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_1_30_2017_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_V15b5Oo0-k2QDmXipNZJPg"
      decimals="-5"
      id="Narr_QtUcv06FwU-UaZWOhB2klA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">11600000</us-gaap:InvestmentsFairValueDisclosure>
    <incy:TotalConsiderationPaidUnderPurchaseAgreement
      contextRef="Duration_1_30_2017_To_1_30_2017_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_6yzhytojOUW72tF5DhREcQ"
      decimals="-5"
      id="Narr_W0WB-lozokuPYVz78OrPdg"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">53000000.0</incy:TotalConsiderationPaidUnderPurchaseAgreement>
    <incy:CollaborationAgreementUpfrontPayment
      contextRef="Duration_1_30_2017_To_1_30_2017_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_6yzhytojOUW72tF5DhREcQ"
      decimals="-5"
      id="Narr_tQoSOB5rqUCMNRjvUj0Vsw"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">45000000.0</incy:CollaborationAgreementUpfrontPayment>
    <incy:PurchasePriceOfCommonStockUnderStockPurchaseAgreement
      contextRef="Duration_1_30_2017_To_1_30_2017_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_6yzhytojOUW72tF5DhREcQ"
      decimals="-5"
      id="Narr_I67q72BM7EuscXY6TZqA_A"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">8000000.0</incy:PurchasePriceOfCommonStockUnderStockPurchaseAgreement>
    <incy:TotalConsiderationPaidUnderPurchaseAgreement
      contextRef="Duration_1_30_2017_To_1_30_2017_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_6yzhytojOUW72tF5DhREcQ"
      decimals="-5"
      id="Narr_ZznVlwPcNUm0N90dUS8Bfg"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">53000000.0</incy:TotalConsiderationPaidUnderPurchaseAgreement>
    <us-gaap:LongTermInvestments
      contextRef="As_Of_12_31_2017_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_3dQm43RaIU-3y4wKYTb_YA"
      decimals="-5"
      id="Narr_P4kcGLF-60GDUcrmSBk-GQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">11600000</us-gaap:LongTermInvestments>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_wgLMqUpIOkW0LR2tv0blfQ"
      decimals="-5"
      id="Narr_-1CROSA1xEOjvt9apSgtvw"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">41400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_3_31_2020_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_9FgpIjXW30il90Hlca16_w"
      decimals="-5"
      id="Narr_hVa36KlKjESxqo0HpTLw6w"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">7600000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2019_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_kOKA_UdywE2p7qUAsKbRXg"
      decimals="-5"
      id="Narr_gqjnhNbqOEuANkBtS5myGQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">9800000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="As_Of_3_31_2020_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_StockPurchaseAgreementMember_9FgpIjXW30il90Hlca16_w"
      decimals="2"
      id="Narr_l2ZgyYA2pE-kKwhqTv1gHA"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.03</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherComprehensiveIncomeMember_5oSPCzH0LUKKkaLwMadeGg"
      decimals="-5"
      id="Narr___dsjf-E8kyUIn04FtS0qg"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-2200000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherComprehensiveIncomeMember_9Lxk-PLyx0aRe3tPfUa9JQ"
      decimals="-5"
      id="Narr_UljHbXfu70WurYjN9gmw9Q"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-4700000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_CalitheraBiosciencesIncMember_ZVATcnAIO0GBu8wTwLvFPg"
      decimals="-5"
      id="Narr_11i4yKevp0CV746R0Li4CA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">2500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_TypeOfArrangementAxis_incy_CalitheraBiosciencesIncMember_gwhsiJOFE0CdmH4_ASRROw"
      decimals="-5"
      id="Narr_9niBNFM5_EihpU_IHBZSlw"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">4600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="As_Of_3_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_TypeOfArrangementAxis_incy_CalitheraBiosciencesIncMember_o_SL5702vkOgfJpisRbc3g"
      decimals="-5"
      id="Narr_S5nRQlypxUCXXZmUNfBmtg"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1300000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="As_Of_12_31_2019_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_FinancialInstrumentAxis_incy_CalitheraBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_incy_CalitheraBiosciencesIncMember_ekerfwlyQkKKU2NodLZECQ"
      decimals="-5"
      id="Narr_W9wDqTHlKEWtsl_aG4NdGg"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1100000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <incy:LicenseAgreementUpfrontPaymentAmountPaid
      contextRef="Duration_12_1_2017_To_12_31_2017_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_Pvqu3UdMtESm4jPlRmjNxw"
      decimals="-5"
      id="Narr__XjBP2fPOUmERu_bLB9Qfw"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">150000000.0</incy:LicenseAgreementUpfrontPaymentAmountPaid>
    <incy:LicenseAgreementAdditionalMilestonePayments
      contextRef="As_Of_12_31_2017_incy_AchievementOfMilestoneAxis_incy_DevelopmentAndRegulatoryMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_1gx5QmF1QESvqesUmo91qw"
      decimals="-5"
      id="Narr_8WNfm4R1t0KiIeEuuurYOQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">420000000.0</incy:LicenseAgreementAdditionalMilestonePayments>
    <incy:LicenseAgreementAdditionalMilestonePayments
      contextRef="As_Of_12_31_2017_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_h51PWrAxiUSRzPvrkcOO8w"
      decimals="-5"
      id="Narr_8prqU3EXTkK8K0Hu8PcydA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">30000000.0</incy:LicenseAgreementAdditionalMilestonePayments>
    <incy:PercentageOfRoyaltyRatePayments
      contextRef="Duration_12_1_2017_To_12_31_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_LuJpKL3-sUqsR3zx1Ui6ug"
      decimals="2"
      id="Narr_zypy9qixpEq7k8skcSCu9g"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.15</incy:PercentageOfRoyaltyRatePayments>
    <incy:PercentageOfRoyaltyRatePayments
      contextRef="Duration_12_1_2017_To_12_31_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_Dn4atemmXECcuSaCHD3Xhw"
      decimals="2"
      id="Narr_e9-HY3LgkkC6gaS7co6nGg"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.24</incy:PercentageOfRoyaltyRatePayments>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_9_1_2018_To_9_30_2018_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_9FaYOW1DOUSCPsDwOUajaQ"
      decimals="-5"
      id="Narr_TIL7G6tRBEK3wR1rINOftQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">10000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_11_1_2018_To_11_30_2018_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_epQaBen2_U6nG4Y4rp6zig"
      decimals="-5"
      id="Narr_RrGpmxkqlk6IAcqGmBZWKg"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">5000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_Bgm0Uqs6EEurpHztiTwV7A"
      decimals="-5"
      id="Narr_yYCjQnnDmEOOnP6Gf9MAKQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">16400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_fZaD2WqykkG-bcDt3R0hsg"
      decimals="-5"
      id="Narr_Siktk8uYxEyRcpAIQME8gw"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">9400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="As_Of_3_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_WXNGj9bwXUmUHfhHKe1dLw"
      decimals="-5"
      id="Narr_-G8Ii3ukzEerUHhXAjf0Jg"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1600000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="As_Of_12_31_2019_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_TypeOfArrangementAxis_incy_MacrogenicsMember_8PlbTBxq-kmWb2R31MsmkQ"
      decimals="-5"
      id="Narr_o_xc25tjSkSML0jcpm5_jg"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1000000.0</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <incy:NumberOfProgramTargets
      contextRef="Duration_1_1_2018_To_1_31_2018_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_e3Og2WQPREynUroSL3ThVw"
      decimals="INF"
      id="Narr_fkHGoh5lq0-4W3ggchDhRA"
      unitRef="Unit_Standard_item_4BIkJQxqZkOMHOIGydcttw">7</incy:NumberOfProgramTargets>
    <incy:LicenseAgreementTargetSelectionAndOptionExerciseFeePayments
      contextRef="As_Of_1_31_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_7z6twVQHkkaobzJI5jhU7g"
      decimals="-5"
      id="Narr_y3D7U1F55U2yqTHyhf3Bzw"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">54000000.0</incy:LicenseAgreementTargetSelectionAndOptionExerciseFeePayments>
    <incy:LicenseAgreementAdditionalMilestonePayments
      contextRef="As_Of_1_31_2018_incy_AchievementOfMilestoneAxis_incy_DevelopmentAndRegulatoryMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_bojg3Cpm70KP1ASJ64IbcA"
      decimals="-5"
      id="Narr_RH9v-LRj_02-guYnRyOI3w"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">50000000.0</incy:LicenseAgreementAdditionalMilestonePayments>
    <incy:LicenseAgreementAdditionalMilestonePayments
      contextRef="As_Of_1_31_2018_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_ggAKdTjZ60mONUG4Cc9HQg"
      decimals="-5"
      id="Narr_2xjKJ76-SE2kOB7fuG5C3w"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">65000000.0</incy:LicenseAgreementAdditionalMilestonePayments>
    <incy:LicenseAgreementUpfrontPaymentAmountPaid
      contextRef="Duration_1_1_2018_To_1_31_2018_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_e3Og2WQPREynUroSL3ThVw"
      decimals="-5"
      id="Narr_sHRo9_Se9kKTgBgP9UKmKA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">10000000.0</incy:LicenseAgreementUpfrontPaymentAmountPaid>
    <incy:PurchaseOfCommonStockUnderStockPurchaseAgreementInShares
      contextRef="Duration_1_1_2018_To_1_1_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_StockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_DgYpD_a5vUiEMdKdZb3MPA"
      decimals="-5"
      id="Narr_cRSCNBMmFUCo0RAhnHxBLg"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">800000</incy:PurchaseOfCommonStockUnderStockPurchaseAgreementInShares>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="As_Of_1_1_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_StockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_h6YyQFHKjUOT_t4PglWApQ"
      decimals="-5"
      id="Narr_PJf9aOQvu0mGKYX2bBF-FA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">10000000.0</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:SharePrice
      contextRef="As_Of_1_1_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_StockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_h6YyQFHKjUOT_t4PglWApQ"
      decimals="2"
      id="Narr_cOOurfWBWEiiPR3wfoSgGQ"
      unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A">12.61</us-gaap:SharePrice>
    <incy:StockPurchaseAgreementLockUpPeriod
      contextRef="Duration_1_8_2018_To_1_8_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_StockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_omIR3ZvvjkKFbSUFw_JzGA"
      id="Narr_y6Ypw_rdc0isyyJL22DE7Q">P12M</incy:StockPurchaseAgreementLockUpPeriod>
    <us-gaap:SharePrice
      contextRef="As_Of_1_8_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_StockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_q4yqPlQDMkKC2b9hPFXgEA"
      decimals="2"
      id="Narr_4yvLY3ug1USXLCHtH9NLAw"
      unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A">9.77</us-gaap:SharePrice>
    <incy:FairValueInputsAmountOfDiscountForLackOfMarketability
      contextRef="Duration_1_8_2018_To_1_8_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_StockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_omIR3ZvvjkKFbSUFw_JzGA"
      decimals="-5"
      id="Narr_1zK0TEHKQEyX37TkXTfDXw"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">100000</incy:FairValueInputsAmountOfDiscountForLackOfMarketability>
    <us-gaap:EquityFairValueDisclosure
      contextRef="As_Of_1_8_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_StockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_q4yqPlQDMkKC2b9hPFXgEA"
      decimals="-5"
      id="Narr_H0DlPBOy00Cbb5VX64izBQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">7600000</us-gaap:EquityFairValueDisclosure>
    <us-gaap:LongTermInvestments
      contextRef="As_Of_12_31_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_StockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_01Y2KuG7C02jQlyf-MJXhA"
      decimals="-5"
      id="Narr_cT5ojGegRECdDxjyXEDoUg"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">7600000</us-gaap:LongTermInvestments>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2018_To_12_31_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_StockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_iPk_0s54fkWZRS_3UlzhOA"
      decimals="-5"
      id="Narr_AicpL_LXdUKHLYlQjv9E4g"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">2400000</us-gaap:ResearchAndDevelopmentExpense>
    <incy:PurchaseOfCommonStockUnderStockPurchaseAgreementInShares
      contextRef="Duration_1_1_2018_To_1_31_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmendedStockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_XLcYraNHWEaKYbjk95TcKg"
      decimals="-5"
      id="Narr_4goPrSK4A0CaNcDBKcqw-w"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">100000</incy:PurchaseOfCommonStockUnderStockPurchaseAgreementInShares>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="As_Of_1_31_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmendedStockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_6YWfGDEPXE2CImLh9b1dmA"
      decimals="-5"
      id="Narr_wUNGghkvZUSAEWNL9aTHpA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1400000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:SharePrice
      contextRef="As_Of_1_31_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmendedStockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_6YWfGDEPXE2CImLh9b1dmA"
      decimals="2"
      id="Narr_LROHMuK4k0KmzAw9auUpdA"
      unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A">9.55</us-gaap:SharePrice>
    <us-gaap:LongTermInvestments
      contextRef="As_Of_12_31_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmendedStockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_VTRtnBqUMkSsfHzFNQIj2A"
      decimals="-5"
      id="Narr_dFqJFwCKwEWTNfbp37EGQg"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1400000</us-gaap:LongTermInvestments>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_AAhSlo2yskG8eSk5D_7vWA"
      decimals="-5"
      id="Narr_5tTjFqb2WEa71k6f3VU8Yw"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">5600000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2019_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_2_qilDUt-02bEAeGgk-4HA"
      decimals="-5"
      id="Narr_XVw4g7HwX0aZEv9YsuJZrg"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">6500000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="As_Of_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_AAhSlo2yskG8eSk5D_7vWA"
      decimals="2"
      id="Narr_qht6vPtaSE-fA9dbKJvOqQ"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.02</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_sIIh4iWJFk2a9UMIC24hHg"
      decimals="-5"
      id="Narr_uG5FsSPUe0OCdgJj5zMzZw"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">900000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_TypeOfArrangementAxis_incy_SyrosPharmaceuticalsIncMember_6HXkrhkugk2ANaoLx9Ffjg"
      decimals="-5"
      id="Narr_6--BuzVkt0GGvfuvvvX0vg"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">3300000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived
      contextRef="Duration_1_1_2019_To_1_31_2019_us-gaap_TypeOfArrangementAxis_incy_InnoventBiologicsIncMember_C_ENlXJVxkyNDvDNsqx1-Q"
      decimals="-5"
      id="Narr_4ZiP-bHLc0SY0Cps4HO2RA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">40000000.0</incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived>
    <incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone
      contextRef="Duration_6_1_2019_To_6_30_2019_incy_AchievementOfMilestoneAxis_incy_RegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_InnoventBiologicsIncMember_FsIzv8L_HEi55lLcoBwVbg"
      decimals="-5"
      id="Narr_dYos60qML0achxAyzO0uXA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">20000000.0</incy:LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone>
    <incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived
      contextRef="Duration_12_1_2018_To_12_31_2018_incy_AchievementOfMilestoneAxis_incy_DevelopmentAndRegulatoryMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_InnoventBiologicsIncMember_REXXiwthXUuKAJa4ox8rdQ"
      decimals="-5"
      id="Narr_015bs0nTbkCSldghvMZQ4w"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">129000000.0</incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived>
    <incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived
      contextRef="Duration_12_1_2018_To_12_31_2018_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_InnoventBiologicsIncMember_cY50RxpP-U6RWVnyPyfrmA"
      decimals="-5"
      id="Narr_0_JrkTFzhEyrsjXMBjAqNg"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">202500000</incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived>
    <incy:NumberOfProductCandidates
      contextRef="Duration_12_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_incy_InnoventBiologicsIncMember_dJHS72SJ40CyscATO6EB5Q"
      decimals="INF"
      id="Narr_qGAqK-FhLkCSSsTw3rsKTA"
      unitRef="Unit_Standard_item_4BIkJQxqZkOMHOIGydcttw">3</incy:NumberOfProductCandidates>
    <incy:LicenseAgreementReimbursableCosts
      contextRef="As_Of_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_InnoventBiologicsIncMember_ur26l_EwbEWNuQbgjhG5pw"
      decimals="-5"
      id="Narr_8hCmlXX2pE-t-C97aDtz0Q"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">3800000</incy:LicenseAgreementReimbursableCosts>
    <incy:LicenseAgreementReimbursableCosts
      contextRef="As_Of_12_31_2019_us-gaap_TypeOfArrangementAxis_incy_InnoventBiologicsIncMember_CDr03ADEikqqqKMjVIsLzw"
      decimals="-5"
      id="Narr_C4C4SdpiHUujrszew5xJqQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">3000000.0</incy:LicenseAgreementReimbursableCosts>
    <incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived
      contextRef="Duration_8_1_2019_To_8_31_2019_us-gaap_TypeOfArrangementAxis_incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember_fTLP0rPirE6Sgn7TSP_gGg"
      decimals="-5"
      id="Narr_S3AbOjVq4EWKW6EX5vLgng"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">17500000</incy:LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived>
    <incy:LicenseAgreementUpfrontPaymentAmountPaid
      contextRef="Duration_8_1_2019_To_8_31_2019_incy_AchievementOfMilestoneAxis_incy_DevelopmentRegulatoryAndCommercialMilestonesMember_us-gaap_TypeOfArrangementAxis_incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember_2LertgtXmUSbLU3ewDQkAw"
      decimals="-5"
      id="Narr_s9TAGrS8Z0qAEahsW63WCA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">37500000</incy:LicenseAgreementUpfrontPaymentAmountPaid>
    <incy:LicenseAgreementResearchAndDevelopmentReimbursedCost
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember_71IYyLEOk0qtHTwC9gMr2g"
      decimals="-5"
      id="Narr_MPGgToDIPEyYCzNvrJEXgA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">200000</incy:LicenseAgreementResearchAndDevelopmentReimbursedCost>
    <incy:LicenseAgreementReimbursableCosts
      contextRef="As_Of_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_CollaborationAndLicenseAgreementWithZaiLabLtdMember_IqSk84yaxE-JJvKAc06yPg"
      decimals="-5"
      id="Narr_6sgC37up50uaEIoAGbWqtA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">200000</incy:LicenseAgreementReimbursableCosts>
    <incy:LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded
      contextRef="Duration_1_1_2020_To_1_31_2020_dei_LegalEntityAxis_incy_IncyteMember_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_joVwB0DtIkOe9vuko8XrMQ"
      decimals="2"
      id="Narr_1Emi9ZV6kkW8bolkAZ298Q"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.55</incy:LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded>
    <incy:LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded
      contextRef="Duration_1_1_2020_To_1_31_2020_srt_CounterpartyNameAxis_incy_MorphosysAgMember_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_6F3K0RN-oUSX6n5Ve-1LHA"
      decimals="2"
      id="Narr_sZSgwdn4ckyi-7djbX2rcw"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.45</incy:LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded>
    <incy:LicenseAgreementUpfrontPaymentAmountPaid
      contextRef="Duration_3_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_rHTnGuemnUagNxNCaIIsSA"
      decimals="-5"
      id="Narr_LUk7eQTR5Eqq-oIkgxi3Sw"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">750000000.0</incy:LicenseAgreementUpfrontPaymentAmountPaid>
    <incy:LicenseAgreementAdditionalMilestonePayments
      contextRef="As_Of_1_31_2020_incy_AchievementOfMilestoneAxis_incy_DevelopmentAndRegulatoryMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_w44LObNwjk6l_m4tp62jQg"
      decimals="-5"
      id="Narr_T3GBUaC5TUiwmNq9EGO3wQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">740000000.0</incy:LicenseAgreementAdditionalMilestonePayments>
    <incy:LicenseAgreementAdditionalMilestonePayments
      contextRef="As_Of_1_31_2020_incy_AchievementOfMilestoneAxis_incy_CommercializationMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_738l7WGg-UO8nbsLnaCpFQ"
      decimals="-5"
      id="Narr_9xCymaHox0CnAmef5v8-yg"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">315000000.0</incy:LicenseAgreementAdditionalMilestonePayments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="As_Of_1_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmericanDepositarySharesMember_zDA5FKw7iUSQ77Y1CYtdhA"
      decimals="2"
      id="Narr_IWUcWCnlOEeJ2-XQTg-7XQ"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="As_Of_1_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmericanDepositarySharesMember_zDA5FKw7iUSQ77Y1CYtdhA"
      decimals="-5"
      id="Narr_8pxZAUe4hkqtlfj5F-Bj7g"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">150000000.0</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:SharePrice
      contextRef="As_Of_1_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmericanDepositarySharesMember_zDA5FKw7iUSQ77Y1CYtdhA"
      decimals="2"
      id="Narr_hdvncp315EmABMpyWADZxg"
      unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A">41.33</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="As_Of_3_3_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmericanDepositarySharesMember_p8hX0lYkjECSDquP0kv7_A"
      decimals="2"
      id="Narr_4pjLS3LTMkCObkhQTLOByA"
      unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A">27.65</us-gaap:SharePrice>
    <incy:FairValueInputsAmountOfDiscountForLackOfMarketability
      contextRef="Duration_3_3_2020_To_3_3_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmericanDepositarySharesMember_rB3V8pH9lUCWt7qCtdhL8g"
      decimals="-5"
      id="Narr_KCIPqqKgIE2agkxw5deDqw"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">4900000</incy:FairValueInputsAmountOfDiscountForLackOfMarketability>
    <us-gaap:EquityFairValueDisclosure
      contextRef="As_Of_3_3_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmericanDepositarySharesMember_p8hX0lYkjECSDquP0kv7_A"
      decimals="-5"
      id="Narr_m9oywAO3VUa-2IY2oy4zpw"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">95500000</us-gaap:EquityFairValueDisclosure>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="As_Of_1_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmericanDepositarySharesMember_zDA5FKw7iUSQ77Y1CYtdhA"
      decimals="-5"
      id="Narr_8EI6p9F3tk-QxjKatOtgQQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">150000000.0</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:LongTermInvestments
      contextRef="As_Of_3_3_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmericanDepositarySharesMember_p8hX0lYkjECSDquP0kv7_A"
      decimals="-5"
      id="Narr_GMCOqxZViEGDQ2DCdLCvQA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">95500000</us-gaap:LongTermInvestments>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_3_3_2020_To_3_3_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmericanDepositarySharesMember_rB3V8pH9lUCWt7qCtdhL8g"
      decimals="-5"
      id="Narr_Ktk3O-hwcUKS20ekYHV87Q"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">54500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:EquityFairValueDisclosure
      contextRef="As_Of_3_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_incy_AmericanDepositarySharesMember_1C9RFh6rfkulw5myLWBnDg"
      decimals="-5"
      id="Narr_uqbY95zr7EiSC8i4DvQW-Q"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">85600000</us-gaap:EquityFairValueDisclosure>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="As_Of_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_GSawLGXUJUqNCpQXIs29TA"
      decimals="2"
      id="Narr_jPSWUEvtUECNDatJ3UJoig"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.03</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_-V355oZpTEGL8BHgB8JTrQ"
      decimals="-5"
      id="Narr_T2wHeT0zgUGj_qRHqc2AdA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-9900000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <incy:CollaborationAgreementProfitLossSharingRatio
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_-V355oZpTEGL8BHgB8JTrQ"
      decimals="2"
      id="Narr_BEOlahf2BEuKhOB_A68b8Q"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.50</incy:CollaborationAgreementProfitLossSharingRatio>
    <incy:CollaborationLossSharingExpense
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_-V355oZpTEGL8BHgB8JTrQ"
      decimals="-5"
      id="Narr_Rmvpj2MtZ0WmRbD-lRiYEg"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">2100000</incy:CollaborationLossSharingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_-V355oZpTEGL8BHgB8JTrQ"
      decimals="-5"
      id="Narr_OvCuVd-dn0GOGZHAcIgAvQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">11600000</us-gaap:ResearchAndDevelopmentExpense>
    <incy:LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded
      contextRef="Duration_1_1_2020_To_3_31_2020_dei_LegalEntityAxis_incy_IncyteMember_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_Hko43zDhUECuypoYAgazng"
      decimals="2"
      id="Narr_02dud3ZSQEyFtewJDKhUaQ"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.55</incy:LicenseAgreementPercentageOfFutureGlobalDevelopmentCostsFunded>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="As_Of_3_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_TypeOfArrangementAxis_incy_MorphosysAgMember_-hgr7X57a0avQlFj1AvRPw"
      decimals="-5"
      id="Narr_0LIr3Iyb2kulFnXt6mkSLA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">13100000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_V2BHdt7kOEiXSIHBbPLdnw">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;10.&#160;&#160;&#160;&#160; &lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Stock compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We recorded $42.5&#160;million and $40.6 million, respectively, of stock compensation expense on the condensed consolidated statements of operations for the three months ended March 31, 2020 and 2019.  Stock compensation expense included within our condensed consolidated statements of operations for the three months ended March 31, 2020 and 2019 included research and development expense of $28.7 million and $27.4 million, respectively. Stock compensation expense included within our condensed consolidated statements of operations for the three months ended March 31, 2020 and 2019 also included selling, general and administrative expense of $13.6 million and $13.0 million, respectively. Stock compensation expense included within our condensed consolidated statements of operations for the three months ended March 31, 2020 and 2019 also included cost of product revenues of $0.2 million for each period. For the three months ended March 31, 2020 and 2019, we capitalized $0.2 million and $0.1 million of stock compensation expense as part of the cost of an asset.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We utilized the Black-Scholes valuation model for estimating the fair value of the stock compensation granted, with the following weighted-average assumptions:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:99.53%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:55.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Employee Stock Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:23.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Employee Stock Purchase Plan&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:55.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:40.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Three Months&#160;Ended March&#160;31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:55.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#x2002;&#x2002;&#x2002;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#x2002;&#x2002;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#x2002;&#x2002;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#x2002;&#x2002;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:55.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Average risk-free interest rates&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1.56 &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&#x2002;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2.51&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&#x2002;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.23 &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&#x2002;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2.27&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&#x2002;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Average expected life (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4.65 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.33&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.25 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:55.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;40 &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;45&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;52 &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;34&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Weighted-average fair value (in dollars)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;28.43 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;31.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;16.00 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;13.31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The risk-free interest rate is derived from the U.S. Federal Reserve rate in effect at the time of grant. The expected life calculation is based on the observed and expected time to the exercise of options by our employees based on historical exercise patterns for similar type options. Expected volatility is based on the historical volatility of our common stock over the period commensurate with the expected life of the options. A dividend yield of zero is assumed based on the fact that we have never paid cash dividends and have no present intention to pay cash dividends. Nonemployee awards are measured on the grant date by estimating the fair value of the equity instruments to be issued using the expected term, similar to our employee awards.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Option activity under our 2010 Amended and Restated Stock Incentive Plan (the &#x201c;2010 Stock Plan&#x201d;) was as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:25.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&#160;Subject&#160;to&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:25.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&#160;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Balance at December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,632,657&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 81.42&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 914,834&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 80.12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (688,202)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26.83&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Options cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (180,342)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 91.57&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Balance at March&#160;31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,678,947&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84.14&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In July 2016, we revised the terms of our annual stock option grants to provide that new option grants would generally have a &lt;span style="-sec-ix-hidden:Hidden_6RWKpuCFUEKpc6a3v7bZKw"&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;10-year&lt;/span&gt;&lt;/span&gt; term and vest over four years, with 25% vesting after one year and the remainder vesting in &lt;span style="-sec-ix-hidden:Hidden_OR5-Cr_KuEOxFj4pvVNKEQ"&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;36&lt;/span&gt;&lt;/span&gt; equal monthly installments. Previously, our option grants generally had &lt;span style="-sec-ix-hidden:Hidden_5i-HSeUv7Eq9b9ehfzeLfA"&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;7-year&lt;/span&gt;&lt;/span&gt; terms and vested over three years, with 33% vesting after one year and the remainder vesting in &lt;span style="-sec-ix-hidden:Hidden_mWa7sHwgO02SjXEAYJrP4Q"&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;24&lt;/span&gt;&lt;/span&gt; equal monthly installments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Restricted stock unit (&#x201c;RSU&#x201d;) and performance share (&#x201c;PSU&#x201d;) award activity under the 2010 Stock Plan was as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:24.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&#160;Subject&#160;to&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:24.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&#160;Awards&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Balance at December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,602,376&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 79.69&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;RSUs granted &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 379,496&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 80.32&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;RSUs released&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (64,426)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 87.36&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;RSUs cancelled &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (39,795)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 80.31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;PSUs cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,250)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 65.76&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Balance at March&#160;31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,865,401&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 79.65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In January&#160;2014, we began granting RSUs and PSUs to our employees at the share price on the date of grant. &#160; Each RSU represents the right to acquire one share of our common stock.  Each RSU granted prior to July 2016 was subject to cliff vesting after three years. In July 2016, we revised the terms of our RSU grants to provide that the awards will vest 25% annually over four years. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In June 2018, we granted 190,000 RSUs and 446,500 PSUs under long term incentive plans with performance and/or service-based milestones with graded and/or cliff vesting over &lt;span style="-sec-ix-hidden:Hidden_w_7MzdT-j0OynAIorIKX9Q"&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;three&lt;/span&gt;&lt;/span&gt; to four years. In April 2019, we granted an additional 100,000 PSUs under one of the existing long term incentive plans with performance based milestones and cliff vesting. For one of the existing long term incentive plans, under which 106,500 PSUs were granted, the actual number of shares of our common stock into which each PSU may convert was subject to a multiplier of up to 267% based on the level at which the performance conditions were achieved. The actual number of shares of our common stock into which each PSU will convert is at a multiplier of 142% based on the performance conditions being achieved as of March 31, 2019 and will continue to vest through June 2022. &#160;For an existing long term incentive plan, under which 150,000 PSUs were granted, the actual number of shares of our common stock into which each PSU may convert was subject to a multiplier of up to 100% if all performance conditions were achieved or 0% if no performance conditions were achieved. The actual number of shares of our common stock into which each PSU will convert is at a multiplier of 100% based on the performance conditions being achieved as of December 31, 2019 and will cliff vest in June 2021. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Compensation expense for the performance-based awards is recorded over the estimated service period for each milestone when the performance conditions are deemed probable of achievement. For the period ended March 31, 2020, the stock compensation expense recorded during the period was for service-based awards and performance conditions deemed probable of achievement and/or achieved. For PSUs containing performance conditions which were not deemed probable of achievement at March 31, 2020, no stock compensation expense was recognized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In July 2018, we granted 77,243 PSUs to executives with performance milestones and graded vesting over four years. &#160;The shares of our common stock into which each PSU may convert is subject to a multiplier up to 150% based on the level at which the performance condition is achieved. Compensation expense for the performance-based awards is recorded over the estimated service period when the performance condition is deemed probable of achievement. The actual number of shares of our common stock into which each PSU converted was at a multiplier of 83% based on the performance condition being achieved as of December 31, 2018. &#160;These PSUs will continue to vest through July 2022. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In July 2019, we granted 86,975 PSUs to executives with a performance milestone and graded vesting over four years. &#160;The shares of our common stock into which each PSU may convert is subject to a multiplier up to 125% based on the level at which the performance condition is achieved. Compensation expense for the performance-based awards is recorded over the estimated service period when the performance condition is deemed probable of achievement. The actual number of shares of our common stock into which each PSU will convert is at a multiplier of 101.8% based on the performance condition being achieved as of December 31, 2019. &#160;These PSUs will continue to vest through July 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes our shares available for grant under the 2010 Stock Plan:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:81.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:81.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:15.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares Available&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:81.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:15.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;for Grant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:81.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Balance at December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,882,122&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Options, RSUs and PSUs granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,673,826)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:81.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Options, RSUs and PSUs cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 247,429&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Balance at March&#160;31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,455,725&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;Based on our historical experience of employee turnover, we have assumed an annualized forfeiture rate of 5% for our options, RSUs and PSUs. Under the true-up provisions of the stock compensation guidance, we will record additional expense if the actual forfeiture rate is lower than we estimated, and will record a recovery of prior expense if the actual forfeiture is higher than we estimated.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Total compensation cost of options granted but not yet vested, as of March 31, 2020, was $95.8 million, which is expected to be recognized over the weighted average period of approximately 1.4 years. Total compensation cost of RSUs granted but not yet vested, as of March 31, 2020, was $93.3 million, which is expected to be recognized over the weighted average period of approximately 1.8 years. &#160;Total compensation cost of PSUs granted but not yet vested, as of March 31, 2020, was $29.5 million, which is expected to be recognized over the weighted average period of 1.8 years, should the underlying performance conditions be deemed probable of achievement.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-5"
      id="Narr_VcfFwxfZBkuV-rXd9139Jg"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">42500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-5"
      id="Narr_E6Bh__aCYkS-PxaxItMUKA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">40600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_hdQWjmjVAUOoLAgOzPKlfg"
      decimals="-5"
      id="Narr_93-_Z5ysoUej5mG8XS8wnQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">28700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_HQ2dp39OO0S03M-igkKhPQ"
      decimals="-5"
      id="Narr_upLOGI38jka6arGnecAadw"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">27400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ayQXfrU-kEqLMW5XKp3dOQ"
      decimals="-5"
      id="Narr_xS2dZ8PrnEeoBkbv4UHwxQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">13600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember__KRsuuuxFUGHFrG9WcT73A"
      decimals="-5"
      id="Narr_AtjuMxS4NEunrOg5xIpKdw"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">13000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_iAoPlqdY8EuohmWI9wvG1Q"
      decimals="-5"
      id="Narr_m6fEQAT4DUimX9186ic4Mg"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_SYkDX7ewnEi-fA1QMyfsXw"
      decimals="-5"
      id="Narr_CuhkY1sJyUWQBH4nQI_GPA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <incy:StockCompensationExpenseCapitalized
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-5"
      id="Narr_4-juIC-dkUqX7FTQP3DHQQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">200000</incy:StockCompensationExpenseCapitalized>
    <incy:StockCompensationExpenseCapitalized
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-5"
      id="Narr_Jgx840j860eb6BoyUYwVvA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">100000</incy:StockCompensationExpenseCapitalized>
    <incy:ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_2oH7JsXj9UqXllMNo4R2jQ">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We utilized the Black-Scholes valuation model for estimating the fair value of the stock compensation granted, with the following weighted-average assumptions:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:99.53%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:55.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Employee Stock Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:23.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Employee Stock Purchase Plan&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:55.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:40.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Three Months&#160;Ended March&#160;31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:55.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#x2002;&#x2002;&#x2002;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#x2002;&#x2002;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#x2002;&#x2002;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#x2002;&#x2002;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:55.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Average risk-free interest rates&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1.56 &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&#x2002;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2.51&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&#x2002;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.23 &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&#x2002;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2.27&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&#x2002;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Average expected life (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4.65 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.33&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.25 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:55.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;40 &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;45&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;52 &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;34&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Weighted-average fair value (in dollars)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;28.43 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;31.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;16.00 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;13.31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</incy:ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Narr_9QoDowqcl0GufNcPWWyGxQ">Black-Scholes valuation model</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tgSRvrejHUqYFIu85rRsPg"
      decimals="4"
      id="Tc_gnvtBwYRoke3j7jdAy9OpQ_4_2"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.0156</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Cbj624ha3kmOoiQSEnwBlw"
      decimals="4"
      id="Tc_-H4YpX7CLk6bqDCqnfKrxQ_4_4"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.0251</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_SVG1T8un0UuAR4xiq6ES-w"
      decimals="4"
      id="Tc_exI4qQIaLUKiVKMirLkcAQ_4_7"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.0023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_W9GbI2-s5ES4CTz48UruiA"
      decimals="4"
      id="Tc_tU9nm2TnMEy8DTPki5OOeA_4_9"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.0227</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tgSRvrejHUqYFIu85rRsPg"
      id="Tc_umgKkYG2kUmm2VuDRgrkEg_5_2">P4Y7M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Cbj624ha3kmOoiQSEnwBlw"
      id="Tc_SLaQg8UAGESwpRWBFp9kaw_5_4">P5Y3M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_SVG1T8un0UuAR4xiq6ES-w"
      id="Tc_0fOOP3OZx02ojNO25Nmddg_5_7">P0Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_W9GbI2-s5ES4CTz48UruiA"
      id="Tc_k_Wt0ozaOE2ShcC2CuPvvA_5_9">P0Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tgSRvrejHUqYFIu85rRsPg"
      decimals="2"
      id="Tc_dEPc4mzEMUGQx15I3DCSDQ_6_2"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Cbj624ha3kmOoiQSEnwBlw"
      decimals="2"
      id="Tc_zzMvPzHMaUCUR17ltSSCLQ_6_4"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_SVG1T8un0UuAR4xiq6ES-w"
      decimals="2"
      id="Tc_OninVhEei0ODjZrirl2hkg_6_7"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_W9GbI2-s5ES4CTz48UruiA"
      decimals="2"
      id="Tc_cr7Vx1k290myb4edy3Ts-g_6_9"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tgSRvrejHUqYFIu85rRsPg"
      decimals="2"
      id="Tc_xgtCUj1JDEKAKZp5PY__VA_7_2"
      unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A">28.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Cbj624ha3kmOoiQSEnwBlw"
      decimals="2"
      id="Tc_YsF14GZzEkqrGuFpo0MHJA_7_4"
      unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A">31.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_SVG1T8un0UuAR4xiq6ES-w"
      decimals="2"
      id="Tc_ujJJeNx3MUez2KdRSTQAWg_7_7"
      unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A">16.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_W9GbI2-s5ES4CTz48UruiA"
      decimals="2"
      id="Tc_LWIcme8naUqDW4pZfrhfqg_7_9"
      unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A">13.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="2"
      id="Narr_CjqxRxKhvkGdTGYtLEzZBw"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_Md1qPoRkbEmHiPWUx0XN1A">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Option activity under our 2010 Amended and Restated Stock Incentive Plan (the &#x201c;2010 Stock Plan&#x201d;) was as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:25.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&#160;Subject&#160;to&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:25.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&#160;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Balance at December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,632,657&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 81.42&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 914,834&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 80.12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (688,202)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26.83&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Options cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (180,342)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 91.57&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Balance at March&#160;31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,678,947&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84.14&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AzTpzCx2FEeghKSIssu86g"
      decimals="INF"
      id="Tc_WZmm9tSoXUW3p8ibA-wGMQ_5_2"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">12632657</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_AzTpzCx2FEeghKSIssu86g"
      decimals="2"
      id="Tc_NpB--Skm6kGjn-KoEvrFEA_5_5"
      unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A">81.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tgSRvrejHUqYFIu85rRsPg"
      decimals="INF"
      id="Tc_7_q0-o0ASUelW__OhjO10w_6_2"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">914834</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tgSRvrejHUqYFIu85rRsPg"
      decimals="2"
      id="Tc_yCb8RIPH00qOnEwrDPAB-w_6_5"
      unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A">80.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tgSRvrejHUqYFIu85rRsPg"
      decimals="INF"
      id="Tc_OtTLAnP86E6O_9SgNKif3A_7_2"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">688202</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tgSRvrejHUqYFIu85rRsPg"
      decimals="2"
      id="Tc_27RxsLhhwUO2SZw9_9wIug_7_5"
      unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A">26.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tgSRvrejHUqYFIu85rRsPg"
      decimals="INF"
      id="Tc_DPnh3a3EUkqCA48c6W7wtg_8_2"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">180342</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tgSRvrejHUqYFIu85rRsPg"
      decimals="2"
      id="Tc_rJhb0uXj9UOV8eEPFC4U5A_8_5"
      unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A">91.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_-W06vJqxfUKkm8FD3tX-XQ"
      decimals="INF"
      id="Tc_5clZpMw55kyiZoqKYzLQ6A_9_2"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">12678947</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_-W06vJqxfUKkm8FD3tX-XQ"
      decimals="2"
      id="Tc_uS2uD8HIoESZKfDzG5WF2w_9_5"
      unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A">84.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_1_2016_To_7_31_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_eVPwouvAqkSAUpm9iX0Giw"
      id="Narr_8HyH_Zwzl0qg0MbeIURFgQ">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_7_1_2016_To_7_31_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_zIOfLPcoIE-WPja313LTug"
      decimals="2"
      id="Narr_NghHLQH4PUCTgmurMC2qHw"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_1_2016_To_7_31_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_zIOfLPcoIE-WPja313LTug"
      id="Narr_atq8ZS7poEmLoUrpA41G5A">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2016_To_6_30_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_R2nXzmWcpEusNX2tgETvVg"
      id="Narr_fqnWwwHf1Eq050tM8IvMVw">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2016_To_6_30_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_L9F2_6Qez0Ox5Fm8qYePbw"
      decimals="2"
      id="Narr_ZOpQa9CnD0epLcjfEk_arg"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.33</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2016_To_6_30_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_L9F2_6Qez0Ox5Fm8qYePbw"
      id="Narr_qAvhFKZYZ0GkugTzIz6Dpg">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <incy:ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_zUf_J-YsSESqBDYeFzVj8Q">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Restricted stock unit (&#x201c;RSU&#x201d;) and performance share (&#x201c;PSU&#x201d;) award activity under the 2010 Stock Plan was as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:24.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&#160;Subject&#160;to&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:24.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&#160;Awards&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Balance at December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,602,376&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 79.69&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;RSUs granted &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 379,496&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 80.32&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;RSUs released&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (64,426)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 87.36&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;RSUs cancelled &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (39,795)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 80.31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;PSUs cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,250)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 65.76&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Balance at March&#160;31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,865,401&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 79.65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</incy:ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="INF"
      id="Tc_7aWcJ4JWh0q1PfdreBM89A_4_2"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">2602376</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="2"
      id="Tc_S217rlh7h0O7md8W9z_qpw_4_5"
      unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A">79.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_VmhuMJCx8kyw979O9O77sA"
      decimals="INF"
      id="Tc_V6dAhq49AUykVdhBuftilw_5_2"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">379496</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_VmhuMJCx8kyw979O9O77sA"
      decimals="2"
      id="Tc_vwGB_JLP10ejUCBOc5S0pA_5_5"
      unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A">80.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue>
    <incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_VmhuMJCx8kyw979O9O77sA"
      decimals="INF"
      id="Tc_cZZrfxKBwUS04aw-seTaJg_6_2"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">64426</incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod>
    <incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_VmhuMJCx8kyw979O9O77sA"
      decimals="2"
      id="Tc_JVGvyJAsEU2Y0jMO-8C51w_6_5"
      unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A">87.36</incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_VmhuMJCx8kyw979O9O77sA"
      decimals="INF"
      id="Tc_ixmL9A60SkGmThStIG6j8Q_7_2"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">39795</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_VmhuMJCx8kyw979O9O77sA"
      decimals="2"
      id="Tc_0Tedd2Y0SE27fBS0i6HHCg_7_5"
      unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A">80.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_CUAHxIXboUW-AGQxTycjxQ"
      decimals="INF"
      id="Tc_gFjakLtTrEGnFxW991oLIw_8_2"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">12250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_CUAHxIXboUW-AGQxTycjxQ"
      decimals="2"
      id="Tc_AlZ4KouH-kqkqpKrS2VDdg_8_5"
      unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A">65.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="INF"
      id="Tc_pwlj1wDHCEC3qsmSAFBabA_9_2"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">2865401</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="2"
      id="Tc_3anfuSsK_0ezs1yOv2DM0g_9_5"
      unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A">79.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits
      contextRef="Duration_1_1_2014_To_1_31_2014_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_a4J1xme2j0qJI7w67u-8Kw"
      decimals="INF"
      id="Narr_mfShpHQAQ0KX5-M8hshbcg"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">1</incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="Duration_1_1_2016_To_6_30_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_yPcPm_5LjUyiK3NWPCSUmg"
      id="Narr_1ycEo83lD06m0NHa27DavA">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_7_1_2016_To_7_31_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_2XwuCwQyq028NRrBWn-7FQ"
      decimals="2"
      id="Narr_n-6rzeEeS0CuoRmf4hbvEw"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_1_2016_To_7_31_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_2XwuCwQyq028NRrBWn-7FQ"
      id="Narr_uST1IjbMBEW-v7abbnSgTg">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_6_1_2018_To_6_30_2018_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_WKzuvMhbXkaBU9jbXYBPQw"
      decimals="INF"
      id="Narr_tpoe-oG6VUGM2ZW5m037-A"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">190000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_6_1_2018_To_6_30_2018_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_vC6oKQwc_UO2IGuLtg5qng"
      decimals="INF"
      id="Narr_HgqgzfwzREy8qiwOi0sUSw"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">446500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="Duration_6_1_2018_To_6_30_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_SZJ4LKIOuESQEpa0eW7EPw"
      id="Narr_QD0gFy7810ifANskMJQScw">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_4_1_2019_To_4_30_2019_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_incy_LongTermIncentivePlanOneMember_dDGsqWzkwEmzRXEky-0cyA"
      decimals="INF"
      id="Narr_KPm1jtVFQUWuRDjIdkDhMA"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_6_1_2018_To_6_30_2018_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_incy_LongTermIncentivePlanOneMember_jsEmMys8p0GNOaeQtFsmZQ"
      decimals="INF"
      id="Narr_fNcfUadD-0Oo6UTUjXonCw"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">106500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor
      contextRef="Duration_6_1_2018_To_6_30_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_incy_LongTermIncentivePlanOneMember_DDOU9aUbe0qDsi2WsRXKrg"
      decimals="2"
      id="Narr_Cgqp__PZQ0yNfGXc76mZkg"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">2.67</incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor>
    <incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor
      contextRef="Duration_3_31_2019_To_3_31_2019_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_incy_LongTermIncentivePlanOneMember_10zMB4kxHUmiN5hoSzLWUw"
      decimals="2"
      id="Narr_JPDNr-p5CUiWBHIz3gv0Nw"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">1.42</incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_6_1_2018_To_6_30_2018_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_incy_LongTermIncentivePlanTwoMember_GfdRdjchm0SNfn7rnmSnFA"
      decimals="INF"
      id="Narr_2A4VZ03MkEmL_V2mX24tlw"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor
      contextRef="Duration_6_1_2018_To_6_30_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_incy_LongTermIncentivePlanTwoMember_F_BDMjdwvUaazt5WAPM0pg"
      decimals="2"
      id="Narr_yu1Oeflgo0yDUXkaGoI-yA"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">1</incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor>
    <incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor
      contextRef="Duration_6_1_2018_To_6_30_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_incy_LongTermIncentivePlanTwoMember_0cnSLqNMKkOiYjDFx0hr1g"
      decimals="2"
      id="Narr_rgaXyoDTk0iEGrA3oo0ubg"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0</incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor>
    <incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor
      contextRef="Duration_12_31_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_incy_LongTermIncentivePlanTwoMember_g0CLhct2S0K4vHe7Em2Zuw"
      decimals="2"
      id="Narr_rFn8_P08mEyEvi2h5Qhmiw"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">1</incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_7_1_2018_To_7_31_2018_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_YelUbuNY80CUvf6lPtpuag"
      decimals="INF"
      id="Narr_zGg-eihchEyykwQagECoNQ"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">77243</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_1_2018_To_7_31_2018_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_YelUbuNY80CUvf6lPtpuag"
      id="Narr_MM_ImwwqLUmqOAWMWbZUXg">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageMultiplierForConversionOfUnitsIntoCommonStock
      contextRef="Duration_7_1_2018_To_7_31_2018_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_YelUbuNY80CUvf6lPtpuag"
      decimals="2"
      id="Narr_bi60a4BvoUqRtZTNCO-HXg"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">1.50</incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageMultiplierForConversionOfUnitsIntoCommonStock>
    <incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_AkK30_Ng-U2hTUpYkJOybQ"
      decimals="2"
      id="Narr_ZxX05KfiHUmUTGY2NbuBug"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.83</incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_7_1_2019_To_7_31_2019_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_TVxp6xaORUq6y8Ownz8CYg"
      decimals="INF"
      id="Narr_WcfcHOVW30KOcmMfb9KNPA"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">86975</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_1_2019_To_7_31_2019_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_TVxp6xaORUq6y8Ownz8CYg"
      id="Narr_UmJ47S1_skuyaFIUPK_D-A">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor
      contextRef="Duration_7_1_2019_To_7_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_xd5AG2VWVEOzpz4FkpHdOg"
      decimals="2"
      id="Narr_ykatAncE10K8QDvf0MaNzA"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">1.25</incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor>
    <incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor
      contextRef="Duration_12_31_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_R6qfbt0g7UGmt1ZGgohMYw"
      decimals="3"
      id="Narr_WvadR6pCBU-1ES1kuyLT-A"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">1.018</incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor>
    <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_DPccJr7BQUCciC1EfIZsmQ">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes our shares available for grant under the 2010 Stock Plan:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:81.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:81.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:15.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares Available&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:81.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:15.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;for Grant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:81.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Balance at December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,882,122&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Options, RSUs and PSUs granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,673,826)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:81.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Options, RSUs and PSUs cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 247,429&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Balance at March&#160;31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,455,725&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="INF"
      id="Tc_Il9tnnHmbUqlvWx5Z_R7bg_3_2"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">9882122</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="INF"
      id="Tc_lm6IRX2F2k2DCQ8HoevzfA_4_2"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">1673826</incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted>
    <incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="INF"
      id="Tc__bAdiqiFcUe2-xPURPS1PA_5_2"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">247429</incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="INF"
      id="Tc_R7LIbVXEvEG3tyPgUnshNw_6_2"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">8455725</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="2"
      id="Narr_vjPhXL5h3U2gGJbBImbHIQ"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.05</incy:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_-W06vJqxfUKkm8FD3tX-XQ"
      decimals="-5"
      id="Narr_QZAHRB-EGE-_9EAK5Cjbuw"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">95800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tgSRvrejHUqYFIu85rRsPg"
      id="Narr_wDNF09gHzkO9n66rS2Vbjg">P1Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_uJymqcnIC0WuSGRiCrl9yQ"
      decimals="-5"
      id="Narr_1JcOo4pRS0q67gxGAD-BQA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">93300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_VmhuMJCx8kyw979O9O77sA"
      id="Narr_0vIfJHH7x0uM9aBBGaIeag">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_y8PVaaJJd06F0gOHPbgysg"
      decimals="-5"
      id="Narr_d9k1fYDPVEmGqkTZAHWdtA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">29500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_CUAHxIXboUW-AGQxTycjxQ"
      id="Narr_zLiEoCpNGE61M4m0myJefw">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_-ryyFvpuOUOasX4Y2GJ3Tg">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;11.&#160;&#160;&#160;&#160; &lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Accrued and other current liabilities&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Accrued and other current liabilities consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:17.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:17.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Royalties&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 73,045&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 73,221&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Clinical related costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 77,913&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 88,710&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Sales allowances&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 96,062&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59,924&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,582&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,732&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,343&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Other current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 60,411&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,020&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Total accrued and other current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 330,034&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 285,950&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_SKtNukAY9Ueh7d9bipX0ZQ">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Accrued and other current liabilities consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:17.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:17.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Royalties&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 73,045&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 73,221&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Clinical related costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 77,913&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 88,710&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Sales allowances&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 96,062&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59,924&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,582&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,732&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,343&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Other current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 60,411&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,020&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Total accrued and other current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 330,034&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 285,950&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_HxonI-eD0Eu2ejxUVJy0wQ_3_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">73045000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_IhftVFD_KkWRpZ0DG9k6Tg_3_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">73221000</us-gaap:AccruedRoyaltiesCurrent>
    <incy:AccruedClinicalRelatedCostsCurrent
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_X24BL7mMKkyAZqxYr1nq3Q_4_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">77913000</incy:AccruedClinicalRelatedCostsCurrent>
    <incy:AccruedClinicalRelatedCostsCurrent
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_-JJVHkvD00-FwTGbibdhKg_4_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">88710000</incy:AccruedClinicalRelatedCostsCurrent>
    <us-gaap:ProvisionForLossOnContracts
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_EzAPZ1ODwEGpi_5IGwvsvg_5_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">96062000</us-gaap:ProvisionForLossOnContracts>
    <us-gaap:ProvisionForLossOnContracts
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_wEt8KHapzkay_CdndiokGA_5_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">59924000</us-gaap:ProvisionForLossOnContracts>
    <us-gaap:ConstructionPayableCurrent
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_HC-dRC2TKUOfQW81KDBfuA_6_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">13582000</us-gaap:ConstructionPayableCurrent>
    <us-gaap:ConstructionPayableCurrent
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_GVOBEv04-EKxdzDKxqNrug_6_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">12732000</us-gaap:ConstructionPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_8NolupSH0kSTpQbCBZte4w_7_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">9021000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_M4qhGyOjj0u3sqrmllv5eg_7_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">9343000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_e4JXickss0Wn7dlTivRxng_8_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">60411000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_1LIMs_SpUU-YZy51zEppZg_8_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">42020000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-3"
      id="Tc_ef93hc-_6EmmNAfQowVskA_9_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">330034000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-3"
      id="Tc_MSI8Ez8VkU6AykAG2QfwfQ_9_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">285950000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_WCQVUC3ZXUyOKGpkA-3ocw">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;12.&#160;&#160;&#160;&#160; &lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Debt&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The components of the convertible senior notes are as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:56.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying&#160;Amount,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:56.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Interest&#160;Rates&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:56.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Debt&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Maturities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:56.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;1.25% Convertible Senior Notes due 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.25&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,524&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,300&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The carrying amount and fair value of our convertible senior notes are as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:59.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:18.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:18.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31, 2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:59.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:59.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;1.25% Convertible Senior Notes due 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,524&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,656&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,300&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,511&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of the 1.25% Convertible Senior Notes due 2020 (the &#x201c;2020 Notes&#x201d;) is based on data from readily available pricing sources which utilize market observable inputs and other characteristics for similar types of instruments, and, therefore, is classified within Level 2 in the fair value hierarchy. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Prior to May 14, 2014, the 2020 Notes were not convertible except in connection with a make-whole fundamental change, as defined in the indenture. Beginning on, and including, May 15, 2014, the 2020 Notes are convertible prior to the close of business on the business day immediately preceding May 15, 2020 only under the following circumstances: (i) during any calendar quarter commencing after the calendar quarter ending on March 31, 2014 (and only during such calendar quarter), if the last reported sale price of our common stock for at least &lt;span style="-sec-ix-hidden:Hidden_1LuKVsI460CF2sHZ2dlGqw"&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;20&lt;/span&gt;&lt;/span&gt; trading days (whether or not consecutive) during a period of &lt;span style="-sec-ix-hidden:Hidden_Rv9y-6kA30urzn5y6CwGRg"&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;30&lt;/span&gt;&lt;/span&gt; consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price for the 2020 Notes on each applicable trading day; (ii) during the five business day period after any five consecutive trading day period (the &#x201c;measurement period&#x201d;) in which the trading price per $1,000 principal amount of the 2020 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate for the 2020 Notes on each such trading day; or (iii) upon the occurrence of specified corporate events. On or after May 15, 2020 until the close of business on the &lt;span style="-sec-ix-hidden:Hidden_LuZKOSV89k6ANKuV9BpZOg"&gt;&lt;span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;second&lt;/span&gt;&lt;/span&gt; scheduled trading day immediately preceding the relevant maturity date, the 2020 Notes are convertible at any time, regardless of the foregoing circumstances. Upon conversion we will pay or deliver, as the case may be, cash, shares of common stock or a combination of cash and shares of common stock, at our election.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On April 1, 2020, the 2020 Notes became convertible through at least June 30, 2020, based on meeting the conversion criteria related to the sale price of our common stock during the calendar quarter ended March 31, 2020 as described in (i) above. The 2020 Notes are reflected in current liabilities on the condensed consolidated balance sheet as of March 31, 2020 due to their maturity date of November 15, 2020, unless earlier purchased or converted.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_3Q4PoaONXky6BT-CO7SYdg">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The components of the convertible senior notes are as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:56.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying&#160;Amount,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:56.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Interest&#160;Rates&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:56.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Debt&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Maturities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:56.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;1.25% Convertible Senior Notes due 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.25&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,524&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,300&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_mf1pSO_8xk-KJN_VOGoSlQ"
      decimals="4"
      id="Tc_aaZduSSApEyf_WdUpas_7w_4_2"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ConvertibleDebt
      contextRef="As_Of_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_Zx-v_c4r70WwWX03gqsXyg"
      decimals="-3"
      id="Tc_zCT6kZHX1EqcQGIsnZC3ZQ_4_7"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">18524000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_rppXeBwyn0KUPPFX6vCgDA"
      decimals="-3"
      id="Tc_JCunXsjfhk2rsMHZ8j_MWQ_4_10"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">18300000</us-gaap:ConvertibleDebt>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_4DOZEC4OB0i9PIfcVNoylg">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The carrying amount and fair value of our convertible senior notes are as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:59.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:18.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:18.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31, 2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:59.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:59.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;1.25% Convertible Senior Notes due 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,524&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,656&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,300&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,511&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_mf1pSO_8xk-KJN_VOGoSlQ"
      decimals="4"
      id="Narr_WEDsMyVyVEKv-3q-S3-wZA"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_dUhGX9pGs0KEez2XYOKNtg"
      decimals="4"
      id="Narr_fQsmjcAM20uA4NysFFKPQg"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ConvertibleDebt
      contextRef="As_Of_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_Zx-v_c4r70WwWX03gqsXyg"
      decimals="-3"
      id="Tc_jVIuOkCwfUma9vJtvf-d5A_4_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">18524000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="As_Of_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_ByXHMCnwhUuLsKezaFFRag"
      decimals="-3"
      id="Tc_oMMi-yNR10--AeNu7V4aFw_4_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">27656000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_rppXeBwyn0KUPPFX6vCgDA"
      decimals="-3"
      id="Tc_aTzwz-vIKUubk00WvWksaA_4_9"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">18300000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_BIl-1RaM1EOPgs_KNzpbiA"
      decimals="-3"
      id="Tc_WIY_T_pyD0KrLBTTWMZlow_4_12"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">32511000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_mf1pSO_8xk-KJN_VOGoSlQ"
      decimals="4"
      id="Narr_6oWsuqCgc0Sx-L1UnzNmlQ"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <incy:DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member_MP4cDjTkq06lAGevzdzYBw"
      decimals="2"
      id="Narr_5ayzhQPlTUyaYd_5bH4oMg"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">1.30</incy:DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice>
    <incy:DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member_MP4cDjTkq06lAGevzdzYBw"
      decimals="0"
      id="Narr_igM1p09gF0STn8sH4e1gQw"
      unitRef="Unit_Standard_item_4BIkJQxqZkOMHOIGydcttw">5</incy:DebtInstrumentConversionObligationNumberOfConsecutiveBusinessDaysAfterConsecutiveTradingDayPeriod>
    <incy:DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member_MP4cDjTkq06lAGevzdzYBw"
      decimals="0"
      id="Narr_I6eI5zuf30WRlNdWPlYhcw"
      unitRef="Unit_Standard_item_4BIkJQxqZkOMHOIGydcttw">5</incy:DebtInstrumentConversionObligationPeriodOfConsecutiveTradingDays>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member_MP4cDjTkq06lAGevzdzYBw"
      decimals="INF"
      id="Narr_261ikMJJ2US31PgpDvO8sg"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">1000</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <incy:DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_DebtInstrumentAxis_incy_ConvertibleSeniorNotes0.375PercentDue2018AndConvertibleSeniorNotes1.25PercentDue2020Member_MP4cDjTkq06lAGevzdzYBw"
      decimals="2"
      id="Narr_SNZrATuSmUCTfpuzRctsYA"
      unitRef="Unit_Standard_pure_G2Y8j23Qxk2YfvyCma9_SQ">0.98</incy:DebtInstrumentConversionObligationTradingPriceAsPercentageOfProductOfLastReportedCommonStockSalePriceAndConversionRateMaximum>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_8P6vUBk8tkm4_t76K1Cacg">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;13. &#160;&#160;&#160;&#160;Employee benefit plans&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Defined Contribution Plans&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We have a defined contribution plan qualified under Section&#160;401(k) of the Internal Revenue Code covering all U.S. employees and defined contribution plans for other Incyte employees in Europe and Japan. &#160;Employees may contribute a portion of their compensation, which is then matched by us, subject to certain limitations. Defined contribution expense for the three months ended March 31, 2020 and 2019 was $3.3&#160;million and $2.9&#160;million, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Defined Benefit Pension Plans&lt;/i&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We have defined benefit pension plans for our employees in Europe which provide benefits to employees upon retirement, death or disability. The assets of the pension plans are held in collective investment accounts represented by the cash surrender value of an insurance policy and are classified as Level 2 within the fair value hierarchy.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The net periodic benefit cost was as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:36.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:36.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:17.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:17.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Service cost&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,457&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,263&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Interest cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 84&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Expected return on plan assets&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (30)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (60)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Amortization of prior service cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 54&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 45&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Amortization of actuarial losses&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 167&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 66&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Net periodic benefit cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,694&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,398&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The components of net periodic benefit cost other than the service cost component are included in other income (expense), net on the condensed consolidated statements of operations. We expect to contribute a total of $4.0 million to the pension plans in 2020 inclusive of the amounts contributed to the plan during the current period. As of March 31, 2020 and December 31, 2019, $24.6 million and $24.1 million, respectively, of accrued pension obligation is recorded in other long term liabilities on the condensed consolidated balance sheets.&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-5"
      id="Narr_goz4G73YA0mSZM8vcIv35w"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">3300000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-5"
      id="Narr_MCoDlmPyFE6HcBUsLbM2pQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">2900000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_8KC3_fQUikSCF85VwYTsxg">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The net periodic benefit cost was as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:36.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:36.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:17.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:17.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Service cost&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,457&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,263&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Interest cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 84&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Expected return on plan assets&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (30)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (60)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Amortization of prior service cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 54&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 45&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Amortization of actuarial losses&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 167&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 66&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Net periodic benefit cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,694&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,398&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_2ihCKS1trkWbsnFCIyJR0g_4_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1457000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_n7CORHVfyEmdxCWpsXtsYA_4_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1263000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_pgdqvRXkSkm2t9n7Jso4hg_5_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">46000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_4T0STSRslEOu55rEjTTbVg_5_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">84000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_oo8ULpsvpUSQ5NDY270n-A_6_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">30000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_3BuKBkri1Ua3R10svglmPg_6_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">60000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_Zv4SSz8Y7UiWvLVsXryeKg_7_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">54000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_DkX92oFHiUOcTfj-iVFsMw_7_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">45000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_wocyLkYy3EimIsTGnSTZFQ_8_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-167000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_vyseC3wuNkCl1P6sYMR1Sg_8_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-66000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_IYF5AmjpM0aOhu1ljN1p-Q_9_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1694000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_6wXqQwCGuUinNMx3Nybx5Q_9_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1398000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-5"
      id="Narr_mb7ewkLXrkWfnY6J4O8pDw"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">4000000.0</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear>
    <us-gaap:DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities
      contextRef="As_Of_3_31_2020_vKc3Rr4kJUyPOeM_AuvTWg"
      decimals="-5"
      id="Narr_EaVI9KL0nUWfVTE5IEDwDw"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">24600000</us-gaap:DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities>
    <us-gaap:DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities
      contextRef="As_Of_12_31_2019_K2jkXRjF1Uqh4HooMj8BGQ"
      decimals="-5"
      id="Narr_DNL0DrwlM0271UnWBEipQA"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">24100000</us-gaap:DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_fWRSZPbDeE-N9HnvAoM_BA">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;14. &#160;&#160;&#160;&#160;Income taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For the three months ended March 31, 2020 and 2019, we recorded income tax expense of approximately $16.6 million and $1.8 million, respectively. The change in tax expense for the three months ended March 31, 2020 was primarily driven by increased federal and state tax liabilities that are not fully sheltered by net operating losses or research and development tax credit carryforwards. The increase was also driven by reduced tax benefits for stock-based compensation in the current period. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of March 31, 2020, a full valuation allowance continues to be recorded against our U.S. and Swiss net deferred tax assets. Based upon our analysis of our historical operating results, as well as projections of our future taxable income (losses) during the periods in which the temporary differences will be recoverable, we believe the uncertainty regarding the realization of our U.S. and Swiss net deferred tax assets requires a full valuation allowance against such net assets as of March 31, 2020. When performing our assessment on projections of future taxable income (losses), we consider factors such as the likelihood of regulatory approval and commercial success of products currently under development, among other factors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The balance of our unrecognized tax benefits (including penalties and interest) increased by approximately $0.1 million during the three months ended March 31, 2020.  The overall net increase is primarily driven by unrecognized tax benefits related to current year operations and research and development tax credits offset by audit settlements in Wisconsin and Italy. After considering valuation allowance impacts, the change in unrecognized tax benefits resulted in a $0.2 million decrease to noncurrent other liabilities on the condensed consolidated balance sheet. &#160; &lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-5"
      id="Narr_qZTr6wUZqEqsB5H7GyF4Ew"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">16600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-5"
      id="Narr_ksJ1jfl7NEGpy_cI1LZZ6w"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">1800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-5"
      id="Narr_ukMTgnb4g0KGzXPzMQUCJQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">100000</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-5"
      id="Narr_uHeoLA2HMkO8ZIlEGV4pNQ"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-200000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_yln78x7XFUq9VsxsGHiJJA">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;15.&#160;&#160;&#160;&#160;Net income (loss) per share&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Net income (loss) per share was calculated as follows for the periods indicated below:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="font-size:8pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="font-size:8pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:76.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands, except per share data)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;Basic Net Income (Loss) Per Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Basic net income (loss) per share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (720,642)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 102,312&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Weighted average common shares outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 216,721&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 214,065&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Basic net income (loss) per share&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (3.33)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.48&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;Diluted Net Income (Loss) Per Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Diluted net income (loss)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (720,642)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 102,312&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Weighted average common shares outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 216,721&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 214,065&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Dilutive stock options and awards&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,996&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Weighted average shares used to compute diluted net income (loss) per share &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 216,721&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 217,061&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;"&gt;Diluted net income (loss) per share&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (3.33)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.47&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The potential common shares that were excluded from the diluted net income (loss) per share computation are as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:33.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:33.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:15.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Outstanding stock options and awards&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,544,348&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,318,013&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Common shares issuable upon conversion of the 2020 Notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 368,939&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 368,939&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Total potential common shares excluded from diluted net income (loss) per share computation&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,913,287&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,686,952&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_r7zNUJmfEEG81uZQWrxlpw">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Net income (loss) per share was calculated as follows for the periods indicated below:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="font-size:8pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="font-size:8pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:76.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands, except per share data)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;Basic Net Income (Loss) Per Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Basic net income (loss) per share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (720,642)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 102,312&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Weighted average common shares outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 216,721&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 214,065&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Basic net income (loss) per share&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (3.33)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.48&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"&gt;Diluted Net Income (Loss) Per Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Diluted net income (loss)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (720,642)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 102,312&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Weighted average common shares outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 216,721&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 214,065&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Dilutive stock options and awards&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,996&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Weighted average shares used to compute diluted net income (loss) per share &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 216,721&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 217,061&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;"&gt;Diluted net income (loss) per share&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"&gt; (3.33)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.47&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_J3PqYvR9iEKYqhHFkuyokA_5_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-720642000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_RbyKipYgEkmYrXar5q9Fxw_5_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">102312000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_OXO9O7y4Z0GvY5Hrfc91Ig_6_3"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">216721000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_nq-we1EA60au4KZtgPOubQ_6_6"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">214065000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="2"
      id="Tc_E7MRbwR9fkKCAg_WgVypqQ_8_3"
      unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A">-3.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="2"
      id="Tc_VEwmLyg-skaKCPyykxHb7A_8_6"
      unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A">0.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_oq4OXnGatkGNmCY7QwUt_Q_11_3"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">-720642000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_H43W3hFOnECKDG1fJHUpHQ_11_6"
      unitRef="Unit_Standard_USD_9OLv9mEIhkemugEzC5R2PQ">102312000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc_23muPSIWmEC9Pcf1FzxOlw_12_3"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">216721000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_-e5LULyws0OyZnYGZ8SvfA_12_6"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">214065000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_8TtylQuRpUeZ7ROGFQgUpQ_14_6"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">2996000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="-3"
      id="Tc__1WUm7TLjEOUM4rFowNuvg_16_3"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">216721000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="-3"
      id="Tc_azIHegAOrkWtNkzYB1svqg_16_6"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">217061000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="2"
      id="Tc_NDL-VYcl6U--nRBZe8P1UA_18_3"
      unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A">-3.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="2"
      id="Tc_FfZRVKv09E6L8LwPToXidQ_18_6"
      unitRef="Unit_Divide_USD_shares_7FYiUP1buk-QFTkTT0m98A">0.47</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_xbq9chBYCkWIzBCRq2A_kQ">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The potential common shares that were excluded from the diluted net income (loss) per share computation are as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:33.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:33.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:15.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Outstanding stock options and awards&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,544,348&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,318,013&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Common shares issuable upon conversion of the 2020 Notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 368,939&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 368,939&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;Total potential common shares excluded from diluted net income (loss) per share computation&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,913,287&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,686,952&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_ZCt4v5dz-02T3ZuSiZnehQ"
      decimals="INF"
      id="Tc_1Vqv25wRuUmjwQjbKJLOzQ_4_2"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">15544348</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_3H_O8pHEdkix4PC8ZgQ7Mg"
      decimals="INF"
      id="Tc_XnUNunVR30m9HKYLYNPUWw_4_4"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">9318013</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_HcQZwZd8o0Wvrjt6JjzvDA"
      decimals="INF"
      id="Tc_soSQCPaiCUmUOZRa920_5w_5_2"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">368939</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_incy_ConvertibleSeniorNotes1.25PercentDue2020Member_2eLdjmLNS0eVWk19LxgYkw"
      decimals="INF"
      id="Tc_TAH0XXlnkE66yirHleQ87g_5_4"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">368939</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      decimals="INF"
      id="Tc_XYIQrPAM70CNVzfBWFx_Pg_6_2"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">15913287</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2019_To_3_31_2019_-O1dxmN1aEifpygNWtAoLA"
      decimals="INF"
      id="Tc__ZGSvCw-k0KnkMSGkLZ6Eg_6_4"
      unitRef="Unit_Standard_shares_ZvmLd8iZnEC69huJ4EosIA">9686952</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_1kDO8w2B3UezXv-oRT-9Ng">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;16.&#160;&#160;&#160;&#160;Contingencies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 0pt 0pt;"&gt;In December 2018, we received a civil investigative demand from the U.S. Department of Justice (&#x201c;DOJ&#x201d;) for documents and information relating to our speaker programs and patient assistance programs, including our support of non-profit organizations that provide financial assistance to eligible patients. We have cooperated with this inquiry.&#160; In November 2019, the &lt;i style="font-style:italic;"&gt;qui tam&lt;/i&gt; complaint underlying the DOJ inquiry was unsealed (&#x201c;Complaint&#x201d;), at which time we learned that a former employee whom we had terminated had made certain allegations relating to the programs described above. &#160;We then became aware that the DOJ had not intervened in the &lt;i style="font-style:italic;"&gt;qui tam&lt;/i&gt; action, and, to our knowledge, the DOJ has not intervened to date. &#160;We filed an answer to the Complaint on January 22, 2020, and the action is proceeding. &#160;We cannot predict the outcome or the timing of the ultimate resolution of the investigation or &lt;i style="font-style:italic;"&gt;qui tam&lt;/i&gt; action, or reasonably estimate the possible range of loss, if any, that may result from these matters. &#160;Accordingly, no reserve has been made with respect to these matters as of March 31, 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 0pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2020_To_3_31_2020_liGz2018hUaFMVhy3aY39A"
      id="Tb_ZQaTrq-W_kmEPR2rZj-0jw">&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;17.&#160;&#160;&#160;&#160;Subsequent event&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In April 2020, the FDA approved PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement as detected by an FDA-approved test. PEMAZYRE is the first and only FDA-approved treatment for this indication, which was approved under accelerated approval based on overall response rate and duration of response. We have retained all rights to PEMAZYRE globally, other than those granted to Innovent Biologics, Inc. to develop and commercialize pemigatinib in hematology and oncology in mainland China, Hong Kong, Macau and Taiwan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Tc_a5ohNrB_5EyyFWGwZ6Bp_Q_24_6"
          xlink:label="Tc_a5ohNrB_5EyyFWGwZ6Bp_Q_24_6"
          xlink:type="locator"/>
        <link:footnote id="_c9570017_4a29_4e55_9a03_0f1ff68137e8" xlink:label="_c9570017_4a29_4e55_9a03_0f1ff68137e8" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size:9pt;">The condensed consolidated balance sheet at December 31, 2019 has been derived from the audited consolidated financial statements at that date.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_a5ohNrB_5EyyFWGwZ6Bp_Q_24_6"
          xlink:to="_c9570017_4a29_4e55_9a03_0f1ff68137e8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc__Q4cAi7CLEqE685HxQZrBA_7_6"
          xlink:label="Tc__Q4cAi7CLEqE685HxQZrBA_7_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc__Q4cAi7CLEqE685HxQZrBA_7_6"
          xlink:to="_c9570017_4a29_4e55_9a03_0f1ff68137e8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_zdRH3cfB0EmnrBFFKDc9dg_27_6"
          xlink:label="Tc_zdRH3cfB0EmnrBFFKDc9dg_27_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_zdRH3cfB0EmnrBFFKDc9dg_27_6"
          xlink:to="_c9570017_4a29_4e55_9a03_0f1ff68137e8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_PlsYpJAIuE6KJU9P-Jf3Yw_42_6"
          xlink:label="Tc_PlsYpJAIuE6KJU9P-Jf3Yw_42_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_PlsYpJAIuE6KJU9P-Jf3Yw_42_6"
          xlink:to="_c9570017_4a29_4e55_9a03_0f1ff68137e8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_c8L6yPRPEUC8H_B5VSapDQ_41_6"
          xlink:label="Tc_c8L6yPRPEUC8H_B5VSapDQ_41_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_c8L6yPRPEUC8H_B5VSapDQ_41_6"
          xlink:to="_c9570017_4a29_4e55_9a03_0f1ff68137e8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_BUeeFiw5Ckut-I6C_gVPRQ_20_6"
          xlink:label="Tc_BUeeFiw5Ckut-I6C_gVPRQ_20_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_BUeeFiw5Ckut-I6C_gVPRQ_20_6"
          xlink:to="_c9570017_4a29_4e55_9a03_0f1ff68137e8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc__MmdO33ZVUeSQzItX2z2Jg_10_6"
          xlink:label="Tc__MmdO33ZVUeSQzItX2z2Jg_10_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc__MmdO33ZVUeSQzItX2z2Jg_10_6"
          xlink:to="_c9570017_4a29_4e55_9a03_0f1ff68137e8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_Fu1im2pBBUiJ7wkCrYnA3A_6_6"
          xlink:label="Tc_Fu1im2pBBUiJ7wkCrYnA3A_6_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_Fu1im2pBBUiJ7wkCrYnA3A_6_6"
          xlink:to="_c9570017_4a29_4e55_9a03_0f1ff68137e8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_DLg7M2GV3E-urgYITOjCRg_30_6"
          xlink:label="Tc_DLg7M2GV3E-urgYITOjCRg_30_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_DLg7M2GV3E-urgYITOjCRg_30_6"
          xlink:to="_c9570017_4a29_4e55_9a03_0f1ff68137e8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_wUmYM7gVikiUMMpr1iCtvQ_33_6"
          xlink:label="Tc_wUmYM7gVikiUMMpr1iCtvQ_33_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_wUmYM7gVikiUMMpr1iCtvQ_33_6"
          xlink:to="_c9570017_4a29_4e55_9a03_0f1ff68137e8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_1R6JqLKHeUKe5p6pBSqHQw_5_6"
          xlink:label="Tc_1R6JqLKHeUKe5p6pBSqHQw_5_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_1R6JqLKHeUKe5p6pBSqHQw_5_6"
          xlink:to="_c9570017_4a29_4e55_9a03_0f1ff68137e8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_XhCxSyAePU2EM_yM-GM1VA_40_6"
          xlink:label="Tc_XhCxSyAePU2EM_yM-GM1VA_40_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_XhCxSyAePU2EM_yM-GM1VA_40_6"
          xlink:to="_c9570017_4a29_4e55_9a03_0f1ff68137e8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_XUvA6ZO9nUaVao0bSM54wA_29_6"
          xlink:label="Tc_XUvA6ZO9nUaVao0bSM54wA_29_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_XUvA6ZO9nUaVao0bSM54wA_29_6"
          xlink:to="_c9570017_4a29_4e55_9a03_0f1ff68137e8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_iiNzPQ3oRkGjQm8ezmHxFw_25_6"
          xlink:label="Tc_iiNzPQ3oRkGjQm8ezmHxFw_25_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_iiNzPQ3oRkGjQm8ezmHxFw_25_6"
          xlink:to="_c9570017_4a29_4e55_9a03_0f1ff68137e8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_Ub3Aii55Skqo4R4y6lscqg_28_6"
          xlink:label="Tc_Ub3Aii55Skqo4R4y6lscqg_28_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_Ub3Aii55Skqo4R4y6lscqg_28_6"
          xlink:to="_c9570017_4a29_4e55_9a03_0f1ff68137e8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_gAYiIHyfn0e7WfvlHupmLg_34_6"
          xlink:label="Tc_gAYiIHyfn0e7WfvlHupmLg_34_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_gAYiIHyfn0e7WfvlHupmLg_34_6"
          xlink:to="_c9570017_4a29_4e55_9a03_0f1ff68137e8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_MA46kpgz80e5rQC71pZaow_16_6"
          xlink:label="Tc_MA46kpgz80e5rQC71pZaow_16_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_MA46kpgz80e5rQC71pZaow_16_6"
          xlink:to="_c9570017_4a29_4e55_9a03_0f1ff68137e8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_UKZZluQUzkylaZpeYQ7Ubg_18_6"
          xlink:label="Tc_UKZZluQUzkylaZpeYQ7Ubg_18_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_UKZZluQUzkylaZpeYQ7Ubg_18_6"
          xlink:to="_c9570017_4a29_4e55_9a03_0f1ff68137e8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_d7F91iwAoUOZJlHXIhwhvA_26_6"
          xlink:label="Tc_d7F91iwAoUOZJlHXIhwhvA_26_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_d7F91iwAoUOZJlHXIhwhvA_26_6"
          xlink:to="_c9570017_4a29_4e55_9a03_0f1ff68137e8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_XhrcmoFpvUStqrhrIbji6A_8_6"
          xlink:label="Tc_XhrcmoFpvUStqrhrIbji6A_8_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_XhrcmoFpvUStqrhrIbji6A_8_6"
          xlink:to="_c9570017_4a29_4e55_9a03_0f1ff68137e8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_tegNf856j0G9fqa17Rp90Q_14_6"
          xlink:label="Tc_tegNf856j0G9fqa17Rp90Q_14_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_tegNf856j0G9fqa17Rp90Q_14_6"
          xlink:to="_c9570017_4a29_4e55_9a03_0f1ff68137e8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_YrbwcyBevUmVYnmfBmOVBA_36_6"
          xlink:label="Tc_YrbwcyBevUmVYnmfBmOVBA_36_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_YrbwcyBevUmVYnmfBmOVBA_36_6"
          xlink:to="_c9570017_4a29_4e55_9a03_0f1ff68137e8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_pGJuowBCK02IV8uC5OqDug_45_6"
          xlink:label="Tc_pGJuowBCK02IV8uC5OqDug_45_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_pGJuowBCK02IV8uC5OqDug_45_6"
          xlink:to="_c9570017_4a29_4e55_9a03_0f1ff68137e8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_AcvH1yHODkm7W7kMpvCnWA_31_6"
          xlink:label="Tc_AcvH1yHODkm7W7kMpvCnWA_31_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_AcvH1yHODkm7W7kMpvCnWA_31_6"
          xlink:to="_c9570017_4a29_4e55_9a03_0f1ff68137e8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_ntl_TJoRok2kvgilDz5AQQ_13_6"
          xlink:label="Tc_ntl_TJoRok2kvgilDz5AQQ_13_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_ntl_TJoRok2kvgilDz5AQQ_13_6"
          xlink:to="_c9570017_4a29_4e55_9a03_0f1ff68137e8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_ln4GC3egGUipgSru4CVulQ_19_6"
          xlink:label="Tc_ln4GC3egGUipgSru4CVulQ_19_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_ln4GC3egGUipgSru4CVulQ_19_6"
          xlink:to="_c9570017_4a29_4e55_9a03_0f1ff68137e8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_gv7DZ6WyZEymq5cyVQQwbA_17_6"
          xlink:label="Tc_gv7DZ6WyZEymq5cyVQQwbA_17_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_gv7DZ6WyZEymq5cyVQQwbA_17_6"
          xlink:to="_c9570017_4a29_4e55_9a03_0f1ff68137e8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_9NYaJZa-M0C39_pKeh_zIA_35_6"
          xlink:label="Tc_9NYaJZa-M0C39_pKeh_zIA_35_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_9NYaJZa-M0C39_pKeh_zIA_35_6"
          xlink:to="_c9570017_4a29_4e55_9a03_0f1ff68137e8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Hidden_00WskpThfUe7BGq8TEau6Q"
          xlink:label="Hidden_00WskpThfUe7BGq8TEau6Q"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Hidden_00WskpThfUe7BGq8TEau6Q"
          xlink:to="_c9570017_4a29_4e55_9a03_0f1ff68137e8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_gwKKyn1Wr0WkIPsoFWzsyg_9_6"
          xlink:label="Tc_gwKKyn1Wr0WkIPsoFWzsyg_9_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_gwKKyn1Wr0WkIPsoFWzsyg_9_6"
          xlink:to="_c9570017_4a29_4e55_9a03_0f1ff68137e8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_02jLG0GJmU2xrTW1J5qO1g_15_6"
          xlink:label="Tc_02jLG0GJmU2xrTW1J5qO1g_15_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_02jLG0GJmU2xrTW1J5qO1g_15_6"
          xlink:to="_c9570017_4a29_4e55_9a03_0f1ff68137e8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_vcYuBQQlAE631jPaw96jNg_12_6"
          xlink:label="Tc_vcYuBQQlAE631jPaw96jNg_12_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_vcYuBQQlAE631jPaw96jNg_12_6"
          xlink:to="_c9570017_4a29_4e55_9a03_0f1ff68137e8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_ljSkJ9leEUupHlFP7dQgdA_43_6"
          xlink:label="Tc_ljSkJ9leEUupHlFP7dQgdA_43_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_ljSkJ9leEUupHlFP7dQgdA_43_6"
          xlink:to="_c9570017_4a29_4e55_9a03_0f1ff68137e8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_OF2q213bxkis1OQGk_1quw_44_6"
          xlink:label="Tc_OF2q213bxkis1OQGk_1quw_44_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_OF2q213bxkis1OQGk_1quw_44_6"
          xlink:to="_c9570017_4a29_4e55_9a03_0f1ff68137e8"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6800073472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock compensation - RSU and PSU (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Jul. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jul. 31, 2016</div></th>
<th class="th"><div>Jan. 31, 2014</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Compensation Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42.5<span></span>
</td>
<td class="nump">$ 40.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Compensation Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Compensation Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits', window );">Number of shares awarded for each RSU (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of units vesting at the end of each calendar year (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">379,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Stock Units (PSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Compensation Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageMultiplierForConversionOfUnitsIntoCommonStock', window );">Multiplier conversion rate of units into common stock (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,243<span></span>
</td>
<td class="nump">446,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor', window );">Multiplying factor</a></td>
<td class="nump">101.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Stock Units (PSUs) | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Compensation Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Stock Units (PSUs) | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Compensation Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor', window );">Multiplying factor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Stock Units (PSUs) | Long term incentive plan - 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Compensation Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor', window );">Multiplying factor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Stock Units (PSUs) | Long term incentive plan - 1 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Compensation Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor', window );">Multiplying factor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">267.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Stock Units (PSUs) | Long term incentive plan - 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Compensation Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor', window );">Multiplying factor</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Stock Units (PSUs) | Long term incentive plan - 2 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Compensation Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor', window );">Multiplying factor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Stock Units (PSUs) | Long term incentive plan - 2 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Compensation Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor', window );">Multiplying factor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, equity instruments other than options, conversion multiplying factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConversionMultiplyingFactor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares awarded for each restricted share units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPerRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageMultiplierForConversionOfUnitsIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the multiplier expressed as a percentage used for conversion of PSU into actual number of shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageMultiplierForConversionOfUnitsIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=incy_LongTermIncentivePlanOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=incy_LongTermIncentivePlanOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=incy_LongTermIncentivePlanTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=incy_LongTermIncentivePlanTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>325</ContextCount>
  <ElementCount>439</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>99</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00405 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00500 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00505 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Organization and business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureOrganizationAndBusiness</Role>
      <ShortName>Organization and business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Summary of significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureRevenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Fair value of financial instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureFairValueOfFinancialInstruments</Role>
      <ShortName>Fair value of financial instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Concentration of credit risk and current expected credit losses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLosses</Role>
      <ShortName>Concentration of credit risk and current expected credit losses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureInventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Property and equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Intangible assets and goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwill</Role>
      <ShortName>Intangible assets and goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>10901 - Disclosure - License agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureLicenseAgreements</Role>
      <ShortName>License agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Stock compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureStockCompensation</Role>
      <ShortName>Stock compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Accrued and other current liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureAccruedAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued and other current liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureDebt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Employee benefit plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureEmployeeBenefitPlans</Role>
      <ShortName>Employee benefit plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>11401 - Disclosure - Income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>11501 - Disclosure - Net income (loss) per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureNetIncomeLossPerShare</Role>
      <ShortName>Net income (loss) per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>11601 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureContingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>11701 - Disclosure - Subsequent event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureSubsequentEvent</Role>
      <ShortName>Subsequent event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Summary of significant accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of significant accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureRevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.incyte.com/role/DisclosureRevenues</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Fair value of financial instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsTables</Role>
      <ShortName>Fair value of financial instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.incyte.com/role/DisclosureFairValueOfFinancialInstruments</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Concentration of credit risk and current expected credit losses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLossesTables</Role>
      <ShortName>Concentration of credit risk and current expected credit losses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLosses</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureInventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.incyte.com/role/DisclosureInventory</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Property and equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.incyte.com/role/DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Intangible assets and goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwillTables</Role>
      <ShortName>Intangible assets and goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwill</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>31003 - Disclosure - Stock compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureStockCompensationTables</Role>
      <ShortName>Stock compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.incyte.com/role/DisclosureStockCompensation</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>31103 - Disclosure - Accrued and other current liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued and other current liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.incyte.com/role/DisclosureAccruedAndOtherCurrentLiabilities</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>31203 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureDebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.incyte.com/role/DisclosureDebt</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>31303 - Disclosure - Employee benefit plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureEmployeeBenefitPlansTables</Role>
      <ShortName>Employee benefit plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.incyte.com/role/DisclosureEmployeeBenefitPlans</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>31503 - Disclosure - Net income (loss) per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureNetIncomeLossPerShareTables</Role>
      <ShortName>Net income (loss) per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.incyte.com/role/DisclosureNetIncomeLossPerShare</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Organization and business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureOrganizationAndBusinessDetails</Role>
      <ShortName>Organization and business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.incyte.com/role/DisclosureOrganizationAndBusiness</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Summary of significant accounting policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of significant accounting policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40202 - Disclosure - Summary of significant accounting policies - Revenue Recognition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails</Role>
      <ShortName>Summary of significant accounting policies - Revenue Recognition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40203 - Disclosure - Summary of significant accounting policies - Recent Accounting Pronouncements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails</Role>
      <ShortName>Summary of significant accounting policies - Recent Accounting Pronouncements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureRevenuesDetails</Role>
      <ShortName>Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.incyte.com/role/DisclosureRevenuesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Fair value of financial instruments - Fair value on a recurring basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair value of financial instruments - Fair value on a recurring basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40402 - Disclosure - Fair value of financial instruments - Marketable securities portfolio (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureFairValueOfFinancialInstrumentsMarketableSecuritiesPortfolioDetails</Role>
      <ShortName>Fair value of financial instruments - Marketable securities portfolio (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Concentration of credit risk and current expected credit losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLossesDetails</Role>
      <ShortName>Concentration of credit risk and current expected credit losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.incyte.com/role/DisclosureConcentrationOfCreditRiskAndCurrentExpectedCreditLossesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureInventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.incyte.com/role/DisclosureInventoryTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Property and equipment, net - Property and equipment, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and equipment, net - Property and equipment, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40702 - Disclosure - Property and equipment, net - Buildings and construction (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetBuildingsAndConstructionDetails</Role>
      <ShortName>Property and equipment, net - Buildings and construction (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>40703 - Disclosure - Property and equipment, net - Lease and maturity of lease liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosurePropertyAndEquipmentNetLeaseAndMaturityOfLeaseLiabilitiesDetails</Role>
      <ShortName>Property and equipment, net - Lease and maturity of lease liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Intangible assets and goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwillDetails</Role>
      <ShortName>Intangible assets and goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.incyte.com/role/DisclosureIntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>40901 - Disclosure - License agreements - Novartis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureLicenseAgreementsNovartisDetails</Role>
      <ShortName>License agreements - Novartis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>40902 - Disclosure - License agreements - Lilly (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureLicenseAgreementsLillyDetails</Role>
      <ShortName>License agreements - Lilly (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>40903 - Disclosure - License agreements - Agenus (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureLicenseAgreementsAgenusDetails</Role>
      <ShortName>License agreements - Agenus (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>40904 - Disclosure - License agreements - Merus (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureLicenseAgreementsMerusDetails</Role>
      <ShortName>License agreements - Merus (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>40905 - Disclosure - License agreements - Calithera (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureLicenseAgreementsCalitheraDetails</Role>
      <ShortName>License agreements - Calithera (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>40906 - Disclosure - License agreements - MacroGenics (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureLicenseAgreementsMacrogenicsDetails</Role>
      <ShortName>License agreements - MacroGenics (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>40907 - Disclosure - License agreements - Syros (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureLicenseAgreementsSyrosDetails</Role>
      <ShortName>License agreements - Syros (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>40908 - Disclosure - License agreements - Innovent (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureLicenseAgreementsInnoventDetails</Role>
      <ShortName>License agreements - Innovent (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>40909 - Disclosure - License agreements - Zai Lab (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureLicenseAgreementsZaiLabDetails</Role>
      <ShortName>License agreements - Zai Lab (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>40910 - Disclosure - License agreements - MorphoSys (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureLicenseAgreementsMorphosysDetails</Role>
      <ShortName>License agreements - MorphoSys (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Stock compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureStockCompensationDetails</Role>
      <ShortName>Stock compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.incyte.com/role/DisclosureStockCompensationTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>41002 - Disclosure - Stock compensation - Option activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureStockCompensationOptionActivityDetails</Role>
      <ShortName>Stock compensation - Option activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>41003 - Disclosure - Stock compensation - RSU and PSU award activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuAwardActivityDetails</Role>
      <ShortName>Stock compensation - RSU and PSU award activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>41004 - Disclosure - Stock compensation - RSU and PSU (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureStockCompensationRsuAndPsuDetails</Role>
      <ShortName>Stock compensation - RSU and PSU (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>41005 - Disclosure - Stock compensation - Shares available for grant (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureStockCompensationSharesAvailableForGrantDetails</Role>
      <ShortName>Stock compensation - Shares available for grant (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Accrued and other current liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued and other current liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.incyte.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Debt - Components of convertible notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.incyte.com/role/DisclosureDebtComponentsOfConvertibleNotesDetails</Role>
      <ShortName>Debt - Components of convertible notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>41202 - Disclosure - Debt - Carrying amount and Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureDebtCarryingAmountAndFairValueDetails</Role>
      <ShortName>Debt - Carrying amount and Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>41203 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureDebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>41301 - Disclosure - Employee benefit plans - Defined Contribution Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureEmployeeBenefitPlansDefinedContributionPlanDetails</Role>
      <ShortName>Employee benefit plans - Defined Contribution Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>41302 - Disclosure - Employee benefit plans - Periodic Benefit Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureEmployeeBenefitPlansPeriodicBenefitCostDetails</Role>
      <ShortName>Employee benefit plans - Periodic Benefit Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>41401 - Disclosure - Income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureIncomeTaxesDetails</Role>
      <ShortName>Income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.incyte.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="incy-20200505x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>41501 - Disclosure - Net income (loss) per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/DisclosureNetIncomeLossPerShareDetails</Role>
      <ShortName>Net income (loss) per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.incyte.com/role/DisclosureNetIncomeLossPerShareTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="incy-20200505x10q.htm">incy-20200505x10q.htm</File>
    <File>incy-20200331xex10d1.htm</File>
    <File>incy-20200331xex10d2.htm</File>
    <File>incy-20200331xex31d1.htm</File>
    <File>incy-20200331xex31d2.htm</File>
    <File>incy-20200331xex32d1.htm</File>
    <File>incy-20200331xex32d2.htm</File>
    <File>incy-20200505.xsd</File>
    <File>incy-20200505_cal.xml</File>
    <File>incy-20200505_def.xml</File>
    <File>incy-20200505_lab.xml</File>
    <File>incy-20200505_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791549376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentration of credit risk and current expected credit losses (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=incy_SalesRevenueGoodsServicesNetMember', window );">Net Product Revenues | Customer Concentration Risk | Customer A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of concentration risk</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=incy_SalesRevenueGoodsServicesNetMember', window );">Net Product Revenues | Customer Concentration Risk | Customer B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of concentration risk</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=incy_SalesRevenueGoodsServicesNetMember', window );">Net Product Revenues | Customer Concentration Risk | Customer C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of concentration risk</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=incy_SalesRevenueGoodsServicesNetMember', window );">Net Product Revenues | Customer Concentration Risk | Customer D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of concentration risk</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Credit Concentration Risk | Collaboration Partner A, B, C and D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of concentration risk</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Credit Concentration Risk | Customer A, B, C and D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of concentration risk</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=incy_SalesRevenueGoodsServicesNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=incy_SalesRevenueGoodsServicesNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=incy_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=incy_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=incy_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=incy_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=incy_CustomerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=incy_CustomerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=incy_CustomerDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=incy_CustomerDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=incy_CollaborationPartneraBAndCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=incy_CollaborationPartneraBAndCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=incy_CustomerABCAndDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=incy_CustomerABCAndDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6781402208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - Recent Accounting Pronouncements (Details)<br> $ in Trillions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract', window );"><strong>Recent Accounting Pronouncements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_CoronavirusAidReliefAndEconomicSecurityActFund', window );">Coronavirus Aid, Relief, and Economic Security (CARES) Act</a></td>
<td class="nump">$ 2.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_CoronavirusAidReliefAndEconomicSecurityActFund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the Coronavirus Aid, Relief, and Economic Security (CARES) Act funding in the US.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_CoronavirusAidReliefAndEconomicSecurityActFund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6786470784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">14. &#160;&#160;&#160;&#160;Income taxes</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the three months ended March 31, 2020 and 2019, we recorded income tax expense of approximately $16.6 million and $1.8 million, respectively. The change in tax expense for the three months ended March 31, 2020 was primarily driven by increased federal and state tax liabilities that are not fully sheltered by net operating losses or research and development tax credit carryforwards. The increase was also driven by reduced tax benefits for stock-based compensation in the current period. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2020, a full valuation allowance continues to be recorded against our U.S. and Swiss net deferred tax assets. Based upon our analysis of our historical operating results, as well as projections of our future taxable income (losses) during the periods in which the temporary differences will be recoverable, we believe the uncertainty regarding the realization of our U.S. and Swiss net deferred tax assets requires a full valuation allowance against such net assets as of March 31, 2020. When performing our assessment on projections of future taxable income (losses), we consider factors such as the likelihood of regulatory approval and commercial success of products currently under development, among other factors.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The balance of our unrecognized tax benefits (including penalties and interest) increased by approximately $0.1 million during the three months ended March 31, 2020.  The overall net increase is primarily driven by unrecognized tax benefits related to current year operations and research and development tax credits offset by audit settlements in Wisconsin and Italy. After considering valuation allowance impacts, the change in unrecognized tax benefits resulted in a $0.2 million decrease to noncurrent other liabilities on the condensed consolidated balance sheet. &#160; </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6799908432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Basis of presentation</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. The condensed consolidated balance sheet as of March 31, 2020, the condensed consolidated statements of operations, comprehensive income (loss), stockholders&#8217; equity, and cash flows for the three months ended March 31, 2020 and 2019, are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which we consider necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. &#160;The condensed consolidated balance sheet at December 31, 2019 has been derived from our audited consolidated financial statements.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although we believe that the disclosures in these financial statements are adequate to make the information presented not misleading, certain information and footnote information normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) have been condensed or omitted pursuant to the rules&#160;and regulations of the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Results for any interim period are not necessarily indicative of results for any future interim period or for the entire year. The accompanying financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form&#160;10-K for the year ended December 31, 2019.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Principles of Consolidation.</i> &#160;The condensed consolidated financial statements include the accounts of Incyte Corporation and our wholly owned subsidiaries. All inter-company accounts, transactions, and profits have been eliminated in consolidation.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Foreign Currency Translation</i>. Operations in non-U.S. entities are recorded in the functional currency of each entity. For financial reporting purposes, the functional currency of an entity is determined by a review of the source of an entity's most predominant cash flows. The results of operations for any non-U.S. dollar functional currency entities are translated from functional currencies into U.S. dollars using the average currency rate during each month. Assets and liabilities are translated using currency rates at the end of the period. Adjustments resulting from translating the financial statements of our foreign entities that use their local currency as the functional currency into U.S. dollars are reflected as a component of other comprehensive income (loss). Transaction gains and losses are recorded in other income (expense), net, in the condensed consolidated statements of operations.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Use of Estimates.</i> &#160;The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Concentrations of Credit Risk.</i> &#160;Cash, cash equivalents, marketable securities, and trade receivables are financial instruments which potentially subject us to concentrations of credit risk. The estimated fair value of financial instruments approximates the carrying value based on available market information. We primarily invest our excess available funds in debt securities and, by policy, limit the amount of credit exposure to any one issuer and to any one type of investment, </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">other than securities issued or guaranteed by the U.S. government and money market funds that meet certain guidelines. Our receivables mainly relate to our product sales of JAKAFI, ICLUSIG and collaborative agreements with pharmaceutical companies. We have not experienced any significant credit losses on cash, cash equivalents, marketable securities, or trade receivables to date and do not require collateral on receivables.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock', window );">Current Expected Credit Losses</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Current Expected Credit Losses. &#160;</i>Effective January 1, 2020, financial assets measured at amortized cost are assessed for future expected credit losses under guidance within ASC 326, Financial Instruments &#8211; Credit Losses, to determine if application of an expected credit losses reserve is necessary. On a quarterly basis, receivables that resulted from revenue transactions within the scope of ASC 606 and recognized on an amortized cost basis are reviewed on a customer-level basis to analyze expectations of future collections based upon past history of collections, payment, aging of receivables and viability of the customer to continue payment, as well as estimates of future economic conditions. Receivables generally consist of two types: receivables from collaborative agreements, including milestones, reimbursements for agreed-upon activities and sales royalties; and receivables from customer product sales. Collaborative agreement receivables are closely monitored relationships with select, reputable industry peers. Collection of receivables is assessed within each collaborative partnership on a quarterly basis, including evaluation of each entity&#8217;s credit quality, financial health and past history of payment. Customer product sales receivables are independently evaluated on a monthly basis, on which unusual items or aged receivables are closely monitored for signs of credit deterioration, or indications of payment refusal. Customer product sales are with specialty pharmaceutical distributors, wholesalers, and certain public and private institutions, some of which whose financial obligations are funded by various government agencies. These receivables are assessed for signs of credit deterioration and in the Company&#8217;s sales history and future expectations of economic conditions, there are minimal instances of bad debts or uncollected receivables. &#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Cash and Cash Equivalents.</i> &#160;Cash and cash equivalents are held in banks or in custodial accounts with banks. Cash equivalents are defined as all liquid investments and money market funds with maturity from date of purchase of 90 days or less that are readily convertible into cash.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities-Available-for-Sale</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Marketable Securities&#8212;Available-for-Sale.</i> &#160;Our marketable securities consist of investments in U.S. government debt securities that are classified as available-for-sale. Available-for-sale securities are carried at fair value, based on quoted market prices and observable inputs, with unrealized gains and losses, net of tax, reported as a separate component of stockholders&#8217; equity. We classify marketable securities that are available for use in current operations as current assets on the condensed consolidated balance sheets. Realized gains and losses and declines in value judged to be other than temporary for available-for-sale securities are included in other income (expense), net on the condensed consolidated statements of operations. &#160;The cost of securities sold is based on the specific identification method.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Accounts Receivable.</i> &#160;As of March 31, 2020 and December 31, 2019, we had a de minimis allowance for doubtful accounts. We provide an allowance for doubtful accounts based on experience and specifically identified risks. Accounts receivable are carried at fair value and charged off against the allowance for doubtful accounts when we determine that recovery is unlikely and we cease collection efforts.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Inventory.</i> &#160;Inventories are determined at the lower of cost and net realizable value with cost determined under the specific identification method and may consist of raw materials, work in process and finished goods. JAKAFI and <span style="-sec-ix-hidden:Hidden_Z0f1rDx3zUCCp3VLdTAwTg"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">ICLUSIG</span></span> raw materials and work-in-process inventory are not subject to expiration and the shelf life of finished goods inventory is 36 months from the start of manufacturing of the finished goods. We evaluate for potential excess inventory by analyzing current and future product demand relative to the remaining product shelf life. We build demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance and patient usage. We classify inventory as current on the condensed consolidated balance sheets when we expect inventory to be consumed for commercial use within the next twelve months.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable Interest Entities</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Variable Interest Entities</i>. We perform an initial and ongoing evaluation of the entities with which we have variable interests, such as equity ownership, in order to<i style="font-style:italic;"> </i>identify entities (i) that do not have sufficient equity investment at risk to permit the entity to finance its activities without additional subordinated financial support or (ii) in which the equity investors lack an essential characteristic of a controlling financial interest as variable interest entities (&#8220;VIE&#8221; or &#8220;VIEs&#8221;). If an entity is identified as a VIE, we perform an assessment to determine whether we have both (i) the power to direct activities that most significantly impact the VIE&#8217;s economic performance and (ii) have the obligation to absorb losses from </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">or the right to receive benefits of the VIE that could potentially be significant to the VIE. If both of these criteria are satisfied, we are identified as the primary beneficiary of the VIE. &#160;As of March 31, 2020, there were no entities in which we held a variable interest which we determined to be VIEs.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LongTermInvestmentPolicyTextBlock', window );">Long Term Investments</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Long Term Investments.</i> Our long term investments consist of equity investments in common stock of publicly-held companies with whom we have entered into collaboration and license agreements. We classify all of our equity investments in common stock of publicly-held companies as long term investments on our condensed consolidated balance sheets. Our equity investments are accounted for at fair value using readily determinable pricing available on a securities exchange on our condensed consolidated balance sheets. All changes in fair value are reported in the condensed consolidated statements of operations as an unrealized gain (loss) on long term investments. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In assessing whether we exercise significant influence over any of the companies in which we hold equity investments, we consider the nature and magnitude of our investment, any voting and protective rights we hold, any participation in the governance of the other company, and other relevant factors such as the presence of a collaboration or other business relationship. Currently, none of our equity investments in publicly-held companies are considered relationships in which we are able to assert control. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Property and Equipment, net.</i> &#160;Property and equipment, net is stated at cost, less accumulated depreciation and amortization. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets. Leasehold improvements are amortized over the shorter of the estimated useful life of the assets or lease term.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Lease Accounting</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Lease Accounting.</i> &#160;Accounting Standard Codification (&#8220;ASC&#8221;) 842, Leases, was adopted for the fiscal year beginning on January 1, 2019. All leases with a lease term greater than 12 months, regardless of lease type classification, are recorded as an obligation on the balance sheet with a corresponding right-of-use asset. Both finance and operating leases are reflected as liabilities on the commencement date of the lease based on the present value of the lease payments to be made over the lease term. Current operating lease liabilities are reflected in accrued and other current liabilities and noncurrent operating lease liabilities are reflected in other liabilities on the condensed consolidated balance sheet. Right-of-use assets are valued at the initial measurement of the lease liability, plus any initial direct costs or rent prepayments, minus lease incentives and any deferred lease payments. Operating lease right-of-use assets are recorded in property and equipment, net on the condensed consolidated balance sheet and lease cost is recognized on a straight-line basis. For finance leases, expense is recognized as separate amortization and interest expense, with higher interest expense in the earlier periods of a lease. Leases with an initial term of 12 months or less are not recorded on the balance sheet and we recognize lease expense for these leases on a straight-line basis over the term of the lease. In determining whether a contract contains a lease, asset and service agreements are assessed at onset and upon modification for criteria of specifically identified assets, control and economic benefit. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Other Intangible Assets, net</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Other Intangible Assets, net.</i> Other intangible assets, net consist of licensed intellectual property rights acquired in business combinations, which are reported at acquisition date fair value, less accumulated amortization. Intangible assets with finite lives are amortized over their estimated useful lives using the straight-line method.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Impairment of Long-Lived Assets.</i> &#160;Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. &#160;If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset. &#160;If the expected cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash flows.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Goodwill.</i> &#160;Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. &#160;Goodwill is not amortized but is tested for impairment at the reporting unit level at least annually as of October 1 or when a triggering event occurs that could indicate a potential impairment by assessing qualitative factors or performing a quantitative analysis in determining whether it is more likely than not that the fair value of net assets are below their carrying amounts. &#160;A reporting unit is the same as, or one level below, an operating segment. Our operations are currently comprised of a single, entity wide reporting </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">unit. We completed our most recent annual impairment assessment as of October 1, 2019 and determined that the carrying value of our goodwill was not impaired. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Income Taxes.</i> &#160;We account for income taxes using the asset and liability approach which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and amounts reportable for income tax purposes. &#160;<span style="background-color:#ffffff;">Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized. </span>The primary factors used to assess the likelihood of realization are our recent history of cumulative earnings or losses, expected reversals of taxable temporary timing differences, forecasts of future taxable income and available tax planning strategies that could be implemented to realize the deferred tax assets. &#160;Upon evaluating and weighting both positive and negative evidence, we concluded that we should continue to maintain the valuation allowance on the majority of our deferred tax assets as of March 31, 2020. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We recognize the tax benefit from an uncertain tax position only if it is more-likely-than-not that the position will be sustained upon examination by the taxing authorities, including resolutions of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit that is recorded for these positions is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. We adjust the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Any interest and penalties on uncertain tax positions are included within the tax provision.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Coronavirus Aid, Relief, and Economic Security (CARES) Act was signed into law in March 2020 to provide an estimated $2.2 trillion designed to stimulate the U.S. economy during the COVID-19 pandemic. &#160;The Act includes tax relief, government loans, grants and investments for entities in affected industries, which has related accounting and financial reporting impacts. &#160;Disclosure for certain income tax accounting measures are required in the period of enactment and disclosure for government loans, investments, grants, and revenue recognition are required in future periods as federal agencies establish rules and procedures to implement the CARES Act. &#160;During the three months ended March 31, 2020, we have not sought any financial relief under the CARES Act and have determined the income tax provision implications to be immaterial. We have further described the expected impact and risks of COVID-19 on our business in the overview to Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations and in Item 1A. Risk Factors.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Financing Costs Related to Long-term Debt</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Financing Costs Related to Long-term Debt.</i> &#160;Costs associated with obtaining long-term debt are deferred and amortized over the term of the related debt using the effective interest method. Such costs are presented as a direct deduction from the carrying amount of the long-term debt liability, consistent with debt discounts, on the condensed consolidated balance sheets.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Income (Loss) Per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Net Income (Loss) Per Share.</i> &#160;Our basic and diluted net income (loss) per share is calculated by dividing the net income (loss) by the weighted average number of shares of common stock outstanding during all periods presented. Options to purchase stock, restricted stock units, performance stock units and shares issuable upon the conversion of convertible debt are included in diluted earnings per share calculations, unless the effects are anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Accumulated Other Comprehensive Income (Loss).</i> &#160;Accumulated other comprehensive income (loss) consists of unrealized gains or losses on marketable securities that are classified as available-for-sale, foreign currency translation gains or losses and defined benefit pension obligations.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Revenue Recognition.</i> &#160;Revenue-generating contracts are assessed under ASC 606, <i style="font-style:italic;">Revenue from contracts with customers</i>, to identify distinct performance obligations, determine the transaction price of the contract and allocate the transaction price to each of the distinct performance obligations. Revenue is recognized when we have satisfied a performance obligation through transferring control of the promised good or service to a customer. Control, in this instance, may mean the ability to prevent other entities from directing the use of, and receiving benefit from, a good or service. We determine at contract inception whether we will transfer control of a promised good or service over time or satisfy the performance obligation at a point in time through analysis of the following criteria: (i) the entity has a present right to payment, (ii) the customer has legal title, (iii) the customer has physical possession, (iv) the customer has the significant </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">risks and rewards of ownership and (v) the customer has accepted the asset. We assess collectability based primarily on the customer&#8217;s payment history and on the creditworthiness of the customer.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration:underline;text-decoration-color:#000000;">Product Revenues</i></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our product revenues consist of U.S. sales of JAKAFI and European sales of ICLUSIG. &#160;Product revenues are recognized once we satisfy the performance obligation at a point in time under the revenue recognition criteria as described above. We sell JAKAFI to our customers in the U.S., which include specialty pharmacies and wholesalers.&#160;We sell ICLUSIG to our customers in the European Union and certain other jurisdictions, which include retail pharmacies, hospital pharmacies and distributors. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We recognize revenues for product received by our customers net of allowances for customer credits, including estimated rebates, chargebacks, discounts, returns, distribution service fees, patient assistance programs, and government rebates, such as Medicare Part D coverage gap reimbursements in the U.S. Product shipping and handling costs are included in cost of product revenues. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Customer Credits:</i> &#160;Our customers are offered various forms of consideration, including allowances, service fees and prompt payment discounts. We expect our customers will earn prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized. Service fees are also deducted from total product sales as they are earned.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Rebates and Discounts:</i> &#160;Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program in the U.S. and mandated discounts in Europe in markets where government-sponsored healthcare systems are the primary payers for healthcare. Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements or legal requirements with public sector benefit providers. The accrual for rebates is based on statutory discount rates and expected utilization as well as historical data we have accumulated since product launches. Our estimates for expected utilization of rebates are based on data received from our customers. Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known prior quarters&#8217; unpaid rebates. If actual future rebates vary from estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Chargebacks: &#160;</i>Chargebacks are discounts that occur when certain contracted customers, which currently consist primarily of group purchasing organizations, Public Health Service institutions, non-profit clinics, and Federal government entities purchasing via the Federal Supply Schedule, purchase directly from our wholesalers. Contracted customers generally purchase the product at a discounted price. The wholesalers, in turn, charges back to us the difference between the price initially paid by the wholesalers and the discounted price paid by the contracted customers. In addition to actual chargebacks received we maintain an accrual for chargebacks based on the estimated contractual discounts on the inventory levels on hand in our distribution channel. &#160;If actual future chargebacks vary from these estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Medicare Part&#160;D Coverage Gap:</i> &#160;Medicare Part&#160;D prescription drug benefit mandates manufacturers to fund 70% of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for the expected Medicare Part&#160;D coverage gap are based on historical invoices received and in part from data received from our customers. Funding of the coverage gap is generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s activity, plus an accrual balance for known prior quarters. If actual future funding varies from estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment. &#160;Additionally, beginning in January 2020, the amount of spending required by eligible patients in the Medicare Part D insurance coverage gap increased 30% due to the expiration of a provision in the Patient Protection and Affordable Care Act, which now results in a change in the True Out of Pocket (TrOOP) calculation methodology. The methodological change has resulted in an increase in required spending by patients and, in turn, an increase in manufacturers&#8217; contributions on behalf of patients in the Medicare Part D insurance coverage gap.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Co-payment Assistance:</i> &#160;Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration:underline;text-decoration-color:#000000;">Product Royalty Revenues</i></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Royalty revenues on commercial sales for ruxolitinib (marketed as JAKAVI<span style="vertical-align:super;">&#174;</span> outside the United States) by Novartis Pharmaceutical International&#160;Ltd. (&#8220;Novartis&#8221;) are based on net sales of licensed products in licensed territories as provided by Novartis. &#160;Royalty revenues on commercial sales for baricitinib (marketed as OLUMIANT) by Eli Lilly and Company (&#8220;Lilly&#8221;) are based on net sales of licensed products in licensed territories as provided by Lilly. We recognize royalty revenues in the period the sales occur.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration:underline;text-decoration-color:#000000;">Milestone and Contract Revenues</i></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our license agreements, which fall within the scope of ASC 606, Revenue from Contracts with Customers, include distinct drug compound out-licensing, collection of upfront payments, milestones or royalty revenues from a counterparty, and provision of commercially available products to suppliers. Our agreements often include contractual milestones, which typically relate to the achievement of pre-specified development, regulatory and commercialization events outside of our control, such as regulatory approval of a compound, first patient dosing or achievement of sales-based thresholds. For such cases, we believe that revenue related to these events should not be recognized until the milestone has been achieved. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Some contracts form collaborative arrangements of various types with third-parties. We assess whether the nature of the arrangement is within the scope of ASC 808, Collaborative Arrangements, in conjunction with the revenue recognition guidance in ASC 606 to determine the nature of the performance obligations and associated transaction prices. A collaborative relationship may exist when we participate in an activity or process with another party, such as performance of research and development services or the exchange of intellectual property for use in clinical trials, when both parties share in the risks and rewards that result from the activity and participate and govern contract activities through a joint steering committee. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The regulatory review and approval process, which includes preclinical testing and clinical trials of each drug candidate, is lengthy, expensive and uncertain. Securing approval by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) requires the submission of extensive preclinical and clinical data and supporting information to the FDA for each indication to establish a drug candidate&#8217;s safety and efficacy. The approval process takes many years, requires the expenditure of substantial resources, involves post-marketing surveillance and may involve ongoing requirements for post-marketing studies. Before commencing clinical investigations of a drug candidate in humans, we must submit an Investigational New Drug application (&#8220;IND&#8221;), which must be reviewed by the FDA.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The steps generally required before a drug may be marketed in the United States include preclinical laboratory tests, animal studies and formulation studies, submission to the FDA of an IND for human clinical testing, performance of adequate and well-controlled clinical trials in three phases, as described below, to establish the safety and efficacy of the drug for each indication, submission of a new drug application (&#8220;NDA&#8221;) or biologics license application (&#8220;BLA&#8221;) to the FDA for review and FDA approval of the NDA or BLA.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Similar requirements exist within foreign regulatory agencies as well. The time required satisfying the FDA requirements or similar requirements of foreign regulatory agencies may vary substantially based on the type, complexity and novelty of the product or the targeted disease.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Preclinical testing includes laboratory evaluation of product pharmacology, drug metabolism, and toxicity, which includes animal studies, to assess potential safety and efficacy as well as product chemistry, stability, formulation, development, and testing. The results of the preclinical tests, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND. The FDA may raise safety concerns or questions about the conduct of the clinical trials included in the IND, and any of these concerns or questions must be resolved before clinical trials can proceed. We cannot be sure that submission of an IND will result in the FDA allowing clinical trials to commence. Clinical </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">trials involve the administration of the investigational drug or the marketed drug to human subjects under the supervision of qualified investigators and in accordance with good clinical practices regulations covering the protection of human subjects. Clinical trials typically are conducted in three sequential phases, but the phases may overlap or be combined. Phase&#160;I usually involves the initial introduction of the investigational drug into healthy volunteers to evaluate its safety, dosage tolerance, absorption, metabolism, distribution and excretion. Phase&#160;II usually involves clinical trials in a limited patient population to evaluate dosage tolerance and optimal dosage, identify possible adverse effects and safety risks, and evaluate and gain preliminary evidence of the efficacy of the drug for specific indications. Phase&#160;III clinical trials usually further evaluate clinical efficacy and safety by testing the drug in its final form in an expanded patient population, providing statistical evidence of efficacy and safety, and providing an adequate basis for labeling. We cannot guarantee that Phase&#160;I, Phase&#160;II or Phase&#160;III testing will be completed successfully within any specified period of time, if at all. Furthermore, we, the institutional review board for a trial, or the FDA may suspend clinical trials at any time on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Generally, the milestone events contained in our collaboration agreements coincide with the progression of our drugs from development, to regulatory approval and then to commercialization. The process of successfully discovering a new development candidate, having it approved and successfully commercialized is highly uncertain. As such, the milestone payments we may earn from our partners involve a significant degree of risk to achieve. Therefore, as a drug candidate progresses through the stages of its life-cycle, the value of the drug candidate generally increases.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration:underline;text-decoration-color:#000000;">Cost of Product Revenues</i></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cost of product revenues includes all JAKAFI related product costs as well as ICLUSIG related product costs. In addition, cost of product revenues include low single-digit royalties under our collaboration and license agreement to Novartis on all future sales of JAKAFI in the United States and the amortization of our licensed intellectual property for ICLUSIG using the straight-line method over the estimated useful life of 12.5 years from the date of acquisition on June 1, 2016 of all of the outstanding shares of ARIAD Pharmaceuticals (Luxembourg) S.&#224;.r.l. (since renamed Incyte Biosciences Luxembourg S.&#224;.r.l.) from ARIAD Pharmaceuticals, Inc. (&#8220;ARIAD&#8221;). Cost of product revenues also includes employee personnel costs, including stock compensation, for those employees dedicated to the production of our commercial products.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Development Costs.</i> &#160;Our policy is to expense research and development costs as incurred, including amounts funded by research and development collaborations. Research and development expenses are comprised of costs we incur in performing research and development activities, including salary and benefits; stock-based compensation expense; outsourced services and other direct expenses, including clinical trial and pharmaceutical development costs; collaboration payments; expenses associated with drug supplies that are not being capitalized; and infrastructure costs, including facilities costs and depreciation expense. If a collaboration is a cost-sharing arrangement in which both we and our collaborator perform development work and share costs, we also recognize, as research and development expense in the period when our collaborator incurs development expenses, our portion of the co-development expenses that we are obligated to reimburse. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We often contract with clinical research organizations (&#8220;CROs&#8221;) to facilitate, coordinate and perform agreed upon research and development of a new drug. To ensure that research and development costs are expensed as incurred, we record monthly accruals for clinical trials and preclinical testing costs based on the work performed under the contract. These CRO contracts typically call for the payment of fees for services at the initiation of the contract and/or upon the achievement of certain clinical trial milestones. In the event that we prepay CRO fees, we record the prepayment as a prepaid asset and amortize the asset into research and development expense over the period of time the contracted research and development services are performed. Most professional fees, including project and clinical management, data management, monitoring, and medical writing fees are incurred throughout the contract period. These professional fees are expensed based on their percentage of completion at a particular date. Our CRO contracts generally include pass through fees. Pass through fees include, but are not limited to, regulatory expenses, investigator fees, travel costs, and other miscellaneous costs, including shipping and printing fees. We expense the costs of pass through fees under our CRO contracts as they are incurred, based on the best information available to us at the time. The estimates of the pass through fees incurred are based on the amount of work completed for the clinical trial and are monitored through correspondence with the CROs, internal reviews and a review of contractual terms. The factors utilized to derive the estimates include the </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">number of patients enrolled, duration of the clinical trial, estimated patient attrition, screening rate and length of the dosing regimen. CRO fees incurred to set up the clinical trial are expensed during the setup period. Under our clinical trial collaboration agreements we may be reimbursed for certain development costs incurred. Such costs are recorded as a reduction of research and development expense in the period in which the related expense is incurred. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock Compensation and Long-term Incentive Plans</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Stock Compensation.</i> &#160;Share-based payment transactions with employees, which include stock options, restricted stock units (&#8220;RSUs&#8221;) and performance shares (&#8220;PSUs&#8221;), are recognized as compensation expense over the requisite service period based on their estimated fair values as well as expected forfeiture rates. &#160;The stock compensation process requires significant judgment and the use of estimates, particularly surrounding Black-Scholes assumptions such as stock price volatility over the option term and expected option lives, as well as expected forfeiture rates and the probability of PSUs vesting. &#160;The fair value of stock options, which are subject to graded vesting, are recognized as compensation expense over the requisite service period using the accelerated attribution method. &#160;The fair value of RSUs that are subject to cliff vesting are recognized as compensation expense over the requisite service period using the straight-line attribution method, and the fair value of RSUs that are subject to graded vesting are recognized as compensation expense over the requisite service period using the accelerated attribution method. &#160;The fair value of PSUs are recognized as compensation expense beginning at the time in which the performance conditions are deemed probable of achievement, which we assess as of the end of each reporting period. Once a performance condition is considered probable, we record compensation expense based on the portion of the service period elapsed to date with respect to that award, with a cumulative catch-up, net of estimated forfeitures, and recognize any remaining compensation expense, if any, over the remaining requisite service period using the straight-line attribution method for PSUs that are subject to cliff vesting and using the accelerated attribution method for PSUs that are subject to graded vesting. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Long Term Incentive Plans.</i> We have long term incentive plans which provide eligible employees with the opportunity to receive performance and service-based incentive compensation, which may be comprised of cash, stock options, restricted stock units and/or performance shares. The payment of cash and the grant or vesting of equity may be contingent upon the achievement of pre-determined regulatory, sales and internal performance milestones. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_BusinessCombinationContingentConsiderationPolicyTextBlock', window );">Acquisition-Related Contingent Consideration</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Acquisition-Related Contingent Consideration.</i> Acquisition-related contingent consideration consists of our future royalty obligations on future net sales of ICLUSIG to Takeda Pharmaceutical Company Limited, which acquired ARIAD (&#8220;Takeda&#8221;). Acquisition-related contingent consideration was recorded on the acquisition date of June 1, 2016 at the estimated fair value of the obligation, in accordance with the acquisition method of accounting. &#160;The fair value measurement is based on significant inputs that are unobservable in the market and thus represents a Level 3 measurement. The fair value of the acquisition-related contingent consideration is remeasured each reporting period, with changes in fair value recorded in the condensed consolidated statements of operations.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaboration loss sharing</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><i style="font-style:italic;">Collaboration loss sharing.</i> &#160;Under collaboration and license agreements with shared commercialization efforts, we record our share of the losses from the co-commercialization efforts in collaboration loss sharing on the condensed consolidated statement of operations. For the three months ended March 31, 2020, collaboration loss sharing represents our 50% share of the United States loss for commercialization of tafasitamab under our agreement with MorphoSys. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recent Accounting Pronouncements</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2016-13, &#8220;Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.&#8221; This guidance applies to all entities and impacts how entities account for credit losses for financial assets measured at amortized cost and available for sale debt securities. ASU 2016-13 requires financial assets measured at amortized cost to be presented at the net amount expected to be collected. The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amounts. An entity must use judgment in determining the relevant information and estimation methods that are appropriate in its circumstances. &#160;For trade receivables, loans and held-to-maturity debt securities, entities will be required to estimate expected credit losses over the lifetime of the asset. &#160;For available-for-sale debt securities, entities will be required to recognize an allowance for credit losses rather than an other-than-temporary impairment that reduces the cost basis of the investment. Further, an entity will recognize any improvements in estimated credit losses on its available-for-sale debt securities immediately in earnings. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon adoption, we assessed each financial asset measured at amortized cost and each available for sale debt security held for the impact of the guidance as of January 1, 2020 and noted an insignificant impact due to the minimal credit risk associated with our financial assets subject to ASC 326. As such, it was concluded that a reserve for credit losses was de minimis on the adoption date. Financial assets will continue to be assessed on a quarterly basis in future periods.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2018, the FASB issued ASU No. 2018-13, &#8220;Fair Value Measurement (Topic 820): Disclosure Framework &#8211; Changes to the Disclosure Requirements for Fair Value Measurement,&#8221; which eliminates the required disclosure of the amount of and reason for transfers between Level 1 and Level 2 of the fair value hierarchy. The guidance also eliminates the required disclosure of the entity&#8217;s valuation process for Level 3 fair value measurements, however public entities are required to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. This guidance is effective for fiscal years beginning after December 15, 2019. We adopted this guidance for the period beginning January 1, 2020 and enhanced our disclosures in Note 4 to the condensed consolidated financial statements to comply with the standard. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2018, the FASB issued ASU No. 2018-14, &#8220;Compensation &#8211; Retirement Benefits &#8211; Defined Benefit Plans &#8211; General,&#8221; an update to Subtopic ASC 715-20. The guidance amended year-end disclosure requirements related to defined benefit pension plans, and does not affect interim disclosures. The guidance is effective for fiscal years ending after December 15, 2020 and is permitted for early adoption. The standard is to be applied on a retrospective basis. Incyte sponsors defined benefit plans for employees located in Europe. We are currently analyzing the impact of ASU No. 2018-14 on the condensed consolidated financial statements.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2018, the FASB issued ASU No. 2018-15, &#8220;Intangibles &#8211; Goodwill and Other &#8211; Internal-Use Software,&#8221; an update to Subtopic ASC 350-40. The guidance directs accounting for service contracts for cloud computing arrangements to follow guidance within ASC 350-40 to determine capitalization of implementation costs. The guidance is effective for fiscal years beginning after December 15, 2019 and may be applied on either a retrospective or prospective basis. We adopted this guidance for the period beginning January 1, 2020 on a prospective basis. New contracts for development of internal-use software were assessed and no qualifying contracts were identified during the period. We will continue to assess contracts and will disclose material, qualifying contracts if identified in future periods.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2018, the FASB issued ASU No. 2018-18, &#8220;Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606.&#8221; The guidance clarifies the interactions between Topic 808 and Topic 606, including clarifications on revenue recognition, unit of account, and reporting disclosure requirements. The guidance is effective for fiscal years beginning after December 15, 2019. We adopted this guidance for the period beginning January 1, 2020 on a retrospective to the date of our initial application of ASC 606, and noted that in assessment of our collaborative agreements, there was no material financial statement impact. Our collaborative arrangements and their associated accounting conclusions are described in detail within Note 9 to the condensed consolidated financial statements.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2019, the FASB issued ASU No. 2019-12, &#8220;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.&#8221; This guidance applies to all entities and aims to reduce the complexity of tax accounting standards while enhancing reporting disclosures. This guidance is effective for fiscal years beginning after December 15, 2020 and interim periods therein. Early adoption is permitted for any annual periods for which financial statements have not been issued and interim periods therein. We are currently analyzing the impact of ASU No. 2019-12 and do not anticipate the adoption of this ASU to have a material impact on our condensed consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_BusinessCombinationContingentConsiderationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for acquisition related contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_BusinessCombinationContingentConsiderationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LongTermInvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long term investments in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LongTermInvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118582676&amp;loc=d3e5728-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118582676&amp;loc=SL6759159-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2AA<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=118582676&amp;loc=SL6759068-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922895-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=119407570&amp;loc=SL82919260-210447<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=119407570&amp;loc=SL82919253-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=119407570&amp;loc=SL82919272-210447<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=119407570&amp;loc=SL82919244-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossFinancialInstrumentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32247-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32280-109318<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=SL6953423-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5033-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5212-111524<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5093-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>55
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+""
MWTG] E!+ P04    "  E@:50*JVXWN\    K @  $0   &1O8U!R;W!S+V-O
M<F4N>&ULS9+!:L,P#(9?9?B>R$EI"R;-I:.G#@8K;.QF;+4UBV-C:R1]^SE>
MFS*V!QCX8NGWIT_@1GFA7,#GX#P&,A@?1MOU42B_86<B+P"B.J.5L4R)/C6/
M+EA)Z1I.X*7ZD">$FO,56"2I)4F8@(6?B:QMM!(JH"07KGBM9KS_#%V&:078
MH<6>(E1E!:R=)OK+V#5P!TPPPF#C=P'U3,S5/[&Y ^R:'*.94\,PE,,BY](.
M%;P][5_RNH7I(\E>87H5C:"+QPV[37Y=;!\/.];6O.8%7Z9SJ%:"K\5R_3ZY
M_O"["UNGS='\8^.;8-O KW_1?@%02P,$%     @ )8&E4)E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M+CC"3!7-U)@33#0K/S"YBS<#1T] 25:,+SU;".:J:*[&G/2B>9F>&;QG=>T
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M971S+W-H965T,RYX;6R-EN^NFC 8QF^%< '2EO\&2:;+LB5;8LZR[7/5*N0
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M[P1G2@619<%*%BSDR\$XJ,A9J--8GK-^A^P'@K;#[N^-KR#Y?U!+ P04
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M,7* "X28JSC4M!,$Z031*A$C)T2T DDJD(07$=/'#J.NF2(?$@@E(X8LIE%
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M Q V9J[O7@.O7=-*'4!Y.N &?H+\-1RY6J&%I>HH]*)CO<.ASMPG?U_$&F\
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MUJ@2A6/I()4K$F8L-&.!&<7,V*@;348RU0:HA"D20^N@&0?,\*EV<<[:,"M
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M@1UH?U.C4=QYTS3,=@9X%4%*LF2SN62*"TV++/J.ILBP=U)H.!IB>Z6X>3F
MQ"&G6_KJN!=-ZX*#%5G'&_@)[E=W--YB,TLE%&@K4!,#=4YOMOM#&N)CP(.
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M8)\(]O\M<2WFO4JVZ*D&UZ1I\J2TO4F3O/#. WO'TYO\"1^G_9MPC32>G&W
METW]KZT-@%(V5SA"+7ZPV5!0AWB\P;,;QVPT@NVF'\3F;US\!E!+ P04
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M_.^:#0F5"\?/_FS&&1L-A]WT?=C\A_/?4$L#!!0    ( "6!I5"*741\M $
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M@MJ'XRV>[31FD^%-/_\@MGSCXC=02P,$%     @ )8&E4%Q4_BBT 0  T@,
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M]_YLYC&;#:>'](/(\HVKGU!+ P04    "  E@:50P\ DGK0!  #2 P  &0
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M=V]R:W-H965T<R]S:&5E=#(P+GAM;'U3VV[;, S]%4$?4,5*V@:!;:#I,&S
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MR\;^U\9X0"G)#8Y0BQ]L,134/AS?X=E.8S89WO3S#V++-RY^ U!+ P04
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ML%WA 92*1$'&]YF3+BDC<'U^97^?:@^U7(2#!U1/LO9=0>\HJ:$1@_*/.'Z
MN9XWE,S%?X(KJ! >E80<%2J75E(-SJ.>68(4+5ZF79JTC_/-[0S;!O 9P!?
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M=',O<VAE970S,"YX;6QM4VUOFS 0_BN6?T!-G'1+(T!J6DV;M$E1IW6?'3C
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M%*\&A\;Z[:W;Z_DMSX95PS*F9/U7E'\ 4$L#!!0    ( "6!I5#'^KK)W0$
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M$[.74U=.AA;]/'#(,O7R#U!+ P04    "  E@:504'G2T[8!  #1 P  &0
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M]:4$C94XT/_H-$[?1AUN WV[IB=?X@*[J, N".S^:3&]:C&&N8T72:-%THC
MW561&.;^J@A979P$W80G:U"IABZ,RRJ[3,4##1?_"9]&ZB?3#>\,.BGKGD^X
MY%HI"\[*YL9Y:=T4+X& VOKMG=OKZ2U/@57]/*9D^:\H_@)02P,$%     @
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MNML-=U K9<%)V6[<&K7ND<T.A]IZ\];9.JY:=*SJIU=$YJ=<_ -02P,$%
M  @ )8&E4,LDGCKW @  W L  !D   !X;"]W;W)K<VAE971S+W-H965T-#,N
M>&ULE5;MCILP$'P5Q ,<V,9\G))(EU15*[72Z:JVOTGB).@ 4]M)KF]?VW <
M@75%\B/89G:\.S!X%U<N7N6),>6]564ME_Y)J>8Q".3NQ*I</O"&U?K.@8LJ
M5WHJCH%L!,OW-J@J QR&<5#E1>VO%G;M6:P6_*S*HF;/PI/GJLK%WS4K^77I
M(_]]X:4XGI19"%:+)C^R'TS];)Z%G@4]R[ZH6"T+7GN"'9;^$WK<8&H"+.)7
MP:YR,/9,*5O.7\WDZW[IAR8C5K*=,A2YOES8AI6E8=)Y_.E(_7Y/$S@<O[-_
MML7K8K:Y9!M>_B[VZK3T4]_;LT-^+M4+OWYA74'4][KJO[$+*S7<9*+WV/%2
MVG]O=Y:*5QV+3J7*W]IK4=OKM;T315T8'("[ -P'(/K? -(%D(\ NT/09F9+
M_92K?+40_.J)]FDUN7DIT"/18N[,HM7.WM/52KUZ61&:+(*+(>HPZQ:#!QC4
M(P+-WF^!H2W6>!*.;S?83!$H3.$M"%@%L01D2) Y""*0(+($T9  A2,96DQL
M,;7%T#BEX4BMS10694DZ$/4F'0JF0Z?IX PFB$&">+X@"4B0S!"DQ=!AI6F<
MX+$@4QC)8APYZDG!=-)).H0XZLE @FR^("B$G1+.D*0#W6A"LRC)1IH .)+0
M&#F,A1SF15-9(A<%:,XGA.\0!C8?(G.$(9."<8*C=*P+  MCUZ-&L)D1X&82
M.BA@ R)ZARRP!5$\1Y9X4F^*DC0<RS*%Q2AV?2,1;&DT]32A+@K8ABB]0Q;8
MB"B;(TLVJ9?&A)"Q+%-81&GB.IU@7^.IKPEU?)PP[$.,YLN"81]B/$.6#C0\
M6S"-HO$'MX,-9=$O"W&<0!AV-09<35S*PC[$T1VRP#[$P$DXEF73@6Z.W%#_
M1CL%@YZH8N)HVT?I[?BY5J;[&*SV+>H3-CW5:'VM6]>VT?R@:?O>[[DX%K7T
MMESICLWV50?.%=-9A@\ZRY-NM?M)R0[*#!,]%FV_V4X4;[I>.N@;^M4_4$L#
M!!0    ( "6!I5!@.CH0+@0  # 5   9    >&PO=V]R:W-H965T<R]S:&5E
M=#0T+GAM;)58VV[C-A3\%4'OC<1#2J(,V\#&2=$"+1!LT>ZS8M,7K"Y>28ZW
M?U_J$M<FAX[R$DO4G,,Y)&?(<'ZNZN_-7JG6^UGD9;/P]VU[G 5!L]ZK(FL>
MJJ,J]9=M51=9JU_K7= <:Y5M^J B#R@,XZ#(#J6_G/=M+_5R7IW:_%"JE]IK
M3D61U?\^JKPZ+WSFOS=\/>SV;=<0+.?';*?^4NW?QY=:OP67+)M#H<KF4)5>
MK;8+_PN;/0O1!?2(?P[JW%P]>UTIKU7UO7OY?;/PPXZ1RM6Z[5)D^N=-K52>
M=YDTCQ]C4O_29Q=X_?R>_=>^>%W,:]:H595_.VS:_<*7OK=1V^R4MU^K\V]J
M+"CRO;'Z/]2;RC6\8Z+[6%=YT__UUJ>FK8HQBZ929#^'WT/9_Y['_.]A.(#&
M )H:P,< ?@D@=C= C %B:D T!D27@'ZZ@J'T?BR?LC9;SNOJ[-7#<CAFW:IC
MLTC/UKIK[">G_Z:'L]&M;TL>A_/@K4LT8AX'#-U@V"UF!3!1=(MY0GGH@@DT
MSPM9@F2I3\"O$FA!X 0<)N!] G'#@!N5#)BXQY0]ALDP30W8$X!Q'D?)+>S9
M[C&2F+& C 5@+'"""":(K#'3+'&"&":( 8/86"$(D^!.$MA) A(XQDG"!')Z
MF2E,D (&J5'F@&'AU:2'#PSWTJ&0WD*[G\2QAIE#LFQZK0P+B=''U:Y&T,1R
ML> 84%SB2H$5P,0GRL4:8!%@06:YD:7H7V0<AJ:)#;#H&D8\=/D0PZ)B0#$)
M=Z3 DF'))\8%BX9)P$*8XR*M@BE)W 5C>3&@+WL*4GML94P.)R&L,$(*,[:B
MU0BZ[BEV=X1U2 QT%)L=,3!Z46@M*XASCS(Y-DB@Z\15%58L\>F;+&'%DKUI
MF6>*U8BYKI>%@I-@YL  H.042\<N2-@""%F -$G9VJ8HY9'%">"DD"X?)^P!
MA'9-\S0R@F[+!\<1A+L]C]Q2PIY"]CZ<6(P2NR<A>23-XQX $D6,F,/_"9L4
MV28ES=,G(8]"*ON<EQ'V,K*]3)JN2;:5848(YV;$L>=QY'FI(P5V,VZ?*MR'
M:^P^W'8?2_<CYF/=(^ ]W7/'B7_2D9]/$QG"W1$9Q_;(;7NT1,:!ZQ$)XL*D
M!(!I''/A$!G']LB!/4K7[&,[X_$G%A"V'P[^#;!,F@-;02:-<'=,FF/WX;;[
MV),%7 4R KA[C+#[<'"2DH[9%M@N1#A]J@2V"V$??BQ7%A///A#G]D"!W4?8
M[F.Y\HB)/V2$<'<8F=YS^]7QG[UM Y&QUA\!)C7]+[BZZBE4O>NOW1IO79W*
MMIOCJ];A:N^)S9[[JR6C_8O@LV==BOU%\WB_#0S^[V*X2_PSJW>'LO%>J[:M
MBOXJ:5M5K=+TPP<]I7N5;2XON=JVW6.BG^OA#F]X::OC>#\97"Y)E_\!4$L#
M!!0    ( "6!I5 ()_;B0P(  #T'   9    >&PO=V]R:W-H965T<R]S:&5E
M=#0U+GAM;(U5VXZ;,!#]%<0'K+E?5@0I256U4BM%6[5]=L@DH 5,;2=L_[ZV
M(2Q+)E5>8GLX<^8<Q_9D/>.OH@20UEM3MV)EEU)VSX2(HH2&BB?60:N^'!EO
MJ%1+?B*BXT /)JFIB><X$6EHU=IY9F([GF?L+.NJA1VWQ+EI*/^[@9KU*]NU
MKX&7ZE1*'2!YUM$3_ #YL]MQM2(3RZ%JH!45:RT.QY6]=I^WKJ<3#.)7!;V8
MS2UM9<_8JUY\/:QL1RN"&@JI*:@:+K"%NM9,2L>?D=2>:NK$^?S*_MF85V;V
M5,"6U;^K@RQ7=F);!SC2<RU?6/\%1D.A;8WNO\$%:@772E2-@M7"_%K%64C6
MC"Q*2D/?AK%JS=B/_-<T/,$;$[PI0=7^7X(_)OCO"8$Q/R@S5C]12?.,L][B
MP[_547THW&=?;6:A@V;OS#?E5JCH)?<3+R,7331B-@/&FV'<"4$4^U3"PTIL
MO)OT18'M+2*,\0H^:L(W^?X'$SY.$* $@2$(/A $BUT8,)'!M(.-,(F\I1<$
ME@1Q&N)R0E1.B,@)%W(&3#BK$WOI0@N"N:,C0G5$B(YHH2-"MB7U0W<A!8$E
M01([N)P8E1,C<NZ<DP0E2!X_)RE*D"(*DL6&8)@4+^(Z^)UT;BG2.SOEWKG6
M[N-67?3:KEWO ;,8*%V^#F3V&#7 3^;=%E;!SJUI&K/HU!O6IC60=_C06+Y3
M?JI:8>V95$^B>;B.C$E06IPG==!+U<NF10U'J:>QFO/A01\6DG5CLR)3Q\S_
M 5!+ P04    "  E@:50A\B4D)X"  !R"@  &0   'AL+W=O<FMS:&5E=',O
M<VAE970T-BYX;6R55NV.HC 4?17" PQM*:!&3?S(9C?93<QL=O=WU:ID@+)M
MU=FWW[8@*EPFS!^AY=S#Z<'3WNE5R#=UXEQ[[WE6J)E_TKJ<!(':G7C.U(LH
M>6&>'(3,F39#>0Q4*3G;NZ(\"PA"<9"SM/#G4S>WD?.I..LL+?A&>NJ<YTS^
M6_),7&<^]F\3K^GQI.U$,)^6[,A_<OVKW$@S"AJ6?9KS0J6B\"0_S/P%GJP)
ML@4.\3OE5_5P[]FE;(5XLX-O^YF/K"*>\9VV%,Q<+GS%L\PR&1U_:U*_>:<M
M?+R_L7]QBS>+V3+%5R+[D^[U:>:/?&_/#^R<Z5=Q_<KK!46^5Z_^.[_PS,"M
M$O..G<B4^_5V9Z5%7K,8*3E[KZYIX:[7FO]6!A>0NH T!>;='Q6$=4%X+Z ?
M%M"Z@-X+8N=6M13GS9II-I]*<?5D]7E+9O]%>$*-^SL[Z<QVSXP]RLQ>YN&8
M3(.+):HQRPI#'C#X&;'N(L)QV& "HZ"102 92](A:(E8=1$8C5HRNI@H@56$
MH!FAJZ=/RZ P 04)J",(GP@BF" ""2) 0=SZ'! F:;D%84:PD!@4$@,$8Y@@
M 0F2X5:,0(+1 "NZ&(I0RPH(@V$A8U#(&" @, %&<,C0<#-P3T[Q #M 4"LD
M*P!$44]8,9C6!28 14]0,!PU''["$CALF ZQI NB*&I; H'B'C%P<'$W<13U
M;#X8CAR./V$)'#J<#+&D"Z*=K11BHGWK@0.,H>3U["$8CAX>#[>$P-DC:( E
M (ABU#Y=(%![)PD>#MZ<RZ-K:I2W$^="VZ/I8;9IG!;$'MRM^26>K*KVYTY3
M=6,_F#RFA?*V0INVP!W>!R$T-QK1B_D;GDP#V PR?M#V-C'WLNJ"JH$69=WA
M!4V;.?\/4$L#!!0    ( "6!I5 WC/@=>P(  /0'   9    >&PO=V]R:W-H
M965T<R]S:&5E=#0W+GAM;(65VXZ;,!"&7P7Q &LPYA212!NBJI5:*=JJVVN'
M. $M8&H[8?OVM0UAB?&F-\&'_Y_YQK$\64_9&R\)$<Y[4[=\[99"="L >%&2
M!O,GVI%6[IPH:["04W8&O&,$'[6IJ0'TO @TN&K=3:;7]FR3T8NHJY;LF<,O
M38/9WRVI:;]V??>V\%*=2Z$6P";K\)G\).)7MV=R!J8HQZHA+:]HZS!R6KO/
M_FKG>\J@%:\5Z?EL[*A2#I2^J<FWX]KU%!&I22%4""P_5Y*3NE:1),>?,:@[
MY53&^?@6_8LN7A9SP)SDM/Y='46Y=A/7.9(3OM3BA?9?R5A0Z#IC]=_)E=12
MKDADCH+67/\ZQ84+VHQ1)$J#WX=OU>IO/^R@<+39#7 TP,F0> \-P6@()H./
M'AK0:$ ?2/JPADKTT>RPP)N,T=YAP[_;876)_!62AU^H17W6>D^>#I>KUPWR
M80:N*M"HV0X:.-,8BGRI".-) B3 1 &M%%#[@YD_"NS^P.H/M!_=51$850R:
M2&M:K?%A'!J%_$=TAX*L*,B"@@R401/.L_@0)@;+4I5$ ;*SA%:6T,)B5+P-
M%UG2V 3.EZ(H3",[2F1%B2PHD8$2+;) "/W88%FJ_"CT/OF/8BM,;($QTFSC
M99H@C4T8B\I'GG>OVBWSA8F=-['R)A9>X[9LD\7-32 R0/*E*/0]XT;LEMD^
MHTT-VKM-V0RL#X[W*/SXX"PUJ7GQP>R%:P@[Z^;!G8)>6J&>B=GJT*!RU:#4
M"VFL/Z>K76I9EQ2WC@8^$@S]\ =FYZKESH$*^3#K]_-$J2 2WGN2MZ&4+7B:
MU.0DU#"68S;TH6$B:#?V6# U^LT_4$L#!!0    ( "6!I5 :9G_P/ ,  - -
M   9    >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;(U776^;,!3]*XCW%7\;
MJB12FVK:I$VJ-FU[IHF3H +.P&FZ?S]C2$;P]<1+@LVYU^<>?#!W<=;-:WM0
MRD3O55FWR_A@S/$^2=K-055Y>Z>/JK9W=KJI<F.'S3YICXW*MRZH*A."D$BJ
MO*CCU<+-/3>KA3Z9LJC5<Q.UIZK*FS^/JM3G98SCR\2W8G\PW42R6ASSO?JN
MS(_C<V-'R37+MJA4W1:ZCAJU6\8/^/Z)I%V 0_PLU+D=74==*2]:OW:#S]ME
MC#I&JE0;TZ7([=^;6JNR[#)9'K^'I/%US2YP?'W)_M$5;XMYR5NUUN6O8FL.
MRSB-HZW:Y:?2?-/G3VHHB,?14/T7]:9*"^^8V#4VNFS=;[0YM4970Q9+I<K?
M^_^B=O_G(?\E# X@0P"9&T"' 'H-P.R_ 6P(8-< AT_Z2IPT3[G)5XM&GZ.F
M?[K'O-M$^)Y9\3?=I-/:W;/JM';V;<5PMDC>ND0#YK''D!&&W"+6/H++*R2Q
M!*XL",B"N'@ZBA<I'$_!>.KBV;@*@B95]!CA,'7/D:94B$DI/HQE&:.!<AA(
MAP%T\(1.C^&C=3Y@DE(ZE1;$X50BF! '"7&/$&'IA!#W%F(8(<HF?'P8E9(+
M>0M[\E?D@2<J0,8"D)# "2280,[>4BD8G\[84JFG!>8DY1/%(!1%%":3@60R
M@$P@ 4:PS]%L/7#@38%G*#* QL5*0KGWO@!@B./ GL;P2P,3@! +I(#?&YC.
M5P6V.H:\[JGBFU@@).54%1_&,R2R "'8ZMAW'B,\D +V'A;S58'-A^4<5:1O
M#$2(IPH("_D'PV[&D)U%( 7L09S-5H7 'B1HABH#:%PN02F1TW,J@,L"NA#8
MU 0R=>CH#IS=\P]O KN0S#F^!]#--D@%PU-9 %@F9.#H(+"I"63J4$VP#0F?
MKPKL0@(=@9XJPOM<L8<+1^E4%@"'!4U#CWIJZ]N[L,>([S$^_<@ ,-GTE9V,
MOETKU>Q=6]!&&WVJ3:?H:+9O/=:V]7"-PF3^@4C;DTC@CN5QZ5:2?TOTO<[7
MO-D7=1N]:&,_NMVW\4YKHRQ]=&>?ZL&V5]=!J7:FNY3VNNE[C'Y@]''HGY)K
M$[?Z"U!+ P04    "  E@:50&S2/XE #  #U#0  &0   'AL+W=O<FMS:&5E
M=',O<VAE970T.2YX;6R-5]N.FS 0_17$!RSXQB5*(N6RV59JI=56;9_9Q$G0
M D[!V6S_OC8X%,RP(@\!S#DS9VS.@.<W4;Y59\ZE\Y%G1;5PSU)>9IY7[<\\
M3ZH'<>&%NG,499Y(=5F>O.I2\N10D_+,P[X?>'F2%NYR7H\]E\NYN,HL+?AS
MZ537/$_*OVN>B=O"1>Y]X"4]G:4>\);S2W+B/[C\>7DNU9771CFD.2^J5!1.
MR8\+=X5F3SC0A!KQ*^6WJG/NZ%)>A7C3%U\/"]?7BGC&]U*'2-3AG6]XENE(
M2L<?$]1M<VIB]_P>?5<7KXIY32J^$=GO]"#/"S=RG0,_)M=,OHC;%VX*8JYC
MJO_&WWFFX%J)RK$7657_._MK)45NHB@I>?+1'-.B/MY,_#L-)F!#P%,)Q!!(
M2\#H4P(U!#J5P R!M03Z*3XP^&!J@M 0PI: PGK]FLFM5VN;R&0Y+\7-*9L'
M[I+HYQK-0O4\[/5@O?SU/;5@E1I]7U(<S[UW'<A@U@T&=S"$T3YF,\2@%N$I
M!:T,#,E8XP&=$M]*,<00QOJ8+8 )<!^S@W*A/N8)PF"X( +.*ZD#D$Z ((+Y
M%.33FD^[?&M9-@TDJ"%%#<%1@*UJMP J]EG41ST.T[$1N0R4RP9\2HBEM\&P
MCA)&(A($EN AC,8Q)2$L)P#E!$,Y>*2>$ P03EZ^".1'$^8C&JP,8H3YUM)L
M 1@*2#0R'S$H)P;D4#@ \N$^X4^>$332:1 @PO+O$P@*1O* K62%,! BM-O5
M$#16#>QO1( LD5T-!(I'\L!]  V=2:EOYZ$#SR!?_T92P1Y&@(FIU1AW!M1]
M' E"HYE@>Z*A/^WNMC,8UFM<XXE@&Z,0*,E^'QA0KT6.SQWL=P08GMJ&1X"5
M(SR:";8R KQ,1[R,82_CZ5[&L)<Q8%-J>7EM0-UR:316+8;-C $STY%^@&&G
MXNFO8@Q[$ ,>''1S/'S1(A^/UVM[L'\7]@T>^L9^DZ\!3&P_'E[GZS#GY:G>
M"U3.7EP+J2W7&6WW&RNLORZM\2V:/2)H',\>(?P*,[5Q8< =I?N^I?'^2VHV
M1-^3\I06E?,JI/H.KK]6CT)(KLKU']0\GM4>K+W(^%'JTU"=E\U&I+F0XF(V
M65Z[TUO^ U!+ P04    "  E@:50RY>0.;(#  #G$   &0   'AL+W=O<FMS
M:&5E=',O<VAE970U,"YX;6R-6.V.FS@4?17$ Q1LP":C)-)D,E4K=:515]W^
M9A(G006<@C/IOOT:XF'!/D[[)\'FW'O/]<>Q+\NK;']T)R%4\*NNFFX5GI0Z
M/T11MSN)NN@^R+-H])N#;.M"Z69[C+IS*XK]8%17$8UC%M5%V83KY=#WTJZ7
M\J*JLA$O;=!=ZKIH_]V(2EY7(0G?.[Z6QY/J.Z+U\EP<Q=]"?3N_M+H5C5[V
M92V:KI1-T(K#*GPD#\\T[PT&Q#^EN':3YZ!/Y57*'WWC\WX5QCTC48F=ZET4
M^N]-/(FJZCUI'C^-TW",V1M.G]^]?QR2U\F\%IUXDM7W<J].JS /@[TX%)=*
M?9773\(DE(6!R?Z+>!.5AO=,=(R=K+KA-]A=.B5KXT53J8M?M_^R&?ZOQO^[
M&3:@QH#^J4%B#)+1@*1W#5)CD(X&27[7(#,&V6@P!(ANJ0]CN2U4L5ZV\AJT
MM^5P+OI51QXR/5N[OG.8G.&='LY.][ZMTY0OH[?>D<%L;A@ZP9 1$6GO8PB*
M0FRH8T[G 9Y<!(GS.6;K8C*.620PT62P3V:)YMA!"AVD@X-TYF!AC92+(3&.
MD<$8F1LCBZT8+L:3!H,A& A!K! W#!LPS8!9Q-0";0$H21-,A4,J'%"QEL8&
M81*+R7W,C$@.B>3 06H1R=UTB34U6Q?#F.7GV8V5>>9O ;DN -?,XHHP%H_M
M?<R,"(FQ=,3 !;.U(W;&A!!BK[@MA.5>0AXM(X"0(V8(9(O-;T!S,E#U'@D%
M+FR],*!IV@E9V+ MAA&+]3,(Z26-19(D+FEF"Q "N93O@^9DL. 2H+C,EBH#
MF@Y-EL2IL[X0C',?(:S.!,@SLP7+@++I7.EKFW7B&=24#\UCSUE!L)(3(.4L
ML>DPAPY@<Q\T)X.UG  1MK5O8T"S79YSFPQWR.@MX2&#]9SD[F'/?"ZPS!*@
MC\P1-P3RW$HH%E$*1)19&WL#09ZU2[$V4J!HW-[9$.2[ZV'9HT#VN+U'(,AS
M8E.L5!3H"[?7FP&Q^WO1H&8[EOF6/\5:18%6<?M8-J!I(.:R<4'>O4BQ3E&@
M4]Q>NQ3HE#<.%B *!(C;YRUU[XE)YF8-4'XZM@3-WV)-H'<O7H:KBUG85Y!H
M4EG5HCT.56X7[.2E47T"D]ZQDGZD?65F]6_(PQ,!_5M=><-^JBMRT/](N7[!
M402:OQ?QT?]4;Y\ _BK:8]ETP:M4NK0<*L"#E$KH88@_Z$5Q$L5^;%3BH/I'
MKI_;6^E]:RAY-I\5HO';QOH_4$L#!!0    ( "6!I5 F/<VFJ@(  +T)   9
M    >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;)56VXZ;,!#]%<0'+(RYF542
M*4E5M5(K15NU??8F3H(6,+6=9/OW-89EB1E4[0N^<&;.S."#9W$3\D6=.=?>
M:U76:NF?M6X>@T#MS[QBZD$TO#9OCD)63)NE/ 6JD9P=K%%5!B0,TZ!B1>VO
M%G9O)U<+<=%E4?.=]-2EJIC\N^&EN"U]\-\VGHK36;<;P6K1L!/_P?7/9B?-
M*AB\'(J*UZH0M2?Y<>FOX7$+M#6PB%\%OZG1W&M3>1;BI5U\/2S]L(V(EWRO
M6Q?,#%>^Y679>C)Q_.F=^@-G:SB>OWG_;),WR3PSQ;>B_%T<]'GI4]\[\".[
ME/I)W+[P/J'$]_KLO_$K+PV\C<1P[$6I[-/;7Y065>_%A%*QUVXL:CO>NC=I
MVIOA!J0W((-!5YQ9@Z@WB-X-8IM\%YE-]1/3;+60XN;)[FLUK#T4\!B98N[;
M35L[^\YDJ\SN=15G=!%<6T<]9M-AR @# R(PW@<*@E%LR,2<W!-LIX@DPQDB
M-(G(VD=W2>2X@QAU$%L'\=@!#9TJ=)C48NJN"BDD!*=)4)H$H0&'IL,D(QH"
M293B-"E*DR(T3LDWZ4=H,I0F0V@BAR;[" U%:2A"$SLT]",T.4J3(S2)0Y-/
M:&@*,<5I(,0%%TX/*YV)%&8T"TBLF2M:F)S7<(8%E>T:",(RERNN2T"$26>$
M";@R 9%F[DH3 45SR@1<FI!,0\UG?G. RPX0W>6N[GK0^+.0#,+026G[?]Q]
M2+A$ =%H[FH4IB*E)$E2-Z(I+,L@FRLS+F9 U)R[:NY!=[]:2N,X=B-"<'E$
MB7M(@]%E6'%YLGV#\O;B4MNF9;0[]"9K8B_3=WC7V'QG\E34RGL6VES)]N(\
M"J&Y"2=\,*4YFUYJ6)3\J-MI9N:R:RBZA19-WRP%0\>V^@=02P,$%     @
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MF8E^JS]T4L%K3RH;+UE2-)^SE_>BS%*CI7(EC7^UWX=C\WUN_PDB(X8+@!&
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M6!F)P,KLM0OC@52,X?Z$N#^AXX_T!:XAPC5$X^])76[1^N8C7E@%[MZ NCD
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MTDD7J.J!XE1-VX0JGC(Q0:?&/.F8(1V0F<2$C!7:R* -'QA8/1!-4 RF3$1
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MA=H+(;F*WK]3.CJJ?P;M).5[J8>A&I=->]Q,I"A,Z^^U_S\6_P!02P,$%
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MN(A"P[M,M,9.%JWY[^W.K9+EP*)3*?EK?\TK<[WV3])D"(,#\!" QP"M_5X
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MA%JG80V M//9O[00D\,;,6PX&# <RAP4L)%@_/']P;!!8, @9OL#@ B-[))
M3+9MA)/>K13-T?3%K;>3Y\HTY9/9L?>^QZ;W^P?O&_?OO#GF5>L]2Z4[2-/G
M':140N<2!?HLG_2WPC@HQ$%UMZF^;_J&N1\H60\? ^'X1;+Z"U!+ P04
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M&YG7S;^W.=5*%ET6+:5(W]IK5C;72_N$HRX,#L!= .X#-/=' :0+(-< ^F$
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M)BY)H.$?$08D,9L*CZ@>(DJ=JX<-BPA %=E49$Q%$IXP!Q5L;43O=P*"38L
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M3B@) SO[1_DA*R/O(S%CO*JJ&_X'K^^=5K7U8D*IBY_C;]D,OX?QC4BM&6Q
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M1\+=GD;G"Y?'YL_M1W,=$SG/$;8( CJ!2!=NUP)$6-D2A&("8$RQDD X)A>
M3!"2B0?*:U#DL'S[&]$T&H1F N"<9NY D AAGB#0D^SWM;>VHO.:RM)<)&X\
M<YDPFRIS*WDNXSQ-8J1W$Z39$*#;B-G'"R1RLOH$BK"=%>E*%.A* BE!BC0<
M2OS+F&);/-!+7&[O(!'&+44:! 78%QSQ@;!/^0431MBGB<^$ 1&&)$4:! 6P
M=NMM#8H29""$?0I@+9#V31&LZ06;.44 HP 6;FOX3(']/)YO2W>@#H>>(9@Q
M"#-GK!M0))"!$!89L*]C'Q ,89%=\KV-?7!#F+F+"XJ0C8 A+#)@'\ZP[" L
ML@OV889@Q@""9A]#5C2IIF12==.Q$-(81)J[A4"B#/E 80B.#-AE,Z3_, 1'
MEOLO+D?PX1[XW $BL]DC R'X< "?# L6P8=?@ ]'\.$^^$"B68:CLT.5_ESS
MJ6C?RJ8+7I36JAX.4;9*:6D<QE>F,'>RV)QN*KG5_:4PU^UXGCC>:+6W9Z71
MZ<!V]1]02P,$%     @ )8&E4(RU5T_\ 0  $P4  !D   !X;"]W;W)K<VAE
M971S+W-H965T-C8N>&UL=511;YLP$/XKB/?5P0%,(X+4M)HV:9.B3MV>'3@"
MJHV9[83NW\\VE+'@OF#?^;OONS.^RP<A7U4#H(,WSCJU#QNM^QU"JFR 4W4G
M>NC,22TDI]J8\HQ4+X%6+H@SA#>;%'':=F&1.]]1%KFX:-9V<)2!NG!.Y9\#
M,#'LPRA\=SRWYT9;!RKRGI[A!^B7_BB-A6:6JN70J59T@81Z'SY$NP.Q> ?X
MV<*@%OO 5G(2XM4:7ZM]N+$) 8-26P9JEBL\ F.6R*3Q>^(,9TD;N-R_LW]V
MM9M:3E3!HV"_VDHW^S +@PIJ>F'Z60Q?8*HG"8.I^&]P!6;@-A.C40JFW#<H
M+TH+/K&85#A]&]>V<^LPGB39%.8/P%, G@.PTT&CD,O\B6I:Y%(,@1SOOJ?V
M%T<[;.ZFM$YW%>[,)*^,]UJ0+,[1U1)-F,.(P0M,-".089\EL$_B@%?A)$O\
M!%MOCEM'L/V/(/43Q%Z"V!'$2P),;HH<,8G#= YSGV4XPM@OE'B%DK50=BN4
MK(0^12G99OB#DE*O4NI1RFZ4TI42CDF,[_TZQ*M#UCK;Z$:'K'2R.$D(OOW)
M:/$H.<BS:T<5E.+2N5&P\,X=_X#=H_X''\?%=RK/;:>"D]"F-=P#KH708-+9
MW)E,&C.A9H-!K>V6F+T<^W0TM.BG$83F.5C\!5!+ P04    "  E@:50)Q:H
M&I,"  !I"   &0   'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q]EFUOVR 0
MQ[^*Y0]0'OT4.9&:5-,F;5+4:=UKFI#$JFT\($GW[0?8\1Q,^Z:&XW]WOP/"
MM;P*^:9.G.OHO:E;M8Q/6G<+ -3NQ!NF'D3'6[-R$+)AVDSE$:A.<K9W3DT-
M,(0I:%C5QJO2V;9R58JSKJN6;V6DSDW#Y-\UK\5U&:/X9GBNCB=M#6!5=NS(
M?W+]J]M*,P-CE'W5\%95HHTD/RSC1[1X0L[!*5XJ?E63<61+>17BS4Z^[9<Q
MM$2\YCMM0S#SN? -KVL;R7#\&8+&8T[K.!W?HG]QQ9MB7IGB&U'_KO;ZM(SS
M.-KS SO7^EE<O_*AH"2.ANJ_\PNOC=R2F!P[42OW-]J=E1;-$,6@-.R]_U:M
M^U[[E8P,;F$'/#C@T2&'GSJ0P8&,#HA^ZD '!SHZ.#WH*W%;\\0T6Y527"/9
MGV['["5""VHV?V>-;J_=FMD=9:R75987);C80(-FW6OP1(/O%9NY(LE&"3
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MST4$:9-5U4JM%&W5[;,#AX#6QM1VPO;O:QN""+%6?8E]#C/#S(EQUG/Q+FL
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MLC@Y_GTKI2Q@BN$*9[K!C9\,#I5UUT]XU\/<#X95W;C2=/I?R?\!4$L#!!0
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MJ7'@7#%-&=_I=CWIF\<T:=A!F>%"C\5P_ X3Q?OQ:A%-]YO-;U!+ P04
M"  E@:50(EUWF0 "   Q!0  &0   'AL+W=O<FMS:&5E=',O<VAE970W,RYX
M;6Q]5-N.VR 0_16+]RZ^)XUL2YNL5JW42M%6;9^)/8FM!>,"B;=_7RY>QYN@
MOA@8SIQS!L,4(Q>OL@50P1NCO2Q1J]2PP5C6+3 B'_@ O=XY<L&(TDMQPG(0
M0!J;Q"B.PS#'C'0]J@H;VXNJX&=%NQ[V(I!GQHCXNP7*QQ)%Z#WPTIU:90*X
M*@9R@A^@?@Y[H5=X9FDZ!KWL>!\(.);H,=KL<H.W@%\=C'(Q#TPE!\Y?S>)K
M4Z+0& (*M3(,1 \7V &EADC;^#-QHEG2)"[G[^S/MG9=RX%(V''ZNVM46Z(U
M"AHXDC-5+WS\ E,]&0JFXK_!!:B&&R=:H^94VF]0GZ7B;&+15AAY<V/7VW%T
M.^GG*<V?$$\)\9R@M?^7D$P)R34AM<4[9[;4)Z)(50@^!L+]K(&8.Q%M$GV8
MM0G:L[-[NEJIHY=JG40%OABB";-UF'B!N2*P9I\E8I_$-KY+CS\*[.X14;CV
M2R3>*A)+D"PEHI6?(/42I)8@_7 ,-RZW#I-;3.]<YEF>W]3B0:W6F=]+YO62
M>;PD-UX<)ENJA*%?)/>*Y!Z1]$8DOROE4WRG@A<WC8$XV4<I@YJ?>V7^Z2(Z
MO_O'V-S4F_A6]P/W?*\TKIE\)^+4]3(X<*7?@;VM1\X5:(_A@SZ#5O>O>4'A
MJ,QTI>?"O6*W4'R8&A2>NV3U#U!+ P04    "  E@:50+V. _O<"  "5"P
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M%IDX*',;ZONJ&12;A9)E.P1[W22^_@M02P,$%     @ )8&E4'*!V;)(H
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M= I"B^.W!FA=N4/?X%MWZ-/Y'MDV(!"/W5#X]H.[Z7R\>RN=C^[;1S<677V
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M"W<W*<QZ9ZS\ QP"5-82\187F[!9.D!+-!+!'MPQ[W(V5,?>C8(7ZHTH QT
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MOL"QS[W,+XP/PL?$5?KJQ;EUDHINRF;CLEZ(-Y.C!BM9AK^Y8%,K+$I"(?E
MSE55]QS$0HYA0K8-) 2RE1;H@9^=LILT8&+%_C)9&XUK6Z.Q?WDOWL[&H8#6
M^9$\:J#$HIN1Q"MO>UZP*Q':>H$R0\6:+BC Q9+M>[?YYA:/%*29 ;-_"M.I
MBUN3;C@8@)T!]_HPB!+7.5O%:#YG#FD.4H&$B'?^!\X'(W[#*J$%J@2^7CN_
M91,T>&5NZBU9(X @;-'$1F>'VK&X4.1]&.\-X#"A1+*S:KAUFU^^>:&XH#A-
MPQ&+0/1W[D\X188[7)V=[Z"W]@U)<I/E(GQ@&"M =;KOE<_[*":D$*\@7B42
M<M,M^:()>A*04&PU-$>^CWT$]E"/;+,1[)1.A  7-2]KW"2*-H:"5!T@=0/A
M^1O3OM6T-;2W[&Z8.0<Z&+#I_"X.L9VN6QNQK?4< =AQ9>+&'4THJ'+5=[IO
MO)L.@RW2?)-?I\O2R:4=+_WPVKW4N, >1<2O?$D''WN#P"XB& !H50K21%*$
M-T(8&;/PM;CS?=%);6!)23 7PS<JOQ;)1'=6.Q>N(Y@#Q:2NN3%,>\^,B*VW
MZ GUR,+FOF&G!T$F%J_0)^5!&? <E)%5#A#U0X.M4)VA&@9IB1XK5*S:G,*R
M$0_UC7/:>"J5:+EXCL I^)ZA>QL4EG++HGB5?\*DK_L6CPIO4:PNM[)TKN=.
MG)3#(,E!EH&E I&YH%"A=IS8OY-Q.\Q2-JMLUIK/Q&$9 (56=RT.7Y1DX%[6
M:/AG_M>,3DK08%=9EL1Q:TP1G2C,*%N2T.!H B\'?T(,*!)R*S,0,,L&Q E"
MJ?^I<?4DT"U %["1?#5'V-/'%E%PFC'^#I/%LEK%EM+T3.)H<(G\Q9+6YAS
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M%\_S8>!@V#Z\"$.07$FF+< J./R?45=)I.(AYYZ2:Q$9"KJP&]?_(3)#[SQ
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M/L#&.%(HLEL8B[%!*6CU='!>H[1_@GC%0_]V1M'W91(\'"7WJY#I@?WF1S*
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M5\M:O-5V$A8]5*=X-IJ,GTZM@$A_%IUZ-AH?0*%:1ZS=7)ME_RXSYW'V(=
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MU=(%E5D2B/B%*RJ$;]@5!S9^D@<V#-6Y@Z9-\LE68E)E-3:P??;EJG?T;C@
M7 /VV70<2O^P=RW,P,X);K+]5EU"@?R.9(5T->!".I%KI+!WL\[BVV&H<RM
M&XW6LD$AK.'TL_8LTOWY BVI=38..KP:RDEHC9NF=7=A7)VC?P"0+')G)&J;
MWGL!)JILEYFT\KIJ>+O >^I5PK$LJ77]FP4C/?>2&\US,2E]7!N)76ZF+G<
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M.K,_;V9<X4;=T^CL.#X&D=,"?SJ=QS/X@@Z![[QOME0VRKG2)/CXU$0<W"@
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M&(+2?JHI#)S2FE%01M1J-:(B&JQ^)T'-\3A U+, 44_G\=G)K!=1DVY4_<?
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M>CPZ^OA<J3I).1E%)7&G[HM\A<"5#O"8Y4?!2YXSD.)F>V:5\L5$@"^SY3W
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M$*@DL5H*W7[0G/K<<R4 P0>I%2$@,L?1:X+ .[0&T!M/73:/G.V!K1.QCTZ
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M4E3XI4<^WAR^^RK^F.<K#/484N&L1K\,1 3J;(FTD<02$AQ3-[$71\&Z]%O
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MAET=;"T4JN1?%39L1D:IL-12NJU9(5*]R] B[OTXIHNWOUR^& #Y OZV,K!
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M6BV&5/LP("V&V'L&Q;5UGI;Z:[!ITW1X&0+9!MDA3K[8!ZRDIW;K8K;=M][
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M'I< :%,]BZC:<U6J/5G?9BTEV)4ZG6JZN(,<1<S 5*H/+W%$<B2\@WL=_94
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MM2/UK()+\T>4.;*=_.-NM__G_P902P,$%     @ )8&E4*H<=G]L @  7@T
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MU]?L(2:FH(Q80?]AS@"3^[71G4/F$+//D-@^OY@,/F4CV%)A.CS$[#,\RE(
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MC^5@N_&C)/?.[=[FL_F/M5?/4$L! A0#%     @ )8&E4!\CSP/     $P(
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M4$L! A0#%     @ )8&E4"!5?%5@ @  C@@  !@              ( !31(
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( "6!I5 P+#&_
M_P,  ,81   8              "  >,4  !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"% ,4    "  E@:50<\^FFF "  !F!P  &
M@ $8&0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ )8&E
M4"A)N&#' P  5A   !@              ( !KAL  'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;%!+ 0(4 Q0    ( "6!I5"KIH"5^ $  /4$   8
M      "  :L?  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M"  E@:50-2F\=8P$   Z%0  &               @ '9(0  >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&UL4$L! A0#%     @ )8&E4)O);7VG 0  T ,  !@
M             ( !FR8  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4
M Q0    ( "6!I5!>>W:ZM $  -(#   9              "  7@H  !X;"]W
M;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ )8&E4/-.]-BT 0
MT@,  !D              ( !8RH  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6Q02P$"% ,4    "  E@:50(P$1Y[(!  #1 P  &0              @ %.
M+   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( "6!I5"5
M,[,_M $  -(#   9              "  3<N  !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL4$L! A0#%     @ )8&E4$<6V3BT 0  T@,  !D
M     ( !(C   'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "6!I5##P"2>M $  -(#   9              "
M ;@Y  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ )8&E
M4"M+NX2T 0  SP,  !D              ( !HSL  'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6Q02P$"% ,4    "  E@:50%BD82+,!  #1 P  &0
M        @ &./0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0
M   ( "6!I5  V1&NM $  -(#   9              "  7@_  !X;"]W;W)K
M<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ )8&E4*_X9"*T 0  T@,
M !D              ( !8T$  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q0
M2P$"% ,4    "  E@:5052,SW+4!  #2 P  &0              @ %.0P
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( "6!I5"#3SJ=
ML0$  -(#   9              "  3I%  !X;"]W;W)K<VAE971S+W-H965T
M,C4N>&UL4$L! A0#%     @ )8&E4&QT3=&S 0  T@,  !D
M ( !(D<  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    "  E
M@:5038O[TA,#  !2#@  &0              @ $,20  >&PO=V]R:W-H965T
M<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( "6!I5!%=7GDMP$  -(#   9
M          "  59,  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#
M%     @ )8&E4+I(-0?> 0   04  !D              ( !1$X  'AL+W=O
M<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    "  E@:50A >-A+0!  #2
M P  &0              @ %94   >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM
M;%!+ 0(4 Q0    ( "6!I5#XMQ1AM0$  -$#   9              "  412
M  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ )8&E4!+2
MP(?$ 0  -@0  !D              ( !,%0  'AL+W=O<FMS:&5E=',O<VAE
M970S,BYX;6Q02P$"% ,4    "  E@:50?@,A6<<!   W!   &0
M    @ $K5@  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (
M "6!I5#'^KK)W0$   $%   9              "  2E8  !X;"]W;W)K<VAE
M971S+W-H965T,S0N>&UL4$L! A0#%     @ )8&E4%!YTM.V 0  T0,  !D
M             ( !/5H  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"
M% ,4    "  E@:5077=&)<4!   W!   &0              @ $J7   >&PO
M=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( "6!I5"#-B9EM@$
M -(#   9              "  29>  !X;"]W;W)K<VAE971S+W-H965T,S<N
M>&UL4$L! A0#%     @ )8&E4*4E)(;" 0  -P0  !D              ( !
M$V   'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    "  E@:50
M=?;H,[D!  #2 P  &0              @ $,8@  >&PO=V]R:W-H965T<R]S
M:&5E=#,Y+GAM;%!+ 0(4 Q0    ( "6!I5 $? *-(0(  + &   9
M      "  ?QC  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%
M  @ )8&E4%P2*-X! @  "P8  !D              ( !5&8  'AL+W=O<FMS
M:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    "  E@:50D.C>0;P!  #6 P
M&0              @ &,:   >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+
M 0(4 Q0    ( "6!I5#+))XZ]P(  -P+   9              "  7]J  !X
M;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ )8&E4& Z.A N
M!   ,!4  !D              ( !K6T  'AL+W=O<FMS:&5E=',O<VAE970T
M-"YX;6Q02P$"% ,4    "  E@:50""?VXD,"   ]!P  &0
M@ $2<@  >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( "6!
MI5"'R)20G@(  '(*   9              "  8QT  !X;"]W;W)K<VAE971S
M+W-H965T-#8N>&UL4$L! A0#%     @ )8&E4#>,^!U[ @  ] <  !D
M         ( !87<  'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4
M    "  E@:50&F9_\#P#  #0#0  &0              @ $3>@  >&PO=V]R
M:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( "6!I5 ;-(_B4 ,  /4-
M   9              "  89]  !X;"]W;W)K<VAE971S+W-H965T-#DN>&UL
M4$L! A0#%     @ )8&E4,N7D#FR P  YQ   !D              ( !#8$
M 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    "  E@:50)CW-
MIJH"  "]"0  &0              @ 'VA   >&PO=V]R:W-H965T<R]S:&5E
M=#4Q+GAM;%!+ 0(4 Q0    ( "6!I5 V'.N)3 4  /0=   9
M  "  =>'  !X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @
M)8&E4)\BT$6$!   ]!<  !D              ( !6HT  'AL+W=O<FMS:&5E
M=',O<VAE970U,RYX;6Q02P$"% ,4    "  E@:50*.^BO_H$  !F&@  &0
M            @ $5D@  >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4
M Q0    ( "6!I5"4K.[GD04  $<?   9              "  4:7  !X;"]W
M;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ )8&E4"Y:WB=.!
M"A4  !D              ( !#IT  'AL+W=O<FMS:&5E=',O<VAE970U-BYX
M;6Q02P$"% ,4    "  E@:50G4;_8Q$#  "+#   &0              @ &3
MH0  >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( "6!I5#*
M@@ D&@0  + 3   9              "  =ND  !X;"]W;W)K<VAE971S+W-H
M965T-3@N>&UL4$L! A0#%     @ )8&E4)#7QB^, @  \ @  !D
M     ( !+*D  'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "6!I5".G9"U)0,  '0,   9              "
M 4RZ  !X;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ )8&E
M4(;X^%X)!   O!4  !D              ( !J+T  'AL+W=O<FMS:&5E=',O
M<VAE970V-2YX;6Q02P$"% ,4    "  E@:50C+573_P!   3!0  &0
M        @ 'HP0  >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0
M   ( "6!I5 G%J@:DP(  &D(   9              "  1O$  !X;"]W;W)K
M<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @ )8&E4&U_YWO6 0  W@0
M !D              ( !Y<8  'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q0
M2P$"% ,4    "  E@:50L+&80/X!  #L!0  &0              @ 'RR
M>&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( "6!I5!;VV'Y
M( (  )L&   9              "  2?+  !X;"]W;W)K<VAE971S+W-H965T
M-S N>&UL4$L! A0#%     @ )8&E4)(19E[> 0  8P0  !D
M ( !?LT  'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"% ,4    "  E
M@:501D2T[)<"  #K"   &0              @ &3SP  >&PO=V]R:W-H965T
M<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    ( "6!I5 B77>9  (  #$%   9
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M<W1Y;&5S+GAM;%!+ 0(4 Q0    ( "6!I5#7H85.O 4  ,(P   /
M      "  ==Z 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  E@:501'W]
MQ& "  !C+   &@              @ ' @ $ >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    "  E@:50M 9O\1$"  !@*P  $P
M    @ %8@P$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     4P!3 +<6  ":
%A0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6786493200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value of financial instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair value of financial instruments.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair value of financial instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">4.&#160;&#160;&#160;&#160; </b><b style="font-weight:bold;">Fair value of financial instruments</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">FASB accounting guidance defines fair value as the price that would be received to sell an asset or paid to transfer a liability (&#8220;the exit price&#8221;) in an orderly transaction between market participants at the measurement date. The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value we use quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of us. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Level&#160;1&#8212;Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Level&#160;2&#8212;Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Level&#160;3&#8212;Valuations based on inputs that are unobservable and models that are significant to the overall fair value measurement.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recurring Fair Value Measurements</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our marketable securities consist of investments in U.S. government debt securities that are classified as available-for-sale. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At March 31, 2020 and December 31, 2019, our Level 2 U.S. government debt securities were valued using readily available pricing sources which utilize market observable inputs, including the current interest rate and other characteristics for similar types of investments. Our long term investments classified as Level 1 were valued using their respective closing stock prices on The Nasdaq Stock Market. &#160;We did not experience any transfers of financial instruments between the fair value hierarchy levels during the three months ended March 31, 2020.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following fair value hierarchy table presents information about each major category of our financial assets measured at fair value on a recurring basis (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:39.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurement&#160;at&#160;Reporting&#160;Date&#160;Using:</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets&#160;for</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical&#160;Assets</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance&#160;as&#160;of</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, 2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,043,241</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,043,241</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Debt securities (government)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 259,351</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 259,351</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Long term investments (Note 9)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 180,993</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 180,993</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,224,234</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 259,351</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,483,585</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:39.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurement&#160;at&#160;Reporting&#160;Date&#160;Using:</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets&#160;for</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical&#160;Assets</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance&#160;as&#160;of</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31, 2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,832,684</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,832,684</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Debt securities (government)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 284,870</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 284,870</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Long term investments (Note 9)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 133,657</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 133,657</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,966,341</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 284,870</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,251,211</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following fair value hierarchy table presents information about each major category of our financial liabilities measured at fair value on a recurring basis as (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:39.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurement&#160;at&#160;Reporting&#160;Date&#160;Using:</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets&#160;for</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical&#160;Liabilities</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance&#160;as&#160;of</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, 2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Acquisition-related contingent consideration</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 275,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 275,000</p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 275,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 275,000</p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100.5%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:39.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurement&#160;at&#160;Reporting&#160;Date&#160;Using:</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets&#160;for</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical&#160;Liabilities</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance&#160;as&#160;of</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31, 2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Acquisition-related contingent consideration</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 277,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 277,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 277,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 277,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following is a rollforward of our Level 3 liabilities (in thousands):</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:82.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Balance at January 1, </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 277,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Contingent consideration earned during the period but not yet paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (8,627)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Change in fair value of contingent consideration</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,627</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Balance at March&#160;31, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 275,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The fair value of the contingent consideration was determined on the date of acquisition, June 1, 2016, using an income approach based on estimated ICLUSIG revenues in the European Union and other countries for the approved third line treatment over 18 years, and discounted to present value at a rate of 10%. The fair value of the contingent consideration is remeasured each reporting period, with changes in fair value recorded in the consolidated statements of operations. The valuation inputs utilized to estimate the fair value of the contingent consideration as of March 31, 2020 included a weighted average cost of capital of 10% and updated projections of future ICLUSIG revenues in the European Union and other </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">countries for the approved third line treatment. The change in fair value of the contingent consideration during the three months ended March 31, 2020 was due primarily to the passage of time as there were no other significant changes in the key assumptions during the period. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We make payments to Takeda quarterly based on the royalties or any additional milestone payments earned in the previous quarter. At March 31, 2020 and December 31, 2019, contingent consideration earned but not yet paid was $8.6 million and $23.0 million, respectively, and was included in accrued and other current liabilities.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"> The following is a summary of our marketable security portfolio for the periods presented (in thousands):</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:99.15%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">March&#160;31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Debt securities (government)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 258,622</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 729</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 259,351</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">December&#160;31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Debt securities (government)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 284,795</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 75</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 284,870</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our available-for-sale debt securities generally have contractual maturity dates of between <span style="-sec-ix-hidden:Hidden_wxfFNirtIkK2gW_Xg1C_gw"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">12</span></span> to 18 months. Debt security assets were assessed for risk of expected credit losses per our accounting policy as described in Note 2. As of March 31, 2020 and December 31, 2019, the available-for-sale debt securities were held in US-government backed funds and Treasury assets and were assessed on an individual security basis to have a de minimis risk of credit loss.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6786403584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets and goodwill<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible assets and goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible assets and goodwill</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">8.&#160;&#160;&#160;&#160;Intangible assets and goodwill</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intangible Assets, Net</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The components of intangible assets were as follows (in thousands, except for useful life):</p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100.55%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:23.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:23.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="color:#0000ff;font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:30.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at March&#160;31, 2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:30.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at December&#160;31, 2019</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:23.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="color:#0000ff;font-size:14pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:23.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average Useful</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:23.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Lives (Years)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td colspan="3" style="background-color:auto;vertical-align:bottom;width:35.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Finite-lived intangible assets:</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:23.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Licensed IP</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;">12.5</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 271,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 82,556</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 188,444</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 271,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 77,172</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 193,828</p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Estimated aggregate amortization expense based on the current carrying value of amortizable intangible assets is as follows (in thousands):</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100.01%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:40.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:40.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remainder of</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:40.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Thereafter</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:40.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Amortization expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,152</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,536</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,536</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,536</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,536</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 86,148</p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Goodwill</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There were no changes to the carrying amount of goodwill for the three months ended March 31, 2020.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6784497712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net income (loss) per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income (loss) per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of calculation of net income (loss) per share</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net income (loss) per share was calculated as follows for the periods indicated below:</p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months&#160;Ended</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:76.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands, except per share data)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Basic Net Income (Loss) Per Share</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Basic net income (loss) per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (720,642)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 102,312</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted average common shares outstanding</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 216,721</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 214,065</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Basic net income (loss) per share</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (3.33)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.48</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Diluted Net Income (Loss) Per Share</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Diluted net income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (720,642)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 102,312</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted average common shares outstanding</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 216,721</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 214,065</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Dilutive stock options and awards</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,996</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted average shares used to compute diluted net income (loss) per share </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 216,721</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 217,061</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;">Diluted net income (loss) per share</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (3.33)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.47</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of antidilutive securities excluded from the computation of earnings per share</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The potential common shares that were excluded from the diluted net income (loss) per share computation are as follows:</p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:33.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months&#160;Ended</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:33.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:15.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Outstanding stock options and awards</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,544,348</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,318,013</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Common shares issuable upon conversion of the 2020 Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 368,939</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 368,939</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Total potential common shares excluded from diluted net income (loss) per share computation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,913,287</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,686,952</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6958527808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of valuation assumptions used for valuation of fair value of stock compensation granted</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We utilized the Black-Scholes valuation model for estimating the fair value of the stock compensation granted, with the following weighted-average assumptions:</p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:99.53%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:55.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Employee Stock Options</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:23.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Employee Stock Purchase Plan</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:55.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:40.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Three Months&#160;Ended March&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:55.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#8194;&#8194;&#8194;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#8194;&#8194;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#8194;&#8194;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#8194;&#8194;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Average risk-free interest rates</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.56 </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;&#8194;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.51</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;&#8194;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.23 </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;&#8194;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.27</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;&#8194;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Average expected life (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4.65 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.25 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Volatility</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">40 </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">45</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">52 </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">34</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Weighted-average fair value (in dollars)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">28.43 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">31.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">16.00 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">13.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of option activity under the 2010 Stock Plan</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Option activity under our 2010 Amended and Restated Stock Incentive Plan (the &#8220;2010 Stock Plan&#8221;) was as follows:</p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:25.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares&#160;Subject&#160;to</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:25.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding&#160;Options</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Balance at December&#160;31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,632,657</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81.42</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 914,834</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80.12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Options exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (688,202)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26.83</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Options cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (180,342)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 91.57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Balance at March&#160;31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,678,947</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84.14</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock', window );">Schedule of RSU award and PSU activity under the 2010 Stock Plan</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Restricted stock unit (&#8220;RSU&#8221;) and performance share (&#8220;PSU&#8221;) award activity under the 2010 Stock Plan was as follows:</p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:24.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares&#160;Subject&#160;to</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:24.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding&#160;Awards</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date Value</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Balance at December&#160;31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,602,376</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79.69</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">RSUs granted </p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 379,496</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80.32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">RSUs released</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (64,426)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 87.36</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">RSUs cancelled </p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (39,795)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">PSUs cancelled</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (12,250)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65.76</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Balance at March&#160;31, 2020</p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,865,401</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Summary of shares available for grant</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our shares available for grant under the 2010 Stock Plan:</p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:81.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:15.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares Available</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:81.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:15.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for Grant</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Balance at December&#160;31, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,882,122</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Options, RSUs and PSUs granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (1,673,826)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Options, RSUs and PSUs cancelled</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 247,429</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Balance at March&#160;31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,455,725</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure represents the schedule of share based compensation other than stock options activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_ScheduleOfShareBasedCompensationOtherThanStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock options plan and employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6786185136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentration of credit risk and current expected credit losses (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Concentration of credit risk and current expected credit losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_SchedulesOfConcentrationOfRiskByRiskFactorRelatedToSpecialtyPharmaceuticalCustomersTableTextBlock', window );">Schedule of concentration of credit risk related to specialty pharmacy customers</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:26.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percentage&#160;of&#160;Total&#160;Net</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:26.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Product&#160;Revenues&#160;for&#160;the</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:26.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months&#160;Ended</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:26.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Customer A</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Customer B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Customer C</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Customer D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_SchedulesOfConcentrationOfRiskByRiskFactorRelatedToSpecialtyPharmaceuticalCustomersTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark, related to the specialty pharmaceutical customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_SchedulesOfConcentrationOfRiskByRiskFactorRelatedToSpecialtyPharmaceuticalCustomersTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792669424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets and goodwill (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Amortization Expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Remainder of 2020</a></td>
<td class="nump">$ 16,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2021</a></td>
<td class="nump">21,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2022</a></td>
<td class="nump">21,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2023</a></td>
<td class="nump">21,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2024</a></td>
<td class="nump">21,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">86,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Changes to carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPeriodIncreaseDecrease', window );">Changes to the carry amount of goodwill</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Licensed IP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted Average Useful Lives (Years)</a></td>
<td class="text">12 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 271,000<span></span>
</td>
<td class="nump">$ 271,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">82,556<span></span>
</td>
<td class="nump">77,172<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 188,444<span></span>
</td>
<td class="nump">$ 193,828<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent Finite Lived And Indefinite Lived Intangible Assets By Major Class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6801016624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License agreements - Merus (Details)<br> $ / shares in Units, $ in Thousands, &#8364; in Millions, shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 23, 2017 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 28, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2017 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 133,657<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,085,287<span></span>
</td>
<td class="nump">$ 270,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) on long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48,132)<span></span>
</td>
<td class="nump">20,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,716,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,481,488<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">503,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">513,340<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MerusNVMember', window );">Merus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementMaximumNumberOfIndependentPrograms', window );">Number of independent programs | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementNumberOfPreclinicalDiscoveryPrograms', window );">Number of preclinical discovery programs | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment', window );">Number of programs under the resulting products are co-funded for development | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds', window );">Associated future global development costs , if elected to co-develop (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementUpfrontPaymentAmountPaid', window );">Upfront payment under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MerusNVMember', window );">Merus | Accrued and other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued and other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MerusNVMember', window );">Merus | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_CollaborationAgreementProfitSharingPercentage', window );">Profit sharing (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_PercentageOfProfitsLosses', window );">Percentage of profit (losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MerusNVMember', window );">Merus | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_PercentageOfRoyaltyRatePayments', window );">Royalty payments on future global net sales (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MerusNVMember', window );">Merus | Minimum | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_PercentageOfRoyaltyRatePayments', window );">Royalty payments on future global net sales (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MerusNVMember', window );">Merus | Minimum | Non-U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_PercentageOfRoyaltyRatePayments', window );">Royalty payments on future global net sales (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MerusNVMember', window );">Merus | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms', window );">Number of additional preclinical discovery programs | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_PercentageOfRoyaltyRatePayments', window );">Royalty payments on future global net sales (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_PercentageOfReverseRoyaltiesOnSaleOfFutureProducts', window );">Percentage of reverse royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MerusNVMember', window );">Merus | Maximum | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_PercentageOfRoyaltyRatePayments', window );">Royalty payments on future global net sales (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_PercentageOfNetSalesPertainingToAdditionalRoyalties', window );">Percentage of additional royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MerusNVMember', window );">Merus | Maximum | Non-U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_PercentageOfRoyaltyRatePayments', window );">Royalty payments on future global net sales (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MerusNVMember', window );">Merus | Maximum | Development and Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementAdditionalMilestonePayments', window );">Additional milestone payments under the license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MerusNVMember', window );">Merus | Maximum | Commercialization Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementAdditionalMilestonePayments', window );">Additional milestone payments under the license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_MerusNVMember', window );">Merus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue', window );">Total revenues | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 31.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss', window );">Net loss | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (55.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_MerusNVMember', window );">Merus | Stock purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares', window );">Purchase of common stock under Stock Purchase Agreement (in shares ) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Purchase price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Per share price | $ / shares</a></td>
<td class="nump">$ 24.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_FairValueInputsAmountOfDiscountForLackOfMarketability', window );">Discount for lack of marketability</a></td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Fair value of shares on the issuance date</a></td>
<td class="nump">72,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_TotalConsiderationPaidUnderPurchaseAgreement', window );">Total consideration paid</a></td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Fair market value of our long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,100<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) on long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,300)<span></span>
</td>
<td class="num">$ (2,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="11"></td></tr>
<tr><td colspan="11"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size:9pt;">The condensed consolidated balance sheet at December 31, 2019 has been derived from the audited consolidated financial statements at that date.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_CollaborationAgreementProfitSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of profits and losses shared under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_CollaborationAgreementProfitSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_FairValueInputsAmountOfDiscountForLackOfMarketability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to the amount of discount used to measure fair value for lack of ability to convert business interests into cash quickly..</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_FairValueInputsAmountOfDiscountForLackOfMarketability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementAdditionalMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the additional milestone payments to be made under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementAdditionalMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementMaximumNumberOfIndependentPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum number of independent programs encompassed under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementMaximumNumberOfIndependentPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of additional preclinical discovery programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementNumberOfPreclinicalDiscoveryPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of preclinical immuno-oncology discovery programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementNumberOfPreclinicalDiscoveryPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementUpfrontPaymentAmountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of the upfront payment made under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementUpfrontPaymentAmountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of programs in which the resulting products are co-funded for development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of associated future global development costs from the initiation of a Phase IIb trial provided the entity elects to co-develop any compounds and/or indications.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_PercentageOfNetSalesPertainingToAdditionalRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of net sales attributable to additional royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_PercentageOfNetSalesPertainingToAdditionalRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_PercentageOfProfitsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of profits (losses).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_PercentageOfProfitsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_PercentageOfReverseRoyaltiesOnSaleOfFutureProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of reverse royalties on sale of future products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_PercentageOfReverseRoyaltiesOnSaleOfFutureProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_PercentageOfRoyaltyRatePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents range of tiered, double-digit royalty payments on future global sales if product is successfully commercialized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_PercentageOfRoyaltyRatePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the purchase of common stock under Stock Purchase Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_TotalConsiderationPaidUnderPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of the total consideration paid under purchase agreement during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_TotalConsiderationPaidUnderPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of the entity's equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33912-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from sale of product and rendering of service reported by equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=incy_MerusNVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=incy_MerusNVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_MerusNVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_MerusNVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=incy_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=incy_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6958575792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Marketable securities-amortized cost</a></td>
<td class="nump">$ 258,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Marketable securities-allowance for credit losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">216,952,325<span></span>
</td>
<td class="nump">216,177,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">216,952,325<span></span>
</td>
<td class="nump">216,177,830<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6787410832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of shares of Common Stock upon exercise of stock options and restricted stock units</a></td>
<td class="nump">772,538<span></span>
</td>
<td class="nump">1,044,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of shares of Common Stock for services rendered</a></td>
<td class="nump">1,957<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6786621792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License agreements - Innovent (Details) - Innovent<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived', window );">Upfront and immediate milestone payment to be received under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementReimbursableCosts', window );">Reimbursable costs included in accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_NumberOfProductCandidates', window );">Product candidates | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_InnoventBiologicsIncMember', window );">Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone', window );">Amount recognized and received for the achievement of a predefined milestone</a></td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_InnoventBiologicsIncMember', window );">Development and Regulatory Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived', window );">Upfront and immediate milestone payment to be received under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_InnoventBiologicsIncMember', window );">Commercialization Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived', window );">Upfront and immediate milestone payment to be received under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 202.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the earning recognized and the payment received for the achievement of a predefined milestone under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementReimbursableCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents reimbursable costs pertaining to license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementReimbursableCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the upfront and immediate milestone payment received under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_NumberOfProductCandidates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of clinical-stage product candidates .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_NumberOfProductCandidates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=incy_InnoventBiologicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=incy_InnoventBiologicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6651145984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee benefit plans - Periodic Benefit Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee benefit plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Employer Service cost</a></td>
<td class="nump">$ 1,457<span></span>
</td>
<td class="nump">$ 1,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">(60)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service cost</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Amortization of actuarial losses</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="nump">$ 1,694<span></span>
</td>
<td class="nump">$ 1,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList', window );">Location of costs excluding the service component</a></td>
<td class="text">us-gaap:OtherNonoperatingIncomeExpense<span></span>
</td>
<td class="text">us-gaap:OtherNonoperatingIncomeExpense<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear', window );">Expected contributions</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities', window );">Accrued pension obligation</a></td>
<td class="nump">$ 24,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension plan. Excludes other postretirement benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActuarialGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActuarialGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contributions received and expected to be received by defined benefit plan from employer in current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes components of net periodic benefit cost (credit), excluding service cost component, for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791543056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and equipment, net - Property and equipment, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, gross</a></td>
<td class="nump">$ 538,366<span></span>
</td>
<td class="nump">$ 499,437<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(128,332)<span></span>
</td>
<td class="num">(121,870)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and Equipment, net</a></td>
<td class="nump">410,034<span></span>
</td>
<td class="nump">377,567<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, gross</a></td>
<td class="nump">15,285<span></span>
</td>
<td class="nump">15,303<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, gross</a></td>
<td class="nump">72,352<span></span>
</td>
<td class="nump">70,510<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, gross</a></td>
<td class="nump">60,077<span></span>
</td>
<td class="nump">59,069<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, gross</a></td>
<td class="nump">10,227<span></span>
</td>
<td class="nump">10,203<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=incy_BuildingAndLeaseholdImprovementsMember', window );">Building and leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, gross</a></td>
<td class="nump">208,276<span></span>
</td>
<td class="nump">208,293<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=incy_OperatingLeaseRightOfUseAssetsMember', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, gross</a></td>
<td class="nump">18,641<span></span>
</td>
<td class="nump">19,672<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, gross</a></td>
<td class="nump">$ 153,508<span></span>
</td>
<td class="nump">$ 116,387<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size:9pt;">The condensed consolidated balance sheet at December 31, 2019 has been derived from the audited consolidated financial statements at that date.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=incy_BuildingAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=incy_BuildingAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=incy_OperatingLeaseRightOfUseAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=incy_OperatingLeaseRightOfUseAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6799307840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value of financial instruments - Fair value on a recurring basis (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 01, 2016</div></th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value of financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long term investments (Note 6)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,993<span></span>
</td>
<td class="nump">$ 133,657<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=incy_AriadPharmaceuticalsMember', window );">ARIAD | Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Roll forward of Level 3 liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_FairValueInputsCashFlowsEstimatedPeriod', window );">Projected cash flows period</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=incy_AriadPharmaceuticalsMember', window );">ARIAD | Discount rate | Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Roll forward of Level 3 liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Valuation input (as a percent)</a></td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=incy_AriadPharmaceuticalsMember', window );">ARIAD | Average Cost of Capital | Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Roll forward of Level 3 liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Valuation input (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=incy_AriadPharmaceuticalsMember', window );">ARIAD | Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Roll forward of Level 3 liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned', window );">Contingent consideration earned during the period but not yet paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,600)<span></span>
</td>
<td class="num">(23,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Roll forward of Level 3 liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned', window );">Contingent consideration earned during the period but not yet paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,627)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,000<span></span>
</td>
<td class="nump">277,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value of financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,043,241<span></span>
</td>
<td class="nump">1,832,684<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities (government)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259,351<span></span>
</td>
<td class="nump">284,870<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long term investments (Note 6)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,993<span></span>
</td>
<td class="nump">133,657<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,483,585<span></span>
</td>
<td class="nump">2,251,211<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Acquisition-related contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,000<span></span>
</td>
<td class="nump">277,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,000<span></span>
</td>
<td class="nump">277,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value of financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,043,241<span></span>
</td>
<td class="nump">1,832,684<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long term investments (Note 6)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,993<span></span>
</td>
<td class="nump">133,657<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,224,234<span></span>
</td>
<td class="nump">1,966,341<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value of financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities (government)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259,351<span></span>
</td>
<td class="nump">284,870<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259,351<span></span>
</td>
<td class="nump">284,870<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value of financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Acquisition-related contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,000<span></span>
</td>
<td class="nump">277,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275,000<span></span>
</td>
<td class="nump">$ 277,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size:9pt;">The condensed consolidated balance sheet at December 31, 2019 has been derived from the audited consolidated financial statements at that date.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the value of a contingent consideration liability attributable to consideration earned by the acquiree in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityConsiderationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_FairValueInputsCashFlowsEstimatedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time used to measure cash flows to find the present value of an amount to be paid or received in the future as an input to measure fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_FairValueInputsCashFlowsEstimatedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=incy_AriadPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=incy_AriadPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_LiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_LiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputCapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputCapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=incy_AccruedAndOtherCurrentLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=incy_AccruedAndOtherCurrentLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6797854784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>issuer </div>
<div>item </div>
<div>instrument</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_ConcentrationOfCreditRiskAbstract', window );"><strong>Concentrations of Credit Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_CreditExposureLimitationNumberOfIssuerOtherThanUnitedStatesGovernmentGuaranteedSecurities', window );">Number of issuer to which company limits the amount of credit exposure other than US Government guaranteed securities | issuer</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_CreditExposureLimitationNumberOfFinancialInvestmentOtherThanUnitedStatesGovernmentGuaranteedSecurities', window );">Number of financial investment to which company limits the amount of credit exposure other than US Government guaranteed securities | instrument</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_VariableInterestEntitiesAbstract', window );"><strong>Variable Interest Entities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_VariableInterestEntitiesNumber', window );">Number of entities in which variable interest held | item</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=incy_JAKAFIMember', window );">JAKAFI</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_InventoryFinishedGoodsUsefulLifeMaximum', window );">Shelf life for finished goods inventory, maximum</a></td>
<td class="text">36 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=incy_ICLUSIGMember', window );">ICLUSIG</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_InventoryFinishedGoodsUsefulLifeMaximum', window );">Shelf life for finished goods inventory, maximum</a></td>
<td class="text">36 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_ConcentrationOfCreditRiskAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_ConcentrationOfCreditRiskAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_CreditExposureLimitationNumberOfFinancialInvestmentOtherThanUnitedStatesGovernmentGuaranteedSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of financial investment to which entity limits the amount of credit exposure other than US Government guaranteed securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_CreditExposureLimitationNumberOfFinancialInvestmentOtherThanUnitedStatesGovernmentGuaranteedSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_CreditExposureLimitationNumberOfIssuerOtherThanUnitedStatesGovernmentGuaranteedSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of issuer to which entity limits the amount of credit exposure other than US Government guaranteed securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_CreditExposureLimitationNumberOfIssuerOtherThanUnitedStatesGovernmentGuaranteedSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_InventoryFinishedGoodsUsefulLifeMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum useful life of merchandise or goods held by the entity that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_InventoryFinishedGoodsUsefulLifeMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_VariableInterestEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_VariableInterestEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_VariableInterestEntitiesNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of Variable Interest Entities as on date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_VariableInterestEntitiesNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=incy_JAKAFIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=incy_JAKAFIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=incy_ICLUSIGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=incy_ICLUSIGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6643236032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock compensation - Option activity (Details) - Stock Options - $ / shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares Subject to Outstanding Options, Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the beginning of the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,632,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">914,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(688,202)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(180,342)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end of the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,678,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Shares Subject to Outstanding Options, Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the beginning of the period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options cancelled (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the end of the period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Termination period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Vesting after one year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Shares Subject to Outstanding Options, Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting Percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Remainder vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Shares Subject to Outstanding Options, Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6643480320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued and other current liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued and Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties</a></td>
<td class="nump">$ 73,045<span></span>
</td>
<td class="nump">$ 73,221<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_AccruedClinicalRelatedCostsCurrent', window );">Clinical related costs</a></td>
<td class="nump">77,913<span></span>
</td>
<td class="nump">88,710<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForLossOnContracts', window );">Sales allowances</a></td>
<td class="nump">96,062<span></span>
</td>
<td class="nump">59,924<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionPayableCurrent', window );">Construction in progress</a></td>
<td class="nump">13,582<span></span>
</td>
<td class="nump">12,732<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">9,021<span></span>
</td>
<td class="nump">9,343<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">60,411<span></span>
</td>
<td class="nump">42,020<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued and other current liabilities</a></td>
<td class="nump">$ 330,034<span></span>
</td>
<td class="nump">$ 285,950<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size:9pt;">The condensed consolidated balance sheet at December 31, 2019 has been derived from the audited consolidated financial statements at that date.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AccruedClinicalRelatedCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical related costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AccruedClinicalRelatedCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForLossOnContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative provision for contract losses not offset against related costs accumulated on the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 35<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68068069&amp;loc=d3e57777-111642<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForLossOnContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6786520016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">12.&#160;&#160;&#160;&#160; </b><b style="font-weight:bold;">Debt</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The components of the convertible senior notes are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:56.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying&#160;Amount,</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:56.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Interest&#160;Rates</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:56.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Debt</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, 2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maturities</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">1.25% Convertible Senior Notes due 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.25</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,524</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,300</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The carrying amount and fair value of our convertible senior notes are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:59.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:18.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, 2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:18.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31, 2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:59.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:59.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">1.25% Convertible Senior Notes due 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,524</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,656</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,300</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,511</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fair value of the 1.25% Convertible Senior Notes due 2020 (the &#8220;2020 Notes&#8221;) is based on data from readily available pricing sources which utilize market observable inputs and other characteristics for similar types of instruments, and, therefore, is classified within Level 2 in the fair value hierarchy. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to May 14, 2014, the 2020 Notes were not convertible except in connection with a make-whole fundamental change, as defined in the indenture. Beginning on, and including, May 15, 2014, the 2020 Notes are convertible prior to the close of business on the business day immediately preceding May 15, 2020 only under the following circumstances: (i) during any calendar quarter commencing after the calendar quarter ending on March 31, 2014 (and only during such calendar quarter), if the last reported sale price of our common stock for at least <span style="-sec-ix-hidden:Hidden_1LuKVsI460CF2sHZ2dlGqw"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">20</span></span> trading days (whether or not consecutive) during a period of <span style="-sec-ix-hidden:Hidden_Rv9y-6kA30urzn5y6CwGRg"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">30</span></span> consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price for the 2020 Notes on each applicable trading day; (ii) during the five business day period after any five consecutive trading day period (the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of the 2020 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate for the 2020 Notes on each such trading day; or (iii) upon the occurrence of specified corporate events. On or after May 15, 2020 until the close of business on the <span style="-sec-ix-hidden:Hidden_LuZKOSV89k6ANKuV9BpZOg"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">second</span></span> scheduled trading day immediately preceding the relevant maturity date, the 2020 Notes are convertible at any time, regardless of the foregoing circumstances. Upon conversion we will pay or deliver, as the case may be, cash, shares of common stock or a combination of cash and shares of common stock, at our election.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April 1, 2020, the 2020 Notes became convertible through at least June 30, 2020, based on meeting the conversion criteria related to the sale price of our common stock during the calendar quarter ended March 31, 2020 as described in (i) above. The 2020 Notes are reflected in current liabilities on the condensed consolidated balance sheet as of March 31, 2020 due to their maturity date of November 15, 2020, unless earlier purchased or converted.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6781045808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LitigationDisclosureAbstract', window );"><strong>Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">16.&#160;&#160;&#160;&#160;Contingencies</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">In December 2018, we received a civil investigative demand from the U.S. Department of Justice (&#8220;DOJ&#8221;) for documents and information relating to our speaker programs and patient assistance programs, including our support of non-profit organizations that provide financial assistance to eligible patients. We have cooperated with this inquiry.&#160; In November 2019, the <i style="font-style:italic;">qui tam</i> complaint underlying the DOJ inquiry was unsealed (&#8220;Complaint&#8221;), at which time we learned that a former employee whom we had terminated had made certain allegations relating to the programs described above. &#160;We then became aware that the DOJ had not intervened in the <i style="font-style:italic;">qui tam</i> action, and, to our knowledge, the DOJ has not intervened to date. &#160;We filed an answer to the Complaint on January 22, 2020, and the action is proceeding. &#160;We cannot predict the outcome or the timing of the ultimate resolution of the investigation or <i style="font-style:italic;">qui tam</i> action, or reasonably estimate the possible range of loss, if any, that may result from these matters. &#160;Accordingly, no reserve has been made with respect to these matters as of March 31, 2020.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LitigationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LitigationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6780889248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value of financial instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair value of financial instruments.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of fair value of assets measured on recurring basis</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following fair value hierarchy table presents information about each major category of our financial assets measured at fair value on a recurring basis (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:39.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurement&#160;at&#160;Reporting&#160;Date&#160;Using:</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets&#160;for</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical&#160;Assets</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance&#160;as&#160;of</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, 2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,043,241</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,043,241</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Debt securities (government)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 259,351</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 259,351</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Long term investments (Note 9)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 180,993</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 180,993</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,224,234</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 259,351</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,483,585</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:39.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurement&#160;at&#160;Reporting&#160;Date&#160;Using:</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets&#160;for</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical&#160;Assets</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance&#160;as&#160;of</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31, 2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,832,684</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,832,684</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Debt securities (government)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 284,870</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 284,870</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Long term investments (Note 9)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 133,657</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 133,657</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,966,341</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 284,870</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,251,211</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of fair value of liabilities measured on recurring basis</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following fair value hierarchy table presents information about each major category of our financial liabilities measured at fair value on a recurring basis as (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:39.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurement&#160;at&#160;Reporting&#160;Date&#160;Using:</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets&#160;for</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical&#160;Liabilities</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance&#160;as&#160;of</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, 2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Acquisition-related contingent consideration</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 275,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 275,000</p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 275,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 275,000</p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100.5%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:39.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurement&#160;at&#160;Reporting&#160;Date&#160;Using:</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets&#160;for</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical&#160;Liabilities</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance&#160;as&#160;of</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31, 2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Acquisition-related contingent consideration</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 277,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 277,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 277,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 277,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of roll forward of Level 3 liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following is a rollforward of our Level 3 liabilities (in thousands):</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:82.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Balance at January 1, </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 277,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Contingent consideration earned during the period but not yet paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (8,627)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Change in fair value of contingent consideration</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,627</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Balance at March&#160;31, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 275,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of marketable securities portfolio</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"> The following is a summary of our marketable security portfolio for the periods presented (in thousands):</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:99.15%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">March&#160;31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Debt securities (government)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 258,622</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 729</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 259,351</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">December&#160;31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Debt securities (government)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 284,795</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 75</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 284,870</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792262496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value of financial instruments - Marketable securities portfolio (Details) - Debt securities (government) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Summary of marketable security portfolio</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 258,622<span></span>
</td>
<td class="nump">$ 284,795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Net Unrealized Gains</a></td>
<td class="nump">729<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 259,351<span></span>
</td>
<td class="nump">$ 284,870<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=incy_CorporateAndGovernmentDebtSecuritiesMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Summary of marketable security portfolio</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Contractual maturity dates</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=incy_CorporateAndGovernmentDebtSecuritiesMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Summary of marketable security portfolio</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Contractual maturity dates</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=incy_CorporateAndGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=incy_CorporateAndGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6798715312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - Revenue Recognition (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_PercentageOfMedicarePartDInsuranceCoverageGapRequiredToBeFundedByManufacturers', window );">Percentage of Medicare Part D insurance coverage gap mandate to be funded by manufacturers</a></td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_MedicarePartDInsuranceCoverageGapIncreaseInEligiblePatientSpendingPercentage', window );">Increase in required patient spending in the Medicare Part D insurance coverage gap (as a percent)</a></td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_MorphosysAgMember', window );">MorphoSys AG</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_CollaborationAgreementProfitLossSharingRatio', window );">Profit (loss) sharing ratio</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=incy_ICLUSIGMember', window );">ICLUSIG</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Amortization period</a></td>
<td class="text">12 years 6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_CollaborationAgreementProfitLossSharingRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio of sharing profit and losses under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_CollaborationAgreementProfitLossSharingRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_MedicarePartDInsuranceCoverageGapIncreaseInEligiblePatientSpendingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the Medicare Part D insurance coverage gap percent increase for required patient spending.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_MedicarePartDInsuranceCoverageGapIncreaseInEligiblePatientSpendingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_PercentageOfMedicarePartDInsuranceCoverageGapRequiredToBeFundedByManufacturers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of Medicare Part D insurance coverage gap mandate to be funded by manufacturers for prescription drugs sold to eligible patients.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_PercentageOfMedicarePartDInsuranceCoverageGapRequiredToBeFundedByManufacturers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=incy_MorphosysAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=incy_MorphosysAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=incy_ICLUSIGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=incy_ICLUSIGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6798984368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net - Buildings and construction (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2018 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,622<span></span>
</td>
<td class="nump">$ 29,058<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Costs for architectural and engineering studies and initial ground preparation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">538,366<span></span>
</td>
<td class="nump">499,437<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Costs for architectural and engineering studies and initial ground preparation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 153,508<span></span>
</td>
<td class="nump">$ 116,387<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealEstatePropertiesAxis=incy_OfficeBuildingMorgesSwitzerlandMember', window );">Office Building in Morges, Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Initial lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend', window );">Options to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRenewalTerm1', window );">Renewal term of agreement to rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Square footage | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Financing lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 31,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">29,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_FinanceLeaseLeaseIncentiveReceivable', window );">Finance Lease, Lease Incentive Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Site preparation, design and construction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealEstatePropertiesAxis=incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember', window );">Land in Y-PARC, Switzerland's largest technology park, Yverdon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRealEstate', window );">Purchase price</a></td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealEstatePropertiesAxis=incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember', window );">Land in Y-PARC, Switzerland's largest technology park, Yverdon | Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Costs for architectural and engineering studies and initial ground preparation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size:9pt;">The condensed consolidated balance sheet at December 31, 2019 has been derived from the audited consolidated financial statements at that date.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_FinanceLeaseLeaseIncentiveReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of lease incentive receivable from landlord under finance leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_FinanceLeaseLeaseIncentiveReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseRenewalTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseRenewalTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireRealEstate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the acquisition of a piece of land, anything permanently fixed to it, including buildings, structures on it and so forth; includes real estate intended to generate income for the owner; excludes real estate acquired for use by the owner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireRealEstate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealEstatePropertiesAxis=incy_OfficeBuildingMorgesSwitzerlandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealEstatePropertiesAxis=incy_OfficeBuildingMorgesSwitzerlandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealEstatePropertiesAxis=incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealEstatePropertiesAxis=incy_LandLocatedWithinYParcSwitzerlandsLargestTechnologyParkInYverdonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791743696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock compensation (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense</a></td>
<td class="nump">$ 42.5<span></span>
</td>
<td class="nump">$ 40.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_StockCompensationExpenseCapitalized', window );">Stock Compensation Expense Capitalized</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate', window );">Assumed annualized forfeiture rate (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average fair value assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed', window );">Valuation method</a></td>
<td class="text">Black-Scholes valuation model<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense</a></td>
<td class="nump">$ 28.7<span></span>
</td>
<td class="nump">27.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense</a></td>
<td class="nump">13.6<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average fair value assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Average risk-free interest rates (as a percent)</a></td>
<td class="nump">0.23%<span></span>
</td>
<td class="nump">2.27%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Average expected life (in years)</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as a percent)</a></td>
<td class="nump">52.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value (in dollars per share)</a></td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="nump">$ 13.31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average fair value assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Average risk-free interest rates (as a percent)</a></td>
<td class="nump">1.56%<span></span>
</td>
<td class="nump">2.51%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Average expected life (in years)</a></td>
<td class="text">4 years 7 months 24 days<span></span>
</td>
<td class="text">5 years 3 months 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as a percent)</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value (in dollars per share)</a></td>
<td class="nump">$ 28.43<span></span>
</td>
<td class="nump">$ 31.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract', window );"><strong>Unrecognized compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost for nonvested option (in dollars)</a></td>
<td class="nump">$ 95.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Vesting period of recognition of the unrecognized compensation cost of nonvested awards</a></td>
<td class="text">1 year 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract', window );"><strong>Unrecognized compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost for nonvested option (in dollars)</a></td>
<td class="nump">$ 93.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Vesting period of recognition of the unrecognized compensation cost of nonvested awards</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Stock Units (PSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract', window );"><strong>Unrecognized compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost for nonvested option (in dollars)</a></td>
<td class="nump">$ 29.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Vesting period of recognition of the unrecognized compensation cost of nonvested awards</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expected annualized forfeiture rate for options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedAnnualizedForfeitureRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_StockCompensationExpenseCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of stock compensation expenses capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_StockCompensationExpenseCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of method used to estimate fair value of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6633909216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock compensation - Shares available for grant (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward', window );"><strong>Shares Available For Grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Outstanding at the beginning of the period (in shares)</a></td>
<td class="nump">9,882,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted', window );">Options, RSUs and PSUs granted (in shares)</a></td>
<td class="num">(1,673,826)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled', window );">Options, RSUs and PSUs cancelled (in shares)</a></td>
<td class="nump">247,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Outstanding at the end of the period (in shares)</a></td>
<td class="nump">8,455,725<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares canceled under an established share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCanceled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares granted under an established share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6967302864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of disaggregated revenue</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As discussed in Note 2, revenues are recognized under guidance within ASC 606 and ASC 808. The following table presents our disaggregated revenue for the periods presented (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:41.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months&#160;Ended</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:41.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:18.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">JAKAFI revenues, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 459,479</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 375,611</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">ICLUSIG revenues, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,248</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,638</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Total product revenues, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 486,727</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 396,249</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">JAKAVI product royalty revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 56,333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45,571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">OLUMIANT product royalty revenues</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,447</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,037</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Total product royalty revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81,780</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 61,608</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Milestone and contract revenues</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 568,507</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.5%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 497,857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6786395280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued and other current liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued and other current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued and other current liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">11.&#160;&#160;&#160;&#160; </b><b style="font-weight:bold;">Accrued and other current liabilities</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accrued and other current liabilities consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:17.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31, </b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:17.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Royalties</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73,045</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73,221</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Clinical related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 77,913</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88,710</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Sales allowances</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 96,062</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59,924</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,582</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,732</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Operating lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,343</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 60,411</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,020</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Total accrued and other current liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 330,034</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 285,950</p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6786127936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net income (loss) per share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income (loss) per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net income (loss) per share</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">15.&#160;&#160;&#160;&#160;Net income (loss) per share</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net income (loss) per share was calculated as follows for the periods indicated below:</p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months&#160;Ended</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:76.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands, except per share data)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Basic Net Income (Loss) Per Share</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Basic net income (loss) per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (720,642)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 102,312</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted average common shares outstanding</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 216,721</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 214,065</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Basic net income (loss) per share</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (3.33)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.48</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Diluted Net Income (Loss) Per Share</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Diluted net income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (720,642)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 102,312</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted average common shares outstanding</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 216,721</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 214,065</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Dilutive stock options and awards</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,996</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted average shares used to compute diluted net income (loss) per share </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 216,721</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 217,061</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;">Diluted net income (loss) per share</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (3.33)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.47</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The potential common shares that were excluded from the diluted net income (loss) per share computation are as follows:</p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:33.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months&#160;Ended</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:33.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:15.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Outstanding stock options and awards</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,544,348</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,318,013</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Common shares issuable upon conversion of the 2020 Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 368,939</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 368,939</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Total potential common shares excluded from diluted net income (loss) per share computation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,913,287</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,686,952</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6786483504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3.&#160;&#160;&#160;&#160; </b><b style="font-weight:bold;">Revenues</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As discussed in Note 2, revenues are recognized under guidance within ASC 606 and ASC 808. The following table presents our disaggregated revenue for the periods presented (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:41.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months&#160;Ended</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:41.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:18.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">JAKAFI revenues, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 459,479</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 375,611</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">ICLUSIG revenues, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,248</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,638</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Total product revenues, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 486,727</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 396,249</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">JAKAVI product royalty revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 56,333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45,571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">OLUMIANT product royalty revenues</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,447</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,037</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Total product royalty revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81,780</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 61,608</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Milestone and contract revenues</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.33%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 568,507</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.5%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 497,857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">For further information on our revenue-generating contracts,<b style="font-weight:bold;"> </b>refer to Note 9 to the condensed consolidated financial statements.<b style="font-weight:bold;"> &#160;</b></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6786540864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">7.&#160;&#160;&#160;&#160;Property and equipment, net</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment, net consists of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri';">&#160;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Office equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,285</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,303</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 72,352</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 70,510</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Computer equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 60,077</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59,069</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Land</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,227</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,203</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Building and leasehold improvements</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 208,276</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 208,293</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Operating lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,641</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,672</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Construction in progress</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 153,508</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 116,387</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 538,366</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 499,437</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Less accumulated depreciation and amortization</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (128,332)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"> (121,870)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 410,034</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 377,567</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2018, we signed an agreement to rent a building in Morges, Switzerland for an initial term of 15 years plus one year of free rent, with multiple options to extend for an additional 20 years. The building will serve as our new European headquarters and will consist of approximately 100,000 square feet of office space. This building will allow for consolidation of our European operations that are currently located in Geneva and Lausanne, Switzerland. Building permits were granted by the local government authorities in September 2018 and construction activity began immediately thereafter. In June 2019, we obtained control of the Morges building to begin our construction activity. At that time, we determined the lease to be a finance lease and recorded a lease liability of $31.1 million and a finance lease right-of-use asset of $29.1 million, net of a lease incentive from our landlord of $2.0 million. As of March 31, 2020, we have capitalized approximately $18.2 million in on site preparation, design and construction costs. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In July 2018, we signed an agreement to purchase land located in Yverdon, Switzerland. The land was purchased, in cash, for approximately $4.8 million. Upon this parcel, we are constructing a large molecule production facility. &#160;</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Construction activity commenced in July 2018 and as of March 31, 2020, we have capitalized approximately $102.8 million in costs for construction, ground preparation and architectural and engineering studies. We currently anticipate the facility will be completed in the second half of 2020.</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are the lessee of several contracts, including those to secure fleet vehicles, buildings and equipment. Our lease agreements do not contain any material residual value guarantees or restrictive covenants. Some of our building leases include options to renew and the exercise of these options is at our discretion. Our current operating lease liabilities are reflected in accrued and other current liabilities and our noncurrent operating lease liabilities are reflected in other liabilities on the condensed consolidated balance sheets and are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:71.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri';">&#160;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Current</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="-sec-ix-hidden:Hidden_DXWVUeF4QEyCGxw9FL_y3g"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Operating lease liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,343</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="-sec-ix-hidden:Hidden_fgS4bxuAUka7K61E668xgw"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Finance lease liabilities</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 910</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 664</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="-sec-ix-hidden:Hidden_DZPOj2yYtU-8JCIk7usOfw"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Operating lease liabilities</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,151</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,854</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="-sec-ix-hidden:Hidden_T_UTUYhcFUKgazgt2tP-VA"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Finance lease liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,959</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,918</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Total lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 53,041</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 53,779</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The cash paid for amounts included in the measurement of our operating lease liabilities as of March 31, 2020 and 2019 was $3.2 million and $2.8 million, respectively, in operating cash flows. The cash paid for amounts included in the measurement of our finance lease liabilities as of March 31, 2020 and 2019 was $0.2 million in financing cash flows. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">As of March 31, 2020, our finance and operating leases had a weighted average lease term of approximately 15.4 and 3.1 years, respectively. The discount rate of our leases is an approximation of an estimated incremental borrowing rate and is dependent upon the term and economics of each agreement. The weighted average discount rate of our finance and operating leases is approximately 3.6% and 4.4%, respectively. </p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">For the three months ended March 31, 2020, we incurred approximately $3.2 million of expense related to our operating leases, approximately $0.6 million of amortization on our finance lease right-of-use assets and approximately $0.3 million of interest expense on our finance lease liabilities. For the three months ended March 31, 2019, we incurred approximately $3.6 million of expense related to our operating leases, approximately $0.2 million of amortization on our finance lease right-of-use assets and a de minimis amount of interest expense on our finance lease liabilities. Rent expense for the three months ended March 31, 2020 and 2019 was approximately $3.5 million and $3.3 million, respectively. For the three months ended March 31, 2020 and 2019, the cost of our short term leases with a term less than 12 months was de minimis. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6786411696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued and other current liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued and other current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued and other current liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accrued and other current liabilities consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:17.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31, </b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:17.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Royalties</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73,045</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73,221</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Clinical related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 77,913</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88,710</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Sales allowances</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 96,062</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59,924</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,582</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,732</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Operating lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,343</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 60,411</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,020</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:55.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Total accrued and other current liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 330,034</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 285,950</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6781399568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_ScheduleOfInventoryTableTextBlock', window );">Schedule of inventory</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our inventory balance consists of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31, </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,275</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,275</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Work-in-process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,228</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,634</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,714</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,596</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,217</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,505</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Inventories-current</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,977</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,400</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Inventories-noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,240</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,105</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_ScheduleOfInventoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of carrying amount of inventories as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_ScheduleOfInventoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6786581984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and business (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract', window );"><strong>Organization and Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6798655104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,043,241<span></span>
</td>
<td colspan="2" class="nump">$ 1,832,684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities-available-for-sale (amortized cost $258,622; allowance for credit losses $0)</a></td>
<td class="nump">259,351<span></span>
</td>
<td colspan="2" class="nump">284,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="nump">351,522<span></span>
</td>
<td colspan="2" class="nump">308,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">13,977<span></span>
</td>
<td colspan="2" class="nump">11,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">48,078<span></span>
</td>
<td colspan="2" class="nump">43,725<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,716,169<span></span>
</td>
<td colspan="2" class="nump">2,481,488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent', window );">Restricted cash and investments</a></td>
<td class="nump">2,548<span></span>
</td>
<td colspan="2" class="nump">1,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long term investments</a></td>
<td class="nump">180,993<span></span>
</td>
<td colspan="2" class="nump">133,657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory</a></td>
<td class="nump">8,240<span></span>
</td>
<td colspan="2" class="nump">5,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">410,034<span></span>
</td>
<td colspan="2" class="nump">377,567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets, net</a></td>
<td class="nump">28,622<span></span>
</td>
<td colspan="2" class="nump">29,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIntangibleAssetsNet', window );">Other intangible assets, net</a></td>
<td class="nump">188,444<span></span>
</td>
<td colspan="2" class="nump">193,828<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">155,593<span></span>
</td>
<td colspan="2" class="nump">155,593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets, net</a></td>
<td class="nump">61,779<span></span>
</td>
<td colspan="2" class="nump">49,431<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,752,422<span></span>
</td>
<td colspan="2" class="nump">3,426,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">60,937<span></span>
</td>
<td colspan="2" class="nump">83,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">57,779<span></span>
</td>
<td colspan="2" class="nump">90,706<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest payable</a></td>
<td class="nump">89<span></span>
</td>
<td colspan="2" class="nump">29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">330,034<span></span>
</td>
<td colspan="2" class="nump">285,950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="nump">910<span></span>
</td>
<td colspan="2" class="nump">664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible senior notes</a></td>
<td class="nump">18,524<span></span>
</td>
<td colspan="2" class="nump">18,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">35,139<span></span>
</td>
<td colspan="2" class="nump">34,044<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">503,412<span></span>
</td>
<td colspan="2" class="nump">513,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">239,861<span></span>
</td>
<td colspan="2" class="nump">242,956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities</a></td>
<td class="nump">31,959<span></span>
</td>
<td colspan="2" class="nump">31,918<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">39,469<span></span>
</td>
<td colspan="2" class="nump">40,130<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">814,701<span></span>
</td>
<td colspan="2" class="nump">828,344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5,000,000 shares authorized; none issued or outstanding as of March 31, 2020 and December 31, 2019</a></td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 400,000,000 shares authorized; 216,952,325 and 216,177,830 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively</a></td>
<td class="nump">217<span></span>
</td>
<td colspan="2" class="nump">216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">4,102,011<span></span>
</td>
<td colspan="2" class="nump">4,044,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(13,107)<span></span>
</td>
<td colspan="2" class="num">(15,542)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(2,151,400)<span></span>
</td>
<td colspan="2" class="num">(1,430,758)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">1,937,721<span></span>
</td>
<td colspan="2" class="nump">2,598,406<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 2,752,422<span></span>
</td>
<td colspan="2" class="nump">$ 3,426,750<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size:9pt;">The condensed consolidated balance sheet at December 31, 2019 has been derived from the audited consolidated financial statements at that date.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6798316016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License agreements - Syros (Details)<br> $ / shares in Units, $ in Thousands, shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 08, 2018 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 01, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 133,657<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,085,287<span></span>
</td>
<td class="nump">$ 270,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) on long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48,132)<span></span>
</td>
<td class="nump">20,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_SyrosPharmaceuticalsIncMember', window );">Syros Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_NumberOfProgramTargets', window );">Number of program targets | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementUpfrontPaymentAmountPaid', window );">Upfront payment under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Fair market value of our long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) on long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_SyrosPharmaceuticalsIncMember', window );">Syros Pharmaceuticals, Inc. | Stock purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares', window );">Purchase of common stock under Stock Purchase Agreement (in shares ) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Purchase price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Per share price | $ / shares</a></td>
<td class="nump">$ 9.77<span></span>
</td>
<td class="nump">$ 12.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_StockPurchaseAgreementLockUpPeriod', window );">Lock-up period</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_FairValueInputsAmountOfDiscountForLackOfMarketability', window );">Discount for lack of marketability</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Fair value of shares on the issuance date</a></td>
<td class="nump">$ 7,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_SyrosPharmaceuticalsIncMember', window );">Syros Pharmaceuticals, Inc. | Amended stock purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares', window );">Purchase of common stock under Stock Purchase Agreement (in shares ) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Purchase price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Per share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_SyrosPharmaceuticalsIncMember', window );">Syros Pharmaceuticals, Inc. | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementTargetSelectionAndOptionExerciseFeePayments', window );">Target selection and option exercise fee payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_SyrosPharmaceuticalsIncMember', window );">Syros Pharmaceuticals, Inc. | Development and Regulatory Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementAdditionalMilestonePayments', window );">Additional milestone payments under the license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_SyrosPharmaceuticalsIncMember', window );">Syros Pharmaceuticals, Inc. | Commercialization Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementAdditionalMilestonePayments', window );">Additional milestone payments under the license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size:9pt;">The condensed consolidated balance sheet at December 31, 2019 has been derived from the audited consolidated financial statements at that date.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_FairValueInputsAmountOfDiscountForLackOfMarketability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to the amount of discount used to measure fair value for lack of ability to convert business interests into cash quickly..</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_FairValueInputsAmountOfDiscountForLackOfMarketability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementAdditionalMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the additional milestone payments to be made under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementAdditionalMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementTargetSelectionAndOptionExerciseFeePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the target selection and option exercise fee payments to be made under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementTargetSelectionAndOptionExerciseFeePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementUpfrontPaymentAmountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of the upfront payment made under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementUpfrontPaymentAmountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_NumberOfProgramTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of program targets identified.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_NumberOfProgramTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the purchase of common stock under Stock Purchase Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_StockPurchaseAgreementLockUpPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the period of time that the company will not sell or otherwise transfer any of the equity method shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_StockPurchaseAgreementLockUpPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of the entity's equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=incy_SyrosPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=incy_SyrosPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_AmendedStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_AmendedStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795787056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th" colspan="2"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2018</a></td>
<td class="nump">$ 213<span></span>
</td>
<td class="nump">$ 3,813,678<span></span>
</td>
<td class="num">$ (10,165)<span></span>
</td>
<td class="num">$ (1,877,759)<span></span>
</td>
<td class="nump">$ 1,925,967<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of shares of Common Stock upon exercise of stock options and settlement of employee restricted stock units</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">15,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,481<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of shares of Common Stock for services rendered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,690<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_AdoptionOfAccountingStandardAdjustmentToRetainedEarnings', window );">Adoption of ASU No. 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">918<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,312<span></span>
</td>
<td class="nump">102,312<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Mar. 31, 2019</a></td>
<td class="nump">214<span></span>
</td>
<td class="nump">3,869,952<span></span>
</td>
<td class="num">(9,247)<span></span>
</td>
<td class="num">(1,775,352)<span></span>
</td>
<td class="nump">2,085,567<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2019</a></td>
<td class="nump">216<span></span>
</td>
<td class="nump">4,044,490<span></span>
</td>
<td class="num">(15,542)<span></span>
</td>
<td class="num">(1,430,758)<span></span>
</td>
<td class="nump">2,598,406<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of shares of Common Stock upon exercise of stock options and settlement of employee restricted stock units</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">14,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,619<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of shares of Common Stock for services rendered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,758<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,435<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(720,642)<span></span>
</td>
<td class="num">(720,642)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Mar. 31, 2020</a></td>
<td class="nump">$ 217<span></span>
</td>
<td class="nump">$ 4,102,011<span></span>
</td>
<td class="num">$ (13,107)<span></span>
</td>
<td class="num">$ (2,151,400)<span></span>
</td>
<td class="nump">$ 1,937,721<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size:9pt;">The condensed consolidated balance sheet at December 31, 2019 has been derived from the audited consolidated financial statements at that date.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AdoptionOfAccountingStandardAdjustmentToRetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in retained earnings due to the adjustment of prepaid tax assets from adoption of new accounting standard.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AdoptionOfAccountingStandardAdjustmentToRetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6798578912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net - Lease and maturity of lease liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract', window );"><strong>Lease liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfResidualValueGuarantee', window );">Lessee, Operating Lease, Existence of Residual Value Guarantee [true false]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lessee, Operating Lease, Existence of Option to Extend [true false]</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">$ 9,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,343<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Accrued Liabilities, Current<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Accrued Liabilities, Current<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities, current</a></td>
<td class="nump">$ 910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 664<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Finance lease liabilities, current<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Finance lease liabilities, current<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, noncurrent</a></td>
<td class="nump">$ 11,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,854<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other Liabilities, Noncurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other Liabilities, Noncurrent<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, noncurrent</a></td>
<td class="nump">$ 31,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,918<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Finance lease liabilities, noncurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Finance lease liabilities, noncurrent<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_OperatingAndFinanceLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 53,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,779<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating lease liabilities</a></td>
<td class="nump">3,200<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Cash paid for financing lease liabilities in operating cash flows</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Cash paid for financing lease liabilities in financing cash flows</a></td>
<td class="nump">$ 187<span></span>
</td>
<td class="nump">195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Maturity of our finance lease liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average lease term, finance leases</a></td>
<td class="text">15 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average lease term, operating leases</a></td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate, operating leases</a></td>
<td class="nump">3.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate, finance leases</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Expense related to our operating leases</a></td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization on our finance lease right-of-use assets</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest expense on finance lease liabilities</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense</a></td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size:9pt;">The condensed consolidated balance sheet at December 31, 2019 has been derived from the audited consolidated financial statements at that date.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_OperatingAndFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating and finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_OperatingAndFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAndLiabilitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfResidualValueGuarantee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee provided residual value guarantee for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfResidualValueGuarantee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6799764544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License agreements - Agenus (Details)<br> $ / shares in Units, $ in Thousands, shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 14, 2017 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 01, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2015 </div>
<div>item</div>
</th>
<th class="th">
<div>Jan. 31, 2015 </div>
<div>item</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 133,657<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,085,287<span></span>
</td>
<td class="nump">$ 270,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) on long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48,132)<span></span>
</td>
<td class="nump">20,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,716,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,481,488<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 503,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">513,340<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_AgenusMember', window );">Agenus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_NumberOfProgramTargets', window );">Number of program targets | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_PercentageOfRoyaltyRatePayments', window );">Royalty payments on future global net sales (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_AgenusMember', window );">Agenus | Development, Regulatory and Commercialization Milestones | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_PercentageOfRoyaltyRatePayments', window );">Royalty payments on future global net sales (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=incy_AgenusMember', window );">Agenus | Development, Regulatory and Commercialization Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_PercentageOfRoyaltyRatePayments', window );">Royalty payments on future global net sales (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_AgenusMember', window );">Agenus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,300<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">10,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) on long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (28,800)<span></span>
</td>
<td class="nump">$ 10,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,600<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_AgenusMember', window );">Agenus | Accrued and other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued and other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_AgenusMember', window );">Agenus | Development, Regulatory and Commercialization Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementAdditionalMilestonePayments', window );">Additional milestone payments under the license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 510,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_AgenusMember', window );">Agenus | Development Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementUpfrontPaymentAmountPaid', window );">Upfront payment under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_AgenusMember', window );">Agenus | Development Milestones | LAG-3 program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementAdditionalMilestonePayments', window );">Additional milestone payments under the license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_AgenusMember', window );">Agenus | Development Milestones | TIM-3 program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_LicenseAgreementAdditionalMilestonePayments', window );">Additional milestone payments under the license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_AgenusMember', window );">Agenus | Stock purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>License agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares', window );">Purchase of common stock under Stock Purchase Agreement (in shares ) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Purchase price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Per share price | $ / shares</a></td>
<td class="nump">$ 4.40<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_FairValueInputsAmountOfDiscountForLackOfMarketability', window );">Discount for lack of marketability</a></td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Fair value of shares on the issuance date</a></td>
<td class="nump">39,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_incy_TotalConsiderationPaidUnderPurchaseAgreement', window );">Total consideration paid</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="13"></td></tr>
<tr><td colspan="13"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size:9pt;">The condensed consolidated balance sheet at December 31, 2019 has been derived from the audited consolidated financial statements at that date.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_FairValueInputsAmountOfDiscountForLackOfMarketability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to the amount of discount used to measure fair value for lack of ability to convert business interests into cash quickly..</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_FairValueInputsAmountOfDiscountForLackOfMarketability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementAdditionalMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the additional milestone payments to be made under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementAdditionalMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_LicenseAgreementUpfrontPaymentAmountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of the upfront payment made under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_LicenseAgreementUpfrontPaymentAmountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_NumberOfProgramTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of program targets identified.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_NumberOfProgramTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_PercentageOfRoyaltyRatePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents range of tiered, double-digit royalty payments on future global sales if product is successfully commercialized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_PercentageOfRoyaltyRatePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the purchase of common stock under Stock Purchase Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_PurchaseOfCommonStockUnderStockPurchaseAgreementInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_TotalConsiderationPaidUnderPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of the total consideration paid under purchase agreement during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_TotalConsiderationPaidUnderPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>incy_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of the entity's equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33912-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from sale of product and rendering of service reported by equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=incy_AgenusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=incy_AgenusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_DevelopmentRegulatoryAndCommercializationMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_DevelopmentRegulatoryAndCommercializationMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_AgenusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_AgenusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_incy_AchievementOfMilestoneAxis=incy_DevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">incy_AchievementOfMilestoneAxis=incy_DevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=incy_LG3ProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=incy_LG3ProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=incy_TIM3ProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=incy_TIM3ProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=incy_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=incy_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6967341168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="nump">$ 16,566<span></span>
</td>
<td class="nump">$ 1,785<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease', window );">Increase in unrecognized tax benefits</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Increase (decrease) noncurrent other liabilities</a></td>
<td class="num">$ (200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
